NA	CHEMICAL	GENE-Y	1	76	Dimemorfan (chemical, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T36	T55	10064839
NA	CHEMICAL	GENE-N	1	92	Dimemorfan (chemical, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T36	T52	10064839
NA	CHEMICAL	GENE-N	1	37	Dimemorfan (chemical, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T36	T54	10064839
NA	CHEMICAL	GENE-Y	0	76	chemical ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T35	T55	10064839
NA	CHEMICAL	GENE-N	0	92	chemical ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T35	T52	10064839
NA	CHEMICAL	GENE-N	0	37	chemical ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T35	T54	10064839
NA	CHEMICAL	GENE-Y	40	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and chemical-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T41	T55	10064839
NA	CHEMICAL	GENE-N	40	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and chemical-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T41	T52	10064839
NA	CHEMICAL	GENE-N	40	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and chemical-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T41	T54	10064839
NA	CHEMICAL	GENE-Y	41	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked chemical sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T42	T55	10064839
NA	CHEMICAL	GENE-N	41	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked chemical sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T42	T52	10064839
NA	CHEMICAL	GENE-N	41	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and NMDA-linked chemical sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T42	T54	10064839
NA	CHEMICAL	GENE-Y	6	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T38	T55	10064839
NA	CHEMICAL	GENE-Y	6	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T44	T55	10064839
NA	CHEMICAL	GENE-Y	6	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T47	T55	10064839
NA	CHEMICAL	GENE-N	6	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T38	T52	10064839
NA	CHEMICAL	GENE-N	6	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T44	T52	10064839
NA	CHEMICAL	GENE-N	6	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T47	T52	10064839
NA	CHEMICAL	GENE-N	6	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T38	T54	10064839
NA	CHEMICAL	GENE-N	6	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T44	T54	10064839
NA	CHEMICAL	GENE-N	6	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of chemical, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of chemical and DR. We found that DF, chemical, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T47	T54	10064839
NA	CHEMICAL	GENE-Y	26	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T39	T55	10064839
NA	CHEMICAL	GENE-Y	26	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T45	T55	10064839
NA	CHEMICAL	GENE-Y	26	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T48	T55	10064839
NA	CHEMICAL	GENE-N	26	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T39	T52	10064839
NA	CHEMICAL	GENE-N	26	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T45	T52	10064839
NA	CHEMICAL	GENE-N	26	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T48	T52	10064839
NA	CHEMICAL	GENE-N	26	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T39	T54	10064839
NA	CHEMICAL	GENE-N	26	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T45	T54	10064839
NA	CHEMICAL	GENE-N	26	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, DF), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form chemical. This study therefore characterized the binding of DF to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and chemical. We found that DF, DM, and chemical were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T48	T54	10064839
NA	CHEMICAL	GENE-Y	2	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T37	T55	10064839
NA	CHEMICAL	GENE-Y	2	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T40	T55	10064839
NA	CHEMICAL	GENE-Y	2	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T43	T55	10064839
NA	CHEMICAL	GENE-Y	2	76	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at gene (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T46	T55	10064839
NA	CHEMICAL	GENE-N	2	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T37	T52	10064839
NA	CHEMICAL	GENE-N	2	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T40	T52	10064839
NA	CHEMICAL	GENE-N	2	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T43	T52	10064839
NA	CHEMICAL	GENE-N	2	92	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at gene (Ki=4-11 microM).	T46	T52	10064839
NA	CHEMICAL	GENE-N	2	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T37	T54	10064839
NA	CHEMICAL	GENE-N	2	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T40	T54	10064839
NA	CHEMICAL	GENE-N	2	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T43	T54	10064839
NA	CHEMICAL	GENE-N	2	37	Dimemorfan ((+)-3-methyl-N-methylmorphinan, chemical), an analog of DM, which has been safely used as an antitussive for more than 20 years, is also known not to form DR. This study therefore characterized the binding of chemical to the gene and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of chemical in mice in comparison with those of DM and DR. We found that chemical, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).	T46	T54	10064839
NA	CHEMICAL	GENE-Y	21	12	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to gene, the very low affinity of DF at chemical sites may suggest that acting on the chemical sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.	T19	T53	10064839
NA	CHEMICAL	GENE-Y	21	12	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to gene, the very low affinity of DF at chemical sites may suggest that acting on the chemical sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.	T20	T53	10064839
NA	CHEMICAL	GENE-Y	43	12	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to gene, the very low affinity of DF at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these chemical analogs.	T21	T53	10064839
NA	CHEMICAL	GENE-Y	19	12	Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to gene, the very low affinity of chemical at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.	T18	T53	10064839
NA	CHEMICAL	GENE-Y	3	2	Use of gene (chemical) II AT1 receptor antagonists for treatment of hypertension is rapidly increasing, yet direct comparisons of the relative efficacy of antagonists to block the renin-gene system in humans are lacking.	T8	T14	10082498
NA	CHEMICAL	GENE-N	3	33	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro gene assay, and reactive changes in plasma Ang II levels.	T13	T30	10082498
NA	CHEMICAL	GENE-N	3	33	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro gene assay, and reactive changes in plasma Ang II levels.	T27	T30	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T13	T15	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T13	T16	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T13	T17	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T13	T29	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T13	T31	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T27	T15	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T27	T16	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T27	T17	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T27	T29	10082498
NA	CHEMICAL	GENE-Y	3	29	Blockade of the renin-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous gene, in vitro gene receptor assay, and reactive changes in plasma gene levels.	T27	T31	10082498
NA	CHEMICAL	GENE-Y	3	3	Blockade of the gene-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	T13	T26	10082498
NA	CHEMICAL	GENE-Y	3	3	Blockade of the gene-chemical system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous Ang II, in vitro Ang II receptor assay, and reactive changes in plasma Ang II levels.	T27	T26	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T15	T13	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T15	T27	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T16	T13	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T16	T27	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T17	T13	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T17	T27	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T29	T13	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T29	T27	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T31	T13	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the renin-gene system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T31	T27	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the gene-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T15	T26	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the gene-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T16	T26	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the gene-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T17	T26	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the gene-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T29	T26	10082498
NA	CHEMICAL	GENE-Y	29	3	Blockade of the gene-angiotensin system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous chemical, in vitro chemical receptor assay, and reactive changes in plasma chemical levels.	T31	T26	10082498
NA	CHEMICAL	GENE-Y	17	8	At 4 hours, losartan blocked 43% of the gene-induced systolic blood pressure increase; valsartan, 51%; and chemical, 88% (P<0.01 between drugs).	T20	T18	10082498
CPR:4	CHEMICAL	GENE-Y	17	8	At 4 hours, losartan blocked 43% of the gene-induced systolic blood pressure increase; valsartan, 51%; and chemical, 88% (P<0.01 between drugs).	T20	T32	10082498
NA	CHEMICAL	GENE-Y	14	8	At 4 hours, losartan blocked 43% of the gene-induced systolic blood pressure increase; chemical, 51%; and irbesartan, 88% (P<0.01 between drugs).	T19	T18	10082498
CPR:4	CHEMICAL	GENE-Y	14	8	At 4 hours, losartan blocked 43% of the gene-induced systolic blood pressure increase; chemical, 51%; and irbesartan, 88% (P<0.01 between drugs).	T19	T32	10082498
CPR:4	CHEMICAL	GENE-N	14	21	This study thus demonstrates that the first administration of the recommended starting dose of chemical induces a greater and longer lasting gene blockade than that of valsartan and losartan in normotensive subjects.	T4	T24	10082498
NA	CHEMICAL	GENE-Y	14	21	This study thus demonstrates that the first administration of the recommended starting dose of chemical induces a greater and longer lasting gene receptor blockade than that of valsartan and losartan in normotensive subjects.	T4	T5	10082498
CPR:4	CHEMICAL	GENE-N	28	21	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting gene blockade than that of chemical and losartan in normotensive subjects.	T6	T24	10082498
NA	CHEMICAL	GENE-Y	28	21	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting gene receptor blockade than that of chemical and losartan in normotensive subjects.	T6	T5	10082498
CPR:4	CHEMICAL	GENE-N	30	21	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting gene blockade than that of valsartan and chemical in normotensive subjects.	T7	T24	10082498
NA	CHEMICAL	GENE-Y	30	21	This study thus demonstrates that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting gene receptor blockade than that of valsartan and chemical in normotensive subjects.	T7	T5	10082498
NA	CHEMICAL	GENE-N	4	10	The affinity of eletriptan (chemical) for a range of gene was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.	T8	T21	10193663
NA	CHEMICAL	GENE-N	4	19	The affinity of eletriptan (chemical) for a range of 5-HT receptors was compared to values obtained for other gene receptor agonists known to be effective in the treatment of migraine.	T8	T25	10193663
NA	CHEMICAL	GENE-N	3	10	The affinity of chemical ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of gene was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.	T5	T21	10193663
NA	CHEMICAL	GENE-N	3	19	The affinity of chemical ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of 5-HT receptors was compared to values obtained for other gene receptor agonists known to be effective in the treatment of migraine.	T5	T25	10193663
NA	CHEMICAL	GENE-Y	3	12	Eletriptan, like sumatriptan, chemical, naratriptan and rizatriptan had highest affinity for the gene, 5-HT1D and putative 5-ht1f receptor.	T9	T26	10193663
NA	CHEMICAL	GENE-Y	3	14	Eletriptan, like sumatriptan, chemical, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, gene and putative 5-ht1f receptor.	T9	T27	10193663
NA	CHEMICAL	GENE-Y	3	17	Eletriptan, like sumatriptan, chemical, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative gene receptor.	T9	T28	10193663
NA	CHEMICAL	GENE-Y	2	12	Eletriptan, like chemical, zolmitriptan, naratriptan and rizatriptan had highest affinity for the gene, 5-HT1D and putative 5-ht1f receptor.	T7	T26	10193663
NA	CHEMICAL	GENE-Y	2	14	Eletriptan, like chemical, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, gene and putative 5-ht1f receptor.	T7	T27	10193663
NA	CHEMICAL	GENE-Y	2	17	Eletriptan, like chemical, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative gene receptor.	T7	T28	10193663
NA	CHEMICAL	GENE-Y	4	12	Eletriptan, like sumatriptan, zolmitriptan, chemical and rizatriptan had highest affinity for the gene, 5-HT1D and putative 5-ht1f receptor.	T10	T26	10193663
NA	CHEMICAL	GENE-Y	4	14	Eletriptan, like sumatriptan, zolmitriptan, chemical and rizatriptan had highest affinity for the human 5-HT1B, gene and putative 5-ht1f receptor.	T10	T27	10193663
NA	CHEMICAL	GENE-Y	4	17	Eletriptan, like sumatriptan, zolmitriptan, chemical and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative gene receptor.	T10	T28	10193663
NA	CHEMICAL	GENE-Y	6	12	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and chemical had highest affinity for the gene, 5-HT1D and putative 5-ht1f receptor.	T11	T26	10193663
NA	CHEMICAL	GENE-Y	6	14	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and chemical had highest affinity for the human 5-HT1B, gene and putative 5-ht1f receptor.	T11	T27	10193663
NA	CHEMICAL	GENE-Y	6	17	Eletriptan, like sumatriptan, zolmitriptan, naratriptan and chemical had highest affinity for the human 5-HT1B, 5-HT1D and putative gene receptor.	T11	T28	10193663
NA	CHEMICAL	GENE-Y	0	12	chemical, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the gene, 5-HT1D and putative 5-ht1f receptor.	T6	T26	10193663
NA	CHEMICAL	GENE-Y	0	14	chemical, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, gene and putative 5-ht1f receptor.	T6	T27	10193663
NA	CHEMICAL	GENE-Y	0	17	chemical, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative gene receptor.	T6	T28	10193663
NA	CHEMICAL	GENE-Y	8	11	Kinetic studies comparing the binding of [3H]eletriptan and chemical to the gene and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	T13	T29	10193663
NA	CHEMICAL	GENE-Y	8	15	Kinetic studies comparing the binding of [3H]eletriptan and chemical to the human recombinant 5-HT1B and gene receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	T13	T30	10193663
NA	CHEMICAL	GENE-Y	6	11	Kinetic studies comparing the binding of chemical and [3H]sumatriptan to the gene and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	T12	T29	10193663
NA	CHEMICAL	GENE-Y	6	15	Kinetic studies comparing the binding of chemical and [3H]sumatriptan to the human recombinant 5-HT1B and gene receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.	T12	T30	10193663
NA	CHEMICAL	GENE-Y	8	11	However, [3H]eletriptan had over 6-fold higher affinity than chemical at the gene receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than chemical at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).	T15	T31	10193663
NA	CHEMICAL	GENE-Y	8	11	However, [3H]eletriptan had over 6-fold higher affinity than chemical at the gene receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than chemical at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).	T16	T31	10193663
NA	CHEMICAL	GENE-Y	8	28	However, [3H]eletriptan had over 6-fold higher affinity than chemical at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than chemical at the gene receptor (K(D): 3.14 and 11.07 nM, respectively).	T15	T32	10193663
NA	CHEMICAL	GENE-Y	8	28	However, [3H]eletriptan had over 6-fold higher affinity than chemical at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than chemical at the gene receptor (K(D): 3.14 and 11.07 nM, respectively).	T16	T32	10193663
NA	CHEMICAL	GENE-Y	1	11	However, chemical had over 6-fold higher affinity than [3H]sumatriptan at the gene receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).	T14	T31	10193663
NA	CHEMICAL	GENE-Y	1	28	However, chemical had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the gene receptor (K(D): 3.14 and 11.07 nM, respectively).	T14	T32	10193663
NA	CHEMICAL	GENE-Y	39	14	Association and dissociation rates for both radioligands could only be accurately determined at the gene receptor and then only at 4 degrees C. At this temperature, [3H]eletriptan had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than chemical (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for chemical).	T2	T20	10193663
NA	CHEMICAL	GENE-Y	39	14	Association and dissociation rates for both radioligands could only be accurately determined at the gene receptor and then only at 4 degrees C. At this temperature, [3H]eletriptan had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than chemical (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for chemical).	T4	T20	10193663
NA	CHEMICAL	GENE-Y	26	14	Association and dissociation rates for both radioligands could only be accurately determined at the gene receptor and then only at 4 degrees C. At this temperature, chemical had a significantly (P<0.05) faster association rate (K(on) 0.249 min(-1) nM(-1)) than [3H]sumatriptan (K(on) 0.024 min(-1) nM(-1)) and a significantly (P<0.05) slower off-rate (K(off) 0.027 min(-1) compared to 0.037 min(-1) for [3H]sumatriptan).	T1	T20	10193663
NA	CHEMICAL	GENE-N	32	24	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the gene with [3H]imipramine, chemical, and [3H]WIN35428, respectively.	T7	T26	10193665
NA	CHEMICAL	GENE-N	31	24	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the gene with chemical, [3H]nisoxetine, and [3H]WIN35428, respectively.	T6	T26	10193665
NA	CHEMICAL	GENE-N	13	24	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 chemical and one metabolite of a neuroleptic (haloperidol metabolite) for the gene with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	T1	T26	10193665
NA	CHEMICAL	GENE-N	34	24	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (haloperidol metabolite) for the gene with [3H]imipramine, [3H]nisoxetine, and chemical, respectively.	T8	T26	10193665
NA	CHEMICAL	GENE-N	20	24	Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 neuroleptics and one metabolite of a neuroleptic (chemical metabolite) for the gene with [3H]imipramine, [3H]nisoxetine, and [3H]WIN35428, respectively.	T2	T26	10193665
NA	CHEMICAL	GENE-Y	13	9	Among neuroleptics, the four most potent compounds at the gene were chemical, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T11	T27	10193665
NA	CHEMICAL	GENE-Y	13	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were chemical, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T11	T28	10193665
NA	CHEMICAL	GENE-Y	28	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chemical, and promazine (K(D) 19-25 nM).	T18	T27	10193665
NA	CHEMICAL	GENE-Y	28	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorpromazine, zotepine, chemical, and promazine (K(D) 19-25 nM).	T18	T28	10193665
NA	CHEMICAL	GENE-Y	15	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, fluperlapine, chemical, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chemical, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T13	T27	10193665
NA	CHEMICAL	GENE-Y	15	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, fluperlapine, chemical, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chemical, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T16	T27	10193665
NA	CHEMICAL	GENE-Y	15	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chemical, and ziprasidone (K(D) 24-39 nM); and at the gene, chemical, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T13	T28	10193665
NA	CHEMICAL	GENE-Y	15	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chemical, and ziprasidone (K(D) 24-39 nM); and at the gene, chemical, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T16	T28	10193665
NA	CHEMICAL	GENE-Y	24	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the chemical transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T15	T27	10193665
NA	CHEMICAL	GENE-Y	14	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, chemical, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T12	T27	10193665
NA	CHEMICAL	GENE-Y	14	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, chemical, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T12	T28	10193665
NA	CHEMICAL	GENE-Y	1	9	Among chemical, the four most potent compounds at the gene were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T9	T27	10193665
NA	CHEMICAL	GENE-Y	1	24	Among chemical, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T9	T28	10193665
NA	CHEMICAL	GENE-Y	17	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, fluperlapine, chlorpromazine, and chemical (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T14	T27	10193665
NA	CHEMICAL	GENE-Y	17	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and chemical (K(D) 24-39 nM); and at the gene, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T14	T28	10193665
NA	CHEMICAL	GENE-Y	10	24	Among neuroleptics, the four most potent compounds at the human chemical transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).	T10	T28	10193665
NA	CHEMICAL	GENE-Y	13	9	Among neuroleptics, the four most potent compounds at the gene were trifluchemical, fluperlapine, chlorchemical, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorchemical, zotepine, chlorprothixene, and chemical (K(D) 19-25 nM).	T19	T27	10193665
NA	CHEMICAL	GENE-Y	13	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were trifluchemical, fluperlapine, chlorchemical, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorchemical, zotepine, chlorprothixene, and chemical (K(D) 19-25 nM).	T19	T28	10193665
NA	CHEMICAL	GENE-Y	27	9	Among neuroleptics, the four most potent compounds at the gene were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, chemical, chlorprothixene, and promazine (K(D) 19-25 nM).	T17	T27	10193665
NA	CHEMICAL	GENE-Y	27	24	Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the gene, chlorpromazine, chemical, chlorprothixene, and promazine (K(D) 19-25 nM).	T17	T28	10193665
NA	CHEMICAL	GENE-Y	10	2	At the gene, only pimozide (K(D) = 69+/-3) chemical (K(D) = 76+/-5) had notable potency.	T22	T29	10193665
NA	CHEMICAL	GENE-Y	6	2	At the gene, only chemical (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.	T21	T29	10193665
NA	CHEMICAL	GENE-Y	9	6	In humans, prolonged administration of the gene agonist chemical leads to a desensitization of gene-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.	T15	T20	10226872
CPR:5	CHEMICAL	GENE-Y	9	6	In humans, prolonged administration of the gene agonist chemical leads to a desensitization of gene-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.	T15	T27	10226872
NA	CHEMICAL	GENE-Y	30	6	In humans, prolonged administration of the gene agonist terbutaline leads to a desensitization of gene-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug chemical.	T10	T20	10226872
NA	CHEMICAL	GENE-Y	30	6	In humans, prolonged administration of the gene agonist terbutaline leads to a desensitization of gene-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug chemical.	T10	T27	10226872
NA	CHEMICAL	GENE-N	6	15	This study investigated the effect of chemical, another antiallergic drug, on terbutaline-induced desensitization of gene-mediated cardiovascular and noncardiovascular responses.	T11	T26	10226872
NA	CHEMICAL	GENE-N	12	15	This study investigated the effect of disodium cromoglycate, another antiallergic drug, on chemical-induced desensitization of gene-mediated cardiovascular and noncardiovascular responses.	T12	T26	10226872
NA	CHEMICAL	GENE-Y	29	0	gene cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist chemical; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.	T16	T28	10226872
NA	CHEMICAL	GENE-Y	29	30	beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist chemical; gene cardiovascular function was assessed by exercise-induced tachycardia.	T16	T30	10226872
CPR:5	CHEMICAL	GENE-N	29	27	beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective gene agonist chemical; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.	T16	T29	10226872
NA	CHEMICAL	GENE-Y	0	17	chemical affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in gene-mediated exercise tachycardia after 2 weeks' administration of terbutaline.	T4	T22	10226872
NA	CHEMICAL	GENE-Y	0	8	chemical affected neither the rightward shift of gene-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of terbutaline.	T4	T21	10226872
NA	CHEMICAL	GENE-Y	26	17	Disodium cromoglycate affected neither the rightward shift of beta 2-adrenoceptor-mediated responses nor the small rightward shift in gene-mediated exercise tachycardia after 2 weeks' administration of chemical.	T5	T22	10226872
NA	CHEMICAL	GENE-Y	26	8	Disodium cromoglycate affected neither the rightward shift of gene-mediated responses nor the small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia after 2 weeks' administration of chemical.	T5	T21	10226872
NA	CHEMICAL	GENE-Y	8	21	Tremulousness observed during the first few days of chemical administration disappeared after 4 to 8 days, indicating development of desensitization of gene-mediated noncardiovascular responses.	T6	T23	10226872
NA	CHEMICAL	GENE-Y	12	17	OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, chemical, on reperfusion induced by gene (TPA) in patients with acute myocardial infarction (AMI).	T12	T15	10362188
CPR:4	CHEMICAL	GENE-Y	12	10	OBJECTIVES: This study examined the effect of a small-molecule, direct gene inhibitor, chemical, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).	T12	T22	10362188
NA	CHEMICAL	GENE-Y	12	20	OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, chemical, on reperfusion induced by tissue plasminogen activator (gene) in patients with acute myocardial infarction (AMI).	T12	T17	10362188
CPR:4	CHEMICAL	GENE-Y	9	19	In vitro and in vivo studies have shown that chemical has advantages over heparin for the inhibition of clot-bound gene and for the enhancement of thrombolysis with TPA.	T7	T19	10362188
NA	CHEMICAL	GENE-Y	9	27	In vitro and in vivo studies have shown that chemical has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with gene.	T7	T20	10362188
NA	CHEMICAL	GENE-Y	16	23	METHODS: One hundred and twenty-five patients with AMI within 6 h were randomized to heparin, low-dose chemical or high-dose chemical in addition to gene.	T8	T21	10362188
NA	CHEMICAL	GENE-Y	16	23	METHODS: One hundred and twenty-five patients with AMI within 6 h were randomized to heparin, low-dose chemical or high-dose chemical in addition to gene.	T9	T21	10362188
NA	CHEMICAL	GENE-Y	1	11	CONCLUSIONS: chemical, as compared with heparin, appears to enhance reperfusion with gene in patients with AMI, particularly in those patients with delayed presentation.	T5	T16	10362188
CPR:4	CHEMICAL	GENE-N	13	6	The functional inhibitory characteristics of the gene blockers (ARB) chemical; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T24	T31	10373224
NA	CHEMICAL	GENE-N	13	6	The functional inhibitory characteristics of the gene type 1 receptor blockers (ARB) chemical; irbesartan; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T24	T14	10373224
CPR:4	CHEMICAL	GENE-N	14	6	The functional inhibitory characteristics of the gene blockers (ARB) candesartan; chemical; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T1	T31	10373224
NA	CHEMICAL	GENE-N	14	6	The functional inhibitory characteristics of the gene type 1 receptor blockers (ARB) candesartan; chemical; and losartan and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T1	T14	10373224
CPR:4	CHEMICAL	GENE-N	21	6	The functional inhibitory characteristics of the gene blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite chemical (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T8	T31	10373224
NA	CHEMICAL	GENE-N	21	6	The functional inhibitory characteristics of the gene type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite chemical (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T8	T14	10373224
CPR:4	CHEMICAL	GENE-N	16	6	The functional inhibitory characteristics of the gene blockers (ARB) candesartan; irbesartan; and chemical and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T3	T31	10373224
NA	CHEMICAL	GENE-N	16	6	The functional inhibitory characteristics of the gene type 1 receptor blockers (ARB) candesartan; irbesartan; and chemical and its active metabolite EXP 3174 (EXP) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T3	T14	10373224
CPR:4	CHEMICAL	GENE-N	21	6	The functional inhibitory characteristics of the gene blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite chemical 3174 (chemical) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T9	T31	10373224
NA	CHEMICAL	GENE-N	21	6	The functional inhibitory characteristics of the gene type 1 receptor blockers (ARB) candesartan; irbesartan; and losartan and its active metabolite chemical 3174 (chemical) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	T9	T14	10373224
NA	CHEMICAL	GENE-Y	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T16	T17	10373224
NA	CHEMICAL	GENE-Y	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T16	T33	10373224
NA	CHEMICAL	GENE-Y	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T32	T17	10373224
NA	CHEMICAL	GENE-Y	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T32	T33	10373224
NA	CHEMICAL	GENE-N	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T16	T17	10373224
NA	CHEMICAL	GENE-N	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T16	T33	10373224
NA	CHEMICAL	GENE-N	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T32	T17	10373224
NA	CHEMICAL	GENE-N	16	18	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the chemical (gene) concentration-response curve.	T32	T33	10373224
NA	CHEMICAL	GENE-N	4	16	In both vascular preparations, chemical caused a marked decrease in the maximal contractile response of the gene (Ang II) concentration-response curve.	T15	T16	10373224
CPR:4	CHEMICAL	GENE-N	4	16	In both vascular preparations, chemical caused a marked decrease in the maximal contractile response of the gene (Ang II) concentration-response curve.	T15	T32	10373224
NA	CHEMICAL	GENE-Y	4	18	In both vascular preparations, chemical caused a marked decrease in the maximal contractile response of the angiotensin II (gene) concentration-response curve.	T15	T17	10373224
CPR:4	CHEMICAL	GENE-Y	4	18	In both vascular preparations, chemical caused a marked decrease in the maximal contractile response of the angiotensin II (gene) concentration-response curve.	T15	T33	10373224
NA	CHEMICAL	GENE-N	4	18	In both vascular preparations, chemical caused a marked decrease in the maximal contractile response of the angiotensin II (gene) concentration-response curve.	T15	T17	10373224
CPR:4	CHEMICAL	GENE-N	4	18	In both vascular preparations, chemical caused a marked decrease in the maximal contractile response of the angiotensin II (gene) concentration-response curve.	T15	T33	10373224
NA	CHEMICAL	GENE-N	18	16	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the gene (chemical) concentration-response curve.	T17	T16	10373224
NA	CHEMICAL	GENE-N	18	16	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the gene (chemical) concentration-response curve.	T17	T32	10373224
NA	CHEMICAL	GENE-N	18	16	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the gene (chemical) concentration-response curve.	T33	T16	10373224
NA	CHEMICAL	GENE-N	18	16	In both vascular preparations, candesartan caused a marked decrease in the maximal contractile response of the gene (chemical) concentration-response curve.	T33	T32	10373224
NA	CHEMICAL	GENE-Y	3	18	Losartan, EXP, and chemical caused a rightward parallel shift without any major effects on the maximal response to gene.	T20	T21	10373224
NA	CHEMICAL	GENE-Y	3	18	Losartan, EXP, and chemical caused a rightward parallel shift without any major effects on the maximal response to gene.	T20	T34	10373224
NA	CHEMICAL	GENE-N	3	18	Losartan, EXP, and chemical caused a rightward parallel shift without any major effects on the maximal response to gene.	T20	T21	10373224
NA	CHEMICAL	GENE-N	3	18	Losartan, EXP, and chemical caused a rightward parallel shift without any major effects on the maximal response to gene.	T20	T34	10373224
NA	CHEMICAL	GENE-Y	0	18	chemical, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T18	T21	10373224
NA	CHEMICAL	GENE-Y	0	18	chemical, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T18	T34	10373224
NA	CHEMICAL	GENE-N	0	18	chemical, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T18	T21	10373224
NA	CHEMICAL	GENE-N	0	18	chemical, EXP, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T18	T34	10373224
NA	CHEMICAL	GENE-Y	1	18	Losartan, chemical, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T19	T21	10373224
NA	CHEMICAL	GENE-Y	1	18	Losartan, chemical, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T19	T34	10373224
NA	CHEMICAL	GENE-N	1	18	Losartan, chemical, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T19	T21	10373224
NA	CHEMICAL	GENE-N	1	18	Losartan, chemical, and irbesartan caused a rightward parallel shift without any major effects on the maximal response to gene.	T19	T34	10373224
NA	CHEMICAL	GENE-Y	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T27	10373224
NA	CHEMICAL	GENE-Y	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T28	10373224
NA	CHEMICAL	GENE-Y	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T4	10373224
NA	CHEMICAL	GENE-Y	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T5	10373224
NA	CHEMICAL	GENE-N	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T27	10373224
NA	CHEMICAL	GENE-N	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T28	10373224
NA	CHEMICAL	GENE-N	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T4	10373224
NA	CHEMICAL	GENE-N	14	20	Cooling of the rat portal vein preparations to 4 degrees C before administration of chemical prevented the persistent inhibition of gene response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the gene response were independent of the incubation temperature before washing.	T2	T5	10373224
NA	CHEMICAL	GENE-Y	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T10	T29	10373224
NA	CHEMICAL	GENE-Y	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T10	T7	10373224
CPR:4	CHEMICAL	GENE-Y	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T6	T29	10373224
NA	CHEMICAL	GENE-Y	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T6	T7	10373224
NA	CHEMICAL	GENE-N	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T10	T29	10373224
NA	CHEMICAL	GENE-N	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T10	T7	10373224
CPR:4	CHEMICAL	GENE-N	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T6	T29	10373224
NA	CHEMICAL	GENE-N	3	13	In addition, when chemical was given to conscious rats, the inhibitory effect on gene-induced blood pressure responses persisted during the 24-hour period despite nondetectable plasma concentrations of chemical at 24 hours.	T6	T7	10373224
NA	CHEMICAL	GENE-Y	4	17	At clinically relevant concentrations, chemical is an insurmountable and long-lasting antagonist of the vascular contractile responses to gene.	T12	T13	10373224
CPR:4	CHEMICAL	GENE-Y	4	17	At clinically relevant concentrations, chemical is an insurmountable and long-lasting antagonist of the vascular contractile responses to gene.	T12	T30	10373224
NA	CHEMICAL	GENE-N	4	17	At clinically relevant concentrations, chemical is an insurmountable and long-lasting antagonist of the vascular contractile responses to gene.	T12	T13	10373224
CPR:4	CHEMICAL	GENE-N	4	17	At clinically relevant concentrations, chemical is an insurmountable and long-lasting antagonist of the vascular contractile responses to gene.	T12	T30	10373224
NA	CHEMICAL	GENE-Y	7	15	We evaluated whether therapeutic blood levels of chemical are associated with selective inhibition of monocyte gene in vitro and ex vivo.	T7	T12	10381787
CPR:4	CHEMICAL	GENE-Y	19	7	Concentration-response curves for the inhibition of monocyte gene and platelet COX-1 were obtained in vitro after the incubation of chemical with whole blood samples.	T5	T17	10381787
CPR:4	CHEMICAL	GENE-Y	19	10	Concentration-response curves for the inhibition of monocyte COX-2 and platelet gene were obtained in vitro after the incubation of chemical with whole blood samples.	T5	T18	10381787
CPR:9	CHEMICAL	GENE-Y	30	41	Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and chemical was measured in plasma as an index of monocyte gene activity.	T8	T19	10381787
CPR:9	CHEMICAL	GENE-Y	3	25	The production of chemical in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet gene activity.	T9	T20	10381787
CPR:4	CHEMICAL	GENE-Y	10	16	In contrast, the administration of 7.5 and 15 mg of chemical caused dose-dependent reductions in monocyte gene activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively.	T2	T13	10381787
CPR:4	CHEMICAL	GENE-Y	10	26	In contrast, the administration of 7.5 and 15 mg of chemical caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet gene activity by 25% and 35%, respectively.	T2	T14	10381787
CPR:4	CHEMICAL	GENE-Y	5	18	Although the IC50 value of chemical for inhibition of COX-1 was 10-fold higher than the IC50 value of gene in vitro, this biochemical selectivity was inadequate to clearly separate the effects of chemical on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	T3	T16	10381787
NA	CHEMICAL	GENE-Y	5	18	Although the IC50 value of chemical for inhibition of COX-1 was 10-fold higher than the IC50 value of gene in vitro, this biochemical selectivity was inadequate to clearly separate the effects of chemical on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	T4	T16	10381787
CPR:4	CHEMICAL	GENE-Y	5	9	Although the IC50 value of chemical for inhibition of gene was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of chemical on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	T3	T15	10381787
NA	CHEMICAL	GENE-Y	5	9	Although the IC50 value of chemical for inhibition of gene was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of chemical on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels.	T4	T15	10381787
NA	CHEMICAL	GENE-N	21	9	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and gene (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and chemical (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T24	T58	10432475
NA	CHEMICAL	GENE-Y	21	7	(-)-Pindolol, which possesses significant affinity for 5-HT1A, gene, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and chemical (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T24	T56	10432475
NA	CHEMICAL	GENE-Y	21	6	(-)-Pindolol, which possesses significant affinity for gene, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and chemical (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T24	T54	10432475
NA	CHEMICAL	GENE-N	21	12	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors gene, dose-dependently increased extracellular levels of dopamine (DA) and chemical (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T24	T48	10432475
NA	CHEMICAL	GENE-N	0	9	chemical, which possesses significant affinity for 5-HT1A, 5-HT1B, and gene (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T1	T58	10432475
NA	CHEMICAL	GENE-Y	0	7	chemical, which possesses significant affinity for 5-HT1A, gene, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T1	T56	10432475
NA	CHEMICAL	GENE-Y	0	6	chemical, which possesses significant affinity for gene, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T1	T54	10432475
NA	CHEMICAL	GENE-N	0	12	chemical, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors gene, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T1	T48	10432475
NA	CHEMICAL	GENE-N	18	9	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and gene (AR)s, dose-dependently increased extracellular levels of chemical (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T21	T58	10432475
NA	CHEMICAL	GENE-Y	18	7	(-)-Pindolol, which possesses significant affinity for 5-HT1A, gene, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of chemical (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T21	T56	10432475
NA	CHEMICAL	GENE-Y	18	6	(-)-Pindolol, which possesses significant affinity for gene, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of chemical (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T21	T54	10432475
NA	CHEMICAL	GENE-N	18	12	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors gene, dose-dependently increased extracellular levels of chemical (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T21	T48	10432475
NA	CHEMICAL	GENE-N	6	9	(-)-Pindolol, which possesses significant affinity for chemical1A, chemical1B, and gene (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus chemical, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T26	T58	10432475
NA	CHEMICAL	GENE-N	6	12	(-)-Pindolol, which possesses significant affinity for chemical1A, chemical1B, and beta 1/2-adrenergic receptors gene, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus chemical, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T26	T48	10432475
NA	CHEMICAL	GENE-N	22	9	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and gene (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (chemical) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T25	T58	10432475
NA	CHEMICAL	GENE-Y	22	7	(-)-Pindolol, which possesses significant affinity for 5-HT1A, gene, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (chemical) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T25	T56	10432475
NA	CHEMICAL	GENE-Y	22	6	(-)-Pindolol, which possesses significant affinity for gene, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (chemical) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T25	T54	10432475
NA	CHEMICAL	GENE-N	22	12	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors gene, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (chemical) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T25	T48	10432475
NA	CHEMICAL	GENE-N	19	9	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and gene (AR)s, dose-dependently increased extracellular levels of dopamine (chemical) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T22	T58	10432475
NA	CHEMICAL	GENE-Y	19	7	(-)-Pindolol, which possesses significant affinity for 5-HT1A, gene, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (chemical) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T22	T56	10432475
NA	CHEMICAL	GENE-Y	19	6	(-)-Pindolol, which possesses significant affinity for gene, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (chemical) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T22	T54	10432475
NA	CHEMICAL	GENE-N	19	12	(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors gene, dose-dependently increased extracellular levels of dopamine (chemical) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.	T22	T48	10432475
NA	CHEMICAL	GENE-Y	14	4	In distinction, the preferential gene antagonist, betaxolol, and the preferential beta 2-AR antagonist, chemical, did not increase basal levels of DA, NAD, or 5-HT.	T28	T52	10432475
CPR:6	CHEMICAL	GENE-Y	14	11	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential gene antagonist, chemical, did not increase basal levels of DA, NAD, or 5-HT.	T28	T53	10432475
CPR:6	CHEMICAL	GENE-Y	7	4	In distinction, the preferential gene antagonist, chemical, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.	T27	T52	10432475
NA	CHEMICAL	GENE-Y	7	11	In distinction, the preferential beta 1-AR antagonist, chemical, and the preferential gene antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.	T27	T53	10432475
NA	CHEMICAL	GENE-Y	24	4	In distinction, the preferential gene antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or chemical.	T31	T52	10432475
NA	CHEMICAL	GENE-Y	24	11	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential gene antagonist, ICI118,551, did not increase basal levels of DA, NAD, or chemical.	T31	T53	10432475
NA	CHEMICAL	GENE-Y	22	4	In distinction, the preferential gene antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, chemical, or 5-HT.	T30	T52	10432475
NA	CHEMICAL	GENE-Y	22	11	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential gene antagonist, ICI118,551, did not increase basal levels of DA, chemical, or 5-HT.	T30	T53	10432475
NA	CHEMICAL	GENE-Y	21	4	In distinction, the preferential gene antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of chemical, NAD, or 5-HT.	T29	T52	10432475
NA	CHEMICAL	GENE-Y	21	11	In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential gene antagonist, ICI118,551, did not increase basal levels of chemical, NAD, or 5-HT.	T29	T53	10432475
NA	CHEMICAL	GENE-Y	9	19	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the chemical-induced increase in DA and NAD levels, while the selective gene antagonist, SB224,289, was ineffective.	T36	T57	10432475
NA	CHEMICAL	GENE-Y	9	2	The selective gene receptor antagonist, WAY100,635, slightly attenuated the chemical-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	T36	T55	10432475
NA	CHEMICAL	GENE-Y	5	19	The selective 5-HT1A receptor antagonist, chemical, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective gene antagonist, SB224,289, was ineffective.	T35	T57	10432475
CPR:6	CHEMICAL	GENE-Y	5	2	The selective gene receptor antagonist, chemical, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	T35	T55	10432475
CPR:6	CHEMICAL	GENE-Y	21	19	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective gene antagonist, chemical, was ineffective.	T39	T57	10432475
NA	CHEMICAL	GENE-Y	21	2	The selective gene receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, chemical, was ineffective.	T39	T55	10432475
NA	CHEMICAL	GENE-Y	14	19	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and chemical levels, while the selective gene antagonist, SB224,289, was ineffective.	T38	T57	10432475
NA	CHEMICAL	GENE-Y	14	2	The selective gene receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and chemical levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	T38	T55	10432475
NA	CHEMICAL	GENE-Y	12	19	The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in chemical and NAD levels, while the selective gene antagonist, SB224,289, was ineffective.	T37	T57	10432475
NA	CHEMICAL	GENE-Y	12	2	The selective gene receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in chemical and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.	T37	T55	10432475
NA	CHEMICAL	GENE-N	4	15	These data suggest that chemical facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of gene and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas 5-HT1B receptors are not involved.	T40	T59	10432475
NA	CHEMICAL	GENE-Y	4	28	These data suggest that chemical facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of 5-HT1A receptors, whereas gene receptors are not involved.	T40	T47	10432475
NA	CHEMICAL	GENE-Y	4	25	These data suggest that chemical facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of beta 1/2-ARs and, to a lesser degree, by stimulation of gene receptors, whereas 5-HT1B receptors are not involved.	T40	T60	10432475
NA	CHEMICAL	GENE-N	2	27	In conclusion, chemical modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at gene, 5-HT1A, and 5-HT1B receptors.	T19	T49	10432475
NA	CHEMICAL	GENE-Y	2	31	In conclusion, chemical modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and gene receptors.	T19	T51	10432475
NA	CHEMICAL	GENE-Y	2	29	In conclusion, chemical modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, gene, and 5-HT1B receptors.	T19	T50	10432475
NA	CHEMICAL	GENE-N	9	27	In conclusion, (-)-pindolol modulates, both alone and together with chemical reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at gene, chemical1A, and chemical1B receptors.	T20	T49	10432475
CPR:4	CHEMICAL	GENE-Y	1	8	UNLABELLED: chemical is a potent and specific peripheral gene (COMT) inhibitor.	T5	T26	10439935
CPR:4	CHEMICAL	GENE-Y	1	9	UNLABELLED: chemical is a potent and specific peripheral catechol-O-methyltransferase (gene) inhibitor.	T5	T28	10439935
NA	CHEMICAL	GENE-Y	8	9	UNLABELLED: Entacapone is a potent and specific peripheral chemical-O-methyltransferase (gene) inhibitor.	T15	T28	10439935
NA	CHEMICAL	GENE-Y	13	18	It has been shown to improve the clinical benefits of levodopa plus an chemical decarboxylase inhibitor (gene) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to levodopa (the 'wearing off' phenomenon).	T9	T25	10439935
NA	CHEMICAL	GENE-Y	10	13	It has been shown to improve the clinical benefits of chemical plus an gene inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to chemical (the 'wearing off' phenomenon).	T12	T24	10439935
NA	CHEMICAL	GENE-Y	10	13	It has been shown to improve the clinical benefits of chemical plus an gene inhibitor (AADC) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to chemical (the 'wearing off' phenomenon).	T7	T24	10439935
NA	CHEMICAL	GENE-Y	10	18	It has been shown to improve the clinical benefits of chemical plus an aromatic L-amino acid decarboxylase inhibitor (gene) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to chemical (the 'wearing off' phenomenon).	T12	T25	10439935
NA	CHEMICAL	GENE-Y	10	18	It has been shown to improve the clinical benefits of chemical plus an aromatic L-amino acid decarboxylase inhibitor (gene) when given to patients with Parkinson's disease and end-of-dose deterioration in the response to chemical (the 'wearing off' phenomenon).	T7	T25	10439935
NA	CHEMICAL	GENE-Y	16	23	In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with chemical (200 mg with each dose of levodopa/gene inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.	T14	T27	10439935
NA	CHEMICAL	GENE-Y	23	23	In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with entacapone (200 mg with each dose of chemical/gene inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.	T16	T27	10439935
NA	CHEMICAL	GENE-Y	0	10	chemical also provided benefits when given with controlled release levodopa/ gene inhibitor or with standard levodopa/gene inhibitor and selegiline in small trials.	T19	T21	10439935
NA	CHEMICAL	GENE-Y	0	10	chemical also provided benefits when given with controlled release levodopa/ gene inhibitor or with standard levodopa/gene inhibitor and selegiline in small trials.	T19	T22	10439935
NA	CHEMICAL	GENE-Y	18	10	Entacapone also provided benefits when given with controlled release levodopa/ gene inhibitor or with standard levodopa/gene inhibitor and chemical in small trials.	T3	T21	10439935
NA	CHEMICAL	GENE-Y	18	10	Entacapone also provided benefits when given with controlled release levodopa/ gene inhibitor or with standard levodopa/gene inhibitor and chemical in small trials.	T3	T22	10439935
NA	CHEMICAL	GENE-Y	9	10	Entacapone also provided benefits when given with controlled release chemical/ gene inhibitor or with standard chemical/gene inhibitor and selegiline in small trials.	T1	T21	10439935
NA	CHEMICAL	GENE-Y	9	10	Entacapone also provided benefits when given with controlled release chemical/ gene inhibitor or with standard chemical/gene inhibitor and selegiline in small trials.	T1	T22	10439935
NA	CHEMICAL	GENE-Y	9	10	Entacapone also provided benefits when given with controlled release chemical/ gene inhibitor or with standard chemical/gene inhibitor and selegiline in small trials.	T2	T21	10439935
NA	CHEMICAL	GENE-Y	9	10	Entacapone also provided benefits when given with controlled release chemical/ gene inhibitor or with standard chemical/gene inhibitor and selegiline in small trials.	T2	T22	10439935
NA	CHEMICAL	GENE-Y	9	9	CONCLUSIONS: The efficacy and tolerability of entacapone administered with chemical/gene inhibitor have not yet been compared with those of other strategies for the treatment of Parkinson's disease.	T8	T23	10439935
CPR:9	CHEMICAL	GENE-Y	3	6	Activation of endothelial chemical synthase (gene) results in the production of chemical (NO) that mediates the vasorelaxing properties of endothelial cells.	T19	T38	10460702
NA	CHEMICAL	GENE-Y	3	6	Activation of endothelial chemical synthase (gene) results in the production of chemical (NO) that mediates the vasorelaxing properties of endothelial cells.	T9	T38	10460702
CPR:9	CHEMICAL	GENE-Y	6	2	Activation of gene (echemicalS) results in the production of nitric oxide (chemical) that mediates the vasorelaxing properties of endothelial cells.	T20	T32	10460702
NA	CHEMICAL	GENE-Y	11	14	The goal of this project was to address the possibility that chemical (5-HT) stimulates gene activity in bovine aortic endothelial cell (BAEC) cultures.	T7	T35	10460702
NA	CHEMICAL	GENE-Y	12	14	The goal of this project was to address the possibility that 5-hydroxytryptamine (chemical) stimulates gene activity in bovine aortic endothelial cell (BAEC) cultures.	T8	T35	10460702
NA	CHEMICAL	GENE-N	14	6	Here, we tested the hypothesis that gene mediate eNOS activation by measuring agonist-stimulated chemical ([3H]L-Cit) formation in BAEC cultures.	T11	T36	10460702
CPR:9	CHEMICAL	GENE-Y	14	9	Here, we tested the hypothesis that 5-HT receptors mediate gene activation by measuring agonist-stimulated chemical ([3H]L-Cit) formation in BAEC cultures.	T11	T37	10460702
NA	CHEMICAL	GENE-N	15	6	Here, we tested the hypothesis that gene mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline (chemical) formation in BAEC cultures.	T12	T36	10460702
CPR:9	CHEMICAL	GENE-Y	15	9	Here, we tested the hypothesis that 5-HT receptors mediate gene activation by measuring agonist-stimulated [3H]L-citrulline (chemical) formation in BAEC cultures.	T12	T37	10460702
NA	CHEMICAL	GENE-Y	6	9	Here, we tested the hypothesis that chemical receptors mediate gene activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures.	T10	T37	10460702
CPR:9	CHEMICAL	GENE-Y	8	13	We found that 5-HT stimulated the conversion of chemical ([3H]L-Arg) to [3H]L-Cit, indicating gene activation.	T14	T39	10460702
CPR:9	CHEMICAL	GENE-Y	11	13	We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to chemical, indicating gene activation.	T16	T39	10460702
CPR:9	CHEMICAL	GENE-Y	9	13	We found that 5-HT stimulated the conversion of [3H]L-arginine (chemical) to [3H]L-Cit, indicating gene activation.	T15	T39	10460702
CPR:3	CHEMICAL	GENE-Y	3	13	We found that chemical stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating gene activation.	T13	T39	10460702
CPR:5	CHEMICAL	GENE-Y	6	3	The high affinity gene receptor agonist, chemical (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.	T17	T40	10460702
NA	CHEMICAL	GENE-Y	8	3	The high affinity gene receptor agonist, 5-nonyloxytryptamine (5-NOT)-stimulated chemical turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.	T18	T40	10460702
NA	CHEMICAL	GENE-N	27	12	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/gene antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and chemical (L-NIO).	T3	T43	10460702
NA	CHEMICAL	GENE-Y	27	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and chemical (L-NIO).	T3	T41	10460702
NA	CHEMICAL	GENE-Y	27	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and chemical (L-NIO).	T3	T42	10460702
CPR:6	CHEMICAL	GENE-Y	27	18	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the gene selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and chemical (L-NIO).	T3	T24	10460702
NA	CHEMICAL	GENE-N	23	12	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/gene antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): chemical (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T1	T43	10460702
NA	CHEMICAL	GENE-Y	23	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): chemical (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T1	T41	10460702
NA	CHEMICAL	GENE-Y	23	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): chemical (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T1	T42	10460702
CPR:6	CHEMICAL	GENE-Y	23	18	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the gene selective antagonists (0.01-10 microM): chemical (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T1	T24	10460702
CPR:6	CHEMICAL	GENE-N	15	12	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/gene antagonist, chemical, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T21	T43	10460702
NA	CHEMICAL	GENE-Y	15	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, chemical, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T21	T41	10460702
CPR:6	CHEMICAL	GENE-Y	15	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, chemical, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T21	T42	10460702
NA	CHEMICAL	GENE-Y	15	18	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, chemical, and the gene selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T21	T24	10460702
NA	CHEMICAL	GENE-N	25	12	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/gene antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (chemical) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T2	T43	10460702
NA	CHEMICAL	GENE-Y	25	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (chemical) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T2	T41	10460702
NA	CHEMICAL	GENE-Y	25	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (chemical) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T2	T42	10460702
CPR:6	CHEMICAL	GENE-Y	25	18	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the gene selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (chemical) and L-N omega-iminoethyl-L-ornithine (L-NIO).	T2	T24	10460702
NA	CHEMICAL	GENE-N	29	12	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/gene antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (chemical).	T4	T43	10460702
NA	CHEMICAL	GENE-Y	29	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (chemical).	T4	T41	10460702
NA	CHEMICAL	GENE-Y	29	7	These responses were effectively blocked by the gene receptor antagonist, isamoltane, the gene/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (chemical).	T4	T42	10460702
CPR:6	CHEMICAL	GENE-Y	29	18	These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the gene selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (chemical).	T4	T24	10460702
NA	CHEMICAL	GENE-Y	6	7	These findings lend evidence of a chemical1B receptor/gene pathway, accounting in part for the activation of gene by chemical.	T5	T30	10460702
CPR:3	CHEMICAL	GENE-Y	6	7	These findings lend evidence of a chemical1B receptor/gene pathway, accounting in part for the activation of gene by chemical.	T5	T31	10460702
NA	CHEMICAL	GENE-Y	11	17	Further investigation is needed to determine the role of other vascular chemical receptors in the stimulation of gene activity.	T6	T34	10460702
NA	CHEMICAL	GENE-N	19	8	We report that the radiation-induced activation of the gene Cds1 [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that ATM gene activity is directly inhibited by chemical in vitro.	T1	T10	10531013
CPR:4	CHEMICAL	GENE-N	19	8	We report that the radiation-induced activation of the gene Cds1 [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that ATM gene activity is directly inhibited by chemical in vitro.	T1	T8	10531013
CPR:4	CHEMICAL	GENE-N	19	8	We report that the radiation-induced activation of the gene Cds1 [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that ATM gene activity is directly inhibited by chemical in vitro.	T5	T10	10531013
NA	CHEMICAL	GENE-N	19	8	We report that the radiation-induced activation of the gene Cds1 [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that ATM gene activity is directly inhibited by chemical in vitro.	T5	T8	10531013
NA	CHEMICAL	GENE-Y	19	9	We report that the radiation-induced activation of the kinase gene [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that ATM kinase activity is directly inhibited by chemical in vitro.	T1	T11	10531013
CPR:4	CHEMICAL	GENE-Y	19	9	We report that the radiation-induced activation of the kinase gene [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that ATM kinase activity is directly inhibited by chemical in vitro.	T5	T11	10531013
NA	CHEMICAL	GENE-Y	19	14	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as gene [5]) is inhibited by chemical in vivo and that ATM kinase activity is directly inhibited by chemical in vitro.	T1	T12	10531013
CPR:4	CHEMICAL	GENE-Y	19	14	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as gene [5]) is inhibited by chemical in vivo and that ATM kinase activity is directly inhibited by chemical in vitro.	T5	T12	10531013
CPR:4	CHEMICAL	GENE-Y	19	24	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that gene kinase activity is directly inhibited by chemical in vitro.	T1	T7	10531013
NA	CHEMICAL	GENE-Y	19	24	We report that the radiation-induced activation of the kinase Cds1 [4] (also known as Chk2 [5]) is inhibited by chemical in vivo and that gene kinase activity is directly inhibited by chemical in vitro.	T5	T7	10531013
CPR:4	CHEMICAL	GENE-Y	20	2	Inhibition of gene provides a molecular explanation of the attenuation of DNA-damage checkpoint responses and for the increased radiosensitivity of chemical-treated cells [6] [7] [8].	T2	T9	10531013
NA	CHEMICAL	GENE-Y	12	14	The objective of this study was to examine the turnover of the chemical transporter (gene) by determining its production rate (r), degradation rate constant (k) and half-life of recovery (t1/2).	T6	T18	10546982
CPR:4	CHEMICAL	GENE-Y	16	3	The turnover of gene was determined from the rate of recovery of binding after administration of chemical, an irreversible inhibitor of ligand binding.	T2	T12	10546982
CPR:4	CHEMICAL	GENE-Y	11	20	In preliminary studies, in vitro incubation of rat cerebral cortex with chemical produced a wash and temperature resistant inhibition of gene binding densities (Bmax).	T3	T13	10546982
NA	CHEMICAL	GENE-Y	0	7	chemical protected against the RTI-76-induced inhibition of gene binding.	T4	T14	10546982
CPR:4	CHEMICAL	GENE-Y	4	7	Citalopram protected against the chemical-induced inhibition of gene binding.	T5	T14	10546982
NA	CHEMICAL	GENE-Y	12	23	Following 6 h of in vivo intracerebroventricular injections of 100 nmol of chemical, there was a dose- and time-dependent reduction (- 60%) of gene binding in hippocampus and striatum, without a change in the Kd.	T7	T16	10546982
CPR:9	CHEMICAL	GENE-Y	5	16	The decrease and recovery of chemical uptake correlated highly (r = 0.93) with the recovery of gene binding.	T1	T11	10546982
NA	CHEMICAL	GENE-Y	11	58	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the gene inhibitors.	T18	T41	10579749
NA	CHEMICAL	GENE-Y	11	58	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the gene inhibitors.	T29	T41	10579749
NA	CHEMICAL	GENE-Y	11	58	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the gene inhibitors.	T40	T41	10579749
NA	CHEMICAL	GENE-Y	11	30	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T18	T37	10579749
NA	CHEMICAL	GENE-Y	11	30	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T29	T37	10579749
NA	CHEMICAL	GENE-Y	11	30	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T40	T37	10579749
NA	CHEMICAL	GENE-Y	11	15	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the gene receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T18	T39	10579749
NA	CHEMICAL	GENE-Y	11	15	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the gene receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T29	T39	10579749
NA	CHEMICAL	GENE-Y	11	15	The availability of selective, potent, orally active and long acting nonpeptide chemical type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the gene receptor that mediates most, if not all, of the important actions of chemical, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T40	T39	10579749
NA	CHEMICAL	GENE-Y	11	30	The availability of selective, potent, orally active and long acting nonpeptide chemicalI type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-angiotensin-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemicalI, and avoid the nonspecificity of the chemical converting enzyme inhibitors.	T19	T37	10579749
NA	CHEMICAL	GENE-Y	11	15	The availability of selective, potent, orally active and long acting nonpeptide chemicalI type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-aldosterone system at the level of the gene receptor that mediates most, if not all, of the important actions of chemicalI, and avoid the nonspecificity of the chemical converting enzyme inhibitors.	T19	T39	10579749
NA	CHEMICAL	GENE-Y	30	11	The availability of selective, potent, orally active and long acting nonpeptide gene antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T17	T43	10579749
NA	CHEMICAL	GENE-Y	30	58	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the gene inhibitors.	T17	T41	10579749
NA	CHEMICAL	GENE-Y	30	11	The availability of selective, potent, orally active and long acting nonpeptide gene type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of gene, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T17	T18	10579749
NA	CHEMICAL	GENE-Y	30	11	The availability of selective, potent, orally active and long acting nonpeptide gene type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of gene, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T17	T29	10579749
NA	CHEMICAL	GENE-Y	30	11	The availability of selective, potent, orally active and long acting nonpeptide gene type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of gene, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T17	T40	10579749
NA	CHEMICAL	GENE-Y	30	11	The availability of selective, potent, orally active and long acting nonpeptide gene II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-gene-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of gene II, and avoid the nonspecificity of the gene I converting enzyme inhibitors.	T17	T16	10579749
NA	CHEMICAL	GENE-Y	30	11	The availability of selective, potent, orally active and long acting nonpeptide gene II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-gene-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of gene II, and avoid the nonspecificity of the gene I converting enzyme inhibitors.	T17	T38	10579749
NA	CHEMICAL	GENE-Y	30	30	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-angiotensin-chemical system at the level of the AT1 receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T17	T37	10579749
NA	CHEMICAL	GENE-Y	30	15	The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-angiotensin-chemical system at the level of the gene receptor that mediates most, if not all, of the important actions of angiotensin II, and avoid the nonspecificity of the angiotensin I converting enzyme inhibitors.	T17	T39	10579749
NA	CHEMICAL	GENE-Y	11	30	The availability of selective, potent, orally active and long acting nonpeptide chemical II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-chemical-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical II, and avoid the nonspecificity of the chemical I converting enzyme inhibitors.	T16	T37	10579749
NA	CHEMICAL	GENE-Y	11	30	The availability of selective, potent, orally active and long acting nonpeptide chemical II type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the gene-chemical-aldosterone system at the level of the AT1 receptor that mediates most, if not all, of the important actions of chemical II, and avoid the nonspecificity of the chemical I converting enzyme inhibitors.	T38	T37	10579749
NA	CHEMICAL	GENE-Y	11	15	The availability of selective, potent, orally active and long acting nonpeptide chemical II type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-chemical-aldosterone system at the level of the gene receptor that mediates most, if not all, of the important actions of chemical II, and avoid the nonspecificity of the chemical I converting enzyme inhibitors.	T16	T39	10579749
NA	CHEMICAL	GENE-Y	11	15	The availability of selective, potent, orally active and long acting nonpeptide chemical II type 1 (gene) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the renin-chemical-aldosterone system at the level of the gene receptor that mediates most, if not all, of the important actions of chemical II, and avoid the nonspecificity of the chemical I converting enzyme inhibitors.	T38	T39	10579749
CPR:6	CHEMICAL	GENE-Y	0	11	chemical was the first, but by no means remained the only, gene receptor antagonist.	T20	T42	10579749
CPR:6	CHEMICAL	GENE-Y	39	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug chemical 280.	T5	T44	10579749
CPR:6	CHEMICAL	GENE-Y	21	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, chemical 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	T31	T44	10579749
CPR:6	CHEMICAL	GENE-Y	19	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: chemical 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug chemical cilexetil 280.	T30	T44	10579749
CPR:6	CHEMICAL	GENE-Y	30	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, chemical 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	T2	T44	10579749
CPR:6	CHEMICAL	GENE-Y	34	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of losartan) 10, tasosartan 20, losartan 50, chemical 100 and the prodrug candesartan cilexetil 280.	T4	T44	10579749
CPR:6	CHEMICAL	GENE-Y	28	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of chemical) 10, tasosartan 20, chemical 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	T1	T44	10579749
CPR:6	CHEMICAL	GENE-Y	28	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, E3174 (the active metabolite of chemical) 10, tasosartan 20, chemical 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	T3	T44	10579749
CPR:6	CHEMICAL	GENE-Y	23	3	Among the current gene receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: candesartan 1, telmisartan 10, chemical (the active metabolite of losartan) 10, tasosartan 20, losartan 50, eprosartan 100 and the prodrug candesartan cilexetil 280.	T32	T44	10579749
CPR:6	CHEMICAL	GENE-Y	18	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, chemical, zolasartan, irbesartan, valsartan, telmisartan, E3174).	T10	T34	10579749
CPR:6	CHEMICAL	GENE-Y	22	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, chemical, E3174).	T14	T34	10579749
CPR:6	CHEMICAL	GENE-Y	17	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (chemical, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	T9	T34	10579749
CPR:6	CHEMICAL	GENE-Y	13	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, chemical, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	T7	T34	10579749
CPR:6	CHEMICAL	GENE-Y	19	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, chemical, irbesartan, valsartan, telmisartan, E3174).	T11	T34	10579749
CPR:6	CHEMICAL	GENE-Y	20	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, chemical, valsartan, telmisartan, E3174).	T12	T34	10579749
CPR:6	CHEMICAL	GENE-Y	14	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, chemical) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	T8	T34	10579749
CPR:6	CHEMICAL	GENE-Y	21	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, chemical, telmisartan, E3174).	T13	T34	10579749
CPR:6	CHEMICAL	GENE-Y	12	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (chemical, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, E3174).	T6	T34	10579749
CPR:6	CHEMICAL	GENE-Y	23	4	The mode of (functional) gene receptor antagonism has been characterized as surmountable/noncompetitive (losartan, tasosartan, eprosartan) or insurmountable/noncompetitive (candesartan, saprisartan, zolasartan, irbesartan, valsartan, telmisartan, chemical).	T15	T34	10579749
NA	CHEMICAL	GENE-Y	26	12	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with gene (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (chemical, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T6	T16	10637238
NA	CHEMICAL	GENE-Y	26	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (chemical, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T6	T17	10637238
NA	CHEMICAL	GENE-Y	26	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (chemical, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T6	T18	10637238
NA	CHEMICAL	GENE-Y	43	12	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with gene (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markchemical; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T11	T16	10637238
NA	CHEMICAL	GENE-Y	43	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markchemical; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T11	T17	10637238
NA	CHEMICAL	GENE-Y	43	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markchemical; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T11	T18	10637238
NA	CHEMICAL	GENE-Y	29	12	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with gene (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and chemical inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T8	T16	10637238
NA	CHEMICAL	GENE-Y	29	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and chemical inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T8	T17	10637238
NA	CHEMICAL	GENE-Y	29	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and chemical inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T8	T18	10637238
NA	CHEMICAL	GENE-Y	27	12	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with gene (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, chemical, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T7	T16	10637238
NA	CHEMICAL	GENE-Y	27	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, chemical, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T7	T17	10637238
NA	CHEMICAL	GENE-Y	27	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, chemical, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T7	T18	10637238
NA	CHEMICAL	GENE-Y	40	12	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with gene (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and chemical inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T10	T16	10637238
NA	CHEMICAL	GENE-Y	40	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and chemical inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T10	T17	10637238
NA	CHEMICAL	GENE-Y	40	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and chemical inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T10	T18	10637238
NA	CHEMICAL	GENE-Y	38	12	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with gene (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus chemical and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T9	T16	10637238
NA	CHEMICAL	GENE-Y	38	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus chemical and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T9	T17	10637238
NA	CHEMICAL	GENE-Y	38	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus chemical and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T9	T18	10637238
NA	CHEMICAL	GENE-Y	12	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with chemical receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T5	T17	10637238
NA	CHEMICAL	GENE-Y	12	14	PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with chemical receptor (gene)-positive or gene-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil inverted question markCAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin inverted question markfluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI inverted question markCAFTH) as front-line therapy for metastatic breast cancer.	T5	T18	10637238
CPR:9	CHEMICAL	GENE-N	11	0	gene are flavoproteins that catalyze two-electron reduction and detoxification of chemical.	T2	T19	10683249
NA	CHEMICAL	GENE-Y	4	14	Two cytosolic forms of chemical oxidoreductases [NAD(P)H:chemical oxidoreductase 1 (NQO1) and NRH:chemical oxidoreductase 2 (gene)] were previously identified, purified, and cloned.	T10	T28	10683249
NA	CHEMICAL	GENE-Y	4	14	Two cytosolic forms of chemical oxidoreductases [NAD(P)H:chemical oxidoreductase 1 (NQO1) and NRH:chemical oxidoreductase 2 (gene)] were previously identified, purified, and cloned.	T7	T28	10683249
NA	CHEMICAL	GENE-Y	4	14	Two cytosolic forms of chemical oxidoreductases [NAD(P)H:chemical oxidoreductase 1 (NQO1) and NRH:chemical oxidoreductase 2 (gene)] were previously identified, purified, and cloned.	T9	T28	10683249
NA	CHEMICAL	GENE-Y	4	9	Two cytosolic forms of chemical oxidoreductases [NAD(P)H:chemical oxidoreductase 1 (gene) and NRH:chemical oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	T10	T26	10683249
NA	CHEMICAL	GENE-Y	4	9	Two cytosolic forms of chemical oxidoreductases [NAD(P)H:chemical oxidoreductase 1 (gene) and NRH:chemical oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	T7	T26	10683249
NA	CHEMICAL	GENE-Y	4	9	Two cytosolic forms of chemical oxidoreductases [NAD(P)H:chemical oxidoreductase 1 (gene) and NRH:chemical oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	T9	T26	10683249
NA	CHEMICAL	GENE-Y	6	11	Two cytosolic forms of quinone oxidoreductases [chemical:quinone oxidoreductase 1 (NQO1) and gene (NQO2)] were previously identified, purified, and cloned.	T8	T27	10683249
NA	CHEMICAL	GENE-N	6	4	Two cytosolic forms of gene [chemical:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	T8	T24	10683249
NA	CHEMICAL	GENE-Y	6	14	Two cytosolic forms of quinone oxidoreductases [chemical:quinone oxidoreductase 1 (NQO1) and NRH:quinone oxidoreductase 2 (gene)] were previously identified, purified, and cloned.	T8	T28	10683249
NA	CHEMICAL	GENE-Y	6	9	Two cytosolic forms of quinone oxidoreductases [chemical:quinone oxidoreductase 1 (gene) and NRH:quinone oxidoreductase 2 (NQO2)] were previously identified, purified, and cloned.	T8	T26	10683249
CPR:9	CHEMICAL	GENE-Y	16	4	A role of cytosolic gene in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of chemical was established.	T11	T29	10683249
CPR:9	CHEMICAL	GENE-N	18	1	The gene activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of chemical and menadione.	T14	T33	10683249
CPR:9	CHEMICAL	GENE-N	20	1	The gene activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and chemical.	T15	T33	10683249
NA	CHEMICAL	GENE-N	10	1	The gene activity showed significantly higher affinity for NADH than chemical as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.	T13	T33	10683249
NA	CHEMICAL	GENE-N	8	1	The gene activity showed significantly higher affinity for chemical than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.	T12	T33	10683249
NA	CHEMICAL	GENE-N	6	1	The gene activity was insensitive to chemical, a potent inhibitor of cytosolic NQO1.	T16	T34	10683249
CPR:4	CHEMICAL	GENE-Y	6	12	The mNQO activity was insensitive to chemical, a potent inhibitor of cytosolic gene.	T16	T35	10683249
NA	CHEMICAL	GENE-N	13	1	The gene activity was partially purified by solubilization of microsomes with detergent Chaps, chemical fractionation, and DEAE-Sephacel column chromatography.	T3	T21	10683249
NA	CHEMICAL	GENE-N	17	1	The gene activity was partially purified by solubilization of microsomes with detergent Chaps, ammonium sulfate fractionation, and chemical-Sephacel column chromatography.	T4	T21	10683249
NA	CHEMICAL	GENE-N	14	2	The microsomal gene proteins are expected to provide additional protection after cytosolic NQOs against chemical toxicity and mutagenicity.	T5	T22	10683249
NA	CHEMICAL	GENE-N	14	12	The microsomal mNQO proteins are expected to provide additional protection after cytosolic gene against chemical toxicity and mutagenicity.	T5	T23	10683249
NA	CHEMICAL	GENE-Y	19	11	The affinity and functional profile of opioids possessing activity at the gene was determined using [3H]nociceptin and nociceptin-stimulated chemical binding.	T4	T31	10688973
CPR:5	CHEMICAL	GENE-Y	4	1	The gene-selective agonist chemical potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).	T5	T32	10688973
NA	CHEMICAL	GENE-N	7	12	Lofentanil exhibited full agonism for enhancement of chemical binding to human recombinant gene receptors (EC(50) 50 nM).	T7	T33	10688973
NA	CHEMICAL	GENE-Y	7	12	Lofentanil exhibited full agonism for enhancement of chemical binding to human recombinant gene receptors (EC(50) 50 nM).	T7	T33	10688973
CPR:5	CHEMICAL	GENE-N	0	12	chemical exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant gene receptors (EC(50) 50 nM).	T6	T33	10688973
CPR:5	CHEMICAL	GENE-Y	0	12	chemical exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant gene receptors (EC(50) 50 nM).	T6	T33	10688973
CPR:5	CHEMICAL	GENE-Y	3	16	The related piperidines chemical and sufentanil and the nonselective opioid receptor agonist etorphine were less potent gene agonists.	T9	T36	10688973
NA	CHEMICAL	GENE-N	3	9	The related piperidines chemical and sufentanil and the nonselective gene agonist etorphine were less potent nociceptin receptor agonists.	T9	T35	10688973
CPR:5	CHEMICAL	GENE-Y	2	16	The related chemical ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent gene agonists.	T8	T36	10688973
NA	CHEMICAL	GENE-N	2	9	The related chemical ohmefentanyl and sufentanil and the nonselective gene agonist etorphine were less potent nociceptin receptor agonists.	T8	T35	10688973
CPR:5	CHEMICAL	GENE-Y	5	16	The related piperidines ohmefentanyl and chemical and the nonselective opioid receptor agonist etorphine were less potent gene agonists.	T10	T36	10688973
NA	CHEMICAL	GENE-N	5	9	The related piperidines ohmefentanyl and chemical and the nonselective gene agonist etorphine were less potent nociceptin receptor agonists.	T10	T35	10688973
CPR:5	CHEMICAL	GENE-Y	12	16	The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist chemical were less potent gene agonists.	T11	T36	10688973
CPR:5	CHEMICAL	GENE-N	12	9	The related piperidines ohmefentanyl and sufentanil and the nonselective gene agonist chemical were less potent nociceptin receptor agonists.	T11	T35	10688973
CPR:6	CHEMICAL	GENE-Y	6	3	The kappa(1)+kappa(3)-opioid receptor agonist/gene antagonist chemical was a pure antagonist at both rat brain and human ORL1 receptors.	T12	T37	10688973
CPR:6	CHEMICAL	GENE-N	6	18	The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist chemical was a pure antagonist at both rat brain and human gene receptors.	T12	T14	10688973
CPR:6	CHEMICAL	GENE-Y	6	18	The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist chemical was a pure antagonist at both rat brain and human gene receptors.	T12	T14	10688973
NA	CHEMICAL	GENE-N	13	2	The nonselective gene partial agonist buprenorphine and the nonselective gene antagonist chemical exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	T2	T15	10688973
CPR:6	CHEMICAL	GENE-N	13	2	The nonselective gene partial agonist buprenorphine and the nonselective gene antagonist chemical exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	T2	T16	10688973
CPR:5	CHEMICAL	GENE-Y	13	26	The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist chemical exhibited pure antagonism at rat brain receptors, but displayed partial agonism at gene receptors.	T2	T19	10688973
CPR:5	CHEMICAL	GENE-N	6	2	The nonselective gene partial agonist chemical and the nonselective gene antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	T1	T15	10688973
NA	CHEMICAL	GENE-N	6	2	The nonselective gene partial agonist chemical and the nonselective gene antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.	T1	T16	10688973
NA	CHEMICAL	GENE-Y	6	26	The nonselective opioid receptor partial agonist chemical and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at gene receptors.	T1	T19	10688973
NA	CHEMICAL	GENE-Y	17	14	In addition, the stereospecificity required at opioid receptors appears to be retained at the gene, since chemical is inactive at both receptors.	T3	T25	10688973
NA	CHEMICAL	GENE-N	17	6	In addition, the stereospecificity required at gene appears to be retained at the nociceptin receptor, since chemical is inactive at both receptors.	T3	T24	10688973
CPR:9	CHEMICAL	GENE-Y	17	0	gene and thymidine kinase are key enzymes involved in the de novo and salvage pathways for chemical synthesis, respectively.	T2	T20	10697523
CPR:9	CHEMICAL	GENE-Y	17	3	Thymidylate synthase and gene are key enzymes involved in the de novo and salvage pathways for chemical synthesis, respectively.	T2	T22	10697523
NA	CHEMICAL	GENE-Y	0	3	chemical synthase and gene are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.	T1	T22	10697523
NA	CHEMICAL	GENE-Y	3	0	gene and chemical kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.	T5	T20	10697523
CPR:4	CHEMICAL	GENE-Y	5	0	gene is inhibited by chemical, forming an inactive ternary complex with intracellular folate.	T4	T21	10697523
NA	CHEMICAL	GENE-Y	14	0	gene is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular chemical.	T6	T21	10697523
NA	CHEMICAL	GENE-Y	21	28	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of chemical synthase inhibition and the decrease of gene activity in the tumor cells.	T14	T24	10697523
CPR:4	CHEMICAL	GENE-Y	7	21	Thirty-week administration of UFT with or without chemical markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of gene inhibition and the decrease of thymidine kinase activity in the tumor cells.	T13	T23	10697523
CPR:4	CHEMICAL	GENE-Y	7	28	Thirty-week administration of UFT with or without chemical markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of gene activity in the tumor cells.	T13	T24	10697523
NA	CHEMICAL	GENE-Y	28	21	Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of gene inhibition and the decrease of chemical kinase activity in the tumor cells.	T15	T23	10697523
CPR:4	CHEMICAL	GENE-Y	3	21	Thirty-week administration of chemical with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of gene inhibition and the decrease of thymidine kinase activity in the tumor cells.	T12	T23	10697523
CPR:4	CHEMICAL	GENE-Y	3	28	Thirty-week administration of chemical with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of gene activity in the tumor cells.	T12	T24	10697523
CPR:9	CHEMICAL	GENE-Y	14	0	gene (ODC) catalyses the first step in the synthesis of the polyamines putrescine, chemical and spermine.	T2	T6	10698696
CPR:9	CHEMICAL	GENE-Y	14	2	Ornithine decarboxylase (gene) catalyses the first step in the synthesis of the polyamines putrescine, chemical and spermine.	T2	T13	10698696
CPR:9	CHEMICAL	GENE-Y	13	0	gene (ODC) catalyses the first step in the synthesis of the polyamines chemical, spermidine and spermine.	T4	T6	10698696
CPR:9	CHEMICAL	GENE-Y	13	2	Ornithine decarboxylase (gene) catalyses the first step in the synthesis of the polyamines chemical, spermidine and spermine.	T4	T13	10698696
NA	CHEMICAL	GENE-Y	0	2	chemical decarboxylase (gene) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine.	T1	T13	10698696
CPR:9	CHEMICAL	GENE-Y	16	0	gene (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and chemical.	T3	T6	10698696
CPR:9	CHEMICAL	GENE-Y	16	2	Ornithine decarboxylase (gene) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and chemical.	T3	T13	10698696
CPR:5	CHEMICAL	GENE-Y	13	1	In gene transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>chemical (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	T3	T22	10742288
CPR:5	CHEMICAL	GENE-Y	17	1	In gene transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>chemical (6.92).	T6	T22	10742288
CPR:5	CHEMICAL	GENE-Y	15	1	In gene transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>chemical (7.05)>noradrenaline (6.92).	T5	T22	10742288
CPR:5	CHEMICAL	GENE-Y	14	1	In gene transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>chemical (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	T4	T22	10742288
CPR:5	CHEMICAL	GENE-Y	11	1	In gene transfected cells the rank order of agonist potency was chemical (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).	T2	T22	10742288
NA	CHEMICAL	GENE-N	22	2	The selective gene ligand rauwolscine antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against chemical was 8.43.	T13	T23	10742288
NA	CHEMICAL	GENE-N	4	2	The selective gene ligand chemical antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43.	T12	T23	10742288
NA	CHEMICAL	GENE-N	14	2	The selective gene ligands prazosin and doxazosin (each 3 microM) had no effect on chemical responses.	T16	T24	10742288
NA	CHEMICAL	GENE-N	6	2	The selective gene ligands prazosin and chemical (each 3 microM) had no effect on noradrenaline responses.	T15	T24	10742288
NA	CHEMICAL	GENE-N	4	2	The selective gene ligands chemical and doxazosin (each 3 microM) had no effect on noradrenaline responses.	T14	T24	10742288
CPR:3	CHEMICAL	GENE-Y	5	0	gene were activated by chemical as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.	T10	T18	10796070
NA	CHEMICAL	GENE-N	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T4	T11	10796070
NA	CHEMICAL	GENE-N	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T4	T12	10796070
NA	CHEMICAL	GENE-N	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T4	T13	10796070
NA	CHEMICAL	GENE-N	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T5	T11	10796070
NA	CHEMICAL	GENE-N	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T5	T12	10796070
NA	CHEMICAL	GENE-N	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T5	T13	10796070
NA	CHEMICAL	GENE-Y	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T4	T11	10796070
NA	CHEMICAL	GENE-Y	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T4	T12	10796070
NA	CHEMICAL	GENE-Y	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T4	T13	10796070
NA	CHEMICAL	GENE-Y	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T5	T11	10796070
NA	CHEMICAL	GENE-Y	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T5	T12	10796070
NA	CHEMICAL	GENE-Y	11	1	The gene antagonist RU-486 (mifepristone) significantly counteracted the effect of chemical on gene activation, indicating that the chemical effect is specific and is mediated through the gene.	T5	T13	10796070
CPR:6	CHEMICAL	GENE-N	5	1	The gene antagonist RU-486 (chemical) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T3	T11	10796070
NA	CHEMICAL	GENE-N	5	1	The gene antagonist RU-486 (chemical) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T3	T12	10796070
NA	CHEMICAL	GENE-N	5	1	The gene antagonist RU-486 (chemical) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T3	T13	10796070
CPR:6	CHEMICAL	GENE-Y	5	1	The gene antagonist RU-486 (chemical) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T3	T11	10796070
NA	CHEMICAL	GENE-Y	5	1	The gene antagonist RU-486 (chemical) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T3	T12	10796070
NA	CHEMICAL	GENE-Y	5	1	The gene antagonist RU-486 (chemical) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T3	T13	10796070
CPR:6	CHEMICAL	GENE-N	4	1	The gene antagonist chemical (mifepristone) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T2	T11	10796070
NA	CHEMICAL	GENE-N	4	1	The gene antagonist chemical (mifepristone) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T2	T12	10796070
NA	CHEMICAL	GENE-N	4	1	The gene antagonist chemical (mifepristone) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T2	T13	10796070
CPR:6	CHEMICAL	GENE-Y	4	1	The gene antagonist chemical (mifepristone) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T2	T11	10796070
NA	CHEMICAL	GENE-Y	4	1	The gene antagonist chemical (mifepristone) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T2	T12	10796070
NA	CHEMICAL	GENE-Y	4	1	The gene antagonist chemical (mifepristone) significantly counteracted the effect of dexamethasone on gene activation, indicating that the dexamethasone effect is specific and is mediated through the gene.	T2	T13	10796070
NA	CHEMICAL	GENE-N	26	3	The presence of gene confers their responsiveness to glucocorticoids and indicates that the airway epithelium may be a target for the anti-inflammatory effects of inhaled chemical.	T7	T15	10796070
NA	CHEMICAL	GENE-Y	26	3	The presence of gene confers their responsiveness to glucocorticoids and indicates that the airway epithelium may be a target for the anti-inflammatory effects of inhaled chemical.	T7	T15	10796070
NA	CHEMICAL	GENE-Y	8	3	CD16, CD15 and gene) and increased expression of aminopeptidase-chemical (CD13).	T1	T6	10800083
NA	CHEMICAL	GENE-Y	8	0	gene, CD15 and CD120b) and increased expression of aminopeptidase-chemical (CD13).	T1	T4	10800083
NA	CHEMICAL	GENE-Y	8	1	CD16, gene and CD120b) and increased expression of aminopeptidase-chemical (CD13).	T1	T5	10800083
NA	CHEMICAL	GENE-Y	8	9	CD16, CD15 and CD120b) and increased expression of aminopeptidase-chemical (gene).	T1	T8	10800083
NA	CHEMICAL	GENE-Y	19	14	As such, relatively little has been published regarding its in vivo effects at the gene (D2) and chemical type 2a (5-HT2a) receptor systems.	T5	T14	10839333
NA	CHEMICAL	GENE-Y	19	17	As such, relatively little has been published regarding its in vivo effects at the dopamine type 2 (gene) and chemical type 2a (5-HT2a) receptor systems.	T5	T16	10839333
NA	CHEMICAL	GENE-Y	14	19	As such, relatively little has been published regarding its in vivo effects at the chemical type 2 (D2) and gene systems.	T4	T17	10839333
NA	CHEMICAL	GENE-Y	14	17	As such, relatively little has been published regarding its in vivo effects at the chemical type 2 (gene) and serotonin type 2a (5-HT2a) receptor systems.	T4	T16	10839333
CPR:3	CHEMICAL	GENE-Y	1	12	RESULTS: chemical was an effective antipsychotic and improved the extrapyramidal symptoms and gene level elevation noted at baseline.	T7	T20	10839333
NA	CHEMICAL	GENE-Y	7	15	Study of the additional subjects revealed that chemical does give rise to transiently high (58%-64%) gene occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours.	T1	T11	10839333
NA	CHEMICAL	GENE-Y	1	6	CONCLUSIONS: chemical shows a transiently high gene occupancy, which decreases to very low levels by the end of the dosing interval.	T3	T12	10839333
NA	CHEMICAL	GENE-Y	36	8	In this study, we compared the insulin and gene binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp human insulin), insulin lispro (B28Lys,B29Pro human insulin), insulin glargine (A21Gly,B31Arg,B32Arg human insulin), insulin detemir (NN304) [B29Lys(chemical), desB30 human insulin], and reference insulin analogs.	T2	T21	10866053
NA	CHEMICAL	GENE-Y	36	21	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp gene), insulin lispro (B28Lys,B29Pro gene), insulin glargine (A21Gly,B31Arg,B32Arg gene), insulin detemir (NN304) [B29Lys(chemical), desB30 gene], and reference insulin analogs.	T2	T23	10866053
NA	CHEMICAL	GENE-Y	36	21	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp gene), insulin lispro (B28Lys,B29Pro gene), insulin glargine (A21Gly,B31Arg,B32Arg gene), insulin detemir (NN304) [B29Lys(chemical), desB30 gene], and reference insulin analogs.	T2	T25	10866053
NA	CHEMICAL	GENE-Y	36	21	In this study, we compared the insulin and IGF-I receptor binding properties and metabolic and mitogenic potencies of insulin aspart (B28Asp gene), insulin lispro (B28Lys,B29Pro gene), insulin glargine (A21Gly,B31Arg,B32Arg gene), insulin detemir (NN304) [B29Lys(chemical), desB30 gene], and reference insulin analogs.	T2	T27	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T20	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T22	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T24	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T26	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T28	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T29	10866053
NA	CHEMICAL	GENE-Y	36	6	In this study, we compared the gene and IGF-I receptor binding properties and metabolic and mitogenic potencies of gene aspart (B28Asp human gene), gene lispro (B28Lys,B29Pro human gene), gene glargine (A21Gly,B31Arg,B32Arg human gene), gene detemir (NN304) [B29Lys(chemical), desB30 human gene], and reference gene analogs.	T2	T30	10866053
NA	CHEMICAL	GENE-Y	4	10	The attachment of a chemical chain to LysB29 provided gene detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.	T1	T14	10866053
NA	CHEMICAL	GENE-Y	12	5	We cloned human and rat gene and expressed this novel 2P domain chemical channel in transiently transfected COS cells.	T5	T17	10887187
NA	CHEMICAL	GENE-N	12	5	We cloned human and rat gene and expressed this novel 2P domain chemical channel in transiently transfected COS cells.	T5	T17	10887187
NA	CHEMICAL	GENE-Y	20	9	Rat TWIK-2 currents are about 15 times larger than gene currents, but both exhibit outward rectification in a physiological chemical gradient and mild inward rectification in symmetrical chemical conditions.	T3	T18	10887187
NA	CHEMICAL	GENE-Y	20	9	Rat TWIK-2 currents are about 15 times larger than gene currents, but both exhibit outward rectification in a physiological chemical gradient and mild inward rectification in symmetrical chemical conditions.	T4	T18	10887187
NA	CHEMICAL	GENE-Y	20	0	gene currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological chemical gradient and mild inward rectification in symmetrical chemical conditions.	T3	T16	10887187
NA	CHEMICAL	GENE-Y	20	0	gene currents are about 15 times larger than human TWIK-2 currents, but both exhibit outward rectification in a physiological chemical gradient and mild inward rectification in symmetrical chemical conditions.	T4	T16	10887187
CPR:4	CHEMICAL	GENE-Y	15	5	In a physiological K(+) gradient, gene is half inhibited by 0.1 mm Ba(2+), quinine, and chemical.	T9	T23	10887187
CPR:4	CHEMICAL	GENE-N	15	5	In a physiological K(+) gradient, gene is half inhibited by 0.1 mm Ba(2+), quinine, and chemical.	T9	T23	10887187
CPR:4	CHEMICAL	GENE-Y	13	5	In a physiological K(+) gradient, gene is half inhibited by 0.1 mm Ba(2+), chemical, and quinidine.	T8	T23	10887187
CPR:4	CHEMICAL	GENE-N	13	5	In a physiological K(+) gradient, gene is half inhibited by 0.1 mm Ba(2+), chemical, and quinidine.	T8	T23	10887187
CPR:4	CHEMICAL	GENE-Y	12	5	In a physiological K(+) gradient, gene is half inhibited by 0.1 mm chemical, quinine, and quinidine.	T7	T23	10887187
CPR:4	CHEMICAL	GENE-N	12	5	In a physiological K(+) gradient, gene is half inhibited by 0.1 mm chemical, quinine, and quinidine.	T7	T23	10887187
NA	CHEMICAL	GENE-Y	3	5	In a physiological chemical gradient, gene is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine.	T6	T23	10887187
NA	CHEMICAL	GENE-N	3	5	In a physiological chemical gradient, gene is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine.	T6	T23	10887187
NA	CHEMICAL	GENE-N	1	5	Finally, chemical 53 in the gene is required for functional expression of TWIK-2 but is not critical for subunit self-assembly.	T10	T24	10887187
NA	CHEMICAL	GENE-Y	1	14	Finally, chemical 53 in the M1P1 external loop is required for functional expression of gene but is not critical for subunit self-assembly.	T10	T25	10887187
NA	CHEMICAL	GENE-N	1	14	Finally, chemical 53 in the M1P1 external loop is required for functional expression of gene but is not critical for subunit self-assembly.	T10	T25	10887187
NA	CHEMICAL	GENE-Y	7	0	gene is the first reported 2P domain chemical channel that inactivates.	T1	T26	10887187
NA	CHEMICAL	GENE-N	7	0	gene is the first reported 2P domain chemical channel that inactivates.	T1	T26	10887187
NA	CHEMICAL	GENE-Y	14	7	The base-line, transient, and delayed activities of gene suggest that this novel 2P domain chemical channel may play an important functional role in cell electrogenesis.	T2	T13	10887187
NA	CHEMICAL	GENE-N	14	7	The base-line, transient, and delayed activities of gene suggest that this novel 2P domain chemical channel may play an important functional role in cell electrogenesis.	T2	T13	10887187
CPR:4	CHEMICAL	GENE-Y	12	16	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of chemical (EPA) blocked gene activity, the terminal enzymatic step in AA synthesis.	T21	T32	10917903
CPR:4	CHEMICAL	GENE-Y	14	16	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (chemical) blocked gene activity, the terminal enzymatic step in AA synthesis.	T22	T32	10917903
NA	CHEMICAL	GENE-Y	23	16	Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked gene activity, the terminal enzymatic step in chemical synthesis.	T23	T32	10917903
CPR:3	CHEMICAL	GENE-N	7	9	BACKGROUND: This study examines the effects of chemical, a gene opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).	T7	T21	10931813
CPR:4	CHEMICAL	GENE-Y	0	23	chemical (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and gene (20 nmol/L) to augment late I(Na) (LQT3 model).	T8	T23	10931813
CPR:4	CHEMICAL	GENE-N	0	19	chemical (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block gene (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).	T8	T22	10931813
CPR:4	CHEMICAL	GENE-Y	14	23	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, chemical (100 micromol/L) to block I(Kr) (LQT2 model), and gene (20 nmol/L) to augment late I(Na) (LQT3 model).	T10	T23	10931813
CPR:4	CHEMICAL	GENE-N	14	19	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, chemical (100 micromol/L) to block gene (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).	T10	T22	10931813
NA	CHEMICAL	GENE-Y	29	23	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and gene (20 nmol/L) to augment late I(chemical) (LQT3 model).	T11	T23	10931813
NA	CHEMICAL	GENE-N	29	19	Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block gene (LQT2 model), and ATX-II (20 nmol/L) to augment late I(chemical) (LQT3 model).	T11	T22	10931813
NA	CHEMICAL	GENE-Y	0	4	Isoproterenol+chemical, d-sotalol, and gene produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).	T13	T24	10931813
NA	CHEMICAL	GENE-Y	0	4	chemical+chromanol 293B, d-sotalol, and gene produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).	T12	T24	10931813
NA	CHEMICAL	GENE-Y	2	4	Isoproterenol+chromanol 293B, chemical, and gene produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation-induced TdP (LQT1, 3/6; LQT2, 3/6; LQT3, 5/6).	T14	T24	10931813
NA	CHEMICAL	GENE-Y	0	10	chemical 20 micromol/L reversed only 50% of the effect of gene and failed to completely suppress TdP in the LQT3 model (5/6 to 3/6).	T4	T16	10931813
NA	CHEMICAL	GENE-N	5	36	CONCLUSIONS: Our data suggest that chemical channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or gene but less so when it is due to augmented late I(Na).	T5	T19	10931813
NA	CHEMICAL	GENE-N	5	34	CONCLUSIONS: Our data suggest that chemical channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced gene or I(Ks) but less so when it is due to augmented late I(Na).	T5	T18	10931813
NA	CHEMICAL	GENE-N	47	5	CONCLUSIONS: Our data suggest that gene openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or I(Ks) but less so when it is due to augmented late I(chemical).	T6	T17	10931813
NA	CHEMICAL	GENE-N	47	36	CONCLUSIONS: Our data suggest that K(+) channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced I(Kr) or gene but less so when it is due to augmented late I(chemical).	T6	T19	10931813
NA	CHEMICAL	GENE-N	47	34	CONCLUSIONS: Our data suggest that K(+) channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation-induced TdP when congenital or acquired LQTS is secondary to reduced gene or I(Ks) but less so when it is due to augmented late I(chemical).	T6	T18	10931813
CPR:9	CHEMICAL	GENE-N	13	0	gene (UCPs) are inner mitochondrial membrane transporters which act as pores for chemical ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	T10	T14	10933891
CPR:9	CHEMICAL	GENE-N	13	2	Uncoupling proteins (gene) are inner mitochondrial membrane transporters which act as pores for chemical ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of ATP synthesis.	T10	T18	10933891
NA	CHEMICAL	GENE-Y	8	12	We have studied the effects of two fibrates, chemical and Wy-14,643, on gene and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	T7	T19	10933891
NA	CHEMICAL	GENE-Y	8	14	We have studied the effects of two fibrates, chemical and Wy-14,643, on UCP-3 and gene mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	T7	T20	10933891
NA	CHEMICAL	GENE-Y	10	12	We have studied the effects of two fibrates, bezafibrate and chemical, on gene and UCP-2 mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	T8	T19	10933891
NA	CHEMICAL	GENE-Y	10	14	We have studied the effects of two fibrates, bezafibrate and chemical, on UCP-3 and gene mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	T8	T20	10933891
CPR:3	CHEMICAL	GENE-Y	1	9	Thus, chemical treatment resulted in an 8-fold induction in gene mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes.	T9	T23	10933891
NA	CHEMICAL	GENE-Y	12	3	In contrast to gene, UCP-2 mRNA levels were only slightly modified by chemical in adipocytes.	T11	T28	10933891
NA	CHEMICAL	GENE-Y	12	4	In contrast to UCP-3, gene mRNA levels were only slightly modified by chemical in adipocytes.	T11	T29	10933891
CPR:3	CHEMICAL	GENE-Y	20	3	The induction in gene expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after chemical or Wy-14,643 treatment.	T1	T15	10933891
CPR:3	CHEMICAL	GENE-Y	22	3	The induction in gene expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or chemical treatment.	T2	T15	10933891
NA	CHEMICAL	GENE-Y	47	6	Since it has been proposed that gene could be involved in the regulation of the use of fatty acids as fuel substrates, the gene induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as chemical.	T6	T16	10933891
NA	CHEMICAL	GENE-Y	47	6	Since it has been proposed that gene could be involved in the regulation of the use of fatty acids as fuel substrates, the gene induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as chemical.	T6	T17	10933891
NA	CHEMICAL	GENE-Y	17	6	Since it has been proposed that gene could be involved in the regulation of the use of chemical as fuel substrates, the gene induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of chemical, limiting their availability to be stored as triglycerides.	T5	T16	10933891
NA	CHEMICAL	GENE-Y	17	6	Since it has been proposed that gene could be involved in the regulation of the use of chemical as fuel substrates, the gene induction achieved after bezafibrate and Wy-14, 643 treatment may indicate a higher oxidation of chemical, limiting their availability to be stored as triglycerides.	T5	T17	10933891
NA	CHEMICAL	GENE-Y	27	6	Since it has been proposed that gene could be involved in the regulation of the use of fatty acids as fuel substrates, the gene induction achieved after chemical and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	T3	T16	10933891
CPR:3	CHEMICAL	GENE-Y	27	6	Since it has been proposed that gene could be involved in the regulation of the use of fatty acids as fuel substrates, the gene induction achieved after chemical and Wy-14, 643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	T3	T17	10933891
NA	CHEMICAL	GENE-Y	29	6	Since it has been proposed that gene could be involved in the regulation of the use of fatty acids as fuel substrates, the gene induction achieved after bezafibrate and chemical treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	T4	T16	10933891
CPR:3	CHEMICAL	GENE-Y	29	6	Since it has been proposed that gene could be involved in the regulation of the use of fatty acids as fuel substrates, the gene induction achieved after bezafibrate and chemical treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as triglycerides.	T4	T17	10933891
NA	CHEMICAL	GENE-N	47	41	Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma gene activity (78%) and hepatic chemical level (70%), when compared with the menadione intoxicated control.	T4	T14	10939639
NA	CHEMICAL	GENE-N	3	41	Pretreating mice with chemical (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma gene activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	T3	T14	10939639
CPR:4	CHEMICAL	GENE-N	29	41	Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against chemical-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma gene activity (78%) and hepatic malondialdehyde level (70%), when compared with the chemical intoxicated control.	T2	T14	10939639
NA	CHEMICAL	GENE-N	29	41	Pretreating mice with schisandrin B (Sch B), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against chemical-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma gene activity (78%) and hepatic malondialdehyde level (70%), when compared with the chemical intoxicated control.	T6	T14	10939639
NA	CHEMICAL	GENE-N	5	41	Pretreating mice with schisandrin B (chemical), a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol/kg for 3 days protected against menadione-induced hepatic oxidative damage in mice, as evidenced by decreases in plasma gene activity (78%) and hepatic malondialdehyde level (70%), when compared with the menadione intoxicated control.	T5	T14	10939639
NA	CHEMICAL	GENE-Y	13	21	In order to define the biochemical mechanism involved in the hepatoprotection afforded by chemical pretreatment, we examined the activity of gene (DTD) in hepatocytes isolated from chemical pretreated rats.	T7	T15	10939639
NA	CHEMICAL	GENE-Y	13	21	In order to define the biochemical mechanism involved in the hepatoprotection afforded by chemical pretreatment, we examined the activity of gene (DTD) in hepatocytes isolated from chemical pretreated rats.	T8	T15	10939639
NA	CHEMICAL	GENE-Y	13	22	In order to define the biochemical mechanism involved in the hepatoprotection afforded by chemical pretreatment, we examined the activity of DT-diaphorase (gene) in hepatocytes isolated from chemical pretreated rats.	T7	T16	10939639
NA	CHEMICAL	GENE-Y	13	22	In order to define the biochemical mechanism involved in the hepatoprotection afforded by chemical pretreatment, we examined the activity of DT-diaphorase (gene) in hepatocytes isolated from chemical pretreated rats.	T8	T16	10939639
CPR:3	CHEMICAL	GENE-Y	3	22	Hepatocytes isolated from chemical pretreated (a daily dose of 1 mmol/kg for 3 days) rats showed a significant increase (25%) in gene activity.	T9	T17	10939639
NA	CHEMICAL	GENE-Y	12	3	The increase in gene activity was associated with the enhanced rate of chemical elimination in the hepatocyte culture.	T10	T18	10939639
NA	CHEMICAL	GENE-Y	28	15	The ensemble of results suggests that the ability of Sch B pretreatment to enhance hepatocellular gene activity may at least in part be attributed to the protection against chemical hepatotoxicity.	T1	T19	10939639
CPR:3	CHEMICAL	GENE-Y	9	15	The ensemble of results suggests that the ability of chemical pretreatment to enhance hepatocellular gene activity may at least in part be attributed to the protection against menadione hepatotoxicity.	T11	T19	10939639
NA	CHEMICAL	GENE-Y	10	15	This study was designed to investigate the delayed effects of chemical and treadmill exercise on gene activity, lipid peroxidation and histology of peripheral tissues of mice.	T7	T18	10942908
CPR:4	CHEMICAL	GENE-Y	4	9	The group treated with chemical alone showed decreased plasma gene (BChE) activity (87% of control), whereas chemical plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.	T12	T19	10942908
NA	CHEMICAL	GENE-Y	4	9	The group treated with chemical alone showed decreased plasma gene (BChE) activity (87% of control), whereas chemical plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.	T13	T19	10942908
CPR:4	CHEMICAL	GENE-Y	4	10	The group treated with chemical alone showed decreased plasma butyrylcholinesterase (gene) activity (87% of control), whereas chemical plus exercise significantly decreased the gene activity (79% of control), indicating an interactive effect of the combination.	T12	T20	10942908
NA	CHEMICAL	GENE-Y	4	10	The group treated with chemical alone showed decreased plasma butyrylcholinesterase (gene) activity (87% of control), whereas chemical plus exercise significantly decreased the gene activity (79% of control), indicating an interactive effect of the combination.	T12	T21	10942908
NA	CHEMICAL	GENE-Y	4	10	The group treated with chemical alone showed decreased plasma butyrylcholinesterase (gene) activity (87% of control), whereas chemical plus exercise significantly decreased the gene activity (79% of control), indicating an interactive effect of the combination.	T13	T20	10942908
CPR:4	CHEMICAL	GENE-Y	4	10	The group treated with chemical alone showed decreased plasma butyrylcholinesterase (gene) activity (87% of control), whereas chemical plus exercise significantly decreased the gene activity (79% of control), indicating an interactive effect of the combination.	T13	T21	10942908
CPR:4	CHEMICAL	GENE-Y	16	1	However, gene activity in triceps muscle decreased significantly (78% of control) in the group treated with chemical plus exercise.	T1	T16	10942908
CPR:3	CHEMICAL	GENE-N	10	0	gene activity in plasma increased slightly (compared to control, chemical or exercise group) in mice treated with chemical plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	T3	T17	10942908
CPR:3	CHEMICAL	GENE-N	10	0	gene activity in plasma increased slightly (compared to control, chemical or exercise group) in mice treated with chemical plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	T4	T17	10942908
NA	CHEMICAL	GENE-Y	15	24	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as chemical and GnRH agonist, exert direct regulatory action on gene (MCP-1) expression by endometrial epithelial cells.	T1	T10	11056242
NA	CHEMICAL	GENE-Y	15	27	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as chemical and GnRH agonist, exert direct regulatory action on monocyte chemotactic protein-1 (gene) expression by endometrial epithelial cells.	T1	T11	11056242
NA	CHEMICAL	GENE-Y	15	17	OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as chemical and gene agonist, exert direct regulatory action on monocyte chemotactic protein-1 (MCP-1) expression by endometrial epithelial cells.	T1	T8	11056242
NA	CHEMICAL	GENE-N	18	16	DESIGN: Primary cultures of epithelial cells isolated from human endometrium were exposed to different concentrations of gene and chemical hormone analogs.	T5	T12	11056242
NA	CHEMICAL	GENE-Y	1	13	RESULT(S): chemical, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T6	T7	11056242
NA	CHEMICAL	GENE-Y	1	13	RESULT(S): chemical, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T6	T9	11056242
CPR:5	CHEMICAL	GENE-Y	1	4	RESULT(S): chemical, a gene agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	T6	T15	11056242
NA	CHEMICAL	GENE-Y	23	13	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and chemical, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T4	T7	11056242
CPR:4	CHEMICAL	GENE-Y	23	13	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and chemical, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T4	T9	11056242
NA	CHEMICAL	GENE-Y	23	4	RESULT(S): Buserelin acetate, a gene agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and chemical, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	T4	T15	11056242
NA	CHEMICAL	GENE-Y	20	13	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas danazol (10(-7)-10(-5) M), a chemical analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T3	T7	11056242
CPR:4	CHEMICAL	GENE-Y	20	13	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas danazol (10(-7)-10(-5) M), a chemical analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T3	T9	11056242
NA	CHEMICAL	GENE-Y	20	4	RESULT(S): Buserelin acetate, a gene agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a chemical analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	T3	T15	11056242
NA	CHEMICAL	GENE-Y	16	13	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas chemical (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T2	T7	11056242
CPR:4	CHEMICAL	GENE-Y	16	13	RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on gene expression, whereas chemical (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on gene expression.	T2	T9	11056242
NA	CHEMICAL	GENE-Y	16	4	RESULT(S): Buserelin acetate, a gene agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas chemical (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.	T2	T15	11056242
NA	CHEMICAL	GENE-Y	10	22	The present studies were undertaken to compare two compounds, a chemical analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting gene agonist, both of which induce NGF synthesis in vivo.	T5	T24	11146120
CPR:4	CHEMICAL	GENE-Y	10	28	The present studies were undertaken to compare two compounds, a chemical analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce gene synthesis in vivo.	T5	T26	11146120
CPR:5	CHEMICAL	GENE-Y	19	22	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and chemical, a long-acting gene agonist, both of which induce NGF synthesis in vivo.	T7	T24	11146120
CPR:3	CHEMICAL	GENE-Y	19	28	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and chemical, a long-acting beta(2)-adrenoceptor agonist, both of which induce gene synthesis in vivo.	T7	T26	11146120
NA	CHEMICAL	GENE-Y	13	22	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (chemical) with minimal calcaemic effects, and clenbuterol, a long-acting gene agonist, both of which induce NGF synthesis in vivo.	T6	T24	11146120
CPR:3	CHEMICAL	GENE-Y	13	28	The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (chemical) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce gene synthesis in vivo.	T6	T26	11146120
CPR:3	CHEMICAL	GENE-Y	0	6	chemical caused significant increases in both gene mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.	T8	T27	11146120
NA	CHEMICAL	GENE-Y	9	4	Effects of clenbuterol on gene mRNA were antagonized by chemical.	T10	T28	11146120
NA	CHEMICAL	GENE-Y	2	4	Effects of chemical on gene mRNA were antagonized by propranolol.	T9	T28	11146120
CPR:3	CHEMICAL	GENE-Y	9	19	Mobility shift assays on whole cell extracts showed that chemical increased AP1 binding in 3T3 cells prior to increasing gene synthesis.	T11	T30	11146120
NA	CHEMICAL	GENE-Y	9	11	Mobility shift assays on whole cell extracts showed that chemical increased gene binding in 3T3 cells prior to increasing NGF synthesis.	T11	T29	11146120
NA	CHEMICAL	GENE-Y	0	5	chemical was without effect on gene mRNA levels in L929 cells, whereas CB1093 caused significant increases in both gene mRNA and protein levels in both 3T3 and L929 cells.	T12	T31	11146120
NA	CHEMICAL	GENE-Y	0	5	chemical was without effect on gene mRNA levels in L929 cells, whereas CB1093 caused significant increases in both gene mRNA and protein levels in both 3T3 and L929 cells.	T12	T32	11146120
NA	CHEMICAL	GENE-Y	12	5	Clenbuterol was without effect on gene mRNA levels in L929 cells, whereas chemical caused significant increases in both gene mRNA and protein levels in both 3T3 and L929 cells.	T13	T31	11146120
CPR:3	CHEMICAL	GENE-Y	12	5	Clenbuterol was without effect on gene mRNA levels in L929 cells, whereas chemical caused significant increases in both gene mRNA and protein levels in both 3T3 and L929 cells.	T13	T32	11146120
NA	CHEMICAL	GENE-Y	3	38	Binding to the chemical nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased VDR binding preceded increased gene mRNA.	T1	T19	11146120
NA	CHEMICAL	GENE-Y	3	7	Binding to the chemical nuclear receptor (gene), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased gene binding preceded increased NGF mRNA.	T1	T16	11146120
NA	CHEMICAL	GENE-Y	3	7	Binding to the chemical nuclear receptor (gene), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of CB1093 and maintained up to 24 h. Increased gene binding preceded increased NGF mRNA.	T1	T18	11146120
NA	CHEMICAL	GENE-Y	26	3	Binding to the gene (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of chemical and maintained up to 24 h. Increased VDR binding preceded increased NGF mRNA.	T2	T15	11146120
NA	CHEMICAL	GENE-Y	26	38	Binding to the vitamin D nuclear receptor (VDR), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of chemical and maintained up to 24 h. Increased VDR binding preceded increased gene mRNA.	T2	T19	11146120
NA	CHEMICAL	GENE-Y	26	7	Binding to the vitamin D nuclear receptor (gene), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of chemical and maintained up to 24 h. Increased gene binding preceded increased NGF mRNA.	T2	T16	11146120
NA	CHEMICAL	GENE-Y	26	7	Binding to the vitamin D nuclear receptor (gene), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of chemical and maintained up to 24 h. Increased gene binding preceded increased NGF mRNA.	T2	T18	11146120
NA	CHEMICAL	GENE-Y	6	14	This study demonstrates that CB1093 and chemical stimulate NGF levels in vitro and that gene binding could be a commonality between the mechanism of NGF induction of these two compounds.	T4	T22	11146120
CPR:3	CHEMICAL	GENE-Y	6	8	This study demonstrates that CB1093 and chemical stimulate gene levels in vitro and that AP-1 binding could be a commonality between the mechanism of gene induction of these two compounds.	T4	T21	11146120
CPR:3	CHEMICAL	GENE-Y	6	8	This study demonstrates that CB1093 and chemical stimulate gene levels in vitro and that AP-1 binding could be a commonality between the mechanism of gene induction of these two compounds.	T4	T23	11146120
NA	CHEMICAL	GENE-Y	4	14	This study demonstrates that chemical and clenbuterol stimulate NGF levels in vitro and that gene binding could be a commonality between the mechanism of NGF induction of these two compounds.	T3	T22	11146120
CPR:3	CHEMICAL	GENE-Y	4	8	This study demonstrates that chemical and clenbuterol stimulate gene levels in vitro and that AP-1 binding could be a commonality between the mechanism of gene induction of these two compounds.	T3	T21	11146120
CPR:3	CHEMICAL	GENE-Y	4	8	This study demonstrates that chemical and clenbuterol stimulate gene levels in vitro and that AP-1 binding could be a commonality between the mechanism of gene induction of these two compounds.	T3	T23	11146120
NA	CHEMICAL	GENE-N	7	11	PURPOSE: To determine whether the volatile anesthetic chemical protects against light-induced gene degeneration in the rodent retina.	T5	T20	11157886
CPR:4	CHEMICAL	GENE-N	1	6	RESULTS: chemical anesthesia reversibly inhibited metabolic gene regeneration and thus prevented gene from absorbing high numbers of photons during light exposure.	T6	T17	11157886
CPR:4	CHEMICAL	GENE-N	1	6	RESULTS: chemical anesthesia reversibly inhibited metabolic gene regeneration and thus prevented gene from absorbing high numbers of photons during light exposure.	T6	T18	11157886
NA	CHEMICAL	GENE-N	8	1	Consequently, gene of mice and rats anesthetized with chemical were completely protected against degeneration induced by white light.	T7	T19	11157886
CPR:4	CHEMICAL	GENE-N	5	10	CONCLUSIONS: After the initial bleach, chemical impeded photon absorption by gene by inhibiting metabolic gene regeneration.	T2	T10	11157886
NA	CHEMICAL	GENE-N	5	10	CONCLUSIONS: After the initial bleach, chemical impeded photon absorption by gene by inhibiting metabolic gene regeneration.	T2	T9	11157886
NA	CHEMICAL	GENE-N	7	27	RATIONALE: A recent study suggested that selective chemical reuptake inhibitors were inactive in 40-week-old male mice in the mouse forced swimming test, possibly because of alteration of gene receptors.	T15	T27	11243491
NA	CHEMICAL	GENE-Y	15	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and chemical reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T21	T33	11243491
NA	CHEMICAL	GENE-Y	15	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and chemical reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T21	T35	11243491
NA	CHEMICAL	GENE-Y	15	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and chemical reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T21	T32	11243491
NA	CHEMICAL	GENE-Y	15	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and chemical reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T21	T34	11243491
NA	CHEMICAL	GENE-Y	8	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (chemical reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T18	T33	11243491
NA	CHEMICAL	GENE-Y	8	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (chemical reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T18	T35	11243491
NA	CHEMICAL	GENE-Y	8	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (chemical reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T18	T32	11243491
NA	CHEMICAL	GENE-Y	8	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (chemical reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T18	T34	11243491
NA	CHEMICAL	GENE-Y	11	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), chemical (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T19	T33	11243491
NA	CHEMICAL	GENE-Y	11	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), chemical (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T19	T35	11243491
NA	CHEMICAL	GENE-Y	11	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), chemical (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T19	T32	11243491
NA	CHEMICAL	GENE-Y	11	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), chemical (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T19	T34	11243491
NA	CHEMICAL	GENE-Y	47	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), chemical (gene agonist)] in the mouse forced swimming test.	T26	T33	11243491
CPR:5	CHEMICAL	GENE-Y	47	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), chemical (gene agonist)] in the mouse forced swimming test.	T26	T35	11243491
NA	CHEMICAL	GENE-Y	47	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), chemical (5-HT1B agonist)] in the mouse forced swimming test.	T26	T32	11243491
NA	CHEMICAL	GENE-Y	47	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), chemical (5-HT1B agonist)] in the mouse forced swimming test.	T26	T34	11243491
NA	CHEMICAL	GENE-Y	7	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), chemical (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T17	T33	11243491
NA	CHEMICAL	GENE-Y	7	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), chemical (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T17	T35	11243491
NA	CHEMICAL	GENE-Y	7	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), chemical (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T17	T32	11243491
NA	CHEMICAL	GENE-Y	7	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), chemical (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T17	T34	11243491
NA	CHEMICAL	GENE-Y	18	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), chemical and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T22	T33	11243491
NA	CHEMICAL	GENE-Y	18	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), chemical and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T22	T35	11243491
NA	CHEMICAL	GENE-Y	18	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), chemical and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T22	T32	11243491
NA	CHEMICAL	GENE-Y	18	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), chemical and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T22	T34	11243491
NA	CHEMICAL	GENE-Y	20	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and chemical (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T23	T33	11243491
NA	CHEMICAL	GENE-Y	20	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and chemical (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T23	T35	11243491
NA	CHEMICAL	GENE-Y	20	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and chemical (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T23	T32	11243491
NA	CHEMICAL	GENE-Y	20	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and chemical (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T23	T34	11243491
NA	CHEMICAL	GENE-Y	5	40	METHODS: Different classes of antidepressants [chemical (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T14	T33	11243491
NA	CHEMICAL	GENE-Y	5	40	METHODS: Different classes of antidepressants [chemical (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T14	T35	11243491
NA	CHEMICAL	GENE-Y	5	38	METHODS: Different classes of antidepressants [chemical (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T14	T32	11243491
NA	CHEMICAL	GENE-Y	5	38	METHODS: Different classes of antidepressants [chemical (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T14	T34	11243491
NA	CHEMICAL	GENE-Y	43	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [chemical (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T25	T33	11243491
NA	CHEMICAL	GENE-Y	43	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [chemical (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T25	T35	11243491
NA	CHEMICAL	GENE-Y	43	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [chemical (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T25	T32	11243491
CPR:5	CHEMICAL	GENE-Y	43	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [chemical (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T25	T34	11243491
NA	CHEMICAL	GENE-Y	13	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T20	T33	11243491
NA	CHEMICAL	GENE-Y	13	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T20	T35	11243491
NA	CHEMICAL	GENE-Y	13	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T24	T33	11243491
NA	CHEMICAL	GENE-Y	13	40	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T24	T35	11243491
NA	CHEMICAL	GENE-Y	13	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T20	T32	11243491
NA	CHEMICAL	GENE-Y	13	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T20	T34	11243491
NA	CHEMICAL	GENE-Y	13	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T24	T32	11243491
NA	CHEMICAL	GENE-Y	13	38	METHODS: Different classes of antidepressants [imipramine (tricyclic), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed chemical and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective chemical reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T24	T34	11243491
NA	CHEMICAL	GENE-Y	6	40	METHODS: Different classes of antidepressants [imipramine (chemical), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T16	T33	11243491
NA	CHEMICAL	GENE-Y	6	40	METHODS: Different classes of antidepressants [imipramine (chemical), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with 5-HT1A and gene receptor agonists [buspirone (partial 5-HT1A agonist), anpirtoline (gene agonist)] in the mouse forced swimming test.	T16	T35	11243491
NA	CHEMICAL	GENE-Y	6	38	METHODS: Different classes of antidepressants [imipramine (chemical), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T16	T32	11243491
NA	CHEMICAL	GENE-Y	6	38	METHODS: Different classes of antidepressants [imipramine (chemical), maprotiline (noradrenline reuptake inhibitor), venlafaxine (mixed serotonin and noradrenaline reuptake inhibitors), fluvoxamine and sertraline (selective serotonin reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with gene and 5-HT1B receptor agonists [buspirone (partial gene agonist), anpirtoline (5-HT1B agonist)] in the mouse forced swimming test.	T16	T34	11243491
NA	CHEMICAL	GENE-Y	40	45	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the CYP4A family led to the cloning of a partial, near full length, cDNA clone with approximately 70% nucleotide and deduced chemical sequence identity to gene.	T10	T16	11246504
NA	CHEMICAL	GENE-N	40	20	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the gene family led to the cloning of a partial, near full length, cDNA clone with approximately 70% nucleotide and deduced chemical sequence identity to human gene11.	T10	T15	11246504
NA	CHEMICAL	GENE-Y	37	45	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the CYP4A family led to the cloning of a partial, near full length, cDNA clone with approximately 70% chemical and deduced amino acid sequence identity to gene.	T9	T16	11246504
NA	CHEMICAL	GENE-N	37	20	Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the gene family led to the cloning of a partial, near full length, cDNA clone with approximately 70% chemical and deduced amino acid sequence identity to human gene11.	T9	T15	11246504
NA	CHEMICAL	GENE-Y	16	13	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, gene, and chemical transferase.	T3	T12	11252887
NA	CHEMICAL	GENE-Y	16	11	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits gene, dihydrofolate reductase, and chemical transferase.	T3	T14	11252887
CPR:4	CHEMICAL	GENE-Y	0	16	chemical (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and gene.	T1	T13	11252887
CPR:4	CHEMICAL	GENE-Y	0	13	chemical (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, gene, and glycinamide ribonucleotide formyl transferase.	T1	T12	11252887
CPR:4	CHEMICAL	GENE-Y	0	11	chemical (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits gene, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	T1	T14	11252887
NA	CHEMICAL	GENE-Y	13	16	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, chemical reductase, and gene.	T2	T13	11252887
NA	CHEMICAL	GENE-Y	13	11	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits gene, chemical reductase, and glycinamide ribonucleotide formyl transferase.	T2	T14	11252887
NA	CHEMICAL	GENE-Y	11	16	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits chemical synthase, dihydrofolate reductase, and gene.	T9	T13	11252887
NA	CHEMICAL	GENE-Y	11	13	Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits chemical synthase, gene, and glycinamide ribonucleotide formyl transferase.	T9	T12	11252887
CPR:4	CHEMICAL	GENE-Y	3	16	Pemetrexed disodium (Alimta, chemical) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and gene.	T6	T13	11252887
CPR:4	CHEMICAL	GENE-Y	3	13	Pemetrexed disodium (Alimta, chemical) is a novel, multitargeted antifolate that inhibits thymidylate synthase, gene, and glycinamide ribonucleotide formyl transferase.	T6	T12	11252887
CPR:4	CHEMICAL	GENE-Y	3	11	Pemetrexed disodium (Alimta, chemical) is a novel, multitargeted antifolate that inhibits gene, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	T6	T14	11252887
CPR:4	CHEMICAL	GENE-Y	2	16	Pemetrexed disodium (chemical, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and gene.	T4	T13	11252887
CPR:4	CHEMICAL	GENE-Y	2	13	Pemetrexed disodium (chemical, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, gene, and glycinamide ribonucleotide formyl transferase.	T4	T12	11252887
CPR:4	CHEMICAL	GENE-Y	2	11	Pemetrexed disodium (chemical, LY231514) is a novel, multitargeted antifolate that inhibits gene, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.	T4	T14	11252887
CPR:3	CHEMICAL	GENE-N	35	8	To mechanistically evaluate this regional selectivity, we assessed gene (COX-2) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and chemical-treated rats.	T1	T17	11304699
CPR:3	CHEMICAL	GENE-N	35	9	To mechanistically evaluate this regional selectivity, we assessed cyclo-oxygenase-2 (gene) expression in the uninvolved mucosa and demonstrated a 3- to 4-fold excess in the distal relative to the proximal bowel in both MIN mice and chemical-treated rats.	T1	T18	11304699
NA	CHEMICAL	GENE-N	5	19	The striking distal predilection of chemical may be, at least partially, explained by distal bowel over-expression of COX-2 and gene.	T4	T16	11304699
NA	CHEMICAL	GENE-N	5	17	The striking distal predilection of chemical may be, at least partially, explained by distal bowel over-expression of gene and PPAR-delta.	T4	T15	11304699
NA	CHEMICAL	GENE-Y	42	12	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with gene leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of chemical to generate phosphatidic acid.	T4	T25	11309392
NA	CHEMICAL	GENE-Y	45	12	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with gene leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate chemical.	T5	T25	11309392
NA	CHEMICAL	GENE-Y	29	12	Previous work from our laboratory showed that stimulation of quiescent fibroblasts with gene leads to the production of two lipid second messengers in the nucleus: an increase in nuclear chemical mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate phosphatidic acid.	T3	T25	11309392
CPR:9	CHEMICAL	GENE-N	9	0	gene (DGK) catalyzes the conversion of diacylglycerol to chemical, making it an attractive candidate for a signal transduction component.	T8	T26	11309392
CPR:9	CHEMICAL	GENE-N	9	2	Diacylglycerol kinase (gene) catalyzes the conversion of diacylglycerol to chemical, making it an attractive candidate for a signal transduction component.	T8	T27	11309392
CPR:9	CHEMICAL	GENE-N	7	0	gene (DGK) catalyzes the conversion of chemical to phosphatidic acid, making it an attractive candidate for a signal transduction component.	T7	T26	11309392
CPR:9	CHEMICAL	GENE-N	7	2	Diacylglycerol kinase (gene) catalyzes the conversion of chemical to phosphatidic acid, making it an attractive candidate for a signal transduction component.	T7	T27	11309392
NA	CHEMICAL	GENE-N	0	2	chemical kinase (gene) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component.	T6	T27	11309392
CPR:4	CHEMICAL	GENE-Y	8	10	We took advantage of the previous observations that chemical inhibits gene (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H.	T1	T12	11309392
NA	CHEMICAL	GENE-Y	9	2	Constitutively active gene inhibited the nuclear stimulated activity, whereas chemical did not have an inhibitory effect.	T2	T16	11309392
CPR:4	CHEMICAL	GENE-Y	0	11	chemical (NDGA) has been shown to inhibit both 5-lipoxygenase and gene and is active against several cancer cell lines and at least one mouse tumor model.	T1	T10	11318430
CPR:4	CHEMICAL	GENE-Y	0	9	chemical (NDGA) has been shown to inhibit both gene and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	T1	T9	11318430
NA	CHEMICAL	GENE-Y	11	9	Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both gene and chemical decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	T7	T9	11318430
CPR:4	CHEMICAL	GENE-Y	2	11	Nordihydroguaiaretic acid (chemical) has been shown to inhibit both 5-lipoxygenase and gene and is active against several cancer cell lines and at least one mouse tumor model.	T3	T10	11318430
CPR:4	CHEMICAL	GENE-Y	2	9	Nordihydroguaiaretic acid (chemical) has been shown to inhibit both gene and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	T3	T9	11318430
NA	CHEMICAL	GENE-N	5	0	gene (CA) is a chemical enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.	T6	T25	11392054
NA	CHEMICAL	GENE-N	5	2	Carbonic anhydrase (gene) is a chemical enzyme that catalyses the reversible hydration reaction of CO2 and plays a major role in the acid-base balance.	T6	T31	11392054
CPR:9	CHEMICAL	GENE-N	14	0	gene (CA) is a zinc enzyme that catalyses the reversible hydration reaction of chemical and plays a major role in the acid-base balance.	T24	T25	11392054
CPR:9	CHEMICAL	GENE-N	14	2	Carbonic anhydrase (gene) is a zinc enzyme that catalyses the reversible hydration reaction of chemical and plays a major role in the acid-base balance.	T24	T31	11392054
NA	CHEMICAL	GENE-Y	8	33	We studied the in vitro effects of noradrenaline, chemical, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T8	T37	11392054
NA	CHEMICAL	GENE-Y	8	15	We studied the in vitro effects of noradrenaline, chemical, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T8	T11	11392054
NA	CHEMICAL	GENE-Y	8	15	We studied the in vitro effects of noradrenaline, chemical, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T8	T35	11392054
NA	CHEMICAL	GENE-Y	8	17	We studied the in vitro effects of noradrenaline, chemical, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T8	T12	11392054
NA	CHEMICAL	GENE-Y	8	17	We studied the in vitro effects of noradrenaline, chemical, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T8	T36	11392054
NA	CHEMICAL	GENE-Y	8	37	We studied the in vitro effects of noradrenaline, chemical, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T8	T38	11392054
NA	CHEMICAL	GENE-Y	23	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, chemical, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T18	T37	11392054
NA	CHEMICAL	GENE-Y	23	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, chemical, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T18	T11	11392054
NA	CHEMICAL	GENE-Y	23	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, chemical, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T18	T35	11392054
NA	CHEMICAL	GENE-Y	23	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, chemical, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T18	T12	11392054
NA	CHEMICAL	GENE-Y	23	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, chemical, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T18	T36	11392054
NA	CHEMICAL	GENE-Y	23	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, chemical, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T18	T38	11392054
NA	CHEMICAL	GENE-Y	15	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T11	T37	11392054
NA	CHEMICAL	GENE-Y	15	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T35	T37	11392054
NA	CHEMICAL	GENE-Y	15	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T11	T12	11392054
NA	CHEMICAL	GENE-Y	15	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T11	T36	11392054
NA	CHEMICAL	GENE-Y	15	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T35	T12	11392054
NA	CHEMICAL	GENE-Y	15	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T35	T36	11392054
NA	CHEMICAL	GENE-Y	15	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T11	T38	11392054
NA	CHEMICAL	GENE-Y	15	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, chemical, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T35	T38	11392054
NA	CHEMICAL	GENE-Y	11	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, chemical, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T9	T37	11392054
NA	CHEMICAL	GENE-Y	11	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, chemical, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T9	T11	11392054
NA	CHEMICAL	GENE-Y	11	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, chemical, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T9	T35	11392054
NA	CHEMICAL	GENE-Y	11	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, chemical, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T9	T12	11392054
NA	CHEMICAL	GENE-Y	11	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, chemical, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T9	T36	11392054
NA	CHEMICAL	GENE-Y	11	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, chemical, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T9	T38	11392054
NA	CHEMICAL	GENE-Y	13	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, chemical, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T10	T37	11392054
NA	CHEMICAL	GENE-Y	13	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, chemical, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T10	T11	11392054
NA	CHEMICAL	GENE-Y	13	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, chemical, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T10	T35	11392054
NA	CHEMICAL	GENE-Y	13	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, chemical, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T10	T12	11392054
NA	CHEMICAL	GENE-Y	13	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, chemical, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T10	T36	11392054
NA	CHEMICAL	GENE-Y	13	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, chemical, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T10	T38	11392054
NA	CHEMICAL	GENE-Y	7	33	We studied the in vitro effects of chemical, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T7	T37	11392054
NA	CHEMICAL	GENE-Y	7	15	We studied the in vitro effects of chemical, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T7	T11	11392054
NA	CHEMICAL	GENE-Y	7	15	We studied the in vitro effects of chemical, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T7	T35	11392054
NA	CHEMICAL	GENE-Y	7	17	We studied the in vitro effects of chemical, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T7	T12	11392054
NA	CHEMICAL	GENE-Y	7	17	We studied the in vitro effects of chemical, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T7	T36	11392054
NA	CHEMICAL	GENE-Y	7	37	We studied the in vitro effects of chemical, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T7	T38	11392054
NA	CHEMICAL	GENE-Y	18	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, chemical, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T13	T37	11392054
NA	CHEMICAL	GENE-Y	18	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, chemical, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T13	T11	11392054
NA	CHEMICAL	GENE-Y	18	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, chemical, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T13	T35	11392054
NA	CHEMICAL	GENE-Y	18	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, chemical, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T13	T12	11392054
NA	CHEMICAL	GENE-Y	18	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, chemical, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T13	T36	11392054
NA	CHEMICAL	GENE-Y	18	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, chemical, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T13	T38	11392054
NA	CHEMICAL	GENE-Y	20	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, chemical, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T15	T37	11392054
NA	CHEMICAL	GENE-Y	20	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, chemical, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T15	T11	11392054
NA	CHEMICAL	GENE-Y	20	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, chemical, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T15	T35	11392054
NA	CHEMICAL	GENE-Y	20	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, chemical, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T15	T12	11392054
NA	CHEMICAL	GENE-Y	20	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, chemical, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T15	T36	11392054
NA	CHEMICAL	GENE-Y	20	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, chemical, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T15	T38	11392054
NA	CHEMICAL	GENE-Y	17	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T12	T37	11392054
NA	CHEMICAL	GENE-Y	17	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T36	T37	11392054
NA	CHEMICAL	GENE-Y	17	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T12	T11	11392054
NA	CHEMICAL	GENE-Y	17	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T12	T35	11392054
NA	CHEMICAL	GENE-Y	17	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T36	T11	11392054
NA	CHEMICAL	GENE-Y	17	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T36	T35	11392054
NA	CHEMICAL	GENE-Y	17	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T12	T38	11392054
NA	CHEMICAL	GENE-Y	17	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, chemical, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T36	T38	11392054
NA	CHEMICAL	GENE-Y	26	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, chemical, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T20	T37	11392054
NA	CHEMICAL	GENE-Y	26	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, chemical, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T20	T11	11392054
NA	CHEMICAL	GENE-Y	26	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, chemical, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T20	T35	11392054
NA	CHEMICAL	GENE-Y	26	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, chemical, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T20	T12	11392054
NA	CHEMICAL	GENE-Y	26	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, chemical, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T20	T36	11392054
NA	CHEMICAL	GENE-Y	26	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, chemical, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T20	T38	11392054
NA	CHEMICAL	GENE-Y	25	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, chemical, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T19	T37	11392054
NA	CHEMICAL	GENE-Y	25	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, chemical, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T19	T11	11392054
NA	CHEMICAL	GENE-Y	25	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, chemical, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T19	T35	11392054
NA	CHEMICAL	GENE-Y	25	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, chemical, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T19	T12	11392054
NA	CHEMICAL	GENE-Y	25	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, chemical, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T19	T36	11392054
NA	CHEMICAL	GENE-Y	25	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, chemical, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T19	T38	11392054
NA	CHEMICAL	GENE-Y	30	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and chemical on purified gene and vascular smooth muscle CA I isolated from rabbits.	T23	T37	11392054
NA	CHEMICAL	GENE-Y	30	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and chemical on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T23	T11	11392054
NA	CHEMICAL	GENE-Y	30	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and chemical on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T23	T35	11392054
NA	CHEMICAL	GENE-Y	30	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and chemical on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T23	T12	11392054
NA	CHEMICAL	GENE-Y	30	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and chemical on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T23	T36	11392054
NA	CHEMICAL	GENE-Y	30	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and chemical on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T23	T38	11392054
NA	CHEMICAL	GENE-Y	27	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, chemical, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T21	T37	11392054
NA	CHEMICAL	GENE-Y	27	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, chemical, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T21	T11	11392054
NA	CHEMICAL	GENE-Y	27	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, chemical, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T21	T35	11392054
NA	CHEMICAL	GENE-Y	27	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, chemical, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T21	T12	11392054
NA	CHEMICAL	GENE-Y	27	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, chemical, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T21	T36	11392054
NA	CHEMICAL	GENE-Y	27	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, chemical, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T21	T38	11392054
NA	CHEMICAL	GENE-Y	28	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, chemical and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T22	T37	11392054
NA	CHEMICAL	GENE-Y	28	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, chemical and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T22	T11	11392054
NA	CHEMICAL	GENE-Y	28	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, chemical and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T22	T35	11392054
NA	CHEMICAL	GENE-Y	28	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, chemical and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T22	T12	11392054
NA	CHEMICAL	GENE-Y	28	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, chemical and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T22	T36	11392054
NA	CHEMICAL	GENE-Y	28	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, chemical and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T22	T38	11392054
NA	CHEMICAL	GENE-Y	22	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, chemical, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T17	T37	11392054
NA	CHEMICAL	GENE-Y	22	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, chemical, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T17	T11	11392054
NA	CHEMICAL	GENE-Y	22	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, clonidine, chemical, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T17	T35	11392054
NA	CHEMICAL	GENE-Y	22	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, chemical, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T17	T12	11392054
NA	CHEMICAL	GENE-Y	22	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, clonidine, chemical, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T17	T36	11392054
NA	CHEMICAL	GENE-Y	22	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, clonidine, chemical, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T17	T38	11392054
NA	CHEMICAL	GENE-Y	21	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, chemical, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T16	T37	11392054
NA	CHEMICAL	GENE-Y	21	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, chemical, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T16	T11	11392054
NA	CHEMICAL	GENE-Y	21	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, prazosin, hydralazine, chemical, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T16	T35	11392054
NA	CHEMICAL	GENE-Y	21	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, chemical, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T16	T12	11392054
NA	CHEMICAL	GENE-Y	21	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, prazosin, hydralazine, chemical, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T16	T36	11392054
NA	CHEMICAL	GENE-Y	21	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, prazosin, hydralazine, chemical, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T16	T38	11392054
NA	CHEMICAL	GENE-Y	19	33	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, chemical, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified gene and vascular smooth muscle CA I isolated from rabbits.	T14	T37	11392054
NA	CHEMICAL	GENE-Y	19	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, chemical, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T14	T11	11392054
NA	CHEMICAL	GENE-Y	19	15	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, gene, vasopressin, indomethacin, chemical, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T14	T35	11392054
NA	CHEMICAL	GENE-Y	19	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, chemical, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T14	T12	11392054
NA	CHEMICAL	GENE-Y	19	17	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, gene, indomethacin, chemical, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell CA I and vascular smooth muscle CA I isolated from rabbits.	T14	T36	11392054
NA	CHEMICAL	GENE-Y	19	37	We studied the in vitro effects of noradrenaline, prostaglandin F2 alpha, thromboxane A2, leukotriene B4, angiotensin II, vasopressin, indomethacin, chemical, hydralazine, clonidine, reserpine, prostaglandin I2, indapamide, furosemide, amlodipine, verapamil and irbesartan on purified human red blood cell gene and vascular smooth muscle gene isolated from rabbits.	T14	T38	11392054
NA	CHEMICAL	GENE-Y	18	4	The temporal profile of gene (BuChE) and in vitro pralidoxime-reactivated BuChE was studied in a cohort of 25 chemical-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	T2	T14	11393267
NA	CHEMICAL	GENE-Y	18	5	The temporal profile of butyrylcholinesterase (gene) and in vitro pralidoxime-reactivated gene was studied in a cohort of 25 chemical-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	T2	T16	11393267
NA	CHEMICAL	GENE-Y	18	5	The temporal profile of butyrylcholinesterase (gene) and in vitro pralidoxime-reactivated gene was studied in a cohort of 25 chemical-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	T2	T18	11393267
NA	CHEMICAL	GENE-Y	9	4	The temporal profile of gene (BuChE) and in vitro chemical-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	T6	T14	11393267
NA	CHEMICAL	GENE-Y	9	5	The temporal profile of butyrylcholinesterase (gene) and in vitro chemical-reactivated gene was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	T6	T16	11393267
CPR:3	CHEMICAL	GENE-Y	9	5	The temporal profile of butyrylcholinesterase (gene) and in vitro chemical-reactivated gene was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of oxime treatment.	T6	T18	11393267
NA	CHEMICAL	GENE-Y	9	4	The temporal profile of gene (BuChE) and in vitro pralidchemical-reactivated BuChE was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of chemical treatment.	T5	T14	11393267
NA	CHEMICAL	GENE-Y	9	5	The temporal profile of butyrylcholinesterase (gene) and in vitro pralidchemical-reactivated gene was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of chemical treatment.	T5	T16	11393267
NA	CHEMICAL	GENE-Y	9	5	The temporal profile of butyrylcholinesterase (gene) and in vitro pralidchemical-reactivated gene was studied in a cohort of 25 organophosphate-poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of chemical treatment.	T5	T18	11393267
CPR:4	CHEMICAL	GENE-Y	17	3	Reactivation potentials of gene (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after chemical ingestion.	T8	T17	11393267
CPR:3	CHEMICAL	GENE-Y	7	3	Reactivation potentials of gene (the difference between chemical-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.	T7	T17	11393267
CPR:4	CHEMICAL	GENE-Y	3	18	Patients who received chemical prior to hospitalization had a higher rate of intermediate syndrome and lower levels of gene at admission than those who had not.	T1	T11	11393267
NA	CHEMICAL	GENE-Y	32	5	The study suggests that (i) gene reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of gene; and (iii) the lack of chemical efficacy in our patients maybe due to their severity of poisoning and the timing of chemical treatment.	T3	T12	11393267
NA	CHEMICAL	GENE-Y	32	5	The study suggests that (i) gene reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of gene; and (iii) the lack of chemical efficacy in our patients maybe due to their severity of poisoning and the timing of chemical treatment.	T3	T13	11393267
NA	CHEMICAL	GENE-Y	32	5	The study suggests that (i) gene reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of gene; and (iii) the lack of chemical efficacy in our patients maybe due to their severity of poisoning and the timing of chemical treatment.	T4	T12	11393267
NA	CHEMICAL	GENE-Y	32	5	The study suggests that (i) gene reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of gene; and (iii) the lack of chemical efficacy in our patients maybe due to their severity of poisoning and the timing of chemical treatment.	T4	T13	11393267
CPR:5	CHEMICAL	GENE-N	11	6	The segments were contracted with the gene agonists brimonidine, apraclonidine, and chemical.	T18	T29	11481271
CPR:5	CHEMICAL	GENE-N	9	6	The segments were contracted with the gene agonists brimonidine, chemical, and oxymetazoline.	T17	T29	11481271
CPR:5	CHEMICAL	GENE-N	8	6	The segments were contracted with the gene agonists chemical, apraclonidine, and oxymetazoline.	T16	T29	11481271
NA	CHEMICAL	GENE-N	26	15	To determine which subtypes of the alpha(2)-adrenoceptor mediate this contraction, antagonists subselective for the different gene were added to the vessel bath before concentration-response curves for chemical were obtained.	T19	T31	11481271
NA	CHEMICAL	GENE-N	26	6	To determine which subtypes of the gene mediate this contraction, antagonists subselective for the different genes were added to the vessel bath before concentration-response curves for chemical were obtained.	T19	T30	11481271
NA	CHEMICAL	GENE-N	13	2	The following gene antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and chemical (alpha(2B)- and alpha(2C)-selective).	T22	T32	11481271
NA	CHEMICAL	GENE-Y	13	7	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (gene-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and chemical (alpha(2B)- and alpha(2C)-selective).	T22	T33	11481271
NA	CHEMICAL	GENE-Y	13	9	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (gene- and alpha(2C)-selective), and chemical (gene- and alpha(2C)-selective).	T22	T34	11481271
CPR:6	CHEMICAL	GENE-Y	13	9	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (gene- and alpha(2C)-selective), and chemical (gene- and alpha(2C)-selective).	T22	T36	11481271
NA	CHEMICAL	GENE-Y	13	11	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and gene-selective), and chemical (alpha(2B)- and gene-selective).	T22	T35	11481271
CPR:6	CHEMICAL	GENE-Y	13	11	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and gene-selective), and chemical (alpha(2B)- and gene-selective).	T22	T37	11481271
NA	CHEMICAL	GENE-N	6	2	The following gene antagonists were applied: chemical (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	T20	T32	11481271
CPR:6	CHEMICAL	GENE-Y	6	7	The following alpha(2)-adrenoceptor antagonists were applied: chemical (gene-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	T20	T33	11481271
NA	CHEMICAL	GENE-Y	6	9	The following alpha(2)-adrenoceptor antagonists were applied: chemical (alpha(2A)-selective), ARC239 (gene- and alpha(2C)-selective), and prazosin (gene- and alpha(2C)-selective).	T20	T34	11481271
NA	CHEMICAL	GENE-Y	6	9	The following alpha(2)-adrenoceptor antagonists were applied: chemical (alpha(2A)-selective), ARC239 (gene- and alpha(2C)-selective), and prazosin (gene- and alpha(2C)-selective).	T20	T36	11481271
NA	CHEMICAL	GENE-Y	6	11	The following alpha(2)-adrenoceptor antagonists were applied: chemical (alpha(2A)-selective), ARC239 (alpha(2B)- and gene-selective), and prazosin (alpha(2B)- and gene-selective).	T20	T35	11481271
NA	CHEMICAL	GENE-Y	6	11	The following alpha(2)-adrenoceptor antagonists were applied: chemical (alpha(2A)-selective), ARC239 (alpha(2B)- and gene-selective), and prazosin (alpha(2B)- and gene-selective).	T20	T37	11481271
NA	CHEMICAL	GENE-N	8	2	The following gene antagonists were applied: BRL44408 (alpha(2A)-selective), chemical (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	T21	T32	11481271
NA	CHEMICAL	GENE-Y	8	7	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (gene-selective), chemical (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).	T21	T33	11481271
CPR:6	CHEMICAL	GENE-Y	8	9	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), chemical (gene- and alpha(2C)-selective), and prazosin (gene- and alpha(2C)-selective).	T21	T34	11481271
NA	CHEMICAL	GENE-Y	8	9	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), chemical (gene- and alpha(2C)-selective), and prazosin (gene- and alpha(2C)-selective).	T21	T36	11481271
CPR:6	CHEMICAL	GENE-Y	8	11	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), chemical (alpha(2B)- and gene-selective), and prazosin (alpha(2B)- and gene-selective).	T21	T35	11481271
NA	CHEMICAL	GENE-Y	8	11	The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), chemical (alpha(2B)- and gene-selective), and prazosin (alpha(2B)- and gene-selective).	T21	T37	11481271
CPR:5	CHEMICAL	GENE-N	22	2	RESULTS: The gene agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, chemical 5.26, and apraclonidine 13.0.	T2	T38	11481271
CPR:5	CHEMICAL	GENE-N	25	2	RESULTS: The gene agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and chemical 13.0.	T3	T38	11481271
CPR:5	CHEMICAL	GENE-N	20	2	RESULTS: The gene agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: chemical 2.11, oxymetazoline 5.26, and apraclonidine 13.0.	T1	T38	11481271
NA	CHEMICAL	GENE-Y	6	34	Schild analyses for the antagonists against chemical yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional gene.	T9	T24	11481271
CPR:6	CHEMICAL	GENE-Y	27	34	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for chemical (6.0) suggesting the presence of functional gene.	T12	T24	11481271
CPR:6	CHEMICAL	GENE-Y	20	34	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for chemical (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional gene.	T10	T24	11481271
CPR:6	CHEMICAL	GENE-Y	22	34	Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), chemical (5.8) and for prazosin (6.0) suggesting the presence of functional gene.	T11	T24	11481271
CPR:5	CHEMICAL	GENE-N	7	2	CONCLUSIONS: The gene agonists brimonidine, apraclonidine, and chemical are potent vasoconstrictors in the porcine ciliary artery.	T15	T26	11481271
CPR:5	CHEMICAL	GENE-N	5	2	CONCLUSIONS: The gene agonists brimonidine, chemical, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.	T14	T26	11481271
CPR:5	CHEMICAL	GENE-N	4	2	CONCLUSIONS: The gene agonists chemical, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.	T13	T26	11481271
NA	CHEMICAL	GENE-Y	19	16	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, gene, and chemical formyltransferase.	T4	T15	11742712
NA	CHEMICAL	GENE-Y	19	14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, gene, dihydrofolate reductase, and chemical formyltransferase.	T4	T14	11742712
CPR:4	CHEMICAL	GENE-Y	0	19	chemical (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and gene.	T1	T16	11742712
CPR:4	CHEMICAL	GENE-Y	0	16	chemical (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, gene, and glycinamide ribonucleotide formyltransferase.	T1	T15	11742712
CPR:4	CHEMICAL	GENE-Y	0	14	chemical (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, gene, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.	T1	T14	11742712
NA	CHEMICAL	GENE-Y	16	19	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, chemical reductase, and gene.	T3	T16	11742712
NA	CHEMICAL	GENE-Y	16	14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, gene, chemical reductase, and glycinamide ribonucleotide formyltransferase.	T3	T14	11742712
NA	CHEMICAL	GENE-Y	14	19	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, chemical synthase, dihydrofolate reductase, and gene.	T2	T16	11742712
NA	CHEMICAL	GENE-Y	14	16	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, chemical synthase, gene, and glycinamide ribonucleotide formyltransferase.	T2	T15	11742712
CPR:4	CHEMICAL	GENE-Y	2	19	Pemetrexed disodium (chemical) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and gene.	T6	T16	11742712
CPR:4	CHEMICAL	GENE-Y	2	16	Pemetrexed disodium (chemical) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, gene, and glycinamide ribonucleotide formyltransferase.	T6	T15	11742712
CPR:4	CHEMICAL	GENE-Y	2	14	Pemetrexed disodium (chemical) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, gene, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.	T6	T14	11742712
NA	CHEMICAL	GENE-Y	12	19	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three chemical-dependent enzymes, thymidylate synthase, dihydrochemical reductase, and gene.	T11	T16	11742712
NA	CHEMICAL	GENE-Y	12	14	Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three chemical-dependent enzymes, gene, dihydrochemical reductase, and glycinamide ribonucleotide formyltransferase.	T11	T14	11742712
NA	CHEMICAL	GENE-Y	11	7	In organisms that synthesize tetrahydrofolate de novo, gene (DHFS) and chemical synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T11	T26	11752472
NA	CHEMICAL	GENE-Y	11	9	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (gene) and chemical synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T11	T27	11752472
NA	CHEMICAL	GENE-Y	11	13	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and chemical synthetase (gene) catalyze the attachment of glutamate residues to the folate molecule.	T11	T29	11752472
NA	CHEMICAL	GENE-N	11	13	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and chemical synthetase (gene) catalyze the attachment of glutamate residues to the folate molecule.	T11	T29	11752472
NA	CHEMICAL	GENE-N	4	11	In organisms that synthesize chemical de novo, dihydrofolate synthetase (DHFS) and gene (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T5	T28	11752472
NA	CHEMICAL	GENE-Y	4	7	In organisms that synthesize chemical de novo, gene (DHFS) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T5	T26	11752472
NA	CHEMICAL	GENE-Y	4	9	In organisms that synthesize chemical de novo, dihydrofolate synthetase (gene) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T5	T27	11752472
NA	CHEMICAL	GENE-Y	4	13	In organisms that synthesize chemical de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (gene) catalyze the attachment of glutamate residues to the folate molecule.	T5	T29	11752472
NA	CHEMICAL	GENE-N	4	13	In organisms that synthesize chemical de novo, dihydrofolate synthetase (DHFS) and folylpolyglutamate synthetase (gene) catalyze the attachment of glutamate residues to the folate molecule.	T5	T29	11752472
NA	CHEMICAL	GENE-N	7	11	In organisms that synthesize tetrahydrofolate de novo, chemical synthetase (DHFS) and gene (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T9	T28	11752472
NA	CHEMICAL	GENE-Y	7	9	In organisms that synthesize tetrahydrofolate de novo, chemical synthetase (gene) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the folate molecule.	T9	T27	11752472
NA	CHEMICAL	GENE-Y	7	13	In organisms that synthesize tetrahydrofolate de novo, chemical synthetase (DHFS) and folylpolyglutamate synthetase (gene) catalyze the attachment of glutamate residues to the folate molecule.	T9	T29	11752472
NA	CHEMICAL	GENE-N	7	13	In organisms that synthesize tetrahydrofolate de novo, chemical synthetase (DHFS) and folylpolyglutamate synthetase (gene) catalyze the attachment of glutamate residues to the folate molecule.	T9	T29	11752472
NA	CHEMICAL	GENE-Y	11	7	In organisms that synthesize tetrahydrofolate de novo, gene (DHFS) and folylpolychemical synthetase (FPGS) catalyze the attachment of chemical residues to the folate molecule.	T12	T26	11752472
NA	CHEMICAL	GENE-Y	11	9	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (gene) and folylpolychemical synthetase (FPGS) catalyze the attachment of chemical residues to the folate molecule.	T12	T27	11752472
NA	CHEMICAL	GENE-Y	11	13	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and folylpolychemical synthetase (gene) catalyze the attachment of chemical residues to the folate molecule.	T12	T29	11752472
NA	CHEMICAL	GENE-N	11	13	In organisms that synthesize tetrahydrofolate de novo, dihydrofolate synthetase (DHFS) and folylpolychemical synthetase (gene) catalyze the attachment of chemical residues to the folate molecule.	T12	T29	11752472
NA	CHEMICAL	GENE-N	4	11	In organisms that synthesize tetrahydrochemical de novo, dihydrochemical synthetase (DHFS) and gene (FPGS) catalyze the attachment of glutamate residues to the chemical molecule.	T13	T28	11752472
NA	CHEMICAL	GENE-Y	4	9	In organisms that synthesize tetrahydrochemical de novo, dihydrochemical synthetase (gene) and folylpolyglutamate synthetase (FPGS) catalyze the attachment of glutamate residues to the chemical molecule.	T13	T27	11752472
NA	CHEMICAL	GENE-Y	4	13	In organisms that synthesize tetrahydrochemical de novo, dihydrochemical synthetase (DHFS) and folylpolyglutamate synthetase (gene) catalyze the attachment of glutamate residues to the chemical molecule.	T13	T29	11752472
NA	CHEMICAL	GENE-N	4	13	In organisms that synthesize tetrahydrochemical de novo, dihydrochemical synthetase (DHFS) and folylpolyglutamate synthetase (gene) catalyze the attachment of glutamate residues to the chemical molecule.	T13	T29	11752472
NA	CHEMICAL	GENE-Y	28	14	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in gene or FPGS activity, and by measuring in vitro glutamate incorporation into dihydrofolate or chemical.	T18	T32	11752472
NA	CHEMICAL	GENE-Y	28	16	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or gene activity, and by measuring in vitro glutamate incorporation into dihydrofolate or chemical.	T18	T33	11752472
NA	CHEMICAL	GENE-N	28	16	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or gene activity, and by measuring in vitro glutamate incorporation into dihydrofolate or chemical.	T18	T33	11752472
NA	CHEMICAL	GENE-Y	26	14	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in gene or FPGS activity, and by measuring in vitro glutamate incorporation into chemical or tetrahydrofolate.	T17	T32	11752472
NA	CHEMICAL	GENE-Y	26	16	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or gene activity, and by measuring in vitro glutamate incorporation into chemical or tetrahydrofolate.	T17	T33	11752472
NA	CHEMICAL	GENE-N	26	16	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or gene activity, and by measuring in vitro glutamate incorporation into chemical or tetrahydrofolate.	T17	T33	11752472
NA	CHEMICAL	GENE-Y	23	14	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in gene or FPGS activity, and by measuring in vitro chemical incorporation into dihydrofolate or tetrahydrofolate.	T16	T32	11752472
NA	CHEMICAL	GENE-Y	23	16	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or gene activity, and by measuring in vitro chemical incorporation into dihydrofolate or tetrahydrofolate.	T16	T33	11752472
NA	CHEMICAL	GENE-N	23	16	The function of each enzyme was demonstrated by complementation of yeast mutants deficient in DHFS or gene activity, and by measuring in vitro chemical incorporation into dihydrofolate or tetrahydrofolate.	T16	T33	11752472
CPR:9	CHEMICAL	GENE-Y	16	0	gene is present exclusively in the mitochondria, making this compartment the sole site of synthesis of chemical in the plant cell.	T19	T34	11752472
NA	CHEMICAL	GENE-N	12	22	The compartmentation of FPGS isoforms is in agreement with the predominance of chemical derivatives and the presence of serine hydroxymethyltransferase and gene in the cytosol, the mitochondria, and the plastids.	T2	T23	11752472
NA	CHEMICAL	GENE-N	12	19	The compartmentation of FPGS isoforms is in agreement with the predominance of chemical derivatives and the presence of gene and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T2	T22	11752472
NA	CHEMICAL	GENE-Y	12	3	The compartmentation of gene isoforms is in agreement with the predominance of chemical derivatives and the presence of serine hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T2	T36	11752472
NA	CHEMICAL	GENE-N	12	3	The compartmentation of gene isoforms is in agreement with the predominance of chemical derivatives and the presence of serine hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T2	T36	11752472
NA	CHEMICAL	GENE-N	22	19	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of gene and chemical interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T4	T22	11752472
NA	CHEMICAL	GENE-Y	22	3	The compartmentation of gene isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of serine hydroxymethyltransferase and chemical interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T4	T36	11752472
NA	CHEMICAL	GENE-N	22	3	The compartmentation of gene isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of serine hydroxymethyltransferase and chemical interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T4	T36	11752472
NA	CHEMICAL	GENE-N	19	22	The compartmentation of FPGS isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of chemical hydroxymethyltransferase and gene in the cytosol, the mitochondria, and the plastids.	T3	T23	11752472
NA	CHEMICAL	GENE-Y	19	3	The compartmentation of gene isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of chemical hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T3	T36	11752472
NA	CHEMICAL	GENE-N	19	3	The compartmentation of gene isoforms is in agreement with the predominance of gamma-glutamyl-conjugated tetrahydrofolate derivatives and the presence of chemical hydroxymethyltransferase and C1-tetrahydrofolate interconverting enzymes in the cytosol, the mitochondria, and the plastids.	T3	T36	11752472
NA	CHEMICAL	GENE-Y	7	4	Thus, the combination of gene with these chemical-mediated reactions can supply each compartment with the polyglutamylated chemical coenzymes required for the reactions of C1 metabolism.	T6	T24	11752472
NA	CHEMICAL	GENE-Y	7	4	Thus, the combination of gene with these chemical-mediated reactions can supply each compartment with the polyglutamylated chemical coenzymes required for the reactions of C1 metabolism.	T7	T24	11752472
NA	CHEMICAL	GENE-N	7	4	Thus, the combination of gene with these chemical-mediated reactions can supply each compartment with the polyglutamylated chemical coenzymes required for the reactions of C1 metabolism.	T6	T24	11752472
NA	CHEMICAL	GENE-N	7	4	Thus, the combination of gene with these chemical-mediated reactions can supply each compartment with the polyglutamylated chemical coenzymes required for the reactions of C1 metabolism.	T7	T24	11752472
NA	CHEMICAL	GENE-Y	23	4	Thus, the combination of gene with these folate-mediated reactions can supply each compartment with the polyglutamylated folate coenzymes required for the reactions of chemical metabolism.	T8	T24	11752472
NA	CHEMICAL	GENE-N	23	4	Thus, the combination of gene with these folate-mediated reactions can supply each compartment with the polyglutamylated folate coenzymes required for the reactions of chemical metabolism.	T8	T24	11752472
NA	CHEMICAL	GENE-Y	15	4	Also, the multicompartmentation of gene in the plant cell suggests that the transported forms of chemical are unconjugated.	T10	T25	11752472
NA	CHEMICAL	GENE-N	15	4	Also, the multicompartmentation of gene in the plant cell suggests that the transported forms of chemical are unconjugated.	T10	T25	11752472
CPR:4	CHEMICAL	GENE-N	1	7	UNLABELLED: chemical is an inhibitor of the gene.	T7	T33	11772142
CPR:4	CHEMICAL	GENE-N	1	6	CONCLUSION: chemical is a well tolerated gene inhibitor.	T18	T31	11772142
NA	CHEMICAL	GENE-Y	6	0	gene is the main determinant of chemical levels.	T19	T31	11799102
NA	CHEMICAL	GENE-Y	6	0	gene is the main determinant of chemical levels.	T43	T31	11799102
NA	CHEMICAL	GENE-Y	7	14	It, therefore, always appeared desirable to reduce chemical levels by direct inhibition of gene.	T2	T35	11799102
NA	CHEMICAL	GENE-Y	7	14	It, therefore, always appeared desirable to reduce chemical levels by direct inhibition of gene.	T33	T35	11799102
CPR:4	CHEMICAL	GENE-Y	12	7	We tested the new orally active nonpeptidic gene inhibitor SPP100 (Aliskiren, an chemical with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.	T18	T42	11799102
CPR:4	CHEMICAL	GENE-Y	10	7	We tested the new orally active nonpeptidic gene inhibitor SPP100 (chemical, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.	T17	T42	11799102
CPR:4	CHEMICAL	GENE-Y	9	7	We tested the new orally active nonpeptidic gene inhibitor chemical (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.	T16	T42	11799102
NA	CHEMICAL	GENE-Y	33	7	We tested the new orally active nonpeptidic gene inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d chemical diet using a double-blind, 3-way crossover protocol.	T20	T42	11799102
NA	CHEMICAL	GENE-Y	18	12	There was a dose-dependent decrease in plasma renin activity, Ang I, and gene following single doses of chemical starting with 40 mg.	T26	T25	11799102
CPR:4	CHEMICAL	GENE-Y	18	12	There was a dose-dependent decrease in plasma renin activity, Ang I, and gene following single doses of chemical starting with 40 mg.	T26	T46	11799102
CPR:4	CHEMICAL	GENE-Y	18	7	There was a dose-dependent decrease in plasma gene activity, Ang I, and Ang II following single doses of chemical starting with 40 mg.	T26	T44	11799102
NA	CHEMICAL	GENE-Y	18	9	There was a dose-dependent decrease in plasma renin activity, gene, and geneI following single doses of chemical starting with 40 mg.	T26	T24	11799102
CPR:4	CHEMICAL	GENE-Y	18	9	There was a dose-dependent decrease in plasma renin activity, gene, and geneI following single doses of chemical starting with 40 mg.	T26	T45	11799102
NA	CHEMICAL	GENE-Y	12	7	There was a dose-dependent decrease in plasma gene activity, Ang I, and chemical following single doses of Aliskiren starting with 40 mg.	T25	T44	11799102
NA	CHEMICAL	GENE-Y	12	7	There was a dose-dependent decrease in plasma gene activity, Ang I, and chemical following single doses of Aliskiren starting with 40 mg.	T46	T44	11799102
NA	CHEMICAL	GENE-Y	9	7	There was a dose-dependent decrease in plasma gene activity, chemical, and chemicalI following single doses of Aliskiren starting with 40 mg.	T24	T44	11799102
NA	CHEMICAL	GENE-Y	9	7	There was a dose-dependent decrease in plasma gene activity, chemical, and chemicalI following single doses of Aliskiren starting with 40 mg.	T45	T44	11799102
NA	CHEMICAL	GENE-Y	31	13	Inhibition was still marked and significant after repeated dosing with maximal decreases in gene levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of chemical was compared with placebo.	T3	T1	11799102
CPR:4	CHEMICAL	GENE-Y	31	13	Inhibition was still marked and significant after repeated dosing with maximal decreases in gene levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of chemical was compared with placebo.	T3	T32	11799102
CPR:3	CHEMICAL	GENE-Y	18	7	At the same time, mean plasma active gene was increased 16- and 34-fold at the highest dose of chemical.	T4	T34	11799102
NA	CHEMICAL	GENE-Y	5	8	In conclusion, the renin inhibitor chemical dose-dependently decreases gene levels in humans following oral administration.	T11	T12	11799102
CPR:4	CHEMICAL	GENE-Y	5	8	In conclusion, the renin inhibitor chemical dose-dependently decreases gene levels in humans following oral administration.	T11	T38	11799102
CPR:4	CHEMICAL	GENE-Y	5	3	In conclusion, the gene inhibitor chemical dose-dependently decreases Ang II levels in humans following oral administration.	T11	T37	11799102
NA	CHEMICAL	GENE-Y	8	3	In conclusion, the gene inhibitor Aliskiren dose-dependently decreases chemical levels in humans following oral administration.	T12	T37	11799102
NA	CHEMICAL	GENE-Y	8	3	In conclusion, the gene inhibitor Aliskiren dose-dependently decreases chemical levels in humans following oral administration.	T38	T37	11799102
CPR:6	CHEMICAL	GENE-N	0	20	chemical has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and gene antagonists in therapy for hypertension and other cardiovascular and renal diseases.	T14	T41	11799102
NA	CHEMICAL	GENE-Y	0	20	chemical has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and gene receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	T14	T15	11799102
CPR:4	CHEMICAL	GENE-Y	0	10	chemical has the potential to become the first orally active gene inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	T14	T39	11799102
CPR:4	CHEMICAL	GENE-Y	0	18	chemical has the potential to become the first orally active renin inhibitor that provides a true alternative to gene-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	T14	T40	11799102
NA	CHEMICAL	GENE-Y	20	10	Aliskiren has the potential to become the first orally active gene inhibitor that provides a true alternative to ACE-inhibitors and chemical receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	T15	T39	11799102
NA	CHEMICAL	GENE-Y	20	18	Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to gene-inhibitors and chemical receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	T15	T40	11799102
NA	CHEMICAL	GENE-Y	13	7	Almost all patients with SUR1 (38/41) or gene (5/7) mutations were resistant to chemical.	T3	T12	11808879
NA	CHEMICAL	GENE-Y	13	4	Almost all patients with gene (38/41) or KIR6.2 (5/7) mutations were resistant to chemical.	T3	T11	11808879
CPR:4	CHEMICAL	GENE-Y	6	3	The earliest known gene inhibitors, namely, chemical and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).	T1	T7	11893059
CPR:4	CHEMICAL	GENE-Y	8	3	The earliest known gene inhibitors, namely, physostigmine and chemical, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).	T2	T7	11893059
CPR:4	CHEMICAL	GENE-Y	0	7	chemical inaugurates a new class of gene inhibitors with longer and more selective action and with manageable adverse effects.	T3	T8	11893059
NA	CHEMICAL	GENE-N	8	40	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase gene phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T3	11970990
NA	CHEMICAL	GENE-N	8	13	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the gene that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T23	11970990
NA	CHEMICAL	GENE-N	8	18	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact gene binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T24	11970990
NA	CHEMICAL	GENE-Y	8	57	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of gene. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T6	11970990
NA	CHEMICAL	GENE-Y	8	31	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing gene and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T26	11970990
NA	CHEMICAL	GENE-Y	8	4	Experimentation using isoforms of gene engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that gene mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T22	11970990
NA	CHEMICAL	GENE-Y	8	4	Experimentation using isoforms of gene engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that gene mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T25	11970990
NA	CHEMICAL	GENE-N	8	34	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and gene to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and gene and be mediated through gene, but not CD2.	T1	T10	11970990
NA	CHEMICAL	GENE-N	8	34	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and gene to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and gene and be mediated through gene, but not CD2.	T1	T27	11970990
NA	CHEMICAL	GENE-N	8	34	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and gene to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and gene and be mediated through gene, but not CD2.	T1	T9	11970990
NA	CHEMICAL	GENE-Y	8	52	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker gene, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to CD2 and CD16 and be mediated through CD16, but not CD2.	T1	T5	11970990
NA	CHEMICAL	GENE-Y	8	32	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human gene and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker gene5, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to gene and CD16 and be mediated through CD16, but not gene.	T1	T11	11970990
NA	CHEMICAL	GENE-Y	8	32	Experimentation using isoforms of alefacept engineered to have chemical substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human gene and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker gene5, and induce release of granzyme B. In the systems used, this signaling is shown to require binding to gene and CD16 and be mediated through CD16, but not gene.	T1	T8	11970990
CPR:4	CHEMICAL	GENE-Y	0	19	chemical--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of gene.	T1	T4	12046682
CPR:4	CHEMICAL	GENE-Y	3	18	As a prodrug chemical is completely converted to its active metabolite A 77 1726 (M1) which blocks the gene, a key enzyme of the pyrimidine de novo synthesis.	T1	T11	12063741
NA	CHEMICAL	GENE-Y	25	18	As a prodrug leflunomide is completely converted to its active metabolite A 77 1726 (M1) which blocks the gene, a key enzyme of the chemical de novo synthesis.	T5	T11	12063741
CPR:4	CHEMICAL	GENE-Y	11	18	As a prodrug leflunomide is completely converted to its active metabolite chemical (M1) which blocks the gene, a key enzyme of the pyrimidine de novo synthesis.	T2	T11	12063741
NA	CHEMICAL	GENE-Y	11	8	Endocrine therapy is first-line therapy for patients with gene-positive or chemical receptor-positive metastatic breast cancer.	T17	T22	12080538
NA	CHEMICAL	GENE-Y	8	11	Endocrine therapy is first-line therapy for patients with chemical receptor-positive or gene-positive metastatic breast cancer.	T12	T25	12080538
NA	CHEMICAL	GENE-Y	6	9	Commonly used endocrine therapies are tamoxifen, chemical, and gene inhibitors.	T7	T20	12080538
NA	CHEMICAL	GENE-Y	5	9	Commonly used endocrine therapies are chemical, megestrol acetate, and gene inhibitors.	T6	T20	12080538
NA	CHEMICAL	GENE-Y	10	1	The gene inhibitors are currently used as second-line therapy after chemical failure.	T13	T21	12080538
CPR:4	CHEMICAL	GENE-Y	5	7	A recent study showed that chemical, an gene inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.	T14	T23	12080538
NA	CHEMICAL	GENE-Y	16	7	A recent study showed that anastrozole, an gene inhibitor, is as effective or even superior to chemical when used as a first-line therapy.	T15	T23	12080538
CPR:4	CHEMICAL	GENE-Y	0	15	chemical, the first agent in this new class, not only induces the degradation of the gene but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.	T18	T19	12080538
CPR:4	CHEMICAL	GENE-Y	0	5	chemical, a specific inhibitor of gene, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.	T16	T29	12082550
NA	CHEMICAL	GENE-Y	3	6	These included diazepam-binding inhibitor/chemical-binding protein, the gene and rhoA.	T3	T24	12082550
NA	CHEMICAL	GENE-Y	3	2	These included gene/chemical-binding protein, the activated transcription factor 4 and rhoA.	T3	T22	12082550
NA	CHEMICAL	GENE-Y	3	11	These included diazepam-binding inhibitor/chemical-binding protein, the activated transcription factor 4 and gene.	T3	T25	12082550
NA	CHEMICAL	GENE-Y	2	6	These included chemical-binding inhibitor/acyl-CoA-binding protein, the gene and rhoA.	T2	T24	12082550
NA	CHEMICAL	GENE-Y	2	3	These included chemical-binding inhibitor/gene the activated transcription factor 4 and rhoA.	T2	T23	12082550
NA	CHEMICAL	GENE-Y	2	11	These included chemical-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and gene.	T2	T25	12082550
NA	CHEMICAL	GENE-Y	26	1	Because gene requires GGPP for its function, this links the microarray and biochemical data and identifies gene as a potential mediator of the anticancer properties of chemical.	T11	T26	12082550
NA	CHEMICAL	GENE-Y	26	1	Because gene requires GGPP for its function, this links the microarray and biochemical data and identifies gene as a potential mediator of the anticancer properties of chemical.	T11	T27	12082550
NA	CHEMICAL	GENE-Y	3	1	Because gene requires chemical for its function, this links the microarray and biochemical data and identifies gene as a potential mediator of the anticancer properties of lovastatin.	T10	T26	12082550
NA	CHEMICAL	GENE-Y	3	1	Because gene requires chemical for its function, this links the microarray and biochemical data and identifies gene as a potential mediator of the anticancer properties of lovastatin.	T10	T27	12082550
NA	CHEMICAL	GENE-N	1	5	The chemical transporter (NET) regulates gene signaling by controlling the availability of synaptic chemical (NE), and it is a direct target for some classes of antidepressant drugs.	T1	T24	12137927
NA	CHEMICAL	GENE-N	1	5	The chemical transporter (NET) regulates gene signaling by controlling the availability of synaptic chemical (NE), and it is a direct target for some classes of antidepressant drugs.	T5	T24	12137927
NA	CHEMICAL	GENE-Y	1	3	The chemical transporter (gene) regulates adrenoreceptor signaling by controlling the availability of synaptic chemical (NE), and it is a direct target for some classes of antidepressant drugs.	T1	T20	12137927
NA	CHEMICAL	GENE-Y	1	3	The chemical transporter (gene) regulates adrenoreceptor signaling by controlling the availability of synaptic chemical (NE), and it is a direct target for some classes of antidepressant drugs.	T5	T20	12137927
NA	CHEMICAL	GENE-Y	3	1	The gene (chemicalT) regulates adrenoreceptor signaling by controlling the availability of synaptic norepinephrine (chemical), and it is a direct target for some classes of antidepressant drugs.	T2	T22	12137927
NA	CHEMICAL	GENE-N	3	5	The norepinephrine transporter (chemicalT) regulates gene signaling by controlling the availability of synaptic norepinephrine (chemical), and it is a direct target for some classes of antidepressant drugs.	T2	T24	12137927
NA	CHEMICAL	GENE-Y	0	5	chemicalT levels are normal in gene knockout (Dbh -/-) mice that lack chemical, demonstrating that the chemicalT does not require endogenous chemical for appropriate regulation under physiological conditions.	T3	T17	12137927
NA	CHEMICAL	GENE-Y	0	5	chemicalT levels are normal in gene knockout (Dbh -/-) mice that lack chemical, demonstrating that the chemicalT does not require endogenous chemical for appropriate regulation under physiological conditions.	T4	T17	12137927
NA	CHEMICAL	GENE-Y	0	8	chemicalT levels are normal in dopamine beta-hydroxylase knockout (gene -/-) mice that lack chemical, demonstrating that the chemicalT does not require endogenous chemical for appropriate regulation under physiological conditions.	T3	T18	12137927
NA	CHEMICAL	GENE-Y	0	8	chemicalT levels are normal in dopamine beta-hydroxylase knockout (gene -/-) mice that lack chemical, demonstrating that the chemicalT does not require endogenous chemical for appropriate regulation under physiological conditions.	T4	T18	12137927
NA	CHEMICAL	GENE-Y	30	2	In contrast, gene knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of chemical and not NE per se.	T9	T21	12137927
NA	CHEMICAL	GENE-Y	30	19	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (DA) have reduced levels of gene, suggesting that it is down-regulated by a complete absence of chemical and not NE per se.	T9	T25	12137927
NA	CHEMICAL	GENE-Y	30	5	In contrast, tyrosine hydroxylase knockout (gene -/-) mice that lack both NE and dopamine (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of chemical and not NE per se.	T9	T23	12137927
NA	CHEMICAL	GENE-Y	13	2	In contrast, gene knockout (Th -/-) mice that lack both NE and chemical (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	T7	T21	12137927
NA	CHEMICAL	GENE-Y	13	19	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and chemical (DA) have reduced levels of gene, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	T7	T25	12137927
NA	CHEMICAL	GENE-Y	13	5	In contrast, tyrosine hydroxylase knockout (gene -/-) mice that lack both NE and chemical (DA) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	T7	T23	12137927
NA	CHEMICAL	GENE-Y	14	2	In contrast, gene knockout (Th -/-) mice that lack both NE and dopamine (chemical) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	T8	T21	12137927
NA	CHEMICAL	GENE-Y	14	19	In contrast, tyrosine hydroxylase knockout (Th -/-) mice that lack both NE and dopamine (chemical) have reduced levels of gene, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	T8	T25	12137927
NA	CHEMICAL	GENE-Y	14	5	In contrast, tyrosine hydroxylase knockout (gene -/-) mice that lack both NE and dopamine (chemical) have reduced levels of NET, suggesting that it is down-regulated by a complete absence of catecholamines and not NE per se.	T8	T23	12137927
NA	CHEMICAL	GENE-Y	11	2	In contrast, gene knockout (Th -/-) mice that lack both chemical and dopamine (DA) have reduced levels of chemicalT, suggesting that it is down-regulated by a complete absence of catecholamines and not chemical per se.	T10	T21	12137927
NA	CHEMICAL	GENE-Y	11	2	In contrast, gene knockout (Th -/-) mice that lack both chemical and dopamine (DA) have reduced levels of chemicalT, suggesting that it is down-regulated by a complete absence of catecholamines and not chemical per se.	T6	T21	12137927
NA	CHEMICAL	GENE-Y	11	5	In contrast, tyrosine hydroxylase knockout (gene -/-) mice that lack both chemical and dopamine (DA) have reduced levels of chemicalT, suggesting that it is down-regulated by a complete absence of catecholamines and not chemical per se.	T10	T23	12137927
NA	CHEMICAL	GENE-Y	11	5	In contrast, tyrosine hydroxylase knockout (gene -/-) mice that lack both chemical and dopamine (DA) have reduced levels of chemicalT, suggesting that it is down-regulated by a complete absence of catecholamines and not chemical per se.	T6	T23	12137927
CPR:4	CHEMICAL	GENE-Y	6	4	Chronic treatment with the gene inhibitor, chemical (DMI), reduced gene levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of gene by antidepressant drugs.	T11	T26	12137927
CPR:4	CHEMICAL	GENE-Y	6	4	Chronic treatment with the gene inhibitor, chemical (DMI), reduced gene levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of gene by antidepressant drugs.	T11	T27	12137927
NA	CHEMICAL	GENE-Y	6	4	Chronic treatment with the gene inhibitor, chemical (DMI), reduced gene levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of gene by antidepressant drugs.	T11	T29	12137927
NA	CHEMICAL	GENE-Y	6	15	Chronic treatment with the NET inhibitor, chemical (DMI), reduced NET levels in both control and gene -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.	T11	T28	12137927
NA	CHEMICAL	GENE-Y	4	15	Chronic treatment with the chemicalT inhibitor, desipramine (DMI), reduced chemicalT levels in both control and gene -/- mice, demonstrating that chemical is not required for the regulation of chemicalT by antidepressant drugs.	T12	T28	12137927
NA	CHEMICAL	GENE-N	3	5	BACKGROUND: Neuronal nicotinic chemical receptor (gene) agonists produce antinociception in animals.	T12	T32	12170059
NA	CHEMICAL	GENE-N	12	4	This study tested whether gene agonists stimulate spinal release of the neurotransmitter chemical either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce chemical release.	T13	T31	12170059
NA	CHEMICAL	GENE-N	12	4	This study tested whether gene agonists stimulate spinal release of the neurotransmitter chemical either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce chemical release.	T14	T31	12170059
NA	CHEMICAL	GENE-Y	21	11	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific gene agonist metanicotine, or nicotine plus nAChR antagonists and chemical measured in the microdialysates.	T17	T33	12170059
NA	CHEMICAL	GENE-N	21	12	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) gene agonist metanicotine, or nicotine plus gene antagonists and chemical measured in the microdialysates.	T17	T34	12170059
CPR:5	CHEMICAL	GENE-Y	14	11	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific gene agonist chemical, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.	T15	T33	12170059
NA	CHEMICAL	GENE-N	14	12	Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) gene agonist chemical, or nicotine plus gene antagonists and norepinephrine measured in the microdialysates.	T15	T34	12170059
CPR:5	CHEMICAL	GENE-Y	8	11	Probes were perfused with artificial cerebrospinal fluid containing chemical, the specific gene agonist metachemical, or chemical plus nAChR antagonists and norepinephrine measured in the microdialysates.	T16	T33	12170059
NA	CHEMICAL	GENE-N	8	12	Probes were perfused with artificial cerebrospinal fluid containing chemical, the specific alpha(4)beta(2*) gene agonist metachemical, or chemical plus gene antagonists and norepinephrine measured in the microdialysates.	T16	T34	12170059
NA	CHEMICAL	GENE-N	8	4	The effects of specific gene antagonists and chemical synthase inhibitors were also examined.	T19	T35	12170059
NA	CHEMICAL	GENE-N	4	8	The effects of specific chemical receptor antagonists and gene inhibitors were also examined.	T18	T36	12170059
NA	CHEMICAL	GENE-N	6	22	RESULTS: Both nicotine and metanicotine induced chemical release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or gene inhibitors.	T3	T25	12170059
NA	CHEMICAL	GENE-N	4	22	RESULTS: Both nicotine and chemical induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or gene inhibitors.	T2	T25	12170059
NA	CHEMICAL	GENE-N	19	22	RESULTS: Both nicotine and metanicotine induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not chemical antagonists or gene inhibitors.	T4	T25	12170059
NA	CHEMICAL	GENE-N	2	22	RESULTS: Both chemical and metachemical induced norepinephrine release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not glutamate antagonists or gene inhibitors.	T1	T25	12170059
NA	CHEMICAL	GENE-Y	6	21	Both of the nicotinic agonists stimulated chemical release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of gene- than alpha(7*)-preferring nAChR antagonists.	T6	T26	12170059
NA	CHEMICAL	GENE-Y	6	23	Both of the nicotinic agonists stimulated chemical release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of alpha(4)beta(2*)- than gene-preferring nAChR antagonists.	T6	T27	12170059
NA	CHEMICAL	GENE-N	6	24	Both of the nicotinic agonists stimulated chemical release in synaptosomes, and the effect of metanicotine was blocked at lower concentrations of alpha(4)beta(2*)- than alpha(7*)-preferring gene antagonists.	T6	T28	12170059
NA	CHEMICAL	GENE-Y	14	21	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of chemical was blocked at lower concentrations of gene- than alpha(7*)-preferring nAChR antagonists.	T7	T26	12170059
NA	CHEMICAL	GENE-Y	14	23	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of chemical was blocked at lower concentrations of alpha(4)beta(2*)- than gene-preferring nAChR antagonists.	T7	T27	12170059
NA	CHEMICAL	GENE-N	14	24	Both of the nicotinic agonists stimulated norepinephrine release in synaptosomes, and the effect of chemical was blocked at lower concentrations of alpha(4)beta(2*)- than alpha(7*)-preferring gene antagonists.	T7	T28	12170059
NA	CHEMICAL	GENE-N	18	9	CONCLUSION: These results suggest that one mechanism by which gene agonists act for analgesia is to stimulate spinal chemical release.	T8	T29	12170059
NA	CHEMICAL	GENE-Y	23	6	They do so by actions on gene, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating chemical release through glutamate release or nitric oxide synthesis.	T9	T30	12170059
NA	CHEMICAL	GENE-Y	29	6	They do so by actions on gene, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating norepinephrine release through glutamate release or chemical synthesis.	T11	T30	12170059
NA	CHEMICAL	GENE-Y	26	6	They do so by actions on gene, and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating norepinephrine release through chemical release or nitric oxide synthesis.	T10	T30	12170059
NA	CHEMICAL	GENE-N	13	20	In addition, there is inhibition of adenosine uptake, eventually resulting in changes in chemical levels, dependent on the type of gene.	T8	T21	12180353
NA	CHEMICAL	GENE-N	11	11	Cilostazol decreases levels of serum triglycerides and causes some increase in gene-chemical levels.	T16	T22	12180353
CPR:3	CHEMICAL	GENE-N	0	11	chemical decreases levels of serum triglycerides and causes some increase in gene-cholesterol levels.	T15	T22	12180353
CPR:9	CHEMICAL	GENE-N	0	10	chemical undergoes intensive and finally complete hepatic metabolism via the gene systems.	T3	T18	12180353
NA	CHEMICAL	GENE-Y	2	21	To identify chemical residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of gene using a model created on basis of homology to the PDE4B crystal structure.	T3	T20	12181427
NA	CHEMICAL	GENE-Y	2	32	To identify chemical residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the gene crystal structure.	T3	T21	12181427
NA	CHEMICAL	GENE-Y	2	7	To identify chemical residues involved in gene-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of geneA using a model created on basis of homology to the PDE4B crystal structure.	T3	T22	12181427
CPR:4	CHEMICAL	GENE-Y	32	36	We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and chemical, specific inhibitors of gene.	T7	T23	12181427
CPR:4	CHEMICAL	GENE-Y	30	36	We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by chemical and cilostazol, specific inhibitors of gene.	T6	T23	12181427
NA	CHEMICAL	GENE-Y	5	36	We changed the residues to chemical using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of gene.	T5	T23	12181427
NA	CHEMICAL	GENE-N	31	4	Mutants Y751A, D950A, and gene had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to chemical (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	T9	T26	12181427
NA	CHEMICAL	GENE-Y	31	18	Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant gene to 7.5 to 156 microM for the mutants), and diminished sensitivity to chemical (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant gene).	T9	T27	12181427
CPR:4	CHEMICAL	GENE-Y	31	18	Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant gene to 7.5 to 156 microM for the mutants), and diminished sensitivity to chemical (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant gene).	T9	T28	12181427
NA	CHEMICAL	GENE-N	31	1	Mutants gene, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to chemical (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	T9	T24	12181427
NA	CHEMICAL	GENE-N	31	2	Mutants Y751A, gene, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to chemical (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	T9	T25	12181427
CPR:4	CHEMICAL	GENE-N	9	4	Mutants Y751A, D950A, and gene had reduced sensitivity to chemical (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	T8	T26	12181427
CPR:4	CHEMICAL	GENE-Y	9	18	Mutants Y751A, D950A, and F1004A had reduced sensitivity to chemical (K(i) changed from 0.66 microM for the recombinant gene to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant gene).	T8	T27	12181427
NA	CHEMICAL	GENE-Y	9	18	Mutants Y751A, D950A, and F1004A had reduced sensitivity to chemical (K(i) changed from 0.66 microM for the recombinant gene to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant gene).	T8	T28	12181427
CPR:4	CHEMICAL	GENE-N	9	1	Mutants gene, D950A, and F1004A had reduced sensitivity to chemical (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	T8	T24	12181427
CPR:4	CHEMICAL	GENE-N	9	2	Mutants Y751A, gene, and F1004A had reduced sensitivity to chemical (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).	T8	T25	12181427
CPR:4	CHEMICAL	GENE-Y	12	21	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for chemical but no difference for milrinone from the recombinant gene.	T10	T15	12181427
CPR:4	CHEMICAL	GENE-N	12	5	In contrast, the mutants T844A, gene and Q975A showed increased K(i) for chemical but no difference for milrinone from the recombinant PDE3A.	T10	T30	12181427
CPR:4	CHEMICAL	GENE-N	12	4	In contrast, the mutants gene, F972A and Q975A showed increased K(i) for chemical but no difference for milrinone from the recombinant PDE3A.	T10	T29	12181427
CPR:4	CHEMICAL	GENE-N	12	7	In contrast, the mutants T844A, F972A and gene showed increased K(i) for chemical but no difference for milrinone from the recombinant PDE3A.	T10	T31	12181427
CPR:4	CHEMICAL	GENE-Y	17	21	In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for chemical from the recombinant gene.	T11	T15	12181427
CPR:4	CHEMICAL	GENE-N	17	5	In contrast, the mutants T844A, gene and Q975A showed increased K(i) for cilostazol but no difference for chemical from the recombinant PDE3A.	T11	T30	12181427
CPR:4	CHEMICAL	GENE-N	17	4	In contrast, the mutants gene, F972A and Q975A showed increased K(i) for cilostazol but no difference for chemical from the recombinant PDE3A.	T11	T29	12181427
CPR:4	CHEMICAL	GENE-N	17	7	In contrast, the mutants T844A, F972A and gene showed increased K(i) for cilostazol but no difference for chemical from the recombinant PDE3A.	T11	T31	12181427
CPR:4	CHEMICAL	GENE-Y	7	5	Molecular models show that the gene inhibitors chemical and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against gene active site.	T1	T16	12181427
NA	CHEMICAL	GENE-Y	7	5	Molecular models show that the gene inhibitors chemical and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against gene active site.	T1	T17	12181427
CPR:4	CHEMICAL	GENE-Y	9	5	Molecular models show that the gene inhibitors cilostazol and chemical share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against gene active site.	T2	T16	12181427
NA	CHEMICAL	GENE-Y	9	5	Molecular models show that the gene inhibitors cilostazol and chemical share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against gene active site.	T2	T17	12181427
CPR:4	CHEMICAL	GENE-Y	33	36	Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the chemical selectivity of gene.	T4	T19	12181427
CPR:4	CHEMICAL	GENE-Y	33	13	Our study implies that highly conserved residuals Y751, D950 and F1004 in the gene families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the chemical selectivity of gene3A.	T4	T18	12181427
CPR:9	CHEMICAL	GENE-N	24	3	The bacterial enzyme gene (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as chemical (Glc1P).	T13	T27	12217700
CPR:9	CHEMICAL	GENE-Y	24	5	The bacterial enzyme maltodextrin phosphorylase (gene) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as chemical (Glc1P).	T13	T33	12217700
CPR:9	CHEMICAL	GENE-N	24	5	The bacterial enzyme maltodextrin phosphorylase (gene) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as chemical (Glc1P).	T13	T33	12217700
NA	CHEMICAL	GENE-N	18	3	The bacterial enzyme gene (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing chemical residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).	T5	T27	12217700
NA	CHEMICAL	GENE-Y	18	5	The bacterial enzyme maltodextrin phosphorylase (gene) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing chemical residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).	T5	T33	12217700
NA	CHEMICAL	GENE-N	18	5	The bacterial enzyme maltodextrin phosphorylase (gene) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing chemical residues of linear oligosaccharides as glucose-1-phosphate (Glc1P).	T5	T33	12217700
CPR:9	CHEMICAL	GENE-N	25	3	The bacterial enzyme gene (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (chemical).	T14	T27	12217700
CPR:9	CHEMICAL	GENE-Y	25	5	The bacterial enzyme maltodextrin phosphorylase (gene) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (chemical).	T14	T33	12217700
CPR:9	CHEMICAL	GENE-N	25	5	The bacterial enzyme maltodextrin phosphorylase (gene) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate (chemical).	T14	T33	12217700
NA	CHEMICAL	GENE-N	43	26	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of gene, with the phosphate group not in close contact with the 5'-phosphate group of the essential chemical (PLP) cofactor.	T20	T35	12217700
NA	CHEMICAL	GENE-Y	43	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential chemical (PLP) cofactor.	T20	T34	12217700
NA	CHEMICAL	GENE-N	43	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential chemical (PLP) cofactor.	T20	T34	12217700
NA	CHEMICAL	GENE-N	38	26	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of gene, with the phosphate group not in close contact with the chemical group of the essential pyridoxal phosphate (PLP) cofactor.	T19	T35	12217700
NA	CHEMICAL	GENE-Y	38	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the chemical group of the essential pyridoxal phosphate (PLP) cofactor.	T19	T34	12217700
NA	CHEMICAL	GENE-N	38	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the chemical group of the essential pyridoxal phosphate (PLP) cofactor.	T19	T34	12217700
NA	CHEMICAL	GENE-N	30	26	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of gene, with the chemical group not in close contact with the 5'-chemical group of the essential pyridoxal chemical (PLP) cofactor.	T18	T35	12217700
NA	CHEMICAL	GENE-Y	30	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the chemical group not in close contact with the 5'-chemical group of the essential pyridoxal chemical (PLP) cofactor.	T18	T34	12217700
NA	CHEMICAL	GENE-N	30	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the chemical group not in close contact with the 5'-chemical group of the essential pyridoxal chemical (PLP) cofactor.	T18	T34	12217700
NA	CHEMICAL	GENE-N	6	26	The 2.0A crystal structure of the MalP/chemical binary complex shows that the chemical substrate adopts a conformation seen previously with both inactive and active forms of gene, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	T16	T35	12217700
NA	CHEMICAL	GENE-N	6	26	The 2.0A crystal structure of the MalP/chemical binary complex shows that the chemical substrate adopts a conformation seen previously with both inactive and active forms of gene, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	T17	T35	12217700
NA	CHEMICAL	GENE-Y	6	6	The 2.0A crystal structure of the gene/chemical binary complex shows that the chemical substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	T16	T34	12217700
NA	CHEMICAL	GENE-Y	6	6	The 2.0A crystal structure of the gene/chemical binary complex shows that the chemical substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	T17	T34	12217700
NA	CHEMICAL	GENE-N	6	6	The 2.0A crystal structure of the gene/chemical binary complex shows that the chemical substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	T16	T34	12217700
NA	CHEMICAL	GENE-N	6	6	The 2.0A crystal structure of the gene/chemical binary complex shows that the chemical substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (PLP) cofactor.	T17	T34	12217700
NA	CHEMICAL	GENE-N	45	26	The 2.0A crystal structure of the MalP/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of gene, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (chemical) cofactor.	T21	T35	12217700
NA	CHEMICAL	GENE-Y	45	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (chemical) cofactor.	T21	T34	12217700
NA	CHEMICAL	GENE-N	45	6	The 2.0A crystal structure of the gene/Glc1P binary complex shows that the Glc1P substrate adopts a conformation seen previously with both inactive and active forms of mammalian GP, with the phosphate group not in close contact with the 5'-phosphate group of the essential pyridoxal phosphate (chemical) cofactor.	T21	T34	12217700
NA	CHEMICAL	GENE-Y	11	3	In the active gene enzyme, the residue Arg569 stabilizes the negative-charged chemical, whereas in the inactive form of GP this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	T22	T36	12217700
NA	CHEMICAL	GENE-N	11	3	In the active gene enzyme, the residue Arg569 stabilizes the negative-charged chemical, whereas in the inactive form of GP this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	T22	T36	12217700
NA	CHEMICAL	GENE-Y	11	18	In the active MalP enzyme, the residue Arg569 stabilizes the negative-charged chemical, whereas in the inactive form of gene this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	T22	T37	12217700
NA	CHEMICAL	GENE-Y	14	3	The comparison between gene structures shows that His377, through a hydrogen bond with the chemical group of Glc1P substrate, triggers a conformational change of the 380s loop.	T1	T23	12217700
NA	CHEMICAL	GENE-N	14	3	The comparison between gene structures shows that His377, through a hydrogen bond with the chemical group of Glc1P substrate, triggers a conformational change of the 380s loop.	T1	T23	12217700
NA	CHEMICAL	GENE-Y	17	3	The comparison between gene structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of chemical substrate, triggers a conformational change of the 380s loop.	T2	T23	12217700
NA	CHEMICAL	GENE-N	17	3	The comparison between gene structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of chemical substrate, triggers a conformational change of the 380s loop.	T2	T23	12217700
NA	CHEMICAL	GENE-Y	12	15	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or chemical, G5) into gene/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.	T4	T25	12217700
NA	CHEMICAL	GENE-N	12	15	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or chemical, G5) into gene/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.	T4	T25	12217700
NA	CHEMICAL	GENE-Y	9	15	The structures solved after the diffusion of oligosaccharides (either chemical, G4 or maltopentaose, G5) into gene/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.	T3	T25	12217700
NA	CHEMICAL	GENE-N	9	15	The structures solved after the diffusion of oligosaccharides (either chemical, G4 or maltopentaose, G5) into gene/Glc1P crystals show the formation of phosphate and elongation of the oligosaccharide chain.	T3	T25	12217700
NA	CHEMICAL	GENE-Y	21	15	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into gene/Glc1P crystals show the formation of chemical and elongation of the oligosaccharide chain.	T7	T25	12217700
NA	CHEMICAL	GENE-N	21	15	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into gene/Glc1P crystals show the formation of chemical and elongation of the oligosaccharide chain.	T7	T25	12217700
NA	CHEMICAL	GENE-Y	15	15	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into gene/chemical crystals show the formation of phosphate and elongation of the oligosaccharide chain.	T6	T25	12217700
NA	CHEMICAL	GENE-N	15	15	The structures solved after the diffusion of oligosaccharides (either maltotetraose, G4 or maltopentaose, G5) into gene/chemical crystals show the formation of phosphate and elongation of the oligosaccharide chain.	T6	T25	12217700
NA	CHEMICAL	GENE-Y	10	10	The relatively large oligosaccharide substrates can diffuse quickly into the gene/chemical crystals and the enzymatic reaction can occur without significant crystal damage.	T12	T26	12217700
NA	CHEMICAL	GENE-N	10	10	The relatively large oligosaccharide substrates can diffuse quickly into the gene/chemical crystals and the enzymatic reaction can occur without significant crystal damage.	T12	T26	12217700
NA	CHEMICAL	GENE-Y	1	22	OBJECTIVE: chemical is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to gene.	T2	T7	12383039
CPR:4	CHEMICAL	GENE-Y	1	12	OBJECTIVE: chemical is the first in a new class of synthetic gene inhibitors that binds reversibly with high affinity to antithrombin III.	T2	T8	12383039
CPR:9	CHEMICAL	GENE-N	22	7	It is caused by a deficiency of gene (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to chemical.	T8	T22	12409268
CPR:9	CHEMICAL	GENE-Y	22	10	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, gene), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to chemical.	T8	T24	12409268
CPR:9	CHEMICAL	GENE-N	22	9	It is caused by a deficiency of propionyl-CoA carboxylase (gene, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to chemical.	T8	T23	12409268
NA	CHEMICAL	GENE-Y	7	10	It is caused by a deficiency of chemical carboxylase (PCC, gene), a biotin-dependent enzyme that catalyzes the carboxylation of chemical to D-methylmalonyl-CoA.	T5	T24	12409268
CPR:9	CHEMICAL	GENE-Y	7	10	It is caused by a deficiency of chemical carboxylase (PCC, gene), a biotin-dependent enzyme that catalyzes the carboxylation of chemical to D-methylmalonyl-CoA.	T7	T24	12409268
NA	CHEMICAL	GENE-N	7	9	It is caused by a deficiency of chemical carboxylase (gene, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of chemical to D-methylmalonyl-CoA.	T5	T23	12409268
CPR:9	CHEMICAL	GENE-N	7	9	It is caused by a deficiency of chemical carboxylase (gene, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of chemical to D-methylmalonyl-CoA.	T7	T23	12409268
NA	CHEMICAL	GENE-N	13	7	It is caused by a deficiency of gene (PCC, EC 6.4.1.3), a chemical-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.	T6	T22	12409268
NA	CHEMICAL	GENE-Y	13	10	It is caused by a deficiency of propionyl-CoA carboxylase (PCC, gene), a chemical-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.	T6	T24	12409268
NA	CHEMICAL	GENE-N	13	9	It is caused by a deficiency of propionyl-CoA carboxylase (gene, EC 6.4.1.3), a chemical-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.	T6	T23	12409268
CPR:4	CHEMICAL	GENE-Y	4	31	Although only clozapine and chemical are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined gene and D(2) blockade.	T28	T59	12445705
CPR:5	CHEMICAL	GENE-Y	4	8	Although only clozapine and chemical are directly acting gene agonists, WAY100635, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	T28	T57	12445705
NA	CHEMICAL	GENE-Y	4	8	Although only clozapine and chemical are directly acting gene agonists, WAY100635, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	T28	T58	12445705
CPR:4	CHEMICAL	GENE-Y	4	33	Although only clozapine and chemical are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and gene blockade.	T28	T60	12445705
CPR:4	CHEMICAL	GENE-Y	10	31	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, chemical, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined gene and D(2) blockade.	T29	T59	12445705
NA	CHEMICAL	GENE-Y	10	8	Although only clozapine and ziprasidone are directly acting gene agonists, chemical, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	T29	T57	12445705
CPR:6	CHEMICAL	GENE-Y	10	8	Although only clozapine and ziprasidone are directly acting gene agonists, chemical, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	T29	T58	12445705
CPR:4	CHEMICAL	GENE-Y	10	33	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, chemical, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and gene blockade.	T29	T60	12445705
CPR:4	CHEMICAL	GENE-Y	2	31	Although only chemical and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined gene and D(2) blockade.	T27	T59	12445705
CPR:5	CHEMICAL	GENE-Y	2	8	Although only chemical and ziprasidone are directly acting gene agonists, WAY100635, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	T27	T57	12445705
NA	CHEMICAL	GENE-Y	2	8	Although only chemical and ziprasidone are directly acting gene agonists, WAY100635, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and D(2) blockade.	T27	T58	12445705
CPR:4	CHEMICAL	GENE-Y	2	33	Although only chemical and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical DA release that may be due to combined 5-HT(2A) and gene blockade.	T27	T60	12445705
NA	CHEMICAL	GENE-Y	23	31	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical chemical release that may be due to combined gene and D(2) blockade.	T31	T59	12445705
NA	CHEMICAL	GENE-Y	23	8	Although only clozapine and ziprasidone are directly acting gene agonists, WAY100635, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical chemical release that may be due to combined 5-HT(2A) and D(2) blockade.	T31	T57	12445705
NA	CHEMICAL	GENE-Y	23	8	Although only clozapine and ziprasidone are directly acting gene agonists, WAY100635, a selective gene antagonist, partially attenuates these atypical APD-induced increases in cortical chemical release that may be due to combined 5-HT(2A) and D(2) blockade.	T31	T58	12445705
NA	CHEMICAL	GENE-Y	23	33	Although only clozapine and ziprasidone are directly acting 5-HT(1A) agonists, WAY100635, a selective 5-HT(1A) antagonist, partially attenuates these atypical APD-induced increases in cortical chemical release that may be due to combined 5-HT(2A) and gene blockade.	T31	T60	12445705
NA	CHEMICAL	GENE-Y	6	9	The present study determined whether quetiapine, chemical and melperone, gene/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T38	T61	12445705
NA	CHEMICAL	GENE-Y	6	27	The present study determined whether quetiapine, chemical and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to gene agonism.	T38	T63	12445705
NA	CHEMICAL	GENE-Y	6	9	The present study determined whether quetiapine, chemical and melperone, 5-HT(2A)/gene antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T38	T62	12445705
NA	CHEMICAL	GENE-Y	5	9	The present study determined whether chemical, iloperidone and melperone, gene/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T37	T61	12445705
NA	CHEMICAL	GENE-Y	5	27	The present study determined whether chemical, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to gene agonism.	T37	T63	12445705
NA	CHEMICAL	GENE-Y	5	9	The present study determined whether chemical, iloperidone and melperone, 5-HT(2A)/gene antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T37	T62	12445705
NA	CHEMICAL	GENE-Y	8	9	The present study determined whether quetiapine, iloperidone and chemical, gene/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T39	T61	12445705
NA	CHEMICAL	GENE-Y	8	27	The present study determined whether quetiapine, iloperidone and chemical, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to gene agonism.	T39	T63	12445705
NA	CHEMICAL	GENE-Y	8	9	The present study determined whether quetiapine, iloperidone and chemical, 5-HT(2A)/gene antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T39	T62	12445705
NA	CHEMICAL	GENE-Y	18	9	The present study determined whether quetiapine, iloperidone and melperone, gene/D(2) antagonist atypical APDs, also increase cortical DA and chemical release, and whether these effects are related to 5-HT(1A) agonism.	T41	T61	12445705
NA	CHEMICAL	GENE-Y	18	27	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical DA and chemical release, and whether these effects are related to gene agonism.	T41	T63	12445705
NA	CHEMICAL	GENE-Y	18	9	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/gene antagonist atypical APDs, also increase cortical DA and chemical release, and whether these effects are related to 5-HT(1A) agonism.	T41	T62	12445705
NA	CHEMICAL	GENE-Y	16	9	The present study determined whether quetiapine, iloperidone and melperone, gene/D(2) antagonist atypical APDs, also increase cortical chemical and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T40	T61	12445705
NA	CHEMICAL	GENE-Y	16	27	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/D(2) antagonist atypical APDs, also increase cortical chemical and ACh release, and whether these effects are related to gene agonism.	T40	T63	12445705
NA	CHEMICAL	GENE-Y	16	9	The present study determined whether quetiapine, iloperidone and melperone, 5-HT(2A)/gene antagonist atypical APDs, also increase cortical chemical and ACh release, and whether these effects are related to 5-HT(1A) agonism.	T40	T62	12445705
NA	CHEMICAL	GENE-Y	5	21	These results indicate that quetiapine, chemical and melperone preferentially increase DA release in the mPFC, compared to the NAC via a gene-related mechanism.	T18	T55	12445705
NA	CHEMICAL	GENE-Y	4	21	These results indicate that chemical, iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a gene-related mechanism.	T16	T55	12445705
NA	CHEMICAL	GENE-Y	7	21	These results indicate that quetiapine, iloperidone and chemical preferentially increase DA release in the mPFC, compared to the NAC via a gene-related mechanism.	T19	T55	12445705
NA	CHEMICAL	GENE-Y	10	21	These results indicate that quetiapine, iloperidone and melperone preferentially increase chemical release in the mPFC, compared to the NAC via a gene-related mechanism.	T20	T55	12445705
CPR:5	CHEMICAL	GENE-Y	8	1	However, gene agonism may be important only for chemical-induced ACh release.	T22	T56	12445705
NA	CHEMICAL	GENE-Y	9	1	However, gene agonism may be important only for quetiapine-induced chemical release.	T23	T56	12445705
CPR:3	CHEMICAL	GENE-N	5	10	BACKGROUND: The novel antiepileptic drug chemical is the first selective gene opener for KCNQ2/3 and KCNQ3/5 channels.	T8	T17	12545144
CPR:3	CHEMICAL	GENE-N	5	17	BACKGROUND: The novel antiepileptic drug chemical is the first selective M-current potassium channel opener for KCNQ2/3 and gene channels.	T8	T16	12545144
CPR:3	CHEMICAL	GENE-N	5	15	BACKGROUND: The novel antiepileptic drug chemical is the first selective M-current potassium channel opener for gene and KCNQ3/5 channels.	T8	T15	12545144
NA	CHEMICAL	GENE-N	11	17	BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current chemical channel opener for KCNQ2/3 and gene channels.	T13	T16	12545144
NA	CHEMICAL	GENE-N	11	15	BACKGROUND: The novel antiepileptic drug retigabine is the first selective M-current chemical channel opener for gene and KCNQ3/5 channels.	T13	T15	12545144
CPR:4	CHEMICAL	GENE-Y	15	13	OBJECTIVE: Because of these physiological effects and the widespread use of the selective gene inhibitor, chemical, we wanted to determine if inhibition of gene would affect incisional skin wound healing.	T3	T12	12588370
NA	CHEMICAL	GENE-Y	15	13	OBJECTIVE: Because of these physiological effects and the widespread use of the selective gene inhibitor, chemical, we wanted to determine if inhibition of gene would affect incisional skin wound healing.	T3	T13	12588370
NA	CHEMICAL	GENE-Y	33	18	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of gene in the wound healing process by comparing the effects of a nonselective COX inhibitor, chemical, with a selective gene inhibitor, SC-791.	T4	T15	12588370
NA	CHEMICAL	GENE-Y	33	18	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of gene in the wound healing process by comparing the effects of a nonselective COX inhibitor, chemical, with a selective gene inhibitor, SC-791.	T4	T17	12588370
CPR:4	CHEMICAL	GENE-N	33	18	METHODS: Using a cutaneous full-thickness, sutured, incisional wound model in hairless SKH-1 mice, we evaluated the role of gene-2 in the wound healing process by comparing the effects of a nonselective gene inhibitor, chemical, with a selective gene-2 inhibitor, SC-791.	T4	T16	12588370
NA	CHEMICAL	GENE-Y	21	2	Neither selective gene, nor nonselective COX inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas chemical treatment resulted in epidermal and granulation tissue atrophy.	T1	T6	12588370
NA	CHEMICAL	GENE-N	21	2	Neither selective gene-2, nor nonselective gene inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas chemical treatment resulted in epidermal and granulation tissue atrophy.	T1	T7	12588370
NA	CHEMICAL	GENE-Y	24	4	In addition, neither selective gene, nor nonselective COX inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas chemical reduced the tensile strength of the wounds by 30-38% throughout the healing period.	T2	T8	12588370
NA	CHEMICAL	GENE-N	24	4	In addition, neither selective gene-2, nor nonselective gene inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas chemical reduced the tensile strength of the wounds by 30-38% throughout the healing period.	T2	T9	12588370
NA	CHEMICAL	GENE-Y	14	16	These radiotracers are close analogues of reboxetine, a potent and selective ligand for the chemical transporter (gene).	T10	T19	12623106
NA	CHEMICAL	GENE-Y	6	14	These radiotracers are close analogues of chemical, a potent and selective ligand for the gene (NET).	T9	T18	12623106
NA	CHEMICAL	GENE-Y	6	16	These radiotracers are close analogues of chemical, a potent and selective ligand for the norepinephrine transporter (gene).	T9	T19	12623106
NA	CHEMICAL	GENE-Y	8	22	In vitro autoradiography studies (rat brain slices) with chemical produced a regional distribution pattern that was consistent with the reported distribution of gene.	T7	T16	12623106
NA	CHEMICAL	GENE-Y	0	13	chemical has the potential to be the first successful PET ligand to image gene.	T8	T17	12623106
CPR:6	CHEMICAL	GENE-Y	8	3	The effects of gene antagonists, promethazine and chemical, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	T19	T29	12657913
CPR:4	CHEMICAL	GENE-Y	8	15	The effects of histamine H1-receptor antagonists, promethazine and chemical, both of which are inhibitors of gene, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	T19	T28	12657913
CPR:6	CHEMICAL	GENE-Y	6	3	The effects of gene antagonists, chemical and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	T16	T29	12657913
CPR:4	CHEMICAL	GENE-Y	6	15	The effects of histamine H1-receptor antagonists, chemical and homochlorcyclizine, both of which are inhibitors of gene, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	T16	T28	12657913
NA	CHEMICAL	GENE-Y	23	3	The effects of gene antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of chemical and reduced chemical were studied in 23 schizophrenic inpatients receiving chemical, 12 to 36 mg/d, for 2 to 29 weeks.	T11	T29	12657913
NA	CHEMICAL	GENE-Y	23	3	The effects of gene antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of chemical and reduced chemical were studied in 23 schizophrenic inpatients receiving chemical, 12 to 36 mg/d, for 2 to 29 weeks.	T12	T29	12657913
NA	CHEMICAL	GENE-Y	23	3	The effects of gene antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of chemical and reduced chemical were studied in 23 schizophrenic inpatients receiving chemical, 12 to 36 mg/d, for 2 to 29 weeks.	T13	T29	12657913
NA	CHEMICAL	GENE-Y	23	15	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of gene, on the steady-state plasma concentrations (Css) of chemical and reduced chemical were studied in 23 schizophrenic inpatients receiving chemical, 12 to 36 mg/d, for 2 to 29 weeks.	T11	T28	12657913
NA	CHEMICAL	GENE-Y	23	15	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of gene, on the steady-state plasma concentrations (Css) of chemical and reduced chemical were studied in 23 schizophrenic inpatients receiving chemical, 12 to 36 mg/d, for 2 to 29 weeks.	T12	T28	12657913
NA	CHEMICAL	GENE-Y	23	15	The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of gene, on the steady-state plasma concentrations (Css) of chemical and reduced chemical were studied in 23 schizophrenic inpatients receiving chemical, 12 to 36 mg/d, for 2 to 29 weeks.	T13	T28	12657913
NA	CHEMICAL	GENE-Y	3	15	The effects of chemical H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of gene, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.	T4	T28	12657913
CPR:4	CHEMICAL	GENE-Y	13	28	Thus, the current study suggests that coadministration of clinical doses of promethazine and chemical increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the gene-catalyzed metabolism of haloperidol and reduced haloperidol.	T6	T30	12657913
CPR:4	CHEMICAL	GENE-Y	11	28	Thus, the current study suggests that coadministration of clinical doses of chemical and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the gene-catalyzed metabolism of haloperidol and reduced haloperidol.	T5	T30	12657913
CPR:9	CHEMICAL	GENE-Y	18	28	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of chemical and reduced chemical via the inhibitory effects on the gene-catalyzed metabolism of chemical and reduced chemical.	T10	T30	12657913
NA	CHEMICAL	GENE-Y	18	28	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of chemical and reduced chemical via the inhibitory effects on the gene-catalyzed metabolism of chemical and reduced chemical.	T7	T30	12657913
NA	CHEMICAL	GENE-Y	18	28	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of chemical and reduced chemical via the inhibitory effects on the gene-catalyzed metabolism of chemical and reduced chemical.	T8	T30	12657913
CPR:9	CHEMICAL	GENE-Y	18	28	Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of chemical and reduced chemical via the inhibitory effects on the gene-catalyzed metabolism of chemical and reduced chemical.	T9	T30	12657913
NA	CHEMICAL	GENE-Y	4	11	In the presence of chemical and arginine, chemical carbamoyltransferase (OTCase) and gene form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas gene remains catalytically active.	T3	T24	12679340
NA	CHEMICAL	GENE-Y	4	11	In the presence of chemical and arginine, chemical carbamoyltransferase (OTCase) and gene form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas gene remains catalytically active.	T3	T30	12679340
NA	CHEMICAL	GENE-Y	4	11	In the presence of chemical and arginine, chemical carbamoyltransferase (OTCase) and gene form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas gene remains catalytically active.	T5	T24	12679340
NA	CHEMICAL	GENE-Y	4	11	In the presence of chemical and arginine, chemical carbamoyltransferase (OTCase) and gene form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas gene remains catalytically active.	T5	T30	12679340
NA	CHEMICAL	GENE-Y	4	9	In the presence of chemical and arginine, chemical carbamoyltransferase (gene) and arginase form a one-to-one enzyme complex in which the activity of gene is inhibited whereas arginase remains catalytically active.	T3	T23	12679340
NA	CHEMICAL	GENE-Y	4	9	In the presence of chemical and arginine, chemical carbamoyltransferase (gene) and arginase form a one-to-one enzyme complex in which the activity of gene is inhibited whereas arginase remains catalytically active.	T3	T29	12679340
NA	CHEMICAL	GENE-Y	4	9	In the presence of chemical and arginine, chemical carbamoyltransferase (gene) and arginase form a one-to-one enzyme complex in which the activity of gene is inhibited whereas arginase remains catalytically active.	T5	T23	12679340
NA	CHEMICAL	GENE-Y	4	9	In the presence of chemical and arginine, chemical carbamoyltransferase (gene) and arginase form a one-to-one enzyme complex in which the activity of gene is inhibited whereas arginase remains catalytically active.	T5	T29	12679340
NA	CHEMICAL	GENE-Y	6	7	In the presence of ornithine and chemical, gene (OTCase) and arginase form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas arginase remains catalytically active.	T4	T25	12679340
NA	CHEMICAL	GENE-Y	6	11	In the presence of ornithine and chemical, ornithine carbamoyltransferase (OTCase) and gene form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas gene remains catalytically active.	T4	T24	12679340
NA	CHEMICAL	GENE-Y	6	11	In the presence of ornithine and chemical, ornithine carbamoyltransferase (OTCase) and gene form a one-to-one enzyme complex in which the activity of OTCase is inhibited whereas gene remains catalytically active.	T4	T30	12679340
NA	CHEMICAL	GENE-Y	6	9	In the presence of ornithine and chemical, ornithine carbamoyltransferase (gene) and arginase form a one-to-one enzyme complex in which the activity of gene is inhibited whereas arginase remains catalytically active.	T4	T23	12679340
NA	CHEMICAL	GENE-Y	6	9	In the presence of ornithine and chemical, ornithine carbamoyltransferase (gene) and arginase form a one-to-one enzyme complex in which the activity of gene is inhibited whereas arginase remains catalytically active.	T4	T29	12679340
NA	CHEMICAL	GENE-Y	3	15	In arginase, two chemical at the C terminus of the protein are crucial for its gene function but not for its catalytic activity and trimeric structure.	T6	T27	12679340
NA	CHEMICAL	GENE-Y	3	1	In gene, two chemical at the C terminus of the protein are crucial for its epigene function but not for its catalytic activity and trimeric structure.	T6	T26	12679340
NA	CHEMICAL	GENE-Y	6	15	In arginase, two cysteines at the chemical terminus of the protein are crucial for its gene function but not for its catalytic activity and trimeric structure.	T7	T27	12679340
NA	CHEMICAL	GENE-Y	6	1	In gene, two cysteines at the chemical terminus of the protein are crucial for its epigene function but not for its catalytic activity and trimeric structure.	T7	T26	12679340
NA	CHEMICAL	GENE-Y	5	25	In OTCase, mutations of putative chemical binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for chemical and impaired the interaction with gene.	T14	T31	12679340
NA	CHEMICAL	GENE-Y	5	25	In OTCase, mutations of putative chemical binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for chemical and impaired the interaction with gene.	T8	T31	12679340
NA	CHEMICAL	GENE-Y	5	1	In gene, mutations of putative chemical binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for chemical and impaired the interaction with arginase.	T14	T28	12679340
NA	CHEMICAL	GENE-Y	5	1	In gene, mutations of putative chemical binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for chemical and impaired the interaction with arginase.	T8	T28	12679340
NA	CHEMICAL	GENE-Y	13	25	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and chemical-256 greatly reduced the affinity for ornithine and impaired the interaction with gene.	T13	T31	12679340
NA	CHEMICAL	GENE-Y	13	1	In gene, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and chemical-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	T13	T28	12679340
NA	CHEMICAL	GENE-Y	11	25	In OTCase, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, chemical-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with gene.	T12	T31	12679340
NA	CHEMICAL	GENE-Y	11	1	In gene, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, chemical-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	T12	T28	12679340
NA	CHEMICAL	GENE-Y	9	25	In OTCase, mutations of putative ornithine binding residues, Asp-182, chemical-184, chemical-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with gene.	T10	T31	12679340
NA	CHEMICAL	GENE-Y	9	25	In OTCase, mutations of putative ornithine binding residues, Asp-182, chemical-184, chemical-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with gene.	T11	T31	12679340
NA	CHEMICAL	GENE-Y	9	1	In gene, mutations of putative ornithine binding residues, Asp-182, chemical-184, chemical-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	T10	T28	12679340
NA	CHEMICAL	GENE-Y	9	1	In gene, mutations of putative ornithine binding residues, Asp-182, chemical-184, chemical-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	T11	T28	12679340
NA	CHEMICAL	GENE-Y	8	25	In OTCase, mutations of putative ornithine binding residues, chemical-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with gene.	T9	T31	12679340
NA	CHEMICAL	GENE-Y	8	1	In gene, mutations of putative ornithine binding residues, chemical-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.	T9	T28	12679340
NA	CHEMICAL	GENE-Y	26	29	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to chemical and to gene and appear to be involved in transducing and enhancing the signal given by chemical for the closure of the catalytic domain.	T1	T22	12679340
NA	CHEMICAL	GENE-Y	26	29	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to chemical and to gene and appear to be involved in transducing and enhancing the signal given by chemical for the closure of the catalytic domain.	T2	T22	12679340
CPR:4	CHEMICAL	GENE-Y	26	24	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of gene to chemical and to arginase and appear to be involved in transducing and enhancing the signal given by chemical for the closure of the catalytic domain.	T1	T21	12679340
NA	CHEMICAL	GENE-Y	26	24	The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of gene to chemical and to arginase and appear to be involved in transducing and enhancing the signal given by chemical for the closure of the catalytic domain.	T2	T21	12679340
NA	CHEMICAL	GENE-Y	2	29	The four chemical residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to gene and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T15	T22	12679340
NA	CHEMICAL	GENE-Y	2	24	The four chemical residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of gene to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T15	T21	12679340
NA	CHEMICAL	GENE-Y	9	29	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to gene and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T16	T22	12679340
NA	CHEMICAL	GENE-Y	9	29	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to gene and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T17	T22	12679340
NA	CHEMICAL	GENE-Y	9	29	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to gene and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T18	T22	12679340
NA	CHEMICAL	GENE-Y	9	29	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of OTCase to ornithine and to gene and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T19	T22	12679340
NA	CHEMICAL	GENE-Y	9	24	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of gene to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T16	T21	12679340
NA	CHEMICAL	GENE-Y	9	24	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of gene to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T17	T21	12679340
NA	CHEMICAL	GENE-Y	9	24	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of gene to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T18	T21	12679340
NA	CHEMICAL	GENE-Y	9	24	The four lysine residues located in the SMG loop, chemical-260, chemical-263, chemical-265, and chemical-268, also play an important role in mediating the sensitivity of gene to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.	T19	T21	12679340
NA	CHEMICAL	GENE-Y	4	18	On the other hand, chemical did not modify the eosinophil spontaneous adhesion to the resting or IL-4 plus gene-stimulated pulmonary endothelial cells.	T6	T14	12692940
NA	CHEMICAL	GENE-Y	4	16	On the other hand, chemical did not modify the eosinophil spontaneous adhesion to the resting or gene plus TNF-alpha-stimulated pulmonary endothelial cells.	T6	T13	12692940
NA	CHEMICAL	GENE-Y	1	5	Similarly, chemical did not modulate gene- or FMLP-activated eosinophil adhesion to the resting endothelial cells.	T8	T15	12692940
NA	CHEMICAL	GENE-N	1	5	The chemical-dependent drug efflux pump gene (P-gp) affects the absorption and disposition of many compounds.	T1	T8	12699389
NA	CHEMICAL	GENE-N	1	6	The chemical-dependent drug efflux pump P-glycoprotein (gene) affects the absorption and disposition of many compounds.	T1	T13	12699389
NA	CHEMICAL	GENE-N	13	20	The assays included in silico predictions, inhibition assays (based on cellular uptake of chemical or calcein AM), and functional assays (gene activity assay and transcellular transport assay, the latter for a subset of compounds).	T3	T14	12699389
NA	CHEMICAL	GENE-N	15	20	The assays included in silico predictions, inhibition assays (based on cellular uptake of rhodamine-123 or chemical), and functional assays (gene activity assay and transcellular transport assay, the latter for a subset of compounds).	T4	T14	12699389
NA	CHEMICAL	GENE-N	4	20	The assays included in chemical predictions, inhibition assays (based on cellular uptake of rhodamine-123 or calcein AM), and functional assays (gene activity assay and transcellular transport assay, the latter for a subset of compounds).	T2	T14	12699389
NA	CHEMICAL	GENE-Y	9	11	5TFI was incorporated into a model target protein, murine chemical reductase (gene), in an isoleucine auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of isoleucine.	T5	T26	12783542
NA	CHEMICAL	GENE-Y	14	8	5TFI was incorporated into a model target protein, gene (mDHFR), in an chemical auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of chemical.	T6	T25	12783542
NA	CHEMICAL	GENE-Y	14	8	5TFI was incorporated into a model target protein, gene (mDHFR), in an chemical auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of chemical.	T9	T25	12783542
NA	CHEMICAL	GENE-Y	14	11	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (gene), in an chemical auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of chemical.	T6	T26	12783542
NA	CHEMICAL	GENE-Y	14	11	5TFI was incorporated into a model target protein, murine dihydrofolate reductase (gene), in an chemical auxotrophic Escherichia coli host strain suspended in 5TFI-supplemented minimal medium depleted of chemical.	T9	T26	12783542
NA	CHEMICAL	GENE-Y	0	8	chemical was incorporated into a model target protein, gene (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in chemical-supplemented minimal medium depleted of isoleucine.	T4	T25	12783542
NA	CHEMICAL	GENE-Y	0	8	chemical was incorporated into a model target protein, gene (mDHFR), in an isoleucine auxotrophic Escherichia coli host strain suspended in chemical-supplemented minimal medium depleted of isoleucine.	T8	T25	12783542
NA	CHEMICAL	GENE-Y	0	11	chemical was incorporated into a model target protein, murine dihydrofolate reductase (gene), in an isoleucine auxotrophic Escherichia coli host strain suspended in chemical-supplemented minimal medium depleted of isoleucine.	T4	T26	12783542
NA	CHEMICAL	GENE-Y	0	11	chemical was incorporated into a model target protein, murine dihydrofolate reductase (gene), in an isoleucine auxotrophic Escherichia coli host strain suspended in chemical-supplemented minimal medium depleted of isoleucine.	T8	T26	12783542
NA	CHEMICAL	GENE-Y	25	10	Measurement of the rate of activation of 5TFI by the gene (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for chemical.	T17	T27	12783542
NA	CHEMICAL	GENE-Y	25	14	Measurement of the rate of activation of 5TFI by the E. coli isoleucyl-tRNA synthetase (gene) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for chemical.	T17	T28	12783542
NA	CHEMICAL	GENE-Y	12	14	Measurement of the rate of activation of 5TFI by the E. coli chemical-tRNA synthetase (gene) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	T16	T28	12783542
NA	CHEMICAL	GENE-Y	7	10	Measurement of the rate of activation of chemical by the gene (IleRS) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	T15	T27	12783542
NA	CHEMICAL	GENE-Y	7	14	Measurement of the rate of activation of chemical by the E. coli isoleucyl-tRNA synthetase (gene) yielded a specificity constant (k(cat)/K(m)) 134-fold lower than that for isoleucine.	T15	T28	12783542
NA	CHEMICAL	GENE-Y	13	7	5TFI was successfully introduced into the cytokine gene (mIL-2) at the encoded chemical positions.	T20	T30	12783542
NA	CHEMICAL	GENE-N	13	6	5TFI was successfully introduced into the gene murine interleukin-2 (mIL-2) at the encoded chemical positions.	T20	T29	12783542
NA	CHEMICAL	GENE-Y	13	9	5TFI was successfully introduced into the cytokine murine interleukin-2 (gene) at the encoded chemical positions.	T20	T31	12783542
NA	CHEMICAL	GENE-Y	0	7	chemical was successfully introduced into the cytokine gene (mIL-2) at the encoded isoleucine positions.	T18	T30	12783542
NA	CHEMICAL	GENE-N	0	6	chemical was successfully introduced into the gene murine interleukin-2 (mIL-2) at the encoded isoleucine positions.	T18	T29	12783542
NA	CHEMICAL	GENE-Y	0	9	chemical was successfully introduced into the cytokine murine interleukin-2 (gene) at the encoded isoleucine positions.	T18	T31	12783542
NA	CHEMICAL	GENE-Y	0	17	chemical yielded no evidence for in vivo incorporation into recombinant proteins, and no evidence for activation by gene in vitro.	T2	T24	12783542
NA	CHEMICAL	GENE-Y	10	16	This binding was not significantly inhibited by the lysine analogue chemical (EACA), indicating that gene binding was not just through lysine binding sites as suggested for other gene binding sites.	T4	T25	1280065
NA	CHEMICAL	GENE-Y	10	16	This binding was not significantly inhibited by the lysine analogue chemical (EACA), indicating that gene binding was not just through lysine binding sites as suggested for other gene binding sites.	T4	T26	1280065
NA	CHEMICAL	GENE-Y	8	16	This binding was not significantly inhibited by the chemical analogue epsilon-amino caproic acid (EACA), indicating that gene binding was not just through chemical binding sites as suggested for other gene binding sites.	T3	T25	1280065
NA	CHEMICAL	GENE-Y	8	16	This binding was not significantly inhibited by the chemical analogue epsilon-amino caproic acid (EACA), indicating that gene binding was not just through chemical binding sites as suggested for other gene binding sites.	T3	T26	1280065
NA	CHEMICAL	GENE-Y	8	16	This binding was not significantly inhibited by the chemical analogue epsilon-amino caproic acid (EACA), indicating that gene binding was not just through chemical binding sites as suggested for other gene binding sites.	T6	T25	1280065
NA	CHEMICAL	GENE-Y	8	16	This binding was not significantly inhibited by the chemical analogue epsilon-amino caproic acid (EACA), indicating that gene binding was not just through chemical binding sites as suggested for other gene binding sites.	T6	T26	1280065
NA	CHEMICAL	GENE-Y	13	16	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (chemical), indicating that gene binding was not just through lysine binding sites as suggested for other gene binding sites.	T5	T25	1280065
NA	CHEMICAL	GENE-Y	13	16	This binding was not significantly inhibited by the lysine analogue epsilon-amino caproic acid (chemical), indicating that gene binding was not just through lysine binding sites as suggested for other gene binding sites.	T5	T26	1280065
CPR:4	CHEMICAL	GENE-Y	11	5	Inhibition of binding of both gene and plasmin to gp330 by chemical was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of gene to gp330.	T1	T14	1280065
NA	CHEMICAL	GENE-Y	11	5	Inhibition of binding of both gene and plasmin to gp330 by chemical was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of gene to gp330.	T1	T19	1280065
CPR:4	CHEMICAL	GENE-Y	11	5	Inhibition of binding of both geneogen and gene to gp330 by chemical was similar, although EACA inhibited the binding of gene to gp330 slightly more than the binding of geneogen to gp330.	T1	T15	1280065
NA	CHEMICAL	GENE-Y	11	5	Inhibition of binding of both geneogen and gene to gp330 by chemical was similar, although EACA inhibited the binding of gene to gp330 slightly more than the binding of geneogen to gp330.	T1	T17	1280065
NA	CHEMICAL	GENE-Y	11	9	Inhibition of binding of both plasminogen and plasmin to gene by chemical was similar, although EACA inhibited the binding of plasmin to gene slightly more than the binding of plasminogen to gene.	T1	T16	1280065
NA	CHEMICAL	GENE-Y	11	9	Inhibition of binding of both plasminogen and plasmin to gene by chemical was similar, although EACA inhibited the binding of plasmin to gene slightly more than the binding of plasminogen to gene.	T1	T18	1280065
NA	CHEMICAL	GENE-Y	11	9	Inhibition of binding of both plasminogen and plasmin to gene by chemical was similar, although EACA inhibited the binding of plasmin to gene slightly more than the binding of plasminogen to gene.	T1	T20	1280065
NA	CHEMICAL	GENE-Y	15	5	Inhibition of binding of both gene and plasmin to gp330 by benzamidine was similar, although chemical inhibited the binding of plasmin to gp330 slightly more than the binding of gene to gp330.	T2	T14	1280065
CPR:4	CHEMICAL	GENE-Y	15	5	Inhibition of binding of both gene and plasmin to gp330 by benzamidine was similar, although chemical inhibited the binding of plasmin to gp330 slightly more than the binding of gene to gp330.	T2	T19	1280065
NA	CHEMICAL	GENE-Y	15	5	Inhibition of binding of both geneogen and gene to gp330 by benzamidine was similar, although chemical inhibited the binding of gene to gp330 slightly more than the binding of geneogen to gp330.	T2	T15	1280065
CPR:4	CHEMICAL	GENE-Y	15	5	Inhibition of binding of both geneogen and gene to gp330 by benzamidine was similar, although chemical inhibited the binding of gene to gp330 slightly more than the binding of geneogen to gp330.	T2	T17	1280065
NA	CHEMICAL	GENE-Y	15	9	Inhibition of binding of both plasminogen and plasmin to gene by benzamidine was similar, although chemical inhibited the binding of plasmin to gene slightly more than the binding of plasminogen to gene.	T2	T16	1280065
NA	CHEMICAL	GENE-Y	15	9	Inhibition of binding of both plasminogen and plasmin to gene by benzamidine was similar, although chemical inhibited the binding of plasmin to gene slightly more than the binding of plasminogen to gene.	T2	T18	1280065
NA	CHEMICAL	GENE-Y	15	9	Inhibition of binding of both plasminogen and plasmin to gene by benzamidine was similar, although chemical inhibited the binding of plasmin to gene slightly more than the binding of plasminogen to gene.	T2	T20	1280065
NA	CHEMICAL	GENE-N	21	2	Involvement of gene was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and chemical (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	T15	T27	12818701
NA	CHEMICAL	GENE-N	21	2	Involvement of genes was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and chemical (0.03-0.3 mg/kg), as well as by the selective gene antagonist, prazosin (0.3 mg/kg).	T15	T30	12818701
CPR:6	CHEMICAL	GENE-N	21	15	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective gene antagonists, phentolamine (0.3-3 mg/kg) and chemical (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	T15	T28	12818701
NA	CHEMICAL	GENE-N	17	2	Involvement of gene was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, chemical (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	T14	T27	12818701
NA	CHEMICAL	GENE-N	17	2	Involvement of genes was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, chemical (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective gene antagonist, prazosin (0.3 mg/kg).	T14	T30	12818701
CPR:6	CHEMICAL	GENE-N	17	15	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective gene antagonists, chemical (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).	T14	T28	12818701
NA	CHEMICAL	GENE-N	32	2	Involvement of gene was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, chemical (0.3 mg/kg).	T16	T27	12818701
CPR:6	CHEMICAL	GENE-N	32	2	Involvement of genes was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective gene antagonist, chemical (0.3 mg/kg).	T16	T30	12818701
NA	CHEMICAL	GENE-N	32	15	Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective gene antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, chemical (0.3 mg/kg).	T16	T28	12818701
CPR:6	CHEMICAL	GENE-N	3	1	The gene antagonist, chemical (0.5 mg/kg), was without antagonistic effects.	T17	T31	12818701
NA	CHEMICAL	GENE-Y	15	0	gene selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, chemical (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T2	T32	12818701
CPR:6	CHEMICAL	GENE-Y	15	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the gene selective antagonist, chemical (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T2	T20	12818701
NA	CHEMICAL	GENE-Y	15	24	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, chemical (L-765314; 0.3-1 mg/kg), as well as the gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T2	T21	12818701
NA	CHEMICAL	GENE-N	15	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, chemical (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the gene subtypes involved.	T2	T22	12818701
NA	CHEMICAL	GENE-Y	27	0	gene selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, chemical (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T4	T32	12818701
NA	CHEMICAL	GENE-Y	27	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, chemical (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T4	T20	12818701
CPR:6	CHEMICAL	GENE-Y	27	24	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the gene selective antagonist, chemical (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T4	T21	12818701
NA	CHEMICAL	GENE-N	27	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, chemical (BMY-7378; 1 mg/kg), were used to delineate the gene subtypes involved.	T4	T22	12818701
CPR:6	CHEMICAL	GENE-Y	3	0	gene selective antagonists, chemical (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T18	T32	12818701
NA	CHEMICAL	GENE-Y	3	12	alpha(1A)-Adrenoceptor selective antagonists, chemical (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T18	T20	12818701
NA	CHEMICAL	GENE-Y	3	24	alpha(1A)-Adrenoceptor selective antagonists, chemical (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T18	T21	12818701
NA	CHEMICAL	GENE-N	3	12	alpha(1A)-Adrenoceptor selective antagonists, chemical (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the gene subtypes involved.	T18	T22	12818701
CPR:6	CHEMICAL	GENE-Y	8	0	gene selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and chemical (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T1	T32	12818701
NA	CHEMICAL	GENE-Y	8	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and chemical (0.1-1 mg/kg), the gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T1	T20	12818701
NA	CHEMICAL	GENE-Y	8	24	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and chemical (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T1	T21	12818701
NA	CHEMICAL	GENE-N	8	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and chemical (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the gene subtypes involved.	T1	T22	12818701
NA	CHEMICAL	GENE-Y	17	0	gene selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (chemical; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T3	T32	12818701
CPR:6	CHEMICAL	GENE-Y	17	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (chemical; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T3	T20	12818701
NA	CHEMICAL	GENE-Y	17	24	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (chemical; 0.3-1 mg/kg), as well as the gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T3	T21	12818701
NA	CHEMICAL	GENE-N	17	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (chemical; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the gene subtypes involved.	T3	T22	12818701
NA	CHEMICAL	GENE-Y	28	0	gene selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (chemical; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T5	T32	12818701
NA	CHEMICAL	GENE-Y	28	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (chemical; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T5	T20	12818701
CPR:6	CHEMICAL	GENE-Y	28	24	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (chemical; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T5	T21	12818701
NA	CHEMICAL	GENE-N	28	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (chemical; 1 mg/kg), were used to delineate the gene subtypes involved.	T5	T22	12818701
CPR:6	CHEMICAL	GENE-Y	4	0	gene selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (chemical; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T19	T32	12818701
NA	CHEMICAL	GENE-Y	4	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (chemical; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T19	T20	12818701
NA	CHEMICAL	GENE-Y	4	24	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (chemical; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.	T19	T21	12818701
NA	CHEMICAL	GENE-N	4	12	alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (chemical; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-gene selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-gene selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the gene subtypes involved.	T19	T22	12818701
CPR:4	CHEMICAL	GENE-Y	15	13	To further investigate this positive correlation and its possible therapeutic implications, a selective gene inhibitor, chemical, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and gene expression levels.	T2	T10	12824918
NA	CHEMICAL	GENE-Y	15	13	To further investigate this positive correlation and its possible therapeutic implications, a selective gene inhibitor, chemical, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and gene expression levels.	T2	T11	12824918
NA	CHEMICAL	GENE-N	12	19	In human kidney, we found unique prazosin-binding sites that were insensitive to chemical and were thus unlikely to be gene.	T32	T42	12827214
NA	CHEMICAL	GENE-N	6	19	In human kidney, we found unique chemical-binding sites that were insensitive to phentolamine and were thus unlikely to be gene.	T25	T42	12827214
NA	CHEMICAL	GENE-N	0	32	chemical bound to the phentolamine-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the phentolamine-sensitive gene (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	T28	T45	12827214
NA	CHEMICAL	GENE-N	4	32	[(3)H]Prazosin bound to the chemical-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the chemical-sensitive gene (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	T29	T45	12827214
NA	CHEMICAL	GENE-N	4	32	[(3)H]Prazosin bound to the chemical-insensitive sites monophasically with a high affinity (pK(d); 9.1+/-0.08, n=8), and the B(max) value (814+/-204 fmol mg(-1) protein, n=8) was more than ten times that of the chemical-sensitive gene (pK(d)=9.9+/-0.13, B(max)=66+/-23 fmol mg(-1) protein, n=7).	T30	T45	12827214
NA	CHEMICAL	GENE-N	33	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the chemical binding.	T4	T40	12827214
NA	CHEMICAL	GENE-N	33	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the chemical binding.	T4	T46	12827214
NA	CHEMICAL	GENE-N	24	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and chemical, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T1	T40	12827214
NA	CHEMICAL	GENE-N	24	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and chemical, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T1	T46	12827214
NA	CHEMICAL	GENE-N	7	2	However, other gene antagonists (tamsulosin, WB4101 and chemical) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T38	T40	12827214
CPR:6	CHEMICAL	GENE-N	7	2	However, other gene antagonists (tamsulosin, WB4101 and chemical) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T38	T46	12827214
NA	CHEMICAL	GENE-N	25	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, chemical and propranolol were without effect on the [(3)H]prazosin binding.	T2	T40	12827214
NA	CHEMICAL	GENE-N	25	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, chemical and propranolol were without effect on the [(3)H]prazosin binding.	T2	T46	12827214
NA	CHEMICAL	GENE-N	27	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and chemical were without effect on the [(3)H]prazosin binding.	T3	T40	12827214
NA	CHEMICAL	GENE-N	27	2	However, other gene antagonists (tamsulosin, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and chemical were without effect on the [(3)H]prazosin binding.	T3	T46	12827214
NA	CHEMICAL	GENE-N	4	2	However, other gene antagonists (chemical, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T36	T40	12827214
CPR:6	CHEMICAL	GENE-N	4	2	However, other gene antagonists (chemical, WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T36	T46	12827214
NA	CHEMICAL	GENE-N	5	2	However, other gene antagonists (tamsulosin, chemical and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T37	T40	12827214
CPR:6	CHEMICAL	GENE-N	5	2	However, other gene antagonists (tamsulosin, chemical and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit gene antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.	T37	T46	12827214
NA	CHEMICAL	GENE-N	25	8	On the other hand, ligands for the renal gene (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of chemical to phentolamine-insensitive sites at micromolar concentrations.	T12	T41	12827214
NA	CHEMICAL	GENE-N	27	8	On the other hand, ligands for the renal gene (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to chemical-insensitive sites at micromolar concentrations.	T13	T41	12827214
NA	CHEMICAL	GENE-N	14	8	On the other hand, ligands for the renal gene (amiloride and triamterene) and for chemical recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	T8	T41	12827214
NA	CHEMICAL	GENE-N	11	8	On the other hand, ligands for the renal gene (amiloride and chemical) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	T7	T41	12827214
NA	CHEMICAL	GENE-N	18	8	On the other hand, ligands for the renal gene (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, chemical and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	T10	T41	12827214
NA	CHEMICAL	GENE-N	17	8	On the other hand, ligands for the renal gene (amiloride and triamterene) and for imidazoline recognition sites (chemical, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	T9	T41	12827214
NA	CHEMICAL	GENE-N	9	8	On the other hand, ligands for the renal gene (chemical and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	T6	T41	12827214
NA	CHEMICAL	GENE-N	20	8	On the other hand, ligands for the renal gene (amiloride and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and chemical) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.	T11	T41	12827214
NA	CHEMICAL	GENE-N	3	18	Photoaffinity labeling with chemical showed phentolamine-insensitive labeling at around 100 kDa, a molecular size larger than that of gene expressed in 293 cells (50-60 and 70-80 kDa, respectively) on electrophoresis.	T14	T43	12827214
NA	CHEMICAL	GENE-N	5	18	Photoaffinity labeling with [(125)I]iodoarylazidoprazosin showed chemical-insensitive labeling at around 100 kDa, a molecular size larger than that of gene expressed in 293 cells (50-60 and 70-80 kDa, respectively) on electrophoresis.	T15	T43	12827214
NA	CHEMICAL	GENE-N	6	12	In contrast, there was no detectable chemical-insensitive binding site but were chemical-sensitive gene in human liver (pK(d)=10.0+/-0.06, B(max)=44+/-6 fmol mg(-1) protein, n=3).	T17	T44	12827214
NA	CHEMICAL	GENE-N	6	12	In contrast, there was no detectable chemical-insensitive binding site but were chemical-sensitive gene in human liver (pK(d)=10.0+/-0.06, B(max)=44+/-6 fmol mg(-1) protein, n=3).	T18	T44	12827214
NA	CHEMICAL	GENE-Y	8	10	The interactions of chi-conopeptide MrIA with the human chemical transporter (gene) were investigated by determining the effects of gene point mutations on the inhibitory potency of MrIA.	T10	T18	12837768
NA	CHEMICAL	GENE-Y	8	10	The interactions of chi-conopeptide MrIA with the human chemical transporter (gene) were investigated by determining the effects of gene point mutations on the inhibitory potency of MrIA.	T10	T25	12837768
NA	CHEMICAL	GENE-Y	13	24	The potency of MrIA was greater for inhibition of uptake by hNET of chemical (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the gene and serotonin transporter were not inhibited by MrIA (to 7 microM).	T5	T20	12837768
NA	CHEMICAL	GENE-Y	13	28	The potency of MrIA was greater for inhibition of uptake by hNET of chemical (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and gene were not inhibited by MrIA (to 7 microM).	T5	T21	12837768
CPR:9	CHEMICAL	GENE-Y	13	11	The potency of MrIA was greater for inhibition of uptake by gene of chemical (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).	T5	T19	12837768
NA	CHEMICAL	GENE-Y	18	24	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than chemical (Ki 4.33 microM), and the gene and serotonin transporter were not inhibited by MrIA (to 7 microM).	T6	T20	12837768
NA	CHEMICAL	GENE-Y	18	28	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than chemical (Ki 4.33 microM), and the human dopamine transporter and gene were not inhibited by MrIA (to 7 microM).	T6	T21	12837768
CPR:9	CHEMICAL	GENE-Y	18	11	The potency of MrIA was greater for inhibition of uptake by gene of [3H]norepinephrine (Ki 1.89 microM) than chemical (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).	T6	T19	12837768
NA	CHEMICAL	GENE-Y	28	24	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the gene and chemical transporter were not inhibited by MrIA (to 7 microM).	T8	T20	12837768
NA	CHEMICAL	GENE-Y	28	11	The potency of MrIA was greater for inhibition of uptake by gene of [3H]norepinephrine (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and chemical transporter were not inhibited by MrIA (to 7 microM).	T8	T19	12837768
NA	CHEMICAL	GENE-Y	18	28	The potency of MrIA was greater for inhibition of uptake by hNET of [3H]norepinephrine (Ki 1.89 microM) than [3H]chemical (Ki 4.33 microM), and the human chemical transporter and gene were not inhibited by MrIA (to 7 microM).	T7	T21	12837768
NA	CHEMICAL	GENE-Y	18	11	The potency of MrIA was greater for inhibition of uptake by gene of [3H]norepinephrine (Ki 1.89 microM) than [3H]chemical (Ki 4.33 microM), and the human chemical transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).	T7	T19	12837768
NA	CHEMICAL	GENE-Y	24	14	Of 18 mutations where hNET amino acid residues were exchanged with those of the gene, MrIA had increased potency for inhibition of chemical uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	T12	T24	12837768
NA	CHEMICAL	GENE-Y	24	4	Of 18 mutations where gene amino acid residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of chemical uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	T12	T23	12837768
NA	CHEMICAL	GENE-Y	5	14	Of 18 mutations where hNET chemical residues were exchanged with those of the gene, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	T9	T24	12837768
NA	CHEMICAL	GENE-Y	5	4	Of 18 mutations where gene chemical residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	T9	T23	12837768
NA	CHEMICAL	GENE-Y	15	4	Of 18 mutations where gene amino acid residues were exchanged with those of the human chemical transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	T11	T23	12837768
CPR:9	CHEMICAL	GENE-Y	14	19	A comparison of the results with previous data for desipramine and cocaine inhibition of chemical uptake by the mutant gene reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	T2	T16	12837768
NA	CHEMICAL	GENE-Y	14	19	A comparison of the results with previous data for desipramine and cocaine inhibition of chemical uptake by the mutant genes reveals that MrIA binding to gene occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	T2	T17	12837768
NA	CHEMICAL	GENE-Y	9	19	A comparison of the results with previous data for chemical and cocaine inhibition of norepinephrine uptake by the mutant gene reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	T1	T16	12837768
NA	CHEMICAL	GENE-Y	9	19	A comparison of the results with previous data for chemical and cocaine inhibition of norepinephrine uptake by the mutant genes reveals that MrIA binding to gene occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.	T1	T17	12837768
NA	CHEMICAL	GENE-Y	41	19	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant gene reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for chemical antidepressants and cocaine.	T3	T16	12837768
NA	CHEMICAL	GENE-Y	41	19	A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant genes reveals that MrIA binding to gene occurs at a site that is distinct from but overlaps with the binding sites for chemical antidepressants and cocaine.	T3	T17	12837768
NA	CHEMICAL	GENE-Y	11	19	A comparison of the results with previous data for desipramine and chemical inhibition of norepinephrine uptake by the mutant gene reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and chemical.	T4	T16	12837768
NA	CHEMICAL	GENE-Y	11	19	A comparison of the results with previous data for desipramine and chemical inhibition of norepinephrine uptake by the mutant genes reveals that MrIA binding to gene occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and chemical.	T4	T17	12837768
CPR:9	CHEMICAL	GENE-Y	31	11	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (gene, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of chemical except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T3	T25	1284246
CPR:9	CHEMICAL	GENE-Y	31	9	A cDNA encoding the complete amino acid sequence of gene (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of chemical except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T3	T23	1284246
CPR:9	CHEMICAL	GENE-N	31	19	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric gene having two Zn2+ in the molecule, which catalyzes the deacylation of chemical except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T3	T21	1284246
CPR:9	CHEMICAL	GENE-Y	31	15	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [gene], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of chemical except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T3	T18	1284246
CPR:9	CHEMICAL	GENE-Y	31	14	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, gene) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of chemical except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T3	T17	1284246
NA	CHEMICAL	GENE-Y	11	9	A cDNA encoding the complete amino acid sequence of gene (chemical aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T12	T23	1284246
NA	CHEMICAL	GENE-N	11	19	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (chemical aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric gene having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T12	T21	1284246
NA	CHEMICAL	GENE-Y	11	15	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (chemical aminohydrolase, ACY-1) [gene], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T12	T18	1284246
NA	CHEMICAL	GENE-Y	11	14	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (chemical aminohydrolase, gene) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T12	T17	1284246
NA	CHEMICAL	GENE-Y	35	11	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (gene, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except chemical, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T4	T25	1284246
NA	CHEMICAL	GENE-Y	35	9	A cDNA encoding the complete amino acid sequence of gene (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except chemical, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T4	T23	1284246
NA	CHEMICAL	GENE-N	35	19	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric gene having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except chemical, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T4	T21	1284246
NA	CHEMICAL	GENE-Y	35	15	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [gene], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except chemical, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T4	T18	1284246
NA	CHEMICAL	GENE-Y	35	14	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, gene) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except chemical, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T4	T17	1284246
NA	CHEMICAL	GENE-Y	5	9	A cDNA encoding the complete chemical sequence of gene (N-acylchemical aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-chemicals except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T5	T23	1284246
NA	CHEMICAL	GENE-N	5	19	A cDNA encoding the complete chemical sequence of aminoacylase 1 (N-acylchemical aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric gene having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-chemicals except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T5	T21	1284246
NA	CHEMICAL	GENE-Y	5	15	A cDNA encoding the complete chemical sequence of aminoacylase 1 (N-acylchemical aminohydrolase, ACY-1) [gene], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-chemicals except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T5	T18	1284246
NA	CHEMICAL	GENE-Y	5	14	A cDNA encoding the complete chemical sequence of aminoacylase 1 (N-acylchemical aminohydrolase, gene) [EC 3.5.1.14], a dimeric metalloprotein having two Zn2+ in the molecule, which catalyzes the deacylation of N-acylated L-chemicals except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T5	T17	1284246
NA	CHEMICAL	GENE-Y	22	11	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (gene, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two chemical in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T2	T25	1284246
NA	CHEMICAL	GENE-Y	22	9	A cDNA encoding the complete amino acid sequence of gene (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric metalloprotein having two chemical in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T2	T23	1284246
NA	CHEMICAL	GENE-N	22	19	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [EC 3.5.1.14], a dimeric gene having two chemical in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T2	T21	1284246
NA	CHEMICAL	GENE-Y	22	15	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, ACY-1) [gene], a dimeric metalloprotein having two chemical in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T2	T18	1284246
NA	CHEMICAL	GENE-Y	22	14	A cDNA encoding the complete amino acid sequence of aminoacylase 1 (N-acylamino acid aminohydrolase, gene) [EC 3.5.1.14], a dimeric metalloprotein having two chemical in the molecule, which catalyzes the deacylation of N-acylated L-amino acids except L-aspartic acid, has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	T2	T17	1284246
NA	CHEMICAL	GENE-Y	45	22	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that gene consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with chemical at the N-terminus.	T10	T22	1284246
NA	CHEMICAL	GENE-Y	42	22	From sequence analysis of the cDNA and the N- and C-terminal amino acid analyses of the purified protein, it is deduced that gene consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 chemical with acetylalanine at the N-terminus.	T9	T22	1284246
NA	CHEMICAL	GENE-Y	11	22	From sequence analysis of the cDNA and the N- and C-terminal chemical analyses of the purified protein, it is deduced that gene consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 chemicals with acetylalanine at the N-terminus.	T8	T22	1284246
NA	CHEMICAL	GENE-Y	5	22	From sequence analysis of the cDchemicalA and the chemical- and C-terminal amino acid analyses of the purified protein, it is deduced that gene consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the chemical-terminus.	T11	T22	1284246
NA	CHEMICAL	GENE-Y	5	22	From sequence analysis of the cDchemicalA and the chemical- and C-terminal amino acid analyses of the purified protein, it is deduced that gene consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 amino acids with acetylalanine at the chemical-terminus.	T6	T22	1284246
NA	CHEMICAL	GENE-Y	1	21	The chemical sequence deduced from the nucleotide sequence of the cDNA from porcine liver was identical to that deduced for gene.	T13	T26	1284246
NA	CHEMICAL	GENE-Y	7	21	The amino acid sequence deduced from the chemical sequence of the cDNA from porcine liver was identical to that deduced for gene.	T14	T26	1284246
NA	CHEMICAL	GENE-N	3	13	Comparison of the chemical sequence of porcine ACY-1 with those of other gene showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	T15	T16	1284246
NA	CHEMICAL	GENE-Y	3	7	Comparison of the chemical sequence of gene with those of other Zn2+-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	T15	T28	1284246
NA	CHEMICAL	GENE-Y	13	7	Comparison of the amino acid sequence of gene with those of other chemical-binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	T1	T28	1284246
NA	CHEMICAL	GENE-Y	20	12	We tested the hypothesis that 2 common polymorphisms in the gene for gene are associated with antihypertensive response to chemical in patients with uncomplicated hypertension.	T3	T14	12844134
NA	CHEMICAL	GENE-Y	15	5	CONCLUSIONS: Our data suggest that gene polymorphisms are important determinants of antihypertensive response to chemical.	T1	T13	12844134
NA	CHEMICAL	GENE-Y	23	9	In the future, codon 49 and 389 genotypes or gene haplotypes might be used to predict the diastolic blood pressure response to chemical in patients with hypertension.	T2	T15	12844134
CPR:4	CHEMICAL	GENE-Y	19	9	Patients stable on warfarin therapy and concurrently taking a gene (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or chemical) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	T7	T22	12901032
CPR:4	CHEMICAL	GENE-Y	19	10	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (gene) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or chemical) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	T7	T23	12901032
CPR:4	CHEMICAL	GENE-Y	22	9	Patients stable on warfarin therapy and concurrently taking a gene (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received chemical 200 mg/day or rofecoxib 25 mg/day for three weeks.	T8	T22	12901032
CPR:4	CHEMICAL	GENE-Y	22	10	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (gene) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received chemical 200 mg/day or rofecoxib 25 mg/day for three weeks.	T8	T23	12901032
CPR:4	CHEMICAL	GENE-Y	17	9	Patients stable on warfarin therapy and concurrently taking a gene (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, chemical, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	T6	T22	12901032
CPR:4	CHEMICAL	GENE-Y	17	10	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (gene) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, chemical, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	T6	T23	12901032
CPR:4	CHEMICAL	GENE-Y	26	9	Patients stable on warfarin therapy and concurrently taking a gene (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or chemical 25 mg/day for three weeks.	T9	T22	12901032
CPR:4	CHEMICAL	GENE-Y	26	10	Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (gene) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or chemical 25 mg/day for three weeks.	T9	T23	12901032
NA	CHEMICAL	GENE-Y	3	9	Patients stable on chemical therapy and concurrently taking a gene (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	T14	T22	12901032
NA	CHEMICAL	GENE-Y	3	10	Patients stable on chemical therapy and concurrently taking a cyclooxygenase-2 (gene) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.	T14	T23	12901032
NA	CHEMICAL	GENE-Y	21	7	Adverse drug reactions were similar for each gene inhibitor, but the rate of edema requiring medical intervention was higher in the chemical group.	T1	T21	12901032
NA	CHEMICAL	GENE-Y	4	4	INTRODUCTION: Blockade of the gene-chemical system (RAS) by ACE inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	T20	T19	12927226
NA	CHEMICAL	GENE-Y	4	4	INTRODUCTION: Blockade of the gene-chemical system (RAS) by ACE inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	T7	T19	12927226
NA	CHEMICAL	GENE-Y	4	8	INTRODUCTION: Blockade of the renin-chemical system (RAS) by gene inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	T20	T22	12927226
NA	CHEMICAL	GENE-Y	4	8	INTRODUCTION: Blockade of the renin-chemical system (RAS) by gene inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	T7	T22	12927226
CPR:4	CHEMICAL	GENE-Y	14	8	We sought to assess the effects of the gene blocker chemical on HRV and BRG.	T9	T21	12927226
NA	CHEMICAL	GENE-Y	14	8	We sought to assess the effects of the gene type 1 (AT1) receptor blocker chemical on HRV and BRG.	T9	T8	12927226
CPR:3	CHEMICAL	GENE-Y	1	18	RESULTS: chemical tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating gene levels (p<0.01).	T11	T13	12927226
NA	CHEMICAL	GENE-Y	1	18	RESULTS: chemical tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating gene levels (p<0.01).	T11	T1	12927226
CPR:6	CHEMICAL	GENE-Y	4	1	CONCLUSIONS: gene antagonism by chemical lowers heart rate variability and baroreflex gain.	T3	T14	12927226
NA	CHEMICAL	GENE-Y	13	15	We speculate that these findings are due to the marked increase in circulating chemical (gene).	T15	T16	12927226
NA	CHEMICAL	GENE-Y	13	15	We speculate that these findings are due to the marked increase in circulating chemical (gene).	T15	T5	12927226
NA	CHEMICAL	GENE-Y	13	15	We speculate that these findings are due to the marked increase in circulating chemical (gene).	T4	T16	12927226
NA	CHEMICAL	GENE-Y	13	15	We speculate that these findings are due to the marked increase in circulating chemical (gene).	T4	T5	12927226
NA	CHEMICAL	GENE-Y	15	13	We speculate that these findings are due to the marked increase in circulating gene (chemical).	T16	T15	12927226
NA	CHEMICAL	GENE-Y	15	13	We speculate that these findings are due to the marked increase in circulating gene (chemical).	T16	T4	12927226
NA	CHEMICAL	GENE-Y	15	13	We speculate that these findings are due to the marked increase in circulating gene (chemical).	T5	T15	12927226
NA	CHEMICAL	GENE-Y	15	13	We speculate that these findings are due to the marked increase in circulating gene (chemical).	T5	T4	12927226
NA	CHEMICAL	GENE-Y	7	10	Further studies are needed to clarify whether chemical type 1 (gene) blockers with potential actions inside the blood-brain barrier (BBB) may have different effects on HRV and BRG.	T6	T18	12927226
NA	CHEMICAL	GENE-Y	0	27	chemical did not prevent or reverse that modulatory activity; moreover, pretreatment with the acetylated peptide did not change the pA2 value displayed by the antagonist at the gene.	T17	T28	1318989
CPR:5	CHEMICAL	GENE-N	8	5	The antinociceptive activity of the gene agonist chemical was also increased in mice treated with alpha N-acetyl beta-endorphin-(1-31).	T18	T29	1318989
NA	CHEMICAL	GENE-N	17	5	The antinociceptive activity of the gene agonist clonidine was also increased in mice treated with alpha chemical beta-endorphin-(1-31).	T19	T29	1318989
NA	CHEMICAL	GENE-N	23	31	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or chemical, agents known to impair the function of gene/Go transducer proteins.	T2	T22	1318989
NA	CHEMICAL	GENE-N	23	31	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or chemical, agents known to impair the function of Gi/gene transducer proteins.	T2	T23	1318989
NA	CHEMICAL	GENE-N	5	31	The reducing activity of alpha chemical beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of gene/Go transducer proteins.	T20	T22	1318989
NA	CHEMICAL	GENE-N	5	31	The reducing activity of alpha chemical beta-endorphin-(1-31) upon morphine- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of Gi/gene transducer proteins.	T20	T23	1318989
NA	CHEMICAL	GENE-N	8	31	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon chemical- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of gene/Go transducer proteins.	T1	T22	1318989
NA	CHEMICAL	GENE-N	8	31	The reducing activity of alpha N-acetyl beta-endorphin-(1-31) upon chemical- and beta-endorphin-induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or N-ethylmaleimide, agents known to impair the function of Gi/gene transducer proteins.	T1	T23	1318989
NA	CHEMICAL	GENE-N	9	20	These results confirm and strengthen the idea of alpha chemical beta-endorphin-(1-31) acting as a non-competitive regulator of mu opioid- and gene-mediated supraspinal antinociception.	T6	T25	1318989
NA	CHEMICAL	GENE-Y	9	17	These results confirm and strengthen the idea of alpha chemical beta-endorphin-(1-31) acting as a non-competitive regulator of gene- and alpha 2-adrenoceptor-mediated supraspinal antinociception.	T6	T24	1318989
CPR:4	CHEMICAL	GENE-Y	0	14	chemical, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress gene and cortisol levels in normal subjects, but not in patients with proven gene-dependent Cushing's disease.	T1	T20	1322429
NA	CHEMICAL	GENE-Y	0	14	chemical, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress gene and cortisol levels in normal subjects, but not in patients with proven gene-dependent Cushing's disease.	T1	T32	1322429
NA	CHEMICAL	GENE-Y	16	14	Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress gene and chemical levels in normal subjects, but not in patients with proven gene-dependent Cushing's disease.	T2	T20	1322429
NA	CHEMICAL	GENE-Y	16	14	Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress gene and chemical levels in normal subjects, but not in patients with proven gene-dependent Cushing's disease.	T2	T32	1322429
CPR:4	CHEMICAL	GENE-Y	14	5	In seven normal subjects, basal gene plasma levels were significantly suppressed 3 h after chemical administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).	T14	T33	1322429
NA	CHEMICAL	GENE-Y	15	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T34	1322429
NA	CHEMICAL	GENE-Y	15	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T34	1322429
NA	CHEMICAL	GENE-Y	15	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T38	1322429
NA	CHEMICAL	GENE-Y	15	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T39	1322429
NA	CHEMICAL	GENE-Y	15	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T38	1322429
NA	CHEMICAL	GENE-Y	15	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T39	1322429
NA	CHEMICAL	GENE-Y	15	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms chemical, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T15	1322429
NA	CHEMICAL	GENE-Y	15	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms chemical, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T35	1322429
NA	CHEMICAL	GENE-Y	15	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms chemical, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T15	1322429
NA	CHEMICAL	GENE-Y	15	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms chemical, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T35	1322429
NA	CHEMICAL	GENE-N	15	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T17	1322429
NA	CHEMICAL	GENE-N	15	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T16	T37	1322429
NA	CHEMICAL	GENE-N	15	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T17	1322429
NA	CHEMICAL	GENE-N	15	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms chemical, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T36	T37	1322429
NA	CHEMICAL	GENE-Y	33	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms gene, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T16	1322429
CPR:4	CHEMICAL	GENE-Y	33	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms gene, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T36	1322429
CPR:4	CHEMICAL	GENE-Y	33	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T34	1322429
CPR:4	CHEMICAL	GENE-Y	33	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T38	1322429
CPR:4	CHEMICAL	GENE-Y	33	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T39	1322429
NA	CHEMICAL	GENE-Y	33	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T15	1322429
CPR:4	CHEMICAL	GENE-Y	33	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T35	1322429
NA	CHEMICAL	GENE-N	33	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T17	1322429
CPR:4	CHEMICAL	GENE-N	33	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by chemical from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T18	T37	1322429
NA	CHEMICAL	GENE-Y	12	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms gene, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T16	1322429
NA	CHEMICAL	GENE-Y	12	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms gene, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T36	1322429
NA	CHEMICAL	GENE-Y	12	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms gene, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T16	1322429
NA	CHEMICAL	GENE-Y	12	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms gene, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T36	1322429
NA	CHEMICAL	GENE-Y	12	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T34	1322429
NA	CHEMICAL	GENE-Y	12	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T34	1322429
NA	CHEMICAL	GENE-Y	12	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T38	1322429
NA	CHEMICAL	GENE-Y	12	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T39	1322429
NA	CHEMICAL	GENE-Y	12	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T38	1322429
NA	CHEMICAL	GENE-Y	12	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms TRH), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T39	1322429
NA	CHEMICAL	GENE-N	12	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T17	1322429
NA	CHEMICAL	GENE-N	12	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T15	T37	1322429
NA	CHEMICAL	GENE-N	12	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T17	1322429
NA	CHEMICAL	GENE-N	12	20	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms chemical, 100 micrograms GH-releasing hormone, and 200 micrograms gene), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T35	T37	1322429
NA	CHEMICAL	GENE-Y	20	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms gene, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T16	1322429
NA	CHEMICAL	GENE-Y	20	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms gene, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T36	1322429
NA	CHEMICAL	GENE-Y	20	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms gene, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T16	1322429
NA	CHEMICAL	GENE-Y	20	15	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms gene, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T36	1322429
NA	CHEMICAL	GENE-Y	20	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T34	1322429
NA	CHEMICAL	GENE-Y	20	8	After the combined pituitary stimulation test (100 micrograms gene, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T34	1322429
NA	CHEMICAL	GENE-Y	20	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T38	1322429
NA	CHEMICAL	GENE-Y	20	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T39	1322429
NA	CHEMICAL	GENE-Y	20	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T38	1322429
NA	CHEMICAL	GENE-Y	20	22	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms GnRH, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the gene peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of gene from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T39	1322429
NA	CHEMICAL	GENE-Y	20	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T15	1322429
NA	CHEMICAL	GENE-Y	20	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T17	T35	1322429
NA	CHEMICAL	GENE-Y	20	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T15	1322429
NA	CHEMICAL	GENE-Y	20	12	After the combined pituitary stimulation test (100 micrograms human CRH, 100 micrograms gene, 100 micrograms GH-releasing hormone, and 200 micrograms chemical), the ACTH peak (maximum increase at 30 min) was significantly blunted by loperamide from 9 +/- 1 to 4 +/- 1 pmol/L (P less than 0.001) and the area under the curve of ACTH from 0-120 min was reduced from 35 +/- 5 to 23 +/- 4 pmol/L.2 h (P less than 0.05).	T37	T35	1322429
NA	CHEMICAL	GENE-Y	22	2	In the gene-hypoglycemia test (0.15 IU/kg BW), neither the ACTH peak nor the area under the curve of ACTH was affected by chemical.	T3	T21	1322429
NA	CHEMICAL	GENE-Y	22	9	In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the gene peak nor the area under the curve of gene was affected by chemical.	T3	T22	1322429
NA	CHEMICAL	GENE-Y	22	9	In the insulin-hypoglycemia test (0.15 IU/kg BW), neither the gene peak nor the area under the curve of gene was affected by chemical.	T3	T23	1322429
NA	CHEMICAL	GENE-Y	29	19	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal gene and cortisol levels nor CRH-stimulated levels were influenced by chemical.	T5	T24	1322429
NA	CHEMICAL	GENE-Y	29	24	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and cortisol levels nor gene-stimulated levels were influenced by chemical.	T5	T25	1322429
NA	CHEMICAL	GENE-Y	21	19	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal gene and chemical levels nor CRH-stimulated levels were influenced by loperamide.	T4	T24	1322429
NA	CHEMICAL	GENE-Y	21	24	In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal ACTH and chemical levels nor gene-stimulated levels were influenced by loperamide.	T4	T25	1322429
NA	CHEMICAL	GENE-Y	6	15	In four cultured human corticotropic adenomas, chemical was not able to reduce basal and CRH-induced gene secretion.	T6	T27	1322429
NA	CHEMICAL	GENE-Y	6	14	In four cultured human corticotropic adenomas, chemical was not able to reduce basal and gene-induced ACTH secretion.	T6	T26	1322429
CPR:4	CHEMICAL	GENE-Y	2	10	In summary, chemical is able to reduce basal and CRH-induced gene and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	T7	T29	1322429
CPR:4	CHEMICAL	GENE-Y	2	9	In summary, chemical is able to reduce basal and gene-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	T7	T28	1322429
NA	CHEMICAL	GENE-Y	12	10	In summary, loperamide is able to reduce basal and CRH-induced gene and chemical levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	T8	T29	1322429
NA	CHEMICAL	GENE-Y	12	9	In summary, loperamide is able to reduce basal and gene-induced ACTH and chemical levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	T8	T28	1322429
NA	CHEMICAL	GENE-Y	0	6	chemical has no significant effect on gene-hypoglycemia-induced ACTH and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.	T9	T30	1322429
NA	CHEMICAL	GENE-Y	0	7	chemical has no significant effect on insulin-hypoglycemia-induced gene and cortisol levels and, therefore, no effect on stress-induced elevation of cortisol levels.	T9	T31	1322429
NA	CHEMICAL	GENE-Y	9	6	Loperamide has no significant effect on gene-hypoglycemia-induced ACTH and chemical levels and, therefore, no effect on stress-induced elevation of chemical levels.	T10	T30	1322429
NA	CHEMICAL	GENE-Y	9	7	Loperamide has no significant effect on insulin-hypoglycemia-induced gene and chemical levels and, therefore, no effect on stress-induced elevation of chemical levels.	T10	T31	1322429
CPR:6	CHEMICAL	GENE-Y	6	9	We also examined the effects of chemical, a gene antagonist, in parallel.	T5	T18	1329582
CPR:9	CHEMICAL	GENE-Y	12	6	The unique role of the enzyme gene (5-LO) in the production of chemical (LTs) makes it a likely target for biochemical manipulation.	T17	T25	1359745
CPR:9	CHEMICAL	GENE-Y	12	7	The unique role of the enzyme 5-lipoxygenase (gene) in the production of chemical (LTs) makes it a likely target for biochemical manipulation.	T17	T26	1359745
CPR:9	CHEMICAL	GENE-Y	13	6	The unique role of the enzyme gene (5-LO) in the production of leukotrienes (chemical) makes it a likely target for biochemical manipulation.	T21	T25	1359745
CPR:9	CHEMICAL	GENE-Y	13	7	The unique role of the enzyme 5-lipoxygenase (gene) in the production of leukotrienes (chemical) makes it a likely target for biochemical manipulation.	T21	T26	1359745
NA	CHEMICAL	GENE-Y	36	4	The rationale for using gene inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of LTs in the inflamed mucosa, LTB4 being the most potent chemotactic and chemokinetic metabolite of chemical.	T13	T24	1359745
NA	CHEMICAL	GENE-Y	26	4	The rationale for using gene inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of LTs in the inflamed mucosa, chemical being the most potent chemotactic and chemokinetic metabolite of arachidonic acid.	T12	T24	1359745
NA	CHEMICAL	GENE-Y	21	4	The rationale for using gene inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of chemical in the inflamed mucosa, LTB4 being the most potent chemotactic and chemokinetic metabolite of arachidonic acid.	T11	T24	1359745
NA	CHEMICAL	GENE-Y	8	15	Furthermore, conventional drugs, such as corticosteroids, sulphasalazine, and chemical, inhibit LT production and specific gene inhibition accelerates healing in animal models of acute colitis.	T15	T27	1359745
NA	CHEMICAL	GENE-Y	6	15	Furthermore, conventional drugs, such as corticosteroids, chemical, and 5-aminosalicylic acid, inhibit LT production and specific gene inhibition accelerates healing in animal models of acute colitis.	T14	T27	1359745
NA	CHEMICAL	GENE-Y	11	15	Furthermore, conventional drugs, such as corticosteroids, sulphasalazine, and 5-aminosalicylic acid, inhibit chemical production and specific gene inhibition accelerates healing in animal models of acute colitis.	T16	T27	1359745
NA	CHEMICAL	GENE-Y	20	4	The compounds identified as gene inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where chemical are potent and more selective inhibitors of gene.	T18	T28	1359745
CPR:4	CHEMICAL	GENE-Y	20	4	The compounds identified as gene inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where chemical are potent and more selective inhibitors of gene.	T18	T29	1359745
CPR:4	CHEMICAL	GENE-Y	1	8	The chemical, zileuton, is the first selective gene inhibitor evaluated for the treatment of patients with IBD.	T19	T30	1359745
CPR:4	CHEMICAL	GENE-Y	3	8	The benzothiophene hydroxyurea, chemical, is the first selective gene inhibitor evaluated for the treatment of patients with IBD.	T20	T30	1359745
NA	CHEMICAL	GENE-Y	9	5	The proof that any putative gene inhibitor is blocking chemical production is an important stage in assessing any such drug.	T7	T23	1359745
NA	CHEMICAL	GENE-Y	14	11	We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of gene/c-Jun chemical-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals.	T1	T43	14506245
NA	CHEMICAL	GENE-Y	14	4	We showed previously that gene antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun chemical-terminal kinase-1, whereas both gene and beta-PDGFR induce mitogenic signals.	T1	T41	14506245
NA	CHEMICAL	GENE-Y	14	4	We showed previously that gene antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun chemical-terminal kinase-1, whereas both gene and beta-PDGFR induce mitogenic signals.	T1	T45	14506245
NA	CHEMICAL	GENE-Y	14	6	We showed previously that alpha-PDGFR antagonizes gene-mediated transformation through activation of stress-activated protein kinase-1/c-Jun chemical-terminal kinase-1, whereas both alpha-PDGFR and gene induce mitogenic signals.	T1	T42	14506245
NA	CHEMICAL	GENE-Y	14	6	We showed previously that alpha-PDGFR antagonizes gene-mediated transformation through activation of stress-activated protein kinase-1/c-Jun chemical-terminal kinase-1, whereas both alpha-PDGFR and gene induce mitogenic signals.	T1	T47	14506245
NA	CHEMICAL	GENE-Y	10	17	Twenty-nine taxi drivers (41-67 years old) were examined for urine chemical/creatinine, von Willebrand factor, anti-thrombin III, t-plasminogen activator-gene-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T1	T8	14564902
NA	CHEMICAL	GENE-Y	10	16	Twenty-nine taxi drivers (41-67 years old) were examined for urine chemical/creatinine, von Willebrand factor, anti-thrombin III, gene-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T1	T7	14564902
NA	CHEMICAL	GENE-Y	10	11	Twenty-nine taxi drivers (41-67 years old) were examined for urine chemical/creatinine, gene, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T1	T5	14564902
NA	CHEMICAL	GENE-Y	10	14	Twenty-nine taxi drivers (41-67 years old) were examined for urine chemical/creatinine, von Willebrand factor, gene, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T1	T6	14564902
NA	CHEMICAL	GENE-Y	10	17	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/chemical, von Willebrand factor, anti-thrombin III, t-plasminogen activator-gene-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T2	T8	14564902
NA	CHEMICAL	GENE-Y	10	16	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/chemical, von Willebrand factor, anti-thrombin III, gene-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T2	T7	14564902
NA	CHEMICAL	GENE-Y	10	11	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/chemical, gene, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T2	T5	14564902
NA	CHEMICAL	GENE-Y	10	14	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/chemical, von Willebrand factor, gene, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood glucose and blood pressure in the morning and at midnight during a duty day and in the following morning.	T2	T6	14564902
NA	CHEMICAL	GENE-Y	23	17	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, anti-thrombin III, t-plasminogen activator-gene-complex, hematocrit, blood chemical and blood pressure in the morning and at midnight during a duty day and in the following morning.	T3	T8	14564902
NA	CHEMICAL	GENE-Y	23	16	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, anti-thrombin III, gene-plasminogen activator inhibitor 1-complex, hematocrit, blood chemical and blood pressure in the morning and at midnight during a duty day and in the following morning.	T3	T7	14564902
NA	CHEMICAL	GENE-Y	23	11	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, gene, anti-thrombin III, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood chemical and blood pressure in the morning and at midnight during a duty day and in the following morning.	T3	T5	14564902
NA	CHEMICAL	GENE-Y	23	14	Twenty-nine taxi drivers (41-67 years old) were examined for urine normetanephrine/creatinine, von Willebrand factor, gene, t-plasminogen activator-plasminogen activator inhibitor 1-complex, hematocrit, blood chemical and blood pressure in the morning and at midnight during a duty day and in the following morning.	T3	T6	14564902
CPR:9	CHEMICAL	GENE-N	15	0	gene (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to chemical, which are essential for DNA synthesis and repair.	T2	T7	14583450
CPR:9	CHEMICAL	GENE-N	15	2	Ribonucleotide reductase (gene) is responsible for the de novo conversion of the ribonucleoside diphosphates to chemical, which are essential for DNA synthesis and repair.	T2	T40	14583450
CPR:9	CHEMICAL	GENE-N	12	0	gene (RR) is responsible for the de novo conversion of the chemical to deoxychemical, which are essential for DNA synthesis and repair.	T5	T7	14583450
CPR:9	CHEMICAL	GENE-N	12	2	Ribonucleotide reductase (gene) is responsible for the de novo conversion of the chemical to deoxychemical, which are essential for DNA synthesis and repair.	T5	T40	14583450
NA	CHEMICAL	GENE-N	0	2	chemical reductase (gene) is responsible for the de novo conversion of the ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.	T1	T40	14583450
NA	CHEMICAL	GENE-Y	29	10	In this study, we investigated the expression and function of gene and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated chemical-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	T4	T44	14583450
NA	CHEMICAL	GENE-N	29	10	In this study, we investigated the expression and function of gene and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated chemical-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	T4	T44	14583450
NA	CHEMICAL	GENE-Y	29	12	In this study, we investigated the expression and function of p53R2 and gene after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated chemical-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	T4	T45	14583450
NA	CHEMICAL	GENE-N	29	12	In this study, we investigated the expression and function of p53R2 and gene after UV treatment in human prostate cancer PC3 cells, which possess mutant p53 with a truncated chemical-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.	T4	T45	14583450
NA	CHEMICAL	GENE-Y	29	10	In this study, we investigated the expression and function of geneR2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant gene with a truncated chemical-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type gene.	T4	T46	14583450
NA	CHEMICAL	GENE-Y	29	10	In this study, we investigated the expression and function of geneR2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant gene with a truncated chemical-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type gene.	T4	T47	14583450
CPR:4	CHEMICAL	GENE-Y	3	5	In PC3 cells, chemical inhibited gene and resulted in increased sensitivity to UV irradiation.	T3	T26	14583450
CPR:4	CHEMICAL	GENE-N	3	5	In PC3 cells, chemical inhibited gene and resulted in increased sensitivity to UV irradiation.	T3	T26	14583450
CPR:4	CHEMICAL	GENE-Y	2	8	In addition, chemical treatment significantly reduced the specific gene activity after SCI as compared to that of vehicle control.	T3	T14	14588118
CPR:4	CHEMICAL	GENE-Y	5	14	Furthermore, RT-PCR analyses revealed that chemical treatment increased expression of interleukin-10 mRNA but decreased gene expression.	T4	T16	14588118
CPR:3	CHEMICAL	GENE-Y	5	10	Furthermore, RT-PCR analyses revealed that chemical treatment increased expression of gene mRNA but decreased tumor necrosis factor-alpha expression.	T4	T15	14588118
NA	CHEMICAL	GENE-N	6	11	These data suggest that, after SCI, chemical treatment modulated expression of gene, attenuated cell death and the size of lesions, and improved functional recovery in the injured rat.	T5	T17	14588118
NA	CHEMICAL	GENE-N	3	10	Increased productivity of chemical in the Str(r) mutant (containing the gene mutation in the S12 protein) may be a result of an aberrant protein synthesis mechanism.	T9	T17	14602594
NA	CHEMICAL	GENE-Y	3	14	Increased productivity of chemical in the Str(r) mutant (containing the K88R mutation in the gene protein) may be a result of an aberrant protein synthesis mechanism.	T9	T18	14602594
NA	CHEMICAL	GENE-N	13	8	The K88R mutant ribosome was characterized by increased gene stability in low chemical concentrations.	T2	T11	14602594
NA	CHEMICAL	GENE-N	13	1	The gene mutant ribosome was characterized by increased 70S complex stability in low chemical concentrations.	T2	T10	14602594
NA	CHEMICAL	GENE-N	28	21	We conclude that this aberrant protein synthesis ability in the Str(r) mutant, which is a result of increased stability of the gene, is responsible for the remarkable chemical production enhancement obtained.	T3	T12	14602594
NA	CHEMICAL	GENE-Y	6	10	OBJECTIVE: To assess the effects of chemical (NP) on gene (AR) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	T3	T16	14619588
NA	CHEMICAL	GENE-Y	6	12	OBJECTIVE: To assess the effects of chemical (NP) on androgen receptor (gene) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	T3	T18	14619588
NA	CHEMICAL	GENE-Y	8	10	OBJECTIVE: To assess the effects of nandrolone phenylpropionate (chemical) on gene (AR) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	T6	T16	14619588
NA	CHEMICAL	GENE-Y	8	12	OBJECTIVE: To assess the effects of nandrolone phenylpropionate (chemical) on androgen receptor (gene) of liver and sexual glands in burned rats for supporting the clinical application of anabolic steroids.	T6	T18	14619588
CPR:3	CHEMICAL	GENE-Y	9	4	RESULTS: The density of gene in liver tissue in chemical group was higher than that in control group (P < 0.05).	T7	T15	14619588
NA	CHEMICAL	GENE-Y	14	3	The density of gene in testis and ovary tissues showed no significant difference between chemical group and control group at every time-point (P > 0.05).	T8	T17	14619588
CPR:3	CHEMICAL	GENE-Y	1	7	CONCLUSION: chemical up-regulated the density of gene in liver tissue, whereas it had no significant effects on the density of gene in testis and ovary tissues.	T1	T11	14619588
NA	CHEMICAL	GENE-Y	1	7	CONCLUSION: chemical up-regulated the density of gene in liver tissue, whereas it had no significant effects on the density of gene in testis and ovary tissues.	T1	T12	14619588
NA	CHEMICAL	GENE-Y	25	5	A mouse model incriminates the gene but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via chemical production.	T4	T11	14659797
NA	CHEMICAL	GENE-Y	10	4	CONCLUSION: Loss of serotonin gene function may predispose to chemical-associated PPH in man.	T2	T10	14659797
NA	CHEMICAL	GENE-Y	3	4	CONCLUSION: Loss of chemical gene function may predispose to fenfluramine-associated PPH in man.	T1	T10	14659797
NA	CHEMICAL	GENE-Y	20	12	We demonstrated by in vitro gel-shift assays that binding interactions of the gene (TBP) were disrupted on chemical (CldAMP)-substituted TATA box consensus sequences.	T8	T21	14722255
NA	CHEMICAL	GENE-N	20	23	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (TBP) were disrupted on chemical (CldAMP)-substituted gene.	T8	T23	14722255
NA	CHEMICAL	GENE-Y	20	16	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (gene) were disrupted on chemical (CldAMP)-substituted TATA box consensus sequences.	T8	T22	14722255
NA	CHEMICAL	GENE-Y	22	12	We demonstrated by in vitro gel-shift assays that binding interactions of the gene (TBP) were disrupted on 2-chlorodeoxyadenosine monophosphate (chemical)-substituted TATA box consensus sequences.	T9	T21	14722255
NA	CHEMICAL	GENE-N	22	23	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (TBP) were disrupted on 2-chlorodeoxyadenosine monophosphate (chemical)-substituted gene.	T9	T23	14722255
NA	CHEMICAL	GENE-Y	22	16	We demonstrated by in vitro gel-shift assays that binding interactions of the human TATA box-binding protein (gene) were disrupted on 2-chlorodeoxyadenosine monophosphate (chemical)-substituted TATA box consensus sequences.	T9	T22	14722255
NA	CHEMICAL	GENE-N	16	3	We hypothesized that gene (pol II) transcriptional processes would therefore be affected by chemical (CldATP) incorporation into a promoter TATA element.	T12	T24	14722255
NA	CHEMICAL	GENE-N	16	23	We hypothesized that human RNA polymerase II (pol II) transcriptional processes would therefore be affected by chemical (CldATP) incorporation into a promoter gene.	T12	T26	14722255
NA	CHEMICAL	GENE-N	16	7	We hypothesized that human RNA polymerase II (gene) transcriptional processes would therefore be affected by chemical (CldATP) incorporation into a promoter TATA element.	T12	T25	14722255
NA	CHEMICAL	GENE-N	18	3	We hypothesized that gene (pol II) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (chemical) incorporation into a promoter TATA element.	T13	T24	14722255
NA	CHEMICAL	GENE-N	18	23	We hypothesized that human RNA polymerase II (pol II) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (chemical) incorporation into a promoter gene.	T13	T26	14722255
NA	CHEMICAL	GENE-N	18	7	We hypothesized that human RNA polymerase II (gene) transcriptional processes would therefore be affected by 2-chlorodeoxyadenosine triphosphate (chemical) incorporation into a promoter TATA element.	T13	T25	14722255
NA	CHEMICAL	GENE-N	6	12	With increasing amounts of HeLa extract, chemical substitution for dAMP within the gene decreased in vitro pol II transcription by approximately 35% compared with control substrates.	T15	T17	14722255
NA	CHEMICAL	GENE-N	6	17	With increasing amounts of HeLa extract, chemical substitution for dAMP within the TATA box decreased in vitro gene transcription by approximately 35% compared with control substrates.	T15	T18	14722255
NA	CHEMICAL	GENE-N	6	12	With increasing amounts of HeLa extract, Clchemical substitution for chemical within the gene decreased in vitro pol II transcription by approximately 35% compared with control substrates.	T1	T17	14722255
NA	CHEMICAL	GENE-N	6	17	With increasing amounts of HeLa extract, Clchemical substitution for chemical within the TATA box decreased in vitro gene transcription by approximately 35% compared with control substrates.	T1	T18	14722255
NA	CHEMICAL	GENE-N	4	5	In contrast, transcription on chemical-substituted gene reached a plateau after 20 min.	T2	T19	14722255
NA	CHEMICAL	GENE-N	1	18	Furthermore, chemical-substituted promoter sequences trapped or sequestered TBP, preventing its dissociation from DNA and subsequent binding to additional gene to reinitiate transcription.	T3	T20	14722255
NA	CHEMICAL	GENE-N	17	12	The aim of the present study was to analyse the role of gene in the chemical-induced myocardial remodeling, especially the interstitial fibrosis.	T10	T17	14757145
CPR:6	CHEMICAL	GENE-Y	10	8	Rats received a concomitant treatment with the selective gene antagonist, chemical (50 mg/kg/day p.o.)	T3	T14	14757145
CPR:5	CHEMICAL	GENE-Y	9	7	or were chronically pretreated with the selective gene agonist chemical (40 microg/kg/h) for 1 week to induce gene desensitization.	T4	T15	14757145
NA	CHEMICAL	GENE-Y	9	7	or were chronically pretreated with the selective gene agonist chemical (40 microg/kg/h) for 1 week to induce gene desensitization.	T4	T16	14757145
CPR:4	CHEMICAL	GENE-Y	3	11	The pretreatment with chemical induced a 59% down-regulation of left ventricular gene compared to control.	T5	T18	14757145
NA	CHEMICAL	GENE-Y	9	3	beta(1)-adrenoceptor blockade and gene down-regulation provided similar protection against chemical-induced cardiac interstitial fibrosis suggesting that both beta-adrenoceptors are involved in such cardiac remodeling process.	T1	T12	14757145
NA	CHEMICAL	GENE-Y	9	0	gene blockade and beta(2)-adrenoceptors down-regulation provided similar protection against chemical-induced cardiac interstitial fibrosis suggesting that both beta-adrenoceptors are involved in such cardiac remodeling process.	T1	T19	14757145
NA	CHEMICAL	GENE-N	9	16	beta(1)-adrenoceptor blockade and beta(2)-adrenoceptors down-regulation provided similar protection against chemical-induced cardiac interstitial fibrosis suggesting that both gene are involved in such cardiac remodeling process.	T1	T13	14757145
CPR:3	CHEMICAL	GENE-N	14	4	TRPM8 (CMR1) is a gene, which can be activated by low temperatures, menthol, chemical and icilin.	T1	T51	14757700
CPR:3	CHEMICAL	GENE-Y	14	0	gene (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, chemical and icilin.	T1	T55	14757700
CPR:3	CHEMICAL	GENE-Y	14	1	TRPM8 (gene) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, chemical and icilin.	T1	T40	14757700
CPR:3	CHEMICAL	GENE-N	13	4	TRPM8 (CMR1) is a gene, which can be activated by low temperatures, chemical, eucalyptol and icilin.	T35	T51	14757700
CPR:3	CHEMICAL	GENE-Y	13	0	gene (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, chemical, eucalyptol and icilin.	T35	T55	14757700
CPR:3	CHEMICAL	GENE-Y	13	1	TRPM8 (gene) is a Ca(2+)-permeable channel, which can be activated by low temperatures, chemical, eucalyptol and icilin.	T35	T40	14757700
NA	CHEMICAL	GENE-Y	4	0	gene (CMR1) is a chemical-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.	T19	T55	14757700
NA	CHEMICAL	GENE-Y	4	1	TRPM8 (gene) is a chemical-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.	T19	T40	14757700
CPR:3	CHEMICAL	GENE-N	16	4	TRPM8 (CMR1) is a gene, which can be activated by low temperatures, menthol, eucalyptol and chemical.	T7	T51	14757700
CPR:3	CHEMICAL	GENE-Y	16	0	gene (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and chemical.	T7	T55	14757700
CPR:3	CHEMICAL	GENE-Y	16	1	TRPM8 (gene) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and chemical.	T7	T40	14757700
NA	CHEMICAL	GENE-Y	9	18	We tested whether substances which are structurally related to chemical, or which produce a cooling sensation, could activate gene, and compared the responses of gene and VR1 to these ligands.	T20	T54	14757700
NA	CHEMICAL	GENE-Y	9	18	We tested whether substances which are structurally related to chemical, or which produce a cooling sensation, could activate gene, and compared the responses of gene and VR1 to these ligands.	T20	T56	14757700
NA	CHEMICAL	GENE-Y	9	26	We tested whether substances which are structurally related to chemical, or which produce a cooling sensation, could activate TRPM8, and compared the responses of TRPM8 and gene to these ligands.	T20	T57	14757700
NA	CHEMICAL	GENE-Y	6	10	The effects of 70 odorants and chemical-related substances on recombinant gene (mTRPM8), expressed in HEK293 cells, were examined using a FLIPR assay.	T21	T58	14757700
NA	CHEMICAL	GENE-Y	6	12	The effects of 70 odorants and chemical-related substances on recombinant mouse TRPM8 (gene), expressed in HEK293 cells, were examined using a FLIPR assay.	T21	T59	14757700
CPR:4	CHEMICAL	GENE-Y	6	15	Known VR1 antagonists (BCTC, thio-BCTC and chemical) were also able to block the response of gene to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T13	T42	14757700
CPR:6	CHEMICAL	GENE-Y	6	1	Known gene antagonists (BCTC, thio-BCTC and chemical) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T13	T41	14757700
CPR:4	CHEMICAL	GENE-Y	4	15	Known VR1 antagonists (BCTC, chemical and capsazepine) were also able to block the response of gene to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T12	T42	14757700
CPR:6	CHEMICAL	GENE-Y	4	1	Known gene antagonists (BCTC, chemical and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T12	T41	14757700
CPR:3	CHEMICAL	GENE-Y	17	15	Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of gene to chemical (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T14	T42	14757700
NA	CHEMICAL	GENE-Y	17	1	Known gene antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to chemical (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T14	T41	14757700
CPR:4	CHEMICAL	GENE-Y	3	15	Known VR1 antagonists (chemical, thio-chemical and capsazepine) were also able to block the response of gene to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T11	T42	14757700
CPR:6	CHEMICAL	GENE-Y	3	1	Known gene antagonists (chemical, thio-chemical and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).	T11	T41	14757700
CPR:3	CHEMICAL	GENE-Y	12	4	The Ca(2+) response of gene-transfected HEK293 cells to the endogenous VR1 agonist chemical was potentiated by low pH.	T16	T44	14757700
CPR:5	CHEMICAL	GENE-Y	12	4	The Ca(2+) response of hgene-transfected HEK293 cells to the endogenous gene agonist chemical was potentiated by low pH.	T16	T45	14757700
NA	CHEMICAL	GENE-Y	1	4	The chemical response of gene-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH.	T15	T44	14757700
NA	CHEMICAL	GENE-Y	1	4	The chemical response of hgene-transfected HEK293 cells to the endogenous gene agonist N-arachidonoyl-dopamine was potentiated by low pH.	T15	T45	14757700
CPR:3	CHEMICAL	GENE-Y	2	5	In contrast, chemical- and icilin-activated gene currents were suppressed by low pH.	T17	T46	14757700
CPR:3	CHEMICAL	GENE-Y	4	5	In contrast, menthol- and chemical-activated gene currents were suppressed by low pH.	T18	T46	14757700
CPR:4	CHEMICAL	GENE-N	4	10	The inhibitory effects of chemical, a nonselective irreversible inhibitor of gene (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	T2	T20	15049511
NA	CHEMICAL	GENE-N	4	15	The inhibitory effects of chemical, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three gene (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	T2	T10	15049511
NA	CHEMICAL	GENE-Y	4	21	The inhibitory effects of chemical, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, gene, and CYP2D6, have been evaluated in vitro.	T2	T13	15049511
NA	CHEMICAL	GENE-Y	4	23	The inhibitory effects of chemical, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and gene, have been evaluated in vitro.	T2	T14	15049511
NA	CHEMICAL	GENE-Y	4	20	The inhibitory effects of chemical, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely gene, CYP2C19, and CYP2D6, have been evaluated in vitro.	T2	T12	15049511
CPR:4	CHEMICAL	GENE-N	4	12	The inhibitory effects of chemical, a nonselective irreversible inhibitor of monoamine oxidase (gene), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	T2	T9	15049511
NA	CHEMICAL	GENE-N	4	17	The inhibitory effects of chemical, a nonselective irreversible inhibitor of monoamine oxidase (MAO), on three cytochrome P450 (gene) enzymes, namely gene2C9, gene2C19, and gene2D6, have been evaluated in vitro.	T2	T11	15049511
NA	CHEMICAL	GENE-N	10	15	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of chemical oxidase (MAO), on three gene (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	T5	T10	15049511
NA	CHEMICAL	GENE-Y	10	21	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of chemical oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, gene, and CYP2D6, have been evaluated in vitro.	T5	T13	15049511
NA	CHEMICAL	GENE-Y	10	23	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of chemical oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and gene, have been evaluated in vitro.	T5	T14	15049511
NA	CHEMICAL	GENE-Y	10	20	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of chemical oxidase (MAO), on three cytochrome P450 (CYP) enzymes, namely gene, CYP2C19, and CYP2D6, have been evaluated in vitro.	T5	T12	15049511
NA	CHEMICAL	GENE-N	10	12	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of chemical oxidase (gene), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.	T5	T9	15049511
NA	CHEMICAL	GENE-N	10	17	The inhibitory effects of tranylcypromine, a nonselective irreversible inhibitor of chemical oxidase (MAO), on three cytochrome P450 (gene) enzymes, namely gene2C9, gene2C19, and gene2D6, have been evaluated in vitro.	T5	T11	15049511
NA	CHEMICAL	GENE-N	11	20	A range of substrate concentrations was coincubated with a range of chemical concentrations in the presence of each of the gene enzymes at 37 degrees C for a predetermined period of time.	T3	T16	15049511
CPR:4	CHEMICAL	GENE-Y	4	10	The results demonstrated that chemical is a competitive inhibitor of gene (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).	T4	T17	15049511
CPR:4	CHEMICAL	GENE-Y	4	16	The results demonstrated that chemical is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and gene (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).	T4	T18	15049511
CPR:4	CHEMICAL	GENE-Y	4	26	The results demonstrated that chemical is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of gene (Ki = 56 microM).	T4	T19	15049511
NA	CHEMICAL	GENE-Y	8	15	However, in certain situations such as high dose chemical therapy, or in poor metabolizers of gene substrates, clinically significant interactions might occur, particularly when chemical is coadministered with drugs with a narrow therapeutic index.	T1	T21	15049511
NA	CHEMICAL	GENE-Y	8	15	However, in certain situations such as high dose chemical therapy, or in poor metabolizers of gene substrates, clinically significant interactions might occur, particularly when chemical is coadministered with drugs with a narrow therapeutic index.	T6	T21	15049511
NA	CHEMICAL	GENE-Y	8	1	The gene gene, which encodes the lysosomal chemical transporter LYAAT1/PAT1, generates multiple alternative mRNAs, some of which encode truncated proteins.	T1	T5	15058382
NA	CHEMICAL	GENE-Y	8	11	The human SLC36A1 gene, which encodes the lysosomal chemical transporter LYAAT1/gene, generates multiple alternative mRNAs, some of which encode truncated proteins.	T1	T7	15058382
NA	CHEMICAL	GENE-Y	13	15	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the chemical transporter gene/PAT2, is most abundant in kidney and muscle.	T3	T11	15058382
NA	CHEMICAL	GENE-Y	13	0	gene is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the chemical transporter tramdorinl/PAT2, is most abundant in kidney and muscle.	T3	T8	15058382
NA	CHEMICAL	GENE-Y	13	9	SLC36A1 is expressed in numerous tissues, whereas expression of gene, which encodes the chemical transporter tramdorinl/PAT2, is most abundant in kidney and muscle.	T3	T9	15058382
NA	CHEMICAL	GENE-Y	13	15	SLC36A1 is expressed in numerous tissues, whereas expression of SLC36A2, which encodes the chemical transporter tramdorinl/gene, is most abundant in kidney and muscle.	T3	T12	15058382
NA	CHEMICAL	GENE-Y	7	0	gene mutants were hypersensitive to hydroxyurea (HU), chemical, and UV-B light but only mildly sensitive to gamma-radiation.	T4	T13	15075397
NA	CHEMICAL	GENE-Y	5	0	gene mutants were hypersensitive to chemical (HU), aphidicolin, and UV-B light but only mildly sensitive to gamma-radiation.	T2	T13	15075397
NA	CHEMICAL	GENE-Y	6	0	gene mutants were hypersensitive to hydroxyurea (chemical), aphidicolin, and UV-B light but only mildly sensitive to gamma-radiation.	T3	T13	15075397
NA	CHEMICAL	GENE-Y	11	16	G2 arrest also was observed in wild-type plants in response to chemical but was defective in gene mutants, resulting in compaction of nuclei and subsequent cell death.	T5	T16	15075397
CPR:4	CHEMICAL	GENE-Y	25	30	Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than chemical, a compound that blocks gene.	T3	T10	15109613
NA	CHEMICAL	GENE-Y	10	30	Studies in rats, mice and monkeys show that GC-1 lowers chemical with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks gene.	T2	T10	15109613
NA	CHEMICAL	GENE-N	6	8	GC-1 also decreases plasma levels of chemical and gene, and induces loss of fat.	T5	T11	15109613
NA	CHEMICAL	GENE-Y	5	10	The hematopoietic class III receptor chemical kinase (RTK) Flt3 (Flk2, gene) has recently received much attention as a potential drug target.	T22	T48	15180525
NA	CHEMICAL	GENE-Y	5	9	The hematopoietic class III receptor chemical kinase (RTK) Flt3 (gene, STK1) has recently received much attention as a potential drug target.	T22	T46	15180525
NA	CHEMICAL	GENE-N	15	12	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/gene and the chemical-3-kinase/Akt signaling cascades.	T23	T43	15180525
NA	CHEMICAL	GENE-Y	15	3	Signal transduction of gene involves activation of several conserved pathways, including the RAS/MAP-Kinase and the chemical-3-kinase/Akt signaling cascades.	T23	T41	15180525
NA	CHEMICAL	GENE-N	15	12	Signal transduction of Flt3 involves activation of several conserved pathways, including the gene/MAP-Kinase and the chemical-3-kinase/Akt signaling cascades.	T23	T42	15180525
NA	CHEMICAL	GENE-N	15	15	Signal transduction of Flt3 involves activation of several conserved pathways, including the RAS/MAP-Kinase and the chemical-3-kinase/gene signaling cascades.	T23	T45	15180525
NA	CHEMICAL	GENE-Y	4	3	Selective inhibitors of gene chemical kinase activity have the potential to suppress aberrant gene signaling.	T24	T50	15180525
NA	CHEMICAL	GENE-Y	4	3	Selective inhibitors of gene chemical kinase activity have the potential to suppress aberrant gene signaling.	T24	T52	15180525
CPR:4	CHEMICAL	GENE-Y	13	29	Although highly homologous to other class III RTKs, Flt3 is resistant to the chemical STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the gene or c-Kit.	T1	T29	15180525
NA	CHEMICAL	GENE-N	13	5	Although highly homologous to other gene, Flt3 is resistant to the chemical STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T1	T26	15180525
CPR:4	CHEMICAL	GENE-Y	13	31	Although highly homologous to other class III RTKs, Flt3 is resistant to the chemical STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or gene.	T1	T30	15180525
NA	CHEMICAL	GENE-Y	13	8	Although highly homologous to other class III RTKs, gene is resistant to the chemical STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T1	T27	15180525
CPR:4	CHEMICAL	GENE-N	13	7	Although highly homologous to other class III gene, Flt3 is resistant to the chemical STI571 (Gleevec, Imatinib), a potent inhibitor of other gene in the family, such as the PDGFbeta-receptor or c-Kit.	T1	T28	15180525
CPR:4	CHEMICAL	GENE-Y	16	29	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, chemical), a potent inhibitor of other RTKs in the family, such as the gene or c-Kit.	T4	T29	15180525
NA	CHEMICAL	GENE-N	16	5	Although highly homologous to other gene, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, chemical), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T4	T26	15180525
CPR:4	CHEMICAL	GENE-Y	16	31	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, chemical), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or gene.	T4	T30	15180525
NA	CHEMICAL	GENE-Y	16	8	Although highly homologous to other class III RTKs, gene is resistant to the phenylaminopyrimidine STI571 (Gleevec, chemical), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T4	T27	15180525
CPR:4	CHEMICAL	GENE-N	16	7	Although highly homologous to other class III gene, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, chemical), a potent inhibitor of other gene in the family, such as the PDGFbeta-receptor or c-Kit.	T4	T28	15180525
CPR:4	CHEMICAL	GENE-Y	15	29	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (chemical, Imatinib), a potent inhibitor of other RTKs in the family, such as the gene or c-Kit.	T3	T29	15180525
NA	CHEMICAL	GENE-N	15	5	Although highly homologous to other gene, Flt3 is resistant to the phenylaminopyrimidine STI571 (chemical, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T3	T26	15180525
CPR:4	CHEMICAL	GENE-Y	15	31	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (chemical, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or gene.	T3	T30	15180525
NA	CHEMICAL	GENE-Y	15	8	Although highly homologous to other class III RTKs, gene is resistant to the phenylaminopyrimidine STI571 (chemical, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T3	T27	15180525
CPR:4	CHEMICAL	GENE-N	15	7	Although highly homologous to other class III gene, Flt3 is resistant to the phenylaminopyrimidine STI571 (chemical, Imatinib), a potent inhibitor of other gene in the family, such as the PDGFbeta-receptor or c-Kit.	T3	T28	15180525
CPR:4	CHEMICAL	GENE-Y	14	29	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine chemical (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the gene or c-Kit.	T2	T29	15180525
NA	CHEMICAL	GENE-N	14	5	Although highly homologous to other gene, Flt3 is resistant to the phenylaminopyrimidine chemical (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T2	T26	15180525
CPR:4	CHEMICAL	GENE-Y	14	31	Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine chemical (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or gene.	T2	T30	15180525
NA	CHEMICAL	GENE-Y	14	8	Although highly homologous to other class III RTKs, gene is resistant to the phenylaminopyrimidine chemical (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or c-Kit.	T2	T27	15180525
CPR:4	CHEMICAL	GENE-N	14	7	Although highly homologous to other class III gene, Flt3 is resistant to the phenylaminopyrimidine chemical (Gleevec, Imatinib), a potent inhibitor of other gene in the family, such as the PDGFbeta-receptor or c-Kit.	T2	T28	15180525
NA	CHEMICAL	GENE-Y	8	3	STI571 binding to gene is prevented by the chemical 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to STI571.	T6	T31	15180525
NA	CHEMICAL	GENE-Y	8	3	STI571 binding to gene is prevented by the chemical 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to STI571.	T6	T32	15180525
NA	CHEMICAL	GENE-Y	21	3	STI571 binding to gene is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to chemical renders the corresponding gene mutant sensitive to STI571.	T8	T31	15180525
NA	CHEMICAL	GENE-Y	21	3	STI571 binding to gene is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to chemical renders the corresponding gene mutant sensitive to STI571.	T8	T32	15180525
NA	CHEMICAL	GENE-Y	0	3	chemical binding to gene is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to chemical.	T5	T31	15180525
NA	CHEMICAL	GENE-Y	0	3	chemical binding to gene is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to chemical.	T5	T32	15180525
NA	CHEMICAL	GENE-Y	0	3	chemical binding to gene is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to chemical.	T9	T31	15180525
CPR:4	CHEMICAL	GENE-Y	0	3	chemical binding to gene is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to chemical.	T9	T32	15180525
NA	CHEMICAL	GENE-Y	13	3	STI571 binding to gene is prevented by the phenylalanine 691 side-chain in the chemical binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to STI571.	T7	T31	15180525
NA	CHEMICAL	GENE-Y	13	3	STI571 binding to gene is prevented by the phenylalanine 691 side-chain in the chemical binding center and mutating this site to threonine renders the corresponding gene mutant sensitive to STI571.	T7	T32	15180525
CPR:4	CHEMICAL	GENE-N	11	33	Compounds of several other structural families, including the quinoxaline AG1296, the chemical D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T12	T35	15180525
CPR:4	CHEMICAL	GENE-Y	11	32	Compounds of several other structural families, including the quinoxaline AG1296, the chemical D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T12	T34	15180525
CPR:4	CHEMICAL	GENE-N	25	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the chemical CT53518, are potent inhibitors of Flt3 gene.	T20	T35	15180525
CPR:4	CHEMICAL	GENE-Y	25	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the chemical CT53518, are potent inhibitors of gene kinase.	T20	T34	15180525
CPR:4	CHEMICAL	GENE-N	19	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the chemical PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T17	T35	15180525
CPR:4	CHEMICAL	GENE-Y	19	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the chemical PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T17	T34	15180525
CPR:4	CHEMICAL	GENE-N	14	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the chemical SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T14	T35	15180525
CPR:4	CHEMICAL	GENE-Y	14	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the chemical SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T14	T34	15180525
CPR:4	CHEMICAL	GENE-N	8	33	Compounds of several other structural families, including the chemical AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T10	T35	15180525
CPR:4	CHEMICAL	GENE-Y	8	32	Compounds of several other structural families, including the chemical AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T10	T34	15180525
CPR:4	CHEMICAL	GENE-N	12	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone chemical, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T13	T35	15180525
CPR:4	CHEMICAL	GENE-Y	12	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone chemical, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T13	T34	15180525
CPR:4	CHEMICAL	GENE-N	27	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline chemical, are potent inhibitors of Flt3 gene.	T21	T35	15180525
CPR:4	CHEMICAL	GENE-Y	27	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline chemical, are potent inhibitors of gene kinase.	T21	T34	15180525
CPR:4	CHEMICAL	GENE-N	22	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and chemical, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T19	T35	15180525
CPR:4	CHEMICAL	GENE-Y	22	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and chemical, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T19	T34	15180525
CPR:4	CHEMICAL	GENE-N	17	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and chemical, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T16	T35	15180525
CPR:4	CHEMICAL	GENE-Y	17	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and chemical, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T16	T34	15180525
CPR:4	CHEMICAL	GENE-N	9	33	Compounds of several other structural families, including the quinoxaline chemical, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T11	T35	15180525
CPR:4	CHEMICAL	GENE-Y	9	32	Compounds of several other structural families, including the quinoxaline chemical, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T11	T34	15180525
CPR:4	CHEMICAL	GENE-N	15	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones chemical and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T15	T35	15180525
CPR:4	CHEMICAL	GENE-Y	15	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones chemical and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T15	T34	15180525
CPR:4	CHEMICAL	GENE-N	20	33	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles chemical and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 gene.	T18	T35	15180525
CPR:4	CHEMICAL	GENE-Y	20	32	Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles chemical and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of gene kinase.	T18	T34	15180525
NA	CHEMICAL	GENE-N	8	0	gene is a known target of chemical.	T7	T19	15192023
NA	CHEMICAL	GENE-N	18	14	We therefore investigated whether inhibition of other members of this enzyme family, namely the gene (HIF)-regulating O2-dependent chemical hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	T9	T20	15192023
NA	CHEMICAL	GENE-N	18	21	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating O2-dependent chemical hydroxylase domain (gene) enzymes, could represent a novel mechanism of action.	T9	T23	15192023
NA	CHEMICAL	GENE-N	18	16	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (gene)-regulating O2-dependent chemical hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	T9	T21	15192023
NA	CHEMICAL	GENE-N	17	18	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating chemical-dependent gene (PHD) enzymes, could represent a novel mechanism of action.	T8	T22	15192023
NA	CHEMICAL	GENE-N	17	14	We therefore investigated whether inhibition of other members of this enzyme family, namely the gene (HIF)-regulating chemical-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	T8	T20	15192023
NA	CHEMICAL	GENE-N	17	21	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (HIF)-regulating chemical-dependent prolyl hydroxylase domain (gene) enzymes, could represent a novel mechanism of action.	T8	T23	15192023
NA	CHEMICAL	GENE-N	17	16	We therefore investigated whether inhibition of other members of this enzyme family, namely the hypoxia-inducible factor (gene)-regulating chemical-dependent prolyl hydroxylase domain (PHD) enzymes, could represent a novel mechanism of action.	T8	T21	15192023
CPR:3	CHEMICAL	GENE-Y	0	19	chemical induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and gene [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T29	15192023
CPR:3	CHEMICAL	GENE-Y	0	15	chemical induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, gene, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T28	15192023
CPR:3	CHEMICAL	GENE-Y	0	14	chemical induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, gene, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T27	15192023
CPR:3	CHEMICAL	GENE-Y	0	13	chemical induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (gene, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T26	15192023
CPR:3	CHEMICAL	GENE-Y	0	7	chemical induced rapid and transient expression of gene and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T24	15192023
CPR:3	CHEMICAL	GENE-Y	0	23	chemical induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [gene]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T30	15192023
CPR:3	CHEMICAL	GENE-N	0	7	chemical induced rapid and transient expression of gene-1alpha and downstream targets of gene (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.	T10	T25	15192023
CPR:3	CHEMICAL	GENE-Y	0	8	chemical dose-dependently inhibited PHD activity and induced nonhydroxylated gene, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.	T11	T32	15192023
CPR:4	CHEMICAL	GENE-N	0	3	chemical dose-dependently inhibited gene activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of gene enzyme activity.	T11	T31	15192023
CPR:4	CHEMICAL	GENE-N	0	3	chemical dose-dependently inhibited gene activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of gene enzyme activity.	T11	T34	15192023
NA	CHEMICAL	GENE-N	0	8	chemical dose-dependently inhibited PHD activity and induced nonhydroxylated gene-1alpha, evidence for gene stabilization specifically by inhibition of PHD enzyme activity.	T11	T33	15192023
CPR:3	CHEMICAL	GENE-Y	2	4	In vivo, chemical induced gene and VEGF protein in tissue extracts and elevated plasma VEGF levels.	T12	T35	15192023
CPR:3	CHEMICAL	GENE-Y	2	6	In vivo, chemical induced HIF-1alpha and gene protein in tissue extracts and elevated plasma gene levels.	T12	T15	15192023
CPR:3	CHEMICAL	GENE-Y	2	6	In vivo, chemical induced HIF-1alpha and gene protein in tissue extracts and elevated plasma gene levels.	T12	T36	15192023
CPR:4	CHEMICAL	GENE-N	1	9	Thus, chemical activates the HIF pathway through inhibition of gene activity and initiates a pro-angiogenic phenotype.	T2	T17	15192023
CPR:3	CHEMICAL	GENE-N	1	4	Thus, chemical activates the gene pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.	T2	T16	15192023
NA	CHEMICAL	GENE-N	8	11	This represents a novel mechanism of action for chemical and presents gene as a potential target for treatment of ischemic disease.	T3	T18	15192023
NA	CHEMICAL	GENE-Y	5	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, chemical, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T11	T18	15198222
NA	CHEMICAL	GENE-Y	5	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, chemical, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T11	T17	15198222
NA	CHEMICAL	GENE-N	5	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, chemical, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T11	T31	15198222
CPR:4	CHEMICAL	GENE-Y	18	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, chemical, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T15	T18	15198222
CPR:4	CHEMICAL	GENE-Y	18	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, chemical, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T15	T17	15198222
NA	CHEMICAL	GENE-N	18	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, chemical, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T15	T31	15198222
NA	CHEMICAL	GENE-Y	3	34	RESULTS: Aspirin, diclofenac, chemical, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T9	T18	15198222
NA	CHEMICAL	GENE-Y	3	32	RESULTS: Aspirin, diclofenac, chemical, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T9	T17	15198222
NA	CHEMICAL	GENE-N	3	13	RESULTS: Aspirin, diclofenac, chemical, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T9	T31	15198222
NA	CHEMICAL	GENE-Y	4	34	RESULTS: Aspirin, diclofenac, indomethacin, chemical, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T10	T18	15198222
NA	CHEMICAL	GENE-Y	4	32	RESULTS: Aspirin, diclofenac, indomethacin, chemical, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T10	T17	15198222
NA	CHEMICAL	GENE-N	4	13	RESULTS: Aspirin, diclofenac, indomethacin, chemical, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T10	T31	15198222
CPR:4	CHEMICAL	GENE-Y	20	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, chemical, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T16	T18	15198222
CPR:4	CHEMICAL	GENE-Y	20	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, chemical, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T16	T17	15198222
NA	CHEMICAL	GENE-N	20	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, chemical, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T16	T31	15198222
NA	CHEMICAL	GENE-Y	2	34	RESULTS: Aspirin, chemical, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T8	T18	15198222
NA	CHEMICAL	GENE-Y	2	32	RESULTS: Aspirin, chemical, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T8	T17	15198222
NA	CHEMICAL	GENE-N	2	13	RESULTS: Aspirin, chemical, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T8	T31	15198222
NA	CHEMICAL	GENE-Y	8	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and chemical had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T12	T18	15198222
NA	CHEMICAL	GENE-Y	8	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and chemical had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T12	T17	15198222
NA	CHEMICAL	GENE-N	8	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and chemical had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T12	T31	15198222
CPR:4	CHEMICAL	GENE-Y	17	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, chemical, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T14	T18	15198222
CPR:4	CHEMICAL	GENE-Y	17	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, chemical, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T14	T17	15198222
NA	CHEMICAL	GENE-N	17	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, chemical, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T14	T31	15198222
CPR:4	CHEMICAL	GENE-Y	22	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and chemical had more than 5 times greater preference for inhibiting COX-2 than gene.	T1	T18	15198222
CPR:4	CHEMICAL	GENE-Y	22	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and chemical had more than 5 times greater preference for inhibiting gene than COX-1.	T1	T17	15198222
NA	CHEMICAL	GENE-N	22	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and chemical had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T1	T31	15198222
NA	CHEMICAL	GENE-Y	1	34	RESULTS: chemical, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T7	T18	15198222
NA	CHEMICAL	GENE-Y	1	32	RESULTS: chemical, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T7	T17	15198222
NA	CHEMICAL	GENE-N	1	13	RESULTS: chemical, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T7	T31	15198222
CPR:4	CHEMICAL	GENE-Y	16	34	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas chemical, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than gene.	T13	T18	15198222
CPR:4	CHEMICAL	GENE-Y	16	32	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas chemical, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene than COX-1.	T13	T17	15198222
NA	CHEMICAL	GENE-N	16	13	RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward gene isozymes, whereas chemical, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting gene-2 than gene-1.	T13	T31	15198222
NA	CHEMICAL	GENE-Y	14	4	CONCLUSIONS AND CLINICAL RELEVANCE: gene was selectively inhibited by etodolac, nimesulide, and NS398; chemical and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	T5	T22	15198222
CPR:4	CHEMICAL	GENE-Y	14	5	CONCLUSIONS AND CLINICAL RELEVANCE: Canine gene was selectively inhibited by etodolac, nimesulide, and NS398; chemical and carprofen also appeared to be preferential gene inhibitors in dogs.	T5	T23	15198222
CPR:4	CHEMICAL	GENE-Y	11	4	CONCLUSIONS AND CLINICAL RELEVANCE: gene was selectively inhibited by etodolac, chemical, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	T3	T22	15198222
NA	CHEMICAL	GENE-Y	11	5	CONCLUSIONS AND CLINICAL RELEVANCE: Canine gene was selectively inhibited by etodolac, chemical, and NS398; tolfenamic acid and carprofen also appeared to be preferential gene inhibitors in dogs.	T3	T23	15198222
NA	CHEMICAL	GENE-Y	17	4	CONCLUSIONS AND CLINICAL RELEVANCE: gene was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and chemical also appeared to be preferential COX-2 inhibitors in dogs.	T6	T22	15198222
CPR:4	CHEMICAL	GENE-Y	17	5	CONCLUSIONS AND CLINICAL RELEVANCE: Canine gene was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and chemical also appeared to be preferential gene inhibitors in dogs.	T6	T23	15198222
CPR:4	CHEMICAL	GENE-Y	10	4	CONCLUSIONS AND CLINICAL RELEVANCE: gene was selectively inhibited by chemical, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	T2	T22	15198222
NA	CHEMICAL	GENE-Y	10	5	CONCLUSIONS AND CLINICAL RELEVANCE: Canine gene was selectively inhibited by chemical, nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential gene inhibitors in dogs.	T2	T23	15198222
CPR:4	CHEMICAL	GENE-Y	13	4	CONCLUSIONS AND CLINICAL RELEVANCE: gene was selectively inhibited by etodolac, nimesulide, and chemical; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.	T4	T22	15198222
NA	CHEMICAL	GENE-Y	13	5	CONCLUSIONS AND CLINICAL RELEVANCE: Canine gene was selectively inhibited by etodolac, nimesulide, and chemical; tolfenamic acid and carprofen also appeared to be preferential gene inhibitors in dogs.	T4	T23	15198222
NA	CHEMICAL	GENE-Y	27	32	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and chemical and for gene (SSBG), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	T18	T38	1526623
NA	CHEMICAL	GENE-Y	27	42	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and chemical and for sex steroid binding globulin (SSBG), the binding of ketoconazole to gene (AR) in vitro was also examined.	T18	T40	1526623
NA	CHEMICAL	GENE-Y	27	36	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and chemical and for sex steroid binding globulin (gene), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	T18	T39	1526623
NA	CHEMICAL	GENE-Y	27	45	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and chemical and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (gene) in vitro was also examined.	T18	T41	1526623
NA	CHEMICAL	GENE-Y	20	32	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for gene (SSBG), the binding of chemical to human androgen receptors (AR) in vitro was also examined.	T17	T38	1526623
NA	CHEMICAL	GENE-Y	20	32	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for gene (SSBG), the binding of chemical to human androgen receptors (AR) in vitro was also examined.	T20	T38	1526623
NA	CHEMICAL	GENE-Y	20	42	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of chemical to gene (AR) in vitro was also examined.	T17	T40	1526623
NA	CHEMICAL	GENE-Y	20	42	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of chemical to gene (AR) in vitro was also examined.	T20	T40	1526623
NA	CHEMICAL	GENE-Y	20	36	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (gene), the binding of chemical to human androgen receptors (AR) in vitro was also examined.	T17	T39	1526623
NA	CHEMICAL	GENE-Y	20	36	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (gene), the binding of chemical to human androgen receptors (AR) in vitro was also examined.	T20	T39	1526623
NA	CHEMICAL	GENE-Y	20	45	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of chemical to human androgen receptors (gene) in vitro was also examined.	T17	T41	1526623
NA	CHEMICAL	GENE-Y	20	45	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of chemical for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of chemical to human androgen receptors (gene) in vitro was also examined.	T20	T41	1526623
NA	CHEMICAL	GENE-Y	43	32	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for gene (SSBG), the binding of ketoconazole to human chemical receptors (AR) in vitro was also examined.	T21	T38	1526623
NA	CHEMICAL	GENE-Y	43	36	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (gene), the binding of ketoconazole to human chemical receptors (AR) in vitro was also examined.	T21	T39	1526623
NA	CHEMICAL	GENE-Y	43	45	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex steroid binding globulin (SSBG), the binding of ketoconazole to human chemical receptors (gene) in vitro was also examined.	T21	T41	1526623
NA	CHEMICAL	GENE-Y	33	42	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex chemical binding globulin (SSBG), the binding of ketoconazole to gene (AR) in vitro was also examined.	T19	T40	1526623
NA	CHEMICAL	GENE-Y	33	36	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex chemical binding globulin (gene), the binding of ketoconazole to human androgen receptors (AR) in vitro was also examined.	T19	T39	1526623
NA	CHEMICAL	GENE-Y	33	45	Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of ketoconazole for receptor proteins for glucocorticoids and 1,25(OH)2 vitamin D3 and for sex chemical binding globulin (SSBG), the binding of ketoconazole to human androgen receptors (gene) in vitro was also examined.	T19	T41	1526623
NA	CHEMICAL	GENE-Y	3	29	Ketoconazole competition with chemical (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to gene was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	T23	T42	1526623
NA	CHEMICAL	GENE-Y	40	29	Ketoconazole competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to gene was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M chemical.	T28	T42	1526623
NA	CHEMICAL	GENE-Y	0	29	chemical competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to gene was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	T22	T42	1526623
NA	CHEMICAL	GENE-Y	26	29	Ketoconazole competition with [3H]methyltrienolone (R1881) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of chemical binding to gene was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	T27	T42	1526623
NA	CHEMICAL	GENE-Y	6	29	Ketoconazole competition with [3H]methyltrienolone (R1881) for chemical binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]R1881 binding to gene was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	T25	T42	1526623
NA	CHEMICAL	GENE-Y	4	29	Ketoconazole competition with [3H]methyltrienolone (chemical) for androgen binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of [3H]chemical binding to gene was achieved by 6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole.	T24	T42	1526623
NA	CHEMICAL	GENE-Y	5	21	Additional binding studies performed with chemical in the presence of increasing amounts of [3H]R1881 showed that the interaction of chemical with gene was competitive when the data were analyzed by the Scatchard method.	T29	T33	1526623
NA	CHEMICAL	GENE-Y	5	21	Additional binding studies performed with chemical in the presence of increasing amounts of [3H]R1881 showed that the interaction of chemical with gene was competitive when the data were analyzed by the Scatchard method.	T2	T33	1526623
NA	CHEMICAL	GENE-Y	13	21	Additional binding studies performed with ketoconazole in the presence of increasing amounts of chemical showed that the interaction of ketoconazole with gene was competitive when the data were analyzed by the Scatchard method.	T30	T33	1526623
NA	CHEMICAL	GENE-Y	9	16	It should be noted, however, that the dose of chemical required for 50% occupancy of the gene is not likely to be achieved in vivo, at least in plasma.	T3	T34	1526623
NA	CHEMICAL	GENE-Y	22	28	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only chemical appears to interact with the gene.	T10	T35	1526623
NA	CHEMICAL	GENE-Y	10	28	Finally, androgen binding studies performed with other imidazoles, such as chemical, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the gene.	T7	T35	1526623
NA	CHEMICAL	GENE-Y	13	28	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, miconazole, and chemical, revealed that in this class of compounds only ketoconazole appears to interact with the gene.	T9	T35	1526623
NA	CHEMICAL	GENE-Y	11	28	Finally, androgen binding studies performed with other imidazoles, such as clotrimazole, chemical, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the gene.	T8	T35	1526623
NA	CHEMICAL	GENE-Y	7	28	Finally, androgen binding studies performed with other chemical, such as clotrimazole, miconazole, and fluconozole, revealed that in this class of compounds only ketoconazole appears to interact with the gene.	T6	T35	1526623
NA	CHEMICAL	GENE-N	0	19	chemical appears to be the first example of a non-steroidal compound which binds competitively to both SSBG and multiple gene, suggesting that the ligand binding sites of these proteins share some features in common.	T12	T37	1526623
NA	CHEMICAL	GENE-Y	0	16	chemical appears to be the first example of a non-steroidal compound which binds competitively to both gene and multiple steroid hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	T12	T36	1526623
NA	CHEMICAL	GENE-N	9	19	Ketoconazole appears to be the first example of a non-chemical compound which binds competitively to both SSBG and multiple gene, suggesting that the ligand binding sites of these proteins share some features in common.	T13	T37	1526623
NA	CHEMICAL	GENE-Y	9	16	Ketoconazole appears to be the first example of a non-chemical compound which binds competitively to both gene and multiple steroid hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	T13	T36	1526623
NA	CHEMICAL	GENE-Y	9	16	Ketoconazole appears to be the first example of a non-chemicalal compound which binds competitively to both gene and multiple chemical hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	T14	T36	1526623
NA	CHEMICAL	GENE-N	2	25	BACKGROUND: Extracellular chemical (ATP, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and gene.	T2	T26	15291969
NA	CHEMICAL	GENE-N	2	22	BACKGROUND: Extracellular chemical (ATP, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic gene receptors and G protein-coupled P2Y receptors.	T2	T23	15291969
NA	CHEMICAL	GENE-N	7	25	BACKGROUND: Extracellular nucleotides (ATP, ADP, UTP and chemical) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and gene.	T6	T26	15291969
NA	CHEMICAL	GENE-N	7	22	BACKGROUND: Extracellular nucleotides (ATP, ADP, UTP and chemical) exert a wide range of biological effects in blood cells mediated by multiple ionotropic gene receptors and G protein-coupled P2Y receptors.	T6	T23	15291969
NA	CHEMICAL	GENE-N	3	25	BACKGROUND: Extracellular nucleotides (chemical, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and gene.	T3	T26	15291969
NA	CHEMICAL	GENE-N	3	22	BACKGROUND: Extracellular nucleotides (chemical, ADP, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic gene receptors and G protein-coupled P2Y receptors.	T3	T23	15291969
NA	CHEMICAL	GENE-N	4	25	BACKGROUND: Extracellular nucleotides (ATP, chemical, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and gene.	T4	T26	15291969
NA	CHEMICAL	GENE-N	4	22	BACKGROUND: Extracellular nucleotides (ATP, chemical, UTP and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic gene receptors and G protein-coupled P2Y receptors.	T4	T23	15291969
NA	CHEMICAL	GENE-N	5	25	BACKGROUND: Extracellular nucleotides (ATP, ADP, chemical and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic P2X receptors and gene.	T5	T26	15291969
NA	CHEMICAL	GENE-N	5	22	BACKGROUND: Extracellular nucleotides (ATP, ADP, chemical and UDP) exert a wide range of biological effects in blood cells mediated by multiple ionotropic gene receptors and G protein-coupled P2Y receptors.	T5	T23	15291969
NA	CHEMICAL	GENE-Y	21	22	CONCLUSIONS: The most interesting findings were the high mRNA expression of P2Y12 receptors in lymphocytes potentially explaining the anti-inflammatory effects of chemical, gene receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.	T1	T24	15291969
NA	CHEMICAL	GENE-Y	21	11	CONCLUSIONS: The most interesting findings were the high mRNA expression of gene receptors in lymphocytes potentially explaining the anti-inflammatory effects of chemical, P2Y13 receptors in monocytes and a previously unrecognised expression of P2X4 in lymphocytes and monocytes.	T1	T22	15291969
NA	CHEMICAL	GENE-Y	21	32	CONCLUSIONS: The most interesting findings were the high mRNA expression of P2Y12 receptors in lymphocytes potentially explaining the anti-inflammatory effects of chemical, P2Y13 receptors in monocytes and a previously unrecognised expression of gene in lymphocytes and monocytes.	T1	T25	15291969
CPR:4	CHEMICAL	GENE-Y	0	7	chemical served as inhibitor of an interfering gene present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.	T1	T2	15292070
NA	CHEMICAL	GENE-Y	0	3	chemical dehydrogenase II (gene) converts retinal to the transcriptional regulator retinoic acid in the developing embryo.	T1	T9	15299009
NA	CHEMICAL	GENE-N	33	16	The x-ray structure of the enzyme revealed an important structural difference between this protein and other gene of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in chemical dehydrogenase II is disordered, whereas in other gene this region forms a well defined wall of the substrate access channel.	T4	T11	15299009
NA	CHEMICAL	GENE-N	33	16	The x-ray structure of the enzyme revealed an important structural difference between this protein and other gene of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in chemical dehydrogenase II is disordered, whereas in other gene this region forms a well defined wall of the substrate access channel.	T4	T8	15299009
NA	CHEMICAL	GENE-Y	24	33	The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-chemical span in the substrate access channel in gene is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.	T3	T10	15299009
NA	CHEMICAL	GENE-N	24	16	The x-ray structure of the enzyme revealed an important structural difference between this protein and other gene of the same enzyme superfamily; a 20-chemical span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other gene this region forms a well defined wall of the substrate access channel.	T3	T11	15299009
NA	CHEMICAL	GENE-N	24	16	The x-ray structure of the enzyme revealed an important structural difference between this protein and other gene of the same enzyme superfamily; a 20-chemical span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other gene this region forms a well defined wall of the substrate access channel.	T3	T8	15299009
CPR:4	CHEMICAL	GENE-Y	5	14	After 12 months of treatment, chemical significantly improved all end points (plasma concentration of gene [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	T6	T11	15325927
NA	CHEMICAL	GENE-Y	5	79	After 12 months of treatment, chemical significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (gene concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	T6	T13	15325927
CPR:4	CHEMICAL	GENE-Y	5	17	After 12 months of treatment, chemical significantly improved all end points (plasma concentration of B-type natriuretic peptide [gene] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma gene concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	T6	T12	15325927
CPR:4	CHEMICAL	GENE-Y	9	16	Univariate regression analyses showed that only the use of chemical was correlated with the decrease in gene concentration (p <0.03).	T1	T8	15325927
NA	CHEMICAL	GENE-Y	27	16	Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of gene (p <0.02), left ventricular dilation (p <0.03), and use of chemical (p <0.04) at baseline were predictive of a decrease in plasma concentration of gene.	T2	T10	15325927
NA	CHEMICAL	GENE-Y	27	16	Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of gene (p <0.02), left ventricular dilation (p <0.03), and use of chemical (p <0.04) at baseline were predictive of a decrease in plasma concentration of gene.	T2	T9	15325927
NA	CHEMICAL	GENE-N	0	9	chemical binds selectively and with high affinity to a gene known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.	T1	T4	15367040
NA	CHEMICAL	GENE-Y	0	14	chemical binds selectively and with high affinity to a synaptic vesicle protein known as gene, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.	T1	T5	15367040
CPR:4	CHEMICAL	GENE-Y	0	17	chemical (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of gene inhibition.	T1	T20	1543672
CPR:4	CHEMICAL	GENE-Y	1	17	Terbinafine (chemical) has primarily fungicidal action against many fungi as a result of its specific mechanism of gene inhibition.	T7	T20	1543672
CPR:4	CHEMICAL	GENE-Y	0	7	chemical is a potent non-competitive inhibitor of gene from Candida (Ki = 30 nM).	T15	T23	1543672
NA	CHEMICAL	GENE-N	0	8	chemical epoxidase is not an enzyme of the gene type, thereby avoiding potential inhibition of this class of enzymes.	T6	T22	1543672
NA	CHEMICAL	GENE-Y	0	7	chemical decreased the stability of TNF-mRNA and gene mRNA.	T11	T20	15446566
NA	CHEMICAL	GENE-Y	0	5	chemical decreased the stability of gene-mRNA and COX-2 mRNA.	T11	T19	15446566
NA	CHEMICAL	GENE-N	1	10	Although chemical inhibits PG biosynthesis, most do not affect the gene activity of COX, which can generate proximate carcinogens.	T12	T24	15446566
NA	CHEMICAL	GENE-N	1	13	Although chemical inhibits PG biosynthesis, most do not affect the peroxidase activity of gene, which can generate proximate carcinogens.	T12	T25	15446566
NA	CHEMICAL	GENE-Y	1	6	Because chemical does not completely inhibit gene expression or PG biosynthesis, a therapeutic strategy combining celecoxib with chemical might be more effective than using either agent alone.	T13	T26	15446566
NA	CHEMICAL	GENE-Y	1	6	Because chemical does not completely inhibit gene expression or PG biosynthesis, a therapeutic strategy combining celecoxib with chemical might be more effective than using either agent alone.	T15	T26	15446566
NA	CHEMICAL	GENE-Y	15	6	Because thalidomide does not completely inhibit gene expression or PG biosynthesis, a therapeutic strategy combining chemical with thalidomide might be more effective than using either agent alone.	T14	T26	15446566
NA	CHEMICAL	GENE-N	11	8	There are few reports describing the mechanism of gene-elevating action of chemical reductase inhibitors (statins).	T10	T30	15474503
NA	CHEMICAL	GENE-Y	20	3	Each statin induced gene expression (mRNA and protein) dose-dependently: the rank order of the gene induction pitavastatin (3 microM)>simvastatin (10 microM)>chemical (30 microM).	T5	T28	15474503
CPR:3	CHEMICAL	GENE-Y	20	3	Each statin induced gene expression (mRNA and protein) dose-dependently: the rank order of the gene induction pitavastatin (3 microM)>simvastatin (10 microM)>chemical (30 microM).	T5	T29	15474503
NA	CHEMICAL	GENE-Y	16	3	Each statin induced gene expression (mRNA and protein) dose-dependently: the rank order of the gene induction chemical (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).	T3	T28	15474503
CPR:3	CHEMICAL	GENE-Y	16	3	Each statin induced gene expression (mRNA and protein) dose-dependently: the rank order of the gene induction chemical (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).	T3	T29	15474503
NA	CHEMICAL	GENE-Y	18	3	Each statin induced gene expression (mRNA and protein) dose-dependently: the rank order of the gene induction pitavastatin (3 microM)>chemical (10 microM)>atorvastatin (30 microM).	T4	T28	15474503
CPR:3	CHEMICAL	GENE-Y	18	3	Each statin induced gene expression (mRNA and protein) dose-dependently: the rank order of the gene induction pitavastatin (3 microM)>chemical (10 microM)>atorvastatin (30 microM).	T4	T29	15474503
NA	CHEMICAL	GENE-Y	10	17	The induction of apoA-I by statins disappeared with addition of chemical, which indicates that the effect is gene inhibition-dependent.	T6	T32	15474503
CPR:4	CHEMICAL	GENE-Y	10	3	The induction of gene by statins disappeared with addition of chemical, which indicates that the effect is HMG-CoA reductase inhibition-dependent.	T6	T31	15474503
NA	CHEMICAL	GENE-Y	17	3	The induction of gene by statins disappeared with addition of mevalonate, which indicates that the effect is chemical reductase inhibition-dependent.	T7	T31	15474503
NA	CHEMICAL	GENE-Y	12	2	Based on gene inhibition, pitavastatin-induced apoA-I more efficiently than simvastatin and chemical.	T12	T33	15474503
CPR:3	CHEMICAL	GENE-Y	12	6	Based on HMG-CoA reductase inhibition, pitavastatin-induced gene more efficiently than simvastatin and chemical.	T12	T34	15474503
NA	CHEMICAL	GENE-Y	5	2	Based on gene inhibition, chemical-induced apoA-I more efficiently than simvastatin and atorvastatin.	T9	T33	15474503
CPR:3	CHEMICAL	GENE-Y	5	6	Based on HMG-CoA reductase inhibition, chemical-induced gene more efficiently than simvastatin and atorvastatin.	T9	T34	15474503
NA	CHEMICAL	GENE-Y	10	2	Based on gene inhibition, pitavastatin-induced apoA-I more efficiently than chemical and atorvastatin.	T11	T33	15474503
CPR:3	CHEMICAL	GENE-Y	10	6	Based on HMG-CoA reductase inhibition, pitavastatin-induced gene more efficiently than chemical and atorvastatin.	T11	T34	15474503
NA	CHEMICAL	GENE-Y	2	6	Based on chemical reductase inhibition, pitavastatin-induced gene more efficiently than simvastatin and atorvastatin.	T8	T34	15474503
NA	CHEMICAL	GENE-Y	4	9	Further study revealed that chemical increased ABCA1 mRNA in gene-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T13	T37	15474503
NA	CHEMICAL	GENE-N	4	16	Further study revealed that chemical increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and gene inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T13	T39	15474503
NA	CHEMICAL	GENE-Y	4	23	Further study revealed that chemical increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased gene production in the HepG2 cells.	T13	T40	15474503
CPR:3	CHEMICAL	GENE-Y	4	6	Further study revealed that chemical increased gene mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T13	T36	15474503
NA	CHEMICAL	GENE-N	4	14	Further study revealed that chemical increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that gene and gene kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T13	T38	15474503
NA	CHEMICAL	GENE-N	9	16	Further study revealed that pitavastatin increased ABCA1 mRNA in chemical reductase-dependent manner and that Rho and gene inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T14	T39	15474503
NA	CHEMICAL	GENE-Y	9	23	Further study revealed that pitavastatin increased ABCA1 mRNA in chemical reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased gene production in the HepG2 cells.	T14	T40	15474503
NA	CHEMICAL	GENE-Y	9	6	Further study revealed that pitavastatin increased gene mRNA in chemical reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T14	T36	15474503
NA	CHEMICAL	GENE-N	9	14	Further study revealed that pitavastatin increased ABCA1 mRNA in chemical reductase-dependent manner and that gene and gene kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.	T14	T38	15474503
NA	CHEMICAL	GENE-Y	21	9	Further study revealed that pitavastatin increased ABCA1 mRNA in gene-dependent manner and that Rho and Rho kinase inhibitor (C3T and chemical) increased apoA-I production in the HepG2 cells.	T15	T37	15474503
CPR:4	CHEMICAL	GENE-N	21	16	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and gene inhibitor (C3T and chemical) increased apoA-I production in the HepG2 cells.	T15	T39	15474503
CPR:3	CHEMICAL	GENE-Y	21	23	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and chemical) increased gene production in the HepG2 cells.	T15	T40	15474503
NA	CHEMICAL	GENE-Y	21	6	Further study revealed that pitavastatin increased gene mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and chemical) increased apoA-I production in the HepG2 cells.	T15	T36	15474503
CPR:4	CHEMICAL	GENE-N	21	14	Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that gene and gene kinase inhibitor (C3T and chemical) increased apoA-I production in the HepG2 cells.	T15	T38	15474503
CPR:4	CHEMICAL	GENE-Y	4	22	These results suggest that chemical efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of gene and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	T1	T19	15474503
CPR:3	CHEMICAL	GENE-Y	4	7	These results suggest that chemical efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T1	T17	15474503
CPR:3	CHEMICAL	GENE-Y	4	7	These results suggest that chemical efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T1	T18	15474503
NA	CHEMICAL	GENE-Y	4	7	These results suggest that chemical efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T1	T21	15474503
CPR:3	CHEMICAL	GENE-Y	4	7	These results suggest that chemical efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T1	T23	15474503
CPR:3	CHEMICAL	GENE-Y	4	36	These results suggest that chemical efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through gene induction and lipidation of apoA-I.	T1	T22	15474503
CPR:4	CHEMICAL	GENE-N	4	27	These results suggest that chemical efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of gene activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	T1	T20	15474503
NA	CHEMICAL	GENE-Y	22	7	These results suggest that pitavastatin efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of chemical reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T2	T17	15474503
NA	CHEMICAL	GENE-Y	22	7	These results suggest that pitavastatin efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of chemical reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T2	T18	15474503
NA	CHEMICAL	GENE-Y	22	7	These results suggest that pitavastatin efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of chemical reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T2	T21	15474503
NA	CHEMICAL	GENE-Y	22	7	These results suggest that pitavastatin efficiently increases gene in the culture medium of HepG2 cells by promoting gene production through inhibition of chemical reductase and suppression of Rho activity and by protecting gene from catabolism through ABCA1 induction and lipidation of gene.	T2	T23	15474503
NA	CHEMICAL	GENE-Y	22	36	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of chemical reductase and suppression of Rho activity and by protecting apoA-I from catabolism through gene induction and lipidation of apoA-I.	T2	T22	15474503
NA	CHEMICAL	GENE-N	22	27	These results suggest that pitavastatin efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of chemical reductase and suppression of gene activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.	T2	T20	15474503
CPR:4	CHEMICAL	GENE-N	19	15	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two gene inhibitors, chemical and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	T5	T17	15557593
CPR:4	CHEMICAL	GENE-Y	19	26	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, chemical and SU11248, were used to disrupt gene-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	T5	T18	15557593
CPR:4	CHEMICAL	GENE-N	19	43	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, chemical and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or gene inhibition.	T5	T19	15557593
NA	CHEMICAL	GENE-Y	16	26	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor chemical kinase inhibitors, imatinib and SU11248, were used to disrupt gene-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	T4	T18	15557593
NA	CHEMICAL	GENE-N	16	43	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor chemical kinase inhibitors, imatinib and SU11248, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or gene inhibition.	T4	T19	15557593
CPR:4	CHEMICAL	GENE-N	21	15	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two gene inhibitors, imatinib and chemical, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	T6	T17	15557593
CPR:4	CHEMICAL	GENE-Y	21	26	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and chemical, were used to disrupt gene-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or VEGFR inhibition.	T6	T18	15557593
CPR:4	CHEMICAL	GENE-N	21	43	MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end-stage pancreatic islet tumors, two receptor tyrosine kinase inhibitors, imatinib and chemical, were used to disrupt PDGFR-mediated pericyte support of tumor endothelial cells in concert with maximum-tolerated dose (MTD) or metronomic chemotherapy and/or gene inhibition.	T6	T19	15557593
CPR:4	CHEMICAL	GENE-N	1	22	RESULTS: chemical, despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or gene inhibition.	T7	T8	15557593
NA	CHEMICAL	GENE-N	9	15	Synovitis in horses is frequently treated by administration of non-chemical anti-inflammatory drugs (NSAIDs), which inhibit gene isoforms (COX-1 and COX-2).	T10	T17	15563928
NA	CHEMICAL	GENE-Y	9	19	Synovitis in horses is frequently treated by administration of non-chemical anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase isoforms (COX-1 and gene).	T10	T19	15563928
NA	CHEMICAL	GENE-Y	9	17	Synovitis in horses is frequently treated by administration of non-chemical anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase isoforms (gene and COX-2).	T10	T18	15563928
NA	CHEMICAL	GENE-Y	23	15	The objective of the present study was to compare the anti-inflammatory effects of the preferential gene inhibitor etodolac with the non-selective COX inhibitor chemical in horses with lipopolysaccharide (LPS)-induced synovitis.	T9	T24	15563928
CPR:4	CHEMICAL	GENE-N	23	15	The objective of the present study was to compare the anti-inflammatory effects of the preferential gene-2 inhibitor etodolac with the non-selective gene inhibitor chemical in horses with lipopolysaccharide (LPS)-induced synovitis.	T9	T25	15563928
CPR:4	CHEMICAL	GENE-Y	23	15	The objective of the present study was to compare the anti-inflammatory effects of the preferential gene-2 inhibitor etodolac with the non-selective gene inhibitor chemical in horses with lipopolysaccharide (LPS)-induced synovitis.	T9	T25	15563928
CPR:4	CHEMICAL	GENE-Y	23	16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable gene prostanoid TXB2 was significantly reduced by chemical (P<0.05), but not etodolac.	T5	T16	15563928
NA	CHEMICAL	GENE-Y	17	16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable gene chemical TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	T3	T16	15563928
NA	CHEMICAL	GENE-Y	27	16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable gene prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not chemical.	T6	T16	15563928
NA	CHEMICAL	GENE-Y	6	16	In addition, both drugs significantly reduced chemical levels (P<0.05) 6-h following LPS injection, whereas the probable gene prostanoid TXB2 was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	T2	T16	15563928
NA	CHEMICAL	GENE-Y	18	16	In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable gene prostanoid chemical was significantly reduced by phenylbutazone (P<0.05), but not etodolac.	T4	T16	15563928
NA	CHEMICAL	GENE-Y	10	20	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; gene (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T30	15612980
NA	CHEMICAL	GENE-Y	10	16	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and A1298C; gene (MS) A2756G; gene reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T27	15612980
NA	CHEMICAL	GENE-N	10	15	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and gene; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T26	15612980
NA	CHEMICAL	GENE-N	10	19	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and A1298C; methionine synthase (MS) gene; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T29	15612980
NA	CHEMICAL	GENE-Y	10	12	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (gene) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T24	15612980
NA	CHEMICAL	GENE-N	10	13	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) gene and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T25	15612980
NA	CHEMICAL	GENE-N	10	24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) gene] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T32	15612980
NA	CHEMICAL	GENE-Y	10	23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (gene) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T31	15612980
NA	CHEMICAL	GENE-Y	10	18	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [chemical reductase (MTHFR) C677T and A1298C; methionine synthase (gene) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T4	T28	15612980
NA	CHEMICAL	GENE-Y	16	10	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [gene (MTHFR) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T23	15612980
NA	CHEMICAL	GENE-Y	16	10	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [gene (MTHFR) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T23	15612980
NA	CHEMICAL	GENE-N	16	15	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and gene; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T26	15612980
NA	CHEMICAL	GENE-N	16	15	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and gene; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T26	15612980
NA	CHEMICAL	GENE-N	16	19	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (MS) gene; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T29	15612980
NA	CHEMICAL	GENE-N	16	19	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (MS) gene; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T29	15612980
NA	CHEMICAL	GENE-Y	16	12	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (gene) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T24	15612980
NA	CHEMICAL	GENE-Y	16	12	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (gene) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T24	15612980
NA	CHEMICAL	GENE-N	16	13	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) gene and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T25	15612980
NA	CHEMICAL	GENE-N	16	13	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) gene and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T25	15612980
NA	CHEMICAL	GENE-N	16	24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) gene] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T32	15612980
NA	CHEMICAL	GENE-N	16	24	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (MTRR) gene] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T32	15612980
NA	CHEMICAL	GENE-Y	16	23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (gene) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T31	15612980
NA	CHEMICAL	GENE-Y	16	23	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (MS) A2756G; chemical synthase reductase (gene) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T31	15612980
NA	CHEMICAL	GENE-Y	16	18	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (gene) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T6	T28	15612980
NA	CHEMICAL	GENE-Y	16	18	We studied several single nucleotide polymorphisms (SNP) in Hcy-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; chemical synthase (gene) A2756G; chemical synthase reductase (MTRR) A66G] in relation to total plasma Hcy levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T7	T28	15612980
NA	CHEMICAL	GENE-Y	8	10	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [gene (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T23	15612980
NA	CHEMICAL	GENE-Y	8	10	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [gene (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T23	15612980
NA	CHEMICAL	GENE-Y	8	20	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; gene (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T30	15612980
NA	CHEMICAL	GENE-Y	8	20	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; gene (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T30	15612980
NA	CHEMICAL	GENE-Y	8	16	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; gene (MS) A2756G; gene reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T27	15612980
NA	CHEMICAL	GENE-Y	8	16	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; gene (MS) A2756G; gene reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T27	15612980
NA	CHEMICAL	GENE-N	8	15	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and gene; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T26	15612980
NA	CHEMICAL	GENE-N	8	15	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and gene; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T26	15612980
NA	CHEMICAL	GENE-N	8	19	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) gene; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T29	15612980
NA	CHEMICAL	GENE-N	8	19	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) gene; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T29	15612980
NA	CHEMICAL	GENE-Y	8	12	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (gene) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T24	15612980
NA	CHEMICAL	GENE-Y	8	12	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (gene) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T24	15612980
NA	CHEMICAL	GENE-N	8	13	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) gene and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T25	15612980
NA	CHEMICAL	GENE-N	8	13	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) gene and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T25	15612980
NA	CHEMICAL	GENE-N	8	24	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) gene] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T32	15612980
NA	CHEMICAL	GENE-N	8	24	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (MTRR) gene] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T32	15612980
NA	CHEMICAL	GENE-Y	8	23	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (gene) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T31	15612980
NA	CHEMICAL	GENE-Y	8	23	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (MS) A2756G; methionine synthase reductase (gene) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T31	15612980
NA	CHEMICAL	GENE-Y	8	18	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (gene) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T2	T28	15612980
NA	CHEMICAL	GENE-Y	8	18	We studied several single nucleotide polymorphisms (SNP) in chemical-regulating genes [methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C; methionine synthase (gene) A2756G; methionine synthase reductase (MTRR) A66G] in relation to total plasma chemical levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	T9	T28	15612980
NA	CHEMICAL	GENE-N	7	2	However, MS gene was significantly associated with chemical levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	T12	T36	15612980
NA	CHEMICAL	GENE-N	7	29	However, MS A2756G was significantly associated with chemical levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR gene (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	T12	T14	15612980
NA	CHEMICAL	GENE-Y	7	28	However, MS A2756G was significantly associated with chemical levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was gene A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	T12	T13	15612980
NA	CHEMICAL	GENE-Y	7	1	However, gene A2756G was significantly associated with chemical levels (AA genotype: 290 +/- 122 pmol/l; AG: 381 +/- 151 pmol/l and GG: 415 +/- 100 pmol/l), as was MTRR A66G (AA: 478 +/- 219 pmol/l, AG: 306 +/- 124 pmol/l and GG: 306 +/- 123 pmol/l).	T12	T35	15612980
NA	CHEMICAL	GENE-N	2	12	Differences in chemical and folate levels with the MTRR A66G and MS gene polymorphisms were noted.	T1	T22	15612980
NA	CHEMICAL	GENE-N	2	9	Differences in chemical and folate levels with the MTRR gene and MS A2756G polymorphisms were noted.	T1	T20	15612980
NA	CHEMICAL	GENE-Y	2	8	Differences in chemical and folate levels with the gene A66G and MS A2756G polymorphisms were noted.	T1	T19	15612980
NA	CHEMICAL	GENE-Y	2	11	Differences in chemical and folate levels with the MTRR A66G and gene A2756G polymorphisms were noted.	T1	T21	15612980
CPR:6	CHEMICAL	GENE-N	13	10	To test this, we studied the possible effect of the gene antagonist, chemical (50 and 100 mg kg(-1)) on serum glucose and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.	T4	T17	15629255
NA	CHEMICAL	GENE-N	13	23	To test this, we studied the possible effect of the endothelin receptor antagonist, chemical (50 and 100 mg kg(-1)) on serum glucose and gene levels as well as on liver glycogen contents in normoglycemic stressed animals.	T4	T18	15629255
NA	CHEMICAL	GENE-Y	13	23	To test this, we studied the possible effect of the endothelin receptor antagonist, chemical (50 and 100 mg kg(-1)) on serum glucose and gene levels as well as on liver glycogen contents in normoglycemic stressed animals.	T4	T18	15629255
NA	CHEMICAL	GENE-N	21	10	To test this, we studied the possible effect of the gene antagonist, bosentan (50 and 100 mg kg(-1)) on serum chemical and insulin levels as well as on liver glycogen contents in normoglycemic stressed animals.	T5	T17	15629255
NA	CHEMICAL	GENE-N	21	23	To test this, we studied the possible effect of the endothelin receptor antagonist, bosentan (50 and 100 mg kg(-1)) on serum chemical and gene levels as well as on liver glycogen contents in normoglycemic stressed animals.	T5	T18	15629255
NA	CHEMICAL	GENE-Y	21	23	To test this, we studied the possible effect of the endothelin receptor antagonist, bosentan (50 and 100 mg kg(-1)) on serum chemical and gene levels as well as on liver glycogen contents in normoglycemic stressed animals.	T5	T18	15629255
NA	CHEMICAL	GENE-N	5	10	In addition, the effect of chemical on serum glucose and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T6	T19	15629255
NA	CHEMICAL	GENE-N	5	10	In addition, the effect of chemical on serum glucose and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T6	T20	15629255
NA	CHEMICAL	GENE-Y	5	10	In addition, the effect of chemical on serum glucose and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T6	T19	15629255
NA	CHEMICAL	GENE-Y	5	10	In addition, the effect of chemical on serum glucose and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T6	T20	15629255
NA	CHEMICAL	GENE-N	8	10	In addition, the effect of bosentan on serum chemical and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T7	T19	15629255
NA	CHEMICAL	GENE-N	8	10	In addition, the effect of bosentan on serum chemical and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T7	T20	15629255
NA	CHEMICAL	GENE-Y	8	10	In addition, the effect of bosentan on serum chemical and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T7	T19	15629255
NA	CHEMICAL	GENE-Y	8	10	In addition, the effect of bosentan on serum chemical and gene levels in both mild and severely diabetic rats and its effect on gene-induced hypoglycemia were also determined.	T7	T20	15629255
NA	CHEMICAL	GENE-N	0	19	chemical partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in gene level in normoglycemic stressed rats.	T1	T11	15629255
NA	CHEMICAL	GENE-Y	0	19	chemical partially prevented stress-induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress-induced decrease in gene level in normoglycemic stressed rats.	T1	T11	15629255
NA	CHEMICAL	GENE-N	0	10	chemical also decreased serum glucose level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T2	T13	15629255
NA	CHEMICAL	GENE-N	0	10	chemical also decreased serum glucose level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T2	T14	15629255
NA	CHEMICAL	GENE-Y	0	10	chemical also decreased serum glucose level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T2	T13	15629255
NA	CHEMICAL	GENE-Y	0	10	chemical also decreased serum glucose level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T2	T14	15629255
NA	CHEMICAL	GENE-N	4	10	Bosentan also decreased serum chemical level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T3	T13	15629255
NA	CHEMICAL	GENE-N	4	10	Bosentan also decreased serum chemical level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T3	T14	15629255
NA	CHEMICAL	GENE-Y	4	10	Bosentan also decreased serum chemical level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T3	T13	15629255
NA	CHEMICAL	GENE-Y	4	10	Bosentan also decreased serum chemical level without any effect on gene secretion in mild diabetic rats and potentiated the hypoglycemic action of gene.	T3	T14	15629255
NA	CHEMICAL	GENE-N	12	29	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), chemical reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T10	T23	15646028
NA	CHEMICAL	GENE-N	12	24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), chemical reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T10	T21	15646028
NA	CHEMICAL	GENE-N	12	21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), chemical reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T10	T19	15646028
NA	CHEMICAL	GENE-N	12	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), chemical reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T10	T24	15646028
NA	CHEMICAL	GENE-N	12	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), chemical reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T10	T22	15646028
NA	CHEMICAL	GENE-N	12	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), chemical reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T10	T20	15646028
NA	CHEMICAL	GENE-N	8	29	Levels of superoxide anion (O2-), reduced or oxidized chemical (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T7	T23	15646028
NA	CHEMICAL	GENE-N	8	24	Levels of superoxide anion (O2-), reduced or oxidized chemical (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T7	T21	15646028
NA	CHEMICAL	GENE-N	8	21	Levels of superoxide anion (O2-), reduced or oxidized chemical (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T7	T19	15646028
NA	CHEMICAL	GENE-N	8	32	Levels of superoxide anion (O2-), reduced or oxidized chemical (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T7	T24	15646028
NA	CHEMICAL	GENE-N	8	27	Levels of superoxide anion (O2-), reduced or oxidized chemical (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T7	T22	15646028
NA	CHEMICAL	GENE-N	8	23	Levels of superoxide anion (O2-), reduced or oxidized chemical (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T7	T20	15646028
NA	CHEMICAL	GENE-N	2	29	Levels of chemical anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T5	T23	15646028
NA	CHEMICAL	GENE-N	2	24	Levels of chemical anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T5	T21	15646028
NA	CHEMICAL	GENE-N	2	21	Levels of chemical anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T5	T19	15646028
NA	CHEMICAL	GENE-N	2	32	Levels of chemical anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T5	T24	15646028
NA	CHEMICAL	GENE-N	2	27	Levels of chemical anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T5	T22	15646028
NA	CHEMICAL	GENE-N	2	23	Levels of chemical anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T5	T20	15646028
NA	CHEMICAL	GENE-N	29	24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), chemical-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T14	T21	15646028
NA	CHEMICAL	GENE-N	29	21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), chemical-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T14	T19	15646028
NA	CHEMICAL	GENE-N	29	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), chemical-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T14	T24	15646028
NA	CHEMICAL	GENE-N	29	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), chemical-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T14	T22	15646028
NA	CHEMICAL	GENE-N	29	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), chemical-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T14	T20	15646028
NA	CHEMICAL	GENE-N	21	29	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (complex-I), chemical-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T12	T23	15646028
NA	CHEMICAL	GENE-N	21	29	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (complex-I), chemical-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T13	T23	15646028
NA	CHEMICAL	GENE-N	21	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (complex-I), chemical-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T12	T24	15646028
NA	CHEMICAL	GENE-N	21	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (complex-I), chemical-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T13	T24	15646028
NA	CHEMICAL	GENE-N	21	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (complex-I), chemical-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T12	T22	15646028
NA	CHEMICAL	GENE-N	21	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (complex-I), chemical-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T13	T22	15646028
NA	CHEMICAL	GENE-N	21	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (gene), chemical-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T12	T20	15646028
NA	CHEMICAL	GENE-N	21	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, chemical-ubiquinone oxidoreductase (gene), chemical-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T13	T20	15646028
NA	CHEMICAL	GENE-N	11	29	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or chemical), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T9	T23	15646028
NA	CHEMICAL	GENE-N	11	24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or chemical), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T9	T21	15646028
NA	CHEMICAL	GENE-N	11	21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or chemical), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T9	T19	15646028
NA	CHEMICAL	GENE-N	11	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or chemical), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T9	T24	15646028
NA	CHEMICAL	GENE-N	11	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or chemical), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T9	T22	15646028
NA	CHEMICAL	GENE-N	11	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or chemical), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T9	T20	15646028
NA	CHEMICAL	GENE-N	9	29	Levels of superoxide anion (O2-), reduced or oxidized glutathione (chemical or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T8	T23	15646028
NA	CHEMICAL	GENE-N	9	24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (chemical or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T8	T21	15646028
NA	CHEMICAL	GENE-N	9	21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (chemical or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T8	T19	15646028
NA	CHEMICAL	GENE-N	9	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (chemical or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T8	T24	15646028
NA	CHEMICAL	GENE-N	9	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (chemical or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T8	T22	15646028
NA	CHEMICAL	GENE-N	9	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (chemical or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T8	T20	15646028
NA	CHEMICAL	GENE-N	20	29	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), chemical, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T11	T23	15646028
NA	CHEMICAL	GENE-N	20	24	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), chemical, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T11	T21	15646028
NA	CHEMICAL	GENE-N	20	21	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), chemical, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T11	T19	15646028
NA	CHEMICAL	GENE-N	20	32	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), chemical, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T11	T24	15646028
NA	CHEMICAL	GENE-N	20	27	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), chemical, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T11	T22	15646028
NA	CHEMICAL	GENE-N	20	23	Levels of superoxide anion (O2-), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), chemical, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T11	T20	15646028
NA	CHEMICAL	GENE-N	4	29	Levels of superoxide anion (chemical), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), gene (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T6	T23	15646028
NA	CHEMICAL	GENE-N	4	24	Levels of superoxide anion (chemical), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), gene (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T6	T21	15646028
NA	CHEMICAL	GENE-N	4	21	Levels of superoxide anion (chemical), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, gene (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T6	T19	15646028
NA	CHEMICAL	GENE-N	4	32	Levels of superoxide anion (chemical), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (gene) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T6	T24	15646028
NA	CHEMICAL	GENE-N	4	27	Levels of superoxide anion (chemical), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (complex-I), NADH-cytochrome c oxidoreductase (gene), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T6	T22	15646028
NA	CHEMICAL	GENE-N	4	23	Levels of superoxide anion (chemical), reduced or oxidized glutathione (GSH or GSSG), thiobarbituric acid reactive substance (TBARS), protein carbonyl (PC), ATP, NADH-ubiquinone oxidoreductase (gene), NADH-cytochrome c oxidoreductase (complex I/II), succinate-cytochrome c oxidoreductase (complex II/III) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	T6	T20	15646028
CPR:3	CHEMICAL	GENE-N	7	20	Pre-irradiation administration of RP-1 enhanced levels of chemical induced increase in complex I (upto 16 h), complex I/III (4 h) gene activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).	T3	T18	15646028
CPR:3	CHEMICAL	GENE-N	7	16	Pre-irradiation administration of RP-1 enhanced levels of chemical induced increase in complex I (upto 16 h), gene (4 h) complex II/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).	T3	T17	15646028
CPR:3	CHEMICAL	GENE-N	7	11	Pre-irradiation administration of RP-1 enhanced levels of chemical induced increase in gene (upto 16 h), gene/III (4 h) geneI/III activity (upto 24 h; p < 0.01) and inhibited the radiation-induced decrease in MMP significantly (24 h; p < 0.01).	T3	T16	15646028
NA	CHEMICAL	GENE-Y	5	19	We investigated the effects of chemical on fulminant hepatitis in C57BL/6J mice induced by lethal challenge of the activating anti-gene antibody, Jo2.	T5	T20	15665864
NA	CHEMICAL	GENE-N	12	3	Jo2-induced activation of gene in liver tissues was inhibited by chemical pretreatment, and yet the direct addition of chemical to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.	T11	T22	15665864
NA	CHEMICAL	GENE-N	12	3	Jo2-induced activation of gene in liver tissues was inhibited by chemical pretreatment, and yet the direct addition of chemical to liver extracts from Jo2-challenged mice failed to block caspase activation in vitro.	T1	T22	15665864
NA	CHEMICAL	GENE-N	12	3	Jo2-induced activation of gene-3 or -9 in liver tissues was inhibited by chemical pretreatment, and yet the direct addition of chemical to liver extracts from Jo2-challenged mice failed to block gene activation in vitro.	T11	T13	15665864
NA	CHEMICAL	GENE-N	12	3	Jo2-induced activation of gene-3 or -9 in liver tissues was inhibited by chemical pretreatment, and yet the direct addition of chemical to liver extracts from Jo2-challenged mice failed to block gene activation in vitro.	T1	T13	15665864
CPR:4	CHEMICAL	GENE-Y	1	7	Moreover, chemical efficiently suppressed the release of gene from mitochondria of the liver tissues from Jo2-challenged mice.	T2	T14	15665864
NA	CHEMICAL	GENE-Y	14	2	In contrast, gene activation and Bid truncation triggered by Jo2 were not diminished by chemical pretreatment in mouse livers.	T3	T15	15665864
NA	CHEMICAL	GENE-Y	14	5	In contrast, caspase-8 activation and gene truncation triggered by Jo2 were not diminished by chemical pretreatment in mouse livers.	T3	T16	15665864
CPR:4	CHEMICAL	GENE-Y	10	20	Our results suggest that easing of Fas-triggered fulminant hepatitis by chemical may involve a mitochondrial apoptotic pathway, probably through preventing gene release and thereby blocking downstream caspase activation.	T4	T18	15665864
CPR:4	CHEMICAL	GENE-N	10	27	Our results suggest that easing of Fas-triggered fulminant hepatitis by chemical may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream gene activation.	T4	T19	15665864
NA	CHEMICAL	GENE-Y	10	6	Our results suggest that easing of gene-triggered fulminant hepatitis by chemical may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream caspase activation.	T4	T17	15665864
NA	CHEMICAL	GENE-Y	3	0	gene (CSE) and chemical-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S.	T5	T36	15671155
NA	CHEMICAL	GENE-Y	3	4	Cystathionine-gamma-lyase (CSE) and chemical-beta-synthase (gene) utilize L-cysteine as substrate to form H2S.	T5	T30	15671155
NA	CHEMICAL	GENE-Y	3	1	Cystathionine-gamma-lyase (gene) and chemical-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S.	T5	T26	15671155
NA	CHEMICAL	GENE-Y	0	3	chemical-gamma-lyase (CSE) and gene (CBS) utilize L-cysteine as substrate to form H2S.	T24	T29	15671155
NA	CHEMICAL	GENE-Y	0	4	chemical-gamma-lyase (CSE) and cystathionine-beta-synthase (gene) utilize L-cysteine as substrate to form H2S.	T24	T30	15671155
NA	CHEMICAL	GENE-Y	0	1	chemical-gamma-lyase (gene) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S.	T24	T26	15671155
CPR:9	CHEMICAL	GENE-Y	6	3	Cystathionine-gamma-lyase (CSE) and gene (CBS) utilize chemical as substrate to form H2S.	T10	T29	15671155
CPR:9	CHEMICAL	GENE-Y	6	0	gene (CSE) and cystathionine-beta-synthase (CBS) utilize chemical as substrate to form H2S.	T10	T36	15671155
CPR:9	CHEMICAL	GENE-Y	6	4	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (gene) utilize chemical as substrate to form H2S.	T10	T30	15671155
CPR:9	CHEMICAL	GENE-Y	6	1	Cystathionine-gamma-lyase (gene) and cystathionine-beta-synthase (CBS) utilize chemical as substrate to form H2S.	T10	T26	15671155
CPR:9	CHEMICAL	GENE-Y	11	3	Cystathionine-gamma-lyase (CSE) and gene (CBS) utilize L-cysteine as substrate to form chemical.	T16	T29	15671155
CPR:9	CHEMICAL	GENE-Y	11	0	gene (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form chemical.	T16	T36	15671155
CPR:9	CHEMICAL	GENE-Y	11	4	Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (gene) utilize L-cysteine as substrate to form chemical.	T16	T30	15671155
CPR:9	CHEMICAL	GENE-Y	11	1	Cystathionine-gamma-lyase (gene) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form chemical.	T16	T26	15671155
NA	CHEMICAL	GENE-Y	4	5	Of these two enzymes, chemical-gamma-lyase (gene) is believed to be the key enzyme that forms H2S in the cardiovascular system.	T17	T33	15671155
CPR:9	CHEMICAL	GENE-Y	15	4	Of these two enzymes, gene (CSE) is believed to be the key enzyme that forms chemical in the cardiovascular system.	T18	T32	15671155
CPR:9	CHEMICAL	GENE-Y	15	5	Of these two enzymes, cystathionine-gamma-lyase (gene) is believed to be the key enzyme that forms chemical in the cardiovascular system.	T18	T33	15671155
NA	CHEMICAL	GENE-Y	8	13	In this paper, we report the presence of chemical synthesizing enzyme activity and gene (as determined by mRNA signal) in the pancreas.	T20	T34	15671155
NA	CHEMICAL	GENE-N	11	28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, chemical (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hypergenemia [plasma gene (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.	T21	T37	15671155
CPR:4	CHEMICAL	GENE-Y	11	9	Also, prophylactic, as well as therapeutic, treatment with the gene inhibitor, chemical (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.	T21	T35	15671155
NA	CHEMICAL	GENE-N	18	28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of chemical-induced pancreatitis and associated lung injury, as determined by 1) hypergenemia [plasma gene (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.	T23	T37	15671155
NA	CHEMICAL	GENE-Y	18	9	Also, prophylactic, as well as therapeutic, treatment with the gene inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of chemical-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f.	T23	T35	15671155
NA	CHEMICAL	GENE-N	12	28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hypergenemia [plasma gene (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T22	T37	15671155
NA	CHEMICAL	GENE-N	12	28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hypergenemia [plasma gene (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T2	T37	15671155
NA	CHEMICAL	GENE-N	12	28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hypergenemia [plasma gene (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T3	T37	15671155
NA	CHEMICAL	GENE-N	12	28	Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hypergenemia [plasma gene (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T4	T37	15671155
CPR:4	CHEMICAL	GENE-Y	12	9	Also, prophylactic, as well as therapeutic, treatment with the gene inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T22	T35	15671155
NA	CHEMICAL	GENE-Y	12	9	Also, prophylactic, as well as therapeutic, treatment with the gene inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T2	T35	15671155
NA	CHEMICAL	GENE-Y	12	9	Also, prophylactic, as well as therapeutic, treatment with the gene inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T3	T35	15671155
NA	CHEMICAL	GENE-Y	12	9	Also, prophylactic, as well as therapeutic, treatment with the gene inhibitor, DL-propargylglycine (chemical), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; chemical, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; chemical, 7811+/-428; P<0.05 chemical c.f.	T4	T35	15671155
CPR:3	CHEMICAL	GENE-Y	25	13	placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic gene (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; chemical, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; chemical, 3.03+/-0.47; P<0.05 chemical c.f.	T6	T27	15671155
NA	CHEMICAL	GENE-Y	25	13	placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic gene (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; chemical, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; chemical, 3.03+/-0.47; P<0.05 chemical c.f.	T7	T27	15671155
NA	CHEMICAL	GENE-Y	25	13	placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic gene (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; chemical, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; chemical, 3.03+/-0.47; P<0.05 chemical c.f.	T8	T27	15671155
CPR:3	CHEMICAL	GENE-Y	25	15	placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (gene) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; chemical, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; chemical, 3.03+/-0.47; P<0.05 chemical c.f.	T6	T28	15671155
NA	CHEMICAL	GENE-Y	25	15	placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (gene) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; chemical, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; chemical, 3.03+/-0.47; P<0.05 chemical c.f.	T7	T28	15671155
NA	CHEMICAL	GENE-Y	25	15	placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (gene) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; chemical, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; chemical, 3.03+/-0.47; P<0.05 chemical c.f.	T8	T28	15671155
NA	CHEMICAL	GENE-Y	11	3	These effects of gene blockade suggest an important proinflammatory role of chemical in regulating the severity of pancreatitis and associated lung injury and raise the possibility that chemical may exert similar activity in other forms of inflammation.	T14	T31	15671155
NA	CHEMICAL	GENE-Y	11	3	These effects of gene blockade suggest an important proinflammatory role of chemical in regulating the severity of pancreatitis and associated lung injury and raise the possibility that chemical may exert similar activity in other forms of inflammation.	T15	T31	15671155
NA	CHEMICAL	GENE-Y	19	4	A model of the gene was used to study the receptor interactions of dopamine, the typical antipsychotics chemical and loxapine, and the atypical antipsychotics clozapine and melperone.	T1	T11	15694653
NA	CHEMICAL	GENE-Y	28	4	A model of the gene was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics clozapine and chemical.	T5	T11	15694653
NA	CHEMICAL	GENE-Y	26	4	A model of the gene was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and loxapine, and the atypical antipsychotics chemical and melperone.	T4	T11	15694653
NA	CHEMICAL	GENE-Y	21	4	A model of the gene was used to study the receptor interactions of dopamine, the typical antipsychotics haloperidol and chemical, and the atypical antipsychotics clozapine and melperone.	T2	T11	15694653
NA	CHEMICAL	GENE-Y	13	20	At doses ranging from 0.02 to 0.2 microg/kg, exenatide dose-dependently reduced postprandial plasma chemical excursion by insulinotropism, suppression of plasma gene, and slowing of gastric emptying.	T2	T6	15700891
NA	CHEMICAL	GENE-N	21	6	Recent insights in the role of gene ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct chemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T7	T24	15737409
NA	CHEMICAL	GENE-Y	21	30	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct chemical absorption inhibitor, as well as the identification of gene (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T7	T22	15737409
NA	CHEMICAL	GENE-Y	21	34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct chemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (gene) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T7	T23	15737409
NA	CHEMICAL	GENE-Y	21	12	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and gene, the discovery of ezetimibe, the first approved direct chemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T7	T34	15737409
NA	CHEMICAL	GENE-Y	21	10	Recent insights in the role of ATP-binding cassette (ABC) transporters gene and ABCG8, the discovery of ezetimibe, the first approved direct chemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T7	T32	15737409
NA	CHEMICAL	GENE-N	16	6	Recent insights in the role of gene ABCG5 and ABCG8, the discovery of chemical, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T2	T24	15737409
NA	CHEMICAL	GENE-Y	16	30	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of chemical, the first approved direct cholesterol absorption inhibitor, as well as the identification of gene (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T2	T22	15737409
NA	CHEMICAL	GENE-Y	16	34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of chemical, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (gene) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T2	T23	15737409
NA	CHEMICAL	GENE-Y	16	12	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and gene, the discovery of chemical, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T2	T34	15737409
NA	CHEMICAL	GENE-Y	16	10	Recent insights in the role of ATP-binding cassette (ABC) transporters gene and ABCG8, the discovery of chemical, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T2	T32	15737409
NA	CHEMICAL	GENE-N	21	6	Recent insights in the role of gene ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T8	T24	15737409
NA	CHEMICAL	GENE-N	21	6	Recent insights in the role of gene ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T9	T24	15737409
NA	CHEMICAL	GENE-Y	21	30	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of gene (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T8	T22	15737409
NA	CHEMICAL	GENE-Y	21	30	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of gene (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T9	T22	15737409
NA	CHEMICAL	GENE-Y	21	34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (gene) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T8	T23	15737409
NA	CHEMICAL	GENE-Y	21	34	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (gene) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T9	T23	15737409
NA	CHEMICAL	GENE-Y	21	12	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and gene, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T8	T34	15737409
NA	CHEMICAL	GENE-Y	21	12	Recent insights in the role of ATP-binding cassette (ABC) transporters ABCG5 and gene, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T9	T34	15737409
NA	CHEMICAL	GENE-Y	21	10	Recent insights in the role of ATP-binding cassette (ABC) transporters gene and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T8	T32	15737409
NA	CHEMICAL	GENE-Y	21	10	Recent insights in the role of ATP-binding cassette (ABC) transporters gene and ABCG8, the discovery of ezetimibe, the first approved direct cholechemical absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as chemical transporter in the gut, focused attention on chemical transport processes in the small intestine and the liver.	T9	T32	15737409
NA	CHEMICAL	GENE-Y	6	30	Recent insights in the role of chemical-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of gene (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T10	T22	15737409
NA	CHEMICAL	GENE-Y	6	34	Recent insights in the role of chemical-binding cassette (ABC) transporters ABCG5 and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (gene) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T10	T23	15737409
NA	CHEMICAL	GENE-Y	6	12	Recent insights in the role of chemical-binding cassette (ABC) transporters ABCG5 and gene, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T10	T34	15737409
NA	CHEMICAL	GENE-Y	6	10	Recent insights in the role of chemical-binding cassette (ABC) transporters gene and ABCG8, the discovery of ezetimibe, the first approved direct cholesterol absorption inhibitor, as well as the identification of Niemann-Pick C1 Like 1 (NPC1L1) protein as sterol transporter in the gut, focused attention on sterol transport processes in the small intestine and the liver.	T10	T32	15737409
NA	CHEMICAL	GENE-Y	18	9	The identification of defective structures in the ABCG5 or gene transporters in patients with the rare disease of sitochemicalemia elucidated their role as chemical efflux pumps regulating at least in parts the intestinal chemical absorption and the hepatic chemical output.	T11	T26	15737409
NA	CHEMICAL	GENE-Y	18	9	The identification of defective structures in the ABCG5 or gene transporters in patients with the rare disease of sitochemicalemia elucidated their role as chemical efflux pumps regulating at least in parts the intestinal chemical absorption and the hepatic chemical output.	T12	T26	15737409
NA	CHEMICAL	GENE-Y	18	9	The identification of defective structures in the ABCG5 or gene transporters in patients with the rare disease of sitochemicalemia elucidated their role as chemical efflux pumps regulating at least in parts the intestinal chemical absorption and the hepatic chemical output.	T13	T26	15737409
NA	CHEMICAL	GENE-Y	18	7	The identification of defective structures in the gene or ABCG8 transporters in patients with the rare disease of sitochemicalemia elucidated their role as chemical efflux pumps regulating at least in parts the intestinal chemical absorption and the hepatic chemical output.	T11	T25	15737409
NA	CHEMICAL	GENE-Y	18	7	The identification of defective structures in the gene or ABCG8 transporters in patients with the rare disease of sitochemicalemia elucidated their role as chemical efflux pumps regulating at least in parts the intestinal chemical absorption and the hepatic chemical output.	T12	T25	15737409
NA	CHEMICAL	GENE-Y	18	7	The identification of defective structures in the gene or ABCG8 transporters in patients with the rare disease of sitochemicalemia elucidated their role as chemical efflux pumps regulating at least in parts the intestinal chemical absorption and the hepatic chemical output.	T13	T25	15737409
NA	CHEMICAL	GENE-N	7	9	ABCG5 and ABCG8 themselves are regulated by chemical via gene (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	T14	T30	15737409
NA	CHEMICAL	GENE-Y	7	2	ABCG5 and gene themselves are regulated by chemical via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	T14	T29	15737409
NA	CHEMICAL	GENE-Y	7	0	gene and ABCG8 themselves are regulated by chemical via liver X receptors (LXRs), which are also activated by oxysterols and some derivatives of plant sterols.	T14	T28	15737409
NA	CHEMICAL	GENE-N	7	12	ABCG5 and ABCG8 themselves are regulated by chemical via liver X receptors (gene), which are also activated by oxysterols and some derivatives of plant sterols.	T14	T31	15737409
NA	CHEMICAL	GENE-N	18	9	ABCG5 and ABCG8 themselves are regulated by cholesterol via gene (LXRs), which are also activated by oxychemical and some derivatives of plant chemical.	T15	T30	15737409
NA	CHEMICAL	GENE-Y	18	2	ABCG5 and gene themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxychemical and some derivatives of plant chemical.	T15	T29	15737409
NA	CHEMICAL	GENE-Y	18	0	gene and ABCG8 themselves are regulated by cholesterol via liver X receptors (LXRs), which are also activated by oxychemical and some derivatives of plant chemical.	T15	T28	15737409
CPR:3	CHEMICAL	GENE-N	18	12	ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (gene), which are also activated by oxychemical and some derivatives of plant chemical.	T15	T31	15737409
CPR:9	CHEMICAL	GENE-N	15	8	NPC1L1 could recently be identified as a major gene for the intestinal uptake of chemical as well as plant sterols.	T17	T35	15737409
CPR:9	CHEMICAL	GENE-Y	15	0	gene could recently be identified as a major sterol transporter for the intestinal uptake of chemical as well as plant sterols.	T17	T33	15737409
CPR:9	CHEMICAL	GENE-N	20	8	NPC1L1 could recently be identified as a major gene for the intestinal uptake of cholesterol as well as plant chemical.	T18	T35	15737409
CPR:9	CHEMICAL	GENE-Y	20	0	gene could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant chemical.	T18	T33	15737409
NA	CHEMICAL	GENE-Y	8	0	gene could recently be identified as a major chemical transporter for the intestinal uptake of cholechemical as well as plant chemicals.	T16	T33	15737409
NA	CHEMICAL	GENE-Y	30	2	Studies in gene knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that gene might also be involved in the mechanism of action of chemical.	T3	T21	15737409
NA	CHEMICAL	GENE-Y	30	2	Studies in gene knockout mice indicate that this transporter is essential for the intestinal uptake of sterols and that gene might also be involved in the mechanism of action of chemical.	T3	T36	15737409
NA	CHEMICAL	GENE-Y	16	2	Studies in gene knockout mice indicate that this transporter is essential for the intestinal uptake of chemical and that gene might also be involved in the mechanism of action of ezetimibe.	T1	T21	15737409
NA	CHEMICAL	GENE-Y	16	2	Studies in gene knockout mice indicate that this transporter is essential for the intestinal uptake of chemical and that gene might also be involved in the mechanism of action of ezetimibe.	T1	T36	15737409
CPR:4	CHEMICAL	GENE-Y	0	8	chemical has an antidepressant effect through blocking the gene.	T1	T11	15787205
NA	CHEMICAL	GENE-Y	3	10	After 3 weeks' chemical treatment we studied the change in gene activity, which corresponds to the occupancy of chemical.	T2	T9	15787205
NA	CHEMICAL	GENE-Y	3	10	After 3 weeks' chemical treatment we studied the change in gene activity, which corresponds to the occupancy of chemical.	T3	T9	15787205
NA	CHEMICAL	GENE-Y	4	6	The average occupancy of chemical on gene was similar to the international findings at 20.84% in 9 depressed patients.	T4	T10	15787205
NA	CHEMICAL	GENE-N	11	6	In vitro studies demonstrated that the gene (RXR) retinoid, chemical, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	T4	T19	15811959
CPR:3	CHEMICAL	GENE-N	11	31	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, chemical, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the gene and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	T4	T23	15811959
CPR:3	CHEMICAL	GENE-Y	11	25	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, chemical, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the gene and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	T4	T21	15811959
NA	CHEMICAL	GENE-N	11	9	In vitro studies demonstrated that the retinoid X receptor (gene) retinoid, chemical, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	T4	T20	15811959
CPR:3	CHEMICAL	GENE-Y	11	27	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, chemical, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and gene subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	T4	T22	15811959
NA	CHEMICAL	GENE-N	10	2	Modulation of gene expression was observed at or above a chemical dose of 150 mg/day.	T1	T7	15811959
NA	CHEMICAL	GENE-Y	10	30	Our results demonstrate that the combination of denileukin diftitox and chemical is well tolerated and that even low doses (150 mg/day) of chemical are capable of in vivo upregulation of gene expression on circulating leukemia cells.	T2	T8	15811959
CPR:3	CHEMICAL	GENE-Y	10	30	Our results demonstrate that the combination of denileukin diftitox and chemical is well tolerated and that even low doses (150 mg/day) of chemical are capable of in vivo upregulation of gene expression on circulating leukemia cells.	T3	T8	15811959
CPR:9	CHEMICAL	GENE-N	20	4	PSMA acts as a gene (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide chemical.	T4	T11	15837926
NA	CHEMICAL	GENE-Y	20	6	PSMA acts as a glutamate carboxypeptidase (gene) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide chemical.	T4	T12	15837926
CPR:9	CHEMICAL	GENE-Y	20	0	gene acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide chemical.	T4	T10	15837926
CPR:9	CHEMICAL	GENE-N	16	4	PSMA acts as a gene (GCPII) on small molecule substrates, including folate, the anticancer drug chemical, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	T3	T11	15837926
CPR:9	CHEMICAL	GENE-Y	16	6	PSMA acts as a glutamate carboxypeptidase (gene) on small molecule substrates, including folate, the anticancer drug chemical, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	T3	T12	15837926
CPR:9	CHEMICAL	GENE-Y	16	0	gene acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug chemical, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	T3	T10	15837926
NA	CHEMICAL	GENE-Y	4	6	PSMA acts as a chemical carboxypeptidase (gene) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-chemical.	T1	T12	15837926
NA	CHEMICAL	GENE-Y	4	0	gene acts as a chemical carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-chemical.	T1	T10	15837926
CPR:9	CHEMICAL	GENE-N	12	4	PSMA acts as a gene (GCPII) on small molecule substrates, including chemical, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	T2	T11	15837926
CPR:9	CHEMICAL	GENE-Y	12	6	PSMA acts as a glutamate carboxypeptidase (gene) on small molecule substrates, including chemical, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	T2	T12	15837926
CPR:9	CHEMICAL	GENE-Y	12	0	gene acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including chemical, the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.	T2	T10	15837926
NA	CHEMICAL	GENE-N	24	19	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to gene, a receptor for chemical-loaded transferrin that lacks protease activity.	T5	T15	15837926
NA	CHEMICAL	GENE-N	24	9	Here we present the 3.5-A crystal structure of the gene, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for chemical-loaded transferrin that lacks protease activity.	T5	T14	15837926
NA	CHEMICAL	GENE-Y	24	19	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to gene receptor, a receptor for chemical-loaded gene that lacks protease activity.	T5	T16	15837926
NA	CHEMICAL	GENE-N	24	28	Here we present the 3.5-A crystal structure of the PSMA ectodomain, which reveals a homodimer with structural similarity to transferrin receptor, a receptor for chemical-loaded transferrin that lacks gene activity.	T5	T17	15837926
NA	CHEMICAL	GENE-N	19	1	Unlike gene, the protease domain of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding chemical patch.	T7	T18	15837926
NA	CHEMICAL	GENE-N	19	4	Unlike transferrin receptor, the gene of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding chemical patch.	T7	T19	15837926
NA	CHEMICAL	GENE-Y	19	7	Unlike transferrin receptor, the protease domain of gene contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding chemical patch.	T7	T20	15837926
NA	CHEMICAL	GENE-N	11	1	Unlike gene, the protease domain of PSMA contains a binuclear chemical site, catalytic residues, and a proposed substrate-binding arginine patch.	T6	T18	15837926
NA	CHEMICAL	GENE-N	11	4	Unlike transferrin receptor, the gene of PSMA contains a binuclear chemical site, catalytic residues, and a proposed substrate-binding arginine patch.	T6	T19	15837926
NA	CHEMICAL	GENE-Y	11	7	Unlike transferrin receptor, the protease domain of gene contains a binuclear chemical site, catalytic residues, and a proposed substrate-binding arginine patch.	T6	T20	15837926
CPR:9	CHEMICAL	GENE-Y	25	3	Elucidation of the gene structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate chemical.	T8	T21	15837926
NA	CHEMICAL	GENE-N	10	6	The two active sites of dimeric gene (ALAS), a chemical (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	T7	T19	15840827
NA	CHEMICAL	GENE-N	10	8	The two active sites of dimeric 5-aminolevulinate synthase (gene), a chemical (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	T7	T23	15840827
NA	CHEMICAL	GENE-N	6	8	The two active sites of dimeric chemical synthase (gene), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	T6	T23	15840827
NA	CHEMICAL	GENE-N	24	6	The two active sites of dimeric gene (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential chemical from each subunit.	T5	T19	15840827
NA	CHEMICAL	GENE-N	24	8	The two active sites of dimeric 5-aminolevulinate synthase (gene), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential chemical from each subunit.	T5	T23	15840827
NA	CHEMICAL	GENE-N	12	6	The two active sites of dimeric gene (ALAS), a pyridoxal 5'-phosphate (chemical)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	T10	T19	15840827
NA	CHEMICAL	GENE-N	12	8	The two active sites of dimeric 5-aminolevulinate synthase (gene), a pyridoxal 5'-phosphate (chemical)-dependent enzyme, are located on the subunit interface with contribution of essential amino acids from each subunit.	T10	T23	15840827
NA	CHEMICAL	GENE-N	10	23	Transient kinetic analysis of the formation and decay of the chemical intermediate EQ(2) indicated that, although their rates were similar in ALAS and gene, accumulation of this intermediate was greater in the gene-catalyzed reaction.	T3	T14	15840827
NA	CHEMICAL	GENE-N	10	23	Transient kinetic analysis of the formation and decay of the chemical intermediate EQ(2) indicated that, although their rates were similar in ALAS and gene, accumulation of this intermediate was greater in the gene-catalyzed reaction.	T3	T15	15840827
NA	CHEMICAL	GENE-N	10	21	Transient kinetic analysis of the formation and decay of the chemical intermediate EQ(2) indicated that, although their rates were similar in gene and 2Xgene, accumulation of this intermediate was greater in the 2Xgene-catalyzed reaction.	T3	T13	15840827
NA	CHEMICAL	GENE-N	5	21	Collectively, these results suggest that chemical is the active form of the coenzyme and forms a more prominent coenzyme structure in gene than in ALAS at pH approximately 7.5.	T4	T16	15840827
NA	CHEMICAL	GENE-N	5	21	Collectively, these results suggest that chemical is the active form of the coenzyme and forms a more prominent coenzyme structure in 2Xgene than in gene at pH approximately 7.5.	T4	T17	15840827
NA	CHEMICAL	GENE-N	8	0	gene (PAD) convert protein-bound arginine residues into chemical residues in a Ca(2+) ion-dependent manner.	T3	T4	15854045
NA	CHEMICAL	GENE-N	8	2	Peptidylarginine deiminases (gene) convert protein-bound arginine residues into chemical residues in a Ca(2+) ion-dependent manner.	T3	T8	15854045
NA	CHEMICAL	GENE-N	0	2	Peptidylchemical deiminases (gene) convert protein-bound chemical residues into citrulline residues in a Ca(2+) ion-dependent manner.	T2	T8	15854045
NA	CHEMICAL	GENE-N	12	0	gene (PAD) convert protein-bound arginine residues into citrulline residues in a chemical ion-dependent manner.	T1	T4	15854045
NA	CHEMICAL	GENE-N	12	2	Peptidylarginine deiminases (gene) convert protein-bound arginine residues into citrulline residues in a chemical ion-dependent manner.	T1	T8	15854045
NA	CHEMICAL	GENE-N	2	11	Galpha(i) inhibits chemical production, but betagamma regulates several molecular pathways, including gene (PKA).	T1	T9	15937104
NA	CHEMICAL	GENE-N	2	0	gene inhibits chemical production, but betagamma regulates several molecular pathways, including protein kinase A (PKA).	T1	T8	15937104
NA	CHEMICAL	GENE-N	2	14	Galpha(i) inhibits chemical production, but betagamma regulates several molecular pathways, including protein kinase A (gene).	T1	T10	15937104
NA	CHEMICAL	GENE-Y	3	4	In rats self-administering chemical, gene antisense in the NAc core, but not shell, eliminates reinstatement of chemical-seeking behavior, a model of human relapse.	T3	T20	15937104
NA	CHEMICAL	GENE-Y	3	4	In rats self-administering chemical, gene antisense in the NAc core, but not shell, eliminates reinstatement of chemical-seeking behavior, a model of human relapse.	T4	T20	15937104
NA	CHEMICAL	GENE-N	15	1	Thus, gene/AGS3 appears to mediate mu opiate receptor activation of PKA signaling as well as chemical-seeking behavior.	T5	T22	15937104
NA	CHEMICAL	GENE-Y	15	5	Thus, Galpha(i3)/betagamma/AGS3 appears to mediate gene activation of PKA signaling as well as chemical-seeking behavior.	T5	T24	15937104
NA	CHEMICAL	GENE-Y	15	1	Thus, Galpha(i3)/betagamma/gene appears to mediate mu opiate receptor activation of PKA signaling as well as chemical-seeking behavior.	T5	T23	15937104
NA	CHEMICAL	GENE-N	15	10	Thus, Galpha(i3)/betagamma/AGS3 appears to mediate mu opiate receptor activation of gene signaling as well as chemical-seeking behavior.	T5	T25	15937104
NA	CHEMICAL	GENE-Y	0	8	chemical (A-381393) was identified as a potent gene antagonist with excellent receptor selectivity.	T1	T30	15992586
NA	CHEMICAL	GENE-Y	2	8	2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole (chemical) was identified as a potent gene antagonist with excellent receptor selectivity.	T21	T30	15992586
NA	CHEMICAL	GENE-N	0	15	chemical competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant gene (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).	T11	T33	15992586
NA	CHEMICAL	GENE-N	28	15	[3H]-spiperone competition binding assays showed that A-381393 potently bound to membrane from cells expressing recombinant gene (Ki=1.5 nM), which was 20-fold higher than that of chemical (Ki=30.4 nM).	T14	T33	15992586
NA	CHEMICAL	GENE-N	6	15	[3H]-spiperone competition binding assays showed that chemical potently bound to membrane from cells expressing recombinant gene (Ki=1.5 nM), which was 20-fold higher than that of clozapine (Ki=30.4 nM).	T12	T33	15992586
NA	CHEMICAL	GENE-N	0	14	chemical exhibited highly selective binding for the dopamine D4.4 receptor (>2700-fold) when compared to gene.	T15	T35	15992586
NA	CHEMICAL	GENE-N	0	7	chemical exhibited highly selective binding for the gene (>2700-fold) when compared to D1, D2, D3 and D5 dopamine receptors.	T15	T34	15992586
NA	CHEMICAL	GENE-Y	4	36	Furthermore, in comparison to chemical and L-745870, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for gene (Ki=370 nM).	T18	T36	15992586
NA	CHEMICAL	GENE-Y	6	36	Furthermore, in comparison to clozapine and chemical, A-381393 exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for gene (Ki=370 nM).	T19	T36	15992586
NA	CHEMICAL	GENE-Y	7	36	Furthermore, in comparison to clozapine and L-745870, chemical exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for gene (Ki=370 nM).	T20	T36	15992586
NA	CHEMICAL	GENE-N	0	27	chemical potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in gene cells.	T22	T38	15992586
NA	CHEMICAL	GENE-N	0	18	chemical potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in gene expressing cells, but not in human dopamine D2L or D3 receptor cells.	T22	T37	15992586
NA	CHEMICAL	GENE-N	15	27	A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-chemical flux in human dopamine D4.4 receptor expressing cells, but not in gene cells.	T25	T38	15992586
NA	CHEMICAL	GENE-N	15	18	A-381393 potently inhibited the functional activity of agonist-induced GTP-gamma-S binding assay and 1 microM dopamine induced-chemical flux in gene expressing cells, but not in human dopamine D2L or D3 receptor cells.	T25	T37	15992586
NA	CHEMICAL	GENE-N	8	27	A-381393 potently inhibited the functional activity of agonist-induced chemical-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in human dopamine D4.4 receptor expressing cells, but not in gene cells.	T23	T38	15992586
NA	CHEMICAL	GENE-N	8	18	A-381393 potently inhibited the functional activity of agonist-induced chemical-gamma-S binding assay and 1 microM dopamine induced-Ca2+ flux in gene expressing cells, but not in human dopamine D2L or D3 receptor cells.	T23	T37	15992586
NA	CHEMICAL	GENE-N	3	14	In contrast to chemical, A-381393 did not exhibit any significant intrinsic activity in a gene.	T4	T31	15992586
NA	CHEMICAL	GENE-N	4	14	In contrast to L-745870, chemical did not exhibit any significant intrinsic activity in a gene.	T5	T31	15992586
NA	CHEMICAL	GENE-N	1	15	Thus, chemical is a novel selective D4 antagonist that will enhance the ability to study gene both in vitro and in vivo.	T9	T32	15992586
CPR:6	CHEMICAL	GENE-Y	10	4	A number of selective gene antagonists have been developed including chemical, granisetron, tropisetron renzapride and zacopride.	T6	T23	1600046
CPR:6	CHEMICAL	GENE-Y	11	4	A number of selective gene antagonists have been developed including ondansetron, chemical, tropisetron renzapride and zacopride.	T7	T23	1600046
CPR:6	CHEMICAL	GENE-Y	12	4	A number of selective gene antagonists have been developed including ondansetron, granisetron, chemical renzapride and zacopride.	T8	T23	1600046
CPR:6	CHEMICAL	GENE-Y	13	4	A number of selective gene antagonists have been developed including ondansetron, granisetron, tropisetron chemical and zacopride.	T9	T23	1600046
CPR:6	CHEMICAL	GENE-Y	15	4	A number of selective gene antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and chemical.	T10	T23	1600046
CPR:5	CHEMICAL	GENE-Y	7	33	While the substituted benzamide prokinetics (for example, chemical, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative gene receptor.	T12	T25	1600046
CPR:4	CHEMICAL	GENE-Y	7	11	While the substituted benzamide prokinetics (for example, chemical, cisapride) also block gene receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.	T12	T24	1600046
CPR:5	CHEMICAL	GENE-Y	8	33	While the substituted benzamide prokinetics (for example, metoclopramide, chemical) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative gene receptor.	T13	T25	1600046
CPR:4	CHEMICAL	GENE-Y	8	11	While the substituted benzamide prokinetics (for example, metoclopramide, chemical) also block gene receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.	T13	T24	1600046
CPR:5	CHEMICAL	GENE-Y	3	33	While the substituted chemical prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative gene receptor.	T11	T25	1600046
CPR:4	CHEMICAL	GENE-Y	3	11	While the substituted chemical prokinetics (for example, metoclopramide, cisapride) also block gene receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.	T11	T24	1600046
NA	CHEMICAL	GENE-Y	17	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, zacopride) and others do not (for example, chemical, granisetron), while tropisetron in high concentrations is a gene antagonist.	T16	T19	1600046
NA	CHEMICAL	GENE-Y	17	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, zacopride) and others do not (for example, chemical, granisetron), while tropisetron in high concentrations is a gene antagonist.	T16	T27	1600046
NA	CHEMICAL	GENE-Y	17	1	Some gene antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, chemical, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	T16	T26	1600046
NA	CHEMICAL	GENE-Y	18	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, chemical), while tropisetron in high concentrations is a gene antagonist.	T17	T19	1600046
NA	CHEMICAL	GENE-Y	18	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, chemical), while tropisetron in high concentrations is a gene antagonist.	T17	T27	1600046
NA	CHEMICAL	GENE-Y	18	1	Some gene antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, chemical), while tropisetron in high concentrations is a 5-HT4 antagonist.	T17	T26	1600046
CPR:6	CHEMICAL	GENE-Y	20	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while chemical in high concentrations is a gene antagonist.	T2	T19	1600046
NA	CHEMICAL	GENE-Y	20	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while chemical in high concentrations is a gene antagonist.	T2	T27	1600046
NA	CHEMICAL	GENE-Y	20	1	Some gene antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while chemical in high concentrations is a 5-HT4 antagonist.	T2	T26	1600046
NA	CHEMICAL	GENE-Y	9	4	Some 5-HT3 antagonists have gene agonist activity (for example, chemical, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a gene antagonist.	T14	T19	1600046
CPR:5	CHEMICAL	GENE-Y	9	4	Some 5-HT3 antagonists have gene agonist activity (for example, chemical, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a gene antagonist.	T14	T27	1600046
CPR:6	CHEMICAL	GENE-Y	9	1	Some gene antagonists have 5-HT4 agonist activity (for example, chemical, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	T14	T26	1600046
NA	CHEMICAL	GENE-Y	10	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, chemical) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a gene antagonist.	T15	T19	1600046
CPR:5	CHEMICAL	GENE-Y	10	4	Some 5-HT3 antagonists have gene agonist activity (for example, renzapride, chemical) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a gene antagonist.	T15	T27	1600046
CPR:6	CHEMICAL	GENE-Y	10	1	Some gene antagonists have 5-HT4 agonist activity (for example, renzapride, chemical) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.	T15	T26	1600046
NA	CHEMICAL	GENE-N	6	1	A gene to niacin (chemical) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	T3	T9	16018973
NA	CHEMICAL	GENE-N	5	1	A gene to chemical (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined.	T2	T9	16018973
NA	CHEMICAL	GENE-Y	12	7	We present our studies to demonstrate that gene, but not HM74, binds chemical at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing gene.	T1	T11	16018973
NA	CHEMICAL	GENE-Y	12	7	We present our studies to demonstrate that gene, but not HM74, binds chemical at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing gene.	T1	T7	16018973
NA	CHEMICAL	GENE-N	12	7	We present our studies to demonstrate that gene, but not HM74, binds chemical at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing gene.	T1	T11	16018973
NA	CHEMICAL	GENE-N	12	7	We present our studies to demonstrate that gene, but not HM74, binds chemical at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing gene.	T1	T7	16018973
NA	CHEMICAL	GENE-N	12	7	We present our studies to demonstrate that geneA, but not gene, binds chemical at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing geneA.	T1	T8	16018973
NA	CHEMICAL	GENE-Y	12	7	We present our studies to demonstrate that geneA, but not gene, binds chemical at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing geneA.	T1	T8	16018973
CPR:3	CHEMICAL	GENE-N	12	19	We present our studies to demonstrate that HM74A, but not HM74, binds chemical at high affinities and effectively mediates gene signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.	T1	T10	16018973
NA	CHEMICAL	GENE-Y	16	1	Furthermore, gene, but not HM74, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by chemical.	T4	T12	16018973
NA	CHEMICAL	GENE-N	16	1	Furthermore, gene, but not HM74, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by chemical.	T4	T12	16018973
NA	CHEMICAL	GENE-N	16	1	Furthermore, geneA, but not gene, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by chemical.	T4	T13	16018973
NA	CHEMICAL	GENE-Y	16	1	Furthermore, geneA, but not gene, expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by chemical.	T4	T13	16018973
NA	CHEMICAL	GENE-Y	18	7	Our results provided direct evidence indicating that gene, but not HM74, was sufficient to mediate anti-lipolytic effect of chemical in adipose tissue.	T5	T14	16018973
NA	CHEMICAL	GENE-N	18	7	Our results provided direct evidence indicating that gene, but not HM74, was sufficient to mediate anti-lipolytic effect of chemical in adipose tissue.	T5	T14	16018973
NA	CHEMICAL	GENE-N	18	7	Our results provided direct evidence indicating that geneA, but not gene, was sufficient to mediate anti-lipolytic effect of chemical in adipose tissue.	T5	T15	16018973
NA	CHEMICAL	GENE-Y	18	7	Our results provided direct evidence indicating that geneA, but not gene, was sufficient to mediate anti-lipolytic effect of chemical in adipose tissue.	T5	T15	16018973
NA	CHEMICAL	GENE-Y	13	31	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (chemical dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (gene) gene-disrupted mutant produced an increased level of succinate.	T16	T36	16232421
NA	CHEMICAL	GENE-Y	13	12	When cultured in YPD medium containing 15% glucose under aerobic conditions, the gene (chemical dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	T16	T33	16232421
NA	CHEMICAL	GENE-Y	13	30	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (chemical dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the gene (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	T16	T35	16232421
CPR:9	CHEMICAL	GENE-Y	23	13	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (gene) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the SDH1 (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T17	T34	16232421
NA	CHEMICAL	GENE-Y	23	13	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (gene) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the SDH1 (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T18	T34	16232421
NA	CHEMICAL	GENE-Y	23	13	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (gene) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the SDH1 (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T19	T34	16232421
CPR:9	CHEMICAL	GENE-Y	23	12	When cultured in YPD medium containing 15% glucose under aerobic conditions, the gene (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the SDH1 (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T17	T33	16232421
NA	CHEMICAL	GENE-Y	23	12	When cultured in YPD medium containing 15% glucose under aerobic conditions, the gene (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the SDH1 (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T18	T33	16232421
NA	CHEMICAL	GENE-Y	23	12	When cultured in YPD medium containing 15% glucose under aerobic conditions, the gene (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the SDH1 (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T19	T33	16232421
NA	CHEMICAL	GENE-Y	23	30	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the gene (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T17	T35	16232421
NA	CHEMICAL	GENE-Y	23	30	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the gene (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T18	T35	16232421
CPR:9	CHEMICAL	GENE-Y	23	30	When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of chemical than the wild-type strain, while the gene (chemical dehydrogenase) gene-disrupted mutant produced an increased level of chemical.	T19	T35	16232421
NA	CHEMICAL	GENE-Y	7	13	When cultured in YPD medium containing 15% chemical under aerobic conditions, the KGD1 (gene) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	T15	T34	16232421
NA	CHEMICAL	GENE-Y	7	31	When cultured in YPD medium containing 15% chemical under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (gene) gene-disrupted mutant produced an increased level of succinate.	T15	T36	16232421
NA	CHEMICAL	GENE-Y	7	12	When cultured in YPD medium containing 15% chemical under aerobic conditions, the gene (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	T15	T33	16232421
NA	CHEMICAL	GENE-Y	7	30	When cultured in YPD medium containing 15% chemical under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the gene (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.	T15	T35	16232421
CPR:9	CHEMICAL	GENE-Y	15	6	On the other hand, the FUM1 (gene) gene disrupted mutant produced significantly higher levels of chemical but did not form malate at all.	T20	T38	16232421
CPR:9	CHEMICAL	GENE-Y	15	5	On the other hand, the gene (fumarase) gene disrupted mutant produced significantly higher levels of chemical but did not form malate at all.	T20	T37	16232421
NA	CHEMICAL	GENE-Y	20	6	On the other hand, the FUM1 (gene) gene disrupted mutant produced significantly higher levels of fumarate but did not form chemical at all.	T21	T38	16232421
NA	CHEMICAL	GENE-Y	20	5	On the other hand, the gene (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form chemical at all.	T21	T37	16232421
NA	CHEMICAL	GENE-Y	14	30	When the growth condition was shifted from aerobic to anaerobic, the increased level of chemical in SDH1 disruptants was no longer observed, whereas the decreased level of chemical in the gene diruptant was still observed.	T3	T29	16232421
CPR:9	CHEMICAL	GENE-Y	14	30	When the growth condition was shifted from aerobic to anaerobic, the increased level of chemical in SDH1 disruptants was no longer observed, whereas the decreased level of chemical in the gene diruptant was still observed.	T4	T29	16232421
CPR:9	CHEMICAL	GENE-Y	14	16	When the growth condition was shifted from aerobic to anaerobic, the increased level of chemical in gene disruptants was no longer observed, whereas the decreased level of chemical in the KGD1 diruptant was still observed.	T3	T28	16232421
NA	CHEMICAL	GENE-Y	14	16	When the growth condition was shifted from aerobic to anaerobic, the increased level of chemical in gene disruptants was no longer observed, whereas the decreased level of chemical in the KGD1 diruptant was still observed.	T4	T28	16232421
CPR:9	CHEMICAL	GENE-N	15	6	A double mutant of the two gene isozyme genes (OSM1 and FRDS) showed a chemical productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	T6	T30	16232421
CPR:9	CHEMICAL	GENE-Y	15	10	A double mutant of the two fumarate reductase isozyme genes (gene and FRDS) showed a chemical productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	T6	T31	16232421
CPR:9	CHEMICAL	GENE-Y	15	12	A double mutant of the two fumarate reductase isozyme genes (OSM1 and gene) showed a chemical productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	T6	T32	16232421
NA	CHEMICAL	GENE-Y	6	10	A double mutant of the two chemical reductase isozyme genes (gene and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	T5	T31	16232421
NA	CHEMICAL	GENE-Y	6	12	A double mutant of the two chemical reductase isozyme genes (OSM1 and gene) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.	T5	T32	16232421
NA	CHEMICAL	GENE-N	29	6	A double mutant of the two gene isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in chemical-buffered solution.	T8	T30	16232421
NA	CHEMICAL	GENE-Y	29	10	A double mutant of the two fumarate reductase isozyme genes (gene and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in chemical-buffered solution.	T8	T31	16232421
NA	CHEMICAL	GENE-Y	29	12	A double mutant of the two fumarate reductase isozyme genes (OSM1 and gene) showed a succinate productivity of 50% as compared to the parent when cells were incubated in chemical-buffered solution.	T8	T32	16232421
NA	CHEMICAL	GENE-Y	6	9	As examples, ketorolac, flurbiprofen, ketoprofen and chemical have increased gene selectivity when compared with naproxen and ibuprofen.	T4	T9	16262557
NA	CHEMICAL	GENE-Y	3	9	As examples, ketorolac, chemical, ketoprofen and indomethacin have increased gene selectivity when compared with naproxen and ibuprofen.	T2	T9	16262557
NA	CHEMICAL	GENE-Y	4	9	As examples, ketorolac, flurbiprofen, chemical and indomethacin have increased gene selectivity when compared with naproxen and ibuprofen.	T3	T9	16262557
NA	CHEMICAL	GENE-Y	2	9	As examples, chemical, flurbiprofen, ketoprofen and indomethacin have increased gene selectivity when compared with naproxen and ibuprofen.	T1	T9	16262557
NA	CHEMICAL	GENE-Y	16	9	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased gene selectivity when compared with naproxen and chemical.	T6	T9	16262557
NA	CHEMICAL	GENE-Y	14	9	As examples, ketorolac, flurbiprofen, ketoprofen and indomethacin have increased gene selectivity when compared with chemical and ibuprofen.	T5	T9	16262557
NA	CHEMICAL	GENE-N	0	4	chemical reductase polymorphism (MTHFR gene) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	T1	T28	16268464
NA	CHEMICAL	GENE-Y	0	3	chemical reductase polymorphism (gene C677T) is an established determinant of homocysteine plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	T1	T27	16268464
NA	CHEMICAL	GENE-Y	10	0	gene polymorphism (MTHFR C677T) is an established determinant of chemical plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	T11	T13	16268464
NA	CHEMICAL	GENE-N	10	4	Methylenetetrahydrofolate reductase polymorphism (MTHFR gene) is an established determinant of chemical plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	T11	T28	16268464
NA	CHEMICAL	GENE-Y	10	3	Methylenetetrahydrofolate reductase polymorphism (gene C677T) is an established determinant of chemical plasma level (t-Hcys) while its association with coronary artery disease (CAD) seems to be more limited.	T11	T27	16268464
NA	CHEMICAL	GENE-Y	13	0	gene polymorphism (MTHFR C677T) is an established determinant of homocysteine plasma level (t-chemical) while its association with coronary artery disease (CAD) seems to be more limited.	T3	T13	16268464
NA	CHEMICAL	GENE-N	13	4	Methylenetetrahydrofolate reductase polymorphism (MTHFR gene) is an established determinant of homocysteine plasma level (t-chemical) while its association with coronary artery disease (CAD) seems to be more limited.	T3	T28	16268464
NA	CHEMICAL	GENE-Y	13	3	Methylenetetrahydrofolate reductase polymorphism (gene C677T) is an established determinant of homocysteine plasma level (t-chemical) while its association with coronary artery disease (CAD) seems to be more limited.	T3	T27	16268464
NA	CHEMICAL	GENE-N	9	21	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and C776G of gene (TCN) to both t-Hcys and CAD needs to be evaluated further.	T4	T25	16268464
NA	CHEMICAL	GENE-N	9	21	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and C776G of gene (TCN) to both t-Hcys and CAD needs to be evaluated further.	T5	T25	16268464
NA	CHEMICAL	GENE-N	9	7	In contrast, the association of the substitutions gene of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T4	T18	16268464
NA	CHEMICAL	GENE-N	9	7	In contrast, the association of the substitutions gene of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T5	T18	16268464
NA	CHEMICAL	GENE-N	9	19	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and gene of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T4	T24	16268464
NA	CHEMICAL	GENE-N	9	19	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and gene of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T5	T24	16268464
NA	CHEMICAL	GENE-Y	9	17	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (gene) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T4	T23	16268464
NA	CHEMICAL	GENE-Y	9	17	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (gene) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T5	T23	16268464
NA	CHEMICAL	GENE-N	9	12	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), gene of chemical synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T4	T21	16268464
NA	CHEMICAL	GENE-N	9	12	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), gene of chemical synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T5	T21	16268464
NA	CHEMICAL	GENE-N	9	22	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and C776G of transcobalamin (gene) to both t-Hcys and CAD needs to be evaluated further.	T4	T26	16268464
NA	CHEMICAL	GENE-N	9	22	In contrast, the association of the substitutions A2756G of chemical synthase (MTR), A66G of chemical synthase reductase (MTRR) and C776G of transcobalamin (gene) to both t-Hcys and CAD needs to be evaluated further.	T5	T26	16268464
NA	CHEMICAL	GENE-Y	9	11	In contrast, the association of the substitutions A2756G of chemical synthase (gene), A66G of chemical synthase reductase (geneR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T4	T20	16268464
NA	CHEMICAL	GENE-Y	9	11	In contrast, the association of the substitutions A2756G of chemical synthase (gene), A66G of chemical synthase reductase (geneR) and C776G of transcobalamin (TCN) to both t-Hcys and CAD needs to be evaluated further.	T5	T20	16268464
NA	CHEMICAL	GENE-Y	25	14	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of gene (MTRR) and C776G of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T22	16268464
NA	CHEMICAL	GENE-Y	25	9	In contrast, the association of the substitutions A2756G of gene (MTR), A66G of gene reductase (MTRR) and C776G of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T19	16268464
NA	CHEMICAL	GENE-N	25	21	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of gene (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T25	16268464
NA	CHEMICAL	GENE-N	25	7	In contrast, the association of the substitutions gene of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T18	16268464
NA	CHEMICAL	GENE-N	25	19	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and gene of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T24	16268464
NA	CHEMICAL	GENE-Y	25	17	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (gene) and C776G of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T23	16268464
NA	CHEMICAL	GENE-N	25	12	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), gene of methionine synthase reductase (MTRR) and C776G of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T21	16268464
NA	CHEMICAL	GENE-N	25	22	In contrast, the association of the substitutions A2756G of methionine synthase (MTR), A66G of methionine synthase reductase (MTRR) and C776G of transcobalamin (gene) to both t-chemical and CAD needs to be evaluated further.	T6	T26	16268464
NA	CHEMICAL	GENE-Y	25	11	In contrast, the association of the substitutions A2756G of methionine synthase (gene), A66G of methionine synthase reductase (geneR) and C776G of transcobalamin (TCN) to both t-chemical and CAD needs to be evaluated further.	T6	T20	16268464
NA	CHEMICAL	GENE-Y	0	23	t-chemical was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of MTRRAA and gene 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).	T10	T30	16268464
NA	CHEMICAL	GENE-Y	0	21	t-chemical was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of geneAA and MTHFR 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).	T10	T29	16268464
NA	CHEMICAL	GENE-Y	3	7	In multivariate analysis, t-chemical > median and geneAA genotype were two significant independent predictors of CAD with respective odds ratios of 3.1 (95 % CI: 1.8-5.1, P < 0.0001) and 4.5 (95% CI: 1.5-13.1, P = 0.0051).	T2	T16	16268464
NA	CHEMICAL	GENE-N	10	13	Vitamin E and probucol significantly suppressed an increase in plasma total-chemical (total-C) and gene chemical compared to HC-control group.	T12	T31	16292755
NA	CHEMICAL	GENE-N	10	13	Vitamin E and probucol significantly suppressed an increase in plasma total-chemical (total-C) and gene chemical compared to HC-control group.	T13	T31	16292755
CPR:4	CHEMICAL	GENE-N	0	13	chemical and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and gene cholesterol compared to HC-control group.	T10	T31	16292755
CPR:4	CHEMICAL	GENE-N	3	13	Vitamin E and chemical significantly suppressed an increase in plasma total-cholesterol (total-C) and gene cholesterol compared to HC-control group.	T11	T31	16292755
NA	CHEMICAL	GENE-N	3	2	However, plasma gene-chemical (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.	T14	T32	16292755
NA	CHEMICAL	GENE-Y	3	11	However, plasma high-density lipoprotein-chemical (HDL-C) and HDL-C/total-C ratio levels and plasma gene activity were only significantly higher in vitamin E group after 8 weeks.	T14	T35	16292755
NA	CHEMICAL	GENE-N	3	4	However, plasma high-density lipoprotein-chemical (gene-C) and gene-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.	T14	T33	16292755
NA	CHEMICAL	GENE-N	3	4	However, plasma high-density lipoprotein-chemical (gene-C) and gene-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.	T14	T34	16292755
CPR:3	CHEMICAL	GENE-N	18	2	However, plasma gene-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in chemical group after 8 weeks.	T15	T32	16292755
CPR:3	CHEMICAL	GENE-Y	18	11	However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma gene activity were only significantly higher in chemical group after 8 weeks.	T15	T35	16292755
CPR:3	CHEMICAL	GENE-N	18	4	However, plasma high-density lipoprotein-cholesterol (gene-C) and gene-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in chemical group after 8 weeks.	T15	T33	16292755
CPR:3	CHEMICAL	GENE-N	18	4	However, plasma high-density lipoprotein-cholesterol (gene-C) and gene-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in chemical group after 8 weeks.	T15	T34	16292755
NA	CHEMICAL	GENE-Y	8	18	Hepatic ACAT activity was significantly lower in both chemical and probucol groups than in HC-control group, while gene activity was the highest only in the probucol group.	T16	T37	16292755
CPR:4	CHEMICAL	GENE-Y	8	1	Hepatic gene activity was significantly lower in both chemical and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.	T16	T36	16292755
NA	CHEMICAL	GENE-Y	11	18	Hepatic ACAT activity was significantly lower in both vitamin E and chemical groups than in HC-control group, while gene activity was the highest only in the chemical group.	T17	T37	16292755
CPR:3	CHEMICAL	GENE-Y	11	18	Hepatic ACAT activity was significantly lower in both vitamin E and chemical groups than in HC-control group, while gene activity was the highest only in the chemical group.	T19	T37	16292755
CPR:4	CHEMICAL	GENE-Y	11	1	Hepatic gene activity was significantly lower in both vitamin E and chemical groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the chemical group.	T17	T36	16292755
NA	CHEMICAL	GENE-Y	11	1	Hepatic gene activity was significantly lower in both vitamin E and chemical groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the chemical group.	T19	T36	16292755
NA	CHEMICAL	GENE-Y	18	1	Hepatic gene activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while chemical reductase activity was the highest only in the probucol group.	T18	T36	16292755
CPR:4	CHEMICAL	GENE-Y	13	4	Hepatic mRNA expressions of gene and apo C-III were significantly lower in chemical group than in other groups.	T2	T27	16292755
CPR:4	CHEMICAL	GENE-Y	13	7	Hepatic mRNA expressions of apo B-100 and gene were significantly lower in chemical group than in other groups.	T2	T28	16292755
NA	CHEMICAL	GENE-N	19	9	Vitamin E supplementation was found to alter the plasma gene-C-related factors; meanwhile, probucol supplementation was very effective in enhancing chemical metabolism, except for a negative effect that reduced plasma gene-C concentration.	T5	T29	16292755
NA	CHEMICAL	GENE-N	19	9	Vitamin E supplementation was found to alter the plasma gene-C-related factors; meanwhile, probucol supplementation was very effective in enhancing chemical metabolism, except for a negative effect that reduced plasma gene-C concentration.	T5	T30	16292755
NA	CHEMICAL	GENE-N	0	9	chemical supplementation was found to alter the plasma gene-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma gene-C concentration.	T3	T29	16292755
NA	CHEMICAL	GENE-N	0	9	chemical supplementation was found to alter the plasma gene-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma gene-C concentration.	T3	T30	16292755
NA	CHEMICAL	GENE-N	12	9	Vitamin E supplementation was found to alter the plasma gene-C-related factors; meanwhile, chemical supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma gene-C concentration.	T4	T29	16292755
CPR:4	CHEMICAL	GENE-N	12	9	Vitamin E supplementation was found to alter the plasma gene-C-related factors; meanwhile, chemical supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma gene-C concentration.	T4	T30	16292755
CPR:6	CHEMICAL	GENE-Y	25	20	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel gene antagonists, such as maraviroc (chemical).	T3	T13	16298345
CPR:6	CHEMICAL	GENE-N	25	20	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel gene antagonists, such as maraviroc (chemical).	T3	T13	16298345
CPR:6	CHEMICAL	GENE-Y	24	20	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel gene antagonists, such as chemical (UK-427,857).	T2	T13	16298345
CPR:6	CHEMICAL	GENE-N	24	20	The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel gene antagonists, such as chemical (UK-427,857).	T2	T13	16298345
NA	CHEMICAL	GENE-Y	19	21	To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and chemical with gene.	T5	T17	16298345
NA	CHEMICAL	GENE-Y	19	7	To do this we cloned and expressed gene from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and chemical with human recombinant gene.	T5	T16	16298345
NA	CHEMICAL	GENE-N	19	7	To do this we cloned and expressed gene from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and chemical with human recombinant gene.	T5	T16	16298345
NA	CHEMICAL	GENE-Y	17	21	To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [chemical]-MIP-1beta and [3H]-maraviroc with gene.	T4	T17	16298345
NA	CHEMICAL	GENE-Y	17	7	To do this we cloned and expressed gene from rhesus macaque and compared the binding properties of [chemical]-MIP-1beta and [3H]-maraviroc with human recombinant gene.	T4	T16	16298345
NA	CHEMICAL	GENE-N	17	7	To do this we cloned and expressed gene from rhesus macaque and compared the binding properties of [chemical]-MIP-1beta and [3H]-maraviroc with human recombinant gene.	T4	T16	16298345
NA	CHEMICAL	GENE-Y	0	7	[chemical]-MIP-1beta bound with similar high affinity to gene from macaque (K(d) = 0.24 +/- 0.05 nM) and human (K(d) = 0.23 +/- 0.05 nM) and with similar kinetic properties.	T6	T18	16298345
NA	CHEMICAL	GENE-N	0	7	[chemical]-MIP-1beta bound with similar high affinity to gene from macaque (K(d) = 0.24 +/- 0.05 nM) and human (K(d) = 0.23 +/- 0.05 nM) and with similar kinetic properties.	T6	T18	16298345
NA	CHEMICAL	GENE-Y	0	6	chemical inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T7	T21	16298345
CPR:6	CHEMICAL	GENE-Y	0	6	chemical inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T7	T22	16298345
NA	CHEMICAL	GENE-N	0	6	chemical inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T7	T21	16298345
CPR:6	CHEMICAL	GENE-N	0	6	chemical inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T7	T22	16298345
NA	CHEMICAL	GENE-Y	31	6	Maraviroc inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular chemical release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T9	T21	16298345
NA	CHEMICAL	GENE-Y	31	6	Maraviroc inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular chemical release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T9	T22	16298345
NA	CHEMICAL	GENE-N	31	6	Maraviroc inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular chemical release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T9	T21	16298345
NA	CHEMICAL	GENE-N	31	6	Maraviroc inhibited binding of [125I]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular chemical release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T9	T22	16298345
NA	CHEMICAL	GENE-Y	4	6	Maraviroc inhibited binding of [chemical]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T8	T21	16298345
NA	CHEMICAL	GENE-Y	4	6	Maraviroc inhibited binding of [chemical]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T8	T22	16298345
NA	CHEMICAL	GENE-N	4	6	Maraviroc inhibited binding of [chemical]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T8	T21	16298345
NA	CHEMICAL	GENE-N	4	6	Maraviroc inhibited binding of [chemical]-MIP-1beta to gene from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through gene from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).	T8	T22	16298345
NA	CHEMICAL	GENE-Y	0	31	chemical bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from gene.	T10	T12	16298345
NA	CHEMICAL	GENE-Y	0	6	chemical bound with high affinity to gene from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque gene.	T10	T11	16298345
NA	CHEMICAL	GENE-N	0	6	chemical bound with high affinity to gene from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque gene.	T10	T11	16298345
CPR:6	CHEMICAL	GENE-Y	6	18	However, as with the human receptor, chemical was shown to be a high affinity, potent functional antagonist of gene thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.	T1	T14	16298345
CPR:6	CHEMICAL	GENE-Y	6	19	However, as with the human receptor, chemical was shown to be a high affinity, potent functional antagonist of macaque gene thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel gene antagonists.	T1	T15	16298345
CPR:6	CHEMICAL	GENE-N	6	19	However, as with the human receptor, chemical was shown to be a high affinity, potent functional antagonist of macaque gene thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel gene antagonists.	T1	T15	16298345
NA	CHEMICAL	GENE-Y	15	7	To better understand the molecular mechanism of gene on tumor suppression, we utilized a complementary chemical microarray composed of approximately 6,000 human cancer-related genes to determine the gene expression pattern altered by re-introduction of p75NTR into PC-3 prostate tumor cells.	T8	T37	16316409
NA	CHEMICAL	GENE-Y	15	35	To better understand the molecular mechanism of p75(NTR) on tumor suppression, we utilized a complementary chemical microarray composed of approximately 6,000 human cancer-related genes to determine the gene expression pattern altered by re-introduction of gene into PC-3 prostate tumor cells.	T8	T39	16316409
NA	CHEMICAL	GENE-Y	6	10	Immunoblot analysis further confirmed increased cellular chemical-binding protein I (gene) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.	T1	T10	16316409
NA	CHEMICAL	GENE-Y	6	23	Immunoblot analysis further confirmed increased cellular chemical-binding protein I (CRABPI) and IGFBP5 protein levels and decreased level of PLAUR protein with increasing gene protein expression.	T1	T13	16316409
NA	CHEMICAL	GENE-Y	6	12	Immunoblot analysis further confirmed increased cellular chemical-binding protein I (CRABPI) and gene protein levels and decreased level of PLAUR protein with increasing p75NTR protein expression.	T1	T11	16316409
NA	CHEMICAL	GENE-Y	6	19	Immunoblot analysis further confirmed increased cellular chemical-binding protein I (CRABPI) and IGFBP5 protein levels and decreased level of gene protein with increasing p75NTR protein expression.	T1	T12	16316409
NA	CHEMICAL	GENE-Y	15	1	As gene was elevated far more than any other genes, we observed that the retinoids, chemical and 9-cis retinoic acid, that bind gene, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T3	T14	16316409
NA	CHEMICAL	GENE-Y	15	1	As gene was elevated far more than any other genes, we observed that the retinoids, chemical and 9-cis retinoic acid, that bind gene, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T3	T15	16316409
NA	CHEMICAL	GENE-Y	15	32	As CRABPI was elevated far more than any other genes, we observed that the retinoids, chemical and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in gene PC-3 cells, but not in neo control PC-3 cells.	T3	T16	16316409
NA	CHEMICAL	GENE-Y	26	1	As gene was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind gene, promoted chemical-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T5	T14	16316409
NA	CHEMICAL	GENE-Y	26	1	As gene was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind gene, promoted chemical-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T5	T15	16316409
NA	CHEMICAL	GENE-Y	26	32	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted chemical-associated functional cell differentiation in gene PC-3 cells, but not in neo control PC-3 cells.	T5	T16	16316409
NA	CHEMICAL	GENE-Y	19	1	As gene was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and chemical, that bind gene, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T4	T14	16316409
NA	CHEMICAL	GENE-Y	19	1	As gene was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and chemical, that bind gene, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T4	T15	16316409
NA	CHEMICAL	GENE-Y	19	32	As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and chemical, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in gene PC-3 cells, but not in neo control PC-3 cells.	T4	T16	16316409
NA	CHEMICAL	GENE-Y	14	1	As gene was elevated far more than any other genes, we observed that the chemical, all-trans retinoic acid and 9-cis retinoic acid, that bind gene, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T2	T14	16316409
NA	CHEMICAL	GENE-Y	14	1	As gene was elevated far more than any other genes, we observed that the chemical, all-trans retinoic acid and 9-cis retinoic acid, that bind gene, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.	T2	T15	16316409
NA	CHEMICAL	GENE-Y	14	32	As CRABPI was elevated far more than any other genes, we observed that the chemical, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in gene PC-3 cells, but not in neo control PC-3 cells.	T2	T16	16316409
NA	CHEMICAL	GENE-Y	4	14	Subsequent examination of the chemical receptors (RARs) expression levels demonstrated an absence of gene in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where gene is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	T6	T19	16316409
NA	CHEMICAL	GENE-Y	4	14	Subsequent examination of the chemical receptors (RARs) expression levels demonstrated an absence of gene in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where gene is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	T6	T21	16316409
NA	CHEMICAL	GENE-Y	4	24	Subsequent examination of the chemical receptors (RARs) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the gene expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	T6	T20	16316409
NA	CHEMICAL	GENE-N	4	7	Subsequent examination of the chemical receptors gene) expression levels demonstrated an absence of RAR-beta in the neo control cells and re-expression in the p75NTR expressing cells, consistent with previous findings where RAR-beta is believed to play a critical role as a tumor suppressor gene that is lost during de-differentiation of prostate epithelial cells.	T6	T18	16316409
NA	CHEMICAL	GENE-Y	24	32	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of chemical that are available to newly up-regulated RAR-beta, gene, and RXR-beta.	T7	T35	16316409
NA	CHEMICAL	GENE-Y	24	31	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of chemical that are available to newly up-regulated gene, RXR-alpha, and RXR-beta.	T7	T34	16316409
NA	CHEMICAL	GENE-Y	24	34	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of chemical that are available to newly up-regulated RAR-beta, RXR-alpha, and gene.	T7	T36	16316409
CPR:3	CHEMICAL	GENE-Y	24	19	Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of gene for localized sequestration of chemical that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	T7	T33	16316409
NA	CHEMICAL	GENE-Y	24	4	Hence, re-expression of the gene appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of chemical that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.	T7	T32	16316409
CPR:3	CHEMICAL	GENE-N	13	9	Its special profile of actions, especially the rise in gene-cholesterol levels induced by chemical, is unique among the currently available pharmacological tools to treat lipid disorders.	T7	T21	16322797
NA	CHEMICAL	GENE-N	9	9	Its special profile of actions, especially the rise in gene-chemical levels induced by nicotinic acid, is unique among the currently available pharmacological tools to treat lipid disorders.	T4	T21	16322797
NA	CHEMICAL	GENE-N	19	2	Recently, a gene, termed GPR109A (HM74A in humans, PUMA-G in mice), was described and shown to mediate the chemical-induced antilipolytic effects in adipocytes.	T9	T22	16322797
NA	CHEMICAL	GENE-Y	19	5	Recently, a G-protein-coupled receptor, termed gene (HM74A in humans, PUMA-G in mice), was described and shown to mediate the chemical-induced antilipolytic effects in adipocytes.	T9	T23	16322797
NA	CHEMICAL	GENE-Y	19	9	Recently, a G-protein-coupled receptor, termed GPR109A (HM74A in humans, gene in mice), was described and shown to mediate the chemical-induced antilipolytic effects in adipocytes.	T9	T25	16322797
NA	CHEMICAL	GENE-Y	19	6	Recently, a G-protein-coupled receptor, termed GPR109A (gene in humans, PUMA-G in mice), was described and shown to mediate the chemical-induced antilipolytic effects in adipocytes.	T9	T24	16322797
NA	CHEMICAL	GENE-Y	13	9	In the present study, we show that mice lacking gene did not show chemical-induced flushing.	T11	T26	16322797
NA	CHEMICAL	GENE-Y	25	15	In addition, flushing in response to nicotinic acid was also abrogated in the absence of gene, and mice lacking prostaglandin D(2) (PGD(2)) and chemical (PGE(2)) receptors had reduced flushing responses.	T15	T27	16322797
NA	CHEMICAL	GENE-Y	21	15	In addition, flushing in response to nicotinic acid was also abrogated in the absence of gene, and mice lacking chemical (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.	T13	T27	16322797
NA	CHEMICAL	GENE-N	6	21	In addition, flushing in response to chemical was also abrogated in the absence of cyclooxygenase type 1, and mice lacking gene had reduced flushing responses.	T12	T28	16322797
NA	CHEMICAL	GENE-Y	6	15	In addition, flushing in response to chemical was also abrogated in the absence of gene, and mice lacking prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.	T12	T27	16322797
NA	CHEMICAL	GENE-Y	27	15	In addition, flushing in response to nicotinic acid was also abrogated in the absence of gene, and mice lacking prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (chemical) receptors had reduced flushing responses.	T16	T27	16322797
NA	CHEMICAL	GENE-Y	23	15	In addition, flushing in response to nicotinic acid was also abrogated in the absence of gene, and mice lacking prostaglandin D(2) (chemical) and prostaglandin E(2) (PGE(2)) receptors had reduced flushing responses.	T14	T27	16322797
NA	CHEMICAL	GENE-Y	27	4	The mouse orthologue of gene, PUMA-G, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated PUMA-G-deficient mice restored the chemical-induced flushing response.	T2	T29	16322797
NA	CHEMICAL	GENE-Y	27	5	The mouse orthologue of GPR109A, gene, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated gene-deficient mice restored the chemical-induced flushing response.	T2	T18	16322797
NA	CHEMICAL	GENE-Y	27	5	The mouse orthologue of GPR109A, gene, is highly expressed in macrophages and other immune cells, and transplantation of wild-type bone marrow into irradiated gene-deficient mice restored the chemical-induced flushing response.	T2	T19	16322797
NA	CHEMICAL	GENE-Y	7	5	Our data clearly indicate that gene mediates chemical-induced flushing and that this effect involves release of PGE(2) and PGD(2), most likely from immune cells of the skin.	T3	T20	16322797
NA	CHEMICAL	GENE-Y	17	5	Our data clearly indicate that gene mediates nicotinic acid-induced flushing and that this effect involves release of chemical and PGD(2), most likely from immune cells of the skin.	T5	T20	16322797
NA	CHEMICAL	GENE-Y	19	5	Our data clearly indicate that gene mediates nicotinic acid-induced flushing and that this effect involves release of PGE(2) and chemical, most likely from immune cells of the skin.	T6	T20	16322797
NA	CHEMICAL	GENE-Y	13	24	OBJECTIVES: The purpose of this research was to find out whether, in humans, chemical-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be gene (beta1AR) genotype-dependent.	T6	T17	16325050
NA	CHEMICAL	GENE-Y	13	25	OBJECTIVES: The purpose of this research was to find out whether, in humans, chemical-induced hemodynamic effects and increase in plasma-renin activity (PRA) might be beta1-adrenoceptor (gene) genotype-dependent.	T6	T18	16325050
NA	CHEMICAL	GENE-Y	13	19	OBJECTIVES: The purpose of this research was to find out whether, in humans, chemical-induced hemodynamic effects and increase in plasma-gene activity (PRA) might be beta1-adrenoceptor (beta1AR) genotype-dependent.	T6	T14	16325050
NA	CHEMICAL	GENE-Y	5	11	RESULTS: With regard to PRA, chemical increased PRA more potently in Arg389-gene versus Gly389-gene subjects.	T5	T24	16325050
NA	CHEMICAL	GENE-Y	5	11	RESULTS: With regard to PRA, chemical increased PRA more potently in Arg389-gene versus Gly389-gene subjects.	T5	T25	16325050
NA	CHEMICAL	GENE-Y	0	13	chemical markedly suppressed the dobutamine-induced PRA increase in Arg389- but only marginally in Gly389-gene subjects.	T7	T26	16325050
NA	CHEMICAL	GENE-Y	4	13	Bisoprolol markedly suppressed the chemical-induced PRA increase in Arg389- but only marginally in Gly389-gene subjects.	T8	T26	16325050
NA	CHEMICAL	GENE-Y	4	20	With regard to hemodynamics, chemical caused larger heart rate and contractility increases and diastolic blood pressure decreases in Arg389- versus Gly389-gene subjects.	T9	T11	16325050
NA	CHEMICAL	GENE-Y	0	18	chemical reduced dobutamine-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-gene subjects.	T1	T12	16325050
NA	CHEMICAL	GENE-Y	2	18	Bisoprolol reduced chemical-induced heart rate and contractility increases and diastolic blood pressure decreases more potently in Arg389- versus Gly389-gene subjects.	T2	T12	16325050
NA	CHEMICAL	GENE-N	24	37	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not chemical, in brain phospholipids by decreasing the activity of an arachidonic acid-selective gene.	T11	T31	16344985
NA	CHEMICAL	GENE-N	20	37	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of chemical, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an chemical-selective gene.	T12	T31	16344985
NA	CHEMICAL	GENE-N	20	37	RATIONALE: Several drugs used to treat bipolar disorder (lithium and carbamazepine), when administered chronically to rats, reduce the turnover of chemical, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an chemical-selective gene.	T7	T31	16344985
CPR:4	CHEMICAL	GENE-N	10	37	RATIONALE: Several drugs used to treat bipolar disorder (lithium and chemical), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective gene.	T19	T31	16344985
CPR:4	CHEMICAL	GENE-N	8	37	RATIONALE: Several drugs used to treat bipolar disorder (chemical and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective gene.	T16	T31	16344985
NA	CHEMICAL	GENE-N	12	19	Although chronic valproic acid produces similar effects on brain arachidonic acid and chemical turnover, it does not alter gene activity, suggesting that it targets a different enzyme in the turnover pathway.	T15	T32	16344985
NA	CHEMICAL	GENE-N	9	19	Although chronic valproic acid produces similar effects on brain chemical and docosahexaenoic acid turnover, it does not alter gene activity, suggesting that it targets a different enzyme in the turnover pathway.	T14	T32	16344985
NA	CHEMICAL	GENE-N	2	19	Although chronic chemical produces similar effects on brain arachidonic acid and docosahexaenoic acid turnover, it does not alter gene activity, suggesting that it targets a different enzyme in the turnover pathway.	T13	T32	16344985
NA	CHEMICAL	GENE-N	8	12	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal chemical synthetases (gene), we show in vitro that valproic acid is a non-competitive inhibitor of gene, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	T17	T34	16344985
NA	CHEMICAL	GENE-N	8	12	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal chemical synthetases (gene), we show in vitro that valproic acid is a non-competitive inhibitor of gene, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	T17	T35	16344985
NA	CHEMICAL	GENE-N	18	5	MATERIALS AND METHODS/RESULTS: By isolating gene (Acsl), we show in vitro that chemical is a non-competitive inhibitor of Acsl, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	T18	T33	16344985
NA	CHEMICAL	GENE-N	18	12	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (gene), we show in vitro that chemical is a non-competitive inhibitor of gene, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	T18	T34	16344985
CPR:4	CHEMICAL	GENE-N	18	12	MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (gene), we show in vitro that chemical is a non-competitive inhibitor of gene, as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	T18	T35	16344985
NA	CHEMICAL	GENE-N	7	1	Furthermore, gene did not produce chemical.	T5	T29	16344985
CPR:4	CHEMICAL	GENE-N	5	13	CONCLUSIONS: This study shows that chemical acts as a non-competitive inhibitor of gene, and that inhibition is substrate-selective.	T6	T30	16344985
NA	CHEMICAL	GENE-N	36	43	This article summarizes some findings of a research that I have pursued for the past 25 years, whose roots are immersed in the field of inherited metabolic disorders, and deal with different aspects of the vitamin chemical, starting with a patient with multiple gene deficiency (MCD).	T5	T13	16359899
CPR:3	CHEMICAL	GENE-Y	19	4	On the other hand, gene (HCS) mRNA levels were markedly low in the deficient animals, and increased upon chemical injection.	T1	T9	16359899
CPR:3	CHEMICAL	GENE-Y	19	6	On the other hand, holocarboxylase synthetase (gene) mRNA levels were markedly low in the deficient animals, and increased upon chemical injection.	T1	T10	16359899
NA	CHEMICAL	GENE-Y	6	4	On the other hand, gene (chemical) mRNA levels were markedly low in the deficient animals, and increased upon biotin injection.	T10	T9	16359899
NA	CHEMICAL	GENE-N	29	40	To probe into the "logic" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for chemical effects on specific genes and proteins, such as HCS and gene, and on their proteomes.	T3	T12	16359899
NA	CHEMICAL	GENE-Y	29	38	To probe into the "logic" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for chemical effects on specific genes and proteins, such as gene and hexokinases, and on their proteomes.	T3	T11	16359899
NA	CHEMICAL	GENE-Y	29	38	To probe into the "logic" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for chemical effects on specific genes and proteins, such as gene and hexokinases, and on their proteomes.	T3	T4	16359899
NA	CHEMICAL	GENE-N	38	40	To probe into the "logic" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for biotin effects on specific genes and proteins, such as chemical and gene, and on their proteomes.	T11	T12	16359899
NA	CHEMICAL	GENE-N	38	40	To probe into the "logic" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for biotin effects on specific genes and proteins, such as chemical and gene, and on their proteomes.	T4	T12	16359899
NA	CHEMICAL	GENE-N	16	4	The specific ligand for gene (SR-B), high density lipoprotein, significantly suppressed PS liposome-induced chemical production.	T14	T42	16371234
NA	CHEMICAL	GENE-N	16	9	The specific ligand for class B scavenger receptor (SR-B), gene, significantly suppressed PS liposome-induced chemical production.	T14	T44	16371234
NA	CHEMICAL	GENE-N	16	8	The specific ligand for class B scavenger receptor (gene), high density lipoprotein, significantly suppressed PS liposome-induced chemical production.	T14	T43	16371234
NA	CHEMICAL	GENE-N	4	0	gene (COX)-2 and membrane-bound chemical synthase-1 (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	T15	T45	16371234
NA	CHEMICAL	GENE-Y	4	7	Cyclooxygenase (COX)-2 and membrane-bound chemical synthase-1 (gene) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	T15	T19	16371234
NA	CHEMICAL	GENE-Y	4	1	Cyclooxygenase gene and membrane-bound chemical synthase-1 (mPGES-1) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	T15	T46	16371234
CPR:4	CHEMICAL	GENE-Y	9	12	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by chemical, a preferential gene inhibitor, but not by NS-398, a selective COX-2 inhibitor.	T4	T24	16371234
NA	CHEMICAL	GENE-Y	9	20	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by chemical, a preferential COX-1 inhibitor, but not by NS-398, a selective gene inhibitor.	T4	T25	16371234
NA	CHEMICAL	GENE-Y	17	12	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential gene inhibitor, but not by chemical, a selective COX-2 inhibitor.	T5	T24	16371234
CPR:4	CHEMICAL	GENE-Y	17	20	Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by chemical, a selective gene inhibitor.	T5	T25	16371234
NA	CHEMICAL	GENE-Y	3	12	Furthermore, PS liposome-induced chemical production was significantly suppressed by indomethacin, a preferential gene inhibitor, but not by NS-398, a selective COX-2 inhibitor.	T3	T24	16371234
NA	CHEMICAL	GENE-Y	3	20	Furthermore, PS liposome-induced chemical production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by NS-398, a selective gene inhibitor.	T3	T25	16371234
CPR:9	CHEMICAL	GENE-Y	25	17	These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially gene, plays the pivotal role in PS liposome-induced chemical production by microglia.	T6	T35	16371234
CPR:9	CHEMICAL	GENE-Y	25	15	These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with gene, especially mPGES-2, plays the pivotal role in PS liposome-induced chemical production by microglia.	T6	T34	16371234
CPR:9	CHEMICAL	GENE-Y	25	9	These observations strongly suggest that the up-regulation of terminal gene that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced chemical production by microglia.	T6	T33	16371234
NA	CHEMICAL	GENE-N	9	12	Although SR-BI plays an essential role in PS liposome-induced chemical production, other gene, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	T7	T37	16371234
NA	CHEMICAL	GENE-N	9	12	Although SR-BI plays an essential role in PS liposome-induced chemical production, other gene, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	T8	T37	16371234
NA	CHEMICAL	GENE-N	9	15	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly gene, could also promote chemical production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	T7	T38	16371234
NA	CHEMICAL	GENE-N	9	15	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly gene, could also promote chemical production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	T8	T38	16371234
NA	CHEMICAL	GENE-Y	9	1	Although gene plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	T7	T36	16371234
NA	CHEMICAL	GENE-Y	9	1	Although gene plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/p42 ERK after PS liposomes treatment.	T8	T36	16371234
NA	CHEMICAL	GENE-N	9	28	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/p42 gene after PS liposomes treatment.	T7	T41	16371234
NA	CHEMICAL	GENE-N	9	28	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/p42 gene after PS liposomes treatment.	T8	T41	16371234
NA	CHEMICAL	GENE-Y	9	27	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/gene ERK after PS liposomes treatment.	T7	T40	16371234
NA	CHEMICAL	GENE-Y	9	27	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including p44/gene ERK after PS liposomes treatment.	T8	T40	16371234
NA	CHEMICAL	GENE-Y	9	27	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including gene/p42 ERK after PS liposomes treatment.	T7	T39	16371234
NA	CHEMICAL	GENE-Y	9	27	Although SR-BI plays an essential role in PS liposome-induced chemical production, other PS-recognizing receptors, possibly PS-specific receptor, could also promote chemical production by transducing intracellular signals including gene/p42 ERK after PS liposomes treatment.	T8	T39	16371234
CPR:4	CHEMICAL	GENE-Y	22	33	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) chemical, sunitinib, and AG013736, which target multiple VEGFRs as well as gene.	T3	T24	16425993
CPR:4	CHEMICAL	GENE-N	22	29	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) chemical, sunitinib, and AG013736, which target multiple gene as well as PDGFR-beta.	T3	T23	16425993
CPR:4	CHEMICAL	GENE-N	22	19	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-gene inhibitors (MKIs) chemical, sunitinib, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.	T3	T21	16425993
CPR:4	CHEMICAL	GENE-Y	23	33	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, chemical, and AG013736, which target multiple VEGFRs as well as gene.	T4	T24	16425993
CPR:4	CHEMICAL	GENE-N	23	29	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, chemical, and AG013736, which target multiple gene as well as PDGFR-beta.	T4	T23	16425993
CPR:4	CHEMICAL	GENE-N	23	19	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-gene inhibitors (MKIs) sorafenib, chemical, and AG013736, which target multiple VEGFRs as well as PDGFR-beta.	T4	T21	16425993
CPR:4	CHEMICAL	GENE-Y	25	33	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and chemical, which target multiple VEGFRs as well as gene.	T5	T24	16425993
CPR:4	CHEMICAL	GENE-N	25	29	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-kinase inhibitors (MKIs) sorafenib, sunitinib, and chemical, which target multiple gene as well as PDGFR-beta.	T5	T23	16425993
CPR:4	CHEMICAL	GENE-N	25	19	Significant advances in the treatment of clear-cell RCC have been derived from agents that target these pathways, including the multiple-gene inhibitors (MKIs) sorafenib, sunitinib, and chemical, which target multiple VEGFRs as well as PDGFR-beta.	T5	T21	16425993
CPR:4	CHEMICAL	GENE-Y	0	27	chemical has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and gene.	T6	T29	16425993
CPR:4	CHEMICAL	GENE-Y	0	16	chemical has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target gene/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.	T6	T26	16425993
CPR:4	CHEMICAL	GENE-N	0	25	chemical has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of gene and PDGFR-beta.	T6	T28	16425993
CPR:4	CHEMICAL	GENE-Y	0	16	chemical has the added advantage of inhibiting multiple different Raf isoforms, which enables it to target TGF-alpha/gene signaling and may also enhance its inhibition of Vgene and PDGFR-beta.	T6	T27	16425993
CPR:4	CHEMICAL	GENE-Y	0	9	chemical has the added advantage of inhibiting multiple different gene isoforms, which enables it to target TGF-alpha/EGFR signaling and may also enhance its inhibition of VEGFR and PDGFR-beta.	T6	T25	16425993
NA	CHEMICAL	GENE-Y	32	19	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum gene (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic chemical synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T2	T9	16449956
NA	CHEMICAL	GENE-Y	32	47	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic chemical synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in gene gene (compound heterozygote with S225X and Ex1-1G>A).	T2	T14	16449956
NA	CHEMICAL	GENE-N	32	54	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic chemical synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and gene).	T2	T17	16449956
NA	CHEMICAL	GENE-Y	32	41	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic chemical synthetase activity (5.5% of control), lack of hepatic gene protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T2	T13	16449956
NA	CHEMICAL	GENE-N	32	52	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic chemical synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with gene and Ex1-1G>A).	T2	T16	16449956
NA	CHEMICAL	GENE-Y	32	23	The diagnosis of CTLN2 was confirmed by elevations of plasma citrulline level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (gene) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic chemical synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T2	T11	16449956
NA	CHEMICAL	GENE-Y	10	19	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum gene (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T1	T9	16449956
NA	CHEMICAL	GENE-Y	10	32	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic gene activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T1	T12	16449956
NA	CHEMICAL	GENE-Y	10	47	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in gene gene (compound heterozygote with S225X and Ex1-1G>A).	T1	T14	16449956
NA	CHEMICAL	GENE-N	10	54	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and gene).	T1	T17	16449956
NA	CHEMICAL	GENE-Y	10	41	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic gene protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T1	T13	16449956
NA	CHEMICAL	GENE-N	10	52	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (PSTI) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with gene and Ex1-1G>A).	T1	T16	16449956
NA	CHEMICAL	GENE-Y	10	23	The diagnosis of CTLN2 was confirmed by elevations of plasma chemical level (384.3 nmol/mL; normal 17-43 nmol/mL) and serum pancreatic secretory trypsin inhibitor (gene) (110 ng/mL; normal 4.6-12.2 ng/mL), decrease in hepatic argininosuccinate synthetase activity (5.5% of control), lack of hepatic citrin protein expression and mutations in SLC25A13 gene (compound heterozygote with S225X and Ex1-1G>A).	T1	T11	16449956
NA	CHEMICAL	GENE-N	21	15	Our previous studies showed that coadministration of cytochrome c and a 20-residue basic peptide, N-WASP181-200 (gene, pI=10.87) inhibits renal accumulation of chemical.	T4	T15	16488503
NA	CHEMICAL	GENE-Y	21	7	Our previous studies showed that coadministration of gene and a 20-residue basic peptide, N-WASP181-200 (NISHTKEKKKGKAKKKRLTK, pI=10.87) inhibits renal accumulation of chemical.	T4	T22	16488503
NA	CHEMICAL	GENE-Y	18	9	In this study, we examined effects of ligands of gene, an endocytic receptor involved in renal uptake of chemical, and basic peptides including N-WASP180-200 and its mutant peptides on chemical binding to isolated rat renal brush-border membrane (BBM).	T5	T19	16488503
NA	CHEMICAL	GENE-Y	18	9	In this study, we examined effects of ligands of gene, an endocytic receptor involved in renal uptake of chemical, and basic peptides including N-WASP180-200 and its mutant peptides on chemical binding to isolated rat renal brush-border membrane (BBM).	T6	T19	16488503
NA	CHEMICAL	GENE-Y	0	13	chemical binding to BBM was inhibited by megalin ligands, basic peptide fragments of gene, and N-WASP181-200 in a concentration-dependent manner.	T7	T21	16488503
NA	CHEMICAL	GENE-Y	0	7	chemical binding to BBM was inhibited by gene ligands, basic peptide fragments of cytochrome c, and N-WASP181-200 in a concentration-dependent manner.	T7	T20	16488503
NA	CHEMICAL	GENE-N	16	31	By substituting glycines for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on chemical binding to BBM was reduced, which may be related to a decrease in the gene content in the peptide.	T11	T23	16488503
NA	CHEMICAL	GENE-N	2	31	By substituting chemical for lysines in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the gene content in the peptide.	T9	T23	16488503
NA	CHEMICAL	GENE-N	4	31	By substituting glycines for chemical in N-WASP181-200 at positions 9 and 15, the inhibitory effect on gentamicin binding to BBM was reduced, which may be related to a decrease in the gene content in the peptide.	T10	T23	16488503
NA	CHEMICAL	GENE-Y	0	9	chemical binding to BBM treated with trypsin, in which gene completely disappeared, was significantly but not completely decreased compared with the native BBM.	T12	T25	16488503
NA	CHEMICAL	GENE-N	0	6	chemical binding to BBM treated with gene, in which megalin completely disappeared, was significantly but not completely decreased compared with the native BBM.	T12	T24	16488503
NA	CHEMICAL	GENE-N	18	6	In addition, treatment of BBM with gene led to a decrease in the inhibitory effect of N-WASP181-200 on chemical binding.	T1	T14	16488503
NA	CHEMICAL	GENE-Y	15	4	These observations support that gene ligands and basic peptides including N-WASP181-200 decrease renal accumulation of chemical by inhibiting its binding to BBM of proximal tubule cells, partly interacting with gene.	T2	T16	16488503
NA	CHEMICAL	GENE-Y	15	4	These observations support that gene ligands and basic peptides including N-WASP181-200 decrease renal accumulation of chemical by inhibiting its binding to BBM of proximal tubule cells, partly interacting with gene.	T2	T17	16488503
NA	CHEMICAL	GENE-N	20	3	In addition, the gene conformation may play an important role in the inhibitory effect of N-WASP181-200 on the binding of chemical to BBM.	T3	T18	16488503
NA	CHEMICAL	GENE-Y	11	4	Several variables associated to gene (TS), the biological target of chemical (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	T5	T10	16596248
NA	CHEMICAL	GENE-Y	11	6	Several variables associated to thymidylate synthase (gene), the biological target of chemical (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	T5	T11	16596248
NA	CHEMICAL	GENE-Y	4	6	Several variables associated to chemical synthase (gene), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	T3	T11	16596248
NA	CHEMICAL	GENE-Y	12	4	Several variables associated to gene (TS), the biological target of 5-fluorouracil (chemical) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	T1	T10	16596248
NA	CHEMICAL	GENE-Y	12	6	Several variables associated to thymidylate synthase (gene), the biological target of 5-fluorouracil (chemical) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	T1	T11	16596248
CPR:4	CHEMICAL	GENE-Y	23	1	Low gene expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with chemical.	T2	T9	16596248
NA	CHEMICAL	GENE-Y	6	13	Leishmania species express three phosphoribosyltransferase enzymes, chemical phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and gene (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T5	T12	16597468
NA	CHEMICAL	GENE-Y	6	9	Leishmania species express three phosphoribosyltransferase enzymes, chemical phosphoribosyltransferase (HGPRT), gene (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T5	T10	16597468
NA	CHEMICAL	GENE-N	6	4	Leishmania species express three gene enzymes, chemical gene (HGPRT), adenine gene (APRT), and xanthine gene (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T5	T14	16597468
NA	CHEMICAL	GENE-Y	6	8	Leishmania species express three phosphoribosyltransferase enzymes, chemical phosphoribosyltransferase (gene), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T5	T9	16597468
NA	CHEMICAL	GENE-Y	6	15	Leishmania species express three phosphoribosyltransferase enzymes, chemical phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (gene), which enable this genus to acquire purine nutrients from their hosts.	T5	T13	16597468
NA	CHEMICAL	GENE-Y	6	11	Leishmania species express three phosphoribosyltransferase enzymes, chemical phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (gene), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T5	T11	16597468
NA	CHEMICAL	GENE-Y	6	9	Leishmania species express three phosphoribosyltransferase enzymes, hypochemical-guanine phosphoribosyltransferase (HGPRT), gene (APRT), and chemical phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T3	T10	16597468
NA	CHEMICAL	GENE-N	6	4	Leishmania species express three gene enzymes, hypochemical-guanine gene (HGPRT), adenine gene (APRT), and chemical gene (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T3	T14	16597468
NA	CHEMICAL	GENE-Y	6	8	Leishmania species express three phosphoribosyltransferase enzymes, hypochemical-guanine phosphoribosyltransferase (gene), adenine phosphoribosyltransferase (APRT), and chemical phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T3	T9	16597468
NA	CHEMICAL	GENE-Y	6	15	Leishmania species express three phosphoribosyltransferase enzymes, hypochemical-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and chemical phosphoribosyltransferase (gene), which enable this genus to acquire purine nutrients from their hosts.	T3	T13	16597468
NA	CHEMICAL	GENE-Y	6	11	Leishmania species express three phosphoribosyltransferase enzymes, hypochemical-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (gene), and chemical phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T3	T11	16597468
NA	CHEMICAL	GENE-Y	9	6	Leishmania species express three phosphoribosyltransferase enzymes, gene (HGPRT), chemical phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T2	T15	16597468
NA	CHEMICAL	GENE-Y	9	13	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), chemical phosphoribosyltransferase (APRT), and gene (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T2	T12	16597468
NA	CHEMICAL	GENE-N	9	4	Leishmania species express three gene enzymes, hypoxanthine-guanine gene (HGPRT), chemical gene (APRT), and xanthine gene (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T2	T14	16597468
NA	CHEMICAL	GENE-Y	9	8	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (gene), chemical phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T2	T9	16597468
NA	CHEMICAL	GENE-Y	9	15	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), chemical phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (gene), which enable this genus to acquire purine nutrients from their hosts.	T2	T13	16597468
NA	CHEMICAL	GENE-Y	9	11	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), chemical phosphoribosyltransferase (gene), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire purine nutrients from their hosts.	T2	T11	16597468
NA	CHEMICAL	GENE-Y	22	6	Leishmania species express three phosphoribosyltransferase enzymes, gene (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire chemical nutrients from their hosts.	T4	T15	16597468
NA	CHEMICAL	GENE-Y	22	13	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and gene (XPRT), which enable this genus to acquire chemical nutrients from their hosts.	T4	T12	16597468
NA	CHEMICAL	GENE-Y	22	9	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), gene (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire chemical nutrients from their hosts.	T4	T10	16597468
NA	CHEMICAL	GENE-N	22	4	Leishmania species express three gene enzymes, hypoxanthine-guanine gene (HGPRT), adenine gene (APRT), and xanthine gene (XPRT), which enable this genus to acquire chemical nutrients from their hosts.	T4	T14	16597468
NA	CHEMICAL	GENE-Y	22	8	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (gene), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire chemical nutrients from their hosts.	T4	T9	16597468
NA	CHEMICAL	GENE-Y	22	15	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (APRT), and xanthine phosphoribosyltransferase (gene), which enable this genus to acquire chemical nutrients from their hosts.	T4	T13	16597468
NA	CHEMICAL	GENE-Y	22	11	Leishmania species express three phosphoribosyltransferase enzymes, hypoxanthine-guanine phosphoribosyltransferase (HGPRT), adenine phosphoribosyltransferase (gene), and xanthine phosphoribosyltransferase (XPRT), which enable this genus to acquire chemical nutrients from their hosts.	T4	T11	16597468
NA	CHEMICAL	GENE-N	14	10	These data support the hypothesis that none of the three gene is essential for chemical salvage or viability by itself and that chemical salvage occurs through multiple anabolic routes in both parasite life cycle stages.	T6	T16	16597468
NA	CHEMICAL	GENE-N	14	10	These data support the hypothesis that none of the three gene is essential for chemical salvage or viability by itself and that chemical salvage occurs through multiple anabolic routes in both parasite life cycle stages.	T7	T16	16597468
NA	CHEMICAL	GENE-N	23	25	In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and chemical-tRNA synthetases (gene) coded by the nuclear genome, and imported.	T6	T15	16597625
NA	CHEMICAL	GENE-N	6	11	We have explored here the human mt-chemical system in which a gene, highly similar to the Escherichia coli enzyme, recognizes a bizarre tRNA(Asp).	T7	T18	16597625
NA	CHEMICAL	GENE-N	13	16	This position is otherwise known as the site of a universally conserved major chemical identity element, gene, also known as a primordial identity signal.	T8	T20	16597625
NA	CHEMICAL	GENE-Y	7	23	Sequence alignments of various AspRSs allowed placing chemical-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of gene-tRNA(Asp) complex.	T2	T11	16597625
NA	CHEMICAL	GENE-N	7	4	Sequence alignments of various gene allowed placing chemical-269 at a position occupied by Asp-220, the residue contacting G73 in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.	T2	T9	16597625
NA	CHEMICAL	GENE-N	7	17	Sequence alignments of various AspRSs allowed placing chemical-269 at a position occupied by Asp-220, the residue contacting gene in the crystallographic structure of E. coli AspRS-tRNA(Asp) complex.	T2	T10	16597625
NA	CHEMICAL	GENE-N	4	17	Sequence alignments of various chemicalRSs allowed placing Gly-269 at a position occupied by chemical-220, the residue contacting gene in the crystallographic structure of E. coli chemicalRS-tRNA(chemical) complex.	T3	T10	16597625
NA	CHEMICAL	GENE-Y	5	7	Replacing this glycine by an chemical renders gene more discriminative to G73.	T5	T12	16597625
NA	CHEMICAL	GENE-N	5	12	Replacing this glycine by an chemical renders human mt-AspRS more discriminative to gene.	T5	T13	16597625
NA	CHEMICAL	GENE-Y	2	7	Replacing this chemical by an aspartate renders gene more discriminative to G73.	T4	T12	16597625
NA	CHEMICAL	GENE-N	2	12	Replacing this chemical by an aspartate renders human mt-AspRS more discriminative to gene.	T4	T13	16597625
NA	CHEMICAL	GENE-N	21	25	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the chemical-activated protein kinase (gene)/malonyl coenzyme A (CoA) fuel-sensing and signaling mechanism.	T1	T9	16642960
NA	CHEMICAL	GENE-N	25	21	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the gene (AMPK)/chemical (CoA) fuel-sensing and signaling mechanism.	T2	T8	16642960
NA	CHEMICAL	GENE-N	25	25	We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the adenosine monophosphate-activated protein kinase (gene)/chemical (CoA) fuel-sensing and signaling mechanism.	T2	T9	16642960
NA	CHEMICAL	GENE-N	9	19	Such dysregulation could be reflected by isolated increases in chemical or by concurrent changes in chemical and gene, both of which would alter intracellular fatty acid partitioning.	T3	T10	16642960
NA	CHEMICAL	GENE-N	9	19	Such dysregulation could be reflected by isolated increases in chemical or by concurrent changes in chemical and gene, both of which would alter intracellular fatty acid partitioning.	T4	T10	16642960
NA	CHEMICAL	GENE-N	16	13	The possibility is also raised that pharmacological agents and other factors that activate gene and/or decrease chemical could be therapeutic targets.	T5	T11	16642960
NA	CHEMICAL	GENE-N	10	20	In previous studies, we have demonstrated that chronic etorphine or chemical (DADLE) treatment of rats results in the reduction of gene binding activities as tolerance develops.	T13	T20	1665782
NA	CHEMICAL	GENE-N	8	20	In previous studies, we have demonstrated that chronic chemical or [D-Ala2,D-Leu5]enkephalin (DADLE) treatment of rats results in the reduction of gene binding activities as tolerance develops.	T10	T20	1665782
NA	CHEMICAL	GENE-N	11	20	In previous studies, we have demonstrated that chronic etorphine or [D-Ala2,D-Leu5]enkephalin (chemical) treatment of rats results in the reduction of gene binding activities as tolerance develops.	T16	T20	1665782
NA	CHEMICAL	GENE-N	2	13	As both chemical and DADLE are relatively non-specific opioid ligands, interacting with both gene, these studies could not determine whether down-regulation of a specific receptor type occurs.	T7	T24	1665782
NA	CHEMICAL	GENE-N	4	13	As both etorphine and chemical are relatively non-specific opioid ligands, interacting with both gene, these studies could not determine whether down-regulation of a specific receptor type occurs.	T8	T24	1665782
CPR:5	CHEMICAL	GENE-Y	14	11	Therefore, in the present studies, animals were rendered tolerant to the gene-selective agonist chemical (DPDPE), and receptor binding activities were measured.	T9	T25	1665782
CPR:5	CHEMICAL	GENE-Y	15	11	Therefore, in the present studies, animals were rendered tolerant to the gene-selective agonist [D-Pen2,D-Pen5]enkephalin (chemical), and receptor binding activities were measured.	T11	T25	1665782
NA	CHEMICAL	GENE-Y	7	1	When gene binding was determined by using chemical, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.	T15	T26	1665782
NA	CHEMICAL	GENE-Y	7	1	When gene binding was determined by using [3H]chemical, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of chemical treatment.	T1	T26	1665782
NA	CHEMICAL	GENE-Y	10	4	To our surprise, when gene binding was determined by using chemical (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.	T3	T18	1665782
NA	CHEMICAL	GENE-Y	29	4	To our surprise, when gene binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of chemical treatment.	T5	T18	1665782
NA	CHEMICAL	GENE-Y	11	4	To our surprise, when gene binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (chemical), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.	T4	T18	1665782
CPR:4	CHEMICAL	GENE-Y	5	9	Our conclusion is that chronic chemical treatment preferentially reduces gene binding activity.	T6	T19	1665782
NA	CHEMICAL	GENE-N	20	16	In vitro binding studies showed that both amoxapine and amitriptyline interact in the nanomolar range with gene receptors labelled by chemical in cortical membranes.	T7	T23	1666997
NA	CHEMICAL	GENE-N	9	16	In vitro binding studies showed that both amoxapine and chemical interact in the nanomolar range with gene receptors labelled by [3H]ketanserin in cortical membranes.	T6	T23	1666997
NA	CHEMICAL	GENE-N	7	16	In vitro binding studies showed that both chemical and amitriptyline interact in the nanomolar range with gene receptors labelled by [3H]ketanserin in cortical membranes.	T5	T23	1666997
NA	CHEMICAL	GENE-Y	5	15	By contrast, neither amoxapine nor chemical can be considered as possible ligands of 5-HT1A and gene receptors because their affinities for these sites are in the micromolar range (or even worse).	T10	T25	1666997
NA	CHEMICAL	GENE-Y	5	13	By contrast, neither amoxapine nor chemical can be considered as possible ligands of gene and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).	T10	T24	1666997
NA	CHEMICAL	GENE-Y	3	15	By contrast, neither chemical nor amitriptyline can be considered as possible ligands of 5-HT1A and gene receptors because their affinities for these sites are in the micromolar range (or even worse).	T9	T25	1666997
NA	CHEMICAL	GENE-Y	3	13	By contrast, neither chemical nor amitriptyline can be considered as possible ligands of gene and 5-HT1B receptors because their affinities for these sites are in the micromolar range (or even worse).	T9	T24	1666997
NA	CHEMICAL	GENE-N	16	12	Interestingly, amoxapine binds with a good affinity (IC50 = 0.30 microM) to gene receptors labelled by chemical in cortical membranes.	T13	T26	1666997
NA	CHEMICAL	GENE-N	1	12	Interestingly, chemical binds with a good affinity (IC50 = 0.30 microM) to gene receptors labelled by [3H]zacopride in cortical membranes.	T12	T26	1666997
NA	CHEMICAL	GENE-N	9	4	Complementary experiments using the gene-dependent Bezold-Jarisch reflex confirmed that chemical really acts in vivo as a gene antagonist (IC50 = 50 micrograms/kg i.v.	T14	T27	1666997
CPR:6	CHEMICAL	GENE-N	9	4	Complementary experiments using the gene-dependent Bezold-Jarisch reflex confirmed that chemical really acts in vivo as a gene antagonist (IC50 = 50 micrograms/kg i.v.	T14	T28	1666997
NA	CHEMICAL	GENE-N	2	7	), whereas chemical is essentially inactive on gene receptors.	T15	T29	1666997
NA	CHEMICAL	GENE-N	30	14	The second part of this study consisted of looking for possible changes in central gene 24 h after either a single or a repeated (for 14 days) treatment with chemical (10 mg/kg i.p.	T1	T18	1666997
NA	CHEMICAL	GENE-N	11	20	Finally we explored whether acute and/or chronic administration of amoxapine or chemical affected the levels of opioid peptides and the gene in various regions of the brain and the spinal cord.	T4	T22	1666997
NA	CHEMICAL	GENE-N	9	20	Finally we explored whether acute and/or chronic administration of chemical or amitriptyline affected the levels of opioid peptides and the gene in various regions of the brain and the spinal cord.	T3	T22	1666997
NA	CHEMICAL	GENE-Y	17	11	Competitive radioligand binding assays were performed using cells expressing either the gene (hSERT) or chemical (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T16	T36	16675639
NA	CHEMICAL	GENE-Y	17	15	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (gene) or chemical (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T16	T37	16675639
NA	CHEMICAL	GENE-Y	17	20	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or chemical (NE) transporter (gene) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T16	T39	16675639
NA	CHEMICAL	GENE-Y	12	17	Competitive radioligand binding assays were performed using cells expressing either the human chemical (5-HT) transporter (hSERT) or gene (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T14	T38	16675639
NA	CHEMICAL	GENE-Y	12	15	Competitive radioligand binding assays were performed using cells expressing either the human chemical (5-HT) transporter (gene) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T14	T37	16675639
NA	CHEMICAL	GENE-Y	12	20	Competitive radioligand binding assays were performed using cells expressing either the human chemical (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (gene) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T14	T39	16675639
NA	CHEMICAL	GENE-Y	13	17	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (chemical) transporter (hSERT) or gene (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T15	T38	16675639
NA	CHEMICAL	GENE-Y	13	15	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (chemical) transporter (gene) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T15	T37	16675639
NA	CHEMICAL	GENE-Y	13	20	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (chemical) transporter (hSERT) or norepinephrine (NE) transporter (gene) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T15	T39	16675639
CPR:4	CHEMICAL	GENE-Y	25	11	Competitive radioligand binding assays were performed using cells expressing either the gene (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for chemical of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T18	T36	16675639
CPR:4	CHEMICAL	GENE-Y	25	17	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or gene (hNET) with K(i) values for chemical of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T18	T38	16675639
CPR:4	CHEMICAL	GENE-Y	25	15	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (gene) or norepinephrine (NE) transporter (hNET) with K(i) values for chemical of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T18	T37	16675639
CPR:4	CHEMICAL	GENE-Y	25	20	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (gene) with K(i) values for chemical of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T18	T39	16675639
NA	CHEMICAL	GENE-Y	18	11	Competitive radioligand binding assays were performed using cells expressing either the gene (hSERT) or norepinephrine (chemical) transporter (hchemicalT) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T17	T36	16675639
NA	CHEMICAL	GENE-Y	18	15	Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (gene) or norepinephrine (chemical) transporter (hchemicalT) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively.	T17	T37	16675639
NA	CHEMICAL	GENE-Y	0	12	chemical showed weak binding affinity (62% inhibition at 100 microM) at the gene.	T19	T40	16675639
CPR:9	CHEMICAL	GENE-Y	2	10	Inhibition of chemical or [3H]NE uptake by DVS for the gene or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	T22	T41	16675639
NA	CHEMICAL	GENE-Y	2	12	Inhibition of chemical or [3H]NE uptake by DVS for the hSERT or gene produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	T22	T42	16675639
NA	CHEMICAL	GENE-Y	4	10	Inhibition of [3H]5-HT or chemical uptake by DVS for the gene or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	T23	T41	16675639
CPR:9	CHEMICAL	GENE-Y	4	12	Inhibition of [3H]5-HT or chemical uptake by DVS for the hSERT or gene produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	T23	T42	16675639
NA	CHEMICAL	GENE-Y	7	10	Inhibition of [3H]5-HT or [3H]NE uptake by chemical for the gene or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	T24	T41	16675639
NA	CHEMICAL	GENE-Y	7	12	Inhibition of [3H]5-HT or [3H]NE uptake by chemical for the hSERT or gene produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively.	T24	T42	16675639
NA	CHEMICAL	GENE-Y	18	13	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory gene autoreceptors, a gene antagonist, chemical (WAY-100635) (0.3 mg/kg s.c.	T4	T34	16675639
CPR:6	CHEMICAL	GENE-Y	18	13	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory gene autoreceptors, a gene antagonist, chemical (WAY-100635) (0.3 mg/kg s.c.	T4	T35	16675639
NA	CHEMICAL	GENE-Y	22	13	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory gene autoreceptors, a gene antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (chemical) (0.3 mg/kg s.c.	T5	T34	16675639
CPR:6	CHEMICAL	GENE-Y	22	13	To mimic chronic selective serotonin reuptake inhibitor treatment and to block the inhibitory gene autoreceptors, a gene antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (chemical) (0.3 mg/kg s.c.	T5	T35	16675639
NA	CHEMICAL	GENE-Y	4	13	To mimic chronic selective chemical reuptake inhibitor treatment and to block the inhibitory gene autoreceptors, a gene antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.	T3	T34	16675639
NA	CHEMICAL	GENE-Y	4	13	To mimic chronic selective chemical reuptake inhibitor treatment and to block the inhibitory gene autoreceptors, a gene antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclo hexanecarboxamide maleate salt (WAY-100635) (0.3 mg/kg s.c.	T3	T35	16675639
NA	CHEMICAL	GENE-Y	17	39	The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal chemical exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and metabolism, and in targets like gene.	T11	T20	16719540
NA	CHEMICAL	GENE-Y	12	14	To individualise fluorouracil administration before the first dose, assessment of the individual chemical dehydrogenase (gene) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of fluorouracil elimination.	T14	T22	16719540
NA	CHEMICAL	GENE-Y	2	12	To individualise chemical administration before the first dose, assessment of the individual gene (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of chemical elimination.	T13	T21	16719540
NA	CHEMICAL	GENE-Y	2	12	To individualise chemical administration before the first dose, assessment of the individual gene (DPD) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of chemical elimination.	T16	T21	16719540
NA	CHEMICAL	GENE-Y	2	14	To individualise chemical administration before the first dose, assessment of the individual dihydropyrimidine dehydrogenase (gene) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of chemical elimination.	T13	T22	16719540
NA	CHEMICAL	GENE-Y	2	14	To individualise chemical administration before the first dose, assessment of the individual dihydropyrimidine dehydrogenase (gene) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of chemical elimination.	T16	T22	16719540
NA	CHEMICAL	GENE-Y	18	6	A complete or partial loss of gene activity in 0.1 and 3-5% of Caucasians, respectively, leads to increased chemical exposure and toxicity.	T17	T23	16719540
NA	CHEMICAL	GENE-Y	24	4	Several methods to assess gene activity in patients have been proposed (genotyping, various phenotyping methods), but each of them has limitations, as has the chemical test dose approach.	T2	T24	16719540
NA	CHEMICAL	GENE-Y	5	13	Whether an adaptation of the chemical starting dose to the results of two gene activity tests before chemical administration a priori, and the adaptation of doses to chemical exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	T10	T19	16719540
NA	CHEMICAL	GENE-Y	5	13	Whether an adaptation of the chemical starting dose to the results of two gene activity tests before chemical administration a priori, and the adaptation of doses to chemical exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	T8	T19	16719540
NA	CHEMICAL	GENE-Y	5	13	Whether an adaptation of the chemical starting dose to the results of two gene activity tests before chemical administration a priori, and the adaptation of doses to chemical exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	T9	T19	16719540
NA	CHEMICAL	GENE-N	8	5	We investigated the relationship between gene expression and chemical activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	T6	T19	16741658
NA	CHEMICAL	GENE-N	5	31	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, gene (Pgp), p53, and bcl-2.	T7	T24	16741658
NA	CHEMICAL	GENE-N	5	31	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, gene (Pgp), p53, and bcl-2.	T8	T24	16741658
NA	CHEMICAL	GENE-Y	5	35	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), p53, and gene.	T7	T27	16741658
NA	CHEMICAL	GENE-Y	5	35	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), p53, and gene.	T8	T27	16741658
NA	CHEMICAL	GENE-Y	5	29	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of gene, bFGF, P-glycoprotein (Pgp), p53, and bcl-2.	T7	T22	16741658
NA	CHEMICAL	GENE-Y	5	29	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of gene, bFGF, P-glycoprotein (Pgp), p53, and bcl-2.	T8	T22	16741658
NA	CHEMICAL	GENE-Y	5	30	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, gene, P-glycoprotein (Pgp), p53, and bcl-2.	T7	T23	16741658
NA	CHEMICAL	GENE-Y	5	30	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, gene, P-glycoprotein (Pgp), p53, and bcl-2.	T8	T23	16741658
NA	CHEMICAL	GENE-N	5	32	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (gene), p53, and bcl-2.	T7	T25	16741658
NA	CHEMICAL	GENE-N	5	32	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (gene), p53, and bcl-2.	T8	T25	16741658
NA	CHEMICAL	GENE-Y	5	33	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), gene, and bcl-2.	T7	T26	16741658
NA	CHEMICAL	GENE-Y	5	33	Bladder tumors were treated with chemical for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of chemical were quantified and correlated with expression of aFGF, bFGF, P-glycoprotein (Pgp), gene, and bcl-2.	T8	T26	16741658
NA	CHEMICAL	GENE-Y	9	0	gene expression did not correlate with tumor sensitivity to chemical, whereas bFGF expression showed an inverse correlation (p < 0.01).	T3	T11	16741658
NA	CHEMICAL	GENE-Y	9	11	aFGF expression did not correlate with tumor sensitivity to chemical, whereas gene expression showed an inverse correlation (p < 0.01).	T3	T12	16741658
NA	CHEMICAL	GENE-Y	7	14	bFGF expression was a stronger predictor of chemical resistance compared to Pgp, p53, or gene.	T4	T16	16741658
NA	CHEMICAL	GENE-Y	7	0	gene expression was a stronger predictor of chemical resistance compared to Pgp, p53, or Bcl-2.	T4	T13	16741658
NA	CHEMICAL	GENE-N	7	11	bFGF expression was a stronger predictor of chemical resistance compared to gene, p53, or Bcl-2.	T4	T14	16741658
NA	CHEMICAL	GENE-Y	7	12	bFGF expression was a stronger predictor of chemical resistance compared to Pgp, gene, or Bcl-2.	T4	T15	16741658
NA	CHEMICAL	GENE-Y	9	7	CONCLUSION: These results support a role of gene in chemical resistance in human patient tumors.	T5	T17	16741658
NA	CHEMICAL	GENE-N	11	14	These hormones induce metamorphosis by controlling gene expression through binding to chemical receptors (gene).	T1	T18	16741870
NA	CHEMICAL	GENE-N	35	44	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic chemical-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a gene and stromelysin 3, a direct TH target gene in Xenopus laevis.	T6	T23	16741870
NA	CHEMICAL	GENE-N	35	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic chemical-Binding Protein (CTHBP)-gene, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T6	T22	16741870
NA	CHEMICAL	GENE-Y	35	49	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic chemical-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and gene, a direct TH target gene in Xenopus laevis.	T6	T24	16741870
NA	CHEMICAL	GENE-N	35	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic chemical-Binding Protein (gene)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T6	T21	16741870
NA	CHEMICAL	GENE-N	35	18	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine gene gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic chemical-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T6	T19	16741870
NA	CHEMICAL	GENE-N	12	34	Since metamorphosis depends on the acquisition of response of tadpole tissues to chemical, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: gene (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T3	T20	16741870
NA	CHEMICAL	GENE-N	12	44	Since metamorphosis depends on the acquisition of response of tadpole tissues to chemical, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a gene and stromelysin 3, a direct TH target gene in Xenopus laevis.	T3	T23	16741870
NA	CHEMICAL	GENE-N	12	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to chemical, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-gene, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T3	T22	16741870
NA	CHEMICAL	GENE-Y	12	49	Since metamorphosis depends on the acquisition of response of tadpole tissues to chemical, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and gene, a direct TH target gene in Xenopus laevis.	T3	T24	16741870
NA	CHEMICAL	GENE-N	12	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to chemical, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (gene)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T3	T21	16741870
NA	CHEMICAL	GENE-N	12	18	Since metamorphosis depends on the acquisition of response of tadpole tissues to chemical, we aimed to determine gene gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-pyruvate kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T3	T19	16741870
NA	CHEMICAL	GENE-N	38	34	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: gene (CTHBP)-M2-chemical kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T7	T20	16741870
NA	CHEMICAL	GENE-N	38	44	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-chemical kinase, a gene encoding a gene and stromelysin 3, a direct TH target gene in Xenopus laevis.	T7	T23	16741870
NA	CHEMICAL	GENE-Y	38	49	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-chemical kinase, a gene encoding a cytosolic TH binding protein and gene, a direct TH target gene in Xenopus laevis.	T7	T24	16741870
NA	CHEMICAL	GENE-N	38	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (gene)-M2-chemical kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T7	T21	16741870
NA	CHEMICAL	GENE-N	38	18	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine gene gene expression patterns in Necturus maculosus as well as the expression of two TH-related genes: Cytosolic Thyroid Hormone-Binding Protein (CTHBP)-M2-chemical kinase, a gene encoding a cytosolic TH binding protein and stromelysin 3, a direct TH target gene in Xenopus laevis.	T7	T19	16741870
NA	CHEMICAL	GENE-N	32	34	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: gene (CchemicalBP)-M2-pyruvate kinase, a gene encoding a cytosolic chemical binding protein and stromelysin 3, a direct chemical target gene in Xenopus laevis.	T5	T20	16741870
NA	CHEMICAL	GENE-N	32	34	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: gene (CchemicalBP)-M2-pyruvate kinase, a gene encoding a cytosolic chemical binding protein and stromelysin 3, a direct chemical target gene in Xenopus laevis.	T8	T20	16741870
NA	CHEMICAL	GENE-N	32	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: Cytosolic Thyroid Hormone-Binding Protein (CchemicalBP)-gene, a gene encoding a cytosolic chemical binding protein and stromelysin 3, a direct chemical target gene in Xenopus laevis.	T5	T22	16741870
NA	CHEMICAL	GENE-N	32	38	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: Cytosolic Thyroid Hormone-Binding Protein (CchemicalBP)-gene, a gene encoding a cytosolic chemical binding protein and stromelysin 3, a direct chemical target gene in Xenopus laevis.	T8	T22	16741870
NA	CHEMICAL	GENE-Y	32	49	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: Cytosolic Thyroid Hormone-Binding Protein (CchemicalBP)-M2-pyruvate kinase, a gene encoding a cytosolic chemical binding protein and gene, a direct chemical target gene in Xenopus laevis.	T5	T24	16741870
NA	CHEMICAL	GENE-Y	32	49	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine TR gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: Cytosolic Thyroid Hormone-Binding Protein (CchemicalBP)-M2-pyruvate kinase, a gene encoding a cytosolic chemical binding protein and gene, a direct chemical target gene in Xenopus laevis.	T8	T24	16741870
NA	CHEMICAL	GENE-N	32	18	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine gene gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: Cytosolic Thyroid Hormone-Binding Protein (CchemicalBP)-M2-pyruvate kinase, a gene encoding a cytosolic chemical binding protein and stromelysin 3, a direct chemical target gene in Xenopus laevis.	T5	T19	16741870
NA	CHEMICAL	GENE-N	32	18	Since metamorphosis depends on the acquisition of response of tadpole tissues to thyroid hormone, we aimed to determine gene gene expression patterns in Necturus maculosus as well as the expression of two chemical-related genes: Cytosolic Thyroid Hormone-Binding Protein (CchemicalBP)-M2-pyruvate kinase, a gene encoding a cytosolic chemical binding protein and stromelysin 3, a direct chemical target gene in Xenopus laevis.	T8	T19	16741870
NA	CHEMICAL	GENE-N	13	15	The tissue RA level is maintained through a cascade of metabolic reactions where chemical dehydrogenases (gene) catalyze the terminal reaction of RA biosynthesis from chemical, a rate-limiting step.	T6	T23	16763553
CPR:9	CHEMICAL	GENE-N	13	15	The tissue RA level is maintained through a cascade of metabolic reactions where chemical dehydrogenases (gene) catalyze the terminal reaction of RA biosynthesis from chemical, a rate-limiting step.	T8	T23	16763553
NA	CHEMICAL	GENE-N	2	13	The tissue chemical level is maintained through a cascade of metabolic reactions where gene (chemicalLDHs) catalyze the terminal reaction of chemical biosynthesis from retinal, a rate-limiting step.	T4	T22	16763553
CPR:9	CHEMICAL	GENE-N	2	13	The tissue chemical level is maintained through a cascade of metabolic reactions where gene (chemicalLDHs) catalyze the terminal reaction of chemical biosynthesis from retinal, a rate-limiting step.	T7	T22	16763553
NA	CHEMICAL	GENE-N	6	11	We showed that dietary supplement of chemical enhanced the expression of gene genes and the cellular RA content in vital organs such as brain, kidney, liver and heart.	T9	T24	16763553
NA	CHEMICAL	GENE-N	4	10	Consistently, the cholesterol-lowering agent (chemical) downregulated the expression of gene genes in several organs especially the liver and in cultured liver cells.	T12	T25	16763553
NA	CHEMICAL	GENE-N	2	10	Consistently, the chemical-lowering agent (pravastatin sodium) downregulated the expression of gene genes in several organs especially the liver and in cultured liver cells.	T11	T25	16763553
CPR:3	CHEMICAL	GENE-Y	1	20	Further, chemical metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of gene (SREBP-1c) that bound to the regulatory regions of these genes.	T14	T28	16763553
NA	CHEMICAL	GENE-N	1	10	Further, chemical metabolites, predominantly the oxysterols, the natural ligands for gene (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	T14	T26	16763553
CPR:3	CHEMICAL	GENE-Y	1	25	Further, chemical metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (gene) that bound to the regulatory regions of these genes.	T14	T29	16763553
NA	CHEMICAL	GENE-N	1	13	Further, chemical metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (gene), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	T14	T27	16763553
CPR:3	CHEMICAL	GENE-Y	5	20	Further, cholesterol metabolites, predominantly the chemical, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of gene (SREBP-1c) that bound to the regulatory regions of these genes.	T15	T28	16763553
NA	CHEMICAL	GENE-N	5	10	Further, cholesterol metabolites, predominantly the chemical, the natural ligands for gene (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	T15	T26	16763553
CPR:3	CHEMICAL	GENE-Y	5	25	Further, cholesterol metabolites, predominantly the chemical, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (gene) that bound to the regulatory regions of these genes.	T15	T29	16763553
NA	CHEMICAL	GENE-N	5	13	Further, cholesterol metabolites, predominantly the chemical, the natural ligands for liver X receptor (gene), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	T15	T27	16763553
NA	CHEMICAL	GENE-N	1	10	Further, cholechemical metabolites, predominantly the oxychemicals, the natural ligands for gene (LXR), induced these genes via upregulation of chemical regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	T16	T26	16763553
NA	CHEMICAL	GENE-Y	1	25	Further, cholechemical metabolites, predominantly the oxychemicals, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of chemical regulatory element binding protein-1c (gene) that bound to the regulatory regions of these genes.	T16	T29	16763553
NA	CHEMICAL	GENE-N	1	13	Further, cholechemical metabolites, predominantly the oxychemicals, the natural ligands for liver X receptor (gene), induced these genes via upregulation of chemical regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.	T16	T27	16763553
NA	CHEMICAL	GENE-Y	14	19	Brain abnormalities in +/rl are similar to psychotic brain and include a reduction in chemical de carboxylase 67 (gene), dendritic arbors and spine density in cortex and hippocampus, and abnormalities in synaptic function including long-term potentiation (LTP).	T2	T7	16769115
CPR:3	CHEMICAL	GENE-N	13	2	Hypermethlyation of gene can be induced by treating mice with chemical, and these mice display brain and behavioral abnormalities similar to +/rl.	T1	T11	16769115
NA	CHEMICAL	GENE-Y	18	23	The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by chemical type 1 receptor (gene) blocker.	T3	T12	16775509
NA	CHEMICAL	GENE-N	14	9	Animals with heart failure demonstrated reductions in both mitochondrial gene expression and myocardial high-energy chemical levels.	T4	T10	16775509
CPR:6	CHEMICAL	GENE-Y	16	14	Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the gene antagonist chemical.	T5	T11	16775509
NA	CHEMICAL	GENE-N	4	13	Since the effect of chemical is mediated via chemical receptors and gene, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	T6	T26	16782282
NA	CHEMICAL	GENE-N	4	13	Since the effect of chemical is mediated via chemical receptors and gene, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	T7	T26	16782282
NA	CHEMICAL	GENE-N	13	9	Since the effect of retinoic acid is mediated via gene and chemical X receptors, we investigated mRNA and protein expression of these receptors during injury-induced degeneration and regeneration.	T8	T25	16782282
NA	CHEMICAL	GENE-Y	9	14	Seven days after crush injury, transcript concentrations of all chemical receptors and of gene were significantly higher than in non-lesioned nerves.	T9	T28	16782282
NA	CHEMICAL	GENE-N	14	9	Seven days after crush injury, transcript concentrations of all gene and of chemical X receptor alpha were significantly higher than in non-lesioned nerves.	T10	T27	16782282
NA	CHEMICAL	GENE-Y	3	12	Protein levels of chemical receptor alpha, chemical receptor beta and gene were upregulated 4, 7 and 14 days after injury.	T12	T31	16782282
NA	CHEMICAL	GENE-Y	3	12	Protein levels of chemical receptor alpha, chemical receptor beta and gene were upregulated 4, 7 and 14 days after injury.	T13	T31	16782282
NA	CHEMICAL	GENE-Y	12	3	Protein levels of gene, retinoic acid receptor beta and chemical X receptor alpha were upregulated 4, 7 and 14 days after injury.	T14	T29	16782282
NA	CHEMICAL	GENE-Y	12	7	Protein levels of retinoic acid receptor alpha, gene and chemical X receptor alpha were upregulated 4, 7 and 14 days after injury.	T14	T30	16782282
NA	CHEMICAL	GENE-Y	5	10	In addition, we observed that chemical receptor alpha and gene appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that gene-staining co-localized with some regenerating axons.	T1	T21	16782282
NA	CHEMICAL	GENE-Y	5	10	In addition, we observed that chemical receptor alpha and gene appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that gene-staining co-localized with some regenerating axons.	T1	T22	16782282
NA	CHEMICAL	GENE-Y	10	5	In addition, we observed that gene and chemical X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that chemical X receptor alpha-staining co-localized with some regenerating axons.	T2	T20	16782282
NA	CHEMICAL	GENE-Y	10	5	In addition, we observed that gene and chemical X receptor alpha appeared in the cell nuclei of macrophages during the lesion-induced inflammatory reaction, and that chemical X receptor alpha-staining co-localized with some regenerating axons.	T3	T20	16782282
NA	CHEMICAL	GENE-N	10	17	Experiments with Schwann cell primary cultures revealed an effect of chemical on the expression of the gene ErbB3, suggesting that one function of chemical consists in the regulation of neuroglial interactions after peripheral nerve injury.	T4	T23	16782282
NA	CHEMICAL	GENE-N	10	17	Experiments with Schwann cell primary cultures revealed an effect of chemical on the expression of the gene ErbB3, suggesting that one function of chemical consists in the regulation of neuroglial interactions after peripheral nerve injury.	T5	T23	16782282
NA	CHEMICAL	GENE-Y	10	19	Experiments with Schwann cell primary cultures revealed an effect of chemical on the expression of the neuregulin receptor gene, suggesting that one function of chemical consists in the regulation of neuroglial interactions after peripheral nerve injury.	T4	T24	16782282
NA	CHEMICAL	GENE-Y	10	19	Experiments with Schwann cell primary cultures revealed an effect of chemical on the expression of the neuregulin receptor gene, suggesting that one function of chemical consists in the regulation of neuroglial interactions after peripheral nerve injury.	T5	T24	16782282
NA	CHEMICAL	GENE-Y	10	5	BACKGROUND: Activating mutations in the gene gene, which encodes a chemical kinase receptor, often cause medullary thyroid carcinoma (MTC).	T8	T20	16782438
CPR:4	CHEMICAL	GENE-N	2	4	We evaluated chemical, a gene inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.	T6	T19	16782438
NA	CHEMICAL	GENE-N	2	37	We evaluated chemical, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant gene.	T6	T21	16782438
NA	CHEMICAL	GENE-N	4	37	We evaluated imatinib, a chemical kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant gene.	T7	T21	16782438
CPR:4	CHEMICAL	GENE-N	1	4	RESULTS: chemical inhibited RET gene phosphorylation in a dose-dependent manner after 1.5 hours of exposure.	T12	T26	16782438
CPR:4	CHEMICAL	GENE-Y	1	3	RESULTS: chemical inhibited gene Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.	T12	T25	16782438
CPR:4	CHEMICAL	GENE-Y	1	3	CONCLUSIONS: chemical inhibits gene-mediated MTC cell growth affecting gene protein levels in vitro in a dose-dependent manner.	T3	T16	16782438
CPR:4	CHEMICAL	GENE-Y	1	3	CONCLUSIONS: chemical inhibits gene-mediated MTC cell growth affecting gene protein levels in vitro in a dose-dependent manner.	T3	T17	16782438
CPR:4	CHEMICAL	GENE-Y	3	7	The concentration of chemical necessary to inhibit gene in vitro, however, makes it impossible to conclude that chemical monotherapy will be a good option for systemic therapy of MTC.	T4	T18	16782438
NA	CHEMICAL	GENE-Y	3	7	The concentration of chemical necessary to inhibit gene in vitro, however, makes it impossible to conclude that chemical monotherapy will be a good option for systemic therapy of MTC.	T5	T18	16782438
NA	CHEMICAL	GENE-N	23	4	With the exception of gene, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a pterin, thus forming the chemical cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	T26	T47	16784786
NA	CHEMICAL	GENE-N	19	4	With the exception of gene, where Mo is a constituent of the FeMo-cofactor, Mo is bound to a chemical, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	T25	T47	16784786
NA	CHEMICAL	GENE-N	13	4	With the exception of gene, where Mo is a constituent of the chemical-cofactor, Mo is bound to a pterin, thus forming the molybdenum cofactor (Moco) which is the active compound at the catalytic site of all other Mo-enzymes.	T23	T47	16784786
NA	CHEMICAL	GENE-N	7	4	With the exception of gene, where chemical is a constituent of the Fechemical-cofactor, chemical is bound to a pterin, thus forming the molybdenum cofactor (chemicalco) which is the active compound at the catalytic site of all other chemical-enzymes.	T22	T47	16784786
NA	CHEMICAL	GENE-N	7	4	With the exception of gene, where chemical is a constituent of the Fechemical-cofactor, chemical is bound to a pterin, thus forming the molybdenum cofactor (chemicalco) which is the active compound at the catalytic site of all other chemical-enzymes.	T24	T47	16784786
NA	CHEMICAL	GENE-N	7	4	With the exception of gene, where chemical is a constituent of the Fechemical-cofactor, chemical is bound to a pterin, thus forming the molybdenum cofactor (chemicalco) which is the active compound at the catalytic site of all other chemical-enzymes.	T27	T47	16784786
NA	CHEMICAL	GENE-Y	60	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone chemical, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T37	T49	16784786
NA	CHEMICAL	GENE-N	60	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone chemical, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T37	T39	16784786
NA	CHEMICAL	GENE-Y	60	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone chemical, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T37	T50	16784786
NA	CHEMICAL	GENE-Y	60	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone chemical, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T37	T48	16784786
NA	CHEMICAL	GENE-Y	20	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing chemical and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T30	T49	16784786
NA	CHEMICAL	GENE-N	20	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing chemical and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T30	T39	16784786
NA	CHEMICAL	GENE-Y	20	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing chemical and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T30	T50	16784786
NA	CHEMICAL	GENE-Y	20	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing chemical and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T30	T48	16784786
NA	CHEMICAL	GENE-Y	50	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of chemical and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T36	T49	16784786
NA	CHEMICAL	GENE-N	50	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of chemical and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T36	T39	16784786
NA	CHEMICAL	GENE-Y	50	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of chemical and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T36	T50	16784786
NA	CHEMICAL	GENE-Y	50	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of chemical and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T36	T48	16784786
NA	CHEMICAL	GENE-Y	77	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic chemical assimilation.	T2	T49	16784786
NA	CHEMICAL	GENE-N	77	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic chemical assimilation.	T2	T39	16784786
NA	CHEMICAL	GENE-Y	77	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic chemical assimilation.	T2	T50	16784786
NA	CHEMICAL	GENE-Y	77	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic chemical assimilation.	T2	T48	16784786
NA	CHEMICAL	GENE-N	30	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) chemical dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T32	T39	16784786
NA	CHEMICAL	GENE-Y	30	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) chemical dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T32	T50	16784786
NA	CHEMICAL	GENE-Y	30	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) chemical dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T32	T48	16784786
NA	CHEMICAL	GENE-Y	43	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) chemical oxidase, which oxidizes a variety of chemicals and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T35	T49	16784786
NA	CHEMICAL	GENE-N	43	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) chemical oxidase, which oxidizes a variety of chemicals and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T35	T39	16784786
NA	CHEMICAL	GENE-Y	43	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) chemical oxidase, which oxidizes a variety of chemicals and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T35	T48	16784786
NA	CHEMICAL	GENE-Y	68	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) chemical reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T1	T49	16784786
NA	CHEMICAL	GENE-Y	68	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) chemical reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T1	T50	16784786
NA	CHEMICAL	GENE-Y	68	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) chemical reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T1	T48	16784786
NA	CHEMICAL	GENE-Y	8	30	In eukaryotes, the most prominent Mo-enzymes are (1) chemical oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess chemical, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T31	T49	16784786
NA	CHEMICAL	GENE-N	8	68	In eukaryotes, the most prominent Mo-enzymes are (1) chemical oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess chemical, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T31	T39	16784786
NA	CHEMICAL	GENE-Y	8	43	In eukaryotes, the most prominent Mo-enzymes are (1) chemical oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess chemical, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T31	T50	16784786
NA	CHEMICAL	GENE-Y	40	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive chemical production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T34	T49	16784786
NA	CHEMICAL	GENE-N	40	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive chemical production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T34	T39	16784786
NA	CHEMICAL	GENE-Y	40	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive chemical production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T34	T50	16784786
NA	CHEMICAL	GENE-Y	40	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive chemical production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T34	T48	16784786
NA	CHEMICAL	GENE-Y	19	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of chemical-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T29	T49	16784786
NA	CHEMICAL	GENE-N	19	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of chemical-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T29	T39	16784786
NA	CHEMICAL	GENE-Y	19	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of chemical-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T29	T50	16784786
CPR:9	CHEMICAL	GENE-Y	19	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of chemical-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T29	T48	16784786
NA	CHEMICAL	GENE-Y	36	30	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in chemical catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T33	T49	16784786
NA	CHEMICAL	GENE-N	36	68	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in chemical catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T33	T39	16784786
NA	CHEMICAL	GENE-Y	36	43	In eukaryotes, the most prominent Mo-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in chemical catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T33	T50	16784786
NA	CHEMICAL	GENE-Y	36	8	In eukaryotes, the most prominent Mo-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in chemical catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T33	T48	16784786
NA	CHEMICAL	GENE-Y	5	30	In eukaryotes, the most prominent chemical-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) gene, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T28	T49	16784786
NA	CHEMICAL	GENE-N	5	68	In eukaryotes, the most prominent chemical-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) gene, which catalyzes the key step in inorganic nitrogen assimilation.	T28	T39	16784786
NA	CHEMICAL	GENE-Y	5	43	In eukaryotes, the most prominent chemical-enzymes are (1) sulfite oxidase, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) gene, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T28	T50	16784786
NA	CHEMICAL	GENE-Y	5	8	In eukaryotes, the most prominent chemical-enzymes are (1) gene, which catalyzes the final step in the degradation of sulfur-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.	T28	T48	16784786
NA	CHEMICAL	GENE-N	18	3	All Mo-enzymes, except gene, need at least one more redox active center, many of them involving chemical in electron transfer.	T5	T40	16784786
NA	CHEMICAL	GENE-N	1	3	All chemical-enzymes, except gene, need at least one more redox active center, many of them involving iron in electron transfer.	T3	T40	16784786
NA	CHEMICAL	GENE-Y	3	0	gene and chemical oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T9	T41	16784786
NA	CHEMICAL	GENE-N	3	10	Xanthine dehydrogenase and chemical oxidase, but not sulfite oxidase and gene, require the post-translational sulfuration of their Mo-site for becoming active.	T9	T44	16784786
NA	CHEMICAL	GENE-Y	3	7	Xanthine dehydrogenase and chemical oxidase, but not gene and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T9	T43	16784786
NA	CHEMICAL	GENE-N	0	10	chemical dehydrogenase and aldehyde oxidase, but not sulfite oxidase and gene, require the post-translational sulfuration of their Mo-site for becoming active.	T8	T44	16784786
NA	CHEMICAL	GENE-Y	0	3	chemical dehydrogenase and gene, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T8	T42	16784786
NA	CHEMICAL	GENE-Y	0	7	chemical dehydrogenase and aldehyde oxidase, but not gene and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T8	T43	16784786
NA	CHEMICAL	GENE-Y	10	0	gene and aldehyde oxidase, but not sulfite oxidase and chemical reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T11	T41	16784786
NA	CHEMICAL	GENE-Y	10	3	Xanthine dehydrogenase and gene, but not sulfite oxidase and chemical reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T11	T42	16784786
NA	CHEMICAL	GENE-Y	10	7	Xanthine dehydrogenase and aldehyde oxidase, but not gene and chemical reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T11	T43	16784786
NA	CHEMICAL	GENE-Y	7	0	gene and aldehyde oxidase, but not chemical oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T10	T41	16784786
NA	CHEMICAL	GENE-N	7	10	Xanthine dehydrogenase and aldehyde oxidase, but not chemical oxidase and gene, require the post-translational sulfuration of their Mo-site for becoming active.	T10	T44	16784786
NA	CHEMICAL	GENE-Y	7	3	Xanthine dehydrogenase and gene, but not chemical oxidase and nitrate reductase, require the post-translational sulfuration of their Mo-site for becoming active.	T10	T42	16784786
NA	CHEMICAL	GENE-Y	18	0	gene and aldehyde oxidase, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their chemical-site for becoming active.	T12	T41	16784786
NA	CHEMICAL	GENE-N	18	10	Xanthine dehydrogenase and aldehyde oxidase, but not sulfite oxidase and gene, require the post-translational sulfuration of their chemical-site for becoming active.	T12	T44	16784786
NA	CHEMICAL	GENE-Y	18	3	Xanthine dehydrogenase and gene, but not sulfite oxidase and nitrate reductase, require the post-translational sulfuration of their chemical-site for becoming active.	T12	T42	16784786
NA	CHEMICAL	GENE-Y	18	7	Xanthine dehydrogenase and aldehyde oxidase, but not gene and nitrate reductase, require the post-translational sulfuration of their chemical-site for becoming active.	T12	T43	16784786
NA	CHEMICAL	GENE-N	17	23	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from l-cysteine in a chemical-dependent manner as typical for gene.	T16	T46	16784786
NA	CHEMICAL	GENE-Y	17	8	This final maturation step is catalyzed by a gene enzyme, which mobilizes sulfur from l-cysteine in a chemical-dependent manner as typical for cysteine desulfurases.	T16	T45	16784786
NA	CHEMICAL	GENE-N	14	23	This final maturation step is catalyzed by a Moco-sulfurase enzyme, which mobilizes sulfur from chemical in a pyridoxal phosphate-dependent manner as typical for gene.	T15	T46	16784786
NA	CHEMICAL	GENE-Y	14	8	This final maturation step is catalyzed by a gene enzyme, which mobilizes sulfur from chemical in a pyridoxal phosphate-dependent manner as typical for cysteine desulfurases.	T15	T45	16784786
NA	CHEMICAL	GENE-Y	14	8	This final maturation step is catalyzed by a gene enzyme, which mobilizes sulfur from l-chemical in a pyridoxal phosphate-dependent manner as typical for chemical desulfurases.	T18	T45	16784786
CPR:3	CHEMICAL	GENE-N	0	24	chemical is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of gene superfamily.	T1	T13	16819260
CPR:3	CHEMICAL	GENE-N	0	12	chemical is a collective term for compounds which bind to and activate gene (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.	T1	T19	16819260
NA	CHEMICAL	GENE-N	0	15	chemical is a collective term for compounds which bind to and activate retinoic acid receptors (gene and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.	T1	T20	16819260
NA	CHEMICAL	GENE-N	0	19	chemical is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and gene), members of nuclear hormone receptor superfamily.	T1	T12	16819260
NA	CHEMICAL	GENE-N	6	12	The most important endogeneous retinoid is chemical (ATRA) which is an gene ligand.	T4	T14	16819260
NA	CHEMICAL	GENE-N	4	12	The most important endogeneous chemical is all-trans-retinoic acid (ATRA) which is an gene ligand.	T3	T14	16819260
NA	CHEMICAL	GENE-N	8	12	The most important endogeneous retinoid is all-trans-retinoic acid (chemical) which is an gene ligand.	T5	T14	16819260
NA	CHEMICAL	GENE-Y	2	10	Among them, chemical (Am80) is an RARalpha- and RARbeta-specific (but gene- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T7	T17	16819260
NA	CHEMICAL	GENE-Y	2	6	Among them, chemical (Am80) is an gene- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T7	T15	16819260
NA	CHEMICAL	GENE-Y	2	8	Among them, chemical (Am80) is an RARalpha- and gene-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T7	T16	16819260
NA	CHEMICAL	GENE-N	2	12	Among them, chemical (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and gene-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T7	T18	16819260
NA	CHEMICAL	GENE-Y	14	10	Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but gene- and RXRs-nonbinding) synthetic chemical that is effective in the treatment of psoriasis patients and relapsed APL.	T9	T17	16819260
NA	CHEMICAL	GENE-Y	14	6	Among them, tamibarotene (Am80) is an gene- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic chemical that is effective in the treatment of psoriasis patients and relapsed APL.	T9	T15	16819260
NA	CHEMICAL	GENE-Y	14	8	Among them, tamibarotene (Am80) is an RARalpha- and gene-specific (but RARgamma- and RXRs-nonbinding) synthetic chemical that is effective in the treatment of psoriasis patients and relapsed APL.	T9	T16	16819260
NA	CHEMICAL	GENE-N	14	12	Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and gene-nonbinding) synthetic chemical that is effective in the treatment of psoriasis patients and relapsed APL.	T9	T18	16819260
NA	CHEMICAL	GENE-Y	3	10	Among them, tamibarotene (chemical) is an RARalpha- and RARbeta-specific (but gene- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T8	T17	16819260
NA	CHEMICAL	GENE-Y	3	6	Among them, tamibarotene (chemical) is an gene- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T8	T15	16819260
NA	CHEMICAL	GENE-Y	3	8	Among them, tamibarotene (chemical) is an RARalpha- and gene-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T8	T16	16819260
NA	CHEMICAL	GENE-N	3	12	Among them, tamibarotene (chemical) is an RARalpha- and RARbeta-specific (but RARgamma- and gene-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.	T8	T18	16819260
NA	CHEMICAL	GENE-Y	23	27	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in chemical (ACh) synthesis and gene (ChAT) mRNA expression.	T3	T17	16828882
NA	CHEMICAL	GENE-N	23	4	We previously showed that gene stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in chemical (ACh) synthesis and choline acetyltransferase (ChAT) mRNA expression.	T3	T15	16828882
NA	CHEMICAL	GENE-Y	23	16	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via gene-mediated pathways, as evidenced by increases in chemical (ACh) synthesis and choline acetyltransferase (ChAT) mRNA expression.	T3	T16	16828882
NA	CHEMICAL	GENE-N	23	29	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in chemical (ACh) synthesis and choline acetyltransferase (gene) mRNA expression.	T3	T18	16828882
NA	CHEMICAL	GENE-Y	23	29	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in chemical (ACh) synthesis and choline acetyltransferase (gene) mRNA expression.	T3	T18	16828882
NA	CHEMICAL	GENE-Y	24	27	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (chemical) synthesis and gene (ChAT) mRNA expression.	T4	T17	16828882
NA	CHEMICAL	GENE-N	24	4	We previously showed that gene stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (chemical) synthesis and choline acetyltransferase (ChAT) mRNA expression.	T4	T15	16828882
NA	CHEMICAL	GENE-Y	24	16	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via gene-mediated pathways, as evidenced by increases in acetylcholine (chemical) synthesis and choline acetyltransferase (ChAT) mRNA expression.	T4	T16	16828882
NA	CHEMICAL	GENE-N	24	29	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (chemical) synthesis and choline acetyltransferase (gene) mRNA expression.	T4	T18	16828882
NA	CHEMICAL	GENE-Y	24	29	We previously showed that antithymocyte globulin stimulates an independent, non-neuronal cholinergic system in T cells via LFA-1-mediated pathways, as evidenced by increases in acetylcholine (chemical) synthesis and choline acetyltransferase (gene) mRNA expression.	T4	T18	16828882
NA	CHEMICAL	GENE-Y	1	15	The chemical-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on CD11a (gene), which leads to immunomodulation.	T5	T23	16828882
NA	CHEMICAL	GENE-Y	1	14	The chemical-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on gene (LFA-1 alpha chain), which leads to immunomodulation.	T5	T22	16828882
NA	CHEMICAL	GENE-N	1	14	The chemical-lowering drug simvastatin inhibits LFA-1 signaling by binding to an allosteric site on gene (LFA-1 alpha chain), which leads to immunomodulation.	T5	T22	16828882
NA	CHEMICAL	GENE-Y	1	5	The chemical-lowering drug simvastatin inhibits gene signaling by binding to an allosteric site on CD11a (gene alpha chain), which leads to immunomodulation.	T5	T20	16828882
NA	CHEMICAL	GENE-Y	3	15	The cholesterol-lowering drug chemical inhibits LFA-1 signaling by binding to an allosteric site on CD11a (gene), which leads to immunomodulation.	T6	T23	16828882
NA	CHEMICAL	GENE-Y	3	14	The cholesterol-lowering drug chemical inhibits LFA-1 signaling by binding to an allosteric site on gene (LFA-1 alpha chain), which leads to immunomodulation.	T6	T22	16828882
NA	CHEMICAL	GENE-N	3	14	The cholesterol-lowering drug chemical inhibits LFA-1 signaling by binding to an allosteric site on gene (LFA-1 alpha chain), which leads to immunomodulation.	T6	T22	16828882
CPR:4	CHEMICAL	GENE-Y	3	5	The cholesterol-lowering drug chemical inhibits gene signaling by binding to an allosteric site on CD11a (gene alpha chain), which leads to immunomodulation.	T6	T20	16828882
NA	CHEMICAL	GENE-Y	10	3	We found that anti-gene monoclonal antibody (mAb) increased ChAT activity, chemical synthesis and release, and expression of ChAT and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T8	T25	16828882
NA	CHEMICAL	GENE-Y	10	3	We found that anti-gene monoclonal antibody (mAb) increased ChAT activity, chemical synthesis and release, and expression of ChAT and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T9	T25	16828882
NA	CHEMICAL	GENE-N	10	3	We found that anti-gene monoclonal antibody (mAb) increased ChAT activity, chemical synthesis and release, and expression of ChAT and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T8	T25	16828882
NA	CHEMICAL	GENE-N	10	3	We found that anti-gene monoclonal antibody (mAb) increased ChAT activity, chemical synthesis and release, and expression of ChAT and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T9	T25	16828882
NA	CHEMICAL	GENE-N	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T8	T26	16828882
NA	CHEMICAL	GENE-N	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T8	T27	16828882
NA	CHEMICAL	GENE-N	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T9	T26	16828882
NA	CHEMICAL	GENE-N	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T9	T27	16828882
NA	CHEMICAL	GENE-Y	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T8	T26	16828882
NA	CHEMICAL	GENE-Y	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T8	T27	16828882
NA	CHEMICAL	GENE-Y	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T9	T26	16828882
NA	CHEMICAL	GENE-Y	10	8	We found that anti-CD11a monoclonal antibody (mAb) increased gene activity, chemical synthesis and release, and expression of gene and M5 muscarinic chemical receptor mRNA in MOLT-3 cells, a human leukemic T cell line.	T9	T27	16828882
CPR:4	CHEMICAL	GENE-Y	0	3	chemical abolished these anti-gene mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.	T10	T29	16828882
CPR:4	CHEMICAL	GENE-N	0	3	chemical abolished these anti-gene mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity.	T10	T29	16828882
NA	CHEMICAL	GENE-Y	16	3	Simvastatin abolished these anti-gene mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its chemical-lowering activity.	T1	T29	16828882
NA	CHEMICAL	GENE-N	16	3	Simvastatin abolished these anti-gene mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its chemical-lowering activity.	T1	T29	16828882
NA	CHEMICAL	GENE-Y	19	14	These results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via gene-mediated pathways, and suggest that chemical exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	T2	T14	16828882
NA	CHEMICAL	GENE-N	19	14	These results indicate that LFA-1 contributes to the regulation of lymphocytic cholinergic activity via gene-mediated pathways, and suggest that chemical exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	T2	T14	16828882
NA	CHEMICAL	GENE-Y	19	4	These results indicate that gene contributes to the regulation of lymphocytic cholinergic activity via CD11a-mediated pathways, and suggest that chemical exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	T2	T13	16828882
CPR:3	CHEMICAL	GENE-N	0	10	chemical, popularly known for its cooling effect, activates TRPM8--a cold-activated gene.	T1	T11	16829128
CPR:3	CHEMICAL	GENE-Y	0	8	chemical, popularly known for its cooling effect, activates gene--a cold-activated thermoTRP ion channel.	T1	T10	16829128
NA	CHEMICAL	GENE-Y	9	24	However, human physiological studies demonstrate a paradoxical role of chemical in modulation of warm sensation, and here, we show that chemical also activates heat-activated gene.	T2	T12	16829128
CPR:3	CHEMICAL	GENE-Y	9	24	However, human physiological studies demonstrate a paradoxical role of chemical in modulation of warm sensation, and here, we show that chemical also activates heat-activated gene.	T3	T12	16829128
CPR:4	CHEMICAL	GENE-Y	4	6	We further show that chemical inhibits gene, potentially explaining the use of chemical as an analgesic.	T4	T13	16829128
NA	CHEMICAL	GENE-Y	4	6	We further show that chemical inhibits gene, potentially explaining the use of chemical as an analgesic.	T5	T13	16829128
NA	CHEMICAL	GENE-N	6	21	Similar to menthol, both camphor and chemical (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other gene.	T8	T16	16829128
CPR:3	CHEMICAL	GENE-Y	6	14	Similar to menthol, both camphor and chemical (initially reported to be specific activators of gene and TRPA1, respectively) also modulate other thermoTRPs.	T8	T14	16829128
CPR:3	CHEMICAL	GENE-Y	6	16	Similar to menthol, both camphor and chemical (initially reported to be specific activators of TRPV3 and gene, respectively) also modulate other thermoTRPs.	T8	T15	16829128
NA	CHEMICAL	GENE-N	4	21	Similar to menthol, both chemical and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other gene.	T7	T16	16829128
CPR:3	CHEMICAL	GENE-Y	4	14	Similar to menthol, both chemical and cinnamaldehyde (initially reported to be specific activators of gene and TRPA1, respectively) also modulate other thermoTRPs.	T7	T14	16829128
CPR:3	CHEMICAL	GENE-Y	4	16	Similar to menthol, both chemical and cinnamaldehyde (initially reported to be specific activators of TRPV3 and gene, respectively) also modulate other thermoTRPs.	T7	T15	16829128
NA	CHEMICAL	GENE-N	2	21	Similar to chemical, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other gene.	T6	T16	16829128
CPR:3	CHEMICAL	GENE-Y	2	14	Similar to chemical, both camphor and cinnamaldehyde (initially reported to be specific activators of gene and TRPA1, respectively) also modulate other thermoTRPs.	T6	T14	16829128
CPR:3	CHEMICAL	GENE-Y	2	16	Similar to chemical, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and gene, respectively) also modulate other thermoTRPs.	T6	T15	16829128
NA	CHEMICAL	GENE-Y	3	9	These PCSCs possessed chemical receptors and KGFR, but not gene as determined by RT-PCR and Western blot, respectively.	T3	T26	16854582
NA	CHEMICAL	GENE-Y	3	6	These PCSCs possessed chemical receptors and gene, but not androgen receptor as determined by RT-PCR and Western blot, respectively.	T3	T25	16854582
NA	CHEMICAL	GENE-Y	9	3	These PCSCs possessed gene and KGFR, but not chemical receptor as determined by RT-PCR and Western blot, respectively.	T4	T23	16854582
NA	CHEMICAL	GENE-Y	9	6	These PCSCs possessed estrogen receptors and gene, but not chemical receptor as determined by RT-PCR and Western blot, respectively.	T4	T25	16854582
NA	CHEMICAL	GENE-N	7	32	Cell proliferation analysis indicated that tamoxifen or chemical reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and gene expression.	T2	T13	16854582
NA	CHEMICAL	GENE-Y	7	30	Cell proliferation analysis indicated that tamoxifen or chemical reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating gene and phospho-Akt expression.	T2	T12	16854582
NA	CHEMICAL	GENE-Y	7	17	Cell proliferation analysis indicated that tamoxifen or chemical reduced cell viability in a dose-dependent manner; however, gene prevented this inhibition, which further demonstrated gene triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	T2	T10	16854582
NA	CHEMICAL	GENE-Y	7	17	Cell proliferation analysis indicated that tamoxifen or chemical reduced cell viability in a dose-dependent manner; however, gene prevented this inhibition, which further demonstrated gene triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	T2	T11	16854582
NA	CHEMICAL	GENE-N	5	32	Cell proliferation analysis indicated that chemical or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating Bcl-2 and gene expression.	T1	T13	16854582
NA	CHEMICAL	GENE-Y	5	30	Cell proliferation analysis indicated that chemical or ICI 182,780 reduced cell viability in a dose-dependent manner; however, KGF prevented this inhibition, which further demonstrated KGF triggered anti-apoptotic machinery through activating gene and phospho-Akt expression.	T1	T12	16854582
NA	CHEMICAL	GENE-Y	5	17	Cell proliferation analysis indicated that chemical or ICI 182,780 reduced cell viability in a dose-dependent manner; however, gene prevented this inhibition, which further demonstrated gene triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	T1	T10	16854582
NA	CHEMICAL	GENE-Y	5	17	Cell proliferation analysis indicated that chemical or ICI 182,780 reduced cell viability in a dose-dependent manner; however, gene prevented this inhibition, which further demonstrated gene triggered anti-apoptotic machinery through activating Bcl-2 and phospho-Akt expression.	T1	T11	16854582
CPR:6	CHEMICAL	GENE-N	32	24	Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated gene and blocked by the transporter antagonist chemical.	T9	T20	16855093
NA	CHEMICAL	GENE-N	6	24	Focal application of the transporter substrate chemical elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated gene and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate.	T8	T20	16855093
CPR:4	CHEMICAL	GENE-Y	19	8	These currents were produced by glutamate-aspartate transporters (GLAST) (gene) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T13	T23	16855093
CPR:6	CHEMICAL	GENE-Y	19	25	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (gene) and were absent from IPCs in GLAST-/- cochleas.	T13	T25	16855093
CPR:4	CHEMICAL	GENE-Y	19	5	These currents were produced by gene (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T13	T21	16855093
CPR:6	CHEMICAL	GENE-Y	19	23	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of gene (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T13	T24	16855093
CPR:4	CHEMICAL	GENE-N	19	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T13	T22	16855093
NA	CHEMICAL	GENE-N	19	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T13	T26	16855093
CPR:4	CHEMICAL	GENE-Y	19	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T13	T22	16855093
NA	CHEMICAL	GENE-Y	19	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by chemical, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T13	T26	16855093
NA	CHEMICAL	GENE-Y	9	5	These currents were produced by gene (GLAST) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T12	T21	16855093
NA	CHEMICAL	GENE-Y	9	5	These currents were produced by gene (GLAST) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T15	T21	16855093
NA	CHEMICAL	GENE-Y	9	23	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of gene (excitatory chemical transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T12	T24	16855093
NA	CHEMICAL	GENE-Y	9	23	These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of gene (excitatory chemical transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T15	T24	16855093
NA	CHEMICAL	GENE-N	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T12	T22	16855093
NA	CHEMICAL	GENE-N	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T12	T26	16855093
NA	CHEMICAL	GENE-N	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T15	T22	16855093
NA	CHEMICAL	GENE-N	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T15	T26	16855093
NA	CHEMICAL	GENE-Y	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T12	T22	16855093
NA	CHEMICAL	GENE-Y	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T12	T26	16855093
NA	CHEMICAL	GENE-Y	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T15	T22	16855093
NA	CHEMICAL	GENE-Y	9	7	These currents were produced by glutamate-aspartate transporters (gene) (excitatory chemical transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory chemical transporter 2) and were absent from IPCs in gene-/- cochleas.	T15	T26	16855093
NA	CHEMICAL	GENE-Y	5	8	These currents were produced by glutamate-chemical transporters (GLAST) (gene) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T11	T23	16855093
NA	CHEMICAL	GENE-Y	5	25	These currents were produced by glutamate-chemical transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (gene) and were absent from IPCs in GLAST-/- cochleas.	T11	T25	16855093
NA	CHEMICAL	GENE-Y	5	23	These currents were produced by glutamate-chemical transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of gene (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T11	T24	16855093
NA	CHEMICAL	GENE-N	5	7	These currents were produced by glutamate-chemical transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T11	T22	16855093
NA	CHEMICAL	GENE-N	5	7	These currents were produced by glutamate-chemical transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T11	T26	16855093
NA	CHEMICAL	GENE-Y	5	7	These currents were produced by glutamate-chemical transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T11	T22	16855093
NA	CHEMICAL	GENE-Y	5	7	These currents were produced by glutamate-chemical transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T11	T26	16855093
NA	CHEMICAL	GENE-Y	5	8	These currents were produced by chemical-aspartate transporters (GLAST) (gene) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T10	T23	16855093
NA	CHEMICAL	GENE-Y	5	8	These currents were produced by chemical-aspartate transporters (GLAST) (gene) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.	T14	T23	16855093
NA	CHEMICAL	GENE-Y	5	25	These currents were produced by chemical-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (gene) and were absent from IPCs in GLAST-/- cochleas.	T10	T25	16855093
NA	CHEMICAL	GENE-Y	5	25	These currents were produced by chemical-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (gene) and were absent from IPCs in GLAST-/- cochleas.	T14	T25	16855093
NA	CHEMICAL	GENE-N	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T10	T22	16855093
NA	CHEMICAL	GENE-N	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T10	T26	16855093
NA	CHEMICAL	GENE-N	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T14	T22	16855093
NA	CHEMICAL	GENE-N	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T14	T26	16855093
NA	CHEMICAL	GENE-Y	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T10	T22	16855093
NA	CHEMICAL	GENE-Y	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T10	T26	16855093
NA	CHEMICAL	GENE-Y	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T14	T22	16855093
NA	CHEMICAL	GENE-Y	5	7	These currents were produced by chemical-aspartate transporters (gene) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of chemical transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in gene-/- cochleas.	T14	T26	16855093
CPR:9	CHEMICAL	GENE-N	16	21	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by chemical, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T2	T17	16855093
NA	CHEMICAL	GENE-N	16	21	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by chemical, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T2	T18	16855093
CPR:9	CHEMICAL	GENE-Y	16	21	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by chemical, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T2	T17	16855093
NA	CHEMICAL	GENE-Y	16	21	Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by chemical, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T2	T18	16855093
NA	CHEMICAL	GENE-N	1	21	Furthermore, chemical-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T1	T17	16855093
NA	CHEMICAL	GENE-N	1	21	Furthermore, chemical-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T1	T18	16855093
NA	CHEMICAL	GENE-Y	1	21	Furthermore, chemical-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T1	T17	16855093
NA	CHEMICAL	GENE-Y	1	21	Furthermore, chemical-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of gene, and examination of cochlea from gene-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	T1	T18	16855093
NA	CHEMICAL	GENE-N	13	3	We compared the gene blocking potencies of chemical with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart.	T17	T25	1687367
NA	CHEMICAL	GENE-N	1	18	and chemical 1 and 5 mg kg-1 body wt., were given intravenously for comparison studies of potency at gene, respectively.	T13	T26	1687367
NA	CHEMICAL	GENE-N	13	17	Following both oral and intravenous dosing, the RR-SR combination was twice potent as chemical in terms of gene antagonism at equivalent doses.	T2	T20	1687367
NA	CHEMICAL	GENE-N	0	7	chemical and the enantiomers lacked affinity at gene while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than labetalol.	T3	T21	1687367
NA	CHEMICAL	GENE-N	0	11	chemical and the enantiomers lacked affinity at alpha 2-adrenoceptors while at gene the order of potency was prazosin much greater than RR-SR greater than labetalol.	T3	T22	1687367
NA	CHEMICAL	GENE-N	25	7	Labetalol and the enantiomers lacked affinity at gene while at alpha 1-adrenoceptors the order of potency was prazosin much greater than RR-SR greater than chemical.	T5	T21	1687367
NA	CHEMICAL	GENE-N	25	11	Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at gene the order of potency was prazosin much greater than RR-SR greater than chemical.	T5	T22	1687367
NA	CHEMICAL	GENE-N	18	7	Labetalol and the enantiomers lacked affinity at gene while at alpha 1-adrenoceptors the order of potency was chemical much greater than RR-SR greater than labetalol.	T4	T21	1687367
NA	CHEMICAL	GENE-N	18	11	Labetalol and the enantiomers lacked affinity at alpha 2-adrenoceptors while at gene the order of potency was chemical much greater than RR-SR greater than labetalol.	T4	T22	1687367
NA	CHEMICAL	GENE-Y	15	1	At gene, the affinity of the compound RR-SR was about 3 times that of chemical.5.	T6	T23	1687367
NA	CHEMICAL	GENE-N	1	19	As chemical is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of gene actions), the combination of RR and SR may be a valuable substitute for chemical in the treatment of systemic hypertension.	T7	T24	1687367
NA	CHEMICAL	GENE-N	1	19	As chemical is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of gene actions), the combination of RR and SR may be a valuable substitute for chemical in the treatment of systemic hypertension.	T8	T24	1687367
CPR:9	CHEMICAL	GENE-Y	14	0	gene (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to chemical (P5C).	T4	T12	16874462
CPR:9	CHEMICAL	GENE-Y	14	2	Proline oxidase (gene), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to chemical (P5C).	T4	T14	16874462
NA	CHEMICAL	GENE-Y	0	2	chemical oxidase (gene), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).	T1	T14	16874462
CPR:9	CHEMICAL	GENE-Y	12	0	gene (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of chemical to pyrroline- 5-carboxylate (P5C).	T3	T12	16874462
CPR:9	CHEMICAL	GENE-Y	12	2	Proline oxidase (gene), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of chemical to pyrroline- 5-carboxylate (P5C).	T3	T14	16874462
CPR:9	CHEMICAL	GENE-Y	16	0	gene (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (chemical).	T5	T12	16874462
CPR:9	CHEMICAL	GENE-Y	16	2	Proline oxidase (gene), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (chemical).	T5	T14	16874462
NA	CHEMICAL	GENE-Y	13	6	Previously we showed that overexpression of gene is associated with generation of reactive chemical species (ROS) and apoptosis in gene-inducible colorectal cancer cells, DLD-1.gene.	T6	T15	16874462
NA	CHEMICAL	GENE-Y	13	6	Previously we showed that overexpression of gene is associated with generation of reactive chemical species (ROS) and apoptosis in gene-inducible colorectal cancer cells, DLD-1.gene.	T6	T16	16874462
NA	CHEMICAL	GENE-Y	13	6	Previously we showed that overexpression of gene is associated with generation of reactive chemical species (ROS) and apoptosis in gene-inducible colorectal cancer cells, DLD-1.gene.	T6	T17	16874462
NA	CHEMICAL	GENE-Y	22	7	To further investigate the molecular basis of gene-induced apoptosis, we utilized the DLD-1.gene cells to show that cells overproducing gene exhibit an chemical-dependent apoptotic response.	T7	T20	16874462
NA	CHEMICAL	GENE-Y	22	7	To further investigate the molecular basis of gene-induced apoptosis, we utilized the DLD-1.gene cells to show that cells overproducing gene exhibit an chemical-dependent apoptotic response.	T7	T21	16874462
CPR:9	CHEMICAL	GENE-Y	22	7	To further investigate the molecular basis of gene-induced apoptosis, we utilized the DLD-1.gene cells to show that cells overproducing gene exhibit an chemical-dependent apoptotic response.	T7	T22	16874462
NA	CHEMICAL	GENE-Y	6	30	The apoptotic effect is specific for chemical, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of chemical to cells with maximally induced gene.	T8	T23	16874462
CPR:9	CHEMICAL	GENE-Y	6	30	The apoptotic effect is specific for chemical, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of chemical to cells with maximally induced gene.	T9	T23	16874462
CPR:9	CHEMICAL	GENE-Y	7	9	We conclude that in the presence of chemical, high gene activity is sufficient to induce mitochondria-mediated apoptosis.	T2	T13	16874462
NA	CHEMICAL	GENE-Y	6	20	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, chemical, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and gene knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	T18	T31	16893531
NA	CHEMICAL	GENE-Y	4	20	METHODS: Antidepressant drugs (reboxetine, chemical, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and gene knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	T16	T31	16893531
NA	CHEMICAL	GENE-Y	5	20	METHODS: Antidepressant drugs (reboxetine, desipramine, chemical, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and gene knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	T17	T31	16893531
NA	CHEMICAL	GENE-Y	3	20	METHODS: Antidepressant drugs (chemical, desipramine, imipramine, venlafaxine, bupropion) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and gene knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	T15	T31	16893531
NA	CHEMICAL	GENE-Y	7	20	METHODS: Antidepressant drugs (reboxetine, desipramine, imipramine, venlafaxine, chemical) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and gene knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	T19	T31	16893531
NA	CHEMICAL	GENE-Y	6	7	The exception was bupropion, a dual chemical transporter/gene blocker, which tended to increase spontaneous locomotor activity.	T2	T24	16893531
CPR:4	CHEMICAL	GENE-Y	3	6	The exception was chemical, a dual gene/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.	T1	T23	16893531
CPR:4	CHEMICAL	GENE-Y	3	7	The exception was chemical, a dual norepinephrine transporter/gene blocker, which tended to increase spontaneous locomotor activity.	T1	T24	16893531
NA	CHEMICAL	GENE-Y	7	6	The exception was bupropion, a dual gene/chemical transporter blocker, which tended to increase spontaneous locomotor activity.	T3	T23	16893531
NA	CHEMICAL	GENE-Y	2	5	Coadministration of chemical and the gene blocker GBR 12909 also increased spontaneous locomotor activity.	T4	T25	16893531
CPR:4	CHEMICAL	GENE-Y	8	5	Coadministration of reboxetine and the gene blocker chemical also increased spontaneous locomotor activity.	T6	T25	16893531
NA	CHEMICAL	GENE-Y	21	0	gene knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in chemical transporter knockout mice.	T10	T26	16893531
NA	CHEMICAL	GENE-Y	0	21	chemical transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas reboxetine had no effect in gene knockout mice.	T7	T27	16893531
NA	CHEMICAL	GENE-Y	16	21	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas chemical had no effect in gene knockout mice.	T9	T27	16893531
NA	CHEMICAL	GENE-Y	16	0	gene knockout mice had low basal spontaneous locomotor activity, which was increased by bupropion, whereas chemical had no effect in norepinephrine transporter knockout mice.	T9	T26	16893531
NA	CHEMICAL	GENE-Y	14	21	Norepinephrine transporter knockout mice had low basal spontaneous locomotor activity, which was increased by chemical, whereas reboxetine had no effect in gene knockout mice.	T8	T27	16893531
NA	CHEMICAL	GENE-Y	14	0	gene knockout mice had low basal spontaneous locomotor activity, which was increased by chemical, whereas reboxetine had no effect in norepinephrine transporter knockout mice.	T8	T26	16893531
NA	CHEMICAL	GENE-Y	7	21	CONCLUSIONS: Acute or chronic inactivation of the chemical transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with gene blockade.	T11	T29	16893531
NA	CHEMICAL	GENE-Y	21	7	CONCLUSIONS: Acute or chronic inactivation of the gene decreases spontaneous locomotor activity in novel and familiar environments unless coupled with chemical transporter blockade.	T12	T28	16893531
NA	CHEMICAL	GENE-Y	5	7	Endocrine therapy that targets the chemical receptor (gene) is a standard of care for the treatment of postmenopausal women with gene-positive breast cancer.	T10	T22	16917142
NA	CHEMICAL	GENE-Y	5	7	Endocrine therapy that targets the chemical receptor (gene) is a standard of care for the treatment of postmenopausal women with gene-positive breast cancer.	T10	T32	16917142
NA	CHEMICAL	GENE-Y	5	2	The selective gene modulator (SgeneM) chemical has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of gene-positive disease.	T9	T26	16917142
NA	CHEMICAL	GENE-Y	5	2	The selective gene modulator (SgeneM) chemical has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of gene-positive disease.	T9	T28	16917142
NA	CHEMICAL	GENE-Y	0	10	chemical blocks the action of estrogen by binding to the gene, and possesses both gene-agonist and antagonist properties.	T11	T30	16917142
CPR:5	CHEMICAL	GENE-Y	0	10	chemical blocks the action of estrogen by binding to the gene, and possesses both gene-agonist and antagonist properties.	T11	T31	16917142
NA	CHEMICAL	GENE-Y	5	10	Tamoxifen blocks the action of chemical by binding to the gene, and possesses both gene-agonist and antagonist properties.	T12	T30	16917142
NA	CHEMICAL	GENE-Y	5	10	Tamoxifen blocks the action of chemical by binding to the gene, and possesses both gene-agonist and antagonist properties.	T12	T31	16917142
NA	CHEMICAL	GENE-Y	17	5	The subsequent development of the gene inhibitors (AIs) is an important therapeutic advance by creating a "no chemical" environment.	T3	T21	16917142
CPR:6	CHEMICAL	GENE-Y	0	4	chemical is a novel gene antagonist that destroys the gene and its signaling pathway and is not associated with tamoxifen-like agonist effects.	T4	T23	16917142
CPR:4	CHEMICAL	GENE-Y	0	4	chemical is a novel gene antagonist that destroys the gene and its signaling pathway and is not associated with tamoxifen-like agonist effects.	T4	T24	16917142
NA	CHEMICAL	GENE-Y	19	4	Fulvestrant is a novel gene antagonist that destroys the gene and its signaling pathway and is not associated with chemical-like agonist effects.	T5	T23	16917142
NA	CHEMICAL	GENE-Y	19	4	Fulvestrant is a novel gene antagonist that destroys the gene and its signaling pathway and is not associated with chemical-like agonist effects.	T5	T24	16917142
NA	CHEMICAL	GENE-Y	26	16	It produces high response rates compared with other SERMs and is not cross-resistant to tamoxifen or gene inhibitors and is equally as effective as the AI chemical in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant tamoxifen therapy.	T7	T25	16917142
NA	CHEMICAL	GENE-Y	14	16	It produces high response rates compared with other SERMs and is not cross-resistant to chemical or gene inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant chemical therapy.	T6	T25	16917142
NA	CHEMICAL	GENE-Y	14	16	It produces high response rates compared with other SERMs and is not cross-resistant to chemical or gene inhibitors and is equally as effective as the AI anastrozole in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant chemical therapy.	T8	T25	16917142
NA	CHEMICAL	GENE-N	38	20	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two gene, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for chemical-dependent protein kinases (cNPKs).	T14	T32	16926278
NA	CHEMICAL	GENE-Y	38	23	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, gene, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for chemical-dependent protein kinases (cNPKs).	T14	T38	16926278
NA	CHEMICAL	GENE-Y	38	26	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, gene (GAFs) (A and B) and a phosphorylation site for chemical-dependent protein kinases (cNPKs).	T14	T39	16926278
NA	CHEMICAL	GENE-Y	38	0	gene (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for chemical-dependent protein kinases (cNPKs).	T14	T25	16926278
NA	CHEMICAL	GENE-N	38	29	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs gene and a phosphorylation site for chemical-dependent protein kinases (cNPKs).	T14	T41	16926278
NA	CHEMICAL	GENE-N	38	42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for chemical-dependent protein kinases (gene).	T14	T43	16926278
NA	CHEMICAL	GENE-Y	38	1	Phosphodiesterase-5 (gene) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for chemical-dependent protein kinases (cNPKs).	T14	T40	16926278
NA	CHEMICAL	GENE-N	24	38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena chemical cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for gene (cNPKs).	T13	T42	16926278
NA	CHEMICAL	GENE-N	24	20	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two gene, Anabaena chemical cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T13	T32	16926278
NA	CHEMICAL	GENE-Y	24	26	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena chemical cyclases, gene (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T13	T39	16926278
NA	CHEMICAL	GENE-Y	24	0	gene (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena chemical cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T13	T25	16926278
NA	CHEMICAL	GENE-N	24	29	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena chemical cyclases, Escherichia coli FhlAs gene and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T13	T41	16926278
NA	CHEMICAL	GENE-N	24	42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena chemical cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (gene).	T13	T43	16926278
NA	CHEMICAL	GENE-Y	24	1	Phosphodiesterase-5 (gene) contains a catalytic domain (C domain) that hydrolyzes cGMP and a regulatory domain (R domain) that contains two mammalian cGMP-binding phosphodiesterase, Anabaena chemical cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T13	T40	16926278
NA	CHEMICAL	GENE-N	10	38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for gene (cNPKs).	T19	T42	16926278
NA	CHEMICAL	GENE-N	10	38	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for gene (cNPKs).	T9	T42	16926278
NA	CHEMICAL	GENE-Y	10	23	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, gene, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T19	T38	16926278
NA	CHEMICAL	GENE-Y	10	23	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, gene, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T9	T38	16926278
NA	CHEMICAL	GENE-Y	10	26	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, gene (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T19	T39	16926278
NA	CHEMICAL	GENE-Y	10	26	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, gene (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T9	T39	16926278
CPR:9	CHEMICAL	GENE-Y	10	0	gene (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T19	T25	16926278
NA	CHEMICAL	GENE-Y	10	0	gene (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T9	T25	16926278
NA	CHEMICAL	GENE-N	10	29	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs gene and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T19	T41	16926278
NA	CHEMICAL	GENE-N	10	29	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs gene and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T9	T41	16926278
NA	CHEMICAL	GENE-N	10	42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (gene).	T19	T43	16926278
NA	CHEMICAL	GENE-N	10	42	Phosphodiesterase-5 (PDE5) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (gene).	T9	T43	16926278
CPR:9	CHEMICAL	GENE-Y	10	1	Phosphodiesterase-5 (gene) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T19	T40	16926278
NA	CHEMICAL	GENE-Y	10	1	Phosphodiesterase-5 (gene) contains a catalytic domain (C domain) that hydrolyzes chemical and a regulatory domain (R domain) that contains two mammalian chemical-binding phosphodiesterase, Anabaena adenylyl cyclases, Escherichia coli FhlAs (GAFs) (A and B) and a phosphorylation site for cyclic nucleotide-dependent protein kinases (cNPKs).	T9	T40	16926278
NA	CHEMICAL	GENE-N	2	4	Binding of chemical to gene increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for chemical or inhibitors.	T15	T44	16926278
NA	CHEMICAL	GENE-N	2	4	Binding of chemical to gene increases cNPK phosphorylation of PDE5 and improves catalytic site affinity for chemical or inhibitors.	T16	T44	16926278
CPR:3	CHEMICAL	GENE-Y	2	9	Binding of chemical to GAF-A increases cNPK phosphorylation of gene and improves catalytic site affinity for chemical or inhibitors.	T15	T46	16926278
NA	CHEMICAL	GENE-Y	2	9	Binding of chemical to GAF-A increases cNPK phosphorylation of gene and improves catalytic site affinity for chemical or inhibitors.	T16	T46	16926278
CPR:3	CHEMICAL	GENE-N	2	6	Binding of chemical to GAF-A increases gene phosphorylation of PDE5 and improves catalytic site affinity for chemical or inhibitors.	T15	T45	16926278
NA	CHEMICAL	GENE-N	2	6	Binding of chemical to GAF-A increases gene phosphorylation of PDE5 and improves catalytic site affinity for chemical or inhibitors.	T16	T45	16926278
NA	CHEMICAL	GENE-N	8	11	GAF-B contributes to dimerization of PDE5, inhibition of chemical binding to gene, and sequestration of the phosphorylation site.	T17	T49	16926278
NA	CHEMICAL	GENE-N	8	0	gene contributes to dimerization of PDE5, inhibition of chemical binding to GAF-A, and sequestration of the phosphorylation site.	T17	T47	16926278
NA	CHEMICAL	GENE-Y	8	5	GAF-B contributes to dimerization of gene, inhibition of chemical binding to GAF-A, and sequestration of the phosphorylation site.	T17	T48	16926278
NA	CHEMICAL	GENE-N	15	35	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained gene; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T55	16926278
NA	CHEMICAL	GENE-Y	15	51	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and gene contained only C domain.	T18	T58	16926278
NA	CHEMICAL	GENE-Y	15	20	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: gene contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T51	16926278
NA	CHEMICAL	GENE-Y	15	39	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; gene contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T56	16926278
NA	CHEMICAL	GENE-Y	15	33	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; gene contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T54	16926278
NA	CHEMICAL	GENE-N	15	3	To probe potential gene effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T50	16926278
NA	CHEMICAL	GENE-N	15	30	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, C domain, and the sequence between gene; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T53	16926278
NA	CHEMICAL	GENE-N	15	22	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained gene, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of GAF-B; and PDE5Delta1-534 contained only C domain.	T18	T52	16926278
NA	CHEMICAL	GENE-N	15	22	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four chemical-terminal truncation mutants were generated: PDE5Delta1-321 contained gene domain, C domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained gene and C domain; PDE5Delta1-465 contained the C domain and the C-terminal portion of gene; and PDE5Delta1-534 contained only C domain.	T18	T57	16926278
NA	CHEMICAL	GENE-Y	24	51	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, chemical domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of GAF-B; and gene contained only chemical domain.	T20	T58	16926278
NA	CHEMICAL	GENE-Y	24	20	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: gene contained GAF-B domain, chemical domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of GAF-B; and PDE5Delta1-534 contained only chemical domain.	T20	T51	16926278
NA	CHEMICAL	GENE-Y	24	39	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, chemical domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and chemical domain; gene contained the chemical domain and the chemical-terminal portion of GAF-B; and PDE5Delta1-534 contained only chemical domain.	T20	T56	16926278
NA	CHEMICAL	GENE-Y	24	33	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, chemical domain, and the sequence between GAF-A and -B; gene contained GAF-B and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of GAF-B; and PDE5Delta1-534 contained only chemical domain.	T20	T54	16926278
NA	CHEMICAL	GENE-N	24	3	To probe potential gene effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, chemical domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of GAF-B; and PDE5Delta1-534 contained only chemical domain.	T20	T50	16926278
NA	CHEMICAL	GENE-N	24	30	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained GAF-B domain, chemical domain, and the sequence between gene; PDE5Delta1-419 contained GAF-B and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of GAF-B; and PDE5Delta1-534 contained only chemical domain.	T20	T53	16926278
NA	CHEMICAL	GENE-N	24	22	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained gene, chemical domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained GAF-B and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of GAF-B; and PDE5Delta1-534 contained only chemical domain.	T20	T52	16926278
NA	CHEMICAL	GENE-N	24	22	To probe potential PDE5 R domain effects on catalytic site affinity for certain inhibitors, four N-terminal truncation mutants were generated: PDE5Delta1-321 contained gene domain, chemical domain, and the sequence between GAF-A and -B; PDE5Delta1-419 contained gene and chemical domain; PDE5Delta1-465 contained the chemical domain and the chemical-terminal portion of gene; and PDE5Delta1-534 contained only chemical domain.	T20	T57	16926278
NA	CHEMICAL	GENE-N	14	5	Truncated proteins with a complete gene were dimers, but those lacking the N-terminal 46 chemical of gene were monomers, indicating that these residues are vital for gene-mediated PDE5 dimerization.	T2	T26	16926278
NA	CHEMICAL	GENE-N	14	5	Truncated proteins with a complete gene were dimers, but those lacking the N-terminal 46 chemical of gene were monomers, indicating that these residues are vital for gene-mediated PDE5 dimerization.	T2	T27	16926278
NA	CHEMICAL	GENE-N	14	5	Truncated proteins with a complete gene were dimers, but those lacking the N-terminal 46 chemical of gene were monomers, indicating that these residues are vital for gene-mediated PDE5 dimerization.	T2	T28	16926278
NA	CHEMICAL	GENE-Y	14	28	Truncated proteins with a complete GAF-B were dimers, but those lacking the N-terminal 46 chemical of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated gene dimerization.	T2	T29	16926278
NA	CHEMICAL	GENE-N	12	5	Truncated proteins with a complete gene were dimers, but those lacking the chemical-terminal 46 amino acids of gene were monomers, indicating that these residues are vital for gene-mediated PDE5 dimerization.	T1	T26	16926278
NA	CHEMICAL	GENE-N	12	5	Truncated proteins with a complete gene were dimers, but those lacking the chemical-terminal 46 amino acids of gene were monomers, indicating that these residues are vital for gene-mediated PDE5 dimerization.	T1	T27	16926278
NA	CHEMICAL	GENE-N	12	5	Truncated proteins with a complete gene were dimers, but those lacking the chemical-terminal 46 amino acids of gene were monomers, indicating that these residues are vital for gene-mediated PDE5 dimerization.	T1	T28	16926278
NA	CHEMICAL	GENE-Y	12	28	Truncated proteins with a complete GAF-B were dimers, but those lacking the chemical-terminal 46 amino acids of GAF-B were monomers, indicating that these residues are vital for GAF-B-mediated gene dimerization.	T1	T29	16926278
CPR:9	CHEMICAL	GENE-Y	6	13	K(m) values of the mutants for chemical were similar to that of full-length gene.	T3	T30	16926278
NA	CHEMICAL	GENE-N	7	17	All PDE5 constructs had similar affinities for chemical, sildenafil, tadalafil, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T4	T33	16926278
NA	CHEMICAL	GENE-N	7	17	All PDE5 constructs had similar affinities for chemical, sildenafil, tadalafil, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T4	T34	16926278
NA	CHEMICAL	GENE-Y	7	1	All gene constructs had similar affinities for chemical, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.	T4	T31	16926278
NA	CHEMICAL	GENE-N	8	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, chemical, tadalafil, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T5	T33	16926278
NA	CHEMICAL	GENE-N	8	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, chemical, tadalafil, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T5	T34	16926278
NA	CHEMICAL	GENE-Y	8	1	All gene constructs had similar affinities for 3-isobutyl-1-methylxanthine, chemical, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.	T5	T31	16926278
NA	CHEMICAL	GENE-N	25	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for chemical-based compounds compared with those lacking a complete gene.	T8	T33	16926278
NA	CHEMICAL	GENE-N	25	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for chemical-based compounds compared with those lacking a complete gene.	T8	T34	16926278
NA	CHEMICAL	GENE-Y	25	1	All gene constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for chemical-based compounds compared with those lacking a complete GAF-B.	T8	T31	16926278
NA	CHEMICAL	GENE-N	9	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, chemical, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T6	T33	16926278
NA	CHEMICAL	GENE-N	9	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, chemical, and UK-122764, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T6	T34	16926278
NA	CHEMICAL	GENE-Y	9	1	All gene constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, chemical, and UK-122764, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.	T6	T31	16926278
NA	CHEMICAL	GENE-N	11	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and chemical, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T7	T33	16926278
NA	CHEMICAL	GENE-N	11	17	All PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and chemical, but mutants containing a complete gene had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete gene.	T7	T34	16926278
NA	CHEMICAL	GENE-Y	11	1	All gene constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and chemical, but mutants containing a complete GAF-B had 7- to 18-fold higher affinity for vardenafil-based compounds compared with those lacking a complete GAF-B.	T7	T31	16926278
NA	CHEMICAL	GENE-N	6	9	This indicated that the N-terminal 46 chemical in gene are required for high vardenafil potency.	T11	T35	16926278
NA	CHEMICAL	GENE-N	14	9	This indicated that the N-terminal 46 amino acids in gene are required for high chemical potency.	T12	T35	16926278
NA	CHEMICAL	GENE-N	4	9	This indicated that the chemical-terminal 46 amino acids in gene are required for high vardenafil potency.	T10	T35	16926278
CPR:5	CHEMICAL	GENE-Y	1	23	OBJECTIVE: chemical, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of gene (PPARgamma).	T3	T19	16938288
CPR:6	CHEMICAL	GENE-Y	1	3	OBJECTIVE: chemical, an gene (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).	T3	T28	16938288
CPR:5	CHEMICAL	GENE-Y	1	27	OBJECTIVE: chemical, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (gene).	T3	T26	16938288
CPR:6	CHEMICAL	GENE-Y	1	8	OBJECTIVE: chemical, an angiotensin II type 1 receptor (gene) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).	T3	T32	16938288
NA	CHEMICAL	GENE-Y	14	6	Since previous studies have demonstrated that gene activators suppressed AT1R expression, we examined whether chemical affects AT1R expression in vascular smooth muscle cells.	T8	T27	16938288
NA	CHEMICAL	GENE-Y	14	9	Since previous studies have demonstrated that PPARgamma activators suppressed gene expression, we examined whether chemical affects gene expression in vascular smooth muscle cells.	T8	T29	16938288
NA	CHEMICAL	GENE-Y	14	9	Since previous studies have demonstrated that PPARgamma activators suppressed gene expression, we examined whether chemical affects gene expression in vascular smooth muscle cells.	T8	T30	16938288
CPR:4	CHEMICAL	GENE-Y	1	6	RESULTS: chemical decreased the expression of gene at the mRNA and protein levels in a dose- and time-dependent manner.	T9	T34	16938288
NA	CHEMICAL	GENE-N	10	1	Decreased gene activity with unchanged mRNA stability suggested that chemical suppressed AT1R gene expression at the transcriptional level.	T10	T35	16938288
CPR:4	CHEMICAL	GENE-Y	10	1	Decreased gene promoter activity with unchanged mRNA stability suggested that chemical suppressed gene gene expression at the transcriptional level.	T10	T36	16938288
NA	CHEMICAL	GENE-Y	14	4	However, the expression of gene was not suppressed by other gene antagonists such as chemical or olmesartan.	T1	T12	16938288
CPR:6	CHEMICAL	GENE-Y	14	4	However, the expression of gene was not suppressed by other gene antagonists such as chemical or olmesartan.	T1	T13	16938288
NA	CHEMICAL	GENE-Y	16	4	However, the expression of gene was not suppressed by other gene antagonists such as candesartan or chemical.	T2	T12	16938288
CPR:6	CHEMICAL	GENE-Y	16	4	However, the expression of gene was not suppressed by other gene antagonists such as candesartan or chemical.	T2	T13	16938288
CPR:6	CHEMICAL	GENE-Y	11	13	Since the suppression of AT1R expression was prevented by pretreatment with chemical, a gene antagonist, gene should have participated in the process.	T4	T15	16938288
NA	CHEMICAL	GENE-Y	11	13	Since the suppression of AT1R expression was prevented by pretreatment with chemical, a gene antagonist, gene should have participated in the process.	T4	T16	16938288
CPR:3	CHEMICAL	GENE-Y	11	4	Since the suppression of gene expression was prevented by pretreatment with chemical, a PPARgamma antagonist, PPARgamma should have participated in the process.	T4	T14	16938288
CPR:4	CHEMICAL	GENE-N	25	13	The deletion and mutation analysis of the AT1R gene promoter indicated that a gene located in the proximal promoter region is responsible for the chemical-induced downregulation.	T5	T18	16938288
CPR:4	CHEMICAL	GENE-Y	25	7	The deletion and mutation analysis of the gene gene promoter indicated that a GC box located in the proximal promoter region is responsible for the chemical-induced downregulation.	T5	T17	16938288
NA	CHEMICAL	GENE-Y	11	18	CONCLUSION: Our data provides a novel insight into an effect of chemical: chemical inhibits AT1R gene expression through gene activation.	T6	T21	16938288
CPR:3	CHEMICAL	GENE-Y	11	18	CONCLUSION: Our data provides a novel insight into an effect of chemical: chemical inhibits AT1R gene expression through gene activation.	T7	T21	16938288
NA	CHEMICAL	GENE-Y	11	14	CONCLUSION: Our data provides a novel insight into an effect of chemical: chemical inhibits gene gene expression through PPARgamma activation.	T6	T20	16938288
CPR:4	CHEMICAL	GENE-Y	11	14	CONCLUSION: Our data provides a novel insight into an effect of chemical: chemical inhibits gene gene expression through PPARgamma activation.	T7	T20	16938288
NA	CHEMICAL	GENE-Y	5	8	Upon differentiation, osteoclasts express vesicular chemical transporter 1 (gene), which is essential for vesicular storage and subsequent exocytosis of chemical in neurons.	T4	T18	16957773
CPR:9	CHEMICAL	GENE-Y	5	8	Upon differentiation, osteoclasts express vesicular chemical transporter 1 (gene), which is essential for vesicular storage and subsequent exocytosis of chemical in neurons.	T5	T18	16957773
CPR:9	CHEMICAL	GENE-Y	8	0	gene is localized in transcytotic vesicles and accumulates chemical.	T6	T19	16957773
NA	CHEMICAL	GENE-Y	5	12	KCl- and ATP-dependent secretion of chemical was absent in osteoclasts prepared from gene-/- knockout mice.	T13	T20	16957773
NA	CHEMICAL	GENE-Y	2	12	KCl- and chemical-dependent secretion of L-glutamate was absent in osteoclasts prepared from gene-/- knockout mice.	T12	T20	16957773
NA	CHEMICAL	GENE-Y	0	12	chemical- and ATP-dependent secretion of L-glutamate was absent in osteoclasts prepared from gene-/- knockout mice.	T11	T20	16957773
NA	CHEMICAL	GENE-Y	7	2	Osteoclasts express gene, a class III metabotropic chemical receptor.	T14	T21	16957773
CPR:4	CHEMICAL	GENE-N	20	35	In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble chemical (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of gene activity.	T1	T7	16971132
CPR:4	CHEMICAL	GENE-N	14	35	In order to produce potent new leads for anticancer drugs, a new series of chemical analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of gene activity.	T3	T7	16971132
CPR:4	CHEMICAL	GENE-N	21	35	In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (chemical, 1) structure features and fitted with functional groups believed to enhance inhibition of gene activity.	T2	T7	16971132
NA	CHEMICAL	GENE-Y	14	0	gene receptor mutant mice consume more food, which leads to late-onset obesity and impaired chemical tolerance.	T3	T6	16973729
NA	CHEMICAL	GENE-Y	2	12	Administration of chemical and fenfluramine, both of which induce anorexic effects via gene receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	T1	T7	16973729
NA	CHEMICAL	GENE-Y	2	15	Administration of chemical and fenfluramine, both of which induce anorexic effects via 5-HT2C receptors and/or gene receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	T1	T8	16973729
NA	CHEMICAL	GENE-Y	4	12	Administration of m-chlorophenylpiperazine and chemical, both of which induce anorexic effects via gene receptors and/or 5-HT1B receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	T2	T7	16973729
NA	CHEMICAL	GENE-Y	4	15	Administration of m-chlorophenylpiperazine and chemical, both of which induce anorexic effects via 5-HT2C receptors and/or gene receptors, suppressed food intake in 5- and 8-wk-old Ay mice, whereas the anorexic effects were attenuated in food-restricted Ay mice.	T2	T8	16973729
NA	CHEMICAL	GENE-Y	17	4	When treatment is started, gene agonists initially stimulate the release of LH, causing a surge in serum chemical that can precipitate a "flare" phenomenon or worsening of disease, particularly in patients with bone metastatic disease.	T1	T5	16985933
NA	CHEMICAL	GENE-N	17	4	When treatment is started, geneRH agonists initially stimulate the release of gene, causing a surge in serum chemical that can precipitate a "flare" phenomenon or worsening of disease, particularly in patients with bone metastatic disease.	T1	T6	16985933
NA	CHEMICAL	GENE-Y	22	27	Results from 1 phase II and 3 phase III clinical trials demonstrate that abarelix produces medical castration more quickly and without causing chemical surge, as compared with gene agonists with or without a nonsteroidal antagonist.	T2	T11	16985933
NA	CHEMICAL	GENE-Y	6	19	AIM: To compare the composition of chemical (FAs) in diet, and the expression of delta-6 desaturase (D6D) and gene (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T6	T23	16988497
NA	CHEMICAL	GENE-Y	6	15	AIM: To compare the composition of chemical (FAs) in diet, and the expression of gene (D6D) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T6	T33	16988497
NA	CHEMICAL	GENE-Y	6	21	AIM: To compare the composition of chemical (FAs) in diet, and the expression of delta-6 desaturase (D6D) and delta-5 desaturase (gene) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T6	T28	16988497
NA	CHEMICAL	GENE-Y	6	17	AIM: To compare the composition of chemical (FAs) in diet, and the expression of delta-6 desaturase (gene) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T6	T20	16988497
NA	CHEMICAL	GENE-Y	8	19	AIM: To compare the composition of fatty acids (chemical) in diet, and the expression of delta-6 desaturase (D6D) and gene (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T8	T23	16988497
NA	CHEMICAL	GENE-Y	8	15	AIM: To compare the composition of fatty acids (chemical) in diet, and the expression of gene (D6D) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T8	T33	16988497
NA	CHEMICAL	GENE-Y	8	21	AIM: To compare the composition of fatty acids (chemical) in diet, and the expression of delta-6 desaturase (D6D) and delta-5 desaturase (gene) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T8	T28	16988497
NA	CHEMICAL	GENE-Y	8	17	AIM: To compare the composition of fatty acids (chemical) in diet, and the expression of delta-6 desaturase (gene) and delta-5 desaturase (D5D) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	T8	T20	16988497
CPR:4	CHEMICAL	GENE-Y	36	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and chemical (LNA) and the expression of PBMC D6D and gene genes.	T16	T19	16988497
NA	CHEMICAL	GENE-Y	36	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and chemical (LNA) and the expression of PBMC D6D and gene genes.	T16	T35	16988497
CPR:4	CHEMICAL	GENE-Y	36	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and chemical (LNA) and the expression of PBMC gene and D5D genes.	T16	T18	16988497
NA	CHEMICAL	GENE-Y	36	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and chemical (LNA) and the expression of PBMC gene and D5D genes.	T16	T34	16988497
CPR:4	CHEMICAL	GENE-Y	32	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of chemical (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and gene genes.	T14	T19	16988497
NA	CHEMICAL	GENE-Y	32	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of chemical (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and gene genes.	T14	T35	16988497
CPR:4	CHEMICAL	GENE-Y	32	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of chemical (LA) and alpha-linolenic acid (LNA) and the expression of PBMC gene and D5D genes.	T14	T18	16988497
NA	CHEMICAL	GENE-Y	32	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of chemical (LA) and alpha-linolenic acid (LNA) and the expression of PBMC gene and D5D genes.	T14	T34	16988497
CPR:4	CHEMICAL	GENE-Y	38	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (chemical) and the expression of PBMC D6D and gene genes.	T17	T19	16988497
NA	CHEMICAL	GENE-Y	38	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (chemical) and the expression of PBMC D6D and gene genes.	T17	T35	16988497
CPR:4	CHEMICAL	GENE-Y	38	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (chemical) and the expression of PBMC gene and D5D genes.	T17	T18	16988497
NA	CHEMICAL	GENE-Y	38	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (chemical) and the expression of PBMC gene and D5D genes.	T17	T34	16988497
CPR:4	CHEMICAL	GENE-Y	34	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of linoleic acid (chemical) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and gene genes.	T15	T19	16988497
NA	CHEMICAL	GENE-Y	34	21	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and gene genes, but a significant negative correlation between dietary intake of linoleic acid (chemical) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and gene genes.	T15	T35	16988497
CPR:4	CHEMICAL	GENE-Y	34	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (chemical) and alpha-linolenic acid (LNA) and the expression of PBMC gene and D5D genes.	T15	T18	16988497
NA	CHEMICAL	GENE-Y	34	19	A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC gene and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (chemical) and alpha-linolenic acid (LNA) and the expression of PBMC gene and D5D genes.	T15	T34	16988497
CPR:3	CHEMICAL	GENE-Y	6	15	CONCLUSION: Intake of high SFAs and chemical appears to increase expression of PBMC D6D and gene genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and gene genes.	T2	T22	16988497
NA	CHEMICAL	GENE-Y	6	15	CONCLUSION: Intake of high SFAs and chemical appears to increase expression of PBMC D6D and gene genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and gene genes.	T2	T25	16988497
CPR:3	CHEMICAL	GENE-Y	6	13	CONCLUSION: Intake of high SFAs and chemical appears to increase expression of PBMC gene and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC gene and D5D genes.	T2	T21	16988497
NA	CHEMICAL	GENE-Y	6	13	CONCLUSION: Intake of high SFAs and chemical appears to increase expression of PBMC gene and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC gene and D5D genes.	T2	T24	16988497
CPR:3	CHEMICAL	GENE-Y	4	15	CONCLUSION: Intake of high chemical and MUFAs appears to increase expression of PBMC D6D and gene genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and gene genes.	T1	T22	16988497
NA	CHEMICAL	GENE-Y	4	15	CONCLUSION: Intake of high chemical and MUFAs appears to increase expression of PBMC D6D and gene genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and gene genes.	T1	T25	16988497
CPR:3	CHEMICAL	GENE-Y	4	13	CONCLUSION: Intake of high chemical and MUFAs appears to increase expression of PBMC gene and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC gene and D5D genes.	T1	T21	16988497
NA	CHEMICAL	GENE-Y	4	13	CONCLUSION: Intake of high chemical and MUFAs appears to increase expression of PBMC gene and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC gene and D5D genes.	T1	T24	16988497
NA	CHEMICAL	GENE-Y	19	15	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and gene genes, whilst high chemical intake appears to decrease expression of PBMC D6D and gene genes.	T3	T22	16988497
CPR:4	CHEMICAL	GENE-Y	19	15	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and gene genes, whilst high chemical intake appears to decrease expression of PBMC D6D and gene genes.	T3	T25	16988497
NA	CHEMICAL	GENE-Y	19	13	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC gene and D5D genes, whilst high chemical intake appears to decrease expression of PBMC gene and D5D genes.	T3	T21	16988497
CPR:4	CHEMICAL	GENE-Y	19	13	CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC gene and D5D genes, whilst high chemical intake appears to decrease expression of PBMC gene and D5D genes.	T3	T24	16988497
NA	CHEMICAL	GENE-Y	22	9	A follow-up study of the expression of D6D and gene genes in Chinese who live in European countries with high SFA and chemical diets would be of interest.	T5	T27	16988497
NA	CHEMICAL	GENE-Y	22	7	A follow-up study of the expression of gene and D5D genes in Chinese who live in European countries with high SFA and chemical diets would be of interest.	T5	T26	16988497
NA	CHEMICAL	GENE-Y	20	9	A follow-up study of the expression of D6D and gene genes in Chinese who live in European countries with high chemical and MUFA diets would be of interest.	T4	T27	16988497
NA	CHEMICAL	GENE-Y	20	7	A follow-up study of the expression of gene and D5D genes in Chinese who live in European countries with high chemical and MUFA diets would be of interest.	T4	T26	16988497
NA	CHEMICAL	GENE-N	0	6	chemical is one of the first gene hormones to be described functionally and subsequently approached as a drug target.	T1	T12	17013809
NA	CHEMICAL	GENE-Y	1	12	Because chemical (1) affects both menstruation and gestation via the chemical receptor (gene), research aimed at modulating its activity is usually surrounded by controversy.	T2	T11	17013809
NA	CHEMICAL	GENE-Y	1	12	Because chemical (1) affects both menstruation and gestation via the chemical receptor (gene), research aimed at modulating its activity is usually surrounded by controversy.	T3	T11	17013809
NA	CHEMICAL	GENE-Y	27	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of chemical; (2) drug-like steroids with different properties from chemical and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T5	T13	17013809
NA	CHEMICAL	GENE-Y	27	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of chemical; (2) drug-like steroids with different properties from chemical and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T5	T14	17013809
NA	CHEMICAL	GENE-Y	27	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of chemical; (2) drug-like steroids with different properties from chemical and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T7	T13	17013809
NA	CHEMICAL	GENE-Y	27	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of chemical; (2) drug-like steroids with different properties from chemical and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T7	T14	17013809
NA	CHEMICAL	GENE-Y	42	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-chemical gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T8	T13	17013809
NA	CHEMICAL	GENE-Y	42	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like steroids that mimic the gestational properties of progesterone; (2) drug-like steroids with different properties from progesterone and expanded therapeutic applications; and (3) non-chemical gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T8	T14	17013809
NA	CHEMICAL	GENE-Y	20	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like chemical that mimic the gestational properties of progesterone; (2) drug-like chemical with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T4	T13	17013809
NA	CHEMICAL	GENE-Y	20	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like chemical that mimic the gestational properties of progesterone; (2) drug-like chemical with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T4	T14	17013809
NA	CHEMICAL	GENE-Y	20	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like chemical that mimic the gestational properties of progesterone; (2) drug-like chemical with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T6	T13	17013809
NA	CHEMICAL	GENE-Y	20	3	However, ligands for gene were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug-like chemical that mimic the gestational properties of progesterone; (2) drug-like chemical with different properties from progesterone and expanded therapeutic applications; and (3) non-steroidal gene ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	T6	T14	17013809
CPR:4	CHEMICAL	GENE-N	0	2	chemical inhibits gene and has shown therapeutic effects in patients with hematologic malignancies.	T2	T9	17023173
NA	CHEMICAL	GENE-N	20	28	We assessed the l-arginine uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral chemical, and sensitivity to trans stimulation of gene, and studied the expression of the genes encoding them by RT-PCR.	T17	T24	17065601
NA	CHEMICAL	GENE-N	3	28	We assessed the chemical uptake kinetics, Na(+) dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of gene, and studied the expression of the genes encoding them by RT-PCR.	T15	T24	17065601
NA	CHEMICAL	GENE-N	6	28	We assessed the l-arginine uptake kinetics, chemical dependence of transport, profiles of cis inhibition of uptake by cationic and neutral amino acids, and sensitivity to trans stimulation of gene, and studied the expression of the genes encoding them by RT-PCR.	T16	T24	17065601
NA	CHEMICAL	GENE-Y	4	18	Our data suggest that chemical is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/gene) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.	T19	T26	17065601
NA	CHEMICAL	GENE-Y	4	22	Our data suggest that chemical is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (gene and SLC7A2), with system B(0+) making a minor contribution.	T19	T27	17065601
CPR:9	CHEMICAL	GENE-Y	4	18	Our data suggest that chemical is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (gene/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.	T19	T25	17065601
NA	CHEMICAL	GENE-Y	4	24	Our data suggest that chemical is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (SLC7A1 and gene), with system B(0+) making a minor contribution.	T19	T28	17065601
NA	CHEMICAL	GENE-Y	20	10	By contrast, system B(0+), associated with system y(+)L (SLC3A2/SLC7A7 and gene), made a major contribution to the transport of cationic chemical in pachytene spermatocytes and early spermatids.	T2	T31	17065601
NA	CHEMICAL	GENE-Y	20	8	By contrast, system B(0+), associated with system y(+)L (SLC3A2/gene and SLC7A6), made a major contribution to the transport of cationic chemical in pachytene spermatocytes and early spermatids.	T2	T30	17065601
NA	CHEMICAL	GENE-Y	20	8	By contrast, system B(0+), associated with system y(+)L (gene/SLC7A7 and SLC7A6), made a major contribution to the transport of cationic chemical in pachytene spermatocytes and early spermatids.	T2	T29	17065601
NA	CHEMICAL	GENE-N	4	2	Furthermore, whereas gene induce chemical (NO) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by gene was observed in these cells.	T9	T21	17065601
NA	CHEMICAL	GENE-N	4	2	Furthermore, whereas gene induce chemical (NO) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by gene was observed in these cells.	T9	T22	17065601
NA	CHEMICAL	GENE-N	18	2	Furthermore, whereas gene induce nitric oxide (NO) production in peritubular and Sertoli cells, little or no upregulation of chemical transport by gene was observed in these cells.	T11	T21	17065601
NA	CHEMICAL	GENE-N	18	2	Furthermore, whereas gene induce nitric oxide (NO) production in peritubular and Sertoli cells, little or no upregulation of chemical transport by gene was observed in these cells.	T11	T22	17065601
NA	CHEMICAL	GENE-N	6	2	Furthermore, whereas gene induce nitric oxide (chemical) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by gene was observed in these cells.	T10	T21	17065601
NA	CHEMICAL	GENE-N	6	2	Furthermore, whereas gene induce nitric oxide (chemical) production in peritubular and Sertoli cells, little or no upregulation of arginine transport by gene was observed in these cells.	T10	T22	17065601
NA	CHEMICAL	GENE-Y	20	22	Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human chemical phosphorylase (gene).	T9	T30	17090056
CPR:9	CHEMICAL	GENE-Y	7	11	KIEs were measured on the arsenolysis of chemical (MTA) catalyzed by gene and were corrected for the forward commitment to catalysis.	T17	T31	17090056
NA	CHEMICAL	GENE-Y	4	9	The primary intrinsic KIEs (chemical and 9-(15)N) suggest that gene has a dissociative S(N)1 transition state with its cationic center at the anomeric carbon and insignificant bond order to the leaving group.	T20	T32	17090056
NA	CHEMICAL	GENE-Y	6	9	The primary intrinsic KIEs (1'-(14)C and chemical) suggest that gene has a dissociative S(N)1 transition state with its cationic center at the anomeric carbon and insignificant bond order to the leaving group.	T21	T32	17090056
NA	CHEMICAL	GENE-Y	23	9	The primary intrinsic KIEs (1'-(14)C and 9-(15)N) suggest that gene has a dissociative S(N)1 transition state with its cationic center at the anomeric chemical and insignificant bond order to the leaving group.	T22	T32	17090056
NA	CHEMICAL	GENE-Y	15	0	gene is characterized by a late S(N)1 transition state with significant participation of the chemical nucleophile.	T16	T29	17090056
NA	CHEMICAL	GENE-Y	16	18	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a chemical:retinol acyltransferase (gene).	T5	T18	17098734
NA	CHEMICAL	GENE-Y	16	18	We show here for zebrafish that embryonic retinoid homeostasis essentially depends on the activity of a leci-thin:chemical acyltransferase (gene).	T6	T18	17098734
CPR:9	CHEMICAL	GENE-Y	19	11	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to gene (raldh2), the key enzyme for chemical synthesis.	T9	T20	17098734
CPR:9	CHEMICAL	GENE-Y	19	14	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (gene), the key enzyme for chemical synthesis.	T9	T21	17098734
NA	CHEMICAL	GENE-Y	19	2	During embryogenesis, gene is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (raldh2), the key enzyme for chemical synthesis.	T9	T19	17098734
NA	CHEMICAL	GENE-Y	11	14	During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to chemical dehydrogenase 2 (gene), the key enzyme for retinoic acid synthesis.	T8	T21	17098734
NA	CHEMICAL	GENE-Y	11	2	During embryogenesis, gene is expressed in mostly non-overlapping domains opposite to chemical dehydrogenase 2 (raldh2), the key enzyme for retinoic acid synthesis.	T8	T19	17098734
NA	CHEMICAL	GENE-Y	15	10	Blocking retinyl ester formation by a targeted knock down of gene results in significantly increased chemical levels, which lead to severe embryonic patterning defects.	T11	T22	17098734
CPR:9	CHEMICAL	GENE-Y	1	10	Blocking chemical formation by a targeted knock down of gene results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.	T10	T22	17098734
NA	CHEMICAL	GENE-Y	24	11	Thus, we provide evidence that a balanced competition between Lratb and gene for yolk vitamin A defines embryonic compartments either for retinyl ester or chemical synthesis.	T14	T24	17098734
NA	CHEMICAL	GENE-Y	24	9	Thus, we provide evidence that a balanced competition between gene and Raldh2 for yolk vitamin A defines embryonic compartments either for retinyl ester or chemical synthesis.	T14	T23	17098734
NA	CHEMICAL	GENE-Y	21	11	Thus, we provide evidence that a balanced competition between Lratb and gene for yolk vitamin A defines embryonic compartments either for chemical or retinoic acid synthesis.	T13	T24	17098734
NA	CHEMICAL	GENE-Y	21	9	Thus, we provide evidence that a balanced competition between gene and Raldh2 for yolk vitamin A defines embryonic compartments either for chemical or retinoic acid synthesis.	T13	T23	17098734
NA	CHEMICAL	GENE-Y	14	11	Thus, we provide evidence that a balanced competition between Lratb and gene for yolk chemical defines embryonic compartments either for retinyl ester or retinoic acid synthesis.	T12	T24	17098734
NA	CHEMICAL	GENE-Y	14	9	Thus, we provide evidence that a balanced competition between gene and Raldh2 for yolk chemical defines embryonic compartments either for retinyl ester or retinoic acid synthesis.	T12	T23	17098734
NA	CHEMICAL	GENE-N	17	0	gene are a class of cell surface receptors for purines that prefer ATP or ADP over chemical.	T23	T24	17110146
NA	CHEMICAL	GENE-N	10	0	gene are a class of cell surface receptors for chemical that prefer ATP or ADP over adenosine.	T19	T24	17110146
NA	CHEMICAL	GENE-N	13	0	gene are a class of cell surface receptors for purines that prefer chemical or ADP over adenosine.	T20	T24	17110146
NA	CHEMICAL	GENE-N	15	0	gene are a class of cell surface receptors for purines that prefer ATP or chemical over adenosine.	T21	T24	17110146
NA	CHEMICAL	GENE-N	5	8	The surface receptors for extracellular chemical are called gene.	T9	T35	17110146
CPR:3	CHEMICAL	GENE-N	0	9	chemical initiates platelet aggregation by 'simultaneous activation of two gene, P2Y1 and P2Y12.	T13	T36	17110146
CPR:3	CHEMICAL	GENE-Y	0	14	chemical initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, P2Y1 and gene.	T13	T38	17110146
CPR:3	CHEMICAL	GENE-Y	0	12	chemical initiates platelet aggregation by 'simultaneous activation of two G protein-coupled receptors, gene and gene2.	T13	T37	17110146
NA	CHEMICAL	GENE-Y	10	0	gene has been shown to be the target of the chemical drugs, ticlopidine and clopidogrel.	T14	T39	17110146
NA	CHEMICAL	GENE-Y	12	0	gene has been shown to be the target of the thienopyridine drugs, chemical and clopidogrel.	T15	T39	17110146
NA	CHEMICAL	GENE-Y	14	0	gene has been shown to be the target of the thienopyridine drugs, ticlopidine and chemical.	T16	T39	17110146
NA	CHEMICAL	GENE-Y	7	5	Here, the active sites of gene for chemical as well as ADP are predicted by bioinformatics and molecular modeling.	T17	T40	17110146
NA	CHEMICAL	GENE-Y	11	5	Here, the active sites of gene for ATP as well as chemical are predicted by bioinformatics and molecular modeling.	T18	T40	17110146
NA	CHEMICAL	GENE-N	33	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (chemical, 222-231).	T29	T28	17110146
NA	CHEMICAL	GENE-N	33	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (chemical, 222-231).	T29	T3	17110146
NA	CHEMICAL	GENE-N	33	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (chemical, 222-231).	T4	T28	17110146
NA	CHEMICAL	GENE-N	33	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (chemical, 222-231).	T4	T3	17110146
NA	CHEMICAL	GENE-N	33	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T29	T1	17110146
NA	CHEMICAL	GENE-N	33	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T29	T26	17110146
NA	CHEMICAL	GENE-N	33	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T4	T1	17110146
NA	CHEMICAL	GENE-N	33	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T4	T26	17110146
NA	CHEMICAL	GENE-N	33	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T29	T27	17110146
NA	CHEMICAL	GENE-N	33	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T29	T2	17110146
NA	CHEMICAL	GENE-N	33	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T4	T27	17110146
NA	CHEMICAL	GENE-N	33	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T4	T2	17110146
NA	CHEMICAL	GENE-Y	33	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T29	T25	17110146
NA	CHEMICAL	GENE-Y	33	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (chemical, 222-231).	T4	T25	17110146
NA	CHEMICAL	GENE-N	21	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T1	T28	17110146
NA	CHEMICAL	GENE-N	21	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T1	T3	17110146
NA	CHEMICAL	GENE-N	21	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T26	T28	17110146
NA	CHEMICAL	GENE-N	21	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T26	T3	17110146
NA	CHEMICAL	GENE-N	21	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T1	T29	17110146
NA	CHEMICAL	GENE-N	21	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T1	T4	17110146
NA	CHEMICAL	GENE-N	21	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T26	T29	17110146
NA	CHEMICAL	GENE-N	21	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T26	T4	17110146
NA	CHEMICAL	GENE-N	21	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T1	T27	17110146
NA	CHEMICAL	GENE-N	21	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T1	T2	17110146
NA	CHEMICAL	GENE-N	21	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T26	T27	17110146
NA	CHEMICAL	GENE-N	21	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (gene, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T26	T2	17110146
NA	CHEMICAL	GENE-Y	21	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T1	T25	17110146
NA	CHEMICAL	GENE-Y	21	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (chemical, 87-96), "middle area" (VGLITNGLAM, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T26	T25	17110146
NA	CHEMICAL	GENE-N	28	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T28	T1	17110146
NA	CHEMICAL	GENE-N	28	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T28	T26	17110146
NA	CHEMICAL	GENE-N	28	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T3	T1	17110146
NA	CHEMICAL	GENE-N	28	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T3	T26	17110146
NA	CHEMICAL	GENE-N	28	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (gene, 222-231).	T28	T29	17110146
NA	CHEMICAL	GENE-N	28	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (gene, 222-231).	T28	T4	17110146
NA	CHEMICAL	GENE-N	28	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (gene, 222-231).	T3	T29	17110146
NA	CHEMICAL	GENE-N	28	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (gene, 222-231).	T3	T4	17110146
NA	CHEMICAL	GENE-N	28	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T28	T27	17110146
NA	CHEMICAL	GENE-N	28	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T28	T2	17110146
NA	CHEMICAL	GENE-N	28	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T3	T27	17110146
NA	CHEMICAL	GENE-N	28	25	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (gene, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T3	T2	17110146
NA	CHEMICAL	GENE-Y	28	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T28	T25	17110146
NA	CHEMICAL	GENE-Y	28	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (VGLITNGLAM, 38-47, and chemical, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T3	T25	17110146
NA	CHEMICAL	GENE-N	25	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T27	T28	17110146
NA	CHEMICAL	GENE-N	25	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T27	T3	17110146
NA	CHEMICAL	GENE-N	25	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T2	T28	17110146
NA	CHEMICAL	GENE-N	25	28	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and gene, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T2	T3	17110146
NA	CHEMICAL	GENE-N	25	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T27	T1	17110146
NA	CHEMICAL	GENE-N	25	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T27	T26	17110146
NA	CHEMICAL	GENE-N	25	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T2	T1	17110146
NA	CHEMICAL	GENE-N	25	21	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (gene, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T2	T26	17110146
NA	CHEMICAL	GENE-N	25	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T27	T29	17110146
NA	CHEMICAL	GENE-N	25	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T27	T4	17110146
NA	CHEMICAL	GENE-N	25	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T2	T29	17110146
NA	CHEMICAL	GENE-N	25	33	And the most probable active sites of P2Y12 were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (gene, 222-231).	T2	T4	17110146
NA	CHEMICAL	GENE-Y	25	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T27	T25	17110146
NA	CHEMICAL	GENE-Y	25	7	And the most probable active sites of gene were predicted using the scoring matrix, which include three distant areas: "head area" (LGTGPLRTFV, 87-96), "middle area" (chemical, 38-47, and LGAKILSVVI, 139-148), and "bottom area" (RTRGVGKVPR, 222-231).	T2	T25	17110146
NA	CHEMICAL	GENE-Y	9	14	Subsequently the structural model of P2Y12 was docked with chemical/ADP in comparison with P2Y1 (gene).	T5	T32	17110146
NA	CHEMICAL	GENE-Y	9	5	Subsequently the structural model of gene was docked with chemical/ADP in comparison with P2Y1 (PDB code 1ddd).	T5	T30	17110146
NA	CHEMICAL	GENE-Y	9	5	Subsequently the structural model of gene2 was docked with chemical/ADP in comparison with gene (PDB code 1ddd).	T5	T31	17110146
NA	CHEMICAL	GENE-Y	9	14	Subsequently the structural model of P2Y12 was docked with ATP/chemical in comparison with P2Y1 (gene).	T6	T32	17110146
NA	CHEMICAL	GENE-Y	9	5	Subsequently the structural model of gene was docked with ATP/chemical in comparison with P2Y1 (PDB code 1ddd).	T6	T30	17110146
NA	CHEMICAL	GENE-Y	9	5	Subsequently the structural model of gene2 was docked with ATP/chemical in comparison with gene (PDB code 1ddd).	T6	T31	17110146
CPR:4	CHEMICAL	GENE-Y	12	4	Our results imply that gene has the potential to be inhibited by ADP/chemical analogs, and it suggests that gene acts as a target of new drugs that inhibit platelet aggregation.	T11	T33	17110146
NA	CHEMICAL	GENE-Y	12	4	Our results imply that gene has the potential to be inhibited by ADP/chemical analogs, and it suggests that gene acts as a target of new drugs that inhibit platelet aggregation.	T11	T34	17110146
CPR:4	CHEMICAL	GENE-Y	12	4	Our results imply that gene has the potential to be inhibited by chemical/ATP analogs, and it suggests that gene acts as a target of new drugs that inhibit platelet aggregation.	T10	T33	17110146
NA	CHEMICAL	GENE-Y	12	4	Our results imply that gene has the potential to be inhibited by chemical/ATP analogs, and it suggests that gene acts as a target of new drugs that inhibit platelet aggregation.	T10	T34	17110146
NA	CHEMICAL	GENE-Y	0	9	chemical (E2) stimulates BC cells proliferation by binding the gene (ER).	T6	T18	17125913
NA	CHEMICAL	GENE-Y	0	11	chemical (E2) stimulates BC cells proliferation by binding the estrogen receptor (gene).	T6	T23	17125913
NA	CHEMICAL	GENE-Y	1	9	Estradiol (chemical) stimulates BC cells proliferation by binding the gene (ER).	T8	T18	17125913
NA	CHEMICAL	GENE-Y	1	11	Estradiol (chemical) stimulates BC cells proliferation by binding the estrogen receptor (gene).	T8	T23	17125913
NA	CHEMICAL	GENE-Y	8	18	Purpose of our study was to evaluate whether chemical regulates MCF-7 cell proliferation by activating ERK1/2, Akt and gene kinases.	T4	T26	17125913
NA	CHEMICAL	GENE-N	8	19	Purpose of our study was to evaluate whether chemical regulates MCF-7 cell proliferation by activating ERK1/2, Akt and PDGFRalpha gene.	T4	T27	17125913
NA	CHEMICAL	GENE-N	8	15	Purpose of our study was to evaluate whether chemical regulates MCF-7 cell proliferation by activating gene, Akt and PDGFRalpha kinases.	T4	T24	17125913
NA	CHEMICAL	GENE-N	8	16	Purpose of our study was to evaluate whether chemical regulates MCF-7 cell proliferation by activating ERK1/2, gene and PDGFRalpha kinases.	T4	T25	17125913
NA	CHEMICAL	GENE-Y	0	6	chemical increased cell proliferation and the gene-antagonist ICI 182,780 blunted it.	T5	T28	17125913
CPR:4	CHEMICAL	GENE-Y	0	2	chemical decreased gene expression, but not ERbeta.	T7	T31	17125913
NA	CHEMICAL	GENE-Y	0	6	chemical decreased ERalpha expression, but not gene.	T7	T32	17125913
CPR:3	CHEMICAL	GENE-Y	0	6	chemical also increased ERK1/2, Akt and gene phosphorylation while ICI blocked it.	T9	T35	17125913
NA	CHEMICAL	GENE-N	0	3	chemical also increased gene, Akt and PDGFRalpha phosphorylation while ICI blocked it.	T9	T33	17125913
CPR:3	CHEMICAL	GENE-N	0	4	chemical also increased ERK1/2, gene and PDGFRalpha phosphorylation while ICI blocked it.	T9	T34	17125913
CPR:3	CHEMICAL	GENE-Y	0	3	chemical rapidly increased gene, c-fos and PDGFA expression.	T10	T39	17125913
CPR:3	CHEMICAL	GENE-N	0	4	chemical rapidly increased c-jun, gene and PDGFA expression.	T10	T40	17125913
CPR:3	CHEMICAL	GENE-N	0	3	chemical rapidly increased gene, c-fos and PDGFA expression.	T10	T39	17125913
CPR:3	CHEMICAL	GENE-Y	0	6	chemical rapidly increased c-jun, c-fos and gene expression.	T10	T41	17125913
CPR:3	CHEMICAL	GENE-Y	0	4	chemical rapidly increased c-jun, gene and PDGFA expression.	T10	T40	17125913
NA	CHEMICAL	GENE-N	6	9	Cells were also co-incubated with the chemical and specific gene inhibitors, which blocked the chemical-stimulated proliferation.	T11	T42	17125913
NA	CHEMICAL	GENE-N	6	9	Cells were also co-incubated with the chemical and specific gene inhibitors, which blocked the chemical-stimulated proliferation.	T12	T42	17125913
CPR:3	CHEMICAL	GENE-Y	6	18	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and gene kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	T1	T16	17125913
NA	CHEMICAL	GENE-Y	6	30	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an gene-dependent mechanism.	T1	T22	17125913
CPR:3	CHEMICAL	GENE-N	6	19	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha gene activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	T1	T17	17125913
NA	CHEMICAL	GENE-N	6	16	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, gene and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	T1	T15	17125913
CPR:3	CHEMICAL	GENE-Y	6	25	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, gene and PDGFA by an ERalpha-dependent mechanism.	T1	T20	17125913
CPR:3	CHEMICAL	GENE-N	6	24	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating gene, c-jun and PDGFA by an ERalpha-dependent mechanism.	T1	T19	17125913
CPR:3	CHEMICAL	GENE-N	6	25	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, gene and PDGFA by an ERalpha-dependent mechanism.	T1	T20	17125913
CPR:3	CHEMICAL	GENE-Y	6	27	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and gene by an ERalpha-dependent mechanism.	T1	T21	17125913
CPR:3	CHEMICAL	GENE-Y	6	24	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating Akt, ERK1/2 and PDGFRalpha kinases activity likely by activating gene, c-jun and PDGFA by an ERalpha-dependent mechanism.	T1	T19	17125913
CPR:3	CHEMICAL	GENE-N	6	15	In conclusion, our results indicate that chemical increases BC cell proliferation in vitro by stimulating gene, ERK1/2 and PDGFRalpha kinases activity likely by activating c-fos, c-jun and PDGFA by an ERalpha-dependent mechanism.	T1	T14	17125913
NA	CHEMICAL	GENE-Y	0	2	chemical (gene) analogs constitute the most widely employed medical treatment for prostatic cancer.	T1	T17	17202804
NA	CHEMICAL	GENE-Y	0	2	chemical (gene) analogs constitute the most widely employed medical treatment for prostatic cancer.	T1	T54	17202804
NA	CHEMICAL	GENE-Y	0	2	chemical (gene) analogs constitute the most widely employed medical treatment for prostatic cancer.	T27	T17	17202804
NA	CHEMICAL	GENE-Y	0	2	chemical (gene) analogs constitute the most widely employed medical treatment for prostatic cancer.	T27	T54	17202804
NA	CHEMICAL	GENE-Y	2	0	gene (chemical) analogs constitute the most widely employed medical treatment for prostatic cancer.	T17	T1	17202804
NA	CHEMICAL	GENE-Y	2	0	gene (chemical) analogs constitute the most widely employed medical treatment for prostatic cancer.	T17	T27	17202804
NA	CHEMICAL	GENE-Y	2	0	gene (chemical) analogs constitute the most widely employed medical treatment for prostatic cancer.	T54	T1	17202804
NA	CHEMICAL	GENE-Y	2	0	gene (chemical) analogs constitute the most widely employed medical treatment for prostatic cancer.	T54	T27	17202804
NA	CHEMICAL	GENE-N	2	9	Since the chemical receptor has been shown to affect gene function, we considered that part of chemical analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	T18	T56	17202804
NA	CHEMICAL	GENE-N	2	9	Since the chemical receptor has been shown to affect gene function, we considered that part of chemical analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	T19	T56	17202804
NA	CHEMICAL	GENE-N	2	9	Since the chemical receptor has been shown to affect gene function, we considered that part of chemical analog actions on prostate cells may be mediated through modulation of the human androgen receptor.	T57	T56	17202804
NA	CHEMICAL	GENE-Y	2	32	Since the chemical receptor has been shown to affect sex steroid hormone receptor function, we considered that part of chemical analog actions on prostate cells may be mediated through modulation of the gene.	T18	T58	17202804
NA	CHEMICAL	GENE-Y	2	32	Since the chemical receptor has been shown to affect sex steroid hormone receptor function, we considered that part of chemical analog actions on prostate cells may be mediated through modulation of the gene.	T19	T58	17202804
NA	CHEMICAL	GENE-Y	2	32	Since the chemical receptor has been shown to affect sex steroid hormone receptor function, we considered that part of chemical analog actions on prostate cells may be mediated through modulation of the gene.	T57	T58	17202804
NA	CHEMICAL	GENE-Y	8	26	Using a model HEK293 cell line expressing the chemical receptor, we demonstrated a novel signalling pathway of the chemical receptor that induces nuclear translocation of the gene that renders it transcriptionally inactive.	T20	T61	17202804
NA	CHEMICAL	GENE-Y	8	26	Using a model HEK293 cell line expressing the chemical receptor, we demonstrated a novel signalling pathway of the chemical receptor that induces nuclear translocation of the gene that renders it transcriptionally inactive.	T21	T61	17202804
NA	CHEMICAL	GENE-N	5	17	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase c-Src and the focal adhesion protein/gene, Hic-5.	T23	T28	17202804
NA	CHEMICAL	GENE-N	5	17	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase c-Src and the focal adhesion protein/gene, Hic-5.	T24	T28	17202804
NA	CHEMICAL	GENE-N	5	15	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase c-Src and the gene/steroid receptor co-factor, Hic-5.	T23	T66	17202804
NA	CHEMICAL	GENE-N	5	15	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase c-Src and the gene/steroid receptor co-factor, Hic-5.	T24	T66	17202804
NA	CHEMICAL	GENE-Y	5	12	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase gene and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T23	T65	17202804
NA	CHEMICAL	GENE-Y	5	12	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase gene and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T24	T65	17202804
NA	CHEMICAL	GENE-Y	5	20	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase c-Src and the focal adhesion protein/steroid receptor co-factor, gene.	T23	T29	17202804
NA	CHEMICAL	GENE-Y	5	20	This mechanism involves the calcium-dependent chemical kinase Pyk2, the non-receptor chemical kinase c-Src and the focal adhesion protein/steroid receptor co-factor, gene.	T24	T29	17202804
NA	CHEMICAL	GENE-Y	5	7	This mechanism involves the calcium-dependent chemical kinase gene, the non-receptor chemical kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T23	T63	17202804
NA	CHEMICAL	GENE-Y	5	7	This mechanism involves the calcium-dependent chemical kinase gene, the non-receptor chemical kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T24	T63	17202804
NA	CHEMICAL	GENE-N	4	9	This mechanism involves the chemical-dependent tyrosine kinase Pyk2, the gene c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T22	T64	17202804
NA	CHEMICAL	GENE-N	4	17	This mechanism involves the chemical-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/gene, Hic-5.	T22	T28	17202804
NA	CHEMICAL	GENE-N	4	15	This mechanism involves the chemical-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the gene/steroid receptor co-factor, Hic-5.	T22	T66	17202804
NA	CHEMICAL	GENE-N	4	5	This mechanism involves the chemical-dependent gene Pyk2, the non-receptor gene c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T22	T62	17202804
NA	CHEMICAL	GENE-Y	4	12	This mechanism involves the chemical-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase gene and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T22	T65	17202804
NA	CHEMICAL	GENE-Y	4	20	This mechanism involves the chemical-dependent tyrosine kinase Pyk2, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, gene.	T22	T29	17202804
NA	CHEMICAL	GENE-Y	4	7	This mechanism involves the chemical-dependent tyrosine kinase gene, the non-receptor tyrosine kinase c-Src and the focal adhesion protein/steroid receptor co-factor, Hic-5.	T22	T63	17202804
NA	CHEMICAL	GENE-Y	6	13	In this setting there is a chemical-induced association and nuclear translocation of the gene with Hic-5.	T2	T31	17202804
NA	CHEMICAL	GENE-Y	6	13	In this setting there is a chemical-induced association and nuclear translocation of the gene with Hic-5.	T30	T31	17202804
NA	CHEMICAL	GENE-Y	6	16	In this setting there is a chemical-induced association and nuclear translocation of the androgen receptor with gene.	T2	T32	17202804
NA	CHEMICAL	GENE-Y	6	16	In this setting there is a chemical-induced association and nuclear translocation of the androgen receptor with gene.	T30	T32	17202804
NA	CHEMICAL	GENE-Y	0	28	chemical-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged gene.	T33	T39	17202804
NA	CHEMICAL	GENE-Y	0	28	chemical-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged gene.	T38	T39	17202804
NA	CHEMICAL	GENE-Y	0	28	chemical-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged gene.	T3	T39	17202804
NA	CHEMICAL	GENE-Y	0	28	chemical-induced Pyk2 activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged gene.	T4	T39	17202804
NA	CHEMICAL	GENE-Y	0	9	chemical-induced Pyk2 activation opposed the association of Hic-5 with gene as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human gene.	T33	T36	17202804
NA	CHEMICAL	GENE-Y	0	9	chemical-induced Pyk2 activation opposed the association of Hic-5 with gene as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human gene.	T38	T36	17202804
CPR:4	CHEMICAL	GENE-Y	0	9	chemical-induced Pyk2 activation opposed the association of Hic-5 with gene as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human gene.	T3	T36	17202804
NA	CHEMICAL	GENE-Y	0	9	chemical-induced Pyk2 activation opposed the association of Hic-5 with gene as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human gene.	T4	T36	17202804
NA	CHEMICAL	GENE-Y	0	7	chemical-induced Pyk2 activation opposed the association of gene with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T33	T35	17202804
NA	CHEMICAL	GENE-Y	0	7	chemical-induced Pyk2 activation opposed the association of gene with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T38	T35	17202804
CPR:4	CHEMICAL	GENE-Y	0	7	chemical-induced Pyk2 activation opposed the association of gene with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T3	T35	17202804
NA	CHEMICAL	GENE-Y	0	7	chemical-induced Pyk2 activation opposed the association of gene with androgen receptor as overexpression of a dominant negative Pyk2 enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T4	T35	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T33	T34	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T33	T37	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T38	T34	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T38	T37	17202804
CPR:3	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T3	T34	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T3	T37	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T4	T34	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation opposed the association of Hic-5 with androgen receptor as overexpression of a dominant negative gene enhanced the chemical-induced nuclear translocation of a green fluorescent protein-tagged human androgen receptor.	T4	T37	17202804
NA	CHEMICAL	GENE-Y	0	16	chemical-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the gene.	T40	T43	17202804
NA	CHEMICAL	GENE-Y	0	16	chemical-induced c-Src activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the gene.	T5	T43	17202804
NA	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.	T40	T41	17202804
CPR:3	CHEMICAL	GENE-Y	0	1	chemical-induced gene activation resulted in the phosphorylation of expressed Hic-5 and promoted its association with the human androgen receptor.	T5	T41	17202804
NA	CHEMICAL	GENE-Y	0	9	chemical-induced c-Src activation resulted in the phosphorylation of expressed gene and promoted its association with the human androgen receptor.	T40	T42	17202804
NA	CHEMICAL	GENE-Y	0	9	chemical-induced c-Src activation resulted in the phosphorylation of expressed gene and promoted its association with the human androgen receptor.	T5	T42	17202804
CPR:3	CHEMICAL	GENE-Y	3	12	In contrast to chemical, GnRH-induced nuclear translocation did not transcriptionally activate the gene.	T6	T45	17202804
NA	CHEMICAL	GENE-Y	3	4	In contrast to chemical, gene-induced nuclear translocation did not transcriptionally activate the androgen receptor.	T6	T44	17202804
NA	CHEMICAL	GENE-Y	3	4	In contrast to chemical, gene-induced nuclear translocation did not transcriptionally activate the androgen receptor.	T6	T7	17202804
NA	CHEMICAL	GENE-Y	4	12	In contrast to testosterone, chemical-induced nuclear translocation did not transcriptionally activate the gene.	T44	T45	17202804
NA	CHEMICAL	GENE-Y	4	12	In contrast to testosterone, chemical-induced nuclear translocation did not transcriptionally activate the gene.	T7	T45	17202804
NA	CHEMICAL	GENE-Y	4	8	We then demonstrated that chemical can also stimulate gene mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.	T46	T47	17202804
NA	CHEMICAL	GENE-Y	4	8	We then demonstrated that chemical can also stimulate gene mobilization in human prostate PC3, BPH-1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.	T8	T47	17202804
NA	CHEMICAL	GENE-Y	33	3	To determine if gene could antagonize androgen effects in normal tissue, we examined the effect of gene on rat ventral prostate organ cultures and demonstrated that gene can functionally antagonize the actions of chemical on prostate cell proliferation and tissue growth.	T12	T10	17202804
NA	CHEMICAL	GENE-Y	33	3	To determine if gene could antagonize androgen effects in normal tissue, we examined the effect of gene on rat ventral prostate organ cultures and demonstrated that gene can functionally antagonize the actions of chemical on prostate cell proliferation and tissue growth.	T12	T11	17202804
NA	CHEMICAL	GENE-Y	33	3	To determine if gene could antagonize androgen effects in normal tissue, we examined the effect of gene on rat ventral prostate organ cultures and demonstrated that gene can functionally antagonize the actions of chemical on prostate cell proliferation and tissue growth.	T12	T48	17202804
NA	CHEMICAL	GENE-Y	33	3	To determine if gene could antagonize androgen effects in normal tissue, we examined the effect of gene on rat ventral prostate organ cultures and demonstrated that gene can functionally antagonize the actions of chemical on prostate cell proliferation and tissue growth.	T12	T49	17202804
NA	CHEMICAL	GENE-Y	33	3	To determine if gene could antagonize androgen effects in normal tissue, we examined the effect of gene on rat ventral prostate organ cultures and demonstrated that gene can functionally antagonize the actions of chemical on prostate cell proliferation and tissue growth.	T12	T50	17202804
NA	CHEMICAL	GENE-Y	33	3	To determine if gene could antagonize androgen effects in normal tissue, we examined the effect of gene on rat ventral prostate organ cultures and demonstrated that gene can functionally antagonize the actions of chemical on prostate cell proliferation and tissue growth.	T12	T9	17202804
NA	CHEMICAL	GENE-Y	3	14	This antagonism of chemical action by GnRH may underlie in part the capacity of gene activation to inhibit prostate tumor growth.	T13	T52	17202804
NA	CHEMICAL	GENE-Y	3	6	This antagonism of chemical action by gene may underlie in part the capacity of gene receptor activation to inhibit prostate tumor growth.	T13	T14	17202804
NA	CHEMICAL	GENE-Y	3	6	This antagonism of chemical action by gene may underlie in part the capacity of gene receptor activation to inhibit prostate tumor growth.	T13	T15	17202804
NA	CHEMICAL	GENE-Y	3	6	This antagonism of chemical action by gene may underlie in part the capacity of gene receptor activation to inhibit prostate tumor growth.	T13	T51	17202804
NA	CHEMICAL	GENE-Y	14	26	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and chemical (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T16	T47	17218486
NA	CHEMICAL	GENE-Y	14	31	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and chemical (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T16	T48	17218486
NA	CHEMICAL	GENE-Y	11	26	Recently, it was reported that METH, AMPH, POHA, and the TAs chemical (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T14	T47	17218486
NA	CHEMICAL	GENE-Y	11	31	Recently, it was reported that METH, AMPH, POHA, and the TAs chemical (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T14	T48	17218486
NA	CHEMICAL	GENE-Y	11	31	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyrchemical (TYR) and beta-phenylethylchemical (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace chemical-associated receptor 1 (gene).	T21	T48	17218486
NA	CHEMICAL	GENE-Y	7	26	Recently, it was reported that METH, AMPH, chemical, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T13	T47	17218486
NA	CHEMICAL	GENE-Y	7	31	Recently, it was reported that METH, AMPH, chemical, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T13	T48	17218486
NA	CHEMICAL	GENE-Y	17	26	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate chemical production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T19	T47	17218486
NA	CHEMICAL	GENE-Y	17	31	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate chemical production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T19	T48	17218486
NA	CHEMICAL	GENE-Y	5	26	Recently, it was reported that chemical, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T11	T47	17218486
NA	CHEMICAL	GENE-Y	5	31	Recently, it was reported that chemical, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T11	T48	17218486
NA	CHEMICAL	GENE-Y	6	26	Recently, it was reported that METH, chemical, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T12	T47	17218486
NA	CHEMICAL	GENE-Y	6	31	Recently, it was reported that METH, chemical, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T12	T48	17218486
NA	CHEMICAL	GENE-Y	15	26	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (chemical) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T18	T47	17218486
NA	CHEMICAL	GENE-Y	15	31	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (TYR) and beta-phenylethylamine (chemical) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T18	T48	17218486
NA	CHEMICAL	GENE-Y	12	26	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (chemical) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing gene (rTAAR1).	T15	T47	17218486
NA	CHEMICAL	GENE-Y	12	31	Recently, it was reported that METH, AMPH, POHA, and the TAs para-tyramine (chemical) and beta-phenylethylamine (PEA) stimulate cAMP production in human embryonic kidney (HEK)-293 cells expressing rat trace amine-associated receptor 1 (gene).	T15	T48	17218486
NA	CHEMICAL	GENE-Y	3	20	The discovery that chemical and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the gene (mTAAR1) and a human-rat chimera (hrChTAAR1).	T22	T50	17218486
NA	CHEMICAL	GENE-Y	3	27	The discovery that chemical and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (gene).	T22	T52	17218486
NA	CHEMICAL	GENE-Y	3	22	The discovery that chemical and AMPH activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (gene) and a human-rat chimera (hrChTAAR1).	T22	T51	17218486
CPR:3	CHEMICAL	GENE-Y	3	8	The discovery that chemical and AMPH activate the gene motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).	T22	T49	17218486
NA	CHEMICAL	GENE-Y	5	20	The discovery that METH and chemical activate the rTAAR1 motivated us to study the effect of these drugs on the gene (mTAAR1) and a human-rat chimera (hrChTAAR1).	T23	T50	17218486
NA	CHEMICAL	GENE-Y	5	27	The discovery that METH and chemical activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (gene).	T23	T52	17218486
NA	CHEMICAL	GENE-Y	5	22	The discovery that METH and chemical activate the rTAAR1 motivated us to study the effect of these drugs on the mouse TAAR1 (gene) and a human-rat chimera (hrChTAAR1).	T23	T51	17218486
CPR:3	CHEMICAL	GENE-Y	5	8	The discovery that METH and chemical activate the gene motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).	T23	T49	17218486
CPR:3	CHEMICAL	GENE-Y	4	29	Furthermore, because S-(+)-isomers of chemical and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of gene.	T25	T53	17218486
CPR:3	CHEMICAL	GENE-Y	6	29	Furthermore, because S-(+)-isomers of METH and chemical are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of gene.	T26	T53	17218486
NA	CHEMICAL	GENE-Y	6	20	In response to METH, AMPH, or chemical exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of gene was concentration- and isomer-dependent.	T30	T36	17218486
NA	CHEMICAL	GENE-Y	11	20	In response to METH, AMPH, or POHA exposure, the accumulation of chemical by HEK-293 cells stably expressing different species of gene was concentration- and isomer-dependent.	T31	T36	17218486
NA	CHEMICAL	GENE-Y	3	20	In response to chemical, AMPH, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of gene was concentration- and isomer-dependent.	T28	T36	17218486
NA	CHEMICAL	GENE-Y	4	20	In response to METH, chemical, or POHA exposure, the accumulation of cAMP by HEK-293 cells stably expressing different species of gene was concentration- and isomer-dependent.	T29	T36	17218486
CPR:3	CHEMICAL	GENE-Y	3	14	EC50 values for chemical were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and gene, respectively.	T1	T39	17218486
CPR:3	CHEMICAL	GENE-Y	3	12	EC50 values for chemical were 0.89, 0.92, and 4.44 microM for rTAAR1, gene, and h-rChTAAR1, respectively.	T1	T38	17218486
CPR:3	CHEMICAL	GENE-Y	3	11	EC50 values for chemical were 0.89, 0.92, and 4.44 microM for gene, mTAAR1, and h-rChTAAR1, respectively.	T1	T37	17218486
NA	CHEMICAL	GENE-Y	0	20	chemical was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the gene but was a partial agonist at h-rChTAAR1.	T3	T41	17218486
NA	CHEMICAL	GENE-Y	0	28	chemical was a potent and full agonist at each species of TAAR1, whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at gene.	T3	T42	17218486
CPR:5	CHEMICAL	GENE-Y	0	11	chemical was a potent and full agonist at each species of gene, whereas TYR was a full agonist for the rodent genes but was a partial agonist at h-rChgene.	T3	T40	17218486
CPR:5	CHEMICAL	GENE-Y	13	20	PEA was a potent and full agonist at each species of TAAR1, whereas chemical was a full agonist for the gene but was a partial agonist at h-rChTAAR1.	T4	T41	17218486
CPR:5	CHEMICAL	GENE-Y	13	28	PEA was a potent and full agonist at each species of TAAR1, whereas chemical was a full agonist for the rodent TAAR1s but was a partial agonist at gene.	T4	T42	17218486
NA	CHEMICAL	GENE-Y	13	11	PEA was a potent and full agonist at each species of gene, whereas chemical was a full agonist for the rodent genes but was a partial agonist at h-rChgene.	T4	T40	17218486
CPR:5	CHEMICAL	GENE-Y	4	11	Interestingly, both isomers of chemical were full agonists at mTAAR1 and gene, whereas both were partial agonists at rTAAR1.	T5	T44	17218486
CPR:5	CHEMICAL	GENE-Y	4	9	Interestingly, both isomers of chemical were full agonists at gene and h-rChTAAR1, whereas both were partial agonists at rTAAR1.	T5	T43	17218486
CPR:5	CHEMICAL	GENE-Y	4	18	Interestingly, both isomers of chemical were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at gene.	T5	T45	17218486
NA	CHEMICAL	GENE-N	18	10	RESULTS: We first showed that expression of the genes encoding gene and heparan chemical 2-sulfotransferase decreased between E13.5 and E17.5.	T1	T27	17221210
NA	CHEMICAL	GENE-Y	8	56	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and gene (Slc2a1; previously known as glucose transporter 2).	T5	T20	17221210
NA	CHEMICAL	GENE-Y	8	43	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), gene (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T17	17221210
NA	CHEMICAL	GENE-Y	8	31	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), gene (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T14	17221210
NA	CHEMICAL	GENE-Y	8	24	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: gene (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T12	17221210
NA	CHEMICAL	GENE-Y	8	40	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as gene), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T16	17221210
NA	CHEMICAL	GENE-Y	8	52	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as gene) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T19	17221210
NA	CHEMICAL	GENE-Y	8	69	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as gene).	T5	T22	17221210
NA	CHEMICAL	GENE-N	8	0	gene-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T11	17221210
NA	CHEMICAL	GENE-Y	8	65	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (gene; previously known as glucose transporter 2).	T5	T21	17221210
NA	CHEMICAL	GENE-Y	8	36	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (gene; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T15	17221210
NA	CHEMICAL	GENE-Y	8	48	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (gene; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T18	17221210
NA	CHEMICAL	GENE-Y	8	30	Insulin-positive cells that developed in the presence of chemical exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (gene), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated glucose transporter), member 2 (Slc2a1; previously known as glucose transporter 2).	T5	T13	17221210
NA	CHEMICAL	GENE-Y	61	43	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), gene (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T17	17221210
NA	CHEMICAL	GENE-Y	61	43	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), gene (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T17	17221210
NA	CHEMICAL	GENE-Y	61	31	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), gene (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T14	17221210
NA	CHEMICAL	GENE-Y	61	31	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), gene (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T14	17221210
NA	CHEMICAL	GENE-Y	61	24	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: gene (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T12	17221210
NA	CHEMICAL	GENE-Y	61	24	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: gene (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T12	17221210
NA	CHEMICAL	GENE-Y	61	40	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as gene), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T16	17221210
NA	CHEMICAL	GENE-Y	61	40	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as gene), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T16	17221210
NA	CHEMICAL	GENE-Y	61	52	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as gene) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T19	17221210
NA	CHEMICAL	GENE-Y	61	52	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as gene) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T19	17221210
NA	CHEMICAL	GENE-N	61	0	gene-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T11	17221210
NA	CHEMICAL	GENE-N	61	0	gene-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T11	17221210
NA	CHEMICAL	GENE-Y	61	65	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (gene; previously known as chemical transporter 2).	T6	T21	17221210
NA	CHEMICAL	GENE-Y	61	65	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (gene; previously known as chemical transporter 2).	T7	T21	17221210
NA	CHEMICAL	GENE-Y	61	36	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (gene; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T15	17221210
NA	CHEMICAL	GENE-Y	61	36	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (gene; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T15	17221210
NA	CHEMICAL	GENE-Y	61	48	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (gene; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T18	17221210
NA	CHEMICAL	GENE-Y	61	48	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (Pdx1), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (gene; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T18	17221210
NA	CHEMICAL	GENE-Y	61	30	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (gene), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T6	T13	17221210
NA	CHEMICAL	GENE-Y	61	30	Insulin-positive cells that developed in the presence of chlorate exhibited a phenotype of mature cells with regard to the expression of the following genes: pancreatic and duodenal homeobox gene 1 (gene), proprotein convertase subtilisin/kexin type 1 (Pcsk1; previously known as pro-hormone convertase 1/3), proprotein convertase subtilisin/kexin type 2 (Pcsk2; previously known as pro-hormone convertase 2) and solute carrier family 2 (facilitated chemical transporter), member 2 (Slc2a1; previously known as chemical transporter 2).	T7	T13	17221210
CPR:3	CHEMICAL	GENE-Y	4	11	Finally, we showed that chemical activated endocrine cell development by inducing gene (Neurog3) expression in early endocrine progenitor cells.	T8	T23	17221210
CPR:3	CHEMICAL	GENE-Y	4	13	Finally, we showed that chemical activated endocrine cell development by inducing neurogenin 3 (gene) expression in early endocrine progenitor cells.	T8	T24	17221210
CPR:9	CHEMICAL	GENE-Y	5	9	The kinetic parameters for the chemical hydration reaction proved gene to possess a kcat of 3.4 x 10(5) s-1 and kcat/KM of 4.9 x 10(7) M-1 s-1 (at pH 7.5 and 20 degrees C).	T13	T30	17228881
NA	CHEMICAL	GENE-Y	1	5	Simple chemical were rather ineffective gene inhibitors, with inhibition constants in the range of 1090-6680 nM.	T16	T37	17228881
CPR:4	CHEMICAL	GENE-Y	9	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, chemical, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T1	T26	17228881
CPR:4	CHEMICAL	GENE-Y	7	23	Some clinically used compounds, such as acetazolamide, chemical, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T22	T26	17228881
CPR:4	CHEMICAL	GENE-Y	8	23	Some clinically used compounds, such as acetazolamide, methazolamide, chemical, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T23	T26	17228881
CPR:4	CHEMICAL	GENE-Y	6	23	Some clinically used compounds, such as chemical, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T21	T26	17228881
CPR:4	CHEMICAL	GENE-Y	11	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, chemical, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T3	T26	17228881
CPR:4	CHEMICAL	GENE-Y	10	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, chemical, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T2	T26	17228881
CPR:4	CHEMICAL	GENE-Y	20	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and indisulam, or the orphan drug chemical, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T7	T26	17228881
CPR:4	CHEMICAL	GENE-Y	12	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, chemical, sulpiride, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T4	T26	17228881
CPR:4	CHEMICAL	GENE-Y	15	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, sulpiride, and chemical, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T6	T26	17228881
CPR:4	CHEMICAL	GENE-Y	13	23	Some clinically used compounds, such as acetazolamide, methazolamide, ethoxzolamide, dichlorophenamide, dorzolamide, brinzolamide, topiramate, chemical, and indisulam, or the orphan drug benzolamide, showed effective gene inhibitory activity, with inhibition constants of 0.8-79 nM.	T5	T26	17228881
CPR:4	CHEMICAL	GENE-Y	4	18	The best inhibitors were chemical and sulpiride (KI values of 0.8-0.9 nM), the latter compound being also a gene-selective inhibitor.	T8	T27	17228881
CPR:4	CHEMICAL	GENE-Y	6	18	The best inhibitors were brinzolamide and chemical (KI values of 0.8-0.9 nM), the latter compound being also a gene-selective inhibitor.	T9	T27	17228881
CPR:4	CHEMICAL	GENE-Y	13	22	The metallic taste reported as a side effect after the treatment with systemic chemical may be due to the inhibition of the gene.	T10	T28	17228881
CPR:9	CHEMICAL	GENE-Y	38	28	Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant CO2 hydrase activity of enamel gene, which leads to the formation of protons and chemical and may have a role in cariogenesis.	T12	T29	17228881
CPR:9	CHEMICAL	GENE-Y	23	28	Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant chemical hydrase activity of enamel gene, which leads to the formation of protons and bicarbonate and may have a role in cariogenesis.	T11	T29	17228881
NA	CHEMICAL	GENE-N	3	5	Transmembrane isoforms of chemical cyclases (gene) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to calcium entry.	T5	T28	17229090
NA	CHEMICAL	GENE-N	26	3	Transmembrane isoforms of gene (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to chemical entry.	T4	T24	17229090
NA	CHEMICAL	GENE-N	26	5	Transmembrane isoforms of adenylate cyclases (gene) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate cAMP production in response to chemical entry.	T4	T28	17229090
CPR:9	CHEMICAL	GENE-N	21	3	Transmembrane isoforms of gene (AC) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate chemical production in response to calcium entry.	T3	T24	17229090
CPR:9	CHEMICAL	GENE-N	21	5	Transmembrane isoforms of adenylate cyclases (gene) integrate a wide variety of extracellular signals from neurotransmitters to morphogens and can also regulate chemical production in response to calcium entry.	T3	T28	17229090
NA	CHEMICAL	GENE-Y	19	9	Based on observations in the barrelless mouse strain, the gene gene (AC1) was involved in the segregation of binocular chemical inputs.	T6	T23	17229090
NA	CHEMICAL	GENE-Y	19	11	Based on observations in the barrelless mouse strain, the Adcy1 gene (gene) was involved in the segregation of binocular chemical inputs.	T6	T25	17229090
NA	CHEMICAL	GENE-Y	10	16	Using a genetic approach we tested the role of the chemical modulated cyclases AC1, AC5 and gene for the segregation retinal fibres.	T7	T47	17229090
NA	CHEMICAL	GENE-Y	10	13	Using a genetic approach we tested the role of the chemical modulated cyclases gene, AC5 and AC8 for the segregation retinal fibres.	T7	T45	17229090
NA	CHEMICAL	GENE-Y	10	14	Using a genetic approach we tested the role of the chemical modulated cyclases AC1, gene and AC8 for the segregation retinal fibres.	T7	T46	17229090
NA	CHEMICAL	GENE-N	20	10	Using a genetic approach we tested the role of the gene AC1, AC5 and AC8 for the segregation chemical fibres.	T8	T44	17229090
NA	CHEMICAL	GENE-Y	20	16	Using a genetic approach we tested the role of the calcium modulated cyclases AC1, AC5 and gene for the segregation chemical fibres.	T8	T47	17229090
NA	CHEMICAL	GENE-Y	20	13	Using a genetic approach we tested the role of the calcium modulated cyclases gene, AC5 and AC8 for the segregation chemical fibres.	T8	T45	17229090
NA	CHEMICAL	GENE-Y	20	14	Using a genetic approach we tested the role of the calcium modulated cyclases AC1, gene and AC8 for the segregation chemical fibres.	T8	T46	17229090
NA	CHEMICAL	GENE-Y	1	7	Ipsilateral chemical axons remained exuberant in the gene(-/-) mice, with overlapping chemical projections from both eyes in the superior colliculus and the visual thalamus.	T1	T12	17229090
NA	CHEMICAL	GENE-Y	1	7	Ipsilateral chemical axons remained exuberant in the gene(-/-) mice, with overlapping chemical projections from both eyes in the superior colliculus and the visual thalamus.	T9	T12	17229090
NA	CHEMICAL	GENE-Y	10	16	Thus, only AC1 is required for the maturation of the chemical axon terminals whereas AC5 and gene are not needed.	T2	T20	17229090
NA	CHEMICAL	GENE-Y	10	2	Thus, only gene is required for the maturation of the chemical axon terminals whereas AC5 and AC8 are not needed.	T2	T18	17229090
NA	CHEMICAL	GENE-Y	10	14	Thus, only AC1 is required for the maturation of the chemical axon terminals whereas gene and AC8 are not needed.	T2	T19	17229090
CPR:4	CHEMICAL	GENE-Y	7	15	Here, we report that the antifibrotic drug chemical (pirfenidone, PFD) elicits growth-inhibitory effects and reduces gene protein levels in human glioma cell lines.	T1	T11	17234158
CPR:4	CHEMICAL	GENE-Y	8	15	Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (chemical, PFD) elicits growth-inhibitory effects and reduces gene protein levels in human glioma cell lines.	T2	T11	17234158
CPR:4	CHEMICAL	GENE-Y	9	15	Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, chemical) elicits growth-inhibitory effects and reduces gene protein levels in human glioma cell lines.	T3	T11	17234158
CPR:4	CHEMICAL	GENE-Y	8	3	This reduction in gene is biologically relevant since chemical treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.	T4	T12	17234158
CPR:4	CHEMICAL	GENE-Y	8	3	This reduction in gene2 is biologically relevant since chemical treatment reduces the growth inhibition of gene-sensitive CCL-64 cells mediated by conditioned media of glioma cells.	T4	T14	17234158
CPR:4	CHEMICAL	GENE-N	0	25	chemical leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta gene furin.	T5	T20	17234158
CPR:4	CHEMICAL	GENE-Y	0	6	chemical leads to a reduction of gene mRNA levels and of the mature gene protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.	T5	T17	17234158
CPR:4	CHEMICAL	GENE-Y	0	6	chemical leads to a reduction of gene mRNA levels and of the mature gene protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.	T5	T18	17234158
CPR:4	CHEMICAL	GENE-Y	0	6	chemical leads to a reduction of gene2 mRNA levels and of the mature gene2 protein due to decreased expression and direct inhibition of the gene pro-protein convertase furin.	T5	T19	17234158
CPR:4	CHEMICAL	GENE-Y	0	27	chemical leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase gene.	T5	T21	17234158
CPR:4	CHEMICAL	GENE-Y	2	9	In addition, chemical reduces the protein levels of the gene, a TGF-beta target gene and furin substrate involved in carcinogenesis.	T6	T22	17234158
CPR:4	CHEMICAL	GENE-Y	2	13	In addition, chemical reduces the protein levels of the matrix metalloproteinase (MMP)-11, a gene target gene and furin substrate involved in carcinogenesis.	T6	T23	17234158
NA	CHEMICAL	GENE-Y	2	17	In addition, chemical reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and gene substrate involved in carcinogenesis.	T6	T24	17234158
NA	CHEMICAL	GENE-Y	3	16	These data define chemical or chemical-related agents as promising agents for human cancers associated with enhanced gene activity.	T7	T10	17234158
NA	CHEMICAL	GENE-Y	3	16	These data define chemical or chemical-related agents as promising agents for human cancers associated with enhanced gene activity.	T8	T10	17234158
NA	CHEMICAL	GENE-N	3	6	UNLABELLED: Bile acid-coenzyme A:chemical N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T7	T32	17256745
NA	CHEMICAL	GENE-Y	3	6	UNLABELLED: Bile acid-coenzyme A:chemical N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T7	T32	17256745
NA	CHEMICAL	GENE-N	2	6	UNLABELLED: Bile acid-chemical:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T6	T32	17256745
NA	CHEMICAL	GENE-Y	2	6	UNLABELLED: Bile acid-chemical:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T6	T32	17256745
CPR:9	CHEMICAL	GENE-Y	18	1	UNLABELLED: gene (BAAT) is the sole enzyme responsible for conjugation of primary and secondary chemical to taurine and glycine.	T2	T21	17256745
CPR:9	CHEMICAL	GENE-N	18	6	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary chemical to taurine and glycine.	T2	T32	17256745
CPR:9	CHEMICAL	GENE-Y	18	6	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary chemical to taurine and glycine.	T2	T32	17256745
NA	CHEMICAL	GENE-N	1	6	UNLABELLED: chemical-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T1	T32	17256745
NA	CHEMICAL	GENE-Y	1	6	UNLABELLED: chemical-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T1	T32	17256745
CPR:9	CHEMICAL	GENE-Y	23	1	UNLABELLED: gene (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and chemical.	T5	T21	17256745
CPR:9	CHEMICAL	GENE-N	23	6	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and chemical.	T5	T32	17256745
CPR:9	CHEMICAL	GENE-Y	23	6	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and chemical.	T5	T32	17256745
CPR:9	CHEMICAL	GENE-Y	21	1	UNLABELLED: gene (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to chemical and glycine.	T3	T21	17256745
CPR:9	CHEMICAL	GENE-N	21	6	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to chemical and glycine.	T3	T32	17256745
CPR:9	CHEMICAL	GENE-Y	21	6	UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to chemical and glycine.	T3	T32	17256745
NA	CHEMICAL	GENE-N	0	6	UchemicalLABELLED: Bile acid-coenzyme A:amino acid chemical-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T8	T32	17256745
NA	CHEMICAL	GENE-Y	0	6	UchemicalLABELLED: Bile acid-coenzyme A:amino acid chemical-acyltransferase (gene) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and glycine.	T8	T32	17256745
CPR:9	CHEMICAL	GENE-N	19	9	The absence or presence of a cytosolic pool of gene has important implications for the intracellular transport of unconjugated/deconjugated chemical.	T9	T30	17256745
CPR:9	CHEMICAL	GENE-Y	19	9	The absence or presence of a cytosolic pool of gene has important implications for the intracellular transport of unconjugated/deconjugated chemical.	T9	T30	17256745
NA	CHEMICAL	GENE-N	5	15	We used immunofluorescence microscopy and chemical permeabilization assays to determine the subcellular location of endogenous gene in primary human and rat hepatocytes.	T10	T31	17256745
NA	CHEMICAL	GENE-Y	5	15	We used immunofluorescence microscopy and chemical permeabilization assays to determine the subcellular location of endogenous gene in primary human and rat hepatocytes.	T10	T31	17256745
CPR:9	CHEMICAL	GENE-N	28	21	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the gene, enzyme that converts riboflavin to chemical) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	T3	T9	17290783
NA	CHEMICAL	GENE-N	28	39	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to chemical) driven by the strong promoters (the regulated RIB1 or constitutive gene) were isolated.	T3	T11	17290783
NA	CHEMICAL	GENE-N	28	36	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the riboflavin kinase, enzyme that converts riboflavin to chemical) driven by the strong promoters (the regulated gene or constitutive TEF1 promoter) were isolated.	T3	T10	17290783
NA	CHEMICAL	GENE-N	28	17	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the gene gene (encoding the riboflavin kinase, enzyme that converts riboflavin to chemical) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	T3	T8	17290783
NA	CHEMICAL	GENE-N	21	39	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the chemical kinase, enzyme that converts chemical to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive gene) were isolated.	T1	T11	17290783
NA	CHEMICAL	GENE-N	21	39	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the chemical kinase, enzyme that converts chemical to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive gene) were isolated.	T2	T11	17290783
NA	CHEMICAL	GENE-N	21	36	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the chemical kinase, enzyme that converts chemical to flavinmononucleotide) driven by the strong promoters (the regulated gene or constitutive TEF1 promoter) were isolated.	T1	T10	17290783
NA	CHEMICAL	GENE-N	21	36	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the FMN1 gene (encoding the chemical kinase, enzyme that converts chemical to flavinmononucleotide) driven by the strong promoters (the regulated gene or constitutive TEF1 promoter) were isolated.	T2	T10	17290783
NA	CHEMICAL	GENE-N	21	17	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the gene gene (encoding the chemical kinase, enzyme that converts chemical to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	T1	T8	17290783
NA	CHEMICAL	GENE-N	21	17	The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the gene gene (encoding the chemical kinase, enzyme that converts chemical to flavinmononucleotide) driven by the strong promoters (the regulated RIB1 or constitutive TEF1 promoter) were isolated.	T2	T8	17290783
NA	CHEMICAL	GENE-N	5	17	The 6-8-fold increase of the chemical kinase activity was shown in the recombinant strains containing the integrated gene gene under the strong constitutive TEF1 promoter.	T5	T14	17290783
NA	CHEMICAL	GENE-N	5	25	The 6-8-fold increase of the chemical kinase activity was shown in the recombinant strains containing the integrated Debaryomyces hansenii FMN1 gene under the strong constitutive gene.	T5	T15	17290783
CPR:4	CHEMICAL	GENE-Y	40	0	gene (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, chemical (DFMO).	T16	T31	1730582
CPR:4	CHEMICAL	GENE-Y	40	3	Mouse ornithine decarboxylase (gene) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, chemical (DFMO).	T16	T36	1730582
NA	CHEMICAL	GENE-Y	22	0	gene (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for chemical and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	T6	T31	1730582
NA	CHEMICAL	GENE-Y	22	3	Mouse ornithine decarboxylase (gene) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for chemical and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).	T6	T36	1730582
NA	CHEMICAL	GENE-Y	1	3	Mouse chemical decarboxylase (gene) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylchemical (DFMO).	T23	T36	1730582
CPR:4	CHEMICAL	GENE-Y	41	0	gene (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (chemical).	T17	T31	1730582
CPR:4	CHEMICAL	GENE-Y	41	3	Mouse ornithine decarboxylase (gene) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (chemical).	T17	T36	1730582
NA	CHEMICAL	GENE-Y	1	34	The chemical binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with gene, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T18	T38	1730582
NA	CHEMICAL	GENE-Y	1	6	The chemical binding lysine in gene was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T18	T37	1730582
NA	CHEMICAL	GENE-Y	25	34	The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with chemical followed by digestion of the carboxymethylated protein with gene, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T21	T38	1730582
NA	CHEMICAL	GENE-Y	25	6	The pyridoxal 5'-phosphate binding lysine in gene was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with chemical followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T21	T37	1730582
NA	CHEMICAL	GENE-Y	4	34	The pyridoxal 5'-phosphate binding chemical in mouse ODC was identified as chemical 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with gene, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T19	T38	1730582
NA	CHEMICAL	GENE-Y	4	34	The pyridoxal 5'-phosphate binding chemical in mouse ODC was identified as chemical 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with gene, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T20	T38	1730582
NA	CHEMICAL	GENE-Y	4	6	The pyridoxal 5'-phosphate binding chemical in gene was identified as chemical 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T19	T37	1730582
NA	CHEMICAL	GENE-Y	4	6	The pyridoxal 5'-phosphate binding chemical in gene was identified as chemical 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T20	T37	1730582
NA	CHEMICAL	GENE-Y	35	6	The pyridoxal 5'-phosphate binding lysine in gene was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase chemical, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.	T22	T37	1730582
NA	CHEMICAL	GENE-N	7	14	This lysine is contained in the sequence chemical, which is found in all known gene from eukaryotes.	T25	T40	1730582
NA	CHEMICAL	GENE-N	7	14	This lysine is contained in the sequence chemical, which is found in all known gene from eukaryotes.	T39	T40	1730582
NA	CHEMICAL	GENE-N	1	7	This chemical is contained in the sequence gene, which is found in all known ODCs from eukaryotes.	T24	T25	1730582
NA	CHEMICAL	GENE-N	1	7	This chemical is contained in the sequence gene, which is found in all known ODCs from eukaryotes.	T24	T39	1730582
NA	CHEMICAL	GENE-N	1	14	This chemical is contained in the sequence PFYAVKC, which is found in all known gene from eukaryotes.	T24	T40	1730582
NA	CHEMICAL	GENE-N	16	25	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the chemical binding lysine in a number of other gene including ODCs from E. coli.	T27	T42	1730582
NA	CHEMICAL	GENE-N	16	12	The preceding amino acids do not conform to the consensus sequence of gene, which contains the chemical binding lysine in a number of other decarboxylases including ODCs from E. coli.	T27	T41	1730582
NA	CHEMICAL	GENE-N	16	27	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the chemical binding lysine in a number of other decarboxylases including gene from E. coli.	T27	T43	1730582
NA	CHEMICAL	GENE-N	2	25	The preceding chemical do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other gene including ODCs from E. coli.	T26	T42	1730582
NA	CHEMICAL	GENE-N	2	12	The preceding chemical do not conform to the consensus sequence of gene, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including ODCs from E. coli.	T26	T41	1730582
NA	CHEMICAL	GENE-N	2	27	The preceding chemical do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including gene from E. coli.	T26	T43	1730582
NA	CHEMICAL	GENE-N	19	25	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding chemical in a number of other gene including ODCs from E. coli.	T28	T42	1730582
NA	CHEMICAL	GENE-N	19	12	The preceding amino acids do not conform to the consensus sequence of gene, which contains the pyridoxal 5'-phosphate binding chemical in a number of other decarboxylases including ODCs from E. coli.	T28	T41	1730582
NA	CHEMICAL	GENE-N	19	27	The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding chemical in a number of other decarboxylases including gene from E. coli.	T28	T43	1730582
NA	CHEMICAL	GENE-Y	11	6	Using a similar procedure to analyze gene labeled by reaction with chemical, it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor.	T1	T32	1730582
NA	CHEMICAL	GENE-Y	19	6	Using a similar procedure to analyze gene labeled by reaction with [5-14C]DFMO, it was found that lysine 69 and chemical 360 formed covalent adducts with the inhibitor.	T3	T32	1730582
NA	CHEMICAL	GENE-Y	16	6	Using a similar procedure to analyze gene labeled by reaction with [5-14C]DFMO, it was found that chemical 69 and cysteine 360 formed covalent adducts with the inhibitor.	T2	T32	1730582
NA	CHEMICAL	GENE-N	20	27	Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -chemical-, which is present in all known gene.	T33	T34	1730582
NA	CHEMICAL	GENE-N	20	27	Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -chemical-, which is present in all known gene.	T5	T34	1730582
NA	CHEMICAL	GENE-N	0	27	chemical 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -WGPTCDGL(I)D-, which is present in all known gene.	T4	T34	1730582
NA	CHEMICAL	GENE-N	0	20	chemical 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -gene-, which is present in all known eukaryote ODCs.	T4	T33	1730582
NA	CHEMICAL	GENE-N	0	20	chemical 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -gene-, which is present in all known eukaryote ODCs.	T4	T5	1730582
CPR:9	CHEMICAL	GENE-Y	6	40	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T18	T36	17311416
CPR:9	CHEMICAL	GENE-Y	6	29	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, gene (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T32	17311416
CPR:9	CHEMICAL	GENE-N	6	19	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the gene of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T28	17311416
CPR:9	CHEMICAL	GENE-N	6	25	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T30	17311416
CPR:9	CHEMICAL	GENE-Y	6	49	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T18	T39	17311416
CPR:9	CHEMICAL	GENE-Y	6	46	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T18	T37	17311416
CPR:9	CHEMICAL	GENE-N	6	38	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T35	17311416
CPR:9	CHEMICAL	GENE-Y	6	36	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T34	17311416
CPR:9	CHEMICAL	GENE-Y	6	34	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T33	17311416
CPR:9	CHEMICAL	GENE-Y	6	47	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T18	T38	17311416
CPR:9	CHEMICAL	GENE-N	6	28	Na+-Dependent transmembrane transport of small neutral chemical, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T18	T31	17311416
NA	CHEMICAL	GENE-Y	6	29	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, gene (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T13	T32	17311416
NA	CHEMICAL	GENE-Y	6	29	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, gene (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T5	T32	17311416
NA	CHEMICAL	GENE-N	6	25	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the gene [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T13	T30	17311416
NA	CHEMICAL	GENE-N	6	25	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the gene [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T5	T30	17311416
NA	CHEMICAL	GENE-Y	6	49	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and gene].	T13	T39	17311416
NA	CHEMICAL	GENE-Y	6	49	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and gene].	T5	T39	17311416
NA	CHEMICAL	GENE-Y	6	46	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (gene), SNAT2, and SNAT4].	T13	T37	17311416
NA	CHEMICAL	GENE-Y	6	46	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (gene), SNAT2, and SNAT4].	T5	T37	17311416
NA	CHEMICAL	GENE-N	6	38	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T13	T35	17311416
NA	CHEMICAL	GENE-N	6	38	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T5	T35	17311416
NA	CHEMICAL	GENE-Y	6	36	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T13	T34	17311416
NA	CHEMICAL	GENE-Y	6	36	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T5	T34	17311416
NA	CHEMICAL	GENE-Y	6	34	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T13	T33	17311416
NA	CHEMICAL	GENE-Y	6	34	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T5	T33	17311416
NA	CHEMICAL	GENE-Y	6	47	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), gene, and SNAT4].	T13	T38	17311416
NA	CHEMICAL	GENE-Y	6	47	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), gene, and SNAT4].	T5	T38	17311416
NA	CHEMICAL	GENE-N	6	28	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [gene, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T13	T31	17311416
NA	CHEMICAL	GENE-N	6	28	Na+-Dependent transmembrane transport of small neutral chemicals, such as glutamine and alanine, is mediated, among others, by the neutral chemical transporters of the solute carrier 1 [gene, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral chemical transporter 1 (SNAT1), SNAT2, and SNAT4].	T5	T31	17311416
CPR:9	CHEMICAL	GENE-Y	10	40	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T21	T36	17311416
CPR:9	CHEMICAL	GENE-Y	10	29	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, gene (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T32	17311416
CPR:9	CHEMICAL	GENE-N	10	19	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the gene of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T28	17311416
CPR:9	CHEMICAL	GENE-N	10	25	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T30	17311416
CPR:9	CHEMICAL	GENE-Y	10	49	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T21	T39	17311416
CPR:9	CHEMICAL	GENE-Y	10	46	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T21	T37	17311416
CPR:9	CHEMICAL	GENE-N	10	38	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T35	17311416
CPR:9	CHEMICAL	GENE-Y	10	36	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T34	17311416
CPR:9	CHEMICAL	GENE-Y	10	34	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T33	17311416
CPR:9	CHEMICAL	GENE-Y	10	47	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T21	T38	17311416
CPR:9	CHEMICAL	GENE-N	10	28	Na+-Dependent transmembrane transport of small neutral amino acids, such as chemical and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T21	T31	17311416
NA	CHEMICAL	GENE-Y	31	40	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T11	T36	17311416
NA	CHEMICAL	GENE-N	31	19	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the gene of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T11	T28	17311416
NA	CHEMICAL	GENE-N	31	25	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T11	T30	17311416
NA	CHEMICAL	GENE-Y	31	49	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T11	T39	17311416
NA	CHEMICAL	GENE-Y	31	46	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T11	T37	17311416
NA	CHEMICAL	GENE-N	31	38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T11	T35	17311416
NA	CHEMICAL	GENE-Y	31	36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T11	T34	17311416
NA	CHEMICAL	GENE-Y	31	34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T11	T33	17311416
NA	CHEMICAL	GENE-Y	31	47	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T11	T38	17311416
NA	CHEMICAL	GENE-N	31	28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, alanine serine chemical transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T11	T31	17311416
CPR:9	CHEMICAL	GENE-Y	12	40	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T23	T36	17311416
NA	CHEMICAL	GENE-Y	12	40	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T9	T36	17311416
CPR:9	CHEMICAL	GENE-N	12	19	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the gene of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T23	T28	17311416
NA	CHEMICAL	GENE-N	12	19	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the gene of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T9	T28	17311416
CPR:9	CHEMICAL	GENE-N	12	25	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T23	T30	17311416
NA	CHEMICAL	GENE-N	12	25	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T9	T30	17311416
CPR:9	CHEMICAL	GENE-Y	12	49	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T23	T39	17311416
NA	CHEMICAL	GENE-Y	12	49	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T9	T39	17311416
CPR:9	CHEMICAL	GENE-Y	12	46	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T23	T37	17311416
NA	CHEMICAL	GENE-Y	12	46	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T9	T37	17311416
NA	CHEMICAL	GENE-N	12	38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T23	T35	17311416
NA	CHEMICAL	GENE-N	12	38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T9	T35	17311416
CPR:9	CHEMICAL	GENE-Y	12	36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T23	T34	17311416
NA	CHEMICAL	GENE-Y	12	36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T9	T34	17311416
CPR:9	CHEMICAL	GENE-Y	12	34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T23	T33	17311416
NA	CHEMICAL	GENE-Y	12	34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T9	T33	17311416
CPR:9	CHEMICAL	GENE-Y	12	47	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T23	T38	17311416
NA	CHEMICAL	GENE-Y	12	47	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T9	T38	17311416
CPR:9	CHEMICAL	GENE-N	12	28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T23	T31	17311416
NA	CHEMICAL	GENE-N	12	28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and chemical, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, chemical serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T9	T31	17311416
NA	CHEMICAL	GENE-Y	30	40	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T10	T36	17311416
NA	CHEMICAL	GENE-N	30	19	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the gene of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T10	T28	17311416
NA	CHEMICAL	GENE-N	30	25	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T10	T30	17311416
NA	CHEMICAL	GENE-Y	30	49	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T10	T39	17311416
NA	CHEMICAL	GENE-Y	30	46	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T10	T37	17311416
NA	CHEMICAL	GENE-N	30	38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T10	T35	17311416
NA	CHEMICAL	GENE-Y	30	36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T10	T34	17311416
NA	CHEMICAL	GENE-Y	30	34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T10	T33	17311416
NA	CHEMICAL	GENE-Y	30	47	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T10	T38	17311416
NA	CHEMICAL	GENE-N	30	28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, alanine chemical cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T10	T31	17311416
NA	CHEMICAL	GENE-Y	40	29	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, gene (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T32	17311416
NA	CHEMICAL	GENE-N	40	19	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the gene of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T28	17311416
NA	CHEMICAL	GENE-N	40	25	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T30	17311416
NA	CHEMICAL	GENE-Y	40	49	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T12	T39	17311416
NA	CHEMICAL	GENE-Y	40	46	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T12	T37	17311416
NA	CHEMICAL	GENE-N	40	38	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T35	17311416
NA	CHEMICAL	GENE-Y	40	36	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T34	17311416
NA	CHEMICAL	GENE-Y	40	34	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T33	17311416
NA	CHEMICAL	GENE-Y	40	47	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T12	T38	17311416
NA	CHEMICAL	GENE-N	40	28	Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [chemical-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T12	T31	17311416
NA	CHEMICAL	GENE-Y	0	40	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [gene (SNAT1), SNAT2, and SNAT4].	T1	T36	17311416
NA	CHEMICAL	GENE-Y	0	29	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, gene (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T32	17311416
NA	CHEMICAL	GENE-N	0	19	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the gene of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T28	17311416
NA	CHEMICAL	GENE-N	0	25	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the gene [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T30	17311416
NA	CHEMICAL	GENE-Y	0	49	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and gene].	T1	T39	17311416
NA	CHEMICAL	GENE-Y	0	46	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (gene), SNAT2, and SNAT4].	T1	T37	17311416
NA	CHEMICAL	GENE-N	0	38	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and gene families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T35	17311416
NA	CHEMICAL	GENE-Y	0	36	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and gene] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T34	17311416
NA	CHEMICAL	GENE-Y	0	34	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (gene), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T33	17311416
NA	CHEMICAL	GENE-Y	0	47	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), gene, and SNAT4].	T1	T38	17311416
NA	CHEMICAL	GENE-N	0	28	chemical-Dependent transmembrane transport of small neutral amino acids, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [gene, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].	T1	T31	17311416
CPR:9	CHEMICAL	GENE-Y	15	31	Here, we describe a new photolabile alanine derivative based on protection of alanine with the chemical (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, gene, and SNAT2.	T17	T41	17311416
CPR:9	CHEMICAL	GENE-Y	15	30	Here, we describe a new photolabile alanine derivative based on protection of alanine with the chemical (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by gene, SNAT1, and SNAT2.	T17	T40	17311416
CPR:9	CHEMICAL	GENE-Y	15	33	Here, we describe a new photolabile alanine derivative based on protection of alanine with the chemical (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and gene.	T17	T42	17311416
CPR:9	CHEMICAL	GENE-Y	6	31	Here, we describe a new photolabile chemical derivative based on protection of chemical with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of chemical transport by ASCT2, gene, and SNAT2.	T15	T41	17311416
CPR:9	CHEMICAL	GENE-Y	6	31	Here, we describe a new photolabile chemical derivative based on protection of chemical with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of chemical transport by ASCT2, gene, and SNAT2.	T16	T41	17311416
CPR:9	CHEMICAL	GENE-Y	6	30	Here, we describe a new photolabile chemical derivative based on protection of chemical with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of chemical transport by gene, SNAT1, and SNAT2.	T15	T40	17311416
CPR:9	CHEMICAL	GENE-Y	6	30	Here, we describe a new photolabile chemical derivative based on protection of chemical with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of chemical transport by gene, SNAT1, and SNAT2.	T16	T40	17311416
CPR:9	CHEMICAL	GENE-Y	6	33	Here, we describe a new photolabile chemical derivative based on protection of chemical with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of chemical transport by ASCT2, SNAT1, and gene.	T15	T42	17311416
CPR:9	CHEMICAL	GENE-Y	6	33	Here, we describe a new photolabile chemical derivative based on protection of chemical with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of chemical transport by ASCT2, SNAT1, and gene.	T16	T42	17311416
CPR:9	CHEMICAL	GENE-Y	16	31	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (chemical) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, gene, and SNAT2.	T19	T41	17311416
CPR:9	CHEMICAL	GENE-Y	16	30	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (chemical) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by gene, SNAT1, and SNAT2.	T19	T40	17311416
CPR:9	CHEMICAL	GENE-Y	16	33	Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (chemical) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and gene.	T19	T42	17311416
NA	CHEMICAL	GENE-Y	4	20	Photolytic release of free chemical results in the generation of significant transient current components in HEK293 cells expressing the ASCT2, gene, and SNAT2 proteins.	T22	T44	17311416
NA	CHEMICAL	GENE-Y	4	19	Photolytic release of free chemical results in the generation of significant transient current components in HEK293 cells expressing the gene, SNAT1, and SNAT2 proteins.	T22	T43	17311416
NA	CHEMICAL	GENE-Y	4	22	Photolytic release of free chemical results in the generation of significant transient current components in HEK293 cells expressing the ASCT2, SNAT1, and gene proteins.	T22	T45	17311416
NA	CHEMICAL	GENE-Y	24	0	gene (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro chemical (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T8	T17	17315258
NA	CHEMICAL	GENE-Y	24	5	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, gene) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro chemical (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T8	T35	17315258
NA	CHEMICAL	GENE-N	24	20	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a gene catalyzing in vitro chemical (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T8	T26	17315258
NA	CHEMICAL	GENE-Y	24	4	Mammalian mitochondrial dihydrolipoamide dehydrogenase (gene, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro chemical (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T8	T34	17315258
NA	CHEMICAL	GENE-Y	38	0	gene (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and chemical (NBT).	T11	T17	17315258
NA	CHEMICAL	GENE-Y	38	5	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, gene) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and chemical (NBT).	T11	T35	17315258
NA	CHEMICAL	GENE-N	38	20	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a gene catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and chemical (NBT).	T11	T26	17315258
NA	CHEMICAL	GENE-Y	38	4	Mammalian mitochondrial dihydrolipoamide dehydrogenase (gene, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and chemical (NBT).	T11	T34	17315258
NA	CHEMICAL	GENE-Y	2	5	Mammalian mitochondrial chemical dehydrogenase (DLDH, gene) catalyzes NAD(+)-dependent oxidation of chemical in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T10	T35	17315258
NA	CHEMICAL	GENE-Y	2	5	Mammalian mitochondrial chemical dehydrogenase (DLDH, gene) catalyzes NAD(+)-dependent oxidation of chemical in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T2	T35	17315258
NA	CHEMICAL	GENE-N	2	20	Mammalian mitochondrial chemical dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of chemical in vivo and can also act as a gene catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T10	T26	17315258
NA	CHEMICAL	GENE-N	2	20	Mammalian mitochondrial chemical dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of chemical in vivo and can also act as a gene catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T2	T26	17315258
NA	CHEMICAL	GENE-Y	2	4	Mammalian mitochondrial chemical dehydrogenase (gene, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of chemical in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T10	T34	17315258
NA	CHEMICAL	GENE-Y	2	4	Mammalian mitochondrial chemical dehydrogenase (gene, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of chemical in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T2	T34	17315258
NA	CHEMICAL	GENE-Y	8	0	gene (DLDH, EC 1.8.1.4) catalyzes chemical-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T15	T17	17315258
NA	CHEMICAL	GENE-Y	8	5	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, gene) catalyzes chemical-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T15	T35	17315258
NA	CHEMICAL	GENE-N	8	20	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes chemical-dependent oxidation of dihydrolipoamide in vivo and can also act as a gene catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T15	T26	17315258
NA	CHEMICAL	GENE-Y	8	4	Mammalian mitochondrial dihydrolipoamide dehydrogenase (gene, EC 1.8.1.4) catalyzes chemical-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T15	T34	17315258
NA	CHEMICAL	GENE-Y	29	0	gene (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (chemical)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T9	T17	17315258
NA	CHEMICAL	GENE-Y	29	5	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, gene) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (chemical)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T9	T35	17315258
NA	CHEMICAL	GENE-N	29	20	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a gene catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (chemical)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T9	T26	17315258
NA	CHEMICAL	GENE-Y	29	4	Mammalian mitochondrial dihydrolipoamide dehydrogenase (gene, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (chemical)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).	T9	T34	17315258
NA	CHEMICAL	GENE-Y	40	0	gene (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (chemical).	T12	T17	17315258
NA	CHEMICAL	GENE-Y	40	5	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, gene) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (chemical).	T12	T35	17315258
NA	CHEMICAL	GENE-N	40	20	Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a gene catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (chemical).	T12	T26	17315258
NA	CHEMICAL	GENE-Y	40	4	Mammalian mitochondrial dihydrolipoamide dehydrogenase (gene, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (chemical).	T12	T34	17315258
NA	CHEMICAL	GENE-N	24	20	Rat brain mitochondrial extracts, used as the source of DLDH, were resolved by nongradient BN-PAGE (9%), which was followed by gene activity staining using chemical as the electron donor and NBT as the electron acceptor.	T13	T36	17315258
NA	CHEMICAL	GENE-Y	24	9	Rat brain mitochondrial extracts, used as the source of gene, were resolved by nongradient BN-PAGE (9%), which was followed by diaphorase activity staining using chemical as the electron donor and NBT as the electron acceptor.	T13	T33	17315258
NA	CHEMICAL	GENE-N	30	20	Rat brain mitochondrial extracts, used as the source of DLDH, were resolved by nongradient BN-PAGE (9%), which was followed by gene activity staining using NADH as the electron donor and chemical as the electron acceptor.	T14	T36	17315258
NA	CHEMICAL	GENE-Y	30	9	Rat brain mitochondrial extracts, used as the source of gene, were resolved by nongradient BN-PAGE (9%), which was followed by diaphorase activity staining using NADH as the electron donor and chemical as the electron acceptor.	T14	T33	17315258
NA	CHEMICAL	GENE-N	23	20	Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures DLDH gene activity using chemical as the substrate.	T1	T40	17315258
NA	CHEMICAL	GENE-Y	23	19	Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures gene dehydrogenase activity using chemical as the substrate.	T1	T39	17315258
NA	CHEMICAL	GENE-N	8	47	Finally, the effects of thiol-reactive reagents such as chemical (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH gene activity.	T4	T28	17315258
NA	CHEMICAL	GENE-N	8	16	Finally, the effects of thiol-reactive reagents such as chemical (NEM) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T4	T23	17315258
NA	CHEMICAL	GENE-N	8	16	Finally, the effects of thiol-reactive reagents such as chemical (NEM) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T4	T25	17315258
NA	CHEMICAL	GENE-Y	8	15	Finally, the effects of thiol-reactive reagents such as chemical (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T4	T22	17315258
NA	CHEMICAL	GENE-Y	8	15	Finally, the effects of thiol-reactive reagents such as chemical (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T4	T24	17315258
NA	CHEMICAL	GENE-Y	8	15	Finally, the effects of thiol-reactive reagents such as chemical (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T4	T27	17315258
NA	CHEMICAL	GENE-N	11	47	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and chemical donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH gene activity.	T6	T28	17315258
NA	CHEMICAL	GENE-N	11	16	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and chemical donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T6	T23	17315258
NA	CHEMICAL	GENE-N	11	16	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and chemical donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T6	T25	17315258
NA	CHEMICAL	GENE-Y	11	15	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and chemical donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T6	T22	17315258
NA	CHEMICAL	GENE-Y	11	15	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and chemical donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T6	T24	17315258
NA	CHEMICAL	GENE-Y	11	15	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (NEM) and chemical donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T6	T27	17315258
NA	CHEMICAL	GENE-N	4	47	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH gene activity.	T3	T28	17315258
NA	CHEMICAL	GENE-N	4	47	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH gene activity.	T7	T28	17315258
NA	CHEMICAL	GENE-N	4	16	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T3	T23	17315258
NA	CHEMICAL	GENE-N	4	16	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T3	T25	17315258
NA	CHEMICAL	GENE-N	4	16	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T7	T23	17315258
NA	CHEMICAL	GENE-N	4	16	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T7	T25	17315258
NA	CHEMICAL	GENE-Y	4	15	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T3	T22	17315258
NA	CHEMICAL	GENE-Y	4	15	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T3	T24	17315258
NA	CHEMICAL	GENE-Y	4	15	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T3	T27	17315258
NA	CHEMICAL	GENE-Y	4	15	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T7	T22	17315258
NA	CHEMICAL	GENE-Y	4	15	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T7	T24	17315258
NA	CHEMICAL	GENE-Y	4	15	Finally, the effects of chemical-reactive reagents such as N-ethylmaleimide (NEM) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these chemical-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T7	T27	17315258
NA	CHEMICAL	GENE-N	9	47	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (chemical) and nitric oxide donors on DLDH diaphorase activity were evaluated, demonstrating that, with this method, DLDH diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH gene activity.	T5	T28	17315258
NA	CHEMICAL	GENE-N	9	16	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (chemical) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T5	T23	17315258
NA	CHEMICAL	GENE-N	9	16	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (chemical) and nitric oxide donors on DLDH gene activity were evaluated, demonstrating that, with this method, DLDH gene activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of DLDH dehydrogenase activity.	T5	T25	17315258
NA	CHEMICAL	GENE-Y	9	15	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (chemical) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T5	T22	17315258
NA	CHEMICAL	GENE-Y	9	15	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (chemical) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T5	T24	17315258
NA	CHEMICAL	GENE-Y	9	15	Finally, the effects of thiol-reactive reagents such as N-ethylmaleimide (chemical) and nitric oxide donors on gene diaphorase activity were evaluated, demonstrating that, with this method, gene diaphorase activity can be determined without having to remove these thiol-reactive reagents that may otherwise interfere with spectrophotometric measurement of gene dehydrogenase activity.	T5	T27	17315258
NA	CHEMICAL	GENE-N	9	12	Immature (reticulated) platelets may modulate the antiplatelet effects of chemical through uninhibited gene (COX)-1 and COX-2.	T2	T19	17319904
NA	CHEMICAL	GENE-Y	9	13	Immature (reticulated) platelets may modulate the antiplatelet effects of chemical through uninhibited cyclooxygenase gene and COX-2.	T2	T20	17319904
NA	CHEMICAL	GENE-Y	9	15	Immature (reticulated) platelets may modulate the antiplatelet effects of chemical through uninhibited cyclooxygenase (COX)-1 and gene.	T2	T21	17319904
NA	CHEMICAL	GENE-N	13	8	Platelet studies included light transmission aggregometry; P-selectin and gene expression, and serum chemical (TxB(2)) levels.	T7	T23	17319904
NA	CHEMICAL	GENE-Y	13	6	Platelet studies included light transmission aggregometry; gene and integrin alpha(IIb)beta(3) expression, and serum chemical (TxB(2)) levels.	T7	T22	17319904
NA	CHEMICAL	GENE-N	15	8	Platelet studies included light transmission aggregometry; P-selectin and gene expression, and serum thromboxane B(2) (chemical) levels.	T8	T23	17319904
NA	CHEMICAL	GENE-Y	15	6	Platelet studies included light transmission aggregometry; gene and integrin alpha(IIb)beta(3) expression, and serum thromboxane B(2) (chemical) levels.	T8	T22	17319904
NA	CHEMICAL	GENE-N	17	7	Baseline platelet aggregation to 1 microg mL(-1) gene, and postaspirin aggregations to 5 microm and 20 microm chemical and gene, were greater in the upper than in the lower tertile of reticulated platelets.	T10	T25	17319904
NA	CHEMICAL	GENE-N	17	7	Baseline platelet aggregation to 1 microg mL(-1) gene, and postaspirin aggregations to 5 microm and 20 microm chemical and gene, were greater in the upper than in the lower tertile of reticulated platelets.	T10	T26	17319904
CPR:3	CHEMICAL	GENE-N	17	3	Stimulated P-selectin and gene expression were also higher in the upper tertile both before and after chemical.	T1	T13	17319904
CPR:3	CHEMICAL	GENE-Y	17	1	Stimulated gene and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after chemical.	T1	T12	17319904
NA	CHEMICAL	GENE-Y	10	24	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of chemical and increased chemical resistance, possibly because of increased reactivity, and uninhibited COX-1 and gene activity.	T3	T18	17319904
NA	CHEMICAL	GENE-Y	10	24	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of chemical and increased chemical resistance, possibly because of increased reactivity, and uninhibited COX-1 and gene activity.	T4	T18	17319904
NA	CHEMICAL	GENE-Y	10	22	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of chemical and increased chemical resistance, possibly because of increased reactivity, and uninhibited gene and COX-2 activity.	T3	T17	17319904
NA	CHEMICAL	GENE-Y	10	22	CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of chemical and increased chemical resistance, possibly because of increased reactivity, and uninhibited gene and COX-2 activity.	T4	T17	17319904
NA	CHEMICAL	GENE-Y	25	9	Utilizing primary mesencephalic neurons, we found expression of both gene (ERalpha) and estrogen receptor beta (ERbeta) with a predominance of ERalpha on both chemical neurons and astrocytes.	T13	T26	17320868
NA	CHEMICAL	GENE-Y	25	14	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and gene (ERbeta) with a predominance of ERalpha on both chemical neurons and astrocytes.	T13	T28	17320868
NA	CHEMICAL	GENE-Y	25	12	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (gene) and estrogen receptor beta (ERbeta) with a predominance of gene on both chemical neurons and astrocytes.	T13	T27	17320868
NA	CHEMICAL	GENE-Y	25	12	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (gene) and estrogen receptor beta (ERbeta) with a predominance of gene on both chemical neurons and astrocytes.	T13	T30	17320868
NA	CHEMICAL	GENE-Y	25	17	Utilizing primary mesencephalic neurons, we found expression of both estrogen receptor alpha (ERalpha) and estrogen receptor beta (gene) with a predominance of ERalpha on both chemical neurons and astrocytes.	T13	T29	17320868
NA	CHEMICAL	GENE-Y	9	12	Utilizing primary mesencephalic neurons, we found expression of both chemical receptor alpha (gene) and chemical receptor beta (ERbeta) with a predominance of gene on both dopamine neurons and astrocytes.	T11	T27	17320868
NA	CHEMICAL	GENE-Y	9	12	Utilizing primary mesencephalic neurons, we found expression of both chemical receptor alpha (gene) and chemical receptor beta (ERbeta) with a predominance of gene on both dopamine neurons and astrocytes.	T11	T30	17320868
NA	CHEMICAL	GENE-Y	9	12	Utilizing primary mesencephalic neurons, we found expression of both chemical receptor alpha (gene) and chemical receptor beta (ERbeta) with a predominance of gene on both dopamine neurons and astrocytes.	T12	T27	17320868
NA	CHEMICAL	GENE-Y	9	12	Utilizing primary mesencephalic neurons, we found expression of both chemical receptor alpha (gene) and chemical receptor beta (ERbeta) with a predominance of gene on both dopamine neurons and astrocytes.	T12	T30	17320868
NA	CHEMICAL	GENE-Y	9	17	Utilizing primary mesencephalic neurons, we found expression of both chemical receptor alpha (ERalpha) and chemical receptor beta (gene) with a predominance of ERalpha on both dopamine neurons and astrocytes.	T11	T29	17320868
NA	CHEMICAL	GENE-Y	9	17	Utilizing primary mesencephalic neurons, we found expression of both chemical receptor alpha (ERalpha) and chemical receptor beta (gene) with a predominance of ERalpha on both dopamine neurons and astrocytes.	T12	T29	17320868
NA	CHEMICAL	GENE-Y	16	23	We also found that 17beta-estradiol protects dopamine neurons from injury induced by the complex I inhibitor, chemical (MPP(+)) in a time- and gene-dependent manner.	T16	T31	17320868
NA	CHEMICAL	GENE-Y	4	23	We also found that chemical protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and gene-dependent manner.	T14	T31	17320868
NA	CHEMICAL	GENE-Y	6	23	We also found that 17beta-estradiol protects chemical neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (MPP(+)) in a time- and gene-dependent manner.	T15	T31	17320868
NA	CHEMICAL	GENE-Y	18	23	We also found that 17beta-estradiol protects dopamine neurons from injury induced by the complex I inhibitor, 1-methyl-4-phenyl pyridinium (chemical) in a time- and gene-dependent manner.	T17	T31	17320868
CPR:6	CHEMICAL	GENE-Y	21	19	At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the gene antagonist, chemical.	T19	T32	17320868
NA	CHEMICAL	GENE-Y	5	19	At least 4 h of chemical pre-treatment was required to elicit protection, an effect that was blocked by the gene antagonist, ICI 182,780.	T18	T32	17320868
NA	CHEMICAL	GENE-Y	22	1	Moreover, gene mediated the protection afforded by estrogen since only the gene agonist, HPTE, but not the ERbeta agonist, DPN, protected against chemical cell loss.	T3	T33	17320868
NA	CHEMICAL	GENE-Y	22	1	Moreover, gene mediated the protection afforded by estrogen since only the gene agonist, HPTE, but not the ERbeta agonist, DPN, protected against chemical cell loss.	T3	T34	17320868
NA	CHEMICAL	GENE-Y	22	17	Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the gene agonist, DPN, protected against chemical cell loss.	T3	T35	17320868
NA	CHEMICAL	GENE-Y	7	1	Moreover, gene mediated the protection afforded by chemical since only the gene agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.	T20	T33	17320868
NA	CHEMICAL	GENE-Y	7	1	Moreover, gene mediated the protection afforded by chemical since only the gene agonist, HPTE, but not the ERbeta agonist, DPN, protected against dopamine cell loss.	T20	T34	17320868
NA	CHEMICAL	GENE-Y	7	17	Moreover, ERalpha mediated the protection afforded by chemical since only the ERalpha agonist, HPTE, but not the gene agonist, DPN, protected against dopamine cell loss.	T20	T35	17320868
NA	CHEMICAL	GENE-Y	19	1	Moreover, gene mediated the protection afforded by estrogen since only the gene agonist, HPTE, but not the ERbeta agonist, chemical, protected against dopamine cell loss.	T2	T33	17320868
NA	CHEMICAL	GENE-Y	19	1	Moreover, gene mediated the protection afforded by estrogen since only the gene agonist, HPTE, but not the ERbeta agonist, chemical, protected against dopamine cell loss.	T2	T34	17320868
CPR:5	CHEMICAL	GENE-Y	19	17	Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the gene agonist, chemical, protected against dopamine cell loss.	T2	T35	17320868
NA	CHEMICAL	GENE-Y	18	10	Since glial cells were shown to express significant levels of gene, we investigated a possible indirect mechanism of chemical-mediated neuroprotection through glial cell interaction.	T4	T24	17320868
NA	CHEMICAL	GENE-Y	7	14	These data indicate that neuroprotection provided by chemical against MPP(+) toxicity is mediated by gene and involves an interplay among at least two cell types.	T8	T25	17320868
NA	CHEMICAL	GENE-Y	9	14	These data indicate that neuroprotection provided by estrogen against chemical toxicity is mediated by gene and involves an interplay among at least two cell types.	T9	T25	17320868
NA	CHEMICAL	GENE-N	10	18	The present study examined the differential cocaine-induced activation of the chemical (cAMP) response element binding protein (gene) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	T8	T15	17324065
CPR:3	CHEMICAL	GENE-N	6	10	The present study examined the differential chemical-induced activation of the gene (CREB) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	T5	T18	17324065
CPR:3	CHEMICAL	GENE-N	6	18	The present study examined the differential chemical-induced activation of the cyclic adenosine monophosphate (cAMP) response element binding protein (gene) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	T5	T15	17324065
NA	CHEMICAL	GENE-N	13	18	The present study examined the differential cocaine-induced activation of the cyclic adenosine monophosphate (chemical) response element binding protein (gene) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	T1	T15	17324065
NA	CHEMICAL	GENE-N	16	0	gene-dependent gene transcription, which may underlie long-lasting drug-induced changes in behavior and the subjective effects of chemical, varies depending on the stage of drug exposure or withdrawal and the cell population involved.	T4	T16	17324065
CPR:3	CHEMICAL	GENE-N	16	7	Using immunohistochemistry, the authors analyzed changes in gene phosphorylation in the NAc after 5 days of chemical, a short or long drug-free period, and a subsequent challenge injection.	T6	T17	17324065
NA	CHEMICAL	GENE-N	1	4	Repeated chemical resulted in gene phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated chemical, but rats challenged after 2 drug-free days yielded a more localized activation of gene in the 3 most dorsomedial zones of the shell.	T7	T12	17324065
CPR:3	CHEMICAL	GENE-N	1	4	Repeated chemical resulted in gene phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated chemical, but rats challenged after 2 drug-free days yielded a more localized activation of gene in the 3 most dorsomedial zones of the shell.	T7	T19	17324065
CPR:3	CHEMICAL	GENE-N	1	4	Repeated chemical resulted in gene phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated chemical, but rats challenged after 2 drug-free days yielded a more localized activation of gene in the 3 most dorsomedial zones of the shell.	T9	T12	17324065
NA	CHEMICAL	GENE-N	1	4	Repeated chemical resulted in gene phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated chemical, but rats challenged after 2 drug-free days yielded a more localized activation of gene in the 3 most dorsomedial zones of the shell.	T9	T19	17324065
CPR:3	CHEMICAL	GENE-N	6	7	The temporal and anatomical determinants of chemical-induced gene activity may indicate functional differences among NAc shell subregions and suggest the involvement of gene in early and late chemical effects.	T2	T13	17324065
NA	CHEMICAL	GENE-N	6	7	The temporal and anatomical determinants of chemical-induced gene activity may indicate functional differences among NAc shell subregions and suggest the involvement of gene in early and late chemical effects.	T2	T14	17324065
NA	CHEMICAL	GENE-N	6	7	The temporal and anatomical determinants of chemical-induced gene activity may indicate functional differences among NAc shell subregions and suggest the involvement of gene in early and late chemical effects.	T3	T13	17324065
NA	CHEMICAL	GENE-N	6	7	The temporal and anatomical determinants of chemical-induced gene activity may indicate functional differences among NAc shell subregions and suggest the involvement of gene in early and late chemical effects.	T3	T14	17324065
CPR:9	CHEMICAL	GENE-Y	7	12	The carboxylation of glutamic acid residues to chemical (Gla) by the gene (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T3	T16	17327402
CPR:9	CHEMICAL	GENE-Y	7	16	The carboxylation of glutamic acid residues to chemical (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gene) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T3	T9	17327402
NA	CHEMICAL	GENE-Y	14	16	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent chemical carboxylase (gene) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T1	T9	17327402
CPR:9	CHEMICAL	GENE-Y	3	12	The carboxylation of chemical residues to gamma-carboxychemical (Gla) by the gene (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T2	T16	17327402
CPR:9	CHEMICAL	GENE-Y	3	16	The carboxylation of chemical residues to gamma-carboxychemical (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gene) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T2	T9	17327402
NA	CHEMICAL	GENE-Y	12	16	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the chemical-dependent gamma-glutamyl carboxylase (gene) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T6	T9	17327402
CPR:9	CHEMICAL	GENE-Y	9	12	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (chemical) by the gene (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T5	T16	17327402
CPR:9	CHEMICAL	GENE-Y	9	16	The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (chemical) by the vitamin K-dependent gamma-glutamyl carboxylase (gene) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	T5	T9	17327402
NA	CHEMICAL	GENE-Y	27	8	Heterozygous mice carrying a null mutation at the gene (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the chemical-dependent clotting factors IX, X, and prothrombin.	T4	T10	17327402
NA	CHEMICAL	GENE-Y	27	34	Heterozygous mice carrying a null mutation at the gamma-carboxylase (Ggcx) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the chemical-dependent clotting factors IX, X, and gene.	T4	T13	17327402
NA	CHEMICAL	GENE-Y	27	9	Heterozygous mice carrying a null mutation at the gamma-carboxylase (gene) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the chemical-dependent clotting factors IX, X, and prothrombin.	T4	T11	17327402
NA	CHEMICAL	GENE-Y	4	9	Genotyping of the single chemical polymorphisms GCLC-129, GCLM-588, GSTA1-52, gene-105 and gene-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T24	17333241
NA	CHEMICAL	GENE-Y	4	9	Genotyping of the single chemical polymorphisms GCLC-129, GCLM-588, GSTA1-52, gene-105 and gene-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T25	17333241
NA	CHEMICAL	GENE-Y	4	17	Genotyping of the single chemical polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and gene were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T16	17333241
NA	CHEMICAL	GENE-Y	4	15	Genotyping of the single chemical polymorphisms GCLC-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of gene and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T15	17333241
NA	CHEMICAL	GENE-Y	4	8	Genotyping of the single chemical polymorphisms GCLC-129, GCLM-588, gene-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T23	17333241
NA	CHEMICAL	GENE-Y	4	6	Genotyping of the single chemical polymorphisms gene-129, GCLM-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T21	17333241
NA	CHEMICAL	GENE-Y	4	7	Genotyping of the single chemical polymorphisms GCLC-129, gene-588, GSTA1-52, GSTP1-105 and GSTP1-114 and deletions of GSTM1 and GSTT1 were performed with real-time PCR or ordinary PCR and subsequent agarose electrophoresis.	T11	T22	17333241
NA	CHEMICAL	GENE-Y	13	6	Furthermore, with respect to GSTM1 and gene there were statistically significant differences in chemical-levels between genotypes among exposed workers but not among controls.	T2	T18	17333241
NA	CHEMICAL	GENE-Y	13	4	Furthermore, with respect to gene and GSTT1 there were statistically significant differences in chemical-levels between genotypes among exposed workers but not among controls.	T2	T17	17333241
NA	CHEMICAL	GENE-Y	8	16	Histamine regulates many functions by binding to four chemical G-coupled receptor proteins (H1R, H2R, H3R and gene).	T23	T31	17334413
NA	CHEMICAL	GENE-Y	8	14	Histamine regulates many functions by binding to four chemical G-coupled receptor proteins (H1R, H2R, gene and H4R).	T23	T30	17334413
NA	CHEMICAL	GENE-Y	8	12	Histamine regulates many functions by binding to four chemical G-coupled receptor proteins (gene, H2R, H3R and H4R).	T23	T57	17334413
NA	CHEMICAL	GENE-Y	8	13	Histamine regulates many functions by binding to four chemical G-coupled receptor proteins (H1R, gene, H3R and H4R).	T23	T59	17334413
NA	CHEMICAL	GENE-N	8	14	Histamine regulates many functions by binding to four chemical G-coupled receptor proteins (H1R, H2R, gene and H4R).	T23	T30	17334413
NA	CHEMICAL	GENE-N	0	8	chemical regulates many functions by binding to four gene (H1R, H2R, H3R and H4R).	T1	T49	17334413
NA	CHEMICAL	GENE-Y	0	16	chemical regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and gene).	T1	T31	17334413
NA	CHEMICAL	GENE-Y	0	14	chemical regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, gene and H4R).	T1	T30	17334413
NA	CHEMICAL	GENE-Y	0	12	chemical regulates many functions by binding to four histamine G-coupled receptor proteins (gene, H2R, H3R and H4R).	T1	T57	17334413
NA	CHEMICAL	GENE-Y	0	13	chemical regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, gene, H3R and H4R).	T1	T59	17334413
NA	CHEMICAL	GENE-N	0	14	chemical regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, gene and H4R).	T1	T30	17334413
NA	CHEMICAL	GENE-N	11	8	As H3R exerts their effects by coupling to gene proteins reducing chemical (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.	T14	T38	17334413
NA	CHEMICAL	GENE-Y	11	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing chemical (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T14	T32	17334413
NA	CHEMICAL	GENE-Y	11	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing chemical (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T14	T46	17334413
NA	CHEMICAL	GENE-N	11	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing chemical (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T14	T32	17334413
NA	CHEMICAL	GENE-N	11	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing chemical (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T14	T46	17334413
NA	CHEMICAL	GENE-N	14	8	As H3R exerts their effects by coupling to gene proteins reducing adenosine 3', 5'-monophosphate (chemical) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.	T19	T38	17334413
NA	CHEMICAL	GENE-Y	14	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (chemical) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T19	T32	17334413
NA	CHEMICAL	GENE-Y	14	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (chemical) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T19	T46	17334413
NA	CHEMICAL	GENE-N	14	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (chemical) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T19	T32	17334413
NA	CHEMICAL	GENE-N	14	1	As gene exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (chemical) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of gene in the regulation of biliary growth.	T19	T46	17334413
CPR:5	CHEMICAL	GENE-Y	6	9	(2) Does in vivo administration of chemical (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T20	T48	17334413
NA	CHEMICAL	GENE-Y	6	9	(2) Does in vivo administration of chemical (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T20	T50	17334413
CPR:5	CHEMICAL	GENE-N	6	9	(2) Does in vivo administration of chemical (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T20	T48	17334413
NA	CHEMICAL	GENE-N	6	9	(2) Does in vivo administration of chemical (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T20	T50	17334413
NA	CHEMICAL	GENE-Y	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T22	T48	17334413
CPR:6	CHEMICAL	GENE-Y	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T22	T50	17334413
NA	CHEMICAL	GENE-Y	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T25	T48	17334413
NA	CHEMICAL	GENE-Y	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T25	T50	17334413
NA	CHEMICAL	GENE-N	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T22	T48	17334413
CPR:6	CHEMICAL	GENE-N	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T22	T50	17334413
NA	CHEMICAL	GENE-N	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T25	T48	17334413
NA	CHEMICAL	GENE-N	11	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (RAMH) (gene agonist), chemical (gene antagonist) or histamine, in the absence/presence of chemical, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T25	T50	17334413
NA	CHEMICAL	GENE-Y	6	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylchemical dihydrobromide (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or chemical, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T24	T48	17334413
NA	CHEMICAL	GENE-Y	6	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylchemical dihydrobromide (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or chemical, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T24	T50	17334413
NA	CHEMICAL	GENE-N	6	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylchemical dihydrobromide (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or chemical, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T24	T48	17334413
NA	CHEMICAL	GENE-N	6	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylchemical dihydrobromide (RAMH) (gene agonist), thioperamide maleate (gene antagonist) or chemical, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T24	T50	17334413
CPR:5	CHEMICAL	GENE-Y	8	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (chemical) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T21	T48	17334413
NA	CHEMICAL	GENE-Y	8	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (chemical) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T21	T50	17334413
CPR:5	CHEMICAL	GENE-N	8	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (chemical) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T21	T48	17334413
NA	CHEMICAL	GENE-N	8	9	(2) Does in vivo administration of (R)-(alpha)-(-)-methylhistamine dihydrobromide (chemical) (gene agonist), thioperamide maleate (gene antagonist) or histamine, in the absence/presence of thioperamide maleate, to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	T21	T50	17334413
NA	CHEMICAL	GENE-N	10	16	and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of chemical-dependent phosphorylation of protein kinase A (PKA)/gene (ERK1/2)/ets-like gene-1 (Elk-1)?	T27	T53	17334413
NA	CHEMICAL	GENE-N	10	13	and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of chemical-dependent phosphorylation of gene (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	T27	T51	17334413
NA	CHEMICAL	GENE-Y	10	20	and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of chemical-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/gene (Elk-1)?	T27	T55	17334413
NA	CHEMICAL	GENE-N	10	20	and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of chemical-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (gene)/ets-like gene-1 (Elk-1)?	T27	T54	17334413
NA	CHEMICAL	GENE-Y	10	22	and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of chemical-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (gene)?	T27	T56	17334413
NA	CHEMICAL	GENE-N	10	16	and (3) Does RAMH inhibit cholangiocyte proliferation by downregulation of chemical-dependent phosphorylation of protein kinase A (gene)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	T27	T52	17334413
NA	CHEMICAL	GENE-N	3	16	and (3) Does chemical inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/gene (ERK1/2)/ets-like gene-1 (Elk-1)?	T26	T53	17334413
NA	CHEMICAL	GENE-N	3	13	and (3) Does chemical inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of gene (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	T26	T51	17334413
NA	CHEMICAL	GENE-Y	3	20	and (3) Does chemical inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/gene (Elk-1)?	T26	T55	17334413
NA	CHEMICAL	GENE-N	3	20	and (3) Does chemical inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (gene)/ets-like gene-1 (Elk-1)?	T26	T54	17334413
NA	CHEMICAL	GENE-Y	3	22	and (3) Does chemical inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (PKA)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (gene)?	T26	T56	17334413
NA	CHEMICAL	GENE-N	3	16	and (3) Does chemical inhibit cholangiocyte proliferation by downregulation of cAMP-dependent phosphorylation of protein kinase A (gene)/extracellular signal-regulated kinase 1/2 (ERK1/2)/ets-like gene-1 (Elk-1)?	T26	T52	17334413
NA	CHEMICAL	GENE-N	25	29	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, chemical levels and PKA, gene and Elk-1 phosphorylation.	T8	T34	17334413
NA	CHEMICAL	GENE-Y	25	31	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, chemical levels and PKA, ERK1/2 and gene phosphorylation.	T8	T35	17334413
NA	CHEMICAL	GENE-N	25	28	Following in vivo treatment of BDL rats with RAMH for 1 week, and in vitro stimulation of BDL cholangiocytes with RAMH, we evaluated cholangiocyte proliferation, chemical levels and gene, ERK1/2 and Elk-1 phosphorylation.	T8	T33	17334413
NA	CHEMICAL	GENE-N	8	29	Following in vivo treatment of BDL rats with chemical for 1 week, and in vitro stimulation of BDL cholangiocytes with chemical, we evaluated cholangiocyte proliferation, cAMP levels and PKA, gene and Elk-1 phosphorylation.	T6	T34	17334413
NA	CHEMICAL	GENE-N	8	29	Following in vivo treatment of BDL rats with chemical for 1 week, and in vitro stimulation of BDL cholangiocytes with chemical, we evaluated cholangiocyte proliferation, cAMP levels and PKA, gene and Elk-1 phosphorylation.	T7	T34	17334413
NA	CHEMICAL	GENE-Y	8	31	Following in vivo treatment of BDL rats with chemical for 1 week, and in vitro stimulation of BDL cholangiocytes with chemical, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and gene phosphorylation.	T6	T35	17334413
NA	CHEMICAL	GENE-Y	8	31	Following in vivo treatment of BDL rats with chemical for 1 week, and in vitro stimulation of BDL cholangiocytes with chemical, we evaluated cholangiocyte proliferation, cAMP levels and PKA, ERK1/2 and gene phosphorylation.	T7	T35	17334413
NA	CHEMICAL	GENE-N	8	28	Following in vivo treatment of BDL rats with chemical for 1 week, and in vitro stimulation of BDL cholangiocytes with chemical, we evaluated cholangiocyte proliferation, cAMP levels and gene, ERK1/2 and Elk-1 phosphorylation.	T6	T33	17334413
NA	CHEMICAL	GENE-N	8	28	Following in vivo treatment of BDL rats with chemical for 1 week, and in vitro stimulation of BDL cholangiocytes with chemical, we evaluated cholangiocyte proliferation, cAMP levels and gene, ERK1/2 and Elk-1 phosphorylation.	T7	T33	17334413
NA	CHEMICAL	GENE-N	9	12	RAMH inhibition of cholangiocyte growth was associated with decreased chemical levels and PKA/gene/Elk-1 phosphorylation.	T17	T40	17334413
NA	CHEMICAL	GENE-Y	9	12	RAMH inhibition of cholangiocyte growth was associated with decreased chemical levels and PKA/ERK1/2/gene phosphorylation.	T17	T41	17334413
NA	CHEMICAL	GENE-N	9	12	RAMH inhibition of cholangiocyte growth was associated with decreased chemical levels and gene/ERK1/2/Elk-1 phosphorylation.	T17	T39	17334413
CPR:4	CHEMICAL	GENE-N	0	12	chemical inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/gene/Elk-1 phosphorylation.	T16	T40	17334413
CPR:4	CHEMICAL	GENE-Y	0	12	chemical inhibition of cholangiocyte growth was associated with decreased cAMP levels and PKA/ERK1/2/gene phosphorylation.	T16	T41	17334413
CPR:4	CHEMICAL	GENE-N	0	12	chemical inhibition of cholangiocyte growth was associated with decreased cAMP levels and gene/ERK1/2/Elk-1 phosphorylation.	T16	T39	17334413
NA	CHEMICAL	GENE-N	2	3	Downregulation of chemical-dependent PKA/gene/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.	T18	T43	17334413
NA	CHEMICAL	GENE-Y	2	3	Downregulation of chemical-dependent PKA/ERK1/2/gene phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.	T18	T44	17334413
NA	CHEMICAL	GENE-N	2	3	Downregulation of chemical-dependent gene/ERK1/2/Elk-1 phosphorylation (by activation of H3R) is important in the inhibition of cholangiocyte growth in liver diseases.	T18	T42	17334413
NA	CHEMICAL	GENE-Y	2	8	Downregulation of chemical-dependent PKA/ERK1/2/Elk-1 phosphorylation (by activation of gene) is important in the inhibition of cholangiocyte growth in liver diseases.	T18	T45	17334413
NA	CHEMICAL	GENE-N	2	8	Downregulation of chemical-dependent PKA/ERK1/2/Elk-1 phosphorylation (by activation of gene) is important in the inhibition of cholangiocyte growth in liver diseases.	T18	T45	17334413
NA	CHEMICAL	GENE-Y	4	0	gene (PRODH) and chemical dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	T9	T12	17344208
NA	CHEMICAL	GENE-Y	4	6	Proline dehydrogenase (PRODH) and chemical dehydrogenase (gene) catalyze the two-step oxidation of proline to glutamate.	T9	T29	17344208
NA	CHEMICAL	GENE-Y	4	2	Proline dehydrogenase (gene) and chemical dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	T9	T19	17344208
CPR:9	CHEMICAL	GENE-Y	14	4	Proline dehydrogenase (PRODH) and gene (P5CDH) catalyze the two-step oxidation of proline to chemical.	T4	T22	17344208
CPR:9	CHEMICAL	GENE-Y	14	0	gene (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to chemical.	T4	T12	17344208
CPR:9	CHEMICAL	GENE-Y	14	6	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (gene) catalyze the two-step oxidation of proline to chemical.	T4	T29	17344208
CPR:9	CHEMICAL	GENE-Y	14	2	Proline dehydrogenase (gene) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to chemical.	T4	T19	17344208
NA	CHEMICAL	GENE-Y	0	4	chemical dehydrogenase (PRODH) and gene (P5CDH) catalyze the two-step oxidation of proline to glutamate.	T1	T22	17344208
NA	CHEMICAL	GENE-Y	0	6	chemical dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (gene) catalyze the two-step oxidation of proline to glutamate.	T1	T29	17344208
NA	CHEMICAL	GENE-Y	0	2	chemical dehydrogenase (gene) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate.	T1	T19	17344208
CPR:9	CHEMICAL	GENE-Y	12	4	Proline dehydrogenase (PRODH) and gene (P5CDH) catalyze the two-step oxidation of chemical to glutamate.	T2	T22	17344208
CPR:9	CHEMICAL	GENE-Y	12	0	gene (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of chemical to glutamate.	T2	T12	17344208
CPR:9	CHEMICAL	GENE-Y	12	6	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (gene) catalyze the two-step oxidation of chemical to glutamate.	T2	T29	17344208
CPR:9	CHEMICAL	GENE-Y	12	2	Proline dehydrogenase (gene) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of chemical to glutamate.	T2	T19	17344208
NA	CHEMICAL	GENE-N	24	11	The 2.0-A resolution structure of Thermus thermophilus PRODH reveals a distorted gene and a hydrophobic alpha-helical domain located above the chemical-terminal ends of the strands of the barrel.	T10	T25	17344208
NA	CHEMICAL	GENE-N	24	18	The 2.0-A resolution structure of Thermus thermophilus PRODH reveals a distorted (betaalpha)(8) barrel catalytic core domain and a gene located above the chemical-terminal ends of the strands of the barrel.	T10	T26	17344208
NA	CHEMICAL	GENE-Y	24	5	The 2.0-A resolution structure of gene reveals a distorted (betaalpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the chemical-terminal ends of the strands of the barrel.	T10	T24	17344208
CPR:9	CHEMICAL	GENE-Y	11	4	Finally, we demonstrate that gene reacts with O(2) producing chemical.	T7	T15	17344208
CPR:9	CHEMICAL	GENE-Y	9	4	Finally, we demonstrate that gene reacts with chemical producing superoxide.	T6	T15	17344208
NA	CHEMICAL	GENE-N	4	18	This is significant because chemical production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between gene.	T8	T18	17344208
CPR:9	CHEMICAL	GENE-Y	4	10	This is significant because chemical production underlies the role of gene in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.	T8	T16	17344208
NA	CHEMICAL	GENE-Y	4	13	This is significant because chemical production underlies the role of human PRODH in gene-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.	T8	T17	17344208
NA	CHEMICAL	GENE-Y	17	20	Creatine (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by chemical methyltransferase absence (gene-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days.	T25	T30	17347380
NA	CHEMICAL	GENE-Y	0	17	chemical (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by gene absence (GAMT-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days.	T1	T34	17347380
NA	CHEMICAL	GENE-Y	0	20	chemical (Cr) levels in skeletal muscle and brain of a mouse model of Cr deficiency caused by guanidinoacetate methyltransferase absence (gene-/-) were studied after Cr supplementation with 2 g.kg body wt-1.day-1 Cr for 35 days.	T1	T30	17347380
NA	CHEMICAL	GENE-Y	0	17	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by gene absence (GAMT-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T11	T34	17347380
NA	CHEMICAL	GENE-Y	0	17	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by gene absence (GAMT-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T12	T34	17347380
NA	CHEMICAL	GENE-Y	0	17	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by gene absence (GAMT-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T21	T34	17347380
NA	CHEMICAL	GENE-Y	0	17	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by gene absence (GAMT-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T3	T34	17347380
NA	CHEMICAL	GENE-Y	0	20	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by guanidinoacetate methyltransferase absence (gene-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T11	T30	17347380
NA	CHEMICAL	GENE-Y	0	20	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by guanidinoacetate methyltransferase absence (gene-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T12	T30	17347380
NA	CHEMICAL	GENE-Y	0	20	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by guanidinoacetate methyltransferase absence (gene-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T21	T30	17347380
NA	CHEMICAL	GENE-Y	0	20	chemicaleatine (chemical) levels in skeletal muscle and brain of a mouse model of chemical deficiency caused by guanidinoacetate methyltransferase absence (gene-/-) were studied after chemical supplementation with 2 g.kg body wt-1.day-1 chemical for 35 days.	T3	T30	17347380
NA	CHEMICAL	GENE-Y	1	19	Localized chemical magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of gene-/- mice before and after Cr supplementation and in control (Con) mice.	T13	T32	17347380
NA	CHEMICAL	GENE-Y	24	19	Localized 1H magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus/hippocampus) and in hind leg muscle of gene-/- mice before and after chemical supplementation and in control (Con) mice.	T14	T32	17347380
NA	CHEMICAL	GENE-Y	5	13	As expected, a signal for chemical was hardly detectable in MR spectra of gene-/- mice before chemical supplementation.	T15	T33	17347380
NA	CHEMICAL	GENE-Y	5	13	As expected, a signal for chemical was hardly detectable in MR spectra of gene-/- mice before chemical supplementation.	T16	T33	17347380
NA	CHEMICAL	GENE-Y	11	15	Only because of the repeated MRS measurements performed in this longitudinal chemical supplementation study on gene-/- mice were we able to discover the initial faster uptake of chemical in skeletal muscle compared with brain, which may represent muscular chemical uptake independent of chemical transporter expression.	T4	T29	17347380
NA	CHEMICAL	GENE-Y	11	15	Only because of the repeated MRS measurements performed in this longitudinal chemical supplementation study on gene-/- mice were we able to discover the initial faster uptake of chemical in skeletal muscle compared with brain, which may represent muscular chemical uptake independent of chemical transporter expression.	T5	T29	17347380
NA	CHEMICAL	GENE-Y	11	15	Only because of the repeated MRS measurements performed in this longitudinal chemical supplementation study on gene-/- mice were we able to discover the initial faster uptake of chemical in skeletal muscle compared with brain, which may represent muscular chemical uptake independent of chemical transporter expression.	T6	T29	17347380
NA	CHEMICAL	GENE-Y	11	15	Only because of the repeated MRS measurements performed in this longitudinal chemical supplementation study on gene-/- mice were we able to discover the initial faster uptake of chemical in skeletal muscle compared with brain, which may represent muscular chemical uptake independent of chemical transporter expression.	T7	T29	17347380
NA	CHEMICAL	GENE-Y	11	14	Our results can provide the basis for additional experiments to optimize chemical supplementation in gene deficiency, as increases in brain chemical are slow in patients after chemical supplementation.	T10	T31	17347380
NA	CHEMICAL	GENE-Y	11	14	Our results can provide the basis for additional experiments to optimize chemical supplementation in gene deficiency, as increases in brain chemical are slow in patients after chemical supplementation.	T8	T31	17347380
NA	CHEMICAL	GENE-Y	11	14	Our results can provide the basis for additional experiments to optimize chemical supplementation in gene deficiency, as increases in brain chemical are slow in patients after chemical supplementation.	T9	T31	17347380
CPR:9	CHEMICAL	GENE-N	7	1	The gene is the predominant chemical degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.	T5	T15	17352685
CPR:4	CHEMICAL	GENE-N	4	1	Consequently, gene inhibitors including chemical and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.	T6	T18	17352685
CPR:4	CHEMICAL	GENE-N	6	1	Consequently, gene inhibitors including cilomilast and chemical have been tested in several models of allergic and irritant skin inflammation.	T7	T18	17352685
NA	CHEMICAL	GENE-Y	17	26	These PDE4 inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the chemical induced skin inflammation in mice and in gene sensitised guinea pigs.	T8	T20	17352685
NA	CHEMICAL	GENE-N	17	1	These gene inhibitors displayed strong anti-inflammatory action in models of allergic contact dermatitis in mice, in the chemical induced skin inflammation in mice and in ovalbumin sensitised guinea pigs.	T8	T19	17352685
CPR:4	CHEMICAL	GENE-N	8	14	Results of early clinical trials with both topically (chemical, CP80,633) and systemically (CC-10004) active gene inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.	T1	T12	17352685
CPR:4	CHEMICAL	GENE-N	9	14	Results of early clinical trials with both topically (cipamfylline, chemical) and systemically (CC-10004) active gene inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.	T2	T12	17352685
NA	CHEMICAL	GENE-Y	14	4	Here, we show that gene also induces expression of arate-limiting enzyme in arginine synthesis, chemical synthetase (AS), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T7	T19	17354225
NA	CHEMICAL	GENE-Y	14	16	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in arginine synthesis, chemical synthetase (gene), thereby linking inflammation with several arginine-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T7	T21	17354225
NA	CHEMICAL	GENE-Y	12	14	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in chemical synthesis, gene (AS), thereby linking inflammation with several chemical-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T6	T20	17354225
NA	CHEMICAL	GENE-Y	12	14	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in chemical synthesis, gene (AS), thereby linking inflammation with several chemical-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T8	T20	17354225
NA	CHEMICAL	GENE-Y	12	4	Here, we show that gene also induces expression of arate-limiting enzyme in chemical synthesis, argininosuccinate synthetase (AS), thereby linking inflammation with several chemical-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T6	T19	17354225
NA	CHEMICAL	GENE-Y	12	4	Here, we show that gene also induces expression of arate-limiting enzyme in chemical synthesis, argininosuccinate synthetase (AS), thereby linking inflammation with several chemical-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T8	T19	17354225
NA	CHEMICAL	GENE-Y	12	16	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in chemical synthesis, argininosuccinate synthetase (gene), thereby linking inflammation with several chemical-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T6	T21	17354225
NA	CHEMICAL	GENE-Y	12	16	Here, we show that TNF-alpha also induces expression of arate-limiting enzyme in chemical synthesis, argininosuccinate synthetase (gene), thereby linking inflammation with several chemical-dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	T8	T21	17354225
NA	CHEMICAL	GENE-Y	21	30	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of chemical, proline, pyrimidines and polyamines, is regulated by gene and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T2	T15	17354225
NA	CHEMICAL	GENE-Y	21	5	In summary, high levels of gene expression, which may be required for several arginine-dependent processes in cancer, including the production of chemical, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T2	T14	17354225
NA	CHEMICAL	GENE-Y	24	30	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, chemical and polyamines, is regulated by gene and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T4	T15	17354225
NA	CHEMICAL	GENE-Y	24	5	In summary, high levels of gene expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, chemical and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T4	T14	17354225
NA	CHEMICAL	GENE-Y	26	30	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and chemical, is regulated by gene and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T5	T15	17354225
NA	CHEMICAL	GENE-Y	26	5	In summary, high levels of gene expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and chemical, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T5	T14	17354225
NA	CHEMICAL	GENE-Y	13	30	In summary, high levels of AS expression, which may be required for several chemical-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by gene and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T1	T15	17354225
NA	CHEMICAL	GENE-Y	13	5	In summary, high levels of gene expression, which may be required for several chemical-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T1	T14	17354225
NA	CHEMICAL	GENE-Y	23	30	In summary, high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, chemical, pyrimidines and polyamines, is regulated by gene and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T3	T15	17354225
NA	CHEMICAL	GENE-Y	23	5	In summary, high levels of gene expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, chemical, pyrimidines and polyamines, is regulated by TNF-alpha and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	T3	T14	17354225
CPR:3	CHEMICAL	GENE-N	11	6	Although considerable functional diversity exists, most gene are activated by chemical binding and then dock to a specific cellular membrane.	T8	T23	17367165
NA	CHEMICAL	GENE-Y	26	9	The C2 domains of protein kinase Calpha (PKCalpha) and gene (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular chemical signal.	T11	T30	17367165
NA	CHEMICAL	GENE-Y	26	4	The C2 domains of gene (PKCalpha) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular chemical signal.	T11	T28	17367165
NA	CHEMICAL	GENE-N	26	1	The gene of protein kinase Calpha (PKCalpha) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular chemical signal.	T11	T27	17367165
NA	CHEMICAL	GENE-Y	26	12	The C2 domains of protein kinase Calpha (PKCalpha) and cytosolic phospholipase A2alpha (gene), for example, are known to dock to different membrane surfaces during an intracellular chemical signal.	T11	T31	17367165
NA	CHEMICAL	GENE-Y	26	7	The C2 domains of protein kinase Calpha (gene) and cytosolic phospholipase A2alpha (cPLA2alpha), for example, are known to dock to different membrane surfaces during an intracellular chemical signal.	T11	T29	17367165
NA	CHEMICAL	GENE-N	0	13	chemical activation targets the PKCalpha C2 domain to the plasma membrane and the gene to the internal membranes, with no detectable spatial overlap.	T12	T35	17367165
NA	CHEMICAL	GENE-N	0	4	chemical activation targets the gene to the plasma membrane and the cPLA2alpha C2 domain to the internal membranes, with no detectable spatial overlap.	T12	T34	17367165
NA	CHEMICAL	GENE-N	19	3	For the isolated gene in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and chemical (PIP2) are together sufficient to recruit the gene to a lipid mixture mimicking the plasma membrane inner leaflet.	T17	T36	17367165
NA	CHEMICAL	GENE-N	19	3	For the isolated genen in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and chemical (PIP2) are together sufficient to recruit the genen to a lipid mixture mimicking the plasma membrane inner leaflet.	T17	T20	17367165
NA	CHEMICAL	GENE-N	16	3	For the isolated gene in the presence of physiological Ca2+ levels, the target lipids chemical (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the gene to a lipid mixture mimicking the plasma membrane inner leaflet.	T15	T36	17367165
NA	CHEMICAL	GENE-N	16	3	For the isolated genen in the presence of physiological Ca2+ levels, the target lipids chemical (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the genen to a lipid mixture mimicking the plasma membrane inner leaflet.	T15	T20	17367165
NA	CHEMICAL	GENE-N	11	3	For the isolated gene in the presence of physiological chemical levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the gene to a lipid mixture mimicking the plasma membrane inner leaflet.	T14	T36	17367165
NA	CHEMICAL	GENE-N	11	3	For the isolated genen in the presence of physiological chemical levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the genen to a lipid mixture mimicking the plasma membrane inner leaflet.	T14	T20	17367165
NA	CHEMICAL	GENE-N	20	3	For the isolated gene in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (chemical) are together sufficient to recruit the gene to a lipid mixture mimicking the plasma membrane inner leaflet.	T18	T36	17367165
NA	CHEMICAL	GENE-N	20	3	For the isolated genen in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (chemical) are together sufficient to recruit the genen to a lipid mixture mimicking the plasma membrane inner leaflet.	T18	T20	17367165
NA	CHEMICAL	GENE-N	17	3	For the isolated gene in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (chemical) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the gene to a lipid mixture mimicking the plasma membrane inner leaflet.	T16	T36	17367165
NA	CHEMICAL	GENE-N	17	3	For the isolated genen in the presence of physiological Ca2+ levels, the target lipids phosphatidylserine (chemical) and phosphatidylinositol-4,5-bisphosphate (PIP2) are together sufficient to recruit the genen to a lipid mixture mimicking the plasma membrane inner leaflet.	T16	T20	17367165
NA	CHEMICAL	GENE-N	8	2	For the gene, the target lipid chemical (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.	T1	T21	17367165
NA	CHEMICAL	GENE-N	25	2	For the gene, the target lipid phosphatidylcholine (PC) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological chemical levels, although the results do not rule out a second, unknown target molecule.	T3	T21	17367165
NA	CHEMICAL	GENE-N	9	2	For the gene, the target lipid phosphatidylcholine (chemical) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological Ca2+ levels, although the results do not rule out a second, unknown target molecule.	T2	T21	17367165
NA	CHEMICAL	GENE-N	13	2	In principle, gene-directed intracellular targeting, which requires coincidence detection of multiple signals (chemical and one or more target lipids), can exhibit two different mechanisms: messenger-activated target affinity (MATA) and target-activated messenger affinity (TAMA).	T5	T22	17367165
NA	CHEMICAL	GENE-N	15	1	The gene studied here both utilize the TAMA mechanism, in which the C2 domain chemical affinity is too low to be activated by physiological chemical signals in most regions of the cell.	T6	T24	17367165
NA	CHEMICAL	GENE-N	15	1	The gene studied here both utilize the TAMA mechanism, in which the C2 domain chemical affinity is too low to be activated by physiological chemical signals in most regions of the cell.	T7	T24	17367165
NA	CHEMICAL	GENE-N	15	1	The genes studied here both utilize the TAMA mechanism, in which the gene chemical affinity is too low to be activated by physiological chemical signals in most regions of the cell.	T6	T25	17367165
NA	CHEMICAL	GENE-N	15	1	The genes studied here both utilize the TAMA mechanism, in which the gene chemical affinity is too low to be activated by physiological chemical signals in most regions of the cell.	T7	T25	17367165
NA	CHEMICAL	GENE-N	21	3	Only when the gene nears its target membrane, which provides a high local concentration of target lipid, is the effective chemical affinity increased by the coupled binding equilibrium to a level that enables substantial chemical activation and target docking.	T10	T26	17367165
NA	CHEMICAL	GENE-N	21	3	Only when the gene nears its target membrane, which provides a high local concentration of target lipid, is the effective chemical affinity increased by the coupled binding equilibrium to a level that enables substantial chemical activation and target docking.	T9	T26	17367165
NA	CHEMICAL	GENE-Y	17	0	gene (BAT) is responsible for the amidation of bile acids with the chemical glycine and taurine.	T4	T14	17379925
NA	CHEMICAL	GENE-Y	17	6	Bile acid coenzyme A:amino acid N-acyltransferase (gene) is responsible for the amidation of bile acids with the chemical glycine and taurine.	T4	T20	17379925
NA	CHEMICAL	GENE-Y	3	6	Bile acid coenzyme A:chemical N-acyltransferase (gene) is responsible for the amidation of bile acids with the chemicals glycine and taurine.	T7	T20	17379925
NA	CHEMICAL	GENE-Y	2	6	Bile acid chemical:amino acid N-acyltransferase (gene) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	T2	T20	17379925
CPR:9	CHEMICAL	GENE-Y	13	0	gene (BAT) is responsible for the amidation of chemical with the amino acids glycine and taurine.	T10	T14	17379925
CPR:9	CHEMICAL	GENE-Y	13	6	Bile acid coenzyme A:amino acid N-acyltransferase (gene) is responsible for the amidation of chemical with the amino acids glycine and taurine.	T10	T20	17379925
NA	CHEMICAL	GENE-Y	0	6	chemical coenzyme A:amino acid N-acyltransferase (gene) is responsible for the amidation of bile acids with the amino acids glycine and taurine.	T1	T20	17379925
NA	CHEMICAL	GENE-Y	21	0	gene (BAT) is responsible for the amidation of bile acids with the amino acids glycine and chemical.	T6	T14	17379925
NA	CHEMICAL	GENE-Y	21	6	Bile acid coenzyme A:amino acid N-acyltransferase (gene) is responsible for the amidation of bile acids with the amino acids glycine and chemical.	T6	T20	17379925
NA	CHEMICAL	GENE-Y	19	0	gene (BAT) is responsible for the amidation of bile acids with the amino acids chemical and taurine.	T5	T14	17379925
NA	CHEMICAL	GENE-Y	19	6	Bile acid coenzyme A:amino acid N-acyltransferase (gene) is responsible for the amidation of bile acids with the amino acids chemical and taurine.	T5	T20	17379925
NA	CHEMICAL	GENE-Y	4	9	Treatment with rosiglitazone or chemical had no effect on gene activity in any subcellular compartment.	T9	T24	17379925
NA	CHEMICAL	GENE-Y	2	9	Treatment with chemical or cholestyramine had no effect on gene activity in any subcellular compartment.	T8	T24	17379925
NA	CHEMICAL	GENE-Y	7	13	These data support the novel finding that chemical treatment does not directly regulate gene activity but does alter the subcellular localization of gene.	T3	T16	17379925
NA	CHEMICAL	GENE-Y	7	13	These data support the novel finding that chemical treatment does not directly regulate gene activity but does alter the subcellular localization of gene.	T3	T17	17379925
NA	CHEMICAL	GENE-Y	4	6	Because of their low chemical synthetase (gene) expression and chemical biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to chemical depletion.	T3	T11	17380207
NA	CHEMICAL	GENE-Y	4	6	Because of their low chemical synthetase (gene) expression and chemical biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to chemical depletion.	T4	T11	17380207
CPR:9	CHEMICAL	GENE-Y	4	6	Because of their low chemical synthetase (gene) expression and chemical biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to chemical depletion.	T5	T11	17380207
NA	CHEMICAL	GENE-Y	19	9	Asparagine secretion by MSCs was directly related to their gene expression levels, suggesting a mechanism - increased concentrations of chemical in the leukemic cell microenvironment - for the protective effects we observed.	T2	T6	17380207
CPR:9	CHEMICAL	GENE-Y	0	9	chemical secretion by MSCs was directly related to their gene expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.	T1	T6	17380207
NA	CHEMICAL	GENE-Y	13	3	Neurotoxicity induced by gene (Abeta) involves glutamate toxicity, resulting from overactivation of chemical (NMDA) receptors and elevation of intracellular calcium.	T1	T36	17403555
NA	CHEMICAL	GENE-Y	13	5	Neurotoxicity induced by beta-amyloid peptide (gene) involves glutamate toxicity, resulting from overactivation of chemical (NMDA) receptors and elevation of intracellular calcium.	T1	T45	17403555
NA	CHEMICAL	GENE-N	7	13	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves chemical toxicity, resulting from overactivation of gene and elevation of intracellular calcium.	T14	T25	17403555
NA	CHEMICAL	GENE-Y	7	3	Neurotoxicity induced by gene (Abeta) involves chemical toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular calcium.	T14	T36	17403555
NA	CHEMICAL	GENE-Y	7	5	Neurotoxicity induced by beta-amyloid peptide (gene) involves chemical toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular calcium.	T14	T45	17403555
NA	CHEMICAL	GENE-N	20	13	Neurotoxicity induced by beta-amyloid peptide (Abeta) involves glutamate toxicity, resulting from overactivation of gene and elevation of intracellular chemical.	T9	T25	17403555
NA	CHEMICAL	GENE-Y	20	3	Neurotoxicity induced by gene (Abeta) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular chemical.	T9	T36	17403555
NA	CHEMICAL	GENE-Y	20	5	Neurotoxicity induced by beta-amyloid peptide (gene) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (NMDA) receptors and elevation of intracellular chemical.	T9	T45	17403555
NA	CHEMICAL	GENE-Y	14	3	Neurotoxicity induced by gene (Abeta) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (chemical) receptors and elevation of intracellular calcium.	T6	T36	17403555
NA	CHEMICAL	GENE-Y	14	5	Neurotoxicity induced by beta-amyloid peptide (gene) involves glutamate toxicity, resulting from overactivation of N-methyl-D-aspartate (chemical) receptors and elevation of intracellular calcium.	T6	T45	17403555
NA	CHEMICAL	GENE-N	5	12	However, the heterogeneity of the chemical receptors, frequently composed of NR1 and gene subunits, has been less studied.	T10	T38	17403555
NA	CHEMICAL	GENE-Y	5	10	However, the heterogeneity of the chemical receptors, frequently composed of gene and NR2A-D subunits, has been less studied.	T10	T37	17403555
NA	CHEMICAL	GENE-Y	6	10	Thus, we determined the contribution of chemical receptor subtypes on gene toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/NR2B subunits.	T11	T40	17403555
NA	CHEMICAL	GENE-Y	6	17	Thus, we determined the contribution of chemical receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/gene or NR1/NR2B subunits.	T11	T42	17403555
NA	CHEMICAL	GENE-Y	6	19	Thus, we determined the contribution of chemical receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing NR1/NR2A or NR1/gene subunits.	T11	T44	17403555
NA	CHEMICAL	GENE-Y	6	17	Thus, we determined the contribution of chemical receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing gene/NR2A or gene/NR2B subunits.	T11	T41	17403555
NA	CHEMICAL	GENE-Y	6	17	Thus, we determined the contribution of chemical receptor subtypes on Abeta(1-40) toxicity in HEK293 cells transiently expressing gene/NR2A or gene/NR2B subunits.	T11	T43	17403555
NA	CHEMICAL	GENE-N	7	2	Analysis of gene (LDH) release and chemical exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T13	T46	17403555
NA	CHEMICAL	GENE-Y	7	14	Analysis of lactate dehydrogenase (LDH) release and chemical exclusion revealed an increase in gene toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T13	T48	17403555
NA	CHEMICAL	GENE-Y	7	17	Analysis of lactate dehydrogenase (LDH) release and chemical exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/gene expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T13	T50	17403555
NA	CHEMICAL	GENE-Y	7	21	Analysis of lactate dehydrogenase (LDH) release and chemical exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/gene, indicating loss of plasma membrane integrity.	T13	T52	17403555
NA	CHEMICAL	GENE-Y	7	17	Analysis of lactate dehydrogenase (LDH) release and chemical exclusion revealed an increase in Abeta(1-40) toxicity upon gene/NR2A expression, compared to gene/NR2B, indicating loss of plasma membrane integrity.	T13	T49	17403555
NA	CHEMICAL	GENE-Y	7	17	Analysis of lactate dehydrogenase (LDH) release and chemical exclusion revealed an increase in Abeta(1-40) toxicity upon gene/NR2A expression, compared to gene/NR2B, indicating loss of plasma membrane integrity.	T13	T51	17403555
NA	CHEMICAL	GENE-N	7	4	Analysis of lactate dehydrogenase (gene) release and chemical exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T13	T47	17403555
NA	CHEMICAL	GENE-Y	2	14	Analysis of chemical dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in gene toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T12	T48	17403555
NA	CHEMICAL	GENE-Y	2	17	Analysis of chemical dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/gene expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T12	T50	17403555
NA	CHEMICAL	GENE-Y	2	21	Analysis of chemical dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/gene, indicating loss of plasma membrane integrity.	T12	T52	17403555
NA	CHEMICAL	GENE-Y	2	17	Analysis of chemical dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon gene/NR2A expression, compared to gene/NR2B, indicating loss of plasma membrane integrity.	T12	T49	17403555
NA	CHEMICAL	GENE-Y	2	17	Analysis of chemical dehydrogenase (LDH) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon gene/NR2A expression, compared to gene/NR2B, indicating loss of plasma membrane integrity.	T12	T51	17403555
NA	CHEMICAL	GENE-N	2	4	Analysis of chemical dehydrogenase (gene) release and trypan blue exclusion revealed an increase in Abeta(1-40) toxicity upon NR1/NR2A expression, compared to NR1/NR2B, indicating loss of plasma membrane integrity.	T12	T47	17403555
NA	CHEMICAL	GENE-Y	4	1	Furthermore, gene decreased intracellular chemical in cells expressing NR1/NR2A.	T15	T53	17403555
NA	CHEMICAL	GENE-Y	4	8	Furthermore, Abeta(1-40) decreased intracellular chemical in cells expressing NR1/gene.	T15	T55	17403555
NA	CHEMICAL	GENE-Y	4	8	Furthermore, Abeta(1-40) decreased intracellular chemical in cells expressing gene/NR2A.	T15	T54	17403555
CPR:6	CHEMICAL	GENE-N	1	5	MK-801 (chemical), a noncompetitive gene antagonist, partially prevented the decrease in cell viability and the energy impairment.	T17	T56	17403555
CPR:6	CHEMICAL	GENE-N	0	5	chemical ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive gene antagonist, partially prevented the decrease in cell viability and the energy impairment.	T16	T56	17403555
NA	CHEMICAL	GENE-Y	11	1	Functional NR1/gene and NR1/NR2B receptor subtypes were further evidenced by single-cell chemical imaging.	T2	T22	17403555
NA	CHEMICAL	GENE-Y	11	3	Functional NR1/NR2A and NR1/gene receptor subtypes were further evidenced by single-cell chemical imaging.	T2	T24	17403555
NA	CHEMICAL	GENE-Y	11	1	Functional gene/NR2A and gene/NR2B receptor subtypes were further evidenced by single-cell chemical imaging.	T2	T21	17403555
NA	CHEMICAL	GENE-Y	11	1	Functional gene/NR2A and gene/NR2B receptor subtypes were further evidenced by single-cell chemical imaging.	T2	T23	17403555
NA	CHEMICAL	GENE-Y	5	16	Stimulation of NR1/NR2A receptors with NMDA/chemical revealed an increase in intracellular calcium in cells pre-exposed to gene.	T4	T28	17403555
NA	CHEMICAL	GENE-Y	5	2	Stimulation of NR1/gene receptors with NMDA/chemical revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	T4	T27	17403555
NA	CHEMICAL	GENE-Y	5	2	Stimulation of gene/NR2A receptors with NMDA/chemical revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	T4	T26	17403555
NA	CHEMICAL	GENE-Y	11	16	Stimulation of NR1/NR2A receptors with NMDA/glycine revealed an increase in intracellular chemical in cells pre-exposed to gene.	T5	T28	17403555
NA	CHEMICAL	GENE-Y	11	2	Stimulation of NR1/gene receptors with NMDA/glycine revealed an increase in intracellular chemical in cells pre-exposed to Abeta(1-40).	T5	T27	17403555
NA	CHEMICAL	GENE-Y	11	2	Stimulation of gene/NR2A receptors with NMDA/glycine revealed an increase in intracellular chemical in cells pre-exposed to Abeta(1-40).	T5	T26	17403555
NA	CHEMICAL	GENE-Y	5	16	Stimulation of NR1/NR2A receptors with chemical/glycine revealed an increase in intracellular calcium in cells pre-exposed to gene.	T3	T28	17403555
NA	CHEMICAL	GENE-Y	5	2	Stimulation of NR1/gene receptors with chemical/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	T3	T27	17403555
NA	CHEMICAL	GENE-Y	5	2	Stimulation of gene/NR2A receptors with chemical/glycine revealed an increase in intracellular calcium in cells pre-exposed to Abeta(1-40).	T3	T26	17403555
NA	CHEMICAL	GENE-N	20	5	These results suggest that NR1/NR2A-composed gene mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in chemical homeostasis.	T8	T33	17403555
NA	CHEMICAL	GENE-Y	20	16	These results suggest that NR1/NR2A-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to gene through changes in chemical homeostasis.	T8	T34	17403555
NA	CHEMICAL	GENE-Y	20	4	These results suggest that NR1/gene-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in chemical homeostasis.	T8	T32	17403555
NA	CHEMICAL	GENE-Y	20	4	These results suggest that gene/NR2A-composed NMDA receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in chemical homeostasis.	T8	T31	17403555
NA	CHEMICAL	GENE-Y	5	16	These results suggest that NR1/NR2A-composed chemical receptors mediate necrotic cell death in HEK293 cells exposed to gene through changes in calcium homeostasis.	T7	T34	17403555
NA	CHEMICAL	GENE-Y	5	4	These results suggest that NR1/gene-composed chemical receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.	T7	T32	17403555
NA	CHEMICAL	GENE-Y	5	4	These results suggest that gene/NR2A-composed chemical receptors mediate necrotic cell death in HEK293 cells exposed to Abeta(1-40) through changes in calcium homeostasis.	T7	T31	17403555
CPR:9	CHEMICAL	GENE-Y	17	3	The use of gene (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to chemical (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	T2	T26	17409318
CPR:9	CHEMICAL	GENE-Y	17	6	The use of Delta 6 desaturase (gene) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to chemical (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	T2	T28	17409318
CPR:9	CHEMICAL	GENE-Y	12	3	The use of gene (D6D) twice in the conversion of chemical (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	T19	T26	17409318
CPR:9	CHEMICAL	GENE-Y	12	6	The use of Delta 6 desaturase (gene) twice in the conversion of chemical (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.	T19	T28	17409318
CPR:9	CHEMICAL	GENE-Y	14	3	The use of gene (D6D) twice in the conversion of alpha-linolenic acid (chemical; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from chemical.	T12	T26	17409318
CPR:9	CHEMICAL	GENE-Y	14	3	The use of gene (D6D) twice in the conversion of alpha-linolenic acid (chemical; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from chemical.	T23	T26	17409318
CPR:9	CHEMICAL	GENE-Y	14	6	The use of Delta 6 desaturase (gene) twice in the conversion of alpha-linolenic acid (chemical; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from chemical.	T12	T28	17409318
CPR:9	CHEMICAL	GENE-Y	14	6	The use of Delta 6 desaturase (gene) twice in the conversion of alpha-linolenic acid (chemical; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from chemical.	T23	T28	17409318
CPR:9	CHEMICAL	GENE-Y	19	3	The use of gene (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (chemical; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of chemical from ALA.	T11	T26	17409318
CPR:9	CHEMICAL	GENE-Y	19	3	The use of gene (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (chemical; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of chemical from ALA.	T8	T26	17409318
CPR:9	CHEMICAL	GENE-Y	19	6	The use of Delta 6 desaturase (gene) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (chemical; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of chemical from ALA.	T11	T28	17409318
CPR:9	CHEMICAL	GENE-Y	19	6	The use of Delta 6 desaturase (gene) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (chemical; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of chemical from ALA.	T8	T28	17409318
NA	CHEMICAL	GENE-Y	21	4	The accumulation of the post-gene products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of >18 microM chemical.	T21	T29	17409318
CPR:9	CHEMICAL	GENE-Y	10	4	The accumulation of the post-gene products of 22:5n-3, 24:6n-3 and chemical, in cell phospholipids was saturated at concentrations of >18 microM ALA.	T20	T29	17409318
NA	CHEMICAL	GENE-Y	15	25	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of chemical suggests that the competition between 24:5n-3 and chemical for gene may contribute to the limited accumulation of DHA in cell membranes.	T7	T27	17409318
CPR:9	CHEMICAL	GENE-Y	15	25	The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of chemical suggests that the competition between 24:5n-3 and chemical for gene may contribute to the limited accumulation of DHA in cell membranes.	T9	T27	17409318
CPR:9	CHEMICAL	GENE-Y	8	25	The parallel pattern of accumulation of 24:6n-3 and chemical in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for gene may contribute to the limited accumulation of chemical in cell membranes.	T10	T27	17409318
NA	CHEMICAL	GENE-Y	8	25	The parallel pattern of accumulation of 24:6n-3 and chemical in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for gene may contribute to the limited accumulation of chemical in cell membranes.	T6	T27	17409318
NA	CHEMICAL	GENE-Y	14	26	We recently reported that the low-dose VKORC1*2 haplotype is an important genetic determinant for chemical dose requirement and is associated with difficulties to attain stable therapeutic gene time--International Normalized Ratio in patients undergoing anticoagulation therapy.	T9	T17	17413769
NA	CHEMICAL	GENE-Y	14	6	We recently reported that the low-dose gene*2 haplotype is an important genetic determinant for chemical dose requirement and is associated with difficulties to attain stable therapeutic prothrombin time--International Normalized Ratio in patients undergoing anticoagulation therapy.	T9	T19	17413769
NA	CHEMICAL	GENE-Y	23	35	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different chemical ratios in their plasma, and whether that was related to gene variants gene*2 and gene*3 or other factors.	T5	T22	17413769
NA	CHEMICAL	GENE-Y	23	35	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different chemical ratios in their plasma, and whether that was related to gene variants gene*2 and gene*3 or other factors.	T5	T23	17413769
NA	CHEMICAL	GENE-Y	23	35	The aim of this study was to investigate whether patients with VKORC1*2 compared with patients carrying high-dose haplotypes VKORC1*3 or VKORC1*4 had different chemical ratios in their plasma, and whether that was related to gene variants gene*2 and gene*3 or other factors.	T5	T24	17413769
NA	CHEMICAL	GENE-Y	23	11	The aim of this study was to investigate whether patients with gene*2 compared with patients carrying high-dose haplotypes gene*3 or gene*4 had different chemical ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.	T5	T18	17413769
NA	CHEMICAL	GENE-Y	23	11	The aim of this study was to investigate whether patients with gene*2 compared with patients carrying high-dose haplotypes gene*3 or gene*4 had different chemical ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.	T5	T20	17413769
NA	CHEMICAL	GENE-Y	23	11	The aim of this study was to investigate whether patients with gene*2 compared with patients carrying high-dose haplotypes gene*3 or gene*4 had different chemical ratios in their plasma, and whether that was related to CYP2C9 variants CYP2C9*2 and CYP2C9*3 or other factors.	T5	T21	17413769
NA	CHEMICAL	GENE-Y	11	17	Samples from patients previously haplotyped for VKORC1 and measured for plasma chemical concentration were genotyped for the gene variants gene*2 and gene*3.	T6	T26	17413769
NA	CHEMICAL	GENE-Y	11	17	Samples from patients previously haplotyped for VKORC1 and measured for plasma chemical concentration were genotyped for the gene variants gene*2 and gene*3.	T6	T27	17413769
NA	CHEMICAL	GENE-Y	11	17	Samples from patients previously haplotyped for VKORC1 and measured for plasma chemical concentration were genotyped for the gene variants gene*2 and gene*3.	T6	T28	17413769
NA	CHEMICAL	GENE-Y	11	6	Samples from patients previously haplotyped for gene and measured for plasma chemical concentration were genotyped for the CYP2C9 variants CYP2C9*2 and CYP2C9*3.	T6	T25	17413769
NA	CHEMICAL	GENE-Y	11	15	Our result shows that there is a significant difference (P<0.01) in chemical ratios between gene*2 and gene*3 or gene*4 patients.	T8	T11	17413769
NA	CHEMICAL	GENE-Y	11	15	Our result shows that there is a significant difference (P<0.01) in chemical ratios between gene*2 and gene*3 or gene*4 patients.	T8	T12	17413769
NA	CHEMICAL	GENE-Y	11	15	Our result shows that there is a significant difference (P<0.01) in chemical ratios between gene*2 and gene*3 or gene*4 patients.	T8	T29	17413769
NA	CHEMICAL	GENE-Y	18	3	We speculate that gene haplotypes possibly are linked to some unidentified factors involved in the metabolic clearance of chemical enantiomers.	T1	T16	17413769
CPR:5	CHEMICAL	GENE-Y	0	21	chemical (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a gene agonist and D2 antagonist.	T1	T18	17468175
CPR:6	CHEMICAL	GENE-Y	0	26	chemical (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and gene antagonist.	T1	T19	17468175
NA	CHEMICAL	GENE-Y	21	26	(-)-Stepholidine (SPD), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a chemical receptor D1 agonist and gene antagonist.	T4	T19	17468175
CPR:5	CHEMICAL	GENE-Y	1	21	(-)-Stepholidine (chemical), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a gene agonist and D2 antagonist.	T8	T18	17468175
CPR:6	CHEMICAL	GENE-Y	1	26	(-)-Stepholidine (chemical), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a dopamine receptor D1 agonist and gene antagonist.	T8	T19	17468175
NA	CHEMICAL	GENE-N	25	5	Insights into dynamical behaviors of gene and their interaction modes with SPD are crucial in understanding the structural and functional characteristics of chemical receptors.	T10	T20	17468175
NA	CHEMICAL	GENE-N	14	5	Insights into dynamical behaviors of gene and their interaction modes with chemical are crucial in understanding the structural and functional characteristics of dopamine receptors.	T9	T20	17468175
NA	CHEMICAL	GENE-N	14	25	Insights into dynamical behaviors of D1 and D2 receptors and their interaction modes with chemical are crucial in understanding the structural and functional characteristics of gene.	T9	T21	17468175
NA	CHEMICAL	GENE-N	26	29	In this study a computational approach, integrating protein structure prediction, automated molecular docking, and molecular dynamics simulations were employed to investigate the dual action mechanism of chemical on the gene, with the eventual aim to develop new drugs for treating diseases affecting the central nervous system such as schizophrenia.	T11	T22	17468175
NA	CHEMICAL	GENE-N	12	4	Potential binding conformations of gene were obtained, and the D1-chemical and D2-chemical complexes were generated, which are in good agreement with most of experimental data.	T13	T24	17468175
NA	CHEMICAL	GENE-N	12	4	Potential binding conformations of gene were obtained, and the D1-chemical and D2-chemical complexes were generated, which are in good agreement with most of experimental data.	T2	T24	17468175
NA	CHEMICAL	GENE-Y	12	6	Potential binding conformations of D1 and gene receptors were obtained, and the D1-chemical and gene-chemical complexes were generated, which are in good agreement with most of experimental data.	T13	T16	17468175
NA	CHEMICAL	GENE-Y	12	6	Potential binding conformations of D1 and gene receptors were obtained, and the D1-chemical and gene-chemical complexes were generated, which are in good agreement with most of experimental data.	T2	T16	17468175
NA	CHEMICAL	GENE-Y	12	4	Potential binding conformations of gene and D2 receptors were obtained, and the gene-chemical and D2-chemical complexes were generated, which are in good agreement with most of experimental data.	T13	T25	17468175
NA	CHEMICAL	GENE-Y	12	4	Potential binding conformations of gene and D2 receptors were obtained, and the gene-chemical and D2-chemical complexes were generated, which are in good agreement with most of experimental data.	T2	T25	17468175
NA	CHEMICAL	GENE-Y	1	1	The gene-chemical structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of chemical.	T3	T17	17468175
NA	CHEMICAL	GENE-Y	1	1	The gene-chemical structure shows that the K-167_EL-2-E-302_EL-3 (EL-2: extracellular loop 2; EL-3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of chemical.	T5	T17	17468175
NA	CHEMICAL	GENE-N	10	1	UNLABELLED: gene overexpressed in human tumors, such as chemical receptors, can be used for in vivo targeting for diagnostic and therapeutic purposes.	T1	T3	17475961
NA	CHEMICAL	GENE-Y	25	3	Variants in the gene gene may account for the large inter-individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving chemical.	T8	T16	17496727
NA	CHEMICAL	GENE-N	14	4	A novel nonsynonymous variant gene was identified, and the kinetic assay demonstrated that the chemical dehydrogenase activity of gene variant was decreased to 10% of the wild-type.	T1	T12	17496727
NA	CHEMICAL	GENE-N	14	4	A novel nonsynonymous variant gene was identified, and the kinetic assay demonstrated that the chemical dehydrogenase activity of gene variant was decreased to 10% of the wild-type.	T1	T14	17496727
NA	CHEMICAL	GENE-N	23	8	The Ki for mycophenolic acid inhibition of the gene variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and chemical did not change significantly.	T4	T15	17496727
NA	CHEMICAL	GENE-N	20	8	The Ki for mycophenolic acid inhibition of the gene variant was comparable with the wild-type, and the variant Km for chemical and nicotinamide adenine dinucleotide did not change significantly.	T3	T15	17496727
CPR:4	CHEMICAL	GENE-N	3	8	The Ki for chemical inhibition of the gene variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.	T2	T15	17496727
NA	CHEMICAL	GENE-Y	16	1	CONCLUSIONS: gene has low genetic diversity, but the nonsynonymous variant L263F has a significant impact on chemical dehydrogenase activity.	T5	T17	17496727
NA	CHEMICAL	GENE-N	16	10	CONCLUSIONS: IMPDH2 has low genetic diversity, but the nonsynonymous variant gene has a significant impact on chemical dehydrogenase activity.	T5	T18	17496727
NA	CHEMICAL	GENE-Y	31	27	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), gene (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T28	17498496
NA	CHEMICAL	GENE-Y	31	23	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), gene (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T19	17498496
NA	CHEMICAL	GENE-Y	31	18	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), gene (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T16	17498496
NA	CHEMICAL	GENE-Y	31	14	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of gene (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T41	17498496
NA	CHEMICAL	GENE-Y	31	35	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), gene and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T32	17498496
NA	CHEMICAL	GENE-Y	31	34	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (gene), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T31	17498496
NA	CHEMICAL	GENE-Y	31	16	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (gene), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T12	17498496
NA	CHEMICAL	GENE-Y	31	37	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and gene after cerebral ischemia-reperfusion in rats.	T1	T33	17498496
NA	CHEMICAL	GENE-Y	31	30	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (gene), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T29	17498496
NA	CHEMICAL	GENE-Y	31	22	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (gene), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T18	17498496
NA	CHEMICAL	GENE-Y	31	26	OBJECTIVE: To investigate the effects of Panax notoginseng saponins (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (gene), intercellular adhesion molecule-1 (ICAM-1), chemical specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T1	T25	17498496
NA	CHEMICAL	GENE-Y	8	31	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), gene (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T30	17498496
NA	CHEMICAL	GENE-Y	8	27	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), gene (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T28	17498496
NA	CHEMICAL	GENE-Y	8	23	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), gene (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T19	17498496
NA	CHEMICAL	GENE-Y	8	18	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), gene (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T16	17498496
NA	CHEMICAL	GENE-Y	8	14	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of gene (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T41	17498496
NA	CHEMICAL	GENE-Y	8	35	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), gene and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T32	17498496
NA	CHEMICAL	GENE-Y	8	34	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (gene), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T31	17498496
NA	CHEMICAL	GENE-Y	8	16	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (gene), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T12	17498496
NA	CHEMICAL	GENE-Y	8	37	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and gene after cerebral ischemia-reperfusion in rats.	T2	T33	17498496
NA	CHEMICAL	GENE-Y	8	30	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (gene), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T29	17498496
NA	CHEMICAL	GENE-Y	8	22	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (gene), interleukin-1 receptor antagonist (IL-1ra), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T18	17498496
NA	CHEMICAL	GENE-Y	8	26	OBJECTIVE: To investigate the effects of Panax notoginseng chemical (PNS) on mRNA expressions of interleukin-1 beta (IL-1 beta), interleukin-1 receptor type I (IL-1RI), interleukin-1 receptor antagonist (gene), intercellular adhesion molecule-1 (ICAM-1), cysteinyl-aspartate specific protease-1 (caspase-1), caspase-3 and caspase-8 after cerebral ischemia-reperfusion in rats.	T2	T25	17498496
NA	CHEMICAL	GENE-N	24	15	We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, gene in maintaining mitochondrial function during excitotoxicity caused by chemical (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	T13	T37	17512091
NA	CHEMICAL	GENE-N	11	15	We examined the critical roles played by the antioxidant, non-protein thiol, chemical and related enzyme, gene in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	T12	T37	17512091
NA	CHEMICAL	GENE-N	26	15	We examined the critical roles played by the antioxidant, non-protein thiol, glutathione and related enzyme, gene in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (chemical), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	T14	T37	17512091
NA	CHEMICAL	GENE-N	10	15	We examined the critical roles played by the antioxidant, non-protein chemical, glutathione and related enzyme, gene in maintaining mitochondrial function during excitotoxicity caused by beta-N-oxalyl amino-L-alanine (L-BOAA), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	T11	T37	17512091
CPR:4	CHEMICAL	GENE-N	0	8	chemical causes loss of GSH and inhibition of gene in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.	T15	T38	17512091
NA	CHEMICAL	GENE-N	20	8	L-BOAA causes loss of GSH and inhibition of gene in lumbosacral cord of male mice through oxidation of chemical groups, while female mice are resistant.	T17	T38	17512091
NA	CHEMICAL	GENE-N	4	8	L-BOAA causes loss of chemical and inhibition of gene in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.	T16	T38	17512091
NA	CHEMICAL	GENE-N	13	21	Reducing GSH levels in female mice CNS by pretreatment with diethyl maleate or chemical did not result in inhibition of gene activity, unlike male mice.	T20	T39	17512091
NA	CHEMICAL	GENE-N	10	21	Reducing GSH levels in female mice CNS by pretreatment with chemical or L-propargyl glycine did not result in inhibition of gene activity, unlike male mice.	T19	T39	17512091
NA	CHEMICAL	GENE-N	1	21	Reducing chemical levels in female mice CNS by pretreatment with diethyl maleate or L-propargyl glycine did not result in inhibition of gene activity, unlike male mice.	T18	T39	17512091
NA	CHEMICAL	GENE-N	9	15	Further, treatment of female mice depleted of GSH with chemical did not induce inhibition of gene indicating that GSH levels were not critical for maintaining gene activity in female mice unlike their male counterpart.	T2	T22	17512091
NA	CHEMICAL	GENE-N	9	15	Further, treatment of female mice depleted of GSH with chemical did not induce inhibition of gene indicating that GSH levels were not critical for maintaining gene activity in female mice unlike their male counterpart.	T2	T23	17512091
NA	CHEMICAL	GENE-N	7	15	Further, treatment of female mice depleted of chemical with L-BOAA did not induce inhibition of gene indicating that chemical levels were not critical for maintaining gene activity in female mice unlike their male counterpart.	T1	T22	17512091
NA	CHEMICAL	GENE-N	7	15	Further, treatment of female mice depleted of chemical with L-BOAA did not induce inhibition of gene indicating that chemical levels were not critical for maintaining gene activity in female mice unlike their male counterpart.	T1	T23	17512091
NA	CHEMICAL	GENE-N	7	15	Further, treatment of female mice depleted of chemical with L-BOAA did not induce inhibition of gene indicating that chemical levels were not critical for maintaining gene activity in female mice unlike their male counterpart.	T3	T22	17512091
NA	CHEMICAL	GENE-N	7	15	Further, treatment of female mice depleted of chemical with L-BOAA did not induce inhibition of gene indicating that chemical levels were not critical for maintaining gene activity in female mice unlike their male counterpart.	T3	T23	17512091
NA	CHEMICAL	GENE-N	3	19	Glutaredoxin, a thiol chemical oxidoreductase helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of gene activity.	T4	T27	17512091
NA	CHEMICAL	GENE-N	3	0	gene, a thiol chemical oxidoreductase helps maintain redox status of proteins and downregulation of glutaredoxin results in loss of mitochondrial complex I activity.	T4	T24	17512091
NA	CHEMICAL	GENE-N	3	14	Glutaredoxin, a thiol chemical oxidoreductase helps maintain redox status of proteins and downregulation of gene results in loss of mitochondrial complex I activity.	T4	T26	17512091
CPR:4	CHEMICAL	GENE-N	21	25	Female mice express higher levels of glutaredoxin in certain CNS regions and downregulation of glutaredoxin using antisense oligonucleotides sensitizes them to chemical toxicity seen as gene loss.	T6	T30	17512091
NA	CHEMICAL	GENE-N	21	6	Female mice express higher levels of gene in certain CNS regions and downregulation of gene using antisense oligonucleotides sensitizes them to chemical toxicity seen as mitochondrial complex I loss.	T6	T28	17512091
NA	CHEMICAL	GENE-N	21	6	Female mice express higher levels of gene in certain CNS regions and downregulation of gene using antisense oligonucleotides sensitizes them to chemical toxicity seen as mitochondrial complex I loss.	T6	T29	17512091
NA	CHEMICAL	GENE-N	9	2	Ovariectomy downregulates gene and renders female mice vulnerable to chemical toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of gene in neuroprotection.	T7	T31	17512091
NA	CHEMICAL	GENE-N	9	2	Ovariectomy downregulates gene and renders female mice vulnerable to chemical toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of gene in neuroprotection.	T7	T34	17512091
CPR:3	CHEMICAL	GENE-N	9	21	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to chemical toxicity as evidenced by activation of AP1, loss of GSH and gene activity indicating the important role of glutaredoxin in neuroprotection.	T7	T33	17512091
CPR:3	CHEMICAL	GENE-Y	9	16	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to chemical toxicity as evidenced by activation of gene, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.	T7	T32	17512091
NA	CHEMICAL	GENE-N	19	2	Ovariectomy downregulates gene and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of chemical and complex I activity indicating the important role of gene in neuroprotection.	T8	T31	17512091
NA	CHEMICAL	GENE-N	19	2	Ovariectomy downregulates gene and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of chemical and complex I activity indicating the important role of gene in neuroprotection.	T8	T34	17512091
NA	CHEMICAL	GENE-N	19	21	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of chemical and gene activity indicating the important role of glutaredoxin in neuroprotection.	T8	T33	17512091
NA	CHEMICAL	GENE-Y	19	16	Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of gene, loss of chemical and complex I activity indicating the important role of glutaredoxin in neuroprotection.	T8	T32	17512091
CPR:3	CHEMICAL	GENE-N	0	18	chemical protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of gene in the CNS.	T9	T35	17512091
NA	CHEMICAL	GENE-Y	3	0	gene is a chemical exchange factor that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation.	T1	T11	17550897
NA	CHEMICAL	GENE-N	12	20	Vav1 consists of multiple structural domains so as to facilitate both its chemical exchange activity and scaffold function following gene (TCR) engagement.	T5	T23	17550897
NA	CHEMICAL	GENE-Y	12	0	gene consists of multiple structural domains so as to facilitate both its chemical exchange activity and scaffold function following T cell antigen receptor (TCR) engagement.	T5	T22	17550897
NA	CHEMICAL	GENE-Y	12	24	Vav1 consists of multiple structural domains so as to facilitate both its chemical exchange activity and scaffold function following T cell antigen receptor (gene) engagement.	T5	T24	17550897
NA	CHEMICAL	GENE-N	12	24	Vav1 consists of multiple structural domains so as to facilitate both its chemical exchange activity and scaffold function following T cell antigen receptor (gene) engagement.	T5	T24	17550897
NA	CHEMICAL	GENE-N	15	22	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for TCR-stimulated chemical mobilization and thus downstream activation of gene.	T6	T28	17550897
NA	CHEMICAL	GENE-N	15	5	Previous studies demonstrated that the gene of Vav1 is required for TCR-stimulated chemical mobilization and thus downstream activation of nuclear factor of activated T cells.	T6	T25	17550897
NA	CHEMICAL	GENE-Y	15	10	Previous studies demonstrated that the calponin homology (CH) domain of gene is required for TCR-stimulated chemical mobilization and thus downstream activation of nuclear factor of activated T cells.	T6	T26	17550897
NA	CHEMICAL	GENE-Y	15	14	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for gene-stimulated chemical mobilization and thus downstream activation of nuclear factor of activated T cells.	T6	T27	17550897
NA	CHEMICAL	GENE-N	15	14	Previous studies demonstrated that the calponin homology (CH) domain of Vav1 is required for gene-stimulated chemical mobilization and thus downstream activation of nuclear factor of activated T cells.	T6	T27	17550897
NA	CHEMICAL	GENE-Y	9	5	However, it remained obscure how gene functions in regulating chemical flux.	T7	T29	17550897
NA	CHEMICAL	GENE-Y	18	12	In an effort to explore molecules interacting with Vav1, we found that gene bound to Vav1 in a chemical-dependent and TCR activation-independent manner.	T8	T31	17550897
NA	CHEMICAL	GENE-Y	18	8	In an effort to explore molecules interacting with gene, we found that calmodulin bound to gene in a chemical-dependent and TCR activation-independent manner.	T8	T30	17550897
NA	CHEMICAL	GENE-Y	18	8	In an effort to explore molecules interacting with gene, we found that calmodulin bound to gene in a chemical-dependent and TCR activation-independent manner.	T8	T32	17550897
NA	CHEMICAL	GENE-Y	18	20	In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to Vav1 in a chemical-dependent and gene activation-independent manner.	T8	T33	17550897
NA	CHEMICAL	GENE-N	18	20	In an effort to explore molecules interacting with Vav1, we found that calmodulin bound to Vav1 in a chemical-dependent and gene activation-independent manner.	T8	T33	17550897
NA	CHEMICAL	GENE-Y	15	29	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in chemical release to the same extent as that of Jurkat cells treated with the gene inhibitor or J.Vav1 cells.	T9	T12	17550897
NA	CHEMICAL	GENE-Y	15	2	Reconstitution of gene-null Jurkat T cells (J.Vav1) with CH-deleted Vav1 exhibited a severe deficiency in chemical release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.	T9	T36	17550897
NA	CHEMICAL	GENE-Y	15	6	Reconstitution of vav1-null Jurkat T cells (J.gene) with CH-deleted gene exhibited a severe deficiency in chemical release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.gene cells.	T9	T13	17550897
NA	CHEMICAL	GENE-Y	15	6	Reconstitution of vav1-null Jurkat T cells (J.gene) with CH-deleted gene exhibited a severe deficiency in chemical release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.gene cells.	T9	T37	17550897
NA	CHEMICAL	GENE-Y	15	6	Reconstitution of vav1-null Jurkat T cells (J.gene) with CH-deleted gene exhibited a severe deficiency in chemical release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.gene cells.	T9	T39	17550897
NA	CHEMICAL	GENE-N	15	8	Reconstitution of vav1-null Jurkat T cells (J.Vav1) with gene-deleted Vav1 exhibited a severe deficiency in chemical release to the same extent as that of Jurkat cells treated with the calmodulin inhibitor or J.Vav1 cells.	T9	T38	17550897
NA	CHEMICAL	GENE-Y	18	5	The defect persisted even when gene was fully activated, indicating a prerequisite role of Vav1 CH domain in chemical signaling.	T2	T15	17550897
NA	CHEMICAL	GENE-N	18	14	The defect persisted even when phospholipase-Cgamma1 was fully activated, indicating a prerequisite role of gene in chemical signaling.	T2	T16	17550897
NA	CHEMICAL	GENE-Y	12	6	The results suggest that Vav1 and gene function cooperatively to potentiate TCR-induced chemical release.	T3	T18	17550897
NA	CHEMICAL	GENE-Y	12	4	The results suggest that gene and calmodulin function cooperatively to potentiate TCR-induced chemical release.	T3	T17	17550897
NA	CHEMICAL	GENE-Y	12	11	The results suggest that Vav1 and calmodulin function cooperatively to potentiate gene-induced chemical release.	T3	T19	17550897
NA	CHEMICAL	GENE-N	12	11	The results suggest that Vav1 and calmodulin function cooperatively to potentiate gene-induced chemical release.	T3	T19	17550897
NA	CHEMICAL	GENE-N	14	8	This study unveiled a mechanism by which the gene is involved in chemical signaling and provides insight into our understanding of the role of Vav1 in T cell activation.	T4	T20	17550897
NA	CHEMICAL	GENE-Y	14	8	This study unveiled a mechanism by which the gene CH domain is involved in chemical signaling and provides insight into our understanding of the role of gene in T cell activation.	T4	T21	17550897
NA	CHEMICAL	GENE-N	29	32	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory chemical transporter (gene) and are both present in neurons during postnatal development.	T8	T20	17554001
NA	CHEMICAL	GENE-Y	29	32	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory chemical transporter (gene) and are both present in neurons during postnatal development.	T8	T20	17554001
CPR:9	CHEMICAL	GENE-Y	21	27	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, chemical and GABA, share the same gene (VIAAT) and are both present in neurons during postnatal development.	T6	T19	17554001
CPR:9	CHEMICAL	GENE-N	21	32	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, chemical and GABA, share the same vesicular inhibitory amino acid transporter (gene) and are both present in neurons during postnatal development.	T6	T20	17554001
CPR:9	CHEMICAL	GENE-Y	21	32	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, chemical and GABA, share the same vesicular inhibitory amino acid transporter (gene) and are both present in neurons during postnatal development.	T6	T20	17554001
CPR:9	CHEMICAL	GENE-Y	23	27	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and chemical, share the same gene (VIAAT) and are both present in neurons during postnatal development.	T7	T19	17554001
CPR:9	CHEMICAL	GENE-N	23	32	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and chemical, share the same vesicular inhibitory amino acid transporter (gene) and are both present in neurons during postnatal development.	T7	T20	17554001
CPR:9	CHEMICAL	GENE-Y	23	32	The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and chemical, share the same vesicular inhibitory amino acid transporter (gene) and are both present in neurons during postnatal development.	T7	T20	17554001
NA	CHEMICAL	GENE-N	9	6	We have expressed VIAAT and the gene for chemical and GABA in a neuroendocrine cell line and measured the quantal release of chemical and GABA using a novel double-sniffer patch-clamp technique.	T11	T22	17554001
CPR:9	CHEMICAL	GENE-N	9	6	We have expressed VIAAT and the gene for chemical and GABA in a neuroendocrine cell line and measured the quantal release of chemical and GABA using a novel double-sniffer patch-clamp technique.	T9	T22	17554001
NA	CHEMICAL	GENE-N	9	3	We have expressed gene and the plasmalemmal transporters for chemical and GABA in a neuroendocrine cell line and measured the quantal release of chemical and GABA using a novel double-sniffer patch-clamp technique.	T11	T21	17554001
CPR:9	CHEMICAL	GENE-N	9	3	We have expressed gene and the plasmalemmal transporters for chemical and GABA in a neuroendocrine cell line and measured the quantal release of chemical and GABA using a novel double-sniffer patch-clamp technique.	T9	T21	17554001
NA	CHEMICAL	GENE-Y	9	3	We have expressed gene and the plasmalemmal transporters for chemical and GABA in a neuroendocrine cell line and measured the quantal release of chemical and GABA using a novel double-sniffer patch-clamp technique.	T11	T21	17554001
CPR:9	CHEMICAL	GENE-Y	9	3	We have expressed gene and the plasmalemmal transporters for chemical and GABA in a neuroendocrine cell line and measured the quantal release of chemical and GABA using a novel double-sniffer patch-clamp technique.	T9	T21	17554001
CPR:9	CHEMICAL	GENE-N	11	6	We have expressed VIAAT and the gene for glycine and chemical in a neuroendocrine cell line and measured the quantal release of glycine and chemical using a novel double-sniffer patch-clamp technique.	T10	T22	17554001
NA	CHEMICAL	GENE-N	11	6	We have expressed VIAAT and the gene for glycine and chemical in a neuroendocrine cell line and measured the quantal release of glycine and chemical using a novel double-sniffer patch-clamp technique.	T12	T22	17554001
CPR:9	CHEMICAL	GENE-N	11	3	We have expressed gene and the plasmalemmal transporters for glycine and chemical in a neuroendocrine cell line and measured the quantal release of glycine and chemical using a novel double-sniffer patch-clamp technique.	T10	T21	17554001
NA	CHEMICAL	GENE-N	11	3	We have expressed gene and the plasmalemmal transporters for glycine and chemical in a neuroendocrine cell line and measured the quantal release of glycine and chemical using a novel double-sniffer patch-clamp technique.	T12	T21	17554001
CPR:9	CHEMICAL	GENE-Y	11	3	We have expressed gene and the plasmalemmal transporters for glycine and chemical in a neuroendocrine cell line and measured the quantal release of glycine and chemical using a novel double-sniffer patch-clamp technique.	T10	T21	17554001
NA	CHEMICAL	GENE-Y	11	3	We have expressed gene and the plasmalemmal transporters for glycine and chemical in a neuroendocrine cell line and measured the quantal release of glycine and chemical using a novel double-sniffer patch-clamp technique.	T12	T21	17554001
NA	CHEMICAL	GENE-N	3	15	We found that chemical is released from vesicles when VIAAT is coexpressed with either the gene GlyT2 or the glial transporter GlyT1.	T13	T24	17554001
NA	CHEMICAL	GENE-N	3	20	We found that chemical is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the gene GlyT1.	T13	T26	17554001
NA	CHEMICAL	GENE-Y	3	22	We found that chemical is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial transporter gene.	T13	T27	17554001
NA	CHEMICAL	GENE-N	3	17	We found that chemical is released from vesicles when VIAAT is coexpressed with either the neuronal transporter gene or the glial transporter GlyT1.	T13	T25	17554001
CPR:9	CHEMICAL	GENE-N	3	9	We found that chemical is released from vesicles when gene is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.	T13	T23	17554001
NA	CHEMICAL	GENE-Y	3	17	We found that chemical is released from vesicles when VIAAT is coexpressed with either the neuronal transporter gene or the glial transporter GlyT1.	T13	T25	17554001
CPR:9	CHEMICAL	GENE-Y	3	9	We found that chemical is released from vesicles when gene is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.	T13	T23	17554001
NA	CHEMICAL	GENE-Y	28	6	However, GlyT2 was more effective than gene, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by VIAAT.	T14	T29	17554001
NA	CHEMICAL	GENE-N	28	1	However, gene was more effective than GlyT1, probably because gene is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by VIAAT.	T14	T28	17554001
NA	CHEMICAL	GENE-N	28	1	However, gene was more effective than GlyT1, probably because gene is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by VIAAT.	T14	T30	17554001
CPR:9	CHEMICAL	GENE-N	28	36	However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by gene.	T14	T31	17554001
NA	CHEMICAL	GENE-Y	28	1	However, gene was more effective than GlyT1, probably because gene is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by VIAAT.	T14	T28	17554001
NA	CHEMICAL	GENE-Y	28	1	However, gene was more effective than GlyT1, probably because gene is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by VIAAT.	T14	T30	17554001
CPR:9	CHEMICAL	GENE-Y	28	36	However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic chemical concentration required for efficient vesicular loading by gene.	T14	T31	17554001
CPR:9	CHEMICAL	GENE-N	10	27	The vesicular inhibitory phenotype was gradually altered from glycinergic to chemicalergic through mixed events when chemical is introduced into the secretory cell and competes for uptake by gene.	T1	T15	17554001
CPR:9	CHEMICAL	GENE-Y	10	27	The vesicular inhibitory phenotype was gradually altered from glycinergic to chemicalergic through mixed events when chemical is introduced into the secretory cell and competes for uptake by gene.	T1	T15	17554001
NA	CHEMICAL	GENE-N	11	21	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of gene, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T2	T17	17554001
CPR:9	CHEMICAL	GENE-N	11	21	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of gene, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T3	T17	17554001
NA	CHEMICAL	GENE-N	11	2	Interestingly, the gene ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T2	T16	17554001
NA	CHEMICAL	GENE-N	11	2	Interestingly, the gene ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T3	T16	17554001
NA	CHEMICAL	GENE-Y	11	21	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of gene, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T2	T17	17554001
CPR:9	CHEMICAL	GENE-Y	11	21	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of gene, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T3	T17	17554001
NA	CHEMICAL	GENE-Y	11	2	Interestingly, the gene ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T2	T16	17554001
NA	CHEMICAL	GENE-Y	11	2	Interestingly, the gene ortholog from Caenorhabditis elegans (UNC-47), a species lacking chemical transmission, also supports chemical exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers chemical specificity.	T3	T16	17554001
NA	CHEMICAL	GENE-N	30	21	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of gene, and a point mutation of UNC-47 that abolishes chemical transmission in the worm confers glycine specificity.	T4	T17	17554001
NA	CHEMICAL	GENE-N	30	2	Interestingly, the gene ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes chemical transmission in the worm confers glycine specificity.	T4	T16	17554001
NA	CHEMICAL	GENE-Y	30	21	Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of gene, and a point mutation of UNC-47 that abolishes chemical transmission in the worm confers glycine specificity.	T4	T17	17554001
NA	CHEMICAL	GENE-Y	30	2	Interestingly, the gene ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes chemical transmission in the worm confers glycine specificity.	T4	T16	17554001
CPR:9	CHEMICAL	GENE-N	10	12	Together, these results suggest that an increased cytosolic availability of chemical in gene-containing terminals was crucial for the emergence of chemicalrgic transmission in vertebrates.	T5	T18	17554001
CPR:9	CHEMICAL	GENE-Y	10	12	Together, these results suggest that an increased cytosolic availability of chemical in gene-containing terminals was crucial for the emergence of chemicalrgic transmission in vertebrates.	T5	T18	17554001
NA	CHEMICAL	GENE-N	10	5	The following AOD was examined: gene (SOD), catalase (CAT), chemical peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T2	T9	17578749
NA	CHEMICAL	GENE-Y	10	8	The following AOD was examined: superoxide dismutase (SOD), gene (CAT), chemical peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T2	T11	17578749
NA	CHEMICAL	GENE-N	10	12	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (gene), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T2	T14	17578749
NA	CHEMICAL	GENE-N	10	12	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (gene), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T2	T17	17578749
NA	CHEMICAL	GENE-N	10	7	The following AOD was examined: superoxide dismutase (gene), catalase (CAT), chemical peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T2	T10	17578749
NA	CHEMICAL	GENE-N	10	7	The following AOD was examined: superoxide dismutase (gene), catalase (CAT), chemical peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T2	T15	17578749
NA	CHEMICAL	GENE-Y	10	9	The following AOD was examined: superoxide dismutase (SOD), catalase (gene), chemical peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T2	T12	17578749
NA	CHEMICAL	GENE-Y	10	9	The following AOD was examined: superoxide dismutase (SOD), catalase (gene), chemical peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T2	T16	17578749
NA	CHEMICAL	GENE-N	5	10	The following AOD was examined: chemical dismutase (SOD), catalase (CAT), gene (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T1	T13	17578749
NA	CHEMICAL	GENE-Y	5	8	The following AOD was examined: chemical dismutase (SOD), gene (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T1	T11	17578749
NA	CHEMICAL	GENE-N	5	12	The following AOD was examined: chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T1	T14	17578749
NA	CHEMICAL	GENE-N	5	12	The following AOD was examined: chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T1	T17	17578749
NA	CHEMICAL	GENE-N	5	7	The following AOD was examined: chemical dismutase (gene), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T1	T10	17578749
NA	CHEMICAL	GENE-N	5	7	The following AOD was examined: chemical dismutase (gene), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T1	T15	17578749
NA	CHEMICAL	GENE-Y	5	9	The following AOD was examined: chemical dismutase (SOD), catalase (gene), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T1	T12	17578749
NA	CHEMICAL	GENE-Y	5	9	The following AOD was examined: chemical dismutase (SOD), catalase (gene), glutathione peroxidase (GPX), vitamin E, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T1	T16	17578749
NA	CHEMICAL	GENE-N	13	10	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), gene (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T3	T13	17578749
NA	CHEMICAL	GENE-N	13	5	The following AOD was examined: gene (SOD), catalase (CAT), glutathione peroxidase (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T3	T9	17578749
NA	CHEMICAL	GENE-Y	13	8	The following AOD was examined: superoxide dismutase (SOD), gene (CAT), glutathione peroxidase (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T3	T11	17578749
NA	CHEMICAL	GENE-N	13	12	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T3	T14	17578749
NA	CHEMICAL	GENE-N	13	12	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T3	T17	17578749
NA	CHEMICAL	GENE-N	13	7	The following AOD was examined: superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T3	T10	17578749
NA	CHEMICAL	GENE-N	13	7	The following AOD was examined: superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T3	T15	17578749
NA	CHEMICAL	GENE-Y	13	9	The following AOD was examined: superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T3	T12	17578749
NA	CHEMICAL	GENE-Y	13	9	The following AOD was examined: superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (GPX), chemical, and vitamin A. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T3	T16	17578749
NA	CHEMICAL	GENE-N	16	10	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), gene (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T4	T13	17578749
NA	CHEMICAL	GENE-N	16	5	The following AOD was examined: gene (SOD), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T4	T9	17578749
NA	CHEMICAL	GENE-Y	16	8	The following AOD was examined: superoxide dismutase (SOD), gene (CAT), glutathione peroxidase (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T4	T11	17578749
NA	CHEMICAL	GENE-N	16	12	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T4	T14	17578749
NA	CHEMICAL	GENE-N	16	12	The following AOD was examined: superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), CAT (p<0.05), and gene (p<0.05).	T4	T17	17578749
NA	CHEMICAL	GENE-N	16	7	The following AOD was examined: superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T4	T10	17578749
NA	CHEMICAL	GENE-N	16	7	The following AOD was examined: superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower gene (p<0.05), CAT (p<0.05), and GPX (p<0.05).	T4	T15	17578749
NA	CHEMICAL	GENE-Y	16	9	The following AOD was examined: superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T4	T12	17578749
NA	CHEMICAL	GENE-Y	16	9	The following AOD was examined: superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (GPX), vitamin E, and chemical. Inactive persons with ID had significantly lower SOD (p<0.05), gene (p<0.05), and GPX (p<0.05).	T4	T16	17578749
CPR:3	CHEMICAL	GENE-N	15	0	gene (GluRs) require external Na+ and Cl- as well as the neurotransmitter chemical for activation.	T2	T14	17581967
CPR:3	CHEMICAL	GENE-N	15	4	Kainate-selective ionotropic glutamate receptors (gene) require external Na+ and Cl- as well as the neurotransmitter chemical for activation.	T2	T19	17581967
NA	CHEMICAL	GENE-N	2	4	Kainate-selective ionotropic chemical receptors (gene) require external Na+ and Cl- as well as the neurotransmitter L-chemical for activation.	T4	T19	17581967
NA	CHEMICAL	GENE-N	0	4	chemical-selective ionotropic glutamate receptors (gene) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.	T1	T19	17581967
CPR:3	CHEMICAL	GENE-N	9	0	gene (GluRs) require external Na+ and chemical as well as the neurotransmitter L-glutamate for activation.	T7	T14	17581967
CPR:3	CHEMICAL	GENE-N	9	4	Kainate-selective ionotropic glutamate receptors (gene) require external Na+ and chemical as well as the neurotransmitter L-glutamate for activation.	T7	T19	17581967
CPR:3	CHEMICAL	GENE-N	7	0	gene (GluRs) require external chemical and Cl- as well as the neurotransmitter L-glutamate for activation.	T6	T14	17581967
CPR:3	CHEMICAL	GENE-N	7	4	Kainate-selective ionotropic glutamate receptors (gene) require external chemical and Cl- as well as the neurotransmitter L-glutamate for activation.	T6	T19	17581967
NA	CHEMICAL	GENE-N	7	9	Although, external anions and cations apparently coactivate chemical receptors (gene) in an identical manner, it has yet to be established how ions of opposite charge achieve this.	T3	T17	17581967
NA	CHEMICAL	GENE-N	7	12	Consequently, other cation species may compete with chemical to regulate the time gene remain in the open state.	T5	T20	17581967
CPR:3	CHEMICAL	GENE-N	3	6	Additionally, Na+ and chemical ions coactivate gene receptors by establishing a dipole, accounting for their common effect on KARs.	T9	T25	17581967
CPR:3	CHEMICAL	GENE-Y	3	6	Additionally, Na+ and chemical ions coactivate gene receptors by establishing a dipole, accounting for their common effect on KARs.	T9	T25	17581967
NA	CHEMICAL	GENE-N	3	18	Additionally, Na+ and chemical ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on gene.	T9	T26	17581967
CPR:3	CHEMICAL	GENE-N	1	6	Additionally, chemical and Cl- ions coactivate gene receptors by establishing a dipole, accounting for their common effect on KARs.	T8	T25	17581967
CPR:3	CHEMICAL	GENE-Y	1	6	Additionally, chemical and Cl- ions coactivate gene receptors by establishing a dipole, accounting for their common effect on KARs.	T8	T25	17581967
NA	CHEMICAL	GENE-N	1	18	Additionally, chemical and Cl- ions coactivate GluR6 receptors by establishing a dipole, accounting for their common effect on gene.	T8	T26	17581967
NA	CHEMICAL	GENE-N	3	6	The same sense thymine-to-chemical polymorphism (c.1629T-C; gene) was shown to preferentially modulate early components in both modalities.	T2	T5	17590520
NA	CHEMICAL	GENE-N	3	5	The same sense thymine-to-chemical polymorphism (c.gene; Ser543Ser) was shown to preferentially modulate early components in both modalities.	T2	T4	17590520
NA	CHEMICAL	GENE-N	3	6	The same sense chemical-to-cytosine polymorphism (c.1629T-C; gene) was shown to preferentially modulate early components in both modalities.	T1	T5	17590520
NA	CHEMICAL	GENE-N	3	5	The same sense chemical-to-cytosine polymorphism (c.gene; Ser543Ser) was shown to preferentially modulate early components in both modalities.	T1	T4	17590520
CPR:4	CHEMICAL	GENE-N	4	12	Phenserine, a derivative of chemical, was first described as an inhibitor of gene (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	T7	T27	17594192
CPR:4	CHEMICAL	GENE-N	4	13	Phenserine, a derivative of chemical, was first described as an inhibitor of acetylcholinesterase (gene) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	T7	T16	17594192
CPR:4	CHEMICAL	GENE-Y	4	13	Phenserine, a derivative of chemical, was first described as an inhibitor of acetylcholinesterase (gene) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	T7	T16	17594192
CPR:4	CHEMICAL	GENE-N	0	12	chemical, a derivative of physostigmine, was first described as an inhibitor of gene (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	T1	T27	17594192
CPR:4	CHEMICAL	GENE-N	0	13	chemical, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (gene) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	T1	T16	17594192
CPR:4	CHEMICAL	GENE-Y	0	13	chemical, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase (gene) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	T1	T16	17594192
NA	CHEMICAL	GENE-Y	0	19	chemical deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of gene (APP) in neuronal cell culture by reducing APP translation.	T8	T21	17594192
CPR:4	CHEMICAL	GENE-N	0	13	chemical deserves attention for an additional quality of action: in addition to inhibiting gene, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation.	T8	T20	17594192
CPR:4	CHEMICAL	GENE-Y	0	13	chemical deserves attention for an additional quality of action: in addition to inhibiting gene, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation.	T8	T20	17594192
NA	CHEMICAL	GENE-Y	0	22	chemical deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (gene) in neuronal cell culture by reducing gene translation.	T8	T22	17594192
CPR:4	CHEMICAL	GENE-Y	0	22	chemical deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (gene) in neuronal cell culture by reducing gene translation.	T8	T23	17594192
NA	CHEMICAL	GENE-Y	6	17	This effect probably involves interaction of chemical with a regulatory element in the 5'-untranslated region of the gene gene that controls gene expression.	T9	T24	17594192
NA	CHEMICAL	GENE-Y	6	17	This effect probably involves interaction of chemical with a regulatory element in the 5'-untranslated region of the gene gene that controls gene expression.	T9	T25	17594192
CPR:4	CHEMICAL	GENE-Y	0	6	chemical apparently reduces translational efficiency of gene mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.	T10	T26	17594192
NA	CHEMICAL	GENE-Y	18	6	Phenserine apparently reduces translational efficiency of gene mRNA into protein, a process that may involve an interaction with chemical and/or an chemical-responsive element.	T11	T26	17594192
NA	CHEMICAL	GENE-Y	18	6	Phenserine apparently reduces translational efficiency of gene mRNA into protein, a process that may involve an interaction with chemical and/or an chemical-responsive element.	T12	T26	17594192
CPR:4	CHEMICAL	GENE-Y	3	5	As a consequence, chemical reduces gene peptide (Abeta) formation in vitro and in vivo.	T13	T28	17594192
CPR:4	CHEMICAL	GENE-Y	3	7	As a consequence, chemical reduces beta-amyloid peptide (gene) formation in vitro and in vivo.	T13	T29	17594192
CPR:4	CHEMICAL	GENE-N	11	19	Phenserine is also unique because of differing actions of its enantiomers: chemical is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T2	T17	17594192
NA	CHEMICAL	GENE-N	11	19	Phenserine is also unique because of differing actions of its enantiomers: chemical is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T2	T18	17594192
CPR:4	CHEMICAL	GENE-Y	11	19	Phenserine is also unique because of differing actions of its enantiomers: chemical is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T2	T17	17594192
NA	CHEMICAL	GENE-Y	11	19	Phenserine is also unique because of differing actions of its enantiomers: chemical is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T2	T18	17594192
NA	CHEMICAL	GENE-N	21	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas chemical ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T3	T17	17594192
CPR:4	CHEMICAL	GENE-N	21	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas chemical ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T3	T18	17594192
NA	CHEMICAL	GENE-Y	21	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas chemical ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T3	T17	17594192
CPR:4	CHEMICAL	GENE-Y	21	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas chemical ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T3	T18	17594192
NA	CHEMICAL	GENE-N	0	19	chemical is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T14	T17	17594192
NA	CHEMICAL	GENE-N	0	19	chemical is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T14	T18	17594192
NA	CHEMICAL	GENE-Y	0	19	chemical is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T14	T17	17594192
NA	CHEMICAL	GENE-Y	0	19	chemical is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('posiphen') has weak activity as an gene inhibitor and can be dosed much higher.	T14	T18	17594192
NA	CHEMICAL	GENE-N	22	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('chemical') has weak activity as an gene inhibitor and can be dosed much higher.	T4	T17	17594192
CPR:4	CHEMICAL	GENE-N	22	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('chemical') has weak activity as an gene inhibitor and can be dosed much higher.	T4	T18	17594192
NA	CHEMICAL	GENE-Y	22	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('chemical') has weak activity as an gene inhibitor and can be dosed much higher.	T4	T17	17594192
CPR:4	CHEMICAL	GENE-Y	22	19	Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of gene, whereas (+)-phenserine ('chemical') has weak activity as an gene inhibitor and can be dosed much higher.	T4	T18	17594192
NA	CHEMICAL	GENE-Y	9	14	Contractile tension of the vas deferens in response to chemical was markedly decreased in gene KO mice, and this contraction was completely abolished in alpha(1)-adrenoceptor triple-KO mice.	T1	T6	17603545
NA	CHEMICAL	GENE-N	9	24	Contractile tension of the vas deferens in response to chemical was markedly decreased in alpha(1A)-adrenoceptor KO mice, and this contraction was completely abolished in gene triple-KO mice.	T1	T7	17603545
CPR:3	CHEMICAL	GENE-Y	16	3	BACKGROUND AND PURPOSE: gene (AMPK) is activated by metformin, phenformin, and the AMP mimetic, chemical (AICAR).	T8	T55	17603555
CPR:3	CHEMICAL	GENE-Y	16	6	BACKGROUND AND PURPOSE: AMP-activated protein kinase (gene) is activated by metformin, phenformin, and the AMP mimetic, chemical (AICAR).	T8	T57	17603555
CPR:3	CHEMICAL	GENE-Y	11	3	BACKGROUND AND PURPOSE: gene (AMPK) is activated by metformin, chemical, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	T42	T55	17603555
CPR:3	CHEMICAL	GENE-Y	11	6	BACKGROUND AND PURPOSE: AMP-activated protein kinase (gene) is activated by metformin, chemical, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	T42	T57	17603555
CPR:3	CHEMICAL	GENE-Y	10	3	BACKGROUND AND PURPOSE: gene (AMPK) is activated by chemical, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	T40	T55	17603555
CPR:3	CHEMICAL	GENE-Y	10	6	BACKGROUND AND PURPOSE: AMP-activated protein kinase (gene) is activated by chemical, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).	T40	T57	17603555
CPR:3	CHEMICAL	GENE-Y	17	3	BACKGROUND AND PURPOSE: gene (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (chemical).	T27	T55	17603555
CPR:3	CHEMICAL	GENE-Y	17	6	BACKGROUND AND PURPOSE: AMP-activated protein kinase (gene) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (chemical).	T27	T57	17603555
NA	CHEMICAL	GENE-Y	16	14	We have completed an extensive study of the pharmacological effects of these drugs on gene activation, chemical concentration, transepithelial amiloride-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	T31	T56	17603555
NA	CHEMICAL	GENE-Y	20	14	We have completed an extensive study of the pharmacological effects of these drugs on gene activation, adenine nucleotide concentration, transepithelial chemical-sensitive (I(chemical)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	T32	T56	17603555
NA	CHEMICAL	GENE-Y	20	14	We have completed an extensive study of the pharmacological effects of these drugs on gene activation, adenine nucleotide concentration, transepithelial chemical-sensitive (I(chemical)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.	T33	T56	17603555
NA	CHEMICAL	GENE-Y	23	14	We have completed an extensive study of the pharmacological effects of these drugs on gene activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and chemical-sensitive basolateral (I(chemical)) short circuit current in H441 lung epithelial cells.	T34	T56	17603555
NA	CHEMICAL	GENE-Y	23	14	We have completed an extensive study of the pharmacological effects of these drugs on gene activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and chemical-sensitive basolateral (I(chemical)) short circuit current in H441 lung epithelial cells.	T35	T56	17603555
NA	CHEMICAL	GENE-Y	9	0	gene activity was measured as the amount of radiolabelled chemical transferred to the SAMS peptide.	T38	T58	17603555
CPR:3	CHEMICAL	GENE-Y	2	7	KEY RESULTS: chemical, AICAR and metformin increased gene activity and decreased I(amiloride).	T43	T59	17603555
CPR:3	CHEMICAL	GENE-Y	5	7	KEY RESULTS: Phenformin, AICAR and chemical increased gene activity and decreased I(amiloride).	T45	T59	17603555
NA	CHEMICAL	GENE-Y	12	7	KEY RESULTS: Phenformin, AICAR and metformin increased gene activity and decreased I(chemical).	T46	T59	17603555
CPR:3	CHEMICAL	GENE-Y	3	7	KEY RESULTS: Phenformin, chemical and metformin increased gene activity and decreased I(amiloride).	T44	T59	17603555
CPR:3	CHEMICAL	GENE-Y	14	1	The gene inhibitor Compound C prevented the action of metformin and AICAR but not chemical.	T4	T60	17603555
NA	CHEMICAL	GENE-Y	9	1	The gene inhibitor Compound C prevented the action of chemical and AICAR but not phenformin.	T1	T60	17603555
NA	CHEMICAL	GENE-Y	11	1	The gene inhibitor Compound C prevented the action of metformin and chemical but not phenformin.	T2	T60	17603555
NA	CHEMICAL	GENE-N	25	12	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical gene (ENaC), which has important implications for the clinical use of chemical.	T22	T50	17603555
NA	CHEMICAL	GENE-Y	25	5	CONCLUSIONS AND IMPLICATIONS: Activation of gene is associated with inhibition of apical amiloride-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of chemical.	T22	T49	17603555
NA	CHEMICAL	GENE-N	25	15	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive Na(+) channels (gene), which has important implications for the clinical use of chemical.	T22	T51	17603555
NA	CHEMICAL	GENE-Y	12	5	CONCLUSIONS AND IMPLICATIONS: Activation of gene is associated with inhibition of apical chemical-sensitive Na(+) channels (ENaC), which has important implications for the clinical use of metformin.	T20	T49	17603555
NA	CHEMICAL	GENE-N	12	15	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical chemical-sensitive Na(+) channels (gene), which has important implications for the clinical use of metformin.	T20	T51	17603555
NA	CHEMICAL	GENE-Y	13	5	CONCLUSIONS AND IMPLICATIONS: Activation of gene is associated with inhibition of apical amiloride-sensitive chemical channels (ENaC), which has important implications for the clinical use of metformin.	T21	T49	17603555
NA	CHEMICAL	GENE-N	13	15	CONCLUSIONS AND IMPLICATIONS: Activation of alpha1-AMPK is associated with inhibition of apical amiloride-sensitive chemical channels (gene), which has important implications for the clinical use of metformin.	T21	T51	17603555
NA	CHEMICAL	GENE-N	7	38	Additional pharmacological effects evoked by AICAR and chemical on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where gene is an important component.	T24	T54	17603555
CPR:3	CHEMICAL	GENE-Y	7	33	Additional pharmacological effects evoked by AICAR and chemical on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of gene in cell systems where Na+K+ATPase is an important component.	T24	T53	17603555
NA	CHEMICAL	GENE-N	7	18	Additional pharmacological effects evoked by AICAR and chemical on I(ouabain), with potential secondary effects on apical Na+ conductance, gene activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	T24	T52	17603555
NA	CHEMICAL	GENE-N	9	38	Additional pharmacological effects evoked by AICAR and phenformin on I(chemical), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where gene is an important component.	T25	T54	17603555
CPR:3	CHEMICAL	GENE-Y	9	33	Additional pharmacological effects evoked by AICAR and phenformin on I(chemical), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of gene in cell systems where Na+K+ATPase is an important component.	T25	T53	17603555
NA	CHEMICAL	GENE-N	9	18	Additional pharmacological effects evoked by AICAR and phenformin on I(chemical), with potential secondary effects on apical Na+ conductance, gene activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	T25	T52	17603555
NA	CHEMICAL	GENE-N	5	38	Additional pharmacological effects evoked by chemical and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where gene is an important component.	T23	T54	17603555
CPR:3	CHEMICAL	GENE-Y	5	33	Additional pharmacological effects evoked by chemical and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of gene in cell systems where Na+K+ATPase is an important component.	T23	T53	17603555
NA	CHEMICAL	GENE-N	5	18	Additional pharmacological effects evoked by chemical and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, gene activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.	T23	T52	17603555
NA	CHEMICAL	GENE-Y	16	33	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical chemical conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of gene in cell systems where chemicalK+ATPase is an important component.	T26	T53	17603555
NA	CHEMICAL	GENE-N	16	18	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical chemical conductance, gene activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where chemicalK+ATPase is an important component.	T26	T52	17603555
NA	CHEMICAL	GENE-Y	16	33	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical chemical+ conductance, EchemicalC activity and monolayer resistance, have important consequences for their use as pharmacological activators of gene in cell systems where chemical+K+ATPase is an important component.	T28	T53	17603555
NA	CHEMICAL	GENE-N	33	18	Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, gene activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPchemical in cell systems where Na+chemical+ATPase is an important component.	T29	T52	17603555
CPR:9	CHEMICAL	GENE-N	7	1	Brain gene (COX), the rate-limiting enzyme in chemical synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.	T15	T29	17604186
CPR:9	CHEMICAL	GENE-N	7	2	Brain cyclooxygenases (gene), the rate-limiting enzyme in chemical synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.	T15	T25	17604186
CPR:4	CHEMICAL	GENE-Y	12	14	Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or chemical (selective gene inhibitor) against chemical kindling in mice.	T10	T27	17604186
NA	CHEMICAL	GENE-N	12	10	Previous studies have explored the protective effect of naproxen (non-selective gene-inhibitor) or chemical (selective gene-2 inhibitor) against chemical kindling in mice.	T10	T26	17604186
NA	CHEMICAL	GENE-Y	8	14	Previous studies have explored the protective effect of chemical (non-selective COX-inhibitor) or rofecoxib (selective gene inhibitor) against chemical kindling in mice.	T9	T27	17604186
CPR:4	CHEMICAL	GENE-N	8	10	Previous studies have explored the protective effect of chemical (non-selective gene-inhibitor) or rofecoxib (selective gene-2 inhibitor) against chemical kindling in mice.	T9	T26	17604186
NA	CHEMICAL	GENE-Y	20	17	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential gene inhibitor) against chemical (PTZ)-induced kindling epilepsy in mice.	T12	T28	17604186
CPR:4	CHEMICAL	GENE-Y	14	17	With this background, the present study was designed to explore the possible effect of chemical (a preferential gene inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.	T11	T28	17604186
NA	CHEMICAL	GENE-Y	21	17	With this background, the present study was designed to explore the possible effect of nimesulide (a preferential gene inhibitor) against pentylenetetrazol (chemical)-induced kindling epilepsy in mice.	T13	T28	17604186
NA	CHEMICAL	GENE-Y	12	14	Compared with normal control group, PTZ-kindled mice had significantly higher levels of chemical, nitrite, gene but had lower levels of reduced glutathione in the whole brain homogenate.	T2	T23	17604186
NA	CHEMICAL	GENE-Y	21	14	Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, nitrite, gene but had lower levels of reduced chemical in the whole brain homogenate.	T4	T23	17604186
NA	CHEMICAL	GENE-Y	13	14	Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, chemical, gene but had lower levels of reduced glutathione in the whole brain homogenate.	T3	T23	17604186
CPR:3	CHEMICAL	GENE-Y	5	14	Compared with normal control group, chemical-kindled mice had significantly higher levels of malondialdehyde, nitrite, gene but had lower levels of reduced glutathione in the whole brain homogenate.	T1	T23	17604186
CPR:4	CHEMICAL	GENE-Y	4	7	These results suggested that chemical, a preferential gene inhibitor offered neuroprotection against PTZ-induced kindling in mice.	T7	T24	17604186
NA	CHEMICAL	GENE-Y	12	7	These results suggested that nimesulide, a preferential gene inhibitor offered neuroprotection against chemical-induced kindling in mice.	T8	T24	17604186
NA	CHEMICAL	GENE-N	0	18	chemical, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by gene (GSTs) before urinary excretion.	T1	T10	17617661
NA	CHEMICAL	GENE-N	0	20	chemical, thought to be responsible for the chemopreventive properties of this food group, are conjugated to glutathione by glutathione S-transferases (gene) before urinary excretion.	T1	T11	17617661
NA	CHEMICAL	GENE-N	16	20	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to chemical by chemical S-transferases (gene) before urinary excretion.	T2	T11	17617661
NA	CHEMICAL	GENE-N	16	20	Isothiocyanates, thought to be responsible for the chemopreventive properties of this food group, are conjugated to chemical by chemical S-transferases (gene) before urinary excretion.	T3	T11	17617661
NA	CHEMICAL	GENE-N	10	5	Cellular oxygen is sensed by gene that chemical hypoxia-inducible factor (HIF) alpha subunits.	T14	T24	17627474
NA	CHEMICAL	GENE-N	10	11	Cellular oxygen is sensed by prolyl-4-hydroxylase domain (PHD) proteins that chemical gene subunits.	T14	T29	17627474
NA	CHEMICAL	GENE-N	1	5	Cellular chemical is sensed by gene that hydroxylate hypoxia-inducible factor (HIF) alpha subunits.	T17	T24	17627474
NA	CHEMICAL	GENE-N	1	11	Cellular chemical is sensed by prolyl-4-hydroxylase domain (PHD) proteins that hydroxylate gene subunits.	T17	T29	17627474
NA	CHEMICAL	GENE-N	5	11	Cellular oxygen is sensed by chemical-4-hydroxylase domain (PHD) proteins that hydroxylate gene subunits.	T12	T29	17627474
NA	CHEMICAL	GENE-N	3	2	Thus, the gene chemical sensors themselves represent effectors of cellular signalling pathways as well as potential drug targets.	T13	T28	17627474
NA	CHEMICAL	GENE-N	17	35	Here, a cell-free in vitro microtiter plate-based peptide hydroxylation assay was used to investigate the influence of chemical, Krebs cycle intermediates, transition metals, and vitamin C and other antioxidants on the activity of purified gene.	T15	T30	17627474
NA	CHEMICAL	GENE-N	25	35	Here, a cell-free in vitro microtiter plate-based peptide hydroxylation assay was used to investigate the influence of ferrous iron, Krebs cycle intermediates, transition metals, and chemical and other antioxidants on the activity of purified gene.	T16	T30	17627474
NA	CHEMICAL	GENE-N	14	0	gene activity depends not only on oxygen availability but is also regulated by iron, chemical, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	T2	T31	17627474
NA	CHEMICAL	GENE-N	6	0	gene activity depends not only on chemical availability but is also regulated by iron, vitamin C, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	T18	T31	17627474
NA	CHEMICAL	GENE-N	13	0	gene activity depends not only on oxygen availability but is also regulated by chemical, vitamin C, and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	T1	T31	17627474
NA	CHEMICAL	GENE-N	10	27	While vitamin C is essential for PHD activity in vitro, chemical had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three gene, demonstrating different functions of these antioxidants.	T9	T22	17627474
NA	CHEMICAL	GENE-N	10	6	While vitamin C is essential for gene activity in vitro, chemical had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three genes, demonstrating different functions of these antioxidants.	T9	T21	17627474
CPR:4	CHEMICAL	GENE-N	18	27	While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or chemical efficiently inhibited the activity of all three gene, demonstrating different functions of these antioxidants.	T11	T22	17627474
NA	CHEMICAL	GENE-N	18	6	While vitamin C is essential for gene activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or chemical efficiently inhibited the activity of all three genes, demonstrating different functions of these antioxidants.	T11	T21	17627474
CPR:4	CHEMICAL	GENE-N	15	27	While vitamin C is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and chemical or n-propyl gallate efficiently inhibited the activity of all three gene, demonstrating different functions of these antioxidants.	T10	T22	17627474
NA	CHEMICAL	GENE-N	15	6	While vitamin C is essential for gene activity in vitro, N-acetyl-L-cysteine had no effect, and chemical or n-propyl gallate efficiently inhibited the activity of all three genes, demonstrating different functions of these antioxidants.	T10	T21	17627474
NA	CHEMICAL	GENE-N	1	27	While chemical is essential for PHD activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three gene, demonstrating different functions of these antioxidants.	T8	T22	17627474
NA	CHEMICAL	GENE-N	1	6	While chemical is essential for gene activity in vitro, N-acetyl-L-cysteine had no effect, and gallic acid or n-propyl gallate efficiently inhibited the activity of all three genes, demonstrating different functions of these antioxidants.	T8	T21	17627474
NA	CHEMICAL	GENE-N	31	25	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, gene (MGSTs), and microsomal chemical synthase 1 (ref.	T25	T42	17632548
NA	CHEMICAL	GENE-Y	31	23	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes gene, microsomal glutathione S-transferases (MGSTs), and microsomal chemical synthase 1 (ref.	T25	T41	17632548
NA	CHEMICAL	GENE-N	31	28	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (gene), and microsomal chemical synthase 1 (ref.	T25	T43	17632548
CPR:9	CHEMICAL	GENE-Y	19	30	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and chemical metabolism that includes 5-lipoxygenase-activating protein, microsomal chemical S-transferases (MGSTs), and gene (ref.	T22	T44	17632548
NA	CHEMICAL	GENE-Y	19	30	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and chemical metabolism that includes 5-lipoxygenase-activating protein, microsomal chemical S-transferases (MGSTs), and gene (ref.	T23	T44	17632548
NA	CHEMICAL	GENE-Y	19	23	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and chemical metabolism that includes gene, microsomal chemical S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	T22	T41	17632548
NA	CHEMICAL	GENE-Y	19	23	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and chemical metabolism that includes gene, microsomal chemical S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	T23	T41	17632548
CPR:9	CHEMICAL	GENE-N	19	28	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and chemical metabolism that includes 5-lipoxygenase-activating protein, microsomal chemical S-transferases (gene), and microsomal prostaglandin E synthase 1 (ref.	T22	T43	17632548
NA	CHEMICAL	GENE-N	19	28	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and chemical metabolism that includes 5-lipoxygenase-activating protein, microsomal chemical S-transferases (gene), and microsomal prostaglandin E synthase 1 (ref.	T23	T43	17632548
CPR:9	CHEMICAL	GENE-Y	17	30	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in chemical and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and gene (ref.	T21	T44	17632548
CPR:9	CHEMICAL	GENE-N	17	25	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in chemical and glutathione metabolism that includes 5-lipoxygenase-activating protein, gene (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	T21	T42	17632548
NA	CHEMICAL	GENE-Y	17	23	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in chemical and glutathione metabolism that includes gene, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.	T21	T41	17632548
CPR:9	CHEMICAL	GENE-N	17	28	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in chemical and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (gene), and microsomal prostaglandin E synthase 1 (ref.	T21	T43	17632548
NA	CHEMICAL	GENE-Y	27	30	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione chemical-transferases (MGchemicalTs), and gene (ref.	T24	T44	17632548
NA	CHEMICAL	GENE-Y	27	23	10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes gene, microsomal glutathione chemical-transferases (MGchemicalTs), and microsomal prostaglandin E synthase 1 (ref.	T24	T41	17632548
NA	CHEMICAL	GENE-Y	10	14	LTC4S conjugates glutathione to LTA4, the endogenous substrate derived from chemical through the gene pathway.	T28	T46	17632548
NA	CHEMICAL	GENE-Y	10	0	gene conjugates glutathione to LTA4, the endogenous substrate derived from chemical through the 5-lipoxygenase pathway.	T28	T45	17632548
NA	CHEMICAL	GENE-Y	2	14	LTC4S conjugates chemical to LTA4, the endogenous substrate derived from arachidonic acid through the gene pathway.	T26	T46	17632548
NA	CHEMICAL	GENE-Y	2	0	gene conjugates chemical to LTA4, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway.	T26	T45	17632548
NA	CHEMICAL	GENE-Y	4	14	LTC4S conjugates glutathione to chemical, the endogenous substrate derived from arachidonic acid through the gene pathway.	T27	T46	17632548
NA	CHEMICAL	GENE-Y	4	0	gene conjugates glutathione to chemical, the endogenous substrate derived from arachidonic acid through the 5-lipoxygenase pathway.	T27	T45	17632548
NA	CHEMICAL	GENE-Y	13	9	In contrast with MGST2 and MGST3 (refs 15, 16), gene does not conjugate chemical to xenobiotics.	T31	T49	17632548
NA	CHEMICAL	GENE-Y	13	5	In contrast with MGST2 and gene (refs 15, 16), LTC4S does not conjugate chemical to xenobiotics.	T31	T48	17632548
NA	CHEMICAL	GENE-Y	13	3	In contrast with gene and MGST3 (refs 15, 16), LTC4S does not conjugate chemical to xenobiotics.	T31	T47	17632548
NA	CHEMICAL	GENE-Y	13	7	Here we show the atomic structure of gene in a complex with chemical at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for chemical and LTA4 that distinguishes LTC4S from other MGSTs.	T1	T50	17632548
NA	CHEMICAL	GENE-Y	13	7	Here we show the atomic structure of gene in a complex with chemical at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for chemical and LTA4 that distinguishes LTC4S from other MGSTs.	T32	T50	17632548
NA	CHEMICAL	GENE-N	13	38	Here we show the atomic structure of human LTC4S in a complex with chemical at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for chemical and LTA4 that distinguishes LTC4S from other gene.	T1	T35	17632548
NA	CHEMICAL	GENE-N	13	38	Here we show the atomic structure of human LTC4S in a complex with chemical at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for chemical and LTA4 that distinguishes LTC4S from other gene.	T32	T35	17632548
NA	CHEMICAL	GENE-Y	13	8	Here we show the atomic structure of human gene in a complex with chemical at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for chemical and LTA4 that distinguishes gene from other MGSTs.	T1	T34	17632548
NA	CHEMICAL	GENE-Y	13	8	Here we show the atomic structure of human gene in a complex with chemical at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for chemical and LTA4 that distinguishes gene from other MGSTs.	T32	T34	17632548
NA	CHEMICAL	GENE-Y	32	7	Here we show the atomic structure of gene in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and chemical that distinguishes LTC4S from other MGSTs.	T2	T50	17632548
NA	CHEMICAL	GENE-N	32	38	Here we show the atomic structure of human LTC4S in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and chemical that distinguishes LTC4S from other gene.	T2	T35	17632548
NA	CHEMICAL	GENE-Y	32	8	Here we show the atomic structure of human gene in a complex with glutathione at 3.3 A resolution by X-ray crystallography and provide insights into the high substrate specificity for glutathione and chemical that distinguishes gene from other MGSTs.	T2	T34	17632548
NA	CHEMICAL	GENE-Y	19	10	These findings provide a structural basis for the development of gene inhibitors for a proinflammatory pathway mediated by three chemical ligands whose stability and potency are different and by multiple chemical receptors whose functions may be non-redundant.	T15	T37	17632548
NA	CHEMICAL	GENE-Y	19	10	These findings provide a structural basis for the development of gene inhibitors for a proinflammatory pathway mediated by three chemical ligands whose stability and potency are different and by multiple chemical receptors whose functions may be non-redundant.	T16	T37	17632548
NA	CHEMICAL	GENE-Y	20	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any chemical allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T2	T15	17704420
NA	CHEMICAL	GENE-Y	20	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any chemical allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T2	T17	17704420
NA	CHEMICAL	GENE-Y	20	18	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and gene, any chemical allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T2	T16	17704420
NA	CHEMICAL	GENE-Y	15	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any chemical allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T1	T15	17704420
NA	CHEMICAL	GENE-Y	15	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any chemical allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T1	T17	17704420
NA	CHEMICAL	GENE-Y	15	18	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any chemical allele, and gene, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T1	T16	17704420
NA	CHEMICAL	GENE-Y	43	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene chemical/chemical or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T3	T15	17704420
NA	CHEMICAL	GENE-Y	43	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene chemical/chemical or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T3	T17	17704420
NA	CHEMICAL	GENE-Y	43	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene chemical/chemical or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T4	T15	17704420
NA	CHEMICAL	GENE-Y	43	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene chemical/chemical or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T4	T17	17704420
NA	CHEMICAL	GENE-Y	43	18	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and gene, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A chemical/chemical or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T3	T16	17704420
NA	CHEMICAL	GENE-Y	43	18	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and gene, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A chemical/chemical or valine/valine) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T4	T16	17704420
NA	CHEMICAL	GENE-Y	45	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or chemical/chemical) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T5	T15	17704420
NA	CHEMICAL	GENE-Y	45	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or chemical/chemical) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T5	T17	17704420
NA	CHEMICAL	GENE-Y	45	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or chemical/chemical) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T6	T15	17704420
NA	CHEMICAL	GENE-Y	45	13	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (gene, any histidine allele, and FCGR3A, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (gene arginine/arginine or chemical/chemical) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T6	T17	17704420
NA	CHEMICAL	GENE-Y	45	18	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and gene, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or chemical/chemical) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T5	T16	17704420
NA	CHEMICAL	GENE-Y	45	18	Combined analysis of these two polymorphisms showed that patients with the favorable genotypes (FCGR2A, any histidine allele, and gene, any phenylalanine allele) showed a median PFS of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes (FCGR2A arginine/arginine or chemical/chemical) had a PFS of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log-rank test).	T6	T16	17704420
CPR:4	CHEMICAL	GENE-Y	0	12	chemical (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits gene (GABA-T), markedly increasing brain GABA levels.	T1	T43	17768678
CPR:4	CHEMICAL	GENE-N	0	7	chemical (PLZ), a nonselective irreversible inhibitor of gene (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	T1	T39	17768678
CPR:4	CHEMICAL	GENE-Y	0	13	chemical (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (gene), markedly increasing brain GABA levels.	T1	T36	17768678
CPR:4	CHEMICAL	GENE-N	0	9	chemical (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (gene), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	T1	T40	17768678
NA	CHEMICAL	GENE-Y	7	12	Phenelzine (PLZ), a nonselective irreversible inhibitor of chemical oxidase (MAO), also inhibits gene (GABA-T), markedly increasing brain GABA levels.	T27	T43	17768678
NA	CHEMICAL	GENE-Y	7	13	Phenelzine (PLZ), a nonselective irreversible inhibitor of chemical oxidase (MAO), also inhibits GABA-transaminase (gene), markedly increasing brain GABA levels.	T27	T36	17768678
NA	CHEMICAL	GENE-N	7	9	Phenelzine (PLZ), a nonselective irreversible inhibitor of chemical oxidase (gene), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	T27	T40	17768678
NA	CHEMICAL	GENE-N	12	7	Phenelzine (PLZ), a nonselective irreversible inhibitor of gene (MAO), also inhibits chemical-transaminase (chemical-T), markedly increasing brain chemical levels.	T14	T39	17768678
NA	CHEMICAL	GENE-N	12	7	Phenelzine (PLZ), a nonselective irreversible inhibitor of gene (MAO), also inhibits chemical-transaminase (chemical-T), markedly increasing brain chemical levels.	T33	T39	17768678
NA	CHEMICAL	GENE-N	12	7	Phenelzine (PLZ), a nonselective irreversible inhibitor of gene (MAO), also inhibits chemical-transaminase (chemical-T), markedly increasing brain chemical levels.	T5	T39	17768678
NA	CHEMICAL	GENE-N	12	9	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (gene), also inhibits chemical-transaminase (chemical-T), markedly increasing brain chemical levels.	T14	T40	17768678
NA	CHEMICAL	GENE-N	12	9	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (gene), also inhibits chemical-transaminase (chemical-T), markedly increasing brain chemical levels.	T33	T40	17768678
NA	CHEMICAL	GENE-N	12	9	Phenelzine (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (gene), also inhibits chemical-transaminase (chemical-T), markedly increasing brain chemical levels.	T5	T40	17768678
CPR:4	CHEMICAL	GENE-Y	1	12	Phenelzine (chemical), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits gene (GABA-T), markedly increasing brain GABA levels.	T6	T43	17768678
CPR:4	CHEMICAL	GENE-N	1	7	Phenelzine (chemical), a nonselective irreversible inhibitor of gene (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	T6	T39	17768678
CPR:4	CHEMICAL	GENE-Y	1	13	Phenelzine (chemical), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase (gene), markedly increasing brain GABA levels.	T6	T36	17768678
CPR:4	CHEMICAL	GENE-N	1	9	Phenelzine (chemical), a nonselective irreversible inhibitor of monoamine oxidase (gene), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.	T6	T40	17768678
NA	CHEMICAL	GENE-N	29	6	PLZ is also a substrate for gene, and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in chemical observed.	T18	T38	17768678
CPR:9	CHEMICAL	GENE-N	0	6	chemical is also a substrate for gene, and studies suggest that a metabolite formed by the action of this enzyme on chemical may be responsible for the increase in GABA observed.	T16	T38	17768678
NA	CHEMICAL	GENE-N	0	6	chemical is also a substrate for gene, and studies suggest that a metabolite formed by the action of this enzyme on chemical may be responsible for the increase in GABA observed.	T17	T38	17768678
NA	CHEMICAL	GENE-N	32	10	To determine whether a metabolite formed by the action of gene on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor chemical (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	T31	T41	17768678
CPR:4	CHEMICAL	GENE-N	32	10	To determine whether a metabolite formed by the action of gene on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor chemical (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	T31	T42	17768678
NA	CHEMICAL	GENE-N	12	10	To determine whether a metabolite formed by the action of gene on chemical may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (TCP) before vehicle or chemical (15 mg/kg), and brains collected 3 h later.	T29	T41	17768678
NA	CHEMICAL	GENE-N	12	10	To determine whether a metabolite formed by the action of gene on chemical may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (TCP) before vehicle or chemical (15 mg/kg), and brains collected 3 h later.	T29	T42	17768678
NA	CHEMICAL	GENE-N	12	10	To determine whether a metabolite formed by the action of gene on chemical may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (TCP) before vehicle or chemical (15 mg/kg), and brains collected 3 h later.	T2	T41	17768678
NA	CHEMICAL	GENE-N	12	10	To determine whether a metabolite formed by the action of gene on chemical may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (TCP) before vehicle or chemical (15 mg/kg), and brains collected 3 h later.	T2	T42	17768678
NA	CHEMICAL	GENE-N	33	10	To determine whether a metabolite formed by the action of gene on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (chemical) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	T32	T41	17768678
CPR:4	CHEMICAL	GENE-N	33	10	To determine whether a metabolite formed by the action of gene on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (chemical) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	T32	T42	17768678
NA	CHEMICAL	GENE-N	21	10	To determine whether a metabolite formed by the action of gene on PLZ may be responsible for the elevation in brain chemical observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	T30	T41	17768678
NA	CHEMICAL	GENE-N	21	10	To determine whether a metabolite formed by the action of gene on PLZ may be responsible for the elevation in brain chemical observed, animals were pretreated with vehicle or the gene inhibitor tranylcypromine (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.	T30	T42	17768678
NA	CHEMICAL	GENE-N	41	52	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with chemical, that a metabolite of PLZ formed by the action of gene is responsible for the elevation of brain ORN observed.	T10	T37	17768678
CPR:9	CHEMICAL	GENE-N	13	52	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in chemical-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the chemical-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of chemical formed by the action of gene is responsible for the elevation of brain ORN observed.	T11	T37	17768678
NA	CHEMICAL	GENE-N	13	52	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in chemical-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the chemical-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of chemical formed by the action of gene is responsible for the elevation of brain ORN observed.	T4	T37	17768678
NA	CHEMICAL	GENE-N	13	52	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in chemical-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the chemical-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of chemical formed by the action of gene is responsible for the elevation of brain ORN observed.	T8	T37	17768678
NA	CHEMICAL	GENE-N	29	52	ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with chemical completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of PLZ formed by the action of gene is responsible for the elevation of brain ORN observed.	T7	T37	17768678
NA	CHEMICAL	GENE-N	0	52	chemical levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain chemical, suggesting, as with GABA, that a metabolite of PLZ formed by the action of gene is responsible for the elevation of brain chemical observed.	T12	T37	17768678
NA	CHEMICAL	GENE-N	0	52	chemical levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain chemical, suggesting, as with GABA, that a metabolite of PLZ formed by the action of gene is responsible for the elevation of brain chemical observed.	T3	T37	17768678
NA	CHEMICAL	GENE-N	0	52	chemical levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain chemical, suggesting, as with GABA, that a metabolite of PLZ formed by the action of gene is responsible for the elevation of brain chemical observed.	T9	T37	17768678
CPR:9	CHEMICAL	GENE-Y	10	18	Nitric oxide (NO) is an important vasorelaxant produced along with chemical from L-arginine in a reaction catalyzed by gene (eNOS).	T23	T36	17869551
CPR:9	CHEMICAL	GENE-Y	10	22	Nitric oxide (NO) is an important vasorelaxant produced along with chemical from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (gene).	T23	T37	17869551
NA	CHEMICAL	GENE-Y	19	22	Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial chemical synthase (gene).	T10	T37	17869551
CPR:9	CHEMICAL	GENE-Y	0	18	chemical (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by gene (eNOS).	T1	T36	17869551
CPR:9	CHEMICAL	GENE-Y	0	22	chemical (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (gene).	T1	T37	17869551
CPR:9	CHEMICAL	GENE-Y	12	18	Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from chemical in a reaction catalyzed by gene (eNOS).	T29	T36	17869551
CPR:9	CHEMICAL	GENE-Y	12	22	Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from chemical in a reaction catalyzed by endothelial nitric oxide synthase (gene).	T29	T37	17869551
CPR:9	CHEMICAL	GENE-Y	2	18	Nitric oxide (chemical) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by gene (echemicalS).	T11	T36	17869551
CPR:4	CHEMICAL	GENE-Y	3	7	As further support, chemical, an inhibitor of gene (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	T31	T34	17869551
CPR:4	CHEMICAL	GENE-Y	3	9	As further support, chemical, an inhibitor of argininosuccinate synthase (gene), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	T31	T35	17869551
NA	CHEMICAL	GENE-Y	7	9	As further support, alpha-methyl-DL-aspartate, an inhibitor of chemical synthase (gene), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.	T2	T35	17869551
NA	CHEMICAL	GENE-Y	14	7	As further support, alpha-methyl-DL-aspartate, an inhibitor of gene (AS), a component of the chemical-NO cycle, inhibited NO production in a dose-dependent manner.	T3	T34	17869551
NA	CHEMICAL	GENE-Y	14	9	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (gene), a component of the chemical-NO cycle, inhibited NO production in a dose-dependent manner.	T3	T35	17869551
NA	CHEMICAL	GENE-Y	14	7	As further support, alpha-methyl-DL-aspartate, an inhibitor of gene (AS), a component of the citrulline-chemical cycle, inhibited chemical production in a dose-dependent manner.	T4	T34	17869551
NA	CHEMICAL	GENE-Y	14	7	As further support, alpha-methyl-DL-aspartate, an inhibitor of gene (AS), a component of the citrulline-chemical cycle, inhibited chemical production in a dose-dependent manner.	T5	T34	17869551
NA	CHEMICAL	GENE-Y	14	9	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (gene), a component of the citrulline-chemical cycle, inhibited chemical production in a dose-dependent manner.	T4	T35	17869551
NA	CHEMICAL	GENE-Y	14	9	As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (gene), a component of the citrulline-chemical cycle, inhibited chemical production in a dose-dependent manner.	T5	T35	17869551
NA	CHEMICAL	GENE-N	7	50	It is more potent and selective than chemical in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than chemical in binding to the histamine H1 and gene.	T4	T14	17916059
NA	CHEMICAL	GENE-N	7	50	It is more potent and selective than chemical in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than chemical in binding to the histamine H1 and gene.	T8	T14	17916059
NA	CHEMICAL	GENE-Y	7	47	It is more potent and selective than chemical in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than chemical in binding to the gene and muscarinic receptors.	T4	T13	17916059
NA	CHEMICAL	GENE-Y	7	47	It is more potent and selective than chemical in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than chemical in binding to the gene and muscarinic receptors.	T8	T13	17916059
NA	CHEMICAL	GENE-N	47	50	It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the chemical H1 and gene.	T9	T14	17916059
NA	CHEMICAL	GENE-N	10	50	It is more potent and selective than citalopram in inhibiting chemical re-uptake in the CNS, and less potent than various other selective chemical re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and gene.	T5	T14	17916059
NA	CHEMICAL	GENE-N	10	50	It is more potent and selective than citalopram in inhibiting chemical re-uptake in the CNS, and less potent than various other selective chemical re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and gene.	T7	T14	17916059
NA	CHEMICAL	GENE-Y	10	47	It is more potent and selective than citalopram in inhibiting chemical re-uptake in the CNS, and less potent than various other selective chemical re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the gene and muscarinic receptors.	T5	T13	17916059
NA	CHEMICAL	GENE-Y	10	47	It is more potent and selective than citalopram in inhibiting chemical re-uptake in the CNS, and less potent than various other selective chemical re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the gene and muscarinic receptors.	T7	T13	17916059
CPR:9	CHEMICAL	GENE-Y	15	12	Caution is necessary only when it is coadministered with drugs metabolised by gene, such as chemical, or administered to the elderly or patients with severe hepatic or renal impairment.	T11	T16	17916059
CPR:6	CHEMICAL	GENE-Y	18	5	AZD6140 is a reversible oral gene receptor antagonist that has been studied in ACS patients in comparison with chemical (DISPERSE-2 study).	T21	T29	17980251
CPR:6	CHEMICAL	GENE-Y	0	5	chemical is a reversible oral gene receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).	T20	T29	17980251
CPR:6	CHEMICAL	GENE-N	0	5	chemical (1) is a non-selective gene antagonist that is used clinically for the treatment of urinary incontinence.	T1	T10	18045203
NA	CHEMICAL	GENE-N	15	20	We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace chemical ((3)H-NMS) binding on gene.	T4	T9	18045203
NA	CHEMICAL	GENE-N	17	20	We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT(3)-scopolamine chloride (chemical) binding on gene.	T5	T9	18045203
NA	CHEMICAL	GENE-N	6	9	Compounds 1 and 2 potently displaced chemical binding at gene, but were less potent at the m2 and m5 subtypes.	T6	T11	18045203
NA	CHEMICAL	GENE-Y	6	20	Compounds 1 and 2 potently displaced chemical binding at m1, m3 and m4 receptors, but were less potent at the gene and m5 subtypes.	T6	T12	18045203
NA	CHEMICAL	GENE-Y	6	22	Compounds 1 and 2 potently displaced chemical binding at m1, m3 and m4 receptors, but were less potent at the m2 and gene subtypes.	T6	T13	18045203
CPR:5	CHEMICAL	GENE-Y	2	5	Administration of chemical, an gene agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.	T1	T10	18450949
CPR:3	CHEMICAL	GENE-Y	2	26	Administration of chemical, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the gene protein level reduced by CTD and increased the AQP1 protein level above the control one.	T1	T11	18450949
CPR:3	CHEMICAL	GENE-Y	2	35	Administration of chemical, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the gene protein level above the control one.	T1	T12	18450949
NA	CHEMICAL	GENE-Y	17	5	Administration of cevimeline hydrochloride, an gene agonist (10 mg/kg for 7 days po), but not chemical (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.	T2	T10	18450949
NA	CHEMICAL	GENE-Y	17	26	Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not chemical (0.3 mg/kg for 7 days po), recovered the gene protein level reduced by CTD and increased the AQP1 protein level above the control one.	T2	T11	18450949
NA	CHEMICAL	GENE-Y	17	35	Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not chemical (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the gene protein level above the control one.	T2	T12	18450949
NA	CHEMICAL	GENE-Y	11	4	The mRNA level of gene was scarcely affected by CTD and chemical administration.	T3	T14	18450949
CPR:3	CHEMICAL	GENE-Y	2	15	Administration of chemical (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the gene protein level reduced by CTD.	T4	T16	18450949
CPR:4	CHEMICAL	GENE-Y	0	7	chemical inhibits the dopamine transporter and the gene, resulting in elevations of these monoamines after impulse release.	T8	T31	18480678
CPR:4	CHEMICAL	GENE-N	0	3	chemical inhibits the gene and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.	T8	T30	18480678
CPR:4	CHEMICAL	GENE-Y	0	3	chemical inhibits the gene and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.	T8	T30	18480678
NA	CHEMICAL	GENE-N	7	3	threo-methylphenidate inhibits the gene and the chemical transporter, resulting in elevations of these monoamines after impulse release.	T16	T30	18480678
NA	CHEMICAL	GENE-Y	7	3	threo-methylphenidate inhibits the gene and the chemical transporter, resulting in elevations of these monoamines after impulse release.	T16	T30	18480678
CPR:9	CHEMICAL	GENE-Y	14	7	threo-methylphenidate inhibits the dopamine transporter and the gene, resulting in elevations of these chemical after impulse release.	T17	T31	18480678
CPR:9	CHEMICAL	GENE-N	14	3	threo-methylphenidate inhibits the gene and the norepinephrine transporter, resulting in elevations of these chemical after impulse release.	T17	T30	18480678
CPR:9	CHEMICAL	GENE-Y	14	3	threo-methylphenidate inhibits the gene and the norepinephrine transporter, resulting in elevations of these chemical after impulse release.	T17	T30	18480678
NA	CHEMICAL	GENE-Y	3	7	threo-methylphenidate inhibits the chemical transporter and the gene, resulting in elevations of these monoamines after impulse release.	T14	T31	18480678
NA	CHEMICAL	GENE-N	11	13	In both rodent and primate animal models, the binding of radiolabeled chemical to gene was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.	T24	T32	18480678
NA	CHEMICAL	GENE-Y	11	13	In both rodent and primate animal models, the binding of radiolabeled chemical to gene was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.	T24	T32	18480678
NA	CHEMICAL	GENE-N	26	13	In both rodent and primate animal models, the binding of radiolabeled d-MPH to gene was found to be selective, saturable, and reversible, whereas binding of chemical was diffuse and nonspecific.	T26	T32	18480678
NA	CHEMICAL	GENE-Y	26	13	In both rodent and primate animal models, the binding of radiolabeled d-MPH to gene was found to be selective, saturable, and reversible, whereas binding of chemical was diffuse and nonspecific.	T26	T32	18480678
NA	CHEMICAL	GENE-N	20	9	The importance of MPH chirality to central nervous system gene targeting has culminated in human imaging studies revealing that chemical binds specifically to striatal structures, whereas l-MPH binding is nonspecific.	T11	T29	18480678
NA	CHEMICAL	GENE-N	27	9	The importance of MPH chirality to central nervous system gene targeting has culminated in human imaging studies revealing that d-MPH binds specifically to striatal structures, whereas chemical binding is nonspecific.	T12	T29	18480678
NA	CHEMICAL	GENE-Y	22	8	We therefore sought to establish a role for gene in malignant glioma cell motility, migration, and invasion and determine the effects of chemical on these cell movement-related processes.	T5	T13	18593927
NA	CHEMICAL	GENE-Y	33	22	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular gene levels and in the absence and presence of sublethal nitrosourea (chemical; CCNU) concentrations.	T7	T14	18593927
NA	CHEMICAL	GENE-Y	32	22	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular gene levels and in the absence and presence of sublethal chemical ([1-(2-chloroethyl)-3-cyclohexyl-l-chemical]; CCNU) concentrations.	T6	T14	18593927
NA	CHEMICAL	GENE-Y	34	22	Scratch wound-healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down-regulation of cellular gene levels and in the absence and presence of sublethal nitrosourea ([1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]; chemical) concentrations.	T1	T14	18593927
CPR:4	CHEMICAL	GENE-Y	6	4	The direct inhibition of gene by chemical is likely a contributing factor.	T3	T9	18593927
CPR:4	CHEMICAL	GENE-Y	9	13	The principal aim of the study was to find chemical analogues that retained gene inhibition but with reduced cytotoxicity.	T12	T27	18604229
NA	CHEMICAL	GENE-Y	21	13	Pharmacological and in silico investigations concerning the interactions of these compounds with the gene channel revealed that compounds carrying a basic chemical in the side chain display a much higher affinity than those lacking such a group.	T6	T23	18604229
NA	CHEMICAL	GENE-Y	3	9	Specifically, B2-O-CH(2)-CH(2)-N-piperidine and chemical revealed a higher affinity towards gene channels than amiodarone.	T8	T24	18604229
NA	CHEMICAL	GENE-Y	1	9	Specifically, chemical and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards gene channels than amiodarone.	T7	T24	18604229
NA	CHEMICAL	GENE-Y	12	9	Specifically, B2-O-CH(2)-CH(2)-N-piperidine and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards gene channels than chemical.	T9	T24	18604229
CPR:4	CHEMICAL	GENE-Y	3	7	CONCLUSIONS AND IMPLICATIONS: chemical analogues with better gene channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and gene channel interaction are mechanistically distinct and separable properties of the compounds.	T10	T25	18604229
NA	CHEMICAL	GENE-Y	3	7	CONCLUSIONS AND IMPLICATIONS: chemical analogues with better gene channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and gene channel interaction are mechanistically distinct and separable properties of the compounds.	T10	T26	18604229
NA	CHEMICAL	GENE-Y	10	7	The interaction of holo- and apo-forms of gene with chemical was studied by a partition equilibrium method.	T7	T11	18620538
NA	CHEMICAL	GENE-Y	17	0	gene, obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for chemical being 1.9.10(6) and 4.2.10(5) M(-1), respectively.	T3	T9	18620538
NA	CHEMICAL	GENE-Y	11	0	gene, obtained by treatment with EDTA, displays one binding site for chemical, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.	T2	T9	18620538
NA	CHEMICAL	GENE-Y	5	0	gene, obtained by treatment with chemical, displays one binding site for fatty acids, the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.	T1	T9	18620538
NA	CHEMICAL	GENE-Y	6	1	However, gene was unable to bind chemical as measured by this technique.	T4	T10	18620538
NA	CHEMICAL	GENE-Y	2	6	Likewise, no chemical bound to gene, isolated using nondenaturing conditions, were detected by gas chromatography.	T5	T12	18620538
NA	CHEMICAL	GENE-Y	14	9	These results demonstrate that the conformational change induced in gene by the removal of chemical enables the protein to interact with fatty acids.	T6	T13	18620538
NA	CHEMICAL	GENE-Y	3	0	gene (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T1	18655903
NA	CHEMICAL	GENE-Y	3	0	gene (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T37	18655903
NA	CHEMICAL	GENE-Y	3	0	gene (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T1	18655903
NA	CHEMICAL	GENE-Y	3	0	gene (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T37	18655903
NA	CHEMICAL	GENE-Y	3	23	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T53	18655903
NA	CHEMICAL	GENE-Y	3	23	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T53	18655903
NA	CHEMICAL	GENE-Y	3	21	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T43	18655903
NA	CHEMICAL	GENE-Y	3	21	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T43	18655903
NA	CHEMICAL	GENE-N	3	33	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T22	T67	18655903
NA	CHEMICAL	GENE-N	3	33	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T59	T67	18655903
NA	CHEMICAL	GENE-Y	3	25	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T22	T57	18655903
NA	CHEMICAL	GENE-Y	3	25	Oxytocin (OT) and chemical (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T59	T57	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T22	T26	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T22	T28	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T22	T42	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T22	T64	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T22	T68	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T22	T6	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T59	T26	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T59	T28	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T59	T42	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T59	T64	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T59	T68	18655903
NA	CHEMICAL	GENE-Y	3	4	Oxytocin (OT) and chemical (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T59	T6	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T2	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T38	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T39	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T22	T3	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T2	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T38	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T39	18655903
NA	CHEMICAL	GENE-Y	3	1	Oxytocin (gene) and chemical (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T59	T3	18655903
NA	CHEMICAL	GENE-Y	0	3	chemical (OT) and gene (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T22	18655903
NA	CHEMICAL	GENE-Y	0	3	chemical (OT) and gene (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T59	18655903
NA	CHEMICAL	GENE-Y	0	3	chemical (OT) and gene (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T22	18655903
NA	CHEMICAL	GENE-Y	0	3	chemical (OT) and gene (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T59	18655903
NA	CHEMICAL	GENE-Y	0	23	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T53	18655903
NA	CHEMICAL	GENE-Y	0	23	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T53	18655903
NA	CHEMICAL	GENE-Y	0	21	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T43	18655903
NA	CHEMICAL	GENE-Y	0	21	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T43	18655903
NA	CHEMICAL	GENE-N	0	33	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T1	T67	18655903
NA	CHEMICAL	GENE-N	0	33	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T37	T67	18655903
NA	CHEMICAL	GENE-Y	0	25	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T1	T57	18655903
NA	CHEMICAL	GENE-Y	0	25	chemical (OT) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The OT (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T37	T57	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T1	T26	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T1	T28	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T1	T42	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T1	T64	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T1	T68	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T1	T6	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T37	T26	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T37	T28	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T37	T42	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T37	T64	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T37	T68	18655903
NA	CHEMICAL	GENE-Y	0	4	chemical (OT) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The OT (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T37	T6	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T2	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T38	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T39	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T1	T3	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T2	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T38	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T39	18655903
NA	CHEMICAL	GENE-Y	0	1	chemical (gene) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The gene (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T37	T3	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T22	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T59	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T22	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T59	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T22	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T59	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T22	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T59	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T22	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T59	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T22	18655903
NA	CHEMICAL	GENE-Y	4	3	Oxytocin (OT) and gene (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T59	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T1	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T37	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T1	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T37	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T1	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T37	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T1	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T37	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T1	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T37	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T1	18655903
NA	CHEMICAL	GENE-Y	4	0	gene (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T37	18655903
NA	CHEMICAL	GENE-Y	4	23	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T53	18655903
NA	CHEMICAL	GENE-Y	4	23	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T53	18655903
NA	CHEMICAL	GENE-Y	4	23	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T53	18655903
NA	CHEMICAL	GENE-Y	4	23	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T53	18655903
NA	CHEMICAL	GENE-Y	4	23	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T53	18655903
NA	CHEMICAL	GENE-Y	4	23	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T53	18655903
NA	CHEMICAL	GENE-Y	4	21	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T43	18655903
NA	CHEMICAL	GENE-Y	4	21	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T43	18655903
NA	CHEMICAL	GENE-Y	4	21	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T43	18655903
NA	CHEMICAL	GENE-Y	4	21	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T43	18655903
NA	CHEMICAL	GENE-Y	4	21	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T43	18655903
NA	CHEMICAL	GENE-Y	4	21	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T43	18655903
NA	CHEMICAL	GENE-N	4	33	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical gene?	T26	T67	18655903
NA	CHEMICAL	GENE-N	4	33	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical gene?	T28	T67	18655903
NA	CHEMICAL	GENE-N	4	33	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical gene?	T42	T67	18655903
NA	CHEMICAL	GENE-N	4	33	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical gene?	T64	T67	18655903
NA	CHEMICAL	GENE-N	4	33	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical gene?	T68	T67	18655903
NA	CHEMICAL	GENE-N	4	33	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical gene?	T6	T67	18655903
NA	CHEMICAL	GENE-Y	4	25	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative chemical V(1c)?	T26	T57	18655903
NA	CHEMICAL	GENE-Y	4	25	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative chemical V(1c)?	T28	T57	18655903
NA	CHEMICAL	GENE-Y	4	25	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative chemical V(1c)?	T42	T57	18655903
NA	CHEMICAL	GENE-Y	4	25	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative chemical V(1c)?	T64	T57	18655903
NA	CHEMICAL	GENE-Y	4	25	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative chemical V(1c)?	T68	T57	18655903
NA	CHEMICAL	GENE-Y	4	25	Oxytocin (OT) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The OT (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative chemical V(1c)?	T6	T57	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T2	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T38	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T39	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T26	T3	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T2	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T38	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T39	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T28	T3	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T2	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T38	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T39	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T42	T3	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T2	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T38	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T39	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T64	T3	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T2	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T38	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T39	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T68	T3	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T2	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T38	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T39	18655903
NA	CHEMICAL	GENE-Y	4	1	Oxytocin (gene) and vasopressin (chemical) mediate their biological actions by acting on four known receptors: The gene (uterine) and the chemical V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative chemical V(1c)?	T6	T3	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T2	T22	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T2	T59	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T38	T22	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T38	T59	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T39	T22	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T39	T59	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T3	T22	18655903
NA	CHEMICAL	GENE-Y	1	3	Oxytocin (chemical) and gene (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T3	T59	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T2	T1	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T2	T37	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T38	T1	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T38	T37	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T39	T1	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T39	T37	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T3	T1	18655903
NA	CHEMICAL	GENE-Y	1	0	gene (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T3	T37	18655903
NA	CHEMICAL	GENE-Y	1	23	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T2	T53	18655903
NA	CHEMICAL	GENE-Y	1	23	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T38	T53	18655903
NA	CHEMICAL	GENE-Y	1	23	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T39	T53	18655903
NA	CHEMICAL	GENE-Y	1	23	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), gene (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T3	T53	18655903
NA	CHEMICAL	GENE-Y	1	21	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T2	T43	18655903
NA	CHEMICAL	GENE-Y	1	21	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T38	T43	18655903
NA	CHEMICAL	GENE-Y	1	21	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T39	T43	18655903
NA	CHEMICAL	GENE-Y	1	21	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP gene (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP V(1c)?	T3	T43	18655903
NA	CHEMICAL	GENE-N	1	33	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T2	T67	18655903
NA	CHEMICAL	GENE-N	1	33	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T38	T67	18655903
NA	CHEMICAL	GENE-N	1	33	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T39	T67	18655903
NA	CHEMICAL	GENE-N	1	33	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative AVP gene?	T3	T67	18655903
NA	CHEMICAL	GENE-Y	1	25	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T2	T57	18655903
NA	CHEMICAL	GENE-Y	1	25	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T38	T57	18655903
NA	CHEMICAL	GENE-Y	1	25	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T39	T57	18655903
NA	CHEMICAL	GENE-Y	1	25	Oxytocin (chemical) and vasopressin (AVP) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the AVP V(1a) (vasopressor), V(1b) (pituitary), gene (renal) receptors and a fifth putative AVP V(1c)?	T3	T57	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T2	T26	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T2	T28	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T2	T42	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T2	T64	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T2	T68	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T2	T6	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T38	T26	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T38	T28	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T38	T42	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T38	T64	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T38	T68	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T38	T6	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T39	T26	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T39	T28	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T39	T42	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T39	T64	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T39	T68	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T39	T6	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T3	T26	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T3	T28	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T3	T42	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T3	T64	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T3	T68	18655903
NA	CHEMICAL	GENE-Y	1	4	Oxytocin (chemical) and vasopressin (gene) mediate their biological actions by acting on four known receptors: The chemical (uterine) and the gene V(1a) (vasopressor), V(1b) (pituitary), V(2) (renal) receptors and a fifth putative gene V(1c)?	T3	T6	18655903
NA	CHEMICAL	GENE-Y	7	10	The pharmacological properties of promising new selective chemical antagonists and gene agonists are also presented.	T29	T70	18655903
NA	CHEMICAL	GENE-Y	7	10	The pharmacological properties of promising new selective chemical antagonists and gene agonists are also presented.	T69	T70	18655903
NA	CHEMICAL	GENE-Y	7	5	The current status of non-peptide gene and chemical antagonists and agonists is also summarized.	T31	T30	18655903
NA	CHEMICAL	GENE-Y	7	5	The current status of non-peptide gene and chemical antagonists and agonists is also summarized.	T31	T71	18655903
NA	CHEMICAL	GENE-Y	7	5	The current status of non-peptide gene and chemical antagonists and agonists is also summarized.	T72	T30	18655903
NA	CHEMICAL	GENE-Y	7	5	The current status of non-peptide gene and chemical antagonists and agonists is also summarized.	T72	T71	18655903
NA	CHEMICAL	GENE-Y	5	7	The current status of non-peptide chemical and gene antagonists and agonists is also summarized.	T30	T31	18655903
NA	CHEMICAL	GENE-Y	5	7	The current status of non-peptide chemical and gene antagonists and agonists is also summarized.	T30	T72	18655903
NA	CHEMICAL	GENE-Y	5	7	The current status of non-peptide chemical and gene antagonists and agonists is also summarized.	T71	T31	18655903
NA	CHEMICAL	GENE-Y	5	7	The current status of non-peptide chemical and gene antagonists and agonists is also summarized.	T71	T72	18655903
NA	CHEMICAL	GENE-Y	7	9	The relative merits of peptide and non-peptide chemical and gene agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T32	T33	18655903
NA	CHEMICAL	GENE-Y	7	9	The relative merits of peptide and non-peptide chemical and gene agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T32	T74	18655903
NA	CHEMICAL	GENE-Y	7	9	The relative merits of peptide and non-peptide chemical and gene agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T73	T33	18655903
NA	CHEMICAL	GENE-Y	7	9	The relative merits of peptide and non-peptide chemical and gene agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T73	T74	18655903
NA	CHEMICAL	GENE-Y	9	7	The relative merits of peptide and non-peptide gene and chemical agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T33	T32	18655903
NA	CHEMICAL	GENE-Y	9	7	The relative merits of peptide and non-peptide gene and chemical agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T33	T73	18655903
NA	CHEMICAL	GENE-Y	9	7	The relative merits of peptide and non-peptide gene and chemical agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T74	T32	18655903
NA	CHEMICAL	GENE-Y	9	7	The relative merits of peptide and non-peptide gene and chemical agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	T74	T73	18655903
NA	CHEMICAL	GENE-Y	33	31	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of gene and chemical than their non-peptide counterparts.	T41	T40	18655903
NA	CHEMICAL	GENE-Y	33	31	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of gene and chemical than their non-peptide counterparts.	T41	T4	18655903
NA	CHEMICAL	GENE-Y	33	31	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of gene and chemical than their non-peptide counterparts.	T5	T40	18655903
NA	CHEMICAL	GENE-Y	33	31	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of gene and chemical than their non-peptide counterparts.	T5	T4	18655903
NA	CHEMICAL	GENE-Y	31	33	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of chemical and gene than their non-peptide counterparts.	T40	T41	18655903
NA	CHEMICAL	GENE-Y	31	33	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of chemical and gene than their non-peptide counterparts.	T40	T5	18655903
NA	CHEMICAL	GENE-Y	31	33	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of chemical and gene than their non-peptide counterparts.	T4	T41	18655903
NA	CHEMICAL	GENE-Y	31	33	Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of chemical and gene than their non-peptide counterparts.	T4	T5	18655903
NA	CHEMICAL	GENE-Y	24	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (chemical, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T51	18655903
NA	CHEMICAL	GENE-Y	24	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (chemical, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T52	18655903
CPR:5	CHEMICAL	GENE-Y	24	25	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (chemical, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T50	18655903
NA	CHEMICAL	GENE-Y	24	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T10	18655903
NA	CHEMICAL	GENE-Y	24	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T45	18655903
NA	CHEMICAL	GENE-Y	24	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T47	18655903
NA	CHEMICAL	GENE-Y	24	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T49	18655903
NA	CHEMICAL	GENE-Y	24	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T13	T8	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T12	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T18	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T44	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T46	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T48	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T54	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T7	18655903
NA	CHEMICAL	GENE-Y	24	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (chemical, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T13	T9	18655903
CPR:5	CHEMICAL	GENE-Y	27	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), chemical (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T51	18655903
NA	CHEMICAL	GENE-Y	27	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), chemical (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T52	18655903
NA	CHEMICAL	GENE-Y	27	25	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, gene agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T50	18655903
NA	CHEMICAL	GENE-Y	27	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T10	18655903
NA	CHEMICAL	GENE-Y	27	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T45	18655903
NA	CHEMICAL	GENE-Y	27	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T47	18655903
NA	CHEMICAL	GENE-Y	27	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T49	18655903
NA	CHEMICAL	GENE-Y	27	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T14	T8	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T12	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T18	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T44	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T46	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T48	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T54	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T7	18655903
NA	CHEMICAL	GENE-Y	27	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), chemical (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T14	T9	18655903
NA	CHEMICAL	GENE-Y	30	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), chemical (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T51	18655903
CPR:5	CHEMICAL	GENE-Y	30	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), chemical (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T52	18655903
NA	CHEMICAL	GENE-Y	30	25	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T50	18655903
NA	CHEMICAL	GENE-Y	30	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T10	18655903
NA	CHEMICAL	GENE-Y	30	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T45	18655903
NA	CHEMICAL	GENE-Y	30	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T47	18655903
NA	CHEMICAL	GENE-Y	30	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T49	18655903
NA	CHEMICAL	GENE-Y	30	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T15	T8	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T12	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T18	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T44	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T46	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T48	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T54	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T7	18655903
NA	CHEMICAL	GENE-Y	30	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), chemical (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T15	T9	18655903
NA	CHEMICAL	GENE-Y	20	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as chemical (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T51	18655903
NA	CHEMICAL	GENE-Y	20	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as chemical (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T52	18655903
NA	CHEMICAL	GENE-Y	20	25	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as chemical (OT agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T50	18655903
NA	CHEMICAL	GENE-Y	20	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as chemical (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T10	18655903
NA	CHEMICAL	GENE-Y	20	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as chemical (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T45	18655903
NA	CHEMICAL	GENE-Y	20	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as chemical (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T47	18655903
NA	CHEMICAL	GENE-Y	20	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as chemical (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T49	18655903
NA	CHEMICAL	GENE-Y	20	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as chemical (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T11	T8	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T12	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T18	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T44	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T46	18655903
CPR:5	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T48	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T54	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T7	18655903
NA	CHEMICAL	GENE-Y	20	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as chemical (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T11	T9	18655903
NA	CHEMICAL	GENE-Y	35	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T51	18655903
NA	CHEMICAL	GENE-Y	35	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T52	18655903
NA	CHEMICAL	GENE-Y	35	25	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T50	18655903
NA	CHEMICAL	GENE-Y	35	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T10	18655903
NA	CHEMICAL	GENE-Y	35	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T45	18655903
NA	CHEMICAL	GENE-Y	35	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T47	18655903
NA	CHEMICAL	GENE-Y	35	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T49	18655903
NA	CHEMICAL	GENE-Y	35	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical OT antagonist) are also in clinical use.	T17	T8	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T12	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T18	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T44	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T46	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T48	18655903
CPR:6	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T54	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T7	18655903
NA	CHEMICAL	GENE-Y	35	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (chemical gene antagonist) are also in clinical use.	T17	T9	18655903
NA	CHEMICAL	GENE-Y	34	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T51	18655903
NA	CHEMICAL	GENE-Y	34	28	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T52	18655903
NA	CHEMICAL	GENE-Y	34	25	In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T50	18655903
NA	CHEMICAL	GENE-Y	34	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T10	18655903
NA	CHEMICAL	GENE-Y	34	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T45	18655903
NA	CHEMICAL	GENE-Y	34	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T47	18655903
NA	CHEMICAL	GENE-Y	34	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T49	18655903
NA	CHEMICAL	GENE-Y	34	9	In addition to OT and to a lesser extent gene (pitressin), a number of OT and gene analogues; such as carbetocin (OT agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile OT antagonist) are also in clinical use.	T16	T8	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T12	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T18	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T44	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T46	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T48	18655903
CPR:6	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T54	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T7	18655903
NA	CHEMICAL	GENE-Y	34	3	In addition to gene and to a lesser extent AVP (pitressin), a number of gene and AVP analogues; such as carbetocin (gene agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and chemical (Tractocile gene antagonist) are also in clinical use.	T16	T9	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T10	T51	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T10	T52	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T45	T51	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T45	T52	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T47	T51	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T47	T52	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T49	T51	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T49	T52	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T8	T51	18655903
NA	CHEMICAL	GENE-Y	9	28	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T8	T52	18655903
NA	CHEMICAL	GENE-Y	9	25	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T10	T50	18655903
NA	CHEMICAL	GENE-Y	9	25	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T45	T50	18655903
NA	CHEMICAL	GENE-Y	9	25	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T47	T50	18655903
NA	CHEMICAL	GENE-Y	9	25	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T49	T50	18655903
NA	CHEMICAL	GENE-Y	9	25	In addition to OT and to a lesser extent chemical (pitressin), a number of OT and chemical analogues; such as carbetocin (OT agonist) dDchemical (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.	T8	T50	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T12	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T18	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T44	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T46	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T48	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T54	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T7	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T10	T9	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T12	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T18	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T44	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T46	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T48	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T54	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T7	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T45	T9	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T12	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T18	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T44	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T46	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T48	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T54	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T7	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T47	T9	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T12	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T18	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T44	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T46	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T48	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T54	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T7	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T49	T9	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T12	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T18	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T44	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T46	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T48	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T54	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T7	18655903
NA	CHEMICAL	GENE-Y	9	3	In addition to gene and to a lesser extent chemical (pitressin), a number of gene and chemical analogues; such as carbetocin (gene agonist) dDchemical (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile gene antagonist) are also in clinical use.	T8	T9	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T52	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T51	18655903
NA	CHEMICAL	GENE-Y	3	28	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (gene agonist), felypressin (gene agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T52	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T50	18655903
NA	CHEMICAL	GENE-Y	3	25	In addition to chemical and to a lesser extent AVP (pitressin), a number of chemical and AVP analogues; such as carbetocin (chemical agonist) dDAVP (desmopressin, gene agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T50	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T12	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T18	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T44	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T46	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T48	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T54	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T7	T8	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T10	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T45	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T47	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T49	18655903
NA	CHEMICAL	GENE-Y	3	9	In addition to chemical and to a lesser extent gene (pitressin), a number of chemical and gene analogues; such as carbetocin (chemical agonist) dDgene (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile chemical antagonist) are also in clinical use.	T9	T8	18655903
NA	CHEMICAL	GENE-Y	8	6	Despite much early promise, no non-peptide gene or chemical antagonists are currently in clinical trials.	T56	T55	18655903
NA	CHEMICAL	GENE-Y	12	27	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, chemical and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/gene, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T20	T61	18655903
CPR:6	CHEMICAL	GENE-Y	12	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, chemical and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T20	T58	18655903
NA	CHEMICAL	GENE-Y	12	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, chemical and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T20	T60	18655903
CPR:6	CHEMICAL	GENE-Y	29	27	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/gene, antagonist chemical (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T23	T61	18655903
NA	CHEMICAL	GENE-Y	29	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist chemical (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T23	T58	18655903
CPR:6	CHEMICAL	GENE-Y	29	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist chemical (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T23	T60	18655903
NA	CHEMICAL	GENE-Y	14	27	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and chemical, are currently in Phase III clinical trials; to date, only the mixed V(2)/gene, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T21	T61	18655903
CPR:6	CHEMICAL	GENE-Y	14	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and chemical, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T21	T58	18655903
NA	CHEMICAL	GENE-Y	14	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and chemical, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T21	T60	18655903
NA	CHEMICAL	GENE-Y	11	27	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, chemical, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/gene, antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T19	T61	18655903
CPR:6	CHEMICAL	GENE-Y	11	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, chemical, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T19	T58	18655903
NA	CHEMICAL	GENE-Y	11	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, chemical, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v.	T19	T60	18655903
CPR:6	CHEMICAL	GENE-Y	30	27	While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/gene, antagonist Conivaptan (chemical), has been approved by the US FDA for clinical use (by i.v.	T24	T61	18655903
NA	CHEMICAL	GENE-Y	30	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (chemical), has been approved by the US FDA for clinical use (by i.v.	T24	T58	18655903
CPR:6	CHEMICAL	GENE-Y	30	7	While a number of orally active non-peptide gene antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed gene/V(1a), antagonist Conivaptan (chemical), has been approved by the US FDA for clinical use (by i.v.	T24	T60	18655903
NA	CHEMICAL	GENE-Y	5	3	Promising new non-peptide gene and chemical antagonists, as well as non-peptide V(2) and chemical agonists are now in pre-clinical development.	T25	T62	18655903
NA	CHEMICAL	GENE-Y	5	3	Promising new non-peptide gene and chemical antagonists, as well as non-peptide V(2) and chemical agonists are now in pre-clinical development.	T27	T62	18655903
NA	CHEMICAL	GENE-Y	5	3	Promising new non-peptide gene and chemical antagonists, as well as non-peptide V(2) and chemical agonists are now in pre-clinical development.	T63	T62	18655903
NA	CHEMICAL	GENE-Y	5	3	Promising new non-peptide gene and chemical antagonists, as well as non-peptide V(2) and chemical agonists are now in pre-clinical development.	T66	T62	18655903
NA	CHEMICAL	GENE-Y	5	11	Promising new non-peptide V(1b) and chemical antagonists, as well as non-peptide gene and chemical agonists are now in pre-clinical development.	T25	T65	18655903
NA	CHEMICAL	GENE-Y	5	11	Promising new non-peptide V(1b) and chemical antagonists, as well as non-peptide gene and chemical agonists are now in pre-clinical development.	T27	T65	18655903
NA	CHEMICAL	GENE-Y	5	11	Promising new non-peptide V(1b) and chemical antagonists, as well as non-peptide gene and chemical agonists are now in pre-clinical development.	T63	T65	18655903
NA	CHEMICAL	GENE-Y	5	11	Promising new non-peptide V(1b) and chemical antagonists, as well as non-peptide gene and chemical agonists are now in pre-clinical development.	T66	T65	18655903
CPR:4	CHEMICAL	GENE-N	4	11	Absorbable drugs (fibric acids, chemical, probucol, HMG-CoA reductase inhibitors) reduce gene (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T6	T18	1868500
CPR:4	CHEMICAL	GENE-N	4	12	Absorbable drugs (fibric acids, chemical, probucol, HMG-CoA reductase inhibitors) reduce plasma very-gene (VLDL) and/or gene (LDL) by a variety of mechanisms.	T6	T20	1868500
NA	CHEMICAL	GENE-Y	4	7	Absorbable drugs (fibric acids, chemical, probucol, gene inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T6	T17	1868500
CPR:4	CHEMICAL	GENE-N	4	14	Absorbable drugs (fibric acids, chemical, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (gene) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T6	T19	1868500
CPR:4	CHEMICAL	GENE-N	4	14	Absorbable drugs (fibric acids, chemical, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (Vgene) and/or low-density lipoproteins (gene) by a variety of mechanisms.	T6	T21	1868500
CPR:4	CHEMICAL	GENE-N	2	11	Absorbable drugs (chemical, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce gene (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T5	T18	1868500
CPR:4	CHEMICAL	GENE-N	2	12	Absorbable drugs (chemical, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-gene (VLDL) and/or gene (LDL) by a variety of mechanisms.	T5	T20	1868500
NA	CHEMICAL	GENE-Y	2	7	Absorbable drugs (chemical, nicotinic acid, probucol, gene inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T5	T17	1868500
CPR:4	CHEMICAL	GENE-N	2	14	Absorbable drugs (chemical, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (gene) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T5	T19	1868500
CPR:4	CHEMICAL	GENE-N	2	14	Absorbable drugs (chemical, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (Vgene) and/or low-density lipoproteins (gene) by a variety of mechanisms.	T5	T21	1868500
CPR:4	CHEMICAL	GENE-N	6	11	Absorbable drugs (fibric acids, nicotinic acid, chemical, HMG-CoA reductase inhibitors) reduce gene (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T7	T18	1868500
CPR:4	CHEMICAL	GENE-N	6	12	Absorbable drugs (fibric acids, nicotinic acid, chemical, HMG-CoA reductase inhibitors) reduce plasma very-gene (VLDL) and/or gene (LDL) by a variety of mechanisms.	T7	T20	1868500
NA	CHEMICAL	GENE-Y	6	7	Absorbable drugs (fibric acids, nicotinic acid, chemical, gene inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T7	T17	1868500
CPR:4	CHEMICAL	GENE-N	6	14	Absorbable drugs (fibric acids, nicotinic acid, chemical, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (gene) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T7	T19	1868500
CPR:4	CHEMICAL	GENE-N	6	14	Absorbable drugs (fibric acids, nicotinic acid, chemical, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (Vgene) and/or low-density lipoproteins (gene) by a variety of mechanisms.	T7	T21	1868500
NA	CHEMICAL	GENE-N	7	11	Absorbable drugs (fibric acids, nicotinic acid, probucol, chemical reductase inhibitors) reduce gene (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T8	T18	1868500
NA	CHEMICAL	GENE-N	7	12	Absorbable drugs (fibric acids, nicotinic acid, probucol, chemical reductase inhibitors) reduce plasma very-gene (VLDL) and/or gene (LDL) by a variety of mechanisms.	T8	T20	1868500
NA	CHEMICAL	GENE-N	7	14	Absorbable drugs (fibric acids, nicotinic acid, probucol, chemical reductase inhibitors) reduce plasma very-low-density lipoproteins (gene) and/or low-density lipoproteins (LDL) by a variety of mechanisms.	T8	T19	1868500
NA	CHEMICAL	GENE-N	7	14	Absorbable drugs (fibric acids, nicotinic acid, probucol, chemical reductase inhibitors) reduce plasma very-low-density lipoproteins (Vgene) and/or low-density lipoproteins (gene) by a variety of mechanisms.	T8	T21	1868500
CPR:4	CHEMICAL	GENE-N	0	10	chemical, in particular, act by stimulating the catabolism of gene and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.	T9	T22	1868500
NA	CHEMICAL	GENE-N	0	10	chemical, in particular, act by stimulating the catabolism of Vgene and also, as a consequence, improving gene delipidation, thus favoring receptor uptake.	T9	T23	1868500
NA	CHEMICAL	GENE-N	0	17	chemical and acipimox interfere with the biosynthesis of LDL and can also improve the clearance of gene/LDL.	T10	T25	1868500
NA	CHEMICAL	GENE-N	0	9	chemical and acipimox interfere with the biosynthesis of gene and can also improve the clearance of Vgene/gene.	T10	T24	1868500
NA	CHEMICAL	GENE-N	0	9	chemical and acipimox interfere with the biosynthesis of gene and can also improve the clearance of Vgene/gene.	T10	T26	1868500
CPR:9	CHEMICAL	GENE-N	4	10	accelerating reverse transport of chemical from high-density lipoproteins to gene.	T12	T28	1868500
CPR:9	CHEMICAL	GENE-N	4	7	accelerating reverse transport of chemical from gene to lower-density lipoproteins.	T12	T27	1868500
NA	CHEMICAL	GENE-N	9	18	Finally, HMG-CoA reductase inhibitors, interfering with the biosynthesis of chemical, can induce an increased expression of liver high-affinity gene.	T14	T15	1868500
NA	CHEMICAL	GENE-Y	9	1	Finally, gene inhibitors, interfering with the biosynthesis of chemical, can induce an increased expression of liver high-affinity lipoprotein receptors.	T14	T29	1868500
NA	CHEMICAL	GENE-N	1	18	Finally, chemical reductase inhibitors, interfering with the biosynthesis of cholesterol, can induce an increased expression of liver high-affinity gene.	T13	T15	1868500
CPR:4	CHEMICAL	GENE-Y	1	13	BACKGROUND: chemical, the first dual inhibitor of epidermal growth factor receptor (EGFR) and gene (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T5	T51	18803986
CPR:4	CHEMICAL	GENE-Y	1	7	BACKGROUND: chemical, the first dual inhibitor of gene (EGFR) and human gene 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T5	T49	18803986
CPR:4	CHEMICAL	GENE-N	1	20	BACKGROUND: chemical, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) gene, was approved by the US Food and Drug Administration (FDA) in 2007.	T5	T37	18803986
CPR:4	CHEMICAL	GENE-Y	1	11	BACKGROUND: chemical, the first dual inhibitor of epidermal growth factor receptor (gene) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T5	T50	18803986
CPR:4	CHEMICAL	GENE-Y	1	19	BACKGROUND: chemical, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (gene) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T5	T35	18803986
NA	CHEMICAL	GENE-Y	20	13	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and gene (HER2) chemical kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T7	T51	18803986
NA	CHEMICAL	GENE-Y	20	7	BACKGROUND: Lapatinib, the first dual inhibitor of gene (EGFR) and human gene 2 (HER2) chemical kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T7	T49	18803986
NA	CHEMICAL	GENE-Y	20	11	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (gene) and human epidermal growth factor receptor 2 (HER2) chemical kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T7	T50	18803986
NA	CHEMICAL	GENE-Y	20	19	BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (gene) chemical kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	T7	T35	18803986
NA	CHEMICAL	GENE-Y	37	27	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (gene) and who have received previous treatment that included an chemical, a taxane, and trastuzumab.	T27	T48	18803986
NA	CHEMICAL	GENE-Y	37	26	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress gene (ErbB2) and who have received previous treatment that included an chemical, a taxane, and trastuzumab.	T27	T47	18803986
NA	CHEMICAL	GENE-Y	8	27	It is indicated for use in combination with chemical for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (gene) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.	T22	T48	18803986
NA	CHEMICAL	GENE-Y	8	26	It is indicated for use in combination with chemical for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress gene (ErbB2) and who have received previous treatment that included an anthracycline, a taxane, and trastuzumab.	T22	T47	18803986
NA	CHEMICAL	GENE-Y	39	27	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress HER2 (gene) and who have received previous treatment that included an anthracycline, a chemical, and trastuzumab.	T28	T48	18803986
NA	CHEMICAL	GENE-Y	39	26	It is indicated for use in combination with capecitabine for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress gene (ErbB2) and who have received previous treatment that included an anthracycline, a chemical, and trastuzumab.	T28	T47	18803986
NA	CHEMICAL	GENE-N	3	7	Search terms included chemical, GW572016, HER2, EGFR, gene, dual-receptor blockade, adverse events, and clinical trials.	T1	T34	18803986
NA	CHEMICAL	GENE-Y	3	6	Search terms included chemical, GW572016, HER2, gene, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	T1	T33	18803986
NA	CHEMICAL	GENE-Y	3	5	Search terms included chemical, GW572016, gene, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	T1	T32	18803986
NA	CHEMICAL	GENE-Y	8	6	Search terms included lapatinib, GW572016, HER2, gene, receptor chemical kinase, dual-receptor blockade, adverse events, and clinical trials.	T3	T33	18803986
NA	CHEMICAL	GENE-Y	8	5	Search terms included lapatinib, GW572016, gene, EGFR, receptor chemical kinase, dual-receptor blockade, adverse events, and clinical trials.	T3	T32	18803986
NA	CHEMICAL	GENE-N	4	7	Search terms included lapatinib, chemical, HER2, EGFR, gene, dual-receptor blockade, adverse events, and clinical trials.	T2	T34	18803986
NA	CHEMICAL	GENE-Y	4	6	Search terms included lapatinib, chemical, HER2, gene, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	T2	T33	18803986
NA	CHEMICAL	GENE-Y	4	5	Search terms included lapatinib, chemical, gene, EGFR, receptor tyrosine kinase, dual-receptor blockade, adverse events, and clinical trials.	T2	T32	18803986
CPR:9	CHEMICAL	GENE-Y	0	6	chemical is metabolized primarily by the gene isozyme, with 1 metabolite remaining active against EGFR but not HER2.	T6	T36	18803986
NA	CHEMICAL	GENE-Y	0	16	chemical is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against gene but not HER2.	T6	T38	18803986
NA	CHEMICAL	GENE-Y	0	19	chemical is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not gene.	T6	T39	18803986
NA	CHEMICAL	GENE-Y	29	15	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an chemical, a taxane, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T12	T40	18803986
NA	CHEMICAL	GENE-Y	8	15	In a Phase III trial comparing lapatinib and chemical with chemical alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and chemical was associated with a numeric improvement in response rate compared with chemical alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T10	T40	18803986
NA	CHEMICAL	GENE-Y	8	15	In a Phase III trial comparing lapatinib and chemical with chemical alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and chemical was associated with a numeric improvement in response rate compared with chemical alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T11	T40	18803986
NA	CHEMICAL	GENE-Y	8	15	In a Phase III trial comparing lapatinib and chemical with chemical alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and chemical was associated with a numeric improvement in response rate compared with chemical alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T15	T40	18803986
NA	CHEMICAL	GENE-Y	8	15	In a Phase III trial comparing lapatinib and chemical with chemical alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of lapatinib and chemical was associated with a numeric improvement in response rate compared with chemical alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T16	T40	18803986
NA	CHEMICAL	GENE-Y	6	15	In a Phase III trial comparing chemical and capecitabine with capecitabine alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of chemical and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T14	T40	18803986
NA	CHEMICAL	GENE-Y	6	15	In a Phase III trial comparing chemical and capecitabine with capecitabine alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a taxane, and trastuzumab, the combination of chemical and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T9	T40	18803986
NA	CHEMICAL	GENE-Y	31	15	In a Phase III trial comparing lapatinib and capecitabine with capecitabine alone in women with gene-positive, locally advanced breast cancer or MBC that had progressed after treatment with an anthracycline, a chemical, and trastuzumab, the combination of lapatinib and capecitabine was associated with a numeric improvement in response rate compared with capecitabine alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43-0.77; P < 0.001).	T13	T40	18803986
CPR:4	CHEMICAL	GENE-N	1	11	CONCLUSIONS: chemical is a dual inhibitor of the EGFR and HER2 gene.	T24	T43	18803986
CPR:4	CHEMICAL	GENE-Y	1	8	CONCLUSIONS: chemical is a dual inhibitor of the gene and HER2 tyrosine kinases.	T24	T41	18803986
CPR:4	CHEMICAL	GENE-Y	1	10	CONCLUSIONS: chemical is a dual inhibitor of the EGFR and gene tyrosine kinases.	T24	T42	18803986
NA	CHEMICAL	GENE-Y	11	8	CONCLUSIONS: Lapatinib is a dual inhibitor of the gene and HER2 chemical kinases.	T25	T41	18803986
NA	CHEMICAL	GENE-Y	11	10	CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and gene chemical kinases.	T25	T42	18803986
NA	CHEMICAL	GENE-Y	11	16	It is approved by the FDA for use in combination with chemical for the treatment of gene-positive MBC that has progressed with standard treatment.	T26	T44	18803986
NA	CHEMICAL	GENE-N	29	7	N2-Acetylphenelzine is a relatively potent inhibitor of gene and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and chemical after acute i.p.	T8	T26	1881457
NA	CHEMICAL	GENE-N	26	7	N2-Acetylphenelzine is a relatively potent inhibitor of gene and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, chemical, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	T6	T26	1881457
NA	CHEMICAL	GENE-N	0	7	chemical is a relatively potent inhibitor of gene and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	T1	T26	1881457
NA	CHEMICAL	GENE-N	20	7	N2-Acetylphenelzine is a relatively potent inhibitor of gene and causes increases in whole-brain levels of noradrenaline and chemical, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	T4	T26	1881457
NA	CHEMICAL	GENE-N	24	7	N2-Acetylphenelzine is a relatively potent inhibitor of gene and causes increases in whole-brain levels of noradrenaline and 5-hydroxytryptamine, and decreases in chemical, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	T5	T26	1881457
NA	CHEMICAL	GENE-N	18	7	N2-Acetylphenelzine is a relatively potent inhibitor of gene and causes increases in whole-brain levels of chemical and 5-hydroxytryptamine, and decreases in homovanillic acid, 5-hydroxyindole-3-acetic acid, and 3,4-dihydroxyphenylacetic acetic after acute i.p.	T3	T26	1881457
CPR:4	CHEMICAL	GENE-N	10	5	Phenelzine is a more potent gene inhibitor than is chemical.	T11	T27	1881457
CPR:4	CHEMICAL	GENE-N	0	5	chemical is a more potent gene inhibitor than is N2-acetylphenelzine.	T9	T27	1881457
CPR:4	CHEMICAL	GENE-N	17	14	Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the gene enzymes for chemical and alanine.	T20	T28	1881457
CPR:4	CHEMICAL	GENE-N	2	14	Acetylation of chemical at the N2 position presumably interferes with the inhibition of the gene enzymes for gamma-aminobutyric acid and alanine.	T17	T28	1881457
CPR:4	CHEMICAL	GENE-N	20	14	Acetylation of phenelzine at the N2 position presumably interferes with the inhibition of the gene enzymes for gamma-aminobutyric acid and chemical.	T21	T28	1881457
CPR:4	CHEMICAL	GENE-N	5	14	Acetylation of phenelzine at the chemical position presumably interferes with the inhibition of the gene enzymes for gamma-aminobutyric acid and alanine.	T18	T28	1881457
NA	CHEMICAL	GENE-N	5	32	However, it is unclear whether chemical agonists produce their neurotrophic effects by acting directly on receptors expressed by the mesencephalic chemicalrgic neurons or indirectly on receptors expressed by astrocytes, via release of gene.	T12	T32	18973551
NA	CHEMICAL	GENE-Y	15	9	In this study, we investigated the effects of the gene-preferring agonists quinpirole and chemical (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	T15	T33	18973551
NA	CHEMICAL	GENE-Y	15	30	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and chemical (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by gene immunoreactivity (TH-IR).	T15	T35	18973551
NA	CHEMICAL	GENE-Y	15	33	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and chemical (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (gene-IR).	T15	T36	18973551
NA	CHEMICAL	GENE-Y	24	9	In this study, we investigated the effects of the gene-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist chemical, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	T18	T33	18973551
NA	CHEMICAL	GENE-Y	24	30	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist chemical, on dopaminergic neurons identified by gene immunoreactivity (TH-IR).	T18	T35	18973551
NA	CHEMICAL	GENE-Y	24	33	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist chemical, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (gene-IR).	T18	T36	18973551
NA	CHEMICAL	GENE-Y	13	9	In this study, we investigated the effects of the gene-preferring agonists chemical and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	T14	T33	18973551
NA	CHEMICAL	GENE-Y	13	30	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists chemical and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by gene immunoreactivity (TH-IR).	T14	T35	18973551
NA	CHEMICAL	GENE-Y	13	33	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists chemical and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (gene-IR).	T14	T36	18973551
NA	CHEMICAL	GENE-Y	16	9	In this study, we investigated the effects of the gene-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (chemical), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (TH-IR).	T17	T33	18973551
NA	CHEMICAL	GENE-Y	16	30	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (chemical), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by gene immunoreactivity (TH-IR).	T17	T35	18973551
NA	CHEMICAL	GENE-Y	16	33	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (chemical), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by tyrosine hydroxylase immunoreactivity (gene-IR).	T17	T36	18973551
NA	CHEMICAL	GENE-Y	9	30	In this study, we investigated the effects of the chemical D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on chemicalrgic neurons identified by gene immunoreactivity (TH-IR).	T13	T35	18973551
NA	CHEMICAL	GENE-Y	9	33	In this study, we investigated the effects of the chemical D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on chemicalrgic neurons identified by tyrosine hydroxylase immunoreactivity (gene-IR).	T13	T36	18973551
NA	CHEMICAL	GENE-Y	30	9	In this study, we investigated the effects of the gene-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by chemical hydroxylase immunoreactivity (TH-IR).	T19	T33	18973551
NA	CHEMICAL	GENE-Y	30	33	In this study, we investigated the effects of the dopamine D3 receptor-preferring agonists quinpirole and 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), as well as of the indirect agonist amphetamine, on dopaminergic neurons identified by chemical hydroxylase immunoreactivity (gene-IR).	T19	T36	18973551
NA	CHEMICAL	GENE-Y	30	36	After 3 days of incubation, both quinpirole (1-10 microm) and 7-OH-DPAT (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and chemical uptake (P < 0.01) of gene-IR-positive mesencephalic neurons.	T1	T23	18973551
NA	CHEMICAL	GENE-Y	6	36	After 3 days of incubation, both chemical (1-10 microm) and 7-OH-DPAT (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and [3H]dopamine uptake (P < 0.01) of gene-IR-positive mesencephalic neurons.	T20	T23	18973551
NA	CHEMICAL	GENE-Y	10	36	After 3 days of incubation, both quinpirole (1-10 microm) and chemical (5-500 nm) dose-dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and [3H]dopamine uptake (P < 0.01) of gene-IR-positive mesencephalic neurons.	T21	T23	18973551
NA	CHEMICAL	GENE-N	21	8	All neurotrophic effects were blocked by the unselective gene antagonist sulpiride (5 microm) and by the selective D3 receptor antagonist chemical at a low dose (50 nm).	T4	T24	18973551
CPR:6	CHEMICAL	GENE-Y	21	8	All neurotrophic effects were blocked by the unselective D2/gene antagonist sulpiride (5 microm) and by the selective gene antagonist chemical at a low dose (50 nm).	T4	T25	18973551
NA	CHEMICAL	GENE-N	11	8	All neurotrophic effects were blocked by the unselective gene antagonist chemical (5 microm) and by the selective D3 receptor antagonist SB-277011-A at a low dose (50 nm).	T3	T24	18973551
NA	CHEMICAL	GENE-Y	11	8	All neurotrophic effects were blocked by the unselective D2/gene antagonist chemical (5 microm) and by the selective gene antagonist SB-277011-A at a low dose (50 nm).	T3	T25	18973551
CPR:4	CHEMICAL	GENE-N	20	8	Quinpirole and 7-OH-DPAT also increased the phosphorylation of gene (ERK) within minutes, an effect blocked by pretreatment with chemical.	T7	T26	18973551
CPR:4	CHEMICAL	GENE-N	20	11	Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (gene) within minutes, an effect blocked by pretreatment with chemical.	T7	T27	18973551
CPR:3	CHEMICAL	GENE-N	0	8	chemical and 7-OH-DPAT also increased the phosphorylation of gene (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.	T5	T26	18973551
CPR:3	CHEMICAL	GENE-N	0	11	chemical and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (gene) within minutes, an effect blocked by pretreatment with SB-277011-A.	T5	T27	18973551
CPR:3	CHEMICAL	GENE-N	2	8	Quinpirole and chemical also increased the phosphorylation of gene (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.	T6	T26	18973551
CPR:3	CHEMICAL	GENE-N	2	11	Quinpirole and chemical also increased the phosphorylation of extracellular signal-regulated kinase (gene) within minutes, an effect blocked by pretreatment with SB-277011-A.	T6	T27	18973551
NA	CHEMICAL	GENE-N	13	3	Inhibition of the gene signalling pathway to ERK was obtained with PD98059, chemical or LY294002, resulting in blockade of neurotrophic effects.	T9	T28	18973551
NA	CHEMICAL	GENE-N	13	8	Inhibition of the D2/D3 receptor signalling pathway to gene was obtained with PD98059, chemical or LY294002, resulting in blockade of neurotrophic effects.	T9	T29	18973551
NA	CHEMICAL	GENE-N	15	3	Inhibition of the gene signalling pathway to ERK was obtained with PD98059, GF109203 or chemical, resulting in blockade of neurotrophic effects.	T10	T28	18973551
NA	CHEMICAL	GENE-N	15	8	Inhibition of the D2/D3 receptor signalling pathway to gene was obtained with PD98059, GF109203 or chemical, resulting in blockade of neurotrophic effects.	T10	T29	18973551
NA	CHEMICAL	GENE-N	12	3	Inhibition of the gene signalling pathway to ERK was obtained with chemical, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	T8	T28	18973551
NA	CHEMICAL	GENE-N	12	8	Inhibition of the D2/D3 receptor signalling pathway to gene was obtained with chemical, GF109203 or LY294002, resulting in blockade of neurotrophic effects.	T8	T29	18973551
NA	CHEMICAL	GENE-N	4	18	These data suggest that chemical agonists increase dendritic arborizations of mesencephalic chemicalrgic neurons via a direct effect on gene, preferentially involving D3 receptor-dependent neurotransmission.	T11	T30	18973551
NA	CHEMICAL	GENE-Y	4	18	These data suggest that chemical agonists increase dendritic arborizations of mesencephalic chemicalrgic neurons via a direct effect on D2/genes, preferentially involving gene-dependent neurotransmission.	T11	T31	18973551
NA	CHEMICAL	GENE-N	4	20	Antihypertensive drugs of the "chemical channel blocker" or "chemical antagonist" class have been used to establish the physiological role of gene in vascular smooth muscle.	T6	T19	18974361
NA	CHEMICAL	GENE-N	4	20	Antihypertensive drugs of the "chemical channel blocker" or "chemical antagonist" class have been used to establish the physiological role of gene in vascular smooth muscle.	T8	T19	18974361
NA	CHEMICAL	GENE-N	21	4	Antihypertensive drugs of the "gene blocker" or "calcium antagonist" class have been used to establish the physiological role of L-type chemical channels in vascular smooth muscle.	T4	T22	18974361
NA	CHEMICAL	GENE-N	8	0	gene play a role in cardiac pacemaking, chemical secretion, and renal hemodynamics, leading to the hypothesis that mixed T- and L-type blockers may have therapeutic advantages over selective L-type blockers.	T7	T21	18974361
NA	CHEMICAL	GENE-N	24	13	The goal of this study was to identify compounds that block the Ca(v)3.2 gene with high affinity, focusing on two classes of compounds: chemical (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).	T9	T24	18974361
NA	CHEMICAL	GENE-Y	24	12	The goal of this study was to identify compounds that block the gene T-type channel with high affinity, focusing on two classes of compounds: chemical (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).	T9	T23	18974361
NA	CHEMICAL	GENE-N	28	13	The goal of this study was to identify compounds that block the Ca(v)3.2 gene with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and chemical (e.g., efonidipine).	T11	T24	18974361
NA	CHEMICAL	GENE-Y	28	12	The goal of this study was to identify compounds that block the gene T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and chemical (e.g., efonidipine).	T11	T23	18974361
NA	CHEMICAL	GENE-N	30	13	The goal of this study was to identify compounds that block the Ca(v)3.2 gene with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., chemical).	T12	T24	18974361
NA	CHEMICAL	GENE-Y	30	12	The goal of this study was to identify compounds that block the gene T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., chemical).	T12	T23	18974361
NA	CHEMICAL	GENE-N	26	13	The goal of this study was to identify compounds that block the Ca(v)3.2 gene with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., chemical) and dihydropyridines (e.g., efonidipine).	T10	T24	18974361
NA	CHEMICAL	GENE-Y	26	12	The goal of this study was to identify compounds that block the gene T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., chemical) and dihydropyridines (e.g., efonidipine).	T10	T23	18974361
NA	CHEMICAL	GENE-Y	6	15	Compounds were tested using a validated chemical influx assay into a cell line expressing recombinant gene channels.	T13	T25	18974361
CPR:4	CHEMICAL	GENE-N	12	15	This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and chemical) as potent gene blockers (IC(50) < 3 microM).	T17	T26	18974361
CPR:4	CHEMICAL	GENE-N	8	15	This study identified four clinically approved antihypertensive drugs (chemical, felodipine, isradipine, and nitrendipine) as potent gene blockers (IC(50) < 3 microM).	T14	T26	18974361
CPR:4	CHEMICAL	GENE-N	9	15	This study identified four clinically approved antihypertensive drugs (efonidipine, chemical, isradipine, and nitrendipine) as potent gene blockers (IC(50) < 3 microM).	T15	T26	18974361
CPR:4	CHEMICAL	GENE-N	10	15	This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, chemical, and nitrendipine) as potent gene blockers (IC(50) < 3 microM).	T16	T26	18974361
NA	CHEMICAL	GENE-N	57	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, chemical, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T16	T22	19002123
NA	CHEMICAL	GENE-N	57	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, chemical, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T16	T23	19002123
NA	CHEMICAL	GENE-N	55	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, chemical, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T14	T22	19002123
NA	CHEMICAL	GENE-N	55	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, chemical, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T14	T23	19002123
NA	CHEMICAL	GENE-N	54	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, chemical, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T13	T22	19002123
NA	CHEMICAL	GENE-N	54	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, chemical, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T13	T23	19002123
NA	CHEMICAL	GENE-N	53	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, chemical, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T12	T22	19002123
NA	CHEMICAL	GENE-N	53	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, chemical, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T12	T23	19002123
NA	CHEMICAL	GENE-N	58	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, chemical, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T17	T22	19002123
NA	CHEMICAL	GENE-N	58	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, chemical, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T17	T23	19002123
NA	CHEMICAL	GENE-N	61	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, chemical, vardenafil and tadalafil.	T18	T22	19002123
NA	CHEMICAL	GENE-N	61	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, chemical, vardenafil and tadalafil.	T18	T23	19002123
NA	CHEMICAL	GENE-N	51	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, chemical, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T10	T22	19002123
NA	CHEMICAL	GENE-N	51	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, chemical, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T10	T23	19002123
NA	CHEMICAL	GENE-N	62	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, chemical and tadalafil.	T19	T22	19002123
NA	CHEMICAL	GENE-N	62	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, chemical and tadalafil.	T19	T23	19002123
NA	CHEMICAL	GENE-N	64	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and chemical.	T20	T22	19002123
NA	CHEMICAL	GENE-N	64	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and chemical.	T20	T23	19002123
NA	CHEMICAL	GENE-N	52	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, chemical, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T11	T22	19002123
NA	CHEMICAL	GENE-N	52	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, chemical, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T11	T23	19002123
NA	CHEMICAL	GENE-N	56	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, chemical, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T15	T22	19002123
NA	CHEMICAL	GENE-N	56	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, chemical, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T15	T23	19002123
NA	CHEMICAL	GENE-N	49	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, chemical, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T8	T22	19002123
NA	CHEMICAL	GENE-N	49	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, chemical, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T8	T23	19002123
NA	CHEMICAL	GENE-N	50	40	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, gene antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, chemical, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T9	T22	19002123
NA	CHEMICAL	GENE-N	50	43	To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, gene inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, chemical, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil.	T9	T23	19002123
NA	CHEMICAL	GENE-Y	13	0	gene is a widely expressed protein that shares structural, but not chemical, homology with gap junction proteins, the connexins.	T13	T17	19023039
NA	CHEMICAL	GENE-N	13	21	Pannexin (Panx) 1 is a widely expressed protein that shares structural, but not chemical, homology with gap junction proteins, the gene.	T13	T20	19023039
CPR:4	CHEMICAL	GENE-Y	19	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately chemical approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	T1	T39	19023039
CPR:4	CHEMICAL	GENE-Y	15	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > chemical (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	T15	T39	19023039
CPR:4	CHEMICAL	GENE-Y	22	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately chemical > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	T2	T39	19023039
CPR:4	CHEMICAL	GENE-Y	25	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > chemical >> probenecid >> flufenamic acid = niflumic acid.	T3	T39	19023039
CPR:4	CHEMICAL	GENE-Y	31	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> chemical = niflumic acid.	T5	T39	19023039
CPR:4	CHEMICAL	GENE-Y	13	5	We found compounds that inhibited gene currents with a rank order of potency: chemical > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	T14	T39	19023039
CPR:4	CHEMICAL	GENE-Y	34	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = chemical.	T6	T39	19023039
CPR:4	CHEMICAL	GENE-Y	29	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> chemical >> flufenamic acid = niflumic acid.	T4	T39	19023039
CPR:4	CHEMICAL	GENE-Y	17	5	We found compounds that inhibited gene currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (chemical) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.	T16	T39	19023039
NA	CHEMICAL	GENE-N	0	16	chemical (ATP, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of gene.	T7	T19	19023039
CPR:4	CHEMICAL	GENE-Y	0	10	chemical (ATP, GTP, and UTP) rapidly and reversibly inhibited gene currents via mechanism(s) independent of purine receptors.	T7	T18	19023039
NA	CHEMICAL	GENE-N	2	16	Triphosphate nucleotides (chemical, GTP, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of gene.	T8	T19	19023039
CPR:4	CHEMICAL	GENE-Y	2	10	Triphosphate nucleotides (chemical, GTP, and UTP) rapidly and reversibly inhibited gene currents via mechanism(s) independent of purine receptors.	T8	T18	19023039
NA	CHEMICAL	GENE-N	3	16	Triphosphate nucleotides (ATP, chemical, and UTP) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of gene.	T9	T19	19023039
CPR:4	CHEMICAL	GENE-Y	3	10	Triphosphate nucleotides (ATP, chemical, and UTP) rapidly and reversibly inhibited gene currents via mechanism(s) independent of purine receptors.	T9	T18	19023039
NA	CHEMICAL	GENE-N	5	16	Triphosphate nucleotides (ATP, GTP, and chemical) rapidly and reversibly inhibited Panx1 currents via mechanism(s) independent of gene.	T10	T19	19023039
CPR:4	CHEMICAL	GENE-Y	5	10	Triphosphate nucleotides (ATP, GTP, and chemical) rapidly and reversibly inhibited gene currents via mechanism(s) independent of purine receptors.	T10	T18	19023039
NA	CHEMICAL	GENE-Y	9	5	When Panx1 was coexpressed with gene (P2X(7)R), chemical was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	T11	T22	19023039
NA	CHEMICAL	GENE-Y	9	8	When Panx1 was coexpressed with purinergic P2X(7) receptor (gene), chemical was found to act as a gene antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited gene currents.	T11	T23	19023039
CPR:6	CHEMICAL	GENE-Y	9	8	When Panx1 was coexpressed with purinergic P2X(7) receptor (gene), chemical was found to act as a gene antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited gene currents.	T11	T24	19023039
NA	CHEMICAL	GENE-Y	9	8	When Panx1 was coexpressed with purinergic P2X(7) receptor (gene), chemical was found to act as a gene antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited gene currents.	T11	T26	19023039
NA	CHEMICAL	GENE-Y	9	1	When gene was coexpressed with purinergic P2X(7) receptor (P2X(7)R), chemical was found to act as a P2X(7)R antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	T11	T21	19023039
NA	CHEMICAL	GENE-Y	20	5	When Panx1 was coexpressed with gene (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit chemical-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	T12	T22	19023039
NA	CHEMICAL	GENE-Y	20	8	When Panx1 was coexpressed with purinergic P2X(7) receptor (gene), DIDS was found to act as a gene antagonist to inhibit chemical-evoked currents, but none of the other compounds inhibited gene currents.	T12	T23	19023039
NA	CHEMICAL	GENE-Y	20	8	When Panx1 was coexpressed with purinergic P2X(7) receptor (gene), DIDS was found to act as a gene antagonist to inhibit chemical-evoked currents, but none of the other compounds inhibited gene currents.	T12	T24	19023039
NA	CHEMICAL	GENE-Y	20	8	When Panx1 was coexpressed with purinergic P2X(7) receptor (gene), DIDS was found to act as a gene antagonist to inhibit chemical-evoked currents, but none of the other compounds inhibited gene currents.	T12	T26	19023039
NA	CHEMICAL	GENE-Y	20	1	When gene was coexpressed with purinergic P2X(7) receptor (P2X(7)R), DIDS was found to act as a P2X(7)R antagonist to inhibit chemical-evoked currents, but none of the other compounds inhibited P2X(7)R currents.	T12	T21	19023039
NA	CHEMICAL	GENE-N	7	13	Little is known about the influence of chemical converting enzyme (ACE) inhibitors on gene (MMP) in right ventricular remodeling.	T10	T28	19057128
NA	CHEMICAL	GENE-Y	7	10	Little is known about the influence of chemical converting enzyme (gene) inhibitors on matrix metalloproteinase (MMP) in right ventricular remodeling.	T10	T27	19057128
NA	CHEMICAL	GENE-N	7	15	Little is known about the influence of chemical converting enzyme (ACE) inhibitors on matrix metalloproteinase (gene) in right ventricular remodeling.	T10	T16	19057128
NA	CHEMICAL	GENE-Y	14	12	We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and gene in chemical-induced right ventricular hypertrophy.	T8	T23	19057128
NA	CHEMICAL	GENE-Y	14	10	We investigated the effect of captopril, an ACE inhibitor, on gene and MMP-9 in chemical-induced right ventricular hypertrophy.	T8	T22	19057128
NA	CHEMICAL	GENE-Y	14	7	We investigated the effect of captopril, an gene inhibitor, on MMP-2 and MMP-9 in chemical-induced right ventricular hypertrophy.	T8	T21	19057128
NA	CHEMICAL	GENE-Y	5	12	We investigated the effect of chemical, an ACE inhibitor, on MMP-2 and gene in monocrotaline-induced right ventricular hypertrophy.	T7	T23	19057128
NA	CHEMICAL	GENE-Y	5	10	We investigated the effect of chemical, an ACE inhibitor, on gene and MMP-9 in monocrotaline-induced right ventricular hypertrophy.	T7	T22	19057128
CPR:4	CHEMICAL	GENE-Y	5	7	We investigated the effect of chemical, an gene inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy.	T7	T21	19057128
CPR:3	CHEMICAL	GENE-Y	12	2	MMP-2 and gene expressions and activities in right ventricles increased significantly in chemical-injected rats and captopril inhibited them.	T3	T18	19057128
CPR:3	CHEMICAL	GENE-Y	12	0	gene and MMP-9 expressions and activities in right ventricles increased significantly in chemical-injected rats and captopril inhibited them.	T3	T17	19057128
CPR:4	CHEMICAL	GENE-Y	15	2	MMP-2 and gene expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and chemical inhibited them.	T4	T18	19057128
CPR:4	CHEMICAL	GENE-Y	15	0	gene and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and chemical inhibited them.	T4	T17	19057128
CPR:3	CHEMICAL	GENE-Y	9	20	These findings indicate that captopril attenuates the development of chemical-induced right ventricular hypertrophy in association with inhibition of MMP-2 and gene in rats.	T6	T20	19057128
CPR:3	CHEMICAL	GENE-Y	9	18	These findings indicate that captopril attenuates the development of chemical-induced right ventricular hypertrophy in association with inhibition of gene and MMP-9 in rats.	T6	T19	19057128
CPR:4	CHEMICAL	GENE-Y	4	20	These findings indicate that chemical attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and gene in rats.	T5	T20	19057128
CPR:4	CHEMICAL	GENE-Y	4	18	These findings indicate that chemical attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of gene and MMP-9 in rats.	T5	T19	19057128
CPR:4	CHEMICAL	GENE-N	32	14	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of gene (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, chemical, and ethoxzolamide.	T8	T36	19119014
CPR:4	CHEMICAL	GENE-Y	32	17	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, gene) with a very different profile as compared to classical inhibitors, such as acetazolamide, chemical, and ethoxzolamide.	T8	T26	19119014
CPR:4	CHEMICAL	GENE-N	32	16	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (gene, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, chemical, and ethoxzolamide.	T8	T24	19119014
CPR:4	CHEMICAL	GENE-N	34	14	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of gene (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and chemical.	T9	T36	19119014
CPR:4	CHEMICAL	GENE-Y	34	17	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, gene) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and chemical.	T9	T26	19119014
CPR:4	CHEMICAL	GENE-N	34	16	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (gene, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and chemical.	T9	T24	19119014
CPR:4	CHEMICAL	GENE-N	31	14	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of gene (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as chemical, methazolamide, and ethoxzolamide.	T7	T36	19119014
CPR:4	CHEMICAL	GENE-Y	31	17	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, gene) with a very different profile as compared to classical inhibitors, such as chemical, methazolamide, and ethoxzolamide.	T7	T26	19119014
CPR:4	CHEMICAL	GENE-N	31	16	Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (gene, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as chemical, methazolamide, and ethoxzolamide.	T7	T24	19119014
CPR:4	CHEMICAL	GENE-N	0	14	chemical and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of gene (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.	T1	T36	19119014
CPR:4	CHEMICAL	GENE-Y	0	17	chemical and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, gene) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.	T1	T26	19119014
CPR:4	CHEMICAL	GENE-N	0	16	chemical and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (gene, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.	T1	T24	19119014
NA	CHEMICAL	GENE-Y	19	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chlorthalidone, chemical, and furosemide being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	T11	T29	19119014
CPR:4	CHEMICAL	GENE-Y	19	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chlorthalidone, chemical, and furosemide being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	T11	T30	19119014
NA	CHEMICAL	GENE-Y	18	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chemical, trichloromethiazide, and furosemide being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	T10	T29	19119014
CPR:4	CHEMICAL	GENE-Y	18	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chemical, trichloromethiazide, and furosemide being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	T10	T30	19119014
NA	CHEMICAL	GENE-Y	21	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chlorthalidone, trichloromethiazide, and chemical being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	T12	T29	19119014
CPR:4	CHEMICAL	GENE-Y	21	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chlorthalidone, trichloromethiazide, and chemical being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).	T12	T30	19119014
NA	CHEMICAL	GENE-Y	33	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas chemical is a much weaker one (K(I) of 2520 nM).	T13	T29	19119014
CPR:4	CHEMICAL	GENE-Y	33	15	Some of these structurally related compounds have a very different behavior against the widespread isozyme gene, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against gene (K(I)s of 65-138 nM), whereas chemical is a much weaker one (K(I) of 2520 nM).	T13	T30	19119014
NA	CHEMICAL	GENE-N	32	26	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against gene, chemical against CA VII and IX, and furosemide against CA I and XIV.	T16	T32	19119014
NA	CHEMICAL	GENE-N	32	18	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against gene; indapamide against CA VII, IX, XII, and XIII, chemical against CA VII and IX, and furosemide against CA I and XIV.	T16	T31	19119014
NA	CHEMICAL	GENE-N	32	34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, chemical against gene, and furosemide against CA I and XIV.	T16	T33	19119014
NA	CHEMICAL	GENE-N	32	41	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, chemical against CA VII and IX, and furosemide against gene.	T16	T34	19119014
NA	CHEMICAL	GENE-N	16	26	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chemical against hCA VB, VII, IX, and XIII; indapamide against gene, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	T14	T32	19119014
NA	CHEMICAL	GENE-N	16	18	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chemical against gene; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	T14	T31	19119014
NA	CHEMICAL	GENE-N	16	34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chemical against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against gene, and furosemide against CA I and XIV.	T14	T33	19119014
NA	CHEMICAL	GENE-N	16	41	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chemical against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against gene.	T14	T34	19119014
NA	CHEMICAL	GENE-N	39	26	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against gene, trichloromethiazide against CA VII and IX, and chemical against CA I and XIV.	T17	T32	19119014
NA	CHEMICAL	GENE-N	39	18	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against gene; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and chemical against CA I and XIV.	T17	T31	19119014
NA	CHEMICAL	GENE-N	39	34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against gene, and chemical against CA I and XIV.	T17	T33	19119014
NA	CHEMICAL	GENE-N	39	41	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; indapamide against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and chemical against gene.	T17	T34	19119014
NA	CHEMICAL	GENE-N	24	26	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; chemical against gene, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	T15	T32	19119014
NA	CHEMICAL	GENE-N	24	18	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against gene; chemical against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against CA I and XIV.	T15	T31	19119014
NA	CHEMICAL	GENE-N	24	34	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; chemical against CA VII, IX, XII, and XIII, trichloromethiazide against gene, and furosemide against CA I and XIV.	T15	T33	19119014
NA	CHEMICAL	GENE-N	24	41	Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, chlorthalidone against hCA VB, VII, IX, and XIII; chemical against CA VII, IX, XII, and XIII, trichloromethiazide against CA VII and IX, and furosemide against gene.	T15	T34	19119014
NA	CHEMICAL	GENE-Y	23	8	Examining the four X-ray crystal structures of their gene adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, chemical, and furosemide scaffolds which may be responsible for this important difference of activity.	T19	T35	19119014
NA	CHEMICAL	GENE-Y	22	8	Examining the four X-ray crystal structures of their gene adducts, we observed several (2-3) active site water molecules interacting with the chemical, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity.	T18	T35	19119014
NA	CHEMICAL	GENE-Y	25	8	Examining the four X-ray crystal structures of their gene adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and chemical scaffolds which may be responsible for this important difference of activity.	T2	T35	19119014
NA	CHEMICAL	GENE-Y	1	4	Indeed, chemical bound to gene has no interactions with active site water molecules.	T3	T25	19119014
NA	CHEMICAL	GENE-Y	0	4	chemical bound within the gene active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong hydrogen bonds with Asn67 and a water molecule.	T4	T27	19119014
NA	CHEMICAL	GENE-Y	24	4	Chlorthalidone bound within the gene active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong chemical bonds with Asn67 and a water molecule.	T6	T27	19119014
NA	CHEMICAL	GENE-Y	18	4	Chlorthalidone bound within the gene active site is in an enolic (lactimic) tautomeric form, with the enolic chemical also participating in two strong hydrogen bonds with Asn67 and a water molecule.	T5	T27	19119014
NA	CHEMICAL	GENE-Y	3	5	The low-affinity sodium chemical cotransporter (gene) is responsible for most of the chemical reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	T13	T35	19281809
CPR:9	CHEMICAL	GENE-Y	3	5	The low-affinity sodium chemical cotransporter (gene) is responsible for most of the chemical reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	T25	T35	19281809
NA	CHEMICAL	GENE-Y	2	5	The low-affinity chemical glucose cotransporter (gene) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	T11	T35	19281809
CPR:4	CHEMICAL	GENE-Y	2	7	We discovered chemical, a novel selective gene inhibitor, and found that selective inhibition of gene increased urinary glucose excretion and consequently decreased plasma glucose levels.	T12	T33	19281809
CPR:4	CHEMICAL	GENE-Y	2	7	We discovered chemical, a novel selective gene inhibitor, and found that selective inhibition of gene increased urinary glucose excretion and consequently decreased plasma glucose levels.	T12	T34	19281809
NA	CHEMICAL	GENE-Y	18	7	We discovered sergliflozin etabonate, a novel selective gene inhibitor, and found that selective inhibition of gene increased urinary chemical excretion and consequently decreased plasma chemical levels.	T14	T33	19281809
NA	CHEMICAL	GENE-Y	18	7	We discovered sergliflozin etabonate, a novel selective gene inhibitor, and found that selective inhibition of gene increased urinary chemical excretion and consequently decreased plasma chemical levels.	T14	T34	19281809
NA	CHEMICAL	GENE-Y	18	7	We discovered sergliflozin etabonate, a novel selective gene inhibitor, and found that selective inhibition of gene increased urinary chemical excretion and consequently decreased plasma chemical levels.	T15	T33	19281809
NA	CHEMICAL	GENE-Y	18	7	We discovered sergliflozin etabonate, a novel selective gene inhibitor, and found that selective inhibition of gene increased urinary chemical excretion and consequently decreased plasma chemical levels.	T15	T34	19281809
NA	CHEMICAL	GENE-Y	9	26	In this report, we examined the antihyperglycemic effects of chemical in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an gene inhibitor (voglibose).	T16	T36	19281809
NA	CHEMICAL	GENE-Y	22	26	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a chemical (gliclazide) and an gene inhibitor (voglibose).	T17	T36	19281809
NA	CHEMICAL	GENE-Y	23	26	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (chemical) and an gene inhibitor (voglibose).	T18	T36	19281809
CPR:4	CHEMICAL	GENE-Y	28	26	In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an gene inhibitor (chemical).	T19	T36	19281809
NA	CHEMICAL	GENE-N	0	22	chemical increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of gene secretion in normal rats.	T20	T37	19281809
NA	CHEMICAL	GENE-N	18	22	Sergliflozin etabonate increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after chemical loading independently of gene secretion in normal rats.	T23	T37	19281809
NA	CHEMICAL	GENE-N	4	22	Sergliflozin etabonate increased urinary chemical excretion in a dose-dependent manner, and inhibited the increase in plasma chemical after sucrose loading independently of gene secretion in normal rats.	T21	T37	19281809
NA	CHEMICAL	GENE-N	4	22	Sergliflozin etabonate increased urinary chemical excretion in a dose-dependent manner, and inhibited the increase in plasma chemical after sucrose loading independently of gene secretion in normal rats.	T22	T37	19281809
CPR:4	CHEMICAL	GENE-N	3	9	Chronic treatment with chemical reduced the levels of gene and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats.	T6	T30	19281809
NA	CHEMICAL	GENE-N	14	9	Chronic treatment with sergliflozin etabonate reduced the levels of gene and fasting plasma chemical, and improved the glycemic response after chemical loading in Zucker fatty rats.	T7	T30	19281809
NA	CHEMICAL	GENE-N	14	9	Chronic treatment with sergliflozin etabonate reduced the levels of gene and fasting plasma chemical, and improved the glycemic response after chemical loading in Zucker fatty rats.	T8	T30	19281809
NA	CHEMICAL	GENE-N	4	15	These data indicate that chemical could improve glycemic control without its use resulting in gene secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes.	T10	T31	19281809
NA	CHEMICAL	GENE-Y	9	20	Our previous study showed that the stimulatory effect of chemical on VSMC proliferation is inhibited by D1-like receptors and the gene, a member of the D2-like receptor family.	T7	T24	19293728
NA	CHEMICAL	GENE-N	9	16	Our previous study showed that the stimulatory effect of chemical on VSMC proliferation is inhibited by gene and the D3 dopamine receptor, a member of the D2-like receptor family.	T7	T23	19293728
NA	CHEMICAL	GENE-N	9	27	Our previous study showed that the stimulatory effect of chemical on VSMC proliferation is inhibited by D1-like receptors and the D3 dopamine receptor, a member of the gene family.	T7	T25	19293728
NA	CHEMICAL	GENE-N	21	16	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by gene and the D3 chemical receptor, a member of the D2-like receptor family.	T8	T23	19293728
NA	CHEMICAL	GENE-N	21	27	Our previous study showed that the stimulatory effect of norepinephrine on VSMC proliferation is inhibited by D1-like receptors and the D3 chemical receptor, a member of the gene family.	T8	T25	19293728
NA	CHEMICAL	GENE-Y	6	8	METHODS: VSMC proliferation was determined by chemical incorporation; gene mRNA and protein expressions were determined by RT-PCR, immunoblotting, and immunohistochemistry.	T9	T33	19293728
NA	CHEMICAL	GENE-Y	12	1	RESULTS: gene increased VSMC proliferation in immortalized aortic A10 cells, determined by chemical incorporation.	T1	T34	19293728
NA	CHEMICAL	GENE-N	14	2	Although the gene, by itself, had no effect on VSMC proliferation, stimulation with chemical, a gene agonist, inhibited the stimulatory effect of insulin.	T2	T10	19293728
CPR:5	CHEMICAL	GENE-N	14	2	Although the gene, by itself, had no effect on VSMC proliferation, stimulation with chemical, a gene agonist, inhibited the stimulatory effect of insulin.	T2	T11	19293728
CPR:4	CHEMICAL	GENE-Y	14	24	Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with chemical, a D1-like receptor agonist, inhibited the stimulatory effect of gene.	T2	T12	19293728
NA	CHEMICAL	GENE-N	4	21	The inhibitory effect of chemical on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a gene antagonist.	T3	T14	19293728
CPR:4	CHEMICAL	GENE-Y	4	6	The inhibitory effect of chemical on gene-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.	T3	T13	19293728
CPR:6	CHEMICAL	GENE-N	19	21	The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by chemical, a gene antagonist.	T4	T14	19293728
NA	CHEMICAL	GENE-Y	19	6	The inhibitory effect of fenoldopam on gene-mediated VSMC proliferation was receptor specific, because its effect could be blocked by chemical, a D1-like receptor antagonist.	T4	T13	19293728
CPR:4	CHEMICAL	GENE-Y	0	3	chemical also inhibited gene mRNA and protein expression, which was time dependent and concentration dependent.	T5	T15	19293728
CPR:4	CHEMICAL	GENE-Y	11	13	A PKC or MAP kinase inhibitor blocked the inhibitory effect of chemical on gene expression, indicating that PKC and MAP kinase were involved in the signaling pathway.	T6	T18	19293728
NA	CHEMICAL	GENE-N	11	3	A PKC or gene inhibitor blocked the inhibitory effect of chemical on insulin receptor expression, indicating that PKC and gene were involved in the signaling pathway.	T6	T17	19293728
NA	CHEMICAL	GENE-N	11	3	A PKC or gene inhibitor blocked the inhibitory effect of chemical on insulin receptor expression, indicating that PKC and gene were involved in the signaling pathway.	T6	T20	19293728
NA	CHEMICAL	GENE-N	11	1	A gene or MAP kinase inhibitor blocked the inhibitory effect of chemical on insulin receptor expression, indicating that gene and MAP kinase were involved in the signaling pathway.	T6	T16	19293728
NA	CHEMICAL	GENE-N	11	1	A gene or MAP kinase inhibitor blocked the inhibitory effect of chemical on insulin receptor expression, indicating that gene and MAP kinase were involved in the signaling pathway.	T6	T19	19293728
NA	CHEMICAL	GENE-Y	16	31	Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by somatic mutations in the chemical glycan-complementation class A gene and the resulting absence of a key complement regulatory protein, gene.	T1	T4	19399743
CPR:9	CHEMICAL	GENE-Y	10	18	The progress of the enzymatic reaction of the hydrolysis of chemical at pH 8 in the presence of gene and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).	T4	T11	19472276
NA	CHEMICAL	GENE-Y	10	18	The progress of the enzymatic reaction of the hydrolysis of acetylchemical at pH 8 in the presence of gene and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product chemical (TCh).	T5	T11	19472276
NA	CHEMICAL	GENE-Y	12	23	In the method employed the capillary was first filled with 30 mM borate-chemical buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) gene solution, (iii) substrate solution with or without inhibitor, (iv) gene solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	T7	T12	19472276
NA	CHEMICAL	GENE-Y	12	23	In the method employed the capillary was first filled with 30 mM borate-chemical buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) gene solution, (iii) substrate solution with or without inhibitor, (iv) gene solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	T7	T13	19472276
NA	CHEMICAL	GENE-Y	12	23	In the method employed the capillary was first filled with 30 mM chemical-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) gene solution, (iii) substrate solution with or without inhibitor, (iv) gene solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	T6	T12	19472276
NA	CHEMICAL	GENE-Y	12	23	In the method employed the capillary was first filled with 30 mM chemical-phosphate buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) gene solution, (iii) substrate solution with or without inhibitor, (iv) gene solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	T6	T13	19472276
NA	CHEMICAL	GENE-N	28	10	The aim of the present study was therefore to investigate gene apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, olanzapine- and chemical-treated schizophrenia patients.	T13	T29	19496999
NA	CHEMICAL	GENE-N	26	10	The aim of the present study was therefore to investigate gene apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among clozapine-, chemical- and haloperidol-treated schizophrenia patients.	T12	T29	19496999
NA	CHEMICAL	GENE-N	25	10	The aim of the present study was therefore to investigate gene apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among chemical-, olanzapine- and haloperidol-treated schizophrenia patients.	T11	T29	19496999
NA	CHEMICAL	GENE-N	12	1	METHODS: gene binding was studied on single-photon emission computed tomography ligand chemical in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.	T15	T30	19496999
NA	CHEMICAL	GENE-N	22	1	METHODS: gene binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with chemical, four with olanzapine and seven with clozapine), six drug-naive patients and seven healthy controls.	T16	T30	19496999
NA	CHEMICAL	GENE-N	25	1	METHODS: gene binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with chemical and seven with clozapine), six drug-naive patients and seven healthy controls.	T17	T30	19496999
NA	CHEMICAL	GENE-N	29	1	METHODS: gene binding was studied on single-photon emission computed tomography ligand [(123)I]epidepride in 13 schizophrenia patients treated with medication (two with haloperidol, four with olanzapine and seven with chemical), six drug-naive patients and seven healthy controls.	T18	T30	19496999
NA	CHEMICAL	GENE-N	25	6	RESULTS: Statistically significant differences in midbrain gene BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, olanzapine and chemical groups.	T1	T31	19496999
NA	CHEMICAL	GENE-N	23	6	RESULTS: Statistically significant differences in midbrain gene BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the clozapine, chemical and haloperidol groups.	T21	T31	19496999
NA	CHEMICAL	GENE-N	22	6	RESULTS: Statistically significant differences in midbrain gene BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the chemical, olanzapine and haloperidol groups.	T20	T31	19496999
CPR:4	CHEMICAL	GENE-Y	3	8	The mechanism of chemical poisoning involves inhibition of gene (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.	T17	T27	19651196
CPR:4	CHEMICAL	GENE-Y	3	9	The mechanism of chemical poisoning involves inhibition of acetylcholinesterase (gene) leading to inactivation of the enzyme which has an important role in neurotransmission.	T17	T28	19651196
NA	CHEMICAL	GENE-Y	7	0	gene inhibition results in the accumulation of chemical at cholinergic receptor sites, producing continuous stimulation of cholinergic fibers throughout the nervous systems.	T18	T29	19651196
CPR:4	CHEMICAL	GENE-Y	8	5	They act by reactivation of gene inhibited by chemical.	T21	T30	19651196
CPR:3	CHEMICAL	GENE-Y	9	1	atropine, gene reactivator such as one of the recommended chemical (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	T8	T26	19651196
CPR:3	CHEMICAL	GENE-Y	11	1	atropine, gene reactivator such as one of the recommended pyridinium oximes (chemical, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	T9	T26	19651196
CPR:3	CHEMICAL	GENE-Y	12	1	atropine, gene reactivator such as one of the recommended pyridinium oximes (pralidoxime, chemical, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	T10	T26	19651196
CPR:3	CHEMICAL	GENE-Y	13	1	atropine, gene reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, chemical and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	T11	T26	19651196
CPR:3	CHEMICAL	GENE-Y	0	1	chemical, gene reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of OP poisoning in humans.	T7	T26	19651196
CPR:3	CHEMICAL	GENE-Y	17	1	atropine, gene reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and chemical are used for the treatment of OP poisoning in humans.	T13	T26	19651196
CPR:3	CHEMICAL	GENE-Y	15	1	atropine, gene reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and chemical) and diazepam are used for the treatment of OP poisoning in humans.	T12	T26	19651196
CPR:4	CHEMICAL	GENE-Y	24	1	atropine, gene reactivator such as one of the recommended pyridinium oximes (pralidoxime, trimedoxime, obidoxime and HI-6) and diazepam are used for the treatment of chemical poisoning in humans.	T14	T26	19651196
NA	CHEMICAL	GENE-Y	0	18	chemical ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of gene plaques in the brain.	T3	T16	19837759
NA	CHEMICAL	GENE-Y	3	18	(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine (chemical) is such as an agent currently in phase III clinical studies for PET of gene plaques in the brain.	T4	T16	19837759
NA	CHEMICAL	GENE-Y	5	7	METHODS: In vitro binding of chemical to gene plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography.	T5	T17	19837759
NA	CHEMICAL	GENE-Y	4	15	In vivo biodistribution of chemical in mice and ex vivo autoradiography of AD transgenic mice (gene/PSEN1) with Abeta aggregates in the brain were performed.	T6	T18	19837759
NA	CHEMICAL	GENE-Y	4	17	In vivo biodistribution of chemical in mice and ex vivo autoradiography of AD transgenic mice (APPswe/PSEN1) with gene aggregates in the brain were performed.	T6	T20	19837759
NA	CHEMICAL	GENE-Y	4	15	In vivo biodistribution of chemical in mice and ex vivo autoradiography of AD transgenic mice (APPswe/gene) with Abeta aggregates in the brain were performed.	T6	T19	19837759
NA	CHEMICAL	GENE-Y	1	10	RESULTS: chemical displayed a high binding affinity and specificity to gene plaques (K(d), 3.72 +/- 0.30 nM).	T8	T10	19837759
NA	CHEMICAL	GENE-Y	0	6	chemical displayed excellent binding affinity to gene plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice.	T1	T12	19837759
NA	CHEMICAL	GENE-Y	5	14	The results lend support that chemical may be a useful PET agent for detecting gene plaques in the living human brain.	T2	T13	19837759
CPR:6	CHEMICAL	GENE-N	0	4	chemical is a second-generation gene antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.	T1	T25	19852528
CPR:6	CHEMICAL	GENE-N	0	5	chemical is a second-generation serotonin gene antagonist, with a distinct pharmacological profile that differs from first-generation gene antagonists.	T1	T23	19852528
NA	CHEMICAL	GENE-N	4	5	Palonosetron is a second-generation chemical gene antagonist, with a distinct pharmacological profile that differs from first-generation gene antagonists.	T15	T23	19852528
CPR:6	CHEMICAL	GENE-N	1	14	Oral chemical is likely to be a useful addition to oral formulations of other gener antagonists in preventing CINV in patients receiving MEC.	T12	T24	19852528
NA	CHEMICAL	GENE-N	31	34	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the chemical, AT-binding sequence gene (AT-bs) through quantification of signals of the disaccharide sequence G-A*.	T4	T6	19888521
NA	CHEMICAL	GENE-N	42	34	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence gene (AT-bs) through quantification of signals of the chemical sequence G-A*.	T5	T6	19888521
NA	CHEMICAL	GENE-N	11	34	Besides providing the content of terminal groups and individual glucosamine and chemical residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence gene (AT-bs) through quantification of signals of the disaccharide sequence G-A*.	T2	T6	19888521
NA	CHEMICAL	GENE-N	9	34	Besides providing the content of terminal groups and individual chemical and uronic acid residues with different sulfate substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence gene (AT-bs) through quantification of signals of the disaccharide sequence G-A*.	T1	T6	19888521
NA	CHEMICAL	GENE-N	16	34	Besides providing the content of terminal groups and individual glucosamine and uronic acid residues with different chemical substituents, the HSQC-NMR spectra permitted us to evaluate and correlate the content of the pentasaccharide, AT-binding sequence gene (AT-bs) through quantification of signals of the disaccharide sequence G-A*.	T3	T6	19888521
NA	CHEMICAL	GENE-Y	15	0	gene (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's chemical (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T9	T22	20053189
NA	CHEMICAL	GENE-Y	15	3	Luteinizing hormone-releasing hormone (gene) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's chemical (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T9	T23	20053189
NA	CHEMICAL	GENE-Y	15	17	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's chemical (gene) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T9	T10	20053189
NA	CHEMICAL	GENE-N	15	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's chemical (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and testosterone levels.	T9	T25	20053189
NA	CHEMICAL	GENE-Y	30	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gene, ultimately leading to its de-sensitization and subsequent reduction of LH and chemical levels.	T11	T24	20053189
NA	CHEMICAL	GENE-Y	30	0	gene (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and chemical levels.	T11	T22	20053189
NA	CHEMICAL	GENE-Y	30	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gene (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and chemical levels.	T11	T9	20053189
NA	CHEMICAL	GENE-Y	30	3	Luteinizing hormone-releasing hormone (gene) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and chemical levels.	T11	T23	20053189
NA	CHEMICAL	GENE-Y	30	17	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (gene) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and chemical levels.	T11	T10	20053189
NA	CHEMICAL	GENE-N	30	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and chemical levels.	T11	T25	20053189
CPR:3	CHEMICAL	GENE-Y	11	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and chemical, stimulate the pituitary's gene, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T8	T24	20053189
CPR:5	CHEMICAL	GENE-Y	11	0	gene (LHRH) agonists, such as buserelin, goserelin, leuprorelin and chemical, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T8	T22	20053189
NA	CHEMICAL	GENE-Y	11	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and chemical, stimulate the pituitary's gene (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T8	T9	20053189
CPR:5	CHEMICAL	GENE-Y	11	3	Luteinizing hormone-releasing hormone (gene) agonists, such as buserelin, goserelin, leuprorelin and chemical, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T8	T23	20053189
NA	CHEMICAL	GENE-Y	11	17	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and chemical, stimulate the pituitary's gonadotrophin-releasing hormone (gene) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T8	T10	20053189
CPR:4	CHEMICAL	GENE-N	11	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as buserelin, goserelin, leuprorelin and chemical, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and testosterone levels.	T8	T25	20053189
CPR:3	CHEMICAL	GENE-Y	9	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, chemical and triptorelin, stimulate the pituitary's gene, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T7	T24	20053189
CPR:5	CHEMICAL	GENE-Y	9	0	gene (LHRH) agonists, such as buserelin, goserelin, chemical and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T7	T22	20053189
NA	CHEMICAL	GENE-Y	9	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, chemical and triptorelin, stimulate the pituitary's gene (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T7	T9	20053189
CPR:5	CHEMICAL	GENE-Y	9	3	Luteinizing hormone-releasing hormone (gene) agonists, such as buserelin, goserelin, chemical and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T7	T23	20053189
NA	CHEMICAL	GENE-Y	9	17	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, chemical and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (gene) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T7	T10	20053189
CPR:4	CHEMICAL	GENE-N	9	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as buserelin, goserelin, chemical and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and testosterone levels.	T7	T25	20053189
CPR:3	CHEMICAL	GENE-Y	8	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, chemical, leuprorelin and triptorelin, stimulate the pituitary's gene, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T6	T24	20053189
CPR:5	CHEMICAL	GENE-Y	8	0	gene (LHRH) agonists, such as buserelin, chemical, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T6	T22	20053189
NA	CHEMICAL	GENE-Y	8	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, chemical, leuprorelin and triptorelin, stimulate the pituitary's gene (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T6	T9	20053189
CPR:5	CHEMICAL	GENE-Y	8	3	Luteinizing hormone-releasing hormone (gene) agonists, such as buserelin, chemical, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T6	T23	20053189
NA	CHEMICAL	GENE-Y	8	17	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, chemical, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (gene) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T6	T10	20053189
CPR:4	CHEMICAL	GENE-N	8	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as buserelin, chemical, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and testosterone levels.	T6	T25	20053189
CPR:3	CHEMICAL	GENE-Y	7	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as chemical, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gene, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T5	T24	20053189
CPR:5	CHEMICAL	GENE-Y	7	0	gene (LHRH) agonists, such as chemical, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T5	T22	20053189
NA	CHEMICAL	GENE-Y	7	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as chemical, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gene (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T5	T9	20053189
CPR:5	CHEMICAL	GENE-Y	7	3	Luteinizing hormone-releasing hormone (gene) agonists, such as chemical, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T5	T23	20053189
NA	CHEMICAL	GENE-Y	7	17	Luteinizing hormone-releasing hormone (LHRH) agonists, such as chemical, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (gene) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T5	T10	20053189
CPR:4	CHEMICAL	GENE-N	7	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as chemical, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and testosterone levels.	T5	T25	20053189
NA	CHEMICAL	GENE-Y	17	0	gene (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (chemical) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T10	T22	20053189
NA	CHEMICAL	GENE-Y	17	15	Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gene (chemical) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T10	T9	20053189
NA	CHEMICAL	GENE-Y	17	3	Luteinizing hormone-releasing hormone (gene) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (chemical) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.	T10	T23	20053189
NA	CHEMICAL	GENE-N	17	3	Luteinizing hormone-releasing hormone (geneRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (chemical) receptor, ultimately leading to its de-sensitization and subsequent reduction of gene and testosterone levels.	T10	T25	20053189
NA	CHEMICAL	GENE-N	15	13	However, this reduction is accompanied by a well described increase or 'surge' in gene and chemical levels, necessitating the concomitant administration of an antiandrogen to combat the potential effects of transient acceleration in cancer activity.	T12	T26	20053189
NA	CHEMICAL	GENE-Y	27	19	Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the gene and consequently do not result in chemical flare.	T17	T28	20053189
NA	CHEMICAL	GENE-Y	27	2	Two pure gene antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the gene receptor and consequently do not result in chemical flare.	T17	T13	20053189
NA	CHEMICAL	GENE-Y	27	2	Two pure gene antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the gene receptor and consequently do not result in chemical flare.	T17	T16	20053189
NA	CHEMICAL	GENE-Y	27	2	Two pure gene antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the gene receptor and consequently do not result in chemical flare.	T17	T27	20053189
NA	CHEMICAL	GENE-Y	9	19	Two pure GnRH antagonists have been developed, abarelix and chemical, that are devoid of any agonist effect on the gene and consequently do not result in testosterone flare.	T15	T28	20053189
NA	CHEMICAL	GENE-Y	9	2	Two pure gene antagonists have been developed, abarelix and chemical, that are devoid of any agonist effect on the gene receptor and consequently do not result in testosterone flare.	T15	T13	20053189
NA	CHEMICAL	GENE-Y	9	2	Two pure gene antagonists have been developed, abarelix and chemical, that are devoid of any agonist effect on the gene receptor and consequently do not result in testosterone flare.	T15	T16	20053189
CPR:6	CHEMICAL	GENE-Y	9	2	Two pure gene antagonists have been developed, abarelix and chemical, that are devoid of any agonist effect on the gene receptor and consequently do not result in testosterone flare.	T15	T27	20053189
NA	CHEMICAL	GENE-Y	7	19	Two pure GnRH antagonists have been developed, chemical and degarelix, that are devoid of any agonist effect on the gene and consequently do not result in testosterone flare.	T14	T28	20053189
NA	CHEMICAL	GENE-Y	7	2	Two pure gene antagonists have been developed, chemical and degarelix, that are devoid of any agonist effect on the gene receptor and consequently do not result in testosterone flare.	T14	T13	20053189
NA	CHEMICAL	GENE-Y	7	2	Two pure gene antagonists have been developed, chemical and degarelix, that are devoid of any agonist effect on the gene receptor and consequently do not result in testosterone flare.	T14	T16	20053189
CPR:6	CHEMICAL	GENE-Y	7	2	Two pure gene antagonists have been developed, chemical and degarelix, that are devoid of any agonist effect on the gene receptor and consequently do not result in testosterone flare.	T14	T27	20053189
NA	CHEMICAL	GENE-Y	0	4	chemical was the first gene antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.	T18	T19	20053189
CPR:6	CHEMICAL	GENE-Y	0	4	chemical was the first gene antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.	T18	T29	20053189
NA	CHEMICAL	GENE-Y	36	4	Abarelix was the first gene antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid chemical suppression is necessary.	T1	T19	20053189
NA	CHEMICAL	GENE-Y	36	4	Abarelix was the first gene antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid chemical suppression is necessary.	T1	T29	20053189
NA	CHEMICAL	GENE-Y	10	13	Pharmacologic advances in the field in the past decades, including chemical and the gene inhibitors, have contributed significantly to the reduced mortality of estrogen-sensitive breast cancer.	T5	T14	20151846
NA	CHEMICAL	GENE-Y	23	13	Pharmacologic advances in the field in the past decades, including tamoxifen and the gene inhibitors, have contributed significantly to the reduced mortality of chemical-sensitive breast cancer.	T6	T14	20151846
CPR:4	CHEMICAL	GENE-Y	0	3	chemical, a pure gene downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.	T8	T15	20151846
NA	CHEMICAL	GENE-Y	8	14	Isovaleric acidemia is an autosomal recessive disease of chemical metabolism due to deficiency of gene.	T4	T11	21207059
CPR:3	CHEMICAL	GENE-Y	3	16	The concentration of chemical required to inhibit the assembly or to induce the disassembly of gene:tubulin microtubules is markedly dependent upon the microtubule protein concentration.	T1	T7	2125244
CPR:3	CHEMICAL	GENE-N	3	18	The concentration of chemical required to inhibit the assembly or to induce the disassembly of chick brain MAP2:gene microtubules is markedly dependent upon the microtubule protein concentration.	T1	T8	2125244
NA	CHEMICAL	GENE-N	6	9	Analysis of this relationship shows that chemical and gene compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T2	T9	2125244
NA	CHEMICAL	GENE-N	6	9	Analysis of this relationship shows that chemical and gene compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T3	T9	2125244
NA	CHEMICAL	GENE-N	6	9	Analysis of this relationship shows that chemical and gene compete for common MAP2 sites, that MAP2 can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T4	T9	2125244
NA	CHEMICAL	GENE-Y	6	13	Analysis of this relationship shows that chemical and tubulin compete for common gene sites, that gene can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T2	T10	2125244
NA	CHEMICAL	GENE-Y	6	13	Analysis of this relationship shows that chemical and tubulin compete for common gene sites, that gene can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T2	T11	2125244
NA	CHEMICAL	GENE-Y	6	13	Analysis of this relationship shows that chemical and tubulin compete for common gene sites, that gene can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T3	T10	2125244
NA	CHEMICAL	GENE-Y	6	13	Analysis of this relationship shows that chemical and tubulin compete for common gene sites, that gene can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T3	T11	2125244
NA	CHEMICAL	GENE-Y	6	13	Analysis of this relationship shows that chemical and tubulin compete for common gene sites, that gene can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T4	T10	2125244
NA	CHEMICAL	GENE-Y	6	13	Analysis of this relationship shows that chemical and tubulin compete for common gene sites, that gene can bind 5-6 moles.mole-1 chemical, and that the Kd of these sites is congruent to 20 microM chemical.	T4	T11	2125244
CPR:4	CHEMICAL	GENE-N	7	15	It is proposed that two molecules of chemical interact with each of the three gene-binding sites of MAP2 and inhibit the MAP2:gene interaction by neutralising two highly conserved basic residues.	T5	T14	2125244
NA	CHEMICAL	GENE-Y	7	18	It is proposed that two molecules of chemical interact with each of the three tubulin-binding sites of gene and inhibit the gene:tubulin interaction by neutralising two highly conserved basic residues.	T5	T12	2125244
CPR:4	CHEMICAL	GENE-Y	7	18	It is proposed that two molecules of chemical interact with each of the three tubulin-binding sites of gene and inhibit the gene:tubulin interaction by neutralising two highly conserved basic residues.	T5	T13	2125244
CPR:4	CHEMICAL	GENE-Y	2	9	PURPOSE: XL184 (chemical) is a potent inhibitor of MET, gene (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T3	T19	21606412
CPR:4	CHEMICAL	GENE-Y	2	15	PURPOSE: XL184 (chemical) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (gene), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T3	T13	21606412
CPR:4	CHEMICAL	GENE-Y	2	8	PURPOSE: XL184 (chemical) is a potent inhibitor of gene, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T3	T18	21606412
CPR:4	CHEMICAL	GENE-Y	2	17	PURPOSE: XL184 (chemical) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and gene, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T3	T14	21606412
CPR:4	CHEMICAL	GENE-Y	1	9	PURPOSE: chemical (cabozantinib) is a potent inhibitor of MET, gene (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T6	T19	21606412
CPR:4	CHEMICAL	GENE-Y	1	15	PURPOSE: chemical (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (gene), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T6	T13	21606412
CPR:4	CHEMICAL	GENE-Y	1	8	PURPOSE: chemical (cabozantinib) is a potent inhibitor of gene, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T6	T18	21606412
CPR:4	CHEMICAL	GENE-Y	1	17	PURPOSE: chemical (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and gene, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.	T6	T14	21606412
NA	CHEMICAL	GENE-Y	0	16	chemical may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, gene, and RET.	T2	T16	21606412
NA	CHEMICAL	GENE-Y	0	15	chemical may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including gene, VEGFR2, and RET.	T2	T15	21606412
NA	CHEMICAL	GENE-Y	0	18	chemical may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and gene.	T2	T17	21606412
NA	CHEMICAL	GENE-Y	6	4	Blood complete counts, high-sensitive gene, chemical and routine biochemical tests were carried out by routine procedures.	T6	T10	22258629
NA	CHEMICAL	GENE-N	7	3	The activities of gene, catalase and chemical peroxidase were found significantly higher in combined treated than untreated rats.	T8	T24	22287617
NA	CHEMICAL	GENE-Y	7	5	The activities of superoxide dismutase, gene and chemical peroxidase were found significantly higher in combined treated than untreated rats.	T8	T25	22287617
NA	CHEMICAL	GENE-N	3	7	The activities of chemical dismutase, catalase and gene were found significantly higher in combined treated than untreated rats.	T7	T26	22287617
NA	CHEMICAL	GENE-Y	3	5	The activities of chemical dismutase, gene and glutathione peroxidase were found significantly higher in combined treated than untreated rats.	T7	T25	22287617
NA	CHEMICAL	GENE-Y	7	3	Oncogenic mutations in gene, which encodes the chemical-3-kinase (PI3K) catalytic subunit p110, occur in 25% of human breast cancers.	T1	T4	22370636
NA	CHEMICAL	GENE-N	11	4	Whole-exome analysis of the Pik3ca(gene)-driven mammary tumors identified multiple mutations, including chemical53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	T2	T14	22370636
NA	CHEMICAL	GENE-Y	11	4	Whole-exome analysis of the gene(H1047R)-driven mammary tumors identified multiple mutations, including chemical53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	T2	T13	22370636
CPR:4	CHEMICAL	GENE-N	10	12	Further, we used this model to test the efficacy of chemical, a gene inhibitor, in clinical development, and showed that the tumors respond to gene inhibition.	T3	T16	22370636
CPR:4	CHEMICAL	GENE-N	10	12	Further, we used this model to test the efficacy of chemical, a gene inhibitor, in clinical development, and showed that the tumors respond to gene inhibition.	T3	T17	22370636
NA	CHEMICAL	GENE-Y	0	14	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, gene, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T14	22447684
NA	CHEMICAL	GENE-Y	0	15	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, gene, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T15	22447684
NA	CHEMICAL	GENE-Y	0	20	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, gene, and Fasn, relative to those in HFD control mice.	T9	T20	22447684
NA	CHEMICAL	GENE-Y	0	18	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, gene, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T18	22447684
NA	CHEMICAL	GENE-Y	0	16	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, gene, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T16	22447684
NA	CHEMICAL	GENE-Y	0	13	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, gene, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T13	22447684
NA	CHEMICAL	GENE-Y	0	11	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including gene, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T11	22447684
NA	CHEMICAL	GENE-Y	0	22	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and gene, relative to those in HFD control mice.	T9	T21	22447684
NA	CHEMICAL	GENE-Y	0	17	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, gene, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T17	22447684
NA	CHEMICAL	GENE-Y	0	19	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, Pon1, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, gene, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T19	22447684
NA	CHEMICAL	GENE-Y	0	12	chemical supplementation altered expression profiles of several lipid metabolism-related genes, including Fnta, gene, Pparg, Aldh1b1, Apoa4, Abcg5, Gpam, Acaca, Cd36, Fdft1, and Fasn, relative to those in HFD control mice.	T9	T12	22447684
NA	CHEMICAL	GENE-Y	1	7	A chemical-inducible transgenic mouse model expressing truncated gene (N89gene) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic gene expression both in 3D 'crypt culture' and in vivo.	T2	T6	22469981
NA	CHEMICAL	GENE-Y	1	7	A chemical-inducible transgenic mouse model expressing truncated gene (N89gene) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic gene expression both in 3D 'crypt culture' and in vivo.	T2	T7	22469981
NA	CHEMICAL	GENE-Y	1	7	A chemical-inducible transgenic mouse model expressing truncated gene (N89gene) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic gene expression both in 3D 'crypt culture' and in vivo.	T2	T8	22469981
NA	CHEMICAL	GENE-N	4	26	By 7 days following chemical withdrawal, gene expression, cell proliferation and tissue morphology were undistinguishable from control animals.In conclusion, these results demonstrate that the reversal of gene signaling by inhibitors should ideally be studied within hours of treatment.	T1	T3	22469981
NA	CHEMICAL	GENE-Y	5	7	The interplay between cardiac sarcoplasmic chemicalATPase and gene is a key regulating factor of contraction and relaxation in the cardiac muscle.	T4	T19	22578098
NA	CHEMICAL	GENE-Y	9	11	In heart failure, aberrations in the inhibition of sarcoplasmic chemicalATPase by gene are associated with anomalies in cardiac functions.	T3	T15	22578098
NA	CHEMICAL	GENE-Y	20	17	The aim of our research was to find molecules able to interfere with the inhibitory activity of gene on sarcoplasmic chemicalATPase.	T5	T17	22578098
NA	CHEMICAL	GENE-N	14	9	By synthesizing and testing a series of alanine point-mutated gene, we identified which chemical was important for the inhibition of the phospholamban function.	T1	T8	22578098
NA	CHEMICAL	GENE-Y	14	23	By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which chemical was important for the inhibition of the gene function.	T1	T9	22578098
NA	CHEMICAL	GENE-N	7	9	By synthesizing and testing a series of chemical point-mutated gene, we identified which amino acid was important for the inhibition of the phospholamban function.	T7	T8	22578098
NA	CHEMICAL	GENE-Y	7	23	By synthesizing and testing a series of chemical point-mutated cyclic peptides, we identified which amino acid was important for the inhibition of the gene function.	T7	T9	22578098
NA	CHEMICAL	GENE-Y	6	11	The structures of active and inactive chemical-mutated cyclic peptides, and of gene, were determined by NMR.	T2	T11	22578098
NA	CHEMICAL	GENE-N	6	7	The structures of active and inactive chemical-mutated gene, and of phospholamban (1-36), were determined by NMR.	T2	T10	22578098
NA	CHEMICAL	GENE-Y	11	13	BMMs are the major source of inflammatory factors and proteases, including chemical protease gene (CTSK).	T1	T4	22614014
NA	CHEMICAL	GENE-N	11	9	BMMs are the major source of inflammatory factors and gene, including chemical protease cathepsin K (CTSK).	T1	T2	22614014
NA	CHEMICAL	GENE-Y	11	15	BMMs are the major source of inflammatory factors and proteases, including chemical protease cathepsin K (gene).	T1	T5	22614014
CPR:9	CHEMICAL	GENE-N	25	0	gene (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and chemical) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T5	T22	2268554
CPR:9	CHEMICAL	GENE-N	25	6	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (gene) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and chemical) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T5	T26	2268554
CPR:9	CHEMICAL	GENE-N	16	0	gene (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and chemical) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T2	T22	2268554
CPR:9	CHEMICAL	GENE-N	16	6	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (gene) purified from human placenta transforms C-21 (pregnenolone and chemical) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T2	T26	2268554
CPR:9	CHEMICAL	GENE-N	23	0	gene (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (chemical and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T4	T22	2268554
CPR:9	CHEMICAL	GENE-N	23	6	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (gene) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (chemical and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T4	T26	2268554
NA	CHEMICAL	GENE-N	2	6	Human placental chemical dehydrogenase/5----4-ene isomerase (gene) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T3	T26	2268554
CPR:9	CHEMICAL	GENE-N	33	0	gene (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding chemical and is thus involved in the biosynthesis of all classes of hormonal steroids.	T6	T22	2268554
CPR:9	CHEMICAL	GENE-N	33	6	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (gene) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding chemical and is thus involved in the biosynthesis of all classes of hormonal steroids.	T6	T26	2268554
CPR:9	CHEMICAL	GENE-N	14	0	gene (3 beta-HSD) purified from human placenta transforms C-21 (chemical and 17 alpha-hydroxy chemical) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T1	T22	2268554
CPR:9	CHEMICAL	GENE-N	14	6	Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (gene) purified from human placenta transforms C-21 (chemical and 17 alpha-hydroxy chemical) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.	T1	T26	2268554
CPR:4	CHEMICAL	GENE-N	3	8	Trilostane, epostane and chemical are potent inhibitors of gene with Ki values of approximately 50 nM.	T9	T23	2268554
CPR:4	CHEMICAL	GENE-N	0	8	chemical, epostane and cyanoketone are potent inhibitors of gene with Ki values of approximately 50 nM.	T7	T23	2268554
CPR:4	CHEMICAL	GENE-N	1	8	Trilostane, chemical and cyanoketone are potent inhibitors of gene with Ki values of approximately 50 nM.	T8	T23	2268554
CPR:4	CHEMICAL	GENE-N	0	4	chemical, a well known gene inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.	T10	T24	2268554
CPR:4	CHEMICAL	GENE-N	0	13	chemical, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of gene with a Ki value of 56 nM.	T10	T25	2268554
CPR:4	CHEMICAL	GENE-N	0	29	chemical, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit gene activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	T14	T27	2268554
CPR:4	CHEMICAL	GENE-N	19	29	Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and chemical that are widely used as oral contraceptives also inhibit gene activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	T17	T27	2268554
CPR:4	CHEMICAL	GENE-N	17	29	Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as chemical and norethindrone that are widely used as oral contraceptives also inhibit gene activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	T16	T27	2268554
CPR:4	CHEMICAL	GENE-N	3	29	Cyproterone acetate, a chemical used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit gene activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	T15	T27	2268554
NA	CHEMICAL	GENE-N	12	3	We also examined gene receptor signaling by in vivo measurement of DHPG-stimulated chemical hydrolysis.	T4	T14	22709946
NA	CHEMICAL	GENE-N	11	3	We also examined gene receptor signaling by in vivo measurement of chemical-stimulated polyphosphoinositides hydrolysis.	T3	T14	22709946
CPR:3	CHEMICAL	GENE-Y	7	17	However, chronic treatment of cLH rats with chemical did not reverse learned helplessness, indicating that the enhanced gene function is not the only player in the behavioral phenotype of this genetic model of depression.	T1	T9	22709946
NA	CHEMICAL	GENE-N	10	15	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (chemical partial agonist) or MS-275 (gene (HDAC) inhibitor), applied after extinction training.	T8	T16	22722028
NA	CHEMICAL	GENE-N	10	17	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (chemical partial agonist) or MS-275 (histone deacetylase (gene) inhibitor), applied after extinction training.	T8	T17	22722028
NA	CHEMICAL	GENE-N	9	15	Rescue of this impaired extinction consolidation/retrieval was achieved with chemical (N-methly-d-aspartate partial agonist) or MS-275 (gene (HDAC) inhibitor), applied after extinction training.	T7	T16	22722028
NA	CHEMICAL	GENE-N	9	17	Rescue of this impaired extinction consolidation/retrieval was achieved with chemical (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (gene) inhibitor), applied after extinction training.	T7	T17	22722028
CPR:4	CHEMICAL	GENE-N	14	15	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or chemical (gene (HDAC) inhibitor), applied after extinction training.	T9	T16	22722028
CPR:4	CHEMICAL	GENE-N	14	17	Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or chemical (histone deacetylase (gene) inhibitor), applied after extinction training.	T9	T17	22722028
NA	CHEMICAL	GENE-Y	18	28	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of chemical (a GABAergic enhancer and HDAC inhibitor) or AMN082 [gene (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T1	T11	22722028
NA	CHEMICAL	GENE-N	18	38	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of chemical (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (gene potentiator) failed to affect extinction acquisition in S1 mice.	T1	T13	22722028
NA	CHEMICAL	GENE-Y	18	32	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of chemical (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (gene) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T1	T12	22722028
CPR:4	CHEMICAL	GENE-N	18	24	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of chemical (a GABAergic enhancer and gene inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T1	T10	22722028
NA	CHEMICAL	GENE-N	29	38	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic chemical receptor 7 (mGlu7) agonist], while MS-275 or PEPA (gene potentiator) failed to affect extinction acquisition in S1 mice.	T3	T13	22722028
NA	CHEMICAL	GENE-Y	29	32	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic chemical receptor 7 (gene) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T3	T12	22722028
NA	CHEMICAL	GENE-N	29	24	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and gene inhibitor) or AMN082 [metabotropic chemical receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T3	T10	22722028
NA	CHEMICAL	GENE-Y	35	28	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [gene (mGlu7) agonist], while chemical or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T4	T11	22722028
CPR:3	CHEMICAL	GENE-N	35	38	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while chemical or PEPA (gene potentiator) failed to affect extinction acquisition in S1 mice.	T4	T13	22722028
NA	CHEMICAL	GENE-Y	35	32	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (gene) agonist], while chemical or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T4	T12	22722028
NA	CHEMICAL	GENE-N	35	24	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and gene inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while chemical or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T4	T10	22722028
CPR:5	CHEMICAL	GENE-Y	27	28	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or chemical [gene (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T2	T11	22722028
NA	CHEMICAL	GENE-N	27	38	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or chemical [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (gene potentiator) failed to affect extinction acquisition in S1 mice.	T2	T13	22722028
CPR:5	CHEMICAL	GENE-Y	27	32	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or chemical [metabotropic glutamate receptor 7 (gene) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T2	T12	22722028
NA	CHEMICAL	GENE-N	27	24	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and gene inhibitor) or chemical [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T2	T10	22722028
NA	CHEMICAL	GENE-Y	38	28	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [gene (mGlu7) agonist], while MS-275 or PEPA (chemical receptor potentiator) failed to affect extinction acquisition in S1 mice.	T6	T11	22722028
NA	CHEMICAL	GENE-Y	38	32	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (gene) agonist], while MS-275 or PEPA (chemical receptor potentiator) failed to affect extinction acquisition in S1 mice.	T6	T12	22722028
NA	CHEMICAL	GENE-N	38	24	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and gene inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (chemical receptor potentiator) failed to affect extinction acquisition in S1 mice.	T6	T10	22722028
NA	CHEMICAL	GENE-Y	37	28	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [gene (mGlu7) agonist], while MS-275 or chemical (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T5	T11	22722028
CPR:3	CHEMICAL	GENE-N	37	38	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or chemical (gene potentiator) failed to affect extinction acquisition in S1 mice.	T5	T13	22722028
NA	CHEMICAL	GENE-Y	37	32	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (gene) agonist], while MS-275 or chemical (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T5	T12	22722028
NA	CHEMICAL	GENE-N	37	24	Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and gene inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or chemical (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.	T5	T10	22722028
CPR:4	CHEMICAL	GENE-Y	14	10	Electroencephalographic recordings during substance consumption showed reduced alpha activity and gene latencies in the chemical group compared to the control group.	T8	T11	22749926
CPR:3	CHEMICAL	GENE-N	7	12	These findings suggest that oral consumption of chemical enhances the efficacy of gene.	T2	T10	22749926
NA	CHEMICAL	GENE-N	12	3	Rats treated with gene plus hCG displayed abnormal estrous cycles with increasing chemical biosynthesis.	T1	T4	22798247
NA	CHEMICAL	GENE-N	12	5	Rats treated with insulin plus gene displayed abnormal estrous cycles with increasing chemical biosynthesis.	T1	T5	22798247
NA	CHEMICAL	GENE-Y	12	34	It was hypothesized that because Hg accumulates in the proximal tubules (PTs), chemical-S-transferases (GST)- (suggestive of kidney damage at the level of PT) would be expected to be more related to Hg exposure than gene (suggestive of kidney damage at the level of the distal tubules).	T4	T15	22893351
NA	CHEMICAL	GENE-N	5	12	It was hypothesized that because chemical accumulates in the proximal tubules (PTs), gene (suggestive of kidney damage at the level of PT) would be expected to be more related to chemical exposure than GST- (suggestive of kidney damage at the level of the distal tubules).	T3	T14	22893351
NA	CHEMICAL	GENE-N	5	12	It was hypothesized that because chemical accumulates in the proximal tubules (PTs), gene (suggestive of kidney damage at the level of PT) would be expected to be more related to chemical exposure than GST- (suggestive of kidney damage at the level of the distal tubules).	T6	T14	22893351
NA	CHEMICAL	GENE-Y	5	34	It was hypothesized that because chemical accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)- (suggestive of kidney damage at the level of PT) would be expected to be more related to chemical exposure than gene (suggestive of kidney damage at the level of the distal tubules).	T3	T15	22893351
NA	CHEMICAL	GENE-Y	5	34	It was hypothesized that because chemical accumulates in the proximal tubules (PTs), glutathione-S-transferases (GST)- (suggestive of kidney damage at the level of PT) would be expected to be more related to chemical exposure than gene (suggestive of kidney damage at the level of the distal tubules).	T6	T15	22893351
NA	CHEMICAL	GENE-Y	12	20	Our study determined whether there was a significant dose-dependent correlation between increasing chemical exposure from dental amalgams and GST- and gene as biomarkers of kidney integrity.	T7	T17	22893351
NA	CHEMICAL	GENE-N	12	18	Our study determined whether there was a significant dose-dependent correlation between increasing chemical exposure from dental amalgams and gene and GST- as biomarkers of kidney integrity.	T7	T16	22893351
NA	CHEMICAL	GENE-Y	26	49	Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to chemical from dental amalgams and urinary levels of GST-, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of gene.	T1	T12	22893351
NA	CHEMICAL	GENE-N	26	34	Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose-dependent correlation between cumulative exposure to chemical from dental amalgams and urinary levels of gene, after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of GST-.	T1	T11	22893351
NA	CHEMICAL	GENE-Y	7	27	Following a 2-h control period during which chemical infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4 basal gene (INS) or portal vein glucose infusion (PoG) was measured.	T3	T7	22923473
NA	CHEMICAL	GENE-Y	7	28	Following a 2-h control period during which chemical infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4 basal insulin (gene) or portal vein glucose infusion (PoG) was measured.	T3	T8	22923473
NA	CHEMICAL	GENE-Y	32	27	Following a 2-h control period during which fructose infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4 basal gene (INS) or portal vein chemical infusion (PoG) was measured.	T4	T7	22923473
NA	CHEMICAL	GENE-Y	32	28	Following a 2-h control period during which fructose infusion was stopped, there was a 2-h experimental period in which the response to hyperglycemia plus either 4 basal insulin (gene) or portal vein chemical infusion (PoG) was measured.	T4	T8	22923473
NA	CHEMICAL	GENE-N	0	1	chemical-glucuronosyltransferases (gene) are a group of drug-metabolizing enzymes that catalyse the conjugation of endogeonous compounds and xenobiotics to yield hydrophilic glucuronides which subsequently undergo excretion.	T1	T9	22943130
CPR:6	CHEMICAL	GENE-N	0	13	chemical is a small-molecule drug that triggers tumor cell apoptosis by selectively antagonizing gene.	T2	T13	22956632
NA	CHEMICAL	GENE-Y	0	15	chemical induces NF-B transcriptional activity leading to expression of several chemokines and cytokines, of which gene (TNF-) is the most important for single-agent tumor activity.	T3	T17	22956632
NA	CHEMICAL	GENE-N	0	10	chemical induces NF-B transcriptional activity leading to expression of several gene and cytokines, of which tumor necrosis factor alpha (TNF-) is the most important for single-agent tumor activity.	T3	T15	22956632
NA	CHEMICAL	GENE-N	0	12	chemical induces NF-B transcriptional activity leading to expression of several chemokines and gene, of which tumor necrosis factor alpha (TNF-) is the most important for single-agent tumor activity.	T3	T16	22956632
CPR:3	CHEMICAL	GENE-N	0	2	chemical induces gene transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (TNF-) is the most important for single-agent tumor activity.	T3	T14	22956632
NA	CHEMICAL	GENE-Y	0	19	chemical induces NF-B transcriptional activity leading to expression of several chemokines and cytokines, of which tumor necrosis factor alpha (gene) is the most important for single-agent tumor activity.	T3	T18	22956632
NA	CHEMICAL	GENE-Y	17	7	Furthermore, elevations in blood neutrophil count, serum gene, and other markers of inflammation corresponded to chemical exposure and toxicity and thus may have utility as safety biomarkers.	T1	T11	22956632
NA	CHEMICAL	GENE-N	31	7	In the current study, we investigated whether gene, leptin, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic chemical metabolism.	T4	T27	22966070
NA	CHEMICAL	GENE-Y	31	8	In the current study, we investigated whether insulin, gene, and obesity can modulate Tub in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic chemical metabolism.	T4	T28	22966070
NA	CHEMICAL	GENE-Y	31	13	In the current study, we investigated whether insulin, leptin, and obesity can modulate gene in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic chemical metabolism.	T4	T29	22966070
NA	CHEMICAL	GENE-Y	1	0	gene chemical phosphorylation (gene-p-tyr) is modulated by nutritional status.	T5	T33	22966070
NA	CHEMICAL	GENE-Y	1	0	gene chemicalosine phosphorylation (gene-p-chemical) is modulated by nutritional status.	T6	T33	22966070
NA	CHEMICAL	GENE-Y	7	11	Tub is a substrate of insulin receptor chemical kinase (IRTK) and gene (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	T7	T38	22966070
NA	CHEMICAL	GENE-Y	7	13	Tub is a substrate of insulin receptor chemical kinase (IRTK) and leptin receptor (LEPR)-gene (JAK2) in hypothalamic nuclei.	T7	T40	22966070
NA	CHEMICAL	GENE-Y	7	13	Tub is a substrate of insulin receptor chemical kinase (IRTK) and leptin receptor (gene)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	T7	T39	22966070
NA	CHEMICAL	GENE-Y	7	9	Tub is a substrate of insulin receptor chemical kinase (gene) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	T7	T37	22966070
NA	CHEMICAL	GENE-Y	7	16	Tub is a substrate of insulin receptor chemical kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (gene) in hypothalamic nuclei.	T7	T41	22966070
NA	CHEMICAL	GENE-Y	7	0	gene is a substrate of insulin receptor chemical kinase (IRTK) and leptin receptor (LEPR)-Janus kinase 2 (JAK2) in hypothalamic nuclei.	T7	T35	22966070
NA	CHEMICAL	GENE-Y	13	33	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, gene, and orexin expression.	T8	T14	22966070
NA	CHEMICAL	GENE-Y	13	33	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, gene, and orexin expression.	T9	T14	22966070
NA	CHEMICAL	GENE-Y	13	31	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, gene, melanin-concentrating hormone, and orexin expression.	T8	T13	22966070
NA	CHEMICAL	GENE-Y	13	31	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, gene, melanin-concentrating hormone, and orexin expression.	T9	T13	22966070
NA	CHEMICAL	GENE-Y	13	30	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on gene, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T8	T12	22966070
NA	CHEMICAL	GENE-Y	13	30	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on gene, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T9	T12	22966070
NA	CHEMICAL	GENE-N	13	26	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of gene or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T8	T10	22966070
NA	CHEMICAL	GENE-N	13	26	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of gene or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T9	T10	22966070
NA	CHEMICAL	GENE-Y	13	36	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and gene expression.	T8	T15	22966070
NA	CHEMICAL	GENE-Y	13	36	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and gene expression.	T9	T15	22966070
NA	CHEMICAL	GENE-Y	13	28	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or gene on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T8	T11	22966070
NA	CHEMICAL	GENE-Y	13	28	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or gene on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T9	T11	22966070
NA	CHEMICAL	GENE-Y	13	2	Inhibition of gene expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T8	T45	22966070
NA	CHEMICAL	GENE-Y	13	2	Inhibition of gene expression in hypothalamus by ASO increased food intake, fasting blood chemical, and hepatic chemical output, decreased O(2) consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T9	T45	22966070
NA	CHEMICAL	GENE-Y	19	33	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, gene, and orexin expression.	T1	T14	22966070
NA	CHEMICAL	GENE-Y	19	31	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, gene, melanin-concentrating hormone, and orexin expression.	T1	T13	22966070
NA	CHEMICAL	GENE-Y	19	30	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of insulin or leptin on gene, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T1	T12	22966070
NA	CHEMICAL	GENE-N	19	26	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of gene or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T1	T10	22966070
NA	CHEMICAL	GENE-Y	19	36	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and gene expression.	T1	T15	22966070
NA	CHEMICAL	GENE-Y	19	28	Inhibition of Tub expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of insulin or gene on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T1	T11	22966070
NA	CHEMICAL	GENE-Y	19	2	Inhibition of gene expression in hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decreased chemical consumption, and blunted the effect of insulin or leptin on proopiomelanocortin, thyroid-releasing hormone, melanin-concentrating hormone, and orexin expression.	T1	T45	22966070
NA	CHEMICAL	GENE-N	26	15	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and gene-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein chemical phosphatase 1B expression.	T3	T18	22966070
NA	CHEMICAL	GENE-Y	26	13	In hypothalamus of mice administered a high-fat diet, there is a reduction in gene and insulin-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein chemical phosphatase 1B expression.	T3	T17	22966070
NA	CHEMICAL	GENE-Y	26	16	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced gene-p-tyr and nuclear translocation, which is reversed by reducing protein chemical phosphatase 1B expression.	T3	T19	22966070
NA	CHEMICAL	GENE-N	16	15	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and gene-induced Tub-p-chemical and nuclear translocation, which is reversed by reducing protein chemicalosine phosphatase 1B expression.	T2	T18	22966070
NA	CHEMICAL	GENE-Y	16	13	In hypothalamus of mice administered a high-fat diet, there is a reduction in gene and insulin-induced Tub-p-chemical and nuclear translocation, which is reversed by reducing protein chemicalosine phosphatase 1B expression.	T2	T17	22966070
NA	CHEMICAL	GENE-Y	16	16	In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced gene-p-chemical and nuclear translocation, which is reversed by reducing protein chemicalosine phosphatase 1B expression.	T2	T19	22966070
NA	CHEMICAL	GENE-Y	12	1	Since gene is supposed to be part of a multimeric repressor of chemical symporter (NIS) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	T6	T13	22982218
NA	CHEMICAL	GENE-N	12	1	Since gene-1 is supposed to be part of a multimeric repressor of chemical symporter (NIS) expression, in this study the effect of the gene inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	T6	T9	22982218
NA	CHEMICAL	GENE-Y	12	15	Since PARP-1 is supposed to be part of a multimeric repressor of chemical symporter (gene) expression, in this study the effect of the PARP inhibitor PJ34 on several properties of thyroid cancer cell lines was investigated.	T6	T19	22982218
NA	CHEMICAL	GENE-Y	26	12	Since PARP-1 is supposed to be part of a multimeric repressor of gene (NIS) expression, in this study the effect of the PARP inhibitor chemical on several properties of thyroid cancer cell lines was investigated.	T1	T15	22982218
NA	CHEMICAL	GENE-Y	26	1	Since gene is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the PARP inhibitor chemical on several properties of thyroid cancer cell lines was investigated.	T1	T13	22982218
CPR:4	CHEMICAL	GENE-N	26	1	Since gene-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the gene inhibitor chemical on several properties of thyroid cancer cell lines was investigated.	T1	T9	22982218
NA	CHEMICAL	GENE-Y	26	15	Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (gene) expression, in this study the effect of the PARP inhibitor chemical on several properties of thyroid cancer cell lines was investigated.	T1	T19	22982218
CPR:3	CHEMICAL	GENE-Y	7	13	In TPC1, BCPAP, FRO, WRO cell lines chemical induced a strong increase in gene mRNA levels.	T2	T10	22982218
CPR:3	CHEMICAL	GENE-N	10	12	Accordingly, in transfection experiments performed in TPC1 cells, treatment with chemical increased gene activity without affecting PARP-1 binding to the promoter sequence.	T4	T11	22982218
NA	CHEMICAL	GENE-Y	10	17	Accordingly, in transfection experiments performed in TPC1 cells, treatment with chemical increased NIS promoter activity without affecting gene binding to the promoter sequence.	T4	T12	22982218
CPR:3	CHEMICAL	GENE-N	10	22	We also investigated the epigenetic status of NIS promoter after chemical treatment in TPC1 cell line: in addition to an increase of gene (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	T5	T16	22982218
NA	CHEMICAL	GENE-N	10	7	We also investigated the epigenetic status of gene after chemical treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	T5	T14	22982218
CPR:3	CHEMICAL	GENE-N	10	26	We also investigated the epigenetic status of NIS promoter after chemical treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (gene, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	T5	T17	22982218
CPR:3	CHEMICAL	GENE-N	10	27	We also investigated the epigenetic status of NIS promoter after chemical treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, gene), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	T5	T18	22982218
CPR:4	CHEMICAL	GENE-Y	1	17	Both chemical also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and gene expressions caused by CSE.	T15	T25	22989703
CPR:4	CHEMICAL	GENE-Y	1	15	Both chemical also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in gene and COX-2 expressions caused by CSE.	T15	T24	22989703
NA	CHEMICAL	GENE-Y	8	17	Both apo-lycopenoic acids also decreased CSE-induced ROS production, chemical formation and reduced the increase in NOX-4 and gene expressions caused by CSE.	T16	T25	22989703
NA	CHEMICAL	GENE-Y	8	15	Both apo-lycopenoic acids also decreased CSE-induced ROS production, chemical formation and reduced the increase in gene and COX-2 expressions caused by CSE.	T16	T24	22989703
CPR:9	CHEMICAL	GENE-Y	27	17	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme gene (BChE), which is capable of breaking down naturally occurring chemical before the drug can influence the reward centers of the brain or affect other areas of the body.	T3	T10	23000451
CPR:9	CHEMICAL	GENE-Y	27	18	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (gene), which is capable of breaking down naturally occurring chemical before the drug can influence the reward centers of the brain or affect other areas of the body.	T3	T11	23000451
CPR:9	CHEMICAL	GENE-N	27	18	Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (gene), which is capable of breaking down naturally occurring chemical before the drug can influence the reward centers of the brain or affect other areas of the body.	T3	T11	23000451
CPR:9	CHEMICAL	GENE-Y	15	7	This prompted the design of variants of gene which exhibit significantly improved catalytic activity against chemical.	T4	T13	23000451
CPR:9	CHEMICAL	GENE-N	15	7	This prompted the design of variants of gene which exhibit significantly improved catalytic activity against chemical.	T4	T13	23000451
NA	CHEMICAL	GENE-Y	11	15	Plants are a promising means to produce large amounts of these chemical hydrolase variants of gene, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.	T5	T15	23000451
NA	CHEMICAL	GENE-N	11	15	Plants are a promising means to produce large amounts of these chemical hydrolase variants of gene, cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.	T5	T15	23000451
CPR:9	CHEMICAL	GENE-Y	3	6	Here, in expressing chemical-hydrolyzing mutants of gene in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered gene proteins with desired properties.	T2	T8	23000451
NA	CHEMICAL	GENE-Y	3	6	Here, in expressing chemical-hydrolyzing mutants of gene in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered gene proteins with desired properties.	T2	T9	23000451
CPR:9	CHEMICAL	GENE-N	3	6	Here, in expressing chemical-hydrolyzing mutants of gene in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered gene proteins with desired properties.	T2	T8	23000451
NA	CHEMICAL	GENE-N	3	6	Here, in expressing chemical-hydrolyzing mutants of gene in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered gene proteins with desired properties.	T2	T9	23000451
NA	CHEMICAL	GENE-N	20	10	Nerve fibers immunoreactive for not only sensory neuromarkers, such as gene (CGRP), but also sympathetic neuromarkers, such as chemical hydroxylase (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	T7	T13	23000507
NA	CHEMICAL	GENE-Y	20	24	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as chemical hydroxylase (TH) and gene (NPY) were increased in the periodontal ligament during ETM.	T7	T17	23000507
NA	CHEMICAL	GENE-N	20	13	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (gene), but also sympathetic neuromarkers, such as chemical hydroxylase (TH) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	T7	T14	23000507
NA	CHEMICAL	GENE-Y	20	26	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as chemical hydroxylase (TH) and neuropeptide Y (gene) were increased in the periodontal ligament during ETM.	T7	T18	23000507
NA	CHEMICAL	GENE-Y	20	22	Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene-related peptide (CGRP), but also sympathetic neuromarkers, such as chemical hydroxylase (gene) and neuropeptide Y (NPY) were increased in the periodontal ligament during ETM.	T7	T16	23000507
NA	CHEMICAL	GENE-N	0	6	chemical-dependent insulinotropic polypeptide (GIP) is an gene that also plays a regulatory role in fat metabolism.	T1	T45	23002036
NA	CHEMICAL	GENE-Y	0	3	chemical-dependent insulinotropic polypeptide (gene) is an incretin hormone that also plays a regulatory role in fat metabolism.	T1	T41	23002036
NA	CHEMICAL	GENE-Y	35	15	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of gene (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T32	23002036
NA	CHEMICAL	GENE-Y	35	22	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of gene (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T34	23002036
NA	CHEMICAL	GENE-Y	35	30	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of gene (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T36	23002036
NA	CHEMICAL	GENE-Y	35	3	In 3T3-L1 cells, gene was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T24	23002036
NA	CHEMICAL	GENE-Y	35	33	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (gene) and chemical-activated protein kinase (chemicalK).	T5	T37	23002036
NA	CHEMICAL	GENE-Y	35	25	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (gene) and reduced phosphorylation of liver kinase B1 (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T35	23002036
NA	CHEMICAL	GENE-Y	35	12	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of gene stimulation of lipoprotein lipase (LPL) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T31	23002036
NA	CHEMICAL	GENE-Y	35	17	In 3T3-L1 cells, resistin was demonstrated to be a key mediator of GIP stimulation of lipoprotein lipase (gene) activity, involving activation of protein kinase B (PKB) and reduced phosphorylation of liver kinase B1 (LKB1) and chemical-activated protein kinase (chemicalK).	T5	T33	23002036
NA	CHEMICAL	GENE-Y	19	16	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/gene/AMPK/LPL pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T49	23002036
NA	CHEMICAL	GENE-Y	19	6	Analysis of primary adipocytes isolated from gene(-/-), gene(+/-), and gene(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in gene(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in gene(+/-) and gene(-/-) adipocytes.	T6	T43	23002036
NA	CHEMICAL	GENE-Y	19	6	Analysis of primary adipocytes isolated from gene(-/-), gene(+/-), and gene(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in gene(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in gene(+/-) and gene(-/-) adipocytes.	T6	T44	23002036
NA	CHEMICAL	GENE-Y	19	6	Analysis of primary adipocytes isolated from gene(-/-), gene(+/-), and gene(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in gene(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in gene(+/-) and gene(-/-) adipocytes.	T6	T46	23002036
NA	CHEMICAL	GENE-Y	19	6	Analysis of primary adipocytes isolated from gene(-/-), gene(+/-), and gene(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in gene(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in gene(+/-) and gene(-/-) adipocytes.	T6	T52	23002036
NA	CHEMICAL	GENE-Y	19	6	Analysis of primary adipocytes isolated from gene(-/-), gene(+/-), and gene(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in gene(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in gene(+/-) and gene(-/-) adipocytes.	T6	T55	23002036
NA	CHEMICAL	GENE-Y	19	6	Analysis of primary adipocytes isolated from gene(-/-), gene(+/-), and gene(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in gene(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in gene(+/-) and gene(-/-) adipocytes.	T6	T56	23002036
NA	CHEMICAL	GENE-Y	19	16	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/gene/LPL pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T50	23002036
NA	CHEMICAL	GENE-Y	19	16	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the gene/LKB1/AMPK/LPL pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T48	23002036
NA	CHEMICAL	GENE-Y	19	13	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that gene stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that gene signaling and/or gene responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T47	23002036
NA	CHEMICAL	GENE-Y	19	13	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that gene stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that gene signaling and/or gene responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T53	23002036
NA	CHEMICAL	GENE-Y	19	13	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that gene stimulated the PKB/LKB1/AMPK/LPL pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that gene signaling and/or gene responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T54	23002036
NA	CHEMICAL	GENE-Y	19	16	Analysis of primary adipocytes isolated from Retn(-/-), Retn(+/-), and Retn(+/+) mice found that GIP stimulated the PKB/LKB1/AMPK/gene pathway and chemical uptake only in Retn(+/+) adipocytes, suggesting that GIP signaling and/or GIP responsiveness were compromised in Retn(+/-) and Retn(-/-) adipocytes.	T6	T51	23002036
NA	CHEMICAL	GENE-N	20	16	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins gene (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T12	23002036
NA	CHEMICAL	GENE-Y	20	4	In addition, genes encoding gene (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T63	23002036
NA	CHEMICAL	GENE-Y	20	8	In addition, genes encoding tumor necrosis factor (TNF), gene (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T10	23002036
NA	CHEMICAL	GENE-N	20	29	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/gene were decreased in Retn(-/-) mice.	T2	T18	23002036
NA	CHEMICAL	GENE-Y	20	11	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (gene), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T11	23002036
NA	CHEMICAL	GENE-Y	20	29	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/gene were decreased in Retn(-/-) mice.	T2	T18	23002036
NA	CHEMICAL	GENE-N	20	19	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (gene)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of gene/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T13	23002036
NA	CHEMICAL	GENE-N	20	19	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (gene)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of gene/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T16	23002036
NA	CHEMICAL	GENE-Y	20	33	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in gene(-/-) mice.	T2	T19	23002036
NA	CHEMICAL	GENE-N	20	22	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (gene), were downregulated, and phosphorylated levels of SAPK/gene/c-Jun were decreased in Retn(-/-) mice.	T2	T15	23002036
NA	CHEMICAL	GENE-N	20	22	In addition, genes encoding tumor necrosis factor (TNF), TNF receptor 2 (TNFR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (gene), were downregulated, and phosphorylated levels of SAPK/gene/c-Jun were decreased in Retn(-/-) mice.	T2	T17	23002036
NA	CHEMICAL	GENE-Y	20	7	In addition, genes encoding tumor necrosis factor (gene), gene receptor 2 (geneR2), and the signaling proteins stress-activated protein kinase (SAPK)/Jun chemical-terminal kinase (JNK), were downregulated, and phosphorylated levels of SAPK/JNK/c-Jun were decreased in Retn(-/-) mice.	T2	T9	23002036
NA	CHEMICAL	GENE-N	8	11	Chromatin immunoprecipitation assays were used to identify a chemical (TPA)-response element (gene) responsible for c-Jun-mediated transcriptional activation of Gipr.	T3	T21	23002036
NA	CHEMICAL	GENE-N	8	14	Chromatin immunoprecipitation assays were used to identify a chemical (TPA)-response element (TRE-III) responsible for gene-mediated transcriptional activation of Gipr.	T3	T22	23002036
NA	CHEMICAL	GENE-Y	8	14	Chromatin immunoprecipitation assays were used to identify a chemical (TPA)-response element (TRE-III) responsible for gene-mediated transcriptional activation of Gipr.	T3	T22	23002036
NA	CHEMICAL	GENE-Y	8	18	Chromatin immunoprecipitation assays were used to identify a chemical (TPA)-response element (TRE-III) responsible for c-Jun-mediated transcriptional activation of gene.	T3	T23	23002036
NA	CHEMICAL	GENE-N	9	11	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (chemical)-response element (gene) responsible for c-Jun-mediated transcriptional activation of Gipr.	T4	T21	23002036
NA	CHEMICAL	GENE-N	9	14	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (chemical)-response element (TRE-III) responsible for gene-mediated transcriptional activation of Gipr.	T4	T22	23002036
NA	CHEMICAL	GENE-Y	9	14	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (chemical)-response element (TRE-III) responsible for gene-mediated transcriptional activation of Gipr.	T4	T22	23002036
NA	CHEMICAL	GENE-Y	9	18	Chromatin immunoprecipitation assays were used to identify a 12-O-tetradecanoylphorbol-13-acetate (chemical)-response element (TRE-III) responsible for c-Jun-mediated transcriptional activation of gene.	T4	T23	23002036
NA	CHEMICAL	GENE-Y	35	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and gene (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and chemical (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T10	T22	23008503
NA	CHEMICAL	GENE-Y	35	10	We examined in cats the 1) ulcerogenic effects of selective gene (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and chemical (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T10	T21	23008503
NA	CHEMICAL	GENE-N	35	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and chemical (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T10	T23	23008503
NA	CHEMICAL	GENE-N	35	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and chemical (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T10	T24	23008503
NA	CHEMICAL	GENE-Y	27	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and gene (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and chemical on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T9	T22	23008503
NA	CHEMICAL	GENE-Y	27	10	We examined in cats the 1) ulcerogenic effects of selective gene (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and chemical on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T9	T21	23008503
NA	CHEMICAL	GENE-N	27	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and chemical on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T9	T23	23008503
NA	CHEMICAL	GENE-N	27	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and chemical on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T9	T24	23008503
CPR:4	CHEMICAL	GENE-Y	15	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and gene (chemical, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T7	T22	23008503
NA	CHEMICAL	GENE-Y	15	10	We examined in cats the 1) ulcerogenic effects of selective gene (SC-560, ketorolac) and COX-2 (chemical, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T7	T21	23008503
NA	CHEMICAL	GENE-N	15	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (chemical, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T7	T23	23008503
NA	CHEMICAL	GENE-N	15	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (chemical, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T7	T24	23008503
CPR:4	CHEMICAL	GENE-Y	16	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and gene (celecoxib, chemical) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T8	T22	23008503
NA	CHEMICAL	GENE-Y	16	10	We examined in cats the 1) ulcerogenic effects of selective gene (SC-560, ketorolac) and COX-2 (celecoxib, chemical) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T8	T21	23008503
NA	CHEMICAL	GENE-N	16	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, chemical) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T8	T23	23008503
NA	CHEMICAL	GENE-N	16	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, chemical) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T8	T24	23008503
NA	CHEMICAL	GENE-Y	12	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, chemical) and gene (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T6	T22	23008503
CPR:4	CHEMICAL	GENE-Y	12	10	We examined in cats the 1) ulcerogenic effects of selective gene (SC-560, chemical) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T6	T21	23008503
NA	CHEMICAL	GENE-N	12	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, chemical) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T6	T23	23008503
NA	CHEMICAL	GENE-N	12	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, chemical) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T6	T24	23008503
NA	CHEMICAL	GENE-Y	11	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (chemical, ketorolac) and gene (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T5	T22	23008503
CPR:4	CHEMICAL	GENE-Y	11	10	We examined in cats the 1) ulcerogenic effects of selective gene (chemical, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T5	T21	23008503
NA	CHEMICAL	GENE-N	11	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (chemical, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T5	T23	23008503
NA	CHEMICAL	GENE-N	11	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (chemical, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T5	T24	23008503
NA	CHEMICAL	GENE-Y	37	14	We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and gene (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (chemical) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T11	T22	23008503
NA	CHEMICAL	GENE-Y	37	10	We examined in cats the 1) ulcerogenic effects of selective gene (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (chemical) level in the duodenum, and 3) localization of COX isoforms in the duodenum.	T11	T21	23008503
NA	CHEMICAL	GENE-N	37	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (chemical) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T11	T23	23008503
NA	CHEMICAL	GENE-N	37	10	We examined in cats the 1) ulcerogenic effects of selective gene-1 (SC-560, ketorolac) and gene-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of gene isoforms and prostaglandin E(2) (chemical) level in the duodenum, and 3) localization of gene isoforms in the duodenum.	T11	T24	23008503
NA	CHEMICAL	GENE-N	11	4	Localization and expression of gene isoforms (by immunohistochemistry, Western blot) and chemical level (by enzyme immunoassay) were examined.	T12	T26	23008503
CPR:4	CHEMICAL	GENE-N	24	7	Second, feeding increased both the expression of gene isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with chemical.	T4	T14	23008503
NA	CHEMICAL	GENE-N	10	7	Second, feeding increased both the expression of gene isoforms and chemical level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine.	T3	T14	23008503
NA	CHEMICAL	GENE-N	33	7	DIR is mediated by phospholipase C and gene (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or chemical receptors.	T7	T20	23019137
NA	CHEMICAL	GENE-N	33	20	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and gene, or by D2 stimulation concurrent with activation of 5-HT(2) or chemical receptors.	T7	T23	23019137
NA	CHEMICAL	GENE-N	33	4	DIR is mediated by gene and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or chemical receptors.	T7	T19	23019137
NA	CHEMICAL	GENE-N	33	31	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of gene or chemical receptors.	T7	T25	23019137
NA	CHEMICAL	GENE-N	33	13	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (gene) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of 5-HT(2) or chemical receptors.	T7	T21	23019137
NA	CHEMICAL	GENE-Y	33	18	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of gene and D1-like DA receptors, or by gene stimulation concurrent with activation of 5-HT(2) or chemical receptors.	T7	T22	23019137
NA	CHEMICAL	GENE-Y	33	18	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of gene and D1-like DA receptors, or by gene stimulation concurrent with activation of 5-HT(2) or chemical receptors.	T7	T24	23019137
NA	CHEMICAL	GENE-N	31	7	DIR is mediated by phospholipase C and gene (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of chemical(2) or neurotensin receptors.	T6	T20	23019137
NA	CHEMICAL	GENE-N	31	33	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of chemical(2) or gene.	T6	T26	23019137
NA	CHEMICAL	GENE-N	31	20	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and gene, or by D2 stimulation concurrent with activation of chemical(2) or neurotensin receptors.	T6	T23	23019137
NA	CHEMICAL	GENE-N	31	4	DIR is mediated by gene and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of chemical(2) or neurotensin receptors.	T6	T19	23019137
NA	CHEMICAL	GENE-Y	31	33	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of chemical(2) or gene receptors.	T6	T7	23019137
NA	CHEMICAL	GENE-N	31	13	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (gene) through concurrent stimulation of D2 and D1-like DA receptors, or by D2 stimulation concurrent with activation of chemical(2) or neurotensin receptors.	T6	T21	23019137
NA	CHEMICAL	GENE-Y	31	18	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of gene and D1-like DA receptors, or by gene stimulation concurrent with activation of chemical(2) or neurotensin receptors.	T6	T22	23019137
NA	CHEMICAL	GENE-Y	31	18	DIR is mediated by phospholipase C and conventional subtype of protein kinase C (cPKC) through concurrent stimulation of gene and D1-like DA receptors, or by gene stimulation concurrent with activation of chemical(2) or neurotensin receptors.	T6	T24	23019137
CPR:3	CHEMICAL	GENE-Y	15	4	Reversal of inhibition by gene agonist quinpirole was produced by serotonin (50 M) and by chemical (5-10 nM).	T10	T32	23019137
NA	CHEMICAL	GENE-Y	15	4	Reversal of inhibition by gene agonist quinpirole was produced by serotonin (50 M) and by chemical (5-10 nM).	T33	T32	23019137
NA	CHEMICAL	GENE-Y	6	15	Reversal of inhibition by D2 agonist chemical was produced by serotonin (50 M) and by gene (5-10 nM).	T8	T10	23019137
NA	CHEMICAL	GENE-Y	6	15	Reversal of inhibition by D2 agonist chemical was produced by serotonin (50 M) and by gene (5-10 nM).	T8	T33	23019137
CPR:5	CHEMICAL	GENE-Y	6	4	Reversal of inhibition by gene agonist chemical was produced by serotonin (50 M) and by neurotensin (5-10 nM).	T8	T32	23019137
NA	CHEMICAL	GENE-Y	10	15	Reversal of inhibition by D2 agonist quinpirole was produced by chemical (50 M) and by gene (5-10 nM).	T9	T10	23019137
NA	CHEMICAL	GENE-Y	10	15	Reversal of inhibition by D2 agonist quinpirole was produced by chemical (50 M) and by gene (5-10 nM).	T9	T33	23019137
CPR:3	CHEMICAL	GENE-Y	10	4	Reversal of inhibition by gene agonist quinpirole was produced by chemical (50 M) and by neurotensin (5-10 nM).	T9	T32	23019137
NA	CHEMICAL	GENE-Y	13	2	Serotonin-induced or gene-induced reversal was blocked by -ARK1 inhibitor, dynasore, or cPKC antagonist chemical (G6976).	T3	T12	23019137
NA	CHEMICAL	GENE-Y	13	2	Serotonin-induced or gene-induced reversal was blocked by -ARK1 inhibitor, dynasore, or cPKC antagonist chemical (G6976).	T3	T2	23019137
CPR:6	CHEMICAL	GENE-N	13	11	Serotonin-induced or neurotensin-induced reversal was blocked by -ARK1 inhibitor, dynasore, or gene antagonist chemical (G6976).	T3	T13	23019137
NA	CHEMICAL	GENE-N	2	11	Serotonin-induced or chemical-induced reversal was blocked by -ARK1 inhibitor, dynasore, or gene antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G6976).	T12	T13	23019137
NA	CHEMICAL	GENE-N	2	11	Serotonin-induced or chemical-induced reversal was blocked by -ARK1 inhibitor, dynasore, or gene antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G6976).	T2	T13	23019137
NA	CHEMICAL	GENE-Y	0	2	chemical-induced or gene-induced reversal was blocked by -ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G6976).	T1	T12	23019137
NA	CHEMICAL	GENE-Y	0	2	chemical-induced or gene-induced reversal was blocked by -ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G6976).	T1	T2	23019137
NA	CHEMICAL	GENE-N	0	11	chemical-induced or neurotensin-induced reversal was blocked by -ARK1 inhibitor, dynasore, or gene antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (G6976).	T1	T13	23019137
NA	CHEMICAL	GENE-Y	14	2	Serotonin-induced or gene-induced reversal was blocked by -ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (chemical).	T4	T12	23019137
NA	CHEMICAL	GENE-Y	14	2	Serotonin-induced or gene-induced reversal was blocked by -ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (chemical).	T4	T2	23019137
CPR:6	CHEMICAL	GENE-N	14	11	Serotonin-induced or neurotensin-induced reversal was blocked by -ARK1 inhibitor, dynasore, or gene antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (chemical).	T4	T13	23019137
NA	CHEMICAL	GENE-Y	20	5	RSV targets and activates the gene; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial chemical dismutase (SOD2).	T19	T40	23042952
NA	CHEMICAL	GENE-Y	20	8	RSV targets and activates the NAD(+)-dependent protein deacetylase gene; in turn, gene induces an intracellular antioxidative mechanism by inducing mitochondrial chemical dismutase (SOD2).	T19	T41	23042952
NA	CHEMICAL	GENE-Y	20	22	RSV targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial chemical dismutase (gene).	T19	T43	23042952
NA	CHEMICAL	GENE-Y	5	19	RSV targets and activates the chemical-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing gene (SOD2).	T16	T42	23042952
NA	CHEMICAL	GENE-Y	5	8	RSV targets and activates the chemical-dependent protein deacetylase gene; in turn, gene induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	T16	T41	23042952
NA	CHEMICAL	GENE-Y	5	22	RSV targets and activates the chemical-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (gene).	T16	T43	23042952
CPR:3	CHEMICAL	GENE-Y	0	5	chemical targets and activates the gene; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	T8	T40	23042952
CPR:3	CHEMICAL	GENE-Y	0	19	chemical targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing gene (SOD2).	T8	T42	23042952
CPR:3	CHEMICAL	GENE-Y	0	8	chemical targets and activates the NAD(+)-dependent protein deacetylase gene; in turn, gene induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (SOD2).	T8	T41	23042952
CPR:3	CHEMICAL	GENE-Y	0	22	chemical targets and activates the NAD(+)-dependent protein deacetylase SIRT1; in turn, SIRT1 induces an intracellular antioxidative mechanism by inducing mitochondrial superoxide dismutase (gene).	T8	T43	23042952
NA	CHEMICAL	GENE-N	1	7	However, chemical, but not 3G-RSV, induced SIRT1-dependent gene deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.	T35	T46	23042952
NA	CHEMICAL	GENE-Y	1	6	However, chemical, but not 3G-RSV, induced gene-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, gene knockdown blunted these effects.	T35	T39	23042952
CPR:3	CHEMICAL	GENE-Y	1	6	However, chemical, but not 3G-RSV, induced gene-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, gene knockdown blunted these effects.	T35	T45	23042952
CPR:3	CHEMICAL	GENE-Y	1	11	However, chemical, but not 3G-RSV, induced SIRT1-dependent histone H3 deacetylation and gene expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.	T35	T47	23042952
NA	CHEMICAL	GENE-N	4	7	However, 4'G-RSV, but not chemical, induced SIRT1-dependent gene deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.	T36	T46	23042952
NA	CHEMICAL	GENE-Y	4	6	However, 4'G-RSV, but not chemical, induced gene-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, gene knockdown blunted these effects.	T36	T39	23042952
NA	CHEMICAL	GENE-Y	4	6	However, 4'G-RSV, but not chemical, induced gene-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with RSV, gene knockdown blunted these effects.	T36	T45	23042952
NA	CHEMICAL	GENE-Y	4	11	However, 4'G-RSV, but not chemical, induced SIRT1-dependent histone H3 deacetylation and gene expression in mouse C2C12 skeletal myoblasts; as with RSV, SIRT1 knockdown blunted these effects.	T36	T47	23042952
NA	CHEMICAL	GENE-N	1	7	However, 4'G-chemical, but not 3G-chemical, induced SIRT1-dependent gene deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with chemical, SIRT1 knockdown blunted these effects.	T2	T46	23042952
NA	CHEMICAL	GENE-Y	1	6	However, 4'G-chemical, but not 3G-chemical, induced gene-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with chemical, gene knockdown blunted these effects.	T2	T39	23042952
NA	CHEMICAL	GENE-Y	1	6	However, 4'G-chemical, but not 3G-chemical, induced gene-dependent histone H3 deacetylation and SOD2 expression in mouse C2C12 skeletal myoblasts; as with chemical, gene knockdown blunted these effects.	T2	T45	23042952
NA	CHEMICAL	GENE-Y	1	11	However, 4'G-chemical, but not 3G-chemical, induced SIRT1-dependent histone H3 deacetylation and gene expression in mouse C2C12 skeletal myoblasts; as with chemical, SIRT1 knockdown blunted these effects.	T2	T47	23042952
CPR:9	CHEMICAL	GENE-Y	7	2	The bihelical gene effluxes chemical from cells and reduces inflammation and atherosclerosis in animal models.	T5	T12	23042953
CPR:9	CHEMICAL	GENE-Y	25	28	Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing chemical by the gene transporter.	T7	T14	23042953
NA	CHEMICAL	GENE-N	38	10	These results provide a rationale for future design of therapeutic gene mimetic peptides and provide new insights into the interaction of hydrophobic residues on genes with phospholipids in the lipid microdomain created by the ABCA1 transporter during the chemical efflux process.	T3	T11	23042953
CPR:9	CHEMICAL	GENE-Y	38	34	These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the gene transporter during the chemical efflux process.	T3	T13	23042953
CPR:6	CHEMICAL	GENE-N	30	25	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/gene antagonist chemical (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T10	T16	23042954
CPR:6	CHEMICAL	GENE-Y	30	25	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (gene)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist chemical (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T10	T15	23042954
CPR:6	CHEMICAL	GENE-Y	30	24	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the gene (GluR5)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist chemical (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T10	T14	23042954
NA	CHEMICAL	GENE-Y	25	25	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (gene)/chemical (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T8	T15	23042954
NA	CHEMICAL	GENE-Y	25	24	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the gene (GluR5)/chemical (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T8	T14	23042954
CPR:6	CHEMICAL	GENE-N	32	25	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/gene antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (chemical) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T11	T16	23042954
CPR:6	CHEMICAL	GENE-Y	32	25	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (gene)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (chemical) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T11	T15	23042954
CPR:6	CHEMICAL	GENE-Y	32	24	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the gene (GluR5)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (chemical) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T11	T14	23042954
NA	CHEMICAL	GENE-Y	27	25	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (gene)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (chemical) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T9	T15	23042954
NA	CHEMICAL	GENE-Y	27	24	To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the gene (GluR5)/-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (chemical) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.	T9	T14	23042954
NA	CHEMICAL	GENE-Y	0	13	chemical-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old gene-Cnn1 mice, and increased numbers of osteoclasts co-cultured with gene-Cnn1 osteoblasts.	T1	T5	23044709
NA	CHEMICAL	GENE-Y	0	13	chemical-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old gene-Cnn1 mice, and increased numbers of osteoclasts co-cultured with gene-Cnn1 osteoblasts.	T1	T7	23044709
NA	CHEMICAL	GENE-Y	0	3	chemical-resistant acid phosphatase (gene) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-Cnn1 mice, and increased numbers of osteoclasts co-cultured with Col1a1-Cnn1 osteoblasts.	T1	T4	23044709
NA	CHEMICAL	GENE-Y	0	13	chemical-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-gene mice, and increased numbers of osteoclasts co-cultured with Col1a1-gene osteoblasts.	T1	T6	23044709
NA	CHEMICAL	GENE-Y	0	13	chemical-resistant acid phosphatase (TRAP) staining revealed increased osteoclast numbers in tibias of 2-month-old Col1a1-gene mice, and increased numbers of osteoclasts co-cultured with Col1a1-gene osteoblasts.	T1	T8	23044709
CPR:9	CHEMICAL	GENE-Y	1	2	Although chemicalsterase (gene) is primarily a hydrolytic enzyme, metabolising the neurotransmitter chemical in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.	T1	T24	23047022
NA	CHEMICAL	GENE-N	17	6	Since AChE does not possess a gene, its anchorage in the membrane is established via the chemical Rich Membrane Anchor (PRiMA), a transmembrane protein.	T11	T28	23047022
NA	CHEMICAL	GENE-Y	17	21	Since AChE does not possess a transmembrane domain, its anchorage in the membrane is established via the chemical Rich Membrane Anchor (gene), a transmembrane protein.	T11	T30	23047022
NA	CHEMICAL	GENE-Y	17	1	Since gene does not possess a transmembrane domain, its anchorage in the membrane is established via the chemical Rich Membrane Anchor (PRiMA), a transmembrane protein.	T11	T27	23047022
NA	CHEMICAL	GENE-N	31	42	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and chemical-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a gene.	T3	T14	23047022
NA	CHEMICAL	GENE-N	31	34	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and chemical-sensitive, but GM6001-insensitive gene, with the possible additional involvement of a thiol isomerase.	T3	T13	23047022
NA	CHEMICAL	GENE-Y	31	9	In an effort to understand the shedding process of gene, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and chemical-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.	T3	T12	23047022
NA	CHEMICAL	GENE-N	33	42	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but chemical-insensitive metalloprotease, with the possible additional involvement of a gene.	T4	T14	23047022
NA	CHEMICAL	GENE-N	33	34	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but chemical-insensitive gene, with the possible additional involvement of a thiol isomerase.	T4	T13	23047022
NA	CHEMICAL	GENE-Y	33	9	In an effort to understand the shedding process of gene, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but chemical-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.	T4	T12	23047022
NA	CHEMICAL	GENE-N	42	34	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive gene, with the possible additional involvement of a chemical isomerase.	T5	T13	23047022
NA	CHEMICAL	GENE-Y	42	9	In an effort to understand the shedding process of gene, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an EDTA- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a chemical isomerase.	T5	T12	23047022
NA	CHEMICAL	GENE-N	29	42	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an chemical- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a gene.	T2	T14	23047022
NA	CHEMICAL	GENE-N	29	34	In an effort to understand the shedding process of AChE, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an chemical- and batimastat-sensitive, but GM6001-insensitive gene, with the possible additional involvement of a thiol isomerase.	T2	T13	23047022
NA	CHEMICAL	GENE-Y	29	9	In an effort to understand the shedding process of gene, we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an chemical- and batimastat-sensitive, but GM6001-insensitive metalloprotease, with the possible additional involvement of a thiol isomerase.	T2	T12	23047022
NA	CHEMICAL	GENE-N	12	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic chemical receptor (gene) agonists carbachol or muscarine, with the effect of carbachol blocked by the gene antagonist atropine.	T6	T17	23047022
NA	CHEMICAL	GENE-N	12	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic chemical receptor (gene) agonists carbachol or muscarine, with the effect of carbachol blocked by the gene antagonist atropine.	T6	T18	23047022
NA	CHEMICAL	GENE-Y	12	3	Cellular release of gene by SH-SY5Y is significantly enhanced by the muscarinic chemical receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.	T6	T15	23047022
CPR:5	CHEMICAL	GENE-N	18	11	Cellular release of AChE by SH-SY5Y is significantly enhanced by the gene (mAChR) agonists carbachol or chemical, with the effect of carbachol blocked by the mAChR antagonist atropine.	T8	T16	23047022
CPR:5	CHEMICAL	GENE-N	18	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists carbachol or chemical, with the effect of carbachol blocked by the gene antagonist atropine.	T8	T17	23047022
NA	CHEMICAL	GENE-N	18	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists carbachol or chemical, with the effect of carbachol blocked by the gene antagonist atropine.	T8	T18	23047022
CPR:3	CHEMICAL	GENE-Y	18	3	Cellular release of gene by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or chemical, with the effect of carbachol blocked by the mAChR antagonist atropine.	T8	T15	23047022
CPR:5	CHEMICAL	GENE-N	16	11	Cellular release of AChE by SH-SY5Y is significantly enhanced by the gene (mAChR) agonists chemical or muscarine, with the effect of chemical blocked by the mAChR antagonist atropine.	T7	T16	23047022
NA	CHEMICAL	GENE-N	16	11	Cellular release of AChE by SH-SY5Y is significantly enhanced by the gene (mAChR) agonists chemical or muscarine, with the effect of chemical blocked by the mAChR antagonist atropine.	T9	T16	23047022
CPR:5	CHEMICAL	GENE-N	16	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists chemical or muscarine, with the effect of chemical blocked by the gene antagonist atropine.	T7	T17	23047022
NA	CHEMICAL	GENE-N	16	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists chemical or muscarine, with the effect of chemical blocked by the gene antagonist atropine.	T7	T18	23047022
NA	CHEMICAL	GENE-N	16	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists chemical or muscarine, with the effect of chemical blocked by the gene antagonist atropine.	T9	T17	23047022
NA	CHEMICAL	GENE-N	16	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists chemical or muscarine, with the effect of chemical blocked by the gene antagonist atropine.	T9	T18	23047022
CPR:3	CHEMICAL	GENE-Y	16	3	Cellular release of gene by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists chemical or muscarine, with the effect of chemical blocked by the mAChR antagonist atropine.	T7	T15	23047022
CPR:3	CHEMICAL	GENE-Y	16	3	Cellular release of gene by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists chemical or muscarine, with the effect of chemical blocked by the mAChR antagonist atropine.	T9	T15	23047022
NA	CHEMICAL	GENE-N	29	11	Cellular release of AChE by SH-SY5Y is significantly enhanced by the gene (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist chemical.	T10	T16	23047022
NA	CHEMICAL	GENE-N	29	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists carbachol or muscarine, with the effect of carbachol blocked by the gene antagonist chemical.	T10	T17	23047022
CPR:6	CHEMICAL	GENE-N	29	14	Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (gene) agonists carbachol or muscarine, with the effect of carbachol blocked by the gene antagonist chemical.	T10	T18	23047022
CPR:4	CHEMICAL	GENE-Y	29	3	Cellular release of gene by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist chemical.	T10	T15	23047022
NA	CHEMICAL	GENE-Y	9	19	Apart from their role in cardiovascular homeostasis and immunomodulation, chemical and cortisol are also implicated in the pathogenesis of gene resistance and type 2 diabetes mellitus (T2DM).	T9	T22	23047828
NA	CHEMICAL	GENE-Y	11	19	Apart from their role in cardiovascular homeostasis and immunomodulation, aldosterone and chemical are also implicated in the pathogenesis of gene resistance and type 2 diabetes mellitus (T2DM).	T11	T22	23047828
NA	CHEMICAL	GENE-N	8	0	gene induced a greater stimulating effect on adrenocortical chemical and cortisol release compared to HDL and LDL.	T3	T15	23047828
NA	CHEMICAL	GENE-N	8	0	Vgene induced a greater stimulating effect on adrenocortical chemical and cortisol release compared to HDL and gene.	T3	T17	23047828
NA	CHEMICAL	GENE-N	8	14	VLDL induced a greater stimulating effect on adrenocortical chemical and cortisol release compared to gene and LDL.	T3	T16	23047828
NA	CHEMICAL	GENE-N	10	0	gene induced a greater stimulating effect on adrenocortical aldosterone and chemical release compared to HDL and LDL.	T4	T15	23047828
NA	CHEMICAL	GENE-N	10	0	Vgene induced a greater stimulating effect on adrenocortical aldosterone and chemical release compared to HDL and gene.	T4	T17	23047828
NA	CHEMICAL	GENE-N	10	14	VLDL induced a greater stimulating effect on adrenocortical aldosterone and chemical release compared to gene and LDL.	T4	T16	23047828
CPR:3	CHEMICAL	GENE-N	2	11	Nevertheless, low chemical concentrations ( 0.1mM, 48 h) increased protein ubiquitination, gene and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2 in SH-SY5Y cells.	T15	T17	23047912
CPR:3	CHEMICAL	GENE-Y	2	14	Nevertheless, low chemical concentrations ( 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and gene activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of elf2 in SH-SY5Y cells.	T15	T18	23047912
CPR:3	CHEMICAL	GENE-Y	2	30	Nevertheless, low chemical concentrations ( 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker CHOP, and enhanced phosphorylation of gene in SH-SY5Y cells.	T15	T20	23047912
CPR:3	CHEMICAL	GENE-Y	2	25	Nevertheless, low chemical concentrations ( 0.1mM, 48 h) increased protein ubiquitination, 20S proteasomal and caspase 12 activity, expression of the endoplasmic reticulum (ER) stress marker gene, and enhanced phosphorylation of elf2 in SH-SY5Y cells.	T15	T19	23047912
NA	CHEMICAL	GENE-Y	6	0	gene (Factor VII) is a chemical-dependent glycoprotein synthesized in hepatocytes.	T7	T19	23050902
NA	CHEMICAL	GENE-Y	6	2	Coagulation FVII (gene) is a chemical-dependent glycoprotein synthesized in hepatocytes.	T7	T36	23050902
CPR:3	CHEMICAL	GENE-Y	12	5	It was reported previously that gene gene (F7) expression was up-regulated by chemical treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.	T6	T28	23050902
CPR:3	CHEMICAL	GENE-Y	12	7	It was reported previously that FVII gene (gene) expression was up-regulated by chemical treatment in hepatitis C virus-infected haemophilia patients; however, its precise mechanism is still unknown.	T6	T34	23050902
CPR:3	CHEMICAL	GENE-Y	10	13	In the present study, we investigated the molecular mechanism of chemical-induced up-regulation of gene expression in HepG2 (human hepatoma cell line).	T8	T37	23050902
NA	CHEMICAL	GENE-N	13	12	We found that intracellular GTP depletion by ribavirin as well as other gene (chemical dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	T11	T38	23050902
NA	CHEMICAL	GENE-Y	13	23	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (chemical dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated gene expression.	T11	T40	23050902
NA	CHEMICAL	GENE-N	18	13	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (gene) inhibitors, such as chemical and 6-mercaptopurine, up-regulated F7 expression.	T12	T39	23050902
NA	CHEMICAL	GENE-N	18	12	We found that intracellular GTP depletion by ribavirin as well as other gene (inosine-5'-monophosphate dehydrogenase) inhibitors, such as chemical and 6-mercaptopurine, up-regulated F7 expression.	T12	T38	23050902
CPR:3	CHEMICAL	GENE-Y	18	23	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as chemical and 6-mercaptopurine, up-regulated gene expression.	T12	T40	23050902
NA	CHEMICAL	GENE-N	21	13	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (gene) inhibitors, such as mycophenolic acid and chemical, up-regulated F7 expression.	T13	T39	23050902
NA	CHEMICAL	GENE-N	21	12	We found that intracellular GTP depletion by ribavirin as well as other gene (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and chemical, up-regulated F7 expression.	T13	T38	23050902
CPR:3	CHEMICAL	GENE-Y	21	23	We found that intracellular GTP depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and chemical, up-regulated gene expression.	T13	T40	23050902
NA	CHEMICAL	GENE-N	7	13	We found that intracellular GTP depletion by chemical as well as other IMPDH (gene) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	T10	T39	23050902
NA	CHEMICAL	GENE-N	7	12	We found that intracellular GTP depletion by chemical as well as other gene (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	T10	T38	23050902
NA	CHEMICAL	GENE-Y	7	23	We found that intracellular GTP depletion by chemical as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated gene expression.	T10	T40	23050902
NA	CHEMICAL	GENE-N	4	13	We found that intracellular chemical depletion by ribavirin as well as other IMPDH (gene) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	T9	T39	23050902
NA	CHEMICAL	GENE-N	4	12	We found that intracellular chemical depletion by ribavirin as well as other gene (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated F7 expression.	T9	T38	23050902
NA	CHEMICAL	GENE-Y	4	23	We found that intracellular chemical depletion by ribavirin as well as other IMPDH (inosine-5'-monophosphate dehydrogenase) inhibitors, such as mycophenolic acid and 6-mercaptopurine, up-regulated gene expression.	T9	T40	23050902
CPR:3	CHEMICAL	GENE-Y	0	3	chemical unregulated ELL (gene mRNA expression before F7 up-regulation.	T14	T45	23050902
CPR:3	CHEMICAL	GENE-Y	0	2	chemical unregulated gene (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before F7 up-regulation.	T14	T44	23050902
CPR:3	CHEMICAL	GENE-Y	0	10	chemical unregulated ELL (eleven-nineteen lysine-rich leukaemia) 3 mRNA expression before gene up-regulation.	T14	T46	23050902
NA	CHEMICAL	GENE-Y	4	2	Ribavirin unregulated gene (eleven-nineteen chemical-rich leukaemia) 3 mRNA expression before F7 up-regulation.	T15	T44	23050902
NA	CHEMICAL	GENE-Y	4	10	Ribavirin unregulated ELL (eleven-nineteen chemical-rich leukaemia) 3 mRNA expression before gene up-regulation.	T15	T46	23050902
NA	CHEMICAL	GENE-Y	3	15	We observed that chemical enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished chemical-induced gene mRNA up-regulation.	T16	T23	23050902
CPR:3	CHEMICAL	GENE-Y	3	15	We observed that chemical enhanced ELL3 recruitment to F7, whereas knockdown of ELL3 diminished chemical-induced gene mRNA up-regulation.	T1	T23	23050902
CPR:3	CHEMICAL	GENE-Y	3	5	We observed that chemical enhanced gene recruitment to F7, whereas knockdown of gene diminished chemical-induced FVII mRNA up-regulation.	T16	T20	23050902
NA	CHEMICAL	GENE-Y	3	5	We observed that chemical enhanced gene recruitment to F7, whereas knockdown of gene diminished chemical-induced FVII mRNA up-regulation.	T16	T22	23050902
NA	CHEMICAL	GENE-Y	3	5	We observed that chemical enhanced gene recruitment to F7, whereas knockdown of gene diminished chemical-induced FVII mRNA up-regulation.	T1	T20	23050902
NA	CHEMICAL	GENE-Y	3	5	We observed that chemical enhanced gene recruitment to F7, whereas knockdown of gene diminished chemical-induced FVII mRNA up-regulation.	T1	T22	23050902
CPR:3	CHEMICAL	GENE-Y	3	8	We observed that chemical enhanced ELL3 recruitment to gene, whereas knockdown of ELL3 diminished chemical-induced FVII mRNA up-regulation.	T16	T21	23050902
NA	CHEMICAL	GENE-Y	3	8	We observed that chemical enhanced ELL3 recruitment to gene, whereas knockdown of ELL3 diminished chemical-induced FVII mRNA up-regulation.	T1	T21	23050902
CPR:3	CHEMICAL	GENE-Y	0	6	chemical also enhanced recruitment of CDK9 (gene) and AFF4 to F7.	T2	T25	23050902
CPR:3	CHEMICAL	GENE-Y	0	10	chemical also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and gene to F7.	T2	T26	23050902
CPR:3	CHEMICAL	GENE-Y	0	5	chemical also enhanced recruitment of gene (cyclin-dependent kinase 9) and AFF4 to F7.	T2	T24	23050902
CPR:3	CHEMICAL	GENE-Y	0	12	chemical also enhanced recruitment of CDK9 (cyclin-dependent kinase 9) and AFF4 to gene.	T2	T27	23050902
CPR:3	CHEMICAL	GENE-N	4	14	These data suggest that chemical-induced intracellular GTP depletion recruits a super elongation complex containing gene, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.	T3	T29	23050902
NA	CHEMICAL	GENE-Y	4	22	These data suggest that chemical-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates gene mRNA transcription elongation.	T3	T33	23050902
CPR:3	CHEMICAL	GENE-Y	4	15	These data suggest that chemical-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, gene and ELL3, to F7, and modulates FVII mRNA transcription elongation.	T3	T30	23050902
CPR:3	CHEMICAL	GENE-Y	4	17	These data suggest that chemical-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and gene, to F7, and modulates FVII mRNA transcription elongation.	T3	T31	23050902
CPR:3	CHEMICAL	GENE-Y	4	19	These data suggest that chemical-induced intracellular GTP depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to gene, and modulates FVII mRNA transcription elongation.	T3	T32	23050902
NA	CHEMICAL	GENE-N	6	14	These data suggest that ribavirin-induced intracellular chemical depletion recruits a super elongation complex containing gene, AFF4 and ELL3, to F7, and modulates FVII mRNA transcription elongation.	T4	T29	23050902
NA	CHEMICAL	GENE-Y	6	22	These data suggest that ribavirin-induced intracellular chemical depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to F7, and modulates gene mRNA transcription elongation.	T4	T33	23050902
NA	CHEMICAL	GENE-Y	6	15	These data suggest that ribavirin-induced intracellular chemical depletion recruits a super elongation complex containing P-TEFb, gene and ELL3, to F7, and modulates FVII mRNA transcription elongation.	T4	T30	23050902
NA	CHEMICAL	GENE-Y	6	17	These data suggest that ribavirin-induced intracellular chemical depletion recruits a super elongation complex containing P-TEFb, AFF4 and gene, to F7, and modulates FVII mRNA transcription elongation.	T4	T31	23050902
NA	CHEMICAL	GENE-Y	6	19	These data suggest that ribavirin-induced intracellular chemical depletion recruits a super elongation complex containing P-TEFb, AFF4 and ELL3, to gene, and modulates FVII mRNA transcription elongation.	T4	T32	23050902
CPR:3	CHEMICAL	GENE-Y	8	9	Collectively, we have elucidated a basal mechanism for chemical-induced gene mRNA up-regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions invivo.	T5	T35	23050902
NA	CHEMICAL	GENE-N	20	11	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and gene (CREB) are involved in regulating chemical (PPA)-mediated appetite suppression.	T3	T34	23052195
NA	CHEMICAL	GENE-Y	20	7	It has been reported that antioxidative enzymes, gene (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating chemical (PPA)-mediated appetite suppression.	T3	T28	23052195
NA	CHEMICAL	GENE-N	20	15	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (gene) are involved in regulating chemical (PPA)-mediated appetite suppression.	T3	T17	23052195
NA	CHEMICAL	GENE-Y	20	9	It has been reported that antioxidative enzymes, neuropeptide Y (gene), and c-AMP response element-binding protein (CREB) are involved in regulating chemical (PPA)-mediated appetite suppression.	T3	T30	23052195
NA	CHEMICAL	GENE-Y	11	7	It has been reported that antioxidative enzymes, gene (NPY), and chemical response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	T8	T28	23052195
NA	CHEMICAL	GENE-N	11	15	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and chemical response element-binding protein (gene) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	T8	T17	23052195
NA	CHEMICAL	GENE-Y	11	9	It has been reported that antioxidative enzymes, neuropeptide Y (gene), and chemical response element-binding protein (CREB) are involved in regulating phenylpropanolamine (PPA)-mediated appetite suppression.	T8	T30	23052195
NA	CHEMICAL	GENE-N	21	11	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and gene (CREB) are involved in regulating phenylpropanolamine (chemical)-mediated appetite suppression.	T4	T34	23052195
NA	CHEMICAL	GENE-Y	21	7	It has been reported that antioxidative enzymes, gene (NPY), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (chemical)-mediated appetite suppression.	T4	T28	23052195
NA	CHEMICAL	GENE-N	21	15	It has been reported that antioxidative enzymes, neuropeptide Y (NPY), and c-AMP response element-binding protein (gene) are involved in regulating phenylpropanolamine (chemical)-mediated appetite suppression.	T4	T17	23052195
NA	CHEMICAL	GENE-Y	21	9	It has been reported that antioxidative enzymes, neuropeptide Y (gene), and c-AMP response element-binding protein (CREB) are involved in regulating phenylpropanolamine (chemical)-mediated appetite suppression.	T4	T30	23052195
NA	CHEMICAL	GENE-N	7	11	Changes in the contents of NPY, Y1R, chemical peroxidase (GP), and gene were assessed and compared.	T6	T24	23052195
NA	CHEMICAL	GENE-Y	7	5	Changes in the contents of gene, Y1R, chemical peroxidase (GP), and CREB were assessed and compared.	T6	T20	23052195
NA	CHEMICAL	GENE-Y	7	6	Changes in the contents of NPY, gene, chemical peroxidase (GP), and CREB were assessed and compared.	T6	T21	23052195
NA	CHEMICAL	GENE-N	7	9	Changes in the contents of NPY, Y1R, chemical peroxidase (gene), and CREB were assessed and compared.	T6	T23	23052195
NA	CHEMICAL	GENE-N	19	29	By contrast, NPY decreased with a biggest reduction about 48% on Day 2 and the pattern of expression during chemical treatment was opposite to those of Y1R, GP, and gene.	T7	T33	23052195
NA	CHEMICAL	GENE-Y	19	2	By contrast, gene decreased with a biggest reduction about 48% on Day 2 and the pattern of expression during chemical treatment was opposite to those of Y1R, GP, and CREB.	T7	T29	23052195
NA	CHEMICAL	GENE-Y	19	26	By contrast, NPY decreased with a biggest reduction about 48% on Day 2 and the pattern of expression during chemical treatment was opposite to those of gene, GP, and CREB.	T7	T31	23052195
NA	CHEMICAL	GENE-N	19	27	By contrast, NPY decreased with a biggest reduction about 48% on Day 2 and the pattern of expression during chemical treatment was opposite to those of Y1R, gene, and CREB.	T7	T32	23052195
NA	CHEMICAL	GENE-N	16	26	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of chemical and the reciprocal regulation between NPY and GP (or gene), revealing an essential role of Y1R in regulating NPY, GP, and gene.	T9	T38	23052195
NA	CHEMICAL	GENE-N	16	26	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of chemical and the reciprocal regulation between NPY and GP (or gene), revealing an essential role of Y1R in regulating NPY, GP, and gene.	T9	T42	23052195
NA	CHEMICAL	GENE-Y	16	22	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of chemical and the reciprocal regulation between gene and GP (or CREB), revealing an essential role of Y1R in regulating gene, GP, and CREB.	T9	T36	23052195
NA	CHEMICAL	GENE-Y	16	22	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of chemical and the reciprocal regulation between gene and GP (or CREB), revealing an essential role of Y1R in regulating gene, GP, and CREB.	T9	T40	23052195
NA	CHEMICAL	GENE-Y	16	9	Central knockdown (using antisense) or inhibition (using antagonist) of gene expression modulated the anorectic response of chemical and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of gene in regulating NPY, GP, and CREB.	T9	T35	23052195
NA	CHEMICAL	GENE-Y	16	9	Central knockdown (using antisense) or inhibition (using antagonist) of gene expression modulated the anorectic response of chemical and the reciprocal regulation between NPY and GP (or CREB), revealing an essential role of gene in regulating NPY, GP, and CREB.	T9	T39	23052195
NA	CHEMICAL	GENE-N	16	24	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of chemical and the reciprocal regulation between NPY and gene (or CREB), revealing an essential role of Y1R in regulating NPY, gene, and CREB.	T9	T37	23052195
NA	CHEMICAL	GENE-N	16	24	Central knockdown (using antisense) or inhibition (using antagonist) of Y1R expression modulated the anorectic response of chemical and the reciprocal regulation between NPY and gene (or CREB), revealing an essential role of Y1R in regulating NPY, gene, and CREB.	T9	T41	23052195
NA	CHEMICAL	GENE-N	19	14	These results suggest that Y1R participates in the reciprocal regulation of NPY, GP, and gene in the hypothalamus during chemical treatment in conscious rats.	T1	T16	23052195
NA	CHEMICAL	GENE-Y	19	11	These results suggest that Y1R participates in the reciprocal regulation of gene, GP, and CREB in the hypothalamus during chemical treatment in conscious rats.	T1	T14	23052195
NA	CHEMICAL	GENE-Y	19	4	These results suggest that gene participates in the reciprocal regulation of NPY, GP, and CREB in the hypothalamus during chemical treatment in conscious rats.	T1	T13	23052195
NA	CHEMICAL	GENE-N	19	12	These results suggest that Y1R participates in the reciprocal regulation of NPY, gene, and CREB in the hypothalamus during chemical treatment in conscious rats.	T1	T15	23052195
NA	CHEMICAL	GENE-N	7	0	gene (KARs), a family of ionotropic chemical receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	T15	T20	23066089
NA	CHEMICAL	GENE-N	7	2	Kainate receptors (gene), a family of ionotropic chemical receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	T15	T35	23066089
NA	CHEMICAL	GENE-N	0	6	chemical receptors (KARs), a family of gene, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	T1	T40	23066089
NA	CHEMICAL	GENE-N	0	2	chemical receptors (gene), a family of ionotropic glutamate receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	T1	T35	23066089
NA	CHEMICAL	GENE-N	6	8	KAR activation is influenced by metabotropic chemical receptor (gene) signaling, but the underlying mechanisms are not understood.	T14	T37	23066089
NA	CHEMICAL	GENE-N	6	0	gene activation is influenced by metabotropic chemical receptor (mGlu) signaling, but the underlying mechanisms are not understood.	T14	T34	23066089
NA	CHEMICAL	GENE-N	6	19	In hippocampal and cortical cultures, the chemical signal caused by activation of native KARs was potentiated by activation of gene.	T16	T44	23066089
NA	CHEMICAL	GENE-N	6	13	In hippocampal and cortical cultures, the chemical signal caused by activation of native gene was potentiated by activation of group I mGlu receptors.	T16	T43	23066089
NA	CHEMICAL	GENE-N	23	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T23	23066089
NA	CHEMICAL	GENE-N	23	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T49	23066089
NA	CHEMICAL	GENE-N	23	37	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the gene inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T22	23066089
NA	CHEMICAL	GENE-N	23	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the gene inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T21	23066089
NA	CHEMICAL	GENE-Y	23	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T2	T27	23066089
NA	CHEMICAL	GENE-Y	23	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T2	T30	23066089
NA	CHEMICAL	GENE-Y	23	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T25	23066089
CPR:4	CHEMICAL	GENE-Y	23	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T48	23066089
NA	CHEMICAL	GENE-Y	23	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T2	T26	23066089
NA	CHEMICAL	GENE-Y	23	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T2	T29	23066089
CPR:4	CHEMICAL	GENE-N	23	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T47	23066089
NA	CHEMICAL	GENE-N	23	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T24	23066089
NA	CHEMICAL	GENE-N	23	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator chemical (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T2	T28	23066089
NA	CHEMICAL	GENE-N	61	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T23	23066089
NA	CHEMICAL	GENE-N	61	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T49	23066089
NA	CHEMICAL	GENE-N	61	37	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the gene inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T22	23066089
NA	CHEMICAL	GENE-N	61	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the gene inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T21	23066089
NA	CHEMICAL	GENE-Y	61	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by chemical potentiated GluK2/gene.	T7	T27	23066089
CPR:3	CHEMICAL	GENE-Y	61	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by chemical potentiated GluK2/gene.	T7	T30	23066089
NA	CHEMICAL	GENE-Y	61	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T25	23066089
NA	CHEMICAL	GENE-Y	61	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T48	23066089
NA	CHEMICAL	GENE-Y	61	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by chemical potentiated gene/GluK5.	T7	T26	23066089
CPR:3	CHEMICAL	GENE-Y	61	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by chemical potentiated gene/GluK5.	T7	T29	23066089
NA	CHEMICAL	GENE-N	61	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by chemical potentiated GluK2/GluK5.	T7	T47	23066089
NA	CHEMICAL	GENE-N	61	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by chemical potentiated GluK2/GluK5.	T7	T24	23066089
CPR:3	CHEMICAL	GENE-N	61	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by chemical potentiated GluK2/GluK5.	T7	T28	23066089
NA	CHEMICAL	GENE-N	40	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T23	23066089
NA	CHEMICAL	GENE-N	40	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T49	23066089
CPR:4	CHEMICAL	GENE-N	40	37	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the gene inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T22	23066089
NA	CHEMICAL	GENE-N	40	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the gene inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T21	23066089
NA	CHEMICAL	GENE-Y	40	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T6	T27	23066089
NA	CHEMICAL	GENE-Y	40	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T6	T30	23066089
NA	CHEMICAL	GENE-Y	40	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T25	23066089
CPR:4	CHEMICAL	GENE-Y	40	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T48	23066089
NA	CHEMICAL	GENE-Y	40	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T6	T26	23066089
NA	CHEMICAL	GENE-Y	40	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T6	T29	23066089
CPR:4	CHEMICAL	GENE-N	40	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T47	23066089
NA	CHEMICAL	GENE-N	40	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T24	23066089
NA	CHEMICAL	GENE-N	40	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor chemical. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T6	T28	23066089
NA	CHEMICAL	GENE-N	31	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T23	23066089
NA	CHEMICAL	GENE-N	31	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T49	23066089
NA	CHEMICAL	GENE-N	31	37	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the gene inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T22	23066089
CPR:4	CHEMICAL	GENE-N	31	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the gene inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T21	23066089
NA	CHEMICAL	GENE-Y	31	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T4	T27	23066089
NA	CHEMICAL	GENE-Y	31	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T4	T30	23066089
NA	CHEMICAL	GENE-Y	31	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T25	23066089
CPR:4	CHEMICAL	GENE-Y	31	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T48	23066089
NA	CHEMICAL	GENE-Y	31	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T4	T26	23066089
NA	CHEMICAL	GENE-Y	31	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T4	T29	23066089
CPR:4	CHEMICAL	GENE-N	31	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T47	23066089
NA	CHEMICAL	GENE-N	31	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T24	23066089
NA	CHEMICAL	GENE-N	31	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor chemical, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T4	T28	23066089
NA	CHEMICAL	GENE-N	37	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T23	23066089
NA	CHEMICAL	GENE-N	37	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T49	23066089
NA	CHEMICAL	GENE-N	37	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the gene inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T21	23066089
NA	CHEMICAL	GENE-Y	37	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T5	T27	23066089
NA	CHEMICAL	GENE-Y	37	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T5	T30	23066089
NA	CHEMICAL	GENE-Y	37	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T25	23066089
NA	CHEMICAL	GENE-Y	37	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T48	23066089
NA	CHEMICAL	GENE-Y	37	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T5	T26	23066089
NA	CHEMICAL	GENE-Y	37	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T5	T29	23066089
NA	CHEMICAL	GENE-N	37	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T47	23066089
NA	CHEMICAL	GENE-N	37	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T24	23066089
NA	CHEMICAL	GENE-N	37	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the chemical kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T5	T28	23066089
NA	CHEMICAL	GENE-N	21	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T23	23066089
NA	CHEMICAL	GENE-N	21	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T49	23066089
NA	CHEMICAL	GENE-N	21	37	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the gene inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T22	23066089
NA	CHEMICAL	GENE-N	21	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the gene inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T21	23066089
NA	CHEMICAL	GENE-Y	21	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T17	T27	23066089
NA	CHEMICAL	GENE-Y	21	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T17	T30	23066089
NA	CHEMICAL	GENE-Y	21	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T25	23066089
NA	CHEMICAL	GENE-Y	21	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T48	23066089
NA	CHEMICAL	GENE-Y	21	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T17	T26	23066089
NA	CHEMICAL	GENE-Y	21	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T17	T29	23066089
NA	CHEMICAL	GENE-N	21	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T47	23066089
NA	CHEMICAL	GENE-N	21	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T24	23066089
NA	CHEMICAL	GENE-N	21	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the chemical chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T17	T28	23066089
NA	CHEMICAL	GENE-N	25	42	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. gene (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T23	23066089
NA	CHEMICAL	GENE-N	25	17	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of gene or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T49	23066089
NA	CHEMICAL	GENE-N	25	37	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the gene inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T22	23066089
NA	CHEMICAL	GENE-N	25	29	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the gene inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T21	23066089
NA	CHEMICAL	GENE-Y	25	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T3	T27	23066089
NA	CHEMICAL	GENE-Y	25	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/gene, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/gene.	T3	T30	23066089
NA	CHEMICAL	GENE-Y	25	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T25	23066089
CPR:4	CHEMICAL	GENE-Y	25	6	The potentiation of heteromeric KARs by gene activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by gene of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T48	23066089
NA	CHEMICAL	GENE-Y	25	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T3	T26	23066089
NA	CHEMICAL	GENE-Y	25	53	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of gene/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated gene/GluK5.	T3	T29	23066089
CPR:4	CHEMICAL	GENE-N	25	4	The potentiation of heteromeric gene by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T47	23066089
NA	CHEMICAL	GENE-N	25	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T24	23066089
NA	CHEMICAL	GENE-N	25	45	The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPS, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (chemical), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A. Protein kinase C (gene) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of gene by phorbol 12-myristate,13-acetate potentiated GluK2/GluK5.	T3	T28	23066089
NA	CHEMICAL	GENE-Y	6	18	Using site-directed mutagenesis, we identified three chemical (Ser833, Ser836, and Ser840) within the membrane proximal region of the gene C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	T8	T31	23066089
NA	CHEMICAL	GENE-Y	6	27	Using site-directed mutagenesis, we identified three chemical (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for gene-mediated potentiation of KARs.	T8	T32	23066089
NA	CHEMICAL	GENE-N	6	30	Using site-directed mutagenesis, we identified three chemical (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of gene.	T8	T33	23066089
NA	CHEMICAL	GENE-Y	7	18	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the gene C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	T10	T31	23066089
NA	CHEMICAL	GENE-Y	7	18	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the gene C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	T11	T31	23066089
NA	CHEMICAL	GENE-Y	7	18	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the gene C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	T9	T31	23066089
NA	CHEMICAL	GENE-Y	7	27	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for gene-mediated potentiation of KARs.	T10	T32	23066089
NA	CHEMICAL	GENE-Y	7	27	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for gene-mediated potentiation of KARs.	T11	T32	23066089
NA	CHEMICAL	GENE-Y	7	27	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for gene-mediated potentiation of KARs.	T9	T32	23066089
NA	CHEMICAL	GENE-N	7	30	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of gene.	T10	T33	23066089
NA	CHEMICAL	GENE-N	7	30	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of gene.	T11	T33	23066089
NA	CHEMICAL	GENE-N	7	30	Using site-directed mutagenesis, we identified three serines (chemical833, chemical836, and chemical840) within the membrane proximal region of the GluK5 C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of gene.	T9	T33	23066089
NA	CHEMICAL	GENE-Y	19	18	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the gene chemical-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.	T12	T31	23066089
NA	CHEMICAL	GENE-Y	19	27	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 chemical-terminal domain that, in combination, are required for gene-mediated potentiation of KARs.	T12	T32	23066089
NA	CHEMICAL	GENE-N	19	30	Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the GluK5 chemical-terminal domain that, in combination, are required for mGlu1-mediated potentiation of gene.	T12	T33	23066089
NA	CHEMICAL	GENE-N	15	17	Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different chemical receptor (gene) subtypes.	T7	T28	23073075
CPR:3	CHEMICAL	GENE-N	0	15	chemical (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different gene (S1PR) subtypes.	T1	T27	23073075
CPR:3	CHEMICAL	GENE-N	0	17	chemical (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (gene) subtypes.	T1	T28	23073075
CPR:3	CHEMICAL	GENE-N	1	15	Fingolimod (chemical), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different gene (S1PR) subtypes.	T6	T27	23073075
CPR:3	CHEMICAL	GENE-N	1	17	Fingolimod (chemical), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (gene) subtypes.	T6	T28	23073075
NA	CHEMICAL	GENE-N	8	10	However, recent evidence suggests that the action of chemical involves gene expressed by cells resident in the CNS, including neurons.	T9	T29	23073075
NA	CHEMICAL	GENE-N	28	21	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the gene (MAPK) and the chemical-3-kinase (PtdIns-3-K) pathways.	T3	T23	23073075
NA	CHEMICAL	GENE-N	28	4	Neuroprotection was attenuated by gene, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the chemical-3-kinase (PtdIns-3-K) pathways.	T3	T30	23073075
NA	CHEMICAL	GENE-Y	28	11	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective gene (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the chemical-3-kinase (PtdIns-3-K) pathways.	T3	T21	23073075
NA	CHEMICAL	GENE-N	28	29	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the chemical-3-kinase (gene) pathways.	T3	T26	23073075
NA	CHEMICAL	GENE-Y	28	13	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (gene) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the chemical-3-kinase (PtdIns-3-K) pathways.	T3	T22	23073075
NA	CHEMICAL	GENE-N	28	25	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (gene) and the chemical-3-kinase (PtdIns-3-K) pathways.	T3	T24	23073075
NA	CHEMICAL	GENE-N	15	21	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, chemical, and by inhibitors of the gene (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	T2	T23	23073075
NA	CHEMICAL	GENE-N	15	28	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, chemical, and by inhibitors of the mitogen associated protein kinase (MAPK) and the gene (PtdIns-3-K) pathways.	T2	T25	23073075
NA	CHEMICAL	GENE-N	15	4	Neuroprotection was attenuated by gene, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, chemical, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	T2	T30	23073075
CPR:6	CHEMICAL	GENE-Y	15	11	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective gene (S1P1R) antagonist, chemical, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	T2	T21	23073075
NA	CHEMICAL	GENE-N	15	29	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, chemical, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (gene) pathways.	T2	T26	23073075
CPR:6	CHEMICAL	GENE-Y	15	13	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (gene) antagonist, chemical, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	T2	T22	23073075
NA	CHEMICAL	GENE-N	15	25	Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, chemical, and by inhibitors of the mitogen associated protein kinase (gene) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.	T2	T24	23073075
NA	CHEMICAL	GENE-Y	23	9	The disposition of anagliptin, an orally active, highly selective gene inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq chemical to six healthy men.	T3	T18	23075005
CPR:4	CHEMICAL	GENE-Y	3	9	The disposition of chemical, an orally active, highly selective gene inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]chemical to six healthy men.	T4	T18	23075005
NA	CHEMICAL	GENE-Y	4	31	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, gene and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	T1	T12	23075005
CPR:9	CHEMICAL	GENE-Y	4	31	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, gene and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	T2	T12	23075005
NA	CHEMICAL	GENE-Y	4	33	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and gene, and M1 a substrate of OAT3, BCRP, gene and MRP4.	T1	T13	23075005
NA	CHEMICAL	GENE-Y	4	33	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and gene, and M1 a substrate of OAT3, BCRP, gene and MRP4.	T1	T16	23075005
CPR:9	CHEMICAL	GENE-Y	4	33	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and gene, and M1 a substrate of OAT3, BCRP, gene and MRP4.	T2	T13	23075005
NA	CHEMICAL	GENE-Y	4	33	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and gene, and M1 a substrate of OAT3, BCRP, gene and MRP4.	T2	T16	23075005
NA	CHEMICAL	GENE-Y	4	29	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of gene, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	T1	T10	23075005
CPR:9	CHEMICAL	GENE-Y	4	29	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of gene, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.	T2	T10	23075005
NA	CHEMICAL	GENE-Y	4	30	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, gene, MDR1 and MRP2, and M1 a substrate of gene, BCRP, MRP2 and MRP4.	T1	T11	23075005
NA	CHEMICAL	GENE-Y	4	30	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, gene, MDR1 and MRP2, and M1 a substrate of gene, BCRP, MRP2 and MRP4.	T1	T14	23075005
CPR:9	CHEMICAL	GENE-Y	4	30	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, gene, MDR1 and MRP2, and M1 a substrate of gene, BCRP, MRP2 and MRP4.	T2	T11	23075005
NA	CHEMICAL	GENE-Y	4	30	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, gene, MDR1 and MRP2, and M1 a substrate of gene, BCRP, MRP2 and MRP4.	T2	T14	23075005
NA	CHEMICAL	GENE-Y	4	40	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, gene, MRP2 and MRP4.	T1	T15	23075005
NA	CHEMICAL	GENE-Y	4	40	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, gene, MRP2 and MRP4.	T2	T15	23075005
NA	CHEMICAL	GENE-Y	4	43	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and gene.	T1	T17	23075005
NA	CHEMICAL	GENE-Y	4	43	Renal clearance of unbound chemical and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that chemical may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and gene.	T2	T17	23075005
NA	CHEMICAL	GENE-Y	28	4	Twice daily injection of gene in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-chemical (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	T3	T13	23085436
NA	CHEMICAL	GENE-N	28	26	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating gene and LDL-chemical (p < 0.001) and improved gene sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	T3	T14	23085436
NA	CHEMICAL	GENE-N	28	26	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating gene and LDL-chemical (p < 0.001) and improved gene sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	T3	T16	23085436
NA	CHEMICAL	GENE-N	28	28	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and gene-chemical (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) glucose tolerance.	T3	T15	23085436
NA	CHEMICAL	GENE-Y	48	4	Twice daily injection of gene in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and LDL-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) chemical tolerance.	T4	T13	23085436
NA	CHEMICAL	GENE-N	48	26	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating gene and LDL-cholesterol (p < 0.001) and improved gene sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) chemical tolerance.	T4	T14	23085436
NA	CHEMICAL	GENE-N	48	26	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating gene and LDL-cholesterol (p < 0.001) and improved gene sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) chemical tolerance.	T4	T16	23085436
NA	CHEMICAL	GENE-N	48	28	Twice daily injection of (pGlu-Gln)-CCK-8 in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating insulin and gene-cholesterol (p < 0.001) and improved insulin sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) chemical tolerance.	T4	T15	23085436
NA	CHEMICAL	GENE-Y	7	10	Energy intake, body weight, circulating insulin and chemical tolerance of gene mice were similar to lean controls.	T5	T19	23085436
NA	CHEMICAL	GENE-N	7	5	Energy intake, body weight, circulating gene and chemical tolerance of (pGlu-Gln)-CCK-8 mice were similar to lean controls.	T5	T18	23085436
NA	CHEMICAL	GENE-Y	11	2	In addition, gene prevented the effect of high fat feeding on chemical accumulation in liver and muscle.	T6	T20	23085436
NA	CHEMICAL	GENE-Y	35	13	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with gene for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating chemical (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved chemical tolerance (p < 0.05) and insulin sensitivity (p < 0.001).	T1	T9	23085436
NA	CHEMICAL	GENE-Y	35	13	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with gene for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating chemical (p < 0.05 to p < 0.01) and insulin (p < 0.05 to p < 0.001) and improved chemical tolerance (p < 0.05) and insulin sensitivity (p < 0.001).	T2	T9	23085436
NA	CHEMICAL	GENE-N	35	44	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating chemical (p < 0.05 to p < 0.01) and gene (p < 0.05 to p < 0.001) and improved chemical tolerance (p < 0.05) and gene sensitivity (p < 0.001).	T1	T10	23085436
NA	CHEMICAL	GENE-N	35	44	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating chemical (p < 0.05 to p < 0.01) and gene (p < 0.05 to p < 0.001) and improved chemical tolerance (p < 0.05) and gene sensitivity (p < 0.001).	T1	T11	23085436
NA	CHEMICAL	GENE-N	35	44	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating chemical (p < 0.05 to p < 0.01) and gene (p < 0.05 to p < 0.001) and improved chemical tolerance (p < 0.05) and gene sensitivity (p < 0.001).	T2	T10	23085436
NA	CHEMICAL	GENE-N	35	44	Beneficial metabolic effects were observed similarly in ob/ob mice treated twice daily with (pGlu-Gln)-CCK-8 for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating chemical (p < 0.05 to p < 0.01) and gene (p < 0.05 to p < 0.001) and improved chemical tolerance (p < 0.05) and gene sensitivity (p < 0.001).	T2	T11	23085436
NA	CHEMICAL	GENE-Y	13	3	Inhibition of the gene (BSEP) can cause intracellular accumulation of chemical and is a risk factor for drug-induced liver injury in humans.	T43	T52	23091188
NA	CHEMICAL	GENE-Y	13	7	Inhibition of the bile salt export pump (gene) can cause intracellular accumulation of chemical and is a risk factor for drug-induced liver injury in humans.	T43	T54	23091188
NA	CHEMICAL	GENE-Y	3	7	Inhibition of the chemical export pump (gene) can cause intracellular accumulation of bile acids and is a risk factor for drug-induced liver injury in humans.	T20	T54	23091188
CPR:4	CHEMICAL	GENE-N	6	1	Antiretroviral gene inhibitors lopinavir (LPV) and chemical (RTV) are reported BSEP inhibitors.	T23	T51	23091188
CPR:4	CHEMICAL	GENE-Y	6	10	Antiretroviral protease inhibitors lopinavir (LPV) and chemical (RTV) are reported gene inhibitors.	T23	T53	23091188
CPR:4	CHEMICAL	GENE-N	3	1	Antiretroviral gene inhibitors chemical (LPV) and ritonavir (RTV) are reported BSEP inhibitors.	T21	T51	23091188
CPR:4	CHEMICAL	GENE-Y	3	10	Antiretroviral protease inhibitors chemical (LPV) and ritonavir (RTV) are reported gene inhibitors.	T21	T53	23091188
CPR:4	CHEMICAL	GENE-N	7	1	Antiretroviral gene inhibitors lopinavir (LPV) and ritonavir (chemical) are reported BSEP inhibitors.	T24	T51	23091188
CPR:4	CHEMICAL	GENE-Y	7	10	Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (chemical) are reported gene inhibitors.	T24	T53	23091188
CPR:4	CHEMICAL	GENE-N	4	1	Antiretroviral gene inhibitors lopinavir (chemical) and ritonavir (RTV) are reported BSEP inhibitors.	T22	T51	23091188
CPR:4	CHEMICAL	GENE-Y	4	10	Antiretroviral protease inhibitors lopinavir (chemical) and ritonavir (RTV) are reported gene inhibitors.	T22	T53	23091188
NA	CHEMICAL	GENE-Y	3	17	Quantification of endogenous chemical in SCRH may reveal important adaptive responses associated with exposure to known gene inhibitors.	T19	T50	23091188
CPR:3	CHEMICAL	GENE-Y	0	3	chemical is a gene secretagogue that also enhances tissue viability in different organs.	T1	T10	23099431
NA	CHEMICAL	GENE-N	8	9	Diabetic rats showed significant (p<0.05) increased in plasma chemical, gene and significant (p<0.05) decreased in circulating insulin and hemoglobin.	T10	T26	23102509
NA	CHEMICAL	GENE-N	8	10	Diabetic rats showed significant (p<0.05) increased in plasma chemical, glycosylated gene and significant (p<0.05) decreased in circulating insulin and gene.	T10	T28	23102509
NA	CHEMICAL	GENE-N	8	17	Diabetic rats showed significant (p<0.05) increased in plasma chemical, glycosylated hemoglobin and significant (p<0.05) decreased in circulating gene and hemoglobin.	T10	T27	23102509
NA	CHEMICAL	GENE-Y	21	10	The altered activities of key enzymes such as glucose-6-phosphatase and gene of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T15	T30	23102509
NA	CHEMICAL	GENE-N	21	40	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of gene (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T15	T34	23102509
NA	CHEMICAL	GENE-Y	21	8	The altered activities of key enzymes such as gene and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T15	T29	23102509
NA	CHEMICAL	GENE-N	21	47	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and gene (ALP).	T15	T24	23102509
NA	CHEMICAL	GENE-N	21	43	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), gene (ALT) and alkaline phosphatase (ALP).	T15	T22	23102509
NA	CHEMICAL	GENE-N	21	19	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, gene, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T15	T32	23102509
NA	CHEMICAL	GENE-N	21	18	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas gene, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T15	T31	23102509
NA	CHEMICAL	GENE-N	21	45	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (gene) and alkaline phosphatase (ALP).	T15	T23	23102509
NA	CHEMICAL	GENE-N	21	49	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (gene).	T15	T25	23102509
NA	CHEMICAL	GENE-N	21	42	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (gene), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T15	T21	23102509
NA	CHEMICAL	GENE-Y	12	21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, gene and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T33	23102509
CPR:9	CHEMICAL	GENE-Y	12	10	The altered activities of key enzymes such as glucose-6-phosphatase and gene of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T30	23102509
NA	CHEMICAL	GENE-N	12	40	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of gene (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T34	23102509
CPR:9	CHEMICAL	GENE-Y	12	8	The altered activities of key enzymes such as gene and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T29	23102509
NA	CHEMICAL	GENE-N	12	47	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and gene (ALP).	T13	T24	23102509
NA	CHEMICAL	GENE-N	12	43	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), gene (ALT) and alkaline phosphatase (ALP).	T13	T22	23102509
NA	CHEMICAL	GENE-N	12	19	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, gene, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T32	23102509
NA	CHEMICAL	GENE-N	12	18	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas gene, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T31	23102509
NA	CHEMICAL	GENE-N	12	45	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (gene) and alkaline phosphatase (ALP).	T13	T23	23102509
NA	CHEMICAL	GENE-N	12	49	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (gene).	T13	T25	23102509
NA	CHEMICAL	GENE-N	12	42	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of chemical metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (gene), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T13	T21	23102509
NA	CHEMICAL	GENE-Y	40	21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, gene and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T16	T33	23102509
NA	CHEMICAL	GENE-Y	40	10	The altered activities of key enzymes such as glucose-6-phosphatase and gene of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T16	T30	23102509
NA	CHEMICAL	GENE-Y	40	8	The altered activities of key enzymes such as gene and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T16	T29	23102509
NA	CHEMICAL	GENE-N	40	47	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and gene (ALP).	T16	T24	23102509
NA	CHEMICAL	GENE-N	40	43	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), gene (ALT) and alkaline phosphatase (ALP).	T16	T22	23102509
NA	CHEMICAL	GENE-N	40	19	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, gene, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T16	T32	23102509
NA	CHEMICAL	GENE-N	40	18	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas gene, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T16	T31	23102509
NA	CHEMICAL	GENE-N	40	45	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (gene) and alkaline phosphatase (ALP).	T16	T23	23102509
NA	CHEMICAL	GENE-N	40	49	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (gene).	T16	T25	23102509
NA	CHEMICAL	GENE-N	40	42	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of chemical transaminase (gene), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T16	T21	23102509
NA	CHEMICAL	GENE-Y	10	21	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, gene and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T12	T33	23102509
NA	CHEMICAL	GENE-N	10	40	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of gene (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T12	T34	23102509
NA	CHEMICAL	GENE-Y	10	8	The altered activities of key enzymes such as gene and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T12	T29	23102509
NA	CHEMICAL	GENE-N	10	47	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and gene (ALP).	T12	T24	23102509
NA	CHEMICAL	GENE-N	10	43	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), gene (ALT) and alkaline phosphatase (ALP).	T12	T22	23102509
NA	CHEMICAL	GENE-N	10	19	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, gene, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T12	T32	23102509
NA	CHEMICAL	GENE-N	10	18	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas gene, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T12	T31	23102509
NA	CHEMICAL	GENE-N	10	45	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (gene) and alkaline phosphatase (ALP).	T12	T23	23102509
NA	CHEMICAL	GENE-N	10	49	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (gene).	T12	T25	23102509
NA	CHEMICAL	GENE-N	10	42	The altered activities of key enzymes such as glucose-6-phosphatase and chemical-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (gene), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T12	T21	23102509
NA	CHEMICAL	GENE-Y	19	21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, gene and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T14	T33	23102509
NA	CHEMICAL	GENE-Y	19	10	The altered activities of key enzymes such as glucose-6-phosphatase and gene of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T14	T30	23102509
NA	CHEMICAL	GENE-N	19	40	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of gene (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T14	T34	23102509
NA	CHEMICAL	GENE-Y	19	8	The altered activities of key enzymes such as gene and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T14	T29	23102509
NA	CHEMICAL	GENE-N	19	47	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and gene (ALP).	T14	T24	23102509
NA	CHEMICAL	GENE-N	19	43	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), gene (ALT) and alkaline phosphatase (ALP).	T14	T22	23102509
NA	CHEMICAL	GENE-N	19	18	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas gene, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T14	T31	23102509
NA	CHEMICAL	GENE-N	19	45	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (gene) and alkaline phosphatase (ALP).	T14	T23	23102509
NA	CHEMICAL	GENE-N	19	49	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (gene).	T14	T25	23102509
NA	CHEMICAL	GENE-N	19	42	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, chemical kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (gene), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T14	T21	23102509
NA	CHEMICAL	GENE-Y	43	21	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, gene and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T33	23102509
NA	CHEMICAL	GENE-Y	43	10	The altered activities of key enzymes such as glucose-6-phosphatase and gene of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T30	23102509
NA	CHEMICAL	GENE-N	43	40	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of gene (AST), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T34	23102509
NA	CHEMICAL	GENE-Y	43	8	The altered activities of key enzymes such as gene and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T29	23102509
NA	CHEMICAL	GENE-N	43	47	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and gene (ALP).	T2	T24	23102509
NA	CHEMICAL	GENE-N	43	19	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, gene, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T32	23102509
NA	CHEMICAL	GENE-N	43	18	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas gene, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T31	23102509
NA	CHEMICAL	GENE-N	43	45	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (gene) and alkaline phosphatase (ALP).	T2	T23	23102509
NA	CHEMICAL	GENE-N	43	49	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), chemical transaminase (ALT) and alkaline phosphatase (gene).	T2	T25	23102509
NA	CHEMICAL	GENE-N	43	42	The altered activities of key enzymes such as glucose-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (gene), chemical transaminase (ALT) and alkaline phosphatase (ALP).	T2	T21	23102509
NA	CHEMICAL	GENE-Y	8	10	The altered activities of key enzymes such as chemical-6-phosphatase and gene of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T11	T30	23102509
NA	CHEMICAL	GENE-N	8	40	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of gene (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T11	T34	23102509
NA	CHEMICAL	GENE-N	8	47	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and gene (ALP).	T11	T24	23102509
NA	CHEMICAL	GENE-N	8	43	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), gene (ALT) and alkaline phosphatase (ALP).	T11	T22	23102509
NA	CHEMICAL	GENE-N	8	19	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, gene, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T11	T32	23102509
NA	CHEMICAL	GENE-N	8	18	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas gene, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T11	T31	23102509
NA	CHEMICAL	GENE-N	8	45	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (gene) and alkaline phosphatase (ALP).	T11	T23	23102509
NA	CHEMICAL	GENE-N	8	49	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (gene).	T11	T25	23102509
NA	CHEMICAL	GENE-N	8	42	The altered activities of key enzymes such as chemical-6-phosphatase and fructose-1,6-bisphosphatase of carbohydrate metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, chemical-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (gene), alanine transaminase (ALT) and alkaline phosphatase (ALP).	T11	T21	23102509
CPR:3	CHEMICAL	GENE-Y	27	19	Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of gene, which was rescued by re-isoprenylation by both chemical and farnesylpyrophosphate.	T8	T24	23103563
NA	CHEMICAL	GENE-Y	27	5	Further we found stimulation of gene-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both chemical and farnesylpyrophosphate.	T8	T23	23103563
CPR:3	CHEMICAL	GENE-Y	29	19	Further we found stimulation of FAS-expression as a result of epigenetic DNA demethylation that was due to down-regulation of gene, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and chemical.	T9	T24	23103563
NA	CHEMICAL	GENE-Y	29	5	Further we found stimulation of gene-expression as a result of epigenetic DNA demethylation that was due to down-regulation of DNMT1, which was rescued by re-isoprenylation by both geranylgeranyl-pyrophosphate and chemical.	T9	T23	23103563
NA	CHEMICAL	GENE-Y	2	8	In contrast, chemical did not affect FAS and gene expression in MC3T3-E1 non-neoplastic cells.	T10	T13	23103563
NA	CHEMICAL	GENE-Y	2	6	In contrast, chemical did not affect gene and DNMT1 expression in MC3T3-E1 non-neoplastic cells.	T10	T12	23103563
NA	CHEMICAL	GENE-N	3	10	Data suggest that chemical via modulation of the activity of small-gene induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of FAS-expression.	T1	T14	23103563
CPR:3	CHEMICAL	GENE-Y	3	21	Data suggest that chemical via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-CpG-demethylation and stimulation of gene-expression.	T1	T16	23103563
NA	CHEMICAL	GENE-N	3	17	Data suggest that chemical via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-gene-demethylation and stimulation of FAS-expression.	T1	T15	23103563
NA	CHEMICAL	GENE-N	3	17	Data suggest that chemical via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-gene-demethylation and stimulation of FAS-expression.	T1	T2	23103563
NA	CHEMICAL	GENE-N	17	10	Data suggest that bisphosphonates via modulation of the activity of small-gene induce apoptosis in neoplastic cells by DNA-chemical-demethylation and stimulation of FAS-expression.	T15	T14	23103563
NA	CHEMICAL	GENE-N	17	10	Data suggest that bisphosphonates via modulation of the activity of small-gene induce apoptosis in neoplastic cells by DNA-chemical-demethylation and stimulation of FAS-expression.	T2	T14	23103563
NA	CHEMICAL	GENE-Y	17	21	Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-chemical-demethylation and stimulation of gene-expression.	T15	T16	23103563
NA	CHEMICAL	GENE-Y	17	21	Data suggest that bisphosphonates via modulation of the activity of small-GTPases induce apoptosis in neoplastic cells by DNA-chemical-demethylation and stimulation of gene-expression.	T2	T16	23103563
NA	CHEMICAL	GENE-Y	4	12	TCDD acts through the chemical receptor (AhR), which interacts with the gene (AR).	T3	T17	23117151
NA	CHEMICAL	GENE-Y	4	7	TCDD acts through the chemical receptor (gene), which interacts with the androgen receptor (AR).	T3	T16	23117151
NA	CHEMICAL	GENE-Y	4	14	TCDD acts through the chemical receptor (AhR), which interacts with the androgen receptor (gene).	T3	T18	23117151
NA	CHEMICAL	GENE-Y	12	4	TCDD acts through the gene (AhR), which interacts with the chemical receptor (AR).	T4	T15	23117151
NA	CHEMICAL	GENE-Y	12	7	TCDD acts through the aryl hydrocarbon receptor (gene), which interacts with the chemical receptor (AR).	T4	T16	23117151
NA	CHEMICAL	GENE-Y	12	14	TCDD acts through the aryl hydrocarbon receptor (AhR), which interacts with the chemical receptor (gene).	T4	T18	23117151
NA	CHEMICAL	GENE-Y	0	4	chemical acts through the gene (AhR), which interacts with the androgen receptor (AR).	T2	T15	23117151
NA	CHEMICAL	GENE-Y	0	12	chemical acts through the aryl hydrocarbon receptor (AhR), which interacts with the gene (AR).	T2	T17	23117151
NA	CHEMICAL	GENE-Y	0	7	chemical acts through the aryl hydrocarbon receptor (gene), which interacts with the androgen receptor (AR).	T2	T16	23117151
NA	CHEMICAL	GENE-Y	0	14	chemical acts through the aryl hydrocarbon receptor (AhR), which interacts with the androgen receptor (gene).	T2	T18	23117151
NA	CHEMICAL	GENE-N	17	20	We investigated the influence of TCDD on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on chemical-activated ARs containing gene within normal length range (16, 22, and 28).	T6	T22	23117151
NA	CHEMICAL	GENE-Y	17	18	We investigated the influence of TCDD on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on chemical-activated gene containing CAG repeats within normal length range (16, 22, and 28).	T6	T21	23117151
NA	CHEMICAL	GENE-N	5	20	We investigated the influence of chemical on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on 5-dihydrotestosterone-activated ARs containing gene within normal length range (16, 22, and 28).	T5	T22	23117151
NA	CHEMICAL	GENE-Y	5	18	We investigated the influence of chemical on prostate cancer cells (PC-3) and non-tumor prostate cells (PNT1A) on 5-dihydrotestosterone-activated gene containing CAG repeats within normal length range (16, 22, and 28).	T5	T21	23117151
CPR:3	CHEMICAL	GENE-Y	10	4	The AhR target gene gene mRNA expression was induced by chemical, but was not affected by the AR CAG length.	T7	T24	23117151
NA	CHEMICAL	GENE-Y	10	1	The gene target gene CYP1A1 mRNA expression was induced by chemical, but was not affected by the AR CAG length.	T7	T23	23117151
NA	CHEMICAL	GENE-N	10	18	The AhR target gene CYP1A1 mRNA expression was induced by chemical, but was not affected by the AR gene length.	T7	T26	23117151
NA	CHEMICAL	GENE-Y	10	17	The AhR target gene CYP1A1 mRNA expression was induced by chemical, but was not affected by the gene CAG length.	T7	T25	23117151
NA	CHEMICAL	GENE-Y	0	5	chemical had no effect on gene activity in PC-3 cells, whereas the shortest gene variant was induced by chemical in PNT1A cells.	T8	T27	23117151
NA	CHEMICAL	GENE-Y	0	5	chemical had no effect on gene activity in PC-3 cells, whereas the shortest gene variant was induced by chemical in PNT1A cells.	T8	T28	23117151
NA	CHEMICAL	GENE-Y	0	5	chemical had no effect on gene activity in PC-3 cells, whereas the shortest gene variant was induced by chemical in PNT1A cells.	T9	T27	23117151
CPR:3	CHEMICAL	GENE-Y	0	5	chemical had no effect on gene activity in PC-3 cells, whereas the shortest gene variant was induced by chemical in PNT1A cells.	T9	T28	23117151
NA	CHEMICAL	GENE-N	8	3	In conclusion, the gene length dependent effect of chemical on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of chemical on AR activity.	T11	T29	23117151
NA	CHEMICAL	GENE-N	8	3	In conclusion, the gene length dependent effect of chemical on AR activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of chemical on AR activity.	T12	T29	23117151
NA	CHEMICAL	GENE-Y	8	10	In conclusion, the CAG length dependent effect of chemical on gene activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of chemical on gene activity.	T11	T30	23117151
NA	CHEMICAL	GENE-Y	8	10	In conclusion, the CAG length dependent effect of chemical on gene activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of chemical on gene activity.	T11	T31	23117151
NA	CHEMICAL	GENE-Y	8	10	In conclusion, the CAG length dependent effect of chemical on gene activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of chemical on gene activity.	T12	T30	23117151
NA	CHEMICAL	GENE-Y	8	10	In conclusion, the CAG length dependent effect of chemical on gene activity in PNT1A, but not in PC-3 cells, indicates as a cell-specific effect of chemical on gene activity.	T12	T31	23117151
NA	CHEMICAL	GENE-N	25	17	Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several gene in mice and replacement of plasmid by chemical reduced the elevation of all assayed gene.	T1	T5	23123257
CPR:4	CHEMICAL	GENE-N	25	17	Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several gene in mice and replacement of plasmid by chemical reduced the elevation of all assayed gene.	T1	T6	23123257
CPR:3	CHEMICAL	GENE-Y	3	13	We found that chemical markedly induced endoplasmic reticulum (ER) stress-related genes, such as gene, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).	T6	T17	23123298
CPR:3	CHEMICAL	GENE-Y	3	28	We found that chemical markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the gene (CHOP).	T6	T20	23123298
CPR:3	CHEMICAL	GENE-Y	3	22	We found that chemical markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, gene (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).	T6	T18	23123298
CPR:3	CHEMICAL	GENE-Y	3	25	We found that chemical markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (gene) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).	T6	T19	23123298
CPR:3	CHEMICAL	GENE-Y	3	32	We found that chemical markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (gene).	T6	T21	23123298
NA	CHEMICAL	GENE-Y	13	3	However, down-regulation of gene and/or CHOP expression by siRNA had no effect on chemical-induced apoptosis in Caki and HCT116 cells.	T7	T22	23123298
NA	CHEMICAL	GENE-Y	13	5	However, down-regulation of ATF4 and/or gene expression by siRNA had no effect on chemical-induced apoptosis in Caki and HCT116 cells.	T7	T23	23123298
NA	CHEMICAL	GENE-Y	20	8	This study aimed to understand the role of gene (Ctr1) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and chemical drugs.	T16	T35	23123662
NA	CHEMICAL	GENE-Y	20	8	This study aimed to understand the role of gene (Ctr1) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (rCtr1) as a membrane transporter of copper and chemical drugs.	T18	T35	23123662
NA	CHEMICAL	GENE-Y	20	32	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of gene (rCtr1) as a membrane transporter of copper and chemical drugs.	T16	T37	23123662
NA	CHEMICAL	GENE-Y	20	32	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of gene (rCtr1) as a membrane transporter of copper and chemical drugs.	T18	T37	23123662
NA	CHEMICAL	GENE-Y	20	34	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (gene) as a membrane transporter of copper and chemical drugs.	T16	T38	23123662
NA	CHEMICAL	GENE-Y	20	34	This study aimed to understand the role of copper transporter 1 (Ctr1) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (gene) as a membrane transporter of copper and chemical drugs.	T18	T38	23123662
NA	CHEMICAL	GENE-Y	20	11	This study aimed to understand the role of copper transporter 1 (gene) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of rat gene (rgene) as a membrane transporter of copper and chemical drugs.	T16	T36	23123662
NA	CHEMICAL	GENE-Y	20	11	This study aimed to understand the role of copper transporter 1 (gene) in the uptake and toxicity of copper and chemical drugs in cultured rat DRG neurons, and the functional activities of rat gene (rgene) as a membrane transporter of copper and chemical drugs.	T18	T36	23123662
NA	CHEMICAL	GENE-Y	8	32	This study aimed to understand the role of chemical transporter 1 (Ctr1) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of gene (rCtr1) as a membrane transporter of chemical and platinum drugs.	T14	T37	23123662
NA	CHEMICAL	GENE-Y	8	32	This study aimed to understand the role of chemical transporter 1 (Ctr1) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of gene (rCtr1) as a membrane transporter of chemical and platinum drugs.	T15	T37	23123662
NA	CHEMICAL	GENE-Y	8	32	This study aimed to understand the role of chemical transporter 1 (Ctr1) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of gene (rCtr1) as a membrane transporter of chemical and platinum drugs.	T17	T37	23123662
NA	CHEMICAL	GENE-Y	8	34	This study aimed to understand the role of chemical transporter 1 (Ctr1) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (gene) as a membrane transporter of chemical and platinum drugs.	T14	T38	23123662
NA	CHEMICAL	GENE-Y	8	34	This study aimed to understand the role of chemical transporter 1 (Ctr1) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (gene) as a membrane transporter of chemical and platinum drugs.	T15	T38	23123662
NA	CHEMICAL	GENE-Y	8	34	This study aimed to understand the role of chemical transporter 1 (Ctr1) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of rat Ctr1 (gene) as a membrane transporter of chemical and platinum drugs.	T17	T38	23123662
NA	CHEMICAL	GENE-Y	8	11	This study aimed to understand the role of chemical transporter 1 (gene) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of rat gene (rgene) as a membrane transporter of chemical and platinum drugs.	T14	T36	23123662
NA	CHEMICAL	GENE-Y	8	11	This study aimed to understand the role of chemical transporter 1 (gene) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of rat gene (rgene) as a membrane transporter of chemical and platinum drugs.	T15	T36	23123662
NA	CHEMICAL	GENE-Y	8	11	This study aimed to understand the role of chemical transporter 1 (gene) in the uptake and toxicity of chemical and platinum drugs in cultured rat DRG neurons, and the functional activities of rat gene (rgene) as a membrane transporter of chemical and platinum drugs.	T17	T36	23123662
CPR:9	CHEMICAL	GENE-Y	16	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of copper, chemical, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	T21	T39	23123662
CPR:9	CHEMICAL	GENE-Y	16	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of copper, chemical, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	T21	T40	23123662
CPR:9	CHEMICAL	GENE-Y	19	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and chemical, in comparison to isogenic vector-transfected control cells.	T23	T39	23123662
CPR:9	CHEMICAL	GENE-Y	19	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and chemical, in comparison to isogenic vector-transfected control cells.	T23	T40	23123662
CPR:9	CHEMICAL	GENE-Y	17	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of copper, oxaliplatin, chemical and carboplatin, in comparison to isogenic vector-transfected control cells.	T22	T39	23123662
CPR:9	CHEMICAL	GENE-Y	17	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of copper, oxaliplatin, chemical and carboplatin, in comparison to isogenic vector-transfected control cells.	T22	T40	23123662
CPR:9	CHEMICAL	GENE-Y	15	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of chemical, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	T20	T39	23123662
CPR:9	CHEMICAL	GENE-Y	15	3	Heterologous expression of gene in HEK293 cells (HEK/gene cells) increased the uptake and cytotoxicity of chemical, oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.	T20	T40	23123662
CPR:9	CHEMICAL	GENE-Y	24	6	Cultured rat DRG neurons endogenously expressed gene protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up chemical, but were resistant to chemical toxicity.	T24	T41	23123662
NA	CHEMICAL	GENE-Y	24	6	Cultured rat DRG neurons endogenously expressed gene protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up chemical, but were resistant to chemical toxicity.	T25	T41	23123662
NA	CHEMICAL	GENE-Y	3	11	The uptake of chemical by both cultured rat DRG neurons and HEK/gene cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by gene.	T26	T30	23123662
CPR:9	CHEMICAL	GENE-Y	3	11	The uptake of chemical by both cultured rat DRG neurons and HEK/gene cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by gene.	T26	T42	23123662
NA	CHEMICAL	GENE-Y	20	11	The uptake of copper by both cultured rat DRG neurons and HEK/gene cells was saturable and inhibited by cold temperature, chemical and zinc, consistent with it being mediated by gene.	T27	T30	23123662
NA	CHEMICAL	GENE-Y	20	11	The uptake of copper by both cultured rat DRG neurons and HEK/gene cells was saturable and inhibited by cold temperature, chemical and zinc, consistent with it being mediated by gene.	T27	T42	23123662
NA	CHEMICAL	GENE-Y	22	11	The uptake of copper by both cultured rat DRG neurons and HEK/gene cells was saturable and inhibited by cold temperature, silver and chemical, consistent with it being mediated by gene.	T1	T30	23123662
NA	CHEMICAL	GENE-Y	22	11	The uptake of copper by both cultured rat DRG neurons and HEK/gene cells was saturable and inhibited by cold temperature, silver and chemical, consistent with it being mediated by gene.	T1	T42	23123662
NA	CHEMICAL	GENE-Y	14	11	The accumulation of platinum by both cultured rat DRG neurons and HEK/gene cells, during chemical exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/gene cells.	T6	T31	23123662
NA	CHEMICAL	GENE-Y	14	11	The accumulation of platinum by both cultured rat DRG neurons and HEK/gene cells, during chemical exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/gene cells.	T6	T32	23123662
NA	CHEMICAL	GENE-Y	3	11	The accumulation of chemical by both cultured rat DRG neurons and HEK/gene cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/gene cells.	T5	T31	23123662
NA	CHEMICAL	GENE-Y	3	11	The accumulation of chemical by both cultured rat DRG neurons and HEK/gene cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by copper only in HEK/gene cells.	T5	T32	23123662
NA	CHEMICAL	GENE-Y	25	11	The accumulation of platinum by both cultured rat DRG neurons and HEK/gene cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by chemical only in HEK/gene cells.	T7	T31	23123662
NA	CHEMICAL	GENE-Y	25	11	The accumulation of platinum by both cultured rat DRG neurons and HEK/gene cells, during oxaliplatin exposure, was saturable and temperature dependent, but was inhibited by chemical only in HEK/gene cells.	T7	T32	23123662
CPR:9	CHEMICAL	GENE-Y	7	2	In conclusion, gene can transport copper and chemical drugs, and sensitizes cells to their cytotoxicities.	T10	T33	23123662
CPR:9	CHEMICAL	GENE-Y	5	2	In conclusion, gene can transport chemical and platinum drugs, and sensitizes cells to their cytotoxicities.	T9	T33	23123662
CPR:9	CHEMICAL	GENE-Y	29	14	DRG neurons display substantial capacity for accumulating copper via a transport process mediated by gene, but appear able to resist copper toxicity and use alternative mechanisms to take up chemical.	T13	T34	23123662
CPR:9	CHEMICAL	GENE-Y	7	14	DRG neurons display substantial capacity for accumulating chemical via a transport process mediated by gene, but appear able to resist chemical toxicity and use alternative mechanisms to take up oxaliplatin.	T11	T34	23123662
NA	CHEMICAL	GENE-Y	7	14	DRG neurons display substantial capacity for accumulating chemical via a transport process mediated by gene, but appear able to resist chemical toxicity and use alternative mechanisms to take up oxaliplatin.	T12	T34	23123662
CPR:4	CHEMICAL	GENE-Y	13	4	Examination of phosphorylation in gene, we found an inhibitory effect by chemical at 20 and 50mM.	T8	T19	23128353
CPR:3	CHEMICAL	GENE-Y	0	16	chemical at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and gene (HO-1), but also caused a reduction in p21 protein expression.	T9	T21	23128353
NA	CHEMICAL	GENE-Y	0	18	chemical at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (gene), but also caused a reduction in p21 protein expression.	T9	T22	23128353
CPR:4	CHEMICAL	GENE-Y	0	25	chemical at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in gene protein expression.	T9	T23	23128353
CPR:3	CHEMICAL	GENE-N	0	14	chemical at 50mM was demonstrated to elevate both the mRNA and protein expression of gene and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	T9	T20	23128353
NA	CHEMICAL	GENE-Y	16	18	Glucosamine at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and chemical oxygenase-1 (gene), but also caused a reduction in p21 protein expression.	T10	T22	23128353
NA	CHEMICAL	GENE-Y	16	25	Glucosamine at 50mM was demonstrated to elevate both the mRNA and protein expression of p53 and chemical oxygenase-1 (HO-1), but also caused a reduction in gene protein expression.	T10	T23	23128353
NA	CHEMICAL	GENE-N	16	14	Glucosamine at 50mM was demonstrated to elevate both the mRNA and protein expression of gene and chemical oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.	T10	T20	23128353
CPR:4	CHEMICAL	GENE-Y	2	4	In addition, chemical attenuated gene protein stability via the proteasomal proteolytic pathway, as well as inducing gene nuclear accumulation.	T1	T12	23128353
CPR:3	CHEMICAL	GENE-Y	2	4	In addition, chemical attenuated gene protein stability via the proteasomal proteolytic pathway, as well as inducing gene nuclear accumulation.	T1	T13	23128353
NA	CHEMICAL	GENE-Y	9	48	Altogether, our results suggest that a high dose of chemical may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and gene expression, and nuclear p21 accumulation.	T2	T17	23128353
NA	CHEMICAL	GENE-Y	9	45	Altogether, our results suggest that a high dose of chemical may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of gene, p53 and HO-1 expression, and nuclear gene accumulation.	T2	T15	23128353
CPR:3	CHEMICAL	GENE-Y	9	45	Altogether, our results suggest that a high dose of chemical may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of gene, p53 and HO-1 expression, and nuclear gene accumulation.	T2	T18	23128353
NA	CHEMICAL	GENE-N	9	46	Altogether, our results suggest that a high dose of chemical may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, gene and HO-1 expression, and nuclear p21 accumulation.	T2	T16	23128353
CPR:4	CHEMICAL	GENE-Y	9	39	Altogether, our results suggest that a high dose of chemical may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in gene phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.	T2	T14	23128353
NA	CHEMICAL	GENE-Y	8	11	The pharmacological potencies of a series of substituted chemical towards gene and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	T7	T24	23131177
NA	CHEMICAL	GENE-Y	8	15	The pharmacological potencies of a series of substituted chemical towards human melatonin MT(1) and gene were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	T7	T25	23131177
NA	CHEMICAL	GENE-N	8	12	The pharmacological potencies of a series of substituted chemical towards human gene MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	T7	T8	23131177
NA	CHEMICAL	GENE-N	8	32	The pharmacological potencies of a series of substituted chemical towards human melatonin MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with gene phosphorylation and cAMP assays.	T7	T26	23131177
NA	CHEMICAL	GENE-Y	12	15	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human chemical MT(1) and gene were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and cAMP assays.	T8	T25	23131177
NA	CHEMICAL	GENE-N	12	32	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human chemical MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with gene phosphorylation and cAMP assays.	T8	T26	23131177
NA	CHEMICAL	GENE-Y	35	11	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards gene and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and chemical assays.	T9	T24	23131177
NA	CHEMICAL	GENE-Y	35	15	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human melatonin MT(1) and gene were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and chemical assays.	T9	T25	23131177
NA	CHEMICAL	GENE-N	35	12	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human gene MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with ERK phosphorylation and chemical assays.	T9	T8	23131177
NA	CHEMICAL	GENE-N	35	32	The pharmacological potencies of a series of substituted N-[3-(3-methoxyphenyl)propyl] amides towards human melatonin MT(1) and MT(2) receptors were evaluated by the FLIPR high-throughput screening assay, whilst their subtype-selectivity was subsequently verified with gene phosphorylation and chemical assays.	T9	T26	23131177
NA	CHEMICAL	GENE-Y	23	8	Structure-activity relationship analysis of highly potent subtype-selective ligands (gene EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the chemical ring dramatically enhanced the gene potency and at the same time decreased MT(1) potency.	T11	T14	23131177
NA	CHEMICAL	GENE-Y	23	8	Structure-activity relationship analysis of highly potent subtype-selective ligands (gene EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the chemical ring dramatically enhanced the gene potency and at the same time decreased MT(1) potency.	T11	T27	23131177
NA	CHEMICAL	GENE-Y	23	36	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a benzyloxyl substituent incorporated at C6 position of the chemical ring dramatically enhanced the MT(2) potency and at the same time decreased gene potency.	T11	T15	23131177
NA	CHEMICAL	GENE-Y	15	8	Structure-activity relationship analysis of highly potent subtype-selective ligands (gene EC(50) 10-90 pM) revealed that a chemical substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the gene potency and at the same time decreased MT(1) potency.	T10	T14	23131177
NA	CHEMICAL	GENE-Y	15	8	Structure-activity relationship analysis of highly potent subtype-selective ligands (gene EC(50) 10-90 pM) revealed that a chemical substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the gene potency and at the same time decreased MT(1) potency.	T10	T27	23131177
NA	CHEMICAL	GENE-Y	15	36	Structure-activity relationship analysis of highly potent subtype-selective ligands (MT(2) EC(50) 10-90 pM) revealed that a chemical substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the MT(2) potency and at the same time decreased gene potency.	T10	T15	23131177
NA	CHEMICAL	GENE-Y	15	12	The most potent subtype-selective ligand, 2q had a substantially higher potency for gene than chemical for elevation of [Ca(2+)]i and inhibition of forskolin-elevated cAMP.	T2	T17	23131177
NA	CHEMICAL	GENE-Y	19	12	The most potent subtype-selective ligand, 2q had a substantially higher potency for gene than melatonin for elevation of [chemical]i and inhibition of forskolin-elevated cAMP.	T3	T17	23131177
NA	CHEMICAL	GENE-N	19	15	The most potent subtype-selective ligand, 2q had a substantially higher potency for MT(2) receptor than gene for elevation of [chemical]i and inhibition of forskolin-elevated cAMP.	T3	T2	23131177
CPR:3	CHEMICAL	GENE-Y	12	6	We show that the expression of gene is induced in response to chemical in MCF-7 cells and that the induction is mediated by ER-regulated enhancers located distally upstream from the gene.	T1	T7	23142699
CPR:3	CHEMICAL	GENE-Y	12	23	We show that the expression of PIM-1 is induced in response to chemical in MCF-7 cells and that the induction is mediated by gene-regulated enhancers located distally upstream from the gene.	T1	T8	23142699
NA	CHEMICAL	GENE-Y	17	4	In sum, identification of gene as an ER target gene adds a novel potential mechanism by which chemical can contribute to breast cancer cell proliferation and carcinogenesis.	T2	T16	23142699
NA	CHEMICAL	GENE-Y	17	7	In sum, identification of PIM-1 as an gene target gene adds a novel potential mechanism by which chemical can contribute to breast cancer cell proliferation and carcinogenesis.	T2	T17	23142699
CPR:9	CHEMICAL	GENE-N	11	20	In this work, the metabolism of four frequently prescribed inhaled GCs, chemical, flunisolide, budesonide, and fluticasone propionate, by the gene family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	T14	T24	23143891
CPR:9	CHEMICAL	GENE-N	16	20	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and chemical, by the gene family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	T17	T24	23143891
CPR:9	CHEMICAL	GENE-N	13	20	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, chemical, budesonide, and fluticasone propionate, by the gene family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	T15	T24	23143891
CPR:9	CHEMICAL	GENE-N	14	20	In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, chemical, and fluticasone propionate, by the gene family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	T16	T24	23143891
CPR:9	CHEMICAL	GENE-Y	17	0	gene, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize chemical, budesonide, and fluticasone propionate.	T1	T19	23143891
CPR:9	CHEMICAL	GENE-Y	21	0	gene, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and chemical.	T3	T19	23143891
CPR:9	CHEMICAL	GENE-Y	19	0	gene, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, chemical, and fluticasone propionate.	T2	T19	23143891
CPR:9	CHEMICAL	GENE-Y	2	7	In contrast, chemical was only metabolized via gene, with no significant turnover by CYP3A5 or CYP3A7.	T4	T20	23143891
NA	CHEMICAL	GENE-Y	2	15	In contrast, chemical was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or gene.	T4	T22	23143891
NA	CHEMICAL	GENE-Y	2	13	In contrast, chemical was only metabolized via CYP3A4, with no significant turnover by gene or CYP3A7.	T4	T21	23143891
NA	CHEMICAL	GENE-N	9	1	The gene (ERK) and the transcription factor chemical response element-binding protein (CREB) were involved in neuroplastic changes associated with learning and memory.	T5	T12	23159329
NA	CHEMICAL	GENE-N	9	13	The extracellular signal-regulated kinase (ERK) and the transcription factor chemical response element-binding protein (gene) were involved in neuroplastic changes associated with learning and memory.	T5	T19	23159329
NA	CHEMICAL	GENE-N	9	4	The extracellular signal-regulated kinase (gene) and the transcription factor chemical response element-binding protein (CREB) were involved in neuroplastic changes associated with learning and memory.	T5	T17	23159329
NA	CHEMICAL	GENE-N	21	5	Activation of both ERK and gene in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in chemical-treated mouse groups.	T1	T23	23159329
NA	CHEMICAL	GENE-N	21	3	Activation of both gene and CREB in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in chemical-treated mouse groups.	T1	T22	23159329
CPR:3	CHEMICAL	GENE-N	21	7	In contrast, activation of both ERK and gene in the PFC was found following memory retrieval but not other processes in chemical-treated mouse groups.	T2	T14	23159329
CPR:3	CHEMICAL	GENE-N	21	5	In contrast, activation of both gene and CREB in the PFC was found following memory retrieval but not other processes in chemical-treated mouse groups.	T2	T13	23159329
CPR:3	CHEMICAL	GENE-N	16	6	Moreover, activation of the ERK and gene signaling pathway in the hippocampus might be involved in chemical-induced spatial memory changes.	T4	T16	23159329
CPR:3	CHEMICAL	GENE-N	16	4	Moreover, activation of the gene and CREB signaling pathway in the hippocampus might be involved in chemical-induced spatial memory changes.	T4	T15	23159329
CPR:3	CHEMICAL	GENE-N	40	16	A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative gene and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by chemical.	T1	T4	23161868
CPR:3	CHEMICAL	GENE-N	40	25	A reporter construct driven by 4 kb of the chicken ras-dva 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential gene, was highly activated in embryonic pituitary cells and up-regulated by chemical.	T1	T5	23161868
CPR:3	CHEMICAL	GENE-Y	40	9	A reporter construct driven by 4 kb of the gene 5'-flanking region, containing six putative pituitary-specific transcription factor-1 (Pit-1) binding sites and two potential glucocorticoid receptor (GR) binding sites, was highly activated in embryonic pituitary cells and up-regulated by chemical.	T1	T3	23161868
CPR:3	CHEMICAL	GENE-N	16	12	However, mutating putative GR binding sites did not substantially reduce induction of gene activity by chemical, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.	T2	T11	23161868
CPR:3	CHEMICAL	GENE-N	16	3	However, mutating putative gene did not substantially reduce induction of ras-dva promoter activity by chemical, suggesting additional DNA elements within the 5'-flanking region are responsible for glucocorticoid regulation.	T2	T10	23161868
NA	CHEMICAL	GENE-N	16	19	However, mutating putative GR binding sites did not substantially reduce induction of ras-dva promoter activity by chemical, suggesting additional gene within the 5'-flanking region are responsible for glucocorticoid regulation.	T2	T12	23161868
NA	CHEMICAL	GENE-Y	32	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, AZ12216052 (AZ) and the gene-specific orthosteric agonist chemical (DCPG).	T2	T10	23164615
CPR:5	CHEMICAL	GENE-Y	32	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, AZ12216052 (AZ) and the gene-specific orthosteric agonist chemical (DCPG).	T2	T11	23164615
NA	CHEMICAL	GENE-Y	32	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, AZ12216052 (AZ) and the gene-specific orthosteric agonist chemical (DCPG).	T2	T12	23164615
NA	CHEMICAL	GENE-Y	25	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, chemical (AZ) and the gene-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).	T1	T10	23164615
NA	CHEMICAL	GENE-Y	25	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, chemical (AZ) and the gene-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).	T1	T11	23164615
NA	CHEMICAL	GENE-Y	25	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, chemical (AZ) and the gene-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).	T1	T12	23164615
NA	CHEMICAL	GENE-Y	33	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, AZ12216052 (AZ) and the gene-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (chemical).	T3	T10	23164615
CPR:5	CHEMICAL	GENE-Y	33	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, AZ12216052 (AZ) and the gene-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (chemical).	T3	T11	23164615
NA	CHEMICAL	GENE-Y	33	5	To investigate the role of gene in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of gene, AZ12216052 (AZ) and the gene-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (chemical).	T3	T12	23164615
NA	CHEMICAL	GENE-Y	21	42	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous chemical being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from chemical release sites, immuno-labeled with gene.	T5	T14	23164615
NA	CHEMICAL	GENE-Y	21	42	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous chemical being stronger during bright light stimulation and with mGluR8 receptors mainly being localized away from chemical release sites, immuno-labeled with gene.	T6	T14	23164615
NA	CHEMICAL	GENE-Y	21	30	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous chemical being stronger during bright light stimulation and with gene receptors mainly being localized away from chemical release sites, immuno-labeled with VGLUT1.	T5	T13	23164615
NA	CHEMICAL	GENE-Y	21	30	The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous chemical being stronger during bright light stimulation and with gene receptors mainly being localized away from chemical release sites, immuno-labeled with VGLUT1.	T6	T13	23164615
NA	CHEMICAL	GENE-Y	9	16	The differential sensitivity of ganglion cell light responses to chemical and AZ supports multiple sites where gene modulates the light responses of ganglion cells.	T7	T9	23164615
NA	CHEMICAL	GENE-Y	1	24	Excessive chemical receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by gene (PSD-95).	T2	T22	23178182
NA	CHEMICAL	GENE-Y	1	27	Excessive chemical receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (gene).	T2	T23	23178182
NA	CHEMICAL	GENE-N	1	27	Excessive chemical receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (gene).	T2	T23	23178182
NA	CHEMICAL	GENE-N	1	3	Excessive chemical receptor (gene)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	T2	T30	23178182
NA	CHEMICAL	GENE-Y	6	24	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of chemical (NO) is involved in the development and maintenance of chronic pain states, and is mediated by gene (PSD-95).	T12	T22	23178182
NA	CHEMICAL	GENE-N	6	1	Excessive gene (NMDAR)-dependent production of chemical (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	T12	T19	23178182
NA	CHEMICAL	GENE-Y	6	27	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of chemical (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (gene).	T12	T23	23178182
NA	CHEMICAL	GENE-N	6	27	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of chemical (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (gene).	T12	T23	23178182
NA	CHEMICAL	GENE-N	6	3	Excessive N-Methyl-d-aspartate receptor (gene)-dependent production of chemical (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	T12	T30	23178182
NA	CHEMICAL	GENE-Y	8	24	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (chemical) is involved in the development and maintenance of chronic pain states, and is mediated by gene (PSD-95).	T15	T22	23178182
NA	CHEMICAL	GENE-N	8	1	Excessive gene (NMDAR)-dependent production of nitric oxide (chemical) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	T15	T19	23178182
NA	CHEMICAL	GENE-Y	8	27	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (chemical) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (gene).	T15	T23	23178182
NA	CHEMICAL	GENE-N	8	27	Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (chemical) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (gene).	T15	T23	23178182
NA	CHEMICAL	GENE-N	8	3	Excessive N-Methyl-d-aspartate receptor (gene)-dependent production of nitric oxide (chemical) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic density protein-95 (PSD-95).	T15	T30	23178182
NA	CHEMICAL	GENE-Y	8	11	By binding to both the NMDAR and neuronal chemical synthase (nchemicalS), gene mediates a specific coupling between NMDAR activation and chemical production.	T10	T27	23178182
NA	CHEMICAL	GENE-Y	8	11	By binding to both the NMDAR and neuronal chemical synthase (nchemicalS), gene mediates a specific coupling between NMDAR activation and chemical production.	T9	T27	23178182
NA	CHEMICAL	GENE-N	8	11	By binding to both the NMDAR and neuronal chemical synthase (nchemicalS), gene mediates a specific coupling between NMDAR activation and chemical production.	T10	T27	23178182
NA	CHEMICAL	GENE-N	8	11	By binding to both the NMDAR and neuronal chemical synthase (nchemicalS), gene mediates a specific coupling between NMDAR activation and chemical production.	T9	T27	23178182
NA	CHEMICAL	GENE-N	8	5	By binding to both the gene and neuronal chemical synthase (nchemicalS), PSD-95 mediates a specific coupling between gene activation and chemical production.	T10	T24	23178182
NA	CHEMICAL	GENE-N	8	5	By binding to both the gene and neuronal chemical synthase (nchemicalS), PSD-95 mediates a specific coupling between gene activation and chemical production.	T10	T28	23178182
NA	CHEMICAL	GENE-N	8	5	By binding to both the gene and neuronal chemical synthase (nchemicalS), PSD-95 mediates a specific coupling between gene activation and chemical production.	T9	T24	23178182
NA	CHEMICAL	GENE-N	8	5	By binding to both the gene and neuronal chemical synthase (nchemicalS), PSD-95 mediates a specific coupling between gene activation and chemical production.	T9	T28	23178182
NA	CHEMICAL	GENE-N	12	26	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/PSD-95/nchemicalS complex by targeting PSD-95, thereby decreasing chemical production without interfering with the NMDAR gene function.	T11	T37	23178182
NA	CHEMICAL	GENE-Y	12	12	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/gene/nchemicalS complex by targeting gene, thereby decreasing chemical production without interfering with the NMDAR ion channel function.	T11	T33	23178182
NA	CHEMICAL	GENE-Y	12	12	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/gene/nchemicalS complex by targeting gene, thereby decreasing chemical production without interfering with the NMDAR ion channel function.	T11	T35	23178182
NA	CHEMICAL	GENE-N	12	12	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/gene/nchemicalS complex by targeting gene, thereby decreasing chemical production without interfering with the NMDAR ion channel function.	T11	T33	23178182
NA	CHEMICAL	GENE-N	12	12	An alternative approach to modulate the NMDAR-related activity is to perturb the NMDAR/gene/nchemicalS complex by targeting gene, thereby decreasing chemical production without interfering with the NMDAR ion channel function.	T11	T35	23178182
NA	CHEMICAL	GENE-N	12	6	An alternative approach to modulate the gene-related activity is to perturb the gene/PSD-95/nchemicalS complex by targeting PSD-95, thereby decreasing chemical production without interfering with the gene ion channel function.	T11	T31	23178182
NA	CHEMICAL	GENE-N	12	6	An alternative approach to modulate the gene-related activity is to perturb the gene/PSD-95/nchemicalS complex by targeting PSD-95, thereby decreasing chemical production without interfering with the gene ion channel function.	T11	T32	23178182
NA	CHEMICAL	GENE-N	12	6	An alternative approach to modulate the gene-related activity is to perturb the gene/PSD-95/nchemicalS complex by targeting PSD-95, thereby decreasing chemical production without interfering with the gene ion channel function.	T11	T36	23178182
CPR:4	CHEMICAL	GENE-Y	10	8	Here, we compared the effects of a dimeric gene inhibitor, chemical, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	T13	T38	23178182
CPR:4	CHEMICAL	GENE-N	10	8	Here, we compared the effects of a dimeric gene inhibitor, chemical, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	T13	T38	23178182
NA	CHEMICAL	GENE-N	10	13	Here, we compared the effects of a dimeric PSD-95 inhibitor, chemical, and the gene antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	T13	T39	23178182
NA	CHEMICAL	GENE-Y	15	8	Here, we compared the effects of a dimeric gene inhibitor, UCCB01-125, and the NMDAR antagonist, chemical, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	T14	T38	23178182
NA	CHEMICAL	GENE-N	15	8	Here, we compared the effects of a dimeric gene inhibitor, UCCB01-125, and the NMDAR antagonist, chemical, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	T14	T38	23178182
CPR:6	CHEMICAL	GENE-N	15	13	Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the gene antagonist, chemical, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	T14	T39	23178182
NA	CHEMICAL	GENE-Y	10	1	The gene is an ubiquitous high affinity chemical-binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.	T9	T18	23182766
NA	CHEMICAL	GENE-Y	13	6	A domain in the carboxy-terminus of gene was identified and characterized as the chemical recognition/interaction amino acid consensus (CRAC).	T6	T17	23182766
NA	CHEMICAL	GENE-Y	15	6	A domain in the carboxy-terminus of gene was identified and characterized as the cholesterol recognition/interaction chemical consensus (CRAC).	T7	T17	23182766
NA	CHEMICAL	GENE-Y	4	6	A domain in the chemical-terminus of gene was identified and characterized as the cholesterol recognition/interaction amino acid consensus (CRAC).	T5	T17	23182766
NA	CHEMICAL	GENE-Y	24	27	We report herein the therapeutic benefit that resulted for the administration of the VLNYYVWR human CRAC sequence to guinea pigs fed with a high chemical diet and gene knock-out B6.129P2-Apoetm1Unc/J mice.	T10	T19	23182766
NA	CHEMICAL	GENE-Y	14	26	CRAC treatment (3 and 30mg/kg once daily for 6 weeks) resulted in reduced circulating chemical levels in guinea pigs fed with 2% high chemical diet and gene knock-out B6.129P2-Apoetm1Unc/J mice.	T11	T20	23182766
NA	CHEMICAL	GENE-Y	14	26	CRAC treatment (3 and 30mg/kg once daily for 6 weeks) resulted in reduced circulating chemical levels in guinea pigs fed with 2% high chemical diet and gene knock-out B6.129P2-Apoetm1Unc/J mice.	T12	T20	23182766
CPR:3	CHEMICAL	GENE-N	6	11	The treatment also prevented the high chemical diet-induced increase in serum gene, total and isoforms, markers of neurological, cardiac and muscular damage.	T3	T15	23182766
CPR:3	CHEMICAL	GENE-Y	2	3	GIP potentiates chemical-stimulated gene secretion and induces energy accumulation into adipose tissue, resulting in obesity.	T1	T13	23192339
NA	CHEMICAL	GENE-Y	2	0	gene potentiates chemical-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity.	T1	T9	23192339
NA	CHEMICAL	GENE-Y	12	18	The present study investigates the combined effect of diet, physical exercise and chemical for 24 weeks, on serum genee (AMH) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.	T6	T9	23194076
NA	CHEMICAL	GENE-Y	12	20	The present study investigates the combined effect of diet, physical exercise and chemical for 24 weeks, on serum Anti-Mllerian Hormone (gene) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.	T6	T12	23194076
NA	CHEMICAL	GENE-Y	14	15	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, chemical, gene (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T17	23194076
NA	CHEMICAL	GENE-Y	14	30	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, chemical, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and gene Resistance (IR) indices were calculated.	T2	T20	23194076
NA	CHEMICAL	GENE-Y	14	21	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, chemical, sex hormone-binding globulin (SHBG), glucose, and gene were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T19	23194076
NA	CHEMICAL	GENE-Y	14	18	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, chemical, sex hormone-binding globulin (gene), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T18	23194076
NA	CHEMICAL	GENE-N	14	11	At baseline, week 12 and week 24, serum levels of AMH, gene, LH, PRL, chemical, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T14	23194076
NA	CHEMICAL	GENE-Y	14	13	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, gene, chemical, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T16	23194076
NA	CHEMICAL	GENE-Y	14	10	At baseline, week 12 and week 24, serum levels of gene, FSH, LH, PRL, chemical, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T13	23194076
NA	CHEMICAL	GENE-N	14	12	At baseline, week 12 and week 24, serum levels of AMH, FSH, gene, PRL, chemical, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T2	T15	23194076
NA	CHEMICAL	GENE-Y	26	15	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, gene (SHBG), glucose, and insulin were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T17	23194076
NA	CHEMICAL	GENE-Y	26	30	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free chemical Index (FAI) and gene Resistance (IR) indices were calculated.	T4	T20	23194076
NA	CHEMICAL	GENE-Y	26	21	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and gene were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T19	23194076
NA	CHEMICAL	GENE-Y	26	18	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (gene), glucose, and insulin were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T18	23194076
NA	CHEMICAL	GENE-N	26	11	At baseline, week 12 and week 24, serum levels of AMH, gene, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T14	23194076
NA	CHEMICAL	GENE-Y	26	13	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, gene, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T16	23194076
NA	CHEMICAL	GENE-Y	26	10	At baseline, week 12 and week 24, serum levels of gene, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T13	23194076
NA	CHEMICAL	GENE-N	26	12	At baseline, week 12 and week 24, serum levels of AMH, FSH, gene, PRL, androgens, sex hormone-binding globulin (SHBG), glucose, and insulin were measured and Free chemical Index (FAI) and Insulin Resistance (IR) indices were calculated.	T4	T15	23194076
NA	CHEMICAL	GENE-Y	19	15	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, gene (SHBG), chemical, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T17	23194076
NA	CHEMICAL	GENE-Y	19	30	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), chemical, and insulin were measured and Free Androgen Index (FAI) and gene Resistance (IR) indices were calculated.	T3	T20	23194076
NA	CHEMICAL	GENE-Y	19	21	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), chemical, and gene were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T19	23194076
NA	CHEMICAL	GENE-Y	19	18	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, PRL, androgens, sex hormone-binding globulin (gene), chemical, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T18	23194076
NA	CHEMICAL	GENE-N	19	11	At baseline, week 12 and week 24, serum levels of AMH, gene, LH, PRL, androgens, sex hormone-binding globulin (SHBG), chemical, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T14	23194076
NA	CHEMICAL	GENE-Y	19	13	At baseline, week 12 and week 24, serum levels of AMH, FSH, LH, gene, androgens, sex hormone-binding globulin (SHBG), chemical, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T16	23194076
NA	CHEMICAL	GENE-Y	19	10	At baseline, week 12 and week 24, serum levels of gene, FSH, LH, PRL, androgens, sex hormone-binding globulin (SHBG), chemical, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T13	23194076
NA	CHEMICAL	GENE-N	19	12	At baseline, week 12 and week 24, serum levels of AMH, FSH, gene, PRL, androgens, sex hormone-binding globulin (SHBG), chemical, and insulin were measured and Free Androgen Index (FAI) and Insulin Resistance (IR) indices were calculated.	T3	T15	23194076
NA	CHEMICAL	GENE-Y	9	5	After 12 weeks LH and gene were increased, while chemical decreased.	T5	T23	23194076
NA	CHEMICAL	GENE-N	9	3	After 12 weeks gene and SHBG were increased, while chemical decreased.	T5	T22	23194076
NA	CHEMICAL	GENE-Y	10	30	We concluded that in overweight and obese women with PCOS chemical administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and gene sensitivity, and increased serum AMH levels.	T7	T10	23194076
CPR:3	CHEMICAL	GENE-Y	10	35	We concluded that in overweight and obese women with PCOS chemical administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum gene levels.	T7	T11	23194076
NA	CHEMICAL	GENE-N	8	26	These actions are mediated by the activation of chemical receptors (ER) alpha (ER) and beta (ER), which regulate target gene transcription (genomic action) through two independent gene (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	T6	T16	23200732
NA	CHEMICAL	GENE-N	8	28	These actions are mediated by the activation of chemical receptors (ER) alpha (ER) and beta (ER), which regulate target gene transcription (genomic action) through two independent activation functions gene and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	T6	T17	23200732
NA	CHEMICAL	GENE-N	8	30	These actions are mediated by the activation of chemical receptors (ER) alpha (ER) and beta (ER), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and gene, but can also elicit rapid membrane initiated steroid signals (MISS).	T6	T18	23200732
NA	CHEMICAL	GENE-Y	8	15	These actions are mediated by the activation of chemical receptors (ER) alpha (ER) and beta (gene), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated steroid signals (MISS).	T6	T15	23200732
NA	CHEMICAL	GENE-N	38	8	These actions are mediated by the activation of gene (ER), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated chemical signals (MISS).	T7	T14	23200732
NA	CHEMICAL	GENE-N	38	26	These actions are mediated by the activation of estrogen receptors (ER) alpha (ER) and beta (ER), which regulate target gene transcription (genomic action) through two independent gene (AF)-1 and AF-2, but can also elicit rapid membrane initiated chemical signals (MISS).	T7	T16	23200732
NA	CHEMICAL	GENE-N	38	28	These actions are mediated by the activation of estrogen receptors (ER) alpha (ER) and beta (ER), which regulate target gene transcription (genomic action) through two independent activation functions gene and AF-2, but can also elicit rapid membrane initiated chemical signals (MISS).	T7	T17	23200732
NA	CHEMICAL	GENE-N	38	30	These actions are mediated by the activation of estrogen receptors (ER) alpha (ER) and beta (ER), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and gene, but can also elicit rapid membrane initiated chemical signals (MISS).	T7	T18	23200732
NA	CHEMICAL	GENE-Y	38	15	These actions are mediated by the activation of estrogen receptors (ER) alpha (ER) and beta (gene), which regulate target gene transcription (genomic action) through two independent activation functions (AF)-1 and AF-2, but can also elicit rapid membrane initiated chemical signals (MISS).	T7	T15	23200732
NA	CHEMICAL	GENE-Y	5	8	However, the use of these chemical or selective gene modulators (SERMs) have also induced undesired effects.	T2	T11	23200732
NA	CHEMICAL	GENE-N	32	20	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of gene (Oat)1 and Oat3 in rat kidney in response to chemical treatment.	T13	T25	23201003
NA	CHEMICAL	GENE-Y	32	23	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter gene and Oat3 in rat kidney in response to chemical treatment.	T13	T26	23201003
NA	CHEMICAL	GENE-Y	32	25	Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of organic anion transporter (Oat)1 and gene in rat kidney in response to chemical treatment.	T13	T27	23201003
CPR:4	CHEMICAL	GENE-Y	1	5	Moreover, chemical decreased expression of gene and Oat3 in rat kidney.	T2	T22	23201003
CPR:4	CHEMICAL	GENE-Y	1	7	Moreover, chemical decreased expression of Oat1 and gene in rat kidney.	T2	T23	23201003
NA	CHEMICAL	GENE-N	7	23	The mechanism of interaction between JBP485 and chemical could be explained at least in part by inhibitory effect of chemical on expression of gene in rat kidney.	T7	T24	23201003
CPR:4	CHEMICAL	GENE-N	7	23	The mechanism of interaction between JBP485 and chemical could be explained at least in part by inhibitory effect of chemical on expression of gene in rat kidney.	T8	T24	23201003
NA	CHEMICAL	GENE-N	5	23	The mechanism of interaction between chemical and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of gene in rat kidney.	T6	T24	23201003
NA	CHEMICAL	GENE-Y	31	11	We describe the synthesis of a core-shell biohybrid consisting of a gene (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of chemical-G2.0-PAMAM or chemical-G3.0-PAMAM dendrons.	T1	T12	23210662
NA	CHEMICAL	GENE-Y	31	11	We describe the synthesis of a core-shell biohybrid consisting of a gene (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of chemical-G2.0-PAMAM or chemical-G3.0-PAMAM dendrons.	T3	T12	23210662
NA	CHEMICAL	GENE-Y	31	14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (gene) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of chemical-G2.0-PAMAM or chemical-G3.0-PAMAM dendrons.	T1	T14	23210662
NA	CHEMICAL	GENE-Y	31	14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (gene) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of chemical-G2.0-PAMAM or chemical-G3.0-PAMAM dendrons.	T3	T14	23210662
NA	CHEMICAL	GENE-Y	31	11	We describe the synthesis of a core-shell biohybrid consisting of a gene (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-chemical or ethynyl-G3.0-chemical dendrons.	T2	T12	23210662
NA	CHEMICAL	GENE-Y	31	11	We describe the synthesis of a core-shell biohybrid consisting of a gene (HSA) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-chemical or ethynyl-G3.0-chemical dendrons.	T4	T12	23210662
NA	CHEMICAL	GENE-Y	31	14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (gene) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-chemical or ethynyl-G3.0-chemical dendrons.	T2	T14	23210662
NA	CHEMICAL	GENE-Y	31	14	We describe the synthesis of a core-shell biohybrid consisting of a human serum albumin (gene) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of ethynyl-G2.0-chemical or ethynyl-G3.0-chemical dendrons.	T4	T14	23210662
NA	CHEMICAL	GENE-Y	3	6	The attachment of chemical-G2.0-PAMAM dendrons to gene yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic PAMAM shell.	T5	T11	23210662
NA	CHEMICAL	GENE-Y	3	6	The attachment of ethynyl-G2.0-chemical dendrons to gene yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic chemical shell.	T6	T11	23210662
NA	CHEMICAL	GENE-Y	3	6	The attachment of ethynyl-G2.0-chemical dendrons to gene yielded a nontoxic core-shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic chemical shell.	T7	T11	23210662
NA	CHEMICAL	GENE-Y	4	9	Significantly higher loading of chemical was observed for dendronized G2-Dgene compared with the native protein due to the availability of binding pockets of the gene core, and interaction with the dendritic shell.	T8	T13	23210662
NA	CHEMICAL	GENE-N	10	23	The present study investigated the effect of neonatal exposure to chemical on hippocampus-dependent novel object recognition test performance and the expression of the gene and its signal transduction pathway-related genes in the hippocampi of young adult and adult mice.	T9	T22	23212306
NA	CHEMICAL	GENE-N	27	24	The hippocampi were collected on PND 50 or PND 85 after the completion of the novel object recognition test, and the expression levels of gene and the chemical receptor and its signal transduction pathway-related genes were examined using real-time RT-PCR.	T13	T23	23212306
NA	CHEMICAL	GENE-Y	20	12	The NMDA receptor subunits NR1 and NR2B and the related protein kinase gene and the transcription factor chemical responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T4	T18	23212306
NA	CHEMICAL	GENE-N	20	1	The gene and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor chemical responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T4	T16	23212306
NA	CHEMICAL	GENE-N	20	11	The NMDA receptor subunits NR1 and NR2B and the related protein gene calcium/calmodulin-dependent protein gene (CaMK)-IV and the transcription factor chemical responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T4	T17	23212306
NA	CHEMICAL	GENE-Y	12	20	The NMDA receptor subunits NR1 and NR2B and the related protein kinase chemical/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor gene mRNA levels were reduced in the PND 50 mice.	T3	T19	23212306
NA	CHEMICAL	GENE-N	12	1	The gene and the related protein kinase chemical/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T3	T16	23212306
NA	CHEMICAL	GENE-N	12	11	The NMDA receptor subunits NR1 and NR2B and the related protein gene chemical/calmodulin-dependent protein gene (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T3	T17	23212306
NA	CHEMICAL	GENE-Y	1	20	The chemical receptor subunits NR1 and NR2B and the related protein kinase calcium/calmodulin-dependent protein kinase (CaMK)-IV and the transcription factor gene mRNA levels were reduced in the PND 50 mice.	T2	T19	23212306
NA	CHEMICAL	GENE-Y	1	12	The chemical receptor subunits NR1 and NR2B and the related protein kinase gene and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T2	T18	23212306
NA	CHEMICAL	GENE-N	1	11	The chemical receptor subunits NR1 and NR2B and the related protein gene calcium/calmodulin-dependent protein gene (CaMK)-IV and the transcription factor cyclic AMP responsive element binding protein (CREB)-1 mRNA levels were reduced in the PND 50 mice.	T2	T17	23212306
NA	CHEMICAL	GENE-N	5	23	These results indicate that neonatal chemical exposure impaired the hippocampus-dependent novel object recognition ability, accompanied by a modulation in the expressions of the gene and neurotrophin in young adult and adult mice.	T7	T21	23212306
NA	CHEMICAL	GENE-Y	4	0	gene is a lysosomal chemical protease whose biological function remains poorly defined.	T1	T2	23215039
NA	CHEMICAL	GENE-N	22	11	The accuracy of DNA synthesis depends on the accuracy of the gene as well as the quality and concentration(s) of the available chemical DNA precursors (dNTPs).	T3	T23	23218950
NA	CHEMICAL	GENE-N	25	11	The accuracy of DNA synthesis depends on the accuracy of the gene as well as the quality and concentration(s) of the available 5'-deoxynucleoside-triphosphate DNA precursors (chemical).	T7	T23	23218950
NA	CHEMICAL	GENE-Y	7	4	These strains, defective in gene and chemical kinase, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.	T10	T21	23218950
NA	CHEMICAL	GENE-Y	4	7	These strains, defective in chemical deaminase and gene, respectively, are characterized by both disturbances of dNTP pools and a mutator phenotype.	T9	T22	23218950
NA	CHEMICAL	GENE-Y	17	7	These strains, defective in dCTP deaminase and gene, respectively, are characterized by both disturbances of chemical pools and a mutator phenotype.	T11	T22	23218950
NA	CHEMICAL	GENE-Y	17	4	These strains, defective in gene and nucleoside diphosphate kinase, respectively, are characterized by both disturbances of chemical pools and a mutator phenotype.	T11	T21	23218950
NA	CHEMICAL	GENE-N	11	41	We show that dcd strains suffer from increased intracellular levels of chemical (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for gene and ATTA transversions (27- and 42-fold enhancement, respectively).	T12	T14	23218950
NA	CHEMICAL	GENE-N	11	43	We show that dcd strains suffer from increased intracellular levels of chemical (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for GCTA and gene transversions (27- and 42-fold enhancement, respectively).	T12	T15	23218950
NA	CHEMICAL	GENE-Y	11	3	We show that gene strains suffer from increased intracellular levels of chemical (4-fold) and reduced levels of dGTP (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for GCTA and ATTA transversions (27- and 42-fold enhancement, respectively).	T12	T25	23218950
NA	CHEMICAL	GENE-N	17	41	We show that dcd strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of chemical (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for gene and ATTA transversions (27- and 42-fold enhancement, respectively).	T13	T14	23218950
NA	CHEMICAL	GENE-N	17	43	We show that dcd strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of chemical (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for GCTA and gene transversions (27- and 42-fold enhancement, respectively).	T13	T15	23218950
NA	CHEMICAL	GENE-Y	17	3	We show that gene strains suffer from increased intracellular levels of dCTP (4-fold) and reduced levels of chemical (2-fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch-repair defective (mutL) background, a strong mutator effect for GCTA and ATTA transversions (27- and 42-fold enhancement, respectively).	T13	T25	23218950
NA	CHEMICAL	GENE-N	7	25	In contrast, ndk strains possess a lowered chemical level (4-fold) and modestly enhanced dCTP level (2-fold), while its mutator effect is specific for just the gene transversions.	T1	T17	23218950
NA	CHEMICAL	GENE-Y	7	2	In contrast, gene strains possess a lowered chemical level (4-fold) and modestly enhanced dCTP level (2-fold), while its mutator effect is specific for just the ATTA transversions.	T1	T16	23218950
NA	CHEMICAL	GENE-N	13	25	In contrast, ndk strains possess a lowered dATP level (4-fold) and modestly enhanced chemical level (2-fold), while its mutator effect is specific for just the gene transversions.	T2	T17	23218950
NA	CHEMICAL	GENE-Y	13	2	In contrast, gene strains possess a lowered dATP level (4-fold) and modestly enhanced chemical level (2-fold), while its mutator effect is specific for just the ATTA transversions.	T2	T16	23218950
NA	CHEMICAL	GENE-Y	11	28	Overall, our analysis reveals for both strains a satisfactory correlation between chemical pool alterations and the replication error rates, and also suggests that a minimal explanation for the gene mutator does not require assumptions beyond the predicted effect of the chemical pools.	T5	T18	23218950
NA	CHEMICAL	GENE-Y	11	28	Overall, our analysis reveals for both strains a satisfactory correlation between chemical pool alterations and the replication error rates, and also suggests that a minimal explanation for the gene mutator does not require assumptions beyond the predicted effect of the chemical pools.	T6	T18	23218950
CPR:4	CHEMICAL	GENE-N	0	12	chemical is able to induce apoptosis through mitochondrial dysfunction and inhibition of gene/Akt signaling pathway in HepG2 cells, however, the effects of chemical on MAPK signaling pathways remain unknown.	T13	T35	23220614
NA	CHEMICAL	GENE-N	0	12	chemical is able to induce apoptosis through mitochondrial dysfunction and inhibition of gene/Akt signaling pathway in HepG2 cells, however, the effects of chemical on MAPK signaling pathways remain unknown.	T15	T35	23220614
NA	CHEMICAL	GENE-N	0	24	chemical is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of chemical on gene signaling pathways remain unknown.	T13	T37	23220614
NA	CHEMICAL	GENE-N	0	24	chemical is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of chemical on gene signaling pathways remain unknown.	T15	T37	23220614
CPR:4	CHEMICAL	GENE-N	0	12	chemical is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/gene signaling pathway in HepG2 cells, however, the effects of chemical on MAPK signaling pathways remain unknown.	T13	T36	23220614
NA	CHEMICAL	GENE-N	0	12	chemical is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/gene signaling pathway in HepG2 cells, however, the effects of chemical on MAPK signaling pathways remain unknown.	T15	T36	23220614
NA	CHEMICAL	GENE-N	7	16	The present study investigated the effects of chemical on this pathway, and the roles of MAPK gene on mitochondrial-mediated apoptosis in HepG2 cells.	T16	T39	23220614
NA	CHEMICAL	GENE-N	7	15	The present study investigated the effects of chemical on this pathway, and the roles of gene kinases on mitochondrial-mediated apoptosis in HepG2 cells.	T16	T38	23220614
CPR:3	CHEMICAL	GENE-N	0	16	chemical significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38 gene.	T20	T43	23220614
NA	CHEMICAL	GENE-N	0	6	chemical significantly inhibited the levels of gene kinase and increased the expression of JNK and p38 kinases.	T20	T40	23220614
CPR:3	CHEMICAL	GENE-N	0	15	chemical significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and gene kinases.	T20	T42	23220614
CPR:3	CHEMICAL	GENE-N	0	13	chemical significantly inhibited the levels of ERK1/2 kinase and increased the expression of gene and p38 kinases.	T20	T41	23220614
NA	CHEMICAL	GENE-Y	1	15	Furthermore, chemical (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of gene to the cytosol fraction, and the levels of cleaved caspase-3.	T21	T47	23220614
NA	CHEMICAL	GENE-Y	1	26	Furthermore, chemical (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved gene.	T21	T48	23220614
NA	CHEMICAL	GENE-N	1	3	Furthermore, chemical (an gene inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	T21	T44	23220614
CPR:3	CHEMICAL	GENE-Y	1	10	Furthermore, chemical (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/gene ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	T21	T46	23220614
CPR:3	CHEMICAL	GENE-Y	1	10	Furthermore, chemical (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the gene/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	T21	T45	23220614
NA	CHEMICAL	GENE-Y	8	15	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the chemical-induced the Bax/Bcl-2 ratio, the release of gene to the cytosol fraction, and the levels of cleaved caspase-3.	T22	T47	23220614
NA	CHEMICAL	GENE-Y	8	26	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the chemical-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved gene.	T22	T48	23220614
NA	CHEMICAL	GENE-N	8	3	Furthermore, U0126 (an gene inhibitor) significantly enhanced the chemical-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	T22	T44	23220614
CPR:3	CHEMICAL	GENE-Y	8	10	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the chemical-induced the Bax/gene ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	T22	T46	23220614
CPR:3	CHEMICAL	GENE-Y	8	10	Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the chemical-induced the gene/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.	T22	T45	23220614
NA	CHEMICAL	GENE-N	1	8	While chemical (a JNK inhibitor) and SB203580 (a gene inhibitor) markedly prevented the expression of these proteins induced by ISO.	T2	T25	23220614
CPR:4	CHEMICAL	GENE-N	1	3	While chemical (a gene inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.	T2	T24	23220614
CPR:4	CHEMICAL	GENE-N	6	8	While SP600125 (a JNK inhibitor) and chemical (a gene inhibitor) markedly prevented the expression of these proteins induced by ISO.	T3	T25	23220614
NA	CHEMICAL	GENE-N	6	3	While SP600125 (a gene inhibitor) and chemical (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.	T3	T24	23220614
CPR:3	CHEMICAL	GENE-N	19	8	While SP600125 (a JNK inhibitor) and SB203580 (a gene inhibitor) markedly prevented the expression of these proteins induced by chemical.	T4	T25	23220614
CPR:3	CHEMICAL	GENE-N	19	3	While SP600125 (a gene inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by chemical.	T4	T24	23220614
NA	CHEMICAL	GENE-N	11	14	Furthermore, the ROS inhibitor (NAC) notably promoted the inhibited effect of chemical on the gene kinase.	T6	T26	23220614
NA	CHEMICAL	GENE-N	4	14	Furthermore, the ROS inhibitor (chemical) notably promoted the inhibited effect of ISO on the gene kinase.	T5	T26	23220614
NA	CHEMICAL	GENE-N	14	6	NAC also suppressed the p-JNK and gene, but failed to reverse the effects of chemical.	T8	T28	23220614
NA	CHEMICAL	GENE-N	14	4	NAC also suppressed the p-gene and p-p38, but failed to reverse the effects of chemical.	T8	T27	23220614
CPR:4	CHEMICAL	GENE-N	0	6	chemical also suppressed the p-JNK and gene, but failed to reverse the effects of ISO.	T7	T28	23220614
CPR:4	CHEMICAL	GENE-N	0	4	chemical also suppressed the p-gene and p-p38, but failed to reverse the effects of ISO.	T7	T27	23220614
CPR:3	CHEMICAL	GENE-N	8	23	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 gene, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T10	T32	23220614
NA	CHEMICAL	GENE-N	8	23	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 gene, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T11	T32	23220614
NA	CHEMICAL	GENE-N	8	16	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating gene kinase and activating JNK and p38 kinases, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T10	T29	23220614
NA	CHEMICAL	GENE-N	8	16	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating gene kinase and activating JNK and p38 kinases, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T11	T29	23220614
NA	CHEMICAL	GENE-N	8	34	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by chemical is able to activate the gene singaling pathway as the upstream signaling molecules.	T10	T33	23220614
CPR:3	CHEMICAL	GENE-N	8	34	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by chemical is able to activate the gene singaling pathway as the upstream signaling molecules.	T11	T33	23220614
CPR:3	CHEMICAL	GENE-N	8	22	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and gene kinases, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T10	T31	23220614
NA	CHEMICAL	GENE-N	8	22	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and gene kinases, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T11	T31	23220614
CPR:3	CHEMICAL	GENE-N	8	20	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating gene and p38 kinases, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T10	T30	23220614
NA	CHEMICAL	GENE-N	8	20	These results demonstrated for the first time that chemical induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating gene and p38 kinases, and ROS stimulated by chemical is able to activate the MAPK singaling pathway as the upstream signaling molecules.	T11	T30	23220614
NA	CHEMICAL	GENE-N	8	10	Initiating event of the mitochondrial-mediated apoptosis induced by chemical is gene signals.	T12	T34	23220614
CPR:4	CHEMICAL	GENE-Y	4	18	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and IMG or chemical inhibited production of gene and FXa in HUVECs.	T11	T33	23220618
NA	CHEMICAL	GENE-Y	4	18	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and IMG or chemical inhibited production of gene and FXa in HUVECs.	T11	T35	23220618
NA	CHEMICAL	GENE-Y	4	18	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and IMG or chemical inhibited production of gene and FXa in HUVECs.	T13	T33	23220618
CPR:4	CHEMICAL	GENE-Y	4	18	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and IMG or chemical inhibited production of gene and FXa in HUVECs.	T13	T35	23220618
CPR:4	CHEMICAL	GENE-Y	4	20	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and IMG or chemical inhibited production of thrombin and gene in HUVECs.	T11	T34	23220618
NA	CHEMICAL	GENE-Y	4	20	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and IMG or chemical inhibited production of thrombin and gene in HUVECs.	T11	T36	23220618
NA	CHEMICAL	GENE-Y	4	20	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and IMG or chemical inhibited production of thrombin and gene in HUVECs.	T13	T34	23220618
CPR:4	CHEMICAL	GENE-Y	4	20	Treatment with IMG and chemical resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and IMG or chemical inhibited production of thrombin and gene in HUVECs.	T13	T36	23220618
CPR:4	CHEMICAL	GENE-Y	2	18	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and chemical or hyperoside inhibited production of gene and FXa in HUVECs.	T10	T33	23220618
NA	CHEMICAL	GENE-Y	2	18	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and chemical or hyperoside inhibited production of gene and FXa in HUVECs.	T10	T35	23220618
NA	CHEMICAL	GENE-Y	2	18	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and chemical or hyperoside inhibited production of gene and FXa in HUVECs.	T12	T33	23220618
CPR:3	CHEMICAL	GENE-Y	2	18	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of gene and FXa, and chemical or hyperoside inhibited production of gene and FXa in HUVECs.	T12	T35	23220618
CPR:4	CHEMICAL	GENE-Y	2	20	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and chemical or hyperoside inhibited production of thrombin and gene in HUVECs.	T10	T34	23220618
NA	CHEMICAL	GENE-Y	2	20	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and chemical or hyperoside inhibited production of thrombin and gene in HUVECs.	T10	T36	23220618
NA	CHEMICAL	GENE-Y	2	20	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and chemical or hyperoside inhibited production of thrombin and gene in HUVECs.	T12	T34	23220618
CPR:4	CHEMICAL	GENE-Y	2	20	Treatment with chemical and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and gene, and chemical or hyperoside inhibited production of thrombin and gene in HUVECs.	T12	T36	23220618
CPR:4	CHEMICAL	GENE-Y	6	14	In addition, treatment with IMG and chemical resulted in inhibition of TNF--induced production of gene, and treatment with IMG resulted in significant reduction of the gene to t-PA ratio.	T16	T20	23220618
NA	CHEMICAL	GENE-Y	6	14	In addition, treatment with IMG and chemical resulted in inhibition of TNF--induced production of gene, and treatment with IMG resulted in significant reduction of the gene to t-PA ratio.	T16	T21	23220618
CPR:4	CHEMICAL	GENE-Y	6	11	In addition, treatment with IMG and chemical resulted in inhibition of gene-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.	T16	T19	23220618
NA	CHEMICAL	GENE-Y	6	27	In addition, treatment with IMG and chemical resulted in inhibition of TNF--induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to gene ratio.	T16	T22	23220618
CPR:4	CHEMICAL	GENE-Y	4	14	In addition, treatment with chemical and hyperoside resulted in inhibition of TNF--induced production of gene, and treatment with chemical resulted in significant reduction of the gene to t-PA ratio.	T15	T20	23220618
NA	CHEMICAL	GENE-Y	4	14	In addition, treatment with chemical and hyperoside resulted in inhibition of TNF--induced production of gene, and treatment with chemical resulted in significant reduction of the gene to t-PA ratio.	T15	T21	23220618
NA	CHEMICAL	GENE-Y	4	14	In addition, treatment with chemical and hyperoside resulted in inhibition of TNF--induced production of gene, and treatment with chemical resulted in significant reduction of the gene to t-PA ratio.	T2	T20	23220618
CPR:4	CHEMICAL	GENE-Y	4	14	In addition, treatment with chemical and hyperoside resulted in inhibition of TNF--induced production of gene, and treatment with chemical resulted in significant reduction of the gene to t-PA ratio.	T2	T21	23220618
CPR:4	CHEMICAL	GENE-Y	4	11	In addition, treatment with chemical and hyperoside resulted in inhibition of gene-induced production of PAI-1, and treatment with chemical resulted in significant reduction of the PAI-1 to t-PA ratio.	T15	T19	23220618
NA	CHEMICAL	GENE-Y	4	11	In addition, treatment with chemical and hyperoside resulted in inhibition of gene-induced production of PAI-1, and treatment with chemical resulted in significant reduction of the PAI-1 to t-PA ratio.	T2	T19	23220618
NA	CHEMICAL	GENE-Y	4	27	In addition, treatment with chemical and hyperoside resulted in inhibition of TNF--induced production of PAI-1, and treatment with chemical resulted in significant reduction of the PAI-1 to gene ratio.	T15	T22	23220618
CPR:4	CHEMICAL	GENE-Y	4	27	In addition, treatment with chemical and hyperoside resulted in inhibition of TNF--induced production of PAI-1, and treatment with chemical resulted in significant reduction of the PAI-1 to gene ratio.	T2	T22	23220618
CPR:9	CHEMICAL	GENE-Y	15	8	Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and gene (LTA(4)H) may balance the chemical (AA) metabolic network and be used as new anti-inflammatory drugs.	T1	T13	23220644
CPR:9	CHEMICAL	GENE-N	15	4	Dual function inhibitors targeting gene (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the chemical (AA) metabolic network and be used as new anti-inflammatory drugs.	T1	T8	23220644
CPR:9	CHEMICAL	GENE-Y	15	11	Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (gene) may balance the chemical (AA) metabolic network and be used as new anti-inflammatory drugs.	T1	T16	23220644
CPR:9	CHEMICAL	GENE-N	15	6	Dual function inhibitors targeting phospholipase A(2) (gene) and leukotriene A(4) hydrolase (LTA(4)H) may balance the chemical (AA) metabolic network and be used as new anti-inflammatory drugs.	T1	T12	23220644
CPR:4	CHEMICAL	GENE-Y	17	19	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (chemical) for gene (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.	T2	T7	23220644
CPR:4	CHEMICAL	GENE-Y	17	26	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (chemical) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and gene (LTA(4)H-h) was found.	T2	T10	23220644
CPR:4	CHEMICAL	GENE-Y	17	24	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (chemical) for human nonpancreatic secretory phospholipase A(2) (gene) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.	T2	T9	23220644
CPR:4	CHEMICAL	GENE-Y	17	30	In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (chemical) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase (gene) was found.	T2	T11	23220644
NA	CHEMICAL	GENE-N	16	6	We wanted to test whether sensory gene are a molecular target for chemical.	T7	T18	23220749
NA	CHEMICAL	GENE-Y	26	14	Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and gene, which are expressed in dorsal root ganglion neurons, are insensitive toward chemical treatment.	T9	T24	23220749
NA	CHEMICAL	GENE-Y	26	6	Here, we show that rTRPV1, rTRPV2, gene, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward chemical treatment.	T9	T21	23220749
NA	CHEMICAL	GENE-Y	26	12	Here, we show that rTRPV1, rTRPV2, rTRPV3, and mTRPV4, as well as gene, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward chemical treatment.	T9	T23	23220749
NA	CHEMICAL	GENE-Y	26	8	Here, we show that rTRPV1, rTRPV2, rTRPV3, and gene, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward chemical treatment.	T9	T22	23220749
NA	CHEMICAL	GENE-Y	26	5	Here, we show that rTRPV1, gene, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward chemical treatment.	T9	T20	23220749
NA	CHEMICAL	GENE-Y	26	4	Here, we show that gene, rTRPV2, rTRPV3, and mTRPV4, as well as hTRPM8, and rTRPM3, which are expressed in dorsal root ganglion neurons, are insensitive toward chemical treatment.	T9	T19	23220749
NA	CHEMICAL	GENE-Y	10	3	On the contrary, gene could be concentration-dependently modulated by chemical.	T11	T26	23220749
CPR:4	CHEMICAL	GENE-N	4	29	Whereas the addition of chemical in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed gene channels, resulting from a reduction of single-channel open times.	T12	T27	23220749
CPR:4	CHEMICAL	GENE-Y	4	29	Whereas the addition of chemical in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed gene channels, resulting from a reduction of single-channel open times.	T12	T27	23220749
NA	CHEMICAL	GENE-N	6	11	In addition, we provide evidence that chemical also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of gene.	T2	T14	23220749
CPR:3	CHEMICAL	GENE-N	6	11	In addition, we provide evidence that chemical also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of gene.	T2	T15	23220749
NA	CHEMICAL	GENE-Y	6	11	In addition, we provide evidence that chemical also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of gene.	T2	T14	23220749
CPR:3	CHEMICAL	GENE-Y	6	11	In addition, we provide evidence that chemical also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of gene.	T2	T15	23220749
NA	CHEMICAL	GENE-N	30	11	In addition, we provide evidence that apomorphine also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which chemical is released upon activation of gene.	T3	T14	23220749
NA	CHEMICAL	GENE-N	30	11	In addition, we provide evidence that apomorphine also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which chemical is released upon activation of gene.	T3	T15	23220749
NA	CHEMICAL	GENE-Y	30	11	In addition, we provide evidence that apomorphine also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which chemical is released upon activation of gene.	T3	T14	23220749
NA	CHEMICAL	GENE-Y	30	11	In addition, we provide evidence that apomorphine also acts on endogenous gene in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which chemical is released upon activation of gene.	T3	T15	23220749
NA	CHEMICAL	GENE-Y	10	4	Our study shows that gene is a target for chemical, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with chemical.	T4	T16	23220749
NA	CHEMICAL	GENE-Y	10	4	Our study shows that gene is a target for chemical, suggesting that an activation of TRPA1 might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with chemical.	T5	T16	23220749
CPR:3	CHEMICAL	GENE-N	10	5	Our study shows that human gene is a target for chemical, suggesting that an activation of gene might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with chemical.	T4	T17	23220749
CPR:3	CHEMICAL	GENE-N	10	5	Our study shows that human gene is a target for chemical, suggesting that an activation of gene might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with chemical.	T5	T17	23220749
CPR:3	CHEMICAL	GENE-Y	10	5	Our study shows that human gene is a target for chemical, suggesting that an activation of gene might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with chemical.	T4	T17	23220749
CPR:3	CHEMICAL	GENE-Y	10	5	Our study shows that human gene is a target for chemical, suggesting that an activation of gene might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with chemical.	T5	T17	23220749
NA	CHEMICAL	GENE-Y	17	0	gene (SCD-1) plays a pivotal role in an increase of triglyceride by an excess of dietary chemical intake.	T2	T10	23221600
NA	CHEMICAL	GENE-Y	17	2	Stearoyl-CoA desaturase-1 (gene) plays a pivotal role in an increase of triglyceride by an excess of dietary chemical intake.	T2	T22	23221600
NA	CHEMICAL	GENE-Y	11	0	gene (SCD-1) plays a pivotal role in an increase of chemical by an excess of dietary carbohydrate intake.	T6	T10	23221600
NA	CHEMICAL	GENE-Y	11	2	Stearoyl-CoA desaturase-1 (gene) plays a pivotal role in an increase of chemical by an excess of dietary carbohydrate intake.	T6	T22	23221600
NA	CHEMICAL	GENE-Y	0	2	chemical desaturase-1 (gene) plays a pivotal role in an increase of triglyceride by an excess of dietary carbohydrate intake.	T1	T22	23221600
NA	CHEMICAL	GENE-Y	1	9	Dietary chemical increase SCD-1 gene expression in liver by gene-dependent and SREBP-1c -independent pathways.	T3	T20	23221600
NA	CHEMICAL	GENE-Y	1	16	Dietary chemical increase SCD-1 gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and gene -independent pathways.	T3	T21	23221600
CPR:3	CHEMICAL	GENE-Y	1	3	Dietary chemical increase gene gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.	T3	T19	23221600
NA	CHEMICAL	GENE-Y	9	16	Dietary carbohydrates increase SCD-1 gene expression in liver by chemical response element binding protein (SREBP)-1c-dependent and gene -independent pathways.	T4	T21	23221600
NA	CHEMICAL	GENE-Y	9	3	Dietary carbohydrates increase gene gene expression in liver by chemical response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.	T4	T19	23221600
CPR:4	CHEMICAL	GENE-N	4	9	Previous report demonstrated that chemical (TH) negatively regulates gene before SREBP-1c was revealed.	T5	T23	23221600
NA	CHEMICAL	GENE-Y	4	14	Previous report demonstrated that chemical (TH) negatively regulates mouse SCD-1 gene promoter before gene was revealed.	T5	T24	23221600
NA	CHEMICAL	GENE-N	36	22	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between gene and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T17	23223177
NA	CHEMICAL	GENE-Y	36	22	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between gene and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T17	23223177
NA	CHEMICAL	GENE-Y	36	24	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and gene, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T18	23223177
NA	CHEMICAL	GENE-N	36	24	We hypothesized that AMPK-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of AMPK on the interaction between Beclin1 and gene, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T18	23223177
NA	CHEMICAL	GENE-N	36	3	We hypothesized that gene-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of gene on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T15	23223177
NA	CHEMICAL	GENE-N	36	3	We hypothesized that gene-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of gene on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T16	23223177
NA	CHEMICAL	GENE-Y	36	3	We hypothesized that gene-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of gene on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T15	23223177
NA	CHEMICAL	GENE-Y	36	3	We hypothesized that gene-induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of gene on the interaction between Beclin1 and Bcl-2, a switch between autophagy and apoptosis, in diabetic mice and high chemical-treated H9c2 cardiac myoblast cells.	T2	T16	23223177
CPR:4	CHEMICAL	GENE-Y	6	11	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited gene (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T3	T20	23223177
CPR:4	CHEMICAL	GENE-Y	6	15	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-gene (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T3	T22	23223177
NA	CHEMICAL	GENE-N	6	22	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted gene binding to Bcl-2.	T3	T24	23223177
NA	CHEMICAL	GENE-Y	6	22	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted gene binding to Bcl-2.	T3	T24	23223177
CPR:4	CHEMICAL	GENE-Y	6	18	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T3	T23	23223177
NA	CHEMICAL	GENE-Y	6	18	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T3	T25	23223177
CPR:4	CHEMICAL	GENE-N	6	18	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T3	T23	23223177
NA	CHEMICAL	GENE-N	6	18	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T3	T25	23223177
CPR:4	CHEMICAL	GENE-N	6	8	Exposure of H9c2 cells to high chemical reduced gene activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T3	T19	23223177
CPR:4	CHEMICAL	GENE-Y	6	8	Exposure of H9c2 cells to high chemical reduced gene activity, inhibited Jun NH2-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T3	T19	23223177
CPR:4	CHEMICAL	GENE-Y	6	15	Exposure of H9c2 cells to high chemical reduced AMPK activity, inhibited Jun NH2-terminal kinase 1 (gene)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T3	T21	23223177
NA	CHEMICAL	GENE-Y	12	15	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-gene (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T4	T22	23223177
NA	CHEMICAL	GENE-N	12	22	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted gene binding to Bcl-2.	T4	T24	23223177
NA	CHEMICAL	GENE-Y	12	22	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted gene binding to Bcl-2.	T4	T24	23223177
NA	CHEMICAL	GENE-Y	12	18	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T4	T23	23223177
NA	CHEMICAL	GENE-Y	12	18	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T4	T25	23223177
NA	CHEMICAL	GENE-N	12	18	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T4	T23	23223177
NA	CHEMICAL	GENE-N	12	18	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (gene) signaling, and promoted Beclin1 binding to gene.	T4	T25	23223177
NA	CHEMICAL	GENE-N	12	8	Exposure of H9c2 cells to high glucose reduced gene activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T4	T19	23223177
NA	CHEMICAL	GENE-Y	12	8	Exposure of H9c2 cells to high glucose reduced gene activity, inhibited Jun chemical-terminal kinase 1 (JNK1)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T4	T19	23223177
NA	CHEMICAL	GENE-Y	12	15	Exposure of H9c2 cells to high glucose reduced AMPK activity, inhibited Jun chemical-terminal kinase 1 (gene)-B-cell lymphoma 2 (Bcl-2) signaling, and promoted Beclin1 binding to Bcl-2.	T4	T21	23223177
NA	CHEMICAL	GENE-N	9	2	Activation of gene, which normalized cardiac autophagy, attenuated high chemical-induced apoptosis in cultured H9c2 cells.	T5	T31	23223177
NA	CHEMICAL	GENE-Y	9	2	Activation of gene, which normalized cardiac autophagy, attenuated high chemical-induced apoptosis in cultured H9c2 cells.	T5	T31	23223177
NA	CHEMICAL	GENE-N	4	17	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating gene and Bcl-2.	T1	T9	23223177
NA	CHEMICAL	GENE-Y	4	17	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating JNK1-Bcl-2 pathways and dissociating gene and Bcl-2.	T1	T9	23223177
NA	CHEMICAL	GENE-Y	4	13	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating JNK1-gene pathways and dissociating Beclin1 and gene.	T1	T10	23223177
CPR:3	CHEMICAL	GENE-Y	4	13	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating JNK1-gene pathways and dissociating Beclin1 and gene.	T1	T8	23223177
NA	CHEMICAL	GENE-N	4	13	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating JNK1-gene pathways and dissociating Beclin1 and gene.	T1	T10	23223177
CPR:3	CHEMICAL	GENE-N	4	13	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating JNK1-gene pathways and dissociating Beclin1 and gene.	T1	T8	23223177
CPR:3	CHEMICAL	GENE-Y	4	13	Finally, chronic administration of chemical in diabetic mice restored cardiac autophagy by activating gene-Bcl-2 pathways and dissociating Beclin1 and Bcl-2.	T1	T7	23223177
NA	CHEMICAL	GENE-Y	29	4	High expression levels of gene (ERCC1) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with chemical-containing chemotherapy.	T12	T28	23228696
NA	CHEMICAL	GENE-Y	29	8	High expression levels of excision repair cross-complementary 1 (gene) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with chemical-containing chemotherapy.	T12	T29	23228696
CPR:3	CHEMICAL	GENE-N	4	11	In this current study, chemical was found to increase phosphorylation of gene (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	T13	T30	23228696
NA	CHEMICAL	GENE-N	4	17	In this current study, chemical was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (gene)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	T13	T31	23228696
CPR:3	CHEMICAL	GENE-Y	4	27	In this current study, chemical was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of gene in H1650 and H1703 cells.	T13	T34	23228696
CPR:3	CHEMICAL	GENE-N	4	14	In this current study, chemical was found to increase phosphorylation of mitogen-activated protein kinase (gene) kinase 3/6 (MKK3/6)-p38 gene as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	T13	T33	23228696
CPR:3	CHEMICAL	GENE-N	4	17	In this current study, chemical was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-gene MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.	T13	T32	23228696
CPR:3	CHEMICAL	GENE-Y	1	2	Moreover, chemical-induced gene protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	T14	T35	23228696
NA	CHEMICAL	GENE-N	1	19	Moreover, chemical-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 gene inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).	T14	T38	23228696
NA	CHEMICAL	GENE-N	1	13	Moreover, chemical-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of gene activity by either a gene MAPK inhibitor SB202190 or gene knockdown with specific small interfering RNA (siRNA).	T14	T36	23228696
NA	CHEMICAL	GENE-N	1	13	Moreover, chemical-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of gene activity by either a gene MAPK inhibitor SB202190 or gene knockdown with specific small interfering RNA (siRNA).	T14	T37	23228696
NA	CHEMICAL	GENE-N	1	13	Moreover, chemical-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of gene activity by either a gene MAPK inhibitor SB202190 or gene knockdown with specific small interfering RNA (siRNA).	T14	T39	23228696
NA	CHEMICAL	GENE-Y	21	2	Moreover, paclitaxel-induced gene protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor chemical or p38 knockdown with specific small interfering RNA (siRNA).	T15	T35	23228696
CPR:4	CHEMICAL	GENE-N	21	19	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 gene inhibitor chemical or p38 knockdown with specific small interfering RNA (siRNA).	T15	T38	23228696
CPR:4	CHEMICAL	GENE-N	21	13	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of gene activity by either a gene MAPK inhibitor chemical or gene knockdown with specific small interfering RNA (siRNA).	T15	T36	23228696
CPR:4	CHEMICAL	GENE-N	21	13	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of gene activity by either a gene MAPK inhibitor chemical or gene knockdown with specific small interfering RNA (siRNA).	T15	T37	23228696
NA	CHEMICAL	GENE-N	21	13	Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of gene activity by either a gene MAPK inhibitor chemical or gene knockdown with specific small interfering RNA (siRNA).	T15	T39	23228696
NA	CHEMICAL	GENE-Y	11	3	Specific inhibition of gene with siRNA was found to enhance the chemical-induced cytotoxic effect and growth inhibition.	T2	T18	23228696
CPR:3	CHEMICAL	GENE-Y	9	12	Furthermore, metformin was able to not only decrease the chemical-induced p38 MAPK-mediated gene expression, but also augment the cytotoxic effect induced by chemical.	T4	T21	23228696
NA	CHEMICAL	GENE-Y	9	12	Furthermore, metformin was able to not only decrease the chemical-induced p38 MAPK-mediated gene expression, but also augment the cytotoxic effect induced by chemical.	T5	T21	23228696
CPR:3	CHEMICAL	GENE-N	9	11	Furthermore, metformin was able to not only decrease the chemical-induced p38 gene-mediated ERCC1 expression, but also augment the cytotoxic effect induced by chemical.	T4	T20	23228696
NA	CHEMICAL	GENE-N	9	11	Furthermore, metformin was able to not only decrease the chemical-induced p38 gene-mediated ERCC1 expression, but also augment the cytotoxic effect induced by chemical.	T5	T20	23228696
CPR:3	CHEMICAL	GENE-N	9	10	Furthermore, metformin was able to not only decrease the chemical-induced gene MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by chemical.	T4	T19	23228696
NA	CHEMICAL	GENE-N	9	10	Furthermore, metformin was able to not only decrease the chemical-induced gene MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by chemical.	T5	T19	23228696
CPR:4	CHEMICAL	GENE-Y	1	12	Furthermore, chemical was able to not only decrease the paclitaxel-induced p38 MAPK-mediated gene expression, but also augment the cytotoxic effect induced by paclitaxel.	T3	T21	23228696
CPR:4	CHEMICAL	GENE-N	1	11	Furthermore, chemical was able to not only decrease the paclitaxel-induced p38 gene-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	T3	T20	23228696
CPR:4	CHEMICAL	GENE-N	1	10	Furthermore, chemical was able to not only decrease the paclitaxel-induced gene MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.	T3	T19	23228696
CPR:4	CHEMICAL	GENE-Y	23	18	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate gene downregulation by metformin and chemical as well as cell viability and DNA repair capacity.	T7	T25	23228696
NA	CHEMICAL	GENE-Y	23	5	Finally, expression of constitutive activate gene or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and chemical as well as cell viability and DNA repair capacity.	T7	T22	23228696
NA	CHEMICAL	GENE-N	23	8	Finally, expression of constitutive activate MKK6 or HA-p38 gene vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and chemical as well as cell viability and DNA repair capacity.	T7	T24	23228696
NA	CHEMICAL	GENE-N	23	7	Finally, expression of constitutive activate MKK6 or HA-gene MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and chemical as well as cell viability and DNA repair capacity.	T7	T23	23228696
CPR:4	CHEMICAL	GENE-Y	21	18	Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate gene downregulation by chemical and paclitaxel as well as cell viability and DNA repair capacity.	T6	T25	23228696
NA	CHEMICAL	GENE-Y	21	5	Finally, expression of constitutive activate gene or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by chemical and paclitaxel as well as cell viability and DNA repair capacity.	T6	T22	23228696
NA	CHEMICAL	GENE-N	21	8	Finally, expression of constitutive activate MKK6 or HA-p38 gene vectors in lung cancer cells was able to abrogate ERCC1 downregulation by chemical and paclitaxel as well as cell viability and DNA repair capacity.	T6	T24	23228696
NA	CHEMICAL	GENE-N	21	7	Finally, expression of constitutive activate MKK6 or HA-gene MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by chemical and paclitaxel as well as cell viability and DNA repair capacity.	T6	T23	23228696
NA	CHEMICAL	GENE-N	15	9	Overall, our results suggest that inhibition of the p38 gene signaling by metformin coupled with chemical therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	T9	T27	23228696
NA	CHEMICAL	GENE-N	15	8	Overall, our results suggest that inhibition of the gene MAPK signaling by metformin coupled with chemical therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	T9	T26	23228696
CPR:4	CHEMICAL	GENE-N	12	9	Overall, our results suggest that inhibition of the p38 gene signaling by chemical coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	T8	T27	23228696
CPR:4	CHEMICAL	GENE-N	12	8	Overall, our results suggest that inhibition of the gene MAPK signaling by chemical coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	T8	T26	23228696
CPR:4	CHEMICAL	GENE-N	0	22	chemical has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal gene.	T1	T17	23228697
CPR:4	CHEMICAL	GENE-N	9	20	This study was designed to test the hypothesis that chemical inhibits CESs with higher potency toward CES1 than CES2, a gene with little lipase activity.	T6	T28	23228697
CPR:4	CHEMICAL	GENE-N	9	23	This study was designed to test the hypothesis that chemical inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little gene activity.	T6	T29	23228697
CPR:4	CHEMICAL	GENE-N	9	11	This study was designed to test the hypothesis that chemical inhibits gene with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.	T6	T25	23228697
CPR:4	CHEMICAL	GENE-Y	9	18	This study was designed to test the hypothesis that chemical inhibits CESs with higher potency toward CES1 than gene, a carboxylesterase with little lipase activity.	T6	T27	23228697
CPR:4	CHEMICAL	GENE-Y	9	16	This study was designed to test the hypothesis that chemical inhibits CESs with higher potency toward gene than CES2, a carboxylesterase with little lipase activity.	T6	T26	23228697
NA	CHEMICAL	GENE-N	23	4	Liver microsomes and recombinant gene were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of chemical of doxazolidine (PPD) and irinotecan.	T8	T30	23228697
NA	CHEMICAL	GENE-N	20	4	Liver microsomes and recombinant gene were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs chemical of p-aminobenzyl carbamate of doxazolidine (PPD) and irinotecan.	T7	T30	23228697
NA	CHEMICAL	GENE-N	26	4	Liver microsomes and recombinant gene were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of chemical (PPD) and irinotecan.	T9	T30	23228697
NA	CHEMICAL	GENE-N	29	4	Liver microsomes and recombinant gene were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of doxazolidine (PPD) and chemical.	T11	T30	23228697
NA	CHEMICAL	GENE-N	27	4	Liver microsomes and recombinant gene were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs pentyl carbamate of p-aminobenzyl carbamate of doxazolidine (chemical) and irinotecan.	T10	T30	23228697
CPR:4	CHEMICAL	GENE-Y	4	9	Contrary to the hypothesis, chemical at 1 nM inhibited gene activity by 75% but no inhibition on CES1, placing gene one of the most sensitive targets of chemical.	T12	T31	23228697
CPR:4	CHEMICAL	GENE-Y	4	9	Contrary to the hypothesis, chemical at 1 nM inhibited gene activity by 75% but no inhibition on CES1, placing gene one of the most sensitive targets of chemical.	T12	T33	23228697
NA	CHEMICAL	GENE-Y	4	17	Contrary to the hypothesis, chemical at 1 nM inhibited CES2 activity by 75% but no inhibition on gene, placing CES2 one of the most sensitive targets of chemical.	T12	T32	23228697
CPR:4	CHEMICAL	GENE-N	19	3	Inhibition of this gene probably presents a major source for altered therapeutic activity of these medicines if co-administered with chemical.	T4	T16	23228697
NA	CHEMICAL	GENE-N	3	5	Regulation of multiple chemical cyclases (gene) provides unique inputs to mediate the synthesis of cAMP, a ubiquitous second messenger that controls many aspects of cellular function.	T1	T13	23229509
CPR:9	CHEMICAL	GENE-N	14	3	Regulation of multiple gene (AC) provides unique inputs to mediate the synthesis of chemical, a ubiquitous second messenger that controls many aspects of cellular function.	T5	T10	23229509
CPR:9	CHEMICAL	GENE-N	14	5	Regulation of multiple adenylyl cyclases (gene) provides unique inputs to mediate the synthesis of chemical, a ubiquitous second messenger that controls many aspects of cellular function.	T5	T13	23229509
NA	CHEMICAL	GENE-N	22	3	On stimulation by gene, the activities of ACs can be further selectively modulated by other pathways to ensure precise control of intracellular chemical responses to specific stimuli.	T2	T8	23229509
CPR:9	CHEMICAL	GENE-N	22	7	On stimulation by G(s), the activities of gene can be further selectively modulated by other pathways to ensure precise control of intracellular chemical responses to specific stimuli.	T2	T9	23229509
NA	CHEMICAL	GENE-Y	8	14	Although both enzymes could fully restore regulation of chemical by G, activation of the gene pathway preferentially synergized with AC7.	T3	T19	23229509
NA	CHEMICAL	GENE-N	8	10	Although both enzymes could fully restore regulation of chemical by gene, activation of the G(13) pathway preferentially synergized with AC7.	T3	T18	23229509
NA	CHEMICAL	GENE-Y	8	19	Although both enzymes could fully restore regulation of chemical by G, activation of the G(13) pathway preferentially synergized with gene.	T3	T20	23229509
NA	CHEMICAL	GENE-N	14	10	Exchange of domains between the two isoforms indicates that the gene and the chemical-terminus of the C1a domain are important for directing selective regulation of AC7 by the G(13) pathway.	T4	T21	23229509
NA	CHEMICAL	GENE-N	14	17	Exchange of domains between the two isoforms indicates that the C1b domain and the chemical-terminus of the gene are important for directing selective regulation of AC7 by the G(13) pathway.	T4	T22	23229509
NA	CHEMICAL	GENE-Y	14	29	Exchange of domains between the two isoforms indicates that the C1b domain and the chemical-terminus of the C1a domain are important for directing selective regulation of AC7 by the gene pathway.	T4	T24	23229509
NA	CHEMICAL	GENE-Y	14	26	Exchange of domains between the two isoforms indicates that the C1b domain and the chemical-terminus of the C1a domain are important for directing selective regulation of gene by the G(13) pathway.	T4	T23	23229509
NA	CHEMICAL	GENE-Y	23	7	An important effector of the ISR is gene (ATF4), a transcription factor that regulates genes involved in redox homeostasis and chemical metabolism and transport.	T10	T22	23229510
NA	CHEMICAL	GENE-Y	23	11	An important effector of the ISR is activating transcription factor 4 (gene), a transcription factor that regulates genes involved in redox homeostasis and chemical metabolism and transport.	T10	T23	23229510
CPR:3	CHEMICAL	GENE-Y	5	15	We identified one compound, E235 chemical, that activated the ISR and dose-dependently increased levels of gene in transformed cells.	T12	T26	23229510
CPR:3	CHEMICAL	GENE-Y	4	15	We identified one compound, chemical (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of gene in transformed cells.	T11	T26	23229510
NA	CHEMICAL	GENE-Y	25	18	A dose-dependent decrease in viability was observed in several mouse and human tumor cell lines, and knockdown of gene significantly increased the antiproliferative effects of chemical.	T1	T27	23229510
NA	CHEMICAL	GENE-Y	0	10	chemical-mediated induction of senescence was not dependent on p21 or gene; however, p21 conferred protection against the growth inhibitory effects of chemical.	T3	T14	23229510
NA	CHEMICAL	GENE-Y	0	10	chemical-mediated induction of senescence was not dependent on p21 or gene; however, p21 conferred protection against the growth inhibitory effects of chemical.	T4	T14	23229510
NA	CHEMICAL	GENE-Y	0	8	chemical-mediated induction of senescence was not dependent on gene or p53; however, gene conferred protection against the growth inhibitory effects of chemical.	T3	T13	23229510
NA	CHEMICAL	GENE-Y	0	8	chemical-mediated induction of senescence was not dependent on gene or p53; however, gene conferred protection against the growth inhibitory effects of chemical.	T3	T15	23229510
NA	CHEMICAL	GENE-Y	0	8	chemical-mediated induction of senescence was not dependent on gene or p53; however, gene conferred protection against the growth inhibitory effects of chemical.	T4	T13	23229510
NA	CHEMICAL	GENE-Y	0	8	chemical-mediated induction of senescence was not dependent on gene or p53; however, gene conferred protection against the growth inhibitory effects of chemical.	T4	T15	23229510
CPR:3	CHEMICAL	GENE-Y	0	16	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, -H2AX, and gene (Chk2), although chemical does not appear to cause physical DNA damage.	T6	T18	23229510
NA	CHEMICAL	GENE-Y	0	16	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, -H2AX, and gene (Chk2), although chemical does not appear to cause physical DNA damage.	T8	T18	23229510
CPR:3	CHEMICAL	GENE-Y	0	12	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-gene, -H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although chemical does not appear to cause physical DNA damage.	T6	T16	23229510
NA	CHEMICAL	GENE-Y	0	12	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-gene, -H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although chemical does not appear to cause physical DNA damage.	T8	T16	23229510
CPR:3	CHEMICAL	GENE-Y	0	14	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, gene, and phosphorylated checkpoint kinase 2 (Chk2), although chemical does not appear to cause physical DNA damage.	T6	T17	23229510
NA	CHEMICAL	GENE-Y	0	14	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, gene, and phosphorylated checkpoint kinase 2 (Chk2), although chemical does not appear to cause physical DNA damage.	T8	T17	23229510
CPR:3	CHEMICAL	GENE-Y	0	20	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, -H2AX, and phosphorylated checkpoint kinase 2 (gene), although chemical does not appear to cause physical DNA damage.	T6	T19	23229510
NA	CHEMICAL	GENE-Y	0	20	chemical also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, -H2AX, and phosphorylated checkpoint kinase 2 (gene), although chemical does not appear to cause physical DNA damage.	T8	T19	23229510
NA	CHEMICAL	GENE-Y	12	16	E235 also activated DNA damage response signaling, resulting in increased levels of chemical15-phosphorylated p53, -H2AX, and gene (Chk2), although E235 does not appear to cause physical DNA damage.	T7	T18	23229510
NA	CHEMICAL	GENE-Y	12	12	E235 also activated DNA damage response signaling, resulting in increased levels of chemical15-gene, -H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.	T7	T16	23229510
NA	CHEMICAL	GENE-Y	12	14	E235 also activated DNA damage response signaling, resulting in increased levels of chemical15-phosphorylated p53, gene, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.	T7	T17	23229510
NA	CHEMICAL	GENE-Y	12	20	E235 also activated DNA damage response signaling, resulting in increased levels of chemical15-phosphorylated p53, -H2AX, and phosphorylated checkpoint kinase 2 (gene), although E235 does not appear to cause physical DNA damage.	T7	T19	23229510
NA	CHEMICAL	GENE-N	31	8	We aim to "tilt" the stability of the gene structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the chemical sequence of the H1, H2, and proximal residues.	T1	T10	23231492
NA	CHEMICAL	GENE-N	31	37	We aim to "tilt" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the chemical sequence of the H1, gene, and proximal residues.	T1	T12	23231492
NA	CHEMICAL	GENE-N	31	8	We aim to "tilt" the stability of the gene loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the chemical sequence of the gene, H2, and proximal residues.	T1	T11	23231492
NA	CHEMICAL	GENE-Y	5	11	Cell culture studies demonstrated that chemical is capable of delivering anti-TNF gene siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of TNF-.	T15	T22	23240892
CPR:4	CHEMICAL	GENE-Y	5	25	Cell culture studies demonstrated that chemical is capable of delivering anti-TNF (tumor necrosis factor)- siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of gene.	T15	T17	23240892
NA	CHEMICAL	GENE-Y	5	10	Cell culture studies demonstrated that chemical is capable of delivering anti-gene (tumor necrosis factor)- siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of gene-.	T15	T21	23240892
NA	CHEMICAL	GENE-Y	7	0	PKAA/anti-gene siRNA nanocomplexes significantly reduced the ALT (chemical transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	T5	T18	23240892
NA	CHEMICAL	GENE-N	7	6	PKAA/anti-TNF- siRNA nanocomplexes significantly reduced the gene (chemical transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	T5	T19	23240892
NA	CHEMICAL	GENE-N	15	7	PKAA/anti-TNF- siRNA nanocomplexes significantly reduced the ALT (gene) and the hepatic cellular damages in chemical-intoxicated mice.	T6	T20	23240892
NA	CHEMICAL	GENE-Y	15	0	PKAA/anti-gene siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in chemical-intoxicated mice.	T6	T18	23240892
NA	CHEMICAL	GENE-N	15	6	PKAA/anti-TNF- siRNA nanocomplexes significantly reduced the gene (alanine transaminase) and the hepatic cellular damages in chemical-intoxicated mice.	T6	T19	23240892
CPR:4	CHEMICAL	GENE-N	0	7	chemical/anti-TNF- siRNA nanocomplexes significantly reduced the ALT (gene) and the hepatic cellular damages in APAP-intoxicated mice.	T4	T20	23240892
NA	CHEMICAL	GENE-Y	0	0	chemical/anti-gene siRNA nanocomplexes significantly reduced the ALT (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	T4	T18	23240892
CPR:4	CHEMICAL	GENE-N	0	6	chemical/anti-TNF- siRNA nanocomplexes significantly reduced the gene (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.	T4	T19	23240892
CPR:4	CHEMICAL	GENE-Y	3	11	We found that chemical can suppress the H2O2-stimulated actin remodeling and gene uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	T6	T17	23246481
CPR:4	CHEMICAL	GENE-N	3	8	We found that chemical can suppress the H2O2-stimulated gene remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	T6	T16	23246481
CPR:3	CHEMICAL	GENE-Y	7	11	We found that wogonin can suppress the chemical-stimulated actin remodeling and gene uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	T7	T17	23246481
CPR:3	CHEMICAL	GENE-N	7	8	We found that wogonin can suppress the chemical-stimulated gene remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.	T7	T16	23246481
CPR:4	CHEMICAL	GENE-Y	4	18	The mechanism revealed that chemical inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of gene and -catenin.	T8	T20	23246481
CPR:4	CHEMICAL	GENE-Y	4	9	The mechanism revealed that chemical inhibited H2O2-induced phosphorylation of gene (cav-1) associating with the suppression of stabilization of VE-cadherin and -catenin.	T8	T18	23246481
CPR:4	CHEMICAL	GENE-Y	4	20	The mechanism revealed that chemical inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and gene.	T8	T21	23246481
CPR:4	CHEMICAL	GENE-Y	4	10	The mechanism revealed that chemical inhibited H2O2-induced phosphorylation of caveolin-1 (gene) associating with the suppression of stabilization of VE-cadherin and -catenin.	T8	T19	23246481
NA	CHEMICAL	GENE-Y	6	18	The mechanism revealed that wogonin inhibited chemical-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of gene and -catenin.	T9	T20	23246481
CPR:3	CHEMICAL	GENE-Y	6	9	The mechanism revealed that wogonin inhibited chemical-induced phosphorylation of gene (cav-1) associating with the suppression of stabilization of VE-cadherin and -catenin.	T9	T18	23246481
NA	CHEMICAL	GENE-Y	6	20	The mechanism revealed that wogonin inhibited chemical-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and gene.	T9	T21	23246481
CPR:3	CHEMICAL	GENE-Y	6	10	The mechanism revealed that wogonin inhibited chemical-induced phosphorylation of caveolin-1 (gene) associating with the suppression of stabilization of VE-cadherin and -catenin.	T9	T19	23246481
CPR:3	CHEMICAL	GENE-Y	3	7	Moreover, wogonin repressed chemical-induced phosphorylation of p38, gene and vascular permeability.	T11	T23	23246481
CPR:3	CHEMICAL	GENE-N	3	6	Moreover, wogonin repressed chemical-induced phosphorylation of gene, cav-1 and vascular permeability.	T11	T22	23246481
CPR:4	CHEMICAL	GENE-Y	1	7	Moreover, chemical repressed anisomycin-induced phosphorylation of p38, gene and vascular permeability.	T10	T23	23246481
CPR:4	CHEMICAL	GENE-N	1	6	Moreover, chemical repressed anisomycin-induced phosphorylation of gene, cav-1 and vascular permeability.	T10	T22	23246481
CPR:4	CHEMICAL	GENE-Y	4	15	These results suggested that chemical could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of gene, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.	T12	T24	23246481
CPR:3	CHEMICAL	GENE-Y	7	15	These results suggested that wogonin could inhibit chemical-induced vascular permeability by downregulating the phosphorylation of gene, and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.	T13	T24	23246481
NA	CHEMICAL	GENE-Y	31	17	In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the gene activity, conformational modifications of the core structure resulted in the identification of fused chemical such as 7i which had an improved gene inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	T1	T4	23253441
CPR:4	CHEMICAL	GENE-Y	31	17	In an attempt to further improve overall profiles of the oxadiazine series of GSMs, in particular the gene activity, conformational modifications of the core structure resulted in the identification of fused chemical such as 7i which had an improved gene inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	T1	T5	23253441
NA	CHEMICAL	GENE-Y	10	17	In an attempt to further improve overall profiles of the chemical series of GSMs, in particular the gene activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved gene inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	T2	T4	23253441
NA	CHEMICAL	GENE-Y	10	17	In an attempt to further improve overall profiles of the chemical series of GSMs, in particular the gene activity, conformational modifications of the core structure resulted in the identification of fused oxadiazepines such as 7i which had an improved gene inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	T2	T5	23253441
CPR:4	CHEMICAL	GENE-Y	38	26	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and gene, These effects could be completely blocked by chemical.	T14	T27	23254198
CPR:4	CHEMICAL	GENE-Y	38	23	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors gene, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by chemical.	T14	T25	23254198
CPR:4	CHEMICAL	GENE-N	38	17	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and gene and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by chemical.	T14	T24	23254198
CPR:4	CHEMICAL	GENE-Y	38	24	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, gene, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by chemical.	T14	T26	23254198
CPR:4	CHEMICAL	GENE-N	38	14	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of gene, Akt, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by chemical.	T14	T22	23254198
CPR:4	CHEMICAL	GENE-N	38	15	Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of MAPK, gene, and p70S6K and up-regulation of antiapoptotic factors survivin, Bcl-2, and X-linked inhibitor of apoptosis protein, These effects could be completely blocked by chemical.	T14	T23	23254198
NA	CHEMICAL	GENE-Y	30	17	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and gene, whereas the stimulatory effects of CE on chemical receptor and amphiregulin expression were weaker than E(2).	T1	T19	23254198
NA	CHEMICAL	GENE-Y	30	33	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on chemical receptor and gene expression were weaker than E(2).	T1	T21	23254198
NA	CHEMICAL	GENE-Y	30	14	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of gene, pS2, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on chemical receptor and amphiregulin expression were weaker than E(2).	T1	T17	23254198
NA	CHEMICAL	GENE-Y	30	15	Gene expression studies demonstrated that CE and E(2) were equally potent on expression of cMyc, gene, and WNT1 inducible signaling pathway protein 2, whereas the stimulatory effects of CE on chemical receptor and amphiregulin expression were weaker than E(2).	T1	T18	23254198
CPR:4	CHEMICAL	GENE-N	2	7	We used chemical, a well-known disruptor of p53-gene interaction, to validate the specificity of the assay.	T2	T22	23261524
CPR:4	CHEMICAL	GENE-Y	2	7	We used chemical, a well-known disruptor of p53-gene interaction, to validate the specificity of the assay.	T2	T22	23261524
CPR:4	CHEMICAL	GENE-Y	2	7	We used chemical, a well-known disruptor of gene-Mdm2 interaction, to validate the specificity of the assay.	T2	T21	23261524
CPR:4	CHEMICAL	GENE-N	2	7	We used chemical, a well-known disruptor of gene-Mdm2 interaction, to validate the specificity of the assay.	T2	T21	23261524
CPR:3	CHEMICAL	GENE-N	7	16	The reduction of BiFC signal mediated by chemical was correlated with an increase in Puma transactivation, gene cleavage, and cell death.	T1	T5	23261524
CPR:3	CHEMICAL	GENE-Y	7	14	The reduction of BiFC signal mediated by chemical was correlated with an increase in gene transactivation, PARP cleavage, and cell death.	T1	T4	23261524
NA	CHEMICAL	GENE-N	8	17	In this study we explored the toxicity of chemical toward NSCs focusing on apoptosis and status of gene survival signaling.	T14	T31	23261589
CPR:4	CHEMICAL	GENE-N	0	15	chemical toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and gene GDNF, BDNF suggesting repressed PI3K/Akt signaling.	T5	T23	23261589
CPR:4	CHEMICAL	GENE-Y	0	12	chemical toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, gene, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	T5	T21	23261589
CPR:4	CHEMICAL	GENE-N	0	11	chemical toxicity coincided with reduced pAkt level and its downstream effectors: gene, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	T5	T20	23261589
CPR:4	CHEMICAL	GENE-Y	0	13	chemical toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, gene and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	T5	T22	23261589
CPR:4	CHEMICAL	GENE-Y	0	16	chemical toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins gene, BDNF suggesting repressed PI3K/Akt signaling.	T5	T24	23261589
CPR:4	CHEMICAL	GENE-N	0	20	chemical toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed gene/Akt signaling.	T5	T26	23261589
CPR:4	CHEMICAL	GENE-N	0	5	chemical toxicity coincided with reduced gene level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.	T5	T19	23261589
CPR:4	CHEMICAL	GENE-Y	0	17	chemical toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, gene suggesting repressed PI3K/Akt signaling.	T5	T25	23261589
CPR:4	CHEMICAL	GENE-N	0	5	chemical toxicity coincided with reduced pgene level and its downstream effectors: pCREB, pGSK-3, Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/gene signaling.	T5	T27	23261589
NA	CHEMICAL	GENE-N	19	22	Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against chemical through activating gene/Akt pathway.	T7	T28	23261589
NA	CHEMICAL	GENE-N	19	22	Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against chemical through activating PI3K/gene pathway.	T7	T29	23261589
CPR:4	CHEMICAL	GENE-N	5	7	This was confirmed on adding chemical the gene inhibitor which abolished the protection.	T8	T30	23261589
NA	CHEMICAL	GENE-N	45	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and chemical.	T25	T31	23261676
NA	CHEMICAL	GENE-Y	45	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and chemical.	T25	T32	23261676
NA	CHEMICAL	GENE-N	45	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and chemical.	T25	T34	23261676
NA	CHEMICAL	GENE-N	45	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and chemical.	T25	T33	23261676
NA	CHEMICAL	GENE-N	35	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, chemical, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T19	T31	23261676
NA	CHEMICAL	GENE-Y	35	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, chemical, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T19	T32	23261676
NA	CHEMICAL	GENE-N	35	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, chemical, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T19	T34	23261676
NA	CHEMICAL	GENE-N	35	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, chemical, isocitrate, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T19	T33	23261676
NA	CHEMICAL	GENE-N	40	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, chemical and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T23	T31	23261676
NA	CHEMICAL	GENE-Y	40	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, succinate, malate, chemical and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T23	T32	23261676
NA	CHEMICAL	GENE-N	40	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, chemical and NADH-dehydrogenases, gene and adenosine triphosphate.	T23	T34	23261676
NA	CHEMICAL	GENE-N	40	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, chemical and gene, cytochrome-C-oxidase and adenosine triphosphate.	T23	T33	23261676
CPR:4	CHEMICAL	GENE-N	0	31	chemical induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T15	T31	23261676
CPR:4	CHEMICAL	GENE-Y	0	33	chemical induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T15	T32	23261676
CPR:4	CHEMICAL	GENE-N	0	43	chemical induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T15	T34	23261676
CPR:4	CHEMICAL	GENE-N	0	42	chemical induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T15	T33	23261676
NA	CHEMICAL	GENE-N	31	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial chemical peroxidase, chemical reductase, reduced chemical, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T17	T34	23261676
NA	CHEMICAL	GENE-N	31	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial chemical peroxidase, chemical reductase, reduced chemical, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T18	T34	23261676
NA	CHEMICAL	GENE-N	31	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial chemical peroxidase, chemical reductase, reduced chemical, isocitrate, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T17	T33	23261676
NA	CHEMICAL	GENE-N	31	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial chemical peroxidase, chemical reductase, reduced chemical, isocitrate, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T18	T33	23261676
NA	CHEMICAL	GENE-N	37	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, chemical, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T20	T31	23261676
NA	CHEMICAL	GENE-Y	37	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, chemical, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T20	T32	23261676
NA	CHEMICAL	GENE-N	37	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, chemical, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T20	T34	23261676
NA	CHEMICAL	GENE-N	37	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, chemical, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T20	T33	23261676
NA	CHEMICAL	GENE-N	38	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, chemical, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T21	T31	23261676
NA	CHEMICAL	GENE-Y	38	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, chemical, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T21	T32	23261676
NA	CHEMICAL	GENE-N	38	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, chemical, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T21	T34	23261676
NA	CHEMICAL	GENE-N	38	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, chemical, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T21	T33	23261676
NA	CHEMICAL	GENE-N	20	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, chemical, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T16	T31	23261676
NA	CHEMICAL	GENE-Y	20	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, chemical, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T16	T32	23261676
NA	CHEMICAL	GENE-N	20	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, chemical, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T16	T34	23261676
NA	CHEMICAL	GENE-N	20	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, chemical, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T16	T33	23261676
NA	CHEMICAL	GENE-N	39	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, succinate, chemical, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T22	T31	23261676
NA	CHEMICAL	GENE-Y	39	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, succinate, chemical, -ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T22	T32	23261676
NA	CHEMICAL	GENE-N	39	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, chemical, -ketoglutarate and NADH-dehydrogenases, gene and adenosine triphosphate.	T22	T34	23261676
NA	CHEMICAL	GENE-N	39	42	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, chemical, -ketoglutarate and gene, cytochrome-C-oxidase and adenosine triphosphate.	T22	T33	23261676
NA	CHEMICAL	GENE-N	42	31	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial gene, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and chemical-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T24	T31	23261676
NA	CHEMICAL	GENE-Y	42	33	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, gene, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and chemical-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.	T24	T32	23261676
NA	CHEMICAL	GENE-N	42	43	Isoproterenol induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, -ketoglutarate and chemical-dehydrogenases, gene and adenosine triphosphate.	T24	T34	23261676
NA	CHEMICAL	GENE-Y	7	5	Four proteins, namely albumin, hemopexin, gene and chemical binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	T1	T9	23261757
NA	CHEMICAL	GENE-Y	7	4	Four proteins, namely albumin, gene, transferrin and chemical binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	T1	T8	23261757
NA	CHEMICAL	GENE-N	7	3	Four proteins, namely gene, hemopexin, transferrin and chemical binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	T1	T7	23261757
NA	CHEMICAL	GENE-N	15	9	They also increased catalase (CAT), superoxide dismutase (SOD) and gene (GSH-Px) activity, while decreasing chemical (MDA) levels in serum and in the livers of mice.	T12	T24	23265459
NA	CHEMICAL	GENE-N	15	5	They also increased catalase (CAT), gene (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing chemical (MDA) levels in serum and in the livers of mice.	T12	T22	23265459
NA	CHEMICAL	GENE-Y	15	3	They also increased gene (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing chemical (MDA) levels in serum and in the livers of mice.	T12	T20	23265459
NA	CHEMICAL	GENE-N	15	11	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (gene) activity, while decreasing chemical (MDA) levels in serum and in the livers of mice.	T12	T25	23265459
NA	CHEMICAL	GENE-N	15	7	They also increased catalase (CAT), superoxide dismutase (gene) and glutathione peroxidase (GSH-Px) activity, while decreasing chemical (MDA) levels in serum and in the livers of mice.	T12	T23	23265459
NA	CHEMICAL	GENE-Y	15	4	They also increased catalase (gene), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing chemical (MDA) levels in serum and in the livers of mice.	T12	T21	23265459
NA	CHEMICAL	GENE-N	9	5	They also increased catalase (CAT), gene (SOD) and chemical peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T10	T22	23265459
NA	CHEMICAL	GENE-Y	9	3	They also increased gene (CAT), superoxide dismutase (SOD) and chemical peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T10	T20	23265459
NA	CHEMICAL	GENE-N	9	11	They also increased catalase (CAT), superoxide dismutase (SOD) and chemical peroxidase (gene) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T10	T25	23265459
NA	CHEMICAL	GENE-N	9	7	They also increased catalase (CAT), superoxide dismutase (gene) and chemical peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T10	T23	23265459
NA	CHEMICAL	GENE-Y	9	4	They also increased catalase (gene), superoxide dismutase (SOD) and chemical peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T10	T21	23265459
NA	CHEMICAL	GENE-N	5	9	They also increased catalase (CAT), chemical dismutase (SOD) and gene (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T9	T24	23265459
NA	CHEMICAL	GENE-Y	5	3	They also increased gene (CAT), chemical dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T9	T20	23265459
NA	CHEMICAL	GENE-N	5	11	They also increased catalase (CAT), chemical dismutase (SOD) and glutathione peroxidase (gene) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T9	T25	23265459
NA	CHEMICAL	GENE-N	5	7	They also increased catalase (CAT), chemical dismutase (gene) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T9	T23	23265459
NA	CHEMICAL	GENE-Y	5	4	They also increased catalase (gene), chemical dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T9	T21	23265459
NA	CHEMICAL	GENE-N	11	9	They also increased catalase (CAT), superoxide dismutase (SOD) and gene (chemical-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T11	T24	23265459
NA	CHEMICAL	GENE-N	11	5	They also increased catalase (CAT), gene (SOD) and glutathione peroxidase (chemical-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T11	T22	23265459
NA	CHEMICAL	GENE-Y	11	3	They also increased gene (CAT), superoxide dismutase (SOD) and glutathione peroxidase (chemical-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T11	T20	23265459
NA	CHEMICAL	GENE-N	11	7	They also increased catalase (CAT), superoxide dismutase (gene) and glutathione peroxidase (chemical-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T11	T23	23265459
NA	CHEMICAL	GENE-Y	11	4	They also increased catalase (gene), superoxide dismutase (SOD) and glutathione peroxidase (chemical-Px) activity, while decreasing malondialdehyde (MDA) levels in serum and in the livers of mice.	T11	T21	23265459
NA	CHEMICAL	GENE-N	16	9	They also increased catalase (CAT), superoxide dismutase (SOD) and gene (GSH-Px) activity, while decreasing malondialdehyde (chemical) levels in serum and in the livers of mice.	T13	T24	23265459
NA	CHEMICAL	GENE-N	16	5	They also increased catalase (CAT), gene (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (chemical) levels in serum and in the livers of mice.	T13	T22	23265459
NA	CHEMICAL	GENE-Y	16	3	They also increased gene (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (chemical) levels in serum and in the livers of mice.	T13	T20	23265459
NA	CHEMICAL	GENE-N	16	11	They also increased catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (gene) activity, while decreasing malondialdehyde (chemical) levels in serum and in the livers of mice.	T13	T25	23265459
NA	CHEMICAL	GENE-N	16	7	They also increased catalase (CAT), superoxide dismutase (gene) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (chemical) levels in serum and in the livers of mice.	T13	T23	23265459
NA	CHEMICAL	GENE-Y	16	4	They also increased catalase (gene), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activity, while decreasing malondialdehyde (chemical) levels in serum and in the livers of mice.	T13	T21	23265459
NA	CHEMICAL	GENE-Y	26	9	DPEP induced dose-dependent reduction of the protein levels of gene (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and chemical (PGE(2)).	T5	T19	23266270
NA	CHEMICAL	GENE-Y	26	15	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and gene (COX-2) and concomitant reduction in the production of NO and chemical (PGE(2)).	T5	T21	23266270
NA	CHEMICAL	GENE-Y	26	16	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (gene) and concomitant reduction in the production of NO and chemical (PGE(2)).	T5	T22	23266270
NA	CHEMICAL	GENE-Y	26	13	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (gene) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and chemical (PGE(2)).	T5	T20	23266270
NA	CHEMICAL	GENE-Y	10	15	DPEP induced dose-dependent reduction of the protein levels of inducible chemical synthase (iNOS) and gene (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T3	T21	23266270
NA	CHEMICAL	GENE-Y	10	16	DPEP induced dose-dependent reduction of the protein levels of inducible chemical synthase (iNOS) and cyclooxygenase-2 (gene) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T3	T22	23266270
NA	CHEMICAL	GENE-Y	10	13	DPEP induced dose-dependent reduction of the protein levels of inducible chemical synthase (gene) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T3	T20	23266270
NA	CHEMICAL	GENE-Y	28	9	DPEP induced dose-dependent reduction of the protein levels of gene (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (chemical).	T6	T19	23266270
NA	CHEMICAL	GENE-Y	28	15	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and gene (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (chemical).	T6	T21	23266270
NA	CHEMICAL	GENE-Y	28	16	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (gene) and concomitant reduction in the production of NO and prostaglandin E(2) (chemical).	T6	T22	23266270
NA	CHEMICAL	GENE-Y	28	13	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (gene) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (chemical).	T6	T20	23266270
CPR:4	CHEMICAL	GENE-Y	0	9	chemical induced dose-dependent reduction of the protein levels of gene (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T2	T19	23266270
CPR:4	CHEMICAL	GENE-Y	0	15	chemical induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and gene (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T2	T21	23266270
CPR:4	CHEMICAL	GENE-Y	0	16	chemical induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (gene) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T2	T22	23266270
CPR:4	CHEMICAL	GENE-Y	0	13	chemical induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (gene) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).	T2	T20	23266270
NA	CHEMICAL	GENE-Y	13	9	DPEP induced dose-dependent reduction of the protein levels of gene (ichemicalS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of chemical and prostaglandin E(2) (PGE(2)).	T4	T19	23266270
NA	CHEMICAL	GENE-Y	13	15	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (ichemicalS) and gene (COX-2) and concomitant reduction in the production of chemical and prostaglandin E(2) (PGE(2)).	T4	T21	23266270
NA	CHEMICAL	GENE-Y	13	16	DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (ichemicalS) and cyclooxygenase-2 (gene) and concomitant reduction in the production of chemical and prostaglandin E(2) (PGE(2)).	T4	T22	23266270
CPR:4	CHEMICAL	GENE-Y	1	9	Additionally, chemical suppressed the production of inflammatory cytokines, including gene (TNF-), interleukin (IL)-1, and IL-6.	T7	T24	23266270
CPR:4	CHEMICAL	GENE-Y	1	13	Additionally, chemical suppressed the production of inflammatory cytokines, including tumor necrosis factor- (TNF-), gene, and IL-6.	T7	T26	23266270
CPR:4	CHEMICAL	GENE-N	1	7	Additionally, chemical suppressed the production of inflammatory gene, including tumor necrosis factor- (TNF-), interleukin (IL)-1, and IL-6.	T7	T23	23266270
CPR:4	CHEMICAL	GENE-Y	1	12	Additionally, chemical suppressed the production of inflammatory cytokines, including tumor necrosis factor- (gene), interleukin (IL)-1, and IL-6.	T7	T25	23266270
CPR:4	CHEMICAL	GENE-Y	1	16	Additionally, chemical suppressed the production of inflammatory cytokines, including tumor necrosis factor- (TNF-), interleukin (IL)-1, and gene.	T7	T27	23266270
NA	CHEMICAL	GENE-N	10	22	We investigated the mechanism by which DPEP inhibits NO and chemical by examining the level of nuclear factor-B (NF-B) activation within the gene (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T11	T30	23266270
NA	CHEMICAL	GENE-N	10	16	We investigated the mechanism by which DPEP inhibits NO and chemical by examining the level of gene (NF-B) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T11	T28	23266270
NA	CHEMICAL	GENE-N	10	18	We investigated the mechanism by which DPEP inhibits NO and chemical by examining the level of nuclear factor-B (gene) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T11	T29	23266270
NA	CHEMICAL	GENE-N	10	25	We investigated the mechanism by which DPEP inhibits NO and chemical by examining the level of nuclear factor-B (NF-B) activation within the mitogen-activated protein kinase (gene) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T11	T31	23266270
NA	CHEMICAL	GENE-N	6	22	We investigated the mechanism by which chemical inhibits NO and PGE(2) by examining the level of nuclear factor-B (NF-B) activation within the gene (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T9	T30	23266270
NA	CHEMICAL	GENE-N	6	16	We investigated the mechanism by which chemical inhibits NO and PGE(2) by examining the level of gene (NF-B) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T9	T28	23266270
NA	CHEMICAL	GENE-N	6	18	We investigated the mechanism by which chemical inhibits NO and PGE(2) by examining the level of nuclear factor-B (gene) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T9	T29	23266270
NA	CHEMICAL	GENE-N	6	25	We investigated the mechanism by which chemical inhibits NO and PGE(2) by examining the level of nuclear factor-B (NF-B) activation within the mitogen-activated protein kinase (gene) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T9	T31	23266270
NA	CHEMICAL	GENE-N	8	22	We investigated the mechanism by which DPEP inhibits chemical and PGE(2) by examining the level of nuclear factor-B (NF-B) activation within the gene (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T10	T30	23266270
NA	CHEMICAL	GENE-N	8	16	We investigated the mechanism by which DPEP inhibits chemical and PGE(2) by examining the level of gene (NF-B) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T10	T28	23266270
NA	CHEMICAL	GENE-N	8	18	We investigated the mechanism by which DPEP inhibits chemical and PGE(2) by examining the level of nuclear factor-B (gene) activation within the mitogen-activated protein kinase (MAPK) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T10	T29	23266270
NA	CHEMICAL	GENE-N	8	25	We investigated the mechanism by which DPEP inhibits chemical and PGE(2) by examining the level of nuclear factor-B (NF-B) activation within the mitogen-activated protein kinase (gene) pathway, which is an inflammation-induced signaling pathway in RAW 264.7 cells.	T10	T31	23266270
CPR:4	CHEMICAL	GENE-N	0	8	chemical inhibited LPS-induced phosphorylation of ERK, JNK, and gene.	T12	T34	23266270
CPR:4	CHEMICAL	GENE-N	0	5	chemical inhibited LPS-induced phosphorylation of gene, JNK, and p38.	T12	T32	23266270
CPR:4	CHEMICAL	GENE-N	0	6	chemical inhibited LPS-induced phosphorylation of ERK, gene, and p38.	T12	T33	23266270
CPR:4	CHEMICAL	GENE-Y	1	7	Furthermore, chemical inhibited the LPS-induced phosphorylation of gene and NF-B p50.	T13	T35	23266270
CPR:4	CHEMICAL	GENE-N	1	11	Furthermore, chemical inhibited the LPS-induced phosphorylation of inhibitor B (IB)- and gene p50.	T13	T36	23266270
CPR:4	CHEMICAL	GENE-Y	1	12	Furthermore, chemical inhibited the LPS-induced phosphorylation of inhibitor B (IB)- and NF-B gene.	T13	T16	23266270
CPR:4	CHEMICAL	GENE-N	9	16	Taken together, the results of this study demonstrate that chemical inhibits LPS-stimulated inflammation by blocking the gene and MAPK pathways in macrophages.	T1	T17	23266270
CPR:4	CHEMICAL	GENE-N	9	18	Taken together, the results of this study demonstrate that chemical inhibits LPS-stimulated inflammation by blocking the NF-B and gene pathways in macrophages.	T1	T18	23266270
NA	CHEMICAL	GENE-Y	17	7	During base excision repair of this mispair, gene is confronted with gap filling opposite chemical.	T14	T27	23267011
NA	CHEMICAL	GENE-Y	7	3	To determine how gene discriminates between chemical, we introduced a point mutation (R283K) to alter insertion specificity.	T16	T28	23267011
NA	CHEMICAL	GENE-N	7	15	To determine how pol  discriminates between chemical, we introduced a point mutation (gene) to alter insertion specificity.	T16	T29	23267011
NA	CHEMICAL	GENE-Y	13	4	Structural studies with R283K gene show that the binary DNA complex has chemical in equilibrium between anti- and syn-forms.	T18	T31	23267011
NA	CHEMICAL	GENE-N	13	3	Structural studies with gene pol  show that the binary DNA complex has chemical in equilibrium between anti- and syn-forms.	T18	T30	23267011
NA	CHEMICAL	GENE-Y	19	4	In contrast to wild-type gene, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating chemical resembles a G-A mismatched structure with chemical adopting an anti-conformation.	T3	T23	23267011
NA	CHEMICAL	GENE-Y	19	4	In contrast to wild-type gene, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating chemical resembles a G-A mismatched structure with chemical adopting an anti-conformation.	T4	T23	23267011
NA	CHEMICAL	GENE-N	19	11	In contrast to wild-type pol , the ternary complex of the gene mutant with an incoming dATP-analogue and templating chemical resembles a G-A mismatched structure with chemical adopting an anti-conformation.	T3	T24	23267011
NA	CHEMICAL	GENE-N	19	11	In contrast to wild-type pol , the ternary complex of the gene mutant with an incoming dATP-analogue and templating chemical resembles a G-A mismatched structure with chemical adopting an anti-conformation.	T4	T24	23267011
NA	CHEMICAL	GENE-Y	16	4	In contrast to wild-type gene, the ternary complex of the R283K mutant with an incoming chemical-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.	T2	T23	23267011
NA	CHEMICAL	GENE-N	16	11	In contrast to wild-type pol , the ternary complex of the gene mutant with an incoming chemical-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.	T2	T24	23267011
NA	CHEMICAL	GENE-N	12	17	These results demonstrate that the incoming nucleotide is unable to induce a chemical conformation without minor groove gene interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	T6	T26	23267011
NA	CHEMICAL	GENE-N	12	15	These results demonstrate that the incoming nucleotide is unable to induce a chemical conformation without gene DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	T6	T25	23267011
NA	CHEMICAL	GENE-N	6	17	These results demonstrate that the incoming chemical is unable to induce a syn-8-oxoG conformation without minor groove gene interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	T5	T26	23267011
NA	CHEMICAL	GENE-N	6	15	These results demonstrate that the incoming chemical is unable to induce a syn-8-oxoG conformation without gene DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of 8-oxoG while modulating fidelity.	T5	T25	23267011
NA	CHEMICAL	GENE-N	12	17	These results demonstrate that the incoming nucleotide is unable to induce a syn-chemical conformation without minor groove gene interactions that influence templating (anti-/syn-equilibrium) of chemical while modulating fidelity.	T7	T26	23267011
NA	CHEMICAL	GENE-N	12	15	These results demonstrate that the incoming nucleotide is unable to induce a syn-chemical conformation without gene DNA polymerase interactions that influence templating (anti-/syn-equilibrium) of chemical while modulating fidelity.	T7	T25	23267011
NA	CHEMICAL	GENE-Y	0	2	chemical and gene treatment reversed these altered parameters to near control.	T14	T19	23267840
NA	CHEMICAL	GENE-N	19	2	Inactivation of gene in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of chemical carbon into lipids, and biomass accumulation.	T1	T9	23274086
NA	CHEMICAL	GENE-N	20	2	Inactivation of gene in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of glucose chemical into lipids, and biomass accumulation.	T2	T9	23274086
NA	CHEMICAL	GENE-Y	6	3	Dual inhibitors of gene (CYP19) and chemical synthase (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	T3	T14	23281812
NA	CHEMICAL	GENE-Y	6	8	Dual inhibitors of aromatase (CYP19) and chemical synthase (gene) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	T3	T17	23281812
NA	CHEMICAL	GENE-Y	6	4	Dual inhibitors of aromatase (gene) and chemical synthase (CYP11B2) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	T3	T15	23281812
NA	CHEMICAL	GENE-Y	17	6	By combining decisive structural features of gene and CYP19 inhibitors into a common template, a series of chemical were designed and synthesized.	T4	T18	23281812
NA	CHEMICAL	GENE-Y	17	8	By combining decisive structural features of CYP11B2 and gene inhibitors into a common template, a series of chemical were designed and synthesized.	T4	T19	23281812
CPR:4	CHEMICAL	GENE-N	1	6	Furthermore, chemical caused mechanism-based inactivation of gene-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.	T1	T14	23282066
CPR:9	CHEMICAL	GENE-N	9	6	Furthermore, MDZ caused mechanism-based inactivation of gene-dependent chemical 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.	T2	T14	23282066
NA	CHEMICAL	GENE-Y	5	22	We previously found that the chemical-enriched microdomains (chemical clusters) in presynaptic neuronal membranes play a key role in the initiation of the gene assembly process.	T2	T10	23294326
NA	CHEMICAL	GENE-Y	5	22	We previously found that the chemical-enriched microdomains (chemical clusters) in presynaptic neuronal membranes play a key role in the initiation of the gene assembly process.	T3	T10	23294326
NA	CHEMICAL	GENE-Y	3	6	However, not all chemical clusters accelerate gene assembly.	T4	T11	23294326
NA	CHEMICAL	GENE-N	16	8	The A assembly was generated on a distinctive gene, which was characterized as the A-sensitive chemical nanocluster (ASIGN).	T5	T15	23294326
NA	CHEMICAL	GENE-Y	16	1	The gene assembly was generated on a distinctive GM1 domain, which was characterized as the gene-sensitive chemical nanocluster (ASIGN).	T5	T14	23294326
NA	CHEMICAL	GENE-Y	16	1	The gene assembly was generated on a distinctive GM1 domain, which was characterized as the gene-sensitive chemical nanocluster (ASIGN).	T5	T16	23294326
NA	CHEMICAL	GENE-Y	4	5	These results suggest that chemical-bound gene (Ggene), which acts as an endogenous seed for gene fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	T1	T6	23294326
NA	CHEMICAL	GENE-Y	4	5	These results suggest that chemical-bound gene (Ggene), which acts as an endogenous seed for gene fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	T1	T7	23294326
NA	CHEMICAL	GENE-Y	4	5	These results suggest that chemical-bound gene (Ggene), which acts as an endogenous seed for gene fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	T1	T8	23294326
NA	CHEMICAL	GENE-Y	1	5	Although chemical (TAM), a selective gene modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.	T14	T22	23295740
NA	CHEMICAL	GENE-Y	2	5	Although tamoxifen (chemical), a selective gene modulator, has been widely used in the treatment of hormone-responsive breast cancer, its estrogen-like effect increases the risk of endometrial cancer.	T7	T22	23295740
NA	CHEMICAL	GENE-N	11	25	In this report, we explored the role of microRNAs (miRNAs) in chemical-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found gene is involved in this process via the regulation of c-Myc.	T9	T23	23295740
NA	CHEMICAL	GENE-Y	11	35	In this report, we explored the role of microRNAs (miRNAs) in chemical-induced epithelial-mesenchymal transition (EMT) in ECC-1 and Ishikawa endometrial cancer cell lines and found miR-200 is involved in this process via the regulation of gene.	T9	T24	23295740
CPR:4	CHEMICAL	GENE-N	20	0	gene, a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to chemical treatment.	T12	T25	23295740
NA	CHEMICAL	GENE-Y	2	35	Consistent with chemical finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas gene decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	T13	T16	23295740
NA	CHEMICAL	GENE-Y	2	32	Consistent with chemical finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and gene increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	T13	T29	23295740
NA	CHEMICAL	GENE-Y	2	16	Consistent with chemical finger E-box binding homeobox 2, which was confirmed as a direct target of gene in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	T13	T27	23295740
NA	CHEMICAL	GENE-Y	2	30	Consistent with chemical finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as gene and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.	T13	T28	23295740
NA	CHEMICAL	GENE-Y	39	2	Consistent with gene, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T1	T26	23295740
NA	CHEMICAL	GENE-Y	39	2	Consistent with gene, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T2	T26	23295740
CPR:4	CHEMICAL	GENE-Y	39	35	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas gene decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T1	T16	23295740
NA	CHEMICAL	GENE-Y	39	35	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas gene decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T2	T16	23295740
CPR:3	CHEMICAL	GENE-Y	39	32	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and gene increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T1	T29	23295740
NA	CHEMICAL	GENE-Y	39	32	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and gene increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T2	T29	23295740
NA	CHEMICAL	GENE-Y	39	16	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of gene in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T1	T27	23295740
NA	CHEMICAL	GENE-Y	39	16	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of gene in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T2	T27	23295740
CPR:3	CHEMICAL	GENE-Y	39	30	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as gene and N-cadherin increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T1	T28	23295740
NA	CHEMICAL	GENE-Y	39	30	Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as gene and N-cadherin increased, whereas E-cadherin decreased in the chemical-treated cells, contributing to chemical-induced EMT in these endometrial cancer cells.	T2	T28	23295740
NA	CHEMICAL	GENE-N	20	14	In addition, we showed that c-Myc directly binds to and represses the promoter of gene miRNAs, and its up-regulation in chemical-treated endometrial cancer cells leads to the down-regulation of gene and eventually to EMT.	T3	T18	23295740
CPR:4	CHEMICAL	GENE-N	20	14	In addition, we showed that c-Myc directly binds to and represses the promoter of gene miRNAs, and its up-regulation in chemical-treated endometrial cancer cells leads to the down-regulation of gene and eventually to EMT.	T3	T19	23295740
NA	CHEMICAL	GENE-Y	20	5	In addition, we showed that gene directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in chemical-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT.	T3	T17	23295740
CPR:4	CHEMICAL	GENE-N	5	9	Collectively, our data suggest that chemical can repress the gene family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.	T4	T20	23295740
CPR:3	CHEMICAL	GENE-Y	5	18	Collectively, our data suggest that chemical can repress the miR-200 family and induce EMT via the up-regulation of gene in endometrial cancer cells.	T4	T21	23295740
CPR:3	CHEMICAL	GENE-Y	7	14	Here, we show that oral administration of chemical, which leads to activation of an gene, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.	T1	T10	23297412
NA	CHEMICAL	GENE-Y	7	29	Here, we show that oral administration of chemical, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in gene-deficient mdx mice.	T1	T11	23297412
NA	CHEMICAL	GENE-Y	14	29	Here, we show that oral administration of resveratrol, which leads to activation of an chemical-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in gene-deficient mdx mice.	T2	T11	23297412
NA	CHEMICAL	GENE-Y	16	3	The pro-hypertrophic co-activator gene protein but not gene mRNA was up-regulated in the mdx heart, and chemical administration down-regulated the gene protein level.	T3	T12	23297412
NA	CHEMICAL	GENE-Y	16	3	The pro-hypertrophic co-activator gene protein but not gene mRNA was up-regulated in the mdx heart, and chemical administration down-regulated the gene protein level.	T3	T13	23297412
CPR:4	CHEMICAL	GENE-Y	16	3	The pro-hypertrophic co-activator gene protein but not gene mRNA was up-regulated in the mdx heart, and chemical administration down-regulated the gene protein level.	T3	T14	23297412
NA	CHEMICAL	GENE-Y	9	16	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the (1)-agonist chemical was inhibited by the overexpression of gene as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels.	T4	T15	23297412
NA	CHEMICAL	GENE-Y	9	25	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the (1)-agonist chemical was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated gene protein levels but not gene mRNA levels.	T4	T16	23297412
NA	CHEMICAL	GENE-Y	9	25	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the (1)-agonist chemical was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated gene protein levels but not gene mRNA levels.	T4	T17	23297412
NA	CHEMICAL	GENE-Y	20	16	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the (1)-agonist phenylephrine was inhibited by the overexpression of gene as well as chemical, both of which down-regulated p300 protein levels but not p300 mRNA levels.	T5	T15	23297412
CPR:4	CHEMICAL	GENE-Y	20	25	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the (1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as chemical, both of which down-regulated gene protein levels but not gene mRNA levels.	T5	T16	23297412
NA	CHEMICAL	GENE-Y	20	25	In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the (1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as chemical, both of which down-regulated gene protein levels but not gene mRNA levels.	T5	T17	23297412
NA	CHEMICAL	GENE-N	14	9	We found that SIRT1 induced p300 down-regulation via the ubiquitin-gene pathway by deacetylation of chemical residues for ubiquitination.	T6	T24	23297412
NA	CHEMICAL	GENE-N	14	9	We found that SIRT1 induced p300 down-regulation via the gene-proteasome pathway by deacetylation of chemical residues for geneation.	T6	T23	23297412
NA	CHEMICAL	GENE-Y	14	3	We found that gene induced p300 down-regulation via the ubiquitin-proteasome pathway by deacetylation of chemical residues for ubiquitination.	T6	T21	23297412
NA	CHEMICAL	GENE-Y	14	5	We found that SIRT1 induced gene down-regulation via the ubiquitin-proteasome pathway by deacetylation of chemical residues for ubiquitination.	T6	T22	23297412
NA	CHEMICAL	GENE-Y	22	20	The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards gene and chemical receptors.	T3	T23	23298577
NA	CHEMICAL	GENE-Y	4	7	The nuclear receptors constitutive chemical receptor (CAR), gene (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T1	T13	23299080
NA	CHEMICAL	GENE-Y	4	12	The nuclear receptors constitutive chemical receptor (CAR), pregnane X receptor (PXR) and gene (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T1	T19	23299080
NA	CHEMICAL	GENE-N	4	1	The gene constitutive chemical receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T1	T8	23299080
NA	CHEMICAL	GENE-Y	4	15	The nuclear receptors constitutive chemical receptor (CAR), pregnane X receptor (PXR) and vitamin D receptor (gene) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T1	T4	23299080
NA	CHEMICAL	GENE-Y	4	10	The nuclear receptors constitutive chemical receptor (CAR), pregnane X receptor (gene) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T1	T18	23299080
NA	CHEMICAL	GENE-Y	4	6	The nuclear receptors constitutive chemical receptor (gene), pregnane X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T1	T12	23299080
NA	CHEMICAL	GENE-Y	12	3	The nuclear receptors gene (CAR), pregnane X receptor (PXR) and chemical receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T3	T5	23299080
NA	CHEMICAL	GENE-Y	12	7	The nuclear receptors constitutive androstane receptor (CAR), gene (PXR) and chemical receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T3	T13	23299080
NA	CHEMICAL	GENE-N	12	1	The gene constitutive androstane receptor (CAR), pregnane X receptor (PXR) and chemical receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T3	T8	23299080
NA	CHEMICAL	GENE-Y	12	15	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and chemical receptor (gene) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T3	T4	23299080
NA	CHEMICAL	GENE-Y	12	10	The nuclear receptors constitutive androstane receptor (CAR), pregnane X receptor (gene) and chemical receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T3	T18	23299080
NA	CHEMICAL	GENE-Y	12	6	The nuclear receptors constitutive androstane receptor (gene), pregnane X receptor (PXR) and chemical receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T3	T12	23299080
NA	CHEMICAL	GENE-Y	7	3	The nuclear receptors gene (CAR), chemical X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T2	T5	23299080
NA	CHEMICAL	GENE-Y	7	12	The nuclear receptors constitutive androstane receptor (CAR), chemical X receptor (PXR) and gene (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T2	T19	23299080
NA	CHEMICAL	GENE-N	7	1	The gene constitutive androstane receptor (CAR), chemical X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T2	T8	23299080
NA	CHEMICAL	GENE-Y	7	15	The nuclear receptors constitutive androstane receptor (CAR), chemical X receptor (PXR) and vitamin D receptor (gene) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T2	T4	23299080
NA	CHEMICAL	GENE-Y	7	10	The nuclear receptors constitutive androstane receptor (CAR), chemical X receptor (gene) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T2	T18	23299080
NA	CHEMICAL	GENE-Y	7	6	The nuclear receptors constitutive androstane receptor (gene), chemical X receptor (PXR) and vitamin D receptor (VDR) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	T2	T12	23299080
CPR:4	CHEMICAL	GENE-Y	4	15	We previously reported that chemical (CA-Xaa-NHOH) acted as both a good antioxidant and gene inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.	T6	T25	23305921
NA	CHEMICAL	GENE-Y	33	15	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and gene inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like chemical.	T4	T25	23305921
NA	CHEMICAL	GENE-Y	20	15	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and gene inhibitor, in particular when chemical was conjugated with proline or amino acids having aromatic ring like phenylalanine.	T1	T25	23305921
NA	CHEMICAL	GENE-Y	27	15	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and gene inhibitor, in particular when caffeic acid was conjugated with proline or chemical having aromatic ring like phenylalanine.	T3	T25	23305921
CPR:4	CHEMICAL	GENE-Y	7	15	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (chemical) acted as both a good antioxidant and gene inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.	T15	T25	23305921
NA	CHEMICAL	GENE-Y	25	15	We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and gene inhibitor, in particular when caffeic acid was conjugated with chemical or amino acids having aromatic ring like phenylalanine.	T2	T25	23305921
NA	CHEMICAL	GENE-Y	10	31	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with chemical and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and gene inhibitors.	T8	T26	23305921
NA	CHEMICAL	GENE-Y	14	31	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and chemical (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and gene inhibitors.	T9	T26	23305921
NA	CHEMICAL	GENE-Y	2	31	Here, various chemical (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and gene inhibitors.	T5	T26	23305921
NA	CHEMICAL	GENE-Y	19	31	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (HCA-Phe-NHOH and chemical) to study the structure and activity relationship as both antioxidants and gene inhibitors.	T11	T26	23305921
NA	CHEMICAL	GENE-Y	17	31	Here, various hydroxycinnamic acid (HCA) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (chemical and HCA-Pro-NHOH) to study the structure and activity relationship as both antioxidants and gene inhibitors.	T10	T26	23305921
NA	CHEMICAL	GENE-Y	4	31	Here, various hydroxycinnamic acid (chemical) derivatives were further conjugated with phenylalanyl hydroxamic acid and prolyl hydroxamic acid (chemical-Phe-NHOH and chemical-Pro-NHOH) to study the structure and activity relationship as both antioxidants and gene inhibitors.	T7	T26	23305921
CPR:4	CHEMICAL	GENE-Y	7	11	In addition, derivatives of caffeic acid and chemical efficiently inhibited gene activity and reduced melanin content in melanocytes Mel-Ab cell.	T22	T27	23305921
CPR:4	CHEMICAL	GENE-Y	4	11	In addition, derivatives of chemical and sinapic acid efficiently inhibited gene activity and reduced melanin content in melanocytes Mel-Ab cell.	T21	T27	23305921
CPR:4	CHEMICAL	GENE-Y	0	7	chemical is a small-molecule inhibitorof JAK1 and gene and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	T1	T14	23307549
CPR:4	CHEMICAL	GENE-Y	0	5	chemical is a small-molecule inhibitorof gene and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.	T1	T13	23307549
NA	CHEMICAL	GENE-Y	22	21	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active gene, chemical (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).	T15	T25	23318731
NA	CHEMICAL	GENE-Y	27	21	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active gene, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and chemical (3-NT).	T17	T25	23318731
NA	CHEMICAL	GENE-Y	25	21	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active gene, 8-epi-prostaglandin F2 alpha (chemical), and 3-nitrotyrosine (3-NT).	T16	T25	23318731
NA	CHEMICAL	GENE-Y	28	21	Ex vivo samples of human oral mucosa were exposed to Pb or BaP, and immunohistochemical staining was performed to evaluate active gene, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (chemical).	T18	T25	23318731
NA	CHEMICAL	GENE-Y	12	21	Ex vivo samples of human oral mucosa were exposed to Pb or chemical, and immunohistochemical staining was performed to evaluate active gene, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).	T13	T25	23318731
NA	CHEMICAL	GENE-Y	10	21	Ex vivo samples of human oral mucosa were exposed to chemical or BaP, and immunohistochemical staining was performed to evaluate active gene, 8-epi-prostaglandin F2 alpha (8-epi-PGF2a), and 3-nitrotyrosine (3-NT).	T12	T25	23318731
CPR:3	CHEMICAL	GENE-Y	2	7	Pb and chemical treatments significantly increased active gene levels in a time-dependent manner.	T20	T26	23318731
CPR:3	CHEMICAL	GENE-Y	0	7	chemical and BaP treatments significantly increased active gene levels in a time-dependent manner.	T19	T26	23318731
NA	CHEMICAL	GENE-N	7	11	TAA increased the number and area of chemical S-transferase placental form (gene)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	T9	T27	23318833
CPR:3	CHEMICAL	GENE-N	0	7	chemical increased the number and area of gene (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	T8	T26	23318833
CPR:3	CHEMICAL	GENE-N	0	11	chemical increased the number and area of glutathione S-transferase placental form (gene)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	T8	T27	23318833
NA	CHEMICAL	GENE-Y	9	7	TAA also increased the numbers of ED2(+), gene(+), and chemical oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.	T13	T28	23318833
NA	CHEMICAL	GENE-N	9	19	TAA also increased the numbers of ED2(+), cyclooxygenase-2(+), and chemical oxygenase-1(+) liver cells, as well as the number of gene(+) lymphocytes.	T13	T30	23318833
CPR:4	CHEMICAL	GENE-Y	0	7	chemical also increased the numbers of ED2(+), gene(+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.	T12	T28	23318833
CPR:4	CHEMICAL	GENE-Y	0	9	chemical also increased the numbers of ED2(+), cyclooxygenase-2(+), and gene(+) liver cells, as well as the number of CD3(+) lymphocytes.	T12	T29	23318833
CPR:4	CHEMICAL	GENE-N	0	19	chemical also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of gene(+) lymphocytes.	T12	T30	23318833
NA	CHEMICAL	GENE-Y	9	14	EMIQ increased liver levels of thiobarbituric acid-reactive substance and chemical, and TUNEL(+) apoptotic cells, gene (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	T1	T17	23318833
NA	CHEMICAL	GENE-N	9	23	EMIQ increased liver levels of thiobarbituric acid-reactive substance and chemical, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within gene(+) foci.	T1	T19	23318833
NA	CHEMICAL	GENE-Y	9	17	EMIQ increased liver levels of thiobarbituric acid-reactive substance and chemical, and TUNEL(+) apoptotic cells, death receptor 5 (gene)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	T1	T18	23318833
NA	CHEMICAL	GENE-Y	5	14	EMIQ increased liver levels of chemical-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, gene (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	T14	T17	23318833
NA	CHEMICAL	GENE-N	5	23	EMIQ increased liver levels of chemical-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and 4-hydroxy-2-nonenal(+) cells within gene(+) foci.	T14	T19	23318833
NA	CHEMICAL	GENE-Y	5	17	EMIQ increased liver levels of chemical-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (gene)(+) cells and 4-hydroxy-2-nonenal(+) cells within GST-P(+) foci.	T14	T18	23318833
NA	CHEMICAL	GENE-Y	20	14	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, gene (DR5)(+) cells and chemical(+) cells within GST-P(+) foci.	T2	T17	23318833
NA	CHEMICAL	GENE-N	20	23	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (DR5)(+) cells and chemical(+) cells within gene(+) foci.	T2	T19	23318833
NA	CHEMICAL	GENE-Y	20	17	EMIQ increased liver levels of thiobarbituric acid-reactive substance and 8-hydroxydeoxyguanosine, and TUNEL(+) apoptotic cells, death receptor 5 (gene)(+) cells and chemical(+) cells within GST-P(+) foci.	T2	T18	23318833
NA	CHEMICAL	GENE-N	9	12	Rapid and voltage-dependent inactivation greatly attenuates outward currents in chemical-a-go-go-related gene (ERG) gene.	T15	T24	23319419
NA	CHEMICAL	GENE-Y	9	11	Rapid and voltage-dependent inactivation greatly attenuates outward currents in chemical-a-go-go-related gene (gene) K(+) channels.	T15	T23	23319419
NA	CHEMICAL	GENE-Y	12	9	Rapid and voltage-dependent inactivation greatly attenuates outward currents in gene (ERG) chemical channels.	T1	T38	23319419
NA	CHEMICAL	GENE-Y	12	11	Rapid and voltage-dependent inactivation greatly attenuates outward currents in ether-a-go-go-related gene (gene) chemical channels.	T1	T23	23319419
NA	CHEMICAL	GENE-N	5	7	In contrast, inactivation of related chemical-a-go-go (EAG) gene is very slow and minimally reduces outward currents.	T7	T33	23319419
NA	CHEMICAL	GENE-Y	5	6	In contrast, inactivation of related chemical-a-go-go (gene) K(+) channels is very slow and minimally reduces outward currents.	T7	T32	23319419
NA	CHEMICAL	GENE-Y	7	5	In contrast, inactivation of related gene (EAG) chemical channels is very slow and minimally reduces outward currents.	T8	T31	23319419
NA	CHEMICAL	GENE-Y	7	6	In contrast, inactivation of related ether-a-go-go (gene) chemical channels is very slow and minimally reduces outward currents.	T8	T32	23319419
CPR:4	CHEMICAL	GENE-Y	1	22	Although chemical greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of gene inactivation without altering its voltage dependence.	T12	T35	23319419
CPR:3	CHEMICAL	GENE-Y	1	4	Although chemical greatly attenuates gene inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.	T12	T34	23319419
NA	CHEMICAL	GENE-Y	9	11	Here, we investigate whether the inverse functional response to chemical in gene and ERG channels is related to differences in chemical binding site or to intrinsic mechanisms of inactivation.	T13	T36	23319419
NA	CHEMICAL	GENE-Y	9	11	Here, we investigate whether the inverse functional response to chemical in gene and ERG channels is related to differences in chemical binding site or to intrinsic mechanisms of inactivation.	T14	T36	23319419
NA	CHEMICAL	GENE-Y	9	13	Here, we investigate whether the inverse functional response to chemical in EAG and gene channels is related to differences in chemical binding site or to intrinsic mechanisms of inactivation.	T13	T37	23319419
NA	CHEMICAL	GENE-Y	9	13	Here, we investigate whether the inverse functional response to chemical in EAG and gene channels is related to differences in chemical binding site or to intrinsic mechanisms of inactivation.	T14	T37	23319419
CPR:5	CHEMICAL	GENE-Y	0	7	chemical is a mixed agonist of mutant gene and gene/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.	T17	T20	23319419
CPR:5	CHEMICAL	GENE-Y	0	7	chemical is a mixed agonist of mutant gene and gene/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.	T17	T21	23319419
CPR:5	CHEMICAL	GENE-Y	0	9	chemical is a mixed agonist of mutant EAG and EAG/gene chimera channels that inactivate by a combination of slow and fast mechanisms.	T17	T22	23319419
NA	CHEMICAL	GENE-Y	8	23	With the exception of three residues, the specific chemical that form the putative binding pocket for ICA in ERG are conserved in gene.	T2	T26	23319419
NA	CHEMICAL	GENE-Y	8	19	With the exception of three residues, the specific chemical that form the putative binding pocket for ICA in gene are conserved in EAG.	T2	T25	23319419
NA	CHEMICAL	GENE-Y	17	23	With the exception of three residues, the specific amino acids that form the putative binding pocket for chemical in ERG are conserved in gene.	T3	T26	23319419
NA	CHEMICAL	GENE-Y	17	19	With the exception of three residues, the specific amino acids that form the putative binding pocket for chemical in gene are conserved in EAG.	T3	T25	23319419
NA	CHEMICAL	GENE-Y	7	3	Mutations introduced into gene to replicate the chemical binding site in ERG did not alter the functional response to chemical.	T4	T27	23319419
NA	CHEMICAL	GENE-Y	7	3	Mutations introduced into gene to replicate the chemical binding site in ERG did not alter the functional response to chemical.	T5	T27	23319419
NA	CHEMICAL	GENE-Y	7	11	Mutations introduced into EAG to replicate the chemical binding site in gene did not alter the functional response to chemical.	T4	T28	23319419
NA	CHEMICAL	GENE-Y	7	11	Mutations introduced into EAG to replicate the chemical binding site in gene did not alter the functional response to chemical.	T5	T28	23319419
NA	CHEMICAL	GENE-Y	5	12	Together these findings suggest that chemical binds to the same site in gene and ERG channels to elicit opposite functional effects.	T6	T29	23319419
NA	CHEMICAL	GENE-Y	5	14	Together these findings suggest that chemical binds to the same site in EAG and gene channels to elicit opposite functional effects.	T6	T30	23319419
NA	CHEMICAL	GENE-N	3	5	The 7 nicotinic chemical receptor (gene) is highly expressed in different regions of the brain and is associated with cognitive function as well as anxiety.	T5	T21	23321689
NA	CHEMICAL	GENE-N	1	5	Previously chemical, which activates both gene, has been shown to have an anxiogenic effect in behavioral tests.	T6	T20	23321689
CPR:6	CHEMICAL	GENE-Y	26	22	PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10mg/kg) that was significantly reduced by the gene antagonist chemical.	T2	T15	23321689
NA	CHEMICAL	GENE-Y	0	22	chemical on the other hand displayed an increase in anxiety-like behavior at a higher dose (10mg/kg) that was significantly reduced by the gene antagonist WAY-100135.	T1	T15	23321689
CPR:6	CHEMICAL	GENE-Y	5	2	However the gene antagonist chemical was unable to reverse these anxiety-like effects seen with PNU-282987.	T3	T16	23321689
NA	CHEMICAL	GENE-Y	15	2	However the gene antagonist methyllycaconitine was unable to reverse these anxiety-like effects seen with chemical.	T4	T16	23321689
NA	CHEMICAL	GENE-Y	21	10	We used lentiviral shRNA to knock down the expression of gene (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/chemical translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T15	T36	23322164
NA	CHEMICAL	GENE-Y	21	17	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and gene (CPT2)-, carnitine/chemical translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T15	T38	23322164
NA	CHEMICAL	GENE-N	21	26	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/chemical translocase (CACT)-, and plasmalemmal gene (OCTN2)-deficient human fibroblasts.	T15	T42	23322164
NA	CHEMICAL	GENE-Y	21	28	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/chemical translocase (CACT)-, and plasmalemmal carnitine transporter (gene)-deficient human fibroblasts.	T15	T43	23322164
NA	CHEMICAL	GENE-Y	21	20	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (gene)-, carnitine/chemical translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T15	T39	23322164
NA	CHEMICAL	GENE-Y	21	13	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (gene) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/chemical translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T15	T37	23322164
NA	CHEMICAL	GENE-Y	21	23	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/chemical translocase (gene)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T15	T41	23322164
NA	CHEMICAL	GENE-Y	17	10	We used lentiviral shRNA to knock down the expression of gene (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T13	T36	23322164
NA	CHEMICAL	GENE-Y	17	10	We used lentiviral shRNA to knock down the expression of gene (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T14	T36	23322164
NA	CHEMICAL	GENE-Y	17	10	We used lentiviral shRNA to knock down the expression of gene (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T16	T36	23322164
NA	CHEMICAL	GENE-Y	17	28	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (gene)-deficient human fibroblasts.	T13	T43	23322164
NA	CHEMICAL	GENE-Y	17	28	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (gene)-deficient human fibroblasts.	T14	T43	23322164
NA	CHEMICAL	GENE-Y	17	28	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (gene)-deficient human fibroblasts.	T16	T43	23322164
NA	CHEMICAL	GENE-Y	17	20	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (gene)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T13	T39	23322164
NA	CHEMICAL	GENE-Y	17	20	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (gene)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T14	T39	23322164
NA	CHEMICAL	GENE-Y	17	20	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (gene)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T16	T39	23322164
NA	CHEMICAL	GENE-Y	17	13	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (gene) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T13	T37	23322164
NA	CHEMICAL	GENE-Y	17	13	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (gene) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T14	T37	23322164
NA	CHEMICAL	GENE-Y	17	13	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (gene) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (CACT)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T16	T37	23322164
NA	CHEMICAL	GENE-Y	17	23	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (gene)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T13	T41	23322164
NA	CHEMICAL	GENE-Y	17	23	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (gene)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T14	T41	23322164
NA	CHEMICAL	GENE-Y	17	23	We used lentiviral shRNA to knock down the expression of medium-chain acyl-CoA dehydrogenase (MCAD) in control and chemical palmitoyltransferase 2 (CPT2)-, chemical/acylchemical translocase (gene)-, and plasmalemmal chemical transporter (OCTN2)-deficient human fibroblasts.	T16	T41	23322164
NA	CHEMICAL	GENE-Y	11	21	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, gene (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T12	T40	23322164
NA	CHEMICAL	GENE-Y	11	17	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (MCAD) in control and gene (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T12	T38	23322164
NA	CHEMICAL	GENE-N	11	26	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal gene (OCTN2)-deficient human fibroblasts.	T12	T42	23322164
NA	CHEMICAL	GENE-Y	11	28	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (gene)-deficient human fibroblasts.	T12	T43	23322164
NA	CHEMICAL	GENE-Y	11	20	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (gene)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T12	T39	23322164
NA	CHEMICAL	GENE-Y	11	13	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (gene) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (CACT)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T12	T37	23322164
NA	CHEMICAL	GENE-Y	11	23	We used lentiviral shRNA to knock down the expression of medium-chain chemical dehydrogenase (MCAD) in control and carnitine palmitoyltransferase 2 (CPT2)-, carnitine/acylcarnitine translocase (gene)-, and plasmalemmal carnitine transporter (OCTN2)-deficient human fibroblasts.	T12	T41	23322164
NA	CHEMICAL	GENE-Y	10	3	In control fibroblasts, gene knockdown markedly increased the production of chemical (3-fold, P<0.01).	T21	T44	23322164
NA	CHEMICAL	GENE-Y	8	0	gene-deficient cell lines also showed extracellular accumulation of chemical (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on gene.	T2	T26	23322164
NA	CHEMICAL	GENE-Y	8	0	gene-deficient cell lines also showed extracellular accumulation of chemical (2.8-fold, P<0.01), suggesting that the cellular export of acylcarnitines does not depend on gene.	T2	T45	23322164
NA	CHEMICAL	GENE-Y	17	0	gene-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of chemical does not depend on gene.	T3	T26	23322164
NA	CHEMICAL	GENE-Y	17	0	gene-deficient cell lines also showed extracellular accumulation of octanoylcarnitine (2.8-fold, P<0.01), suggesting that the cellular export of chemical does not depend on gene.	T3	T45	23322164
NA	CHEMICAL	GENE-Y	10	3	In contrast, in gene- and CACT-deficient cells, the accumulation of chemical in the medium did not significantly increase in the MCAD knockdown.	T4	T27	23322164
NA	CHEMICAL	GENE-Y	10	20	In contrast, in CPT2- and CACT-deficient cells, the accumulation of chemical in the medium did not significantly increase in the gene knockdown.	T4	T29	23322164
NA	CHEMICAL	GENE-Y	10	5	In contrast, in CPT2- and gene-deficient cells, the accumulation of chemical in the medium did not significantly increase in the MCAD knockdown.	T4	T28	23322164
CPR:9	CHEMICAL	GENE-Y	55	44	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and gene are involved in the mitochondrial synthesis and export of chemical.	T10	T35	23322164
CPR:9	CHEMICAL	GENE-Y	55	40	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. gene and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of chemical.	T10	T34	23322164
NA	CHEMICAL	GENE-Y	55	3	This shows that gene and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of chemical.	T10	T32	23322164
NA	CHEMICAL	GENE-Y	55	5	This shows that CPT2 and gene are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of chemical.	T10	T33	23322164
NA	CHEMICAL	GENE-Y	10	40	This shows that CPT2 and CACT are crucial for mitochondrial chemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. gene and carnitine/chemical translocase are involved in the mitochondrial synthesis and export of chemicals.	T5	T34	23322164
NA	CHEMICAL	GENE-Y	10	40	This shows that CPT2 and CACT are crucial for mitochondrial chemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. gene and carnitine/chemical translocase are involved in the mitochondrial synthesis and export of chemicals.	T9	T34	23322164
CPR:9	CHEMICAL	GENE-Y	10	3	This shows that gene and CACT are crucial for mitochondrial chemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/chemical translocase are involved in the mitochondrial synthesis and export of chemicals.	T5	T32	23322164
NA	CHEMICAL	GENE-Y	10	3	This shows that gene and CACT are crucial for mitochondrial chemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/chemical translocase are involved in the mitochondrial synthesis and export of chemicals.	T9	T32	23322164
CPR:9	CHEMICAL	GENE-Y	10	5	This shows that CPT2 and gene are crucial for mitochondrial chemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/chemical translocase are involved in the mitochondrial synthesis and export of chemicals.	T5	T33	23322164
NA	CHEMICAL	GENE-Y	10	5	This shows that CPT2 and gene are crucial for mitochondrial chemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and carnitine/chemical translocase are involved in the mitochondrial synthesis and export of chemicals.	T9	T33	23322164
NA	CHEMICAL	GENE-Y	10	40	This shows that CPT2 and CACT are crucial for mitochondrial acylchemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. gene and chemical/acylchemical translocase are involved in the mitochondrial synthesis and export of acylchemicals.	T8	T34	23322164
NA	CHEMICAL	GENE-Y	10	3	This shows that gene and CACT are crucial for mitochondrial acylchemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and chemical/acylchemical translocase are involved in the mitochondrial synthesis and export of acylchemicals.	T8	T32	23322164
NA	CHEMICAL	GENE-Y	10	5	This shows that CPT2 and gene are crucial for mitochondrial acylchemical formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. Carnitine palmitoyltransferase 2 and chemical/acylchemical translocase are involved in the mitochondrial synthesis and export of acylchemicals.	T8	T33	23322164
NA	CHEMICAL	GENE-Y	40	44	This shows that CPT2 and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. chemical palmitoyltransferase 2 and gene are involved in the mitochondrial synthesis and export of acylcarnitines.	T7	T35	23322164
NA	CHEMICAL	GENE-Y	40	3	This shows that gene and CACT are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. chemical palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	T7	T32	23322164
NA	CHEMICAL	GENE-Y	40	5	This shows that CPT2 and gene are crucial for mitochondrial acylcarnitine formation and export to the extracellular fluids in mFAOD.-Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J. A., Ventura, F. V., Houten, S. M. chemical palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.	T7	T33	23322164
NA	CHEMICAL	GENE-N	11	13	When evaluated for their effects on human 34 or 42 nicotinic chemical receptors (gene), several of these compounds were shown to be active as nAChR antagonists.	T8	T12	23327794
NA	CHEMICAL	GENE-N	11	13	When evaluated for their effects on human 34 or 42 nicotinic chemical receptors (genes), several of these compounds were shown to be active as gene antagonists.	T8	T13	23327794
NA	CHEMICAL	GENE-N	6	35	As a result of this study, chemical (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit nicotinic receptor antagonistic activity for both the gene subtypes.	T9	T10	23327794
CPR:6	CHEMICAL	GENE-N	6	28	As a result of this study, chemical (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit gene antagonistic activity for both the h34 and h42 receptor subtypes.	T9	T14	23327794
NA	CHEMICAL	GENE-Y	29	27	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express gene-D28k, a chemical-binding protein previously associated with resistance to injury in PD and in animal models.	T4	T17	23331067
NA	CHEMICAL	GENE-Y	29	27	In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express calbindin-gene, a chemical-binding protein previously associated with resistance to injury in PD and in animal models.	T4	T18	23331067
NA	CHEMICAL	GENE-Y	20	7	Cell-mapping studies in wild-type mice revealed that gene is primarily expressed in the ventral SN, a region particularly susceptible to chemical and other dopaminergic neurotoxins.	T5	T20	23331067
NA	CHEMICAL	GENE-Y	8	1	Furthermore, gene-expressing SN cells are preferentially lost following chemical treatment.	T1	T21	23331067
NA	CHEMICAL	GENE-Y	14	5	Finally, SN mDA neurons in gene hemizygous mice show increased sensitivity when exposed to chemical.	T2	T6	23331067
NA	CHEMICAL	GENE-Y	13	15	Thus, SN mDA neurons are represented by at least two distinct subpopulations including chemical-resistant Pitx3-autonomous, gene-positive neurons, and gene-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	T3	T10	23331067
NA	CHEMICAL	GENE-Y	13	15	Thus, SN mDA neurons are represented by at least two distinct subpopulations including chemical-resistant Pitx3-autonomous, gene-positive neurons, and gene-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	T3	T9	23331067
NA	CHEMICAL	GENE-Y	13	19	Thus, SN mDA neurons are represented by at least two distinct subpopulations including chemical-resistant Pitx3-autonomous, calbindin-positive neurons, and calbindin-negative gene-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	T3	T11	23331067
NA	CHEMICAL	GENE-Y	13	14	Thus, SN mDA neurons are represented by at least two distinct subpopulations including chemical-resistant gene-autonomous, calbindin-positive neurons, and calbindin-negative Pitx-3-dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	T3	T8	23331067
NA	CHEMICAL	GENE-Y	4	2	IKK phosphorylates gene at chemical-26 (Ser26) and primes it for inactivation.	T1	T24	23332762
NA	CHEMICAL	GENE-N	4	0	gene phosphorylates BAD at chemical-26 (Ser26) and primes it for inactivation.	T1	T23	23332762
NA	CHEMICAL	GENE-Y	5	2	IKK phosphorylates gene at serine-26 (chemical26) and primes it for inactivation.	T2	T24	23332762
NA	CHEMICAL	GENE-N	5	0	gene phosphorylates BAD at serine-26 (chemical26) and primes it for inactivation.	T2	T23	23332762
NA	CHEMICAL	GENE-Y	2	10	Elimination of chemical26 phosphorylation promotes BAD proapoptotic activity, thereby accelerating gene-induced apoptosis in cultured cells and increasing mortality in animals.	T3	T26	23332762
NA	CHEMICAL	GENE-Y	2	5	Elimination of chemical26 phosphorylation promotes gene proapoptotic activity, thereby accelerating TNF-induced apoptosis in cultured cells and increasing mortality in animals.	T3	T25	23332762
NA	CHEMICAL	GENE-Y	18	7	PURPOSE: To characterise further the previously observed gene (CYP3A4) interaction of the dual orexin receptor antagonist chemical.	T5	T25	23334403
CPR:6	CHEMICAL	GENE-N	18	15	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual gene antagonist chemical.	T5	T22	23334403
NA	CHEMICAL	GENE-Y	18	10	PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (gene) interaction of the dual orexin receptor antagonist chemical.	T5	T26	23334403
NA	CHEMICAL	GENE-Y	21	15	This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal gene inhibition, whereas the interaction with chemical is more due to hepatic gene inhibition.	T11	T23	23334403
NA	CHEMICAL	GENE-Y	21	15	This suggests that the observed interaction of almorexant with simvastatin is mainly caused by intestinal gene inhibition, whereas the interaction with chemical is more due to hepatic gene inhibition.	T11	T24	23334403
NA	CHEMICAL	GENE-Y	9	15	This suggests that the observed interaction of almorexant with chemical is mainly caused by intestinal gene inhibition, whereas the interaction with atorvastatin is more due to hepatic gene inhibition.	T10	T23	23334403
NA	CHEMICAL	GENE-Y	9	15	This suggests that the observed interaction of almorexant with chemical is mainly caused by intestinal gene inhibition, whereas the interaction with atorvastatin is more due to hepatic gene inhibition.	T10	T24	23334403
NA	CHEMICAL	GENE-Y	7	15	This suggests that the observed interaction of chemical with simvastatin is mainly caused by intestinal gene inhibition, whereas the interaction with atorvastatin is more due to hepatic gene inhibition.	T9	T23	23334403
NA	CHEMICAL	GENE-Y	7	15	This suggests that the observed interaction of chemical with simvastatin is mainly caused by intestinal gene inhibition, whereas the interaction with atorvastatin is more due to hepatic gene inhibition.	T9	T24	23334403
NA	CHEMICAL	GENE-Y	38	17	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of gene, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chemical, tolbutamide, metoprolol and midazolam, respectively.	T2	T9	23339682
NA	CHEMICAL	GENE-Y	38	18	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, gene, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chemical, tolbutamide, metoprolol and midazolam, respectively.	T2	T10	23339682
NA	CHEMICAL	GENE-Y	38	20	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, gene and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chemical, tolbutamide, metoprolol and midazolam, respectively.	T2	T12	23339682
NA	CHEMICAL	GENE-Y	38	22	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and gene, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chemical, tolbutamide, metoprolol and midazolam, respectively.	T2	T13	23339682
NA	CHEMICAL	GENE-Y	38	19	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, gene, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chemical, tolbutamide, metoprolol and midazolam, respectively.	T2	T11	23339682
NA	CHEMICAL	GENE-Y	39	17	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of gene, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, chemical, metoprolol and midazolam, respectively.	T3	T9	23339682
NA	CHEMICAL	GENE-Y	39	18	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, gene, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, chemical, metoprolol and midazolam, respectively.	T3	T10	23339682
NA	CHEMICAL	GENE-Y	39	20	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, gene and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, chemical, metoprolol and midazolam, respectively.	T3	T12	23339682
NA	CHEMICAL	GENE-Y	39	22	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and gene, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, chemical, metoprolol and midazolam, respectively.	T3	T13	23339682
NA	CHEMICAL	GENE-Y	39	19	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, gene, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, chemical, metoprolol and midazolam, respectively.	T3	T11	23339682
NA	CHEMICAL	GENE-Y	40	17	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of gene, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, chemical and midazolam, respectively.	T4	T9	23339682
NA	CHEMICAL	GENE-Y	40	18	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, gene, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, chemical and midazolam, respectively.	T4	T10	23339682
NA	CHEMICAL	GENE-Y	40	20	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, gene and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, chemical and midazolam, respectively.	T4	T12	23339682
NA	CHEMICAL	GENE-Y	40	22	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and gene, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, chemical and midazolam, respectively.	T4	T13	23339682
NA	CHEMICAL	GENE-Y	40	19	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, gene, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, chemical and midazolam, respectively.	T4	T11	23339682
NA	CHEMICAL	GENE-Y	42	17	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of gene, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and chemical, respectively.	T5	T9	23339682
NA	CHEMICAL	GENE-Y	42	18	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, gene, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and chemical, respectively.	T5	T10	23339682
NA	CHEMICAL	GENE-Y	42	20	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, gene and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and chemical, respectively.	T5	T12	23339682
NA	CHEMICAL	GENE-Y	42	22	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and gene, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and chemical, respectively.	T5	T13	23339682
NA	CHEMICAL	GENE-Y	42	19	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, gene, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and chemical, respectively.	T5	T11	23339682
NA	CHEMICAL	GENE-Y	37	17	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of gene, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: chemical, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	T1	T9	23339682
NA	CHEMICAL	GENE-Y	37	18	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, gene, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: chemical, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	T1	T10	23339682
NA	CHEMICAL	GENE-Y	37	20	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, gene and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: chemical, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	T1	T12	23339682
NA	CHEMICAL	GENE-Y	37	22	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and gene, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: chemical, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	T1	T13	23339682
NA	CHEMICAL	GENE-Y	37	19	Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, gene, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: chemical, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.	T1	T11	23339682
NA	CHEMICAL	GENE-N	20	26	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)chemical(283)), as well as in the gene of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T8	T45	23341458
NA	CHEMICAL	GENE-N	20	12	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical gene, giving rise to mature BMP-2 (Arg(282)chemical(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T8	T43	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)chemical(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T8	T41	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)chemical(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T8	T11	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)chemical(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T8	T44	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)chemical(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T8	T46	23341458
NA	CHEMICAL	GENE-Y	20	8	N-terminal sequencing indicated that pro-BMP-2 was cleaved by gene at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)chemical(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T8	T42	23341458
NA	CHEMICAL	GENE-N	20	26	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the gene of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T1	T45	23341458
NA	CHEMICAL	GENE-N	20	26	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the gene of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T7	T45	23341458
NA	CHEMICAL	GENE-N	20	12	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical gene, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T1	T43	23341458
NA	CHEMICAL	GENE-N	20	12	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical gene, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T7	T43	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T1	T41	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T7	T41	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (chemical(289)Lys(290)).	T1	T11	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (chemical(289)Lys(290)).	T1	T44	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (chemical(289)Lys(290)).	T1	T46	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (chemical(289)Lys(290)).	T7	T11	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (chemical(289)Lys(290)).	T7	T44	23341458
NA	CHEMICAL	GENE-Y	20	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (chemical(289)Lys(290)).	T7	T46	23341458
NA	CHEMICAL	GENE-Y	20	8	N-terminal sequencing indicated that pro-BMP-2 was cleaved by gene at the canonical PC cleavage site, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T1	T42	23341458
NA	CHEMICAL	GENE-Y	20	8	N-terminal sequencing indicated that pro-BMP-2 was cleaved by gene at the canonical PC cleavage site, giving rise to mature BMP-2 (chemical(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (chemical(289)Lys(290)).	T7	T42	23341458
NA	CHEMICAL	GENE-N	39	26	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the gene of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)chemical(290)).	T2	T45	23341458
NA	CHEMICAL	GENE-N	39	12	N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical gene, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)chemical(290)).	T2	T43	23341458
NA	CHEMICAL	GENE-Y	39	4	N-terminal sequencing indicated that gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)chemical(290)).	T2	T41	23341458
NA	CHEMICAL	GENE-Y	39	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)chemical(290)).	T2	T11	23341458
NA	CHEMICAL	GENE-Y	39	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)chemical(290)).	T2	T44	23341458
NA	CHEMICAL	GENE-Y	39	4	N-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)chemical(290)).	T2	T46	23341458
NA	CHEMICAL	GENE-Y	39	8	N-terminal sequencing indicated that pro-BMP-2 was cleaved by gene at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)chemical(290)).	T2	T42	23341458
NA	CHEMICAL	GENE-N	0	12	chemical-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical gene, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T6	T43	23341458
NA	CHEMICAL	GENE-N	0	12	chemical-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical gene, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T9	T43	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T6	T41	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T9	T41	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T6	T11	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T6	T44	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T6	T46	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T9	T11	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T9	T44	23341458
NA	CHEMICAL	GENE-Y	0	4	chemical-terminal sequencing indicated that pro-gene was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature gene (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature gene, generating a truncated mature gene peptide (Arg(289)Lys(290)).	T9	T46	23341458
NA	CHEMICAL	GENE-Y	0	8	chemical-terminal sequencing indicated that pro-BMP-2 was cleaved by gene at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T6	T42	23341458
NA	CHEMICAL	GENE-Y	0	8	chemical-terminal sequencing indicated that pro-BMP-2 was cleaved by gene at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)Gln(283)), as well as in the chemical-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)Lys(290)).	T9	T42	23341458
NA	CHEMICAL	GENE-Y	14	2	Similarly, mature gene was also cleaved to a truncated peptide within its N-terminal region (chemical(289)Lys(290)).	T4	T12	23341458
NA	CHEMICAL	GENE-Y	14	2	Similarly, mature gene was also cleaved to a truncated peptide within its N-terminal region (Arg(289)chemical(290)).	T5	T12	23341458
NA	CHEMICAL	GENE-Y	12	2	Similarly, mature gene was also cleaved to a truncated peptide within its chemical-terminal region (Arg(289)Lys(290)).	T3	T12	23341458
NA	CHEMICAL	GENE-Y	12	4	Key findings suggest that gene attenuates a broad number of cocaine and chemical induced behaviors and associated neuronal activity in rodents.	T14	T12	23348754
NA	CHEMICAL	GENE-Y	12	4	Key findings suggest that gene attenuates a broad number of cocaine and chemical induced behaviors and associated neuronal activity in rodents.	T14	T23	23348754
NA	CHEMICAL	GENE-N	12	4	Key findings suggest that gene attenuates a broad number of cocaine and chemical induced behaviors and associated neuronal activity in rodents.	T14	T12	23348754
NA	CHEMICAL	GENE-N	12	4	Key findings suggest that gene attenuates a broad number of cocaine and chemical induced behaviors and associated neuronal activity in rodents.	T14	T23	23348754
NA	CHEMICAL	GENE-Y	10	4	Key findings suggest that gene attenuates a broad number of chemical and methamphetamine induced behaviors and associated neuronal activity in rodents.	T13	T12	23348754
NA	CHEMICAL	GENE-Y	10	4	Key findings suggest that gene attenuates a broad number of chemical and methamphetamine induced behaviors and associated neuronal activity in rodents.	T13	T23	23348754
NA	CHEMICAL	GENE-N	10	4	Key findings suggest that gene attenuates a broad number of chemical and methamphetamine induced behaviors and associated neuronal activity in rodents.	T13	T12	23348754
NA	CHEMICAL	GENE-N	10	4	Key findings suggest that gene attenuates a broad number of chemical and methamphetamine induced behaviors and associated neuronal activity in rodents.	T13	T23	23348754
NA	CHEMICAL	GENE-Y	12	6	Evidence also outlines a role for gene in the prosocial effects of chemical (MDMA, Ecstasy) in both rodents and humans.	T2	T16	23348754
NA	CHEMICAL	GENE-Y	12	6	Evidence also outlines a role for gene in the prosocial effects of chemical (MDMA, Ecstasy) in both rodents and humans.	T2	T1	23348754
NA	CHEMICAL	GENE-N	12	6	Evidence also outlines a role for gene in the prosocial effects of chemical (MDMA, Ecstasy) in both rodents and humans.	T2	T16	23348754
NA	CHEMICAL	GENE-N	12	6	Evidence also outlines a role for gene in the prosocial effects of chemical (MDMA, Ecstasy) in both rodents and humans.	T2	T1	23348754
NA	CHEMICAL	GENE-Y	14	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, chemical) in both rodents and humans.	T4	T16	23348754
NA	CHEMICAL	GENE-Y	14	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, chemical) in both rodents and humans.	T4	T1	23348754
NA	CHEMICAL	GENE-N	14	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, chemical) in both rodents and humans.	T4	T16	23348754
NA	CHEMICAL	GENE-N	14	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA, chemical) in both rodents and humans.	T4	T1	23348754
NA	CHEMICAL	GENE-Y	13	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (chemical, Ecstasy) in both rodents and humans.	T3	T16	23348754
NA	CHEMICAL	GENE-Y	13	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (chemical, Ecstasy) in both rodents and humans.	T3	T1	23348754
NA	CHEMICAL	GENE-N	13	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (chemical, Ecstasy) in both rodents and humans.	T3	T16	23348754
NA	CHEMICAL	GENE-N	13	6	Evidence also outlines a role for gene in the prosocial effects of 3,4-methylenedioxymethamphetamine (chemical, Ecstasy) in both rodents and humans.	T3	T1	23348754
NA	CHEMICAL	GENE-Y	29	8	Clinical trials should now investigate the effectiveness of gene as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of chemical that are currently being investigated.	T6	T17	23348754
NA	CHEMICAL	GENE-Y	29	8	Clinical trials should now investigate the effectiveness of gene as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of chemical that are currently being investigated.	T6	T5	23348754
NA	CHEMICAL	GENE-N	29	8	Clinical trials should now investigate the effectiveness of gene as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of chemical that are currently being investigated.	T6	T17	23348754
NA	CHEMICAL	GENE-N	29	8	Clinical trials should now investigate the effectiveness of gene as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of chemical that are currently being investigated.	T6	T5	23348754
NA	CHEMICAL	GENE-N	14	8	The HHEX/IDE T2D locus is associated with decreased gene secretion in response to oral chemical stimulation in humans.	T1	T8	23349488
NA	CHEMICAL	GENE-Y	14	8	The HHEX/IDE T2D locus is associated with decreased gene secretion in response to oral chemical stimulation in humans.	T1	T8	23349488
NA	CHEMICAL	GENE-Y	14	1	The gene/IDE T2D locus is associated with decreased insulin secretion in response to oral chemical stimulation in humans.	T1	T6	23349488
NA	CHEMICAL	GENE-Y	14	1	The HHEX/gene T2D locus is associated with decreased insulin secretion in response to oral chemical stimulation in humans.	T1	T7	23349488
NA	CHEMICAL	GENE-N	3	5	We find that chemical stimulated gene secretion (GSIS) is decreased in Ide KO mice due to impaired replenishment of the releasable pool of granules and that the Ide gene is haploinsufficient.	T2	T10	23349488
NA	CHEMICAL	GENE-Y	3	5	We find that chemical stimulated gene secretion (GSIS) is decreased in Ide KO mice due to impaired replenishment of the releasable pool of granules and that the Ide gene is haploinsufficient.	T2	T10	23349488
NA	CHEMICAL	GENE-Y	3	11	We find that chemical stimulated insulin secretion (GSIS) is decreased in gene KO mice due to impaired replenishment of the releasable pool of granules and that the gene gene is haploinsufficient.	T2	T11	23349488
NA	CHEMICAL	GENE-Y	3	11	We find that chemical stimulated insulin secretion (GSIS) is decreased in gene KO mice due to impaired replenishment of the releasable pool of granules and that the gene gene is haploinsufficient.	T2	T12	23349488
NA	CHEMICAL	GENE-N	6	8	Lineage-tracing studies using sequential administration of chemical analogs, gene-driven cre-lox, and low-frequency ubiquitous cre-lox reveal that PDL does not convert progenitors to the -cell lineage.	T1	T7	23349489
NA	CHEMICAL	GENE-N	6	12	Lineage-tracing studies using sequential administration of chemical analogs, rat insulin 2 promoter-driven gene-lox, and low-frequency ubiquitous gene-lox reveal that PDL does not convert progenitors to the -cell lineage.	T1	T2	23349489
NA	CHEMICAL	GENE-N	6	12	Lineage-tracing studies using sequential administration of chemical analogs, rat insulin 2 promoter-driven gene-lox, and low-frequency ubiquitous gene-lox reveal that PDL does not convert progenitors to the -cell lineage.	T1	T4	23349489
NA	CHEMICAL	GENE-N	6	12	Lineage-tracing studies using sequential administration of chemical analogs, rat insulin 2 promoter-driven cre-gene, and low-frequency ubiquitous cre-gene reveal that PDL does not convert progenitors to the -cell lineage.	T1	T3	23349489
NA	CHEMICAL	GENE-N	6	12	Lineage-tracing studies using sequential administration of chemical analogs, rat insulin 2 promoter-driven cre-gene, and low-frequency ubiquitous cre-gene reveal that PDL does not convert progenitors to the -cell lineage.	T1	T5	23349489
NA	CHEMICAL	GENE-N	29	26	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic gene agonist chemical (DOI).	T9	T32	23353901
NA	CHEMICAL	GENE-Y	29	14	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) gene receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist chemical (DOI).	T9	T46	23353901
NA	CHEMICAL	GENE-N	29	14	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) gene receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist chemical (DOI).	T9	T46	23353901
NA	CHEMICAL	GENE-N	12	26	There are seemingly conflicting data in the literature regarding the role of chemical (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic gene agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	T17	T32	23353901
NA	CHEMICAL	GENE-Y	12	14	There are seemingly conflicting data in the literature regarding the role of chemical (5-HT) gene receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	T17	T46	23353901
NA	CHEMICAL	GENE-N	12	14	There are seemingly conflicting data in the literature regarding the role of chemical (5-HT) gene receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI).	T17	T46	23353901
NA	CHEMICAL	GENE-N	30	26	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic gene agonist 2,5-dimethoxy-4-iodoamphetamine (chemical).	T10	T32	23353901
NA	CHEMICAL	GENE-Y	30	14	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) gene receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (chemical).	T10	T46	23353901
NA	CHEMICAL	GENE-N	30	14	There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) gene receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (chemical).	T10	T46	23353901
NA	CHEMICAL	GENE-Y	16	10	The present experiments tested the hypothesis that both classes of gene receptor compounds could attenuate the chemical-elicited-HTR in a single strain of mice, C57Bl/6J.	T11	T40	23353901
NA	CHEMICAL	GENE-N	16	10	The present experiments tested the hypothesis that both classes of gene receptor compounds could attenuate the chemical-elicited-HTR in a single strain of mice, C57Bl/6J.	T11	T40	23353901
NA	CHEMICAL	GENE-N	12	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T47	23353901
NA	CHEMICAL	GENE-N	12	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T43	23353901
NA	CHEMICAL	GENE-Y	12	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T41	23353901
CPR:5	CHEMICAL	GENE-Y	12	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T42	23353901
NA	CHEMICAL	GENE-Y	12	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T45	23353901
NA	CHEMICAL	GENE-N	12	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T41	23353901
CPR:5	CHEMICAL	GENE-N	12	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T42	23353901
NA	CHEMICAL	GENE-N	12	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T45	23353901
NA	CHEMICAL	GENE-Y	12	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novelchemical (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T18	T44	23353901
NA	CHEMICAL	GENE-N	11	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T47	23353901
NA	CHEMICAL	GENE-N	11	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T43	23353901
CPR:5	CHEMICAL	GENE-Y	11	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T41	23353901
NA	CHEMICAL	GENE-Y	11	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T42	23353901
NA	CHEMICAL	GENE-Y	11	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T45	23353901
CPR:5	CHEMICAL	GENE-N	11	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T41	23353901
NA	CHEMICAL	GENE-N	11	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T42	23353901
NA	CHEMICAL	GENE-N	11	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T45	23353901
NA	CHEMICAL	GENE-Y	11	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and chemical), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T16	T44	23353901
NA	CHEMICAL	GENE-N	7	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T47	23353901
NA	CHEMICAL	GENE-N	7	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T43	23353901
CPR:5	CHEMICAL	GENE-Y	7	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T41	23353901
NA	CHEMICAL	GENE-Y	7	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T42	23353901
NA	CHEMICAL	GENE-Y	7	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T45	23353901
CPR:5	CHEMICAL	GENE-N	7	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T41	23353901
NA	CHEMICAL	GENE-N	7	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T42	23353901
NA	CHEMICAL	GENE-N	7	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T45	23353901
NA	CHEMICAL	GENE-Y	7	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, chemical, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T14	T44	23353901
NA	CHEMICAL	GENE-N	5	29	Commercially-available 5-HT2C agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T47	23353901
NA	CHEMICAL	GENE-N	5	17	Commercially-available 5-HT2C agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T43	23353901
CPR:5	CHEMICAL	GENE-Y	5	1	Commercially-available gene agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T41	23353901
NA	CHEMICAL	GENE-Y	5	1	Commercially-available gene agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T42	23353901
NA	CHEMICAL	GENE-Y	5	1	Commercially-available gene agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T45	23353901
CPR:5	CHEMICAL	GENE-N	5	1	Commercially-available gene agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T41	23353901
NA	CHEMICAL	GENE-N	5	1	Commercially-available gene agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T42	23353901
NA	CHEMICAL	GENE-N	5	1	Commercially-available gene agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T45	23353901
NA	CHEMICAL	GENE-Y	5	17	Commercially-available 5-HT2C agonists (CP 809101, chemical, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T13	T44	23353901
NA	CHEMICAL	GENE-N	30	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T47	23353901
NA	CHEMICAL	GENE-N	30	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T43	23353901
NA	CHEMICAL	GENE-Y	30	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T41	23353901
NA	CHEMICAL	GENE-Y	30	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T42	23353901
NA	CHEMICAL	GENE-Y	30	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T45	23353901
NA	CHEMICAL	GENE-N	30	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T41	23353901
NA	CHEMICAL	GENE-N	30	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T42	23353901
NA	CHEMICAL	GENE-N	30	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T45	23353901
NA	CHEMICAL	GENE-Y	30	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (chemical) receptors attenuated the DOI-elicited-HTR.	T23	T44	23353901
NA	CHEMICAL	GENE-N	3	29	Commercially-available 5-HT2C agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T47	23353901
NA	CHEMICAL	GENE-N	3	17	Commercially-available 5-HT2C agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T43	23353901
CPR:5	CHEMICAL	GENE-Y	3	1	Commercially-available gene agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T41	23353901
NA	CHEMICAL	GENE-Y	3	1	Commercially-available gene agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T42	23353901
NA	CHEMICAL	GENE-Y	3	1	Commercially-available gene agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T45	23353901
CPR:5	CHEMICAL	GENE-N	3	1	Commercially-available gene agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T41	23353901
NA	CHEMICAL	GENE-N	3	1	Commercially-available gene agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T42	23353901
NA	CHEMICAL	GENE-N	3	1	Commercially-available gene agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T45	23353901
NA	CHEMICAL	GENE-Y	3	17	Commercially-available 5-HT2C agonists (chemical, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T12	T44	23353901
NA	CHEMICAL	GENE-N	27	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (chemical), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T47	23353901
NA	CHEMICAL	GENE-N	27	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T43	23353901
NA	CHEMICAL	GENE-Y	27	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T41	23353901
NA	CHEMICAL	GENE-Y	27	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T42	23353901
CPR:6	CHEMICAL	GENE-Y	27	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T45	23353901
NA	CHEMICAL	GENE-N	27	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T41	23353901
NA	CHEMICAL	GENE-N	27	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T42	23353901
CPR:6	CHEMICAL	GENE-N	27	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T45	23353901
NA	CHEMICAL	GENE-Y	27	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (chemical), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T22	T44	23353901
NA	CHEMICAL	GENE-N	25	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T47	23353901
NA	CHEMICAL	GENE-N	25	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (chemical), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T43	23353901
NA	CHEMICAL	GENE-Y	25	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T41	23353901
NA	CHEMICAL	GENE-Y	25	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T42	23353901
NA	CHEMICAL	GENE-Y	25	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T45	23353901
NA	CHEMICAL	GENE-N	25	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T41	23353901
NA	CHEMICAL	GENE-N	25	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T42	23353901
NA	CHEMICAL	GENE-N	25	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (chemical), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T45	23353901
CPR:6	CHEMICAL	GENE-Y	25	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (chemical), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T21	T44	23353901
NA	CHEMICAL	GENE-N	9	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T47	23353901
NA	CHEMICAL	GENE-N	9	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T43	23353901
CPR:5	CHEMICAL	GENE-Y	9	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T41	23353901
NA	CHEMICAL	GENE-Y	9	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T42	23353901
NA	CHEMICAL	GENE-Y	9	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T45	23353901
CPR:5	CHEMICAL	GENE-N	9	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T41	23353901
NA	CHEMICAL	GENE-N	9	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T42	23353901
NA	CHEMICAL	GENE-N	9	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T45	23353901
NA	CHEMICAL	GENE-Y	9	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, chemical, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T15	T44	23353901
NA	CHEMICAL	GENE-N	13	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T47	23353901
NA	CHEMICAL	GENE-N	13	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T43	23353901
NA	CHEMICAL	GENE-Y	13	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T41	23353901
CPR:5	CHEMICAL	GENE-Y	13	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T42	23353901
NA	CHEMICAL	GENE-Y	13	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T45	23353901
NA	CHEMICAL	GENE-N	13	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T41	23353901
CPR:5	CHEMICAL	GENE-N	13	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T42	23353901
NA	CHEMICAL	GENE-N	13	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T45	23353901
NA	CHEMICAL	GENE-Y	13	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (chemical)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the DOI-elicited-HTR.	T19	T44	23353901
NA	CHEMICAL	GENE-N	34	29	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and gene (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T47	23353901
NA	CHEMICAL	GENE-N	34	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene antagonist activity), and antagonists selective for 5-HT2A (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T43	23353901
NA	CHEMICAL	GENE-Y	34	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T41	23353901
NA	CHEMICAL	GENE-Y	34	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T42	23353901
NA	CHEMICAL	GENE-Y	34	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T45	23353901
NA	CHEMICAL	GENE-N	34	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T41	23353901
NA	CHEMICAL	GENE-N	34	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T42	23353901
NA	CHEMICAL	GENE-N	34	1	Commercially-available gene agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type gene agonists (with 5-HT2A/2B antagonist activity), and antagonists selective for 5-HT2A (M100907), gene (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T45	23353901
NA	CHEMICAL	GENE-Y	34	17	Commercially-available 5-HT2C agonists (CP 809101, Ro 60-0175, WAY 161503, mCPP, and 1-methylpsilocin), novel4-phenyl-2-N,N-dimethyl-aminotetralin (PAT)-type 5-HT2C agonists (with gene/2B antagonist activity), and antagonists selective for gene (M100907), 5-HT2C (SB-242084), and 5-HT2B/2C (SB-206553) receptors attenuated the chemical-elicited-HTR.	T1	T44	23353901
NA	CHEMICAL	GENE-Y	10	1	The gene agonists and M100907 decreased locomotion, SB-242084 increased locomotion, chemical resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	T4	T25	23353901
NA	CHEMICAL	GENE-N	10	1	The gene agonists and M100907 decreased locomotion, SB-242084 increased locomotion, chemical resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	T4	T25	23353901
NA	CHEMICAL	GENE-Y	7	1	The gene agonists and M100907 decreased locomotion, chemical increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	T3	T25	23353901
NA	CHEMICAL	GENE-N	7	1	The gene agonists and M100907 decreased locomotion, chemical increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	T3	T25	23353901
NA	CHEMICAL	GENE-Y	4	1	The gene agonists and chemical decreased locomotion, SB-242084 increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	T2	T25	23353901
NA	CHEMICAL	GENE-N	4	1	The gene agonists and chemical decreased locomotion, SB-242084 increased locomotion, SB-206553 resulted in dose-dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	T2	T25	23353901
NA	CHEMICAL	GENE-Y	12	21	Invitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate gene receptor-mediated PLC signaling in HEK cells.	T5	T27	23353901
CPR:3	CHEMICAL	GENE-Y	12	21	Invitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate gene receptor-mediated PLC signaling in HEK cells.	T6	T27	23353901
NA	CHEMICAL	GENE-Y	12	6	Invitro molecular pharmacology studies showed that gene agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate mouse gene receptor-mediated PLC signaling in HEK cells.	T5	T26	23353901
NA	CHEMICAL	GENE-Y	12	6	Invitro molecular pharmacology studies showed that gene agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate mouse gene receptor-mediated PLC signaling in HEK cells.	T6	T26	23353901
NA	CHEMICAL	GENE-N	12	6	Invitro molecular pharmacology studies showed that gene agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate mouse gene receptor-mediated PLC signaling in HEK cells.	T5	T26	23353901
NA	CHEMICAL	GENE-N	12	6	Invitro molecular pharmacology studies showed that gene agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate mouse gene receptor-mediated PLC signaling in HEK cells.	T6	T26	23353901
NA	CHEMICAL	GENE-N	12	24	Invitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate mouse 5-HT2C receptor-mediated gene signaling in HEK cells.	T5	T28	23353901
NA	CHEMICAL	GENE-N	12	24	Invitro molecular pharmacology studies showed that 5-HT2C agonists potent for attenuating the chemical-elicited-HTR also reduced the efficacy of chemical to activate mouse 5-HT2C receptor-mediated gene signaling in HEK cells.	T6	T28	23353901
NA	CHEMICAL	GENE-Y	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T7	T31	23353901
NA	CHEMICAL	GENE-Y	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T7	T33	23353901
NA	CHEMICAL	GENE-Y	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T7	T34	23353901
NA	CHEMICAL	GENE-Y	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T8	T31	23353901
NA	CHEMICAL	GENE-Y	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T8	T33	23353901
NA	CHEMICAL	GENE-Y	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T8	T34	23353901
NA	CHEMICAL	GENE-N	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T7	T31	23353901
NA	CHEMICAL	GENE-N	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T7	T33	23353901
NA	CHEMICAL	GENE-N	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T7	T34	23353901
NA	CHEMICAL	GENE-N	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T8	T31	23353901
NA	CHEMICAL	GENE-N	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T8	T33	23353901
NA	CHEMICAL	GENE-N	10	3	Results indicate that gene receptor agonists and antagonists attenuate the chemical-elicited-HTR in C57Bl/6J mice, and suggest that structurally diverse gene ligands result in different gene receptor signaling outcomes compared to chemical.	T8	T34	23353901
CPR:9	CHEMICAL	GENE-Y	0	8	chemical N-demethylation in vitro is catalyzed by hepatic gene (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	T1	T30	23361846
CPR:9	CHEMICAL	GENE-Y	0	12	chemical N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and gene, but clinical disposition is often attributed to gene.	T1	T24	23361846
CPR:9	CHEMICAL	GENE-Y	0	12	chemical N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and gene, but clinical disposition is often attributed to gene.	T1	T32	23361846
CPR:9	CHEMICAL	GENE-Y	0	10	chemical N-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (gene) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	T1	T31	23361846
CPR:9	CHEMICAL	GENE-Y	1	8	Methadone chemical-demethylation in vitro is catalyzed by hepatic gene (CYP2B6) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	T2	T30	23361846
CPR:9	CHEMICAL	GENE-Y	1	12	Methadone chemical-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and gene, but clinical disposition is often attributed to gene.	T2	T24	23361846
CPR:9	CHEMICAL	GENE-Y	1	12	Methadone chemical-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (CYP2B6) and gene, but clinical disposition is often attributed to gene.	T2	T32	23361846
CPR:9	CHEMICAL	GENE-Y	1	10	Methadone chemical-demethylation in vitro is catalyzed by hepatic cytochrome P4502B6 (gene) and CYP3A4, but clinical disposition is often attributed to CYP3A4.	T2	T31	23361846
NA	CHEMICAL	GENE-Y	26	6	This investigation tested the hypothesis that gene is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based gene inhibitor chemical, given orally for 4 days.	T9	T25	23361846
CPR:4	CHEMICAL	GENE-Y	26	6	This investigation tested the hypothesis that gene is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based gene inhibitor chemical, given orally for 4 days.	T9	T27	23361846
NA	CHEMICAL	GENE-N	26	6	This investigation tested the hypothesis that gene2B6 is a prominent gene isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based gene2B6 inhibitor chemical, given orally for 4 days.	T9	T26	23361846
CPR:9	CHEMICAL	GENE-Y	15	6	This investigation tested the hypothesis that gene is a prominent CYP isoform responsible for clinical chemical N-demethylation and clearance, using the in vivo mechanism-based gene inhibitor ticlopidine, given orally for 4 days.	T7	T25	23361846
NA	CHEMICAL	GENE-Y	15	6	This investigation tested the hypothesis that gene is a prominent CYP isoform responsible for clinical chemical N-demethylation and clearance, using the in vivo mechanism-based gene inhibitor ticlopidine, given orally for 4 days.	T7	T27	23361846
CPR:9	CHEMICAL	GENE-N	15	6	This investigation tested the hypothesis that gene2B6 is a prominent gene isoform responsible for clinical chemical N-demethylation and clearance, using the in vivo mechanism-based gene2B6 inhibitor ticlopidine, given orally for 4 days.	T7	T26	23361846
CPR:9	CHEMICAL	GENE-Y	16	6	This investigation tested the hypothesis that gene is a prominent CYP isoform responsible for clinical methadone chemical-demethylation and clearance, using the in vivo mechanism-based gene inhibitor ticlopidine, given orally for 4 days.	T8	T25	23361846
NA	CHEMICAL	GENE-Y	16	6	This investigation tested the hypothesis that gene is a prominent CYP isoform responsible for clinical methadone chemical-demethylation and clearance, using the in vivo mechanism-based gene inhibitor ticlopidine, given orally for 4 days.	T8	T27	23361846
CPR:9	CHEMICAL	GENE-N	16	6	This investigation tested the hypothesis that gene2B6 is a prominent gene isoform responsible for clinical methadone chemical-demethylation and clearance, using the in vivo mechanism-based gene2B6 inhibitor ticlopidine, given orally for 4 days.	T8	T26	23361846
NA	CHEMICAL	GENE-N	12	6	A preliminary clinical investigation with the gene substrate probe alfentanil established that chemical did not inhibit intestinal or hepatic gene.	T11	T28	23361846
NA	CHEMICAL	GENE-N	12	6	A preliminary clinical investigation with the gene substrate probe alfentanil established that chemical did not inhibit intestinal or hepatic gene.	T11	T29	23361846
NA	CHEMICAL	GENE-N	9	6	A preliminary clinical investigation with the gene substrate probe chemical established that ticlopidine did not inhibit intestinal or hepatic gene.	T10	T28	23361846
NA	CHEMICAL	GENE-N	9	6	A preliminary clinical investigation with the gene substrate probe chemical established that ticlopidine did not inhibit intestinal or hepatic gene.	T10	T29	23361846
NA	CHEMICAL	GENE-Y	3	0	gene inhibition reduces chemical N-demethylation and clearance, and alters chemical concentrations, demonstrating an important role for gene in clinical chemical disposition.	T3	T22	23361846
NA	CHEMICAL	GENE-Y	3	0	gene inhibition reduces chemical N-demethylation and clearance, and alters chemical concentrations, demonstrating an important role for gene in clinical chemical disposition.	T3	T23	23361846
NA	CHEMICAL	GENE-Y	3	0	gene inhibition reduces chemical N-demethylation and clearance, and alters chemical concentrations, demonstrating an important role for gene in clinical chemical disposition.	T5	T22	23361846
NA	CHEMICAL	GENE-Y	3	0	gene inhibition reduces chemical N-demethylation and clearance, and alters chemical concentrations, demonstrating an important role for gene in clinical chemical disposition.	T5	T23	23361846
NA	CHEMICAL	GENE-Y	3	0	gene inhibition reduces chemical N-demethylation and clearance, and alters chemical concentrations, demonstrating an important role for gene in clinical chemical disposition.	T6	T22	23361846
CPR:9	CHEMICAL	GENE-Y	3	0	gene inhibition reduces chemical N-demethylation and clearance, and alters chemical concentrations, demonstrating an important role for gene in clinical chemical disposition.	T6	T23	23361846
NA	CHEMICAL	GENE-Y	4	0	gene inhibition reduces methadone chemical-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for gene in clinical methadone disposition.	T4	T22	23361846
NA	CHEMICAL	GENE-Y	4	0	gene inhibition reduces methadone chemical-demethylation and clearance, and alters methadone concentrations, demonstrating an important role for gene in clinical methadone disposition.	T4	T23	23361846
CPR:3	CHEMICAL	GENE-N	21	41	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, chemical, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of gene (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T27	23373701
CPR:5	CHEMICAL	GENE-N	21	16	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the gene (D2R) agonist, chemical, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T23	23373701
CPR:3	CHEMICAL	GENE-N	21	44	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, chemical, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (gene), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T28	23373701
CPR:3	CHEMICAL	GENE-Y	21	44	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, chemical, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (gene), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T28	23373701
CPR:3	CHEMICAL	GENE-Y	21	29	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, chemical, triggered an increase in the expression of gene that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T26	23373701
CPR:3	CHEMICAL	GENE-N	21	29	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, chemical, triggered an increase in the expression of gene that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T26	23373701
CPR:5	CHEMICAL	GENE-N	21	19	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (gene) agonist, chemical, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T25	23373701
CPR:5	CHEMICAL	GENE-Y	21	19	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (gene) agonist, chemical, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T2	T25	23373701
NA	CHEMICAL	GENE-N	7	41	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of gene (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T27	23373701
NA	CHEMICAL	GENE-N	7	44	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (gene), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T28	23373701
NA	CHEMICAL	GENE-Y	7	44	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (gene), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T28	23373701
NA	CHEMICAL	GENE-Y	7	29	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of gene that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T26	23373701
NA	CHEMICAL	GENE-N	7	29	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of gene that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T26	23373701
NA	CHEMICAL	GENE-N	7	19	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (gene) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T25	23373701
NA	CHEMICAL	GENE-Y	7	19	We found that treatment of both differentiated chemicalrgic-like SH-SY5Y cells and rat midbrain slices with the chemical D2 receptor (gene) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T1	T25	23373701
NA	CHEMICAL	GENE-N	41	16	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the gene (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of chemical-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T23	23373701
NA	CHEMICAL	GENE-N	41	44	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of chemical-finger protein 268 (gene), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T28	23373701
NA	CHEMICAL	GENE-Y	41	44	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of chemical-finger protein 268 (gene), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T28	23373701
NA	CHEMICAL	GENE-Y	41	29	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of gene that was temporally preceded by an increase in the levels of chemical-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T26	23373701
NA	CHEMICAL	GENE-N	41	29	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of gene that was temporally preceded by an increase in the levels of chemical-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T26	23373701
NA	CHEMICAL	GENE-N	41	19	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (gene) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of chemical-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T25	23373701
NA	CHEMICAL	GENE-Y	41	19	We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (gene) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of chemical-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.	T3	T25	23373701
CPR:4	CHEMICAL	GENE-N	4	12	Moreover, the D2R inhibitor chemical blocked the increase of both GDNF and gene expression following potassium-evoked dopamine release in SH-SY5Y cells.	T4	T31	23373701
CPR:4	CHEMICAL	GENE-Y	4	12	Moreover, the D2R inhibitor chemical blocked the increase of both GDNF and gene expression following potassium-evoked dopamine release in SH-SY5Y cells.	T4	T31	23373701
CPR:4	CHEMICAL	GENE-Y	4	10	Moreover, the D2R inhibitor chemical blocked the increase of both gene and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.	T4	T30	23373701
CPR:4	CHEMICAL	GENE-N	4	10	Moreover, the D2R inhibitor chemical blocked the increase of both gene and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.	T4	T30	23373701
CPR:4	CHEMICAL	GENE-N	4	2	Moreover, the gene inhibitor chemical blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.	T4	T29	23373701
CPR:4	CHEMICAL	GENE-Y	4	2	Moreover, the gene inhibitor chemical blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.	T4	T29	23373701
NA	CHEMICAL	GENE-N	15	12	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and gene expression following chemical-evoked dopamine release in SH-SY5Y cells.	T5	T31	23373701
NA	CHEMICAL	GENE-Y	15	12	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and gene expression following chemical-evoked dopamine release in SH-SY5Y cells.	T5	T31	23373701
NA	CHEMICAL	GENE-Y	15	10	Moreover, the D2R inhibitor raclopride blocked the increase of both gene and Zif268 expression following chemical-evoked dopamine release in SH-SY5Y cells.	T5	T30	23373701
NA	CHEMICAL	GENE-N	15	10	Moreover, the D2R inhibitor raclopride blocked the increase of both gene and Zif268 expression following chemical-evoked dopamine release in SH-SY5Y cells.	T5	T30	23373701
NA	CHEMICAL	GENE-N	15	2	Moreover, the gene inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following chemical-evoked dopamine release in SH-SY5Y cells.	T5	T29	23373701
NA	CHEMICAL	GENE-Y	15	2	Moreover, the gene inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following chemical-evoked dopamine release in SH-SY5Y cells.	T5	T29	23373701
NA	CHEMICAL	GENE-N	16	12	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and gene expression following potassium-evoked chemical release in SH-SY5Y cells.	T6	T31	23373701
NA	CHEMICAL	GENE-Y	16	12	Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and gene expression following potassium-evoked chemical release in SH-SY5Y cells.	T6	T31	23373701
NA	CHEMICAL	GENE-Y	16	10	Moreover, the D2R inhibitor raclopride blocked the increase of both gene and Zif268 expression following potassium-evoked chemical release in SH-SY5Y cells.	T6	T30	23373701
NA	CHEMICAL	GENE-N	16	10	Moreover, the D2R inhibitor raclopride blocked the increase of both gene and Zif268 expression following potassium-evoked chemical release in SH-SY5Y cells.	T6	T30	23373701
NA	CHEMICAL	GENE-N	16	2	Moreover, the gene inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked chemical release in SH-SY5Y cells.	T6	T29	23373701
NA	CHEMICAL	GENE-Y	16	2	Moreover, the gene inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked chemical release in SH-SY5Y cells.	T6	T29	23373701
NA	CHEMICAL	GENE-N	7	10	Here, we have perturbed vibrational motions in chemical reductase (gene) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and (2)H).	T4	T10	23373704
NA	CHEMICAL	GENE-N	25	7	Here, we have perturbed vibrational motions in gene (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope (chemical, (15)N, and (2)H).	T5	T9	23373704
NA	CHEMICAL	GENE-N	25	10	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (gene) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope (chemical, (15)N, and (2)H).	T5	T10	23373704
NA	CHEMICAL	GENE-N	26	7	Here, we have perturbed vibrational motions in gene (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, chemical, and (2)H).	T6	T9	23373704
NA	CHEMICAL	GENE-N	26	10	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (gene) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, chemical, and (2)H).	T6	T10	23373704
NA	CHEMICAL	GENE-N	28	7	Here, we have perturbed vibrational motions in gene (PETNR) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and chemical).	T7	T9	23373704
NA	CHEMICAL	GENE-N	28	10	Here, we have perturbed vibrational motions in pentaerythritol tetranitrate reductase (gene) by isotopic substitution where all non-exchangeable atoms were replaced with the corresponding heavy isotope ((13)C, (15)N, and chemical).	T7	T10	23373704
NA	CHEMICAL	GENE-Y	0	3	chemical synthetase 4 (gene) is involved in several cellular functions including steroidogenesis, synaptic development and cancer metastasis.	T1	T9	23376217
NA	CHEMICAL	GENE-Y	4	7	We demonstrated hCG and chemical regulation of gene mRNA in mouse steroidogenic MA-10 Leydig cells.	T3	T11	23376217
NA	CHEMICAL	GENE-N	4	2	We demonstrated gene and chemical regulation of Acsl4 mRNA in mouse steroidogenic MA-10 Leydig cells.	T3	T10	23376217
NA	CHEMICAL	GENE-N	23	6	Functional characterization revealed that the specificity protein/gene Sp1 binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of Acsl4 transcription.	T2	T19	23376217
NA	CHEMICAL	GENE-N	23	6	Functional characterization revealed that the specificity protein/gene Sp1 binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of Acsl4 transcription.	T4	T19	23376217
NA	CHEMICAL	GENE-N	23	5	Functional characterization revealed that the gene/Krppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of Acsl4 transcription.	T2	T18	23376217
NA	CHEMICAL	GENE-N	23	5	Functional characterization revealed that the gene/Krppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of Acsl4 transcription.	T4	T18	23376217
NA	CHEMICAL	GENE-Y	23	33	Functional characterization revealed that the specificity protein/Krppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of gene transcription.	T2	T7	23376217
NA	CHEMICAL	GENE-Y	23	33	Functional characterization revealed that the specificity protein/Krppel-like factor Sp1 binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of gene transcription.	T4	T7	23376217
NA	CHEMICAL	GENE-Y	23	8	Functional characterization revealed that the specificity protein/Krppel-like factor gene binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of Acsl4 transcription.	T2	T20	23376217
NA	CHEMICAL	GENE-Y	23	8	Functional characterization revealed that the specificity protein/Krppel-like factor gene binding site in the proximal promoter is involved in basal activity and that the chemical response element-binding site is involved in chemical stimulation of Acsl4 transcription.	T4	T20	23376217
CPR:4	CHEMICAL	GENE-N	7	17	In this paper a series of new chemical derivatives has been designed, synthesized and evaluated as the gene inhibitors.	T2	T4	23376249
CPR:3	CHEMICAL	GENE-N	0	10	chemical, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK gene pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	T1	T19	23376356
CPR:3	CHEMICAL	GENE-Y	0	14	chemical, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced gene phosphorylation, but did not activate JNK.	T1	T20	23376356
CPR:4	CHEMICAL	GENE-N	0	3	chemical, a specific gene/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	T1	T15	23376356
CPR:3	CHEMICAL	GENE-N	0	9	chemical, a specific PI3K/AKT inhibitor, selectively activated the p38 gene kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	T1	T18	23376356
CPR:3	CHEMICAL	GENE-N	0	8	chemical, a specific PI3K/AKT inhibitor, selectively activated the gene MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	T1	T17	23376356
NA	CHEMICAL	GENE-N	0	20	chemical, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate gene.	T1	T21	23376356
CPR:4	CHEMICAL	GENE-N	0	3	chemical, a specific PI3K/gene inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.	T1	T16	23376356
CPR:4	CHEMICAL	GENE-N	3	4	The pharmacological inhibitors chemical (gene inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	T2	T22	23376356
NA	CHEMICAL	GENE-N	3	9	The pharmacological inhibitors chemical (p38 inhibitor) and SP600125 (a gene inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	T2	T23	23376356
NA	CHEMICAL	GENE-N	18	4	The pharmacological inhibitors SB203580 (gene inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from chemical-induced apoptosis.	T4	T22	23376356
NA	CHEMICAL	GENE-N	18	9	The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a gene inhibitor) protected primary cultures of rat CGCs from chemical-induced apoptosis.	T4	T23	23376356
NA	CHEMICAL	GENE-N	7	4	The pharmacological inhibitors SB203580 (gene inhibitor) and chemical (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	T3	T22	23376356
CPR:4	CHEMICAL	GENE-N	7	9	The pharmacological inhibitors SB203580 (p38 inhibitor) and chemical (a gene inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	T3	T23	23376356
NA	CHEMICAL	GENE-N	20	4	We previously demonstrated that gene (P-gp) modulation at the blood-brain barrier (BBB) contributes highly to BUP-related respiratory toxicity, by limiting chemical entrance into the brain.	T21	T34	23376546
NA	CHEMICAL	GENE-N	20	5	We previously demonstrated that P-glycoprotein (gene) modulation at the blood-brain barrier (BBB) contributes highly to BUP-related respiratory toxicity, by limiting chemical entrance into the brain.	T21	T35	23376546
NA	CHEMICAL	GENE-N	15	4	We previously demonstrated that gene (P-gp) modulation at the blood-brain barrier (BBB) contributes highly to chemical-related respiratory toxicity, by limiting Nchemical entrance into the brain.	T20	T34	23376546
NA	CHEMICAL	GENE-N	15	5	We previously demonstrated that P-glycoprotein (gene) modulation at the blood-brain barrier (BBB) contributes highly to chemical-related respiratory toxicity, by limiting Nchemical entrance into the brain.	T20	T35	23376546
NA	CHEMICAL	GENE-N	23	10	In this work, we sought to investigate the role of gene-mediated transport at the BBB in gender and strain-related variability of BUP and chemical-induced respiratory effects in mice.	T24	T36	23376546
NA	CHEMICAL	GENE-N	21	10	In this work, we sought to investigate the role of gene-mediated transport at the BBB in gender and strain-related variability of chemical and Nchemical-induced respiratory effects in mice.	T23	T36	23376546
NA	CHEMICAL	GENE-N	8	3	No differences in gene expression or BUP and chemical transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.	T13	T32	23376546
NA	CHEMICAL	GENE-N	6	3	No differences in gene expression or chemical and Nchemical transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.	T12	T32	23376546
NA	CHEMICAL	GENE-N	22	4	Our results suggest that gene-mediated transport across the BBB does not play a key-role in gender and strain-related variability in BUP and chemical-induced respiratory toxicity in mice.	T16	T33	23376546
NA	CHEMICAL	GENE-N	20	4	Our results suggest that gene-mediated transport across the BBB does not play a key-role in gender and strain-related variability in chemical and Nchemical-induced respiratory toxicity in mice.	T15	T33	23376546
CPR:3	CHEMICAL	GENE-Y	3	11	Today, we used chemical, a hypoxia mimetic that inhibits proteasomal gene degradation and generates reactive oxygen species (ROS).	T1	T15	23380477
NA	CHEMICAL	GENE-Y	16	11	Today, we used cobalt chloride, a hypoxia mimetic that inhibits proteasomal gene degradation and generates reactive chemical species (ROS).	T2	T15	23380477
NA	CHEMICAL	GENE-Y	3	10	We focused on chemical-induced cell death in a DNA-binding mutated gene neuroblastoma cell line (SKNBE(2c)).	T3	T16	23380477
NA	CHEMICAL	GENE-N	21	10	An autophagic signaling was evidenced by an increase of Beclin-1, gene, and LC3-II expression whereas the p53(mut) presence decreased with chemical time exposure.	T4	T18	23380477
NA	CHEMICAL	GENE-Y	21	9	An autophagic signaling was evidenced by an increase of gene, ATG 5-12, and LC3-II expression whereas the p53(mut) presence decreased with chemical time exposure.	T4	T17	23380477
NA	CHEMICAL	GENE-Y	21	13	An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and gene expression whereas the p53(mut) presence decreased with chemical time exposure.	T4	T19	23380477
CPR:4	CHEMICAL	GENE-Y	21	17	An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the gene(mut) presence decreased with chemical time exposure.	T4	T20	23380477
NA	CHEMICAL	GENE-Y	6	1	The gene isoform, additionally, has an chemical-terminal PDZ domain.	T6	T16	23382379
NA	CHEMICAL	GENE-N	6	7	The myosin-18A isoform, additionally, has an chemical-terminal gene.	T6	T17	23382379
NA	CHEMICAL	GENE-N	7	0	gene binding was unchanged by presence of chemical.	T1	T21	23382379
NA	CHEMICAL	GENE-Y	4	1	Both gene isoforms bound chemical, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.	T2	T7	23382379
NA	CHEMICAL	GENE-N	4	21	Both myosin-18A isoforms bound chemical, but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by gene.	T2	T8	23382379
NA	CHEMICAL	GENE-Y	9	1	Both gene isoforms bound N-methylanthraniloyl-nucleotides, but the rate of chemical hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.	T3	T7	23382379
NA	CHEMICAL	GENE-N	9	21	Both myosin-18A isoforms bound N-methylanthraniloyl-nucleotides, but the rate of chemical hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by gene.	T3	T8	23382379
NA	CHEMICAL	GENE-Y	10	23	Phosphorylation of the regulatory light chain had no effect on chemical hydrolysis, and neither did the addition of tropomyosin or of GOLPH3, a gene binding partner.	T4	T9	23382379
NA	CHEMICAL	GENE-Y	31	3	Electron microscopy of gene-S1 showed that the lever is strongly angled with respect to the long axis of the motor domain, suggesting a pre-power stroke conformation regardless of the presence of chemical.	T5	T10	23382379
CPR:4	CHEMICAL	GENE-Y	9	14	Cellular responses to DNA damage induced by etoposide or chemical include down-regulation of endogenous gene coincident with increases in p53.	T3	T28	23382381
CPR:3	CHEMICAL	GENE-Y	9	19	Cellular responses to DNA damage induced by etoposide or chemical include down-regulation of endogenous supervillin coincident with increases in gene.	T3	T29	23382381
CPR:4	CHEMICAL	GENE-Y	7	14	Cellular responses to DNA damage induced by chemical or doxorubicin include down-regulation of endogenous gene coincident with increases in p53.	T2	T28	23382381
CPR:3	CHEMICAL	GENE-Y	7	19	Cellular responses to DNA damage induced by chemical or doxorubicin include down-regulation of endogenous supervillin coincident with increases in gene.	T2	T29	23382381
NA	CHEMICAL	GENE-Y	6	5	USP7 binds directly to the gene chemical terminus and can deubiquitinate and stabilize gene.	T1	T13	23382381
NA	CHEMICAL	GENE-Y	6	5	USP7 binds directly to the gene chemical terminus and can deubiquitinate and stabilize gene.	T1	T14	23382381
NA	CHEMICAL	GENE-N	6	0	gene binds directly to the supervillin chemical terminus and can deubiquitinate and stabilize supervillin.	T1	T12	23382381
NA	CHEMICAL	GENE-Y	6	0	gene binds directly to the supervillin chemical terminus and can deubiquitinate and stabilize supervillin.	T1	T12	23382381
NA	CHEMICAL	GENE-N	23	62	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and chemical exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), gene (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% chemical.	T10	T25	23384447
NA	CHEMICAL	GENE-N	23	62	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and chemical exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), gene (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% chemical.	T12	T25	23384447
NA	CHEMICAL	GENE-N	23	59	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and chemical exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of gene (1.5mg/ml), very-gene (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% chemical.	T10	T24	23384447
NA	CHEMICAL	GENE-N	23	59	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and chemical exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of gene (1.5mg/ml), very-gene (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% chemical.	T12	T24	23384447
NA	CHEMICAL	GENE-N	66	62	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), gene (1.0mg/ml) and chemical (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	T11	T25	23384447
NA	CHEMICAL	GENE-N	66	59	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and sugar diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of gene (1.5mg/ml), very-gene (1.0mg/ml) and chemical (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	T11	T24	23384447
NA	CHEMICAL	GENE-N	20	62	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and chemical diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of low-density lipoprotein (1.5mg/ml), gene (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	T9	T25	23384447
NA	CHEMICAL	GENE-N	20	59	To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and chemical diet and ethanol exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004-2005 in the presence or absence of gene (1.5mg/ml), very-gene (1.0mg/ml) and glucose (10mmol/L) (LVG), and in the absence or presence of 0.1% ethanol.	T9	T24	23384447
NA	CHEMICAL	GENE-N	38	28	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and gene (PAI), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T1	T17	23384447
NA	CHEMICAL	GENE-N	38	28	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and gene (PAI), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T2	T17	23384447
NA	CHEMICAL	GENE-Y	38	25	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of gene (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T1	T15	23384447
NA	CHEMICAL	GENE-Y	38	25	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of gene (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T2	T15	23384447
NA	CHEMICAL	GENE-Y	38	41	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial chemical synthase (gene) protein expression and chemical (NO) release.	T1	T20	23384447
NA	CHEMICAL	GENE-Y	38	41	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial chemical synthase (gene) protein expression and chemical (NO) release.	T2	T20	23384447
NA	CHEMICAL	GENE-Y	38	26	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (gene) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T1	T16	23384447
NA	CHEMICAL	GENE-Y	38	26	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (gene) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T2	T16	23384447
NA	CHEMICAL	GENE-N	38	31	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (gene), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T1	T18	23384447
NA	CHEMICAL	GENE-N	38	31	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (gene), while causing no changes in endothelial chemical synthase (eNOS) protein expression and chemical (NO) release.	T2	T18	23384447
NA	CHEMICAL	GENE-Y	41	37	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in gene (echemicalS) protein expression and nitric oxide (chemical) release.	T3	T19	23384447
NA	CHEMICAL	GENE-N	41	28	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and gene (PAI), while causing no changes in endothelial nitric oxide synthase (echemicalS) protein expression and nitric oxide (chemical) release.	T3	T17	23384447
NA	CHEMICAL	GENE-Y	41	25	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of gene (ET-1) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (echemicalS) protein expression and nitric oxide (chemical) release.	T3	T15	23384447
NA	CHEMICAL	GENE-Y	41	26	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (gene) and plasminogen activator inhibitor (PAI), while causing no changes in endothelial nitric oxide synthase (echemicalS) protein expression and nitric oxide (chemical) release.	T3	T16	23384447
NA	CHEMICAL	GENE-N	41	31	NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of endothelin-1 (ET-1) and plasminogen activator inhibitor (gene), while causing no changes in endothelial nitric oxide synthase (echemicalS) protein expression and nitric oxide (chemical) release.	T3	T18	23384447
NA	CHEMICAL	GENE-Y	32	13	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, gene protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of ET-1, chemical and PAI.	T5	T21	23384447
NA	CHEMICAL	GENE-Y	32	31	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of gene, chemical and PAI.	T5	T22	23384447
NA	CHEMICAL	GENE-N	32	34	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, eNOS protein expression, and NO release and caused membrane damage, but caused no changes in the secretion of ET-1, chemical and gene.	T5	T23	23384447
NA	CHEMICAL	GENE-Y	13	31	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, echemicalS protein expression, and chemical release and caused membrane damage, but caused no changes in the secretion of gene, prostacyclin and PAI.	T4	T22	23384447
NA	CHEMICAL	GENE-N	13	34	In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, echemicalS protein expression, and chemical release and caused membrane damage, but caused no changes in the secretion of ET-1, prostacyclin and gene.	T4	T23	23384447
NA	CHEMICAL	GENE-N	13	18	We apply DFTB in a QM/MM framework to perform vibrational analysis of buried chemical in bacteriorhodopsin and gene.	T6	T12	23385325
NA	CHEMICAL	GENE-N	13	16	We apply DFTB in a QM/MM framework to perform vibrational analysis of buried chemical in gene and channelrhodopsin-2.	T6	T11	23385325
NA	CHEMICAL	GENE-Y	8	4	Despite the importance of gene*28 in chemical pharmacogenetics, our capability to predict drug-induced severe toxicity remains limited.	T10	T20	23386248
NA	CHEMICAL	GENE-Y	13	10	Our results suggest that specific SNPs in UGT1A, other than gene*28, may influence chemical toxicity and should be considered to refine pharmacogenetic testing.	T1	T19	23386248
NA	CHEMICAL	GENE-N	13	7	Our results suggest that specific SNPs in gene, other than gene1*28, may influence chemical toxicity and should be considered to refine pharmacogenetic testing.	T1	T18	23386248
NA	CHEMICAL	GENE-Y	0	6	chemical action is exerted through the gene.	T1	T22	23386417
NA	CHEMICAL	GENE-N	13	6	We also established the number of gene in exon 1 of the chemical receptor gene by GeneScan analysis.	T4	T16	23386417
NA	CHEMICAL	GENE-Y	6	15	The sCT released from NP stimulated chemical production in human T47D breast cancer cells expressing gene.	T1	T10	23391443
NA	CHEMICAL	GENE-Y	22	12	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), gene (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T17	23395804
NA	CHEMICAL	GENE-Y	22	16	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), gene (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T20	23395804
NA	CHEMICAL	GENE-N	22	9	Ion-poor conditions led to increases in the expression of gene (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T15	23395804
NA	CHEMICAL	GENE-Y	22	15	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; gene), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T19	23395804
NA	CHEMICAL	GENE-Y	22	19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; gene), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T22	23395804
NA	CHEMICAL	GENE-Y	22	11	Ion-poor conditions led to increases in the expression of PRL receptor (gene), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T16	23395804
NA	CHEMICAL	GENE-Y	22	18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (gene; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T21	23395804
NA	CHEMICAL	GENE-Y	22	25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; gene) transcripts within the gill.	T6	T25	23395804
NA	CHEMICAL	GENE-Y	22	24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (gene; trpv6) transcripts within the gill.	T6	T24	23395804
NA	CHEMICAL	GENE-Y	22	14	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (gene; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial chemical channel (ecac; trpv6) transcripts within the gill.	T6	T18	23395804
NA	CHEMICAL	GENE-Y	12	21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and gene (ecac; trpv6) transcripts within the gill.	T3	T23	23395804
NA	CHEMICAL	GENE-Y	12	16	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), gene (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T20	23395804
NA	CHEMICAL	GENE-N	12	9	Ion-poor conditions led to increases in the expression of gene (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T15	23395804
NA	CHEMICAL	GENE-Y	12	15	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; gene), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T19	23395804
NA	CHEMICAL	GENE-Y	12	19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; gene), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T22	23395804
NA	CHEMICAL	GENE-Y	12	11	Ion-poor conditions led to increases in the expression of PRL receptor (gene), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T16	23395804
NA	CHEMICAL	GENE-Y	12	18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (gene; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T21	23395804
NA	CHEMICAL	GENE-Y	12	25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; gene) transcripts within the gill.	T3	T25	23395804
NA	CHEMICAL	GENE-Y	12	24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (ncc; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (gene; trpv6) transcripts within the gill.	T3	T24	23395804
NA	CHEMICAL	GENE-Y	12	14	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/chemical cotransporter (gene; slc12a10.2), Na(+)/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T3	T18	23395804
NA	CHEMICAL	GENE-Y	12	21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and gene (ecac; trpv6) transcripts within the gill.	T2	T23	23395804
NA	CHEMICAL	GENE-Y	12	21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and gene (ecac; trpv6) transcripts within the gill.	T4	T23	23395804
NA	CHEMICAL	GENE-N	12	9	Ion-poor conditions led to increases in the expression of gene (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T2	T15	23395804
NA	CHEMICAL	GENE-N	12	9	Ion-poor conditions led to increases in the expression of gene (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T4	T15	23395804
NA	CHEMICAL	GENE-Y	12	15	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; gene), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T2	T19	23395804
NA	CHEMICAL	GENE-Y	12	15	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; gene), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T4	T19	23395804
NA	CHEMICAL	GENE-Y	12	19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; gene), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T2	T22	23395804
NA	CHEMICAL	GENE-Y	12	19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; gene), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T4	T22	23395804
NA	CHEMICAL	GENE-Y	12	11	Ion-poor conditions led to increases in the expression of PRL receptor (gene), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T2	T16	23395804
NA	CHEMICAL	GENE-Y	12	11	Ion-poor conditions led to increases in the expression of PRL receptor (gene), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T4	T16	23395804
NA	CHEMICAL	GENE-Y	12	18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (gene; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T2	T21	23395804
NA	CHEMICAL	GENE-Y	12	18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (gene; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T4	T21	23395804
NA	CHEMICAL	GENE-Y	12	25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; gene) transcripts within the gill.	T2	T25	23395804
NA	CHEMICAL	GENE-Y	12	25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; gene) transcripts within the gill.	T4	T25	23395804
NA	CHEMICAL	GENE-Y	12	24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (gene; trpv6) transcripts within the gill.	T2	T24	23395804
NA	CHEMICAL	GENE-Y	12	24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (ncc; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (gene; trpv6) transcripts within the gill.	T4	T24	23395804
NA	CHEMICAL	GENE-Y	12	14	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (gene; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T2	T18	23395804
NA	CHEMICAL	GENE-Y	12	14	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), chemical/Cl(-) cotransporter (gene; slc12a10.2), chemical/H(+) exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T4	T18	23395804
NA	CHEMICAL	GENE-Y	16	12	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), gene (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T17	23395804
NA	CHEMICAL	GENE-Y	16	21	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and gene (ecac; trpv6) transcripts within the gill.	T5	T23	23395804
NA	CHEMICAL	GENE-N	16	9	Ion-poor conditions led to increases in the expression of gene (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T15	23395804
NA	CHEMICAL	GENE-Y	16	15	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; gene), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T19	23395804
NA	CHEMICAL	GENE-Y	16	19	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; gene), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T22	23395804
NA	CHEMICAL	GENE-Y	16	11	Ion-poor conditions led to increases in the expression of PRL receptor (gene), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T16	23395804
NA	CHEMICAL	GENE-Y	16	18	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (gene; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T21	23395804
NA	CHEMICAL	GENE-Y	16	25	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; gene) transcripts within the gill.	T5	T25	23395804
NA	CHEMICAL	GENE-Y	16	24	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (ncc; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (gene; trpv6) transcripts within the gill.	T5	T24	23395804
NA	CHEMICAL	GENE-Y	16	14	Ion-poor conditions led to increases in the expression of PRL receptor (prlra), Na(+)/Cl(-) cotransporter (gene; slc12a10.2), Na(+)/chemical exchanger (nhe3b; slc9a3.2), and epithelial Ca(2+) channel (ecac; trpv6) transcripts within the gill.	T5	T18	23395804
NA	CHEMICAL	GENE-N	26	20	These results suggest that PRL signaling through PRL receptors in the gill regulates the expression of ncc, thereby linking this gene with an effector of chemical uptake in zebrafish for the first time.	T1	T11	23395804
NA	CHEMICAL	GENE-N	26	7	These results suggest that PRL signaling through gene in the gill regulates the expression of ncc, thereby linking this pituitary hormone with an effector of chemical uptake in zebrafish for the first time.	T1	T39	23395804
NA	CHEMICAL	GENE-Y	26	16	These results suggest that PRL signaling through PRL receptors in the gill regulates the expression of gene, thereby linking this pituitary hormone with an effector of chemical uptake in zebrafish for the first time.	T1	T10	23395804
NA	CHEMICAL	GENE-Y	26	4	These results suggest that gene signaling through gene receptors in the gill regulates the expression of ncc, thereby linking this pituitary hormone with an effector of chemical uptake in zebrafish for the first time.	T1	T38	23395804
NA	CHEMICAL	GENE-Y	16	16	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and chemical-gene complex was bound to JunD, which forms heterodimers with FosB.	T2	T14	23397032
NA	CHEMICAL	GENE-Y	16	7	Dexamethasone suppressed IL-11 gene transcription enhanced by gene without affecting FosB expression or Smad1 phosphorylation, and chemical-GC receptor complex was bound to JunD, which forms heterodimers with FosB.	T2	T12	23397032
NA	CHEMICAL	GENE-Y	16	2	Dexamethasone suppressed gene gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and chemical-GC receptor complex was bound to JunD, which forms heterodimers with FosB.	T2	T11	23397032
NA	CHEMICAL	GENE-Y	16	10	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting gene expression or Smad1 phosphorylation, and chemical-GC receptor complex was bound to JunD, which forms heterodimers with gene.	T2	T13	23397032
NA	CHEMICAL	GENE-Y	16	10	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting gene expression or Smad1 phosphorylation, and chemical-GC receptor complex was bound to JunD, which forms heterodimers with gene.	T2	T16	23397032
NA	CHEMICAL	GENE-Y	16	22	Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and chemical-GC receptor complex was bound to gene, which forms heterodimers with FosB.	T2	T15	23397032
NA	CHEMICAL	GENE-Y	0	16	chemical suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and dexamethasone-gene complex was bound to JunD, which forms heterodimers with FosB.	T1	T14	23397032
NA	CHEMICAL	GENE-Y	0	7	chemical suppressed IL-11 gene transcription enhanced by gene without affecting FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with FosB.	T1	T12	23397032
CPR:4	CHEMICAL	GENE-Y	0	2	chemical suppressed gene gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with FosB.	T1	T11	23397032
NA	CHEMICAL	GENE-Y	0	10	chemical suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting gene expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with gene.	T1	T13	23397032
NA	CHEMICAL	GENE-Y	0	10	chemical suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting gene expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with gene.	T1	T16	23397032
NA	CHEMICAL	GENE-Y	0	22	chemical suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting FosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to gene, which forms heterodimers with FosB.	T1	T15	23397032
NA	CHEMICAL	GENE-Y	8	3	High doses of gene counteracted the effect of chemical on apoptosis of mPOBs, which was blunted by neutralizing anti-IL-11 antibody or IL-11 small interfering RNA.	T3	T17	23397032
NA	CHEMICAL	GENE-Y	8	18	High doses of PTH(1-34) counteracted the effect of chemical on apoptosis of mPOBs, which was blunted by neutralizing anti-gene antibody or gene small interfering RNA.	T3	T18	23397032
NA	CHEMICAL	GENE-Y	8	18	High doses of PTH(1-34) counteracted the effect of chemical on apoptosis of mPOBs, which was blunted by neutralizing anti-gene antibody or gene small interfering RNA.	T3	T19	23397032
NA	CHEMICAL	GENE-Y	24	4	These results demonstrate that gene and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that gene and chemical may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.	T4	T20	23397032
NA	CHEMICAL	GENE-Y	24	4	These results demonstrate that gene and GCs interact to regulate IL-11 expression in parallel with osteoblast differentiation and apoptosis and suggest that gene and chemical may regulate osteoblast differentiation and apoptosis via their effect on IL-11 expression.	T4	T22	23397032
NA	CHEMICAL	GENE-Y	24	10	These results demonstrate that PTH(1-34) and GCs interact to regulate gene expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and chemical may regulate osteoblast differentiation and apoptosis via their effect on gene expression.	T4	T21	23397032
NA	CHEMICAL	GENE-Y	24	10	These results demonstrate that PTH(1-34) and GCs interact to regulate gene expression in parallel with osteoblast differentiation and apoptosis and suggest that PTH(1-34) and chemical may regulate osteoblast differentiation and apoptosis via their effect on gene expression.	T4	T23	23397032
NA	CHEMICAL	GENE-N	8	12	Number and area of preneoplastic foci positive for chemical S-transferase placental form (gene) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.	T15	T29	23402856
CPR:3	CHEMICAL	GENE-N	30	8	Number and area of preneoplastic foci positive for gene (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with chemical or HCB alone.	T18	T28	23402856
CPR:3	CHEMICAL	GENE-N	30	12	Number and area of preneoplastic foci positive for glutathione S-transferase placental form (gene) were consistently higher in these groups than the sum of individual values in the groups treated with chemical or HCB alone.	T18	T29	23402856
CPR:3	CHEMICAL	GENE-N	32	8	Number and area of preneoplastic foci positive for gene (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or chemical alone.	T19	T28	23402856
CPR:3	CHEMICAL	GENE-N	32	12	Number and area of preneoplastic foci positive for glutathione S-transferase placental form (gene) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or chemical alone.	T19	T29	23402856
NA	CHEMICAL	GENE-N	4	21	Consistent with these findings, chemical and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and gene induction, which may lead to more efficient metabolic activation of chemical and HCB.	T1	T30	23402856
NA	CHEMICAL	GENE-N	4	21	Consistent with these findings, chemical and HCB had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and gene induction, which may lead to more efficient metabolic activation of chemical and HCB.	T20	T30	23402856
NA	CHEMICAL	GENE-N	6	21	Consistent with these findings, HEP and chemical had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and gene induction, which may lead to more efficient metabolic activation of HEP and chemical.	T22	T30	23402856
NA	CHEMICAL	GENE-N	6	21	Consistent with these findings, HEP and chemical had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and gene induction, which may lead to more efficient metabolic activation of HEP and chemical.	T2	T30	23402856
NA	CHEMICAL	GENE-N	34	21	On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of gene-positive foci and that higher risks are associated with a combination of residual chemical pesticides in foods than with individual residual chemical pesticides.	T6	T27	23402856
NA	CHEMICAL	GENE-N	34	21	On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of gene-positive foci and that higher risks are associated with a combination of residual chemical pesticides in foods than with individual residual chemical pesticides.	T7	T27	23402856
CPR:3	CHEMICAL	GENE-N	9	21	On the basis of these findings, we conclude that chemical and HCB have additive and synergistic effects on the development of gene-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.	T3	T27	23402856
CPR:3	CHEMICAL	GENE-N	11	21	On the basis of these findings, we conclude that HEP and chemical have additive and synergistic effects on the development of gene-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.	T5	T27	23402856
NA	CHEMICAL	GENE-N	21	34	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of chemical to induce histological changes in the intestine and to activate the MAPK gene, p38 and JNK.	T3	T15	23403092
NA	CHEMICAL	GENE-N	21	33	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of chemical to induce histological changes in the intestine and to activate the gene ERK 1/2, p38 and JNK.	T3	T14	23403092
NA	CHEMICAL	GENE-N	21	36	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of chemical to induce histological changes in the intestine and to activate the MAPK ERK 1/2, gene and JNK.	T3	T16	23403092
NA	CHEMICAL	GENE-N	21	38	Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of chemical to induce histological changes in the intestine and to activate the MAPK ERK 1/2, p38 and gene.	T3	T17	23403092
CPR:3	CHEMICAL	GENE-N	16	25	Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to chemical lead to similar intestinal lesions and activation of gene.	T2	T11	23403092
NA	CHEMICAL	GENE-N	19	22	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of chemical (MDA) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T12	T29	23403272
NA	CHEMICAL	GENE-N	19	36	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of chemical (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and gene (SOD) in EA.hy926 cells.	T12	T31	23403272
NA	CHEMICAL	GENE-N	19	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of chemical (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (gene) in EA.hy926 cells.	T12	T32	23403272
NA	CHEMICAL	GENE-N	19	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of chemical (MDA) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T12	T30	23403272
CPR:4	CHEMICAL	GENE-N	5	22	In particular, we showed that chemical significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T10	T29	23403272
CPR:3	CHEMICAL	GENE-N	5	36	In particular, we showed that chemical significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and gene (SOD) in EA.hy926 cells.	T10	T31	23403272
CPR:3	CHEMICAL	GENE-N	5	38	In particular, we showed that chemical significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (gene) in EA.hy926 cells.	T10	T32	23403272
CPR:4	CHEMICAL	GENE-N	5	24	In particular, we showed that chemical significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T10	T30	23403272
NA	CHEMICAL	GENE-N	33	22	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, chemical (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T15	T29	23403272
NA	CHEMICAL	GENE-N	33	36	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, chemical (GSH) and gene (SOD) in EA.hy926 cells.	T15	T31	23403272
NA	CHEMICAL	GENE-N	33	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, chemical (GSH) and superoxide dismutase (gene) in EA.hy926 cells.	T15	T32	23403272
NA	CHEMICAL	GENE-N	33	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, chemical (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T15	T30	23403272
NA	CHEMICAL	GENE-N	36	22	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and chemical dismutase (SOD) in EA.hy926 cells.	T17	T29	23403272
NA	CHEMICAL	GENE-N	36	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and chemical dismutase (gene) in EA.hy926 cells.	T17	T32	23403272
NA	CHEMICAL	GENE-N	36	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and chemical dismutase (SOD) in EA.hy926 cells.	T17	T30	23403272
NA	CHEMICAL	GENE-N	22	36	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and chemical dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and gene (SOD) in EA.hy926 cells.	T14	T31	23403272
NA	CHEMICAL	GENE-N	22	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and chemical dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (gene) in EA.hy926 cells.	T14	T32	23403272
NA	CHEMICAL	GENE-N	22	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and chemical dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T14	T30	23403272
NA	CHEMICAL	GENE-N	13	22	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive chemical species (ROS), the level of malondialdehyde (MDA) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T11	T29	23403272
NA	CHEMICAL	GENE-N	13	36	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive chemical species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and gene (SOD) in EA.hy926 cells.	T11	T31	23403272
NA	CHEMICAL	GENE-N	13	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive chemical species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (gene) in EA.hy926 cells.	T11	T32	23403272
NA	CHEMICAL	GENE-N	13	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive chemical species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T11	T30	23403272
NA	CHEMICAL	GENE-N	34	22	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (chemical) and superoxide dismutase (SOD) in EA.hy926 cells.	T16	T29	23403272
NA	CHEMICAL	GENE-N	34	36	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (chemical) and gene (SOD) in EA.hy926 cells.	T16	T31	23403272
NA	CHEMICAL	GENE-N	34	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (chemical) and superoxide dismutase (gene) in EA.hy926 cells.	T16	T32	23403272
NA	CHEMICAL	GENE-N	34	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (chemical) and superoxide dismutase (SOD) in EA.hy926 cells.	T16	T30	23403272
NA	CHEMICAL	GENE-N	20	22	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (chemical) and gene (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T13	T29	23403272
NA	CHEMICAL	GENE-N	20	36	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (chemical) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and gene (SOD) in EA.hy926 cells.	T13	T31	23403272
NA	CHEMICAL	GENE-N	20	38	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (chemical) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (gene) in EA.hy926 cells.	T13	T32	23403272
NA	CHEMICAL	GENE-N	20	24	In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (chemical) and lactate dehydrogenase (gene) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.	T13	T30	23403272
CPR:3	CHEMICAL	GENE-Y	5	8	Treatment of these cells with chemical significantly induced gene expression.	T18	T21	23403272
NA	CHEMICAL	GENE-Y	1	7	Moreover, chemical promoted the nuclear translocation of gene (Nrf-2).	T1	T22	23403272
NA	CHEMICAL	GENE-Y	1	13	Moreover, chemical promoted the nuclear translocation of nuclear factor erythroid 2 related factor-2 (gene).	T1	T23	23403272
CPR:3	CHEMICAL	GENE-Y	1	2	The chemical-induced gene expression was abrogated by Nrf2 siRNA.	T2	T24	23403272
NA	CHEMICAL	GENE-Y	1	7	The chemical-induced HO-1 expression was abrogated by gene siRNA.	T2	T25	23403272
CPR:4	CHEMICAL	GENE-Y	5	3	Furthermore, inhibition of gene with chemical (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.	T3	T26	23403272
CPR:3	CHEMICAL	GENE-Y	15	3	Furthermore, inhibition of gene with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of chemical against radiation-induced damage in EA.hy926 cells.	T5	T26	23403272
CPR:4	CHEMICAL	GENE-Y	8	3	Furthermore, inhibition of gene with zinc protoporphyrin IX (chemical) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.	T4	T26	23403272
CPR:3	CHEMICAL	GENE-Y	4	13	Our findings confirmed that chemical protected EA.hy926 cells against radiation-induced injury through the Nrf2/gene pathway.	T6	T28	23403272
CPR:3	CHEMICAL	GENE-Y	4	13	Our findings confirmed that chemical protected EA.hy926 cells against radiation-induced injury through the gene/HO-1 pathway.	T6	T27	23403272
NA	CHEMICAL	GENE-Y	11	14	The use of a combination of a serotonin 5-HT3 receptor antagonist, chemical and a gene antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	T4	T11	23404093
NA	CHEMICAL	GENE-Y	11	8	The use of a combination of a serotonin gene receptor antagonist, chemical and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	T4	T10	23404093
NA	CHEMICAL	GENE-Y	7	14	The use of a combination of a chemical 5-HT3 receptor antagonist, dexamethasone and a gene antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	T3	T11	23404093
NA	CHEMICAL	GENE-Y	7	8	The use of a combination of a chemical gene receptor antagonist, dexamethasone and a neurokinin 1 (NK1) receptor antagonist has significantly improved the control of acute and delayed emesis in single-day chemotherapy.	T3	T10	23404093
CPR:6	CHEMICAL	GENE-Y	0	3	chemical, a second-generation gene receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation gene receptor antagonists appears to be the most effective agent in its class.	T5	T12	23404093
NA	CHEMICAL	GENE-Y	0	3	chemical, a second-generation gene receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation gene receptor antagonists appears to be the most effective agent in its class.	T5	T13	23404093
NA	CHEMICAL	GENE-Y	29	10	Aprepitant, the first and only agent clinically available in the gene antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and chemical to control CINV.	T7	T14	23404093
NA	CHEMICAL	GENE-Y	29	25	Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the gene receptor antagonists and chemical to control CINV.	T7	T15	23404093
CPR:6	CHEMICAL	GENE-Y	0	10	chemical, the first and only agent clinically available in the gene antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.	T6	T14	23404093
NA	CHEMICAL	GENE-Y	0	25	chemical, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the gene receptor antagonists and dexamethasone to control CINV.	T6	T15	23404093
CPR:6	CHEMICAL	GENE-Y	2	5	Rolapitant and chemical are other gene antagonists that are currently in phase III clinical trials.	T9	T16	23404093
CPR:6	CHEMICAL	GENE-Y	0	5	chemical and netupitant are other gene antagonists that are currently in phase III clinical trials.	T8	T16	23404093
NA	CHEMICAL	GENE-Y	4	6	The case study of chemical synthase (gene) illustrates how such an equilibrium holds lessons for disease mechanisms, drug discovery, understanding drug side effects, and identifying proteins wherein drug discovery efforts might focus on quaternary structure dynamics.	T3	T10	23409765
NA	CHEMICAL	GENE-Y	15	22	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins chemical hydroxylase, HIV integrase, pyruvate kinase, and gene. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T1	T7	23409765
NA	CHEMICAL	GENE-N	15	19	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins chemical hydroxylase, HIV integrase, gene, and tumor necrosis factor . Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T1	T6	23409765
NA	CHEMICAL	GENE-Y	15	34	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins chemical hydroxylase, HIV integrase, pyruvate kinase, and tumor necrosis factor . Also highlighted is the quaternary structure equilibrium of gene and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T1	T8	23409765
NA	CHEMICAL	GENE-Y	15	17	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins chemical hydroxylase, gene, pyruvate kinase, and tumor necrosis factor . Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T1	T5	23409765
NA	CHEMICAL	GENE-Y	19	15	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins gene, HIV integrase, chemical kinase, and tumor necrosis factor . Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T2	T4	23409765
NA	CHEMICAL	GENE-Y	19	22	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, chemical kinase, and gene. Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T2	T7	23409765
NA	CHEMICAL	GENE-Y	19	34	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, HIV integrase, chemical kinase, and tumor necrosis factor . Also highlighted is the quaternary structure equilibrium of gene and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T2	T8	23409765
NA	CHEMICAL	GENE-Y	19	17	Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease-associated putative morpheeins phenylalanine hydroxylase, gene, chemical kinase, and tumor necrosis factor . Also highlighted is the quaternary structure equilibrium of transthyretin and successful drug discovery efforts focused on controlling its quaternary structure dynamics.	T2	T5	23409765
NA	CHEMICAL	GENE-N	13	42	As part of a comprehensive study of the physiochemical and biological properties of chemical, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-linoleate model system and gene cholesterol (LDL-C) oxidation assay.	T11	T14	23411235
NA	CHEMICAL	GENE-N	13	45	As part of a comprehensive study of the physiochemical and biological properties of chemical, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-linoleate model system and low-density lipoprotein cholesterol (gene-C) oxidation assay.	T11	T15	23411235
NA	CHEMICAL	GENE-N	44	42	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-linoleate model system and gene chemical (LDL-C) oxidation assay.	T3	T14	23411235
NA	CHEMICAL	GENE-N	44	45	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-linoleate model system and low-density lipoprotein chemical (gene-C) oxidation assay.	T3	T15	23411235
NA	CHEMICAL	GENE-N	38	42	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, chemical-linoleate model system and gene cholesterol (LDL-C) oxidation assay.	T1	T14	23411235
NA	CHEMICAL	GENE-N	38	45	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, chemical-linoleate model system and low-density lipoprotein cholesterol (gene-C) oxidation assay.	T1	T15	23411235
NA	CHEMICAL	GENE-N	38	42	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-chemical model system and gene cholesterol (LDL-C) oxidation assay.	T2	T14	23411235
NA	CHEMICAL	GENE-N	38	45	As part of a comprehensive study of the physiochemical and biological properties of phytosteryl phenolates, successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, -carotene-chemical model system and low-density lipoprotein cholesterol (gene-C) oxidation assay.	T2	T15	23411235
CPR:4	CHEMICAL	GENE-N	7	4	Moderate inhibitory effect of gene-C oxidation by chemical was observed.	T10	T16	23411235
CPR:4	CHEMICAL	GENE-Y	1	15	Aqueous chemical (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting gene (IC(50), 55 g/ml), with moderate COX-1 (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	T8	T10	23411279
CPR:4	CHEMICAL	GENE-Y	1	26	Aqueous chemical (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 g/ml), with moderate COX-1 (IC(50), 66 g/ml) and gene (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	T8	T12	23411279
CPR:4	CHEMICAL	GENE-Y	1	21	Aqueous chemical (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 g/ml), with moderate gene (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	T8	T11	23411279
CPR:4	CHEMICAL	GENE-N	1	15	Aqueous chemical (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-gene (IC(50), 55 g/ml), with moderate COX-1 (IC(50), 66 g/ml) and COX-2 (IC(50), 119 g/ml) inhibitory effects on the COX pathway, whereas faba bean hull extracts exerted relatively mild gene inhibitory activity.	T8	T14	23411279
CPR:4	CHEMICAL	GENE-N	1	21	Aqueous chemical (80%) extract of lentil hulls exhibited high antioxidant and anti-inflammatory activities preferentially inhibiting 15-LOX (IC(50), 55 g/ml), with moderate gene-1 (IC(50), 66 g/ml) and gene-2 (IC(50), 119 g/ml) inhibitory effects on the gene pathway, whereas faba bean hull extracts exerted relatively mild LOX inhibitory activity.	T8	T13	23411279
CPR:9	CHEMICAL	GENE-Y	7	0	gene (HDC) catalyses the formation of chemical, a bioactive amine.	T8	T12	23411280
CPR:9	CHEMICAL	GENE-Y	7	2	Histidine decarboxylase (gene) catalyses the formation of chemical, a bioactive amine.	T8	T15	23411280
NA	CHEMICAL	GENE-Y	0	2	chemical decarboxylase (gene) catalyses the formation of histamine, a bioactive amine.	T1	T15	23411280
CPR:9	CHEMICAL	GENE-Y	7	0	gene (HDC) catalyses the formation of histchemical, a bioactive chemical.	T10	T12	23411280
CPR:9	CHEMICAL	GENE-Y	7	2	Histidine decarboxylase (gene) catalyses the formation of histchemical, a bioactive chemical.	T10	T15	23411280
NA	CHEMICAL	GENE-Y	9	3	Agents that control gene activity are beneficial for treating chemical-mediated symptoms, such as allergies and stomach ulceration.	T2	T13	23411280
CPR:4	CHEMICAL	GENE-Y	8	5	We searched for inhibitors of gene from the chemical extract of the petal of Filipendula ulmaria, also called meadowsweet.	T3	T14	23411280
NA	CHEMICAL	GENE-N	15	17	High throughput screening led to the identification of a novel series of quinolone 7 nicotinic chemical receptor (gene) agonists.	T5	T8	23414838
CPR:5	CHEMICAL	GENE-Y	12	13	High throughput screening led to the identification of a novel series of chemical gene (nAChR) agonists.	T4	T9	23414838
CPR:5	CHEMICAL	GENE-N	12	17	High throughput screening led to the identification of a novel series of chemical 7 nicotinic acetylcholine receptor (gene) agonists.	T4	T8	23414838
CPR:4	CHEMICAL	GENE-N	12	6	SAR and lead optimization studies for gene inhibitors based on amino acid-derived chemical are described.	T6	T13	23416002
CPR:4	CHEMICAL	GENE-N	10	6	SAR and lead optimization studies for gene inhibitors based on chemical-derived quinazolines are described.	T5	T13	23416002
NA	CHEMICAL	GENE-N	7	10	Studies demonstrated that these amino acid derived chemical were mainly pan-gene inhibitors.	T2	T9	23416002
NA	CHEMICAL	GENE-N	4	10	Studies demonstrated that these chemical derived quinazolinones were mainly pan-gene inhibitors.	T1	T9	23416002
CPR:4	CHEMICAL	GENE-N	11	4	This is distinct from gene inhibitors based on non-amino acid derived chemical, where high selectivity against PKA could be obtained.	T4	T12	23416002
CPR:4	CHEMICAL	GENE-N	11	16	This is distinct from Rock inhibitors based on non-amino acid derived chemical, where high selectivity against gene could be obtained.	T4	T14	23416002
CPR:4	CHEMICAL	GENE-N	8	4	This is distinct from gene inhibitors based on non-chemical derived quinazolinones, where high selectivity against PKA could be obtained.	T3	T12	23416002
CPR:4	CHEMICAL	GENE-N	8	16	This is distinct from Rock inhibitors based on non-chemical derived quinazolinones, where high selectivity against gene could be obtained.	T3	T14	23416002
CPR:4	CHEMICAL	GENE-Y	3	1	The gene inhibitor, chemical, is used in the clinic for its anti-inflammatory activity.	T5	T23	23416065
NA	CHEMICAL	GENE-Y	6	20	About 99% of a dose of chemical is unavailable for reaction with the target enzyme, because chemical strongly binds to gene (HSA).	T2	T19	23416065
NA	CHEMICAL	GENE-Y	6	20	About 99% of a dose of chemical is unavailable for reaction with the target enzyme, because chemical strongly binds to gene (HSA).	T3	T19	23416065
NA	CHEMICAL	GENE-Y	6	23	About 99% of a dose of chemical is unavailable for reaction with the target enzyme, because chemical strongly binds to human serum albumin (gene).	T2	T20	23416065
NA	CHEMICAL	GENE-Y	6	23	About 99% of a dose of chemical is unavailable for reaction with the target enzyme, because chemical strongly binds to human serum albumin (gene).	T3	T20	23416065
NA	CHEMICAL	GENE-Y	15	8	To reduce the binding affinity of diflunisal to gene, we designed and synthesized the prodrug chemical.	T6	T21	23416065
NA	CHEMICAL	GENE-Y	6	8	To reduce the binding affinity of chemical to gene, we designed and synthesized the prodrug acetylchemical.	T4	T21	23416065
NA	CHEMICAL	GENE-N	10	17	The crystal structure of HSA complexed with fatty acid and chemical revealed that chemical binds to the gene and that upon binding, it acetylates lysine 199.	T8	T24	23416065
NA	CHEMICAL	GENE-N	10	17	The crystal structure of HSA complexed with fatty acid and chemical revealed that chemical binds to the gene and that upon binding, it acetylates lysine 199.	T9	T24	23416065
NA	CHEMICAL	GENE-Y	10	4	The crystal structure of gene complexed with fatty acid and chemical revealed that chemical binds to the IIA subdomain and that upon binding, it acetylates lysine 199.	T8	T22	23416065
NA	CHEMICAL	GENE-Y	10	4	The crystal structure of gene complexed with fatty acid and chemical revealed that chemical binds to the IIA subdomain and that upon binding, it acetylates lysine 199.	T9	T22	23416065
NA	CHEMICAL	GENE-N	7	17	The crystal structure of HSA complexed with chemical and acetyldiflunisal revealed that acetyldiflunisal binds to the gene and that upon binding, it acetylates lysine 199.	T7	T24	23416065
NA	CHEMICAL	GENE-Y	7	4	The crystal structure of gene complexed with chemical and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.	T7	T22	23416065
NA	CHEMICAL	GENE-N	25	17	The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the gene and that upon binding, it acetylates chemical 199.	T10	T24	23416065
NA	CHEMICAL	GENE-Y	25	4	The crystal structure of gene complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates chemical 199.	T10	T22	23416065
NA	CHEMICAL	GENE-Y	9	1	The gene had twofold weaker binding affinity for chemical as demonstrated by fluorescence quenching.	T13	T25	23416065
NA	CHEMICAL	GENE-Y	5	11	Reduced binding affinity means that chemical is more easily released from gene into the circulation.	T14	T26	23416065
NA	CHEMICAL	GENE-Y	24	12	Taken together, our results not only provide a template for design of gene-based prodrugs, but also pave the way toward more effective use of chemical in the clinic.	T1	T18	23416065
NA	CHEMICAL	GENE-N	15	12	In the present study, we investigated the possible effects of BPA on gene-signaling molecules and chemical oxidation in skeletal muscle of male rat.	T11	T24	23424204
NA	CHEMICAL	GENE-N	10	12	In the present study, we investigated the possible effects of chemical on gene-signaling molecules and glucose oxidation in skeletal muscle of male rat.	T10	T24	23424204
NA	CHEMICAL	GENE-Y	17	9	Although there was no change in the levels of gene (IR), Akt (protein kinase B) and chemical transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T25	23424204
NA	CHEMICAL	GENE-N	17	13	Although there was no change in the levels of insulin receptor (IR), Akt (gene) and chemical transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T28	23424204
NA	CHEMICAL	GENE-Y	17	19	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and chemical transporter-4 (gene) messenger RNA, BPA significantly decreased the IR, Akt and gene protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T18	23424204
NA	CHEMICAL	GENE-Y	17	19	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and chemical transporter-4 (gene) messenger RNA, BPA significantly decreased the IR, Akt and gene protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T30	23424204
NA	CHEMICAL	GENE-N	17	12	Although there was no change in the levels of insulin receptor (IR), gene (protein kinase B) and chemical transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, gene and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T17	23424204
NA	CHEMICAL	GENE-N	17	12	Although there was no change in the levels of insulin receptor (IR), gene (protein kinase B) and chemical transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the IR, gene and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T27	23424204
NA	CHEMICAL	GENE-Y	17	11	Although there was no change in the levels of insulin receptor (gene), Akt (protein kinase B) and chemical transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the gene, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T26	23424204
NA	CHEMICAL	GENE-Y	17	11	Although there was no change in the levels of insulin receptor (gene), Akt (protein kinase B) and chemical transporter-4 (GLUT4) messenger RNA, BPA significantly decreased the gene, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T13	T31	23424204
NA	CHEMICAL	GENE-Y	22	17	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and gene (GLUT4) messenger RNA, chemical significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T29	23424204
NA	CHEMICAL	GENE-Y	22	9	Although there was no change in the levels of gene (IR), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, chemical significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T25	23424204
NA	CHEMICAL	GENE-N	22	13	Although there was no change in the levels of insulin receptor (IR), Akt (gene) and glucose transporter-4 (GLUT4) messenger RNA, chemical significantly decreased the IR, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T28	23424204
CPR:4	CHEMICAL	GENE-Y	22	19	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (gene) messenger RNA, chemical significantly decreased the IR, Akt and gene protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T18	23424204
NA	CHEMICAL	GENE-Y	22	19	Although there was no change in the levels of insulin receptor (IR), Akt (protein kinase B) and glucose transporter-4 (gene) messenger RNA, chemical significantly decreased the IR, Akt and gene protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T30	23424204
CPR:4	CHEMICAL	GENE-N	22	12	Although there was no change in the levels of insulin receptor (IR), gene (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, chemical significantly decreased the IR, gene and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T17	23424204
NA	CHEMICAL	GENE-N	22	12	Although there was no change in the levels of insulin receptor (IR), gene (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, chemical significantly decreased the IR, gene and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T27	23424204
NA	CHEMICAL	GENE-Y	22	11	Although there was no change in the levels of insulin receptor (gene), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, chemical significantly decreased the gene, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T26	23424204
CPR:4	CHEMICAL	GENE-Y	22	11	Although there was no change in the levels of insulin receptor (gene), Akt (protein kinase B) and glucose transporter-4 (GLUT4) messenger RNA, chemical significantly decreased the gene, Akt and GLUT4 protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	T14	T31	23424204
NA	CHEMICAL	GENE-N	11	6	There was an increase in serum gene and decrease in serum chemical levels but fasting blood glucose level remained unaltered.	T2	T19	23424204
NA	CHEMICAL	GENE-N	16	6	There was an increase in serum gene and decrease in serum testosterone levels but fasting blood chemical level remained unaltered.	T3	T19	23424204
NA	CHEMICAL	GENE-Y	13	10	In conclusion, BPA has adverse effects on phosphorylation of Akt, gene translocation and chemical oxidation.	T5	T21	23424204
NA	CHEMICAL	GENE-N	13	9	In conclusion, BPA has adverse effects on phosphorylation of gene, GLUT4 translocation and chemical oxidation.	T5	T20	23424204
CPR:4	CHEMICAL	GENE-Y	2	10	In conclusion, chemical has adverse effects on phosphorylation of Akt, gene translocation and (14)C-glucose oxidation.	T4	T21	23424204
CPR:4	CHEMICAL	GENE-N	2	9	In conclusion, chemical has adverse effects on phosphorylation of gene, GLUT4 translocation and (14)C-glucose oxidation.	T4	T20	23424204
NA	CHEMICAL	GENE-N	27	24	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and gene: chemical dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T24	T44	23424207
NA	CHEMICAL	GENE-N	27	17	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, gene, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: chemical dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T24	T41	23424207
NA	CHEMICAL	GENE-N	27	21	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, gene and testicular steroidogenic enzymes: chemical dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T24	T43	23424207
NA	CHEMICAL	GENE-N	27	19	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, gene, alkaline phosphatase and testicular steroidogenic enzymes: chemical dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T24	T42	23424207
NA	CHEMICAL	GENE-N	27	30	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: chemical dehydrogenase (HSD), gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T24	T47	23424207
NA	CHEMICAL	GENE-N	27	29	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: chemical dehydrogenase (gene), 17-gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T24	T46	23424207
NA	CHEMICAL	GENE-N	16	24	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and gene: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T44	23424207
NA	CHEMICAL	GENE-N	16	27	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: gene (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T45	23424207
NA	CHEMICAL	GENE-N	16	17	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, gene, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T41	23424207
NA	CHEMICAL	GENE-N	16	21	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, lactate dehydrogenase, acid phosphatase, gene and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T43	23424207
NA	CHEMICAL	GENE-N	16	19	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, lactate dehydrogenase, gene, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T42	23424207
NA	CHEMICAL	GENE-N	16	30	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T47	23424207
NA	CHEMICAL	GENE-N	16	29	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma chemical, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (gene), 17-gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T22	T46	23424207
NA	CHEMICAL	GENE-N	17	24	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, chemical dehydrogenase, acid phosphatase, alkaline phosphatase and gene: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T23	T44	23424207
NA	CHEMICAL	GENE-N	17	27	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, chemical dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: gene (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T23	T45	23424207
NA	CHEMICAL	GENE-N	17	21	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, chemical dehydrogenase, acid phosphatase, gene and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T23	T43	23424207
NA	CHEMICAL	GENE-N	17	19	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, chemical dehydrogenase, gene, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T23	T42	23424207
NA	CHEMICAL	GENE-N	17	30	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, chemical dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T23	T47	23424207
NA	CHEMICAL	GENE-N	17	29	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, chemical dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (gene), 17-gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T23	T46	23424207
NA	CHEMICAL	GENE-N	41	24	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and gene: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T44	23424207
NA	CHEMICAL	GENE-N	41	27	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: gene (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T45	23424207
NA	CHEMICAL	GENE-N	41	17	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, gene, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T41	23424207
NA	CHEMICAL	GENE-N	41	21	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, gene and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T43	23424207
NA	CHEMICAL	GENE-N	41	19	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, gene, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T42	23424207
NA	CHEMICAL	GENE-N	41	30	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), gene activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T47	23424207
NA	CHEMICAL	GENE-N	41	29	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (gene), 17-gene activities as well as epididymal sperm counts and motility, while chemical and Se treatment reversed this change to control values.	T25	T46	23424207
NA	CHEMICAL	GENE-N	43	24	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and gene: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T44	23424207
NA	CHEMICAL	GENE-N	43	27	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: gene (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T45	23424207
NA	CHEMICAL	GENE-N	43	17	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, gene, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T41	23424207
NA	CHEMICAL	GENE-N	43	21	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, gene and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T43	23424207
NA	CHEMICAL	GENE-N	43	19	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, gene, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T42	23424207
NA	CHEMICAL	GENE-N	43	30	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), gene activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T47	23424207
NA	CHEMICAL	GENE-N	43	29	The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (gene), 17-gene activities as well as epididymal sperm counts and motility, while RUT and chemical treatment reversed this change to control values.	T26	T46	23424207
CPR:4	CHEMICAL	GENE-N	5	24	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and gene: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T44	23424207
CPR:4	CHEMICAL	GENE-N	5	27	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: gene (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T45	23424207
CPR:4	CHEMICAL	GENE-N	5	17	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, gene, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T41	23424207
CPR:4	CHEMICAL	GENE-N	5	21	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, gene and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T43	23424207
CPR:4	CHEMICAL	GENE-N	5	19	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, gene, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), 17-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T42	23424207
CPR:4	CHEMICAL	GENE-N	5	30	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (HSD), gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T47	23424207
CPR:4	CHEMICAL	GENE-N	5	29	The obtained results showed that chemical increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3-hydroxysteroid dehydrogenase (gene), 17-gene activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.	T21	T46	23424207
NA	CHEMICAL	GENE-N	21	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T29	T48	23424207
NA	CHEMICAL	GENE-N	21	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T32	T48	23424207
NA	CHEMICAL	GENE-N	21	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T33	T48	23424207
NA	CHEMICAL	GENE-N	21	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T35	T48	23424207
NA	CHEMICAL	GENE-Y	21	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T29	T50	23424207
NA	CHEMICAL	GENE-Y	21	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T32	T50	23424207
NA	CHEMICAL	GENE-Y	21	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T33	T50	23424207
NA	CHEMICAL	GENE-Y	21	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T35	T50	23424207
NA	CHEMICAL	GENE-N	21	23	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (gene), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T29	T53	23424207
NA	CHEMICAL	GENE-N	21	23	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (gene), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T32	T53	23424207
NA	CHEMICAL	GENE-N	21	23	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (gene), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T33	T53	23424207
NA	CHEMICAL	GENE-N	21	23	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (gene), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T35	T53	23424207
NA	CHEMICAL	GENE-N	21	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T29	T49	23424207
NA	CHEMICAL	GENE-N	21	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T32	T49	23424207
NA	CHEMICAL	GENE-N	21	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T33	T49	23424207
NA	CHEMICAL	GENE-N	21	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T35	T49	23424207
NA	CHEMICAL	GENE-Y	21	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T29	T51	23424207
NA	CHEMICAL	GENE-Y	21	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T32	T51	23424207
NA	CHEMICAL	GENE-Y	21	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T33	T51	23424207
NA	CHEMICAL	GENE-Y	21	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (GST)).	T35	T51	23424207
NA	CHEMICAL	GENE-N	21	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (gene)).	T29	T40	23424207
NA	CHEMICAL	GENE-N	21	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (gene)).	T32	T40	23424207
NA	CHEMICAL	GENE-N	21	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (gene)).	T33	T40	23424207
NA	CHEMICAL	GENE-N	21	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (GR), chemical (GSH), and chemical-S-transferase (gene)).	T35	T40	23424207
NA	CHEMICAL	GENE-Y	21	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (gene), chemical (GSH), and chemical-S-transferase (GST)).	T29	T55	23424207
NA	CHEMICAL	GENE-Y	21	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (gene), chemical (GSH), and chemical-S-transferase (GST)).	T32	T55	23424207
NA	CHEMICAL	GENE-Y	21	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (gene), chemical (GSH), and chemical-S-transferase (GST)).	T33	T55	23424207
NA	CHEMICAL	GENE-Y	21	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), chemical peroxidase (GSH-Px), chemical reductase (gene), chemical (GSH), and chemical-S-transferase (GST)).	T35	T55	23424207
NA	CHEMICAL	GENE-N	16	30	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and gene (GST)).	T28	T56	23424207
NA	CHEMICAL	GENE-N	16	21	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (CAT), gene (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T52	23424207
NA	CHEMICAL	GENE-Y	16	24	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), gene (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T54	23424207
NA	CHEMICAL	GENE-Y	16	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), gene (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T50	23424207
NA	CHEMICAL	GENE-N	16	23	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T53	23424207
NA	CHEMICAL	GENE-N	16	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (gene), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T49	23424207
NA	CHEMICAL	GENE-Y	16	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (gene), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T51	23424207
NA	CHEMICAL	GENE-N	16	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (gene)).	T28	T40	23424207
NA	CHEMICAL	GENE-Y	16	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (chemical dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (gene), glutathione (GSH), and glutathione-S-transferase (GST)).	T28	T55	23424207
NA	CHEMICAL	GENE-N	23	30	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and gene (GST)).	T31	T56	23424207
NA	CHEMICAL	GENE-N	23	30	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and gene (GST)).	T34	T56	23424207
NA	CHEMICAL	GENE-N	23	21	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), gene (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T52	23424207
NA	CHEMICAL	GENE-N	23	21	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), gene (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T52	23424207
NA	CHEMICAL	GENE-Y	23	24	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), gene (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T54	23424207
NA	CHEMICAL	GENE-Y	23	24	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), gene (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T54	23424207
NA	CHEMICAL	GENE-N	23	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T48	23424207
NA	CHEMICAL	GENE-N	23	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T48	23424207
NA	CHEMICAL	GENE-Y	23	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T50	23424207
NA	CHEMICAL	GENE-Y	23	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T50	23424207
NA	CHEMICAL	GENE-N	23	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T49	23424207
NA	CHEMICAL	GENE-N	23	18	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T49	23424207
NA	CHEMICAL	GENE-Y	23	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T51	23424207
NA	CHEMICAL	GENE-Y	23	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T51	23424207
NA	CHEMICAL	GENE-N	23	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (gene)).	T31	T40	23424207
NA	CHEMICAL	GENE-N	23	31	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (GR), glutathione (chemical), and glutathione-S-transferase (gene)).	T34	T40	23424207
NA	CHEMICAL	GENE-Y	23	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (gene), glutathione (chemical), and glutathione-S-transferase (GST)).	T31	T55	23424207
NA	CHEMICAL	GENE-Y	23	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (chemical-Px), glutathione reductase (gene), glutathione (chemical), and glutathione-S-transferase (GST)).	T34	T55	23424207
CPR:4	CHEMICAL	GENE-N	3	30	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and gene (GST)).	T27	T56	23424207
CPR:4	CHEMICAL	GENE-N	3	21	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), gene (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T52	23424207
CPR:4	CHEMICAL	GENE-Y	3	24	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), gene (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T54	23424207
CPR:4	CHEMICAL	GENE-N	3	16	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (gene (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T48	23424207
CPR:4	CHEMICAL	GENE-Y	3	19	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), gene (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T50	23424207
CPR:4	CHEMICAL	GENE-N	3	23	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (gene), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T53	23424207
CPR:4	CHEMICAL	GENE-N	3	18	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (gene), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T49	23424207
CPR:4	CHEMICAL	GENE-Y	3	20	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (gene), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T51	23424207
CPR:4	CHEMICAL	GENE-N	3	31	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (gene)).	T27	T40	23424207
CPR:4	CHEMICAL	GENE-Y	3	26	Acute intoxication with chemical was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (gene), glutathione (GSH), and glutathione-S-transferase (GST)).	T27	T55	23424207
NA	CHEMICAL	GENE-N	18	21	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (chemicalOD), catalase (CAT), gene (GchemicalH-Px), glutathione reductase (GR), glutathione (GchemicalH), and glutathione-chemical-transferase (GchemicalT)).	T36	T52	23424207
NA	CHEMICAL	GENE-Y	18	24	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (chemicalOD), catalase (CAT), glutathione peroxidase (GchemicalH-Px), gene (GR), glutathione (GchemicalH), and glutathione-chemical-transferase (GchemicalT)).	T36	T54	23424207
NA	CHEMICAL	GENE-N	18	16	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (gene (chemicalOD), catalase (CAT), glutathione peroxidase (GchemicalH-Px), glutathione reductase (GR), glutathione (GchemicalH), and glutathione-chemical-transferase (GchemicalT)).	T36	T48	23424207
NA	CHEMICAL	GENE-Y	18	19	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (chemicalOD), gene (CAT), glutathione peroxidase (GchemicalH-Px), glutathione reductase (GR), glutathione (GchemicalH), and glutathione-chemical-transferase (GchemicalT)).	T36	T50	23424207
NA	CHEMICAL	GENE-Y	18	20	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (chemicalOD), catalase (gene), glutathione peroxidase (GchemicalH-Px), glutathione reductase (GR), glutathione (GchemicalH), and glutathione-chemical-transferase (GchemicalT)).	T36	T51	23424207
NA	CHEMICAL	GENE-Y	18	26	Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (chemicalOD), catalase (CAT), glutathione peroxidase (GchemicalH-Px), glutathione reductase (gene), glutathione (GchemicalH), and glutathione-chemical-transferase (GchemicalT)).	T36	T55	23424207
CPR:4	CHEMICAL	GENE-Y	4	1	The gene inhibitor chemical (300M, 24h) completely abolished MeHg-induced DA release.	T3	T27	23425605
NA	CHEMICAL	GENE-Y	9	1	The gene inhibitor -methyltyrosine (300M, 24h) completely abolished chemical-induced DA release.	T4	T27	23425605
NA	CHEMICAL	GENE-Y	10	16	MeHg significantly increased DA precursor accumulation in cells treated with chemical (10M), revealing that MeHg increases gene activity.	T6	T28	23425605
NA	CHEMICAL	GENE-Y	0	16	chemical significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10M), revealing that chemical increases gene activity.	T5	T28	23425605
CPR:3	CHEMICAL	GENE-Y	0	16	chemical significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10M), revealing that chemical increases gene activity.	T7	T28	23425605
NA	CHEMICAL	GENE-Y	5	35	The solubility-driven structural modification of chemical is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low gene inhibition.	T5	T10	23428155
CPR:4	CHEMICAL	GENE-Y	6	35	The solubility-driven structural modification of (pyridin-3-yl) chemicals is described, which resulted in the development of a new series of chemical analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low gene inhibition.	T2	T10	23428155
NA	CHEMICAL	GENE-Y	31	35	The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of benzoxazinyl-oxazolidinone analogues with high antibacterial activity against Gram-positive pathogens, including that against chemical-resistant strains and low gene inhibition.	T3	T10	23428155
NA	CHEMICAL	GENE-N	26	5	Secondary point mutations in the gene (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (chemical) and sorafenib.	T4	T27	23430109
CPR:4	CHEMICAL	GENE-Y	26	9	Secondary point mutations in the Fms-like tyrosine kinase 3 (gene) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the gene inhibitors AC220 (chemical) and sorafenib.	T4	T24	23430109
NA	CHEMICAL	GENE-N	26	13	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (gene) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (chemical) and sorafenib.	T4	T35	23430109
NA	CHEMICAL	GENE-N	28	5	Secondary point mutations in the gene (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and chemical.	T5	T27	23430109
CPR:4	CHEMICAL	GENE-Y	28	9	Secondary point mutations in the Fms-like tyrosine kinase 3 (gene) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the gene inhibitors AC220 (quizartinib) and chemical.	T5	T24	23430109
NA	CHEMICAL	GENE-N	28	13	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (gene) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and chemical.	T5	T35	23430109
NA	CHEMICAL	GENE-Y	6	9	Secondary point mutations in the Fms-like chemical kinase 3 (gene) chemical kinase domain (KD) are common causes of acquired clinical resistance to the gene inhibitors AC220 (quizartinib) and sorafenib.	T10	T24	23430109
NA	CHEMICAL	GENE-Y	6	9	Secondary point mutations in the Fms-like chemical kinase 3 (gene) chemical kinase domain (KD) are common causes of acquired clinical resistance to the gene inhibitors AC220 (quizartinib) and sorafenib.	T12	T24	23430109
NA	CHEMICAL	GENE-N	6	13	Secondary point mutations in the Fms-like chemical kinase 3 (FLT3) chemical kinase domain (gene) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.	T10	T35	23430109
NA	CHEMICAL	GENE-N	6	13	Secondary point mutations in the Fms-like chemical kinase 3 (FLT3) chemical kinase domain (gene) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.	T12	T35	23430109
NA	CHEMICAL	GENE-N	25	5	Secondary point mutations in the gene (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors chemical (quizartinib) and sorafenib.	T3	T27	23430109
CPR:4	CHEMICAL	GENE-Y	25	9	Secondary point mutations in the Fms-like tyrosine kinase 3 (gene) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the gene inhibitors chemical (quizartinib) and sorafenib.	T3	T24	23430109
NA	CHEMICAL	GENE-N	25	13	Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (gene) are common causes of acquired clinical resistance to the FLT3 inhibitors chemical (quizartinib) and sorafenib.	T3	T35	23430109
NA	CHEMICAL	GENE-N	0	13	chemical (AP24534) is a multikinase inhibitor with in vitro and clinical activity in gene inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	T6	T26	23430109
CPR:4	CHEMICAL	GENE-N	0	4	chemical (AP24534) is a gene inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	T6	T25	23430109
NA	CHEMICAL	GENE-N	0	22	chemical (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of gene mutation.	T6	T28	23430109
NA	CHEMICAL	GENE-N	13	4	Ponatinib (AP24534) is a gene inhibitor with in vitro and clinical activity in chemical kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	T8	T25	23430109
NA	CHEMICAL	GENE-N	13	22	Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in chemical kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of gene mutation.	T8	T28	23430109
NA	CHEMICAL	GENE-N	1	13	Ponatinib (chemical) is a multikinase inhibitor with in vitro and clinical activity in gene inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	T7	T26	23430109
CPR:4	CHEMICAL	GENE-N	1	4	Ponatinib (chemical) is a gene inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.	T7	T25	23430109
NA	CHEMICAL	GENE-N	1	22	Ponatinib (chemical) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of gene mutation.	T7	T28	23430109
NA	CHEMICAL	GENE-Y	0	20	chemical has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in gene.	T9	T29	23430109
NA	CHEMICAL	GENE-Y	20	11	We assessed the in vitro activity of ponatinib against clinically relevant gene-ITD mutant isoforms that confer resistance to AC220 or chemical.	T14	T30	23430109
NA	CHEMICAL	GENE-Y	7	11	We assessed the in vitro activity of chemical against clinically relevant gene-ITD mutant isoforms that confer resistance to AC220 or sorafenib.	T11	T30	23430109
NA	CHEMICAL	GENE-Y	18	11	We assessed the in vitro activity of ponatinib against clinically relevant gene-ITD mutant isoforms that confer resistance to chemical or sorafenib.	T13	T30	23430109
NA	CHEMICAL	GENE-N	5	18	Substitution of the FLT3 "gatekeeper" chemical with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the gene (AL) residue D835 conferred a high degree of resistance.	T15	T33	23430109
NA	CHEMICAL	GENE-N	5	8	Substitution of the FLT3 "gatekeeper" chemical with leucine (gene) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.	T15	T32	23430109
NA	CHEMICAL	GENE-Y	5	3	Substitution of the gene "gatekeeper" chemical with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the gene activation loop (AL) residue D835 conferred a high degree of resistance.	T15	T31	23430109
NA	CHEMICAL	GENE-N	5	21	Substitution of the FLT3 "gatekeeper" chemical with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (gene) residue D835 conferred a high degree of resistance.	T15	T34	23430109
NA	CHEMICAL	GENE-N	13	18	Substitution of the FLT3 "gatekeeper" phenylalanine with leucine (F691L) conferred mild resistance to chemical, but substitutions at the gene (AL) residue D835 conferred a high degree of resistance.	T17	T33	23430109
NA	CHEMICAL	GENE-N	13	8	Substitution of the FLT3 "gatekeeper" phenylalanine with leucine (gene) conferred mild resistance to chemical, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.	T17	T32	23430109
NA	CHEMICAL	GENE-Y	13	3	Substitution of the gene "gatekeeper" phenylalanine with leucine (F691L) conferred mild resistance to chemical, but substitutions at the gene activation loop (AL) residue D835 conferred a high degree of resistance.	T17	T31	23430109
NA	CHEMICAL	GENE-N	13	21	Substitution of the FLT3 "gatekeeper" phenylalanine with leucine (F691L) conferred mild resistance to chemical, but substitutions at the FLT3 activation loop (gene) residue D835 conferred a high degree of resistance.	T17	T34	23430109
NA	CHEMICAL	GENE-N	7	18	Substitution of the FLT3 "gatekeeper" phenylalanine with chemical (F691L) conferred mild resistance to ponatinib, but substitutions at the gene (AL) residue D835 conferred a high degree of resistance.	T16	T33	23430109
NA	CHEMICAL	GENE-N	7	8	Substitution of the FLT3 "gatekeeper" phenylalanine with chemical (gene) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.	T16	T32	23430109
NA	CHEMICAL	GENE-Y	7	3	Substitution of the gene "gatekeeper" phenylalanine with chemical (F691L) conferred mild resistance to ponatinib, but substitutions at the gene activation loop (AL) residue D835 conferred a high degree of resistance.	T16	T31	23430109
NA	CHEMICAL	GENE-N	7	21	Substitution of the FLT3 "gatekeeper" phenylalanine with chemical (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (gene) residue D835 conferred a high degree of resistance.	T16	T34	23430109
NA	CHEMICAL	GENE-Y	4	9	The switch control inhibitor chemical was similarly inactive against gene AL mutations.	T1	T20	23430109
NA	CHEMICAL	GENE-Y	17	9	On the basis of its in vitro activity against gene TKI-resistant F691 substitutions, further clinical evaluation of chemical in TKI-naive and select TKI-resistant gene-ITD+ AML patients is warranted.	T2	T21	23430109
NA	CHEMICAL	GENE-Y	17	9	On the basis of its in vitro activity against gene TKI-resistant F691 substitutions, further clinical evaluation of chemical in TKI-naive and select TKI-resistant gene-ITD+ AML patients is warranted.	T2	T22	23430109
NA	CHEMICAL	GENE-N	35	5	However, the involvement of the gene-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pangene inhibitor chemical.	T10	T17	23432582
CPR:4	CHEMICAL	GENE-N	35	5	However, the involvement of the gene-dependent pathway in the process of cell death induced by either BSC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pangene inhibitor chemical.	T10	T18	23432582
NA	CHEMICAL	GENE-N	16	5	However, the involvement of the gene-dependent pathway in the process of cell death induced by either chemical 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pangene inhibitor z-VAD-fmk.	T9	T17	23432582
NA	CHEMICAL	GENE-N	16	5	However, the involvement of the gene-dependent pathway in the process of cell death induced by either chemical 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pangene inhibitor z-VAD-fmk.	T9	T18	23432582
CPR:4	CHEMICAL	GENE-Y	22	5	Moreover, since reduced levels of gene and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after chemical 3g or 3n treatment our results suggest that chemical treated cells die from lethal mitosis.	T2	T19	23432582
NA	CHEMICAL	GENE-Y	22	5	Moreover, since reduced levels of gene and Chk2 proteins but no change in p53 levels could be detected in MCF-7 cells after chemical 3g or 3n treatment our results suggest that chemical treated cells die from lethal mitosis.	T3	T19	23432582
CPR:4	CHEMICAL	GENE-Y	22	7	Moreover, since reduced levels of p21CIP1 and gene proteins but no change in p53 levels could be detected in MCF-7 cells after chemical 3g or 3n treatment our results suggest that chemical treated cells die from lethal mitosis.	T2	T20	23432582
NA	CHEMICAL	GENE-Y	22	7	Moreover, since reduced levels of p21CIP1 and gene proteins but no change in p53 levels could be detected in MCF-7 cells after chemical 3g or 3n treatment our results suggest that chemical treated cells die from lethal mitosis.	T3	T20	23432582
NA	CHEMICAL	GENE-Y	22	13	Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in gene levels could be detected in MCF-7 cells after chemical 3g or 3n treatment our results suggest that chemical treated cells die from lethal mitosis.	T2	T12	23432582
NA	CHEMICAL	GENE-Y	22	13	Moreover, since reduced levels of p21CIP1 and Chk2 proteins but no change in gene levels could be detected in MCF-7 cells after chemical 3g or 3n treatment our results suggest that chemical treated cells die from lethal mitosis.	T3	T12	23432582
NA	CHEMICAL	GENE-Y	11	6	These compounds were evaluated for their gene (AChE) inhibitory activity and chemical was found to be the most potent against AChE with IC50 4.16 mol/L.	T6	T8	23434223
CPR:4	CHEMICAL	GENE-Y	11	7	These compounds were evaluated for their acetylcholinesterase (gene) inhibitory activity and chemical was found to be the most potent against gene with IC50 4.16 mol/L.	T6	T10	23434223
NA	CHEMICAL	GENE-Y	11	7	These compounds were evaluated for their acetylcholinesterase (gene) inhibitory activity and chemical was found to be the most potent against gene with IC50 4.16 mol/L.	T6	T9	23434223
NA	CHEMICAL	GENE-Y	9	0	gene (OPN), an extracellular matrix protein, has a functional arginine-glycine-chemical (RGD) domain for binding to integrin.	T10	T24	23434829
NA	CHEMICAL	GENE-N	9	16	Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-glycine-chemical (RGD) domain for binding to gene.	T10	T27	23434829
NA	CHEMICAL	GENE-Y	9	1	Osteopontin (gene), an extracellular matrix protein, has a functional arginine-glycine-chemical (RGD) domain for binding to integrin.	T10	T25	23434829
NA	CHEMICAL	GENE-Y	9	0	gene (OPN), an extracellular matrix protein, has a functional chemical-glycine-aspartic acid (RGD) domain for binding to integrin.	T8	T24	23434829
NA	CHEMICAL	GENE-N	9	16	Osteopontin (OPN), an extracellular matrix protein, has a functional chemical-glycine-aspartic acid (RGD) domain for binding to gene.	T8	T27	23434829
NA	CHEMICAL	GENE-Y	9	1	Osteopontin (gene), an extracellular matrix protein, has a functional chemical-glycine-aspartic acid (RGD) domain for binding to integrin.	T8	T25	23434829
NA	CHEMICAL	GENE-Y	9	0	gene (OPN), an extracellular matrix protein, has a functional arginine-chemical-aspartic acid (RGD) domain for binding to integrin.	T9	T24	23434829
NA	CHEMICAL	GENE-N	9	16	Osteopontin (OPN), an extracellular matrix protein, has a functional arginine-chemical-aspartic acid (RGD) domain for binding to gene.	T9	T27	23434829
NA	CHEMICAL	GENE-Y	9	1	Osteopontin (gene), an extracellular matrix protein, has a functional arginine-chemical-aspartic acid (RGD) domain for binding to integrin.	T9	T25	23434829
NA	CHEMICAL	GENE-N	13	8	OPN increased the mRNA and protein expression of gene (P-gp), a subfamily of chemical-binding cassette transporter in a concentration- and time-dependent manner.	T11	T30	23434829
NA	CHEMICAL	GENE-N	13	9	OPN increased the mRNA and protein expression of p-glycoprotein (gene), a subfamily of chemical-binding cassette transporter in a concentration- and time-dependent manner.	T11	T31	23434829
NA	CHEMICAL	GENE-Y	13	0	gene increased the mRNA and protein expression of p-glycoprotein (P-gp), a subfamily of chemical-binding cassette transporter in a concentration- and time-dependent manner.	T11	T29	23434829
NA	CHEMICAL	GENE-Y	0	15	chemical (DUN), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and gene increased the drug pumping-out activity.	T12	T36	23434829
NA	CHEMICAL	GENE-Y	1	15	Daunomycin (chemical), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and gene increased the drug pumping-out activity.	T13	T36	23434829
NA	CHEMICAL	GENE-N	2	9	OPN inhibited chemical-induced cell death, which was antagonized by gene monoclonal antibody.	T14	T38	23434829
NA	CHEMICAL	GENE-Y	2	0	gene inhibited chemical-induced cell death, which was antagonized by v3 monoclonal antibody.	T14	T37	23434829
NA	CHEMICAL	GENE-Y	3	9	Long-term treatment with chemical further enhanced the expression of gene.	T1	T15	23434829
NA	CHEMICAL	GENE-Y	6	3	Knockdown of endogenous gene potentiated the chemical-induced apoptosis of PC-3 cells.	T2	T16	23434829
CPR:9	CHEMICAL	GENE-N	14	20	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, chemical, and rapamycin, which are also gene substrates.	T5	T18	23434829
NA	CHEMICAL	GENE-Y	14	3	Furthermore, knockdown of gene enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, chemical, and rapamycin, which are also P-gp substrates.	T5	T17	23434829
CPR:9	CHEMICAL	GENE-N	13	20	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, chemical, actinomycin-D, and rapamycin, which are also gene substrates.	T4	T18	23434829
NA	CHEMICAL	GENE-Y	13	3	Furthermore, knockdown of gene enhanced cell death caused by other drugs, including paclitaxel, chemical, actinomycin-D, and rapamycin, which are also P-gp substrates.	T4	T17	23434829
CPR:9	CHEMICAL	GENE-N	12	20	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including chemical, doxorubicin, actinomycin-D, and rapamycin, which are also gene substrates.	T3	T18	23434829
NA	CHEMICAL	GENE-Y	12	3	Furthermore, knockdown of gene enhanced cell death caused by other drugs, including chemical, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.	T3	T17	23434829
CPR:9	CHEMICAL	GENE-N	16	20	Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and chemical, which are also gene substrates.	T6	T18	23434829
NA	CHEMICAL	GENE-Y	16	3	Furthermore, knockdown of gene enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and chemical, which are also P-gp substrates.	T6	T17	23434829
NA	CHEMICAL	GENE-Y	13	6	The animal studies also showed that gene knockdown enhanced the cytotoxic action of chemical.	T7	T19	23434829
NA	CHEMICAL	GENE-Y	3	0	gene is a serine/chemical kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	T5	T14	23436791
NA	CHEMICAL	GENE-Y	3	0	gene is a chemical/threonine kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	T3	T14	23436791
NA	CHEMICAL	GENE-Y	13	7	In an effort to discover new potent gene inhibitors, a previously identified ATP-competitive chemical scaffold was expanded to derive structure-activity relationship data.	T7	T19	23436791
NA	CHEMICAL	GENE-Y	12	7	In an effort to discover new potent gene inhibitors, a previously identified chemical-competitive indolyl-pyrrolone scaffold was expanded to derive structure-activity relationship data.	T6	T19	23436791
NA	CHEMICAL	GENE-Y	36	25	A synergistic effect in the inhibition of cell proliferation by ATP-competitive and ATP-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all gene inhibitors tested in showed synergism with the known anticancer agent, chemical.	T4	T16	23436791
NA	CHEMICAL	GENE-Y	10	25	A synergistic effect in the inhibition of cell proliferation by chemical-competitive and chemical-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all gene inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.	T1	T16	23436791
NA	CHEMICAL	GENE-Y	10	25	A synergistic effect in the inhibition of cell proliferation by chemical-competitive and chemical-noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all gene inhibitors tested in showed synergism with the known anticancer agent, paclitaxel.	T2	T16	23436791
NA	CHEMICAL	GENE-Y	4	1	PURPOSE: gene inhibitors and chemical are the mainstay of pharmacological intervention for the cognitive symptoms of Alzheimer's disease (AD).	T9	T14	23443628
NA	CHEMICAL	GENE-Y	13	2	Introduction: The gene, which belongs to the group II subfamily of metabotropic chemical receptors (mGlu) along with the mGlu3 receptor, has proven to be of particular importance in neuropharmacology.	T4	T7	23452205
NA	CHEMICAL	GENE-Y	13	19	Introduction: The mGlu2 receptor, which belongs to the group II subfamily of metabotropic chemical receptors (mGlu) along with the gene, has proven to be of particular importance in neuropharmacology.	T4	T6	23452205
NA	CHEMICAL	GENE-Y	11	7	Preferentially expressed on presynaptic nerve terminals, the gene negatively modulates chemical and GABA release and is widely distributed in the brain.	T1	T8	23452205
NA	CHEMICAL	GENE-Y	13	7	Preferentially expressed on presynaptic nerve terminals, the gene negatively modulates glutamate and chemical release and is widely distributed in the brain.	T2	T8	23452205
NA	CHEMICAL	GENE-Y	18	3	High levels of gene are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where chemical hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.	T3	T9	23452205
NA	CHEMICAL	GENE-Y	25	13	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and gene (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T17	T28	23454148
NA	CHEMICAL	GENE-N	25	8	Compared with normally-fed counterparts, PM-CP rats exhibited higher gene, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T17	T26	23454148
NA	CHEMICAL	GENE-Y	25	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T17	T30	23454148
NA	CHEMICAL	GENE-N	25	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T17	T32	23454148
NA	CHEMICAL	GENE-N	25	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted xanthine oxidase activities.	T17	T33	23454148
NA	CHEMICAL	GENE-Y	25	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, gene and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T17	T27	23454148
NA	CHEMICAL	GENE-Y	25	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted gene activities.	T17	T34	23454148
NA	CHEMICAL	GENE-Y	25	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased chemical dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T17	T29	23454148
NA	CHEMICAL	GENE-Y	8	13	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and gene (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T12	T28	23454148
NA	CHEMICAL	GENE-Y	8	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T12	T31	23454148
NA	CHEMICAL	GENE-Y	8	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T12	T30	23454148
NA	CHEMICAL	GENE-N	8	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T12	T32	23454148
NA	CHEMICAL	GENE-N	8	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted xanthine oxidase activities.	T12	T33	23454148
NA	CHEMICAL	GENE-Y	8	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, gene and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T12	T27	23454148
NA	CHEMICAL	GENE-Y	8	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted gene activities.	T12	T34	23454148
NA	CHEMICAL	GENE-Y	8	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher chemical S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T12	T29	23454148
NA	CHEMICAL	GENE-Y	13	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and chemical S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T15	T31	23454148
NA	CHEMICAL	GENE-N	13	8	Compared with normally-fed counterparts, PM-CP rats exhibited higher gene, aminopeptidase N and chemical S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T15	T26	23454148
NA	CHEMICAL	GENE-Y	13	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and chemical S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T15	T30	23454148
NA	CHEMICAL	GENE-N	13	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and chemical S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T15	T32	23454148
NA	CHEMICAL	GENE-N	13	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and chemical S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted xanthine oxidase activities.	T15	T33	23454148
NA	CHEMICAL	GENE-Y	13	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, gene and chemical S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T15	T27	23454148
NA	CHEMICAL	GENE-Y	13	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and chemical S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted gene activities.	T15	T34	23454148
NA	CHEMICAL	GENE-Y	13	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and chemical S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T15	T29	23454148
NA	CHEMICAL	GENE-Y	41	13	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and gene (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T28	23454148
NA	CHEMICAL	GENE-Y	41	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T31	23454148
NA	CHEMICAL	GENE-N	41	8	Compared with normally-fed counterparts, PM-CP rats exhibited higher gene, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T26	23454148
NA	CHEMICAL	GENE-Y	41	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T30	23454148
NA	CHEMICAL	GENE-N	41	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T32	23454148
NA	CHEMICAL	GENE-N	41	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted chemical oxidase activities.	T21	T33	23454148
NA	CHEMICAL	GENE-Y	41	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, gene and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T27	23454148
NA	CHEMICAL	GENE-Y	41	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted chemical oxidase activities.	T21	T29	23454148
NA	CHEMICAL	GENE-Y	37	13	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and gene (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T28	23454148
NA	CHEMICAL	GENE-Y	37	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T31	23454148
NA	CHEMICAL	GENE-N	37	8	Compared with normally-fed counterparts, PM-CP rats exhibited higher gene, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T26	23454148
NA	CHEMICAL	GENE-Y	37	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T30	23454148
NA	CHEMICAL	GENE-N	37	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T32	23454148
NA	CHEMICAL	GENE-Y	37	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, gene and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T27	23454148
NA	CHEMICAL	GENE-Y	37	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted gene activities.	T20	T34	23454148
NA	CHEMICAL	GENE-Y	37	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher chemical reductase and depleted xanthine oxidase activities.	T20	T29	23454148
NA	CHEMICAL	GENE-Y	33	13	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and gene (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T28	23454148
NA	CHEMICAL	GENE-Y	33	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T31	23454148
NA	CHEMICAL	GENE-N	33	8	Compared with normally-fed counterparts, PM-CP rats exhibited higher gene, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T26	23454148
NA	CHEMICAL	GENE-Y	33	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T30	23454148
NA	CHEMICAL	GENE-N	33	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T32	23454148
CPR:3	CHEMICAL	GENE-N	33	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher gene and depleted xanthine oxidase activities.	T19	T33	23454148
NA	CHEMICAL	GENE-Y	33	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, gene and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T27	23454148
CPR:4	CHEMICAL	GENE-Y	33	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted gene activities.	T19	T34	23454148
NA	CHEMICAL	GENE-Y	33	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-chemical rats showed higher quinone reductase and depleted xanthine oxidase activities.	T19	T29	23454148
NA	CHEMICAL	GENE-Y	9	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T13	T31	23454148
NA	CHEMICAL	GENE-Y	9	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T16	T31	23454148
NA	CHEMICAL	GENE-Y	9	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T13	T30	23454148
NA	CHEMICAL	GENE-Y	9	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T16	T30	23454148
NA	CHEMICAL	GENE-N	9	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T13	T32	23454148
NA	CHEMICAL	GENE-N	9	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T16	T32	23454148
NA	CHEMICAL	GENE-N	9	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted xanthine oxidase activities.	T13	T33	23454148
NA	CHEMICAL	GENE-N	9	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted xanthine oxidase activities.	T16	T33	23454148
NA	CHEMICAL	GENE-Y	9	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, gene and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T13	T27	23454148
NA	CHEMICAL	GENE-Y	9	10	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, gene and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T16	T27	23454148
NA	CHEMICAL	GENE-Y	9	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted gene activities.	T13	T34	23454148
NA	CHEMICAL	GENE-Y	9	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted gene activities.	T16	T34	23454148
NA	CHEMICAL	GENE-Y	9	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T13	T29	23454148
NA	CHEMICAL	GENE-Y	9	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione chemical-transferase, aminopeptidase N and cysteine chemical-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T16	T29	23454148
NA	CHEMICAL	GENE-Y	11	13	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and gene (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T14	T28	23454148
NA	CHEMICAL	GENE-Y	11	25	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased gene and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T14	T31	23454148
NA	CHEMICAL	GENE-N	11	8	Compared with normally-fed counterparts, PM-CP rats exhibited higher gene, aminopeptidase chemical and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T14	T26	23454148
NA	CHEMICAL	GENE-Y	11	19	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and cysteine S-conjugate beta-lyase (CCBL) and lower gene activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T14	T30	23454148
NA	CHEMICAL	GENE-N	11	28	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and gene activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T14	T32	23454148
NA	CHEMICAL	GENE-N	11	37	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher gene and depleted xanthine oxidase activities.	T14	T33	23454148
NA	CHEMICAL	GENE-Y	11	41	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted gene activities.	T14	T34	23454148
NA	CHEMICAL	GENE-Y	11	16	Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase chemical and cysteine S-conjugate beta-lyase (gene) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-MMC rats showed higher quinone reductase and depleted xanthine oxidase activities.	T14	T29	23454148
CPR:9	CHEMICAL	GENE-Y	7	14	Conclusively, protein malnutrition alters CP, FU and chemical metabolism in rat stomach by enhancing gene pathway for CP activation, delaying FU elimination and activating two-electron reduction of chemical, potentiating their gastrotoxicity.	T5	T25	23454148
NA	CHEMICAL	GENE-Y	7	14	Conclusively, protein malnutrition alters CP, FU and chemical metabolism in rat stomach by enhancing gene pathway for CP activation, delaying FU elimination and activating two-electron reduction of chemical, potentiating their gastrotoxicity.	T7	T25	23454148
NA	CHEMICAL	GENE-N	0	6	chemical (NAC, 33 mM) and the gene (JNK) inhibitor (SP600125, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.	T1	T9	23454527
NA	CHEMICAL	GENE-N	0	9	chemical (NAC, 33 mM) and the c-jun N-terminal kinase (gene) inhibitor (SP600125, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.	T1	T10	23454527
CPR:4	CHEMICAL	GENE-N	11	6	N-acetylcysteine (NAC, 33 mM) and the gene (JNK) inhibitor (chemical, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.	T4	T9	23454527
CPR:4	CHEMICAL	GENE-N	11	9	N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (gene) inhibitor (chemical, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.	T4	T10	23454527
NA	CHEMICAL	GENE-N	1	6	N-acetylcysteine (chemical, 33 mM) and the gene (JNK) inhibitor (SP600125, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.	T2	T9	23454527
NA	CHEMICAL	GENE-N	1	9	N-acetylcysteine (chemical, 33 mM) and the c-jun N-terminal kinase (gene) inhibitor (SP600125, 33 M) further decreased the viability in the presence of DEP (200 g/ml) and 3.3% FCS.	T2	T10	23454527
NA	CHEMICAL	GENE-N	3	10	The endogenous steroid chemical (LCA) dilates cerebral arteries via gene activation, which requires recognition by a BK 1 site that includes Thr169.	T11	T32	23455312
NA	CHEMICAL	GENE-Y	3	18	The endogenous steroid chemical (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a gene site that includes Thr169.	T11	T33	23455312
NA	CHEMICAL	GENE-N	2	10	The endogenous chemical lithocholic acid (LCA) dilates cerebral arteries via gene activation, which requires recognition by a BK 1 site that includes Thr169.	T9	T32	23455312
NA	CHEMICAL	GENE-Y	2	18	The endogenous chemical lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a gene site that includes Thr169.	T9	T33	23455312
NA	CHEMICAL	GENE-N	5	10	The endogenous steroid lithocholic acid (chemical) dilates cerebral arteries via gene activation, which requires recognition by a BK 1 site that includes Thr169.	T12	T32	23455312
NA	CHEMICAL	GENE-Y	5	18	The endogenous steroid lithocholic acid (chemical) dilates cerebral arteries via BK channel activation, which requires recognition by a gene site that includes Thr169.	T12	T33	23455312
NA	CHEMICAL	GENE-N	23	10	The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via gene activation, which requires recognition by a BK 1 site that includes chemical169.	T13	T32	23455312
NA	CHEMICAL	GENE-Y	23	18	The endogenous steroid lithocholic acid (LCA) dilates cerebral arteries via BK channel activation, which requires recognition by a gene site that includes chemical169.	T13	T33	23455312
CPR:3	CHEMICAL	GENE-Y	0	3	chemical activated the gene cloned from rat cerebral artery myocytes with a potency (EC50 = 53 M) similar to and an efficacy (2.5 potentiation) significantly greater than that of LCA.	T18	T36	23455312
CPR:3	CHEMICAL	GENE-Y	33	3	HENA activated the gene cloned from rat cerebral artery myocytes with a potency (EC50 = 53 M) similar to and an efficacy (2.5 potentiation) significantly greater than that of chemical.	T19	T36	23455312
NA	CHEMICAL	GENE-Y	28	21	HENA failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets gene via the BK 1 chemical-sensing site.	T2	T23	23455312
NA	CHEMICAL	GENE-N	28	21	HENA failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets gene via the BK 1 chemical-sensing site.	T2	T23	23455312
NA	CHEMICAL	GENE-Y	28	26	HENA failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets 1-containing BK channels via the gene chemical-sensing site.	T2	T24	23455312
CPR:3	CHEMICAL	GENE-Y	0	21	chemical failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets gene via the BK 1 steroid-sensing site.	T1	T23	23455312
CPR:3	CHEMICAL	GENE-N	0	21	chemical failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets gene via the BK 1 steroid-sensing site.	T1	T23	23455312
NA	CHEMICAL	GENE-Y	0	26	chemical failed to activate the channels made of cbv1 + 2, 3, 4, or 1T169A, indicating that this drug selectively targets 1-containing BK channels via the gene steroid-sensing site.	T1	T24	23455312
NA	CHEMICAL	GENE-Y	0	8	chemical failed to dilate the arteries from the gene knockout mouse, underscoring BK 1's role in chemical action.	T5	T25	23455312
NA	CHEMICAL	GENE-Y	0	8	chemical failed to dilate the arteries from the gene knockout mouse, underscoring BK 1's role in chemical action.	T6	T25	23455312
NA	CHEMICAL	GENE-Y	0	12	chemical failed to dilate the arteries from the KCNMB1 knockout mouse, underscoring gene's role in chemical action.	T5	T26	23455312
NA	CHEMICAL	GENE-Y	0	12	chemical failed to dilate the arteries from the KCNMB1 knockout mouse, underscoring gene's role in chemical action.	T6	T26	23455312
NA	CHEMICAL	GENE-N	4	14	Finally, carotid artery-infusion of chemical (45 M) dilated the pial cerebral arterioles via selective gene targeting.	T7	T28	23455312
NA	CHEMICAL	GENE-Y	10	15	In conclusion, we have identified for the first time a nonchemicalal agent that selectively activates gene by targeting the chemical-sensing site in BK 1, rendering vasodilation.	T8	T29	23455312
NA	CHEMICAL	GENE-N	10	15	In conclusion, we have identified for the first time a nonchemicalal agent that selectively activates gene by targeting the chemical-sensing site in BK 1, rendering vasodilation.	T8	T29	23455312
NA	CHEMICAL	GENE-Y	10	24	In conclusion, we have identified for the first time a nonchemicalal agent that selectively activates 1-containing BK channels by targeting the chemical-sensing site in gene, rendering vasodilation.	T8	T31	23455312
CPR:6	CHEMICAL	GENE-Y	7	1	RATIONALE: gene antagonists, such as chemical, have been shown to possess cognitive-enhancing and wakefulness-promoting effects.	T10	T17	23455597
NA	CHEMICAL	GENE-Y	18	14	CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to gene antagonists, indicates that chemical is unlikely to possess a high potential for abuse in the human population and suggests that gene antagonists, as a class, are similar in this regard.	T7	T18	23455597
CPR:6	CHEMICAL	GENE-Y	18	14	CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to gene antagonists, indicates that chemical is unlikely to possess a high potential for abuse in the human population and suggests that gene antagonists, as a class, are similar in this regard.	T7	T19	23455597
NA	CHEMICAL	GENE-N	18	6	Additionally, a structural model of the gene obtained by molecular dynamics simulation and energy minimization suggests that the chemical moiety of phospho-S16 could compete with the phospho-substrate.	T3	T15	23456038
CPR:9	CHEMICAL	GENE-Y	2	5	Uptake of chemical (5nM) by gene was reduced by 82%-95%.	T3	T12	23461378
CPR:9	CHEMICAL	GENE-Y	21	11	This methodology was subsequently used to assess the relative contribution of gene uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), chemical (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).	T6	T13	23461378
CPR:9	CHEMICAL	GENE-Y	23	11	This methodology was subsequently used to assess the relative contribution of gene uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), chemical (84%-98%) and lopinavir (64%-89%).	T1	T13	23461378
CPR:9	CHEMICAL	GENE-Y	17	11	This methodology was subsequently used to assess the relative contribution of gene uptake in human hepatocytes for chemical (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).	T4	T13	23461378
CPR:9	CHEMICAL	GENE-Y	26	11	This methodology was subsequently used to assess the relative contribution of gene uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and chemical (64%-89%).	T2	T13	23461378
CPR:9	CHEMICAL	GENE-Y	19	11	This methodology was subsequently used to assess the relative contribution of gene uptake in human hepatocytes for olmesartan (42%-62%), chemical (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).	T5	T13	23461378
NA	CHEMICAL	GENE-Y	26	22	A glucose tolerance test with 75g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2h for gene, glucose, FFA and chemical.	T9	T20	23461841
NA	CHEMICAL	GENE-Y	1	22	A chemical tolerance test with 75g chemical load was performed before and after treatment, collecting blood at 0, 1 and 2h for gene, chemical, FFA and aldosterone.	T5	T20	23461841
NA	CHEMICAL	GENE-Y	1	22	A chemical tolerance test with 75g chemical load was performed before and after treatment, collecting blood at 0, 1 and 2h for gene, chemical, FFA and aldosterone.	T6	T20	23461841
NA	CHEMICAL	GENE-Y	1	22	A chemical tolerance test with 75g chemical load was performed before and after treatment, collecting blood at 0, 1 and 2h for gene, chemical, FFA and aldosterone.	T8	T20	23461841
NA	CHEMICAL	GENE-Y	17	11	Since FFAs are known to be involved in the development of gene resistance, these results suggest that chemical may be useful for lowering gene resistance in PCOS patients.	T2	T18	23461841
NA	CHEMICAL	GENE-Y	17	11	Since FFAs are known to be involved in the development of gene resistance, these results suggest that chemical may be useful for lowering gene resistance in PCOS patients.	T2	T19	23461841
NA	CHEMICAL	GENE-N	3	5	It decreased blood chemical, stimulated gene secretion in type 2 diabetic patients.	T30	T57	23466488
NA	CHEMICAL	GENE-Y	19	11	The objective of the present investigation was to evaluate l-glutamine increases gene (GLP-1) (7-36) amide secretion in chemical-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	T23	T54	23466488
NA	CHEMICAL	GENE-Y	19	14	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (gene) (7-36) amide secretion in chemical-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	T23	T55	23466488
NA	CHEMICAL	GENE-Y	19	11	The objective of the present investigation was to evaluate l-glutamine increases gene (GLP-1) (7-36) amide secretion in streptozotocin-chemical (STZ-NTM) induced diabetic Sprague Dawley rats.	T24	T54	23466488
NA	CHEMICAL	GENE-Y	19	14	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (gene) (7-36) amide secretion in streptozotocin-chemical (STZ-NTM) induced diabetic Sprague Dawley rats.	T24	T55	23466488
CPR:3	CHEMICAL	GENE-Y	9	11	The objective of the present investigation was to evaluate chemical increases gene (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	T18	T54	23466488
CPR:3	CHEMICAL	GENE-Y	9	14	The objective of the present investigation was to evaluate chemical increases glucagon like peptide-1 (gene) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.	T18	T55	23466488
NA	CHEMICAL	GENE-Y	16	11	The objective of the present investigation was to evaluate l-glutamine increases gene (GLP-1) (7-36) chemical secretion in streptozotocin-nicotinchemical (STZ-NTM) induced diabetic Sprague Dawley rats.	T22	T54	23466488
NA	CHEMICAL	GENE-Y	16	14	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (gene) (7-36) chemical secretion in streptozotocin-nicotinchemical (STZ-NTM) induced diabetic Sprague Dawley rats.	T22	T55	23466488
NA	CHEMICAL	GENE-Y	20	11	The objective of the present investigation was to evaluate l-glutamine increases gene (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-chemical) induced diabetic Sprague Dawley rats.	T26	T54	23466488
NA	CHEMICAL	GENE-Y	20	14	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (gene) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-chemical) induced diabetic Sprague Dawley rats.	T26	T55	23466488
NA	CHEMICAL	GENE-Y	20	11	The objective of the present investigation was to evaluate l-glutamine increases gene (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (chemical-NTM) induced diabetic Sprague Dawley rats.	T25	T54	23466488
NA	CHEMICAL	GENE-Y	20	14	The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (gene) (7-36) amide secretion in streptozotocin-nicotinamide (chemical-NTM) induced diabetic Sprague Dawley rats.	T25	T55	23466488
NA	CHEMICAL	GENE-N	32	35	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, chemical, glutathione peroxidase, gene) were measured after 8week.	T4	T48	23466488
NA	CHEMICAL	GENE-N	32	28	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (gene, reduced glutathione, chemical, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T4	T46	23466488
NA	CHEMICAL	GENE-N	32	33	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, chemical, gene, glutathione S transferase) were measured after 8week.	T4	T47	23466488
NA	CHEMICAL	GENE-N	32	1	Glycosylated gene, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, chemical, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T4	T42	23466488
NA	CHEMICAL	GENE-N	32	19	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic gene, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, chemical, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T4	T45	23466488
NA	CHEMICAL	GENE-Y	32	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, chemical, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T4	T43	23466488
NA	CHEMICAL	GENE-Y	32	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, chemical, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T4	T44	23466488
NA	CHEMICAL	GENE-N	31	28	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (gene, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T3	T46	23466488
NA	CHEMICAL	GENE-N	31	28	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (gene, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T5	T46	23466488
NA	CHEMICAL	GENE-N	31	28	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (gene, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T6	T46	23466488
NA	CHEMICAL	GENE-N	31	1	Glycosylated gene, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T3	T42	23466488
NA	CHEMICAL	GENE-N	31	1	Glycosylated gene, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T5	T42	23466488
NA	CHEMICAL	GENE-N	31	1	Glycosylated gene, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T6	T42	23466488
NA	CHEMICAL	GENE-N	31	19	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic gene, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T3	T45	23466488
NA	CHEMICAL	GENE-N	31	19	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic gene, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T5	T45	23466488
NA	CHEMICAL	GENE-N	31	19	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic gene, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T6	T45	23466488
NA	CHEMICAL	GENE-Y	31	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T3	T43	23466488
NA	CHEMICAL	GENE-Y	31	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T3	T44	23466488
NA	CHEMICAL	GENE-Y	31	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T5	T43	23466488
NA	CHEMICAL	GENE-Y	31	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T5	T44	23466488
NA	CHEMICAL	GENE-Y	31	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T6	T43	23466488
NA	CHEMICAL	GENE-Y	31	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) amide, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced chemical, malondialdehyde, chemical peroxidase, chemical S transferase) were measured after 8week.	T6	T44	23466488
NA	CHEMICAL	GENE-N	10	35	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) chemical, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, gene) were measured after 8week.	T2	T48	23466488
NA	CHEMICAL	GENE-N	10	28	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) chemical, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (gene, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T2	T46	23466488
NA	CHEMICAL	GENE-N	10	33	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) chemical, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, gene, glutathione S transferase) were measured after 8week.	T2	T47	23466488
NA	CHEMICAL	GENE-N	10	1	Glycosylated gene, lipid profile, plasma and colonic active (GLP-1) (7-36) chemical, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T2	T42	23466488
NA	CHEMICAL	GENE-N	10	19	Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) chemical, mRNA expression of proglucagon GLP-1, plasma and pancreatic gene, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T2	T45	23466488
NA	CHEMICAL	GENE-Y	10	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) chemical, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T2	T43	23466488
NA	CHEMICAL	GENE-Y	10	8	Glycosylated haemoglobin, lipid profile, plasma and colonic active (gene) (7-36) chemical, mRNA expression of proglucagon gene, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8week.	T2	T44	23466488
NA	CHEMICAL	GENE-N	1	8	Plasma chemical, active GLP-1 (7-36) amide concentration and gene levels were measured after chemical loading.	T12	T50	23466488
NA	CHEMICAL	GENE-N	1	8	Plasma chemical, active GLP-1 (7-36) amide concentration and gene levels were measured after chemical loading.	T14	T50	23466488
NA	CHEMICAL	GENE-Y	1	3	Plasma chemical, active gene (7-36) amide concentration and insulin levels were measured after chemical loading.	T12	T49	23466488
NA	CHEMICAL	GENE-Y	1	3	Plasma chemical, active gene (7-36) amide concentration and insulin levels were measured after chemical loading.	T14	T49	23466488
NA	CHEMICAL	GENE-N	5	8	Plasma glucose, active GLP-1 (7-36) chemical concentration and gene levels were measured after glucose loading.	T13	T50	23466488
NA	CHEMICAL	GENE-Y	5	3	Plasma glucose, active gene (7-36) chemical concentration and insulin levels were measured after glucose loading.	T13	T49	23466488
NA	CHEMICAL	GENE-Y	5	9	The docking data indicated that chemical bind to the gene.	T15	T51	23466488
NA	CHEMICAL	GENE-N	25	8	l-glutamine decreased plasma glucose, increased plasma and pancreatic gene, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in chemical-nicotinamide induced diabetic rats.	T20	T52	23466488
NA	CHEMICAL	GENE-Y	25	14	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active gene (7-36) amide secretion as well as decreased oxidative stress in chemical-nicotinamide induced diabetic rats.	T20	T53	23466488
NA	CHEMICAL	GENE-N	25	8	l-glutamine decreased plasma glucose, increased plasma and pancreatic gene, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-chemical induced diabetic rats.	T21	T52	23466488
NA	CHEMICAL	GENE-Y	25	14	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active gene (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-chemical induced diabetic rats.	T21	T53	23466488
CPR:3	CHEMICAL	GENE-N	0	8	chemical decreased plasma glucose, increased plasma and pancreatic gene, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	T16	T52	23466488
CPR:3	CHEMICAL	GENE-Y	0	14	chemical decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active gene (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	T16	T53	23466488
NA	CHEMICAL	GENE-N	3	8	l-glutamine decreased plasma chemical, increased plasma and pancreatic gene, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	T17	T52	23466488
NA	CHEMICAL	GENE-Y	3	14	l-glutamine decreased plasma chemical, increased plasma and pancreatic insulin, increased plasma and colonic active gene (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.	T17	T53	23466488
NA	CHEMICAL	GENE-N	16	8	l-glutamine decreased plasma glucose, increased plasma and pancreatic gene, increased plasma and colonic active GLP-1 (7-36) chemical secretion as well as decreased oxidative stress in streptozotocin-nicotinchemical induced diabetic rats.	T19	T52	23466488
NA	CHEMICAL	GENE-Y	16	14	l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active gene (7-36) chemical secretion as well as decreased oxidative stress in streptozotocin-nicotinchemical induced diabetic rats.	T19	T53	23466488
NA	CHEMICAL	GENE-N	24	15	In this study, we report and analyze the functional consequences of three novel missense mutations, gene, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-chemical-finger (C-ZF) domain of ZEB2.	T1	T12	23466526
NA	CHEMICAL	GENE-N	24	16	In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, gene and p.His1045Arg, identified in the highly conserved C-chemical-finger (C-ZF) domain of ZEB2.	T1	T13	23466526
NA	CHEMICAL	GENE-N	24	18	In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and gene, identified in the highly conserved C-chemical-finger (C-ZF) domain of ZEB2.	T1	T14	23466526
NA	CHEMICAL	GENE-Y	24	28	In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-chemical-finger (C-ZF) domain of gene.	T1	T16	23466526
NA	CHEMICAL	GENE-Y	12	7	While these behaviors can be modulated by gene (CRF) and chemical signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.	T5	T18	23470280
NA	CHEMICAL	GENE-Y	12	10	While these behaviors can be modulated by corticotropin releasing factor (gene) and chemical signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.	T5	T19	23470280
NA	CHEMICAL	GENE-N	26	19	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, gene agonist chemical (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	T7	T21	23470280
NA	CHEMICAL	GENE-Y	26	18	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that gene, dopamine (DA) and the -adrenergic receptor agonist chemical (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	T7	T20	23470280
NA	CHEMICAL	GENE-N	46	19	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, gene agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic chemical release.	T9	T21	23470280
NA	CHEMICAL	GENE-Y	46	18	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that gene, dopamine (DA) and the -adrenergic receptor agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic chemical release.	T9	T20	23470280
NA	CHEMICAL	GENE-Y	19	18	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that gene, chemical (DA) and the -adrenergic receptor agonist isoproterenol (ISO) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	T6	T20	23470280
NA	CHEMICAL	GENE-N	27	19	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that CRF, gene agonist isoproterenol (chemical) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	T8	T21	23470280
NA	CHEMICAL	GENE-Y	27	18	Utilizing whole-cell patch-clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that gene, dopamine (DA) and the -adrenergic receptor agonist isoproterenol (chemical) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic glutamate release.	T8	T20	23470280
NA	CHEMICAL	GENE-N	13	8	While previous work from our lab suggests that gene mediate the effect of chemical on excitatory transmission in other subregions of the extended amygdala, blockade of gene in the CeAL failed to significantly alter effects of DA and ISO on glutamatergic transmission.	T10	T12	23470280
NA	CHEMICAL	GENE-N	13	8	While previous work from our lab suggests that gene mediate the effect of chemical on excitatory transmission in other subregions of the extended amygdala, blockade of gene in the CeAL failed to significantly alter effects of DA and ISO on glutamatergic transmission.	T10	T25	23470280
NA	CHEMICAL	GENE-N	38	8	While previous work from our lab suggests that gene mediate the effect of catecholamines on excitatory transmission in other subregions of the extended amygdala, blockade of gene in the CeAL failed to significantly alter effects of DA and chemical on glutamatergic transmission.	T1	T12	23470280
NA	CHEMICAL	GENE-N	38	8	While previous work from our lab suggests that gene mediate the effect of catecholamines on excitatory transmission in other subregions of the extended amygdala, blockade of gene in the CeAL failed to significantly alter effects of DA and chemical on glutamatergic transmission.	T1	T25	23470280
NA	CHEMICAL	GENE-Y	4	6	These findings suggest that chemical and gene enhancement of glutamatergic transmission onto CeAL neurons occurs via distinct mechanisms.	T2	T13	23470280
NA	CHEMICAL	GENE-Y	4	1	While gene increased spontaneous chemical release in the CeAL, gene caused no significant changes to optogenetically evoked chemical release in this region.	T3	T14	23470280
NA	CHEMICAL	GENE-Y	4	1	While gene increased spontaneous chemical release in the CeAL, gene caused no significant changes to optogenetically evoked chemical release in this region.	T3	T15	23470280
NA	CHEMICAL	GENE-Y	4	1	While gene increased spontaneous chemical release in the CeAL, gene caused no significant changes to optogenetically evoked chemical release in this region.	T4	T14	23470280
NA	CHEMICAL	GENE-Y	4	1	While gene increased spontaneous chemical release in the CeAL, gene caused no significant changes to optogenetically evoked chemical release in this region.	T4	T15	23470280
NA	CHEMICAL	GENE-Y	9	4	We examined whether the gene gene (OXTR) single chemical polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	T2	T5	23470776
NA	CHEMICAL	GENE-Y	9	7	We examined whether the oxytocin receptor gene (gene) single chemical polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	T2	T6	23470776
NA	CHEMICAL	GENE-Y	4	7	We examined whether the chemical receptor gene (gene) single nucleotide polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict/constraint) and economic stress on post-traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	T1	T6	23470776
NA	CHEMICAL	GENE-Y	19	15	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of gene, corresponding to a chemical-to-proline mutation at residue 107.	T1	T8	23473037
NA	CHEMICAL	GENE-Y	19	15	Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of gene, corresponding to a leucine-to-chemical mutation at residue 107.	T2	T8	23473037
NA	CHEMICAL	GENE-N	10	14	Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of chemical, cytokines, and gene.	T3	T15	23473037
NA	CHEMICAL	GENE-N	10	12	Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of chemical, gene, and chemokines.	T3	T14	23473037
NA	CHEMICAL	GENE-Y	10	4	Expression of SIRT1-L107P in gene-producing cells resulted in overproduction of chemical, cytokines, and chemokines.	T3	T12	23473037
NA	CHEMICAL	GENE-N	10	2	Expression of SIRT1-gene in insulin-producing cells resulted in overproduction of chemical, cytokines, and chemokines.	T3	T11	23473037
NA	CHEMICAL	GENE-Y	10	2	Expression of gene-L107P in insulin-producing cells resulted in overproduction of chemical, cytokines, and chemokines.	T3	T10	23473037
NA	CHEMICAL	GENE-N	28	10	In the present study, hinokitiol (1 and 2M) inhibited the gene-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, chemical, and ADP.	T13	T26	23473801
NA	CHEMICAL	GENE-Y	28	27	In the present study, hinokitiol (1 and 2M) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including gene, chemical, and ADP.	T13	T27	23473801
CPR:4	CHEMICAL	GENE-N	4	10	In the present study, chemical (1 and 2M) inhibited the gene-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and ADP.	T12	T26	23473801
NA	CHEMICAL	GENE-Y	4	27	In the present study, chemical (1 and 2M) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including gene, arachidonic acid, and ADP.	T12	T27	23473801
NA	CHEMICAL	GENE-N	31	10	In the present study, hinokitiol (1 and 2M) inhibited the gene-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including thrombin, arachidonic acid, and chemical.	T14	T26	23473801
NA	CHEMICAL	GENE-Y	31	27	In the present study, hinokitiol (1 and 2M) inhibited the collagen-induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including gene, arachidonic acid, and chemical.	T14	T27	23473801
CPR:4	CHEMICAL	GENE-N	0	12	chemical inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), gene (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T31	23473801
CPR:4	CHEMICAL	GENE-Y	0	5	chemical inhibited the phosphorylation of gene, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T28	23473801
CPR:4	CHEMICAL	GENE-N	0	8	chemical inhibited the phosphorylation of phospholipase C (PLC)2, gene (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T29	23473801
CPR:4	CHEMICAL	GENE-N	0	19	chemical inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in gene-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T34	23473801
CPR:4	CHEMICAL	GENE-N	0	15	chemical inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (gene), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T32	23473801
CPR:4	CHEMICAL	GENE-N	0	11	chemical inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (gene), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T30	23473801
CPR:4	CHEMICAL	GENE-N	0	17	chemical inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and gene in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (OH) formation.	T15	T33	23473801
NA	CHEMICAL	GENE-N	29	12	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), gene (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T31	23473801
NA	CHEMICAL	GENE-Y	29	5	Hinokitiol inhibited the phosphorylation of gene, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T28	23473801
NA	CHEMICAL	GENE-N	29	8	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, gene (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T29	23473801
NA	CHEMICAL	GENE-N	29	19	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in gene-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T34	23473801
NA	CHEMICAL	GENE-N	29	15	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (gene), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T32	23473801
NA	CHEMICAL	GENE-N	29	11	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (gene), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T30	23473801
NA	CHEMICAL	GENE-N	29	17	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and gene in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and chemical radical (OH) formation.	T17	T33	23473801
NA	CHEMICAL	GENE-N	26	12	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), gene (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T31	23473801
NA	CHEMICAL	GENE-Y	26	5	Hinokitiol inhibited the phosphorylation of gene, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T28	23473801
NA	CHEMICAL	GENE-N	26	8	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, gene (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T29	23473801
NA	CHEMICAL	GENE-N	26	19	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in gene-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T34	23473801
NA	CHEMICAL	GENE-N	26	15	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (gene), and Akt in collagen-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T32	23473801
NA	CHEMICAL	GENE-N	26	11	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (gene), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T30	23473801
NA	CHEMICAL	GENE-N	26	17	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and gene in collagen-activated human platelets, and significantly reduced intracellular chemical mobilization and hydroxyl radical (OH) formation.	T16	T33	23473801
NA	CHEMICAL	GENE-N	31	12	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), gene (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T31	23473801
NA	CHEMICAL	GENE-Y	31	5	Hinokitiol inhibited the phosphorylation of gene, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T28	23473801
NA	CHEMICAL	GENE-N	31	8	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, gene (PKC), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T29	23473801
NA	CHEMICAL	GENE-N	31	19	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt in gene-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T34	23473801
NA	CHEMICAL	GENE-N	31	15	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (gene), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T32	23473801
NA	CHEMICAL	GENE-N	31	11	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (gene), mitogen-activated protein kinases (MAPKs), and Akt in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T30	23473801
NA	CHEMICAL	GENE-N	31	17	Hinokitiol inhibited the phosphorylation of phospholipase C (PLC)2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and gene in collagen-activated human platelets, and significantly reduced intracellular calcium mobilization and hydroxyl radical (chemical) formation.	T18	T33	23473801
CPR:4	CHEMICAL	GENE-N	0	4	chemical also reduced the gene activation and platelet aggregation stimulated by PDBu.	T19	T35	23473801
NA	CHEMICAL	GENE-Y	0	13	chemical did not influence the binding of a fluorescent triflavin probe to the gene on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.	T3	T21	23473801
NA	CHEMICAL	GENE-Y	26	13	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the gene on platelet membrane, and neither ODQ nor SQ22536 significantly reversed the chemical-mediated inhibition of platelet aggregation.	T6	T21	23473801
NA	CHEMICAL	GENE-Y	22	13	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the gene on platelet membrane, and neither ODQ nor chemical significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.	T5	T21	23473801
NA	CHEMICAL	GENE-Y	20	13	Hinokitiol did not influence the binding of a fluorescent triflavin probe to the gene on platelet membrane, and neither chemical nor SQ22536 significantly reversed the hinokitiol-mediated inhibition of platelet aggregation.	T4	T21	23473801
CPR:4	CHEMICAL	GENE-N	2	22	In conclusion, chemical may inhibit platelet activation by inhibiting the PLC2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of gene and Akt.	T7	T24	23473801
CPR:4	CHEMICAL	GENE-Y	2	10	In conclusion, chemical may inhibit platelet activation by inhibiting the gene-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.	T7	T22	23473801
CPR:4	CHEMICAL	GENE-N	2	10	In conclusion, chemical may inhibit platelet activation by inhibiting the PLC2-gene cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and Akt.	T7	T23	23473801
CPR:4	CHEMICAL	GENE-N	2	24	In conclusion, chemical may inhibit platelet activation by inhibiting the PLC2-PKC cascade and hydroxyl radical formation, followed by suppressing the activation of MAPKs and gene.	T7	T25	23473801
NA	CHEMICAL	GENE-N	13	22	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC2-PKC cascade and chemical radical formation, followed by suppressing the activation of gene and Akt.	T8	T24	23473801
NA	CHEMICAL	GENE-Y	13	10	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the gene-PKC cascade and chemical radical formation, followed by suppressing the activation of MAPKs and Akt.	T8	T22	23473801
NA	CHEMICAL	GENE-N	13	10	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC2-gene cascade and chemical radical formation, followed by suppressing the activation of MAPKs and Akt.	T8	T23	23473801
NA	CHEMICAL	GENE-N	13	24	In conclusion, hinokitiol may inhibit platelet activation by inhibiting the PLC2-PKC cascade and chemical radical formation, followed by suppressing the activation of MAPKs and gene.	T8	T25	23473801
NA	CHEMICAL	GENE-Y	4	12	A series of novel chemical were designed, synthesized and biologically evaluated for gene inhibition.	T3	T5	23474386
NA	CHEMICAL	GENE-Y	4	12	Of the new compounds, Dmt(1)-(R)-Pro(2)-Trp(3)-chemical(4) (analogue 12) displayed the highest affinity toward gene, in the picomolar range (Ki() = 3.72 pM).	T11	T20	23477419
NA	CHEMICAL	GENE-Y	4	12	Of the new compounds, Dmt(1)-chemical(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward gene, in the picomolar range (Ki() = 3.72 pM).	T9	T20	23477419
NA	CHEMICAL	GENE-Y	4	12	Of the new compounds, Dmt(1)-(R)-Pro(2)-chemical(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward gene, in the picomolar range (Ki() = 3.72 pM).	T10	T20	23477419
NA	CHEMICAL	GENE-Y	4	12	Of the new compounds, chemical(1)-(R)-Pro(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward gene, in the picomolar range (Ki() = 3.72 pM).	T8	T20	23477419
NA	CHEMICAL	GENE-Y	37	7	We report that two common variants of gene (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and chemical36 to less frequently used codons.	T3	T5	23478260
NA	CHEMICAL	GENE-Y	37	10	We report that two common variants of high-temperature requirement A1 (gene) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of gene that convert common codons for Ala34 and chemical36 to less frequently used codons.	T3	T6	23478260
NA	CHEMICAL	GENE-Y	37	10	We report that two common variants of high-temperature requirement A1 (gene) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of gene that convert common codons for Ala34 and chemical36 to less frequently used codons.	T3	T7	23478260
NA	CHEMICAL	GENE-Y	35	7	We report that two common variants of gene (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for chemical34 and Gly36 to less frequently used codons.	T2	T5	23478260
NA	CHEMICAL	GENE-Y	35	10	We report that two common variants of high-temperature requirement A1 (gene) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of gene that convert common codons for chemical34 and Gly36 to less frequently used codons.	T2	T6	23478260
NA	CHEMICAL	GENE-Y	35	10	We report that two common variants of high-temperature requirement A1 (gene) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of gene that convert common codons for chemical34 and Gly36 to less frequently used codons.	T2	T7	23478260
NA	CHEMICAL	GENE-Y	0	15	chemical-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1pM BoNT/A despite cleaving <20% of the gene.	T2	T15	23485402
NA	CHEMICAL	GENE-Y	0	9	chemical-sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1pM gene despite cleaving <20% of the SNAP-25.	T2	T14	23485402
NA	CHEMICAL	GENE-N	4	9	Moreover, limited cleavage of SchemicalAP-25 was conferred onto the gene from BochemicalT/E when fused to the chemical-terminus of BochemicalT/A.	T1	T8	23485402
NA	CHEMICAL	GENE-Y	37	5	To understand the role of gene dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and gene(dim/dim) mice administered the potent GC chemical (DEX).	T6	T26	23493372
NA	CHEMICAL	GENE-Y	37	5	To understand the role of gene dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and gene(dim/dim) mice administered the potent GC chemical (DEX).	T6	T27	23493372
NA	CHEMICAL	GENE-Y	38	5	To understand the role of gene dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and gene(dim/dim) mice administered the potent GC dexamethasone (chemical).	T7	T26	23493372
NA	CHEMICAL	GENE-Y	38	5	To understand the role of gene dimerization-dependent targets in multiple tissues, we measured metabolic fluxes through several disease-relevant GC target pathways using heavy water labeling and mass spectrometry in wild-type and gene(dim/dim) mice administered the potent GC dexamethasone (chemical).	T7	T27	23493372
NA	CHEMICAL	GENE-Y	1	9	Absolute chemical synthesis was increased in both wild-type and gene(dim/dim) mice by DEX in the inguinal and epididymal fat depots.	T8	T28	23493372
NA	CHEMICAL	GENE-Y	12	9	Absolute triglyceride synthesis was increased in both wild-type and gene(dim/dim) mice by chemical in the inguinal and epididymal fat depots.	T9	T28	23493372
NA	CHEMICAL	GENE-Y	7	0	gene(dim/dim) mice showed an exaggerated response to chemical in both depots.	T1	T29	23493372
NA	CHEMICAL	GENE-Y	13	15	De novo lipogenesis was also greatly increased in both depots in response to chemical in gene(dim/dim), but not wild-type mice.	T2	T12	23493372
NA	CHEMICAL	GENE-Y	6	20	In contrast, the inhibitory effect of chemical on bone and skin collagen synthesis rates was greater in wild-type compared with gene(dim/dim) mice.	T3	T13	23493372
NA	CHEMICAL	GENE-N	6	9	Wild-type mice were more sensitive to chemical-dependent decreases in gene sensitivity than GR(dim/dim) mice.	T4	T14	23493372
NA	CHEMICAL	GENE-Y	6	12	Wild-type mice were more sensitive to chemical-dependent decreases in insulin sensitivity than gene(dim/dim) mice.	T4	T15	23493372
NA	CHEMICAL	GENE-Y	8	2	Wild-type and gene(dim/dim) mice were equally sensitive to chemical-dependent decreases in muscle protein synthesis.	T5	T16	23493372
NA	CHEMICAL	GENE-Y	34	0	gene (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in -cells has been reported to impair insulin secretion leading to chemical intolerance.	T4	T16	23493568
NA	CHEMICAL	GENE-N	34	30	X-box binding protein 1 (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in -cells has been reported to impair gene secretion leading to chemical intolerance.	T4	T18	23493568
NA	CHEMICAL	GENE-Y	34	30	X-box binding protein 1 (XBP1) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in -cells has been reported to impair gene secretion leading to chemical intolerance.	T4	T18	23493568
NA	CHEMICAL	GENE-Y	34	4	X-box binding protein 1 (gene) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in -cells has been reported to impair insulin secretion leading to chemical intolerance.	T4	T17	23493568
NA	CHEMICAL	GENE-Y	3	13	XBPKO mice exhibited chemical intolerance, mild insulin resistance and an inability to suppress gene secretion following chemical stimulation.	T5	T26	23493568
NA	CHEMICAL	GENE-Y	3	13	XBPKO mice exhibited chemical intolerance, mild insulin resistance and an inability to suppress gene secretion following chemical stimulation.	T6	T26	23493568
NA	CHEMICAL	GENE-N	3	6	XBPKO mice exhibited chemical intolerance, mild gene resistance and an inability to suppress glucagon secretion following chemical stimulation.	T5	T25	23493568
NA	CHEMICAL	GENE-N	3	6	XBPKO mice exhibited chemical intolerance, mild gene resistance and an inability to suppress glucagon secretion following chemical stimulation.	T6	T25	23493568
NA	CHEMICAL	GENE-Y	3	6	XBPKO mice exhibited chemical intolerance, mild gene resistance and an inability to suppress glucagon secretion following chemical stimulation.	T5	T25	23493568
NA	CHEMICAL	GENE-Y	3	6	XBPKO mice exhibited chemical intolerance, mild gene resistance and an inability to suppress glucagon secretion following chemical stimulation.	T6	T25	23493568
NA	CHEMICAL	GENE-Y	3	0	geneKO mice exhibited chemical intolerance, mild insulin resistance and an inability to suppress glucagon secretion following chemical stimulation.	T5	T24	23493568
NA	CHEMICAL	GENE-Y	3	0	geneKO mice exhibited chemical intolerance, mild insulin resistance and an inability to suppress glucagon secretion following chemical stimulation.	T6	T24	23493568
NA	CHEMICAL	GENE-N	7	1	Interestingly, gene treatment of XBPKD cells reduced chemical phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.	T1	T31	23493568
NA	CHEMICAL	GENE-Y	7	1	Interestingly, gene treatment of XBPKD cells reduced chemical phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.	T1	T31	23493568
NA	CHEMICAL	GENE-Y	7	10	Interestingly, insulin treatment of XBPKD cells reduced chemical phosphorylation of gene (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of gene.	T1	T7	23493568
NA	CHEMICAL	GENE-Y	7	10	Interestingly, insulin treatment of XBPKD cells reduced chemical phosphorylation of gene (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of gene.	T1	T9	23493568
NA	CHEMICAL	GENE-Y	7	4	Interestingly, insulin treatment of geneKD cells reduced chemical phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.	T1	T32	23493568
NA	CHEMICAL	GENE-N	7	15	Interestingly, insulin treatment of XBPKD cells reduced chemical phosphorylation of IRS-1 (pY(896)), and phosphorylation of gene, while enhancing serine phosphorylation (pS(307)) of IRS-1.	T1	T8	23493568
NA	CHEMICAL	GENE-N	18	1	Interestingly, gene treatment of XBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing chemical phosphorylation (pS(307)) of IRS-1.	T2	T31	23493568
NA	CHEMICAL	GENE-Y	18	1	Interestingly, gene treatment of XBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing chemical phosphorylation (pS(307)) of IRS-1.	T2	T31	23493568
NA	CHEMICAL	GENE-Y	18	10	Interestingly, insulin treatment of XBPKD cells reduced tyrosine phosphorylation of gene (pY(896)), and phosphorylation of Akt, while enhancing chemical phosphorylation (pS(307)) of gene.	T2	T7	23493568
NA	CHEMICAL	GENE-Y	18	10	Interestingly, insulin treatment of XBPKD cells reduced tyrosine phosphorylation of gene (pY(896)), and phosphorylation of Akt, while enhancing chemical phosphorylation (pS(307)) of gene.	T2	T9	23493568
NA	CHEMICAL	GENE-Y	18	4	Interestingly, insulin treatment of geneKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing chemical phosphorylation (pS(307)) of IRS-1.	T2	T32	23493568
NA	CHEMICAL	GENE-N	18	15	Interestingly, insulin treatment of XBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of gene, while enhancing chemical phosphorylation (pS(307)) of IRS-1.	T2	T8	23493568
NA	CHEMICAL	GENE-Y	18	8	Consequently the XBPKD cells exhibited blunted suppression of gene secretion following insulin treatment in the presence of high chemical.	T3	T11	23493568
NA	CHEMICAL	GENE-N	18	11	Consequently the XBPKD cells exhibited blunted suppression of glucagon secretion following gene treatment in the presence of high chemical.	T3	T12	23493568
NA	CHEMICAL	GENE-Y	18	11	Consequently the XBPKD cells exhibited blunted suppression of glucagon secretion following gene treatment in the presence of high chemical.	T3	T12	23493568
NA	CHEMICAL	GENE-Y	18	2	Consequently the geneKD cells exhibited blunted suppression of glucagon secretion following insulin treatment in the presence of high chemical.	T3	T10	23493568
NA	CHEMICAL	GENE-N	38	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; chemical was included as the classical non-endogenous gene ligand.	T11	T26	23494106
NA	CHEMICAL	GENE-N	17	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four chemical compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T4	T26	23494106
NA	CHEMICAL	GENE-N	27	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one chemical (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T9	T26	23494106
NA	CHEMICAL	GENE-N	19	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (chemical, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T5	T26	23494106
NA	CHEMICAL	GENE-N	23	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and chemical) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T8	T26	23494106
NA	CHEMICAL	GENE-N	20	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, chemical, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T6	T26	23494106
NA	CHEMICAL	GENE-N	21	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, chemical and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T7	T26	23494106
NA	CHEMICAL	GENE-N	28	45	Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (chemical) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous gene ligand.	T10	T26	23494106
NA	CHEMICAL	GENE-N	22	4	Furthermore, no impact on gene release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and IL-12/23p40.	T1	T17	23494106
NA	CHEMICAL	GENE-Y	22	8	Furthermore, no impact on cytokine release (i.e., on gene, IL-6, IL-12/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and IL-12/23p40.	T1	T18	23494106
NA	CHEMICAL	GENE-N	22	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, gene/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and gene/23p40.	T1	T20	23494106
CPR:4	CHEMICAL	GENE-N	22	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, gene/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and gene/23p40.	T1	T24	23494106
NA	CHEMICAL	GENE-Y	22	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/gene and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and IL-12/gene.	T1	T21	23494106
CPR:4	CHEMICAL	GENE-Y	22	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/gene and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and IL-12/gene.	T1	T25	23494106
NA	CHEMICAL	GENE-Y	22	12	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and gene levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of gene and IL-12/23p40.	T1	T22	23494106
CPR:4	CHEMICAL	GENE-Y	22	12	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and gene levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of gene and IL-12/23p40.	T1	T23	23494106
NA	CHEMICAL	GENE-Y	22	9	Furthermore, no impact on cytokine release (i.e., on IL-10, gene, IL-12/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with chemical and JWH-122 which caused a decrease of TNF and IL-12/23p40.	T1	T19	23494106
NA	CHEMICAL	GENE-N	24	4	Furthermore, no impact on gene release (i.e., on IL-10, IL-6, IL-12/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and IL-12/23p40.	T2	T17	23494106
NA	CHEMICAL	GENE-Y	24	8	Furthermore, no impact on cytokine release (i.e., on gene, IL-6, IL-12/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and IL-12/23p40.	T2	T18	23494106
NA	CHEMICAL	GENE-N	24	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, gene/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and gene/23p40.	T2	T20	23494106
CPR:4	CHEMICAL	GENE-N	24	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, gene/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and gene/23p40.	T2	T24	23494106
NA	CHEMICAL	GENE-Y	24	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/gene and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and IL-12/gene.	T2	T21	23494106
CPR:4	CHEMICAL	GENE-Y	24	10	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/gene and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and IL-12/gene.	T2	T25	23494106
NA	CHEMICAL	GENE-Y	24	12	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and gene levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of gene and IL-12/23p40.	T2	T22	23494106
CPR:4	CHEMICAL	GENE-Y	24	12	Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and gene levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of gene and IL-12/23p40.	T2	T23	23494106
NA	CHEMICAL	GENE-Y	24	9	Furthermore, no impact on cytokine release (i.e., on IL-10, gene, IL-12/23p40 and TNF levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and chemical which caused a decrease of TNF and IL-12/23p40.	T2	T19	23494106
NA	CHEMICAL	GENE-Y	11	22	In this randomized double-blind placebo-controlled cross-over trial, the effects of a chemical supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to gene (anti-gene) and oxLDL (anti-oxLDL) were investigated.	T3	T7	23494802
NA	CHEMICAL	GENE-Y	11	22	In this randomized double-blind placebo-controlled cross-over trial, the effects of a chemical supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to gene (anti-gene) and oxLDL (anti-oxLDL) were investigated.	T3	T8	23494802
NA	CHEMICAL	GENE-N	11	25	In this randomized double-blind placebo-controlled cross-over trial, the effects of a chemical supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-Hsp27) and gene (anti-gene) were investigated.	T3	T10	23494802
NA	CHEMICAL	GENE-N	11	25	In this randomized double-blind placebo-controlled cross-over trial, the effects of a chemical supplement on serum pro-oxidant-antioxidant balance (PAB) and antibody titres to Hsp27 (anti-Hsp27) and gene (anti-gene) were investigated.	T3	T9	23494802
CPR:4	CHEMICAL	GENE-Y	0	13	chemical markedly reduced AA performance and activities of cytochrome c oxidase (COX) and gene (AChE) in all regions.	T9	T20	23494944
CPR:4	CHEMICAL	GENE-N	0	8	chemical markedly reduced AA performance and activities of gene (COX) and acetylcholinesterase (AChE) in all regions.	T9	T18	23494944
CPR:4	CHEMICAL	GENE-Y	0	14	chemical markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (gene) in all regions.	T9	T21	23494944
CPR:4	CHEMICAL	GENE-N	0	11	chemical markedly reduced AA performance and activities of cytochrome c oxidase (gene) and acetylcholinesterase (AChE) in all regions.	T9	T19	23494944
NA	CHEMICAL	GENE-Y	12	19	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and chemical dismutase activity, markedly corrected COX and gene activities, and moderately improved TGC.	T2	T15	23494944
NA	CHEMICAL	GENE-N	12	17	GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and chemical dismutase activity, markedly corrected gene and AChE activities, and moderately improved TGC.	T2	T14	23494944
CPR:4	CHEMICAL	GENE-N	8	12	GTLE pretreatment completely reversed the damaging effects of chemical on AA and gene activity, markedly corrected COX and AChE activities, and moderately improved TGC.	T11	T13	23494944
CPR:4	CHEMICAL	GENE-Y	8	19	GTLE pretreatment completely reversed the damaging effects of chemical on AA and superoxide dismutase activity, markedly corrected COX and gene activities, and moderately improved TGC.	T11	T15	23494944
CPR:4	CHEMICAL	GENE-N	8	17	GTLE pretreatment completely reversed the damaging effects of chemical on AA and superoxide dismutase activity, markedly corrected gene and AChE activities, and moderately improved TGC.	T11	T14	23494944
NA	CHEMICAL	GENE-Y	16	6	By modulating expression levels of endogenous gene in primary cortical neurons, the frequency and amplitude of chemical oscillations is modified, implying a key role for gene in maintaining neuronal chemical homeostasis essential for synaptic transmission.	T1	T18	23495999
NA	CHEMICAL	GENE-Y	16	6	By modulating expression levels of endogenous gene in primary cortical neurons, the frequency and amplitude of chemical oscillations is modified, implying a key role for gene in maintaining neuronal chemical homeostasis essential for synaptic transmission.	T1	T20	23495999
NA	CHEMICAL	GENE-Y	16	6	By modulating expression levels of endogenous gene in primary cortical neurons, the frequency and amplitude of chemical oscillations is modified, implying a key role for gene in maintaining neuronal chemical homeostasis essential for synaptic transmission.	T2	T18	23495999
NA	CHEMICAL	GENE-Y	16	6	By modulating expression levels of endogenous gene in primary cortical neurons, the frequency and amplitude of chemical oscillations is modified, implying a key role for gene in maintaining neuronal chemical homeostasis essential for synaptic transmission.	T2	T20	23495999
NA	CHEMICAL	GENE-Y	2	14	Furthermore, the chemical (11) selectively induced apoptosis in A549 cells without affecting the gene activity level.	T4	T6	23499825
NA	CHEMICAL	GENE-Y	7	18	Female C57BL/6 mice were exposed to dextran chemical (DSS) and treated by intrarectal administration with either CD.siRNA gene or a control solution.	T1	T17	23500058
NA	CHEMICAL	GENE-Y	14	16	The present study aimed to determine the protective effects and the underlying mechanisms of chemical on gene (OVA)-induced allergic inflammation in a mouse model of allergic asthma.	T10	T12	23500387
NA	CHEMICAL	GENE-Y	14	17	The present study aimed to determine the protective effects and the underlying mechanisms of chemical on ovalbumin (gene)-induced allergic inflammation in a mouse model of allergic asthma.	T10	T14	23500387
NA	CHEMICAL	GENE-N	27	36	Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by chemical and eosin (HE) staining, BALF levels of Treg/Th17 gene were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	T7	T17	23500387
NA	CHEMICAL	GENE-N	29	36	Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright-Giemsa staining, histological assessment was measured by hematoxylin and chemical (HE) staining, BALF levels of Treg/Th17 gene were measured by enzyme-linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	T8	T17	23500387
CPR:4	CHEMICAL	GENE-Y	4	11	Our study demonstrated that chemical inhibited OVA-induced increases in eosinophil count; gene level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.	T9	T19	23500387
CPR:3	CHEMICAL	GENE-Y	4	21	Our study demonstrated that chemical inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased gene level in bronchoalveolar lavage fluid.	T9	T20	23500387
CPR:4	CHEMICAL	GENE-Y	4	6	Our study demonstrated that chemical inhibited gene-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.	T9	T18	23500387
CPR:4	CHEMICAL	GENE-Y	4	7	Histological studies demonstrated that chemical substantially inhibited gene-induced eosinophilia in lung tissue.	T1	T13	23500387
CPR:4	CHEMICAL	GENE-Y	10	5	The results in vivo show gene-induced significantly broke Treg/Th17 balance; chemical treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.	T3	T15	23500387
NA	CHEMICAL	GENE-N	17	5	Kinesin superfamily proteins (KIFs) are gene driven by the energy derived from the hydrolysis of chemical.	T1	T22	23500491
NA	CHEMICAL	GENE-N	17	0	gene (KIFs) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of chemical.	T1	T13	23500491
NA	CHEMICAL	GENE-N	17	3	Kinesin superfamily proteins (gene) are microtubule-based molecular motors driven by the energy derived from the hydrolysis of chemical.	T1	T19	23500491
NA	CHEMICAL	GENE-N	6	34	Previous studies have revealed that the chemical binding step is crucial both for the power stroke to produce motility and for the inter-domain regulation of chemicalase activity to guarantee the processive movement of dimeric gene.	T2	T20	23500491
NA	CHEMICAL	GENE-Y	16	8	Here, we report the first crystal structure of gene complexed with the non-hydrolyzable ATP analog, AMPPNP (chemical), at 1.7 resolution.	T5	T21	23500491
NA	CHEMICAL	GENE-Y	15	8	Here, we report the first crystal structure of gene complexed with the non-hydrolyzable ATP analog, chemical (adenylyl imidodiphosphate), at 1.7 resolution.	T4	T21	23500491
NA	CHEMICAL	GENE-Y	13	8	Here, we report the first crystal structure of gene complexed with the non-hydrolyzable chemical analog, AMPPNP (adenylyl imidodiphosphate), at 1.7 resolution.	T3	T21	23500491
NA	CHEMICAL	GENE-Y	25	7	By combining our structure with previously solved gene structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the chemical-binding pocket during ATP binding is achieved by closure of the backdoor.	T8	T23	23500491
NA	CHEMICAL	GENE-Y	12	7	By combining our structure with previously solved gene structures complexed with two chemical analogs, molecular snapshots during chemical binding reveal that the closure of the nucleotide-binding pocket during chemical binding is achieved by closure of the backdoor.	T6	T23	23500491
NA	CHEMICAL	GENE-Y	12	7	By combining our structure with previously solved gene structures complexed with two chemical analogs, molecular snapshots during chemical binding reveal that the closure of the nucleotide-binding pocket during chemical binding is achieved by closure of the backdoor.	T7	T23	23500491
NA	CHEMICAL	GENE-Y	12	7	By combining our structure with previously solved gene structures complexed with two chemical analogs, molecular snapshots during chemical binding reveal that the closure of the nucleotide-binding pocket during chemical binding is achieved by closure of the backdoor.	T9	T23	23500491
NA	CHEMICAL	GENE-Y	14	15	Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that chemical-terminal gene peptides might be considered a promising bone anabolic therapy.	T3	T16	23500550
NA	CHEMICAL	GENE-Y	14	6	In addition, putative osteogenic actions of gene might be ascribed not only to its chemical-terminal domain but also to its PTH-unrelated C-terminal region.	T1	T17	23500550
NA	CHEMICAL	GENE-Y	14	6	In addition, putative osteogenic actions of generP might be ascribed not only to its chemical-terminal domain but also to its gene-unrelated C-terminal region.	T1	T4	23500550
NA	CHEMICAL	GENE-Y	21	6	In addition, putative osteogenic actions of gene might be ascribed not only to its N-terminal domain but also to its PTH-unrelated chemical-terminal region.	T2	T17	23500550
NA	CHEMICAL	GENE-Y	21	6	In addition, putative osteogenic actions of generP might be ascribed not only to its N-terminal domain but also to its gene-unrelated chemical-terminal region.	T2	T4	23500550
NA	CHEMICAL	GENE-Y	3	4	While studies of chemical, gene, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics.	T1	T3	23504356
NA	CHEMICAL	GENE-Y	33	22	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, gene (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T13	23510370
NA	CHEMICAL	GENE-Y	33	37	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), gene (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T23	23510370
NA	CHEMICAL	GENE-Y	33	21	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, gene, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T12	23510370
NA	CHEMICAL	GENE-Y	33	20	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for gene, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the gene gene by in situ hybridization analysis.	T1	T11	23510370
NA	CHEMICAL	GENE-Y	33	20	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for gene, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the gene gene by in situ hybridization analysis.	T1	T2	23510370
NA	CHEMICAL	GENE-N	33	26	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), gene (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T17	23510370
NA	CHEMICAL	GENE-Y	33	31	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, gene, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T20	23510370
NA	CHEMICAL	GENE-Y	33	25	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/gene/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T15	23510370
NA	CHEMICAL	GENE-Y	33	25	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/gene), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T16	23510370
NA	CHEMICAL	GENE-Y	33	25	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (gene/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T14	23510370
NA	CHEMICAL	GENE-Y	33	43	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and gene (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T25	23510370
NA	CHEMICAL	GENE-Y	33	44	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (gene), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T26	23510370
NA	CHEMICAL	GENE-Y	33	29	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, gene, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T19	23510370
NA	CHEMICAL	GENE-Y	33	41	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (gene) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T24	23510370
NA	CHEMICAL	GENE-Y	33	36	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (CK) AE1/AE3, CK 7, pendrin, human chemical symporter (gene), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T22	23510370
NA	CHEMICAL	GENE-N	33	27	The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for thyroglobulin, thyroperoxidase, thyroid transcription factor-1 (TTF-1/Titf-1/Nkx2.1), cytokeratin (gene) AE1/AE3, gene 7, pendrin, human chemical symporter (hNIS), paired box gene 8 (PAX8) and FOXE1 (TTF-2), as well as positivity for the messenger RNA of the thyroglobulin gene by in situ hybridization analysis.	T1	T18	23510370
NA	CHEMICAL	GENE-N	25	37	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with chemical, which is a widely used proton pump inhibitor that binds to gene in the stomach and colon.	T3	T10	23511016
CPR:4	CHEMICAL	GENE-N	25	31	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with chemical, which is a widely used gene inhibitor that binds to genes in the stomach and colon.	T3	T9	23511016
NA	CHEMICAL	GENE-N	23	37	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (chemical), with pantoprazole, which is a widely used proton pump inhibitor that binds to gene in the stomach and colon.	T2	T10	23511016
CPR:4	CHEMICAL	GENE-N	23	31	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (chemical), with pantoprazole, which is a widely used gene inhibitor that binds to genes in the stomach and colon.	T2	T9	23511016
NA	CHEMICAL	GENE-N	14	37	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a chemical-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to gene in the stomach and colon.	T1	T10	23511016
CPR:4	CHEMICAL	GENE-N	14	31	To overcome this limitation, we de novo synthesized a conjugate that covalently combines a chemical-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used gene inhibitor that binds to genes in the stomach and colon.	T1	T9	23511016
NA	CHEMICAL	GENE-N	5	7	The involvement of brain nicotinic chemical receptors (gene) in the neurotoxicological effects of soman, a potent chemicalsterase (AChE) inhibitor and a chemical warfare agent, is not clear.	T8	T22	23511125
NA	CHEMICAL	GENE-Y	5	17	The involvement of brain nicotinic chemical receptors (nAChRs) in the neurotoxicological effects of soman, a potent chemicalsterase (gene) inhibitor and a chemical warfare agent, is not clear.	T8	T14	23511125
NA	CHEMICAL	GENE-N	9	16	To test the hypothesis that AChE inhibition builds sufficient chemical (ACh) in the brain and facilitates gene-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	T9	T21	23511125
NA	CHEMICAL	GENE-Y	9	5	To test the hypothesis that gene inhibition builds sufficient chemical (ACh) in the brain and facilitates nAChR-dependent glutamate transmission, we used whole-cell patch-clamp technique to record spontaneous glutamate excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	T9	T20	23511125
NA	CHEMICAL	GENE-N	17	16	To test the hypothesis that AChE inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates gene-dependent chemical transmission, we used whole-cell patch-clamp technique to record spontaneous chemical excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	T10	T21	23511125
NA	CHEMICAL	GENE-N	17	16	To test the hypothesis that AChE inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates gene-dependent chemical transmission, we used whole-cell patch-clamp technique to record spontaneous chemical excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	T11	T21	23511125
NA	CHEMICAL	GENE-Y	17	5	To test the hypothesis that gene inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates nAChR-dependent chemical transmission, we used whole-cell patch-clamp technique to record spontaneous chemical excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	T10	T20	23511125
NA	CHEMICAL	GENE-Y	17	5	To test the hypothesis that gene inhibition builds sufficient acetylcholine (ACh) in the brain and facilitates nAChR-dependent chemical transmission, we used whole-cell patch-clamp technique to record spontaneous chemical excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	T11	T20	23511125
CPR:4	CHEMICAL	GENE-Y	18	16	Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible gene inhibitor chemical (100nM).	T1	T24	23511125
NA	CHEMICAL	GENE-N	13	12	These results support the concept that AChE inhibition is able to recruit gene-dependent chemical transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of soman.	T7	T16	23511125
NA	CHEMICAL	GENE-Y	13	6	These results support the concept that gene inhibition is able to recruit nAChR-dependent chemical transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of soman.	T7	T15	23511125
NA	CHEMICAL	GENE-N	25	14	The objective of the study was to establish an in vivo method for assessing gene (CYP3A) activity using therapeutically inert nanogram doses of chemical.	T3	T18	23511711
NA	CHEMICAL	GENE-Y	25	17	The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (gene) activity using therapeutically inert nanogram doses of chemical.	T3	T19	23511711
NA	CHEMICAL	GENE-N	25	17	The objective of the study was to establish an in vivo method for assessing cytochrome P450 3A (gene) activity using therapeutically inert nanogram doses of chemical.	T3	T19	23511711
NA	CHEMICAL	GENE-Y	8	17	We administered four escalating single doses of oral chemical (0.0001-3mg) to 12 healthy participants, stratified according to gene carrier status, to assess pharmacokinetics linearity.	T4	T15	23511711
CPR:4	CHEMICAL	GENE-Y	9	7	We then evaluated the interactions with the gene inhibitor chemical (400mg q.d.)	T5	T16	23511711
CPR:4	CHEMICAL	GENE-N	9	7	We then evaluated the interactions with the gene inhibitor chemical (400mg q.d.)	T5	T16	23511711
CPR:4	CHEMICAL	GENE-Y	14	0	gene carrier status had no influence on midazolam oral clearance or its inhibition by chemical.	T10	T17	23511711
CPR:9	CHEMICAL	GENE-Y	7	0	gene carrier status had no influence on chemical oral clearance or its inhibition by ketoconazole.	T9	T17	23511711
NA	CHEMICAL	GENE-Y	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T11	T13	23511711
NA	CHEMICAL	GENE-Y	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T11	T14	23511711
NA	CHEMICAL	GENE-Y	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T1	T13	23511711
NA	CHEMICAL	GENE-Y	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T1	T14	23511711
NA	CHEMICAL	GENE-Y	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T2	T13	23511711
NA	CHEMICAL	GENE-Y	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T2	T14	23511711
NA	CHEMICAL	GENE-N	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T11	T13	23511711
NA	CHEMICAL	GENE-N	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T11	T14	23511711
NA	CHEMICAL	GENE-N	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T1	T13	23511711
NA	CHEMICAL	GENE-N	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T1	T14	23511711
NA	CHEMICAL	GENE-N	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T2	T13	23511711
NA	CHEMICAL	GENE-N	7	41	This is the first study showing that chemical pharmacokinetics is linear in a 30,000-fold concentration range, and therefore that nano- and microgram doses of chemical can reliably predict the pharmacokinetics of chemical in therapeutic doses and can be used to assess gene activity even in the presence of strong gene inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038/clpt.2013.27.	T2	T14	23511711
CPR:9	CHEMICAL	GENE-N	12	6	It is possible that variations in gene enzyme-mediated metabolism of chemical may contribute to this phenomenon.	T4	T14	23512537
NA	CHEMICAL	GENE-Y	19	34	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of chemical in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the gene in lung and liver cells.	T5	T18	23512537
NA	CHEMICAL	GENE-N	19	9	This hypothesis was explored by evaluating the contributions of gene, and esterase enzymes in the metabolism of chemical in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.	T5	T15	23512537
CPR:9	CHEMICAL	GENE-N	19	13	This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and gene enzymes in the metabolism of chemical in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.	T5	T16	23512537
NA	CHEMICAL	GENE-N	19	9	This hypothesis was explored by evaluating the contributions of gene4, 3A5, 3A7, and esterase enzymes in the metabolism of chemical in vitro and relating metabolism to changes in gene enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.	T5	T17	23512537
CPR:9	CHEMICAL	GENE-Y	4	0	gene and CYP3A5 metabolized chemical via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize chemical.	T7	T19	23512537
NA	CHEMICAL	GENE-Y	4	0	gene and CYP3A5 metabolized chemical via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize chemical.	T8	T19	23512537
NA	CHEMICAL	GENE-Y	4	16	CYP3A4 and CYP3A5 metabolized chemical via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; gene did not metabolize chemical.	T7	T21	23512537
NA	CHEMICAL	GENE-Y	4	16	CYP3A4 and CYP3A5 metabolized chemical via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; gene did not metabolize chemical.	T8	T21	23512537
CPR:9	CHEMICAL	GENE-Y	4	2	CYP3A4 and gene metabolized chemical via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize chemical.	T7	T20	23512537
NA	CHEMICAL	GENE-Y	4	2	CYP3A4 and gene metabolized chemical via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize chemical.	T8	T20	23512537
CPR:9	CHEMICAL	GENE-Y	8	4	These studies show that gene and CYP3A5 metabolize chemical to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence chemical disposition in humans.	T1	T11	23512537
NA	CHEMICAL	GENE-Y	8	4	These studies show that gene and CYP3A5 metabolize chemical to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence chemical disposition in humans.	T2	T11	23512537
CPR:9	CHEMICAL	GENE-Y	8	6	These studies show that CYP3A4 and gene metabolize chemical to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence chemical disposition in humans.	T1	T12	23512537
NA	CHEMICAL	GENE-Y	8	6	These studies show that CYP3A4 and gene metabolize chemical to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence chemical disposition in humans.	T2	T12	23512537
NA	CHEMICAL	GENE-N	4	20	The antiherpetic action of chemical was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the gene production using a bioassay and ELISA method.	T8	T16	23512754
CPR:3	CHEMICAL	GENE-Y	13	9	In macrophages, levels of TNF-, IFN-, NO, IL-6 and gene were increased by chemical used alone or in combination with HSV-2.	T11	T20	23512754
CPR:3	CHEMICAL	GENE-Y	13	5	In macrophages, levels of TNF-, gene, NO, IL-6 and IL-10 were increased by chemical used alone or in combination with HSV-2.	T11	T18	23512754
CPR:3	CHEMICAL	GENE-Y	13	4	In macrophages, levels of gene, IFN-, NO, IL-6 and IL-10 were increased by chemical used alone or in combination with HSV-2.	T11	T17	23512754
CPR:3	CHEMICAL	GENE-Y	13	7	In macrophages, levels of TNF-, IFN-, NO, gene and IL-10 were increased by chemical used alone or in combination with HSV-2.	T11	T19	23512754
CPR:3	CHEMICAL	GENE-Y	1	9	Besides, chemical not only synergized TNF- production combined with gene, but also prolonged its expression in time.	T1	T14	23512754
CPR:3	CHEMICAL	GENE-Y	1	5	Besides, chemical not only synergized gene production combined with IFN-, but also prolonged its expression in time.	T1	T13	23512754
CPR:3	CHEMICAL	GENE-N	3	13	Results indicate that chemical inhibits HSV-2 multiplication in epithelial cells and also increases gene production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.	T2	T15	23512754
CPR:4	CHEMICAL	GENE-Y	20	18	A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an gene inhibitor, chemical.	T2	T7	23517558
NA	CHEMICAL	GENE-Y	7	34	Sixty one compounds, grouped as the 6H, chemical, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced gene (TNF-) production by these cells.	T14	T20	23517733
NA	CHEMICAL	GENE-N	7	19	Sixty one compounds, grouped as the 6H, chemical, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on gene (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-) production by these cells.	T14	T18	23517733
NA	CHEMICAL	GENE-Y	7	38	Sixty one compounds, grouped as the 6H, chemical, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (gene) production by these cells.	T14	T21	23517733
NA	CHEMICAL	GENE-N	7	21	Sixty one compounds, grouped as the 6H, chemical, 6-acylaminoalkyl and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (gene)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-) production by these cells.	T14	T19	23517733
NA	CHEMICAL	GENE-Y	10	34	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and chemical derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced gene (TNF-) production by these cells.	T16	T20	23517733
NA	CHEMICAL	GENE-N	10	19	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and chemical derivatives, were tested for cytotoxicity, their effects on gene (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-) production by these cells.	T16	T18	23517733
NA	CHEMICAL	GENE-Y	10	38	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and chemical derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (gene) production by these cells.	T16	T21	23517733
NA	CHEMICAL	GENE-N	10	21	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, 6-acylaminoalkyl and chemical derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (gene)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-) production by these cells.	T16	T19	23517733
NA	CHEMICAL	GENE-Y	8	34	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, chemical and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced gene (TNF-) production by these cells.	T15	T20	23517733
NA	CHEMICAL	GENE-N	8	19	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, chemical and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on gene (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-) production by these cells.	T15	T18	23517733
NA	CHEMICAL	GENE-Y	8	38	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, chemical and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (PHA)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (gene) production by these cells.	T15	T21	23517733
NA	CHEMICAL	GENE-N	8	21	Sixty one compounds, grouped as the 6H, 6-dialkylaminoalkyl, chemical and sulfonylaminoalkyl derivatives, were tested for cytotoxicity, their effects on phytohemagglutin A (gene)-induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-) production by these cells.	T15	T19	23517733
NA	CHEMICAL	GENE-Y	0	8	chemical was shown to induce rapid oncosis in gene-expressing cells.	T9	T24	23519149
NA	CHEMICAL	GENE-Y	4	15	We have shown that chemical is more active in cells harboring epithelial phenotype with high gene and low vimentin expression.	T14	T25	23519149
NA	CHEMICAL	GENE-Y	4	18	We have shown that chemical is more active in cells harboring epithelial phenotype with high E-cadherin and low gene expression.	T14	T26	23519149
NA	CHEMICAL	GENE-Y	12	3	In addition, high gene and Muc1 expression was correlated with sensitivity to chemical, whereas the presence of KRAS activating mutations was associated with resistance.	T16	T27	23519149
NA	CHEMICAL	GENE-Y	12	5	In addition, high ErbB3 and gene expression was correlated with sensitivity to chemical, whereas the presence of KRAS activating mutations was associated with resistance.	T16	T28	23519149
NA	CHEMICAL	GENE-Y	12	17	In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to chemical, whereas the presence of gene activating mutations was associated with resistance.	T16	T29	23519149
CPR:4	CHEMICAL	GENE-Y	7	8	In DU-PM cells with acquired resistance to chemical, gene expression was decreased, while Bcl2 was increased.	T2	T19	23519149
CPR:3	CHEMICAL	GENE-Y	7	13	In DU-PM cells with acquired resistance to chemical, ErbB3 expression was decreased, while gene was increased.	T2	T20	23519149
NA	CHEMICAL	GENE-Y	6	0	gene is a well known P/Q-type chemical channel blocker and has been shown to affect presynaptic chemical currents as well postsynaptic potentials.	T1	T5	23523780
NA	CHEMICAL	GENE-Y	6	0	gene is a well known P/Q-type chemical channel blocker and has been shown to affect presynaptic chemical currents as well postsynaptic potentials.	T4	T5	23523780
CPR:4	CHEMICAL	GENE-N	2	11	Administration of chemical, a GABAA inhibitor, isolated a single response to gene, which was characterized by a reduction in network activity.	T2	T7	23523780
CPR:4	CHEMICAL	GENE-N	2	4	Administration of chemical, a gene inhibitor, isolated a single response to -agatoxin, which was characterized by a reduction in network activity.	T2	T6	23523780
NA	CHEMICAL	GENE-Y	33	34	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of silver stain or reduced immunolabeling of chemical-hydroxylase-positive (gene(+)) neurons.	T16	T24	23523781
NA	CHEMICAL	GENE-Y	27	33	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of chemical stain or reduced immunolabeling of gene-positive (TH(+)) neurons.	T15	T23	23523781
NA	CHEMICAL	GENE-Y	27	34	There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of chemical stain or reduced immunolabeling of tyrosine-hydroxylase-positive (gene(+)) neurons.	T15	T24	23523781
NA	CHEMICAL	GENE-Y	33	10	This study also suggests that even if the reduction in gene(+) neurons reported by others occurs in PQ-treated mice, this apparent phenotypic change is unaccompanied by neuronal cell death or by modification of chemical levels in the striatum.	T6	T21	23523781
CPR:4	CHEMICAL	GENE-N	16	23	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the chemical group at the CAP moiety as gene (HDAC) inhibitors.	T1	T10	23526814
CPR:4	CHEMICAL	GENE-N	16	25	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the chemical group at the CAP moiety as histone deacetylase (gene) inhibitors.	T1	T11	23526814
CPR:4	CHEMICAL	GENE-N	11	23	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and chemical (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as gene (HDAC) inhibitors.	T8	T10	23526814
CPR:4	CHEMICAL	GENE-N	11	25	Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and chemical (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (gene) inhibitors.	T8	T11	23526814
CPR:4	CHEMICAL	GENE-N	7	23	Herein we report novel pyrrole- and benzene-based chemical (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as gene (HDAC) inhibitors.	T6	T10	23526814
CPR:4	CHEMICAL	GENE-N	7	25	Herein we report novel pyrrole- and benzene-based chemical (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (gene) inhibitors.	T6	T11	23526814
CPR:4	CHEMICAL	GENE-N	6	23	Herein we report novel pyrrole- and chemical-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as gene (HDAC) inhibitors.	T4	T10	23526814
CPR:4	CHEMICAL	GENE-N	6	25	Herein we report novel pyrrole- and chemical-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (gene) inhibitors.	T4	T11	23526814
CPR:4	CHEMICAL	GENE-N	4	23	Herein we report novel chemical- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as gene (HDAC) inhibitors.	T2	T10	23526814
CPR:4	CHEMICAL	GENE-N	4	25	Herein we report novel chemical- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (gene) inhibitors.	T2	T11	23526814
CPR:3	CHEMICAL	GENE-N	14	19	Compounds 8b and 10c selectively inhibited HDAC6 at the nanomolar level, whereas the other chemical effected an increase in gene levels in human acute myeloid leukemia U937 cells.	T3	T13	23526814
NA	CHEMICAL	GENE-Y	14	6	Compounds 8b and 10c selectively inhibited gene at the nanomolar level, whereas the other chemical effected an increase in acetyl--tubulin levels in human acute myeloid leukemia U937 cells.	T3	T12	23526814
CPR:4	CHEMICAL	GENE-Y	0	5	chemical is the first synthetic gene inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.	T5	T8	23528299
CPR:4	CHEMICAL	GENE-Y	8	4	As a potent synthetic gene inhibitor (IC50=850nM, versus chemical of 8.1M), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than chemical.	T1	T9	23528299
CPR:4	CHEMICAL	GENE-Y	8	4	As a potent synthetic gene inhibitor (IC50=850nM, versus chemical of 8.1M), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than chemical.	T3	T9	23528299
CPR:4	CHEMICAL	GENE-Y	11	4	As a potent synthetic gene inhibitor (IC50=850nM, versus bestatin of 8.1M), chemical was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.	T2	T9	23528299
CPR:9	CHEMICAL	GENE-N	12	5	Both types of granules contain gene that catalyzes oxidative cross-linking of chemical.	T2	T12	23530959
NA	CHEMICAL	GENE-N	2	4	With no chemical kinases (gene) play important roles in plant growth and development.	T10	T18	23535337
NA	CHEMICAL	GENE-Y	21	4	Here, we report that gene is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by NaCl and chemical treatment.	T3	T17	23535337
NA	CHEMICAL	GENE-Y	19	4	Here, we report that gene is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by chemical and sorbitol treatment.	T2	T17	23535337
NA	CHEMICAL	GENE-Y	31	7	Compared to the wild-type, the T-DNA knock-out gene mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the NaCl and chemical treatment, respectively.	T5	T19	23535337
NA	CHEMICAL	GENE-Y	29	7	Compared to the wild-type, the T-DNA knock-out gene mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the chemical and sorbitol treatment, respectively.	T4	T19	23535337
NA	CHEMICAL	GENE-Y	13	1	The gene mutant also accumulated 1.43-fold more proline than the wild-type in the chemical treatment.	T7	T20	23535337
NA	CHEMICAL	GENE-Y	7	1	The gene mutant also accumulated 1.43-fold more chemical than the wild-type in the sorbitol treatment.	T6	T20	23535337
CPR:3	CHEMICAL	GENE-N	3	5	Under NaCl and chemical stresses, gene (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	T9	T21	23535337
NA	CHEMICAL	GENE-Y	3	9	Under NaCl and chemical stresses, catalase (CAT) activity in gene mutant was 1.92- and 3.7-times of that in Col-0, respectively.	T9	T23	23535337
CPR:3	CHEMICAL	GENE-N	3	6	Under NaCl and chemical stresses, catalase (gene) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	T9	T22	23535337
CPR:3	CHEMICAL	GENE-N	1	5	Under chemical and sorbitol stresses, gene (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	T8	T21	23535337
NA	CHEMICAL	GENE-Y	1	9	Under chemical and sorbitol stresses, catalase (CAT) activity in gene mutant was 1.92- and 3.7-times of that in Col-0, respectively.	T8	T23	23535337
CPR:3	CHEMICAL	GENE-N	1	6	Under chemical and sorbitol stresses, catalase (gene) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.	T8	T22	23535337
NA	CHEMICAL	GENE-Y	31	21	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of gene enhances the tolerance to salt stress, and accumulating more chemical and higher activities of CAT and POD might result in the higher tolerance of WNK8 to osmotic stress.	T1	T13	23535337
NA	CHEMICAL	GENE-Y	31	21	Taken together, we revealed that maintaining higher CAT and POD activities might be one of the reasons that the disruption of Atgene enhances the tolerance to salt stress, and accumulating more chemical and higher activities of CAT and POD might result in the higher tolerance of gene to osmotic stress.	T1	T16	23535337
NA	CHEMICAL	GENE-N	31	7	Taken together, we revealed that maintaining higher gene and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more chemical and higher activities of gene and POD might result in the higher tolerance of WNK8 to osmotic stress.	T1	T14	23535337
NA	CHEMICAL	GENE-N	31	7	Taken together, we revealed that maintaining higher gene and POD activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more chemical and higher activities of gene and POD might result in the higher tolerance of WNK8 to osmotic stress.	T1	T27	23535337
NA	CHEMICAL	GENE-N	31	9	Taken together, we revealed that maintaining higher CAT and gene activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more chemical and higher activities of CAT and gene might result in the higher tolerance of WNK8 to osmotic stress.	T1	T15	23535337
NA	CHEMICAL	GENE-N	31	9	Taken together, we revealed that maintaining higher CAT and gene activities might be one of the reasons that the disruption of AtWNK8 enhances the tolerance to salt stress, and accumulating more chemical and higher activities of CAT and gene might result in the higher tolerance of WNK8 to osmotic stress.	T1	T28	23535337
CPR:4	CHEMICAL	GENE-Y	7	12	Immunofluorescence staining and western blotting demonstrated that chemical treatment reduced GFAP and gene expression in the retinas of OLETF rats.	T7	T10	23536314
CPR:4	CHEMICAL	GENE-Y	7	10	Immunofluorescence staining and western blotting demonstrated that chemical treatment reduced gene and VEGF expression in the retinas of OLETF rats.	T7	T9	23536314
CPR:5	CHEMICAL	GENE-Y	15	8	Other dams received 1.8ng/kg/day of a mixture of gene (AhR) agonists (non-ortho PCBs, chemical and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	T8	T16	23537661
NA	CHEMICAL	GENE-Y	15	11	Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (gene) agonists (non-ortho PCBs, chemical and PC-dibenzofurans) without or with 0.5M (0.5Mgene).	T8	T17	23537661
NA	CHEMICAL	GENE-Y	15	11	Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (gene) agonists (non-ortho PCBs, chemical and PC-dibenzofurans) without or with 0.5M (0.5Mgene).	T8	T9	23537661
CPR:5	CHEMICAL	GENE-Y	17	8	Other dams received 1.8ng/kg/day of a mixture of gene (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and chemical) without or with 0.5M (0.5MAhR).	T1	T16	23537661
NA	CHEMICAL	GENE-Y	17	11	Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (gene) agonists (non-ortho PCBs, PC-dibenzodioxins and chemical) without or with 0.5M (0.5Mgene).	T1	T17	23537661
NA	CHEMICAL	GENE-Y	17	11	Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (gene) agonists (non-ortho PCBs, PC-dibenzodioxins and chemical) without or with 0.5M (0.5Mgene).	T1	T9	23537661
CPR:5	CHEMICAL	GENE-Y	13	8	Other dams received 1.8ng/kg/day of a mixture of gene (AhR) agonists (chemicals, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).	T7	T16	23537661
NA	CHEMICAL	GENE-Y	13	11	Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (gene) agonists (chemicals, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5Mgene).	T7	T17	23537661
NA	CHEMICAL	GENE-Y	13	11	Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (gene) agonists (chemicals, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5Mgene).	T7	T9	23537661
NA	CHEMICAL	GENE-Y	9	11	Other dams received 1.8ng/kg/day of a mixture of aryl chemical receptor (gene) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5Mgene).	T6	T17	23537661
NA	CHEMICAL	GENE-Y	9	11	Other dams received 1.8ng/kg/day of a mixture of aryl chemical receptor (gene) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5Mgene).	T6	T9	23537661
NA	CHEMICAL	GENE-N	3	6	Phlebotomy and dietary chemical restriction reduces gene in NAFLD/NASH patients.	T5	T29	23538201
NA	CHEMICAL	GENE-N	43	4	Hepatic mRNA expression of gene, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic chemical concentrations were higher in HIE than HI.	T1	T20	23538201
NA	CHEMICAL	GENE-Y	43	29	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and gene mRNA levels were increased in CE compared to C. In Experiment 2, hepatic chemical concentrations were higher in HIE than HI.	T1	T25	23538201
NA	CHEMICAL	GENE-Y	43	27	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, gene, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic chemical concentrations were higher in HIE than HI.	T1	T24	23538201
NA	CHEMICAL	GENE-N	43	9	Hepatic mRNA expression of transferrin receptor 1 and 2, gene, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic chemical concentrations were higher in HIE than HI.	T1	T21	23538201
NA	CHEMICAL	GENE-Y	43	11	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and gene were increased more in CE than C, and in HE than H. In duodenum, DMT1, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic chemical concentrations were higher in HIE than HI.	T1	T22	23538201
NA	CHEMICAL	GENE-Y	43	26	Hepatic mRNA expression of transferrin receptor 1 and 2, ferritins, and hepcidin were increased more in CE than C, and in HE than H. In duodenum, gene, ferritinH, and hephaestin mRNA levels were increased in CE compared to C. In Experiment 2, hepatic chemical concentrations were higher in HIE than HI.	T1	T23	23538201
NA	CHEMICAL	GENE-N	2	43	Although the chemical deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (chemical receptor, gene, Rab11A).	T1	T6	23541399
NA	CHEMICAL	GENE-N	2	43	Although the chemical deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (chemical receptor, gene, Rab11A).	T3	T6	23541399
NA	CHEMICAL	GENE-Y	2	44	Although the chemical deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (chemical receptor, calmodulin, gene).	T1	T7	23541399
NA	CHEMICAL	GENE-Y	2	44	Although the chemical deprivation from pre-puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood (chemical receptor, calmodulin, gene).	T3	T7	23541399
CPR:4	CHEMICAL	GENE-Y	18	10	We report the discovery of a novel series of ATP-competitive gene (JAK3) inhibitors based on the chemical scaffold.	T1	T8	23541670
CPR:4	CHEMICAL	GENE-Y	18	13	We report the discovery of a novel series of ATP-competitive Janus kinase 3 (gene) inhibitors based on the chemical scaffold.	T1	T9	23541670
NA	CHEMICAL	GENE-Y	9	10	We report the discovery of a novel series of chemical-competitive gene (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold.	T2	T8	23541670
NA	CHEMICAL	GENE-Y	9	13	We report the discovery of a novel series of chemical-competitive Janus kinase 3 (gene) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold.	T2	T9	23541670
CPR:4	CHEMICAL	GENE-N	0	11	chemical inhibited the phosphorylation and activation of AKT and STAT3 through gene signaling blockade.	T5	T11	23542114
CPR:4	CHEMICAL	GENE-Y	0	9	chemical inhibited the phosphorylation and activation of AKT and gene through Notch signaling blockade.	T5	T10	23542114
CPR:4	CHEMICAL	GENE-N	0	7	chemical inhibited the phosphorylation and activation of gene and STAT3 through Notch signaling blockade.	T5	T9	23542114
CPR:4	CHEMICAL	GENE-N	5	20	These data show that the chemical is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of gene pathway.	T6	T12	23542114
NA	CHEMICAL	GENE-Y	26	0	gene and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with gene peaking in large (11-18 mm) chemical-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	T3	T18	23546605
NA	CHEMICAL	GENE-Y	26	0	gene and RXFP2 mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with gene peaking in large (11-18 mm) chemical-active follicles and RXFP2 peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	T3	T20	23546605
NA	CHEMICAL	GENE-Y	26	2	INSL3 and gene mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) chemical-active follicles and gene peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	T3	T19	23546605
NA	CHEMICAL	GENE-Y	26	2	INSL3 and gene mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with INSL3 peaking in large (11-18 mm) chemical-active follicles and gene peaking in 9- to 10-mm follicles before declining in larger (11-18 mm) follicles.	T3	T21	23546605
NA	CHEMICAL	GENE-Y	30	37	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptor while increasing chemical secretion and expression of STAR and gene.	T1	T8	23546605
NA	CHEMICAL	GENE-Y	30	24	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both gene and its receptor while increasing chemical secretion and expression of STAR and CYP11A1.	T1	T6	23546605
NA	CHEMICAL	GENE-Y	30	35	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of LH greatly attenuated expression of both INSL3 and its receptor while increasing chemical secretion and expression of gene and CYP11A1.	T1	T7	23546605
NA	CHEMICAL	GENE-N	30	18	To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of gene greatly attenuated expression of both INSL3 and its receptor while increasing chemical secretion and expression of STAR and CYP11A1.	T1	T5	23546605
NA	CHEMICAL	GENE-Y	2	0	gene and chemical followed a similar pattern, both increasing after luteolysis, before falling sharply after the LH surge.	T2	T10	23546605
NA	CHEMICAL	GENE-N	2	16	INSL3 and chemical followed a similar pattern, both increasing after luteolysis, before falling sharply after the gene surge.	T2	T11	23546605
NA	CHEMICAL	GENE-Y	37	12	Aim: In this study we explored the association between genetic variations in gene and PDE7B genes, residing on chromosome 6q23, and disease severity in -hemoglobinopathy patients, as well as the association between these variants with response to chemical (HU) treatment.	T1	T9	23556445
NA	CHEMICAL	GENE-Y	37	14	Aim: In this study we explored the association between genetic variations in MAP3K5 and gene genes, residing on chromosome 6q23, and disease severity in -hemoglobinopathy patients, as well as the association between these variants with response to chemical (HU) treatment.	T1	T10	23556445
CPR:4	CHEMICAL	GENE-Y	28	11	The high fat diet significantly increased hepatic mRNA expressions of PPAR, gene and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with chemical.	T6	T14	23561166
CPR:4	CHEMICAL	GENE-Y	28	13	The high fat diet significantly increased hepatic mRNA expressions of PPAR, SREBP1C and gene genes in comparison to the control diet, which was subsequently reversed by supplementation with chemical.	T6	T15	23561166
CPR:4	CHEMICAL	GENE-Y	28	10	The high fat diet significantly increased hepatic mRNA expressions of gene, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with chemical.	T6	T13	23561166
CPR:4	CHEMICAL	GENE-Y	2	13	In addition, chemical supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and gene compared to the control group.	T7	T18	23561166
CPR:4	CHEMICAL	GENE-Y	2	11	In addition, chemical supplementation significantly reduced hepatic mRNA abundance of FAS, gene and G6Pase compared to the control group.	T7	T17	23561166
CPR:4	CHEMICAL	GENE-Y	2	10	In addition, chemical supplementation significantly reduced hepatic mRNA abundance of gene, ATPCL and G6Pase compared to the control group.	T7	T16	23561166
CPR:3	CHEMICAL	GENE-Y	10	5	Finally, epididymal mRNA abundance of gene was significantly increased by chemical supplementation, compared to levels in the control and HF groups.	T8	T19	23561166
CPR:3	CHEMICAL	GENE-Y	5	2	Enhancement of gene expression by chemical was further confirmed in differentiated 3T3-L1 adipocytes.	T9	T20	23561166
NA	CHEMICAL	GENE-Y	13	9	This Letter describes the further chemical optimization of the gene PAM MLPCN probes chemical and ML172.	T12	T18	23562060
NA	CHEMICAL	GENE-N	13	9	This Letter describes the further chemical optimization of the gene PAM MLPCN probes chemical and ML172.	T12	T18	23562060
NA	CHEMICAL	GENE-Y	15	9	This Letter describes the further chemical optimization of the gene PAM MLPCN probes ML129 and chemical.	T13	T18	23562060
NA	CHEMICAL	GENE-N	15	9	This Letter describes the further chemical optimization of the gene PAM MLPCN probes ML129 and chemical.	T13	T18	23562060
NA	CHEMICAL	GENE-Y	21	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related isatin core that possessed a southern chemical linkage.	T5	T15	23562060
NA	CHEMICAL	GENE-Y	21	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related isatin core that possessed a southern chemical linkage.	T5	T16	23562060
NA	CHEMICAL	GENE-N	21	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related isatin core that possessed a southern chemical linkage.	T5	T15	23562060
NA	CHEMICAL	GENE-N	21	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related isatin core that possessed a southern chemical linkage.	T5	T16	23562060
NA	CHEMICAL	GENE-Y	15	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related chemical core that possessed a southern phenethyl ether linkage.	T4	T15	23562060
NA	CHEMICAL	GENE-Y	15	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related chemical core that possessed a southern phenethyl ether linkage.	T4	T16	23562060
NA	CHEMICAL	GENE-N	15	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related chemical core that possessed a southern phenethyl ether linkage.	T4	T15	23562060
NA	CHEMICAL	GENE-N	15	6	An HTS campaign identified several weak gene PAMs (gene EC50 >10M) with a structurally related chemical core that possessed a southern phenethyl ether linkage.	T4	T16	23562060
NA	CHEMICAL	GENE-N	16	44	While SAR within the HTS series was very shallow and unable to be optimized, grafting the chemical linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent gene selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T6	T20	23562060
NA	CHEMICAL	GENE-Y	16	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the chemical linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T6	T17	23562060
NA	CHEMICAL	GENE-Y	16	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the chemical linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T6	T19	23562060
NA	CHEMICAL	GENE-N	16	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the chemical linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T6	T17	23562060
NA	CHEMICAL	GENE-N	16	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the chemical linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T6	T19	23562060
NA	CHEMICAL	GENE-N	31	44	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (chemical), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent gene selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T10	T20	23562060
NA	CHEMICAL	GENE-Y	31	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (chemical), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T10	T17	23562060
NA	CHEMICAL	GENE-Y	31	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (chemical), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T10	T19	23562060
NA	CHEMICAL	GENE-N	31	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (chemical), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T10	T17	23562060
NA	CHEMICAL	GENE-N	31	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (chemical), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T10	T19	23562060
NA	CHEMICAL	GENE-N	21	44	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the chemical/ML172 cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent gene selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T7	T20	23562060
NA	CHEMICAL	GENE-Y	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the chemical/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T7	T17	23562060
NA	CHEMICAL	GENE-Y	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the chemical/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T7	T19	23562060
NA	CHEMICAL	GENE-N	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the chemical/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T7	T17	23562060
NA	CHEMICAL	GENE-N	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the chemical/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T7	T19	23562060
NA	CHEMICAL	GENE-N	21	44	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/chemical cores led to the first sub-micromolar M5 PAM, ML326 (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent gene selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T8	T20	23562060
NA	CHEMICAL	GENE-Y	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/chemical cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T8	T17	23562060
NA	CHEMICAL	GENE-Y	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/chemical cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T8	T19	23562060
NA	CHEMICAL	GENE-N	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/chemical cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T8	T17	23562060
NA	CHEMICAL	GENE-N	21	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/chemical cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T8	T19	23562060
NA	CHEMICAL	GENE-N	30	44	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar M5 PAM, chemical (VU0467903), (human and rat M5 EC50s of 409nM and 500nM, respectively) with excellent gene selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T9	T20	23562060
NA	CHEMICAL	GENE-Y	30	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, chemical (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T9	T17	23562060
NA	CHEMICAL	GENE-Y	30	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, chemical (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T9	T19	23562060
NA	CHEMICAL	GENE-N	30	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, chemical (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T9	T17	23562060
NA	CHEMICAL	GENE-N	30	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, chemical (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mAChR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the ACh CRC.	T9	T19	23562060
NA	CHEMICAL	GENE-Y	44	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mchemicalR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the chemical CRC.	T11	T17	23562060
NA	CHEMICAL	GENE-Y	44	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mchemicalR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the chemical CRC.	T11	T19	23562060
NA	CHEMICAL	GENE-N	44	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mchemicalR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the chemical CRC.	T11	T17	23562060
NA	CHEMICAL	GENE-N	44	28	While SAR within the HTS series was very shallow and unable to be optimized, grafting the phenethyl ether linkage onto the ML129/ML172 cores led to the first sub-micromolar gene PAM, ML326 (VU0467903), (human and rat gene EC50s of 409nM and 500nM, respectively) with excellent mchemicalR selectivity (M1-M4 EC50s >30M) and a robust 20-fold leftward shift of the chemical CRC.	T11	T19	23562060
NA	CHEMICAL	GENE-Y	34	7	However, the favorable metabolic phenotype observed in gene-deficient hosts was lost in gene(-/-) mice also lacking adaptive immunity (gene(-/-)xRag2(-/-)), demonstrating that gene expression in the adaptive rather than the innate immune system impacts host chemical homeostasis.	T1	T10	23562076
NA	CHEMICAL	GENE-Y	34	7	However, the favorable metabolic phenotype observed in gene-deficient hosts was lost in gene(-/-) mice also lacking adaptive immunity (gene(-/-)xRag2(-/-)), demonstrating that gene expression in the adaptive rather than the innate immune system impacts host chemical homeostasis.	T1	T11	23562076
NA	CHEMICAL	GENE-Y	34	7	However, the favorable metabolic phenotype observed in gene-deficient hosts was lost in gene(-/-) mice also lacking adaptive immunity (gene(-/-)xRag2(-/-)), demonstrating that gene expression in the adaptive rather than the innate immune system impacts host chemical homeostasis.	T1	T13	23562076
NA	CHEMICAL	GENE-Y	34	7	However, the favorable metabolic phenotype observed in gene-deficient hosts was lost in gene(-/-) mice also lacking adaptive immunity (gene(-/-)xRag2(-/-)), demonstrating that gene expression in the adaptive rather than the innate immune system impacts host chemical homeostasis.	T1	T9	23562076
NA	CHEMICAL	GENE-Y	34	18	However, the favorable metabolic phenotype observed in T-bet-deficient hosts was lost in T-bet(-/-) mice also lacking adaptive immunity (T-bet(-/-)xgene(-/-)), demonstrating that T-bet expression in the adaptive rather than the innate immune system impacts host chemical homeostasis.	T1	T12	23562076
CPR:3	CHEMICAL	GENE-Y	5	15	Western blot assay demonstrated that chemical decreased Bcl-2 level and induced Bax translocation to cause gene release.	T6	T14	23567243
CPR:4	CHEMICAL	GENE-Y	5	7	Western blot assay demonstrated that chemical decreased gene level and induced Bax translocation to cause cytochrome c release.	T6	T12	23567243
CPR:3	CHEMICAL	GENE-Y	5	11	Western blot assay demonstrated that chemical decreased Bcl-2 level and induced gene translocation to cause cytochrome c release.	T6	T13	23567243
NA	CHEMICAL	GENE-N	18	4	Meanwhile, the alterations of gene, p-CDK1 and p-cdc25c levels were also observed in response to chemical treatment.	T7	T17	23567243
NA	CHEMICAL	GENE-Y	18	10	Meanwhile, the alterations of cyclin A and B1, p-CDK1 and gene levels were also observed in response to chemical treatment.	T7	T19	23567243
NA	CHEMICAL	GENE-Y	18	8	Meanwhile, the alterations of cyclin A and B1, gene and p-cdc25c levels were also observed in response to chemical treatment.	T7	T18	23567243
CPR:3	CHEMICAL	GENE-N	0	5	chemical and rutin also increased gene activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).	T15	T24	23570998
CPR:3	CHEMICAL	GENE-N	2	5	Quercetin and chemical also increased gene activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).	T16	T24	23570998
CPR:3	CHEMICAL	GENE-Y	3	25	Further, both the chemical were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, gene and osteocalcin.	T17	T22	23570998
CPR:3	CHEMICAL	GENE-Y	3	22	Further, both the chemical were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like gene, osterix, RunX2, osteoprotegerin and osteocalcin.	T17	T19	23570998
CPR:3	CHEMICAL	GENE-Y	3	27	Further, both the chemical were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and gene.	T17	T23	23570998
CPR:3	CHEMICAL	GENE-Y	3	23	Further, both the chemical were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, gene, RunX2, osteoprotegerin and osteocalcin.	T17	T20	23570998
CPR:3	CHEMICAL	GENE-Y	3	24	Further, both the chemical were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, gene, osteoprotegerin and osteocalcin.	T17	T21	23570998
NA	CHEMICAL	GENE-N	23	5	Despite the presence of a gene at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using chemical demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.	T12	T19	23572520
NA	CHEMICAL	GENE-Y	23	13	Despite the presence of a GSNO binding site at the active site of gene, isothermal titration calorimetry as well as nitrosation experiments using chemical demonstrate that GSNO binding does not precede S-nitrosation of gene.	T12	T15	23572520
NA	CHEMICAL	GENE-Y	23	13	Despite the presence of a GSNO binding site at the active site of gene, isothermal titration calorimetry as well as nitrosation experiments using chemical demonstrate that GSNO binding does not precede S-nitrosation of gene.	T12	T20	23572520
NA	CHEMICAL	GENE-N	3	0	gene (ALT), chemical aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	T28	T43	23578993
NA	CHEMICAL	GENE-N	3	6	Alanine aminotransferase (ALT), chemical aminotransferase (AST), gene (ALP), Bilirubin were measured in serum.	T28	T47	23578993
NA	CHEMICAL	GENE-N	3	2	Alanine aminotransferase (gene), chemical aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	T28	T44	23578993
NA	CHEMICAL	GENE-N	3	8	Alanine aminotransferase (ALT), chemical aminotransferase (AST), Alkaline phosphatase (gene), Bilirubin were measured in serum.	T28	T48	23578993
NA	CHEMICAL	GENE-N	3	5	Alanine aminotransferase (ALT), chemical aminotransferase (gene), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	T28	T46	23578993
NA	CHEMICAL	GENE-N	9	3	Alanine aminotransferase (ALT), gene (AST), Alkaline phosphatase (ALP), chemical were measured in serum.	T29	T45	23578993
NA	CHEMICAL	GENE-N	9	0	gene (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), chemical were measured in serum.	T29	T43	23578993
NA	CHEMICAL	GENE-N	9	6	Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), gene (ALP), chemical were measured in serum.	T29	T47	23578993
NA	CHEMICAL	GENE-N	9	2	Alanine aminotransferase (gene), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), chemical were measured in serum.	T29	T44	23578993
NA	CHEMICAL	GENE-N	9	8	Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (gene), chemical were measured in serum.	T29	T48	23578993
NA	CHEMICAL	GENE-N	9	5	Alanine aminotransferase (ALT), Aspartate aminotransferase (gene), Alkaline phosphatase (ALP), chemical were measured in serum.	T29	T46	23578993
NA	CHEMICAL	GENE-N	0	3	chemical aminotransferase (ALT), gene (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	T27	T45	23578993
NA	CHEMICAL	GENE-N	0	6	chemical aminotransferase (ALT), Aspartate aminotransferase (AST), gene (ALP), Bilirubin were measured in serum.	T27	T47	23578993
NA	CHEMICAL	GENE-N	0	2	chemical aminotransferase (gene), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	T27	T44	23578993
NA	CHEMICAL	GENE-N	0	8	chemical aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (gene), Bilirubin were measured in serum.	T27	T48	23578993
NA	CHEMICAL	GENE-N	0	5	chemical aminotransferase (ALT), Aspartate aminotransferase (gene), Alkaline phosphatase (ALP), Bilirubin were measured in serum.	T27	T46	23578993
NA	CHEMICAL	GENE-N	0	7	chemical (HP), lipid peroxidation (LPO), catalase (CAT), gene (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	T30	T51	23578993
NA	CHEMICAL	GENE-Y	0	5	chemical (HP), lipid peroxidation (LPO), gene (CAT), Glutathione peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	T30	T49	23578993
NA	CHEMICAL	GENE-N	0	9	chemical (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (gene) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	T30	T52	23578993
NA	CHEMICAL	GENE-Y	0	6	chemical (HP), lipid peroxidation (LPO), catalase (gene), Glutathione peroxidase (GPx) and Glutathione (GSH) were determined in liver samples by colorimetric methods.	T30	T50	23578993
NA	CHEMICAL	GENE-Y	7	5	Hydroxyproline (HP), lipid peroxidation (LPO), gene (CAT), chemical peroxidase (GPx) and chemical (GSH) were determined in liver samples by colorimetric methods.	T31	T49	23578993
NA	CHEMICAL	GENE-Y	7	5	Hydroxyproline (HP), lipid peroxidation (LPO), gene (CAT), chemical peroxidase (GPx) and chemical (GSH) were determined in liver samples by colorimetric methods.	T32	T49	23578993
NA	CHEMICAL	GENE-N	7	9	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), chemical peroxidase (gene) and chemical (GSH) were determined in liver samples by colorimetric methods.	T31	T52	23578993
NA	CHEMICAL	GENE-N	7	9	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), chemical peroxidase (gene) and chemical (GSH) were determined in liver samples by colorimetric methods.	T32	T52	23578993
NA	CHEMICAL	GENE-Y	7	6	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (gene), chemical peroxidase (GPx) and chemical (GSH) were determined in liver samples by colorimetric methods.	T31	T50	23578993
NA	CHEMICAL	GENE-Y	7	6	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (gene), chemical peroxidase (GPx) and chemical (GSH) were determined in liver samples by colorimetric methods.	T32	T50	23578993
NA	CHEMICAL	GENE-N	12	7	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), gene (GPx) and Glutathione (chemical) were determined in liver samples by colorimetric methods.	T33	T51	23578993
NA	CHEMICAL	GENE-Y	12	5	Hydroxyproline (HP), lipid peroxidation (LPO), gene (CAT), Glutathione peroxidase (GPx) and Glutathione (chemical) were determined in liver samples by colorimetric methods.	T33	T49	23578993
NA	CHEMICAL	GENE-N	12	9	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (CAT), Glutathione peroxidase (gene) and Glutathione (chemical) were determined in liver samples by colorimetric methods.	T33	T52	23578993
NA	CHEMICAL	GENE-Y	12	6	Hydroxyproline (HP), lipid peroxidation (LPO), catalase (gene), Glutathione peroxidase (GPx) and Glutathione (chemical) were determined in liver samples by colorimetric methods.	T33	T50	23578993
CPR:9	CHEMICAL	GENE-Y	12	0	gene (CYP 450 2E1), activity was determined as hydroxylation of chemical in liver microsomes.	T34	T53	23578993
CPR:9	CHEMICAL	GENE-Y	12	3	Cytochrome P450 2E1 (gene), activity was determined as hydroxylation of chemical in liver microsomes.	T34	T54	23578993
NA	CHEMICAL	GENE-N	9	6	Serum markers of liver damage (AST, gene, ALP and chemical) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T1	T39	23578993
NA	CHEMICAL	GENE-N	9	7	Serum markers of liver damage (AST, ALT, gene and chemical) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T1	T40	23578993
NA	CHEMICAL	GENE-N	9	5	Serum markers of liver damage (gene, ALT, ALP and chemical) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T1	T38	23578993
CPR:3	CHEMICAL	GENE-N	13	6	Serum markers of liver damage (AST, gene, ALP and Bilirubin) were increased by chemical and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T3	T39	23578993
CPR:3	CHEMICAL	GENE-N	13	7	Serum markers of liver damage (AST, ALT, gene and Bilirubin) were increased by chemical and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T3	T40	23578993
CPR:3	CHEMICAL	GENE-N	13	5	Serum markers of liver damage (gene, ALT, ALP and Bilirubin) were increased by chemical and TAA intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T3	T38	23578993
CPR:3	CHEMICAL	GENE-N	15	6	Serum markers of liver damage (AST, gene, ALP and Bilirubin) were increased by CCl4 and chemical intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T4	T39	23578993
CPR:3	CHEMICAL	GENE-N	15	7	Serum markers of liver damage (AST, ALT, gene and Bilirubin) were increased by CCl4 and chemical intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T4	T40	23578993
CPR:3	CHEMICAL	GENE-N	15	5	Serum markers of liver damage (gene, ALT, ALP and Bilirubin) were increased by CCl4 and chemical intoxication (p<0.001), whereas co-treatment with NAC reversed such changes (p<0.001).	T4	T38	23578993
CPR:4	CHEMICAL	GENE-N	21	6	Serum markers of liver damage (AST, gene, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with chemical reversed such changes (p<0.001).	T5	T39	23578993
CPR:4	CHEMICAL	GENE-N	21	7	Serum markers of liver damage (AST, ALT, gene and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with chemical reversed such changes (p<0.001).	T5	T40	23578993
CPR:4	CHEMICAL	GENE-N	21	5	Serum markers of liver damage (gene, ALT, ALP and Bilirubin) were increased by CCl4 and TAA intoxication (p<0.001), whereas co-treatment with chemical reversed such changes (p<0.001).	T5	T38	23578993
NA	CHEMICAL	GENE-N	5	8	LPO was increased while as chemical, CAT and gene decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001).	T10	T42	23578993
NA	CHEMICAL	GENE-Y	5	6	LPO was increased while as chemical, gene and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of NAC restored these liver markers to normal levels (p<0.001).	T10	T41	23578993
CPR:3	CHEMICAL	GENE-N	20	8	LPO was increased while as GSH, CAT and gene decreased by the administration of CCl4 and TAA (p<0.001); co-administration of chemical restored these liver markers to normal levels (p<0.001).	T12	T42	23578993
CPR:3	CHEMICAL	GENE-Y	20	6	LPO was increased while as GSH, gene and GPx decreased by the administration of CCl4 and TAA (p<0.001); co-administration of chemical restored these liver markers to normal levels (p<0.001).	T12	T41	23578993
CPR:3	CHEMICAL	GENE-N	30	16	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory gene, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high chemical diet.	T12	T23	23583258
CPR:3	CHEMICAL	GENE-Y	30	19	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and gene, caused by a mixture of oxysterols representative of a high chemical diet.	T12	T25	23583258
CPR:3	CHEMICAL	GENE-Y	30	17	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, gene and IL-8, caused by a mixture of oxysterols representative of a high chemical diet.	T12	T24	23583258
CPR:3	CHEMICAL	GENE-N	25	16	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory gene, IL-6 and IL-8, caused by a mixture of chemical representative of a high cholesterol diet.	T11	T23	23583258
CPR:3	CHEMICAL	GENE-Y	25	19	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and gene, caused by a mixture of chemical representative of a high cholesterol diet.	T11	T25	23583258
CPR:3	CHEMICAL	GENE-Y	25	17	This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, gene and IL-8, caused by a mixture of chemical representative of a high cholesterol diet.	T11	T24	23583258
NA	CHEMICAL	GENE-N	23	28	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive chemical species through the colonic gene NOX1 activation.	T14	T26	23583258
NA	CHEMICAL	GENE-Y	23	29	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive chemical species through the colonic NADPH-oxidase gene activation.	T14	T27	23583258
NA	CHEMICAL	GENE-Y	28	29	This strong pro-inflammatory effect appeared to be dependent on the net imbalance of red-ox equilibrium with the production of excessive levels of reactive oxygen species through the colonic chemical-oxidase gene activation.	T15	T27	23583258
CPR:4	CHEMICAL	GENE-N	24	6	Oxysterol-dependent NOX1 activation, as well as gene synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular chemical and flavonoids.	T2	T30	23583258
CPR:4	CHEMICAL	GENE-Y	24	1	Oxysterol-dependent gene activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular chemical and flavonoids.	T2	T29	23583258
CPR:4	CHEMICAL	GENE-N	27	6	Oxysterol-dependent NOX1 activation, as well as gene synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and chemical.	T3	T30	23583258
CPR:4	CHEMICAL	GENE-Y	27	1	Oxysterol-dependent gene activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and chemical.	T3	T29	23583258
CPR:3	CHEMICAL	GENE-N	0	6	chemical-dependent NOX1 activation, as well as gene synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.	T17	T30	23583258
CPR:3	CHEMICAL	GENE-Y	0	1	chemical-dependent gene activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.	T17	T29	23583258
CPR:3	CHEMICAL	GENE-N	27	22	Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in gene synthesis induced by dietary chemical.	T4	T21	23583258
CPR:3	CHEMICAL	GENE-Y	27	16	Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial gene down-regulation and was ineffective in interleukin synthesis induced by dietary chemical.	T4	T20	23583258
NA	CHEMICAL	GENE-Y	35	22	Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related gene induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary chemical.	T10	T22	23583258
CPR:3	CHEMICAL	GENE-Y	21	22	Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking chemical-related gene induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary chemicals.	T9	T22	23583258
CPR:4	CHEMICAL	GENE-Y	7	22	Besides this direct activity, an excess of chemical compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related gene induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.	T8	T22	23583258
NA	CHEMICAL	GENE-Y	1	12	Elevated chemical AUC in virtual rheumatoid arthritis patients, following 100 pg/mL of gene was comparable to observed clinical data (59% versus 58%).	T1	T7	23588308
NA	CHEMICAL	GENE-Y	15	10	In virtual bone marrow transplant (BMT) patients, 500 pg/ml of gene resulted in increase in chemical AUC that was in good agreement with the observed data (45% versus 39%).	T2	T9	23588308
NA	CHEMICAL	GENE-Y	9	15	In a different group of BMT patients treated with chemical, the magnitude of interaction with gene was under predicted ~3-fold.	T3	T11	23588308
NA	CHEMICAL	GENE-Y	26	32	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme chemical dehydrogenase (DPD, encoded by the gene gene).	T5	T9	23588312
NA	CHEMICAL	GENE-Y	26	28	The responses to 5-FU, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme chemical dehydrogenase (gene, encoded by the DPYD gene).	T5	T8	23588312
NA	CHEMICAL	GENE-Y	3	26	The responses to chemical, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme gene (DPD, encoded by the DPYD gene).	T3	T7	23588312
NA	CHEMICAL	GENE-Y	3	32	The responses to chemical, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (DPD, encoded by the gene gene).	T3	T9	23588312
NA	CHEMICAL	GENE-Y	3	28	The responses to chemical, with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme dihydropyrimidine dehydrogenase (gene, encoded by the DPYD gene).	T3	T8	23588312
NA	CHEMICAL	GENE-N	25	6	In the African-American cohort, after excluding gene carriers, homozygous carriers of C29R showed 27% higher DPD activity as compared with noncarriers (609152 and 480152 pmol chemical min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038/clpt.2013.69.	T2	T17	23588312
NA	CHEMICAL	GENE-N	25	11	In the African-American cohort, after excluding Y186C carriers, homozygous carriers of gene showed 27% higher DPD activity as compared with noncarriers (609152 and 480152 pmol chemical min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038/clpt.2013.69.	T2	T18	23588312
NA	CHEMICAL	GENE-Y	25	15	In the African-American cohort, after excluding Y186C carriers, homozygous carriers of C29R showed 27% higher gene activity as compared with noncarriers (609152 and 480152 pmol chemical min(-1) mg(-1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038/clpt.2013.69.	T2	T19	23588312
CPR:4	CHEMICAL	GENE-Y	0	19	chemical deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, gene, and LC3.	T5	T21	23589329
CPR:4	CHEMICAL	GENE-N	0	21	chemical deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of p62, Keap1, and gene.	T5	T22	23589329
CPR:4	CHEMICAL	GENE-Y	0	18	chemical deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of gene, Keap1, and LC3.	T5	T20	23589329
CPR:3	CHEMICAL	GENE-Y	1	3	Thus, chemical activates gene through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of gene.	T6	T23	23589329
CPR:3	CHEMICAL	GENE-Y	1	3	Thus, chemical activates gene through a non-canonical mechanism (p62-dependent), leading to a chronic, sustained activation of gene.	T6	T25	23589329
NA	CHEMICAL	GENE-Y	1	8	Thus, chemical activates Nrf2 through a non-canonical mechanism (gene-dependent), leading to a chronic, sustained activation of Nrf2.	T6	T24	23589329
NA	CHEMICAL	GENE-Y	8	11	In contrast, activation of Nrf2 by sulforaphane and chemical depend upon gene-C151 and not p62 (the canonical mechanism).	T8	T27	23589329
CPR:3	CHEMICAL	GENE-Y	8	4	In contrast, activation of gene by sulforaphane and chemical depend upon Keap1-C151 and not p62 (the canonical mechanism).	T8	T26	23589329
NA	CHEMICAL	GENE-Y	8	14	In contrast, activation of Nrf2 by sulforaphane and chemical depend upon Keap1-C151 and not gene (the canonical mechanism).	T8	T29	23589329
NA	CHEMICAL	GENE-Y	6	11	In contrast, activation of Nrf2 by chemical and tert-butylhydroquinone depend upon gene-C151 and not p62 (the canonical mechanism).	T7	T27	23589329
CPR:3	CHEMICAL	GENE-Y	6	4	In contrast, activation of gene by chemical and tert-butylhydroquinone depend upon Keap1-C151 and not p62 (the canonical mechanism).	T7	T26	23589329
NA	CHEMICAL	GENE-Y	6	14	In contrast, activation of Nrf2 by chemical and tert-butylhydroquinone depend upon Keap1-C151 and not gene (the canonical mechanism).	T7	T29	23589329
CPR:3	CHEMICAL	GENE-Y	6	11	Collectively, these findings provide evidence that chemical causes prolonged activation of gene through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of gene found in certain human cancers.	T3	T12	23589329
CPR:3	CHEMICAL	GENE-Y	6	11	Collectively, these findings provide evidence that chemical causes prolonged activation of gene through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of gene found in certain human cancers.	T3	T13	23589329
NA	CHEMICAL	GENE-N	8	18	We report the effects of ethanol intake and chemical treatment (at doses of 100g/100gBW/day) on sex hormones and gene in the ovaries, oviducts and uteri of ethanol-preferring rats.	T10	T38	23591044
NA	CHEMICAL	GENE-N	5	18	We report the effects of chemical intake and melatonin treatment (at doses of 100g/100gBW/day) on sex hormones and gene in the ovaries, oviducts and uteri of chemical-preferring rats.	T12	T38	23591044
NA	CHEMICAL	GENE-N	5	18	We report the effects of chemical intake and melatonin treatment (at doses of 100g/100gBW/day) on sex hormones and gene in the ovaries, oviducts and uteri of chemical-preferring rats.	T9	T38	23591044
NA	CHEMICAL	GENE-Y	17	29	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, chemical and melatonin receptor subunits (AR, ER- and ER-, PRA, PRB and gene, respectively).	T15	T45	23591044
NA	CHEMICAL	GENE-Y	17	23	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, chemical and melatonin receptor subunits (AR, gene and ER-, PRA, PRB and MT1R, respectively).	T15	T41	23591044
NA	CHEMICAL	GENE-Y	17	25	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, chemical and melatonin receptor subunits (AR, ER- and gene, PRA, PRB and MT1R, respectively).	T15	T42	23591044
NA	CHEMICAL	GENE-Y	17	26	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, chemical and melatonin receptor subunits (AR, ER- and ER-, gene, PRB and MT1R, respectively).	T15	T43	23591044
NA	CHEMICAL	GENE-Y	17	27	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, chemical and melatonin receptor subunits (AR, ER- and ER-, PRA, gene and MT1R, respectively).	T15	T44	23591044
NA	CHEMICAL	GENE-Y	17	22	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, chemical and melatonin receptor subunits (gene, ER- and ER-, PRA, PRB and MT1R, respectively).	T15	T40	23591044
NA	CHEMICAL	GENE-Y	19	29	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and chemical receptor subunits (AR, ER- and ER-, PRA, PRB and gene, respectively).	T16	T45	23591044
NA	CHEMICAL	GENE-Y	19	23	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and chemical receptor subunits (AR, gene and ER-, PRA, PRB and MT1R, respectively).	T16	T41	23591044
NA	CHEMICAL	GENE-Y	19	25	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and chemical receptor subunits (AR, ER- and gene, PRA, PRB and MT1R, respectively).	T16	T42	23591044
NA	CHEMICAL	GENE-Y	19	26	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and chemical receptor subunits (AR, ER- and ER-, gene, PRB and MT1R, respectively).	T16	T43	23591044
NA	CHEMICAL	GENE-Y	19	27	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and chemical receptor subunits (AR, ER- and ER-, PRA, gene and MT1R, respectively).	T16	T44	23591044
NA	CHEMICAL	GENE-Y	19	22	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, estrogen, progesterone and chemical receptor subunits (gene, ER- and ER-, PRA, PRB and MT1R, respectively).	T16	T40	23591044
NA	CHEMICAL	GENE-Y	15	29	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate chemical, estrogen, progesterone and melatonin receptor subunits (AR, ER- and ER-, PRA, PRB and gene, respectively).	T13	T45	23591044
NA	CHEMICAL	GENE-Y	15	23	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate chemical, estrogen, progesterone and melatonin receptor subunits (AR, gene and ER-, PRA, PRB and MT1R, respectively).	T13	T41	23591044
NA	CHEMICAL	GENE-Y	15	25	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate chemical, estrogen, progesterone and melatonin receptor subunits (AR, ER- and gene, PRA, PRB and MT1R, respectively).	T13	T42	23591044
NA	CHEMICAL	GENE-Y	15	26	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate chemical, estrogen, progesterone and melatonin receptor subunits (AR, ER- and ER-, gene, PRB and MT1R, respectively).	T13	T43	23591044
NA	CHEMICAL	GENE-Y	15	27	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate chemical, estrogen, progesterone and melatonin receptor subunits (AR, ER- and ER-, PRA, gene and MT1R, respectively).	T13	T44	23591044
NA	CHEMICAL	GENE-Y	15	22	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate chemical, estrogen, progesterone and melatonin receptor subunits (gene, ER- and ER-, PRA, PRB and MT1R, respectively).	T13	T40	23591044
NA	CHEMICAL	GENE-Y	16	29	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, chemical, progesterone and melatonin receptor subunits (AR, ER- and ER-, PRA, PRB and gene, respectively).	T14	T45	23591044
NA	CHEMICAL	GENE-Y	16	23	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, chemical, progesterone and melatonin receptor subunits (AR, gene and ER-, PRA, PRB and MT1R, respectively).	T14	T41	23591044
NA	CHEMICAL	GENE-Y	16	25	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, chemical, progesterone and melatonin receptor subunits (AR, ER- and gene, PRA, PRB and MT1R, respectively).	T14	T42	23591044
NA	CHEMICAL	GENE-Y	16	26	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, chemical, progesterone and melatonin receptor subunits (AR, ER- and ER-, gene, PRB and MT1R, respectively).	T14	T43	23591044
NA	CHEMICAL	GENE-Y	16	27	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, chemical, progesterone and melatonin receptor subunits (AR, ER- and ER-, PRA, gene and MT1R, respectively).	T14	T44	23591044
NA	CHEMICAL	GENE-Y	16	22	After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate androgen, chemical, progesterone and melatonin receptor subunits (gene, ER- and ER-, PRA, PRB and MT1R, respectively).	T14	T40	23591044
NA	CHEMICAL	GENE-Y	14	1	Ovarian gene was not influenced by either treatment, and oviduct gene was reduced after ethanol-chemical combination.	T26	T46	23591044
CPR:4	CHEMICAL	GENE-Y	14	1	Ovarian gene was not influenced by either treatment, and oviduct gene was reduced after ethanol-chemical combination.	T26	T47	23591044
NA	CHEMICAL	GENE-Y	14	1	Ovarian gene was not influenced by either treatment, and oviduct gene was reduced after chemical-melatonin combination.	T25	T46	23591044
CPR:4	CHEMICAL	GENE-Y	14	1	Ovarian gene was not influenced by either treatment, and oviduct gene was reduced after chemical-melatonin combination.	T25	T47	23591044
CPR:4	CHEMICAL	GENE-Y	12	1	Oviduct gene, ER- and uterine ER- were down-regulated by either ethanol or chemical.	T28	T48	23591044
CPR:4	CHEMICAL	GENE-Y	12	2	Oviduct ER-, gene and uterine gene were down-regulated by either ethanol or chemical.	T28	T49	23591044
CPR:4	CHEMICAL	GENE-Y	12	2	Oviduct ER-, gene and uterine gene were down-regulated by either ethanol or chemical.	T28	T50	23591044
CPR:4	CHEMICAL	GENE-Y	10	1	Oviduct gene, ER- and uterine ER- were down-regulated by either chemical or melatonin.	T27	T48	23591044
CPR:4	CHEMICAL	GENE-Y	10	2	Oviduct ER-, gene and uterine gene were down-regulated by either chemical or melatonin.	T27	T49	23591044
CPR:4	CHEMICAL	GENE-Y	10	2	Oviduct ER-, gene and uterine gene were down-regulated by either chemical or melatonin.	T27	T50	23591044
NA	CHEMICAL	GENE-Y	11	2	Conversely, ovarian gene and PRB were positively regulated by ethanol and ethanol-chemical combination, whereas gene was down-regulated in the uterus and oviduct after ethanol consumption.	T3	T35	23591044
NA	CHEMICAL	GENE-Y	11	2	Conversely, ovarian gene and PRB were positively regulated by ethanol and ethanol-chemical combination, whereas gene was down-regulated in the uterus and oviduct after ethanol consumption.	T3	T51	23591044
NA	CHEMICAL	GENE-Y	11	4	Conversely, ovarian PRA and gene were positively regulated by ethanol and ethanol-chemical combination, whereas PRA was down-regulated in the uterus and oviduct after ethanol consumption.	T3	T52	23591044
NA	CHEMICAL	GENE-Y	9	2	Conversely, ovarian gene and PRB were positively regulated by chemical and chemical-melatonin combination, whereas gene was down-regulated in the uterus and oviduct after chemical consumption.	T1	T35	23591044
NA	CHEMICAL	GENE-Y	9	2	Conversely, ovarian gene and PRB were positively regulated by chemical and chemical-melatonin combination, whereas gene was down-regulated in the uterus and oviduct after chemical consumption.	T1	T51	23591044
NA	CHEMICAL	GENE-Y	9	2	Conversely, ovarian gene and PRB were positively regulated by chemical and chemical-melatonin combination, whereas gene was down-regulated in the uterus and oviduct after chemical consumption.	T2	T35	23591044
NA	CHEMICAL	GENE-Y	9	2	Conversely, ovarian gene and PRB were positively regulated by chemical and chemical-melatonin combination, whereas gene was down-regulated in the uterus and oviduct after chemical consumption.	T2	T51	23591044
CPR:4	CHEMICAL	GENE-Y	9	2	Conversely, ovarian gene and PRB were positively regulated by chemical and chemical-melatonin combination, whereas gene was down-regulated in the uterus and oviduct after chemical consumption.	T4	T35	23591044
NA	CHEMICAL	GENE-Y	9	2	Conversely, ovarian gene and PRB were positively regulated by chemical and chemical-melatonin combination, whereas gene was down-regulated in the uterus and oviduct after chemical consumption.	T4	T51	23591044
NA	CHEMICAL	GENE-Y	9	4	Conversely, ovarian PRA and gene were positively regulated by chemical and chemical-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after chemical consumption.	T1	T52	23591044
NA	CHEMICAL	GENE-Y	9	4	Conversely, ovarian PRA and gene were positively regulated by chemical and chemical-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after chemical consumption.	T2	T52	23591044
NA	CHEMICAL	GENE-Y	9	4	Conversely, ovarian PRA and gene were positively regulated by chemical and chemical-melatonin combination, whereas PRA was down-regulated in the uterus and oviduct after chemical consumption.	T4	T52	23591044
CPR:3	CHEMICAL	GENE-Y	8	0	gene was increased in ovaries and uteri of chemical-treated rats.	T5	T36	23591044
NA	CHEMICAL	GENE-N	2	17	Ethanol and chemical exert opposite effects on E2 and P4, and they differentially regulate the expression of gene in female reproductive tissues.	T7	T37	23591044
NA	CHEMICAL	GENE-N	0	17	chemical and melatonin exert opposite effects on E2 and P4, and they differentially regulate the expression of gene in female reproductive tissues.	T6	T37	23591044
NA	CHEMICAL	GENE-Y	8	22	We also investigated the effect of Ph1 on chemical transients in cultured dorsal root ganglia (DRG) neurons and HEK293 cells expressing the gene receptor.	T10	T20	23597507
NA	CHEMICAL	GENE-Y	14	23	Intraplantar or intrathecal administered Ph1 reduced both nocifensive behavior and mechanical hypersensitivity induced by chemical similarly to that observed with SB366791, a specific gene antagonist.	T11	T21	23597507
CPR:6	CHEMICAL	GENE-Y	20	23	Intraplantar or intrathecal administered Ph1 reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with chemical, a specific gene antagonist.	T12	T21	23597507
NA	CHEMICAL	GENE-Y	5	15	Moreover, Ph1 did not inhibit chemical-activated currents in patch-clamp recordings of HEK293 cells that expressed gene receptors.	T7	T18	23597507
CPR:4	CHEMICAL	GENE-N	5	3	Recently, the c-Abl gene inhibitor chemical (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.	T11	T47	23598363
CPR:4	CHEMICAL	GENE-Y	5	2	Recently, the gene kinase inhibitor chemical (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.	T11	T46	23598363
NA	CHEMICAL	GENE-N	19	3	Recently, the c-Abl gene inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against chemical.	T13	T47	23598363
NA	CHEMICAL	GENE-Y	19	2	Recently, the gene kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against chemical.	T13	T46	23598363
CPR:4	CHEMICAL	GENE-N	5	3	Recently, the c-Abl gene inhibitor chemical mesylate (chemical) has become the focus of research as a fertoprotective drug against cisplatin.	T12	T47	23598363
CPR:4	CHEMICAL	GENE-Y	5	2	Recently, the gene kinase inhibitor chemical mesylate (chemical) has become the focus of research as a fertoprotective drug against cisplatin.	T12	T46	23598363
CPR:3	CHEMICAL	GENE-Y	5	9	We found that, before apoptosis, chemical induces c-Abl and gene expression in the oocyte.	T17	T49	23598363
CPR:3	CHEMICAL	GENE-Y	5	7	We found that, before apoptosis, chemical induces gene and TAp73 expression in the oocyte.	T17	T48	23598363
NA	CHEMICAL	GENE-Y	6	25	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/gene and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T19	T23	23598363
CPR:3	CHEMICAL	GENE-Y	6	25	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/gene and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T2	T23	23598363
NA	CHEMICAL	GENE-Y	6	31	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of gene and upregulation of Bax, thereby abrogating oocyte cell death.	T19	T24	23598363
CPR:4	CHEMICAL	GENE-Y	6	31	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of gene and upregulation of Bax, thereby abrogating oocyte cell death.	T2	T24	23598363
NA	CHEMICAL	GENE-Y	6	25	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of gene/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T19	T22	23598363
CPR:3	CHEMICAL	GENE-Y	6	25	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of gene/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T2	T22	23598363
NA	CHEMICAL	GENE-Y	6	35	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of gene, thereby abrogating oocyte cell death.	T19	T25	23598363
CPR:3	CHEMICAL	GENE-Y	6	35	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of gene, thereby abrogating oocyte cell death.	T2	T25	23598363
CPR:3	CHEMICAL	GENE-Y	6	17	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of gene, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T19	T21	23598363
NA	CHEMICAL	GENE-Y	6	17	While imatinib was unable to block chemical-induced DNA damage and damage response, such as the upregulation of gene, imatinib inhibited the chemical-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T2	T21	23598363
NA	CHEMICAL	GENE-Y	1	25	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/gene and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T18	T23	23598363
CPR:4	CHEMICAL	GENE-Y	1	25	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/gene and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T1	T23	23598363
NA	CHEMICAL	GENE-Y	1	31	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of gene and upregulation of Bax, thereby abrogating oocyte cell death.	T18	T24	23598363
CPR:3	CHEMICAL	GENE-Y	1	31	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of gene and upregulation of Bax, thereby abrogating oocyte cell death.	T1	T24	23598363
NA	CHEMICAL	GENE-Y	1	25	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of gene/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T18	T22	23598363
CPR:4	CHEMICAL	GENE-Y	1	25	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of gene/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T1	T22	23598363
NA	CHEMICAL	GENE-Y	1	35	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of gene, thereby abrogating oocyte cell death.	T18	T25	23598363
CPR:4	CHEMICAL	GENE-Y	1	35	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of gene, thereby abrogating oocyte cell death.	T1	T25	23598363
NA	CHEMICAL	GENE-Y	1	17	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of gene, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T18	T21	23598363
NA	CHEMICAL	GENE-Y	1	17	While chemical was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of gene, chemical inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.	T1	T21	23598363
CPR:3	CHEMICAL	GENE-Y	24	21	Surprisingly, the conditional deletion of Trp63, but not Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and gene caused by chemical.	T4	T29	23598363
NA	CHEMICAL	GENE-Y	24	5	Surprisingly, the conditional deletion of gene, but not Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by chemical.	T4	T26	23598363
CPR:3	CHEMICAL	GENE-Y	24	19	Surprisingly, the conditional deletion of Trp63, but not Np63, in oocytes inhibited apoptosis, as well as the accumulation of gene and TAp73 caused by chemical.	T4	T28	23598363
NA	CHEMICAL	GENE-Y	24	8	Surprisingly, the conditional deletion of Trp63, but not gene, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by chemical.	T4	T27	23598363
NA	CHEMICAL	GENE-Y	5	21	Surprisingly, the conditional deletion of chemical63, but not Np63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and gene caused by cisplatin.	T3	T29	23598363
NA	CHEMICAL	GENE-Y	5	19	Surprisingly, the conditional deletion of chemical63, but not Np63, in oocytes inhibited apoptosis, as well as the accumulation of gene and TAp73 caused by cisplatin.	T3	T28	23598363
NA	CHEMICAL	GENE-Y	5	8	Surprisingly, the conditional deletion of chemical63, but not gene, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.	T3	T27	23598363
NA	CHEMICAL	GENE-Y	10	4	These data suggest that gene is the master regulator of chemical-induced oocyte death.	T5	T30	23598363
NA	CHEMICAL	GENE-Y	10	7	The expression kinetics of TAp63, c-Abl and gene suggest that chemical activates TAp63-dependent expression of c-Abl and gene and, in turn, the activation of gene by c-Abl-induced BAX expression.	T6	T33	23598363
CPR:3	CHEMICAL	GENE-Y	10	7	The expression kinetics of TAp63, c-Abl and gene suggest that chemical activates TAp63-dependent expression of c-Abl and gene and, in turn, the activation of gene by c-Abl-induced BAX expression.	T6	T36	23598363
CPR:3	CHEMICAL	GENE-Y	10	7	The expression kinetics of TAp63, c-Abl and gene suggest that chemical activates TAp63-dependent expression of c-Abl and gene and, in turn, the activation of gene by c-Abl-induced BAX expression.	T6	T37	23598363
NA	CHEMICAL	GENE-Y	10	4	The expression kinetics of gene, c-Abl and TAp73 suggest that chemical activates gene-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	T6	T31	23598363
CPR:3	CHEMICAL	GENE-Y	10	4	The expression kinetics of gene, c-Abl and TAp73 suggest that chemical activates gene-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.	T6	T34	23598363
NA	CHEMICAL	GENE-Y	10	5	The expression kinetics of TAp63, gene and TAp73 suggest that chemical activates TAp63-dependent expression of gene and TAp73 and, in turn, the activation of TAp73 by gene-induced BAX expression.	T6	T32	23598363
CPR:3	CHEMICAL	GENE-Y	10	5	The expression kinetics of TAp63, gene and TAp73 suggest that chemical activates TAp63-dependent expression of gene and TAp73 and, in turn, the activation of TAp73 by gene-induced BAX expression.	T6	T35	23598363
CPR:3	CHEMICAL	GENE-Y	10	5	The expression kinetics of TAp63, gene and TAp73 suggest that chemical activates TAp63-dependent expression of gene and TAp73 and, in turn, the activation of TAp73 by gene-induced BAX expression.	T6	T38	23598363
CPR:3	CHEMICAL	GENE-Y	10	27	The expression kinetics of TAp63, c-Abl and TAp73 suggest that chemical activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced gene expression.	T6	T39	23598363
CPR:3	CHEMICAL	GENE-N	8	14	Our findings indicate that imatinib protects oocytes from chemical-induced cell death by inhibiting c-Abl gene, which would otherwise activate TAp73-BAX-mediated apoptosis.	T8	T41	23598363
CPR:3	CHEMICAL	GENE-Y	8	19	Our findings indicate that imatinib protects oocytes from chemical-induced cell death by inhibiting c-Abl kinase, which would otherwise activate gene-BAX-mediated apoptosis.	T8	T42	23598363
CPR:3	CHEMICAL	GENE-Y	8	13	Our findings indicate that imatinib protects oocytes from chemical-induced cell death by inhibiting gene kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.	T8	T40	23598363
CPR:3	CHEMICAL	GENE-Y	8	19	Our findings indicate that imatinib protects oocytes from chemical-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-gene-mediated apoptosis.	T8	T43	23598363
CPR:3	CHEMICAL	GENE-N	4	14	Our findings indicate that chemical protects oocytes from cisplatin-induced cell death by inhibiting c-Abl gene, which would otherwise activate TAp73-BAX-mediated apoptosis.	T7	T41	23598363
CPR:4	CHEMICAL	GENE-Y	4	19	Our findings indicate that chemical protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate gene-BAX-mediated apoptosis.	T7	T42	23598363
CPR:4	CHEMICAL	GENE-Y	4	13	Our findings indicate that chemical protects oocytes from cisplatin-induced cell death by inhibiting gene kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.	T7	T40	23598363
CPR:4	CHEMICAL	GENE-Y	4	19	Our findings indicate that chemical protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-gene-mediated apoptosis.	T7	T43	23598363
NA	CHEMICAL	GENE-N	14	5	Thus, imatinib and other c-Abl gene inhibitors provide an intriguing new way to halt chemical-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.	T10	T45	23598363
NA	CHEMICAL	GENE-Y	14	4	Thus, imatinib and other gene kinase inhibitors provide an intriguing new way to halt chemical-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.	T10	T44	23598363
CPR:4	CHEMICAL	GENE-N	1	5	Thus, chemical and other c-Abl gene inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.	T9	T45	23598363
CPR:4	CHEMICAL	GENE-Y	1	4	Thus, chemical and other gene kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.	T9	T44	23598363
NA	CHEMICAL	GENE-N	12	5	To clarify the roles of gene in hyperaccumulation of cadmium and chemical in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.	T6	T27	23598904
NA	CHEMICAL	GENE-N	10	5	To clarify the roles of gene in hyperaccumulation of chemical and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and MnCl2, respectively.	T5	T27	23598904
NA	CHEMICAL	GENE-N	29	5	To clarify the roles of gene in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to chemical and MnCl2, respectively.	T9	T27	23598904
NA	CHEMICAL	GENE-N	31	5	To clarify the roles of gene in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and chemical, respectively.	T10	T27	23598904
NA	CHEMICAL	GENE-N	18	5	To clarify the roles of gene in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, Cd-resistant and chemical-resistant cells were developed from RBL-2H3 cells by continuous exposure to CdCl2 and chemicalCl2, respectively.	T8	T27	23598904
NA	CHEMICAL	GENE-N	16	5	To clarify the roles of gene in hyperaccumulation of cadmium and manganese in RBL-2H3 cells, chemical-resistant and Mn-resistant cells were developed from RBL-2H3 cells by continuous exposure to chemicalCl2 and MnCl2, respectively.	T7	T27	23598904
NA	CHEMICAL	GENE-N	6	15	RBL-Cdr cells also showed cross-resistance to chemical and AgNO3 probably due to enhanced expression of gene.	T18	T28	23598904
NA	CHEMICAL	GENE-N	8	15	RBL-Cdr cells also showed cross-resistance to HgCl2 and chemical probably due to enhanced expression of gene.	T19	T28	23598904
CPR:9	CHEMICAL	GENE-Y	9	16	Among the possible transporters involved in the uptake of chemical and Mn(2+), the expression of ZIP8 (gene), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	T21	T30	23598904
CPR:9	CHEMICAL	GENE-Y	9	22	Among the possible transporters involved in the uptake of chemical and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by gene, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	T21	T25	23598904
CPR:9	CHEMICAL	GENE-Y	9	15	Among the possible transporters involved in the uptake of chemical and Mn(2+), the expression of gene (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	T21	T29	23598904
CPR:9	CHEMICAL	GENE-Y	11	16	Among the possible transporters involved in the uptake of Cd(2+) and chemical, the expression of ZIP8 (gene), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	T22	T30	23598904
CPR:9	CHEMICAL	GENE-Y	11	22	Among the possible transporters involved in the uptake of Cd(2+) and chemical, the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by gene, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	T22	T25	23598904
CPR:9	CHEMICAL	GENE-Y	11	15	Among the possible transporters involved in the uptake of Cd(2+) and chemical, the expression of gene (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.	T22	T29	23598904
CPR:9	CHEMICAL	GENE-Y	15	4	These results suggest that gene plays a pivotal role in the transport and toxicity of chemical and Mn(2+) in RBL-2H3 cells.	T1	T26	23598904
CPR:9	CHEMICAL	GENE-Y	17	4	These results suggest that gene plays a pivotal role in the transport and toxicity of Cd(2+) and chemical in RBL-2H3 cells.	T2	T26	23598904
NA	CHEMICAL	GENE-Y	10	19	In the present work we show that reduction sensitive and chemical-stable heteromers can be reconstituted in vitro by mixing gene with either serglycin, versican or CSPGs isolated from various monocytic cell lines.	T3	T19	23601700
NA	CHEMICAL	GENE-N	10	25	In the present work we show that reduction sensitive and chemical-stable heteromers can be reconstituted in vitro by mixing proMMP-9 with either serglycin, versican or gene isolated from various monocytic cell lines.	T3	T20	23601700
NA	CHEMICAL	GENE-Y	5	6	In addition, a strong but chemical-soluble geneCSPG heteromer was formed.	T4	T21	23601700
NA	CHEMICAL	GENE-N	5	6	In addition, a strong but chemical-soluble proMMP-9gene heteromer was formed.	T4	T22	23601700
NA	CHEMICAL	GENE-Y	12	24	As for the heteromer isolated from THP-1 cells, the in vitro reconstituted chemical-stable and chemical-soluble heteromers had a weaker binding to gelatin than the gene monomer.	T7	T24	23601700
NA	CHEMICAL	GENE-Y	12	24	As for the heteromer isolated from THP-1 cells, the in vitro reconstituted chemical-stable and chemical-soluble heteromers had a weaker binding to gelatin than the gene monomer.	T8	T24	23601700
NA	CHEMICAL	GENE-Y	10	4	However, the presence of gene inhibited the formation of the chemical-soluble heteromer, but not the chemical-stable reduction sensitive heteromer.	T1	T13	23601700
NA	CHEMICAL	GENE-Y	10	4	However, the presence of gene inhibited the formation of the chemical-soluble heteromer, but not the chemical-stable reduction sensitive heteromer.	T2	T13	23601700
CPR:4	CHEMICAL	GENE-N	19	22	Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of chemical inhibitors of gene (CA) assembly are described.	T1	T7	23601710
CPR:4	CHEMICAL	GENE-N	19	24	Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of chemical inhibitors of HIV capsid (gene) assembly are described.	T1	T8	23601710
NA	CHEMICAL	GENE-N	5	22	Detailed structure-activity relationships of the C3-chemical moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of gene (CA) assembly are described.	T4	T7	23601710
NA	CHEMICAL	GENE-N	5	24	Detailed structure-activity relationships of the C3-chemical moiety that allow for the optimization of antiviral potency of a series of 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors of HIV capsid (gene) assembly are described.	T4	T8	23601710
NA	CHEMICAL	GENE-N	16	39	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and chemical (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T4	T24	23602986
NA	CHEMICAL	GENE-N	16	41	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and chemical (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T4	T25	23602986
NA	CHEMICAL	GENE-N	13	39	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), chemical (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T20	T24	23602986
NA	CHEMICAL	GENE-N	13	41	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), chemical (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T20	T25	23602986
NA	CHEMICAL	GENE-N	11	39	The present work evaluated the effects of nicotine (NIC), cotinine (COT), chemical (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T16	T24	23602986
NA	CHEMICAL	GENE-N	11	41	The present work evaluated the effects of nicotine (NIC), cotinine (COT), chemical (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T16	T25	23602986
NA	CHEMICAL	GENE-N	7	39	The present work evaluated the effects of chemical (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T9	T24	23602986
NA	CHEMICAL	GENE-N	7	41	The present work evaluated the effects of chemical (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T9	T25	23602986
NA	CHEMICAL	GENE-N	9	39	The present work evaluated the effects of nicotine (NIC), chemical (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T11	T24	23602986
NA	CHEMICAL	GENE-N	9	41	The present work evaluated the effects of nicotine (NIC), chemical (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T11	T25	23602986
NA	CHEMICAL	GENE-N	17	39	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (chemical) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T8	T24	23602986
NA	CHEMICAL	GENE-N	17	41	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (chemical) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T8	T25	23602986
NA	CHEMICAL	GENE-N	10	39	The present work evaluated the effects of nicotine (NIC), cotinine (chemical), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T15	T24	23602986
NA	CHEMICAL	GENE-N	10	41	The present work evaluated the effects of nicotine (NIC), cotinine (chemical), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T15	T25	23602986
NA	CHEMICAL	GENE-N	12	39	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (chemical), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T19	T24	23602986
NA	CHEMICAL	GENE-N	12	41	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (chemical), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T19	T25	23602986
NA	CHEMICAL	GENE-N	8	39	The present work evaluated the effects of nicotine (chemical), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T10	T24	23602986
NA	CHEMICAL	GENE-N	8	41	The present work evaluated the effects of nicotine (chemical), cotinine (COT), mecamylamine (MEC), methyllycaconitine (MLA) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T10	T25	23602986
NA	CHEMICAL	GENE-N	14	39	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (chemical) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of gene (ERK 1/2).	T2	T24	23602986
NA	CHEMICAL	GENE-N	14	41	The present work evaluated the effects of nicotine (NIC), cotinine (COT), mecamylamine (MEC), methyllycaconitine (chemical) and dihydro-beta-eritroidine (DHE) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of Extracellular-Signal-Regulated Kinase (gene).	T2	T25	23602986
NA	CHEMICAL	GENE-N	13	6	Cotinine also increased the phosphorylation of gene in a similar fashion as chemical.	T1	T23	23602986
NA	CHEMICAL	GENE-N	0	6	chemical also increased the phosphorylation of gene in a similar fashion as nicotine.	T21	T23	23602986
CPR:3	CHEMICAL	GENE-Y	19	17	Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, AT1AR and gene following chemical (SA) treatment.	T6	T23	23603059
CPR:3	CHEMICAL	GENE-Y	19	15	Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 AT1R subtypes, gene and AT1BR following chemical (SA) treatment.	T6	T22	23603059
CPR:3	CHEMICAL	GENE-N	19	13	Quantitative real-time PCR analysis revealed significant increases in the mRNA levels of 2 gene subtypes, AT1AR and AT1BR following chemical (SA) treatment.	T6	T21	23603059
NA	CHEMICAL	GENE-Y	13	17	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun chemical-terminal kinases (JchemicalK) and gene (AP-1).	T8	T26	23603059
NA	CHEMICAL	GENE-Y	13	20	In addition, western blot analysis revealed that SA enhances the phosphorylations of c-Jun chemical-terminal kinases (JchemicalK) and activated protein 1 (gene).	T8	T27	23603059
NA	CHEMICAL	GENE-N	16	2	Finally, SA-induced gene expression was found to be prevented both by NAC and specific JNK inhibitor, chemical, strongly indicating that gene upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.	T1	T13	23603059
CPR:4	CHEMICAL	GENE-N	16	2	Finally, SA-induced gene expression was found to be prevented both by NAC and specific JNK inhibitor, chemical, strongly indicating that gene upregulation is a result of the ROS-mediated activation of the JNK signaling pathway.	T1	T28	23603059
CPR:4	CHEMICAL	GENE-N	16	14	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific gene inhibitor, chemical, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the gene signaling pathway.	T1	T12	23603059
NA	CHEMICAL	GENE-N	16	14	Finally, SA-induced AT1R expression was found to be prevented both by NAC and specific gene inhibitor, chemical, strongly indicating that AT1R upregulation is a result of the ROS-mediated activation of the gene signaling pathway.	T1	T14	23603059
CPR:3	CHEMICAL	GENE-N	6	10	Taken together, our results indicate that chemical indeed upregulates the gene expression, thus highlighting a role of chemical-induced aberrant gene signaling in the pathogenesis of hypertension.	T2	T15	23603059
NA	CHEMICAL	GENE-N	6	10	Taken together, our results indicate that chemical indeed upregulates the gene expression, thus highlighting a role of chemical-induced aberrant gene signaling in the pathogenesis of hypertension.	T2	T16	23603059
NA	CHEMICAL	GENE-N	6	10	Taken together, our results indicate that chemical indeed upregulates the gene expression, thus highlighting a role of chemical-induced aberrant gene signaling in the pathogenesis of hypertension.	T3	T15	23603059
CPR:3	CHEMICAL	GENE-N	6	10	Taken together, our results indicate that chemical indeed upregulates the gene expression, thus highlighting a role of chemical-induced aberrant gene signaling in the pathogenesis of hypertension.	T3	T16	23603059
CPR:4	CHEMICAL	GENE-Y	16	8	The mRNA levels of SOD1, CAT, GPx and gene were increased significantly (P<0.05) in the combined chemical+NaAsO2 treatment group.	T9	T18	23603382
CPR:3	CHEMICAL	GENE-Y	16	4	The mRNA levels of gene, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined chemical+NaAsO2 treatment group.	T9	T15	23603382
CPR:3	CHEMICAL	GENE-N	16	6	The mRNA levels of SOD1, CAT, gene and Txnrd1 were increased significantly (P<0.05) in the combined chemical+NaAsO2 treatment group.	T9	T17	23603382
CPR:3	CHEMICAL	GENE-Y	16	5	The mRNA levels of SOD1, gene, GPx and Txnrd1 were increased significantly (P<0.05) in the combined chemical+NaAsO2 treatment group.	T9	T16	23603382
CPR:4	CHEMICAL	GENE-Y	16	8	The mRNA levels of SOD1, CAT, GPx and gene were increased significantly (P<0.05) in the combined Na2SeO3+chemical treatment group.	T10	T18	23603382
CPR:4	CHEMICAL	GENE-Y	16	4	The mRNA levels of gene, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+chemical treatment group.	T10	T15	23603382
CPR:4	CHEMICAL	GENE-N	16	6	The mRNA levels of SOD1, CAT, gene and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+chemical treatment group.	T10	T17	23603382
CPR:4	CHEMICAL	GENE-Y	16	5	The mRNA levels of SOD1, gene, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+chemical treatment group.	T10	T16	23603382
CPR:3	CHEMICAL	GENE-N	12	3	The expressions of gene and HO-1 were significantly (P<0.05) increased in the chemical group and reduced in the combined treatment group.	T12	T19	23603382
CPR:3	CHEMICAL	GENE-Y	12	5	The expressions of HSP70 and gene were significantly (P<0.05) increased in the chemical group and reduced in the combined treatment group.	T12	T20	23603382
NA	CHEMICAL	GENE-Y	37	33	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on gene (AR) and chemical formation in rat lenses with high levels of glucose.	T5	T12	23604720
NA	CHEMICAL	GENE-Y	37	35	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on aldose reductase (gene) and chemical formation in rat lenses with high levels of glucose.	T5	T13	23604720
NA	CHEMICAL	GENE-Y	46	33	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on gene (AR) and galactitol formation in rat lenses with high levels of chemical.	T6	T12	23604720
NA	CHEMICAL	GENE-Y	46	35	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on aldose reductase (gene) and galactitol formation in rat lenses with high levels of chemical.	T6	T13	23604720
NA	CHEMICAL	GENE-Y	33	35	As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on chemical reductase (gene) and galactitol formation in rat lenses with high levels of glucose.	T4	T13	23604720
CPR:4	CHEMICAL	GENE-Y	5	21	From the 10 isolated compounds, chemical showed the most potent inhibition, with IC50 values of 0.30 and 0.67M for rAR and gene, respectively.	T9	T19	23604720
CPR:4	CHEMICAL	GENE-Y	5	19	From the 10 isolated compounds, chemical showed the most potent inhibition, with IC50 values of 0.30 and 0.67M for gene and rhAR, respectively.	T9	T18	23604720
CPR:4	CHEMICAL	GENE-Y	11	16	In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, chemical showed competitive inhibition of gene.	T10	T11	23604720
NA	CHEMICAL	GENE-N	6	4	Enzyme activities such as gene, chemical, catalase and lipid peroxidation were also determined in the stomach tissues.	T17	T23	23608239
NA	CHEMICAL	GENE-Y	6	7	Enzyme activities such as superoxide dismutase, chemical, gene and lipid peroxidation were also determined in the stomach tissues.	T17	T24	23608239
NA	CHEMICAL	GENE-Y	4	7	Enzyme activities such as chemical dismutase, glutathione, gene and lipid peroxidation were also determined in the stomach tissues.	T16	T24	23608239
NA	CHEMICAL	GENE-N	22	10	Consequently significant changes were observed in enzyme activities such as gene, CAT, GSH and LPO in the stomach tissues when compared with chemical control group.	T8	T21	23608239
NA	CHEMICAL	GENE-Y	22	11	Consequently significant changes were observed in enzyme activities such as SOD, gene, GSH and LPO in the stomach tissues when compared with chemical control group.	T8	T22	23608239
NA	CHEMICAL	GENE-N	12	10	Consequently significant changes were observed in enzyme activities such as gene, CAT, chemical and LPO in the stomach tissues when compared with ethanol control group.	T7	T21	23608239
NA	CHEMICAL	GENE-Y	12	11	Consequently significant changes were observed in enzyme activities such as SOD, gene, chemical and LPO in the stomach tissues when compared with ethanol control group.	T7	T22	23608239
NA	CHEMICAL	GENE-N	33	23	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that MK2 catalytic activity directly regulated the promoters of the fast fiber-specific gene and the slow fiber-specific sarco/endoplasmic reticulum chemical-ATPase (SERCA) 2 gene.	T2	T21	23608535
NA	CHEMICAL	GENE-Y	33	12	Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that gene catalytic activity directly regulated the promoters of the fast fiber-specific myosin heavy chain IId/x and the slow fiber-specific sarco/endoplasmic reticulum chemical-ATPase (SERCA) 2 gene.	T2	T19	23608535
NA	CHEMICAL	GENE-N	8	3	These results link gene to the regulation of chemical dynamics and identify enzymatic activity of gene as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in gene(-/-) mice.	T1	T3	23608535
NA	CHEMICAL	GENE-N	8	3	These results link gene to the regulation of chemical dynamics and identify enzymatic activity of gene as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in gene(-/-) mice.	T1	T5	23608535
NA	CHEMICAL	GENE-N	8	3	These results link gene to the regulation of chemical dynamics and identify enzymatic activity of gene as a critical factor for modulating cross-striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in gene(-/-) mice.	T1	T7	23608535
CPR:9	CHEMICAL	GENE-Y	11	4	Recent observations revealed that gene catalyzes N-glucuronidation of chemical-containing compounds.	T3	T40	23611809
CPR:9	CHEMICAL	GENE-Y	16	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, chemical, tamoxifen, ketoconazole and midazolam.	T16	T41	23611809
CPR:9	CHEMICAL	GENE-Y	11	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of chemical, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	T11	T41	23611809
CPR:9	CHEMICAL	GENE-Y	18	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, chemical and midazolam.	T18	T41	23611809
CPR:9	CHEMICAL	GENE-Y	12	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, chemical, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	T12	T41	23611809
CPR:9	CHEMICAL	GENE-Y	15	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, chemical, diphenhydramine, tamoxifen, ketoconazole and midazolam.	T15	T41	23611809
CPR:9	CHEMICAL	GENE-Y	13	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, chemical, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	T13	T41	23611809
CPR:9	CHEMICAL	GENE-Y	20	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and chemical.	T19	T41	23611809
CPR:9	CHEMICAL	GENE-Y	14	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, chemical, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.	T14	T41	23611809
CPR:9	CHEMICAL	GENE-Y	17	2	Using recombinant gene, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, chemical, ketoconazole and midazolam.	T17	T41	23611809
NA	CHEMICAL	GENE-Y	21	11	These are drugs that were previously reported to be substrates for gene or UGT1A3 and that contain in their structure either chemical, cyclic amines, or an imidazole group.	T20	T42	23611809
NA	CHEMICAL	GENE-Y	21	13	These are drugs that were previously reported to be substrates for UGT1A4 or gene and that contain in their structure either chemical, cyclic amines, or an imidazole group.	T20	T43	23611809
NA	CHEMICAL	GENE-Y	24	11	These are drugs that were previously reported to be substrates for gene or UGT1A3 and that contain in their structure either tertiary aliphatic amines, chemical, or an imidazole group.	T21	T42	23611809
NA	CHEMICAL	GENE-Y	24	13	These are drugs that were previously reported to be substrates for UGT1A4 or gene and that contain in their structure either tertiary aliphatic amines, chemical, or an imidazole group.	T21	T43	23611809
NA	CHEMICAL	GENE-Y	28	11	These are drugs that were previously reported to be substrates for gene or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an chemical group.	T22	T42	23611809
NA	CHEMICAL	GENE-Y	28	13	These are drugs that were previously reported to be substrates for UGT1A4 or gene and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an chemical group.	T22	T43	23611809
NA	CHEMICAL	GENE-Y	8	0	gene was inactive in the glucuronidation of desipramine, chemical, carbamazepine and afloqualone.	T24	T44	23611809
NA	CHEMICAL	GENE-Y	9	0	gene was inactive in the glucuronidation of desipramine, nortriptyline, chemical and afloqualone.	T25	T44	23611809
NA	CHEMICAL	GENE-Y	7	0	gene was inactive in the glucuronidation of chemical, nortriptyline, carbamazepine and afloqualone.	T23	T44	23611809
NA	CHEMICAL	GENE-Y	11	0	gene was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine and chemical.	T26	T44	23611809
NA	CHEMICAL	GENE-Y	5	14	This group of drugs contains chemical, and these results suggest that gene preferably conjugates tertiary amines.	T27	T45	23611809
CPR:9	CHEMICAL	GENE-Y	17	14	This group of drugs contains secondary or primary amines, and these results suggest that gene preferably conjugates chemical.	T28	T45	23611809
NA	CHEMICAL	GENE-Y	10	5	This preference is partial because gene did not conjugate the chemical in trifluoperazine.	T1	T29	23611809
NA	CHEMICAL	GENE-Y	14	5	This preference is partial because gene did not conjugate the tertiary cyclic amine in chemical.	T2	T29	23611809
CPR:9	CHEMICAL	GENE-Y	14	9	Kinetic analyses revealed that the affinity and clearance of gene for amitriptyline, imipramine, and chemical are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	T6	T30	23611809
CPR:9	CHEMICAL	GENE-Y	14	23	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and chemical are significantly higher than the corresponding values of gene and UGT1A3, although the Vmax values of gene toward these drugs are considerably higher.	T6	T31	23611809
CPR:9	CHEMICAL	GENE-Y	14	23	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and chemical are significantly higher than the corresponding values of gene and UGT1A3, although the Vmax values of gene toward these drugs are considerably higher.	T6	T33	23611809
CPR:9	CHEMICAL	GENE-Y	14	25	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and chemical are significantly higher than the corresponding values of UGT1A4 and gene, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	T6	T32	23611809
CPR:9	CHEMICAL	GENE-Y	11	9	Kinetic analyses revealed that the affinity and clearance of gene for chemical, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	T4	T30	23611809
CPR:9	CHEMICAL	GENE-Y	11	23	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for chemical, imipramine, and diphenhydramine are significantly higher than the corresponding values of gene and UGT1A3, although the Vmax values of gene toward these drugs are considerably higher.	T4	T31	23611809
CPR:9	CHEMICAL	GENE-Y	11	23	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for chemical, imipramine, and diphenhydramine are significantly higher than the corresponding values of gene and UGT1A3, although the Vmax values of gene toward these drugs are considerably higher.	T4	T33	23611809
NA	CHEMICAL	GENE-Y	11	25	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for chemical, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and gene, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	T4	T32	23611809
CPR:9	CHEMICAL	GENE-Y	12	9	Kinetic analyses revealed that the affinity and clearance of gene for amitriptyline, chemical, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	T5	T30	23611809
CPR:9	CHEMICAL	GENE-Y	12	23	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, chemical, and diphenhydramine are significantly higher than the corresponding values of gene and UGT1A3, although the Vmax values of gene toward these drugs are considerably higher.	T5	T31	23611809
CPR:9	CHEMICAL	GENE-Y	12	23	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, chemical, and diphenhydramine are significantly higher than the corresponding values of gene and UGT1A3, although the Vmax values of gene toward these drugs are considerably higher.	T5	T33	23611809
CPR:9	CHEMICAL	GENE-Y	12	25	Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, chemical, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and gene, although the Vmax values of UGT1A4 toward these drugs are considerably higher.	T5	T32	23611809
CPR:9	CHEMICAL	GENE-Y	17	12	In conclusion, this study expands the understanding of the substrate specificity of gene, highlighting its preference for chemical with higher affinities and clearance values than those of UGT1A4 and UGT1A3.	T9	T35	23611809
CPR:9	CHEMICAL	GENE-Y	17	28	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for chemical with higher affinities and clearance values than those of gene and UGT1A3.	T9	T36	23611809
CPR:9	CHEMICAL	GENE-Y	17	30	In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for chemical with higher affinities and clearance values than those of UGT1A4 and gene.	T9	T37	23611809
CPR:6	CHEMICAL	GENE-Y	0	4	chemical (SB) is an gene (IL-8RB) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	T1	T14	23611835
CPR:6	CHEMICAL	GENE-Y	0	7	chemical (SB) is an IL-8 receptor B (gene) antagonist that has previously been shown to inhibit IL-8-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	T1	T16	23611835
CPR:4	CHEMICAL	GENE-Y	0	4	chemical (SB) is an gene receptor B (geneRB) antagonist that has previously been shown to inhibit gene-based cancer cell invasion, and to possess in vivo anti-inflammatory and anti-nociceptive effects.	T1	T22	23611835
NA	CHEMICAL	GENE-Y	11	14	Molecular docking studies suggested that SB has a good affinity towards chemical-binding site on gene subunit.	T2	T20	23611835
CPR:6	CHEMICAL	GENE-Y	2	14	Of note, chemical which is a close structural analogue of SB225002 with a potent gene antagonistic activity did not exhibit a similar antimitotic activity.	T3	T21	23611835
CPR:6	CHEMICAL	GENE-Y	10	14	Of note, SB265610 which is a close structural analogue of chemical with a potent gene antagonistic activity did not exhibit a similar antimitotic activity.	T4	T21	23611835
NA	CHEMICAL	GENE-N	8	38	In this report, we utilized a library of chemical that produce two and three GAG chains on the same scaffold, respectively, thus mimicking PGs, to examine the importance of GAG valency and chain type in regulating FGF/gene interactions in vivo in zebrafish.	T4	T20	23614643
NA	CHEMICAL	GENE-N	8	38	In this report, we utilized a library of chemical that produce two and three GAG chains on the same scaffold, respectively, thus mimicking PGs, to examine the importance of GAG valency and chain type in regulating gene/geneR interactions in vivo in zebrafish.	T4	T19	23614643
CPR:4	CHEMICAL	GENE-N	14	11	In support of this observation, elongation can be reversed by the gene inhibitor chemical, mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.	T1	T9	23614643
NA	CHEMICAL	GENE-Y	14	20	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor chemical, mRNA for the FGFR antagonist gene, or FGF8 morpholino.	T1	T11	23614643
NA	CHEMICAL	GENE-N	14	18	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor chemical, mRNA for the gene antagonist sprouty4, or FGF8 morpholino.	T1	T10	23614643
NA	CHEMICAL	GENE-Y	14	22	In support of this observation, elongation can be reversed by the tyrosine kinase inhibitor chemical, mRNA for the FGFR antagonist sprouty4, or gene morpholino.	T1	T12	23614643
NA	CHEMICAL	GENE-N	21	11	Furthermore, expression of a multivalent but not a monovalent GAG containing gene proteoglycan recapitulates the elongation phenotype observed with the bivalent chemical.	T3	T13	23614643
NA	CHEMICAL	GENE-Y	11	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T10	T35	23615471
NA	CHEMICAL	GENE-Y	11	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T11	T35	23615471
NA	CHEMICAL	GENE-Y	11	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T12	T35	23615471
NA	CHEMICAL	GENE-Y	11	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T13	T35	23615471
NA	CHEMICAL	GENE-Y	11	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T7	T35	23615471
NA	CHEMICAL	GENE-Y	11	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T9	T35	23615471
NA	CHEMICAL	GENE-Y	11	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, gene, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T27	23615471
NA	CHEMICAL	GENE-Y	11	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, gene, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T27	23615471
NA	CHEMICAL	GENE-Y	11	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, gene, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T27	23615471
NA	CHEMICAL	GENE-Y	11	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, gene, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T27	23615471
NA	CHEMICAL	GENE-Y	11	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, gene, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T27	23615471
NA	CHEMICAL	GENE-Y	11	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, gene, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T27	23615471
NA	CHEMICAL	GENE-Y	11	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T10	T36	23615471
NA	CHEMICAL	GENE-Y	11	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T11	T36	23615471
NA	CHEMICAL	GENE-Y	11	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T12	T36	23615471
NA	CHEMICAL	GENE-Y	11	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T13	T36	23615471
NA	CHEMICAL	GENE-Y	11	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T7	T36	23615471
NA	CHEMICAL	GENE-Y	11	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T9	T36	23615471
NA	CHEMICAL	GENE-N	11	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, gene, chemical-gene Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T30	23615471
NA	CHEMICAL	GENE-N	11	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, gene, chemical-gene Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T30	23615471
NA	CHEMICAL	GENE-N	11	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, gene, chemical-gene Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T30	23615471
NA	CHEMICAL	GENE-N	11	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, gene, chemical-gene Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T30	23615471
NA	CHEMICAL	GENE-N	11	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, gene, chemical-gene Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T30	23615471
NA	CHEMICAL	GENE-N	11	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, gene, chemical-gene Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T30	23615471
NA	CHEMICAL	GENE-Y	11	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, gene, FOXO3a, chemical-gene Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T26	23615471
NA	CHEMICAL	GENE-Y	11	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, gene, FOXO3a, chemical-gene Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T26	23615471
NA	CHEMICAL	GENE-Y	11	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, gene, FOXO3a, chemical-gene Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T26	23615471
NA	CHEMICAL	GENE-Y	11	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, gene, FOXO3a, chemical-gene Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T26	23615471
NA	CHEMICAL	GENE-Y	11	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, gene, FOXO3a, chemical-gene Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T26	23615471
NA	CHEMICAL	GENE-Y	11	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, gene, FOXO3a, chemical-gene Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T26	23615471
NA	CHEMICAL	GENE-Y	11	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, gene, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T25	23615471
NA	CHEMICAL	GENE-Y	11	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, gene, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T25	23615471
NA	CHEMICAL	GENE-Y	11	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, gene, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T25	23615471
NA	CHEMICAL	GENE-Y	11	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, gene, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T25	23615471
NA	CHEMICAL	GENE-Y	11	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, gene, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T25	23615471
NA	CHEMICAL	GENE-Y	11	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, gene, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T25	23615471
NA	CHEMICAL	GENE-Y	11	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T34	23615471
NA	CHEMICAL	GENE-Y	11	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T34	23615471
NA	CHEMICAL	GENE-Y	11	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T34	23615471
NA	CHEMICAL	GENE-Y	11	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T34	23615471
NA	CHEMICAL	GENE-Y	11	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T34	23615471
NA	CHEMICAL	GENE-Y	11	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T34	23615471
NA	CHEMICAL	GENE-Y	11	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T21	23615471
NA	CHEMICAL	GENE-Y	11	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T21	23615471
NA	CHEMICAL	GENE-Y	11	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T21	23615471
NA	CHEMICAL	GENE-Y	11	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T21	23615471
NA	CHEMICAL	GENE-Y	11	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T21	23615471
NA	CHEMICAL	GENE-Y	11	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T21	23615471
NA	CHEMICAL	GENE-Y	11	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T22	23615471
NA	CHEMICAL	GENE-Y	11	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T22	23615471
NA	CHEMICAL	GENE-Y	11	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T22	23615471
NA	CHEMICAL	GENE-Y	11	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T22	23615471
NA	CHEMICAL	GENE-Y	11	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T22	23615471
NA	CHEMICAL	GENE-Y	11	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T22	23615471
NA	CHEMICAL	GENE-Y	11	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T20	23615471
NA	CHEMICAL	GENE-Y	11	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T20	23615471
NA	CHEMICAL	GENE-Y	11	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T20	23615471
NA	CHEMICAL	GENE-Y	11	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T20	23615471
NA	CHEMICAL	GENE-Y	11	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T20	23615471
NA	CHEMICAL	GENE-Y	11	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T20	23615471
NA	CHEMICAL	GENE-N	11	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, chemical-gene Ser473, chemical-gene Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T19	23615471
NA	CHEMICAL	GENE-N	11	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, chemical-gene Ser473, chemical-gene Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T19	23615471
NA	CHEMICAL	GENE-N	11	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, chemical-gene Ser473, chemical-gene Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T19	23615471
NA	CHEMICAL	GENE-N	11	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, chemical-gene Ser473, chemical-gene Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T19	23615471
NA	CHEMICAL	GENE-N	11	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, chemical-gene Ser473, chemical-gene Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T19	23615471
NA	CHEMICAL	GENE-N	11	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, chemical-gene Ser473, chemical-gene Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, Rb, chemical-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T19	23615471
NA	CHEMICAL	GENE-Y	11	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, gene, chemical-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T10	T32	23615471
NA	CHEMICAL	GENE-Y	11	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, gene, chemical-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T11	T32	23615471
NA	CHEMICAL	GENE-Y	11	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, gene, chemical-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T12	T32	23615471
NA	CHEMICAL	GENE-Y	11	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, gene, chemical-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T13	T32	23615471
NA	CHEMICAL	GENE-Y	11	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, gene, chemical-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T7	T32	23615471
NA	CHEMICAL	GENE-Y	11	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, chemical-Akt Ser473, chemical-Akt Thr 308, GSK3, FOXO1, FOXO3a, chemical-FOXO1 Thr24, chemical-FoxO3a Thr32, NF-B, chemical-NF-B Ser536, gene, chemical-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T9	T32	23615471
CPR:4	CHEMICAL	GENE-Y	2	21	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, gene Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T29	23615471
CPR:4	CHEMICAL	GENE-N	2	24	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, gene Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T31	23615471
CPR:4	CHEMICAL	GENE-Y	2	19	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, gene Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T28	23615471
CPR:4	CHEMICAL	GENE-N	2	11	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, gene Ser473, gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T23	23615471
CPR:4	CHEMICAL	GENE-N	2	11	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, gene Ser473, gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T24	23615471
CPR:4	CHEMICAL	GENE-Y	2	27	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T33	23615471
CPR:4	CHEMICAL	GENE-Y	2	31	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T6	T35	23615471
CPR:4	CHEMICAL	GENE-Y	2	18	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, gene, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T27	23615471
CPR:3	CHEMICAL	GENE-Y	2	38	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T6	T36	23615471
CPR:4	CHEMICAL	GENE-N	2	23	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, gene, phospho-gene Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T30	23615471
CPR:4	CHEMICAL	GENE-Y	2	17	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, gene, FOXO3a, phospho-gene Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T26	23615471
CPR:4	CHEMICAL	GENE-Y	2	16	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, gene, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T25	23615471
CPR:4	CHEMICAL	GENE-Y	2	29	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T34	23615471
CPR:4	CHEMICAL	GENE-Y	2	9	Treatment with chemical decreased protein abundance of Akt, Akt1, gene, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T21	23615471
CPR:4	CHEMICAL	GENE-Y	2	10	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, gene, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T22	23615471
CPR:4	CHEMICAL	GENE-Y	2	8	Treatment with chemical decreased protein abundance of Akt, gene, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T20	23615471
CPR:4	CHEMICAL	GENE-N	2	7	Treatment with chemical decreased protein abundance of gene, gene1, gene2, gene3, phospho-gene Ser473, phospho-gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T19	23615471
CPR:4	CHEMICAL	GENE-Y	2	26	Treatment with chemical decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B Ser536, gene, phospho-gene Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T6	T32	23615471
NA	CHEMICAL	GENE-Y	12	21	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, gene Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T29	23615471
NA	CHEMICAL	GENE-Y	12	21	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, gene Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T29	23615471
NA	CHEMICAL	GENE-N	12	24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, gene chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T31	23615471
NA	CHEMICAL	GENE-N	12	24	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, gene chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T31	23615471
NA	CHEMICAL	GENE-Y	12	19	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, gene Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T28	23615471
NA	CHEMICAL	GENE-Y	12	19	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, gene Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T28	23615471
NA	CHEMICAL	GENE-N	12	11	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, gene chemical473, gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T23	23615471
NA	CHEMICAL	GENE-N	12	11	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, gene chemical473, gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T24	23615471
NA	CHEMICAL	GENE-N	12	11	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, gene chemical473, gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T23	23615471
NA	CHEMICAL	GENE-N	12	11	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, gene chemical473, gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T24	23615471
NA	CHEMICAL	GENE-Y	12	27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, gene chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T33	23615471
NA	CHEMICAL	GENE-Y	12	27	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, gene chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T33	23615471
NA	CHEMICAL	GENE-Y	12	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T14	T35	23615471
NA	CHEMICAL	GENE-Y	12	31	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and gene, but increased cell cycle inhibitor p27Kip.	T8	T35	23615471
NA	CHEMICAL	GENE-Y	12	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, gene, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T27	23615471
NA	CHEMICAL	GENE-Y	12	18	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, gene, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T27	23615471
NA	CHEMICAL	GENE-Y	12	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T14	T36	23615471
NA	CHEMICAL	GENE-Y	12	38	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor gene.	T8	T36	23615471
NA	CHEMICAL	GENE-N	12	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, gene, phospho-gene chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T30	23615471
NA	CHEMICAL	GENE-N	12	23	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, gene, phospho-gene chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T30	23615471
NA	CHEMICAL	GENE-Y	12	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, gene, FOXO3a, phospho-gene Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T26	23615471
NA	CHEMICAL	GENE-Y	12	17	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, gene, FOXO3a, phospho-gene Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T26	23615471
NA	CHEMICAL	GENE-Y	12	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, gene, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T25	23615471
NA	CHEMICAL	GENE-Y	12	16	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, gene, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T25	23615471
NA	CHEMICAL	GENE-Y	12	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T34	23615471
NA	CHEMICAL	GENE-Y	12	29	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, gene, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T34	23615471
NA	CHEMICAL	GENE-Y	12	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T21	23615471
NA	CHEMICAL	GENE-Y	12	9	Treatment with CAPE decreased protein abundance of Akt, Akt1, gene, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T21	23615471
NA	CHEMICAL	GENE-Y	12	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T22	23615471
NA	CHEMICAL	GENE-Y	12	10	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, gene, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T22	23615471
NA	CHEMICAL	GENE-Y	12	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T20	23615471
NA	CHEMICAL	GENE-Y	12	8	Treatment with CAPE decreased protein abundance of Akt, gene, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T20	23615471
NA	CHEMICAL	GENE-N	12	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, phospho-gene chemical473, phospho-gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T19	23615471
NA	CHEMICAL	GENE-N	12	7	Treatment with CAPE decreased protein abundance of gene, gene1, gene2, gene3, phospho-gene chemical473, phospho-gene Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, Rb, phospho-Rb chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T19	23615471
NA	CHEMICAL	GENE-Y	12	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, gene, phospho-gene chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T14	T32	23615471
NA	CHEMICAL	GENE-Y	12	26	Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt chemical473, phospho-Akt Thr 308, GSK3, FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-B, phospho-NF-B chemical536, gene, phospho-gene chemical807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.	T8	T32	23615471
NA	CHEMICAL	GENE-Y	13	4	Overexpression of Akt1 or gene in TW2.6 cells rescued growth inhibition caused by chemical treatment.	T15	T38	23615471
NA	CHEMICAL	GENE-Y	13	2	Overexpression of gene or Akt2 in TW2.6 cells rescued growth inhibition caused by chemical treatment.	T15	T37	23615471
NA	CHEMICAL	GENE-Y	9	17	Among the transcription factors that play critical roles in chemical metabolism are NF-E2-related factor 2 (Nrf2) and gene (ATF4).	T13	T33	23618921
NA	CHEMICAL	GENE-Y	9	12	Among the transcription factors that play critical roles in chemical metabolism are gene (Nrf2) and activating transcription factor 4 (ATF4).	T13	T31	23618921
NA	CHEMICAL	GENE-Y	9	21	Among the transcription factors that play critical roles in chemical metabolism are NF-E2-related factor 2 (Nrf2) and activating transcription factor 4 (gene).	T13	T34	23618921
NA	CHEMICAL	GENE-Y	9	15	Among the transcription factors that play critical roles in chemical metabolism are NF-E2-related factor 2 (gene) and activating transcription factor 4 (ATF4).	T13	T32	23618921
CPR:3	CHEMICAL	GENE-Y	4	13	Here we show that chemical rapidly increases the levels of both Nrf2 and gene as well as Nrf2- and gene-dependent gene transcription via distinct mechanisms.	T19	T36	23618921
CPR:3	CHEMICAL	GENE-Y	4	13	Here we show that chemical rapidly increases the levels of both Nrf2 and gene as well as Nrf2- and gene-dependent gene transcription via distinct mechanisms.	T19	T38	23618921
CPR:3	CHEMICAL	GENE-Y	4	11	Here we show that chemical rapidly increases the levels of both gene and ATF4 as well as gene- and ATF4-dependent gene transcription via distinct mechanisms.	T19	T35	23618921
CPR:3	CHEMICAL	GENE-Y	4	11	Here we show that chemical rapidly increases the levels of both gene and ATF4 as well as gene- and ATF4-dependent gene transcription via distinct mechanisms.	T19	T37	23618921
NA	CHEMICAL	GENE-N	1	19	Although chemical greatly increases the stability of both Nrf2 and ATF4, only the effect on ATF4 is dependent on gene activity.	T2	T26	23618921
CPR:3	CHEMICAL	GENE-Y	1	10	Although chemical greatly increases the stability of both Nrf2 and gene, only the effect on gene is dependent on protein kinase activity.	T2	T24	23618921
NA	CHEMICAL	GENE-Y	1	10	Although chemical greatly increases the stability of both Nrf2 and gene, only the effect on gene is dependent on protein kinase activity.	T2	T25	23618921
CPR:3	CHEMICAL	GENE-Y	1	8	Although chemical greatly increases the stability of both gene and ATF4, only the effect on ATF4 is dependent on protein kinase activity.	T2	T23	23618921
NA	CHEMICAL	GENE-Y	12	5	Using siRNA we found that gene, but not Nrf2, is important for chemical's ability to increase GSH levels under basal conditions whereas both gene and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	T3	T27	23618921
NA	CHEMICAL	GENE-Y	12	5	Using siRNA we found that gene, but not Nrf2, is important for chemical's ability to increase GSH levels under basal conditions whereas both gene and Nrf2 appear to cooperate to increase GSH levels under oxidative stress conditions.	T3	T29	23618921
NA	CHEMICAL	GENE-Y	12	8	Using siRNA we found that ATF4, but not gene, is important for chemical's ability to increase GSH levels under basal conditions whereas both ATF4 and gene appear to cooperate to increase GSH levels under oxidative stress conditions.	T3	T28	23618921
NA	CHEMICAL	GENE-Y	12	8	Using siRNA we found that ATF4, but not gene, is important for chemical's ability to increase GSH levels under basal conditions whereas both ATF4 and gene appear to cooperate to increase GSH levels under oxidative stress conditions.	T3	T30	23618921
NA	CHEMICAL	GENE-Y	16	5	Using siRNA we found that gene, but not Nrf2, is important for fisetin's ability to increase chemical levels under basal conditions whereas both gene and Nrf2 appear to cooperate to increase chemical levels under oxidative stress conditions.	T4	T27	23618921
NA	CHEMICAL	GENE-Y	16	5	Using siRNA we found that gene, but not Nrf2, is important for fisetin's ability to increase chemical levels under basal conditions whereas both gene and Nrf2 appear to cooperate to increase chemical levels under oxidative stress conditions.	T4	T29	23618921
NA	CHEMICAL	GENE-Y	16	5	Using siRNA we found that gene, but not Nrf2, is important for fisetin's ability to increase chemical levels under basal conditions whereas both gene and Nrf2 appear to cooperate to increase chemical levels under oxidative stress conditions.	T6	T27	23618921
NA	CHEMICAL	GENE-Y	16	5	Using siRNA we found that gene, but not Nrf2, is important for fisetin's ability to increase chemical levels under basal conditions whereas both gene and Nrf2 appear to cooperate to increase chemical levels under oxidative stress conditions.	T6	T29	23618921
NA	CHEMICAL	GENE-Y	16	8	Using siRNA we found that ATF4, but not gene, is important for fisetin's ability to increase chemical levels under basal conditions whereas both ATF4 and gene appear to cooperate to increase chemical levels under oxidative stress conditions.	T4	T28	23618921
NA	CHEMICAL	GENE-Y	16	8	Using siRNA we found that ATF4, but not gene, is important for fisetin's ability to increase chemical levels under basal conditions whereas both ATF4 and gene appear to cooperate to increase chemical levels under oxidative stress conditions.	T4	T30	23618921
NA	CHEMICAL	GENE-Y	16	8	Using siRNA we found that ATF4, but not gene, is important for fisetin's ability to increase chemical levels under basal conditions whereas both ATF4 and gene appear to cooperate to increase chemical levels under oxidative stress conditions.	T6	T28	23618921
NA	CHEMICAL	GENE-Y	16	8	Using siRNA we found that ATF4, but not gene, is important for fisetin's ability to increase chemical levels under basal conditions whereas both ATF4 and gene appear to cooperate to increase chemical levels under oxidative stress conditions.	T6	T30	23618921
NA	CHEMICAL	GENE-N	25	16	Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of gene, i.e., ASGPR, were prepared starting from a chemical conjugate.	T3	T20	23621358
NA	CHEMICAL	GENE-N	25	19	Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., gene, were prepared starting from a chemical conjugate.	T3	T21	23621358
NA	CHEMICAL	GENE-N	16	19	Polymeric micelles potentially able to carry to hepatocytes a ribavirin (RBV) prodrug, exploiting the presence of chemical receptors, i.e., gene, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	T2	T21	23621358
NA	CHEMICAL	GENE-N	9	16	Polymeric micelles potentially able to carry to hepatocytes a chemical (RBV) prodrug, exploiting the presence of gene, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	T13	T20	23621358
NA	CHEMICAL	GENE-N	9	19	Polymeric micelles potentially able to carry to hepatocytes a chemical (RBV) prodrug, exploiting the presence of carbohydrate receptors, i.e., gene, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	T13	T21	23621358
NA	CHEMICAL	GENE-N	10	16	Polymeric micelles potentially able to carry to hepatocytes a ribavirin (chemical) prodrug, exploiting the presence of gene, i.e., ASGPR, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	T15	T20	23621358
NA	CHEMICAL	GENE-N	10	19	Polymeric micelles potentially able to carry to hepatocytes a ribavirin (chemical) prodrug, exploiting the presence of carbohydrate receptors, i.e., gene, were prepared starting from a galactosylated polylactide-polyaminoacid conjugate.	T15	T21	23621358
NA	CHEMICAL	GENE-N	0	21	chemical-containing monooxygenases (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including gene and FMO6P), but remain to be investigated in cynomolgus macaque.	T1	T28	23623750
NA	CHEMICAL	GENE-Y	0	23	chemical-containing monooxygenases (FMOs), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and gene), but remain to be investigated in cynomolgus macaque.	T1	T29	23623750
NA	CHEMICAL	GENE-N	0	2	chemical-containing monooxygenases (gene), drug-metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including FMO1-5 and FMO6P), but remain to be investigated in cynomolgus macaque.	T1	T32	23623750
NA	CHEMICAL	GENE-N	0	21	chemical sequences of cynomolgus FMO1-5, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with gene.	T9	T34	23623750
NA	CHEMICAL	GENE-N	0	5	chemical sequences of cynomolgus gene, respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with human gene.	T9	T33	23623750
NA	CHEMICAL	GENE-Y	16	0	gene, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and chemical, respectively.	T3	T46	23623750
CPR:9	CHEMICAL	GENE-Y	16	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized benzydamine, and FMO1/gene and gene also metabolized methimazole and chemical, respectively.	T3	T14	23623750
CPR:9	CHEMICAL	GENE-Y	16	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized benzydamine, and FMO1/gene and gene also metabolized methimazole and chemical, respectively.	T3	T15	23623750
NA	CHEMICAL	GENE-Y	16	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized benzydamine, and FMO1/gene and gene also metabolized methimazole and chemical, respectively.	T3	T48	23623750
CPR:9	CHEMICAL	GENE-Y	16	1	Cynomolgus gene, FMO2, FMO3, and FMO5 metabolized benzydamine, and gene/FMO3 and FMO3 also metabolized methimazole and chemical, respectively.	T3	T13	23623750
NA	CHEMICAL	GENE-Y	16	2	Cynomolgus FMO1, gene, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and chemical, respectively.	T3	T47	23623750
NA	CHEMICAL	GENE-Y	16	5	Cynomolgus FMO1, FMO2, FMO3, and gene metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized methimazole and chemical, respectively.	T3	T49	23623750
NA	CHEMICAL	GENE-Y	14	0	gene, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized chemical and trimethylamine, respectively.	T2	T46	23623750
CPR:9	CHEMICAL	GENE-Y	14	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized benzydamine, and FMO1/gene and gene also metabolized chemical and trimethylamine, respectively.	T2	T14	23623750
CPR:9	CHEMICAL	GENE-Y	14	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized benzydamine, and FMO1/gene and gene also metabolized chemical and trimethylamine, respectively.	T2	T15	23623750
NA	CHEMICAL	GENE-Y	14	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized benzydamine, and FMO1/gene and gene also metabolized chemical and trimethylamine, respectively.	T2	T48	23623750
CPR:9	CHEMICAL	GENE-Y	14	1	Cynomolgus gene, FMO2, FMO3, and FMO5 metabolized benzydamine, and gene/FMO3 and FMO3 also metabolized chemical and trimethylamine, respectively.	T2	T13	23623750
NA	CHEMICAL	GENE-Y	14	2	Cynomolgus FMO1, gene, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized chemical and trimethylamine, respectively.	T2	T47	23623750
NA	CHEMICAL	GENE-Y	14	5	Cynomolgus FMO1, FMO2, FMO3, and gene metabolized benzydamine, and FMO1/FMO3 and FMO3 also metabolized chemical and trimethylamine, respectively.	T2	T49	23623750
CPR:9	CHEMICAL	GENE-Y	7	0	gene, FMO2, FMO3, and FMO5 metabolized chemical, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	T10	T46	23623750
NA	CHEMICAL	GENE-Y	7	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized chemical, and FMO1/gene and gene also metabolized methimazole and trimethylamine, respectively.	T10	T14	23623750
NA	CHEMICAL	GENE-Y	7	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized chemical, and FMO1/gene and gene also metabolized methimazole and trimethylamine, respectively.	T10	T15	23623750
CPR:9	CHEMICAL	GENE-Y	7	3	Cynomolgus FMO1, FMO2, gene, and FMO5 metabolized chemical, and FMO1/gene and gene also metabolized methimazole and trimethylamine, respectively.	T10	T48	23623750
NA	CHEMICAL	GENE-Y	7	1	Cynomolgus gene, FMO2, FMO3, and FMO5 metabolized chemical, and gene/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	T10	T13	23623750
CPR:9	CHEMICAL	GENE-Y	7	2	Cynomolgus FMO1, gene, FMO3, and FMO5 metabolized chemical, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	T10	T47	23623750
CPR:9	CHEMICAL	GENE-Y	7	5	Cynomolgus FMO1, FMO2, FMO3, and gene metabolized chemical, and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.	T10	T49	23623750
CPR:9	CHEMICAL	GENE-Y	2	6	Rates of chemical N-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in chemical N-oxygenation might be partly accounted for by the variable gene expression.	T4	T16	23623750
NA	CHEMICAL	GENE-Y	2	6	Rates of chemical N-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in chemical N-oxygenation might be partly accounted for by the variable gene expression.	T4	T17	23623750
NA	CHEMICAL	GENE-Y	2	6	Rates of chemical N-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in chemical N-oxygenation might be partly accounted for by the variable gene expression.	T4	T18	23623750
NA	CHEMICAL	GENE-Y	2	6	Rates of chemical N-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in chemical N-oxygenation might be partly accounted for by the variable gene expression.	T6	T16	23623750
NA	CHEMICAL	GENE-Y	2	6	Rates of chemical N-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in chemical N-oxygenation might be partly accounted for by the variable gene expression.	T6	T17	23623750
CPR:9	CHEMICAL	GENE-Y	2	6	Rates of chemical N-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in chemical N-oxygenation might be partly accounted for by the variable gene expression.	T6	T18	23623750
CPR:9	CHEMICAL	GENE-Y	3	6	Rates of benzydamine chemical-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in benzydamine chemical-oxygenation might be partly accounted for by the variable gene expression.	T5	T16	23623750
NA	CHEMICAL	GENE-Y	3	6	Rates of benzydamine chemical-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in benzydamine chemical-oxygenation might be partly accounted for by the variable gene expression.	T5	T17	23623750
NA	CHEMICAL	GENE-Y	3	6	Rates of benzydamine chemical-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in benzydamine chemical-oxygenation might be partly accounted for by the variable gene expression.	T5	T18	23623750
NA	CHEMICAL	GENE-Y	3	6	Rates of benzydamine chemical-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in benzydamine chemical-oxygenation might be partly accounted for by the variable gene expression.	T7	T16	23623750
NA	CHEMICAL	GENE-Y	3	6	Rates of benzydamine chemical-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in benzydamine chemical-oxygenation might be partly accounted for by the variable gene expression.	T7	T17	23623750
CPR:9	CHEMICAL	GENE-Y	3	6	Rates of benzydamine chemical-oxygenation (catalyzed by gene) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with gene protein expression, indicating that the inter-animal variations in benzydamine chemical-oxygenation might be partly accounted for by the variable gene expression.	T7	T18	23623750
CPR:9	CHEMICAL	GENE-Y	3	0	gene metabolized chemical only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.	T8	T19	23623750
CPR:9	CHEMICAL	GENE-Y	3	26	Cynomolgus FMO6 metabolized chemical only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, gene, and FMO5 which were all functional.	T8	T24	23623750
CPR:9	CHEMICAL	GENE-Y	3	24	Cynomolgus FMO6 metabolized chemical only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus gene, FMO2, FMO3, and FMO5 which were all functional.	T8	T22	23623750
CPR:9	CHEMICAL	GENE-Y	3	25	Cynomolgus FMO6 metabolized chemical only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, gene, FMO3, and FMO5 which were all functional.	T8	T23	23623750
NA	CHEMICAL	GENE-Y	3	1	Cynomolgus gene metabolized chemical only slightly, but minimal expression of gene in all tissue precludes the importance of gene in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.	T8	T20	23623750
NA	CHEMICAL	GENE-Y	3	1	Cynomolgus gene metabolized chemical only slightly, but minimal expression of gene in all tissue precludes the importance of gene in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.	T8	T21	23623750
CPR:9	CHEMICAL	GENE-Y	3	28	Cynomolgus FMO6 metabolized chemical only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and gene which were all functional.	T8	T25	23623750
NA	CHEMICAL	GENE-Y	29	11	The aim of this study was to determine the effects of gene gene polymorphism and its effects on PON and AChE enzyme activities in individuals who were exposed to chemical insecticides due to occupational reasons, and to profile the probability of susceptibility to chemical compounds.	T2	T20	23625910
NA	CHEMICAL	GENE-Y	29	11	The aim of this study was to determine the effects of gene gene polymorphism and its effects on PON and AChE enzyme activities in individuals who were exposed to chemical insecticides due to occupational reasons, and to profile the probability of susceptibility to chemical compounds.	T3	T20	23625910
NA	CHEMICAL	GENE-Y	29	20	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on PON and gene enzyme activities in individuals who were exposed to chemical insecticides due to occupational reasons, and to profile the probability of susceptibility to chemical compounds.	T2	T22	23625910
NA	CHEMICAL	GENE-Y	29	20	The aim of this study was to determine the effects of PON1 gene polymorphism and its effects on PON and gene enzyme activities in individuals who were exposed to chemical insecticides due to occupational reasons, and to profile the probability of susceptibility to chemical compounds.	T3	T22	23625910
NA	CHEMICAL	GENE-Y	29	11	The aim of this study was to determine the effects of gene1 gene polymorphism and its effects on gene and AChE enzyme activities in individuals who were exposed to chemical insecticides due to occupational reasons, and to profile the probability of susceptibility to chemical compounds.	T2	T21	23625910
NA	CHEMICAL	GENE-Y	29	11	The aim of this study was to determine the effects of gene1 gene polymorphism and its effects on gene and AChE enzyme activities in individuals who were exposed to chemical insecticides due to occupational reasons, and to profile the probability of susceptibility to chemical compounds.	T3	T21	23625910
NA	CHEMICAL	GENE-N	1	16	The chemical sensor STIM1 is crucial for activation of store-operated chemical entry (SOCE) through TRPC and gene.	T3	T12	23625915
NA	CHEMICAL	GENE-N	1	16	The chemical sensor STIM1 is crucial for activation of store-operated chemical entry (SOCE) through TRPC and gene.	T8	T12	23625915
NA	CHEMICAL	GENE-Y	1	3	The chemical sensor gene is crucial for activation of store-operated chemical entry (SOCE) through TRPC and Orai channels.	T3	T29	23625915
NA	CHEMICAL	GENE-Y	1	3	The chemical sensor gene is crucial for activation of store-operated chemical entry (SOCE) through TRPC and Orai channels.	T8	T29	23625915
NA	CHEMICAL	GENE-N	1	14	The chemical sensor STIM1 is crucial for activation of store-operated chemical entry (SOCE) through gene and Orai channels.	T3	T47	23625915
NA	CHEMICAL	GENE-N	1	14	The chemical sensor STIM1 is crucial for activation of store-operated chemical entry (SOCE) through gene and Orai channels.	T8	T47	23625915
NA	CHEMICAL	GENE-N	6	13	Here we show that SOCE activates chemical-activated protein kinase (chemicalK); its effector p38 gene (p38 MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	T2	T34	23625915
NA	CHEMICAL	GENE-Y	6	19	Here we show that SOCE activates chemical-activated protein kinase (chemicalK); its effector p38 mitogen-activated protein kinase (p38 MAPK) phosphorylates gene, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	T2	T37	23625915
NA	CHEMICAL	GENE-Y	6	12	Here we show that SOCE activates chemical-activated protein kinase (chemicalK); its effector gene mitogen-activated protein kinase (gene MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	T2	T33	23625915
NA	CHEMICAL	GENE-Y	6	12	Here we show that SOCE activates chemical-activated protein kinase (chemicalK); its effector gene mitogen-activated protein kinase (gene MAPK) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	T2	T35	23625915
NA	CHEMICAL	GENE-N	6	17	Here we show that SOCE activates chemical-activated protein kinase (chemicalK); its effector p38 mitogen-activated protein kinase (p38 gene) phosphorylates STIM1, thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	T2	T36	23625915
NA	CHEMICAL	GENE-Y	10	7	Activation of AMPK using AICAR resulted in gene phosphorylation on chemical residues and prevented PAR-1-induced Ca2+ entry.	T5	T39	23625915
NA	CHEMICAL	GENE-Y	10	14	Activation of AMPK using AICAR resulted in STIM1 phosphorylation on chemical residues and prevented gene-induced Ca2+ entry.	T5	T40	23625915
NA	CHEMICAL	GENE-Y	10	2	Activation of gene using AICAR resulted in STIM1 phosphorylation on chemical residues and prevented PAR-1-induced Ca2+ entry.	T5	T38	23625915
CPR:3	CHEMICAL	GENE-Y	4	7	Activation of AMPK using chemical resulted in gene phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.	T4	T39	23625915
CPR:4	CHEMICAL	GENE-Y	4	14	Activation of AMPK using chemical resulted in STIM1 phosphorylation on serine residues and prevented gene-induced Ca2+ entry.	T4	T40	23625915
CPR:3	CHEMICAL	GENE-Y	4	2	Activation of gene using chemical resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.	T4	T38	23625915
NA	CHEMICAL	GENE-Y	15	7	Activation of AMPK using AICAR resulted in gene phosphorylation on serine residues and prevented PAR-1-induced chemical entry.	T6	T39	23625915
NA	CHEMICAL	GENE-Y	15	14	Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented gene-induced chemical entry.	T6	T40	23625915
NA	CHEMICAL	GENE-Y	15	2	Activation of gene using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced chemical entry.	T6	T38	23625915
CPR:4	CHEMICAL	GENE-Y	1	4	Further, chemical pretreatment blocked gene-induced increase in permeability of mouse-lung microvessels.	T7	T41	23625915
CPR:4	CHEMICAL	GENE-Y	1	9	Interestingly, chemical, a selective inhibitor of p38 MAPK, blocked gene phosphorylation and led to sustained gene-puncta formation and Ca2+ entry.	T9	T49	23625915
NA	CHEMICAL	GENE-Y	1	9	Interestingly, chemical, a selective inhibitor of p38 MAPK, blocked gene phosphorylation and led to sustained gene-puncta formation and Ca2+ entry.	T9	T50	23625915
CPR:4	CHEMICAL	GENE-N	1	7	Interestingly, chemical, a selective inhibitor of p38 gene, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.	T9	T48	23625915
CPR:4	CHEMICAL	GENE-N	1	6	Interestingly, chemical, a selective inhibitor of gene MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.	T9	T46	23625915
NA	CHEMICAL	GENE-Y	18	9	Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked gene phosphorylation and led to sustained gene-puncta formation and chemical entry.	T1	T49	23625915
NA	CHEMICAL	GENE-Y	18	9	Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked gene phosphorylation and led to sustained gene-puncta formation and chemical entry.	T1	T50	23625915
NA	CHEMICAL	GENE-N	18	7	Interestingly, SB203580, a selective inhibitor of p38 gene, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and chemical entry.	T1	T48	23625915
NA	CHEMICAL	GENE-N	18	6	Interestingly, SB203580, a selective inhibitor of gene MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and chemical entry.	T1	T46	23625915
NA	CHEMICAL	GENE-N	14	24	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the chemical side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, gene and ferredoxin.	T4	T25	23628605
NA	CHEMICAL	GENE-N	14	24	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the chemical side-chain cleavage enzyme, P450scc, and its two electron-transfer partners, gene reductase and gene.	T4	T26	23628605
CPR:9	CHEMICAL	GENE-Y	14	18	Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the chemical side-chain cleavage enzyme, gene, and its two electron-transfer partners, ferredoxin reductase and ferredoxin.	T4	T24	23628605
NA	CHEMICAL	GENE-Y	5	9	Several other steroidogenic enzymes, including chemical dehydrogenase, 11-hydroxylase and gene also reside in mitochondria.	T8	T29	23628605
NA	CHEMICAL	GENE-Y	5	7	Several other steroidogenic enzymes, including chemical dehydrogenase, gene and aldosterone synthase also reside in mitochondria.	T8	T28	23628605
NA	CHEMICAL	GENE-Y	9	5	Several other steroidogenic enzymes, including gene, 11-hydroxylase and chemical synthase also reside in mitochondria.	T9	T27	23628605
NA	CHEMICAL	GENE-Y	9	7	Several other steroidogenic enzymes, including 3-hydroxysteroid dehydrogenase, gene and chemical synthase also reside in mitochondria.	T9	T28	23628605
NA	CHEMICAL	GENE-Y	23	31	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of vitamin D. The access of chemical to the mitochondria is regulated by the gene, StAR, serving as the acute regulator of steroidogenesis.	T11	T30	23628605
NA	CHEMICAL	GENE-Y	23	35	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of vitamin D. The access of chemical to the mitochondria is regulated by the steroidogenic acute regulatory protein, gene, serving as the acute regulator of steroidogenesis.	T11	T31	23628605
NA	CHEMICAL	GENE-Y	18	31	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of chemical. The access of cholesterol to the mitochondria is regulated by the gene, StAR, serving as the acute regulator of steroidogenesis.	T10	T30	23628605
NA	CHEMICAL	GENE-Y	18	35	Similarly, the mitochondria of renal tubular cells contain two key enzymes participating in the activation and degradation of chemical. The access of cholesterol to the mitochondria is regulated by the steroidogenic acute regulatory protein, gene, serving as the acute regulator of steroidogenesis.	T10	T31	23628605
CPR:9	CHEMICAL	GENE-Y	10	15	The precise fashion in which these proteins interact and move chemical from the OMM to gene, and the means by which chemical is loaded into the OMM, remain unclear.	T1	T22	23628605
NA	CHEMICAL	GENE-Y	10	15	The precise fashion in which these proteins interact and move chemical from the OMM to gene, and the means by which chemical is loaded into the OMM, remain unclear.	T2	T22	23628605
NA	CHEMICAL	GENE-Y	28	7	Human deficiency diseases have been described for gene and for all the mitochondrial steroidogenic enzymes, but not for the electron transfer proteins or for the components of the chemical import machine.	T3	T23	23628605
CPR:4	CHEMICAL	GENE-N	8	10	New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and chemical gene inhibitors (MMPIs) were designed, synthesized, and evaluated.	T7	T11	23631440
CPR:4	CHEMICAL	GENE-N	5	10	New series of pyrrolidine mercaptosulfide, chemical, and 3-mercapto-4-arylsulfonamido pyrrolidine gene inhibitors (MMPIs) were designed, synthesized, and evaluated.	T3	T11	23631440
CPR:4	CHEMICAL	GENE-N	3	10	New series of chemical, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamido pyrrolidine gene inhibitors (MMPIs) were designed, synthesized, and evaluated.	T1	T11	23631440
CPR:4	CHEMICAL	GENE-Y	7	31	Exhibiting unique properties over other MMPIs (e.g., chemical), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), gene (~2 to 50 nM), and MMP-14 (~4 to 60 nM).	T2	T14	23631440
CPR:4	CHEMICAL	GENE-Y	7	37	Exhibiting unique properties over other MMPIs (e.g., chemical), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and gene (~4 to 60 nM).	T2	T15	23631440
CPR:4	CHEMICAL	GENE-Y	7	26	Exhibiting unique properties over other MMPIs (e.g., chemical), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including gene (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).	T2	T13	23631440
CPR:4	CHEMICAL	GENE-N	7	19	Exhibiting unique properties over other MMPIs (e.g., chemical), these newly reported compounds are capable of modulating activities of several gene in the low nanomolar range, including MMP-2 (~2 to 50 nM), MMP-13 (~2 to 50 nM), and MMP-14 (~4 to 60 nM).	T2	T12	23631440
NA	CHEMICAL	GENE-N	5	25	Our previous work with the chemical functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the gene tested.	T4	T20	23631440
NA	CHEMICAL	GENE-N	10	25	Our previous work with the mercaptosulfide functionality attached to both chemical and pyrrolidine frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the gene tested.	T5	T20	23631440
NA	CHEMICAL	GENE-N	12	25	Our previous work with the mercaptosulfide functionality attached to both cyclopentane and chemical frameworks demonstrated that the cis-(3S,4R)- stereochemistry was optimal for all of the gene tested.	T6	T20	23631440
NA	CHEMICAL	GENE-Y	13	5	An X-ray crystal structure of gene in complex with the drug chemical was solved at 2.14  resolution.	T5	T8	23633618
NA	CHEMICAL	GENE-Y	1	1	The gene-chemical structure is nearly superimposable on a previously solved closed structure in a ligand free state.	T3	T10	23633618
CPR:9	CHEMICAL	GENE-N	25	20	Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon gene hydrolysis release the corresponding chemical.	T4	T14	23638842
CPR:9	CHEMICAL	GENE-N	17	20	Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in chemical, which upon gene hydrolysis release the corresponding isothiocyanates.	T3	T14	23638842
NA	CHEMICAL	GENE-N	6	4	acephala sabellica) bioactivated with gene (bioactive chemical) (10mg/kg/day intraperitoneally), in an experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis.	T6	T15	23638842
CPR:4	CHEMICAL	GENE-N	16	20	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive chemical significantly decreased gene translocation, pro-inflammatory cytokine production such as interleukin-1 (IL-1), and apoptosis (Bax and caspase 3 expression).	T1	T8	23638842
CPR:4	CHEMICAL	GENE-Y	16	29	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive chemical significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as gene (IL-1), and apoptosis (Bax and caspase 3 expression).	T1	T10	23638842
CPR:4	CHEMICAL	GENE-Y	16	35	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive chemical significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1 (IL-1), and apoptosis (Bax and gene expression).	T1	T13	23638842
CPR:4	CHEMICAL	GENE-N	16	25	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive chemical significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory gene production such as interleukin-1 (IL-1), and apoptosis (Bax and caspase 3 expression).	T1	T9	23638842
CPR:4	CHEMICAL	GENE-Y	16	30	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive chemical significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1 (gene), and apoptosis (Bax and caspase 3 expression).	T1	T11	23638842
CPR:4	CHEMICAL	GENE-Y	16	33	RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive chemical significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1 (IL-1), and apoptosis (gene and caspase 3 expression).	T1	T12	23638842
NA	CHEMICAL	GENE-N	10	21	Herein, we investigated the effect of a natural neuroprotective flavonoid, chemical, on H2O2-induced disruption of phase II detoxifying enzyme system and gene (CREB) phosphorylation.	T16	T34	23639191
NA	CHEMICAL	GENE-N	10	15	Herein, we investigated the effect of a natural neuroprotective flavonoid, chemical, on H2O2-induced disruption of gene system and cAMP response element binding protein (CREB) phosphorylation.	T16	T33	23639191
NA	CHEMICAL	GENE-N	10	26	Herein, we investigated the effect of a natural neuroprotective flavonoid, chemical, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (gene) phosphorylation.	T16	T35	23639191
NA	CHEMICAL	GENE-N	21	15	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of gene system and chemical response element binding protein (CREB) phosphorylation.	T18	T33	23639191
NA	CHEMICAL	GENE-N	21	26	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and chemical response element binding protein (gene) phosphorylation.	T18	T35	23639191
CPR:4	CHEMICAL	GENE-N	12	21	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on chemical-induced disruption of phase II detoxifying enzyme system and gene (CREB) phosphorylation.	T17	T34	23639191
CPR:4	CHEMICAL	GENE-N	12	15	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on chemical-induced disruption of gene system and cAMP response element binding protein (CREB) phosphorylation.	T17	T33	23639191
CPR:4	CHEMICAL	GENE-N	12	26	Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on chemical-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (gene) phosphorylation.	T17	T35	23639191
NA	CHEMICAL	GENE-Y	12	5	The level of phosphorylated CREB, gene (Nrf2), chemical synthetase (-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	T21	T37	23639191
NA	CHEMICAL	GENE-N	12	3	The level of gene, nuclear factor erythroid 2-related factor 2 (Nrf2), chemical synthetase (-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	T21	T36	23639191
NA	CHEMICAL	GENE-Y	12	16	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), chemical synthetase (-GCS) and gene (HO-1) were measured by western blot method.	T21	T41	23639191
NA	CHEMICAL	GENE-Y	12	14	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), chemical synthetase (gene) and heme oxygenase 1 (HO-1) were measured by western blot method.	T21	T40	23639191
NA	CHEMICAL	GENE-Y	12	19	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (Nrf2), chemical synthetase (-GCS) and heme oxygenase 1 (gene) were measured by western blot method.	T21	T42	23639191
NA	CHEMICAL	GENE-Y	12	11	The level of phosphorylated CREB, nuclear factor erythroid 2-related factor 2 (gene), chemical synthetase (-GCS) and heme oxygenase 1 (HO-1) were measured by western blot method.	T21	T38	23639191
CPR:4	CHEMICAL	GENE-Y	3	6	In H2O2-treated cells, chemical also suppressed gene release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.	T7	T25	23639191
NA	CHEMICAL	GENE-Y	1	6	In chemical-treated cells, calycopterin also suppressed gene release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.	T6	T25	23639191
CPR:3	CHEMICAL	GENE-N	1	17	Moreover, chemical, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, gene and Nrf2, which play an important role in antioxidant capacity of the cell.	T8	T26	23639191
CPR:3	CHEMICAL	GENE-Y	1	19	Moreover, chemical, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and gene, which play an important role in antioxidant capacity of the cell.	T8	T27	23639191
NA	CHEMICAL	GENE-N	5	17	Moreover, calycopterin, in presence of chemical inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, gene and Nrf2, which play an important role in antioxidant capacity of the cell.	T9	T26	23639191
NA	CHEMICAL	GENE-Y	5	19	Moreover, calycopterin, in presence of chemical inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and gene, which play an important role in antioxidant capacity of the cell.	T9	T27	23639191
CPR:3	CHEMICAL	GENE-Y	11	6	There was also an increase in gene and HO-1 levels in chemical pretreated cells.	T10	T28	23639191
CPR:3	CHEMICAL	GENE-Y	11	8	There was also an increase in -GCS and gene levels in chemical pretreated cells.	T10	T29	23639191
CPR:3	CHEMICAL	GENE-N	5	12	In the presence of H2O2, chemical inhibited decrease in GSH level and gene activity.	T12	T30	23639191
NA	CHEMICAL	GENE-N	4	12	In the presence of chemical, calycopterin inhibited decrease in GSH level and gene activity.	T11	T30	23639191
NA	CHEMICAL	GENE-N	9	12	In the presence of H2O2, calycopterin inhibited decrease in chemical level and gene activity.	T13	T30	23639191
NA	CHEMICAL	GENE-N	11	25	CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, chemical, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of gene phosphorylation and Nrf2 pathway.	T14	T31	23639191
NA	CHEMICAL	GENE-Y	11	28	CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, chemical, against H2O2-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and gene pathway.	T14	T32	23639191
NA	CHEMICAL	GENE-N	13	25	CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against chemical-induced oxidative stress in differentiated PC12 cells by modulating the level of gene phosphorylation and Nrf2 pathway.	T15	T31	23639191
NA	CHEMICAL	GENE-Y	13	28	CONCLUSION: We provided documentation of neuroprotective effect of a natural flavone, calycopterin, against chemical-induced oxidative stress in differentiated PC12 cells by modulating the level of CREB phosphorylation and gene pathway.	T15	T32	23639191
CPR:3	CHEMICAL	GENE-Y	17	14	In the present study, using in vitro Th17 differentiation model, we examined effects of gene activation by chemical (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.	T4	T18	23639249
CPR:3	CHEMICAL	GENE-Y	19	14	In the present study, using in vitro Th17 differentiation model, we examined effects of gene activation by indoxyl 3-sulfate (chemical), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.	T5	T18	23639249
NA	CHEMICAL	GENE-Y	21	4	I3S increased expression of gene, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as chemical (TCDD), a prototypical AhR ligand.	T7	T19	23639249
NA	CHEMICAL	GENE-Y	21	25	I3S increased expression of RORt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as chemical (TCDD), a prototypical gene ligand.	T7	T20	23639249
NA	CHEMICAL	GENE-Y	22	4	I3S increased expression of gene, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (chemical), a prototypical AhR ligand.	T8	T19	23639249
NA	CHEMICAL	GENE-Y	22	25	I3S increased expression of RORt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (chemical), a prototypical gene ligand.	T8	T20	23639249
CPR:3	CHEMICAL	GENE-Y	0	4	chemical increased expression of gene, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.	T6	T19	23639249
NA	CHEMICAL	GENE-Y	0	25	chemical increased expression of RORt, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical gene ligand.	T6	T20	23639249
CPR:3	CHEMICAL	GENE-Y	24	2	Activation of gene, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and chemical.	T10	T21	23639249
CPR:3	CHEMICAL	GENE-Y	24	8	Activation of STAT3, which is phosphorylated by the gene signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and chemical.	T10	T22	23639249
CPR:3	CHEMICAL	GENE-Y	22	2	Activation of gene, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by chemical and TCDD.	T9	T21	23639249
CPR:3	CHEMICAL	GENE-Y	22	8	Activation of STAT3, which is phosphorylated by the gene signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by chemical and TCDD.	T9	T22	23639249
NA	CHEMICAL	GENE-Y	25	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of gene activity by chemical (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T13	T15	23639249
NA	CHEMICAL	GENE-Y	25	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of gene activity by chemical (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T13	T23	23639249
CPR:4	CHEMICAL	GENE-Y	25	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of gene activity by chemical (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T13	T25	23639249
CPR:4	CHEMICAL	GENE-Y	25	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of gene activity by chemical (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T13	T27	23639249
NA	CHEMICAL	GENE-Y	25	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by chemical (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T13	T16	23639249
CPR:4	CHEMICAL	GENE-Y	25	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by chemical (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T13	T28	23639249
NA	CHEMICAL	GENE-Y	25	10	Phosphorylation of c-Src, which was shown to be activated by gene ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by chemical (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	T13	T24	23639249
NA	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T12	T15	23639249
CPR:3	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T12	T23	23639249
NA	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T12	T25	23639249
NA	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T12	T27	23639249
CPR:3	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T2	T15	23639249
NA	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T2	T23	23639249
NA	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T2	T25	23639249
NA	CHEMICAL	GENE-Y	18	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T2	T27	23639249
NA	CHEMICAL	GENE-Y	18	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T12	T16	23639249
NA	CHEMICAL	GENE-Y	18	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T12	T28	23639249
CPR:3	CHEMICAL	GENE-Y	18	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T2	T16	23639249
NA	CHEMICAL	GENE-Y	18	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and chemical, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T2	T28	23639249
NA	CHEMICAL	GENE-Y	18	10	Phosphorylation of c-Src, which was shown to be activated by gene ligands, was also increased by I3S and chemical, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	T12	T24	23639249
NA	CHEMICAL	GENE-Y	18	10	Phosphorylation of c-Src, which was shown to be activated by gene ligands, was also increased by I3S and chemical, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and chemical on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	T2	T24	23639249
NA	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T11	T15	23639249
CPR:3	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T11	T23	23639249
NA	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T11	T25	23639249
NA	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T11	T27	23639249
CPR:3	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T1	T15	23639249
NA	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T1	T23	23639249
NA	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T1	T25	23639249
NA	CHEMICAL	GENE-Y	16	2	Phosphorylation of gene, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of gene activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both gene and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of gene, which in turn stimulates STAT3 activation.	T1	T27	23639249
NA	CHEMICAL	GENE-Y	16	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T11	T16	23639249
NA	CHEMICAL	GENE-Y	16	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T11	T28	23639249
CPR:3	CHEMICAL	GENE-Y	16	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T1	T16	23639249
NA	CHEMICAL	GENE-Y	16	34	Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by chemical and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and gene, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates gene activation.	T1	T28	23639249
NA	CHEMICAL	GENE-Y	16	10	Phosphorylation of c-Src, which was shown to be activated by gene ligands, was also increased by chemical and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	T11	T24	23639249
NA	CHEMICAL	GENE-Y	16	10	Phosphorylation of c-Src, which was shown to be activated by gene ligands, was also increased by chemical and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of chemical and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.	T1	T24	23639249
CPR:3	CHEMICAL	GENE-Y	4	21	Finally, we found that chemical worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of gene-producing cells in draining lymph nodes.	T3	T17	23639249
NA	CHEMICAL	GENE-Y	41	39	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, gene and chemical carboxykinase activities, liver glycogen.	T9	T15	23639586
NA	CHEMICAL	GENE-Y	41	30	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of gene activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and chemical carboxykinase activities, liver glycogen.	T9	T14	23639586
NA	CHEMICAL	GENE-N	41	9	Analyses of these genes identified over-represented functions associated with gene signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/GSSG ratio, glucose-6-phosphatase and chemical carboxykinase activities, liver glycogen.	T9	T13	23639586
NA	CHEMICAL	GENE-Y	12	41	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and gene activities, liver glycogen.	T4	T16	23639586
NA	CHEMICAL	GENE-Y	12	41	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and gene activities, liver glycogen.	T5	T16	23639586
NA	CHEMICAL	GENE-Y	12	41	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and gene activities, liver glycogen.	T8	T16	23639586
NA	CHEMICAL	GENE-Y	12	30	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of gene activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T4	T14	23639586
NA	CHEMICAL	GENE-Y	12	30	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of gene activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T5	T14	23639586
NA	CHEMICAL	GENE-Y	12	30	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of gene activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T8	T14	23639586
NA	CHEMICAL	GENE-N	12	9	Analyses of these genes identified over-represented functions associated with gene signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T4	T13	23639586
NA	CHEMICAL	GENE-N	12	9	Analyses of these genes identified over-represented functions associated with gene signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T5	T13	23639586
NA	CHEMICAL	GENE-N	12	9	Analyses of these genes identified over-represented functions associated with gene signaling pathway, chemical metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum chemical, GSH/GSSG ratio, chemical-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T8	T13	23639586
NA	CHEMICAL	GENE-Y	37	41	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/chemical ratio, glucose-6-phosphatase and gene activities, liver glycogen.	T7	T16	23639586
NA	CHEMICAL	GENE-Y	37	39	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/chemical ratio, gene and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T7	T15	23639586
NA	CHEMICAL	GENE-Y	37	30	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of gene activity and reduction of serum glucose, GSH/chemical ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T7	T14	23639586
NA	CHEMICAL	GENE-N	37	9	Analyses of these genes identified over-represented functions associated with gene signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, GSH/chemical ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T7	T13	23639586
NA	CHEMICAL	GENE-Y	37	41	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, chemical/GSSG ratio, glucose-6-phosphatase and gene activities, liver glycogen.	T6	T16	23639586
NA	CHEMICAL	GENE-Y	37	39	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, chemical/GSSG ratio, gene and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T6	T15	23639586
NA	CHEMICAL	GENE-Y	37	30	Analyses of these genes identified over-represented functions associated with insulin signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of gene activity and reduction of serum glucose, chemical/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T6	T14	23639586
NA	CHEMICAL	GENE-N	37	9	Analyses of these genes identified over-represented functions associated with gene signaling pathway, glucose metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of Caspase-3 activity and reduction of serum glucose, chemical/GSSG ratio, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, liver glycogen.	T6	T13	23639586
NA	CHEMICAL	GENE-N	14	28	These data suggest that TP treatment could alter the hepatic redox status, reduce serum chemical and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in gene signaling pathway, chemical metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.	T2	T12	23639586
NA	CHEMICAL	GENE-N	14	28	These data suggest that TP treatment could alter the hepatic redox status, reduce serum chemical and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in gene signaling pathway, chemical metabolism pathway and cell stress pathway, all of which might contribute to the overall TP-induced hepatotoxicity.	T3	T12	23639586
NA	CHEMICAL	GENE-Y	29	10	TCDD treatment of the cells largely prevented the activation of gene, a regulator of translation initiation and substrate of the mammalian target of chemical (mTOR).	T11	T26	23639626
NA	CHEMICAL	GENE-Y	29	30	TCDD treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of chemical (gene).	T11	T28	23639626
NA	CHEMICAL	GENE-Y	0	10	chemical treatment of the cells largely prevented the activation of gene, a regulator of translation initiation and substrate of the mammalian target of rapamycin (mTOR).	T9	T26	23639626
NA	CHEMICAL	GENE-Y	0	26	chemical treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the gene (mTOR).	T9	T27	23639626
NA	CHEMICAL	GENE-Y	0	30	chemical treatment of the cells largely prevented the activation of eukaryotic translation initiation factor 4E-binding protein 1, a regulator of translation initiation and substrate of the mammalian target of rapamycin (gene).	T9	T28	23639626
NA	CHEMICAL	GENE-Y	20	23	By "working upwards" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with chemical phosphorylation of gene.	T13	T33	23639626
NA	CHEMICAL	GENE-Y	20	12	By "working upwards" from mTOR, we observed that TCDD inhibited endogenous and gene-induced AKT and ERK activation by interfering with chemical phosphorylation of insulin receptor substrate 1.	T13	T30	23639626
NA	CHEMICAL	GENE-Y	20	4	By "working upwards" from gene, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with chemical phosphorylation of insulin receptor substrate 1.	T13	T29	23639626
NA	CHEMICAL	GENE-N	20	15	By "working upwards" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and gene activation by interfering with chemical phosphorylation of insulin receptor substrate 1.	T13	T32	23639626
NA	CHEMICAL	GENE-N	20	13	By "working upwards" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced gene and ERK activation by interfering with chemical phosphorylation of insulin receptor substrate 1.	T13	T31	23639626
NA	CHEMICAL	GENE-Y	8	23	By "working upwards" from mTOR, we observed that chemical inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of gene.	T12	T33	23639626
CPR:4	CHEMICAL	GENE-Y	8	12	By "working upwards" from mTOR, we observed that chemical inhibited endogenous and gene-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.	T12	T30	23639626
NA	CHEMICAL	GENE-Y	8	4	By "working upwards" from gene, we observed that chemical inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.	T12	T29	23639626
CPR:4	CHEMICAL	GENE-N	8	15	By "working upwards" from mTOR, we observed that chemical inhibited endogenous and IGF-I-induced AKT and gene activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.	T12	T32	23639626
CPR:4	CHEMICAL	GENE-N	8	13	By "working upwards" from mTOR, we observed that chemical inhibited endogenous and IGF-I-induced gene and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.	T12	T31	23639626
CPR:3	CHEMICAL	GENE-Y	6	13	This inhibition was mediated by a chemical-induced secreted factor which was identified as gene (IGFBP-4).	T14	T34	23639626
CPR:3	CHEMICAL	GENE-Y	6	19	This inhibition was mediated by a chemical-induced secreted factor which was identified as insulin-like growth factor binding protein 4 (gene).	T14	T35	23639626
NA	CHEMICAL	GENE-Y	10	3	The induction of gene protein was dependent on a functional chemical receptor and was preceded by a rapid increase in the level of gene mRNA indicating that gene is a previously unknown transcriptional target of TCDD in 5L cells.	T1	T18	23639626
NA	CHEMICAL	GENE-Y	10	3	The induction of gene protein was dependent on a functional chemical receptor and was preceded by a rapid increase in the level of gene mRNA indicating that gene is a previously unknown transcriptional target of TCDD in 5L cells.	T1	T20	23639626
NA	CHEMICAL	GENE-Y	10	3	The induction of gene protein was dependent on a functional chemical receptor and was preceded by a rapid increase in the level of gene mRNA indicating that gene is a previously unknown transcriptional target of TCDD in 5L cells.	T1	T21	23639626
NA	CHEMICAL	GENE-Y	36	10	The induction of IGFBP-4 protein was dependent on a functional gene and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of chemical in 5L cells.	T2	T19	23639626
NA	CHEMICAL	GENE-Y	36	3	The induction of gene protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of gene mRNA indicating that gene is a previously unknown transcriptional target of chemical in 5L cells.	T2	T18	23639626
CPR:4	CHEMICAL	GENE-Y	36	3	The induction of gene protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of gene mRNA indicating that gene is a previously unknown transcriptional target of chemical in 5L cells.	T2	T20	23639626
NA	CHEMICAL	GENE-Y	36	3	The induction of gene protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of gene mRNA indicating that gene is a previously unknown transcriptional target of chemical in 5L cells.	T2	T21	23639626
NA	CHEMICAL	GENE-Y	5	0	gene was not induced by chemical in the parental cell line of 5L cells, Fao, and in various closely related rat hepatoma cell lines as well as in other unrelated cell types.	T3	T22	23639626
NA	CHEMICAL	GENE-Y	20	8	The observations suggest that in 5L cells the gene gene may have got under the control of a promoter containing chemical responsive element(s) leading to the induction of IGFBP-4 by TCDD.	T4	T23	23639626
NA	CHEMICAL	GENE-Y	20	28	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing chemical responsive element(s) leading to the induction of gene by TCDD.	T4	T25	23639626
NA	CHEMICAL	GENE-N	30	20	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing gene leading to the induction of IGFBP-4 by chemical.	T5	T24	23639626
NA	CHEMICAL	GENE-Y	30	8	The observations suggest that in 5L cells the gene gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of IGFBP-4 by chemical.	T5	T23	23639626
CPR:3	CHEMICAL	GENE-Y	30	28	The observations suggest that in 5L cells the Igfbp-4 gene may have got under the control of a promoter containing dioxin responsive element(s) leading to the induction of gene by chemical.	T5	T25	23639626
NA	CHEMICAL	GENE-Y	6	12	Similar concentrations of these compounds blocked chemical-induced growth of MCF-7 cells, but gene (ER) interactions do not seem to be involved.	T25	T46	2386945
NA	CHEMICAL	GENE-Y	6	14	Similar concentrations of these compounds blocked chemical-induced growth of MCF-7 cells, but estrogen receptor (gene) interactions do not seem to be involved.	T25	T47	2386945
NA	CHEMICAL	GENE-Y	12	14	Similar concentrations of these compounds blocked estradiol-induced growth of MCF-7 cells, but chemical receptor (gene) interactions do not seem to be involved.	T26	T47	2386945
NA	CHEMICAL	GENE-Y	2	23	Pimozide and chemical had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of gene by estradiol.	T28	T49	2386945
NA	CHEMICAL	GENE-Y	2	14	Pimozide and chemical had no effect on the estradiol binding properties of the MCF-7 gene, nor did pimozide interfere with the induction of progesterone receptors by estradiol.	T28	T48	2386945
NA	CHEMICAL	GENE-Y	23	14	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 gene, nor did pimozide interfere with the induction of chemical receptors by estradiol.	T31	T48	2386945
NA	CHEMICAL	GENE-Y	8	23	Pimozide and thioridazine had no effect on the chemical binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of gene by chemical.	T1	T49	2386945
NA	CHEMICAL	GENE-Y	8	23	Pimozide and thioridazine had no effect on the chemical binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of gene by chemical.	T29	T49	2386945
NA	CHEMICAL	GENE-Y	8	14	Pimozide and thioridazine had no effect on the chemical binding properties of the MCF-7 gene, nor did pimozide interfere with the induction of progesterone receptors by chemical.	T1	T48	2386945
NA	CHEMICAL	GENE-Y	8	14	Pimozide and thioridazine had no effect on the chemical binding properties of the MCF-7 gene, nor did pimozide interfere with the induction of progesterone receptors by chemical.	T29	T48	2386945
NA	CHEMICAL	GENE-Y	17	23	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did chemical interfere with the induction of gene by estradiol.	T30	T49	2386945
NA	CHEMICAL	GENE-Y	17	14	Pimozide and thioridazine had no effect on the estradiol binding properties of the MCF-7 gene, nor did chemical interfere with the induction of progesterone receptors by estradiol.	T30	T48	2386945
NA	CHEMICAL	GENE-Y	0	23	chemical and thioridazine had no effect on the estradiol binding properties of the MCF-7 ER, nor did pimozide interfere with the induction of gene by estradiol.	T27	T49	2386945
NA	CHEMICAL	GENE-Y	0	14	chemical and thioridazine had no effect on the estradiol binding properties of the MCF-7 gene, nor did pimozide interfere with the induction of progesterone receptors by estradiol.	T27	T48	2386945
NA	CHEMICAL	GENE-N	6	12	Furthermore, pimozide also inhibited incorporation of chemical into MCF-7 cells stimulated by gene in serum-free medium.	T3	T34	2386945
NA	CHEMICAL	GENE-N	1	12	Furthermore, chemical also inhibited incorporation of [3H]thymidine into MCF-7 cells stimulated by gene in serum-free medium.	T2	T34	2386945
NA	CHEMICAL	GENE-Y	3	22	The Ki for chemical in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), gene (0.54 microM), and epidermal growth factor (0.43 microM).	T4	T36	2386945
NA	CHEMICAL	GENE-Y	3	29	The Ki for chemical in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of insulin (0.42 microM), insulin-like growth factor I (0.54 microM), and gene (0.43 microM).	T4	T37	2386945
NA	CHEMICAL	GENE-Y	3	19	The Ki for chemical in serum-free medium alone, 0.46 microM, was similar to that determined in the presence of gene (0.42 microM), gene-like growth factor I (0.54 microM), and epidermal growth factor (0.43 microM).	T4	T35	2386945
NA	CHEMICAL	GENE-Y	6	10	Pimozide also blocked cell growth and chemical incorporation into the gene-positive T47D and ZR75-1B human breast cancer cell lines and the gene-negative human breast cancer cell line, MDA-MB-231.	T7	T38	2386945
NA	CHEMICAL	GENE-Y	6	10	Pimozide also blocked cell growth and chemical incorporation into the gene-positive T47D and ZR75-1B human breast cancer cell lines and the gene-negative human breast cancer cell line, MDA-MB-231.	T7	T39	2386945
NA	CHEMICAL	GENE-Y	0	10	chemical also blocked cell growth and [3H]thymidine incorporation into the gene-positive T47D and ZR75-1B human breast cancer cell lines and the gene-negative human breast cancer cell line, MDA-MB-231.	T6	T38	2386945
NA	CHEMICAL	GENE-Y	0	10	chemical also blocked cell growth and [3H]thymidine incorporation into the gene-positive T47D and ZR75-1B human breast cancer cell lines and the gene-negative human breast cancer cell line, MDA-MB-231.	T6	T39	2386945
CPR:6	CHEMICAL	GENE-Y	8	15	Although numerous mechanisms of action of pimozide and chemical have been identified, both drugs are gene antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.	T9	T40	2386945
CPR:6	CHEMICAL	GENE-Y	6	15	Although numerous mechanisms of action of chemical and thioridazine have been identified, both drugs are gene antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.	T8	T40	2386945
NA	CHEMICAL	GENE-Y	27	8	Inhibition of MCF-7 cell growth by the selective gene antagonists W-13 and W-12 is consistent with a role for gene antagonism in the broad growth-inhibitory properties of chemical.	T15	T41	2386945
CPR:4	CHEMICAL	GENE-Y	27	8	Inhibition of MCF-7 cell growth by the selective gene antagonists W-13 and W-12 is consistent with a role for gene antagonism in the broad growth-inhibitory properties of chemical.	T15	T42	2386945
CPR:6	CHEMICAL	GENE-Y	10	8	Inhibition of MCF-7 cell growth by the selective gene antagonists chemical and W-12 is consistent with a role for gene antagonism in the broad growth-inhibitory properties of pimozide.	T12	T41	2386945
NA	CHEMICAL	GENE-Y	10	8	Inhibition of MCF-7 cell growth by the selective gene antagonists chemical and W-12 is consistent with a role for gene antagonism in the broad growth-inhibitory properties of pimozide.	T12	T42	2386945
CPR:6	CHEMICAL	GENE-Y	12	8	Inhibition of MCF-7 cell growth by the selective gene antagonists W-13 and chemical is consistent with a role for gene antagonism in the broad growth-inhibitory properties of pimozide.	T13	T41	2386945
NA	CHEMICAL	GENE-Y	12	8	Inhibition of MCF-7 cell growth by the selective gene antagonists W-13 and chemical is consistent with a role for gene antagonism in the broad growth-inhibitory properties of pimozide.	T13	T42	2386945
NA	CHEMICAL	GENE-N	5	15	We conclude that pimozide and chemical may be useful in the control of estradiol- and gene-induced growth of ER-positive and ER-negative human breast tumors.	T17	T43	2386945
NA	CHEMICAL	GENE-Y	5	19	We conclude that pimozide and chemical may be useful in the control of estradiol- and polypeptide hormone-induced growth of gene-positive and gene-negative human breast tumors.	T17	T44	2386945
NA	CHEMICAL	GENE-Y	5	19	We conclude that pimozide and chemical may be useful in the control of estradiol- and polypeptide hormone-induced growth of gene-positive and gene-negative human breast tumors.	T17	T45	2386945
NA	CHEMICAL	GENE-N	13	15	We conclude that pimozide and thioridazine may be useful in the control of chemical- and gene-induced growth of ER-positive and ER-negative human breast tumors.	T18	T43	2386945
NA	CHEMICAL	GENE-Y	13	19	We conclude that pimozide and thioridazine may be useful in the control of chemical- and polypeptide hormone-induced growth of gene-positive and gene-negative human breast tumors.	T18	T44	2386945
NA	CHEMICAL	GENE-Y	13	19	We conclude that pimozide and thioridazine may be useful in the control of chemical- and polypeptide hormone-induced growth of gene-positive and gene-negative human breast tumors.	T18	T45	2386945
NA	CHEMICAL	GENE-N	3	15	We conclude that chemical and thioridazine may be useful in the control of estradiol- and gene-induced growth of ER-positive and ER-negative human breast tumors.	T16	T43	2386945
NA	CHEMICAL	GENE-Y	3	19	We conclude that chemical and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of gene-positive and gene-negative human breast tumors.	T16	T44	2386945
NA	CHEMICAL	GENE-Y	3	19	We conclude that chemical and thioridazine may be useful in the control of estradiol- and polypeptide hormone-induced growth of gene-positive and gene-negative human breast tumors.	T16	T45	2386945
NA	CHEMICAL	GENE-Y	5	21	Levels of homovanillic acid (HVA), chemical (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of gene (MAO-A) by clorgyline (4 mg/kg i.p.	T14	T37	2506486
NA	CHEMICAL	GENE-Y	5	25	Levels of homovanillic acid (HVA), chemical (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T14	T38	2506486
NA	CHEMICAL	GENE-Y	9	21	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and chemical (DHPG) in plasma and the striatium were measured after inhibition of gene (MAO-A) by clorgyline (4 mg/kg i.p.	T27	T37	2506486
NA	CHEMICAL	GENE-Y	9	25	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and chemical (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T27	T38	2506486
NA	CHEMICAL	GENE-Y	2	21	Levels of chemical (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of gene (MAO-A) by clorgyline (4 mg/kg i.p.	T2	T37	2506486
NA	CHEMICAL	GENE-Y	2	25	Levels of chemical (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T2	T38	2506486
CPR:4	CHEMICAL	GENE-Y	27	21	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of gene (MAO-A) by chemical (4 mg/kg i.p.	T9	T37	2506486
CPR:4	CHEMICAL	GENE-Y	27	25	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by chemical (4 mg/kg i.p.	T9	T38	2506486
NA	CHEMICAL	GENE-Y	21	25	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of chemical oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T8	T38	2506486
NA	CHEMICAL	GENE-Y	7	21	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (chemical) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of gene (MAO-A) by clorgyline (4 mg/kg i.p.	T21	T37	2506486
NA	CHEMICAL	GENE-Y	7	25	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (chemical) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T21	T38	2506486
NA	CHEMICAL	GENE-Y	10	21	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (chemical) in plasma and the striatium were measured after inhibition of gene (MAO-A) by clorgyline (4 mg/kg i.p.	T32	T37	2506486
NA	CHEMICAL	GENE-Y	10	25	Levels of homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (chemical) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T32	T38	2506486
NA	CHEMICAL	GENE-Y	4	21	Levels of homovanillic acid (chemical), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of gene (MAO-A) by clorgyline (4 mg/kg i.p.	T12	T37	2506486
NA	CHEMICAL	GENE-Y	4	25	Levels of homovanillic acid (chemical), dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylglycol (DHPG) in plasma and the striatium were measured after inhibition of monoamine oxidase type A (gene) by clorgyline (4 mg/kg i.p.	T12	T38	2506486
CPR:4	CHEMICAL	GENE-Y	3	1	), gene by chemical (1 mg/kg i.p.	T10	T39	2506486
CPR:4	CHEMICAL	GENE-Y	6	2	), both gene and MAO-B by chemical (75 mg/kg i.p.)	T11	T40	2506486
CPR:4	CHEMICAL	GENE-Y	6	4	), both MAO-A and gene by chemical (75 mg/kg i.p.)	T11	T41	2506486
CPR:4	CHEMICAL	GENE-N	5	3	or peripheral neuronal gene by chemical (40 mg/kg i.p.).	T13	T42	2506486
NA	CHEMICAL	GENE-Y	46	17	The results suggest that most of the HVA in plasma is derived from deamination of DA by gene in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of chemical in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	T5	T36	2506486
NA	CHEMICAL	GENE-Y	60	17	The results suggest that most of the HVA in plasma is derived from deamination of DA by gene in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with chemical provide an improved but limited indication of central dopaminergic activity.	T7	T36	2506486
NA	CHEMICAL	GENE-Y	22	17	The results suggest that most of the HVA in plasma is derived from deamination of DA by gene in peripheral neurons; that chemical in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	T3	T36	2506486
NA	CHEMICAL	GENE-Y	35	17	The results suggest that most of the HVA in plasma is derived from deamination of DA by gene in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that chemical in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	T4	T36	2506486
CPR:9	CHEMICAL	GENE-Y	7	17	The results suggest that most of the chemical in plasma is derived from deamination of DA by gene in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of chemical after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	T31	T36	2506486
NA	CHEMICAL	GENE-Y	7	17	The results suggest that most of the chemical in plasma is derived from deamination of DA by gene in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of chemical after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	T6	T36	2506486
CPR:9	CHEMICAL	GENE-Y	15	17	The results suggest that most of the HVA in plasma is derived from deamination of chemical by gene in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	T1	T36	2506486
NA	CHEMICAL	GENE-Y	16	12	This lack of difference was unexpected since the genes for catalase and gene, also called chemical hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	T1	T3	2554783
NA	CHEMICAL	GENE-Y	16	10	This lack of difference was unexpected since the genes for gene and esterase D, also called chemical hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	T1	T2	2554783
NA	CHEMICAL	GENE-Y	35	30	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, gene (LDH-X), and serum chemical levels.	T2	T10	2751392
NA	CHEMICAL	GENE-Y	35	32	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, lactate dehydrogenase-X (gene), and serum chemical levels.	T2	T11	2751392
NA	CHEMICAL	GENE-Y	30	32	This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm-specific enzyme, chemical dehydrogenase-X (gene), and serum testosterone levels.	T1	T11	2751392
NA	CHEMICAL	GENE-Y	10	2	Testicular cytosolic gene activity was determined by oxidation of reduced chemical (NADH).	T3	T12	2751392
NA	CHEMICAL	GENE-Y	13	2	Testicular cytosolic gene activity was determined by oxidation of reduced nicotinamide adenine dinucleotide (chemical).	T4	T12	2751392
NA	CHEMICAL	GENE-Y	4	0	gene activity and serum chemical levels were similar for both genotypes at 180 days of age.	T7	T15	2751392
NA	CHEMICAL	GENE-Y	19	15	The delay of testicular maturation in the jaundiced males seems to be due to lower gene activity and serum chemical levels.	T8	T16	2751392
NA	CHEMICAL	GENE-Y	3	15	The effect of chemical - a peripheral opiate agonist - on plasma ACTH response to gene (CRH) has been investigated in 6 patients with Addison's disease.	T1	T16	2832297
NA	CHEMICAL	GENE-Y	3	12	The effect of chemical - a peripheral opiate agonist - on plasma gene response to Corticotropin-releasing Hormone (CRH) has been investigated in 6 patients with Addison's disease.	T1	T15	2832297
NA	CHEMICAL	GENE-Y	3	17	The effect of chemical - a peripheral opiate agonist - on plasma ACTH response to Corticotropin-releasing Hormone (gene) has been investigated in 6 patients with Addison's disease.	T1	T4	2832297
NA	CHEMICAL	GENE-Y	1	3	After chemical administration gene levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an gene increase; the pattern of gene response to CRH was slightly delayed.	T2	T10	2832297
CPR:4	CHEMICAL	GENE-Y	1	3	After chemical administration gene levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an gene increase; the pattern of gene response to CRH was slightly delayed.	T2	T7	2832297
CPR:3	CHEMICAL	GENE-Y	1	3	After chemical administration gene levels fell to a nadir of 135 +/- 76 pg/ml, and then CRH was still able to induce an gene increase; the pattern of gene response to CRH was slightly delayed.	T2	T9	2832297
NA	CHEMICAL	GENE-Y	1	16	After chemical administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then gene was still able to induce an ACTH increase; the pattern of ACTH response to gene was slightly delayed.	T2	T11	2832297
NA	CHEMICAL	GENE-Y	1	16	After chemical administration ACTH levels fell to a nadir of 135 +/- 76 pg/ml, and then gene was still able to induce an ACTH increase; the pattern of ACTH response to gene was slightly delayed.	T2	T8	2832297
CPR:4	CHEMICAL	GENE-Y	0	8	chemical is known to be an inhibitor of gene, and recent data have shown this drug to antagonize muscarinic receptors as well.	T1	T20	2857786
CPR:6	CHEMICAL	GENE-N	0	18	chemical is known to be an inhibitor of acetylcholinesterase, and recent data have shown this drug to antagonize gene as well.	T1	T18	2857786
NA	CHEMICAL	GENE-Y	23	34	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with chemical) could be eliminated by prior treatment of tissues with the gene inhibitor neostigmine.	T13	T21	2857786
CPR:4	CHEMICAL	GENE-Y	36	34	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the gene inhibitor chemical.	T14	T21	2857786
NA	CHEMICAL	GENE-Y	0	34	chemical was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the gene inhibitor neostigmine.	T11	T21	2857786
NA	CHEMICAL	GENE-N	13	25	These data suggested that ambenonium had a dual effect on tissue responses to chemical-producing potentiation by blockade of chemicalsterase and concomitant antagonism by blockade of gene.	T2	T19	2857786
CPR:4	CHEMICAL	GENE-Y	4	18	These data suggested that chemical had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of gene and concomitant antagonism by blockade of muscarinic receptors.	T15	T17	2857786
CPR:4	CHEMICAL	GENE-N	4	25	These data suggested that chemical had a dual effect on tissue responses to acetylcholine-producing potentiation by blockade of acetylcholinesterase and concomitant antagonism by blockade of gene.	T15	T19	2857786
CPR:4	CHEMICAL	GENE-Y	17	9	However, betaxolol produces less systemic beta 2- and possibly gene blockade than either timolol or chemical.	T4	T28	2891463
CPR:4	CHEMICAL	GENE-Y	1	9	However, chemical produces less systemic beta 2- and possibly gene blockade than either timolol or levobunolol.	T2	T28	2891463
CPR:4	CHEMICAL	GENE-Y	15	9	However, betaxolol produces less systemic beta 2- and possibly gene blockade than either chemical or levobunolol.	T3	T28	2891463
NA	CHEMICAL	GENE-N	2	6	Autoradiography of chemical gels of cross-linked gene showed only three protein bands specifically binding salmon calcitonin.	T5	T8	3004987
CPR:9	CHEMICAL	GENE-Y	6	0	gene usually catalyzes the conversion of chemical to o-diphenols and oxidation of diphenols to the corresponding quinones.	T12	T27	3094574
CPR:9	CHEMICAL	GENE-Y	8	0	gene usually catalyzes the conversion of monophenols to o-chemical and oxidation of chemical to the corresponding quinones.	T23	T27	3094574
NA	CHEMICAL	GENE-Y	13	17	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, chemical dismutase, ascorbate oxidase, gene, and peroxidase.	T14	T33	3094574
NA	CHEMICAL	GENE-N	13	15	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, chemical dismutase, gene, dopamine beta-hydroxylase, and peroxidase.	T14	T32	3094574
NA	CHEMICAL	GENE-N	13	10	None of the following enzymes tested catalyzed the new reaction: gene, ceruloplasmin, chemical dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	T14	T29	3094574
NA	CHEMICAL	GENE-Y	13	12	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, gene, chemical dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	T14	T30	3094574
NA	CHEMICAL	GENE-N	13	20	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, chemical dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and gene.	T14	T34	3094574
NA	CHEMICAL	GENE-Y	15	17	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, chemical oxidase, gene, and peroxidase.	T15	T33	3094574
NA	CHEMICAL	GENE-N	15	13	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, gene, chemical oxidase, dopamine beta-hydroxylase, and peroxidase.	T15	T31	3094574
NA	CHEMICAL	GENE-N	15	10	None of the following enzymes tested catalyzed the new reaction: gene, ceruloplasmin, superoxide dismutase, chemical oxidase, dopamine beta-hydroxylase, and peroxidase.	T15	T29	3094574
NA	CHEMICAL	GENE-Y	15	12	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, gene, superoxide dismutase, chemical oxidase, dopamine beta-hydroxylase, and peroxidase.	T15	T30	3094574
NA	CHEMICAL	GENE-N	15	20	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, chemical oxidase, dopamine beta-hydroxylase, and gene.	T15	T34	3094574
NA	CHEMICAL	GENE-Y	10	17	None of the following enzymes tested catalyzed the new reaction: chemical oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, gene, and peroxidase.	T13	T33	3094574
NA	CHEMICAL	GENE-N	10	13	None of the following enzymes tested catalyzed the new reaction: chemical oxidase, ceruloplasmin, gene, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	T13	T31	3094574
NA	CHEMICAL	GENE-N	10	15	None of the following enzymes tested catalyzed the new reaction: chemical oxidase, ceruloplasmin, superoxide dismutase, gene, dopamine beta-hydroxylase, and peroxidase.	T13	T32	3094574
NA	CHEMICAL	GENE-Y	10	12	None of the following enzymes tested catalyzed the new reaction: chemical oxidase, gene, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and peroxidase.	T13	T30	3094574
NA	CHEMICAL	GENE-N	10	20	None of the following enzymes tested catalyzed the new reaction: chemical oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, dopamine beta-hydroxylase, and gene.	T13	T34	3094574
NA	CHEMICAL	GENE-N	17	13	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, gene, ascorbate oxidase, chemical beta-hydroxylase, and peroxidase.	T16	T31	3094574
NA	CHEMICAL	GENE-N	17	15	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, gene, chemical beta-hydroxylase, and peroxidase.	T16	T32	3094574
NA	CHEMICAL	GENE-N	17	10	None of the following enzymes tested catalyzed the new reaction: gene, ceruloplasmin, superoxide dismutase, ascorbate oxidase, chemical beta-hydroxylase, and peroxidase.	T16	T29	3094574
NA	CHEMICAL	GENE-Y	17	12	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, gene, superoxide dismutase, ascorbate oxidase, chemical beta-hydroxylase, and peroxidase.	T16	T30	3094574
NA	CHEMICAL	GENE-N	17	20	None of the following enzymes tested catalyzed the new reaction: galactose oxidase, ceruloplasmin, superoxide dismutase, ascorbate oxidase, chemical beta-hydroxylase, and gene.	T16	T34	3094574
CPR:4	CHEMICAL	GENE-N	6	0	gene inhibitors such as phenylthiourea, chemical, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	T19	T35	3094574
CPR:4	CHEMICAL	GENE-N	5	0	gene inhibitors such as chemical, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	T18	T35	3094574
CPR:4	CHEMICAL	GENE-N	9	0	gene inhibitors such as phenylthiourea, potassium cyanide, and chemical inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.	T20	T35	3094574
NA	CHEMICAL	GENE-N	22	0	gene inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site chemical of the enzyme in the catalysis.	T21	T35	3094574
CPR:4	CHEMICAL	GENE-Y	0	6	chemical, a well-known competitive inhibitor of gene, competitively inhibited the new reaction also.	T22	T36	3094574
CPR:9	CHEMICAL	GENE-N	24	4	Present studies demonstrate that gene will also catalyze quinone methide production with the same active site copper if a suitable substrate such as chemical is provided.	T10	T28	3094574
CPR:9	CHEMICAL	GENE-N	9	4	Present studies demonstrate that gene will also catalyze chemical production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.	T9	T28	3094574
CPR:3	CHEMICAL	GENE-Y	26	12	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain gene (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by chemical (EACA), as well as fibrin(ogen).	T3	T23	3146348
CPR:3	CHEMICAL	GENE-Y	26	3	The activation of gene [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by chemical (EACA), as well as fibrin(ogen).	T3	T15	3146348
CPR:3	CHEMICAL	GENE-Y	26	5	The activation of human [Glu1]plasminogen [gene) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by chemical (EACA), as well as fibrin(ogen).	T3	T19	3146348
CPR:3	CHEMICAL	GENE-Y	26	15	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (gene) is inhibited by Cl-, at physiological concentrations, and stimulated by chemical (EACA), as well as fibrin(ogen).	T3	T13	3146348
CPR:3	CHEMICAL	GENE-Y	28	12	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain gene (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (chemical), as well as fibrin(ogen).	T4	T23	3146348
CPR:3	CHEMICAL	GENE-Y	28	3	The activation of gene [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (chemical), as well as fibrin(ogen).	T4	T15	3146348
CPR:3	CHEMICAL	GENE-Y	28	5	The activation of human [Glu1]plasminogen [gene) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (chemical), as well as fibrin(ogen).	T4	T19	3146348
CPR:3	CHEMICAL	GENE-Y	28	15	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (gene) is inhibited by Cl-, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (chemical), as well as fibrin(ogen).	T4	T13	3146348
CPR:4	CHEMICAL	GENE-Y	19	12	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain gene (t-PA) is inhibited by chemical, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	T2	T23	3146348
CPR:4	CHEMICAL	GENE-Y	19	3	The activation of gene [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by chemical, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	T2	T15	3146348
CPR:4	CHEMICAL	GENE-Y	19	5	The activation of human [Glu1]plasminogen [gene) by human recombinant (rec) two-chain tissue plasminogen activator (t-PA) is inhibited by chemical, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	T2	T19	3146348
CPR:4	CHEMICAL	GENE-Y	19	15	The activation of human [Glu1]plasminogen [( Glu1]Pg) by human recombinant (rec) two-chain tissue plasminogen activator (gene) is inhibited by chemical, at physiological concentrations, and stimulated by epsilon-aminocaproic acid (EACA), as well as fibrin(ogen).	T2	T13	3146348
NA	CHEMICAL	GENE-Y	0	9	chemical functions as a result of its binding to gene, with a Ki of approximately 9.0 mM, thereby rendering gene a less effective substrate for two-chain rec-t-PA.	T5	T16	3146348
NA	CHEMICAL	GENE-Y	0	9	chemical functions as a result of its binding to gene, with a Ki of approximately 9.0 mM, thereby rendering gene a less effective substrate for two-chain rec-t-PA.	T5	T17	3146348
NA	CHEMICAL	GENE-Y	0	26	chemical functions as a result of its binding to [Glu1]Pg, with a Ki of approximately 9.0 mM, thereby rendering [Glu1]Pg a less effective substrate for two-chain rec-gene.	T5	T18	3146348
NA	CHEMICAL	GENE-N	29	0	gene appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-t-PA, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of chemical.	T9	T20	3146348
NA	CHEMICAL	GENE-Y	29	14	Fibrinogen appears to exert its stimulatory properties mainly through effects on the enzyme, two-chain rec-gene, with a Ka of approximately 3.7 microM in activation systems containing physiological levels of chemical.	T9	T21	3146348
NA	CHEMICAL	GENE-N	12	14	Analysis of the results of this paper reveals that normal plasma components, chemical and gene, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-t-PA, in in vitro systems.	T10	T22	3146348
NA	CHEMICAL	GENE-Y	12	23	Analysis of the results of this paper reveals that normal plasma components, chemical and fibrinogen, exert major regulatory roles on the ability of gene to be activated by two-chain rec-t-PA, in in vitro systems.	T10	T24	3146348
NA	CHEMICAL	GENE-Y	12	29	Analysis of the results of this paper reveals that normal plasma components, chemical and fibrinogen, exert major regulatory roles on the ability of [Glu1]Pg to be activated by two-chain rec-gene, in in vitro systems.	T10	T25	3146348
NA	CHEMICAL	GENE-Y	3	37	The presence of chemical inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of gene.	T1	T14	3146348
NA	CHEMICAL	GENE-N	3	18	The presence of chemical inhibits the stimulation of [Glu1]Pg activation that would normally occur in the presence of gene, a result of possible importance to the observation that some degree of systemic geneolysis accompanies therapeutic use of tissue plasminogen activator.	T1	T12	3146348
CPR:4	CHEMICAL	GENE-Y	3	8	The presence of chemical inhibits the stimulation of gene activation that would normally occur in the presence of fibrinogen, a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of tissue plasminogen activator.	T1	T11	3146348
NA	CHEMICAL	GENE-Y	11	6	We also analyzed the formation of 125I-gene -inhibitor complexes by chemical polyacrylamide gel electrophoresis (SDS-PAGE).	T9	T27	6725552
NA	CHEMICAL	GENE-Y	14	6	We also analyzed the formation of 125I-gene -inhibitor complexes by sodium dodecyl sulfate chemical gel electrophoresis (SDS-PAGE).	T10	T27	6725552
NA	CHEMICAL	GENE-Y	6	6	We also analyzed the formation of chemical-gene -inhibitor complexes by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).	T8	T27	6725552
NA	CHEMICAL	GENE-Y	14	15	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with chemical-1-inhibitor, gene, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	T11	T30	6725552
NA	CHEMICAL	GENE-Y	14	18	In purified systems, the bimolecular rate constants for the reactions of Factor XIIf with chemical-1-inhibitor, alpha 2-antiplasmin, and gene were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	T11	T31	6725552
NA	CHEMICAL	GENE-Y	14	11	In purified systems, the bimolecular rate constants for the reactions of gene with chemical-1-inhibitor, alpha 2-antiplasmin, and antithrombin III were 18.5, 0.91, and 0.32 X 10(4) M-1 min-1, respectively.	T11	T28	6725552
NA	CHEMICAL	GENE-Y	11	11	Furthermore, SDS-PAGE analysis revealed that 1:1 stoichiometric complexes were formed between chemical-gene and each of these three inhibitors.	T12	T32	6725552
NA	CHEMICAL	GENE-Y	25	15	This constant was reduced to 1.8 X 10(-2) min-1 when Factor XIIf was inactivated by gene-deficient plasma that had been immunodepleted (less than 5%) of chemical-1-inhibitor.	T1	T15	6725552
NA	CHEMICAL	GENE-Y	25	10	This constant was reduced to 1.8 X 10(-2) min-1 when gene was inactivated by prekallikrein-deficient plasma that had been immunodepleted (less than 5%) of chemical-1-inhibitor.	T1	T14	6725552
NA	CHEMICAL	GENE-Y	11	29	In addition, after inactivation in normal plasma, 74% of the active chemical-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with gene and antithrombin III.	T2	T19	6725552
NA	CHEMICAL	GENE-Y	11	32	In addition, after inactivation in normal plasma, 74% of the active chemical-Factor XIIf was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and gene.	T2	T20	6725552
NA	CHEMICAL	GENE-Y	11	20	In addition, after inactivation in normal plasma, 74% of the active chemical-Factor XIIf was found to form a complex with gene, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	T2	T18	6725552
NA	CHEMICAL	GENE-Y	11	11	In addition, after inactivation in normal plasma, 74% of the active chemical-gene was found to form a complex with C-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	T2	T17	6725552
NA	CHEMICAL	GENE-Y	20	29	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with chemical-1-inhibitor, whereas 26% of the enzyme formed complexes with gene and antithrombin III.	T3	T19	6725552
NA	CHEMICAL	GENE-Y	20	32	In addition, after inactivation in normal plasma, 74% of the active 125I-Factor XIIf was found to form a complex with chemical-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and gene.	T3	T20	6725552
NA	CHEMICAL	GENE-Y	20	11	In addition, after inactivation in normal plasma, 74% of the active 125I-gene was found to form a complex with chemical-1-inhibitor, whereas 26% of the enzyme formed complexes with alpha 2-antiplasmin and antithrombin III.	T3	T17	6725552
NA	CHEMICAL	GENE-Y	12	10	Furthermore, 42% of the labeled enzyme was still complexed with gene when chemical-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional gene.	T5	T21	6725552
NA	CHEMICAL	GENE-Y	12	10	Furthermore, 42% of the labeled enzyme was still complexed with gene when chemical-Factor XII was inactivated in hereditary angioedema plasma that contained 32% of functional gene.	T5	T23	6725552
NA	CHEMICAL	GENE-Y	12	12	Furthermore, 42% of the labeled enzyme was still complexed with C-1-inhibitor when chemical-gene was inactivated in hereditary angioedema plasma that contained 32% of functional C-1-inhibitor.	T5	T22	6725552
NA	CHEMICAL	GENE-Y	10	12	Furthermore, 42% of the labeled enzyme was still complexed with chemical-1-inhibitor when 125I-gene was inactivated in hereditary angioedema plasma that contained 32% of functional chemical-1-inhibitor.	T4	T22	6725552
NA	CHEMICAL	GENE-Y	10	12	Furthermore, 42% of the labeled enzyme was still complexed with chemical-1-inhibitor when 125I-gene was inactivated in hereditary angioedema plasma that contained 32% of functional chemical-1-inhibitor.	T6	T22	6725552
NA	CHEMICAL	GENE-Y	8	13	This study quantitatively demonstrates the dominant role of chemical-1-inhibitor in the inactivation of gene in the plasma milieu.	T7	T26	6725552
NA	CHEMICAL	GENE-Y	18	12	To explore the relationship between catecholamine transport and ion permeation through the gene, we established a human chemical transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	T16	T32	7500004
NA	CHEMICAL	GENE-Y	18	20	To explore the relationship between catecholamine transport and ion permeation through the NE transporter, we established a human chemical transporter (gene) cell line suitable for biochemical analysis and patch-clamp recording.	T16	T34	7500004
NA	CHEMICAL	GENE-Y	5	17	To explore the relationship between chemical transport and ion permeation through the NE transporter, we established a gene (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	T13	T33	7500004
NA	CHEMICAL	GENE-Y	5	12	To explore the relationship between chemical transport and ion permeation through the gene, we established a human norepinephrine transporter (hNET) cell line suitable for biochemical analysis and patch-clamp recording.	T13	T32	7500004
NA	CHEMICAL	GENE-Y	5	20	To explore the relationship between chemical transport and ion permeation through the NE transporter, we established a human norepinephrine transporter (gene) cell line suitable for biochemical analysis and patch-clamp recording.	T13	T34	7500004
NA	CHEMICAL	GENE-Y	12	17	To explore the relationship between catecholamine transport and ion permeation through the chemical transporter, we established a gene (hchemicalT) cell line suitable for biochemical analysis and patch-clamp recording.	T15	T33	7500004
NA	CHEMICAL	GENE-Y	35	3	Stable transfection of gene cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and gene-specific antibodies, (2) high-affinity, chemical-dependent transport of NE, and (3) inhibitor sensitivities similar to those of native membranes.	T18	T35	7500004
NA	CHEMICAL	GENE-Y	35	3	Stable transfection of gene cDNA into HEK-293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and gene-specific antibodies, (2) high-affinity, chemical-dependent transport of NE, and (3) inhibitor sensitivities similar to those of native membranes.	T18	T36	7500004
CPR:4	CHEMICAL	GENE-Y	13	3	Whole-cell voltage-clamp of gene-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and chemical that are absent in parental cells.	T22	T37	7500004
NA	CHEMICAL	GENE-Y	7	3	Whole-cell voltage-clamp of gene-293 cells reveals NE-induced, chemical-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.	T21	T37	7500004
NA	CHEMICAL	GENE-N	7	10	To explain our observations, we propose that hchemicalTs function as gene with an indefinite stoichiometry relating ion flux to chemical transport.	T6	T31	7500004
NA	CHEMICAL	GENE-N	1	17	The chemical-terminal portion of TSG-6 shows sequence homology to members of the cartilage link protein family of gene.	T5	T13	7516184
NA	CHEMICAL	GENE-N	1	4	The chemical-terminal portion of gene shows sequence homology to members of the cartilage link protein family of hyaluronan binding proteins.	T5	T28	7516184
NA	CHEMICAL	GENE-Y	1	4	The chemical-terminal portion of gene shows sequence homology to members of the cartilage link protein family of hyaluronan binding proteins.	T5	T28	7516184
NA	CHEMICAL	GENE-N	1	4	The chemical-terminal half of gene contains a so-called chemicalUB domain, characteristic for developmentally regulated proteins.	T3	T15	7516184
NA	CHEMICAL	GENE-Y	1	4	The chemical-terminal half of gene contains a so-called chemicalUB domain, characteristic for developmentally regulated proteins.	T3	T15	7516184
NA	CHEMICAL	GENE-N	18	13	The protein that binds TSG-6 was purified from human serum and identified as gene (I alpha I) by chemical-terminal microsequencing.	T6	T22	7516184
NA	CHEMICAL	GENE-N	18	14	The protein that binds TSG-6 was purified from human serum and identified as inter-alpha-inhibitor (gene) by chemical-terminal microsequencing.	T6	T23	7516184
NA	CHEMICAL	GENE-N	18	4	The protein that binds gene was purified from human serum and identified as inter-alpha-inhibitor (I alpha I) by chemical-terminal microsequencing.	T6	T21	7516184
NA	CHEMICAL	GENE-Y	18	4	The protein that binds gene was purified from human serum and identified as inter-alpha-inhibitor (I alpha I) by chemical-terminal microsequencing.	T6	T21	7516184
NA	CHEMICAL	GENE-N	49	5	Experiments with recombinant TSG-6 and gene purified from human serum showed that the TSG-6/gene complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/gene complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T11	7516184
NA	CHEMICAL	GENE-N	49	5	Experiments with recombinant TSG-6 and gene purified from human serum showed that the TSG-6/gene complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/gene complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T30	7516184
NA	CHEMICAL	GENE-N	49	5	Experiments with recombinant TSG-6 and gene purified from human serum showed that the TSG-6/gene complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/gene complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T9	7516184
NA	CHEMICAL	GENE-N	49	5	Experiments with recombinant TSG-6 and gene purified from human serum showed that the TSG-6/gene complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/gene complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T11	7516184
NA	CHEMICAL	GENE-N	49	5	Experiments with recombinant TSG-6 and gene purified from human serum showed that the TSG-6/gene complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/gene complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T30	7516184
NA	CHEMICAL	GENE-N	49	5	Experiments with recombinant TSG-6 and gene purified from human serum showed that the TSG-6/gene complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The TSG-6/gene complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T9	7516184
NA	CHEMICAL	GENE-N	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T10	7516184
NA	CHEMICAL	GENE-N	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T29	7516184
NA	CHEMICAL	GENE-N	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T8	7516184
NA	CHEMICAL	GENE-N	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T10	7516184
NA	CHEMICAL	GENE-N	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T29	7516184
NA	CHEMICAL	GENE-N	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T8	7516184
NA	CHEMICAL	GENE-Y	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T10	7516184
NA	CHEMICAL	GENE-Y	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T29	7516184
NA	CHEMICAL	GENE-Y	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T1	T8	7516184
NA	CHEMICAL	GENE-Y	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T10	7516184
NA	CHEMICAL	GENE-Y	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T29	7516184
NA	CHEMICAL	GENE-Y	49	3	Experiments with recombinant gene and I alpha I purified from human serum showed that the gene/I alpha I complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The gene/I alpha I complex was cleaved by chondroitin chemical ABC lyase, suggesting that cross-linking by chondroitin chemical is required for the stability of the complex.	T2	T8	7516184
NA	CHEMICAL	GENE-N	19	22	BACKGROUND: The active metabolite of the anti-inflammatory drug nabumetone has been characterized as a selective inhibitor of the inducible chemical H synthase (gene).	T6	T28	7554708
CPR:4	CHEMICAL	GENE-N	8	19	BACKGROUND: The active metabolite of the anti-inflammatory drug chemical has been characterized as a selective inhibitor of the inducible gene (PGHS).	T17	T25	7554708
CPR:4	CHEMICAL	GENE-N	8	22	BACKGROUND: The active metabolite of the anti-inflammatory drug chemical has been characterized as a selective inhibitor of the inducible prostaglandin H synthase (gene).	T17	T28	7554708
NA	CHEMICAL	GENE-Y	10	29	METHODS: We measured the urinary excretion of products of platelet (chemical [TXB2]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive gene pathway.	T11	T30	7554708
NA	CHEMICAL	GENE-Y	15	29	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (chemical [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive gene pathway.	T13	T30	7554708
NA	CHEMICAL	GENE-Y	20	29	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) chemical metabolism as in vivo indexes of the constitutive gene pathway.	T15	T30	7554708
NA	CHEMICAL	GENE-Y	18	29	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [TXB2]) and renal (prostaglandin IF2 alpha [chemical]) arachidonate metabolism as in vivo indexes of the constitutive gene pathway.	T14	T30	7554708
NA	CHEMICAL	GENE-Y	12	29	METHODS: We measured the urinary excretion of products of platelet (11-dehydro-thromboxane B2 [chemical]) and renal (prostaglandin IF2 alpha [PGF2 alpha]) arachidonate metabolism as in vivo indexes of the constitutive gene pathway.	T12	T30	7554708
CPR:9	CHEMICAL	GENE-N	4	16	Moreover, the production of chemical during whole blood clotting was assessed as an index of the gene activity of platelet PGHS-1 ex vivo.	T16	T31	7554708
CPR:9	CHEMICAL	GENE-Y	4	20	Moreover, the production of chemical during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet gene ex vivo.	T16	T32	7554708
CPR:9	CHEMICAL	GENE-Y	20	13	The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet gene, caused a cumulative inhibition of urinary chemical and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.	T5	T24	7554708
CPR:4	CHEMICAL	GENE-Y	5	13	The daily administration of low-dose chemical (40 mg), a selective inhibitor of platelet gene, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.	T4	T24	7554708
CPR:9	CHEMICAL	GENE-Y	20	13	The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet gene, caused a cumulative inhibition of urinary 11-dehydro-chemical and whole blood chemical production that recovered with a timecourse consistent with platelet turnover.	T7	T24	7554708
CPR:4	CHEMICAL	GENE-N	1	6	CONCLUSIONS: chemical does dose-dependently inhibit the gene activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.	T8	T26	7554708
CPR:4	CHEMICAL	GENE-Y	1	10	CONCLUSIONS: chemical does dose-dependently inhibit the cyclooxygenase activity of platelet gene of healthy subjects both in vivo and ex vivo.	T8	T27	7554708
NA	CHEMICAL	GENE-Y	32	11	This analysis revealed significant differences in the expression level of the gene (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T4	T24	7601910
NA	CHEMICAL	GENE-Y	32	25	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), gene (CRBP-1), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T4	T18	7601910
NA	CHEMICAL	GENE-N	32	39	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (RAR gamma), and gene (CREB).	T4	T22	7601910
NA	CHEMICAL	GENE-Y	32	17	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), gene (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T4	T16	7601910
NA	CHEMICAL	GENE-Y	32	22	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (gene), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T4	T17	7601910
NA	CHEMICAL	GENE-Y	32	36	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (gene), and cAMP response element binding protein (CREB).	T4	T21	7601910
NA	CHEMICAL	GENE-Y	32	31	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (gene), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T4	T19	7601910
NA	CHEMICAL	GENE-Y	32	16	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (gene), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T4	T15	7601910
NA	CHEMICAL	GENE-N	32	44	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), chemical receptor gamma (RAR gamma), and cAMP response element binding protein (gene).	T4	T23	7601910
NA	CHEMICAL	GENE-Y	12	25	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), gene (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T2	T18	7601910
NA	CHEMICAL	GENE-N	12	39	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and gene (CREB).	T2	T22	7601910
NA	CHEMICAL	GENE-Y	12	17	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), gene (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T2	T16	7601910
NA	CHEMICAL	GENE-Y	12	32	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), gene (RAR gamma), and cAMP response element binding protein (CREB).	T2	T20	7601910
NA	CHEMICAL	GENE-Y	12	22	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (gene), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T2	T17	7601910
NA	CHEMICAL	GENE-Y	12	36	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (gene), and cAMP response element binding protein (CREB).	T2	T21	7601910
NA	CHEMICAL	GENE-Y	12	31	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (gene), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T2	T19	7601910
NA	CHEMICAL	GENE-Y	12	16	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (gene), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T2	T15	7601910
NA	CHEMICAL	GENE-N	12	44	This analysis revealed significant differences in the expression level of the nicotinic chemical receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (gene).	T2	T23	7601910
NA	CHEMICAL	GENE-Y	28	11	This analysis revealed significant differences in the expression level of the gene (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T3	T24	7601910
NA	CHEMICAL	GENE-N	28	39	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and gene (CREB).	T3	T22	7601910
NA	CHEMICAL	GENE-Y	28	17	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), gene (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T3	T16	7601910
NA	CHEMICAL	GENE-Y	28	32	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), gene (RAR gamma), and cAMP response element binding protein (CREB).	T3	T20	7601910
NA	CHEMICAL	GENE-Y	28	22	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (gene), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T3	T17	7601910
NA	CHEMICAL	GENE-Y	28	36	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (gene), and cAMP response element binding protein (CREB).	T3	T21	7601910
NA	CHEMICAL	GENE-Y	28	31	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (gene), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T3	T19	7601910
NA	CHEMICAL	GENE-Y	28	16	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (gene), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (CREB).	T3	T15	7601910
NA	CHEMICAL	GENE-N	28	44	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular chemical binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and cAMP response element binding protein (gene).	T3	T23	7601910
NA	CHEMICAL	GENE-Y	39	11	This analysis revealed significant differences in the expression level of the gene (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (CREB).	T5	T24	7601910
NA	CHEMICAL	GENE-Y	39	25	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), gene (CRBP-1), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (CREB).	T5	T18	7601910
NA	CHEMICAL	GENE-Y	39	17	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), gene (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (CREB).	T5	T16	7601910
NA	CHEMICAL	GENE-Y	39	32	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), gene (RAR gamma), and chemical response element binding protein (CREB).	T5	T20	7601910
NA	CHEMICAL	GENE-Y	39	22	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (gene), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (CREB).	T5	T17	7601910
NA	CHEMICAL	GENE-Y	39	36	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (gene), and chemical response element binding protein (CREB).	T5	T21	7601910
NA	CHEMICAL	GENE-Y	39	31	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (gene), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (CREB).	T5	T19	7601910
NA	CHEMICAL	GENE-Y	39	16	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (gene), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (CREB).	T5	T15	7601910
NA	CHEMICAL	GENE-N	39	44	This analysis revealed significant differences in the expression level of the nicotinic acetylcholine receptor subunit alpha (NAChR), transforming growth factor beta 2 (TGF beta 2), type 1 cellular retinoid binding protein (CRBP-1), retinoic acid receptor gamma (RAR gamma), and chemical response element binding protein (gene).	T5	T23	7601910
NA	CHEMICAL	GENE-Y	3	17	The presence of chemical binding protein (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the gene, was investigated in a pilot study of primary malignant melanomas and their metastases.	T2	T4	7703721
NA	CHEMICAL	GENE-N	3	6	The presence of chemical binding protein (gene), a 54 kD cytosolic glycoprotein, which is distinct from the estrogen receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	T2	T8	7703721
NA	CHEMICAL	GENE-N	17	3	The presence of gene (EMBP), a 54 kD cytosolic glycoprotein, which is distinct from the chemical receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	T1	T5	7703721
NA	CHEMICAL	GENE-N	17	6	The presence of estramustine binding protein (gene), a 54 kD cytosolic glycoprotein, which is distinct from the chemical receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	T1	T8	7703721
NA	CHEMICAL	GENE-Y	0	19	chemical (0.1%) failed to significantly attenuate either serotonin or platelet-activating-factor induced vascular permeability changes indicating high selectivity for the gene.	T21	T24	7714410
CPR:4	CHEMICAL	GENE-Y	15	11	(2) Exposure histories vary in secondary 11q23 leukemia, as the only gene inhibitor was chemical in one case, and, in another case, no gene inhibitor was administered.	T1	T2	7756657
NA	CHEMICAL	GENE-Y	15	11	(2) Exposure histories vary in secondary 11q23 leukemia, as the only gene inhibitor was chemical in one case, and, in another case, no gene inhibitor was administered.	T1	T3	7756657
NA	CHEMICAL	GENE-N	5	11	There are two isozymes of chemical endoperoxide (PGH) synthase (cyclooxygenase) called gene or COX I and II.	T12	T35	7825862
NA	CHEMICAL	GENE-N	5	9	There are two isozymes of chemical endoperoxide (PGH) synthase (gene) called PGH synthase-1 and -2 or COX I and II.	T12	T32	7825862
NA	CHEMICAL	GENE-N	5	16	There are two isozymes of chemical endoperoxide (PGH) synthase (cyclooxygenase) called PGH synthase-1 and -2 or gene.	T12	T14	7825862
CPR:4	CHEMICAL	GENE-Y	3	10	Indomethacin, piroxicam, and chemical were found to preferentially inhibit gene.	T3	T13	7825862
CPR:4	CHEMICAL	GENE-Y	0	10	chemical, piroxicam, and sulindac sulfide were found to preferentially inhibit gene.	T1	T13	7825862
CPR:4	CHEMICAL	GENE-Y	1	10	Indomethacin, chemical, and sulindac sulfide were found to preferentially inhibit gene.	T2	T13	7825862
CPR:4	CHEMICAL	GENE-Y	0	9	chemical, the active metabolite of Relafen, inhibits murine gene preferentially.	T5	T15	7825862
CPR:4	CHEMICAL	GENE-Y	6	9	6-Methoxy-2-naphthylacetic acid, the active metabolite of chemical, inhibits murine gene preferentially.	T6	T15	7825862
NA	CHEMICAL	GENE-Y	26	3	Aspirin irreversibly inhibits gene, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form chemical (15-HETE) instead of PGH2.	T9	T16	7825862
CPR:9	CHEMICAL	GENE-Y	26	20	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of gene causes this enzyme to form chemical (15-HETE) instead of PGH2.	T9	T17	7825862
NA	CHEMICAL	GENE-Y	28	3	Aspirin irreversibly inhibits gene, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (chemical) instead of PGH2.	T10	T16	7825862
CPR:9	CHEMICAL	GENE-Y	28	20	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of gene causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (chemical) instead of PGH2.	T10	T17	7825862
CPR:4	CHEMICAL	GENE-Y	0	3	chemical irreversibly inhibits gene, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	T7	T16	7825862
NA	CHEMICAL	GENE-Y	0	20	chemical irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of gene causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	T7	T17	7825862
NA	CHEMICAL	GENE-Y	17	3	Aspirin irreversibly inhibits gene, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, chemical treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	T8	T16	7825862
NA	CHEMICAL	GENE-Y	17	20	Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, chemical treatment of gene causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.	T8	T17	7825862
NA	CHEMICAL	GENE-Y	7	0	gene receptors mediate the satiating effect of chemical, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and sertraline cause anorexia is not clear.	T3	T17	7902561
NA	CHEMICAL	GENE-Y	20	0	gene receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as fluoxetine and chemical cause anorexia is not clear.	T6	T17	7902561
NA	CHEMICAL	GENE-Y	18	0	gene receptors mediate the satiating effect of dexfenfluramine, whereas the mechanism by which 5-HT uptake inhibitors such as chemical and sertraline cause anorexia is not clear.	T5	T17	7902561
NA	CHEMICAL	GENE-N	7	40	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and chemical seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of chemical, to stimulate directly gene.	T10	T18	7902561
CPR:3	CHEMICAL	GENE-N	7	40	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and chemical seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of chemical, to stimulate directly gene.	T14	T18	7902561
NA	CHEMICAL	GENE-N	3	40	Anorexia induced by chemical, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly gene.	T7	T18	7902561
NA	CHEMICAL	GENE-N	5	40	Anorexia induced by (+)-amphetamine, phentermine, chemical and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly gene.	T9	T18	7902561
NA	CHEMICAL	GENE-N	21	40	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of chemical and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly gene.	T11	T18	7902561
NA	CHEMICAL	GENE-N	4	40	Anorexia induced by (+)-amphetamine, chemical, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly gene.	T8	T18	7902561
NA	CHEMICAL	GENE-N	23	40	Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or chemical from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly gene.	T12	T18	7902561
NA	CHEMICAL	GENE-N	11	5	It has been suggested that gene and D1 chemical receptors are involved in their effect on food intake.	T15	T19	7902561
NA	CHEMICAL	GENE-N	23	5	Under these conditions, blockade of gene with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both chemical (5-MeO-T) and tryptamine.	T51	T69	8032658
NA	CHEMICAL	GENE-N	23	5	Under these conditions, blockade of gene with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxychemical (5-MeO-T) and chemical.	T53	T69	8032658
CPR:4	CHEMICAL	GENE-N	8	5	Under these conditions, blockade of gene with chemical (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (5-MeO-T) and tryptamine.	T50	T69	8032658
NA	CHEMICAL	GENE-N	24	5	Under these conditions, blockade of gene with pargyline (100 microM for 15 min) caused a leftward displacement of concentration-effect curves for both 5-methoxytryptamine (chemical) and tryptamine.	T52	T69	8032658
NA	CHEMICAL	GENE-Y	35	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and chemical (8-OH-DPAT) were very weak or inactive.	T16	T62	8032658
NA	CHEMICAL	GENE-Y	35	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and chemical (8-OH-DPAT) were very weak or inactive.	T16	T61	8032658
CPR:5	CHEMICAL	GENE-Y	16	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including chemical (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T8	T62	8032658
CPR:5	CHEMICAL	GENE-Y	16	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including chemical (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T8	T61	8032658
NA	CHEMICAL	GENE-Y	32	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst chemical, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T13	T62	8032658
NA	CHEMICAL	GENE-Y	32	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst chemical, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T13	T61	8032658
NA	CHEMICAL	GENE-Y	33	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, chemical and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T15	T62	8032658
NA	CHEMICAL	GENE-Y	33	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, chemical and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T15	T61	8032658
CPR:5	CHEMICAL	GENE-Y	23	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and chemical were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T12	T62	8032658
CPR:5	CHEMICAL	GENE-Y	23	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and chemical were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T12	T61	8032658
NA	CHEMICAL	GENE-Y	37	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (chemical) were very weak or inactive.	T17	T62	8032658
NA	CHEMICAL	GENE-Y	37	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (chemical) were very weak or inactive.	T17	T61	8032658
CPR:5	CHEMICAL	GENE-Y	18	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), chemical, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T10	T62	8032658
CPR:5	CHEMICAL	GENE-Y	18	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), chemical, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T10	T61	8032658
CPR:5	CHEMICAL	GENE-Y	20	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, chemical and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T11	T62	8032658
CPR:5	CHEMICAL	GENE-Y	20	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (m-CPP), Ru 24969, chemical and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T11	T61	8032658
CPR:5	CHEMICAL	GENE-Y	17	13	In addition several ligands known to act as agonists at either 5-HT2A or gene receptors including 1-m-chlorophenylpiperazine (chemical), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T9	T62	8032658
CPR:5	CHEMICAL	GENE-Y	17	11	In addition several ligands known to act as agonists at either gene or 5-HT2C receptors including 1-m-chlorophenylpiperazine (chemical), Ru 24969, MK 212 and SCH 23390 were also agonists in rat fundus whilst sumatriptan, renzapride and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were very weak or inactive.	T9	T61	8032658
NA	CHEMICAL	GENE-N	13	21	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of chemical and yohimbine, the close pharmacological identity of gene in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.	T44	T64	8032658
NA	CHEMICAL	GENE-Y	13	31	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of chemical and yohimbine, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned gene receptor is maintained.	T44	T65	8032658
NA	CHEMICAL	GENE-N	15	21	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and chemical, the close pharmacological identity of gene in rat stomach fundus and the recently cloned 5-HT2B receptor is maintained.	T45	T64	8032658
NA	CHEMICAL	GENE-Y	15	31	We conclude that despite small differences concerning the enantiomeric selectivity and affinity of rauwolscine and chemical, the close pharmacological identity of 5-HT receptors in rat stomach fundus and the recently cloned gene receptor is maintained.	T45	T65	8032658
NA	CHEMICAL	GENE-N	0	7	chemical, which demonstrates some selectivity for gene in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of 5-HT2B function both in vitro and in vivo.	T47	T66	8032658
NA	CHEMICAL	GENE-Y	0	27	chemical, which demonstrates some selectivity for 5-HT receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of gene function both in vitro and in vivo.	T47	T67	8032658
NA	CHEMICAL	GENE-N	15	9	Only strains of P. aeruginosa producing large amounts of gene may be resistant to both chemical and cefepime.	T5	T20	8150771
NA	CHEMICAL	GENE-N	17	9	Only strains of P. aeruginosa producing large amounts of gene may be resistant to both ceftazidime and chemical.	T6	T20	8150771
CPR:4	CHEMICAL	GENE-Y	4	7	The mechanism by which chemical (NE) down-regulates gene (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.	T3	T29	8294418
CPR:4	CHEMICAL	GENE-N	4	10	The mechanism by which chemical (NE) down-regulates alpha 1B-adrenergic receptor (gene) mRNA was studied in rabbit aortic smooth muscle cells.	T3	T35	8294418
CPR:4	CHEMICAL	GENE-Y	5	7	The mechanism by which norepinephrine (chemical) down-regulates gene (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.	T8	T29	8294418
CPR:4	CHEMICAL	GENE-N	5	10	The mechanism by which norepinephrine (chemical) down-regulates alpha 1B-adrenergic receptor (gene) mRNA was studied in rabbit aortic smooth muscle cells.	T8	T35	8294418
NA	CHEMICAL	GENE-Y	1	4	NE, chemical, and gene each decreased alpha-AR mRNA levels by 70-80%.	T2	T24	8294418
CPR:4	CHEMICAL	GENE-N	1	7	NE, chemical, and bradykinin each decreased gene mRNA levels by 70-80%.	T2	T25	8294418
NA	CHEMICAL	GENE-Y	0	4	chemical, phorbol esters, and gene each decreased alpha-AR mRNA levels by 70-80%.	T1	T24	8294418
CPR:4	CHEMICAL	GENE-N	0	7	chemical, phorbol esters, and bradykinin each decreased gene mRNA levels by 70-80%.	T1	T25	8294418
CPR:4	CHEMICAL	GENE-N	5	1	The gene inhibitor chemical (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.	T4	T26	8294418
NA	CHEMICAL	GENE-N	12	1	The gene inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of chemical and NE and decreased basal mRNA levels by 52 +/- 3%.	T6	T26	8294418
CPR:4	CHEMICAL	GENE-N	7	1	The gene inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (chemical) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.	T5	T26	8294418
NA	CHEMICAL	GENE-N	15	1	The gene inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and chemical and decreased basal mRNA levels by 52 +/- 3%.	T7	T26	8294418
CPR:3	CHEMICAL	GENE-N	1	7	Neither chemical nor EGTA inhibited down-regulation of gene mRNA by NE.	T9	T27	8294418
CPR:3	CHEMICAL	GENE-N	3	7	Neither ryanodine nor chemical inhibited down-regulation of gene mRNA by NE.	T10	T27	8294418
CPR:4	CHEMICAL	GENE-N	10	7	Neither ryanodine nor EGTA inhibited down-regulation of gene mRNA by chemical.	T11	T27	8294418
CPR:4	CHEMICAL	GENE-N	0	3	chemical caused gene mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal gene mRNA level.	T12	T28	8294418
CPR:4	CHEMICAL	GENE-N	0	3	chemical caused gene mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal gene mRNA level.	T12	T30	8294418
NA	CHEMICAL	GENE-N	21	3	Actinomycin D caused gene mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of chemical to decrease basal gene mRNA level.	T13	T28	8294418
NA	CHEMICAL	GENE-N	21	3	Actinomycin D caused gene mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of chemical to decrease basal gene mRNA level.	T13	T30	8294418
CPR:4	CHEMICAL	GENE-N	3	9	Both NE and chemical increased the rate of gene mRNA degradation.	T15	T31	8294418
CPR:4	CHEMICAL	GENE-N	1	9	Both chemical and phorbol esters increased the rate of gene mRNA degradation.	T14	T31	8294418
NA	CHEMICAL	GENE-Y	3	6	In NE-desensitized cells, chemical and gene each caused the expected down-regulation of alpha-AR mRNA.	T17	T32	8294418
CPR:4	CHEMICAL	GENE-N	3	13	In NE-desensitized cells, chemical and bradykinin each caused the expected down-regulation of gene mRNA.	T17	T33	8294418
NA	CHEMICAL	GENE-Y	1	6	In chemical-desensitized cells, phorbol esters and gene each caused the expected down-regulation of alpha-AR mRNA.	T16	T32	8294418
CPR:4	CHEMICAL	GENE-N	1	13	In chemical-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of gene mRNA.	T16	T33	8294418
CPR:4	CHEMICAL	GENE-N	4	1	The gene inhibitor chemical prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	T18	T34	8294418
NA	CHEMICAL	GENE-N	4	21	The protein phosphatase inhibitor chemical prolonged the normally transient effect of NE for at least 24 h. We conclude that gene exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a gene substrate and 2) a permissive effect on alpha-AR gene transcription.	T18	T22	8294418
NA	CHEMICAL	GENE-N	4	21	The protein phosphatase inhibitor chemical prolonged the normally transient effect of NE for at least 24 h. We conclude that gene exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a gene substrate and 2) a permissive effect on alpha-AR gene transcription.	T18	T36	8294418
NA	CHEMICAL	GENE-N	4	29	The protein phosphatase inhibitor chemical prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on gene mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on gene gene transcription.	T18	T21	8294418
NA	CHEMICAL	GENE-N	4	29	The protein phosphatase inhibitor chemical prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on gene mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on gene gene transcription.	T18	T23	8294418
NA	CHEMICAL	GENE-N	12	1	The gene inhibitor okadaic acid prolonged the normally transient effect of chemical for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	T19	T34	8294418
NA	CHEMICAL	GENE-N	12	21	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of chemical for at least 24 h. We conclude that gene exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a gene substrate and 2) a permissive effect on alpha-AR gene transcription.	T19	T22	8294418
NA	CHEMICAL	GENE-N	12	21	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of chemical for at least 24 h. We conclude that gene exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a gene substrate and 2) a permissive effect on alpha-AR gene transcription.	T19	T36	8294418
NA	CHEMICAL	GENE-N	12	29	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of chemical for at least 24 h. We conclude that protein kinase C exerts two opposing effects on gene mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on gene gene transcription.	T19	T21	8294418
NA	CHEMICAL	GENE-N	12	29	The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of chemical for at least 24 h. We conclude that protein kinase C exerts two opposing effects on gene mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on gene gene transcription.	T19	T23	8294418
NA	CHEMICAL	GENE-Y	24	18	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, gene, and 5-HT2; 5-HT is serotonin (chemical)] were used as primers for the sequential reactions.	T18	T36	8384716
NA	CHEMICAL	GENE-Y	24	17	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [gene, 5-HT1C, and 5-HT2; 5-HT is serotonin (chemical)] were used as primers for the sequential reactions.	T18	T35	8384716
NA	CHEMICAL	GENE-Y	24	20	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and gene; 5-HT is serotonin (chemical)] were used as primers for the sequential reactions.	T18	T37	8384716
NA	CHEMICAL	GENE-Y	1	18	Degenerate chemical corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, gene, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T14	T36	8384716
NA	CHEMICAL	GENE-Y	1	17	Degenerate chemical corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [gene, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T14	T35	8384716
NA	CHEMICAL	GENE-Y	1	20	Degenerate chemical corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and gene; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T14	T37	8384716
NA	CHEMICAL	GENE-Y	5	18	Degenerate oligonucleotides corresponding to conserved chemical from transmembrane domains III, V, and VI of known receptors [5-HT1A, gene, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T15	T36	8384716
NA	CHEMICAL	GENE-Y	5	17	Degenerate oligonucleotides corresponding to conserved chemical from transmembrane domains III, V, and VI of known receptors [gene, 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T15	T35	8384716
NA	CHEMICAL	GENE-Y	5	20	Degenerate oligonucleotides corresponding to conserved chemical from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and gene; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T15	T37	8384716
NA	CHEMICAL	GENE-Y	23	18	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, gene, and 5-HT2; 5-HT is chemical (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T17	T36	8384716
NA	CHEMICAL	GENE-Y	23	17	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [gene, 5-HT1C, and 5-HT2; 5-HT is chemical (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T17	T35	8384716
NA	CHEMICAL	GENE-Y	23	20	Degenerate oligonucleotides corresponding to conserved amino acids from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and gene; 5-HT is chemical (5-hydroxytryptamine)] were used as primers for the sequential reactions.	T17	T37	8384716
NA	CHEMICAL	GENE-N	27	21	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (MR77) containing an gene encoding a 366-chemical seven-transmembrane domain protein.	T19	T39	8384716
NA	CHEMICAL	GENE-Y	27	18	The resulting product was subcloned and used to screen a rat genomic library to identify a full-length clone (gene) containing an intronless open reading frame encoding a 366-chemical seven-transmembrane domain protein.	T19	T38	8384716
NA	CHEMICAL	GENE-Y	14	27	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% chemical identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and gene receptors, respectively.	T21	T44	8384716
NA	CHEMICAL	GENE-Y	14	24	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% chemical identity with the known rat 5-HT1A, rat 5-HT1B, gene, and human 5-HT1E receptors, respectively.	T21	T43	8384716
NA	CHEMICAL	GENE-Y	14	20	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% chemical identity with the known gene, rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.	T21	T41	8384716
NA	CHEMICAL	GENE-Y	14	22	Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% chemical identity with the known rat 5-HT1A, gene, rat 5-HT1D, and human 5-HT1E receptors, respectively.	T21	T42	8384716
NA	CHEMICAL	GENE-N	18	16	The specific binding is displaced by the selective 5-HT1D agonist sumatriptan but not by the mixed gene agonist chemical.	T7	T26	8384716
NA	CHEMICAL	GENE-Y	18	8	The specific binding is displaced by the selective gene agonist sumatriptan but not by the mixed 5-HT1A/1D agonist chemical.	T7	T25	8384716
NA	CHEMICAL	GENE-N	10	16	The specific binding is displaced by the selective 5-HT1D agonist chemical but not by the mixed gene agonist 5-carboxyamidotryptamine.	T6	T26	8384716
CPR:5	CHEMICAL	GENE-Y	10	8	The specific binding is displaced by the selective gene agonist chemical but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.	T6	T25	8384716
CPR:4	CHEMICAL	GENE-N	15	10	HeLa cells transfected with the MR77 gene exhibited inhibition of gene in response to chemical.	T12	T28	8384716
NA	CHEMICAL	GENE-Y	15	5	HeLa cells transfected with the gene gene exhibited inhibition of adenylate cyclase in response to chemical.	T12	T27	8384716
NA	CHEMICAL	GENE-Y	10	5	HeLa cells transfected with the gene gene exhibited inhibition of chemical cyclase in response to serotonin.	T11	T27	8384716
NA	CHEMICAL	GENE-Y	4	0	gene thus represents a chemical receptor of the chemical1 class, and we propose that, based on the pharmacological characterization, gene represents an additional chemical1E-like receptor.	T13	T30	8384716
NA	CHEMICAL	GENE-Y	4	0	gene thus represents a chemical receptor of the chemical1 class, and we propose that, based on the pharmacological characterization, gene represents an additional chemical1E-like receptor.	T13	T33	8384716
NA	CHEMICAL	GENE-N	20	42	The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of chemical cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial gene, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	T27	T41	8425287
NA	CHEMICAL	GENE-N	5	20	The antiarrhythmic effects of exogenous chemical and Valsalva on this form of VT may be due to receptor-mediated inhibition of gene or to noncardiac receptor-mediated effects, i.e., exogenous chemical may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	T26	T40	8425287
NA	CHEMICAL	GENE-N	5	20	The antiarrhythmic effects of exogenous chemical and Valsalva on this form of VT may be due to receptor-mediated inhibition of gene or to noncardiac receptor-mediated effects, i.e., exogenous chemical may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	T28	T40	8425287
NA	CHEMICAL	GENE-N	5	42	The antiarrhythmic effects of exogenous chemical and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous chemical may modulate VT through alterations in autonomic tone by activation of arterial gene, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	T26	T41	8425287
CPR:3	CHEMICAL	GENE-N	5	42	The antiarrhythmic effects of exogenous chemical and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous chemical may modulate VT through alterations in autonomic tone by activation of arterial gene, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	T28	T41	8425287
CPR:6	CHEMICAL	GENE-Y	6	9	VT recurred with the addition of chemical, a competitive gene antagonist.	T8	T34	8425287
NA	CHEMICAL	GENE-Y	8	9	VT recurred with the addition of aminophylline, a chemical gene antagonist.	T42	T34	8425287
NA	CHEMICAL	GENE-N	9	12	), a cholinesterase inhibitor that potentiates the effects of chemical at the gene, terminated VT in four of four patients, an effect that was reversed by atropine.	T11	T36	8425287
NA	CHEMICAL	GENE-Y	9	2	), a gene inhibitor that potentiates the effects of chemical at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.	T11	T35	8425287
CPR:4	CHEMICAL	GENE-N	28	12	), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the gene, terminated VT in four of four patients, an effect that was reversed by chemical.	T13	T36	8425287
NA	CHEMICAL	GENE-Y	28	2	), a gene inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by chemical.	T13	T35	8425287
NA	CHEMICAL	GENE-N	26	18	It can be identified by termination of the tachycardia in response to activation of the adenosine A1 or gene, which results in inhibition of chemical cyclase.	T20	T38	8425287
NA	CHEMICAL	GENE-Y	26	15	It can be identified by termination of the tachycardia in response to activation of the gene or muscarinic cholinergic receptor, which results in inhibition of chemical cyclase.	T20	T37	8425287
NA	CHEMICAL	GENE-N	15	18	It can be identified by termination of the tachycardia in response to activation of the chemical A1 or gene, which results in inhibition of adenylate cyclase.	T19	T38	8425287
NA	CHEMICAL	GENE-N	15	26	It can be identified by termination of the tachycardia in response to activation of the chemical A1 or muscarinic cholinergic receptor, which results in inhibition of gene.	T19	T39	8425287
CPR:3	CHEMICAL	GENE-Y	1	3	Amantadine (chemical) induced gene expression in the central, dorsal-medial and ventral-medial part of the striatum.	T2	T24	8566141
CPR:3	CHEMICAL	GENE-Y	0	3	chemical (1-aminoadamantane) induced gene expression in the central, dorsal-medial and ventral-medial part of the striatum.	T1	T24	8566141
NA	CHEMICAL	GENE-Y	18	4	The distribution pattern of gene induced by amantadine was more similar to those seen with dopaminomimetics than with chemical (NMDA) receptor antagonists.	T4	T20	8566141
NA	CHEMICAL	GENE-N	7	18	The distribution pattern of Fos induced by chemical was more similar to those seen with dopaminomimetics than with gene antagonists.	T3	T21	8566141
CPR:3	CHEMICAL	GENE-Y	7	4	The distribution pattern of gene induced by chemical was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.	T3	T20	8566141
NA	CHEMICAL	GENE-Y	19	4	The distribution pattern of gene induced by amantadine was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (chemical) receptor antagonists.	T5	T20	8566141
NA	CHEMICAL	GENE-Y	15	3	Pretreatment with the gene antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked chemical induction of Fos in the striatum.	T10	T22	8566141
NA	CHEMICAL	GENE-N	15	10	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the gene antagonist, MK-801, blocked chemical induction of Fos in the striatum.	T10	T23	8566141
CPR:3	CHEMICAL	GENE-Y	15	18	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked chemical induction of gene in the striatum.	T10	T25	8566141
NA	CHEMICAL	GENE-N	3	10	Pretreatment with the chemical D1 receptor antagonist, SCH23390, and the gene antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	T6	T23	8566141
NA	CHEMICAL	GENE-Y	3	18	Pretreatment with the chemical D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of gene in the striatum.	T6	T25	8566141
CPR:6	CHEMICAL	GENE-Y	7	3	Pretreatment with the gene antagonist, chemical, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	T7	T22	8566141
NA	CHEMICAL	GENE-N	7	10	Pretreatment with the dopamine D1 receptor antagonist, chemical, and the gene antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	T7	T23	8566141
CPR:4	CHEMICAL	GENE-Y	7	18	Pretreatment with the dopamine D1 receptor antagonist, chemical, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of gene in the striatum.	T7	T25	8566141
NA	CHEMICAL	GENE-Y	13	3	Pretreatment with the gene antagonist, SCH23390, and the NMDA receptor antagonist, chemical, blocked amantadine induction of Fos in the striatum.	T9	T22	8566141
CPR:6	CHEMICAL	GENE-N	13	10	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the gene antagonist, chemical, blocked amantadine induction of Fos in the striatum.	T9	T23	8566141
CPR:4	CHEMICAL	GENE-Y	13	18	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, chemical, blocked amantadine induction of gene in the striatum.	T9	T25	8566141
NA	CHEMICAL	GENE-Y	10	3	Pretreatment with the gene antagonist, SCH23390, and the chemical receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.	T8	T22	8566141
NA	CHEMICAL	GENE-Y	10	18	Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the chemical receptor antagonist, MK-801, blocked amantadine induction of gene in the striatum.	T8	T25	8566141
NA	CHEMICAL	GENE-Y	1	12	However, chemical induction of Fos in the striatum was unaffected by the gene antagonist, sulpiride.	T11	T27	8566141
CPR:3	CHEMICAL	GENE-Y	1	4	However, chemical induction of gene in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.	T11	T26	8566141
CPR:6	CHEMICAL	GENE-Y	16	12	However, amantadine induction of Fos in the striatum was unaffected by the gene antagonist, chemical.	T13	T27	8566141
NA	CHEMICAL	GENE-Y	16	4	However, amantadine induction of gene in the striatum was unaffected by the dopamine D2 receptor antagonist, chemical.	T13	T26	8566141
NA	CHEMICAL	GENE-Y	12	4	However, amantadine induction of gene in the striatum was unaffected by the chemical D2 receptor antagonist, sulpiride.	T12	T26	8566141
NA	CHEMICAL	GENE-N	4	18	These results suggest that chemical induction of Fos in the rat striatum is related to dopamine D1 and gene.	T14	T30	8566141
NA	CHEMICAL	GENE-Y	4	15	These results suggest that chemical induction of Fos in the rat striatum is related to gene and NMDA receptors.	T14	T29	8566141
CPR:3	CHEMICAL	GENE-Y	4	7	These results suggest that chemical induction of gene in the rat striatum is related to dopamine D1 and NMDA receptors.	T14	T28	8566141
NA	CHEMICAL	GENE-N	15	18	These results suggest that amantadine induction of Fos in the rat striatum is related to chemical D1 and gene.	T15	T30	8566141
NA	CHEMICAL	GENE-Y	15	7	These results suggest that amantadine induction of gene in the rat striatum is related to chemical D1 and NMDA receptors.	T15	T28	8566141
NA	CHEMICAL	GENE-Y	18	15	These results suggest that amantadine induction of Fos in the rat striatum is related to gene and chemical receptors.	T16	T29	8566141
NA	CHEMICAL	GENE-Y	18	7	These results suggest that amantadine induction of gene in the rat striatum is related to dopamine D1 and chemical receptors.	T16	T28	8566141
CPR:4	CHEMICAL	GENE-Y	5	13	bolus); finally, 8 rabbits received chemical (ATA), an inhibitor of platelet glycoprotein Ib/gene interaction (10 mg/kg i.v.	T1	T15	8697470
CPR:4	CHEMICAL	GENE-N	5	12	bolus); finally, 8 rabbits received chemical (ATA), an inhibitor of platelet gene/von Willebrand factor interaction (10 mg/kg i.v.	T1	T14	8697470
CPR:4	CHEMICAL	GENE-Y	7	13	bolus); finally, 8 rabbits received aurintrycarboxilic acid (chemical), an inhibitor of platelet glycoprotein Ib/gene interaction (10 mg/kg i.v.	T2	T15	8697470
CPR:4	CHEMICAL	GENE-N	7	12	bolus); finally, 8 rabbits received aurintrycarboxilic acid (chemical), an inhibitor of platelet gene/von Willebrand factor interaction (10 mg/kg i.v.	T2	T14	8697470
NA	CHEMICAL	GENE-Y	10	2	Infusion of gene failed to restore CFVs in ridogrel e chemical treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by gene was overcome by inhibition of platelet function.	T4	T29	8697470
NA	CHEMICAL	GENE-Y	10	2	Infusion of gene failed to restore CFVs in ridogrel e chemical treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by gene was overcome by inhibition of platelet function.	T4	T30	8697470
NA	CHEMICAL	GENE-Y	12	14	Activated partial thromboplastin time, and ex vivo platelet aggregation in response to chemical and gene, were not different after FVIIai infusion, while progene time was slightly but significantly prolonged as compared to baseline values.	T5	T32	8697470
NA	CHEMICAL	GENE-Y	12	19	Activated partial thromboplastin time, and ex vivo platelet aggregation in response to chemical and thrombin, were not different after gene infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.	T5	T33	8697470
NA	CHEMICAL	GENE-Y	20	17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and Cl-], human NE (gene) in the chemical transporter gene family.	T7	T17	8710929
NA	CHEMICAL	GENE-N	10	20	Here we report channel-like events from a presumably fixed stoichiometry [chemical (NE)+, Na+, and Cl-], human NE (hNET) in the gene gene family.	T2	T18	8710929
NA	CHEMICAL	GENE-Y	10	17	Here we report channel-like events from a presumably fixed stoichiometry [chemical (NE)+, Na+, and Cl-], human NE (gene) in the gamma-aminobutyric acid transporter gene family.	T2	T17	8710929
NA	CHEMICAL	GENE-N	14	20	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and chemical], human NE (hNET) in the gene gene family.	T5	T18	8710929
NA	CHEMICAL	GENE-Y	14	17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, Na+, and chemical], human NE (gene) in the gamma-aminobutyric acid transporter gene family.	T5	T17	8710929
NA	CHEMICAL	GENE-N	12	20	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, chemical, and Cl-], human NE (hNET) in the gene gene family.	T4	T18	8710929
NA	CHEMICAL	GENE-Y	12	17	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (NE)+, chemical, and Cl-], human NE (gene) in the gamma-aminobutyric acid transporter gene family.	T4	T17	8710929
NA	CHEMICAL	GENE-N	11	20	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (chemical)+, Na+, and Cl-], human chemical (hchemicalT) in the gene gene family.	T3	T18	8710929
NA	CHEMICAL	GENE-N	11	20	Here we report channel-like events from a presumably fixed stoichiometry [norepinephrine (chemical)+, Na+, and Cl-], human chemical (hchemicalT) in the gene gene family.	T6	T18	8710929
CPR:9	CHEMICAL	GENE-Y	8	10	These events are stimulated by NE and by chemical, an gene substrate, and they are blocked by cocaine and the antidepressant desipramine.	T9	T19	8710929
CPR:4	CHEMICAL	GENE-Y	21	10	These events are stimulated by NE and by guanethidine, an gene substrate, and they are blocked by cocaine and the antidepressant chemical.	T11	T19	8710929
CPR:4	CHEMICAL	GENE-Y	17	10	These events are stimulated by NE and by guanethidine, an gene substrate, and they are blocked by chemical and the antidepressant desipramine.	T10	T19	8710929
NA	CHEMICAL	GENE-Y	72	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T20	8733007
NA	CHEMICAL	GENE-Y	72	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T19	8733007
NA	CHEMICAL	GENE-Y	72	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T6	8733007
NA	CHEMICAL	GENE-N	72	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T10	T15	8733007
NA	CHEMICAL	GENE-Y	72	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T18	8733007
NA	CHEMICAL	GENE-Y	72	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T13	8733007
NA	CHEMICAL	GENE-Y	72	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T14	8733007
NA	CHEMICAL	GENE-Y	72	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of chemical; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T10	T21	8733007
NA	CHEMICAL	GENE-Y	119	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T20	8733007
NA	CHEMICAL	GENE-Y	119	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T19	8733007
NA	CHEMICAL	GENE-Y	119	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T6	8733007
NA	CHEMICAL	GENE-N	119	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T1	T15	8733007
NA	CHEMICAL	GENE-Y	119	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T18	8733007
CPR:6	CHEMICAL	GENE-Y	119	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T13	8733007
CPR:6	CHEMICAL	GENE-Y	119	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T14	8733007
NA	CHEMICAL	GENE-Y	119	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist chemical; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T1	T21	8733007
NA	CHEMICAL	GENE-Y	42	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T20	8733007
NA	CHEMICAL	GENE-Y	42	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T19	8733007
NA	CHEMICAL	GENE-Y	42	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T6	8733007
NA	CHEMICAL	GENE-N	42	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T8	T15	8733007
NA	CHEMICAL	GENE-Y	42	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T18	8733007
NA	CHEMICAL	GENE-Y	42	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T13	8733007
NA	CHEMICAL	GENE-Y	42	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T14	8733007
NA	CHEMICAL	GENE-Y	42	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or chemical; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T8	T21	8733007
NA	CHEMICAL	GENE-Y	92	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T20	8733007
NA	CHEMICAL	GENE-Y	92	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T19	8733007
NA	CHEMICAL	GENE-Y	92	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T6	8733007
NA	CHEMICAL	GENE-N	92	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T11	T15	8733007
NA	CHEMICAL	GENE-Y	92	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T18	8733007
NA	CHEMICAL	GENE-Y	92	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T13	8733007
NA	CHEMICAL	GENE-Y	92	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T14	8733007
NA	CHEMICAL	GENE-Y	92	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with chemical and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T11	T21	8733007
NA	CHEMICAL	GENE-Y	29	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T19	T20	8733007
NA	CHEMICAL	GENE-Y	29	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T6	T20	8733007
NA	CHEMICAL	GENE-N	29	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T19	T15	8733007
NA	CHEMICAL	GENE-N	29	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T6	T15	8733007
NA	CHEMICAL	GENE-Y	29	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T19	T18	8733007
NA	CHEMICAL	GENE-Y	29	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T6	T18	8733007
NA	CHEMICAL	GENE-Y	29	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T19	T13	8733007
NA	CHEMICAL	GENE-Y	29	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T19	T14	8733007
NA	CHEMICAL	GENE-Y	29	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T19	T21	8733007
NA	CHEMICAL	GENE-Y	29	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T6	T13	8733007
NA	CHEMICAL	GENE-Y	29	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T6	T14	8733007
NA	CHEMICAL	GENE-Y	29	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-chemical systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T6	T21	8733007
NA	CHEMICAL	GENE-Y	40	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T20	8733007
NA	CHEMICAL	GENE-Y	40	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T19	8733007
NA	CHEMICAL	GENE-Y	40	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T6	8733007
NA	CHEMICAL	GENE-N	40	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T7	T15	8733007
NA	CHEMICAL	GENE-Y	40	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T18	8733007
NA	CHEMICAL	GENE-Y	40	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T13	8733007
NA	CHEMICAL	GENE-Y	40	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T14	8733007
NA	CHEMICAL	GENE-Y	40	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of chemical or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist RU28318; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T7	T21	8733007
CPR:6	CHEMICAL	GENE-Y	101	97	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the gene (MR) antagonist chemical; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T20	8733007
NA	CHEMICAL	GENE-Y	101	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist chemical; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T19	8733007
NA	CHEMICAL	GENE-Y	101	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-gene systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist chemical; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T6	8733007
NA	CHEMICAL	GENE-N	101	140	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist chemical; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on gene formation by cardiac fibroblasts are conflicting.	T12	T15	8733007
NA	CHEMICAL	GENE-Y	101	29	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue gene-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist chemical; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T18	8733007
NA	CHEMICAL	GENE-Y	101	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist chemical; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T13	8733007
NA	CHEMICAL	GENE-Y	101	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist chemical; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T14	8733007
CPR:6	CHEMICAL	GENE-Y	101	99	In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (gene) antagonist chemical; (v) is via classical gene, in that it is blocked by concurrent administration of the gene antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.	T12	T21	8733007
NA	CHEMICAL	GENE-Y	10	24	Although there is a high probability that the action of chemical to cause cardiac fibrosis in this experimental model is an effect via non-epithelial gene, the locus of chemical action remains to be established, as do the molecular mechanisms linking gene occupancy by chemical and collagen deposition.	T2	T16	8733007
NA	CHEMICAL	GENE-Y	10	24	Although there is a high probability that the action of chemical to cause cardiac fibrosis in this experimental model is an effect via non-epithelial gene, the locus of chemical action remains to be established, as do the molecular mechanisms linking gene occupancy by chemical and collagen deposition.	T2	T17	8733007
NA	CHEMICAL	GENE-Y	10	24	Although there is a high probability that the action of chemical to cause cardiac fibrosis in this experimental model is an effect via non-epithelial gene, the locus of chemical action remains to be established, as do the molecular mechanisms linking gene occupancy by chemical and collagen deposition.	T3	T16	8733007
NA	CHEMICAL	GENE-Y	10	24	Although there is a high probability that the action of chemical to cause cardiac fibrosis in this experimental model is an effect via non-epithelial gene, the locus of chemical action remains to be established, as do the molecular mechanisms linking gene occupancy by chemical and collagen deposition.	T3	T17	8733007
NA	CHEMICAL	GENE-Y	10	24	Although there is a high probability that the action of chemical to cause cardiac fibrosis in this experimental model is an effect via non-epithelial gene, the locus of chemical action remains to be established, as do the molecular mechanisms linking gene occupancy by chemical and collagen deposition.	T4	T16	8733007
NA	CHEMICAL	GENE-Y	10	24	Although there is a high probability that the action of chemical to cause cardiac fibrosis in this experimental model is an effect via non-epithelial gene, the locus of chemical action remains to be established, as do the molecular mechanisms linking gene occupancy by chemical and collagen deposition.	T4	T17	8733007
NA	CHEMICAL	GENE-N	15	17	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal chemical oxidase (gene), because it is a much more potent gene inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	T1	T36	8740147
NA	CHEMICAL	GENE-N	15	17	Previous studies have resulted in the classification of amezinium as a selective inhibitor of neuronal chemical oxidase (gene), because it is a much more potent gene inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	T1	T40	8740147
CPR:4	CHEMICAL	GENE-N	8	15	Previous studies have resulted in the classification of chemical as a selective inhibitor of neuronal gene (MAO), because it is a much more potent MAO inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	T22	T35	8740147
CPR:4	CHEMICAL	GENE-N	8	17	Previous studies have resulted in the classification of chemical as a selective inhibitor of neuronal monoamine oxidase (gene), because it is a much more potent gene inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	T22	T36	8740147
CPR:4	CHEMICAL	GENE-N	8	17	Previous studies have resulted in the classification of chemical as a selective inhibitor of neuronal monoamine oxidase (gene), because it is a much more potent gene inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	T22	T40	8740147
NA	CHEMICAL	GENE-N	12	34	In the present study, the effects of amezinium on the deamination of chemical were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal gene.	T20	T50	8740147
NA	CHEMICAL	GENE-N	30	34	In the present study, the effects of amezinium on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the chemical transporter is non-neuronal gene.	T21	T50	8740147
NA	CHEMICAL	GENE-N	7	34	In the present study, the effects of chemical on the deamination of noradrenaline were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the catecholamine transporter is non-neuronal gene.	T19	T50	8740147
CPR:9	CHEMICAL	GENE-N	15	10	In addition, another drug that is both a substrate of gene and a MAO inhibitor, chemical, was investigated in the study.	T23	T51	8740147
CPR:4	CHEMICAL	GENE-N	15	13	In addition, another drug that is both a substrate of uptake1 and a gene inhibitor, chemical, was investigated in the study.	T23	T52	8740147
NA	CHEMICAL	GENE-N	12	16	The first aim of the study was to show whether amezinium and chemical are substrates of gene in rat lungs.	T25	T53	8740147
NA	CHEMICAL	GENE-N	10	16	The first aim of the study was to show whether chemical and debrisoquine are substrates of gene in rat lungs.	T24	T53	8740147
NA	CHEMICAL	GENE-Y	7	10	After loading of isolated perfused lungs with chemical (MAO and gene (COMT) inhibited), the efflux of chemical was measured for 30 min.	T26	T55	8740147
NA	CHEMICAL	GENE-Y	7	10	After loading of isolated perfused lungs with chemical (MAO and gene (COMT) inhibited), the efflux of chemical was measured for 30 min.	T29	T55	8740147
NA	CHEMICAL	GENE-Y	7	11	After loading of isolated perfused lungs with chemical (MAO and catechol-O-methyltransferase (gene) inhibited), the efflux of chemical was measured for 30 min.	T26	T56	8740147
NA	CHEMICAL	GENE-Y	7	11	After loading of isolated perfused lungs with chemical (MAO and catechol-O-methyltransferase (gene) inhibited), the efflux of chemical was measured for 30 min.	T29	T56	8740147
NA	CHEMICAL	GENE-N	7	8	After loading of isolated perfused lungs with chemical (gene and catechol-O-methyltransferase (COMT) inhibited), the efflux of chemical was measured for 30 min.	T26	T54	8740147
NA	CHEMICAL	GENE-N	7	8	After loading of isolated perfused lungs with chemical (gene and catechol-O-methyltransferase (COMT) inhibited), the efflux of chemical was measured for 30 min.	T29	T54	8740147
NA	CHEMICAL	GENE-Y	10	11	After loading of isolated perfused lungs with 3H-noradrenaline (MAO and chemical-O-methyltransferase (gene) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	T27	T56	8740147
NA	CHEMICAL	GENE-N	10	8	After loading of isolated perfused lungs with 3H-noradrenaline (gene and chemical-O-methyltransferase (COMT) inhibited), the efflux of 3H-noradrenaline was measured for 30 min.	T27	T54	8740147
NA	CHEMICAL	GENE-Y	6	7	In lungs perfused with 1 nmol/l chemical (gene inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	T4	T38	8740147
NA	CHEMICAL	GENE-Y	6	7	In lungs perfused with 1 nmol/l 3H-chemical (gene inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of chemical deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of chemical deamination, respectively.	T6	T38	8740147
NA	CHEMICAL	GENE-Y	6	7	In lungs perfused with 1 nmol/l 3H-chemical (gene inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of chemical deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of chemical deamination, respectively.	T8	T38	8740147
NA	CHEMICAL	GENE-Y	31	7	In lungs perfused with 1 nmol/l 3H-noradrenaline (gene inhibited), 10, 30 and 300 nmol/l amezinium caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l chemical caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	T7	T38	8740147
NA	CHEMICAL	GENE-Y	14	7	In lungs perfused with 1 nmol/l 3H-noradrenaline (gene inhibited), 10, 30 and 300 nmol/l chemical caused 58%, 76% and 74% inhibition of noradrenaline deamination, respectively, and 30, 300 and 3000 nmol/l debrisoquine caused 56%, 89% and 96% inhibition of noradrenaline deamination, respectively.	T5	T38	8740147
NA	CHEMICAL	GENE-Y	15	17	When MAO-B was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of chemical by gene in the lungs.	T10	T41	8740147
NA	CHEMICAL	GENE-Y	15	1	When gene was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of chemical by MAO-A in the lungs.	T10	T39	8740147
CPR:4	CHEMICAL	GENE-Y	7	17	When MAO-B was also inhibited, 10 nmol/l chemical caused 84% inhibition of the deamination of noradrenaline by gene in the lungs.	T9	T41	8740147
NA	CHEMICAL	GENE-Y	7	1	When gene was also inhibited, 10 nmol/l chemical caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs.	T9	T39	8740147
NA	CHEMICAL	GENE-N	8	17	In contrast, in hearts perfused with 10 nmol/l chemical under conditions where the amine was accumulated by gene (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	T11	T42	8740147
NA	CHEMICAL	GENE-N	8	19	In contrast, in hearts perfused with 10 nmol/l chemical under conditions where the amine was accumulated by uptake2 (COMT, gene and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	T11	T44	8740147
NA	CHEMICAL	GENE-Y	8	18	In contrast, in hearts perfused with 10 nmol/l chemical under conditions where the amine was accumulated by uptake2 (gene, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of noradrenaline.	T11	T43	8740147
NA	CHEMICAL	GENE-N	8	17	In contrast, in hearts perfused with 10 nmol/l 3H-chemical under conditions where the amine was accumulated by gene (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of chemical.	T14	T42	8740147
NA	CHEMICAL	GENE-N	8	19	In contrast, in hearts perfused with 10 nmol/l 3H-chemical under conditions where the amine was accumulated by uptake2 (COMT, gene and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of chemical.	T14	T44	8740147
NA	CHEMICAL	GENE-Y	8	18	In contrast, in hearts perfused with 10 nmol/l 3H-chemical under conditions where the amine was accumulated by uptake2 (gene, uptake1 and vesicular transport inhibited), 10 nmol/l amezinium had no effect and 300 nmol/l amezinium caused only 36% inhibition of deamination of chemical.	T14	T43	8740147
NA	CHEMICAL	GENE-N	26	17	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by gene (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l chemical had no effect and 300 nmol/l chemical caused only 36% inhibition of deamination of noradrenaline.	T12	T42	8740147
NA	CHEMICAL	GENE-N	26	17	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by gene (COMT, uptake1 and vesicular transport inhibited), 10 nmol/l chemical had no effect and 300 nmol/l chemical caused only 36% inhibition of deamination of noradrenaline.	T13	T42	8740147
NA	CHEMICAL	GENE-N	26	19	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, gene and vesicular transport inhibited), 10 nmol/l chemical had no effect and 300 nmol/l chemical caused only 36% inhibition of deamination of noradrenaline.	T12	T44	8740147
NA	CHEMICAL	GENE-N	26	19	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (COMT, gene and vesicular transport inhibited), 10 nmol/l chemical had no effect and 300 nmol/l chemical caused only 36% inhibition of deamination of noradrenaline.	T13	T44	8740147
NA	CHEMICAL	GENE-Y	26	18	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (gene, uptake1 and vesicular transport inhibited), 10 nmol/l chemical had no effect and 300 nmol/l chemical caused only 36% inhibition of deamination of noradrenaline.	T12	T43	8740147
NA	CHEMICAL	GENE-Y	26	18	In contrast, in hearts perfused with 10 nmol/l 3H-noradrenaline under conditions where the amine was accumulated by uptake2 (gene, uptake1 and vesicular transport inhibited), 10 nmol/l chemical had no effect and 300 nmol/l chemical caused only 36% inhibition of deamination of noradrenaline.	T13	T43	8740147
CPR:9	CHEMICAL	GENE-N	20	61	The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and chemical is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by gene.	T16	T46	8740147
CPR:4	CHEMICAL	GENE-N	20	28	The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and chemical is about 20 times more potent for gene inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.	T16	T45	8740147
CPR:9	CHEMICAL	GENE-N	12	61	The results when considered with previous reports in the literature show that chemical is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by gene.	T15	T46	8740147
CPR:4	CHEMICAL	GENE-N	12	28	The results when considered with previous reports in the literature show that chemical is about 1000 times more potent and debrisoquine is about 20 times more potent for gene inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.	T15	T45	8740147
CPR:9	CHEMICAL	GENE-N	0	13	chemical is much less potent as a MAO inhibitor in cells with the gene, such as the myocardial cells of the heart.	T17	T48	8740147
CPR:4	CHEMICAL	GENE-N	0	7	chemical is much less potent as a gene inhibitor in cells with the uptake2 transporter, such as the myocardial cells of the heart.	T17	T47	8740147
CPR:4	CHEMICAL	GENE-Y	7	12	The results also confirmed previous reports that chemical is highly selective for gene.	T18	T49	8740147
NA	CHEMICAL	GENE-Y	23	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen chemical, a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T9	T20	8836617
NA	CHEMICAL	GENE-Y	23	17	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and ketotifen chemical, a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T9	T23	8836617
CPR:6	CHEMICAL	GENE-Y	23	28	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen chemical, a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T9	T24	8836617
CPR:6	CHEMICAL	GENE-Y	7	9	We have investigated the effects of CP-99,994 chemical, a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T12	T20	8836617
NA	CHEMICAL	GENE-Y	7	17	We have investigated the effects of CP-99,994 chemical, a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T12	T23	8836617
NA	CHEMICAL	GENE-Y	7	28	We have investigated the effects of CP-99,994 chemical, a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T12	T24	8836617
NA	CHEMICAL	GENE-Y	15	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 chemical, a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T6	T20	8836617
CPR:6	CHEMICAL	GENE-Y	15	17	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 chemical, a gene antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T6	T23	8836617
NA	CHEMICAL	GENE-Y	15	28	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 chemical, a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T6	T24	8836617
NA	CHEMICAL	GENE-Y	42	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous chemical.	T13	T20	8836617
NA	CHEMICAL	GENE-Y	42	17	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous chemical.	T13	T23	8836617
NA	CHEMICAL	GENE-Y	42	28	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous chemical.	T13	T24	8836617
NA	CHEMICAL	GENE-Y	15	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]chemical), a chemical B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T7	T20	8836617
NA	CHEMICAL	GENE-Y	15	28	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]chemical), a chemical B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T7	T24	8836617
CPR:6	CHEMICAL	GENE-Y	6	9	We have investigated the effects of chemical [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T11	T20	8836617
NA	CHEMICAL	GENE-Y	6	17	We have investigated the effects of chemical [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T11	T23	8836617
NA	CHEMICAL	GENE-Y	6	28	We have investigated the effects of chemical [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T11	T24	8836617
NA	CHEMICAL	GENE-Y	28	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a chemical H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T10	T20	8836617
NA	CHEMICAL	GENE-Y	28	17	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a chemical H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T10	T23	8836617
NA	CHEMICAL	GENE-Y	22	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and chemical (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T8	T20	8836617
NA	CHEMICAL	GENE-Y	22	17	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and chemical (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T8	T23	8836617
CPR:6	CHEMICAL	GENE-Y	22	28	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and chemical (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T8	T24	8836617
NA	CHEMICAL	GENE-Y	13	9	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a gene antagonist, chemical (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T5	T20	8836617
CPR:6	CHEMICAL	GENE-Y	13	17	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, chemical (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a gene antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T5	T23	8836617
NA	CHEMICAL	GENE-Y	13	28	We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, chemical (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a gene antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.	T5	T24	8836617
NA	CHEMICAL	GENE-Y	7	16	The increase in vascular permeability induced by chemical in the rat airway was mediated predominantly by gene stimulation.	T3	T21	8836617
NA	CHEMICAL	GENE-Y	7	1	The gene (HERG) encodes a chemical channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier chemical current (IKr).	T13	T30	9486667
NA	CHEMICAL	GENE-Y	7	1	The gene (HERG) encodes a chemical channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier chemical current (IKr).	T3	T30	9486667
NA	CHEMICAL	GENE-Y	7	4	The human ether-a-go-go-related gene (gene) encodes a chemical channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier chemical current (IKr).	T13	T29	9486667
NA	CHEMICAL	GENE-Y	7	4	The human ether-a-go-go-related gene (gene) encodes a chemical channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier chemical current (IKr).	T3	T29	9486667
NA	CHEMICAL	GENE-N	7	25	The human ether-a-go-go-related gene (HERG) encodes a chemical channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier chemical current (gene).	T13	T25	9486667
NA	CHEMICAL	GENE-N	7	25	The human ether-a-go-go-related gene (HERG) encodes a chemical channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier chemical current (gene).	T3	T25	9486667
CPR:4	CHEMICAL	GENE-Y	20	0	gene/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic chemical drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.	T8	T26	9486667
CPR:4	CHEMICAL	GENE-N	20	0	HERG/gene channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic chemical drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations.	T8	T28	9486667
CPR:4	CHEMICAL	GENE-Y	24	0	gene/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as chemical, E4031, and MK-499, at submicromolar concentrations.	T9	T26	9486667
CPR:4	CHEMICAL	GENE-N	24	0	HERG/gene channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as chemical, E4031, and MK-499, at submicromolar concentrations.	T9	T28	9486667
CPR:4	CHEMICAL	GENE-Y	27	0	gene/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and chemical, at submicromolar concentrations.	T11	T26	9486667
CPR:4	CHEMICAL	GENE-N	27	0	HERG/gene channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and chemical, at submicromolar concentrations.	T11	T28	9486667
CPR:4	CHEMICAL	GENE-Y	25	0	gene/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, chemical, and MK-499, at submicromolar concentrations.	T10	T26	9486667
CPR:4	CHEMICAL	GENE-N	25	0	HERG/gene channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, chemical, and MK-499, at submicromolar concentrations.	T10	T28	9486667
NA	CHEMICAL	GENE-Y	14	5	By contrast, the closely related gene (BEAG) is 100-fold less sensitive to chemical.	T12	T31	9486667
NA	CHEMICAL	GENE-Y	14	8	By contrast, the closely related bovine ether-a-go-go channel (gene) is 100-fold less sensitive to chemical.	T12	T32	9486667
NA	CHEMICAL	GENE-Y	24	13	To identify the molecular determinants for dofetilide block, we first engineered chimeras between gene and BEAG and then used site-directed mutagenesis to localize single chemical residues responsible for block.	T15	T34	9486667
NA	CHEMICAL	GENE-Y	24	15	To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and gene and then used site-directed mutagenesis to localize single chemical residues responsible for block.	T15	T35	9486667
NA	CHEMICAL	GENE-Y	6	13	To identify the molecular determinants for chemical block, we first engineered chimeras between gene and BEAG and then used site-directed mutagenesis to localize single amino acid residues responsible for block.	T14	T34	9486667
NA	CHEMICAL	GENE-Y	6	15	To identify the molecular determinants for chemical block, we first engineered chimeras between HERG and gene and then used site-directed mutagenesis to localize single amino acid residues responsible for block.	T14	T35	9486667
NA	CHEMICAL	GENE-Y	8	17	Thus, our results indicate that important determinants of chemical binding are localized to the pore region of gene.	T1	T18	9486667
NA	CHEMICAL	GENE-N	14	11	Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG gene for chemical, whereas C-type inactivation could not be recovered.	T5	T24	9486667
NA	CHEMICAL	GENE-N	14	5	Moreover, the reverse mutation BEAG gene increased the affinity of BEAG K+ channels for chemical, whereas C-type inactivation could not be recovered.	T5	T22	9486667
NA	CHEMICAL	GENE-Y	14	4	Moreover, the reverse mutation gene T432S increased the affinity of gene K+ channels for chemical, whereas C-type inactivation could not be recovered.	T5	T21	9486667
NA	CHEMICAL	GENE-Y	14	4	Moreover, the reverse mutation gene T432S increased the affinity of gene K+ channels for chemical, whereas C-type inactivation could not be recovered.	T5	T23	9486667
NA	CHEMICAL	GENE-N	11	5	Moreover, the reverse mutation BEAG gene increased the affinity of BEAG chemical channels for dofetilide, whereas C-type inactivation could not be recovered.	T4	T22	9486667
NA	CHEMICAL	GENE-Y	11	4	Moreover, the reverse mutation gene T432S increased the affinity of gene chemical channels for dofetilide, whereas C-type inactivation could not be recovered.	T4	T21	9486667
NA	CHEMICAL	GENE-Y	11	4	Moreover, the reverse mutation gene T432S increased the affinity of gene chemical channels for dofetilide, whereas C-type inactivation could not be recovered.	T4	T23	9486667
NA	CHEMICAL	GENE-Y	11	5	Thus, the serine in position gene 620 may participate directly in chemical binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.	T7	T27	9486667
NA	CHEMICAL	GENE-Y	2	5	Thus, the chemical in position gene 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.	T6	T27	9486667
CPR:4	CHEMICAL	GENE-Y	10	8	Treatment using a combination of testosterone and the gene inhibitor chemical may have significantly better effects on sexual function and also seizure frequency than testosterone alone.	T4	T10	9521275
NA	CHEMICAL	GENE-Y	5	8	Treatment using a combination of chemical and the gene inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than chemical alone.	T3	T10	9521275
NA	CHEMICAL	GENE-Y	5	8	Treatment using a combination of chemical and the gene inhibitor testolactone may have significantly better effects on sexual function and also seizure frequency than chemical alone.	T5	T10	9521275
NA	CHEMICAL	GENE-Y	15	16	For example, it is clear that the closed conformation of the regulatory N-terminal domain in chemical-bound gene (cTnC) presents a much different binding surface for chemical-sensitizing compounds than previously thought.	T6	T20	9525919
NA	CHEMICAL	GENE-Y	15	16	For example, it is clear that the closed conformation of the regulatory N-terminal domain in chemical-bound gene (cTnC) presents a much different binding surface for chemical-sensitizing compounds than previously thought.	T7	T20	9525919
NA	CHEMICAL	GENE-Y	15	19	For example, it is clear that the closed conformation of the regulatory N-terminal domain in chemical-bound cardiac troponin C (gene) presents a much different binding surface for chemical-sensitizing compounds than previously thought.	T6	T21	9525919
NA	CHEMICAL	GENE-Y	15	19	For example, it is clear that the closed conformation of the regulatory N-terminal domain in chemical-bound cardiac troponin C (gene) presents a much different binding surface for chemical-sensitizing compounds than previously thought.	T7	T21	9525919
NA	CHEMICAL	GENE-Y	12	16	For example, it is clear that the closed conformation of the regulatory chemical-terminal domain in Ca2+-bound gene (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.	T5	T20	9525919
NA	CHEMICAL	GENE-Y	12	19	For example, it is clear that the closed conformation of the regulatory chemical-terminal domain in Ca2+-bound cardiac troponin C (gene) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.	T5	T21	9525919
NA	CHEMICAL	GENE-Y	19	23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for chemical and bepridil on gene.	T8	T23	9525919
NA	CHEMICAL	GENE-Y	21	23	We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and chemical on gene.	T9	T23	9525919
NA	CHEMICAL	GENE-Y	17	12	Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled gene indicate that bepridil and chemical bind to similar sites but only in the presence of Ca2+.	T12	T24	9525919
NA	CHEMICAL	GENE-Y	11	12	Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [chemical]Met-labeled gene indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.	T10	T24	9525919
NA	CHEMICAL	GENE-Y	15	12	Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled gene indicate that chemical and trifluoperazine bind to similar sites but only in the presence of Ca2+.	T11	T24	9525919
NA	CHEMICAL	GENE-Y	28	12	Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled gene indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of chemical.	T13	T24	9525919
NA	CHEMICAL	GENE-Y	8	14	There are 3-4 drug binding sites in the chemical- and C-terminal domains of intact gene that exhibit fast exchange on the chemicalMR time scale.	T14	T25	9525919
NA	CHEMICAL	GENE-Y	15	3	This subregion in gene makes a likely target against which to design new and selective chemical-sensitizing compounds.	T4	T18	9525919
NA	CHEMICAL	GENE-Y	10	14	Genetic analysis has demonstrated complete linkage between the human thiazide-sensitive chemical cotransporter gene (gene or TSC) and Gitelman's syndrome (GS).	T12	T17	9596079
NA	CHEMICAL	GENE-Y	10	16	Genetic analysis has demonstrated complete linkage between the human thiazide-sensitive chemical cotransporter gene (NCCT or gene) and Gitelman's syndrome (GS).	T12	T18	9596079
NA	CHEMICAL	GENE-Y	9	14	Genetic analysis has demonstrated complete linkage between the human chemical-sensitive sodium chloride cotransporter gene (gene or TSC) and Gitelman's syndrome (GS).	T10	T17	9596079
NA	CHEMICAL	GENE-Y	9	16	Genetic analysis has demonstrated complete linkage between the human chemical-sensitive sodium chloride cotransporter gene (NCCT or gene) and Gitelman's syndrome (GS).	T10	T18	9596079
NA	CHEMICAL	GENE-Y	19	13	This study was performed to determine whether peripheral blood mononuclear cells (PBMC) express gene mRNA and whether defective PBMC chemical cotransport could be demonstrated in GS.	T9	T22	9596079
NA	CHEMICAL	GENE-Y	14	13	Furthermore, functional evidence is provided that the underlying cause of GS is defective gene chemical cotransport.	T8	T21	9596079
NA	CHEMICAL	GENE-Y	29	19	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with gene inhibitors, etoposide and mitoxantrone, and an alkylating agent, chemical.	T3	T8	9631585
CPR:4	CHEMICAL	GENE-Y	24	19	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with gene inhibitors, etoposide and chemical, and an alkylating agent, cyclophosphamide.	T2	T8	9631585
CPR:4	CHEMICAL	GENE-Y	22	19	A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with gene inhibitors, chemical and mitoxantrone, and an alkylating agent, cyclophosphamide.	T1	T8	9631585
CPR:4	CHEMICAL	GENE-Y	0	7	chemical (deprenyl), a selective, irreversible inhibitor of gene (MAO-B) is widely used in the treatment of Parkinson's disease.	T1	T40	9673855
CPR:4	CHEMICAL	GENE-Y	0	11	chemical (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (gene) is widely used in the treatment of Parkinson's disease.	T1	T41	9673855
NA	CHEMICAL	GENE-Y	7	11	Selegiline (deprenyl), a selective, irreversible inhibitor of chemical oxidase type B (gene) is widely used in the treatment of Parkinson's disease.	T28	T41	9673855
CPR:4	CHEMICAL	GENE-Y	1	7	Selegiline (chemical), a selective, irreversible inhibitor of gene (MAO-B) is widely used in the treatment of Parkinson's disease.	T2	T40	9673855
CPR:4	CHEMICAL	GENE-Y	1	11	Selegiline (chemical), a selective, irreversible inhibitor of monoamine oxidase type B (gene) is widely used in the treatment of Parkinson's disease.	T2	T41	9673855
CPR:4	CHEMICAL	GENE-N	5	3	Unlike the nonselective gene inhibitors, chemical does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.	T25	T39	9673855
NA	CHEMICAL	GENE-N	10	3	Unlike the nonselective gene inhibitors, selegiline does not significantly potentiate chemical-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.	T26	T39	9673855
CPR:4	CHEMICAL	GENE-Y	21	19	A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible gene inhibitor, chemical.	T13	T37	9673855
NA	CHEMICAL	GENE-N	21	13	A low tyramine diet is recommended if selegiline is used together with nonselective gene inhibitors or the selective, reversible gene-A inhibitor, chemical.	T13	T36	9673855
NA	CHEMICAL	GENE-Y	7	19	A low tyramine diet is recommended if chemical is used together with nonselective MAO inhibitors or the selective, reversible gene inhibitor, moclobemide.	T12	T37	9673855
CPR:4	CHEMICAL	GENE-N	7	13	A low tyramine diet is recommended if chemical is used together with nonselective gene inhibitors or the selective, reversible gene-A inhibitor, moclobemide.	T12	T36	9673855
NA	CHEMICAL	GENE-Y	2	19	A low chemical diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible gene inhibitor, moclobemide.	T11	T37	9673855
NA	CHEMICAL	GENE-N	2	13	A low chemical diet is recommended if selegiline is used together with nonselective gene inhibitors or the selective, reversible gene-A inhibitor, moclobemide.	T11	T36	9673855
NA	CHEMICAL	GENE-N	19	23	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and chemical on CFTR gene in excised, inside-out patches from L-cells were evaluated.	T2	T28	9710435
NA	CHEMICAL	GENE-Y	19	13	To determine whether this inhibition of ICl was due to the inhibition of gene, the effects of ibuprofen and chemical on gene Cl- channels in excised, inside-out patches from L-cells were evaluated.	T2	T26	9710435
NA	CHEMICAL	GENE-Y	19	13	To determine whether this inhibition of ICl was due to the inhibition of gene, the effects of ibuprofen and chemical on gene Cl- channels in excised, inside-out patches from L-cells were evaluated.	T2	T27	9710435
NA	CHEMICAL	GENE-N	17	23	To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of chemical and salicylic acid on CFTR gene in excised, inside-out patches from L-cells were evaluated.	T1	T28	9710435
NA	CHEMICAL	GENE-Y	17	13	To determine whether this inhibition of ICl was due to the inhibition of gene, the effects of chemical and salicylic acid on gene Cl- channels in excised, inside-out patches from L-cells were evaluated.	T1	T26	9710435
NA	CHEMICAL	GENE-Y	17	13	To determine whether this inhibition of ICl was due to the inhibition of gene, the effects of chemical and salicylic acid on gene Cl- channels in excised, inside-out patches from L-cells were evaluated.	T1	T27	9710435
CPR:4	CHEMICAL	GENE-Y	0	4	chemical (300 microM) reduced gene Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to 0.59+/-0.04 pA (n = 3).	T3	T29	9710435
CPR:4	CHEMICAL	GENE-Y	1	6	Similarly, chemical (3 mM) reduced gene Cl- current by 50+/-8% with an apparent reduction in single channel amplitude from 1.08+/-0.03 pA to 0.48+/-0.06 pA (n = 4).	T4	T30	9710435
CPR:4	CHEMICAL	GENE-N	11	29	Based on these results, we conclude that the NSAIDs ibuprofen and chemical inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR gene as well as basolateral membrane K+ channels.	T7	T32	9710435
CPR:4	CHEMICAL	GENE-N	11	36	Based on these results, we conclude that the NSAIDs ibuprofen and chemical inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane gene.	T7	T33	9710435
CPR:4	CHEMICAL	GENE-Y	11	28	Based on these results, we conclude that the NSAIDs ibuprofen and chemical inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of gene Cl- channels as well as basolateral membrane K+ channels.	T7	T31	9710435
CPR:4	CHEMICAL	GENE-N	9	29	Based on these results, we conclude that the NSAIDs chemical and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR gene as well as basolateral membrane K+ channels.	T6	T32	9710435
CPR:4	CHEMICAL	GENE-N	9	36	Based on these results, we conclude that the NSAIDs chemical and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane gene.	T6	T33	9710435
CPR:4	CHEMICAL	GENE-Y	9	28	Based on these results, we conclude that the NSAIDs chemical and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of gene Cl- channels as well as basolateral membrane K+ channels.	T6	T31	9710435
NA	CHEMICAL	GENE-N	14	29	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit chemical-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR gene as well as basolateral membrane K+ channels.	T8	T32	9710435
NA	CHEMICAL	GENE-N	14	36	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit chemical-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR Cl- channels as well as basolateral membrane gene.	T8	T33	9710435
NA	CHEMICAL	GENE-Y	14	28	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit chemical-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of gene Cl- channels as well as basolateral membrane K+ channels.	T8	T31	9710435
NA	CHEMICAL	GENE-N	36	29	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of CFTR gene as well as basolateral membrane chemical channels.	T10	T32	9710435
NA	CHEMICAL	GENE-Y	36	28	Based on these results, we conclude that the NSAIDs ibuprofen and salicylic acid inhibit cAMP-mediated Cl- secretion in human colonic and airway epithelia via a direct inhibition of gene Cl- channels as well as basolateral membrane chemical channels.	T10	T31	9710435
NA	CHEMICAL	GENE-Y	17	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and chemical antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist ritanserin.	T10	T26	9832994
NA	CHEMICAL	GENE-Y	17	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and chemical antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist ritanserin.	T10	T25	9832994
NA	CHEMICAL	GENE-Y	17	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and chemical antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist ritanserin.	T10	T24	9832994
NA	CHEMICAL	GENE-N	17	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and chemical antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	T10	T23	9832994
NA	CHEMICAL	GENE-Y	12	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and chemical, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist ritanserin.	T7	T26	9832994
NA	CHEMICAL	GENE-Y	12	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and chemical, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist ritanserin.	T7	T25	9832994
CPR:6	CHEMICAL	GENE-Y	12	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as pizotifen and chemical, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist ritanserin.	T7	T24	9832994
CPR:6	CHEMICAL	GENE-N	12	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as pizotifen and chemical, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	T7	T23	9832994
NA	CHEMICAL	GENE-Y	23	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and chemical are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist ritanserin.	T12	T26	9832994
NA	CHEMICAL	GENE-Y	23	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and chemical are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist ritanserin.	T12	T25	9832994
NA	CHEMICAL	GENE-Y	23	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and chemical are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist ritanserin.	T12	T24	9832994
NA	CHEMICAL	GENE-N	23	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and chemical are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	T12	T23	9832994
CPR:6	CHEMICAL	GENE-Y	40	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist chemical.	T14	T26	9832994
CPR:6	CHEMICAL	GENE-Y	40	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist chemical.	T14	T25	9832994
NA	CHEMICAL	GENE-Y	40	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist chemical.	T14	T24	9832994
NA	CHEMICAL	GENE-N	40	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist chemical.	T14	T23	9832994
NA	CHEMICAL	GENE-Y	10	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as chemical and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist ritanserin.	T6	T26	9832994
NA	CHEMICAL	GENE-Y	10	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as chemical and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist ritanserin.	T6	T25	9832994
CPR:6	CHEMICAL	GENE-Y	10	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as chemical and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist ritanserin.	T6	T24	9832994
CPR:6	CHEMICAL	GENE-N	10	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as chemical and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	T6	T23	9832994
NA	CHEMICAL	GENE-Y	21	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as chemical and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist ritanserin.	T11	T26	9832994
NA	CHEMICAL	GENE-Y	21	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as chemical and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist ritanserin.	T11	T25	9832994
NA	CHEMICAL	GENE-Y	21	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as chemical and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist ritanserin.	T11	T24	9832994
NA	CHEMICAL	GENE-N	21	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as chemical and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	T11	T23	9832994
NA	CHEMICAL	GENE-Y	29	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of chemical-induced behavioural inhibition in rats than the more selective 5-HT2A/gene antagonist ritanserin.	T13	T26	9832994
NA	CHEMICAL	GENE-Y	29	38	These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of chemical-induced behavioural inhibition in rats than the more selective gene/5-HT2C antagonist ritanserin.	T13	T25	9832994
NA	CHEMICAL	GENE-Y	29	5	These data indicate that mixed 5-HT1/gene receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of chemical-induced behavioural inhibition in rats than the more selective geneA/geneC antagonist ritanserin.	T13	T24	9832994
NA	CHEMICAL	GENE-N	29	5	These data indicate that mixed gene/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of chemical-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.	T13	T23	9832994
CPR:4	CHEMICAL	GENE-Y	8	6	The cardiovascular effects of three different gene inhibitors: chemical, tacrine and rivastigmine injected by intravenous (i.v.)	T19	T32	9851542
CPR:4	CHEMICAL	GENE-Y	11	6	The cardiovascular effects of three different gene inhibitors: physostigmine, tacrine and chemical injected by intravenous (i.v.)	T2	T32	9851542
CPR:4	CHEMICAL	GENE-Y	9	6	The cardiovascular effects of three different gene inhibitors: physostigmine, chemical and rivastigmine injected by intravenous (i.v.)	T21	T32	9851542
CPR:6	CHEMICAL	GENE-N	10	6	The alpha1-adrenoceptor antagonist prazosin or the gene antagonist, chemical partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T20	T35	9851542
NA	CHEMICAL	GENE-N	10	1	The gene antagonist prazosin or the vasopressin V1 receptor antagonist, chemical partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T20	T34	9851542
NA	CHEMICAL	GENE-N	6	1	The gene antagonist prazosin or the chemical V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] chemical partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T18	T34	9851542
NA	CHEMICAL	GENE-N	6	1	The gene antagonist prazosin or the chemical V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] chemical partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T36	T34	9851542
NA	CHEMICAL	GENE-N	3	6	The alpha1-adrenoceptor antagonist chemical or the gene antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T17	T35	9851542
CPR:6	CHEMICAL	GENE-N	3	1	The gene antagonist chemical or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T17	T34	9851542
NA	CHEMICAL	GENE-Y	3	6	The alpha1-adrenoceptor antagonist chemical or the gene V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] gene partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T17	T18	9851542
NA	CHEMICAL	GENE-Y	3	6	The alpha1-adrenoceptor antagonist chemical or the gene V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] gene partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.	T17	T36	9851542
NA	CHEMICAL	GENE-N	18	6	The alpha1-adrenoceptor antagonist prazosin or the gene antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced chemical pressor effect and mostly abolished it when administered concomitantly.	T22	T35	9851542
NA	CHEMICAL	GENE-N	18	1	The gene antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced chemical pressor effect and mostly abolished it when administered concomitantly.	T22	T34	9851542
NA	CHEMICAL	GENE-Y	18	6	The alpha1-adrenoceptor antagonist prazosin or the gene V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] gene partially but significantly reduced chemical pressor effect and mostly abolished it when administered concomitantly.	T22	T18	9851542
NA	CHEMICAL	GENE-Y	18	6	The alpha1-adrenoceptor antagonist prazosin or the gene V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] gene partially but significantly reduced chemical pressor effect and mostly abolished it when administered concomitantly.	T22	T36	9851542
NA	CHEMICAL	GENE-Y	38	23	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the gene antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist chemical (ID50 = 31.19 microg).	T6	T26	9851542
NA	CHEMICAL	GENE-Y	38	13	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the gene antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist chemical (ID50 = 31.19 microg).	T6	T25	9851542
CPR:6	CHEMICAL	GENE-Y	38	34	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the gene antagonist chemical (ID50 = 31.19 microg).	T6	T27	9851542
NA	CHEMICAL	GENE-N	38	4	administration of the non-selective gene antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist chemical (ID50 = 31.19 microg).	T6	T24	9851542
CPR:6	CHEMICAL	GENE-Y	27	23	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the gene antagonist chemical (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T5	T26	9851542
NA	CHEMICAL	GENE-Y	27	13	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the gene antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist chemical (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T5	T25	9851542
NA	CHEMICAL	GENE-Y	27	34	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist chemical (ID50 = 1.39 microg) and the gene antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T5	T27	9851542
NA	CHEMICAL	GENE-N	27	4	administration of the non-selective gene antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist chemical (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T5	T24	9851542
NA	CHEMICAL	GENE-Y	17	23	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist chemical (ID50 = 4.33 microg), the gene antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T4	T26	9851542
CPR:6	CHEMICAL	GENE-Y	17	13	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the gene antagonist chemical (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T4	T25	9851542
NA	CHEMICAL	GENE-Y	17	34	administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist chemical (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the gene antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T4	T27	9851542
NA	CHEMICAL	GENE-N	17	4	administration of the non-selective gene antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist chemical (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T4	T24	9851542
NA	CHEMICAL	GENE-Y	7	23	administration of the non-selective muscarinic receptor antagonist chemical (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the gene antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T3	T26	9851542
NA	CHEMICAL	GENE-Y	7	13	administration of the non-selective muscarinic receptor antagonist chemical (ID50 = 1.45 microg), the gene antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T3	T25	9851542
NA	CHEMICAL	GENE-Y	7	34	administration of the non-selective muscarinic receptor antagonist chemical (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the gene antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T3	T27	9851542
CPR:6	CHEMICAL	GENE-N	7	4	administration of the non-selective gene antagonist chemical (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).	T3	T24	9851542
NA	CHEMICAL	GENE-N	10	4	Central injection of such gene antagonists did not affect chemical-induced bradycardia.	T7	T28	9851542
NA	CHEMICAL	GENE-Y	32	21	Our results show that acetylcholinesterase inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central gene inducing a secondary increase in sympathetic outflow and chemical release.	T8	T30	9851542
NA	CHEMICAL	GENE-Y	32	4	Our results show that gene inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central muscarinic M2 receptors inducing a secondary increase in sympathetic outflow and chemical release.	T8	T29	9851542
CPR:4	CHEMICAL	GENE-Y	0	7	chemical block of human cardiac (hH1) and gene was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	T1	T15	9876137
CPR:4	CHEMICAL	GENE-Y	0	3	chemical block of gene and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	T1	T10	9876137
NA	CHEMICAL	GENE-Y	11	3	Cocaine block of gene and rat skeletal (mu1) muscle chemical channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.	T7	T10	9876137
NA	CHEMICAL	GENE-Y	37	10	Cocaine block of hH1 channels was greater than block of gene at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to chemical block.	T6	T14	9876137
NA	CHEMICAL	GENE-Y	37	3	Cocaine block of gene was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of gene in this voltage range makes them more susceptible to chemical block.	T6	T13	9876137
CPR:4	CHEMICAL	GENE-Y	37	3	Cocaine block of gene was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of gene in this voltage range makes them more susceptible to chemical block.	T6	T16	9876137
CPR:4	CHEMICAL	GENE-Y	0	10	chemical block of hH1 channels was greater than block of gene at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.	T5	T14	9876137
CPR:4	CHEMICAL	GENE-Y	0	3	chemical block of gene was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of gene in this voltage range makes them more susceptible to cocaine block.	T5	T13	9876137
CPR:4	CHEMICAL	GENE-Y	0	3	chemical block of gene was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of gene in this voltage range makes them more susceptible to cocaine block.	T5	T16	9876137
